,Country,Year,Indicator:Maternal mortality ratio (per 100 000 live births),Type_of_Medicine,Measure,Total_Sales_Value
0,Australia,2016,6,B-Blood and blood forming organs,Million of national currency units,667.0
1,Australia,2016,6,M-Musculo-skeletal system,Million US$ at exchange rate,316.7
2,Australia,2016,6,M-Musculo-skeletal system,Million of national currency units,426.0
3,Australia,2016,6,R03-Drugs for obstructive airway diseases,Million of national currency units,629.0
4,Australia,2016,6,B-Blood and blood forming organs,Million US$ at exchange rate,495.8
5,Australia,2016,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",460.0
6,Australia,2016,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,467.6
7,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,361.3
8,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.9
9,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",335.1
10,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,486.0
11,Australia,2016,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.1
12,Australia,2016,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",293.8
13,Australia,2016,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.1
14,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.1
15,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.2
16,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",19.5
17,Australia,2016,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.0
18,Australia,2016,6,B-Blood and blood forming organs,% of total sales,4.4
19,Australia,2016,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.5
20,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",438.6
21,Australia,2016,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.3
22,Australia,2016,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.9
23,Australia,2016,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",433.7
24,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,472.8
25,Australia,2016,6,R03-Drugs for obstructive airway diseases,% of total sales,4.1
26,Australia,2016,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,636.0
27,Australia,2016,6,R-Respiratory system,"Million US$, purchasing power parity",489.6
28,Australia,2016,6,R-Respiratory system,"/capita, US$ exchange rate",21.8
29,Australia,2016,6,R-Respiratory system,Million US$ at exchange rate,527.8
30,Australia,2016,6,C08-Calcium channel blockers,Million of national currency units,133.0
31,Australia,2016,6,R-Respiratory system,"/capita, US$ purchasing power parity",20.2
32,Australia,2016,6,R-Respiratory system,% of total sales,4.6
33,Australia,2016,6,C07-Beta blocking agents,"Million US$, purchasing power parity",105.5
34,Australia,2016,6,C07-Beta blocking agents,Million US$ at exchange rate,113.7
35,Australia,2016,6,C07-Beta blocking agents,Million of national currency units,153.0
36,Australia,2016,6,C07-Beta blocking agents,% of total sales,1.0
37,Australia,2016,6,R-Respiratory system,Million of national currency units,710.0
38,Australia,2016,6,C07-Beta blocking agents,"/capita, US$ exchange rate",4.7
39,Australia,2016,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.4
40,Australia,2016,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",42.5
41,Australia,2016,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1028.1
42,Australia,2016,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",953.7
43,Australia,2016,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.4
44,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.2
45,Australia,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.9
46,Australia,2016,6,A-Alimentary tract and metabolism,% of total sales,9.0
47,Australia,2016,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1
48,Australia,2016,6,C08-Calcium channel blockers,Million US$ at exchange rate,98.9
49,Australia,2016,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",91.7
50,Australia,2016,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8
51,Australia,2016,6,A-Alimentary tract and metabolism,Million of national currency units,1383.0
52,Australia,2016,6,M-Musculo-skeletal system,% of total sales,2.8
53,Australia,2016,6,C08-Calcium channel blockers,% of total sales,0.9
54,Australia,2016,6,A02A-Antacids,% of total sales,0.0
55,Australia,2016,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.2
56,Australia,2016,6,G-Genito urinary system and sex hormones,% of total sales,2.3
57,Australia,2016,6,A02A-Antacids,"Million US$, purchasing power parity",0.0
58,Australia,2016,6,A02A-Antacids,Million US$ at exchange rate,0.0
59,Australia,2016,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
60,Australia,2016,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
61,Australia,2016,6,J-Antiinfectives for systemic use,Million of national currency units,3422.0
62,Australia,2016,6,C-Cardiovascular system,Million of national currency units,1860.0
63,Australia,2016,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,2543.8
64,Australia,2016,6,G-Genito urinary system and sex hormones,Million of national currency units,359.0
65,Australia,2016,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",247.6
66,Australia,2016,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.0
67,Australia,2016,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,266.9
68,Australia,2016,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",191.7
69,Australia,2016,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.5
70,Australia,2016,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,206.7
71,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,224.0
72,Australia,2016,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
73,Australia,2016,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.9
74,Australia,2016,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,278.0
75,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.5
76,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.4
77,Australia,2016,6,A02A-Antacids,Million of national currency units,0.0
78,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,166.5
79,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.9
80,Australia,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",154.5
81,Australia,2016,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.2
82,Australia,2016,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",488.9
83,Australia,2016,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.8
84,Australia,2016,6,J01-Antibacterials for systemic use,% of total sales,2.6
85,Australia,2016,6,C10-Lipid modifying agents,% of total sales,4.6
86,Australia,2016,6,Products not elsewhere classified,% of total sales,28.5
87,Australia,2016,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
88,Australia,2016,6,Products not elsewhere classified,"Million US$, purchasing power parity",3003.8
89,Australia,2016,6,Products not elsewhere classified,Million of national currency units,4356.0
90,Australia,2016,6,Products not elsewhere classified,Million US$ at exchange rate,3238.1
91,Australia,2016,6,Products not elsewhere classified,"/capita, US$ exchange rate",133.9
92,Australia,2016,6,C10-Lipid modifying agents,Million of national currency units,709.0
93,Australia,2016,6,C10-Lipid modifying agents,Million US$ at exchange rate,527.1
94,Australia,2016,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",124.2
95,Australia,2016,6,C-Cardiovascular system,% of total sales,12.2
96,Australia,2016,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2359.7
97,Australia,2016,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",53.0
98,Australia,2016,6,C-Cardiovascular system,"Million US$, purchasing power parity",1282.6
99,Australia,2016,6,C-Cardiovascular system,Million US$ at exchange rate,1382.7
100,Australia,2016,6,C-Cardiovascular system,"/capita, US$ exchange rate",57.2
101,Australia,2016,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",105.2
102,Australia,2016,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",270.3
103,Australia,2016,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,291.4
104,Australia,2016,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.0
105,Australia,2016,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",97.5
106,Australia,2016,6,J01-Antibacterials for systemic use,Million of national currency units,392.0
107,Australia,2016,6,J-Antiinfectives for systemic use,% of total sales,22.4
108,Australia,2016,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",3.4
109,Australia,2016,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
110,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,14.9
111,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",13.8
112,Australia,2016,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
113,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
114,Australia,2016,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.5
115,Australia,2016,6,C01A-Cardiac glycosides,% of total sales,0.0
116,Australia,2016,6,C03-Diuretics,Million of national currency units,46.0
117,Australia,2016,6,C03-Diuretics,Million US$ at exchange rate,34.2
118,Australia,2016,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.0
119,Australia,2016,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.8
120,Australia,2016,6,C01A-Cardiac glycosides,Million of national currency units,5.0
121,Australia,2016,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.7
122,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,20.0
123,Australia,2016,6,C02-Antihypertensives,% of total sales,0.6
124,Australia,2016,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.9
125,Australia,2016,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",446.8
126,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
127,Australia,2016,6,N-Nervous system,Million US$ at exchange rate,1411.7
128,Australia,2016,6,N-Nervous system,"Million US$, purchasing power parity",1309.5
129,Australia,2016,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.8
130,Australia,2016,6,N05C-Hypnotics and sedatives,Million of national currency units,28.0
131,Australia,2016,6,N-Nervous system,Million of national currency units,1899.0
132,Australia,2016,6,N05B-Anxiolytics,% of total sales,0.3
133,Australia,2016,6,A10-Drugs used in diabetes,% of total sales,4.2
134,Australia,2016,6,N05B-Anxiolytics,Million of national currency units,45.0
135,Australia,2016,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.3
136,Australia,2016,6,N-Nervous system,"/capita, US$ purchasing power parity",54.1
137,Australia,2016,6,N-Nervous system,"/capita, US$ exchange rate",58.4
138,Australia,2016,6,N-Nervous system,% of total sales,12.4
139,Australia,2016,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
140,Australia,2016,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9
141,Australia,2016,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",19.3
142,Australia,2016,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.8
143,Australia,2016,6,N05C-Hypnotics and sedatives,% of total sales,0.2
144,Australia,2016,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",436.3
145,Australia,2016,6,N06A-Antidepressants,Million of national currency units,441.0
146,Australia,2016,6,Total pharmaceutical sales,"Million US$, purchasing power parity",10554.0
147,Australia,2016,6,Total pharmaceutical sales,"/capita, US$ exchange rate",470.3
148,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",79.3
149,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.5
150,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,115.0
151,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,85.5
152,Australia,2016,6,Total pharmaceutical sales,Million of national currency units,15305.0
153,Australia,2016,6,Total pharmaceutical sales,Million US$ at exchange rate,11377.4
154,Australia,2016,6,A10-Drugs used in diabetes,Million of national currency units,648.0
155,Australia,2016,6,N05B-Anxiolytics,Million US$ at exchange rate,33.5
156,Australia,2016,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.6
157,Australia,2016,6,N06A-Antidepressants,"Million US$, purchasing power parity",304.1
158,Australia,2016,6,N06A-Antidepressants,Million US$ at exchange rate,327.8
159,Australia,2016,6,N06A-Antidepressants,% of total sales,2.9
160,Australia,2016,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.6
161,Australia,2016,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
162,Australia,2016,6,C03-Diuretics,% of total sales,0.3
163,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
164,Australia,2016,6,A10-Drugs used in diabetes,Million US$ at exchange rate,481.7
165,Australia,2016,6,C03-Diuretics,"/capita, US$ exchange rate",1.4
166,Australia,2016,6,C03-Diuretics,"Million US$, purchasing power parity",31.7
167,Australia,2016,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.3
168,Australia,2016,6,C02-Antihypertensives,Million of national currency units,98.0
169,Australia,2016,6,N02-Analgesics,"Million US$, purchasing power parity",342.7
170,Australia,2016,6,N02-Analgesics,"/capita, US$ exchange rate",15.3
171,Australia,2016,6,N02-Analgesics,Million US$ at exchange rate,369.5
172,Australia,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.3
173,Australia,2016,6,N02-Analgesics,Million of national currency units,497.0
174,Australia,2016,6,C02-Antihypertensives,Million US$ at exchange rate,72.9
175,Australia,2016,6,C02-Antihypertensives,"Million US$, purchasing power parity",67.6
176,Australia,2016,6,N05B-Anxiolytics,"Million US$, purchasing power parity",31.0
177,Australia,2016,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.2
178,Australia,2016,6,N02-Analgesics,% of total sales,3.2
179,Australia,2015,6,B-Blood and blood forming organs,Million of national currency units,617.0
180,Australia,2015,6,M-Musculo-skeletal system,Million of national currency units,401.0
181,Australia,2015,6,M-Musculo-skeletal system,Million US$ at exchange rate,301.3
182,Australia,2015,6,R03-Drugs for obstructive airway diseases,Million of national currency units,618.0
183,Australia,2015,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,464.3
184,Australia,2015,6,B-Blood and blood forming organs,Million US$ at exchange rate,463.5
185,Australia,2015,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",418.7
186,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,369.6
187,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",333.9
188,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.5
189,Australia,2015,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.6
190,Australia,2015,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",272.1
191,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,492.0
192,Australia,2015,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.4
193,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.3
194,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.5
195,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.4
196,Australia,2015,6,B-Blood and blood forming organs,% of total sales,5.0
197,Australia,2015,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.6
198,Australia,2015,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.5
199,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",460.7
200,Australia,2015,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.5
201,Australia,2015,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.6
202,Australia,2015,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",419.4
203,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,510.1
204,Australia,2015,6,R03-Drugs for obstructive airway diseases,% of total sales,5.0
205,Australia,2015,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,679.0
206,Australia,2015,6,R-Respiratory system,"/capita, US$ exchange rate",22.0
207,Australia,2015,6,R-Respiratory system,"Million US$, purchasing power parity",473.0
208,Australia,2015,6,R-Respiratory system,Million US$ at exchange rate,523.6
209,Australia,2015,6,C08-Calcium channel blockers,Million of national currency units,124.0
210,Australia,2015,6,R-Respiratory system,"/capita, US$ purchasing power parity",19.9
211,Australia,2015,6,R-Respiratory system,% of total sales,5.7
212,Australia,2015,6,C07-Beta blocking agents,"Million US$, purchasing power parity",97.7
213,Australia,2015,6,C07-Beta blocking agents,Million of national currency units,144.0
214,Australia,2015,6,C07-Beta blocking agents,Million US$ at exchange rate,108.2
215,Australia,2015,6,C07-Beta blocking agents,"/capita, US$ exchange rate",4.5
216,Australia,2015,6,C07-Beta blocking agents,% of total sales,1.2
217,Australia,2015,6,R-Respiratory system,Million of national currency units,697.0
218,Australia,2015,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.1
219,Australia,2015,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",42.7
220,Australia,2015,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",38.5
221,Australia,2015,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1016.5
222,Australia,2015,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",918.1
223,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.0
224,Australia,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.0
225,Australia,2015,6,A-Alimentary tract and metabolism,% of total sales,11.0
226,Australia,2015,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9
227,Australia,2015,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5
228,Australia,2015,6,C08-Calcium channel blockers,Million US$ at exchange rate,93.2
229,Australia,2015,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",84.1
230,Australia,2015,6,A-Alimentary tract and metabolism,Million of national currency units,1353.0
231,Australia,2015,6,C08-Calcium channel blockers,% of total sales,1.0
232,Australia,2015,6,A02A-Antacids,% of total sales,0.0
233,Australia,2015,6,G-Genito urinary system and sex hormones,% of total sales,2.4
234,Australia,2015,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",8.5
235,Australia,2015,6,A02A-Antacids,"Million US$, purchasing power parity",1.4
236,Australia,2015,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
237,Australia,2015,6,A02A-Antacids,"/capita, US$ exchange rate",0.1
238,Australia,2015,6,A02A-Antacids,Million US$ at exchange rate,1.5
239,Australia,2015,6,J-Antiinfectives for systemic use,Million of national currency units,822.0
240,Australia,2015,6,C-Cardiovascular system,Million of national currency units,1992.0
241,Australia,2015,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,617.5
242,Australia,2015,6,G-Genito urinary system and sex hormones,Million of national currency units,298.0
243,Australia,2015,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",202.2
244,Australia,2015,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.4
245,Australia,2015,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,223.9
246,Australia,2015,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",149.3
247,Australia,2015,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.9
248,Australia,2015,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,165.3
249,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,191.0
250,Australia,2015,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
251,Australia,2015,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
252,Australia,2015,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,220.0
253,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6
254,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.4
255,Australia,2015,6,A02A-Antacids,Million of national currency units,2.0
256,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,143.5
257,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.0
258,Australia,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",129.6
259,Australia,2015,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",23.4
260,Australia,2015,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",25.9
261,Australia,2015,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",556.4
262,Australia,2015,6,J01-Antibacterials for systemic use,% of total sales,3.0
263,Australia,2015,6,C10-Lipid modifying agents,% of total sales,6.7
264,Australia,2015,6,Products not elsewhere classified,% of total sales,32.5
265,Australia,2015,6,Products not elsewhere classified,"Million US$, purchasing power parity",2705.5
266,Australia,2015,6,Products not elsewhere classified,Million of national currency units,3987.0
267,Australia,2015,6,Products not elsewhere classified,Million US$ at exchange rate,2995.3
268,Australia,2015,6,Products not elsewhere classified,"/capita, US$ exchange rate",125.8
269,Australia,2015,6,C10-Lipid modifying agents,Million of national currency units,820.0
270,Australia,2015,6,C10-Lipid modifying agents,Million US$ at exchange rate,616.0
271,Australia,2015,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",113.6
272,Australia,2015,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.3
273,Australia,2015,6,C-Cardiovascular system,% of total sales,16.2
274,Australia,2015,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",557.8
275,Australia,2015,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",56.8
276,Australia,2015,6,C-Cardiovascular system,"Million US$, purchasing power parity",1351.7
277,Australia,2015,6,C-Cardiovascular system,Million US$ at exchange rate,1496.5
278,Australia,2015,6,C-Cardiovascular system,"/capita, US$ exchange rate",62.8
279,Australia,2015,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",25.9
280,Australia,2015,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",246.3
281,Australia,2015,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,272.7
282,Australia,2015,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.5
283,Australia,2015,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.4
284,Australia,2015,6,J01-Antibacterials for systemic use,Million of national currency units,363.0
285,Australia,2015,6,J-Antiinfectives for systemic use,% of total sales,6.7
286,Australia,2015,6,M-Musculo-skeletal system,% of total sales,3.3
287,Australia,2015,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
288,Australia,2015,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",3.4
289,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,14.3
290,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.9
291,Australia,2015,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
292,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
293,Australia,2015,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.6
294,Australia,2015,6,C01A-Cardiac glycosides,% of total sales,0.0
295,Australia,2015,6,C03-Diuretics,Million of national currency units,43.0
296,Australia,2015,6,C03-Diuretics,Million US$ at exchange rate,32.3
297,Australia,2015,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.5
298,Australia,2015,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.9
299,Australia,2015,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.6
300,Australia,2015,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.8
301,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,19.0
302,Australia,2015,6,C01A-Cardiac glycosides,Million of national currency units,5.0
303,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5
304,Australia,2015,6,C02-Antihypertensives,% of total sales,0.7
305,Australia,2015,6,N-Nervous system,"Million US$, purchasing power parity",1306.9
306,Australia,2015,6,N-Nervous system,Million US$ at exchange rate,1446.9
307,Australia,2015,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.0
308,Australia,2015,6,N05C-Hypnotics and sedatives,Million of national currency units,24.0
309,Australia,2015,6,N-Nervous system,Million of national currency units,1926.0
310,Australia,2015,6,N05B-Anxiolytics,% of total sales,0.3
311,Australia,2015,6,A10-Drugs used in diabetes,% of total sales,5.0
312,Australia,2015,6,N05B-Anxiolytics,Million of national currency units,39.0
313,Australia,2015,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.1
314,Australia,2015,6,N-Nervous system,"/capita, US$ purchasing power parity",54.9
315,Australia,2015,6,N-Nervous system,% of total sales,15.7
316,Australia,2015,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
317,Australia,2015,6,N-Nervous system,"/capita, US$ exchange rate",60.8
318,Australia,2015,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
319,Australia,2015,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",16.3
320,Australia,2015,6,N05C-Hypnotics and sedatives,% of total sales,0.2
321,Australia,2015,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.7
322,Australia,2015,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",418.7
323,Australia,2015,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",350.0
324,Australia,2015,6,N06A-Antidepressants,Million of national currency units,438.0
325,Australia,2015,6,Total pharmaceutical sales,"Million US$, purchasing power parity",8335.5
326,Australia,2015,6,Total pharmaceutical sales,"/capita, US$ exchange rate",387.5
327,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",80.7
328,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.8
329,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,119.0
330,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,89.4
331,Australia,2015,6,N06A-Antidepressants,Million US$ at exchange rate,329.1
332,Australia,2015,6,N05B-Anxiolytics,"Million US$, purchasing power parity",26.5
333,Australia,2015,6,Total pharmaceutical sales,Million of national currency units,12284.0
334,Australia,2015,6,Total pharmaceutical sales,Million US$ at exchange rate,9228.5
335,Australia,2015,6,A10-Drugs used in diabetes,Million of national currency units,617.0
336,Australia,2015,6,N05B-Anxiolytics,Million US$ at exchange rate,29.3
337,Australia,2015,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.8
338,Australia,2015,6,N06A-Antidepressants,"Million US$, purchasing power parity",297.2
339,Australia,2015,6,N06A-Antidepressants,% of total sales,3.6
340,Australia,2015,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.5
341,Australia,2015,6,C03-Diuretics,% of total sales,0.4
342,Australia,2015,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
343,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0
344,Australia,2015,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.2
345,Australia,2015,6,A10-Drugs used in diabetes,Million US$ at exchange rate,463.5
346,Australia,2015,6,C03-Diuretics,"Million US$, purchasing power parity",29.2
347,Australia,2015,6,C03-Diuretics,"/capita, US$ exchange rate",1.4
348,Australia,2015,6,N02-Analgesics,"Million US$, purchasing power parity",375.9
349,Australia,2015,6,C02-Antihypertensives,Million of national currency units,91.0
350,Australia,2015,6,N02-Analgesics,"/capita, US$ exchange rate",17.5
351,Australia,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.4
352,Australia,2015,6,N02-Analgesics,Million of national currency units,554.0
353,Australia,2015,6,N02-Analgesics,Million US$ at exchange rate,416.2
354,Australia,2015,6,C02-Antihypertensives,"Million US$, purchasing power parity",61.7
355,Australia,2015,6,C02-Antihypertensives,Million US$ at exchange rate,68.4
356,Australia,2015,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.8
357,Australia,2015,6,N02-Analgesics,% of total sales,4.5
358,Australia,2014,6,M-Musculo-skeletal system,Million of national currency units,383.0
359,Australia,2014,6,B-Blood and blood forming organs,Million of national currency units,545.0
360,Australia,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,345.2
361,Australia,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,634.0
362,Australia,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,571.5
363,Australia,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,491.3
364,Australia,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",375.2
365,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,479.6
366,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",20.4
367,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",366.3
368,Australia,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.7
369,Australia,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",263.7
370,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,532.0
371,Australia,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.2
372,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",20.7
373,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9
374,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.1
375,Australia,2014,6,B-Blood and blood forming organs,% of total sales,4.6
376,Australia,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.0
377,Australia,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.9
378,Australia,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.6
379,Australia,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.3
380,Australia,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",436.5
381,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,636.4
382,Australia,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,5.3
383,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,706.0
384,Australia,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",486.1
385,Australia,2014,6,R-Respiratory system,"/capita, US$ exchange rate",25.3
386,Australia,2014,6,R-Respiratory system,Million US$ at exchange rate,594.0
387,Australia,2014,6,R-Respiratory system,"Million US$, purchasing power parity",453.7
388,Australia,2014,6,C08-Calcium channel blockers,Million of national currency units,119.0
389,Australia,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",19.3
390,Australia,2014,6,R-Respiratory system,% of total sales,5.5
391,Australia,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",97.8
392,Australia,2014,6,C07-Beta blocking agents,Million of national currency units,142.0
393,Australia,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,128.0
394,Australia,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",5.5
395,Australia,2014,6,C07-Beta blocking agents,% of total sales,1.2
396,Australia,2014,6,R-Respiratory system,Million of national currency units,659.0
397,Australia,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.2
398,Australia,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,107.3
399,Australia,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.9
400,Australia,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.6
401,Australia,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",930.1
402,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.5
403,Australia,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.6
404,Australia,2014,6,A-Alimentary tract and metabolism,% of total sales,11.4
405,Australia,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1217.8
406,Australia,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.6
407,Australia,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5
408,Australia,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",81.9
409,Australia,2014,6,A-Alimentary tract and metabolism,Million of national currency units,1351.0
410,Australia,2014,6,M-Musculo-skeletal system,% of total sales,3.2
411,Australia,2014,6,C08-Calcium channel blockers,% of total sales,1.0
412,Australia,2014,6,A02A-Antacids,% of total sales,0.0
413,Australia,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",7.0
414,Australia,2014,6,G-Genito urinary system and sex hormones,% of total sales,2.0
415,Australia,2014,6,A02A-Antacids,"Million US$, purchasing power parity",0.7
416,Australia,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
417,Australia,2014,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
418,Australia,2014,6,J-Antiinfectives for systemic use,Million of national currency units,801.0
419,Australia,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,240.0
420,Australia,2014,6,C-Cardiovascular system,Million of national currency units,2200.0
421,Australia,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,722.0
422,Australia,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",165.2
423,Australia,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.2
424,Australia,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,216.3
425,Australia,2014,6,A02A-Antacids,Million US$ at exchange rate,0.9
426,Australia,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",115.0
427,Australia,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.4
428,Australia,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,150.5
429,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,168.0
430,Australia,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.4
431,Australia,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.9
432,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
433,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.9
434,Australia,2014,6,A02A-Antacids,Million of national currency units,1.0
435,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,151.4
436,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",115.7
437,Australia,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.5
438,Australia,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,167.0
439,Australia,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.1
440,Australia,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",707.8
441,Australia,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",39.5
442,Australia,2014,6,C10-Lipid modifying agents,% of total sales,8.6
443,Australia,2014,6,J01-Antibacterials for systemic use,% of total sales,2.7
444,Australia,2014,6,Products not elsewhere classified,% of total sales,30.4
445,Australia,2014,6,Products not elsewhere classified,"Million US$, purchasing power parity",2489.5
446,Australia,2014,6,Products not elsewhere classified,Million of national currency units,3616.0
447,Australia,2014,6,Products not elsewhere classified,Million US$ at exchange rate,3259.5
448,Australia,2014,6,Products not elsewhere classified,"/capita, US$ exchange rate",138.8
449,Australia,2014,6,C10-Lipid modifying agents,Million of national currency units,1028.0
450,Australia,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,926.7
451,Australia,2014,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",106.0
452,Australia,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.4
453,Australia,2014,6,C-Cardiovascular system,% of total sales,18.5
454,Australia,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",30.8
455,Australia,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",551.5
456,Australia,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",1514.6
457,Australia,2014,6,C-Cardiovascular system,Million US$ at exchange rate,1983.1
458,Australia,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",64.5
459,Australia,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",84.5
460,Australia,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",220.3
461,Australia,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,288.5
462,Australia,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.3
463,Australia,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.5
464,Australia,2014,6,J-Antiinfectives for systemic use,% of total sales,6.7
465,Australia,2014,6,J01-Antibacterials for systemic use,Million of national currency units,320.0
466,Australia,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
467,Australia,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
468,Australia,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.8
469,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.1
470,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",13.1
471,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
472,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
473,Australia,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.3
474,Australia,2014,6,C01A-Cardiac glycosides,% of total sales,0.0
475,Australia,2014,6,C03-Diuretics,Million US$ at exchange rate,34.3
476,Australia,2014,6,C03-Diuretics,Million of national currency units,38.0
477,Australia,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.6
478,Australia,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.2
479,Australia,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.4
480,Australia,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.6
481,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,19.0
482,Australia,2014,6,C01A-Cardiac glycosides,Million of national currency units,4.0
483,Australia,2014,6,C02-Antihypertensives,% of total sales,0.7
484,Australia,2014,6,N-Nervous system,"Million US$, purchasing power parity",1324.6
485,Australia,2014,6,N-Nervous system,Million US$ at exchange rate,1734.3
486,Australia,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.9
487,Australia,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,21.0
488,Australia,2014,6,N05B-Anxiolytics,% of total sales,0.3
489,Australia,2014,6,A10-Drugs used in diabetes,% of total sales,5.0
490,Australia,2014,6,N05B-Anxiolytics,Million of national currency units,33.0
491,Australia,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0
492,Australia,2014,6,N-Nervous system,Million of national currency units,1924.0
493,Australia,2014,6,N-Nervous system,% of total sales,16.2
494,Australia,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",56.4
495,Australia,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
496,Australia,2014,6,N-Nervous system,"/capita, US$ exchange rate",73.9
497,Australia,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
498,Australia,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.5
499,Australia,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.6
500,Australia,2014,6,N05C-Hypnotics and sedatives,% of total sales,0.2
501,Australia,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",348.6
502,Australia,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",8184.6
503,Australia,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",456.5
504,Australia,2014,6,N06A-Antidepressants,Million of national currency units,464.0
505,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",84.0
506,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.7
507,Australia,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",405.5
508,Australia,2014,6,N06A-Antidepressants,Million US$ at exchange rate,418.3
509,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,122.0
510,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,110.0
511,Australia,2014,6,Total pharmaceutical sales,Million of national currency units,11888.0
512,Australia,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",22.7
513,Australia,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,10716.1
514,Australia,2014,6,A10-Drugs used in diabetes,Million of national currency units,589.0
515,Australia,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,29.7
516,Australia,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",17.8
517,Australia,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",319.5
518,Australia,2014,6,N06A-Antidepressants,% of total sales,3.9
519,Australia,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.6
520,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.6
521,Australia,2014,6,C03-Diuretics,% of total sales,0.3
522,Australia,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
523,Australia,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0
524,Australia,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,530.9
525,Australia,2014,6,C03-Diuretics,"Million US$, purchasing power parity",26.2
526,Australia,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.1
527,Australia,2014,6,C03-Diuretics,"/capita, US$ exchange rate",1.5
528,Australia,2014,6,C02-Antihypertensives,Million of national currency units,83.0
529,Australia,2014,6,N02-Analgesics,"Million US$, purchasing power parity",355.3
530,Australia,2014,6,N02-Analgesics,Million of national currency units,516.0
531,Australia,2014,6,N02-Analgesics,Million US$ at exchange rate,465.1
532,Australia,2014,6,N02-Analgesics,"/capita, US$ exchange rate",19.8
533,Australia,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",57.1
534,Australia,2014,6,C02-Antihypertensives,Million US$ at exchange rate,74.8
535,Australia,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.1
536,Australia,2014,6,N02-Analgesics,% of total sales,4.3
537,Australia,2013,6,M-Musculo-skeletal system,Million of national currency units,378.0
538,Australia,2013,6,B-Blood and blood forming organs,Million of national currency units,481.0
539,Australia,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,364.9
540,Australia,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,464.4
541,Australia,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,617.0
542,Australia,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,595.7
543,Australia,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",332.4
544,Australia,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",261.2
545,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,568.6
546,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",407.0
547,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",24.6
548,Australia,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.8
549,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,589.0
550,Australia,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.3
551,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.1
552,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3
553,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.9
554,Australia,2013,6,B-Blood and blood forming organs,% of total sales,4.1
555,Australia,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",14.4
556,Australia,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.1
557,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",511.4
558,Australia,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.4
559,Australia,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",426.4
560,Australia,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",25.8
561,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,714.4
562,Australia,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,5.2
563,Australia,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,740.0
564,Australia,2013,6,R-Respiratory system,"/capita, US$ exchange rate",26.6
565,Australia,2013,6,R-Respiratory system,"Million US$, purchasing power parity",440.9
566,Australia,2013,6,R-Respiratory system,Million US$ at exchange rate,615.9
567,Australia,2013,6,C08-Calcium channel blockers,Million of national currency units,131.0
568,Australia,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",19.1
569,Australia,2013,6,R-Respiratory system,% of total sales,5.4
570,Australia,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",104.3
571,Australia,2013,6,C07-Beta blocking agents,Million of national currency units,151.0
572,Australia,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,145.8
573,Australia,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.3
574,Australia,2013,6,C07-Beta blocking agents,% of total sales,1.3
575,Australia,2013,6,R-Respiratory system,Million of national currency units,638.0
576,Australia,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.5
577,Australia,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",58.4
578,Australia,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.8
579,Australia,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",966.7
580,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.0
581,Australia,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.6
582,Australia,2013,6,A-Alimentary tract and metabolism,% of total sales,11.8
583,Australia,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,126.5
584,Australia,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1350.6
585,Australia,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5
586,Australia,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.9
587,Australia,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",90.5
588,Australia,2013,6,A-Alimentary tract and metabolism,Million of national currency units,1399.0
589,Australia,2013,6,M-Musculo-skeletal system,% of total sales,3.2
590,Australia,2013,6,C08-Calcium channel blockers,% of total sales,1.1
591,Australia,2013,6,A02A-Antacids,% of total sales,0.0
592,Australia,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.7
593,Australia,2013,6,G-Genito urinary system and sex hormones,% of total sales,1.9
594,Australia,2013,6,A02A-Antacids,"Million US$, purchasing power parity",1.4
595,Australia,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
596,Australia,2013,6,A02A-Antacids,"/capita, US$ exchange rate",0.1
597,Australia,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,225.0
598,Australia,2013,6,J-Antiinfectives for systemic use,Million of national currency units,790.0
599,Australia,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,762.7
600,Australia,2013,6,C-Cardiovascular system,Million of national currency units,2516.0
601,Australia,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.4
602,Australia,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",155.5
603,Australia,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,217.2
604,Australia,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",110.6
605,Australia,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.7
606,Australia,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,154.5
607,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,156.0
608,Australia,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.8
609,Australia,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.4
610,Australia,2013,6,A02A-Antacids,Million US$ at exchange rate,1.9
611,Australia,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,160.0
612,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3
613,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.7
614,Australia,2013,6,A02A-Antacids,Million of national currency units,2.0
615,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,150.6
616,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",107.8
617,Australia,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.5
618,Australia,2013,6,C-Cardiovascular system,Million US$ at exchange rate,2428.9
619,Australia,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",38.5
620,Australia,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",890.0
621,Australia,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",53.8
622,Australia,2013,6,C10-Lipid modifying agents,% of total sales,10.9
623,Australia,2013,6,J01-Antibacterials for systemic use,% of total sales,2.7
624,Australia,2013,6,Products not elsewhere classified,% of total sales,27.4
625,Australia,2013,6,Products not elsewhere classified,"Million US$, purchasing power parity",2238.2
626,Australia,2013,6,Products not elsewhere classified,"/capita, US$ exchange rate",135.2
627,Australia,2013,6,Products not elsewhere classified,Million of national currency units,3239.0
628,Australia,2013,6,Products not elsewhere classified,Million US$ at exchange rate,3126.9
629,Australia,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,1243.4
630,Australia,2013,6,C10-Lipid modifying agents,Million of national currency units,1288.0
631,Australia,2013,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",96.8
632,Australia,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.6
633,Australia,2013,6,C-Cardiovascular system,% of total sales,21.3
634,Australia,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",33.0
635,Australia,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",545.9
636,Australia,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",1738.6
637,Australia,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.2
638,Australia,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",105.0
639,Australia,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",221.1
640,Australia,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,308.9
641,Australia,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.4
642,Australia,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.6
643,Australia,2013,6,J-Antiinfectives for systemic use,% of total sales,6.7
644,Australia,2013,6,J01-Antibacterials for systemic use,Million of national currency units,320.0
645,Australia,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
646,Australia,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
647,Australia,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.8
648,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.4
649,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.4
650,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
651,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5
652,Australia,2013,6,C01A-Cardiac glycosides,% of total sales,0.0
653,Australia,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.7
654,Australia,2013,6,C03-Diuretics,Million US$ at exchange rate,35.7
655,Australia,2013,6,C03-Diuretics,Million of national currency units,37.0
656,Australia,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.6
657,Australia,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",24.8
658,Australia,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.7
659,Australia,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.9
660,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,18.0
661,Australia,2013,6,C02-Antihypertensives,% of total sales,0.7
662,Australia,2013,6,C01A-Cardiac glycosides,Million of national currency units,4.0
663,Australia,2013,6,N-Nervous system,"Million US$, purchasing power parity",1380.7
664,Australia,2013,6,N-Nervous system,Million US$ at exchange rate,1928.9
665,Australia,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.3
666,Australia,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,21.0
667,Australia,2013,6,N-Nervous system,Million of national currency units,1998.0
668,Australia,2013,6,N05B-Anxiolytics,% of total sales,0.3
669,Australia,2013,6,A10-Drugs used in diabetes,% of total sales,5.0
670,Australia,2013,6,N05B-Anxiolytics,Million of national currency units,34.0
671,Australia,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0
672,Australia,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.5
673,Australia,2013,6,N-Nervous system,% of total sales,16.9
674,Australia,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",59.7
675,Australia,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
676,Australia,2013,6,N-Nervous system,"/capita, US$ exchange rate",83.4
677,Australia,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9
678,Australia,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.6
679,Australia,2013,6,N05C-Hypnotics and sedatives,% of total sales,0.2
680,Australia,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",410.5
681,Australia,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",353.2
682,Australia,2013,6,N06A-Antidepressants,Million US$ at exchange rate,505.9
683,Australia,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",8167.9
684,Australia,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",493.4
685,Australia,2013,6,N06A-Antidepressants,Million of national currency units,524.0
686,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",88.5
687,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.3
688,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,128.0
689,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,123.6
690,Australia,2013,6,Total pharmaceutical sales,Million of national currency units,11820.0
691,Australia,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,11411.0
692,Australia,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",23.5
693,Australia,2013,6,A10-Drugs used in diabetes,Million of national currency units,594.0
694,Australia,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,32.8
695,Australia,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",21.9
696,Australia,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",362.1
697,Australia,2013,6,N06A-Antidepressants,% of total sales,4.4
698,Australia,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.7
699,Australia,2013,6,C03-Diuretics,% of total sales,0.3
700,Australia,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
701,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.8
702,Australia,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1
703,Australia,2013,6,C02-Antihypertensives,Million of national currency units,88.0
704,Australia,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,573.4
705,Australia,2013,6,C03-Diuretics,"Million US$, purchasing power parity",25.6
706,Australia,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.1
707,Australia,2013,6,C03-Diuretics,"/capita, US$ exchange rate",1.5
708,Australia,2013,6,N02-Analgesics,"Million US$, purchasing power parity",347.6
709,Australia,2013,6,N02-Analgesics,"/capita, US$ exchange rate",21.0
710,Australia,2013,6,N02-Analgesics,Million of national currency units,503.0
711,Australia,2013,6,N02-Analgesics,Million US$ at exchange rate,485.6
712,Australia,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",60.8
713,Australia,2013,6,C02-Antihypertensives,Million US$ at exchange rate,85.0
714,Australia,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.0
715,Australia,2013,6,N02-Analgesics,% of total sales,4.3
716,Australia,2012,6,M-Musculo-skeletal system,Million of national currency units,312.0
717,Australia,2012,6,B-Blood and blood forming organs,Million of national currency units,405.0
718,Australia,2012,6,M-Musculo-skeletal system,Million US$ at exchange rate,323.0
719,Australia,2012,6,B-Blood and blood forming organs,Million US$ at exchange rate,419.3
720,Australia,2012,6,R03-Drugs for obstructive airway diseases,Million of national currency units,586.0
721,Australia,2012,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,606.8
722,Australia,2012,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",263.0
723,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",325.9
724,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,519.8
725,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.9
726,Australia,2012,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.2
727,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,502.0
728,Australia,2012,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.9
729,Australia,2012,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",202.6
730,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.1
731,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4
732,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.6
733,Australia,2012,6,B-Blood and blood forming organs,% of total sales,3.9
734,Australia,2012,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.4
735,Australia,2012,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",11.6
736,Australia,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",16.7
737,Australia,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.7
738,Australia,2012,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",380.5
739,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,581.9
740,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",364.9
741,Australia,2012,6,R03-Drugs for obstructive airway diseases,% of total sales,5.7
742,Australia,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,562.0
743,Australia,2012,6,R-Respiratory system,"/capita, US$ exchange rate",27.2
744,Australia,2012,6,R-Respiratory system,Million US$ at exchange rate,619.2
745,Australia,2012,6,R-Respiratory system,"Million US$, purchasing power parity",388.3
746,Australia,2012,6,R-Respiratory system,"/capita, US$ purchasing power parity",17.1
747,Australia,2012,6,C08-Calcium channel blockers,Million of national currency units,118.0
748,Australia,2012,6,R-Respiratory system,% of total sales,5.8
749,Australia,2012,6,C07-Beta blocking agents,"Million US$, purchasing power parity",89.0
750,Australia,2012,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.2
751,Australia,2012,6,C07-Beta blocking agents,Million of national currency units,137.0
752,Australia,2012,6,C07-Beta blocking agents,Million US$ at exchange rate,141.9
753,Australia,2012,6,C07-Beta blocking agents,% of total sales,1.3
754,Australia,2012,6,R-Respiratory system,Million of national currency units,598.0
755,Australia,2012,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.9
756,Australia,2012,6,C08-Calcium channel blockers,Million US$ at exchange rate,122.2
757,Australia,2012,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",55.3
758,Australia,2012,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",34.7
759,Australia,2012,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",788.3
760,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.8
761,Australia,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.3
762,Australia,2012,6,A-Alimentary tract and metabolism,% of total sales,11.7
763,Australia,2012,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.4
764,Australia,2012,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.4
765,Australia,2012,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",76.6
766,Australia,2012,6,A-Alimentary tract and metabolism,Million of national currency units,1214.0
767,Australia,2012,6,M-Musculo-skeletal system,% of total sales,3.0
768,Australia,2012,6,C08-Calcium channel blockers,% of total sales,1.1
769,Australia,2012,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1257.0
770,Australia,2012,6,Products not elsewhere classified,Million of national currency units,2822.0
771,Australia,2012,6,A02A-Antacids,% of total sales,0.0
772,Australia,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",4.4
773,Australia,2012,6,G-Genito urinary system and sex hormones,% of total sales,1.5
774,Australia,2012,6,A02A-Antacids,"Million US$, purchasing power parity",1.3
775,Australia,2012,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
776,Australia,2012,6,A02A-Antacids,"/capita, US$ exchange rate",0.1
777,Australia,2012,6,J-Antiinfectives for systemic use,Million of national currency units,446.0
778,Australia,2012,6,G-Genito urinary system and sex hormones,Million of national currency units,155.0
779,Australia,2012,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,461.8
780,Australia,2012,6,C-Cardiovascular system,Million of national currency units,2538.0
781,Australia,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.1
782,Australia,2012,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",100.6
783,Australia,2012,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,160.5
784,Australia,2012,6,A02A-Antacids,Million US$ at exchange rate,2.1
785,Australia,2012,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.9
786,Australia,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.7
787,Australia,2012,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,106.6
788,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,98.0
789,Australia,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.9
790,Australia,2012,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.0
791,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.9
792,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.8
793,Australia,2012,6,A02A-Antacids,Million of national currency units,2.0
794,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,101.5
795,Australia,2012,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,103.0
796,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.6
797,Australia,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.5
798,Australia,2012,6,C-Cardiovascular system,Million US$ at exchange rate,2627.9
799,Australia,2012,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",43.9
800,Australia,2012,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",998.6
801,Australia,2012,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",70.0
802,Australia,2012,6,C10-Lipid modifying agents,% of total sales,14.9
803,Australia,2012,6,J01-Antibacterials for systemic use,% of total sales,1.8
804,Australia,2012,6,Products not elsewhere classified,% of total sales,27.3
805,Australia,2012,6,Products not elsewhere classified,"Million US$, purchasing power parity",1832.3
806,Australia,2012,6,Products not elsewhere classified,"/capita, US$ exchange rate",128.5
807,Australia,2012,6,Products not elsewhere classified,Million US$ at exchange rate,2921.9
808,Australia,2012,6,C10-Lipid modifying agents,Million US$ at exchange rate,1592.5
809,Australia,2012,6,C10-Lipid modifying agents,Million of national currency units,1538.0
810,Australia,2012,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",80.6
811,Australia,2012,6,C-Cardiovascular system,% of total sales,24.5
812,Australia,2012,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",20.3
813,Australia,2012,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",289.6
814,Australia,2012,6,C-Cardiovascular system,"Million US$, purchasing power parity",1647.9
815,Australia,2012,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",72.5
816,Australia,2012,6,C-Cardiovascular system,"/capita, US$ exchange rate",115.6
817,Australia,2012,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",119.5
818,Australia,2012,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,190.5
819,Australia,2012,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",5.3
820,Australia,2012,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.4
821,Australia,2012,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",12.7
822,Australia,2012,6,J-Antiinfectives for systemic use,% of total sales,4.3
823,Australia,2012,6,J01-Antibacterials for systemic use,Million of national currency units,184.0
824,Australia,2012,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
825,Australia,2012,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
826,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.6
827,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.0
828,Australia,2012,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.6
829,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
830,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5
831,Australia,2012,6,C01A-Cardiac glycosides,% of total sales,0.0
832,Australia,2012,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.8
833,Australia,2012,6,C03-Diuretics,Million US$ at exchange rate,31.1
834,Australia,2012,6,C03-Diuretics,Million of national currency units,30.0
835,Australia,2012,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.2
836,Australia,2012,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.6
837,Australia,2012,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.6
838,Australia,2012,6,C01A-Cardiac glycosides,Million US$ at exchange rate,4.1
839,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0
840,Australia,2012,6,C01A-Cardiac glycosides,Million of national currency units,4.0
841,Australia,2012,6,C02-Antihypertensives,% of total sales,0.8
842,Australia,2012,6,N-Nervous system,"Million US$, purchasing power parity",1148.0
843,Australia,2012,6,N-Nervous system,Million US$ at exchange rate,1830.6
844,Australia,2012,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,17.6
845,Australia,2012,6,N05C-Hypnotics and sedatives,Million of national currency units,17.0
846,Australia,2012,6,N05B-Anxiolytics,% of total sales,0.3
847,Australia,2012,6,A10-Drugs used in diabetes,% of total sales,5.0
848,Australia,2012,6,N-Nervous system,Million of national currency units,1768.0
849,Australia,2012,6,N05B-Anxiolytics,Million of national currency units,27.0
850,Australia,2012,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",11.0
851,Australia,2012,6,N-Nervous system,% of total sales,17.1
852,Australia,2012,6,N-Nervous system,"/capita, US$ purchasing power parity",50.5
853,Australia,2012,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
854,Australia,2012,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.8
855,Australia,2012,6,N-Nervous system,"/capita, US$ exchange rate",80.5
856,Australia,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.5
857,Australia,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
858,Australia,2012,6,N05C-Hypnotics and sedatives,% of total sales,0.2
859,Australia,2012,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",295.8
860,Australia,2012,6,N06A-Antidepressants,Million US$ at exchange rate,461.8
861,Australia,2012,6,Total pharmaceutical sales,"Million US$, purchasing power parity",6723.5
862,Australia,2012,6,Total pharmaceutical sales,"/capita, US$ exchange rate",471.6
863,Australia,2012,6,N06A-Antidepressants,Million of national currency units,446.0
864,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",55.2
865,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.9
866,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,85.0
867,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,88.0
868,Australia,2012,6,Total pharmaceutical sales,Million of national currency units,10355.0
869,Australia,2012,6,Total pharmaceutical sales,Million US$ at exchange rate,10721.7
870,Australia,2012,6,N05B-Anxiolytics,"Million US$, purchasing power parity",17.5
871,Australia,2012,6,A10-Drugs used in diabetes,Million of national currency units,519.0
872,Australia,2012,6,N05B-Anxiolytics,Million US$ at exchange rate,28.0
873,Australia,2012,6,N06A-Antidepressants,"/capita, US$ exchange rate",20.3
874,Australia,2012,6,N06A-Antidepressants,"Million US$, purchasing power parity",289.6
875,Australia,2012,6,N06A-Antidepressants,% of total sales,4.3
876,Australia,2012,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.7
877,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",2.4
878,Australia,2012,6,C03-Diuretics,% of total sales,0.3
879,Australia,2012,6,C02-Antihypertensives,Million of national currency units,78.0
880,Australia,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
881,Australia,2012,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
882,Australia,2012,6,A10-Drugs used in diabetes,Million US$ at exchange rate,537.4
883,Australia,2012,6,C03-Diuretics,"Million US$, purchasing power parity",19.5
884,Australia,2012,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",337.0
885,Australia,2012,6,C03-Diuretics,"/capita, US$ purchasing power parity",0.9
886,Australia,2012,6,C03-Diuretics,"/capita, US$ exchange rate",1.4
887,Australia,2012,6,N02-Analgesics,"Million US$, purchasing power parity",281.1
888,Australia,2012,6,N02-Analgesics,"/capita, US$ exchange rate",19.7
889,Australia,2012,6,N02-Analgesics,Million of national currency units,433.0
890,Australia,2012,6,N02-Analgesics,Million US$ at exchange rate,448.3
891,Australia,2012,6,C02-Antihypertensives,Million US$ at exchange rate,80.8
892,Australia,2012,6,C02-Antihypertensives,"Million US$, purchasing power parity",50.6
893,Australia,2012,6,N02-Analgesics,"/capita, US$ purchasing power parity",12.4
894,Australia,2012,6,N02-Analgesics,% of total sales,4.2
895,Australia,2011,6,M-Musculo-skeletal system,Million of national currency units,309.0
896,Australia,2011,6,B-Blood and blood forming organs,Million of national currency units,417.0
897,Australia,2011,6,M-Musculo-skeletal system,Million US$ at exchange rate,318.7
898,Australia,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,430.1
899,Australia,2011,6,R03-Drugs for obstructive airway diseases,Million of national currency units,562.0
900,Australia,2011,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,579.7
901,Australia,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",276.0
902,Australia,2011,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",204.5
903,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",375.2
904,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,584.9
905,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",26.2
906,Australia,2011,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.3
907,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,567.0
908,Australia,2011,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.2
909,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9
910,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.0
911,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",28.1
912,Australia,2011,6,B-Blood and blood forming organs,% of total sales,4.1
913,Australia,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.3
914,Australia,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.4
915,Australia,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",16.6
916,Australia,2011,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",371.9
917,Australia,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",25.9
918,Australia,2011,6,R03-Drugs for obstructive airway diseases,% of total sales,5.5
919,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,628.2
920,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",403.0
921,Australia,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,609.0
922,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",16.8
923,Australia,2011,6,R-Respiratory system,"/capita, US$ exchange rate",26.4
924,Australia,2011,6,R-Respiratory system,Million US$ at exchange rate,590.0
925,Australia,2011,6,R-Respiratory system,"Million US$, purchasing power parity",378.5
926,Australia,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",16.9
927,Australia,2011,6,C08-Calcium channel blockers,Million of national currency units,142.0
928,Australia,2011,6,R-Respiratory system,% of total sales,5.6
929,Australia,2011,6,C08-Calcium channel blockers,Million US$ at exchange rate,146.5
930,Australia,2011,6,C07-Beta blocking agents,"Million US$, purchasing power parity",93.3
931,Australia,2011,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.5
932,Australia,2011,6,C07-Beta blocking agents,Million US$ at exchange rate,145.4
933,Australia,2011,6,R-Respiratory system,Million of national currency units,572.0
934,Australia,2011,6,C07-Beta blocking agents,% of total sales,1.4
935,Australia,2011,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.2
936,Australia,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.2
937,Australia,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",36.1
938,Australia,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",806.1
939,Australia,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.5
940,Australia,2011,6,A-Alimentary tract and metabolism,% of total sales,11.9
941,Australia,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1256.4
942,Australia,2011,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.6
943,Australia,2011,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.2
944,Australia,2011,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",94.0
945,Australia,2011,6,M-Musculo-skeletal system,% of total sales,3.0
946,Australia,2011,6,A-Alimentary tract and metabolism,Million of national currency units,1218.0
947,Australia,2011,6,C08-Calcium channel blockers,% of total sales,1.4
948,Australia,2011,6,Products not elsewhere classified,Million of national currency units,2515.0
949,Australia,2011,6,A02A-Antacids,% of total sales,0.0
950,Australia,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",4.2
951,Australia,2011,6,G-Genito urinary system and sex hormones,% of total sales,1.4
952,Australia,2011,6,A02A-Antacids,"Million US$, purchasing power parity",1.3
953,Australia,2011,6,A02A-Antacids,"/capita, US$ exchange rate",0.1
954,Australia,2011,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
955,Australia,2011,6,J-Antiinfectives for systemic use,Million of national currency units,386.0
956,Australia,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,143.0
957,Australia,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,398.2
958,Australia,2011,6,C-Cardiovascular system,Million of national currency units,2825.0
959,Australia,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",6.6
960,Australia,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",94.6
961,Australia,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,147.5
962,Australia,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.6
963,Australia,2011,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.2
964,Australia,2011,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,103.1
965,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,86.0
966,Australia,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.0
967,Australia,2011,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.0
968,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8
969,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.5
970,Australia,2011,6,A02A-Antacids,Million US$ at exchange rate,2.1
971,Australia,2011,6,A02A-Antacids,Million of national currency units,2.0
972,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",56.9
973,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,88.7
974,Australia,2011,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,100.0
975,Australia,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.0
976,Australia,2011,6,C-Cardiovascular system,Million US$ at exchange rate,2914.0
977,Australia,2011,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",52.0
978,Australia,2011,6,C10-Lipid modifying agents,% of total sales,17.1
979,Australia,2011,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",1162.1
980,Australia,2011,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",81.1
981,Australia,2011,6,J01-Antibacterials for systemic use,% of total sales,1.9
982,Australia,2011,6,Products not elsewhere classified,% of total sales,24.5
983,Australia,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",1664.4
984,Australia,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",116.1
985,Australia,2011,6,Products not elsewhere classified,Million US$ at exchange rate,2594.2
986,Australia,2011,6,C10-Lipid modifying agents,Million US$ at exchange rate,1811.3
987,Australia,2011,6,C10-Lipid modifying agents,Million of national currency units,1756.0
988,Australia,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",74.5
989,Australia,2011,6,C-Cardiovascular system,% of total sales,27.5
990,Australia,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",17.8
991,Australia,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",255.5
992,Australia,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",1869.6
993,Australia,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",83.7
994,Australia,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",130.4
995,Australia,2011,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",131.0
996,Australia,2011,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",5.9
997,Australia,2011,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.1
998,Australia,2011,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,204.2
999,Australia,2011,6,C07-Beta blocking agents,Million of national currency units,141.0
1000,Australia,2011,6,J-Antiinfectives for systemic use,% of total sales,3.8
1001,Australia,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",11.4
1002,Australia,2011,6,J01-Antibacterials for systemic use,Million of national currency units,198.0
1003,Australia,2011,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
1004,Australia,2011,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
1005,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.5
1006,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.3
1007,Australia,2011,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.6
1008,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
1009,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5
1010,Australia,2011,6,C01A-Cardiac glycosides,% of total sales,0.0
1011,Australia,2011,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.9
1012,Australia,2011,6,C03-Diuretics,Million US$ at exchange rate,30.9
1013,Australia,2011,6,C03-Diuretics,Million of national currency units,30.0
1014,Australia,2011,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1
1015,Australia,2011,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.7
1016,Australia,2011,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.3
1017,Australia,2011,6,C01A-Cardiac glycosides,Million US$ at exchange rate,4.1
1018,Australia,2011,6,C02-Antihypertensives,% of total sales,0.7
1019,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0
1020,Australia,2011,6,C01A-Cardiac glycosides,Million of national currency units,4.0
1021,Australia,2011,6,N-Nervous system,"Million US$, purchasing power parity",1184.6
1022,Australia,2011,6,N-Nervous system,Million US$ at exchange rate,1846.4
1023,Australia,2011,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.6
1024,Australia,2011,6,N05C-Hypnotics and sedatives,Million of national currency units,18.0
1025,Australia,2011,6,N05B-Anxiolytics,% of total sales,0.3
1026,Australia,2011,6,A10-Drugs used in diabetes,% of total sales,4.6
1027,Australia,2011,6,N-Nervous system,Million of national currency units,1790.0
1028,Australia,2011,6,N05B-Anxiolytics,Million of national currency units,28.0
1029,Australia,2011,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",11.9
1030,Australia,2011,6,N-Nervous system,% of total sales,17.4
1031,Australia,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",53.0
1032,Australia,2011,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
1033,Australia,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.5
1034,Australia,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
1035,Australia,2011,6,N-Nervous system,"/capita, US$ exchange rate",82.6
1036,Australia,2011,6,N05C-Hypnotics and sedatives,% of total sales,0.2
1037,Australia,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",304.0
1038,Australia,2011,6,N02-Analgesics,Million of national currency units,408.0
1039,Australia,2011,6,N06A-Antidepressants,Million US$ at exchange rate,503.4
1040,Australia,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",6790.6
1041,Australia,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",473.8
1042,Australia,2011,6,N06A-Antidepressants,Million of national currency units,488.0
1043,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.3
1044,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",61.5
1045,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,93.0
1046,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,95.9
1047,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",2.8
1048,Australia,2011,6,Total pharmaceutical sales,Million of national currency units,10261.0
1049,Australia,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,10584.2
1050,Australia,2011,6,N05B-Anxiolytics,"Million US$, purchasing power parity",18.5
1051,Australia,2011,6,A10-Drugs used in diabetes,Million of national currency units,470.0
1052,Australia,2011,6,N05B-Anxiolytics,Million US$ at exchange rate,28.9
1053,Australia,2011,6,N06A-Antidepressants,"/capita, US$ exchange rate",22.5
1054,Australia,2011,6,N06A-Antidepressants,"Million US$, purchasing power parity",323.0
1055,Australia,2011,6,N06A-Antidepressants,% of total sales,4.8
1056,Australia,2011,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.5
1057,Australia,2011,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.8
1058,Australia,2011,6,C03-Diuretics,% of total sales,0.3
1059,Australia,2011,6,C02-Antihypertensives,Million of national currency units,72.0
1060,Australia,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9
1061,Australia,2011,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
1062,Australia,2011,6,C03-Diuretics,"Million US$, purchasing power parity",19.9
1063,Australia,2011,6,A10-Drugs used in diabetes,Million US$ at exchange rate,484.8
1064,Australia,2011,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",311.0
1065,Australia,2011,6,C03-Diuretics,"/capita, US$ purchasing power parity",0.9
1066,Australia,2011,6,C03-Diuretics,"/capita, US$ exchange rate",1.4
1067,Australia,2011,6,N02-Analgesics,"Million US$, purchasing power parity",270.0
1068,Australia,2011,6,N02-Analgesics,"/capita, US$ exchange rate",18.8
1069,Australia,2011,6,N02-Analgesics,Million US$ at exchange rate,420.9
1070,Australia,2011,6,C02-Antihypertensives,"Million US$, purchasing power parity",47.6
1071,Australia,2011,6,C02-Antihypertensives,Million US$ at exchange rate,74.3
1072,Australia,2011,6,N02-Analgesics,"/capita, US$ purchasing power parity",12.1
1073,Australia,2011,6,N02-Analgesics,% of total sales,4.0
1074,Australia,2010,5,Total pharmaceutical sales,Million of national currency units,9795.0
1075,Australia,2010,5,M-Musculo-skeletal system,Million of national currency units,324.0
1076,Australia,2010,5,B-Blood and blood forming organs,Million of national currency units,406.0
1077,Australia,2010,5,B-Blood and blood forming organs,Million US$ at exchange rate,372.4
1078,Australia,2010,5,M-Musculo-skeletal system,Million US$ at exchange rate,297.2
1079,Australia,2010,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,497.2
1080,Australia,2010,5,R03-Drugs for obstructive airway diseases,Million of national currency units,542.0
1081,Australia,2010,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",270.0
1082,Australia,2010,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",215.5
1083,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",417.7
1084,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,576.1
1085,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",26.1
1086,Australia,2010,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.5
1087,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,628.0
1088,Australia,2010,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.8
1089,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0
1090,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",24.6
1091,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.9
1092,Australia,2010,5,B-Blood and blood forming organs,% of total sales,4.1
1093,Australia,2010,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",16.9
1094,Australia,2010,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.3
1095,Australia,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",16.4
1096,Australia,2010,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",360.5
1097,Australia,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.6
1098,Australia,2010,5,R03-Drugs for obstructive airway diseases,% of total sales,5.5
1099,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,543.0
1100,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",393.7
1101,Australia,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,592.0
1102,Australia,2010,5,R-Respiratory system,"/capita, US$ exchange rate",22.9
1103,Australia,2010,5,R-Respiratory system,Million US$ at exchange rate,505.4
1104,Australia,2010,5,R-Respiratory system,"Million US$, purchasing power parity",366.4
1105,Australia,2010,5,R-Respiratory system,"/capita, US$ purchasing power parity",16.6
1106,Australia,2010,5,C08-Calcium channel blockers,Million of national currency units,159.0
1107,Australia,2010,5,C08-Calcium channel blockers,Million US$ at exchange rate,145.9
1108,Australia,2010,5,R-Respiratory system,% of total sales,5.6
1109,Australia,2010,5,C07-Beta blocking agents,"Million US$, purchasing power parity",94.4
1110,Australia,2010,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.9
1111,Australia,2010,5,C07-Beta blocking agents,Million US$ at exchange rate,130.3
1112,Australia,2010,5,R-Respiratory system,Million of national currency units,551.0
1113,Australia,2010,5,C07-Beta blocking agents,% of total sales,1.4
1114,Australia,2010,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.3
1115,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.0
1116,Australia,2010,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.1
1117,Australia,2010,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",37.0
1118,Australia,2010,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",816.0
1119,Australia,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,6.4
1120,Australia,2010,5,A-Alimentary tract and metabolism,% of total sales,12.5
1121,Australia,2010,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.6
1122,Australia,2010,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8
1123,Australia,2010,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",105.7
1124,Australia,2010,5,M-Musculo-skeletal system,% of total sales,3.3
1125,Australia,2010,5,A-Alimentary tract and metabolism,Million of national currency units,1227.0
1126,Australia,2010,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,1125.5
1127,Australia,2010,5,C08-Calcium channel blockers,% of total sales,1.6
1128,Australia,2010,5,Products not elsewhere classified,Million of national currency units,2266.0
1129,Australia,2010,5,A02A-Antacids,% of total sales,0.0
1130,Australia,2010,5,G-Genito urinary system and sex hormones,% of total sales,1.4
1131,Australia,2010,5,A02A-Antacids,"Million US$, purchasing power parity",1.3
1132,Australia,2010,5,A02A-Antacids,"/capita, US$ exchange rate",0.1
1133,Australia,2010,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
1134,Australia,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",4.2
1135,Australia,2010,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,324.7
1136,Australia,2010,5,J-Antiinfectives for systemic use,Million of national currency units,354.0
1137,Australia,2010,5,G-Genito urinary system and sex hormones,Million of national currency units,138.0
1138,Australia,2010,5,C-Cardiovascular system,Million of national currency units,2744.0
1139,Australia,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",5.7
1140,Australia,2010,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,126.6
1141,Australia,2010,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",91.8
1142,Australia,2010,5,C-Cardiovascular system,Million US$ at exchange rate,2517.1
1143,Australia,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.2
1144,Australia,2010,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,91.7
1145,Australia,2010,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.5
1146,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,79.0
1147,Australia,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.0
1148,Australia,2010,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.0
1149,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8
1150,Australia,2010,5,A02A-Antacids,Million US$ at exchange rate,1.8
1151,Australia,2010,5,A02A-Antacids,Million of national currency units,2.0
1152,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.4
1153,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",52.5
1154,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,72.5
1155,Australia,2010,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,100.0
1156,Australia,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3
1157,Australia,2010,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",50.7
1158,Australia,2010,5,C10-Lipid modifying agents,% of total sales,17.2
1159,Australia,2010,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",69.9
1160,Australia,2010,5,J01-Antibacterials for systemic use,% of total sales,2.0
1161,Australia,2010,5,Products not elsewhere classified,% of total sales,23.1
1162,Australia,2010,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",1117.3
1163,Australia,2010,5,Products not elsewhere classified,"Million US$, purchasing power parity",1507.0
1164,Australia,2010,5,Products not elsewhere classified,"/capita, US$ exchange rate",94.3
1165,Australia,2010,5,Products not elsewhere classified,Million US$ at exchange rate,2078.6
1166,Australia,2010,5,C10-Lipid modifying agents,Million US$ at exchange rate,1541.1
1167,Australia,2010,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",68.4
1168,Australia,2010,5,C10-Lipid modifying agents,Million of national currency units,1680.0
1169,Australia,2010,5,C-Cardiovascular system,% of total sales,28.0
1170,Australia,2010,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",235.4
1171,Australia,2010,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.7
1172,Australia,2010,5,C-Cardiovascular system,"Million US$, purchasing power parity",1824.9
1173,Australia,2010,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",82.8
1174,Australia,2010,5,C-Cardiovascular system,"/capita, US$ exchange rate",114.2
1175,Australia,2010,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",129.0
1176,Australia,2010,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",5.9
1177,Australia,2010,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.1
1178,Australia,2010,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,178.0
1179,Australia,2010,5,J-Antiinfectives for systemic use,% of total sales,3.6
1180,Australia,2010,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.7
1181,Australia,2010,5,J01-Antibacterials for systemic use,Million of national currency units,194.0
1182,Australia,2010,5,C07-Beta blocking agents,Million of national currency units,142.0
1183,Australia,2010,5,C01A-Cardiac glycosides,Million of national currency units,4.0
1184,Australia,2010,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
1185,Australia,2010,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
1186,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.3
1187,Australia,2010,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.7
1188,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,15.6
1189,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
1190,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5
1191,Australia,2010,5,C01A-Cardiac glycosides,% of total sales,0.0
1192,Australia,2010,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",12.8
1193,Australia,2010,5,C03-Diuretics,Million US$ at exchange rate,28.4
1194,Australia,2010,5,C03-Diuretics,Million of national currency units,31.0
1195,Australia,2010,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.9
1196,Australia,2010,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.7
1197,Australia,2010,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
1198,Australia,2010,5,C01A-Cardiac glycosides,Million US$ at exchange rate,3.7
1199,Australia,2010,5,C02-Antihypertensives,% of total sales,0.7
1200,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0
1201,Australia,2010,5,A10-Drugs used in diabetes,Million of national currency units,424.0
1202,Australia,2010,5,N-Nervous system,"Million US$, purchasing power parity",1135.3
1203,Australia,2010,5,N-Nervous system,Million US$ at exchange rate,1565.8
1204,Australia,2010,5,N05C-Hypnotics and sedatives,Million of national currency units,19.0
1205,Australia,2010,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,17.4
1206,Australia,2010,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",12.6
1207,Australia,2010,5,A10-Drugs used in diabetes,% of total sales,4.3
1208,Australia,2010,5,N05B-Anxiolytics,% of total sales,0.3
1209,Australia,2010,5,N-Nervous system,Million of national currency units,1707.0
1210,Australia,2010,5,N05B-Anxiolytics,Million of national currency units,29.0
1211,Australia,2010,5,N05B-Anxiolytics,Million US$ at exchange rate,26.6
1212,Australia,2010,5,N-Nervous system,% of total sales,17.4
1213,Australia,2010,5,N-Nervous system,"/capita, US$ purchasing power parity",51.5
1214,Australia,2010,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
1215,Australia,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.6
1216,Australia,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
1217,Australia,2010,5,N-Nervous system,"/capita, US$ exchange rate",71.1
1218,Australia,2010,5,N05C-Hypnotics and sedatives,% of total sales,0.2
1219,Australia,2010,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",295.7
1220,Australia,2010,5,N02-Analgesics,Million of national currency units,378.0
1221,Australia,2010,5,N06A-Antidepressants,Million US$ at exchange rate,429.3
1222,Australia,2010,5,Total pharmaceutical sales,"Million US$, purchasing power parity",6514.3
1223,Australia,2010,5,Total pharmaceutical sales,"/capita, US$ exchange rate",407.8
1224,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.2
1225,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",3.1
1226,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",67.8
1227,Australia,2010,5,N06A-Antidepressants,Million of national currency units,468.0
1228,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,102.0
1229,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,93.6
1230,Australia,2010,5,Total pharmaceutical sales,Million US$ at exchange rate,8984.9
1231,Australia,2010,5,N05B-Anxiolytics,"Million US$, purchasing power parity",19.3
1232,Australia,2010,5,N06A-Antidepressants,"/capita, US$ exchange rate",19.5
1233,Australia,2010,5,N06A-Antidepressants,"Million US$, purchasing power parity",311.2
1234,Australia,2010,5,N06A-Antidepressants,% of total sales,4.8
1235,Australia,2010,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.1
1236,Australia,2010,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.9
1237,Australia,2010,5,C03-Diuretics,% of total sales,0.3
1238,Australia,2010,5,C02-Antihypertensives,Million of national currency units,64.0
1239,Australia,2010,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
1240,Australia,2010,5,A10-Drugs used in diabetes,Million US$ at exchange rate,388.9
1241,Australia,2010,5,C03-Diuretics,"Million US$, purchasing power parity",20.6
1242,Australia,2010,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",282.0
1243,Australia,2010,5,C03-Diuretics,"/capita, US$ purchasing power parity",0.9
1244,Australia,2010,5,C03-Diuretics,"/capita, US$ exchange rate",1.3
1245,Australia,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0
1246,Australia,2010,5,N02-Analgesics,"Million US$, purchasing power parity",251.4
1247,Australia,2010,5,N02-Analgesics,"/capita, US$ exchange rate",15.7
1248,Australia,2010,5,N02-Analgesics,Million US$ at exchange rate,346.7
1249,Australia,2010,5,C02-Antihypertensives,"Million US$, purchasing power parity",42.6
1250,Australia,2010,5,C02-Antihypertensives,Million US$ at exchange rate,58.7
1251,Australia,2010,5,N02-Analgesics,"/capita, US$ purchasing power parity",11.4
1252,Australia,2010,5,N02-Analgesics,% of total sales,3.9
1253,Australia,2017,6,B-Blood and blood forming organs,Million of national currency units,748.0
1254,Australia,2017,6,M-Musculo-skeletal system,Million of national currency units,429.0
1255,Australia,2017,6,M-Musculo-skeletal system,Million US$ at exchange rate,328.8
1256,Australia,2017,6,R03-Drugs for obstructive airway diseases,Million of national currency units,650.0
1257,Australia,2017,6,B-Blood and blood forming organs,Million US$ at exchange rate,573.3
1258,Australia,2017,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",506.2
1259,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,346.4
1260,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.1
1261,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",305.9
1262,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,452.0
1263,Australia,2017,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.4
1264,Australia,2017,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",290.3
1265,Australia,2017,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.8
1266,Australia,2017,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,498.2
1267,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.5
1268,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.0
1269,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",404.7
1270,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",18.6
1271,Australia,2017,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.6
1272,Australia,2017,6,B-Blood and blood forming organs,% of total sales,5.1
1273,Australia,2017,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",23.3
1274,Australia,2017,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.3
1275,Australia,2017,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.9
1276,Australia,2017,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",439.9
1277,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,458.3
1278,Australia,2017,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,598.0
1279,Australia,2017,6,R03-Drugs for obstructive airway diseases,% of total sales,4.4
1280,Australia,2017,6,R-Respiratory system,"Million US$, purchasing power parity",493.4
1281,Australia,2017,6,R-Respiratory system,"/capita, US$ exchange rate",22.7
1282,Australia,2017,6,R-Respiratory system,Million US$ at exchange rate,558.7
1283,Australia,2017,6,C08-Calcium channel blockers,Million of national currency units,130.0
1284,Australia,2017,6,R-Respiratory system,"/capita, US$ purchasing power parity",20.1
1285,Australia,2017,6,R-Respiratory system,% of total sales,4.9
1286,Australia,2017,6,R-Respiratory system,Million of national currency units,729.0
1287,Australia,2017,6,C07-Beta blocking agents,"Million US$, purchasing power parity",103.5
1288,Australia,2017,6,C07-Beta blocking agents,Million of national currency units,153.0
1289,Australia,2017,6,C07-Beta blocking agents,Million US$ at exchange rate,117.3
1290,Australia,2017,6,C07-Beta blocking agents,% of total sales,1.0
1291,Australia,2017,6,C07-Beta blocking agents,"/capita, US$ exchange rate",4.8
1292,Australia,2017,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.2
1293,Australia,2017,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",44.4
1294,Australia,2017,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,1091.4
1295,Australia,2017,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",963.8
1296,Australia,2017,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.2
1297,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.4
1298,Australia,2017,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.1
1299,Australia,2017,6,A-Alimentary tract and metabolism,% of total sales,9.6
1300,Australia,2017,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1
1301,Australia,2017,6,C08-Calcium channel blockers,Million US$ at exchange rate,99.6
1302,Australia,2017,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",88.0
1303,Australia,2017,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.6
1304,Australia,2017,6,A-Alimentary tract and metabolism,Million of national currency units,1424.0
1305,Australia,2017,6,C08-Calcium channel blockers,% of total sales,0.9
1306,Australia,2017,6,M-Musculo-skeletal system,% of total sales,2.9
1307,Australia,2017,6,A02A-Antacids,% of total sales,0.0
1308,Australia,2017,6,G-Genito urinary system and sex hormones,% of total sales,2.5
1309,Australia,2017,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.0
1310,Australia,2017,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
1311,Australia,2017,6,A02A-Antacids,"Million US$, purchasing power parity",0.0
1312,Australia,2017,6,A02A-Antacids,Million US$ at exchange rate,0.0
1313,Australia,2017,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
1314,Australia,2017,6,J-Antiinfectives for systemic use,Million of national currency units,2540.0
1315,Australia,2017,6,C-Cardiovascular system,Million of national currency units,1798.0
1316,Australia,2017,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,1946.7
1317,Australia,2017,6,G-Genito urinary system and sex hormones,Million of national currency units,362.0
1318,Australia,2017,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",245.0
1319,Australia,2017,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3
1320,Australia,2017,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,277.4
1321,Australia,2017,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",183.4
1322,Australia,2017,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.4
1323,Australia,2017,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,271.0
1324,Australia,2017,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,207.7
1325,Australia,2017,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
1326,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,237.0
1327,Australia,2017,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.5
1328,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.5
1329,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6
1330,Australia,2017,6,A02A-Antacids,Million of national currency units,0.0
1331,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,181.6
1332,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.4
1333,Australia,2017,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",160.4
1334,Australia,2017,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",18.5
1335,Australia,2017,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.0
1336,Australia,2017,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",456.2
1337,Australia,2017,6,J01-Antibacterials for systemic use,% of total sales,2.7
1338,Australia,2017,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.9
1339,Australia,2017,6,C10-Lipid modifying agents,% of total sales,4.6
1340,Australia,2017,6,Products not elsewhere classified,% of total sales,31.0
1341,Australia,2017,6,Products not elsewhere classified,"Million US$, purchasing power parity",3104.5
1342,Australia,2017,6,Products not elsewhere classified,Million US$ at exchange rate,3515.6
1343,Australia,2017,6,Products not elsewhere classified,Million of national currency units,4587.0
1344,Australia,2017,6,C10-Lipid modifying agents,Million of national currency units,674.0
1345,Australia,2017,6,C10-Lipid modifying agents,Million US$ at exchange rate,516.6
1346,Australia,2017,6,Products not elsewhere classified,"/capita, US$ exchange rate",142.9
1347,Australia,2017,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",126.2
1348,Australia,2017,6,C-Cardiovascular system,% of total sales,12.2
1349,Australia,2017,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1719.1
1350,Australia,2017,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",49.5
1351,Australia,2017,6,C-Cardiovascular system,"Million US$, purchasing power parity",1216.9
1352,Australia,2017,6,C-Cardiovascular system,Million US$ at exchange rate,1378.0
1353,Australia,2017,6,C-Cardiovascular system,"/capita, US$ exchange rate",56.0
1354,Australia,2017,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",79.2
1355,Australia,2017,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,302.7
1356,Australia,2017,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",267.3
1357,Australia,2017,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.3
1358,Australia,2017,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",69.9
1359,Australia,2017,6,J01-Antibacterials for systemic use,Million of national currency units,395.0
1360,Australia,2017,6,J-Antiinfectives for systemic use,% of total sales,17.2
1361,Australia,2017,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",3.4
1362,Australia,2017,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
1363,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,15.3
1364,Australia,2017,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.8
1365,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
1366,Australia,2017,6,C01A-Cardiac glycosides,% of total sales,0.0
1367,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",13.5
1368,Australia,2017,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
1369,Australia,2017,6,C03-Diuretics,Million of national currency units,48.0
1370,Australia,2017,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",485.9
1371,Australia,2017,6,C02-Antihypertensives,"/capita, US$ exchange rate",3.3
1372,Australia,2017,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.9
1373,Australia,2017,6,C01A-Cardiac glycosides,Million of national currency units,5.0
1374,Australia,2017,6,C01A-Cardiac glycosides,Million US$ at exchange rate,3.8
1375,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,20.0
1376,Australia,2017,6,C02-Antihypertensives,% of total sales,0.7
1377,Australia,2017,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.4
1378,Australia,2017,6,N-Nervous system,Million US$ at exchange rate,1471.5
1379,Australia,2017,6,N-Nervous system,Million of national currency units,1920.0
1380,Australia,2017,6,N-Nervous system,"Million US$, purchasing power parity",1299.4
1381,Australia,2017,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,21.5
1382,Australia,2017,6,N05C-Hypnotics and sedatives,Million of national currency units,28.0
1383,Australia,2017,6,N05B-Anxiolytics,% of total sales,0.3
1384,Australia,2017,6,A10-Drugs used in diabetes,% of total sales,4.9
1385,Australia,2017,6,N05B-Anxiolytics,Million of national currency units,48.0
1386,Australia,2017,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.3
1387,Australia,2017,6,N-Nervous system,"/capita, US$ purchasing power parity",52.8
1388,Australia,2017,6,N-Nervous system,"/capita, US$ exchange rate",59.8
1389,Australia,2017,6,N-Nervous system,% of total sales,13.0
1390,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
1391,Australia,2017,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9
1392,Australia,2017,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",19.0
1393,Australia,2017,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
1394,Australia,2017,6,N05C-Hypnotics and sedatives,% of total sales,0.2
1395,Australia,2017,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.8
1396,Australia,2017,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",406.6
1397,Australia,2017,6,N06A-Antidepressants,Million of national currency units,433.0
1398,Australia,2017,6,Total pharmaceutical sales,"/capita, US$ exchange rate",460.4
1399,Australia,2017,6,Total pharmaceutical sales,"Million US$, purchasing power parity",9999.0
1400,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",70.4
1401,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.2
1402,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,104.0
1403,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,79.7
1404,Australia,2017,6,N06A-Antidepressants,Million US$ at exchange rate,331.9
1405,Australia,2017,6,Total pharmaceutical sales,Million of national currency units,14774.0
1406,Australia,2017,6,Total pharmaceutical sales,Million US$ at exchange rate,11323.2
1407,Australia,2017,6,A10-Drugs used in diabetes,Million of national currency units,718.0
1408,Australia,2017,6,N05B-Anxiolytics,Million US$ at exchange rate,36.8
1409,Australia,2017,6,N06A-Antidepressants,"Million US$, purchasing power parity",293.1
1410,Australia,2017,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.5
1411,Australia,2017,6,N06A-Antidepressants,% of total sales,2.9
1412,Australia,2017,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.9
1413,Australia,2017,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
1414,Australia,2017,6,C03-Diuretics,% of total sales,0.3
1415,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.7
1416,Australia,2017,6,N05B-Anxiolytics,"Million US$, purchasing power parity",32.5
1417,Australia,2017,6,C03-Diuretics,"/capita, US$ purchasing power parity",1.3
1418,Australia,2017,6,C03-Diuretics,Million US$ at exchange rate,36.8
1419,Australia,2017,6,A10-Drugs used in diabetes,Million US$ at exchange rate,550.3
1420,Australia,2017,6,C03-Diuretics,"/capita, US$ exchange rate",1.5
1421,Australia,2017,6,C03-Diuretics,"Million US$, purchasing power parity",32.5
1422,Australia,2017,6,N02-Analgesics,"Million US$, purchasing power parity",346.5
1423,Australia,2017,6,N02-Analgesics,"/capita, US$ exchange rate",16.0
1424,Australia,2017,6,N02-Analgesics,Million US$ at exchange rate,392.4
1425,Australia,2017,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",2.9
1426,Australia,2017,6,N02-Analgesics,Million of national currency units,512.0
1427,Australia,2017,6,C02-Antihypertensives,Million US$ at exchange rate,82.0
1428,Australia,2017,6,C02-Antihypertensives,Million of national currency units,107.0
1429,Australia,2017,6,C02-Antihypertensives,"Million US$, purchasing power parity",72.4
1430,Australia,2017,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.1
1431,Australia,2017,6,N02-Analgesics,% of total sales,3.5
1432,Austria,2016,5,N-Nervous system,% of total sales,14.8
1433,Austria,2016,5,N-Nervous system,"Million US$, purchasing power parity",571.1
1434,Austria,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",65.4
1435,Austria,2016,5,N-Nervous system,"/capita, US$ exchange rate",56.2
1436,Austria,2016,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,69.3
1437,Austria,2016,5,J01-Antibacterials for systemic use,Million of national currency units,62.6
1438,Austria,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,288.4
1439,Austria,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",335.4
1440,Austria,2016,5,J-Antiinfectives for systemic use,Million of national currency units,260.6
1441,Austria,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.4
1442,Austria,2016,5,J-Antiinfectives for systemic use,% of total sales,8.7
1443,Austria,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",33.0
1444,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
1445,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.1
1446,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.0
1447,Austria,2016,5,N02-Analgesics,"/capita, US$ exchange rate",8.3
1448,Austria,2016,5,N02-Analgesics,Million US$ at exchange rate,72.7
1449,Austria,2016,5,N02-Analgesics,"Million US$, purchasing power parity",84.5
1450,Austria,2016,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.4
1451,Austria,2016,5,N02-Analgesics,Million of national currency units,65.7
1452,Austria,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0
1453,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,60.9
1454,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",70.8
1455,Austria,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,55.0
1456,Austria,2016,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.1
1457,Austria,2016,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.0
1458,Austria,2016,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
1459,Austria,2016,5,A02A-Antacids,% of total sales,0.0
1460,Austria,2016,5,A10-Drugs used in diabetes,Million of national currency units,149.7
1461,Austria,2016,5,A10-Drugs used in diabetes,Million US$ at exchange rate,165.8
1462,Austria,2016,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",192.7
1463,Austria,2016,5,N02-Analgesics,% of total sales,2.2
1464,Austria,2016,5,A10-Drugs used in diabetes,% of total sales,5.0
1465,Austria,2016,5,A02A-Antacids,Million of national currency units,0.6
1466,Austria,2016,5,N02-Analgesics,"/capita, US$ purchasing power parity",9.7
1467,Austria,2016,5,A02A-Antacids,"/capita, US$ exchange rate",0.1
1468,Austria,2016,5,A02A-Antacids,"Million US$, purchasing power parity",0.8
1469,Austria,2016,5,A02A-Antacids,Million US$ at exchange rate,0.6
1470,Austria,2016,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",80.6
1471,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",66.6
1472,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",53.5
1473,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.3
1474,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.6
1475,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,46.0
1476,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,41.6
1477,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7
1478,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.6
1479,Austria,2016,5,R-Respiratory system,% of total sales,5.7
1480,Austria,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",25.4
1481,Austria,2016,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.5
1482,Austria,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
1483,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,51.7
1484,Austria,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,57.3
1485,Austria,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
1486,Austria,2016,5,N05C-Hypnotics and sedatives,% of total sales,0.1
1487,Austria,2016,5,N06A-Antidepressants,% of total sales,2.8
1488,Austria,2016,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.6
1489,Austria,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1
1490,Austria,2016,5,M-Musculo-skeletal system,% of total sales,3.4
1491,Austria,2016,5,N06A-Antidepressants,"Million US$, purchasing power parity",110.0
1492,Austria,2016,5,N06A-Antidepressants,Million US$ at exchange rate,94.6
1493,Austria,2016,5,N06A-Antidepressants,Million of national currency units,85.5
1494,Austria,2016,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.8
1495,Austria,2016,5,R-Respiratory system,Million of national currency units,172.2
1496,Austria,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",132.3
1497,Austria,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.0
1498,Austria,2016,5,M-Musculo-skeletal system,Million of national currency units,102.8
1499,Austria,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,113.7
1500,Austria,2016,5,R-Respiratory system,Million US$ at exchange rate,190.6
1501,Austria,2016,5,R-Respiratory system,"Million US$, purchasing power parity",221.6
1502,Austria,2016,5,R-Respiratory system,"/capita, US$ exchange rate",21.8
1503,Austria,2016,5,N-Nervous system,Million of national currency units,443.7
1504,Austria,2016,5,B-Blood and blood forming organs,% of total sales,9.3
1505,Austria,2016,5,Products not elsewhere classified,Million of national currency units,920.3
1506,Austria,2016,5,N-Nervous system,Million US$ at exchange rate,491.2
1507,Austria,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",360.9
1508,Austria,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,310.3
1509,Austria,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.3
1510,Austria,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.5
1511,Austria,2016,5,J01-Antibacterials for systemic use,% of total sales,2.1
1512,Austria,2016,5,Products not elsewhere classified,% of total sales,30.6
1513,Austria,2016,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2
1514,Austria,2016,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.9
1515,Austria,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",1184.5
1516,Austria,2016,5,Products not elsewhere classified,Million US$ at exchange rate,1018.7
1517,Austria,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",135.6
1518,Austria,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",116.6
1519,Austria,2016,5,R03-Drugs for obstructive airway diseases,Million of national currency units,146.7
1520,Austria,2016,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0
1521,Austria,2016,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,162.3
1522,Austria,2016,5,N05B-Anxiolytics,"/capita, US$ exchange rate",0.8
1523,Austria,2016,5,N05C-Hypnotics and sedatives,Million of national currency units,2.7
1524,Austria,2016,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.0
1525,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.1
1526,Austria,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.4
1527,Austria,2016,5,N05B-Anxiolytics,% of total sales,0.2
1528,Austria,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.6
1529,Austria,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.6
1530,Austria,2016,5,B-Blood and blood forming organs,Million of national currency units,280.4
1531,Austria,2016,5,R03-Drugs for obstructive airway diseases,% of total sales,4.9
1532,Austria,2016,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",188.8
1533,Austria,2016,5,N05B-Anxiolytics,Million US$ at exchange rate,7.2
1534,Austria,2016,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.4
1535,Austria,2016,5,N05B-Anxiolytics,Million of national currency units,6.5
1536,Austria,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7
1537,Austria,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,328.7
1538,Austria,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",382.2
1539,Austria,2016,5,A-Alimentary tract and metabolism,Million of national currency units,296.9
1540,Austria,2016,5,A-Alimentary tract and metabolism,% of total sales,9.9
1541,Austria,2016,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.6
1542,Austria,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",37.6
1543,Austria,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.7
1544,Austria,2016,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.4
1545,Austria,2016,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.4
1546,Austria,2016,5,C07-Beta blocking agents,% of total sales,1.5
1547,Austria,2016,5,C07-Beta blocking agents,"Million US$, purchasing power parity",56.1
1548,Austria,2016,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.5
1549,Austria,2016,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",14.0
1550,Austria,2016,5,C08-Calcium channel blockers,Million US$ at exchange rate,12.0
1551,Austria,2016,5,C08-Calcium channel blockers,Million of national currency units,10.9
1552,Austria,2016,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.9
1553,Austria,2016,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",15.1
1554,Austria,2016,5,C10-Lipid modifying agents,Million US$ at exchange rate,113.1
1555,Austria,2016,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",131.5
1556,Austria,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.0
1557,Austria,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",54.2
1558,Austria,2016,5,C10-Lipid modifying agents,% of total sales,3.4
1559,Austria,2016,5,C-Cardiovascular system,% of total sales,14.2
1560,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,176.2
1561,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",204.9
1562,Austria,2016,5,C08-Calcium channel blockers,% of total sales,0.4
1563,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,159.2
1564,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.3
1565,Austria,2016,5,C10-Lipid modifying agents,Million of national currency units,102.2
1566,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.2
1567,Austria,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.5
1568,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
1569,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
1570,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
1571,Austria,2016,5,C02-Antihypertensives,Million of national currency units,48.7
1572,Austria,2016,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.2
1573,Austria,2016,5,C02-Antihypertensives,"Million US$, purchasing power parity",62.7
1574,Austria,2016,5,C02-Antihypertensives,Million US$ at exchange rate,53.9
1575,Austria,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3869.5
1576,Austria,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",380.9
1577,Austria,2016,5,Total pharmaceutical sales,Million of national currency units,3006.4
1578,Austria,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,3327.8
1579,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.5
1580,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.8
1581,Austria,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",442.9
1582,Austria,2016,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.8
1583,Austria,2016,5,C03-Diuretics,"Million US$, purchasing power parity",21.7
1584,Austria,2016,5,C03-Diuretics,"/capita, US$ exchange rate",2.1
1585,Austria,2016,5,C03-Diuretics,Million of national currency units,16.9
1586,Austria,2016,5,C03-Diuretics,Million US$ at exchange rate,18.7
1587,Austria,2016,5,C07-Beta blocking agents,Million of national currency units,43.6
1588,Austria,2016,5,C07-Beta blocking agents,Million US$ at exchange rate,48.3
1589,Austria,2016,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.5
1590,Austria,2016,5,C03-Diuretics,% of total sales,0.6
1591,Austria,2016,5,C01A-Cardiac glycosides,% of total sales,0.0
1592,Austria,2016,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
1593,Austria,2016,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",7.2
1594,Austria,2016,5,C02-Antihypertensives,% of total sales,1.6
1595,Austria,2016,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5
1596,Austria,2016,5,C01A-Cardiac glycosides,Million of national currency units,0.5
1597,Austria,2016,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
1598,Austria,2016,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
1599,Austria,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,46.6
1600,Austria,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,51.6
1601,Austria,2016,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.4
1602,Austria,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.9
1603,Austria,2016,5,G-Genito urinary system and sex hormones,% of total sales,1.5
1604,Austria,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",60.0
1605,Austria,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",5.9
1606,Austria,2016,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",17.3
1607,Austria,2016,5,C-Cardiovascular system,Million of national currency units,427.9
1608,Austria,2016,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,14.9
1609,Austria,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",550.8
1610,Austria,2016,5,C-Cardiovascular system,Million US$ at exchange rate,473.7
1611,Austria,2015,5,N-Nervous system,% of total sales,15.9
1612,Austria,2015,5,N-Nervous system,"Million US$, purchasing power parity",582.2
1613,Austria,2015,5,N-Nervous system,"/capita, US$ exchange rate",59.7
1614,Austria,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",67.4
1615,Austria,2015,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,72.3
1616,Austria,2015,5,J01-Antibacterials for systemic use,Million of national currency units,65.2
1617,Austria,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,326.8
1618,Austria,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",368.8
1619,Austria,2015,5,J-Antiinfectives for systemic use,Million of national currency units,294.6
1620,Austria,2015,5,J-Antiinfectives for systemic use,% of total sales,10.1
1621,Austria,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",42.7
1622,Austria,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.8
1623,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
1624,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.8
1625,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6
1626,Austria,2015,5,N02-Analgesics,Million US$ at exchange rate,70.2
1627,Austria,2015,5,N02-Analgesics,"/capita, US$ exchange rate",8.1
1628,Austria,2015,5,N02-Analgesics,"Million US$, purchasing power parity",79.2
1629,Austria,2015,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.4
1630,Austria,2015,5,N02-Analgesics,Million of national currency units,63.3
1631,Austria,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9
1632,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,58.3
1633,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",65.8
1634,Austria,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,52.6
1635,Austria,2015,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.4
1636,Austria,2015,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.2
1637,Austria,2015,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
1638,Austria,2015,5,A02A-Antacids,% of total sales,0.0
1639,Austria,2015,5,A10-Drugs used in diabetes,Million US$ at exchange rate,148.7
1640,Austria,2015,5,A10-Drugs used in diabetes,Million of national currency units,134.0
1641,Austria,2015,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",167.8
1642,Austria,2015,5,N02-Analgesics,% of total sales,2.2
1643,Austria,2015,5,A10-Drugs used in diabetes,% of total sales,4.6
1644,Austria,2015,5,A02A-Antacids,Million of national currency units,0.2
1645,Austria,2015,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",81.6
1646,Austria,2015,5,N02-Analgesics,"/capita, US$ purchasing power parity",9.2
1647,Austria,2015,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
1648,Austria,2015,5,A02A-Antacids,Million US$ at exchange rate,0.2
1649,Austria,2015,5,A02A-Antacids,"Million US$, purchasing power parity",0.3
1650,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",95.7
1651,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",52.4
1652,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.4
1653,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.8
1654,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,46.4
1655,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,41.8
1656,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
1657,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.1
1658,Austria,2015,5,R-Respiratory system,% of total sales,5.8
1659,Austria,2015,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2
1660,Austria,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
1661,Austria,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",24.4
1662,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,76.5
1663,Austria,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,84.8
1664,Austria,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
1665,Austria,2015,5,N05C-Hypnotics and sedatives,% of total sales,0.1
1666,Austria,2015,5,N06A-Antidepressants,% of total sales,3.3
1667,Austria,2015,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.8
1668,Austria,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.5
1669,Austria,2015,5,M-Musculo-skeletal system,% of total sales,3.4
1670,Austria,2015,5,N06A-Antidepressants,Million of national currency units,95.3
1671,Austria,2015,5,N06A-Antidepressants,"Million US$, purchasing power parity",119.3
1672,Austria,2015,5,N06A-Antidepressants,Million US$ at exchange rate,105.7
1673,Austria,2015,5,N06A-Antidepressants,"/capita, US$ exchange rate",12.2
1674,Austria,2015,5,R-Respiratory system,Million of national currency units,168.4
1675,Austria,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",125.4
1676,Austria,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.9
1677,Austria,2015,5,M-Musculo-skeletal system,Million of national currency units,100.2
1678,Austria,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,111.1
1679,Austria,2015,5,R-Respiratory system,Million US$ at exchange rate,186.9
1680,Austria,2015,5,R-Respiratory system,"Million US$, purchasing power parity",210.9
1681,Austria,2015,5,R-Respiratory system,"/capita, US$ exchange rate",21.6
1682,Austria,2015,5,N-Nervous system,Million of national currency units,465.1
1683,Austria,2015,5,B-Blood and blood forming organs,% of total sales,8.4
1684,Austria,2015,5,Products not elsewhere classified,Million of national currency units,832.2
1685,Austria,2015,5,N-Nervous system,Million US$ at exchange rate,516.0
1686,Austria,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",308.3
1687,Austria,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,273.2
1688,Austria,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.7
1689,Austria,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",31.6
1690,Austria,2015,5,J01-Antibacterials for systemic use,% of total sales,2.2
1691,Austria,2015,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.4
1692,Austria,2015,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.4
1693,Austria,2015,5,Products not elsewhere classified,% of total sales,28.4
1694,Austria,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",1041.8
1695,Austria,2015,5,Products not elsewhere classified,Million US$ at exchange rate,923.3
1696,Austria,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",120.5
1697,Austria,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",106.8
1698,Austria,2015,5,R03-Drugs for obstructive airway diseases,Million of national currency units,146.9
1699,Austria,2015,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0
1700,Austria,2015,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,162.9
1701,Austria,2015,5,N05B-Anxiolytics,% of total sales,0.2
1702,Austria,2015,5,N05C-Hypnotics and sedatives,Million of national currency units,2.6
1703,Austria,2015,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.9
1704,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.1
1705,Austria,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.4
1706,Austria,2015,5,N05B-Anxiolytics,"/capita, US$ exchange rate",0.9
1707,Austria,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.3
1708,Austria,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.9
1709,Austria,2015,5,B-Blood and blood forming organs,Million of national currency units,246.3
1710,Austria,2015,5,R03-Drugs for obstructive airway diseases,% of total sales,5.0
1711,Austria,2015,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.5
1712,Austria,2015,5,N05B-Anxiolytics,Million US$ at exchange rate,7.6
1713,Austria,2015,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",183.8
1714,Austria,2015,5,N05B-Anxiolytics,Million of national currency units,6.8
1715,Austria,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,329.7
1716,Austria,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",372.0
1717,Austria,2015,5,A-Alimentary tract and metabolism,Million of national currency units,297.1
1718,Austria,2015,5,A-Alimentary tract and metabolism,% of total sales,10.1
1719,Austria,2015,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.0
1720,Austria,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",38.1
1721,Austria,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7
1722,Austria,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.0
1723,Austria,2015,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6
1724,Austria,2015,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.4
1725,Austria,2015,5,C07-Beta blocking agents,% of total sales,1.5
1726,Austria,2015,5,C07-Beta blocking agents,"Million US$, purchasing power parity",55.7
1727,Austria,2015,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.7
1728,Austria,2015,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",25.8
1729,Austria,2015,5,C08-Calcium channel blockers,Million of national currency units,20.6
1730,Austria,2015,5,C08-Calcium channel blockers,Million US$ at exchange rate,22.9
1731,Austria,2015,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.2
1732,Austria,2015,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.8
1733,Austria,2015,5,C10-Lipid modifying agents,Million US$ at exchange rate,105.3
1734,Austria,2015,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",118.8
1735,Austria,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",61.8
1736,Austria,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",54.8
1737,Austria,2015,5,C10-Lipid modifying agents,% of total sales,3.2
1738,Austria,2015,5,C-Cardiovascular system,% of total sales,14.6
1739,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,174.8
1740,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",197.2
1741,Austria,2015,5,C08-Calcium channel blockers,% of total sales,0.7
1742,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,157.5
1743,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4
1744,Austria,2015,5,C10-Lipid modifying agents,Million of national currency units,94.9
1745,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.2
1746,Austria,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.8
1747,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
1748,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
1749,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
1750,Austria,2015,5,C02-Antihypertensives,Million of national currency units,45.7
1751,Austria,2015,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.9
1752,Austria,2015,5,C02-Antihypertensives,"Million US$, purchasing power parity",57.2
1753,Austria,2015,5,C02-Antihypertensives,Million US$ at exchange rate,50.7
1754,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.8
1755,Austria,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3666.5
1756,Austria,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",376.0
1757,Austria,2015,5,Total pharmaceutical sales,Million of national currency units,2928.9
1758,Austria,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,3249.6
1759,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.8
1760,Austria,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",424.2
1761,Austria,2015,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.0
1762,Austria,2015,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.6
1763,Austria,2015,5,C03-Diuretics,"Million US$, purchasing power parity",20.6
1764,Austria,2015,5,C03-Diuretics,"/capita, US$ exchange rate",2.1
1765,Austria,2015,5,C03-Diuretics,Million of national currency units,16.5
1766,Austria,2015,5,C03-Diuretics,Million US$ at exchange rate,18.3
1767,Austria,2015,5,C07-Beta blocking agents,Million of national currency units,44.5
1768,Austria,2015,5,C07-Beta blocking agents,Million US$ at exchange rate,49.4
1769,Austria,2015,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.4
1770,Austria,2015,5,C03-Diuretics,% of total sales,0.6
1771,Austria,2015,5,C01A-Cardiac glycosides,% of total sales,0.0
1772,Austria,2015,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
1773,Austria,2015,5,C02-Antihypertensives,% of total sales,1.6
1774,Austria,2015,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6
1775,Austria,2015,5,C01A-Cardiac glycosides,Million of national currency units,0.5
1776,Austria,2015,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
1777,Austria,2015,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7
1778,Austria,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,45.5
1779,Austria,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,50.5
1780,Austria,2015,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.0
1781,Austria,2015,5,C-Cardiovascular system,Million of national currency units,426.9
1782,Austria,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.6
1783,Austria,2015,5,G-Genito urinary system and sex hormones,% of total sales,1.6
1784,Austria,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",57.0
1785,Austria,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",5.8
1786,Austria,2015,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",16.3
1787,Austria,2015,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,14.4
1788,Austria,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",534.4
1789,Austria,2015,5,C-Cardiovascular system,Million US$ at exchange rate,473.6
1790,Austria,2014,5,N-Nervous system,% of total sales,17.1
1791,Austria,2014,5,N-Nervous system,"/capita, US$ exchange rate",74.2
1792,Austria,2014,5,N-Nervous system,"Million US$, purchasing power parity",597.9
1793,Austria,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",70.0
1794,Austria,2014,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,87.8
1795,Austria,2014,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",82.7
1796,Austria,2014,5,J01-Antibacterials for systemic use,Million of national currency units,66.1
1797,Austria,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",302.3
1798,Austria,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,320.8
1799,Austria,2014,5,J-Antiinfectives for systemic use,Million of national currency units,241.5
1800,Austria,2014,5,J-Antiinfectives for systemic use,% of total sales,8.7
1801,Austria,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.4
1802,Austria,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.5
1803,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
1804,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.9
1805,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.5
1806,Austria,2014,5,N02-Analgesics,"/capita, US$ exchange rate",9.6
1807,Austria,2014,5,N02-Analgesics,"/capita, US$ purchasing power parity",9.0
1808,Austria,2014,5,N02-Analgesics,Million US$ at exchange rate,81.9
1809,Austria,2014,5,N02-Analgesics,"Million US$, purchasing power parity",77.1
1810,Austria,2014,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.5
1811,Austria,2014,5,N02-Analgesics,Million of national currency units,61.6
1812,Austria,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9
1813,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",64.0
1814,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,67.9
1815,Austria,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,51.1
1816,Austria,2014,5,A02A-Antacids,Million of national currency units,0.1
1817,Austria,2014,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.1
1818,Austria,2014,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
1819,Austria,2014,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.2
1820,Austria,2014,5,A02A-Antacids,% of total sales,0.0
1821,Austria,2014,5,A10-Drugs used in diabetes,Million US$ at exchange rate,164.5
1822,Austria,2014,5,A10-Drugs used in diabetes,Million of national currency units,123.8
1823,Austria,2014,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",155.0
1824,Austria,2014,5,A10-Drugs used in diabetes,% of total sales,4.4
1825,Austria,2014,5,N02-Analgesics,% of total sales,2.2
1826,Austria,2014,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
1827,Austria,2014,5,A02A-Antacids,"Million US$, purchasing power parity",0.2
1828,Austria,2014,5,A02A-Antacids,Million US$ at exchange rate,0.2
1829,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",53.3
1830,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.4
1831,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",99.7
1832,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.6
1833,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,56.5
1834,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,42.6
1835,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.7
1836,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.9
1837,Austria,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
1838,Austria,2014,5,R-Respiratory system,% of total sales,5.9
1839,Austria,2014,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.5
1840,Austria,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4
1841,Austria,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",24.0
1842,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,79.6
1843,Austria,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,105.8
1844,Austria,2014,5,N05C-Hypnotics and sedatives,% of total sales,0.1
1845,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.2
1846,Austria,2014,5,N06A-Antidepressants,% of total sales,3.9
1847,Austria,2014,5,M-Musculo-skeletal system,% of total sales,3.6
1848,Austria,2014,5,N06A-Antidepressants,Million of national currency units,109.5
1849,Austria,2014,5,N06A-Antidepressants,"Million US$, purchasing power parity",137.1
1850,Austria,2014,5,N06A-Antidepressants,Million US$ at exchange rate,145.5
1851,Austria,2014,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.0
1852,Austria,2014,5,N06A-Antidepressants,"/capita, US$ exchange rate",17.0
1853,Austria,2014,5,R-Respiratory system,Million of national currency units,163.8
1854,Austria,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",125.9
1855,Austria,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.6
1856,Austria,2014,5,M-Musculo-skeletal system,Million of national currency units,100.5
1857,Austria,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,133.6
1858,Austria,2014,5,R-Respiratory system,"Million US$, purchasing power parity",205.0
1859,Austria,2014,5,R-Respiratory system,Million US$ at exchange rate,217.5
1860,Austria,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.7
1861,Austria,2014,5,R-Respiratory system,"/capita, US$ exchange rate",25.5
1862,Austria,2014,5,N-Nervous system,Million of national currency units,477.6
1863,Austria,2014,5,B-Blood and blood forming organs,% of total sales,7.9
1864,Austria,2014,5,Products not elsewhere classified,Million of national currency units,767.7
1865,Austria,2014,5,N-Nervous system,Million US$ at exchange rate,634.5
1866,Austria,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",275.5
1867,Austria,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,292.4
1868,Austria,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.2
1869,Austria,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",34.2
1870,Austria,2014,5,Products not elsewhere classified,Million US$ at exchange rate,1020.0
1871,Austria,2014,5,J01-Antibacterials for systemic use,% of total sales,2.4
1872,Austria,2014,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.3
1873,Austria,2014,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.7
1874,Austria,2014,5,Products not elsewhere classified,% of total sales,27.5
1875,Austria,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",961.1
1876,Austria,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",119.3
1877,Austria,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",112.5
1878,Austria,2014,5,R03-Drugs for obstructive airway diseases,Million of national currency units,141.9
1879,Austria,2014,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0
1880,Austria,2014,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,188.5
1881,Austria,2014,5,N05B-Anxiolytics,% of total sales,0.3
1882,Austria,2014,5,N05C-Hypnotics and sedatives,Million of national currency units,2.8
1883,Austria,2014,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.7
1884,Austria,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.5
1885,Austria,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.8
1886,Austria,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.1
1887,Austria,2014,5,B-Blood and blood forming organs,Million of national currency units,220.1
1888,Austria,2014,5,R03-Drugs for obstructive airway diseases,% of total sales,5.1
1889,Austria,2014,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
1890,Austria,2014,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.8
1891,Austria,2014,5,N05B-Anxiolytics,Million US$ at exchange rate,9.4
1892,Austria,2014,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",177.7
1893,Austria,2014,5,N05B-Anxiolytics,Million of national currency units,7.1
1894,Austria,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.0
1895,Austria,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,381.4
1896,Austria,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",359.4
1897,Austria,2014,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.0
1898,Austria,2014,5,A-Alimentary tract and metabolism,Million of national currency units,287.1
1899,Austria,2014,5,A-Alimentary tract and metabolism,% of total sales,10.3
1900,Austria,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",44.6
1901,Austria,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.0
1902,Austria,2014,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8
1903,Austria,2014,5,C07-Beta blocking agents,% of total sales,1.7
1904,Austria,2014,5,C07-Beta blocking agents,"Million US$, purchasing power parity",57.8
1905,Austria,2014,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.2
1906,Austria,2014,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",34.5
1907,Austria,2014,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3
1908,Austria,2014,5,C08-Calcium channel blockers,Million of national currency units,27.6
1909,Austria,2014,5,C08-Calcium channel blockers,Million US$ at exchange rate,36.7
1910,Austria,2014,5,C08-Calcium channel blockers,% of total sales,1.0
1911,Austria,2014,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.3
1912,Austria,2014,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.5
1913,Austria,2014,5,C10-Lipid modifying agents,Million US$ at exchange rate,122.0
1914,Austria,2014,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",115.0
1915,Austria,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.4
1916,Austria,2014,5,C10-Lipid modifying agents,% of total sales,3.3
1917,Austria,2014,5,C-Cardiovascular system,% of total sales,15.5
1918,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,213.4
1919,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",201.1
1920,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,160.7
1921,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.8
1922,Austria,2014,5,C10-Lipid modifying agents,Million of national currency units,91.8
1923,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.0
1924,Austria,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.5
1925,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
1926,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
1927,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
1928,Austria,2014,5,C02-Antihypertensives,Million of national currency units,42.7
1929,Austria,2014,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.6
1930,Austria,2014,5,C02-Antihypertensives,"Million US$, purchasing power parity",53.4
1931,Austria,2014,5,C02-Antihypertensives,Million US$ at exchange rate,56.7
1932,Austria,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3489.5
1933,Austria,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",433.3
1934,Austria,2014,5,Total pharmaceutical sales,Million of national currency units,2787.4
1935,Austria,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,3703.1
1936,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.6
1937,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.0
1938,Austria,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",408.3
1939,Austria,2014,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.2
1940,Austria,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",67.3
1941,Austria,2014,5,C03-Diuretics,"Million US$, purchasing power parity",20.6
1942,Austria,2014,5,C03-Diuretics,"/capita, US$ exchange rate",2.6
1943,Austria,2014,5,C03-Diuretics,Million of national currency units,16.5
1944,Austria,2014,5,C03-Diuretics,Million US$ at exchange rate,21.9
1945,Austria,2014,5,C07-Beta blocking agents,Million of national currency units,46.2
1946,Austria,2014,5,C07-Beta blocking agents,Million US$ at exchange rate,61.3
1947,Austria,2014,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.4
1948,Austria,2014,5,C03-Diuretics,% of total sales,0.6
1949,Austria,2014,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.3
1950,Austria,2014,5,C01A-Cardiac glycosides,% of total sales,0.0
1951,Austria,2014,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
1952,Austria,2014,5,C02-Antihypertensives,% of total sales,1.5
1953,Austria,2014,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
1954,Austria,2014,5,C01A-Cardiac glycosides,Million of national currency units,0.6
1955,Austria,2014,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
1956,Austria,2014,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7
1957,Austria,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,60.2
1958,Austria,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,45.3
1959,Austria,2014,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.1
1960,Austria,2014,5,C-Cardiovascular system,Million of national currency units,432.8
1961,Austria,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.6
1962,Austria,2014,5,G-Genito urinary system and sex hormones,% of total sales,1.6
1963,Austria,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",56.7
1964,Austria,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.0
1965,Austria,2014,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",16.4
1966,Austria,2014,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,17.4
1967,Austria,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",541.8
1968,Austria,2014,5,C-Cardiovascular system,Million US$ at exchange rate,574.9
1969,Austria,2013,5,N-Nervous system,% of total sales,18.0
1970,Austria,2013,5,N-Nervous system,"/capita, US$ exchange rate",74.2
1971,Austria,2013,5,N-Nervous system,"Million US$, purchasing power parity",594.4
1972,Austria,2013,5,N-Nervous system,"/capita, US$ purchasing power parity",70.1
1973,Austria,2013,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,92.6
1974,Austria,2013,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",87.5
1975,Austria,2013,5,J01-Antibacterials for systemic use,Million of national currency units,69.7
1976,Austria,2013,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",229.4
1977,Austria,2013,5,J-Antiinfectives for systemic use,Million of national currency units,182.9
1978,Austria,2013,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,242.9
1979,Austria,2013,5,J-Antiinfectives for systemic use,% of total sales,6.9
1980,Austria,2013,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.1
1981,Austria,2013,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.6
1982,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
1983,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.9
1984,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.4
1985,Austria,2013,5,N02-Analgesics,Million US$ at exchange rate,78.1
1986,Austria,2013,5,N02-Analgesics,"/capita, US$ exchange rate",9.2
1987,Austria,2013,5,N02-Analgesics,"/capita, US$ purchasing power parity",8.7
1988,Austria,2013,5,N02-Analgesics,"Million US$, purchasing power parity",73.8
1989,Austria,2013,5,N02-Analgesics,Million of national currency units,58.8
1990,Austria,2013,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.5
1991,Austria,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.1
1992,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.0
1993,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,50.2
1994,Austria,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,66.6
1995,Austria,2013,5,A02A-Antacids,Million of national currency units,0.1
1996,Austria,2013,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.0
1997,Austria,2013,5,A02A-Antacids,% of total sales,0.0
1998,Austria,2013,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.0
1999,Austria,2013,5,A10-Drugs used in diabetes,Million US$ at exchange rate,152.9
2000,Austria,2013,5,A10-Drugs used in diabetes,Million of national currency units,115.2
2001,Austria,2013,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
2002,Austria,2013,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",144.5
2003,Austria,2013,5,A10-Drugs used in diabetes,% of total sales,4.4
2004,Austria,2013,5,N02-Analgesics,% of total sales,2.2
2005,Austria,2013,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
2006,Austria,2013,5,A02A-Antacids,Million US$ at exchange rate,0.2
2007,Austria,2013,5,A02A-Antacids,"Million US$, purchasing power parity",0.2
2008,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",54.5
2009,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.0
2010,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",104.2
2011,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.8
2012,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,57.6
2013,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,43.4
2014,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.3
2015,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.2
2016,Austria,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
2017,Austria,2013,5,R-Respiratory system,% of total sales,6.2
2018,Austria,2013,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2
2019,Austria,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4
2020,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,83.0
2021,Austria,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,110.3
2022,Austria,2013,5,N05C-Hypnotics and sedatives,% of total sales,0.1
2023,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.4
2024,Austria,2013,5,R-Respiratory system,"/capita, US$ purchasing power parity",24.4
2025,Austria,2013,5,N06A-Antidepressants,% of total sales,4.1
2026,Austria,2013,5,R-Respiratory system,Million of national currency units,164.6
2027,Austria,2013,5,M-Musculo-skeletal system,% of total sales,3.8
2028,Austria,2013,5,N06A-Antidepressants,Million of national currency units,107.2
2029,Austria,2013,5,N06A-Antidepressants,"Million US$, purchasing power parity",134.5
2030,Austria,2013,5,N06A-Antidepressants,Million US$ at exchange rate,142.4
2031,Austria,2013,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.9
2032,Austria,2013,5,N06A-Antidepressants,"/capita, US$ exchange rate",16.8
2033,Austria,2013,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",127.0
2034,Austria,2013,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.9
2035,Austria,2013,5,M-Musculo-skeletal system,Million of national currency units,101.2
2036,Austria,2013,5,M-Musculo-skeletal system,Million US$ at exchange rate,134.4
2037,Austria,2013,5,R-Respiratory system,"Million US$, purchasing power parity",206.5
2038,Austria,2013,5,R-Respiratory system,Million US$ at exchange rate,218.6
2039,Austria,2013,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.0
2040,Austria,2013,5,R-Respiratory system,"/capita, US$ exchange rate",25.8
2041,Austria,2013,5,N-Nervous system,Million of national currency units,473.8
2042,Austria,2013,5,B-Blood and blood forming organs,% of total sales,7.3
2043,Austria,2013,5,Products not elsewhere classified,Million of national currency units,712.5
2044,Austria,2013,5,N-Nervous system,Million US$ at exchange rate,629.3
2045,Austria,2013,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",240.2
2046,Austria,2013,5,B-Blood and blood forming organs,Million US$ at exchange rate,254.2
2047,Austria,2013,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.3
2048,Austria,2013,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.0
2049,Austria,2013,5,Products not elsewhere classified,Million US$ at exchange rate,946.3
2050,Austria,2013,5,J01-Antibacterials for systemic use,% of total sales,2.6
2051,Austria,2013,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.9
2052,Austria,2013,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.3
2053,Austria,2013,5,Products not elsewhere classified,"Million US$, purchasing power parity",893.9
2054,Austria,2013,5,Products not elsewhere classified,"/capita, US$ exchange rate",111.6
2055,Austria,2013,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",105.4
2056,Austria,2013,5,Products not elsewhere classified,% of total sales,27.0
2057,Austria,2013,5,R03-Drugs for obstructive airway diseases,Million of national currency units,143.5
2058,Austria,2013,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0
2059,Austria,2013,5,N05B-Anxiolytics,% of total sales,0.3
2060,Austria,2013,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,190.6
2061,Austria,2013,5,N05C-Hypnotics and sedatives,Million of national currency units,2.6
2062,Austria,2013,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.4
2063,Austria,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6
2064,Austria,2013,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
2065,Austria,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.2
2066,Austria,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.5
2067,Austria,2013,5,B-Blood and blood forming organs,Million of national currency units,191.4
2068,Austria,2013,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4
2069,Austria,2013,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.5
2070,Austria,2013,5,N05B-Anxiolytics,Million US$ at exchange rate,9.0
2071,Austria,2013,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",180.1
2072,Austria,2013,5,N05B-Anxiolytics,Million of national currency units,6.8
2073,Austria,2013,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,365.9
2074,Austria,2013,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",345.6
2075,Austria,2013,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.2
2076,Austria,2013,5,A-Alimentary tract and metabolism,Million of national currency units,275.5
2077,Austria,2013,5,A-Alimentary tract and metabolism,% of total sales,10.5
2078,Austria,2013,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",43.1
2079,Austria,2013,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.8
2080,Austria,2013,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.9
2081,Austria,2013,5,C07-Beta blocking agents,% of total sales,1.8
2082,Austria,2013,5,C07-Beta blocking agents,"Million US$, purchasing power parity",58.4
2083,Austria,2013,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.3
2084,Austria,2013,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",35.7
2085,Austria,2013,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5
2086,Austria,2013,5,C08-Calcium channel blockers,Million of national currency units,28.4
2087,Austria,2013,5,C08-Calcium channel blockers,Million US$ at exchange rate,37.8
2088,Austria,2013,5,C08-Calcium channel blockers,% of total sales,1.1
2089,Austria,2013,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.1
2090,Austria,2013,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.3
2091,Austria,2013,5,C10-Lipid modifying agents,Million US$ at exchange rate,119.6
2092,Austria,2013,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",113.0
2093,Austria,2013,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",64.8
2094,Austria,2013,5,C-Cardiovascular system,% of total sales,16.6
2095,Austria,2013,5,C10-Lipid modifying agents,% of total sales,3.4
2096,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",209.6
2097,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,221.9
2098,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,167.1
2099,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3
2100,Austria,2013,5,C10-Lipid modifying agents,Million of national currency units,90.0
2101,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.2
2102,Austria,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.7
2103,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
2104,Austria,2013,5,C02-Antihypertensives,Million of national currency units,42.1
2105,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
2106,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
2107,Austria,2013,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.6
2108,Austria,2013,5,C02-Antihypertensives,"Million US$, purchasing power parity",52.8
2109,Austria,2013,5,C02-Antihypertensives,Million US$ at exchange rate,55.9
2110,Austria,2013,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3306.0
2111,Austria,2013,5,Total pharmaceutical sales,"/capita, US$ exchange rate",412.7
2112,Austria,2013,5,Total pharmaceutical sales,Million of national currency units,2635.2
2113,Austria,2013,5,Total pharmaceutical sales,Million US$ at exchange rate,3499.8
2114,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.7
2115,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.1
2116,Austria,2013,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",389.9
2117,Austria,2013,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.3
2118,Austria,2013,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.2
2119,Austria,2013,5,C03-Diuretics,"Million US$, purchasing power parity",19.3
2120,Austria,2013,5,C03-Diuretics,"/capita, US$ exchange rate",2.4
2121,Austria,2013,5,C03-Diuretics,Million of national currency units,15.4
2122,Austria,2013,5,C03-Diuretics,Million US$ at exchange rate,20.5
2123,Austria,2013,5,C07-Beta blocking agents,Million of national currency units,46.5
2124,Austria,2013,5,C07-Beta blocking agents,Million US$ at exchange rate,61.8
2125,Austria,2013,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.3
2126,Austria,2013,5,C03-Diuretics,% of total sales,0.6
2127,Austria,2013,5,C01A-Cardiac glycosides,% of total sales,0.0
2128,Austria,2013,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
2129,Austria,2013,5,C02-Antihypertensives,% of total sales,1.6
2130,Austria,2013,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.7
2131,Austria,2013,5,C01A-Cardiac glycosides,Million of national currency units,0.6
2132,Austria,2013,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
2133,Austria,2013,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7
2134,Austria,2013,5,C-Cardiovascular system,"/capita, US$ exchange rate",68.6
2135,Austria,2013,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,60.2
2136,Austria,2013,5,G-Genito urinary system and sex hormones,Million of national currency units,45.4
2137,Austria,2013,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,14.0
2138,Austria,2013,5,C-Cardiovascular system,Million of national currency units,437.7
2139,Austria,2013,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",56.9
2140,Austria,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.7
2141,Austria,2013,5,G-Genito urinary system and sex hormones,% of total sales,1.7
2142,Austria,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.1
2143,Austria,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.2
2144,Austria,2013,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",17.5
2145,Austria,2013,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,18.6
2146,Austria,2013,5,C-Cardiovascular system,"Million US$, purchasing power parity",549.1
2147,Austria,2013,5,C-Cardiovascular system,Million US$ at exchange rate,581.3
2148,Austria,2012,5,N-Nervous system,% of total sales,18.6
2149,Austria,2012,5,N-Nervous system,"/capita, US$ exchange rate",74.2
2150,Austria,2012,5,N-Nervous system,"Million US$, purchasing power parity",598.7
2151,Austria,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",71.0
2152,Austria,2012,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,87.6
2153,Austria,2012,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",83.8
2154,Austria,2012,5,J01-Antibacterials for systemic use,Million of national currency units,68.2
2155,Austria,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",218.4
2156,Austria,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,228.4
2157,Austria,2012,5,J-Antiinfectives for systemic use,Million of national currency units,177.7
2158,Austria,2012,5,J-Antiinfectives for systemic use,% of total sales,6.8
2159,Austria,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",27.1
2160,Austria,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",25.9
2161,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
2162,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.3
2163,Austria,2012,5,N02-Analgesics,Million US$ at exchange rate,77.4
2164,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.0
2165,Austria,2012,5,N02-Analgesics,"/capita, US$ exchange rate",9.2
2166,Austria,2012,5,N02-Analgesics,"/capita, US$ purchasing power parity",8.8
2167,Austria,2012,5,N02-Analgesics,"Million US$, purchasing power parity",74.1
2168,Austria,2012,5,N02-Analgesics,Million of national currency units,60.3
2169,Austria,2012,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.5
2170,Austria,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0
2171,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",59.1
2172,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,61.8
2173,Austria,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,48.1
2174,Austria,2012,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.1
2175,Austria,2012,5,A02A-Antacids,% of total sales,0.0
2176,Austria,2012,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8
2177,Austria,2012,5,A10-Drugs used in diabetes,Million US$ at exchange rate,142.0
2178,Austria,2012,5,A10-Drugs used in diabetes,Million of national currency units,110.5
2179,Austria,2012,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",135.8
2180,Austria,2012,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
2181,Austria,2012,5,A10-Drugs used in diabetes,% of total sales,4.2
2182,Austria,2012,5,N02-Analgesics,% of total sales,2.3
2183,Austria,2012,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
2184,Austria,2012,5,A02A-Antacids,Million US$ at exchange rate,0.2
2185,Austria,2012,5,A02A-Antacids,"Million US$, purchasing power parity",0.2
2186,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",53.3
2187,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.5
2188,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.6
2189,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,55.7
2190,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.9
2191,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.4
2192,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",108.5
2193,Austria,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
2194,Austria,2012,5,R-Respiratory system,% of total sales,6.2
2195,Austria,2012,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2
2196,Austria,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4
2197,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,43.4
2198,Austria,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",23.5
2199,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,88.3
2200,Austria,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,113.4
2201,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.3
2202,Austria,2012,5,N05C-Hypnotics and sedatives,% of total sales,0.1
2203,Austria,2012,5,N06A-Antidepressants,% of total sales,3.9
2204,Austria,2012,5,N06A-Antidepressants,Million of national currency units,103.2
2205,Austria,2012,5,R-Respiratory system,Million of national currency units,161.4
2206,Austria,2012,5,M-Musculo-skeletal system,% of total sales,4.1
2207,Austria,2012,5,N06A-Antidepressants,"Million US$, purchasing power parity",126.8
2208,Austria,2012,5,N06A-Antidepressants,Million US$ at exchange rate,132.6
2209,Austria,2012,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.0
2210,Austria,2012,5,N06A-Antidepressants,"/capita, US$ exchange rate",15.7
2211,Austria,2012,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",132.4
2212,Austria,2012,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",16.4
2213,Austria,2012,5,M-Musculo-skeletal system,Million of national currency units,107.7
2214,Austria,2012,5,M-Musculo-skeletal system,Million US$ at exchange rate,138.4
2215,Austria,2012,5,R-Respiratory system,"Million US$, purchasing power parity",198.4
2216,Austria,2012,5,R-Respiratory system,Million US$ at exchange rate,207.4
2217,Austria,2012,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.7
2218,Austria,2012,5,R-Respiratory system,"/capita, US$ exchange rate",24.6
2219,Austria,2012,5,N-Nervous system,Million of national currency units,487.1
2220,Austria,2012,5,B-Blood and blood forming organs,% of total sales,6.3
2221,Austria,2012,5,N-Nervous system,Million US$ at exchange rate,625.9
2222,Austria,2012,5,Products not elsewhere classified,Million of national currency units,664.5
2223,Austria,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",202.5
2224,Austria,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,211.7
2225,Austria,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.0
2226,Austria,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.1
2227,Austria,2012,5,Products not elsewhere classified,Million US$ at exchange rate,853.7
2228,Austria,2012,5,J01-Antibacterials for systemic use,% of total sales,2.6
2229,Austria,2012,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.4
2230,Austria,2012,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.9
2231,Austria,2012,5,Products not elsewhere classified,% of total sales,25.4
2232,Austria,2012,5,Products not elsewhere classified,"Million US$, purchasing power parity",816.7
2233,Austria,2012,5,Products not elsewhere classified,"/capita, US$ exchange rate",101.3
2234,Austria,2012,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",96.9
2235,Austria,2012,5,R03-Drugs for obstructive airway diseases,Million of national currency units,139.9
2236,Austria,2012,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.9
2237,Austria,2012,5,N05B-Anxiolytics,% of total sales,0.2
2238,Austria,2012,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,179.7
2239,Austria,2012,5,N05C-Hypnotics and sedatives,Million of national currency units,2.6
2240,Austria,2012,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3
2241,Austria,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
2242,Austria,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.4
2243,Austria,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.3
2244,Austria,2012,5,B-Blood and blood forming organs,Million of national currency units,164.8
2245,Austria,2012,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4
2246,Austria,2012,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.0
2247,Austria,2012,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0
2248,Austria,2012,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",171.9
2249,Austria,2012,5,N05B-Anxiolytics,Million of national currency units,6.5
2250,Austria,2012,5,N05B-Anxiolytics,Million US$ at exchange rate,8.3
2251,Austria,2012,5,A02A-Antacids,Million of national currency units,0.1
2252,Austria,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",335.6
2253,Austria,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,350.8
2254,Austria,2012,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.3
2255,Austria,2012,5,A-Alimentary tract and metabolism,Million of national currency units,273.0
2256,Austria,2012,5,A-Alimentary tract and metabolism,% of total sales,10.4
2257,Austria,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",41.6
2258,Austria,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.8
2259,Austria,2012,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.5
2260,Austria,2012,5,C07-Beta blocking agents,% of total sales,2.0
2261,Austria,2012,5,C07-Beta blocking agents,"Million US$, purchasing power parity",63.0
2262,Austria,2012,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.8
2263,Austria,2012,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",36.2
2264,Austria,2012,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5
2265,Austria,2012,5,C08-Calcium channel blockers,Million of national currency units,29.5
2266,Austria,2012,5,C08-Calcium channel blockers,Million US$ at exchange rate,37.8
2267,Austria,2012,5,C08-Calcium channel blockers,% of total sales,1.1
2268,Austria,2012,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.6
2269,Austria,2012,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.9
2270,Austria,2012,5,C10-Lipid modifying agents,Million US$ at exchange rate,131.1
2271,Austria,2012,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",125.4
2272,Austria,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.4
2273,Austria,2012,5,C-Cardiovascular system,% of total sales,18.5
2274,Austria,2012,5,C10-Lipid modifying agents,% of total sales,3.9
2275,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",239.2
2276,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,250.0
2277,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,194.6
2278,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",29.7
2279,Austria,2012,5,C10-Lipid modifying agents,Million of national currency units,102.1
2280,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.4
2281,Austria,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.4
2282,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
2283,Austria,2012,5,C02-Antihypertensives,Million of national currency units,41.4
2284,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
2285,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
2286,Austria,2012,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.3
2287,Austria,2012,5,C02-Antihypertensives,Million US$ at exchange rate,53.2
2288,Austria,2012,5,C02-Antihypertensives,"Million US$, purchasing power parity",50.9
2289,Austria,2012,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.0
2290,Austria,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3211.4
2291,Austria,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",398.2
2292,Austria,2012,5,Total pharmaceutical sales,Million of national currency units,2613.0
2293,Austria,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,3357.1
2294,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.4
2295,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.0
2296,Austria,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",381.0
2297,Austria,2012,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.3
2298,Austria,2012,5,C03-Diuretics,"Million US$, purchasing power parity",19.2
2299,Austria,2012,5,C03-Diuretics,"/capita, US$ exchange rate",2.4
2300,Austria,2012,5,C03-Diuretics,Million US$ at exchange rate,20.1
2301,Austria,2012,5,C07-Beta blocking agents,Million of national currency units,51.3
2302,Austria,2012,5,C07-Beta blocking agents,Million US$ at exchange rate,65.9
2303,Austria,2012,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.3
2304,Austria,2012,5,C03-Diuretics,Million of national currency units,15.6
2305,Austria,2012,5,C03-Diuretics,% of total sales,0.6
2306,Austria,2012,5,C01A-Cardiac glycosides,% of total sales,0.0
2307,Austria,2012,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
2308,Austria,2012,5,C02-Antihypertensives,% of total sales,1.6
2309,Austria,2012,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
2310,Austria,2012,5,C01A-Cardiac glycosides,Million of national currency units,0.6
2311,Austria,2012,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
2312,Austria,2012,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.8
2313,Austria,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,58.3
2314,Austria,2012,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.7
2315,Austria,2012,5,C-Cardiovascular system,Million of national currency units,483.2
2316,Austria,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",73.6
2317,Austria,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,45.4
2318,Austria,2012,5,G-Genito urinary system and sex hormones,% of total sales,1.7
2319,Austria,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.6
2320,Austria,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",55.8
2321,Austria,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",6.9
2322,Austria,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.1
2323,Austria,2012,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",16.8
2324,Austria,2012,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,17.6
2325,Austria,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",593.9
2326,Austria,2012,5,C-Cardiovascular system,Million US$ at exchange rate,620.8
2327,Austria,2011,5,N-Nervous system,% of total sales,19.2
2328,Austria,2011,5,N06A-Antidepressants,Million US$ at exchange rate,138.3
2329,Austria,2011,5,N-Nervous system,"/capita, US$ exchange rate",81.3
2330,Austria,2011,5,N-Nervous system,"Million US$, purchasing power parity",589.6
2331,Austria,2011,5,N-Nervous system,"/capita, US$ purchasing power parity",70.3
2332,Austria,2011,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",86.4
2333,Austria,2011,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,100.0
2334,Austria,2011,5,J01-Antibacterials for systemic use,Million of national currency units,71.8
2335,Austria,2011,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",200.3
2336,Austria,2011,5,J-Antiinfectives for systemic use,Million of national currency units,166.5
2337,Austria,2011,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,231.8
2338,Austria,2011,5,J-Antiinfectives for systemic use,% of total sales,6.5
2339,Austria,2011,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",27.6
2340,Austria,2011,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.9
2341,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
2342,Austria,2011,5,N02-Analgesics,Million US$ at exchange rate,82.8
2343,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.9
2344,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.0
2345,Austria,2011,5,N02-Analgesics,"/capita, US$ purchasing power parity",8.5
2346,Austria,2011,5,N02-Analgesics,"/capita, US$ exchange rate",9.9
2347,Austria,2011,5,N02-Analgesics,"Million US$, purchasing power parity",71.5
2348,Austria,2011,5,N02-Analgesics,Million of national currency units,59.5
2349,Austria,2011,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.5
2350,Austria,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0
2351,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",57.7
2352,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,47.9
2353,Austria,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,66.7
2354,Austria,2011,5,A02A-Antacids,Million of national currency units,0.1
2355,Austria,2011,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.9
2356,Austria,2011,5,A02A-Antacids,% of total sales,0.0
2357,Austria,2011,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.3
2358,Austria,2011,5,A10-Drugs used in diabetes,Million US$ at exchange rate,144.9
2359,Austria,2011,5,A10-Drugs used in diabetes,Million of national currency units,104.1
2360,Austria,2011,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",125.2
2361,Austria,2011,5,A10-Drugs used in diabetes,% of total sales,4.1
2362,Austria,2011,5,N02-Analgesics,% of total sales,2.3
2363,Austria,2011,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
2364,Austria,2011,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
2365,Austria,2011,5,A02A-Antacids,Million US$ at exchange rate,0.2
2366,Austria,2011,5,A02A-Antacids,"Million US$, purchasing power parity",0.2
2367,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.2
2368,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.0
2369,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.1
2370,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.1
2371,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,59.2
2372,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.8
2373,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.8
2374,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",115.8
2375,Austria,2011,5,R-Respiratory system,% of total sales,6.3
2376,Austria,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
2377,Austria,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4
2378,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,134.0
2379,Austria,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,96.2
2380,Austria,2011,5,N05C-Hypnotics and sedatives,% of total sales,0.1
2381,Austria,2011,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2
2382,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,42.6
2383,Austria,2011,5,N06A-Antidepressants,% of total sales,3.9
2384,Austria,2011,5,N06A-Antidepressants,Million of national currency units,99.3
2385,Austria,2011,5,R-Respiratory system,Million of national currency units,159.6
2386,Austria,2011,5,M-Musculo-skeletal system,% of total sales,4.3
2387,Austria,2011,5,N06A-Antidepressants,"Million US$, purchasing power parity",119.5
2388,Austria,2011,5,N06A-Antidepressants,"/capita, US$ exchange rate",16.5
2389,Austria,2011,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.2
2390,Austria,2011,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",131.7
2391,Austria,2011,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.2
2392,Austria,2011,5,M-Musculo-skeletal system,Million of national currency units,109.5
2393,Austria,2011,5,M-Musculo-skeletal system,Million US$ at exchange rate,152.4
2394,Austria,2011,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.7
2395,Austria,2011,5,R-Respiratory system,"Million US$, purchasing power parity",192.0
2396,Austria,2011,5,R-Respiratory system,Million US$ at exchange rate,222.2
2397,Austria,2011,5,R-Respiratory system,"/capita, US$ purchasing power parity",22.9
2398,Austria,2011,5,R-Respiratory system,"/capita, US$ exchange rate",26.5
2399,Austria,2011,5,N-Nervous system,Million of national currency units,490.1
2400,Austria,2011,5,B-Blood and blood forming organs,% of total sales,5.7
2401,Austria,2011,5,Products not elsewhere classified,Million of national currency units,617.8
2402,Austria,2011,5,N-Nervous system,Million US$ at exchange rate,682.3
2403,Austria,2011,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",175.4
2404,Austria,2011,5,B-Blood and blood forming organs,Million US$ at exchange rate,203.0
2405,Austria,2011,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.9
2406,Austria,2011,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",24.2
2407,Austria,2011,5,Products not elsewhere classified,Million US$ at exchange rate,859.9
2408,Austria,2011,5,J01-Antibacterials for systemic use,% of total sales,2.8
2409,Austria,2011,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.9
2410,Austria,2011,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.3
2411,Austria,2011,5,Products not elsewhere classified,"/capita, US$ exchange rate",102.5
2412,Austria,2011,5,Products not elsewhere classified,"Million US$, purchasing power parity",743.1
2413,Austria,2011,5,Products not elsewhere classified,% of total sales,24.2
2414,Austria,2011,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",88.6
2415,Austria,2011,5,R03-Drugs for obstructive airway diseases,Million of national currency units,136.9
2416,Austria,2011,5,N05B-Anxiolytics,% of total sales,0.3
2417,Austria,2011,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.9
2418,Austria,2011,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,190.6
2419,Austria,2011,5,N05C-Hypnotics and sedatives,Million of national currency units,2.6
2420,Austria,2011,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.7
2421,Austria,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
2422,Austria,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.6
2423,Austria,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.7
2424,Austria,2011,5,B-Blood and blood forming organs,Million of national currency units,145.8
2425,Austria,2011,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4
2426,Austria,2011,5,N05B-Anxiolytics,"Million US$, purchasing power parity",7.8
2427,Austria,2011,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
2428,Austria,2011,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",164.7
2429,Austria,2011,5,N05B-Anxiolytics,Million of national currency units,6.5
2430,Austria,2011,5,N05B-Anxiolytics,Million US$ at exchange rate,9.0
2431,Austria,2011,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",327.7
2432,Austria,2011,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,379.2
2433,Austria,2011,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4
2434,Austria,2011,5,A-Alimentary tract and metabolism,Million of national currency units,272.4
2435,Austria,2011,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",45.2
2436,Austria,2011,5,A-Alimentary tract and metabolism,% of total sales,10.7
2437,Austria,2011,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.0
2438,Austria,2011,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.2
2439,Austria,2011,5,C07-Beta blocking agents,% of total sales,2.3
2440,Austria,2011,5,C07-Beta blocking agents,"Million US$, purchasing power parity",69.0
2441,Austria,2011,5,C07-Beta blocking agents,"/capita, US$ exchange rate",9.5
2442,Austria,2011,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",36.7
2443,Austria,2011,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1
2444,Austria,2011,5,C08-Calcium channel blockers,Million of national currency units,30.5
2445,Austria,2011,5,C08-Calcium channel blockers,% of total sales,1.2
2446,Austria,2011,5,C08-Calcium channel blockers,Million US$ at exchange rate,42.5
2447,Austria,2011,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.0
2448,Austria,2011,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.7
2449,Austria,2011,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",123.4
2450,Austria,2011,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.1
2451,Austria,2011,5,C-Cardiovascular system,% of total sales,19.5
2452,Austria,2011,5,C10-Lipid modifying agents,% of total sales,4.0
2453,Austria,2011,5,C10-Lipid modifying agents,Million US$ at exchange rate,142.8
2454,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",237.0
2455,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,197.0
2456,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,274.2
2457,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",32.7
2458,Austria,2011,5,C10-Lipid modifying agents,Million of national currency units,102.6
2459,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.7
2460,Austria,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.2
2461,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
2462,Austria,2011,5,C02-Antihypertensives,Million of national currency units,39.6
2463,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.3
2464,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
2465,Austria,2011,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.6
2466,Austria,2011,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.7
2467,Austria,2011,5,C02-Antihypertensives,Million US$ at exchange rate,55.2
2468,Austria,2011,5,C02-Antihypertensives,"Million US$, purchasing power parity",47.7
2469,Austria,2011,5,Total pharmaceutical sales,"Million US$, purchasing power parity",3066.7
2470,Austria,2011,5,Total pharmaceutical sales,"/capita, US$ exchange rate",422.9
2471,Austria,2011,5,Total pharmaceutical sales,Million of national currency units,2549.6
2472,Austria,2011,5,Total pharmaceutical sales,Million US$ at exchange rate,3548.9
2473,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,10.6
2474,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.2
2475,Austria,2011,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",365.4
2476,Austria,2011,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.6
2477,Austria,2011,5,C03-Diuretics,"/capita, US$ exchange rate",2.6
2478,Austria,2011,5,C03-Diuretics,"Million US$, purchasing power parity",18.5
2479,Austria,2011,5,C03-Diuretics,Million US$ at exchange rate,21.4
2480,Austria,2011,5,C07-Beta blocking agents,Million of national currency units,57.4
2481,Austria,2011,5,C07-Beta blocking agents,Million US$ at exchange rate,79.9
2482,Austria,2011,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
2483,Austria,2011,5,C03-Diuretics,% of total sales,0.6
2484,Austria,2011,5,C03-Diuretics,Million of national currency units,15.4
2485,Austria,2011,5,C01A-Cardiac glycosides,% of total sales,0.0
2486,Austria,2011,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
2487,Austria,2011,5,C02-Antihypertensives,% of total sales,1.6
2488,Austria,2011,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.9
2489,Austria,2011,5,C01A-Cardiac glycosides,Million of national currency units,0.7
2490,Austria,2011,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
2491,Austria,2011,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.8
2492,Austria,2011,5,C-Cardiovascular system,"/capita, US$ exchange rate",82.3
2493,Austria,2011,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,61.1
2494,Austria,2011,5,G-Genito urinary system and sex hormones,Million of national currency units,43.9
2495,Austria,2011,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.9
2496,Austria,2011,5,C-Cardiovascular system,Million of national currency units,495.9
2497,Austria,2011,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",52.8
2498,Austria,2011,5,G-Genito urinary system and sex hormones,% of total sales,1.7
2499,Austria,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.3
2500,Austria,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.3
2501,Austria,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.3
2502,Austria,2011,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,19.3
2503,Austria,2011,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",16.7
2504,Austria,2011,5,C-Cardiovascular system,"Million US$, purchasing power parity",596.5
2505,Austria,2011,5,C-Cardiovascular system,Million US$ at exchange rate,690.3
2506,Austria,2010,5,N-Nervous system,"/capita, US$ exchange rate",74.1
2507,Austria,2010,5,N-Nervous system,"/capita, US$ purchasing power parity",66.3
2508,Austria,2010,5,N-Nervous system,"Million US$, purchasing power parity",554.9
2509,Austria,2010,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",88.2
2510,Austria,2010,5,J01-Antibacterials for systemic use,Million of national currency units,74.3
2511,Austria,2010,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,98.5
2512,Austria,2010,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",193.3
2513,Austria,2010,5,J-Antiinfectives for systemic use,Million of national currency units,162.8
2514,Austria,2010,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,215.8
2515,Austria,2010,5,J-Antiinfectives for systemic use,% of total sales,6.5
2516,Austria,2010,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",25.8
2517,Austria,2010,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.1
2518,Austria,2010,5,N-Nervous system,% of total sales,18.7
2519,Austria,2010,5,A10-Drugs used in diabetes,Million of national currency units,96.6
2520,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
2521,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.8
2522,Austria,2010,5,N02-Analgesics,"/capita, US$ purchasing power parity",8.8
2523,Austria,2010,5,N02-Analgesics,"/capita, US$ exchange rate",9.8
2524,Austria,2010,5,N02-Analgesics,"Million US$, purchasing power parity",73.4
2525,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.5
2526,Austria,2010,5,N02-Analgesics,Million of national currency units,61.9
2527,Austria,2010,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.6
2528,Austria,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.1
2529,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",56.5
2530,Austria,2010,5,A02A-Antacids,Million of national currency units,0.2
2531,Austria,2010,5,N02-Analgesics,Million US$ at exchange rate,82.0
2532,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,47.6
2533,Austria,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,63.0
2534,Austria,2010,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.7
2535,Austria,2010,5,A02A-Antacids,% of total sales,0.0
2536,Austria,2010,5,A10-Drugs used in diabetes,Million US$ at exchange rate,128.1
2537,Austria,2010,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.3
2538,Austria,2010,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",114.7
2539,Austria,2010,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
2540,Austria,2010,5,A10-Drugs used in diabetes,% of total sales,3.9
2541,Austria,2010,5,A02A-Antacids,Million US$ at exchange rate,0.3
2542,Austria,2010,5,N02-Analgesics,% of total sales,2.5
2543,Austria,2010,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
2544,Austria,2010,5,A02A-Antacids,"Million US$, purchasing power parity",0.2
2545,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",50.0
2546,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.1
2547,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.0
2548,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.7
2549,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,55.8
2550,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.3
2551,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.3
2552,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",127.9
2553,Austria,2010,5,R-Respiratory system,% of total sales,6.2
2554,Austria,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
2555,Austria,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4
2556,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,142.8
2557,Austria,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,107.7
2558,Austria,2010,5,N05C-Hypnotics and sedatives,% of total sales,0.1
2559,Austria,2010,5,M-Musculo-skeletal system,Million of national currency units,109.6
2560,Austria,2010,5,N06A-Antidepressants,Million of national currency units,94.0
2561,Austria,2010,5,N06A-Antidepressants,% of total sales,3.8
2562,Austria,2010,5,R-Respiratory system,Million of national currency units,154.8
2563,Austria,2010,5,M-Musculo-skeletal system,% of total sales,4.4
2564,Austria,2010,5,N06A-Antidepressants,"Million US$, purchasing power parity",111.6
2565,Austria,2010,5,N06A-Antidepressants,"/capita, US$ exchange rate",14.9
2566,Austria,2010,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.3
2567,Austria,2010,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.4
2568,Austria,2010,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",130.1
2569,Austria,2010,5,M-Musculo-skeletal system,Million US$ at exchange rate,145.2
2570,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,42.1
2571,Austria,2010,5,R-Respiratory system,"Million US$, purchasing power parity",183.8
2572,Austria,2010,5,R-Respiratory system,Million US$ at exchange rate,205.3
2573,Austria,2010,5,R-Respiratory system,"/capita, US$ purchasing power parity",22.0
2574,Austria,2010,5,R-Respiratory system,"/capita, US$ exchange rate",24.5
2575,Austria,2010,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.6
2576,Austria,2010,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.0
2577,Austria,2010,5,N-Nervous system,Million of national currency units,467.4
2578,Austria,2010,5,B-Blood and blood forming organs,% of total sales,6.1
2579,Austria,2010,5,Products not elsewhere classified,Million US$ at exchange rate,773.7
2580,Austria,2010,5,Products not elsewhere classified,Million of national currency units,583.6
2581,Austria,2010,5,N-Nervous system,Million US$ at exchange rate,619.6
2582,Austria,2010,5,N06A-Antidepressants,Million US$ at exchange rate,124.6
2583,Austria,2010,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",179.5
2584,Austria,2010,5,B-Blood and blood forming organs,Million US$ at exchange rate,200.4
2585,Austria,2010,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.5
2586,Austria,2010,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",24.0
2587,Austria,2010,5,J01-Antibacterials for systemic use,% of total sales,3.0
2588,Austria,2010,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.8
2589,Austria,2010,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.6
2590,Austria,2010,5,Products not elsewhere classified,"/capita, US$ exchange rate",92.5
2591,Austria,2010,5,Products not elsewhere classified,"Million US$, purchasing power parity",693.0
2592,Austria,2010,5,Products not elsewhere classified,% of total sales,23.4
2593,Austria,2010,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",82.9
2594,Austria,2010,5,R03-Drugs for obstructive airway diseases,Million of national currency units,132.5
2595,Austria,2010,5,N05B-Anxiolytics,% of total sales,0.2
2596,Austria,2010,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.9
2597,Austria,2010,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,175.7
2598,Austria,2010,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3
2599,Austria,2010,5,N05C-Hypnotics and sedatives,Million of national currency units,2.5
2600,Austria,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
2601,Austria,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.8
2602,Austria,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.0
2603,Austria,2010,5,B-Blood and blood forming organs,Million of national currency units,151.2
2604,Austria,2010,5,R03-Drugs for obstructive airway diseases,% of total sales,5.3
2605,Austria,2010,5,N05B-Anxiolytics,"Million US$, purchasing power parity",7.3
2606,Austria,2010,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0
2607,Austria,2010,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",157.3
2608,Austria,2010,5,N05B-Anxiolytics,Million of national currency units,6.2
2609,Austria,2010,5,N05B-Anxiolytics,Million US$ at exchange rate,8.2
2610,Austria,2010,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",325.9
2611,Austria,2010,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.9
2612,Austria,2010,5,A-Alimentary tract and metabolism,Million of national currency units,274.4
2613,Austria,2010,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,363.8
2614,Austria,2010,5,C08-Calcium channel blockers,% of total sales,1.4
2615,Austria,2010,5,A-Alimentary tract and metabolism,% of total sales,11.0
2616,Austria,2010,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",43.5
2617,Austria,2010,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.0
2618,Austria,2010,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.0
2619,Austria,2010,5,C07-Beta blocking agents,% of total sales,2.6
2620,Austria,2010,5,C07-Beta blocking agents,"Million US$, purchasing power parity",75.7
2621,Austria,2010,5,C07-Beta blocking agents,"/capita, US$ exchange rate",10.1
2622,Austria,2010,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",40.9
2623,Austria,2010,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5
2624,Austria,2010,5,C08-Calcium channel blockers,Million of national currency units,34.5
2625,Austria,2010,5,C08-Calcium channel blockers,Million US$ at exchange rate,45.7
2626,Austria,2010,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.7
2627,Austria,2010,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.3
2628,Austria,2010,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",114.5
2629,Austria,2010,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.7
2630,Austria,2010,5,C-Cardiovascular system,% of total sales,20.0
2631,Austria,2010,5,C10-Lipid modifying agents,% of total sales,3.9
2632,Austria,2010,5,C10-Lipid modifying agents,Million US$ at exchange rate,127.8
2633,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",232.0
2634,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,259.1
2635,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,195.4
2636,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",31.0
2637,Austria,2010,5,C10-Lipid modifying agents,Million of national currency units,96.4
2638,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.8
2639,Austria,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.7
2640,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
2641,Austria,2010,5,C02-Antihypertensives,Million of national currency units,39.3
2642,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
2643,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
2644,Austria,2010,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.2
2645,Austria,2010,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.6
2646,Austria,2010,5,C02-Antihypertensives,Million US$ at exchange rate,52.1
2647,Austria,2010,5,C02-Antihypertensives,"Million US$, purchasing power parity",46.6
2648,Austria,2010,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2959.9
2649,Austria,2010,5,Total pharmaceutical sales,"/capita, US$ exchange rate",395.2
2650,Austria,2010,5,Total pharmaceutical sales,Million of national currency units,2493.0
2651,Austria,2010,5,Total pharmaceutical sales,Million US$ at exchange rate,3305.0
2652,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.0
2653,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.1
2654,Austria,2010,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",353.9
2655,Austria,2010,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.8
2656,Austria,2010,5,C03-Diuretics,"/capita, US$ exchange rate",2.5
2657,Austria,2010,5,C03-Diuretics,"Million US$, purchasing power parity",18.8
2658,Austria,2010,5,C03-Diuretics,Million US$ at exchange rate,21.0
2659,Austria,2010,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
2660,Austria,2010,5,C07-Beta blocking agents,Million US$ at exchange rate,84.5
2661,Austria,2010,5,C07-Beta blocking agents,Million of national currency units,63.7
2662,Austria,2010,5,C03-Diuretics,% of total sales,0.6
2663,Austria,2010,5,C01A-Cardiac glycosides,Million of national currency units,0.7
2664,Austria,2010,5,C01A-Cardiac glycosides,% of total sales,0.0
2665,Austria,2010,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
2666,Austria,2010,5,C02-Antihypertensives,% of total sales,1.6
2667,Austria,2010,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0
2668,Austria,2010,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
2669,Austria,2010,5,C03-Diuretics,Million of national currency units,15.8
2670,Austria,2010,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.9
2671,Austria,2010,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,57.9
2672,Austria,2010,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",51.8
2673,Austria,2010,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,14.5
2674,Austria,2010,5,C-Cardiovascular system,Million of national currency units,498.0
2675,Austria,2010,5,G-Genito urinary system and sex hormones,Million of national currency units,43.7
2676,Austria,2010,5,G-Genito urinary system and sex hormones,% of total sales,1.8
2677,Austria,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",6.9
2678,Austria,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.2
2679,Austria,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.3
2680,Austria,2010,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",17.3
2681,Austria,2010,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,19.3
2682,Austria,2010,5,C-Cardiovascular system,"/capita, US$ exchange rate",78.9
2683,Austria,2010,5,C-Cardiovascular system,"Million US$, purchasing power parity",591.3
2684,Austria,2010,5,C-Cardiovascular system,Million US$ at exchange rate,660.2
2685,Austria,2017,5,N-Nervous system,% of total sales,14.1
2686,Austria,2017,5,N-Nervous system,"Million US$, purchasing power parity",567.4
2687,Austria,2017,5,N-Nervous system,"/capita, US$ exchange rate",56.5
2688,Austria,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",64.5
2689,Austria,2017,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,67.6
2690,Austria,2017,5,N-Nervous system,Million US$ at exchange rate,496.7
2691,Austria,2017,5,J01-Antibacterials for systemic use,Million of national currency units,59.8
2692,Austria,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,300.3
2693,Austria,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",343.1
2694,Austria,2017,5,J-Antiinfectives for systemic use,Million of national currency units,265.9
2695,Austria,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",39.0
2696,Austria,2017,5,J-Antiinfectives for systemic use,% of total sales,8.5
2697,Austria,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",34.1
2698,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
2699,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.3
2700,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.3
2701,Austria,2017,5,N02-Analgesics,"/capita, US$ exchange rate",8.7
2702,Austria,2017,5,N02-Analgesics,Million US$ at exchange rate,76.4
2703,Austria,2017,5,N02-Analgesics,"Million US$, purchasing power parity",87.2
2704,Austria,2017,5,G03-Sex hormones and modulators of the genital system,% of total sales,0.4
2705,Austria,2017,5,N02-Analgesics,Million of national currency units,67.6
2706,Austria,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0
2707,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,63.9
2708,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",73.0
2709,Austria,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,56.5
2710,Austria,2017,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.3
2711,Austria,2017,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.3
2712,Austria,2017,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
2713,Austria,2017,5,A02A-Antacids,% of total sales,0.0
2714,Austria,2017,5,A10-Drugs used in diabetes,Million of national currency units,165.7
2715,Austria,2017,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",213.8
2716,Austria,2017,5,A10-Drugs used in diabetes,Million US$ at exchange rate,187.2
2717,Austria,2017,5,N02-Analgesics,% of total sales,2.2
2718,Austria,2017,5,A10-Drugs used in diabetes,% of total sales,5.3
2719,Austria,2017,5,A02A-Antacids,Million of national currency units,0.9
2720,Austria,2017,5,N02-Analgesics,"/capita, US$ purchasing power parity",9.9
2721,Austria,2017,5,A02A-Antacids,"Million US$, purchasing power parity",1.1
2722,Austria,2017,5,A02A-Antacids,"/capita, US$ exchange rate",0.1
2723,Austria,2017,5,A02A-Antacids,Million US$ at exchange rate,1.0
2724,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,45.7
2725,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",49.7
2726,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",52.2
2727,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.2
2728,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",4.9
2729,Austria,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7
2730,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,40.5
2731,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2
2732,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.7
2733,Austria,2017,5,R-Respiratory system,% of total sales,5.7
2734,Austria,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",26.0
2735,Austria,2017,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.8
2736,Austria,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4
2737,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,38.5
2738,Austria,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,43.5
2739,Austria,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.4
2740,Austria,2017,5,N05C-Hypnotics and sedatives,% of total sales,0.1
2741,Austria,2017,5,N06A-Antidepressants,% of total sales,2.6
2742,Austria,2017,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.7
2743,Austria,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.5
2744,Austria,2017,5,M-Musculo-skeletal system,% of total sales,3.4
2745,Austria,2017,5,N06A-Antidepressants,"Million US$, purchasing power parity",103.3
2746,Austria,2017,5,N06A-Antidepressants,Million US$ at exchange rate,90.4
2747,Austria,2017,5,N06A-Antidepressants,Million of national currency units,80.1
2748,Austria,2017,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.3
2749,Austria,2017,5,R-Respiratory system,Million of national currency units,177.4
2750,Austria,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",136.1
2751,Austria,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.5
2752,Austria,2017,5,M-Musculo-skeletal system,Million of national currency units,105.5
2753,Austria,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,119.2
2754,Austria,2017,5,R-Respiratory system,Million US$ at exchange rate,200.4
2755,Austria,2017,5,R-Respiratory system,"Million US$, purchasing power parity",228.9
2756,Austria,2017,5,R-Respiratory system,"/capita, US$ exchange rate",22.8
2757,Austria,2017,5,N-Nervous system,Million of national currency units,439.7
2758,Austria,2017,5,B-Blood and blood forming organs,% of total sales,9.9
2759,Austria,2017,5,Products not elsewhere classified,Million of national currency units,987.4
2760,Austria,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",399.7
2761,Austria,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,350.0
2762,Austria,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.4
2763,Austria,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.8
2764,Austria,2017,5,J01-Antibacterials for systemic use,% of total sales,1.9
2765,Austria,2017,5,Products not elsewhere classified,% of total sales,31.6
2766,Austria,2017,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.8
2767,Austria,2017,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.7
2768,Austria,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",1274.1
2769,Austria,2017,5,Products not elsewhere classified,Million US$ at exchange rate,1115.5
2770,Austria,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",144.8
2771,Austria,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",126.8
2772,Austria,2017,5,B-Blood and blood forming organs,Million of national currency units,309.8
2773,Austria,2017,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.0
2774,Austria,2017,5,R03-Drugs for obstructive airway diseases,Million of national currency units,148.3
2775,Austria,2017,5,N05B-Anxiolytics,"/capita, US$ exchange rate",0.8
2776,Austria,2017,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,167.5
2777,Austria,2017,5,N05B-Anxiolytics,% of total sales,0.2
2778,Austria,2017,5,N05C-Hypnotics and sedatives,Million of national currency units,2.9
2779,Austria,2017,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3
2780,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.3
2781,Austria,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.9
2782,Austria,2017,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",77.2
2783,Austria,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.0
2784,Austria,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.8
2785,Austria,2017,5,R03-Drugs for obstructive airway diseases,% of total sales,4.7
2786,Austria,2017,5,N05B-Anxiolytics,Million US$ at exchange rate,7.3
2787,Austria,2017,5,N05B-Anxiolytics,"Million US$, purchasing power parity",8.4
2788,Austria,2017,5,N05B-Anxiolytics,Million of national currency units,6.5
2789,Austria,2017,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",191.4
2790,Austria,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,343.6
2791,Austria,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",392.5
2792,Austria,2017,5,A-Alimentary tract and metabolism,Million of national currency units,304.2
2793,Austria,2017,5,A-Alimentary tract and metabolism,% of total sales,9.7
2794,Austria,2017,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.5
2795,Austria,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",39.1
2796,Austria,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.6
2797,Austria,2017,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.3
2798,Austria,2017,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.0
2799,Austria,2017,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3
2800,Austria,2017,5,C07-Beta blocking agents,"Million US$, purchasing power parity",53.0
2801,Austria,2017,5,C07-Beta blocking agents,% of total sales,1.3
2802,Austria,2017,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",13.0
2803,Austria,2017,5,C08-Calcium channel blockers,Million US$ at exchange rate,11.4
2804,Austria,2017,5,C08-Calcium channel blockers,Million of national currency units,10.1
2805,Austria,2017,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.2
2806,Austria,2017,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",16.2
2807,Austria,2017,5,C10-Lipid modifying agents,Million US$ at exchange rate,125.0
2808,Austria,2017,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",142.8
2809,Austria,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.8
2810,Austria,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",55.8
2811,Austria,2017,5,C10-Lipid modifying agents,% of total sales,3.5
2812,Austria,2017,5,C-Cardiovascular system,% of total sales,13.9
2813,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,181.3
2814,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",207.0
2815,Austria,2017,5,C08-Calcium channel blockers,% of total sales,0.3
2816,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,160.5
2817,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.1
2818,Austria,2017,5,C10-Lipid modifying agents,Million of national currency units,110.6
2819,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.6
2820,Austria,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.5
2821,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
2822,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
2823,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
2824,Austria,2017,5,C02-Antihypertensives,"Million US$, purchasing power parity",64.0
2825,Austria,2017,5,C02-Antihypertensives,"/capita, US$ exchange rate",6.4
2826,Austria,2017,5,C02-Antihypertensives,Million of national currency units,49.6
2827,Austria,2017,5,C02-Antihypertensives,Million US$ at exchange rate,56.0
2828,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.5
2829,Austria,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4035.1
2830,Austria,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,3532.8
2831,Austria,2017,5,Total pharmaceutical sales,Million of national currency units,3127.2
2832,Austria,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",401.6
2833,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.4
2834,Austria,2017,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.6
2835,Austria,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",458.7
2836,Austria,2017,5,C03-Diuretics,"Million US$, purchasing power parity",23.6
2837,Austria,2017,5,C03-Diuretics,"/capita, US$ exchange rate",2.4
2838,Austria,2017,5,C03-Diuretics,Million of national currency units,18.3
2839,Austria,2017,5,C03-Diuretics,Million US$ at exchange rate,20.7
2840,Austria,2017,5,C07-Beta blocking agents,Million of national currency units,41.1
2841,Austria,2017,5,C07-Beta blocking agents,Million US$ at exchange rate,46.4
2842,Austria,2017,5,C03-Diuretics,"/capita, US$ purchasing power parity",2.7
2843,Austria,2017,5,C03-Diuretics,% of total sales,0.6
2844,Austria,2017,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
2845,Austria,2017,5,C01A-Cardiac glycosides,% of total sales,0.0
2846,Austria,2017,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",7.3
2847,Austria,2017,5,C02-Antihypertensives,% of total sales,1.6
2848,Austria,2017,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5
2849,Austria,2017,5,C01A-Cardiac glycosides,Million of national currency units,0.4
2850,Austria,2017,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
2851,Austria,2017,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
2852,Austria,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,46.1
2853,Austria,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,52.1
2854,Austria,2017,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.4
2855,Austria,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.8
2856,Austria,2017,5,G-Genito urinary system and sex hormones,% of total sales,1.5
2857,Austria,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",59.5
2858,Austria,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",5.9
2859,Austria,2017,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",17.3
2860,Austria,2017,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,15.2
2861,Austria,2017,5,C-Cardiovascular system,Million of national currency units,434.7
2862,Austria,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",560.8
2863,Austria,2017,5,C-Cardiovascular system,Million US$ at exchange rate,491.0
2864,Belgium,2010,6,C03-Diuretics,Million US$ at exchange rate,50.5
2865,Belgium,2010,6,Total pharmaceutical sales,Million of national currency units,5881.5
2866,Belgium,2010,6,C03-Diuretics,"Million US$, purchasing power parity",45.6
2867,Belgium,2010,6,C03-Diuretics,"/capita, US$ exchange rate",4.6
2868,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,122.5
2869,Belgium,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,317.7
2870,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,162.4
2871,Belgium,2010,6,C03-Diuretics,Million of national currency units,38.1
2872,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",146.4
2873,Belgium,2010,6,N06A-Antidepressants,Million of national currency units,186.8
2874,Belgium,2010,6,N06A-Antidepressants,"Million US$, purchasing power parity",223.2
2875,Belgium,2010,6,N06A-Antidepressants,Million US$ at exchange rate,247.6
2876,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.9
2877,Belgium,2010,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.2
2878,Belgium,2010,6,C03-Diuretics,% of total sales,0.6
2879,Belgium,2010,6,N05C-Hypnotics and sedatives,Million of national currency units,67.6
2880,Belgium,2010,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",80.9
2881,Belgium,2010,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,89.7
2882,Belgium,2010,6,G-Genito urinary system and sex hormones,% of total sales,4.1
2883,Belgium,2010,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.8
2884,Belgium,2010,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6
2885,Belgium,2010,6,C01A-Cardiac glycosides,Million of national currency units,1.3
2886,Belgium,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.3
2887,Belgium,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",29.2
2888,Belgium,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",286.5
2889,Belgium,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.2
2890,Belgium,2010,6,N05C-Hypnotics and sedatives,% of total sales,1.2
2891,Belgium,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.4
2892,Belgium,2010,6,C07-Beta blocking agents,% of total sales,1.8
2893,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.0
2894,Belgium,2010,6,C07-Beta blocking agents,"Million US$, purchasing power parity",129.6
2895,Belgium,2010,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",11.9
2896,Belgium,2010,6,C07-Beta blocking agents,"/capita, US$ exchange rate",13.2
2897,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,177.4
2898,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,235.2
2899,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,135.6
2900,Belgium,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,239.7
2901,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.5
2902,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.6
2903,Belgium,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",212.0
2904,Belgium,2010,6,C07-Beta blocking agents,Million US$ at exchange rate,143.7
2905,Belgium,2010,6,M-Musculo-skeletal system,% of total sales,4.3
2906,Belgium,2010,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.5
2907,Belgium,2010,6,N06A-Antidepressants,"/capita, US$ exchange rate",22.7
2908,Belgium,2010,6,N06A-Antidepressants,% of total sales,3.2
2909,Belgium,2010,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.5
2910,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
2911,Belgium,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.4
2912,Belgium,2010,6,C07-Beta blocking agents,Million of national currency units,108.4
2913,Belgium,2010,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",299.2
2914,Belgium,2010,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",30.5
2915,Belgium,2010,6,M-Musculo-skeletal system,Million of national currency units,250.3
2916,Belgium,2010,6,M-Musculo-skeletal system,Million US$ at exchange rate,331.9
2917,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.1
2918,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9
2919,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8
2920,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,% of total sales,2.3
2921,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",14.9
2922,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.2
2923,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,16.0
2924,Belgium,2010,6,N02-Analgesics,"/capita, US$ exchange rate",29.9
2925,Belgium,2010,6,N02-Analgesics,"/capita, US$ purchasing power parity",26.9
2926,Belgium,2010,6,N02-Analgesics,% of total sales,4.2
2927,Belgium,2010,6,N02-Analgesics,Million of national currency units,245.6
2928,Belgium,2010,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
2929,Belgium,2010,6,N02-Analgesics,"Million US$, purchasing power parity",293.5
2930,Belgium,2010,6,N02-Analgesics,Million US$ at exchange rate,325.6
2931,Belgium,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",645.2
2932,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.5
2933,Belgium,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,7797.2
2934,Belgium,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",715.6
2935,Belgium,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7030.2
2936,Belgium,2010,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",166.8
2937,Belgium,2010,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.0
2938,Belgium,2010,6,A10-Drugs used in diabetes,Million of national currency units,139.5
2939,Belgium,2010,6,A10-Drugs used in diabetes,Million US$ at exchange rate,184.9
2940,Belgium,2010,6,N-Nervous system,% of total sales,17.3
2941,Belgium,2010,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.3
2942,Belgium,2010,6,A10-Drugs used in diabetes,% of total sales,2.4
2943,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
2944,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.3
2945,Belgium,2010,6,N05B-Anxiolytics,"/capita, US$ exchange rate",7.8
2946,Belgium,2010,6,N05B-Anxiolytics,"Million US$, purchasing power parity",76.9
2947,Belgium,2010,6,N05B-Anxiolytics,% of total sales,1.1
2948,Belgium,2010,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.1
2949,Belgium,2010,6,C01A-Cardiac glycosides,% of total sales,0.0
2950,Belgium,2010,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
2951,Belgium,2010,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
2952,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",133.9
2953,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.6
2954,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,112.0
2955,Belgium,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,148.5
2956,Belgium,2010,6,N-Nervous system,Million of national currency units,1019.6
2957,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",162.1
2958,Belgium,2010,6,N-Nervous system,Million US$ at exchange rate,1351.7
2959,Belgium,2010,6,C02-Antihypertensives,Million US$ at exchange rate,23.5
2960,Belgium,2010,6,C02-Antihypertensives,Million of national currency units,17.7
2961,Belgium,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",111.9
2962,Belgium,2010,6,N-Nervous system,"/capita, US$ exchange rate",124.1
2963,Belgium,2010,6,N-Nervous system,"Million US$, purchasing power parity",1218.7
2964,Belgium,2010,6,C02-Antihypertensives,% of total sales,0.3
2965,Belgium,2010,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,179.8
2966,Belgium,2010,6,N05B-Anxiolytics,Million of national currency units,64.4
2967,Belgium,2010,6,N05B-Anxiolytics,Million US$ at exchange rate,85.3
2968,Belgium,2010,6,C02-Antihypertensives,"Million US$, purchasing power parity",21.2
2969,Belgium,2010,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.2
2970,Belgium,2010,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.9
2971,Belgium,2010,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",299.4
2972,Belgium,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.5
2973,Belgium,2010,6,A02A-Antacids,"/capita, US$ exchange rate",1.3
2974,Belgium,2010,6,R03-Drugs for obstructive airway diseases,Million of national currency units,250.5
2975,Belgium,2010,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,332.1
2976,Belgium,2010,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.2
2977,Belgium,2010,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,333.3
2978,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,234.8
2979,Belgium,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.5
2980,Belgium,2010,6,J01-Antibacterials for systemic use,Million of national currency units,251.4
2981,Belgium,2010,6,R03-Drugs for obstructive airway diseases,% of total sales,4.3
2982,Belgium,2010,6,C10-Lipid modifying agents,Million US$ at exchange rate,416.1
2983,Belgium,2010,6,C08-Calcium channel blockers,% of total sales,1.2
2984,Belgium,2010,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",34.4
2985,Belgium,2010,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",8.8
2986,Belgium,2010,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.9
2987,Belgium,2010,6,A02A-Antacids,Million US$ at exchange rate,14.2
2988,Belgium,2010,6,A02A-Antacids,"Million US$, purchasing power parity",12.8
2989,Belgium,2010,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",38.2
2990,Belgium,2010,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",375.1
2991,Belgium,2010,6,A02A-Antacids,Million of national currency units,10.7
2992,Belgium,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",131.1
2993,Belgium,2010,6,A02A-Antacids,% of total sales,0.2
2994,Belgium,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",54.6
2995,Belgium,2010,6,Products not elsewhere classified,% of total sales,20.3
2996,Belgium,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",145.5
2997,Belgium,2010,6,Products not elsewhere classified,Million of national currency units,1195.5
2998,Belgium,2010,6,Products not elsewhere classified,Million US$ at exchange rate,1584.9
2999,Belgium,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",1428.9
3000,Belgium,2010,6,C10-Lipid modifying agents,% of total sales,5.3
3001,Belgium,2010,6,C10-Lipid modifying agents,Million of national currency units,313.8
3002,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.8
3003,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.0
3004,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",28.6
3005,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,311.3
3006,Belgium,2010,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",280.7
3007,Belgium,2010,6,B-Blood and blood forming organs,% of total sales,7.6
3008,Belgium,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",49.3
3009,Belgium,2010,6,B-Blood and blood forming organs,Million of national currency units,448.9
3010,Belgium,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,595.2
3011,Belgium,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",536.6
3012,Belgium,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",56.2
3013,Belgium,2010,6,R-Respiratory system,% of total sales,8.7
3014,Belgium,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",68.8
3015,Belgium,2010,6,R-Respiratory system,"Million US$, purchasing power parity",612.9
3016,Belgium,2010,6,R-Respiratory system,Million US$ at exchange rate,679.7
3017,Belgium,2010,6,R-Respiratory system,"/capita, US$ exchange rate",62.4
3018,Belgium,2010,6,J-Antiinfectives for systemic use,% of total sales,9.7
3019,Belgium,2010,6,C08-Calcium channel blockers,Million of national currency units,72.4
3020,Belgium,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",62.7
3021,Belgium,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.5
3022,Belgium,2010,6,A-Alimentary tract and metabolism,% of total sales,10.7
3023,Belgium,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",749.5
3024,Belgium,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",76.3
3025,Belgium,2010,6,R-Respiratory system,Million of national currency units,512.7
3026,Belgium,2010,6,A-Alimentary tract and metabolism,Million of national currency units,627.0
3027,Belgium,2010,6,C-Cardiovascular system,Million US$ at exchange rate,1184.9
3028,Belgium,2010,6,C-Cardiovascular system,Million of national currency units,893.8
3029,Belgium,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,831.3
3030,Belgium,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,757.6
3031,Belgium,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",683.1
3032,Belgium,2010,6,J-Antiinfectives for systemic use,Million of national currency units,571.5
3033,Belgium,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",1068.3
3034,Belgium,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",108.7
3035,Belgium,2010,6,J01-Antibacterials for systemic use,% of total sales,4.3
3036,Belgium,2010,6,C08-Calcium channel blockers,Million US$ at exchange rate,95.9
3037,Belgium,2010,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",86.5
3038,Belgium,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",98.1
3039,Belgium,2010,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",300.5
3040,Belgium,2010,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",30.6
3041,Belgium,2010,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",27.6
3042,Belgium,2010,6,C-Cardiovascular system,% of total sales,15.2
3043,Belgium,2011,6,C03-Diuretics,Million US$ at exchange rate,51.3
3044,Belgium,2011,6,C03-Diuretics,"/capita, US$ exchange rate",4.6
3045,Belgium,2011,6,C03-Diuretics,"Million US$, purchasing power parity",44.3
3046,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,125.4
3047,Belgium,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,336.1
3048,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,174.6
3049,Belgium,2011,6,C03-Diuretics,Million of national currency units,36.9
3050,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",150.8
3051,Belgium,2011,6,N06A-Antidepressants,Million of national currency units,188.6
3052,Belgium,2011,6,N06A-Antidepressants,"Million US$, purchasing power parity",226.7
3053,Belgium,2011,6,N06A-Antidepressants,Million US$ at exchange rate,262.5
3054,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.8
3055,Belgium,2011,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.0
3056,Belgium,2011,6,C03-Diuretics,% of total sales,0.6
3057,Belgium,2011,6,N05C-Hypnotics and sedatives,Million of national currency units,71.2
3058,Belgium,2011,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",85.5
3059,Belgium,2011,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,99.1
3060,Belgium,2011,6,G-Genito urinary system and sex hormones,% of total sales,4.0
3061,Belgium,2011,6,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0
3062,Belgium,2011,6,C01A-Cardiac glycosides,Million of national currency units,1.5
3063,Belgium,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.3
3064,Belgium,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",30.5
3065,Belgium,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",290.3
3066,Belgium,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.0
3067,Belgium,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.7
3068,Belgium,2011,6,N05C-Hypnotics and sedatives,% of total sales,1.2
3069,Belgium,2011,6,C07-Beta blocking agents,% of total sales,1.7
3070,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.9
3071,Belgium,2011,6,C07-Beta blocking agents,"Million US$, purchasing power parity",119.6
3072,Belgium,2011,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.8
3073,Belgium,2011,6,C07-Beta blocking agents,"/capita, US$ exchange rate",12.5
3074,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,176.7
3075,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,246.0
3076,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,132.5
3077,Belgium,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,241.5
3078,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.2
3079,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.3
3080,Belgium,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",212.4
3081,Belgium,2011,6,C07-Beta blocking agents,Million US$ at exchange rate,138.5
3082,Belgium,2011,6,M-Musculo-skeletal system,% of total sales,4.2
3083,Belgium,2011,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.3
3084,Belgium,2011,6,N06A-Antidepressants,"/capita, US$ exchange rate",23.8
3085,Belgium,2011,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.5
3086,Belgium,2011,6,N06A-Antidepressants,% of total sales,3.1
3087,Belgium,2011,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.8
3088,Belgium,2011,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",31.6
3089,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
3090,Belgium,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.7
3091,Belgium,2011,6,C07-Beta blocking agents,Million of national currency units,99.5
3092,Belgium,2011,6,M-Musculo-skeletal system,Million of national currency units,250.8
3093,Belgium,2011,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",301.5
3094,Belgium,2011,6,M-Musculo-skeletal system,Million US$ at exchange rate,349.2
3095,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",18.1
3096,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9
3097,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.6
3098,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,% of total sales,2.2
3099,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",14.4
3100,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.0
3101,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.1
3102,Belgium,2011,6,N02-Analgesics,"/capita, US$ exchange rate",32.2
3103,Belgium,2011,6,N02-Analgesics,"/capita, US$ purchasing power parity",27.8
3104,Belgium,2011,6,N02-Analgesics,% of total sales,4.3
3105,Belgium,2011,6,N02-Analgesics,Million of national currency units,255.3
3106,Belgium,2011,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
3107,Belgium,2011,6,N02-Analgesics,"Million US$, purchasing power parity",306.9
3108,Belgium,2011,6,N02-Analgesics,Million US$ at exchange rate,355.3
3109,Belgium,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",652.7
3110,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.7
3111,Belgium,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,8342.4
3112,Belgium,2011,6,Total pharmaceutical sales,Million of national currency units,5993.3
3113,Belgium,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",755.8
3114,Belgium,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7204.3
3115,Belgium,2011,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",180.8
3116,Belgium,2011,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.0
3117,Belgium,2011,6,A10-Drugs used in diabetes,Million of national currency units,150.4
3118,Belgium,2011,6,A10-Drugs used in diabetes,Million US$ at exchange rate,209.4
3119,Belgium,2011,6,N-Nervous system,% of total sales,17.5
3120,Belgium,2011,6,A10-Drugs used in diabetes,% of total sales,2.5
3121,Belgium,2011,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.4
3122,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
3123,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.8
3124,Belgium,2011,6,N05B-Anxiolytics,"/capita, US$ exchange rate",8.2
3125,Belgium,2011,6,N05B-Anxiolytics,"Million US$, purchasing power parity",78.2
3126,Belgium,2011,6,N05B-Anxiolytics,% of total sales,1.1
3127,Belgium,2011,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.1
3128,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",14.8
3129,Belgium,2011,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
3130,Belgium,2011,6,C01A-Cardiac glycosides,% of total sales,0.0
3131,Belgium,2011,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
3132,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",141.3
3133,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,117.5
3134,Belgium,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,163.6
3135,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",159.3
3136,Belgium,2011,6,N-Nervous system,Million of national currency units,1050.7
3137,Belgium,2011,6,C02-Antihypertensives,Million US$ at exchange rate,28.8
3138,Belgium,2011,6,C02-Antihypertensives,Million of national currency units,20.7
3139,Belgium,2011,6,N-Nervous system,Million US$ at exchange rate,1462.5
3140,Belgium,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",114.4
3141,Belgium,2011,6,N-Nervous system,"/capita, US$ exchange rate",132.5
3142,Belgium,2011,6,N-Nervous system,"Million US$, purchasing power parity",1263.0
3143,Belgium,2011,6,C02-Antihypertensives,% of total sales,0.3
3144,Belgium,2011,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,184.5
3145,Belgium,2011,6,N05B-Anxiolytics,Million of national currency units,65.0
3146,Belgium,2011,6,N05B-Anxiolytics,Million US$ at exchange rate,90.5
3147,Belgium,2011,6,C02-Antihypertensives,"Million US$, purchasing power parity",24.9
3148,Belgium,2011,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.3
3149,Belgium,2011,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.6
3150,Belgium,2011,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",306.7
3151,Belgium,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.2
3152,Belgium,2011,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,355.1
3153,Belgium,2011,6,J01-Antibacterials for systemic use,Million of national currency units,244.6
3154,Belgium,2011,6,R03-Drugs for obstructive airway diseases,Million of national currency units,255.1
3155,Belgium,2011,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.3
3156,Belgium,2011,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,340.5
3157,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,233.0
3158,Belgium,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.8
3159,Belgium,2011,6,R03-Drugs for obstructive airway diseases,% of total sales,4.3
3160,Belgium,2011,6,A02A-Antacids,"/capita, US$ exchange rate",1.4
3161,Belgium,2011,6,C08-Calcium channel blockers,% of total sales,1.1
3162,Belgium,2011,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",35.7
3163,Belgium,2011,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",8.5
3164,Belgium,2011,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.4
3165,Belgium,2011,6,A02A-Antacids,Million US$ at exchange rate,16.0
3166,Belgium,2011,6,A02A-Antacids,"Million US$, purchasing power parity",13.8
3167,Belgium,2011,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",41.4
3168,Belgium,2011,6,C10-Lipid modifying agents,Million US$ at exchange rate,456.5
3169,Belgium,2011,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",394.3
3170,Belgium,2011,6,A02A-Antacids,Million of national currency units,11.5
3171,Belgium,2011,6,A02A-Antacids,% of total sales,0.2
3172,Belgium,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",134.5
3173,Belgium,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",56.0
3174,Belgium,2011,6,Products not elsewhere classified,% of total sales,20.6
3175,Belgium,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",155.7
3176,Belgium,2011,6,Products not elsewhere classified,Million of national currency units,1234.9
3177,Belgium,2011,6,Products not elsewhere classified,Million US$ at exchange rate,1719.0
3178,Belgium,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",1484.5
3179,Belgium,2011,6,C10-Lipid modifying agents,% of total sales,5.5
3180,Belgium,2011,6,C10-Lipid modifying agents,Million of national currency units,328.0
3181,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.4
3182,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.9
3183,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",29.4
3184,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,324.3
3185,Belgium,2011,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",280.0
3186,Belgium,2011,6,B-Blood and blood forming organs,% of total sales,7.4
3187,Belgium,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",48.4
3188,Belgium,2011,6,B-Blood and blood forming organs,Million of national currency units,444.1
3189,Belgium,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,618.2
3190,Belgium,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",533.9
3191,Belgium,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",56.9
3192,Belgium,2011,6,R-Respiratory system,% of total sales,8.7
3193,Belgium,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.5
3194,Belgium,2011,6,R-Respiratory system,Million US$ at exchange rate,726.9
3195,Belgium,2011,6,R-Respiratory system,"Million US$, purchasing power parity",627.7
3196,Belgium,2011,6,R-Respiratory system,"/capita, US$ exchange rate",65.8
3197,Belgium,2011,6,J-Antiinfectives for systemic use,% of total sales,9.8
3198,Belgium,2011,6,C08-Calcium channel blockers,Million of national currency units,67.8
3199,Belgium,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",63.8
3200,Belgium,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",73.9
3201,Belgium,2011,6,A-Alimentary tract and metabolism,% of total sales,10.8
3202,Belgium,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",778.6
3203,Belgium,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",81.7
3204,Belgium,2011,6,R-Respiratory system,Million of national currency units,522.2
3205,Belgium,2011,6,C-Cardiovascular system,Million of national currency units,889.8
3206,Belgium,2011,6,A-Alimentary tract and metabolism,Million of national currency units,647.7
3207,Belgium,2011,6,C-Cardiovascular system,Million US$ at exchange rate,1238.6
3208,Belgium,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,901.6
3209,Belgium,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,815.8
3210,Belgium,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",704.5
3211,Belgium,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",1069.6
3212,Belgium,2011,6,J-Antiinfectives for systemic use,Million of national currency units,586.1
3213,Belgium,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",112.2
3214,Belgium,2011,6,J01-Antibacterials for systemic use,% of total sales,4.1
3215,Belgium,2011,6,C08-Calcium channel blockers,Million US$ at exchange rate,94.4
3216,Belgium,2011,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",81.5
3217,Belgium,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",96.9
3218,Belgium,2011,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",30.8
3219,Belgium,2011,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",26.6
3220,Belgium,2011,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",294.1
3221,Belgium,2011,6,C-Cardiovascular system,% of total sales,14.8
3222,Belgium,2012,6,C03-Diuretics,Million US$ at exchange rate,45.8
3223,Belgium,2012,6,C03-Diuretics,"/capita, US$ exchange rate",4.1
3224,Belgium,2012,6,C03-Diuretics,"Million US$, purchasing power parity",43.4
3225,Belgium,2012,6,C03-Diuretics,Million of national currency units,35.7
3226,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,124.4
3227,Belgium,2012,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,303.9
3228,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",151.3
3229,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,159.8
3230,Belgium,2012,6,N06A-Antidepressants,Million of national currency units,185.6
3231,Belgium,2012,6,N06A-Antidepressants,"Million US$, purchasing power parity",225.7
3232,Belgium,2012,6,N06A-Antidepressants,Million US$ at exchange rate,238.4
3233,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.4
3234,Belgium,2012,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.9
3235,Belgium,2012,6,C03-Diuretics,% of total sales,0.6
3236,Belgium,2012,6,N05C-Hypnotics and sedatives,Million of national currency units,70.2
3237,Belgium,2012,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",85.4
3238,Belgium,2012,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,90.2
3239,Belgium,2012,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.8
3240,Belgium,2012,6,G-Genito urinary system and sex hormones,% of total sales,4.0
3241,Belgium,2012,6,C01A-Cardiac glycosides,Million of national currency units,1.4
3242,Belgium,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.4
3243,Belgium,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.9
3244,Belgium,2012,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",287.7
3245,Belgium,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.1
3246,Belgium,2012,6,N05C-Hypnotics and sedatives,% of total sales,1.2
3247,Belgium,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.7
3248,Belgium,2012,6,C07-Beta blocking agents,% of total sales,1.6
3249,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.7
3250,Belgium,2012,6,C07-Beta blocking agents,"Million US$, purchasing power parity",119.0
3251,Belgium,2012,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.7
3252,Belgium,2012,6,C07-Beta blocking agents,"/capita, US$ exchange rate",11.3
3253,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,158.3
3254,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,203.4
3255,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,124.1
3256,Belgium,2012,6,G-Genito urinary system and sex hormones,Million of national currency units,236.6
3257,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",18.3
3258,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.3
3259,Belgium,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",192.6
3260,Belgium,2012,6,C07-Beta blocking agents,Million US$ at exchange rate,125.7
3261,Belgium,2012,6,M-Musculo-skeletal system,% of total sales,4.2
3262,Belgium,2012,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.3
3263,Belgium,2012,6,N06A-Antidepressants,"/capita, US$ exchange rate",21.5
3264,Belgium,2012,6,N06A-Antidepressants,% of total sales,3.1
3265,Belgium,2012,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.3
3266,Belgium,2012,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",28.9
3267,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
3268,Belgium,2012,6,C07-Beta blocking agents,Million of national currency units,97.8
3269,Belgium,2012,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",303.7
3270,Belgium,2012,6,M-Musculo-skeletal system,Million of national currency units,249.7
3271,Belgium,2012,6,M-Musculo-skeletal system,Million US$ at exchange rate,320.8
3272,Belgium,2012,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7
3273,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",18.4
3274,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
3275,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.7
3276,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,19.4
3277,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,% of total sales,2.1
3278,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",13.6
3279,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.1
3280,Belgium,2012,6,N02-Analgesics,"/capita, US$ exchange rate",28.9
3281,Belgium,2012,6,N02-Analgesics,% of total sales,4.2
3282,Belgium,2012,6,N02-Analgesics,"/capita, US$ purchasing power parity",27.4
3283,Belgium,2012,6,N02-Analgesics,"Million US$, purchasing power parity",304.4
3284,Belgium,2012,6,N02-Analgesics,Million of national currency units,250.3
3285,Belgium,2012,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
3286,Belgium,2012,6,N02-Analgesics,Million US$ at exchange rate,321.5
3287,Belgium,2012,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",650.4
3288,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.4
3289,Belgium,2012,6,Total pharmaceutical sales,Million US$ at exchange rate,7630.9
3290,Belgium,2012,6,Total pharmaceutical sales,Million of national currency units,5939.4
3291,Belgium,2012,6,Total pharmaceutical sales,"/capita, US$ exchange rate",687.0
3292,Belgium,2012,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7224.3
3293,Belgium,2012,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",188.8
3294,Belgium,2012,6,A10-Drugs used in diabetes,Million of national currency units,155.2
3295,Belgium,2012,6,A10-Drugs used in diabetes,Million US$ at exchange rate,199.4
3296,Belgium,2012,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.0
3297,Belgium,2012,6,N-Nervous system,% of total sales,16.9
3298,Belgium,2012,6,A10-Drugs used in diabetes,% of total sales,2.6
3299,Belgium,2012,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.0
3300,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
3301,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.8
3302,Belgium,2012,6,N05B-Anxiolytics,% of total sales,1.1
3303,Belgium,2012,6,N05B-Anxiolytics,"/capita, US$ exchange rate",7.4
3304,Belgium,2012,6,N05B-Anxiolytics,"Million US$, purchasing power parity",77.6
3305,Belgium,2012,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.0
3306,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.6
3307,Belgium,2012,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
3308,Belgium,2012,6,C01A-Cardiac glycosides,% of total sales,0.0
3309,Belgium,2012,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
3310,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",142.5
3311,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,117.2
3312,Belgium,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,150.6
3313,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",151.0
3314,Belgium,2012,6,N-Nervous system,Million of national currency units,1005.5
3315,Belgium,2012,6,C02-Antihypertensives,Million of national currency units,19.6
3316,Belgium,2012,6,N-Nervous system,Million US$ at exchange rate,1291.9
3317,Belgium,2012,6,N-Nervous system,"/capita, US$ exchange rate",116.3
3318,Belgium,2012,6,N-Nervous system,"/capita, US$ purchasing power parity",110.1
3319,Belgium,2012,6,C02-Antihypertensives,Million US$ at exchange rate,25.2
3320,Belgium,2012,6,N-Nervous system,"Million US$, purchasing power parity",1223.1
3321,Belgium,2012,6,C02-Antihypertensives,% of total sales,0.3
3322,Belgium,2012,6,N05B-Anxiolytics,Million of national currency units,63.8
3323,Belgium,2012,6,N05B-Anxiolytics,Million US$ at exchange rate,82.0
3324,Belgium,2012,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,159.5
3325,Belgium,2012,6,C02-Antihypertensives,"Million US$, purchasing power parity",23.9
3326,Belgium,2012,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
3327,Belgium,2012,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1
3328,Belgium,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.6
3329,Belgium,2012,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",308.6
3330,Belgium,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.4
3331,Belgium,2012,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,326.0
3332,Belgium,2012,6,J01-Antibacterials for systemic use,Million of national currency units,225.8
3333,Belgium,2012,6,R03-Drugs for obstructive airway diseases,Million of national currency units,253.7
3334,Belgium,2012,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.3
3335,Belgium,2012,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,290.2
3336,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,226.4
3337,Belgium,2012,6,A02A-Antacids,"/capita, US$ exchange rate",1.3
3338,Belgium,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.8
3339,Belgium,2012,6,R03-Drugs for obstructive airway diseases,% of total sales,4.3
3340,Belgium,2012,6,C10-Lipid modifying agents,Million US$ at exchange rate,379.9
3341,Belgium,2012,6,C08-Calcium channel blockers,% of total sales,1.1
3342,Belgium,2012,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",32.4
3343,Belgium,2012,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.4
3344,Belgium,2012,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.0
3345,Belgium,2012,6,A02A-Antacids,Million US$ at exchange rate,14.9
3346,Belgium,2012,6,A02A-Antacids,"Million US$, purchasing power parity",14.1
3347,Belgium,2012,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",34.2
3348,Belgium,2012,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",359.7
3349,Belgium,2012,6,A02A-Antacids,Million of national currency units,11.6
3350,Belgium,2012,6,A02A-Antacids,% of total sales,0.2
3351,Belgium,2012,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",140.7
3352,Belgium,2012,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",52.1
3353,Belgium,2012,6,Products not elsewhere classified,% of total sales,21.6
3354,Belgium,2012,6,Products not elsewhere classified,"/capita, US$ exchange rate",148.6
3355,Belgium,2012,6,Products not elsewhere classified,Million of national currency units,1284.3
3356,Belgium,2012,6,Products not elsewhere classified,Million US$ at exchange rate,1650.1
3357,Belgium,2012,6,Products not elsewhere classified,"Million US$, purchasing power parity",1562.2
3358,Belgium,2012,6,C10-Lipid modifying agents,% of total sales,5.0
3359,Belgium,2012,6,C10-Lipid modifying agents,Million of national currency units,295.7
3360,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.8
3361,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.8
3362,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.2
3363,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,290.9
3364,Belgium,2012,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",275.4
3365,Belgium,2012,6,B-Blood and blood forming organs,% of total sales,7.6
3366,Belgium,2012,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",49.3
3367,Belgium,2012,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",548.0
3368,Belgium,2012,6,B-Blood and blood forming organs,Million of national currency units,450.6
3369,Belgium,2012,6,B-Blood and blood forming organs,Million US$ at exchange rate,578.9
3370,Belgium,2012,6,R-Respiratory system,"/capita, US$ purchasing power parity",56.6
3371,Belgium,2012,6,R-Respiratory system,% of total sales,8.7
3372,Belgium,2012,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.9
3373,Belgium,2012,6,R-Respiratory system,Million US$ at exchange rate,664.4
3374,Belgium,2012,6,R-Respiratory system,"Million US$, purchasing power parity",629.0
3375,Belgium,2012,6,R-Respiratory system,"/capita, US$ exchange rate",59.8
3376,Belgium,2012,6,J-Antiinfectives for systemic use,% of total sales,9.8
3377,Belgium,2012,6,C08-Calcium channel blockers,Million of national currency units,63.9
3378,Belgium,2012,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",67.5
3379,Belgium,2012,6,A-Alimentary tract and metabolism,% of total sales,10.9
3380,Belgium,2012,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",787.5
3381,Belgium,2012,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",74.9
3382,Belgium,2012,6,R-Respiratory system,Million of national currency units,517.1
3383,Belgium,2012,6,C-Cardiovascular system,Million of national currency units,840.1
3384,Belgium,2012,6,A-Alimentary tract and metabolism,Million of national currency units,647.4
3385,Belgium,2012,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,831.8
3386,Belgium,2012,6,C-Cardiovascular system,Million US$ at exchange rate,1079.3
3387,Belgium,2012,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,750.0
3388,Belgium,2012,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",710.0
3389,Belgium,2012,6,J-Antiinfectives for systemic use,Million of national currency units,583.7
3390,Belgium,2012,6,C-Cardiovascular system,"Million US$, purchasing power parity",1021.8
3391,Belgium,2012,6,C-Cardiovascular system,"/capita, US$ exchange rate",97.2
3392,Belgium,2012,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",63.9
3393,Belgium,2012,6,C08-Calcium channel blockers,Million US$ at exchange rate,82.0
3394,Belgium,2012,6,J01-Antibacterials for systemic use,% of total sales,3.8
3395,Belgium,2012,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",77.7
3396,Belgium,2012,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",274.7
3397,Belgium,2012,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",92.0
3398,Belgium,2012,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",24.7
3399,Belgium,2012,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.1
3400,Belgium,2012,6,C-Cardiovascular system,% of total sales,14.1
3401,Belgium,2016,5,C03-Diuretics,Million US$ at exchange rate,36.5
3402,Belgium,2016,5,C03-Diuretics,Million of national currency units,33.0
3403,Belgium,2016,5,C03-Diuretics,"Million US$, purchasing power parity",42.2
3404,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,126.2
3405,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,139.7
3406,Belgium,2016,5,N06A-Antidepressants,Million of national currency units,130.1
3407,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.3
3408,Belgium,2016,5,N06A-Antidepressants,Million US$ at exchange rate,144.0
3409,Belgium,2016,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
3410,Belgium,2016,5,C03-Diuretics,"/capita, US$ exchange rate",3.2
3411,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",161.6
3412,Belgium,2016,5,C03-Diuretics,% of total sales,0.5
3413,Belgium,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,249.6
3414,Belgium,2016,5,N05C-Hypnotics and sedatives,Million of national currency units,77.6
3415,Belgium,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.5
3416,Belgium,2016,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,85.9
3417,Belgium,2016,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0
3418,Belgium,2016,5,C01A-Cardiac glycosides,Million of national currency units,0.9
3419,Belgium,2016,5,G-Genito urinary system and sex hormones,% of total sales,3.6
3420,Belgium,2016,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",99.4
3421,Belgium,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.0
3422,Belgium,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",288.7
3423,Belgium,2016,5,N05C-Hypnotics and sedatives,% of total sales,1.2
3424,Belgium,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.6
3425,Belgium,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.8
3426,Belgium,2016,5,N06A-Antidepressants,"Million US$, purchasing power parity",166.5
3427,Belgium,2016,5,C07-Beta blocking agents,% of total sales,1.4
3428,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
3429,Belgium,2016,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.7
3430,Belgium,2016,5,C07-Beta blocking agents,"Million US$, purchasing power parity",110.3
3431,Belgium,2016,5,C07-Beta blocking agents,Million US$ at exchange rate,95.3
3432,Belgium,2016,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.4
3433,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",18.4
3434,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,163.2
3435,Belgium,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,225.5
3436,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,109.3
3437,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,180.7
3438,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.9
3439,Belgium,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",209.0
3440,Belgium,2016,5,M-Musculo-skeletal system,% of total sales,4.1
3441,Belgium,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",24.8
3442,Belgium,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.7
3443,Belgium,2016,5,N06A-Antidepressants,% of total sales,2.1
3444,Belgium,2016,5,N06A-Antidepressants,"/capita, US$ exchange rate",12.7
3445,Belgium,2016,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.7
3446,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.3
3447,Belgium,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
3448,Belgium,2016,5,C07-Beta blocking agents,Million of national currency units,86.1
3449,Belgium,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",325.6
3450,Belgium,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,281.5
3451,Belgium,2016,5,M-Musculo-skeletal system,Million of national currency units,254.3
3452,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.0
3453,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,16.4
3454,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
3455,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.4
3456,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.4
3457,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
3458,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,14.8
3459,Belgium,2016,5,N02-Analgesics,"/capita, US$ exchange rate",24.1
3460,Belgium,2016,5,N02-Analgesics,"Million US$, purchasing power parity",316.0
3461,Belgium,2016,5,N02-Analgesics,% of total sales,4.0
3462,Belgium,2016,5,N02-Analgesics,"/capita, US$ purchasing power parity",27.9
3463,Belgium,2016,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
3464,Belgium,2016,5,N02-Analgesics,Million of national currency units,246.8
3465,Belgium,2016,5,N02-Analgesics,Million US$ at exchange rate,273.2
3466,Belgium,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",705.4
3467,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",140.0
3468,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.7
3469,Belgium,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",609.8
3470,Belgium,2016,5,N-Nervous system,% of total sales,14.6
3471,Belgium,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,6910.0
3472,Belgium,2016,5,Total pharmaceutical sales,Million of national currency units,6242.6
3473,Belgium,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",7993.0
3474,Belgium,2016,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",245.6
3475,Belgium,2016,5,A10-Drugs used in diabetes,Million US$ at exchange rate,212.4
3476,Belgium,2016,5,A10-Drugs used in diabetes,Million of national currency units,191.8
3477,Belgium,2016,5,A10-Drugs used in diabetes,% of total sales,3.1
3478,Belgium,2016,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.7
3479,Belgium,2016,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.7
3480,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
3481,Belgium,2016,5,N05B-Anxiolytics,% of total sales,1.2
3482,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.6
3483,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.3
3484,Belgium,2016,5,N05B-Anxiolytics,"Million US$, purchasing power parity",92.8
3485,Belgium,2016,5,N05B-Anxiolytics,"/capita, US$ exchange rate",7.1
3486,Belgium,2016,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.2
3487,Belgium,2016,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
3488,Belgium,2016,5,C01A-Cardiac glycosides,% of total sales,0.0
3489,Belgium,2016,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.1
3490,Belgium,2016,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
3491,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",139.6
3492,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,120.7
3493,Belgium,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,109.0
3494,Belgium,2016,5,N-Nervous system,Million of national currency units,910.9
3495,Belgium,2016,5,C02-Antihypertensives,Million of national currency units,25.9
3496,Belgium,2016,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,121.0
3497,Belgium,2016,5,N-Nervous system,"/capita, US$ exchange rate",89.0
3498,Belgium,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",102.9
3499,Belgium,2016,5,N-Nervous system,Million US$ at exchange rate,1008.3
3500,Belgium,2016,5,N-Nervous system,"Million US$, purchasing power parity",1166.3
3501,Belgium,2016,5,C02-Antihypertensives,% of total sales,0.4
3502,Belgium,2016,5,N05B-Anxiolytics,Million US$ at exchange rate,80.2
3503,Belgium,2016,5,N05B-Anxiolytics,Million of national currency units,72.5
3504,Belgium,2016,5,C02-Antihypertensives,"Million US$, purchasing power parity",33.2
3505,Belgium,2016,5,C02-Antihypertensives,Million US$ at exchange rate,28.7
3506,Belgium,2016,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.9
3507,Belgium,2016,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.5
3508,Belgium,2016,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,269.6
3509,Belgium,2016,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",311.9
3510,Belgium,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.8
3511,Belgium,2016,5,J01-Antibacterials for systemic use,Million of national currency units,197.1
3512,Belgium,2016,5,A02A-Antacids,"Million US$, purchasing power parity",12.5
3513,Belgium,2016,5,R03-Drugs for obstructive airway diseases,Million of national currency units,243.6
3514,Belgium,2016,5,A02A-Antacids,"/capita, US$ exchange rate",1.0
3515,Belgium,2016,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.1
3516,Belgium,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.5
3517,Belgium,2016,5,R03-Drugs for obstructive airway diseases,% of total sales,3.9
3518,Belgium,2016,5,C08-Calcium channel blockers,% of total sales,0.7
3519,Belgium,2016,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.6
3520,Belgium,2016,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5
3521,Belgium,2016,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.2
3522,Belgium,2016,5,A02A-Antacids,Million US$ at exchange rate,10.8
3523,Belgium,2016,5,C10-Lipid modifying agents,Million US$ at exchange rate,241.4
3524,Belgium,2016,5,A02A-Antacids,Million of national currency units,9.8
3525,Belgium,2016,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.3
3526,Belgium,2016,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",279.3
3527,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,190.4
3528,Belgium,2016,5,A02A-Antacids,% of total sales,0.2
3529,Belgium,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",187.2
3530,Belgium,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",161.8
3531,Belgium,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",54.7
3532,Belgium,2016,5,Products not elsewhere classified,% of total sales,26.5
3533,Belgium,2016,5,Products not elsewhere classified,Million of national currency units,1656.3
3534,Belgium,2016,5,Products not elsewhere classified,Million US$ at exchange rate,1833.4
3535,Belgium,2016,5,C10-Lipid modifying agents,Million of national currency units,218.1
3536,Belgium,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",2120.7
3537,Belgium,2016,5,C10-Lipid modifying agents,% of total sales,3.5
3538,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",18.6
3539,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",21.5
3540,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,210.7
3541,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.0
3542,Belgium,2016,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",243.7
3543,Belgium,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",716.6
3544,Belgium,2016,5,B-Blood and blood forming organs,% of total sales,9.0
3545,Belgium,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",63.2
3546,Belgium,2016,5,B-Blood and blood forming organs,Million of national currency units,559.7
3547,Belgium,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,619.5
3548,Belgium,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",57.7
3549,Belgium,2016,5,R-Respiratory system,% of total sales,8.2
3550,Belgium,2016,5,R-Respiratory system,Million US$ at exchange rate,565.2
3551,Belgium,2016,5,R-Respiratory system,"/capita, US$ exchange rate",49.9
3552,Belgium,2016,5,R-Respiratory system,"Million US$, purchasing power parity",653.8
3553,Belgium,2016,5,J-Antiinfectives for systemic use,% of total sales,10.2
3554,Belgium,2016,5,C08-Calcium channel blockers,Million of national currency units,45.9
3555,Belgium,2016,5,A-Alimentary tract and metabolism,% of total sales,10.9
3556,Belgium,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",62.0
3557,Belgium,2016,5,C-Cardiovascular system,% of total sales,11.0
3558,Belgium,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",76.6
3559,Belgium,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",71.7
3560,Belgium,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",867.6
3561,Belgium,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",66.2
3562,Belgium,2016,5,C-Cardiovascular system,Million of national currency units,686.7
3563,Belgium,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,750.1
3564,Belgium,2016,5,A-Alimentary tract and metabolism,Million of national currency units,677.6
3565,Belgium,2016,5,J-Antiinfectives for systemic use,Million of national currency units,634.8
3566,Belgium,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,702.6
3567,Belgium,2016,5,R-Respiratory system,Million of national currency units,510.7
3568,Belgium,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",812.7
3569,Belgium,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",879.3
3570,Belgium,2016,5,C-Cardiovascular system,Million US$ at exchange rate,760.2
3571,Belgium,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",67.1
3572,Belgium,2016,5,C08-Calcium channel blockers,Million US$ at exchange rate,50.9
3573,Belgium,2016,5,J01-Antibacterials for systemic use,% of total sales,3.2
3574,Belgium,2016,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",58.8
3575,Belgium,2016,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",252.4
3576,Belgium,2016,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,218.2
3577,Belgium,2016,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.3
3578,Belgium,2016,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",19.3
3579,Belgium,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",77.6
3580,Belgium,2014,6,C03-Diuretics,Million US$ at exchange rate,46.1
3581,Belgium,2014,6,C03-Diuretics,"Million US$, purchasing power parity",43.4
3582,Belgium,2014,6,C03-Diuretics,Million of national currency units,34.7
3583,Belgium,2014,6,C03-Diuretics,"/capita, US$ exchange rate",4.1
3584,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,123.1
3585,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",153.8
3586,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,163.6
3587,Belgium,2014,6,N06A-Antidepressants,Million of national currency units,179.1
3588,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.6
3589,Belgium,2014,6,N06A-Antidepressants,Million US$ at exchange rate,238.0
3590,Belgium,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.9
3591,Belgium,2014,6,C03-Diuretics,% of total sales,0.6
3592,Belgium,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,301.1
3593,Belgium,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,75.3
3594,Belgium,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.3
3595,Belgium,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,100.0
3596,Belgium,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5
3597,Belgium,2014,6,G-Genito urinary system and sex hormones,% of total sales,3.8
3598,Belgium,2014,6,C01A-Cardiac glycosides,Million of national currency units,1.1
3599,Belgium,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",94.0
3600,Belgium,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",26.9
3601,Belgium,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",283.2
3602,Belgium,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.9
3603,Belgium,2014,6,N05C-Hypnotics and sedatives,% of total sales,1.3
3604,Belgium,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.4
3605,Belgium,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",223.8
3606,Belgium,2014,6,C07-Beta blocking agents,% of total sales,1.5
3607,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
3608,Belgium,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.2
3609,Belgium,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",114.8
3610,Belgium,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,122.1
3611,Belgium,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",10.9
3612,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,144.1
3613,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,113.7
3614,Belgium,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,226.7
3615,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,191.4
3616,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.1
3617,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",16.1
3618,Belgium,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",180.0
3619,Belgium,2014,6,M-Musculo-skeletal system,% of total sales,4.3
3620,Belgium,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.4
3621,Belgium,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",21.2
3622,Belgium,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",30.2
3623,Belgium,2014,6,N06A-Antidepressants,% of total sales,3.0
3624,Belgium,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.0
3625,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
3626,Belgium,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.7
3627,Belgium,2014,6,C07-Beta blocking agents,Million of national currency units,91.9
3628,Belgium,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",318.5
3629,Belgium,2014,6,M-Musculo-skeletal system,Million of national currency units,254.9
3630,Belgium,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,338.6
3631,Belgium,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
3632,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.4
3633,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
3634,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.8
3635,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,20.6
3636,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.9
3637,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.7
3638,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.5
3639,Belgium,2014,6,N02-Analgesics,"/capita, US$ exchange rate",28.0
3640,Belgium,2014,6,N02-Analgesics,% of total sales,4.0
3641,Belgium,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",26.3
3642,Belgium,2014,6,N02-Analgesics,"Million US$, purchasing power parity",295.3
3643,Belgium,2014,6,N02-Analgesics,Million of national currency units,236.3
3644,Belgium,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
3645,Belgium,2014,6,N02-Analgesics,Million US$ at exchange rate,314.0
3646,Belgium,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",663.1
3647,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.5
3648,Belgium,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,7901.2
3649,Belgium,2014,6,Total pharmaceutical sales,Million of national currency units,5947.5
3650,Belgium,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7432.3
3651,Belgium,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",704.9
3652,Belgium,2014,6,N-Nervous system,% of total sales,16.1
3653,Belgium,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",214.2
3654,Belgium,2014,6,A10-Drugs used in diabetes,Million of national currency units,171.4
3655,Belgium,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,227.7
3656,Belgium,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.3
3657,Belgium,2014,6,A10-Drugs used in diabetes,% of total sales,2.9
3658,Belgium,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.1
3659,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
3660,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.4
3661,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.1
3662,Belgium,2014,6,N05B-Anxiolytics,% of total sales,1.2
3663,Belgium,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",8.3
3664,Belgium,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",87.8
3665,Belgium,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.8
3666,Belgium,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
3667,Belgium,2014,6,C01A-Cardiac glycosides,% of total sales,0.0
3668,Belgium,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
3669,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",138.5
3670,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,147.2
3671,Belgium,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,110.8
3672,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",142.0
3673,Belgium,2014,6,N-Nervous system,Million of national currency units,958.5
3674,Belgium,2014,6,C02-Antihypertensives,Million of national currency units,20.2
3675,Belgium,2014,6,N-Nervous system,Million US$ at exchange rate,1273.4
3676,Belgium,2014,6,N-Nervous system,"/capita, US$ exchange rate",113.6
3677,Belgium,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",106.9
3678,Belgium,2014,6,N-Nervous system,"Million US$, purchasing power parity",1197.8
3679,Belgium,2014,6,C02-Antihypertensives,% of total sales,0.3
3680,Belgium,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,93.4
3681,Belgium,2014,6,N05B-Anxiolytics,Million of national currency units,70.3
3682,Belgium,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,151.0
3683,Belgium,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",25.2
3684,Belgium,2014,6,C02-Antihypertensives,Million US$ at exchange rate,26.8
3685,Belgium,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.2
3686,Belgium,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.4
3687,Belgium,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,333.1
3688,Belgium,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",313.3
3689,Belgium,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.7
3690,Belgium,2014,6,J01-Antibacterials for systemic use,Million of national currency units,213.6
3691,Belgium,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,250.7
3692,Belgium,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.2
3693,Belgium,2014,6,A02A-Antacids,"/capita, US$ exchange rate",1.2
3694,Belgium,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.0
3695,Belgium,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,4.2
3696,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,199.3
3697,Belgium,2014,6,C08-Calcium channel blockers,% of total sales,1.0
3698,Belgium,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.2
3699,Belgium,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.8
3700,Belgium,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.4
3701,Belgium,2014,6,A02A-Antacids,Million US$ at exchange rate,13.9
3702,Belgium,2014,6,A02A-Antacids,"Million US$, purchasing power parity",13.1
3703,Belgium,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,300.6
3704,Belgium,2014,6,A02A-Antacids,Million of national currency units,10.5
3705,Belgium,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",26.8
3706,Belgium,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",282.8
3707,Belgium,2014,6,A02A-Antacids,% of total sales,0.2
3708,Belgium,2014,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",160.9
3709,Belgium,2014,6,Products not elsewhere classified,"/capita, US$ exchange rate",171.1
3710,Belgium,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",59.4
3711,Belgium,2014,6,Products not elsewhere classified,% of total sales,24.3
3712,Belgium,2014,6,Products not elsewhere classified,Million of national currency units,1443.5
3713,Belgium,2014,6,Products not elsewhere classified,Million US$ at exchange rate,1917.7
3714,Belgium,2014,6,C10-Lipid modifying agents,Million of national currency units,226.3
3715,Belgium,2014,6,Products not elsewhere classified,"Million US$, purchasing power parity",1803.9
3716,Belgium,2014,6,C10-Lipid modifying agents,% of total sales,3.8
3717,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.6
3718,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.2
3719,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.4
3720,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,264.8
3721,Belgium,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",249.1
3722,Belgium,2014,6,B-Blood and blood forming organs,% of total sales,8.4
3723,Belgium,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",55.9
3724,Belgium,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",626.5
3725,Belgium,2014,6,B-Blood and blood forming organs,Million of national currency units,501.4
3726,Belgium,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,666.1
3727,Belgium,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",56.4
3728,Belgium,2014,6,R-Respiratory system,% of total sales,8.5
3729,Belgium,2014,6,R-Respiratory system,Million US$ at exchange rate,671.6
3730,Belgium,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.6
3731,Belgium,2014,6,R-Respiratory system,"Million US$, purchasing power parity",631.7
3732,Belgium,2014,6,R-Respiratory system,"/capita, US$ exchange rate",59.9
3733,Belgium,2014,6,J-Antiinfectives for systemic use,% of total sales,9.7
3734,Belgium,2014,6,C08-Calcium channel blockers,Million of national currency units,57.1
3735,Belgium,2014,6,A-Alimentary tract and metabolism,% of total sales,10.6
3736,Belgium,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",68.3
3737,Belgium,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",64.3
3738,Belgium,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",791.5
3739,Belgium,2014,6,R-Respiratory system,Million of national currency units,505.5
3740,Belgium,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",75.1
3741,Belgium,2014,6,C-Cardiovascular system,Million of national currency units,724.2
3742,Belgium,2014,6,A-Alimentary tract and metabolism,Million of national currency units,633.4
3743,Belgium,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,841.4
3744,Belgium,2014,6,C-Cardiovascular system,Million US$ at exchange rate,962.1
3745,Belgium,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,765.8
3746,Belgium,2014,6,J-Antiinfectives for systemic use,Million of national currency units,576.4
3747,Belgium,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",720.3
3748,Belgium,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",905.0
3749,Belgium,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",85.8
3750,Belgium,2014,6,J01-Antibacterials for systemic use,% of total sales,3.6
3751,Belgium,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,75.9
3752,Belgium,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",80.7
3753,Belgium,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",71.4
3754,Belgium,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,283.7
3755,Belgium,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",266.9
3756,Belgium,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",23.8
3757,Belgium,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",25.3
3758,Belgium,2014,6,C-Cardiovascular system,% of total sales,12.2
3759,Belgium,2015,5,C03-Diuretics,Million US$ at exchange rate,37.2
3760,Belgium,2015,5,C03-Diuretics,Million of national currency units,33.5
3761,Belgium,2015,5,C03-Diuretics,"Million US$, purchasing power parity",41.9
3762,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,126.9
3763,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",158.6
3764,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,140.8
3765,Belgium,2015,5,C03-Diuretics,"/capita, US$ exchange rate",3.3
3766,Belgium,2015,5,N06A-Antidepressants,Million of national currency units,155.6
3767,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.5
3768,Belgium,2015,5,N06A-Antidepressants,Million US$ at exchange rate,172.7
3769,Belgium,2015,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
3770,Belgium,2015,5,C03-Diuretics,% of total sales,0.5
3771,Belgium,2015,5,N05C-Hypnotics and sedatives,Million of national currency units,78.0
3772,Belgium,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.9
3773,Belgium,2015,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,86.6
3774,Belgium,2015,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.1
3775,Belgium,2015,5,G-Genito urinary system and sex hormones,% of total sales,3.6
3776,Belgium,2015,5,C01A-Cardiac glycosides,Million of national currency units,1.0
3777,Belgium,2015,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",97.6
3778,Belgium,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.1
3779,Belgium,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",280.9
3780,Belgium,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,249.3
3781,Belgium,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.7
3782,Belgium,2015,5,N05C-Hypnotics and sedatives,% of total sales,1.3
3783,Belgium,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.7
3784,Belgium,2015,5,C07-Beta blocking agents,% of total sales,1.4
3785,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5
3786,Belgium,2015,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.7
3787,Belgium,2015,5,C07-Beta blocking agents,"Million US$, purchasing power parity",109.2
3788,Belgium,2015,5,C07-Beta blocking agents,Million US$ at exchange rate,96.9
3789,Belgium,2015,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.6
3790,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,154.7
3791,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,111.0
3792,Belgium,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,224.7
3793,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,171.7
3794,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.2
3795,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.2
3796,Belgium,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",193.4
3797,Belgium,2015,5,M-Musculo-skeletal system,% of total sales,4.1
3798,Belgium,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.2
3799,Belgium,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.4
3800,Belgium,2015,5,N06A-Antidepressants,"/capita, US$ exchange rate",15.3
3801,Belgium,2015,5,N06A-Antidepressants,% of total sales,2.5
3802,Belgium,2015,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.3
3803,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.1
3804,Belgium,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
3805,Belgium,2015,5,C07-Beta blocking agents,Million of national currency units,87.3
3806,Belgium,2015,5,N06A-Antidepressants,"Million US$, purchasing power parity",194.5
3807,Belgium,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",320.4
3808,Belgium,2015,5,M-Musculo-skeletal system,Million of national currency units,256.3
3809,Belgium,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,284.4
3810,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",138.8
3811,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.1
3812,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
3813,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5
3814,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,16.9
3815,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
3816,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.3
3817,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.3
3818,Belgium,2015,5,N02-Analgesics,"/capita, US$ exchange rate",23.6
3819,Belgium,2015,5,N02-Analgesics,% of total sales,3.9
3820,Belgium,2015,5,N02-Analgesics,"/capita, US$ purchasing power parity",26.6
3821,Belgium,2015,5,N02-Analgesics,"Million US$, purchasing power parity",299.9
3822,Belgium,2015,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
3823,Belgium,2015,5,N02-Analgesics,Million of national currency units,239.9
3824,Belgium,2015,5,N02-Analgesics,Million US$ at exchange rate,266.2
3825,Belgium,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",686.5
3826,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.9
3827,Belgium,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",609.3
3828,Belgium,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,6869.7
3829,Belgium,2015,5,Total pharmaceutical sales,Million of national currency units,6191.6
3830,Belgium,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",7739.6
3831,Belgium,2015,5,N-Nervous system,% of total sales,15.2
3832,Belgium,2015,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",223.5
3833,Belgium,2015,5,A10-Drugs used in diabetes,Million of national currency units,178.8
3834,Belgium,2015,5,A10-Drugs used in diabetes,Million US$ at exchange rate,198.4
3835,Belgium,2015,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.6
3836,Belgium,2015,5,A10-Drugs used in diabetes,% of total sales,2.9
3837,Belgium,2015,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.8
3838,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
3839,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.8
3840,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.2
3841,Belgium,2015,5,N05B-Anxiolytics,% of total sales,1.1
3842,Belgium,2015,5,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9
3843,Belgium,2015,5,N05B-Anxiolytics,"Million US$, purchasing power parity",87.1
3844,Belgium,2015,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.7
3845,Belgium,2015,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
3846,Belgium,2015,5,C01A-Cardiac glycosides,% of total sales,0.0
3847,Belgium,2015,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2
3848,Belgium,2015,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
3849,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",137.2
3850,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,109.7
3851,Belgium,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,121.7
3852,Belgium,2015,5,N-Nervous system,Million of national currency units,940.8
3853,Belgium,2015,5,C02-Antihypertensives,Million of national currency units,24.3
3854,Belgium,2015,5,N-Nervous system,"/capita, US$ exchange rate",92.6
3855,Belgium,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",104.3
3856,Belgium,2015,5,N-Nervous system,Million US$ at exchange rate,1043.8
3857,Belgium,2015,5,N-Nervous system,"Million US$, purchasing power parity",1176.0
3858,Belgium,2015,5,C02-Antihypertensives,Million US$ at exchange rate,27.0
3859,Belgium,2015,5,C02-Antihypertensives,% of total sales,0.4
3860,Belgium,2015,5,N05B-Anxiolytics,Million US$ at exchange rate,77.3
3861,Belgium,2015,5,N05B-Anxiolytics,Million of national currency units,69.7
3862,Belgium,2015,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,123.2
3863,Belgium,2015,5,C02-Antihypertensives,"Million US$, purchasing power parity",30.4
3864,Belgium,2015,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.7
3865,Belgium,2015,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.4
3866,Belgium,2015,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,274.9
3867,Belgium,2015,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",309.7
3868,Belgium,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.4
3869,Belgium,2015,5,J01-Antibacterials for systemic use,Million of national currency units,215.7
3870,Belgium,2015,5,R03-Drugs for obstructive airway diseases,Million of national currency units,247.8
3871,Belgium,2015,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.1
3872,Belgium,2015,5,A02A-Antacids,"/capita, US$ exchange rate",1.0
3873,Belgium,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.5
3874,Belgium,2015,5,R03-Drugs for obstructive airway diseases,% of total sales,4.0
3875,Belgium,2015,5,C08-Calcium channel blockers,% of total sales,0.8
3876,Belgium,2015,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.4
3877,Belgium,2015,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.8
3878,Belgium,2015,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.4
3879,Belgium,2015,5,A02A-Antacids,Million US$ at exchange rate,11.1
3880,Belgium,2015,5,A02A-Antacids,"Million US$, purchasing power parity",12.5
3881,Belgium,2015,5,C10-Lipid modifying agents,Million US$ at exchange rate,243.8
3882,Belgium,2015,5,A02A-Antacids,Million of national currency units,10.0
3883,Belgium,2015,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.6
3884,Belgium,2015,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",274.7
3885,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,196.5
3886,Belgium,2015,5,A02A-Antacids,% of total sales,0.2
3887,Belgium,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",173.0
3888,Belgium,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",153.6
3889,Belgium,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",51.4
3890,Belgium,2015,5,Products not elsewhere classified,% of total sales,25.2
3891,Belgium,2015,5,Products not elsewhere classified,Million of national currency units,1560.4
3892,Belgium,2015,5,Products not elsewhere classified,Million US$ at exchange rate,1731.3
3893,Belgium,2015,5,C10-Lipid modifying agents,Million of national currency units,219.7
3894,Belgium,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",1950.5
3895,Belgium,2015,5,C10-Lipid modifying agents,% of total sales,3.5
3896,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",19.3
3897,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",21.8
3898,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.2
3899,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,218.0
3900,Belgium,2015,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",245.6
3901,Belgium,2015,5,B-Blood and blood forming organs,% of total sales,8.4
3902,Belgium,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",58.0
3903,Belgium,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",653.4
3904,Belgium,2015,5,B-Blood and blood forming organs,Million of national currency units,522.8
3905,Belgium,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,580.0
3906,Belgium,2015,5,C-Cardiovascular system,% of total sales,11.3
3907,Belgium,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",58.3
3908,Belgium,2015,5,R-Respiratory system,% of total sales,8.5
3909,Belgium,2015,5,R-Respiratory system,Million US$ at exchange rate,583.5
3910,Belgium,2015,5,R-Respiratory system,"/capita, US$ exchange rate",51.8
3911,Belgium,2015,5,R-Respiratory system,"Million US$, purchasing power parity",657.4
3912,Belgium,2015,5,J-Antiinfectives for systemic use,% of total sales,11.0
3913,Belgium,2015,5,C08-Calcium channel blockers,Million of national currency units,48.6
3914,Belgium,2015,5,A-Alimentary tract and metabolism,% of total sales,10.5
3915,Belgium,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",67.0
3916,Belgium,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",75.5
3917,Belgium,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.2
3918,Belgium,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",814.2
3919,Belgium,2015,5,R-Respiratory system,Million of national currency units,525.9
3920,Belgium,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.1
3921,Belgium,2015,5,C-Cardiovascular system,Million of national currency units,701.7
3922,Belgium,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,722.7
3923,Belgium,2015,5,A-Alimentary tract and metabolism,Million of national currency units,651.4
3924,Belgium,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,755.4
3925,Belgium,2015,5,J-Antiinfectives for systemic use,Million of national currency units,680.8
3926,Belgium,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",851.0
3927,Belgium,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",877.1
3928,Belgium,2015,5,C-Cardiovascular system,Million US$ at exchange rate,778.5
3929,Belgium,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",69.1
3930,Belgium,2015,5,C08-Calcium channel blockers,Million US$ at exchange rate,53.9
3931,Belgium,2015,5,J01-Antibacterials for systemic use,% of total sales,3.5
3932,Belgium,2015,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",60.7
3933,Belgium,2015,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",269.6
3934,Belgium,2015,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,239.3
3935,Belgium,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",77.8
3936,Belgium,2015,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",23.9
3937,Belgium,2015,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",21.2
3938,Belgium,2013,6,C03-Diuretics,Million US$ at exchange rate,46.8
3939,Belgium,2013,6,C03-Diuretics,"/capita, US$ exchange rate",4.2
3940,Belgium,2013,6,C03-Diuretics,"Million US$, purchasing power parity",43.7
3941,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,124.8
3942,Belgium,2013,6,C03-Diuretics,Million of national currency units,35.2
3943,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,165.8
3944,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",154.8
3945,Belgium,2013,6,N06A-Antidepressants,Million of national currency units,181.3
3946,Belgium,2013,6,N06A-Antidepressants,Million US$ at exchange rate,240.8
3947,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.9
3948,Belgium,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.9
3949,Belgium,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,308.1
3950,Belgium,2013,6,C03-Diuretics,% of total sales,0.6
3951,Belgium,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,75.4
3952,Belgium,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.8
3953,Belgium,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,100.2
3954,Belgium,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.6
3955,Belgium,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",93.6
3956,Belgium,2013,6,G-Genito urinary system and sex hormones,% of total sales,3.9
3957,Belgium,2013,6,C01A-Cardiac glycosides,Million of national currency units,1.2
3958,Belgium,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.6
3959,Belgium,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",224.9
3960,Belgium,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",287.7
3961,Belgium,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.0
3962,Belgium,2013,6,N05C-Hypnotics and sedatives,% of total sales,1.3
3963,Belgium,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.4
3964,Belgium,2013,6,C07-Beta blocking agents,% of total sales,1.6
3965,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
3966,Belgium,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.8
3967,Belgium,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",120.4
3968,Belgium,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",11.6
3969,Belgium,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,128.9
3970,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,142.9
3971,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,118.0
3972,Belgium,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,232.0
3973,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,189.8
3974,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.0
3975,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.9
3976,Belgium,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",177.2
3977,Belgium,2013,6,M-Musculo-skeletal system,% of total sales,4.2
3978,Belgium,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.0
3979,Belgium,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",21.6
3980,Belgium,2013,6,N06A-Antidepressants,% of total sales,3.0
3981,Belgium,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.2
3982,Belgium,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",30.0
3983,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
3984,Belgium,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.9
3985,Belgium,2013,6,C07-Beta blocking agents,Million of national currency units,97.1
3986,Belgium,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",312.5
3987,Belgium,2013,6,M-Musculo-skeletal system,Million of national currency units,251.9
3988,Belgium,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,334.6
3989,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.1
3990,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
3991,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.8
3992,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,2.0
3993,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",13.1
3994,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,15.4
3995,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,20.5
3996,Belgium,2013,6,N02-Analgesics,"/capita, US$ exchange rate",29.2
3997,Belgium,2013,6,N02-Analgesics,% of total sales,4.1
3998,Belgium,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",27.3
3999,Belgium,2013,6,N02-Analgesics,"Million US$, purchasing power parity",304.5
4000,Belgium,2013,6,N02-Analgesics,Million of national currency units,245.5
4001,Belgium,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
4002,Belgium,2013,6,N02-Analgesics,Million US$ at exchange rate,326.1
4003,Belgium,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",661.1
4004,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.0
4005,Belgium,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",707.9
4006,Belgium,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,7899.5
4007,Belgium,2013,6,Total pharmaceutical sales,Million of national currency units,5947.9
4008,Belgium,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",7378.0
4009,Belgium,2013,6,N-Nervous system,% of total sales,16.5
4010,Belgium,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",202.5
4011,Belgium,2013,6,A10-Drugs used in diabetes,Million of national currency units,163.2
4012,Belgium,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,216.8
4013,Belgium,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.4
4014,Belgium,2013,6,A10-Drugs used in diabetes,% of total sales,2.7
4015,Belgium,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.1
4016,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
4017,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.7
4018,Belgium,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",8.1
4019,Belgium,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",84.5
4020,Belgium,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.6
4021,Belgium,2013,6,N05B-Anxiolytics,% of total sales,1.1
4022,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.6
4023,Belgium,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
4024,Belgium,2013,6,C01A-Cardiac glycosides,% of total sales,0.0
4025,Belgium,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
4026,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",141.9
4027,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,114.4
4028,Belgium,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,151.9
4029,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",146.4
4030,Belgium,2013,6,N-Nervous system,Million of national currency units,978.6
4031,Belgium,2013,6,C02-Antihypertensives,Million of national currency units,19.3
4032,Belgium,2013,6,N-Nervous system,Million US$ at exchange rate,1299.7
4033,Belgium,2013,6,N-Nervous system,"/capita, US$ exchange rate",116.5
4034,Belgium,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",108.8
4035,Belgium,2013,6,N-Nervous system,"Million US$, purchasing power parity",1213.9
4036,Belgium,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
4037,Belgium,2013,6,C02-Antihypertensives,Million US$ at exchange rate,25.7
4038,Belgium,2013,6,C02-Antihypertensives,% of total sales,0.3
4039,Belgium,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,90.4
4040,Belgium,2013,6,N05B-Anxiolytics,Million of national currency units,68.1
4041,Belgium,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,156.7
4042,Belgium,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",24.0
4043,Belgium,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1
4044,Belgium,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
4045,Belgium,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,340.5
4046,Belgium,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",318.0
4047,Belgium,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.5
4048,Belgium,2013,6,J01-Antibacterials for systemic use,Million of national currency units,218.9
4049,Belgium,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,256.4
4050,Belgium,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",1.2
4051,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,218.2
4052,Belgium,2013,6,A02A-Antacids,"/capita, US$ exchange rate",1.3
4053,Belgium,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.5
4054,Belgium,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,4.3
4055,Belgium,2013,6,C08-Calcium channel blockers,% of total sales,1.0
4056,Belgium,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.9
4057,Belgium,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.4
4058,Belgium,2013,6,A02A-Antacids,Million US$ at exchange rate,14.7
4059,Belgium,2013,6,A02A-Antacids,"Million US$, purchasing power parity",13.8
4060,Belgium,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,337.2
4061,Belgium,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",30.2
4062,Belgium,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",314.9
4063,Belgium,2013,6,A02A-Antacids,Million of national currency units,11.1
4064,Belgium,2013,6,A02A-Antacids,% of total sales,0.2
4065,Belgium,2013,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",147.2
4066,Belgium,2013,6,Products not elsewhere classified,"/capita, US$ exchange rate",157.7
4067,Belgium,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",58.5
4068,Belgium,2013,6,Products not elsewhere classified,% of total sales,22.3
4069,Belgium,2013,6,Products not elsewhere classified,Million of national currency units,1324.7
4070,Belgium,2013,6,Products not elsewhere classified,Million US$ at exchange rate,1759.4
4071,Belgium,2013,6,C10-Lipid modifying agents,Million of national currency units,253.9
4072,Belgium,2013,6,Products not elsewhere classified,"Million US$, purchasing power parity",1643.2
4073,Belgium,2013,6,C10-Lipid modifying agents,% of total sales,4.3
4074,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.0
4075,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.2
4076,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.7
4077,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,289.7
4078,Belgium,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",270.6
4079,Belgium,2013,6,B-Blood and blood forming organs,% of total sales,8.3
4080,Belgium,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",54.6
4081,Belgium,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",609.2
4082,Belgium,2013,6,B-Blood and blood forming organs,Million of national currency units,491.1
4083,Belgium,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,652.3
4084,Belgium,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",28.2
4085,Belgium,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",59.0
4086,Belgium,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.2
4087,Belgium,2013,6,R-Respiratory system,% of total sales,8.9
4088,Belgium,2013,6,R-Respiratory system,Million US$ at exchange rate,705.1
4089,Belgium,2013,6,R-Respiratory system,"/capita, US$ exchange rate",63.2
4090,Belgium,2013,6,R-Respiratory system,"Million US$, purchasing power parity",658.5
4091,Belgium,2013,6,J-Antiinfectives for systemic use,% of total sales,9.8
4092,Belgium,2013,6,C08-Calcium channel blockers,Million of national currency units,57.9
4093,Belgium,2013,6,A-Alimentary tract and metabolism,% of total sales,10.9
4094,Belgium,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.2
4095,Belgium,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",64.6
4096,Belgium,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",805.9
4097,Belgium,2013,6,R-Respiratory system,Million of national currency units,530.9
4098,Belgium,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",77.3
4099,Belgium,2013,6,C-Cardiovascular system,Million of national currency units,782.9
4100,Belgium,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,862.9
4101,Belgium,2013,6,A-Alimentary tract and metabolism,Million of national currency units,649.7
4102,Belgium,2013,6,C-Cardiovascular system,Million US$ at exchange rate,1039.8
4103,Belgium,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,772.0
4104,Belgium,2013,6,J-Antiinfectives for systemic use,Million of national currency units,581.3
4105,Belgium,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",721.0
4106,Belgium,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",971.2
4107,Belgium,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",93.2
4108,Belgium,2013,6,J01-Antibacterials for systemic use,% of total sales,3.7
4109,Belgium,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,76.9
4110,Belgium,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",87.0
4111,Belgium,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",71.8
4112,Belgium,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,290.7
4113,Belgium,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",271.5
4114,Belgium,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.1
4115,Belgium,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",24.3
4116,Belgium,2013,6,C-Cardiovascular system,% of total sales,13.2
4117,Belgium,2017,5,C03-Diuretics,Million US$ at exchange rate,37.1
4118,Belgium,2017,5,C03-Diuretics,Million of national currency units,32.8
4119,Belgium,2017,5,C03-Diuretics,"Million US$, purchasing power parity",42.3
4120,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,128.1
4121,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,144.7
4122,Belgium,2017,5,C03-Diuretics,"/capita, US$ exchange rate",3.3
4123,Belgium,2017,5,N06A-Antidepressants,Million of national currency units,125.3
4124,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.7
4125,Belgium,2017,5,N06A-Antidepressants,Million US$ at exchange rate,141.6
4126,Belgium,2017,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
4127,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",165.2
4128,Belgium,2017,5,C03-Diuretics,% of total sales,0.5
4129,Belgium,2017,5,N05C-Hypnotics and sedatives,Million of national currency units,77.2
4130,Belgium,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.3
4131,Belgium,2017,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,87.2
4132,Belgium,2017,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0
4133,Belgium,2017,5,G-Genito urinary system and sex hormones,% of total sales,3.4
4134,Belgium,2017,5,C01A-Cardiac glycosides,Million of national currency units,0.8
4135,Belgium,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.2
4136,Belgium,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,252.5
4137,Belgium,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",288.2
4138,Belgium,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.7
4139,Belgium,2017,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",99.5
4140,Belgium,2017,5,N05C-Hypnotics and sedatives,% of total sales,1.2
4141,Belgium,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",8.7
4142,Belgium,2017,5,C07-Beta blocking agents,% of total sales,1.3
4143,Belgium,2017,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.4
4144,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
4145,Belgium,2017,5,C07-Beta blocking agents,"Million US$, purchasing power parity",106.6
4146,Belgium,2017,5,C07-Beta blocking agents,Million US$ at exchange rate,93.4
4147,Belgium,2017,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.2
4148,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,155.3
4149,Belgium,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,223.5
4150,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,108.0
4151,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.4
4152,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.6
4153,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,175.4
4154,Belgium,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",200.2
4155,Belgium,2017,5,M-Musculo-skeletal system,% of total sales,3.8
4156,Belgium,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",24.6
4157,Belgium,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.1
4158,Belgium,2017,5,N06A-Antidepressants,% of total sales,1.9
4159,Belgium,2017,5,N06A-Antidepressants,"/capita, US$ exchange rate",12.4
4160,Belgium,2017,5,N06A-Antidepressants,"Million US$, purchasing power parity",161.5
4161,Belgium,2017,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.2
4162,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5
4163,Belgium,2017,5,C07-Beta blocking agents,Million of national currency units,82.7
4164,Belgium,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
4165,Belgium,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",319.3
4166,Belgium,2017,5,M-Musculo-skeletal system,Million of national currency units,247.7
4167,Belgium,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,279.8
4168,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",19.2
4169,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,16.8
4170,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
4171,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5
4172,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.2
4173,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
4174,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,14.9
4175,Belgium,2017,5,N02-Analgesics,"/capita, US$ exchange rate",24.5
4176,Belgium,2017,5,N02-Analgesics,"Million US$, purchasing power parity",318.0
4177,Belgium,2017,5,N02-Analgesics,% of total sales,3.8
4178,Belgium,2017,5,N02-Analgesics,"/capita, US$ purchasing power parity",28.0
4179,Belgium,2017,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
4180,Belgium,2017,5,N02-Analgesics,Million US$ at exchange rate,278.6
4181,Belgium,2017,5,N02-Analgesics,Million of national currency units,246.6
4182,Belgium,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",741.6
4183,Belgium,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",649.8
4184,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",139.2
4185,Belgium,2017,5,N-Nervous system,% of total sales,13.8
4186,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.7
4187,Belgium,2017,5,Total pharmaceutical sales,Million of national currency units,6543.2
4188,Belgium,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,7391.7
4189,Belgium,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",8435.9
4190,Belgium,2017,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",259.9
4191,Belgium,2017,5,A10-Drugs used in diabetes,Million US$ at exchange rate,227.8
4192,Belgium,2017,5,A10-Drugs used in diabetes,Million of national currency units,201.6
4193,Belgium,2017,5,A10-Drugs used in diabetes,% of total sales,3.1
4194,Belgium,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",102.1
4195,Belgium,2017,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.0
4196,Belgium,2017,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.9
4197,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6
4198,Belgium,2017,5,N05B-Anxiolytics,% of total sales,1.1
4199,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.4
4200,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.8
4201,Belgium,2017,5,N05B-Anxiolytics,"Million US$, purchasing power parity",88.7
4202,Belgium,2017,5,N05B-Anxiolytics,"/capita, US$ exchange rate",6.8
4203,Belgium,2017,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",7.8
4204,Belgium,2017,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
4205,Belgium,2017,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.1
4206,Belgium,2017,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
4207,Belgium,2017,5,C01A-Cardiac glycosides,% of total sales,0.0
4208,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",134.8
4209,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,118.1
4210,Belgium,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,104.5
4211,Belgium,2017,5,N-Nervous system,Million of national currency units,901.0
4212,Belgium,2017,5,C02-Antihypertensives,Million of national currency units,26.1
4213,Belgium,2017,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,122.0
4214,Belgium,2017,5,N-Nervous system,"/capita, US$ exchange rate",89.5
4215,Belgium,2017,5,N-Nervous system,Million US$ at exchange rate,1017.8
4216,Belgium,2017,5,N-Nervous system,"Million US$, purchasing power parity",1161.6
4217,Belgium,2017,5,C02-Antihypertensives,% of total sales,0.4
4218,Belgium,2017,5,N05B-Anxiolytics,Million US$ at exchange rate,77.7
4219,Belgium,2017,5,N05B-Anxiolytics,Million of national currency units,68.8
4220,Belgium,2017,5,C02-Antihypertensives,"Million US$, purchasing power parity",33.6
4221,Belgium,2017,5,C02-Antihypertensives,Million US$ at exchange rate,29.5
4222,Belgium,2017,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.0
4223,Belgium,2017,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.6
4224,Belgium,2017,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,283.9
4225,Belgium,2017,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",324.0
4226,Belgium,2017,5,J01-Antibacterials for systemic use,Million of national currency units,189.6
4227,Belgium,2017,5,A02A-Antacids,"Million US$, purchasing power parity",12.3
4228,Belgium,2017,5,R03-Drugs for obstructive airway diseases,Million of national currency units,251.3
4229,Belgium,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",25.0
4230,Belgium,2017,5,A02A-Antacids,"/capita, US$ exchange rate",0.9
4231,Belgium,2017,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.1
4232,Belgium,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.5
4233,Belgium,2017,5,R03-Drugs for obstructive airway diseases,% of total sales,3.8
4234,Belgium,2017,5,C08-Calcium channel blockers,% of total sales,0.7
4235,Belgium,2017,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.1
4236,Belgium,2017,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.9
4237,Belgium,2017,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3
4238,Belgium,2017,5,A02A-Antacids,Million US$ at exchange rate,10.8
4239,Belgium,2017,5,C10-Lipid modifying agents,Million US$ at exchange rate,240.3
4240,Belgium,2017,5,A02A-Antacids,Million of national currency units,9.5
4241,Belgium,2017,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",21.1
4242,Belgium,2017,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",274.2
4243,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,175.5
4244,Belgium,2017,5,A02A-Antacids,% of total sales,0.1
4245,Belgium,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",216.6
4246,Belgium,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",189.8
4247,Belgium,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",59.1
4248,Belgium,2017,5,Products not elsewhere classified,% of total sales,29.2
4249,Belgium,2017,5,C10-Lipid modifying agents,Million of national currency units,212.7
4250,Belgium,2017,5,Products not elsewhere classified,Million of national currency units,1910.8
4251,Belgium,2017,5,Products not elsewhere classified,Million US$ at exchange rate,2158.6
4252,Belgium,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",2463.6
4253,Belgium,2017,5,C10-Lipid modifying agents,% of total sales,3.3
4254,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",17.4
4255,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.9
4256,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,198.3
4257,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",226.3
4258,Belgium,2017,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.7
4259,Belgium,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",767.1
4260,Belgium,2017,5,B-Blood and blood forming organs,% of total sales,9.1
4261,Belgium,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",67.4
4262,Belgium,2017,5,B-Blood and blood forming organs,Million of national currency units,595.0
4263,Belgium,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,672.1
4264,Belgium,2017,5,C-Cardiovascular system,% of total sales,10.0
4265,Belgium,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",57.8
4266,Belgium,2017,5,R-Respiratory system,% of total sales,7.8
4267,Belgium,2017,5,R-Respiratory system,"/capita, US$ exchange rate",50.6
4268,Belgium,2017,5,R-Respiratory system,Million US$ at exchange rate,575.9
4269,Belgium,2017,5,R-Respiratory system,"Million US$, purchasing power parity",657.2
4270,Belgium,2017,5,A-Alimentary tract and metabolism,% of total sales,10.7
4271,Belgium,2017,5,J-Antiinfectives for systemic use,% of total sales,10.3
4272,Belgium,2017,5,C08-Calcium channel blockers,Million of national currency units,43.1
4273,Belgium,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.9
4274,Belgium,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",79.1
4275,Belgium,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",76.4
4276,Belgium,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",899.3
4277,Belgium,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",69.3
4278,Belgium,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,788.0
4279,Belgium,2017,5,C-Cardiovascular system,Million of national currency units,655.8
4280,Belgium,2017,5,A-Alimentary tract and metabolism,Million of national currency units,697.5
4281,Belgium,2017,5,J-Antiinfectives for systemic use,Million of national currency units,674.1
4282,Belgium,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,761.5
4283,Belgium,2017,5,R-Respiratory system,Million of national currency units,509.8
4284,Belgium,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",869.1
4285,Belgium,2017,5,C-Cardiovascular system,Million US$ at exchange rate,740.9
4286,Belgium,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",845.5
4287,Belgium,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",65.1
4288,Belgium,2017,5,C08-Calcium channel blockers,Million US$ at exchange rate,48.7
4289,Belgium,2017,5,J01-Antibacterials for systemic use,% of total sales,2.9
4290,Belgium,2017,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",55.6
4291,Belgium,2017,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",244.4
4292,Belgium,2017,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,214.2
4293,Belgium,2017,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",21.5
4294,Belgium,2017,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",18.8
4295,Belgium,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.3
4296,Canada,2017,10,C-Cardiovascular system,Million of national currency units,3999.3
4297,Canada,2017,10,N-Nervous system,"/capita, US$ purchasing power parity",128.8
4298,Canada,2017,10,C-Cardiovascular system,"Million US$, purchasing power parity",3298.9
4299,Canada,2017,10,C-Cardiovascular system,Million US$ at exchange rate,3081.3
4300,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,22.7
4301,Canada,2017,10,N-Nervous system,% of total sales,19.2
4302,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
4303,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
4304,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",24.3
4305,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.0
4306,Canada,2017,10,G03-Sex hormones and modulators of the genital system,% of total sales,2.7
4307,Canada,2017,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.4
4308,Canada,2017,10,C-Cardiovascular system,"/capita, US$ exchange rate",84.3
4309,Canada,2017,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.3
4310,Canada,2017,10,G-Genito urinary system and sex hormones,% of total sales,5.1
4311,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0
4312,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
4313,Canada,2017,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",17.2
4314,Canada,2017,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",671.0
4315,Canada,2017,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",24.5
4316,Canada,2017,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.2
4317,Canada,2017,10,B-Blood and blood forming organs,% of total sales,3.9
4318,Canada,2017,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1920.3
4319,Canada,2017,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,1793.6
4320,Canada,2017,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",958.4
4321,Canada,2017,10,N-Nervous system,"Million US$, purchasing power parity",4706.2
4322,Canada,2017,10,J-Antiinfectives for systemic use,Million of national currency units,2328.0
4323,Canada,2017,10,N-Nervous system,Million of national currency units,5705.3
4324,Canada,2017,10,N-Nervous system,Million US$ at exchange rate,4395.7
4325,Canada,2017,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",90.3
4326,Canada,2017,10,C-Cardiovascular system,% of total sales,13.4
4327,Canada,2017,10,B-Blood and blood forming organs,Million of national currency units,1161.9
4328,Canada,2017,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,813.5
4329,Canada,2017,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,626.8
4330,Canada,2017,10,N-Nervous system,"/capita, US$ exchange rate",120.3
4331,Canada,2017,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",49.1
4332,Canada,2017,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.5
4333,Canada,2017,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",52.5
4334,Canada,2017,10,B-Blood and blood forming organs,Million US$ at exchange rate,895.2
4335,Canada,2017,10,J-Antiinfectives for systemic use,% of total sales,7.8
4336,Canada,2017,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.6
4337,Canada,2017,10,J01-Antibacterials for systemic use,Million of national currency units,694.6
4338,Canada,2017,10,C03-Diuretics,% of total sales,0.8
4339,Canada,2017,10,C03-Diuretics,"/capita, US$ purchasing power parity",5.1
4340,Canada,2017,10,M-Musculo-skeletal system,Million of national currency units,929.4
4341,Canada,2017,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,535.2
4342,Canada,2017,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",766.6
4343,Canada,2017,10,M-Musculo-skeletal system,Million US$ at exchange rate,716.1
4344,Canada,2017,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",573.0
4345,Canada,2017,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.0
4346,Canada,2017,10,C08-Calcium channel blockers,Million of national currency units,531.6
4347,Canada,2017,10,C08-Calcium channel blockers,Million US$ at exchange rate,409.6
4348,Canada,2017,10,M-Musculo-skeletal system,% of total sales,3.1
4349,Canada,2017,10,C03-Diuretics,"Million US$, purchasing power parity",187.0
4350,Canada,2017,10,C03-Diuretics,"/capita, US$ exchange rate",4.8
4351,Canada,2017,10,C03-Diuretics,Million of national currency units,226.7
4352,Canada,2017,10,C03-Diuretics,Million US$ at exchange rate,174.7
4353,Canada,2017,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4
4354,Canada,2017,10,C07-Beta blocking agents,"/capita, US$ exchange rate",6.9
4355,Canada,2017,10,C07-Beta blocking agents,Million US$ at exchange rate,251.8
4356,Canada,2017,10,C07-Beta blocking agents,"Million US$, purchasing power parity",269.6
4357,Canada,2017,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.8
4358,Canada,2017,10,C10-Lipid modifying agents,% of total sales,4.1
4359,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",430.0
4360,Canada,2017,10,C07-Beta blocking agents,% of total sales,1.1
4361,Canada,2017,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",25.9
4362,Canada,2017,10,J01-Antibacterials for systemic use,% of total sales,2.3
4363,Canada,2017,10,C10-Lipid modifying agents,Million US$ at exchange rate,947.3
4364,Canada,2017,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.6
4365,Canada,2017,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.7
4366,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,401.6
4367,Canada,2017,10,C07-Beta blocking agents,Million of national currency units,326.8
4368,Canada,2017,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",1014.2
4369,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,521.3
4370,Canada,2017,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",438.5
4371,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.4
4372,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.0
4373,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
4374,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.6
4375,Canada,2017,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8
4376,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",254.6
4377,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,237.8
4378,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.6
4379,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.5
4380,Canada,2017,10,C02-Antihypertensives,"Million US$, purchasing power parity",106.9
4381,Canada,2017,10,C01A-Cardiac glycosides,% of total sales,0.1
4382,Canada,2017,10,C02-Antihypertensives,Million of national currency units,129.6
4383,Canada,2017,10,C02-Antihypertensives,Million US$ at exchange rate,99.9
4384,Canada,2017,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",13.7
4385,Canada,2017,10,C01A-Cardiac glycosides,Million US$ at exchange rate,12.8
4386,Canada,2017,10,C10-Lipid modifying agents,Million of national currency units,1229.5
4387,Canada,2017,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
4388,Canada,2017,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
4389,Canada,2017,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.9
4390,Canada,2017,10,C02-Antihypertensives,% of total sales,0.4
4391,Canada,2017,10,G-Genito urinary system and sex hormones,Million of national currency units,1517.6
4392,Canada,2017,10,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
4393,Canada,2017,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",11.2
4394,Canada,2017,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",12.0
4395,Canada,2017,10,C08-Calcium channel blockers,% of total sales,1.8
4396,Canada,2017,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1169.2
4397,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1009.3
4398,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1310.0
4399,Canada,2017,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,308.6
4400,Canada,2017,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1080.6
4401,Canada,2017,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",32.0
4402,Canada,2017,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1251.8
4403,Canada,2017,10,C01A-Cardiac glycosides,Million of national currency units,16.6
4404,Canada,2017,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3337.3
4405,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.3
4406,Canada,2017,10,N06A-Antidepressants,% of total sales,4.7
4407,Canada,2017,10,A-Alimentary tract and metabolism,Million of national currency units,4045.8
4408,Canada,2017,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,3117.1
4409,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,765.8
4410,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,994.0
4411,Canada,2017,10,R-Respiratory system,Million of national currency units,1991.3
4412,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",22.4
4413,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.0
4414,Canada,2017,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",819.9
4415,Canada,2017,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.3
4416,Canada,2017,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.6
4417,Canada,2017,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",167.3
4418,Canada,2017,10,N05C-Hypnotics and sedatives,Million of national currency units,202.8
4419,Canada,2017,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,156.2
4420,Canada,2017,10,N06A-Antidepressants,"Million US$, purchasing power parity",1148.0
4421,Canada,2017,10,N06A-Antidepressants,"/capita, US$ exchange rate",29.3
4422,Canada,2017,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",31.4
4423,Canada,2017,10,N05C-Hypnotics and sedatives,% of total sales,0.7
4424,Canada,2017,10,N06A-Antidepressants,Million of national currency units,1391.7
4425,Canada,2017,10,N06A-Antidepressants,Million US$ at exchange rate,1072.2
4426,Canada,2017,10,Products not elsewhere classified,Million US$ at exchange rate,5837.3
4427,Canada,2017,10,Products not elsewhere classified,"Million US$, purchasing power parity",6249.7
4428,Canada,2017,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",36.0
4429,Canada,2017,10,R03-Drugs for obstructive airway diseases,% of total sales,5.4
4430,Canada,2017,10,Products not elsewhere classified,Million of national currency units,7576.5
4431,Canada,2017,10,Products not elsewhere classified,"/capita, US$ exchange rate",159.7
4432,Canada,2017,10,A02A-Antacids,Million US$ at exchange rate,1.2
4433,Canada,2017,10,A02A-Antacids,"Million US$, purchasing power parity",1.3
4434,Canada,2017,10,A02A-Antacids,"/capita, US$ exchange rate",0.0
4435,Canada,2017,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
4436,Canada,2017,10,A02A-Antacids,Million of national currency units,1.6
4437,Canada,2017,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",171.0
4438,Canada,2017,10,Products not elsewhere classified,% of total sales,25.4
4439,Canada,2017,10,R-Respiratory system,"/capita, US$ purchasing power parity",44.9
4440,Canada,2017,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",85.3
4441,Canada,2017,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",91.3
4442,Canada,2017,10,R-Respiratory system,Million US$ at exchange rate,1534.2
4443,Canada,2017,10,R-Respiratory system,"/capita, US$ exchange rate",42.0
4444,Canada,2017,10,R-Respiratory system,"Million US$, purchasing power parity",1642.6
4445,Canada,2017,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1227.6
4446,Canada,2017,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1314.4
4447,Canada,2017,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",33.6
4448,Canada,2017,10,A-Alimentary tract and metabolism,% of total sales,13.6
4449,Canada,2017,10,R-Respiratory system,% of total sales,6.7
4450,Canada,2017,10,R03-Drugs for obstructive airway diseases,Million of national currency units,1593.4
4451,Canada,2017,10,N05B-Anxiolytics,% of total sales,0.5
4452,Canada,2017,10,A02A-Antacids,% of total sales,0.0
4453,Canada,2017,10,N02-Analgesics,"/capita, US$ exchange rate",22.7
4454,Canada,2017,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1794.7
4455,Canada,2017,10,N02-Analgesics,"/capita, US$ purchasing power parity",24.3
4456,Canada,2017,10,N02-Analgesics,% of total sales,3.6
4457,Canada,2017,10,N02-Analgesics,Million of national currency units,1077.1
4458,Canada,2017,10,N02-Analgesics,Million US$ at exchange rate,829.9
4459,Canada,2017,10,A10-Drugs used in diabetes,Million US$ at exchange rate,1676.3
4460,Canada,2017,10,A10-Drugs used in diabetes,Million of national currency units,2175.7
4461,Canada,2017,10,Total pharmaceutical sales,Million of national currency units,29776.2
4462,Canada,2017,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",45.9
4463,Canada,2017,10,A10-Drugs used in diabetes,% of total sales,7.3
4464,Canada,2017,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",49.1
4465,Canada,2017,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",672.1
4466,Canada,2017,10,Total pharmaceutical sales,Million US$ at exchange rate,22941.2
4467,Canada,2017,10,Total pharmaceutical sales,"Million US$, purchasing power parity",24561.7
4468,Canada,2017,10,Total pharmaceutical sales,"/capita, US$ exchange rate",627.7
4469,Canada,2017,10,N05B-Anxiolytics,"Million US$, purchasing power parity",132.1
4470,Canada,2017,10,N05B-Anxiolytics,Million US$ at exchange rate,123.4
4471,Canada,2017,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.6
4472,Canada,2017,10,N05B-Anxiolytics,"/capita, US$ exchange rate",3.4
4473,Canada,2017,10,N05B-Anxiolytics,Million of national currency units,160.2
4474,Canada,2017,10,N02-Analgesics,"Million US$, purchasing power parity",888.5
4475,Canada,2016,10,N-Nervous system,"/capita, US$ purchasing power parity",128.7
4476,Canada,2016,10,C-Cardiovascular system,Million of national currency units,3942.4
4477,Canada,2016,10,C-Cardiovascular system,"Million US$, purchasing power parity",3266.2
4478,Canada,2016,10,C-Cardiovascular system,Million US$ at exchange rate,2974.0
4479,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.9
4480,Canada,2016,10,N-Nervous system,% of total sales,19.8
4481,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",24.0
4482,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
4483,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
4484,Canada,2016,10,C-Cardiovascular system,"/capita, US$ exchange rate",82.4
4485,Canada,2016,10,G03-Sex hormones and modulators of the genital system,% of total sales,2.8
4486,Canada,2016,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.5
4487,Canada,2016,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.1
4488,Canada,2016,10,G-Genito urinary system and sex hormones,% of total sales,5.2
4489,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.4
4490,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1
4491,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
4492,Canada,2016,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.8
4493,Canada,2016,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",666.8
4494,Canada,2016,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",22.2
4495,Canada,2016,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.4
4496,Canada,2016,10,B-Blood and blood forming organs,% of total sales,3.8
4497,Canada,2016,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1901.4
4498,Canada,2016,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,1731.3
4499,Canada,2016,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",881.7
4500,Canada,2016,10,N-Nervous system,"/capita, US$ exchange rate",117.2
4501,Canada,2016,10,N-Nervous system,"Million US$, purchasing power parity",4646.5
4502,Canada,2016,10,J-Antiinfectives for systemic use,Million of national currency units,2295.1
4503,Canada,2016,10,N-Nervous system,Million of national currency units,5608.5
4504,Canada,2016,10,N-Nervous system,Million US$ at exchange rate,4230.9
4505,Canada,2016,10,C-Cardiovascular system,% of total sales,13.9
4506,Canada,2016,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",90.5
4507,Canada,2016,10,B-Blood and blood forming organs,Million of national currency units,1064.2
4508,Canada,2016,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,804.9
4509,Canada,2016,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,607.2
4510,Canada,2016,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",47.9
4511,Canada,2016,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",52.7
4512,Canada,2016,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.0
4513,Canada,2016,10,B-Blood and blood forming organs,Million US$ at exchange rate,802.8
4514,Canada,2016,10,J-Antiinfectives for systemic use,% of total sales,8.1
4515,Canada,2016,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.0
4516,Canada,2016,10,J01-Antibacterials for systemic use,Million of national currency units,687.1
4517,Canada,2016,10,C03-Diuretics,% of total sales,0.8
4518,Canada,2016,10,M-Musculo-skeletal system,Million of national currency units,910.8
4519,Canada,2016,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,518.3
4520,Canada,2016,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",569.2
4521,Canada,2016,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",754.6
4522,Canada,2016,10,M-Musculo-skeletal system,Million US$ at exchange rate,687.1
4523,Canada,2016,10,C03-Diuretics,"/capita, US$ purchasing power parity",4.9
4524,Canada,2016,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.9
4525,Canada,2016,10,C08-Calcium channel blockers,Million of national currency units,546.9
4526,Canada,2016,10,C08-Calcium channel blockers,Million US$ at exchange rate,412.6
4527,Canada,2016,10,M-Musculo-skeletal system,% of total sales,3.2
4528,Canada,2016,10,C03-Diuretics,"/capita, US$ exchange rate",4.5
4529,Canada,2016,10,C03-Diuretics,"Million US$, purchasing power parity",177.5
4530,Canada,2016,10,C03-Diuretics,Million of national currency units,214.3
4531,Canada,2016,10,C03-Diuretics,Million US$ at exchange rate,161.7
4532,Canada,2016,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4
4533,Canada,2016,10,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7
4534,Canada,2016,10,C07-Beta blocking agents,Million US$ at exchange rate,241.9
4535,Canada,2016,10,C07-Beta blocking agents,"Million US$, purchasing power parity",265.7
4536,Canada,2016,10,C07-Beta blocking agents,% of total sales,1.1
4537,Canada,2016,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",28.4
4538,Canada,2016,10,C10-Lipid modifying agents,% of total sales,4.4
4539,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",412.9
4540,Canada,2016,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",25.9
4541,Canada,2016,10,J01-Antibacterials for systemic use,% of total sales,2.4
4542,Canada,2016,10,C10-Lipid modifying agents,Million US$ at exchange rate,934.8
4543,Canada,2016,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.4
4544,Canada,2016,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.8
4545,Canada,2016,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",1026.6
4546,Canada,2016,10,C07-Beta blocking agents,Million of national currency units,320.7
4547,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,376.0
4548,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,498.4
4549,Canada,2016,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",453.1
4550,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5
4551,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.4
4552,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
4553,Canada,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.4
4554,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.2
4555,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",266.7
4556,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,242.8
4557,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.6
4558,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.7
4559,Canada,2016,10,C02-Antihypertensives,"Million US$, purchasing power parity",98.8
4560,Canada,2016,10,C02-Antihypertensives,Million of national currency units,119.2
4561,Canada,2016,10,C01A-Cardiac glycosides,% of total sales,0.1
4562,Canada,2016,10,C02-Antihypertensives,Million US$ at exchange rate,89.9
4563,Canada,2016,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",14.6
4564,Canada,2016,10,C10-Lipid modifying agents,Million of national currency units,1239.2
4565,Canada,2016,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
4566,Canada,2016,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4
4567,Canada,2016,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.7
4568,Canada,2016,10,C02-Antihypertensives,% of total sales,0.4
4569,Canada,2016,10,G-Genito urinary system and sex hormones,Million of national currency units,1485.0
4570,Canada,2016,10,C02-Antihypertensives,"/capita, US$ exchange rate",2.5
4571,Canada,2016,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",11.4
4572,Canada,2016,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",12.5
4573,Canada,2016,10,C08-Calcium channel blockers,% of total sales,1.9
4574,Canada,2016,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1120.2
4575,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,959.6
4576,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1272.1
4577,Canada,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,321.9
4578,Canada,2016,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1053.9
4579,Canada,2016,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",31.0
4580,Canada,2016,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1230.3
4581,Canada,2016,10,C01A-Cardiac glycosides,Million US$ at exchange rate,13.3
4582,Canada,2016,10,C01A-Cardiac glycosides,Million of national currency units,17.6
4583,Canada,2016,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3166.9
4584,Canada,2016,10,A02A-Antacids,% of total sales,0.0
4585,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.7
4586,Canada,2016,10,N06A-Antidepressants,% of total sales,5.0
4587,Canada,2016,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,2883.6
4588,Canada,2016,10,A-Alimentary tract and metabolism,Million of national currency units,3822.6
4589,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,782.4
4590,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1037.1
4591,Canada,2016,10,R-Respiratory system,Million of national currency units,1936.0
4592,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",23.8
4593,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.7
4594,Canada,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",859.2
4595,Canada,2016,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.3
4596,Canada,2016,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.7
4597,Canada,2016,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",168.6
4598,Canada,2016,10,N05C-Hypnotics and sedatives,Million of national currency units,203.5
4599,Canada,2016,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,153.5
4600,Canada,2016,10,N06A-Antidepressants,"Million US$, purchasing power parity",1174.8
4601,Canada,2016,10,N06A-Antidepressants,"/capita, US$ exchange rate",29.6
4602,Canada,2016,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",32.5
4603,Canada,2016,10,N05C-Hypnotics and sedatives,% of total sales,0.7
4604,Canada,2016,10,N06A-Antidepressants,Million of national currency units,1418.0
4605,Canada,2016,10,N06A-Antidepressants,Million US$ at exchange rate,1069.7
4606,Canada,2016,10,Products not elsewhere classified,Million US$ at exchange rate,5108.0
4607,Canada,2016,10,Products not elsewhere classified,"Million US$, purchasing power parity",5609.8
4608,Canada,2016,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",35.3
4609,Canada,2016,10,Products not elsewhere classified,"/capita, US$ exchange rate",141.5
4610,Canada,2016,10,R03-Drugs for obstructive airway diseases,% of total sales,5.4
4611,Canada,2016,10,Products not elsewhere classified,Million of national currency units,6771.3
4612,Canada,2016,10,A02A-Antacids,Million US$ at exchange rate,1.1
4613,Canada,2016,10,A02A-Antacids,"Million US$, purchasing power parity",1.2
4614,Canada,2016,10,A02A-Antacids,"/capita, US$ exchange rate",0.0
4615,Canada,2016,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
4616,Canada,2016,10,A02A-Antacids,Million of national currency units,1.5
4617,Canada,2016,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",155.4
4618,Canada,2016,10,Products not elsewhere classified,% of total sales,23.9
4619,Canada,2016,10,R-Respiratory system,"/capita, US$ purchasing power parity",44.4
4620,Canada,2016,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",79.9
4621,Canada,2016,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",87.7
4622,Canada,2016,10,R-Respiratory system,Million US$ at exchange rate,1460.5
4623,Canada,2016,10,R-Respiratory system,"Million US$, purchasing power parity",1603.9
4624,Canada,2016,10,R-Respiratory system,"/capita, US$ exchange rate",40.4
4625,Canada,2016,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1161.7
4626,Canada,2016,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1275.8
4627,Canada,2016,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.2
4628,Canada,2016,10,A-Alimentary tract and metabolism,% of total sales,13.5
4629,Canada,2016,10,R-Respiratory system,% of total sales,6.8
4630,Canada,2016,10,R03-Drugs for obstructive airway diseases,Million of national currency units,1540.0
4631,Canada,2016,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1613.1
4632,Canada,2016,10,N02-Analgesics,"/capita, US$ exchange rate",23.3
4633,Canada,2016,10,N02-Analgesics,"/capita, US$ purchasing power parity",25.6
4634,Canada,2016,10,N02-Analgesics,% of total sales,3.9
4635,Canada,2016,10,Total pharmaceutical sales,Million of national currency units,28334.3
4636,Canada,2016,10,N02-Analgesics,Million of national currency units,1117.2
4637,Canada,2016,10,N02-Analgesics,Million US$ at exchange rate,842.8
4638,Canada,2016,10,A10-Drugs used in diabetes,Million US$ at exchange rate,1468.8
4639,Canada,2016,10,A10-Drugs used in diabetes,Million of national currency units,1947.1
4640,Canada,2016,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",40.7
4641,Canada,2016,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",44.7
4642,Canada,2016,10,A10-Drugs used in diabetes,% of total sales,6.9
4643,Canada,2016,10,Total pharmaceutical sales,"Million US$, purchasing power parity",23474.1
4644,Canada,2016,10,Total pharmaceutical sales,Million US$ at exchange rate,21374.5
4645,Canada,2016,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",650.1
4646,Canada,2016,10,Total pharmaceutical sales,"/capita, US$ exchange rate",591.9
4647,Canada,2016,10,N05B-Anxiolytics,"/capita, US$ exchange rate",3.4
4648,Canada,2016,10,N05B-Anxiolytics,"Million US$, purchasing power parity",135.4
4649,Canada,2016,10,N05B-Anxiolytics,Million US$ at exchange rate,123.3
4650,Canada,2016,10,N05B-Anxiolytics,% of total sales,0.6
4651,Canada,2016,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.7
4652,Canada,2016,10,N02-Analgesics,"Million US$, purchasing power parity",925.6
4653,Canada,2016,10,N05B-Anxiolytics,Million of national currency units,163.4
4654,Canada,2015,11,N-Nervous system,"/capita, US$ purchasing power parity",122.0
4655,Canada,2015,11,C-Cardiovascular system,Million of national currency units,3888.7
4656,Canada,2015,11,C-Cardiovascular system,"Million US$, purchasing power parity",3115.8
4657,Canada,2015,11,C-Cardiovascular system,Million US$ at exchange rate,3040.9
4658,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,22.1
4659,Canada,2015,11,N-Nervous system,% of total sales,20.0
4660,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",22.7
4661,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
4662,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
4663,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.6
4664,Canada,2015,11,C-Cardiovascular system,"/capita, US$ exchange rate",85.2
4665,Canada,2015,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.0
4666,Canada,2015,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.2
4667,Canada,2015,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.9
4668,Canada,2015,11,G-Genito urinary system and sex hormones,% of total sales,5.6
4669,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2
4670,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
4671,Canada,2015,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",17.7
4672,Canada,2015,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.4
4673,Canada,2015,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.9
4674,Canada,2015,11,B-Blood and blood forming organs,% of total sales,3.5
4675,Canada,2015,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1960.8
4676,Canada,2015,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,1913.7
4677,Canada,2015,11,N-Nervous system,"/capita, US$ exchange rate",119.1
4678,Canada,2015,11,J-Antiinfectives for systemic use,Million of national currency units,2447.2
4679,Canada,2015,11,N-Nervous system,"Million US$, purchasing power parity",4355.4
4680,Canada,2015,11,N-Nervous system,Million of national currency units,5435.7
4681,Canada,2015,11,N-Nervous system,Million US$ at exchange rate,4250.7
4682,Canada,2015,11,C-Cardiovascular system,% of total sales,14.3
4683,Canada,2015,11,B-Blood and blood forming organs,Million of national currency units,954.8
4684,Canada,2015,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",87.3
4685,Canada,2015,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",648.5
4686,Canada,2015,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,809.3
4687,Canada,2015,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,632.9
4688,Canada,2015,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",54.9
4689,Canada,2015,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.6
4690,Canada,2015,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,28.3
4691,Canada,2015,11,B-Blood and blood forming organs,Million US$ at exchange rate,746.6
4692,Canada,2015,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",765.0
4693,Canada,2015,11,J-Antiinfectives for systemic use,% of total sales,9.0
4694,Canada,2015,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.9
4695,Canada,2015,11,C03-Diuretics,% of total sales,0.8
4696,Canada,2015,11,J01-Antibacterials for systemic use,Million of national currency units,678.2
4697,Canada,2015,11,M-Musculo-skeletal system,Million of national currency units,907.0
4698,Canada,2015,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,530.4
4699,Canada,2015,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",543.4
4700,Canada,2015,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",726.7
4701,Canada,2015,11,M-Musculo-skeletal system,Million US$ at exchange rate,709.3
4702,Canada,2015,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.4
4703,Canada,2015,11,C08-Calcium channel blockers,Million US$ at exchange rate,426.7
4704,Canada,2015,11,C08-Calcium channel blockers,Million of national currency units,545.6
4705,Canada,2015,11,M-Musculo-skeletal system,% of total sales,3.3
4706,Canada,2015,11,C03-Diuretics,"/capita, US$ purchasing power parity",4.6
4707,Canada,2015,11,C03-Diuretics,"/capita, US$ exchange rate",4.5
4708,Canada,2015,11,C03-Diuretics,"Million US$, purchasing power parity",165.9
4709,Canada,2015,11,C03-Diuretics,Million of national currency units,207.0
4710,Canada,2015,11,C03-Diuretics,Million US$ at exchange rate,161.9
4711,Canada,2015,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.1
4712,Canada,2015,11,C07-Beta blocking agents,"/capita, US$ exchange rate",6.9
4713,Canada,2015,11,C07-Beta blocking agents,% of total sales,1.2
4714,Canada,2015,11,C07-Beta blocking agents,"Million US$, purchasing power parity",253.6
4715,Canada,2015,11,C07-Beta blocking agents,Million US$ at exchange rate,247.5
4716,Canada,2015,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.8
4717,Canada,2015,11,C10-Lipid modifying agents,% of total sales,4.6
4718,Canada,2015,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",27.1
4719,Canada,2015,11,J01-Antibacterials for systemic use,% of total sales,2.5
4720,Canada,2015,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.9
4721,Canada,2015,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.2
4722,Canada,2015,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",991.4
4723,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",379.8
4724,Canada,2015,11,C07-Beta blocking agents,Million of national currency units,316.5
4725,Canada,2015,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",437.2
4726,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,370.7
4727,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,474.0
4728,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.4
4729,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5
4730,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7
4731,Canada,2015,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6
4732,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",270.8
4733,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,264.3
4734,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.6
4735,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.4
4736,Canada,2015,11,C02-Antihypertensives,"Million US$, purchasing power parity",83.6
4737,Canada,2015,11,C10-Lipid modifying agents,Million of national currency units,1237.3
4738,Canada,2015,11,C02-Antihypertensives,Million of national currency units,104.3
4739,Canada,2015,11,C02-Antihypertensives,Million US$ at exchange rate,81.6
4740,Canada,2015,11,C01A-Cardiac glycosides,% of total sales,0.1
4741,Canada,2015,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",15.2
4742,Canada,2015,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
4743,Canada,2015,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4
4744,Canada,2015,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.3
4745,Canada,2015,11,C02-Antihypertensives,% of total sales,0.4
4746,Canada,2015,11,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
4747,Canada,2015,11,G-Genito urinary system and sex hormones,Million of national currency units,1511.3
4748,Canada,2015,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1181.8
4749,Canada,2015,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",12.2
4750,Canada,2015,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",12.0
4751,Canada,2015,11,C10-Lipid modifying agents,Million US$ at exchange rate,967.6
4752,Canada,2015,11,C08-Calcium channel blockers,% of total sales,2.0
4753,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,961.1
4754,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",984.7
4755,Canada,2015,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,338.0
4756,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1229.0
4757,Canada,2015,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.9
4758,Canada,2015,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",33.1
4759,Canada,2015,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1210.9
4760,Canada,2015,11,C01A-Cardiac glycosides,Million US$ at exchange rate,14.9
4761,Canada,2015,11,C01A-Cardiac glycosides,Million of national currency units,19.0
4762,Canada,2015,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",83.8
4763,Canada,2015,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3064.8
4764,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.2
4765,Canada,2015,11,N06A-Antidepressants,% of total sales,5.3
4766,Canada,2015,11,A-Alimentary tract and metabolism,Million of national currency units,3825.0
4767,Canada,2015,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,2991.1
4768,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,896.9
4769,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1146.9
4770,Canada,2015,11,R-Respiratory system,Million of national currency units,1874.5
4771,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",25.7
4772,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",25.1
4773,Canada,2015,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",919.0
4774,Canada,2015,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.5
4775,Canada,2015,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.6
4776,Canada,2015,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",163.6
4777,Canada,2015,11,N05C-Hypnotics and sedatives,Million of national currency units,204.2
4778,Canada,2015,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,159.7
4779,Canada,2015,11,N05C-Hypnotics and sedatives,% of total sales,0.8
4780,Canada,2015,11,N06A-Antidepressants,"Million US$, purchasing power parity",1148.1
4781,Canada,2015,11,N06A-Antidepressants,"/capita, US$ exchange rate",31.4
4782,Canada,2015,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",32.2
4783,Canada,2015,11,N06A-Antidepressants,Million of national currency units,1432.9
4784,Canada,2015,11,N06A-Antidepressants,Million US$ at exchange rate,1120.5
4785,Canada,2015,11,Products not elsewhere classified,Million US$ at exchange rate,4788.3
4786,Canada,2015,11,Products not elsewhere classified,"Million US$, purchasing power parity",4906.2
4787,Canada,2015,11,Products not elsewhere classified,"/capita, US$ exchange rate",134.1
4788,Canada,2015,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",33.6
4789,Canada,2015,11,Products not elsewhere classified,Million of national currency units,6123.2
4790,Canada,2015,11,R03-Drugs for obstructive airway diseases,% of total sales,5.5
4791,Canada,2015,11,A02A-Antacids,Million US$ at exchange rate,1.1
4792,Canada,2015,11,A02A-Antacids,"Million US$, purchasing power parity",1.1
4793,Canada,2015,11,A02A-Antacids,"/capita, US$ exchange rate",0.0
4794,Canada,2015,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
4795,Canada,2015,11,A02A-Antacids,% of total sales,0.0
4796,Canada,2015,11,A02A-Antacids,Million of national currency units,1.4
4797,Canada,2015,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",137.4
4798,Canada,2015,11,Products not elsewhere classified,% of total sales,22.6
4799,Canada,2015,11,R-Respiratory system,"/capita, US$ purchasing power parity",42.1
4800,Canada,2015,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",85.8
4801,Canada,2015,11,R-Respiratory system,Million US$ at exchange rate,1465.8
4802,Canada,2015,11,R-Respiratory system,"Million US$, purchasing power parity",1502.0
4803,Canada,2015,11,R-Respiratory system,"/capita, US$ exchange rate",41.1
4804,Canada,2015,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1171.9
4805,Canada,2015,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1200.8
4806,Canada,2015,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.8
4807,Canada,2015,11,A-Alimentary tract and metabolism,% of total sales,14.1
4808,Canada,2015,11,R-Respiratory system,% of total sales,6.9
4809,Canada,2015,11,R03-Drugs for obstructive airway diseases,Million of national currency units,1498.6
4810,Canada,2015,11,N05B-Anxiolytics,% of total sales,0.6
4811,Canada,2015,11,N02-Analgesics,"/capita, US$ purchasing power parity",25.1
4812,Canada,2015,11,N02-Analgesics,"/capita, US$ exchange rate",24.5
4813,Canada,2015,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1363.8
4814,Canada,2015,11,Total pharmaceutical sales,Million of national currency units,27126.4
4815,Canada,2015,11,N02-Analgesics,% of total sales,4.1
4816,Canada,2015,11,N02-Analgesics,Million of national currency units,1117.2
4817,Canada,2015,11,N02-Analgesics,Million US$ at exchange rate,873.6
4818,Canada,2015,11,A10-Drugs used in diabetes,Million US$ at exchange rate,1331.0
4819,Canada,2015,11,A10-Drugs used in diabetes,Million of national currency units,1702.1
4820,Canada,2015,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",37.3
4821,Canada,2015,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",38.2
4822,Canada,2015,11,A10-Drugs used in diabetes,% of total sales,6.3
4823,Canada,2015,11,Total pharmaceutical sales,"Million US$, purchasing power parity",21735.2
4824,Canada,2015,11,Total pharmaceutical sales,Million US$ at exchange rate,21212.6
4825,Canada,2015,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",608.8
4826,Canada,2015,11,Total pharmaceutical sales,"/capita, US$ exchange rate",594.1
4827,Canada,2015,11,N05B-Anxiolytics,"Million US$, purchasing power parity",130.7
4828,Canada,2015,11,N05B-Anxiolytics,Million US$ at exchange rate,127.5
4829,Canada,2015,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.7
4830,Canada,2015,11,N05B-Anxiolytics,"/capita, US$ exchange rate",3.6
4831,Canada,2015,11,N02-Analgesics,"Million US$, purchasing power parity",895.2
4832,Canada,2015,11,N05B-Anxiolytics,Million of national currency units,163.1
4833,Canada,2014,11,C-Cardiovascular system,Million of national currency units,3973.2
4834,Canada,2014,11,C-Cardiovascular system,"Million US$, purchasing power parity",3229.3
4835,Canada,2014,11,C-Cardiovascular system,Million US$ at exchange rate,3596.5
4836,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",23.5
4837,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,26.2
4838,Canada,2014,11,N-Nervous system,% of total sales,20.9
4839,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
4840,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
4841,Canada,2014,11,C-Cardiovascular system,"/capita, US$ exchange rate",101.5
4842,Canada,2014,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.1
4843,Canada,2014,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.7
4844,Canada,2014,11,G-Genito urinary system and sex hormones,% of total sales,5.9
4845,Canada,2014,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.3
4846,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
4847,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
4848,Canada,2014,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",20.4
4849,Canada,2014,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.0
4850,Canada,2014,11,B-Blood and blood forming organs,% of total sales,3.4
4851,Canada,2014,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",22.2
4852,Canada,2014,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1363.9
4853,Canada,2014,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,1519.0
4854,Canada,2014,11,N-Nervous system,"/capita, US$ exchange rate",135.9
4855,Canada,2014,11,N-Nervous system,"/capita, US$ purchasing power parity",122.1
4856,Canada,2014,11,N-Nervous system,Million of national currency units,5321.8
4857,Canada,2014,11,J-Antiinfectives for systemic use,Million of national currency units,1678.1
4858,Canada,2014,11,N-Nervous system,"Million US$, purchasing power parity",4325.4
4859,Canada,2014,11,N-Nervous system,Million US$ at exchange rate,4817.2
4860,Canada,2014,11,C-Cardiovascular system,% of total sales,15.6
4861,Canada,2014,11,B-Blood and blood forming organs,Million of national currency units,870.2
4862,Canada,2014,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,798.1
4863,Canada,2014,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",91.1
4864,Canada,2014,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,722.4
4865,Canada,2014,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",648.7
4866,Canada,2014,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.5
4867,Canada,2014,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",42.9
4868,Canada,2014,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,28.9
4869,Canada,2014,11,B-Blood and blood forming organs,Million US$ at exchange rate,787.7
4870,Canada,2014,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",707.3
4871,Canada,2014,11,J-Antiinfectives for systemic use,% of total sales,6.6
4872,Canada,2014,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,618.4
4873,Canada,2014,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7
4874,Canada,2014,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.2
4875,Canada,2014,11,C03-Diuretics,% of total sales,0.8
4876,Canada,2014,11,J01-Antibacterials for systemic use,Million of national currency units,683.2
4877,Canada,2014,11,M-Musculo-skeletal system,Million of national currency units,988.0
4878,Canada,2014,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",555.3
4879,Canada,2014,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",803.0
4880,Canada,2014,11,M-Musculo-skeletal system,Million US$ at exchange rate,894.3
4881,Canada,2014,11,C03-Diuretics,"/capita, US$ purchasing power parity",4.6
4882,Canada,2014,11,C08-Calcium channel blockers,Million US$ at exchange rate,495.6
4883,Canada,2014,11,C08-Calcium channel blockers,Million of national currency units,547.5
4884,Canada,2014,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",445.0
4885,Canada,2014,11,M-Musculo-skeletal system,% of total sales,3.9
4886,Canada,2014,11,C03-Diuretics,Million of national currency units,201.9
4887,Canada,2014,11,C03-Diuretics,"/capita, US$ exchange rate",5.2
4888,Canada,2014,11,C03-Diuretics,"Million US$, purchasing power parity",164.1
4889,Canada,2014,11,C03-Diuretics,Million US$ at exchange rate,182.8
4890,Canada,2014,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.1
4891,Canada,2014,11,C07-Beta blocking agents,% of total sales,1.2
4892,Canada,2014,11,C07-Beta blocking agents,"/capita, US$ exchange rate",8.0
4893,Canada,2014,11,C07-Beta blocking agents,"Million US$, purchasing power parity",253.3
4894,Canada,2014,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",31.4
4895,Canada,2014,11,C10-Lipid modifying agents,% of total sales,5.4
4896,Canada,2014,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",35.0
4897,Canada,2014,11,C07-Beta blocking agents,Million US$ at exchange rate,282.1
4898,Canada,2014,11,J01-Antibacterials for systemic use,% of total sales,2.7
4899,Canada,2014,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",17.5
4900,Canada,2014,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.7
4901,Canada,2014,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",1113.6
4902,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",368.9
4903,Canada,2014,11,C07-Beta blocking agents,Million of national currency units,311.6
4904,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,410.9
4905,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,453.9
4906,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.6
4907,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.7
4908,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
4909,Canada,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.4
4910,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.7
4911,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",365.9
4912,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,407.5
4913,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.5
4914,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.3
4915,Canada,2014,11,C02-Antihypertensives,"Million US$, purchasing power parity",74.8
4916,Canada,2014,11,C10-Lipid modifying agents,Million of national currency units,1370.1
4917,Canada,2014,11,C02-Antihypertensives,Million of national currency units,92.0
4918,Canada,2014,11,C02-Antihypertensives,Million US$ at exchange rate,83.3
4919,Canada,2014,11,C01A-Cardiac glycosides,% of total sales,0.1
4920,Canada,2014,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",16.7
4921,Canada,2014,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
4922,Canada,2014,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
4923,Canada,2014,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1
4924,Canada,2014,11,C02-Antihypertensives,% of total sales,0.4
4925,Canada,2014,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1369.1
4926,Canada,2014,11,G-Genito urinary system and sex hormones,Million of national currency units,1512.5
4927,Canada,2014,11,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
4928,Canada,2014,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",12.6
4929,Canada,2014,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",14.0
4930,Canada,2014,11,C10-Lipid modifying agents,Million US$ at exchange rate,1240.2
4931,Canada,2014,11,C08-Calcium channel blockers,% of total sales,2.1
4932,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1094.1
4933,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",982.4
4934,Canada,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,450.2
4935,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.9
4936,Canada,2014,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1208.7
4937,Canada,2014,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",38.6
4938,Canada,2014,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1229.3
4939,Canada,2014,11,C01A-Cardiac glycosides,Million US$ at exchange rate,18.6
4940,Canada,2014,11,C01A-Cardiac glycosides,Million of national currency units,20.5
4941,Canada,2014,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2745.1
4942,Canada,2014,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",86.3
4943,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.4
4944,Canada,2014,11,N06A-Antidepressants,% of total sales,5.9
4945,Canada,2014,11,A-Alimentary tract and metabolism,Million of national currency units,3377.5
4946,Canada,2014,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,3057.3
4947,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1027.3
4948,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1134.9
4949,Canada,2014,11,R-Respiratory system,Million of national currency units,1794.4
4950,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",26.0
4951,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",922.4
4952,Canada,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",29.0
4953,Canada,2014,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.1
4954,Canada,2014,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.6
4955,Canada,2014,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",162.4
4956,Canada,2014,11,N05C-Hypnotics and sedatives,Million of national currency units,199.8
4957,Canada,2014,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,180.9
4958,Canada,2014,11,N06A-Antidepressants,"/capita, US$ exchange rate",38.2
4959,Canada,2014,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",34.3
4960,Canada,2014,11,N06A-Antidepressants,"Million US$, purchasing power parity",1216.3
4961,Canada,2014,11,N06A-Antidepressants,Million of national currency units,1496.5
4962,Canada,2014,11,N05C-Hypnotics and sedatives,% of total sales,0.8
4963,Canada,2014,11,N06A-Antidepressants,Million US$ at exchange rate,1354.6
4964,Canada,2014,11,Products not elsewhere classified,Million US$ at exchange rate,5021.1
4965,Canada,2014,11,Products not elsewhere classified,"Million US$, purchasing power parity",4508.4
4966,Canada,2014,11,Products not elsewhere classified,"/capita, US$ exchange rate",141.7
4967,Canada,2014,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",33.6
4968,Canada,2014,11,R03-Drugs for obstructive airway diseases,% of total sales,5.7
4969,Canada,2014,11,Products not elsewhere classified,Million of national currency units,5547.0
4970,Canada,2014,11,A02A-Antacids,Million US$ at exchange rate,1.2
4971,Canada,2014,11,A02A-Antacids,"Million US$, purchasing power parity",1.1
4972,Canada,2014,11,A02A-Antacids,"/capita, US$ exchange rate",0.0
4973,Canada,2014,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
4974,Canada,2014,11,A02A-Antacids,% of total sales,0.0
4975,Canada,2014,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",127.2
4976,Canada,2014,11,Products not elsewhere classified,% of total sales,21.7
4977,Canada,2014,11,A02A-Antacids,Million of national currency units,1.3
4978,Canada,2014,11,R-Respiratory system,"/capita, US$ purchasing power parity",41.2
4979,Canada,2014,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",77.5
4980,Canada,2014,11,R-Respiratory system,Million US$ at exchange rate,1624.3
4981,Canada,2014,11,R-Respiratory system,"Million US$, purchasing power parity",1458.4
4982,Canada,2014,11,R-Respiratory system,"/capita, US$ exchange rate",45.8
4983,Canada,2014,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1325.2
4984,Canada,2014,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1189.9
4985,Canada,2014,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",37.4
4986,Canada,2014,11,A-Alimentary tract and metabolism,% of total sales,13.2
4987,Canada,2014,11,R-Respiratory system,% of total sales,7.0
4988,Canada,2014,11,R03-Drugs for obstructive airway diseases,Million of national currency units,1464.0
4989,Canada,2014,11,N02-Analgesics,"/capita, US$ purchasing power parity",25.4
4990,Canada,2014,11,N02-Analgesics,"/capita, US$ exchange rate",28.3
4991,Canada,2014,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1230.6
4992,Canada,2014,11,Total pharmaceutical sales,Million of national currency units,25517.0
4993,Canada,2014,11,N02-Analgesics,% of total sales,4.3
4994,Canada,2014,11,N02-Analgesics,Million US$ at exchange rate,1002.9
4995,Canada,2014,11,N02-Analgesics,Million of national currency units,1107.9
4996,Canada,2014,11,A10-Drugs used in diabetes,Million US$ at exchange rate,1370.5
4997,Canada,2014,11,A10-Drugs used in diabetes,Million of national currency units,1514.1
4998,Canada,2014,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",38.7
4999,Canada,2014,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",34.7
5000,Canada,2014,11,A10-Drugs used in diabetes,% of total sales,5.9
5001,Canada,2014,11,Total pharmaceutical sales,"Million US$, purchasing power parity",20739.5
5002,Canada,2014,11,Total pharmaceutical sales,Million US$ at exchange rate,23097.6
5003,Canada,2014,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",585.2
5004,Canada,2014,11,Total pharmaceutical sales,"/capita, US$ exchange rate",651.8
5005,Canada,2014,11,N05B-Anxiolytics,"Million US$, purchasing power parity",133.1
5006,Canada,2014,11,N05B-Anxiolytics,Million US$ at exchange rate,148.3
5007,Canada,2014,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.8
5008,Canada,2014,11,N05B-Anxiolytics,"/capita, US$ exchange rate",4.2
5009,Canada,2014,11,N05B-Anxiolytics,% of total sales,0.6
5010,Canada,2014,11,N02-Analgesics,"Million US$, purchasing power parity",900.5
5011,Canada,2014,11,N05B-Anxiolytics,Million of national currency units,163.8
5012,Canada,2013,11,C-Cardiovascular system,Million of national currency units,4082.7
5013,Canada,2013,11,C-Cardiovascular system,"Million US$, purchasing power parity",3335.5
5014,Canada,2013,11,C-Cardiovascular system,Million US$ at exchange rate,3963.3
5015,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",23.3
5016,Canada,2013,11,N-Nervous system,% of total sales,21.3
5017,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
5018,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
5019,Canada,2013,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.2
5020,Canada,2013,11,G-Genito urinary system and sex hormones,% of total sales,6.0
5021,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
5022,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
5023,Canada,2013,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",18.3
5024,Canada,2013,11,C-Cardiovascular system,"/capita, US$ exchange rate",113.0
5025,Canada,2013,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.7
5026,Canada,2013,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.0
5027,Canada,2013,11,B-Blood and blood forming organs,% of total sales,3.1
5028,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,27.7
5029,Canada,2013,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1210.9
5030,Canada,2013,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.4
5031,Canada,2013,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,1438.8
5032,Canada,2013,11,N-Nervous system,"/capita, US$ exchange rate",144.6
5033,Canada,2013,11,N-Nervous system,"/capita, US$ purchasing power parity",121.7
5034,Canada,2013,11,J-Antiinfectives for systemic use,Million of national currency units,1482.2
5035,Canada,2013,11,N-Nervous system,Million of national currency units,5224.8
5036,Canada,2013,11,N-Nervous system,Million US$ at exchange rate,5071.9
5037,Canada,2013,11,N-Nervous system,"Million US$, purchasing power parity",4268.6
5038,Canada,2013,11,C-Cardiovascular system,% of total sales,16.6
5039,Canada,2013,11,B-Blood and blood forming organs,Million of national currency units,774.2
5040,Canada,2013,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",95.1
5041,Canada,2013,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,784.7
5042,Canada,2013,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",641.1
5043,Canada,2013,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,761.7
5044,Canada,2013,11,B-Blood and blood forming organs,Million US$ at exchange rate,751.6
5045,Canada,2013,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.5
5046,Canada,2013,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,28.5
5047,Canada,2013,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",41.0
5048,Canada,2013,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",632.5
5049,Canada,2013,11,J-Antiinfectives for systemic use,% of total sales,6.0
5050,Canada,2013,11,C10-Lipid modifying agents,Million of national currency units,1484.4
5051,Canada,2013,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,658.8
5052,Canada,2013,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.0
5053,Canada,2013,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",27.4
5054,Canada,2013,11,C03-Diuretics,% of total sales,0.8
5055,Canada,2013,11,J01-Antibacterials for systemic use,Million of national currency units,678.7
5056,Canada,2013,11,M-Musculo-skeletal system,Million of national currency units,989.4
5057,Canada,2013,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",554.5
5058,Canada,2013,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",808.3
5059,Canada,2013,11,M-Musculo-skeletal system,Million US$ at exchange rate,960.5
5060,Canada,2013,11,C08-Calcium channel blockers,Million US$ at exchange rate,545.8
5061,Canada,2013,11,C08-Calcium channel blockers,Million of national currency units,562.3
5062,Canada,2013,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",459.4
5063,Canada,2013,11,M-Musculo-skeletal system,% of total sales,4.0
5064,Canada,2013,11,C03-Diuretics,"/capita, US$ exchange rate",5.5
5065,Canada,2013,11,C03-Diuretics,"/capita, US$ purchasing power parity",4.7
5066,Canada,2013,11,C03-Diuretics,"Million US$, purchasing power parity",163.5
5067,Canada,2013,11,C03-Diuretics,Million of national currency units,200.1
5068,Canada,2013,11,C03-Diuretics,Million US$ at exchange rate,194.2
5069,Canada,2013,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2
5070,Canada,2013,11,C07-Beta blocking agents,% of total sales,1.3
5071,Canada,2013,11,C07-Beta blocking agents,"Million US$, purchasing power parity",252.0
5072,Canada,2013,11,C07-Beta blocking agents,"/capita, US$ exchange rate",8.5
5073,Canada,2013,11,C10-Lipid modifying agents,% of total sales,6.0
5074,Canada,2013,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",34.6
5075,Canada,2013,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",41.1
5076,Canada,2013,11,C07-Beta blocking agents,Million US$ at exchange rate,299.5
5077,Canada,2013,11,J01-Antibacterials for systemic use,% of total sales,2.8
5078,Canada,2013,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",18.8
5079,Canada,2013,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",1212.7
5080,Canada,2013,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.8
5081,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",355.5
5082,Canada,2013,11,C07-Beta blocking agents,Million of national currency units,308.5
5083,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,435.1
5084,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,422.4
5085,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.0
5086,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.9
5087,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
5088,Canada,2013,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.1
5089,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",371.8
5090,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.6
5091,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.1
5092,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.6
5093,Canada,2013,11,C02-Antihypertensives,"Million US$, purchasing power parity",62.5
5094,Canada,2013,11,C02-Antihypertensives,"/capita, US$ exchange rate",2.1
5095,Canada,2013,11,C02-Antihypertensives,Million of national currency units,76.5
5096,Canada,2013,11,C02-Antihypertensives,Million US$ at exchange rate,74.3
5097,Canada,2013,11,C01A-Cardiac glycosides,% of total sales,0.1
5098,Canada,2013,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",17.7
5099,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,441.8
5100,Canada,2013,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.6
5101,Canada,2013,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
5102,Canada,2013,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.8
5103,Canada,2013,11,C02-Antihypertensives,% of total sales,0.3
5104,Canada,2013,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1430.8
5105,Canada,2013,11,G-Genito urinary system and sex hormones,Million of national currency units,1473.9
5106,Canada,2013,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",13.1
5107,Canada,2013,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",15.6
5108,Canada,2013,11,C10-Lipid modifying agents,Million US$ at exchange rate,1441.0
5109,Canada,2013,11,C08-Calcium channel blockers,% of total sales,2.3
5110,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1172.3
5111,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",986.6
5112,Canada,2013,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,455.1
5113,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",33.4
5114,Canada,2013,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1207.6
5115,Canada,2013,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",40.8
5116,Canada,2013,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1204.2
5117,Canada,2013,11,C01A-Cardiac glycosides,Million US$ at exchange rate,21.1
5118,Canada,2013,11,C01A-Cardiac glycosides,Million of national currency units,21.7
5119,Canada,2013,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.3
5120,Canada,2013,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2651.3
5121,Canada,2013,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",89.8
5122,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.9
5123,Canada,2013,11,N06A-Antidepressants,% of total sales,5.9
5124,Canada,2013,11,A-Alimentary tract and metabolism,Million of national currency units,3245.2
5125,Canada,2013,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,3150.3
5126,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1160.7
5127,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1195.7
5128,Canada,2013,11,R-Respiratory system,Million of national currency units,1729.2
5129,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",27.8
5130,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",33.1
5131,Canada,2013,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",976.9
5132,Canada,2013,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.3
5133,Canada,2013,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.5
5134,Canada,2013,11,N05C-Hypnotics and sedatives,Million of national currency units,193.2
5135,Canada,2013,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,187.5
5136,Canada,2013,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",157.8
5137,Canada,2013,11,N05C-Hypnotics and sedatives,% of total sales,0.8
5138,Canada,2013,11,N06A-Antidepressants,"/capita, US$ exchange rate",40.3
5139,Canada,2013,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",33.9
5140,Canada,2013,11,N06A-Antidepressants,"Million US$, purchasing power parity",1189.9
5141,Canada,2013,11,N06A-Antidepressants,Million of national currency units,1456.4
5142,Canada,2013,11,N06A-Antidepressants,Million US$ at exchange rate,1413.8
5143,Canada,2013,11,R-Respiratory system,Million US$ at exchange rate,1678.6
5144,Canada,2013,11,Products not elsewhere classified,Million US$ at exchange rate,4992.5
5145,Canada,2013,11,Products not elsewhere classified,"Million US$, purchasing power parity",4201.8
5146,Canada,2013,11,Products not elsewhere classified,"/capita, US$ exchange rate",142.3
5147,Canada,2013,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.6
5148,Canada,2013,11,R03-Drugs for obstructive airway diseases,% of total sales,5.7
5149,Canada,2013,11,Products not elsewhere classified,Million of national currency units,5143.0
5150,Canada,2013,11,A02A-Antacids,Million US$ at exchange rate,1.3
5151,Canada,2013,11,A02A-Antacids,"Million US$, purchasing power parity",1.1
5152,Canada,2013,11,A02A-Antacids,"/capita, US$ exchange rate",0.0
5153,Canada,2013,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
5154,Canada,2013,11,A02A-Antacids,% of total sales,0.0
5155,Canada,2013,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",119.8
5156,Canada,2013,11,Products not elsewhere classified,% of total sales,20.9
5157,Canada,2013,11,A02A-Antacids,Million of national currency units,1.3
5158,Canada,2013,11,R-Respiratory system,"/capita, US$ purchasing power parity",40.3
5159,Canada,2013,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",75.6
5160,Canada,2013,11,R-Respiratory system,"Million US$, purchasing power parity",1412.7
5161,Canada,2013,11,R-Respiratory system,"/capita, US$ exchange rate",47.8
5162,Canada,2013,11,A-Alimentary tract and metabolism,% of total sales,13.2
5163,Canada,2013,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1143.6
5164,Canada,2013,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.7
5165,Canada,2013,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1358.8
5166,Canada,2013,11,R-Respiratory system,% of total sales,7.0
5167,Canada,2013,11,R03-Drugs for obstructive airway diseases,Million of national currency units,1399.8
5168,Canada,2013,11,N02-Analgesics,"/capita, US$ purchasing power parity",25.5
5169,Canada,2013,11,N02-Analgesics,"/capita, US$ exchange rate",30.3
5170,Canada,2013,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1118.5
5171,Canada,2013,11,Total pharmaceutical sales,Million of national currency units,24579.2
5172,Canada,2013,11,N02-Analgesics,% of total sales,4.4
5173,Canada,2013,11,N02-Analgesics,Million US$ at exchange rate,1061.6
5174,Canada,2013,11,A10-Drugs used in diabetes,Million US$ at exchange rate,1328.9
5175,Canada,2013,11,N02-Analgesics,Million of national currency units,1093.6
5176,Canada,2013,11,A10-Drugs used in diabetes,Million of national currency units,1369.0
5177,Canada,2013,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",37.9
5178,Canada,2013,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.9
5179,Canada,2013,11,A10-Drugs used in diabetes,% of total sales,5.6
5180,Canada,2013,11,Total pharmaceutical sales,"Million US$, purchasing power parity",20081.0
5181,Canada,2013,11,Total pharmaceutical sales,Million US$ at exchange rate,23860.1
5182,Canada,2013,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",572.4
5183,Canada,2013,11,Total pharmaceutical sales,"/capita, US$ exchange rate",680.1
5184,Canada,2013,11,N02-Analgesics,"Million US$, purchasing power parity",893.5
5185,Canada,2013,11,N05B-Anxiolytics,"Million US$, purchasing power parity",134.2
5186,Canada,2013,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.8
5187,Canada,2013,11,N05B-Anxiolytics,"/capita, US$ exchange rate",4.5
5188,Canada,2013,11,N05B-Anxiolytics,Million US$ at exchange rate,159.4
5189,Canada,2013,11,N05B-Anxiolytics,% of total sales,0.7
5190,Canada,2013,11,N05B-Anxiolytics,Million of national currency units,164.2
5191,Canada,2012,11,C-Cardiovascular system,Million of national currency units,4627.3
5192,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
5193,Canada,2012,11,C-Cardiovascular system,"Million US$, purchasing power parity",3717.9
5194,Canada,2012,11,C-Cardiovascular system,Million US$ at exchange rate,4630.2
5195,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",24.6
5196,Canada,2012,11,N-Nervous system,% of total sales,21.4
5197,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
5198,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
5199,Canada,2012,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.1
5200,Canada,2012,11,G-Genito urinary system and sex hormones,% of total sales,5.9
5201,Canada,2012,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",17.4
5202,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
5203,Canada,2012,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.7
5204,Canada,2012,11,C-Cardiovascular system,"/capita, US$ exchange rate",133.4
5205,Canada,2012,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",107.1
5206,Canada,2012,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.2
5207,Canada,2012,11,B-Blood and blood forming organs,% of total sales,3.1
5208,Canada,2012,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.4
5209,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,30.6
5210,Canada,2012,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1158.4
5211,Canada,2012,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,1442.7
5212,Canada,2012,11,N-Nervous system,"/capita, US$ exchange rate",149.9
5213,Canada,2012,11,N-Nervous system,"/capita, US$ purchasing power parity",120.4
5214,Canada,2012,11,N-Nervous system,Million of national currency units,5200.6
5215,Canada,2012,11,N-Nervous system,Million US$ at exchange rate,5203.9
5216,Canada,2012,11,N-Nervous system,"Million US$, purchasing power parity",4178.5
5217,Canada,2012,11,J-Antiinfectives for systemic use,Million of national currency units,1441.8
5218,Canada,2012,11,C-Cardiovascular system,% of total sales,19.0
5219,Canada,2012,11,B-Blood and blood forming organs,Million of national currency units,742.9
5220,Canada,2012,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,751.1
5221,Canada,2012,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,751.6
5222,Canada,2012,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",603.5
5223,Canada,2012,11,B-Blood and blood forming organs,Million US$ at exchange rate,743.4
5224,Canada,2012,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",33.4
5225,Canada,2012,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",41.6
5226,Canada,2012,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,30.6
5227,Canada,2012,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",596.9
5228,Canada,2012,11,J-Antiinfectives for systemic use,% of total sales,5.9
5229,Canada,2012,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,694.6
5230,Canada,2012,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7
5231,Canada,2012,11,C03-Diuretics,% of total sales,0.8
5232,Canada,2012,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",28.3
5233,Canada,2012,11,J01-Antibacterials for systemic use,Million of national currency units,694.2
5234,Canada,2012,11,M-Musculo-skeletal system,Million of national currency units,980.8
5235,Canada,2012,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",557.8
5236,Canada,2012,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",788.0
5237,Canada,2012,11,M-Musculo-skeletal system,Million US$ at exchange rate,981.4
5238,Canada,2012,11,C08-Calcium channel blockers,Million US$ at exchange rate,613.8
5239,Canada,2012,11,M-Musculo-skeletal system,% of total sales,4.0
5240,Canada,2012,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",492.8
5241,Canada,2012,11,C08-Calcium channel blockers,Million of national currency units,613.4
5242,Canada,2012,11,C03-Diuretics,Million of national currency units,198.4
5243,Canada,2012,11,C03-Diuretics,"/capita, US$ exchange rate",5.7
5244,Canada,2012,11,C03-Diuretics,"/capita, US$ purchasing power parity",4.6
5245,Canada,2012,11,C03-Diuretics,Million US$ at exchange rate,198.5
5246,Canada,2012,11,C03-Diuretics,"Million US$, purchasing power parity",159.4
5247,Canada,2012,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4
5248,Canada,2012,11,C07-Beta blocking agents,% of total sales,1.3
5249,Canada,2012,11,C07-Beta blocking agents,"Million US$, purchasing power parity",258.3
5250,Canada,2012,11,C07-Beta blocking agents,"/capita, US$ exchange rate",9.3
5251,Canada,2012,11,C10-Lipid modifying agents,% of total sales,7.5
5252,Canada,2012,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",42.2
5253,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.9
5254,Canada,2012,11,C07-Beta blocking agents,Million US$ at exchange rate,321.7
5255,Canada,2012,11,J01-Antibacterials for systemic use,% of total sales,2.9
5256,Canada,2012,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",1465.0
5257,Canada,2012,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",20.0
5258,Canada,2012,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",16.1
5259,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",332.5
5260,Canada,2012,11,C07-Beta blocking agents,Million of national currency units,321.5
5261,Canada,2012,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",52.6
5262,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,413.8
5263,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,414.1
5264,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.6
5265,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7
5266,Canada,2012,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.6
5267,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",364.9
5268,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.1
5269,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",31.5
5270,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.5
5271,Canada,2012,11,C02-Antihypertensives,"Million US$, purchasing power parity",59.0
5272,Canada,2012,11,C02-Antihypertensives,"/capita, US$ exchange rate",2.1
5273,Canada,2012,11,C02-Antihypertensives,Million of national currency units,73.4
5274,Canada,2012,11,C02-Antihypertensives,Million US$ at exchange rate,73.4
5275,Canada,2012,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",17.9
5276,Canada,2012,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.6
5277,Canada,2012,11,C01A-Cardiac glycosides,% of total sales,0.1
5278,Canada,2012,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
5279,Canada,2012,11,C10-Lipid modifying agents,Million of national currency units,1823.4
5280,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,454.4
5281,Canada,2012,11,C02-Antihypertensives,% of total sales,0.3
5282,Canada,2012,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.7
5283,Canada,2012,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1431.5
5284,Canada,2012,11,G-Genito urinary system and sex hormones,Million of national currency units,1430.6
5285,Canada,2012,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",14.2
5286,Canada,2012,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",17.7
5287,Canada,2012,11,C10-Lipid modifying agents,Million US$ at exchange rate,1824.6
5288,Canada,2012,11,C08-Calcium channel blockers,% of total sales,2.5
5289,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1363.6
5290,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1094.9
5291,Canada,2012,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,454.1
5292,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",39.3
5293,Canada,2012,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1362.7
5294,Canada,2012,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",41.2
5295,Canada,2012,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1149.4
5296,Canada,2012,11,C01A-Cardiac glycosides,Million US$ at exchange rate,22.3
5297,Canada,2012,11,C01A-Cardiac glycosides,Million of national currency units,22.3
5298,Canada,2012,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.1
5299,Canada,2012,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2570.7
5300,Canada,2012,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",92.2
5301,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.3
5302,Canada,2012,11,A-Alimentary tract and metabolism,Million of national currency units,3199.5
5303,Canada,2012,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,3201.5
5304,Canada,2012,11,N06A-Antidepressants,% of total sales,5.9
5305,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1299.0
5306,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1298.2
5307,Canada,2012,11,R-Respiratory system,Million of national currency units,1676.3
5308,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",30.0
5309,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",37.4
5310,Canada,2012,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1043.1
5311,Canada,2012,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.4
5312,Canada,2012,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.3
5313,Canada,2012,11,N05C-Hypnotics and sedatives,Million of national currency units,187.0
5314,Canada,2012,11,N05C-Hypnotics and sedatives,% of total sales,0.8
5315,Canada,2012,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,187.1
5316,Canada,2012,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",150.2
5317,Canada,2012,11,N06A-Antidepressants,"/capita, US$ exchange rate",41.6
5318,Canada,2012,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",33.4
5319,Canada,2012,11,N06A-Antidepressants,"Million US$, purchasing power parity",1160.4
5320,Canada,2012,11,N06A-Antidepressants,Million of national currency units,1444.2
5321,Canada,2012,11,N06A-Antidepressants,Million US$ at exchange rate,1445.1
5322,Canada,2012,11,Products not elsewhere classified,Million US$ at exchange rate,4586.9
5323,Canada,2012,11,Products not elsewhere classified,"Million US$, purchasing power parity",3683.1
5324,Canada,2012,11,Products not elsewhere classified,"/capita, US$ exchange rate",132.1
5325,Canada,2012,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",31.3
5326,Canada,2012,11,R03-Drugs for obstructive airway diseases,% of total sales,5.6
5327,Canada,2012,11,Products not elsewhere classified,Million of national currency units,4584.0
5328,Canada,2012,11,A02A-Antacids,"Million US$, purchasing power parity",1.1
5329,Canada,2012,11,A02A-Antacids,"/capita, US$ exchange rate",0.0
5330,Canada,2012,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
5331,Canada,2012,11,A02A-Antacids,% of total sales,0.0
5332,Canada,2012,11,A02A-Antacids,Million US$ at exchange rate,1.4
5333,Canada,2012,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",106.1
5334,Canada,2012,11,A02A-Antacids,Million of national currency units,1.4
5335,Canada,2012,11,Products not elsewhere classified,% of total sales,18.9
5336,Canada,2012,11,R-Respiratory system,Million US$ at exchange rate,1677.4
5337,Canada,2012,11,R-Respiratory system,% of total sales,6.9
5338,Canada,2012,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",74.1
5339,Canada,2012,11,R-Respiratory system,"/capita, US$ purchasing power parity",38.8
5340,Canada,2012,11,R-Respiratory system,"Million US$, purchasing power parity",1346.9
5341,Canada,2012,11,R-Respiratory system,"/capita, US$ exchange rate",48.3
5342,Canada,2012,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1085.0
5343,Canada,2012,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.9
5344,Canada,2012,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1351.3
5345,Canada,2012,11,A-Alimentary tract and metabolism,% of total sales,13.2
5346,Canada,2012,11,R03-Drugs for obstructive airway diseases,Million of national currency units,1350.4
5347,Canada,2012,11,N02-Analgesics,"/capita, US$ purchasing power parity",25.8
5348,Canada,2012,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",991.2
5349,Canada,2012,11,N02-Analgesics,% of total sales,4.6
5350,Canada,2012,11,Total pharmaceutical sales,Million of national currency units,24297.8
5351,Canada,2012,11,N02-Analgesics,Million US$ at exchange rate,1116.2
5352,Canada,2012,11,N02-Analgesics,Million of national currency units,1115.5
5353,Canada,2012,11,A10-Drugs used in diabetes,Million of national currency units,1233.7
5354,Canada,2012,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",35.6
5355,Canada,2012,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",28.6
5356,Canada,2012,11,A10-Drugs used in diabetes,% of total sales,5.1
5357,Canada,2012,11,Total pharmaceutical sales,"Million US$, purchasing power parity",19522.5
5358,Canada,2012,11,Total pharmaceutical sales,Million US$ at exchange rate,24313.2
5359,Canada,2012,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",562.4
5360,Canada,2012,11,Total pharmaceutical sales,"/capita, US$ exchange rate",700.4
5361,Canada,2012,11,N02-Analgesics,"Million US$, purchasing power parity",896.3
5362,Canada,2012,11,A10-Drugs used in diabetes,Million US$ at exchange rate,1234.5
5363,Canada,2012,11,N05B-Anxiolytics,"Million US$, purchasing power parity",132.4
5364,Canada,2012,11,N05B-Anxiolytics,Million US$ at exchange rate,164.9
5365,Canada,2012,11,N05B-Anxiolytics,"/capita, US$ exchange rate",4.8
5366,Canada,2012,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.8
5367,Canada,2012,11,N05B-Anxiolytics,% of total sales,0.7
5368,Canada,2012,11,N02-Analgesics,"/capita, US$ exchange rate",32.2
5369,Canada,2012,11,N05B-Anxiolytics,Million of national currency units,164.8
5370,Chile,2015,14,B-Blood and blood forming organs,Million of national currency units,92673.7
5371,Chile,2015,14,B-Blood and blood forming organs,Million US$ at exchange rate,141.7
5372,Chile,2015,14,G-Genito urinary system and sex hormones,Million of national currency units,165236.3
5373,Chile,2015,14,C10-Lipid modifying agents,"Million US$, purchasing power parity",101.3
5374,Chile,2015,14,G-Genito urinary system and sex hormones,Million US$ at exchange rate,252.6
5375,Chile,2015,14,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",422.4
5376,Chile,2015,14,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.6
5377,Chile,2015,14,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.2
5378,Chile,2015,14,B-Blood and blood forming organs,% of total sales,5.1
5379,Chile,2015,14,B-Blood and blood forming organs,"Million US$, purchasing power parity",236.9
5380,Chile,2015,14,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.9
5381,Chile,2015,14,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.4
5382,Chile,2015,14,C10-Lipid modifying agents,% of total sales,2.2
5383,Chile,2015,14,A-Alimentary tract and metabolism,% of total sales,17.4
5384,Chile,2015,14,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4
5385,Chile,2015,14,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
5386,Chile,2015,14,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",812.4
5387,Chile,2015,14,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.2
5388,Chile,2015,14,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",27.0
5389,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.2
5390,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.7
5391,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
5392,Chile,2015,14,C01A-Cardiac glycosides,Million of national currency units,173.5
5393,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,43736.2
5394,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,66.9
5395,Chile,2015,14,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",111.8
5396,Chile,2015,14,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.1
5397,Chile,2015,14,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.5
5398,Chile,2015,14,G03-Sex hormones and modulators of the genital system,Million of national currency units,117332.5
5399,Chile,2015,14,G-Genito urinary system and sex hormones,% of total sales,9.1
5400,Chile,2015,14,C10-Lipid modifying agents,Million US$ at exchange rate,60.6
5401,Chile,2015,14,C01A-Cardiac glycosides,% of total sales,0.0
5402,Chile,2015,14,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
5403,Chile,2015,14,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
5404,Chile,2015,14,G03-Sex hormones and modulators of the genital system,% of total sales,6.4
5405,Chile,2015,14,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",16.7
5406,Chile,2015,14,A-Alimentary tract and metabolism,Million of national currency units,317777.7
5407,Chile,2015,14,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,179.4
5408,Chile,2015,14,A-Alimentary tract and metabolism,Million US$ at exchange rate,485.8
5409,Chile,2015,14,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",299.9
5410,Chile,2015,14,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.0
5411,Chile,2015,14,Total pharmaceutical sales,"/capita, US$ purchasing power parity",259.4
5412,Chile,2015,14,C07-Beta blocking agents,Million of national currency units,16311.0
5413,Chile,2015,14,C07-Beta blocking agents,Million US$ at exchange rate,24.9
5414,Chile,2015,14,Total pharmaceutical sales,Million US$ at exchange rate,2788.0
5415,Chile,2015,14,Total pharmaceutical sales,"Million US$, purchasing power parity",4662.0
5416,Chile,2015,14,Total pharmaceutical sales,"/capita, US$ exchange rate",155.1
5417,Chile,2015,14,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5
5418,Chile,2015,14,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
5419,Chile,2015,14,C02-Antihypertensives,"Million US$, purchasing power parity",9.1
5420,Chile,2015,14,C-Cardiovascular system,% of total sales,7.6
5421,Chile,2015,14,C07-Beta blocking agents,"Million US$, purchasing power parity",41.7
5422,Chile,2015,14,C02-Antihypertensives,% of total sales,0.2
5423,Chile,2015,14,C-Cardiovascular system,Million of national currency units,138496.2
5424,Chile,2015,14,C03-Diuretics,Million US$ at exchange rate,10.4
5425,Chile,2015,14,C03-Diuretics,Million of national currency units,6793.5
5426,Chile,2015,14,C-Cardiovascular system,Million US$ at exchange rate,211.7
5427,Chile,2015,14,C-Cardiovascular system,"/capita, US$ exchange rate",11.8
5428,Chile,2015,14,C-Cardiovascular system,"Million US$, purchasing power parity",354.0
5429,Chile,2015,14,C03-Diuretics,"/capita, US$ purchasing power parity",1.0
5430,Chile,2015,14,C03-Diuretics,% of total sales,0.4
5431,Chile,2015,14,Total pharmaceutical sales,Million of national currency units,1823693.1
5432,Chile,2015,14,C-Cardiovascular system,"/capita, US$ purchasing power parity",19.7
5433,Chile,2015,14,C03-Diuretics,"Million US$, purchasing power parity",17.4
5434,Chile,2015,14,C03-Diuretics,"/capita, US$ exchange rate",0.6
5435,Chile,2015,14,C08-Calcium channel blockers,% of total sales,0.4
5436,Chile,2015,14,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0
5437,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,49040.7
5438,Chile,2015,14,C08-Calcium channel blockers,"Million US$, purchasing power parity",17.2
5439,Chile,2015,14,C08-Calcium channel blockers,Million US$ at exchange rate,10.3
5440,Chile,2015,14,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.6
5441,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.7
5442,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",7.0
5443,Chile,2015,14,C10-Lipid modifying agents,Million of national currency units,39621.5
5444,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",125.4
5445,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,75.0
5446,Chile,2015,14,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.2
5447,Chile,2015,14,C02-Antihypertensives,Million US$ at exchange rate,5.4
5448,Chile,2015,14,C02-Antihypertensives,Million of national currency units,3557.7
5449,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
5450,Chile,2015,14,C07-Beta blocking agents,"/capita, US$ exchange rate",1.4
5451,Chile,2015,14,C07-Beta blocking agents,% of total sales,0.9
5452,Chile,2015,14,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.3
5453,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,2.6
5454,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1679.1
5455,Chile,2015,14,C08-Calcium channel blockers,Million of national currency units,6710.2
5456,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.2
5457,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.1
5458,Chile,2015,14,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.3
5459,Chile,2015,14,N-Nervous system,"/capita, US$ purchasing power parity",40.3
5460,Chile,2015,14,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.3
5461,Chile,2015,14,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.8
5462,Chile,2015,14,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",202.9
5463,Chile,2015,14,N06A-Antidepressants,% of total sales,3.1
5464,Chile,2015,14,J01-Antibacterials for systemic use,% of total sales,4.4
5465,Chile,2015,14,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.4
5466,Chile,2015,14,A10-Drugs used in diabetes,% of total sales,4.8
5467,Chile,2015,14,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",12.4
5468,Chile,2015,14,A10-Drugs used in diabetes,Million of national currency units,87238.4
5469,Chile,2015,14,A10-Drugs used in diabetes,Million US$ at exchange rate,133.4
5470,Chile,2015,14,A10-Drugs used in diabetes,"Million US$, purchasing power parity",223.0
5471,Chile,2015,14,N06A-Antidepressants,Million of national currency units,56272.0
5472,Chile,2015,14,N06A-Antidepressants,"Million US$, purchasing power parity",143.9
5473,Chile,2015,14,N06A-Antidepressants,Million US$ at exchange rate,86.0
5474,Chile,2015,14,M-Musculo-skeletal system,Million of national currency units,123321.4
5475,Chile,2015,14,N05C-Hypnotics and sedatives,% of total sales,0.5
5476,Chile,2015,14,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.0
5477,Chile,2015,14,Products not elsewhere classified,"Million US$, purchasing power parity",616.7
5478,Chile,2015,14,Products not elsewhere classified,"/capita, US$ exchange rate",20.5
5479,Chile,2015,14,N06A-Antidepressants,"/capita, US$ exchange rate",4.8
5480,Chile,2015,14,Products not elsewhere classified,% of total sales,13.2
5481,Chile,2015,14,Products not elsewhere classified,"/capita, US$ purchasing power parity",34.3
5482,Chile,2015,14,R-Respiratory system,% of total sales,9.6
5483,Chile,2015,14,R-Respiratory system,"/capita, US$ purchasing power parity",25.0
5484,Chile,2015,14,A02A-Antacids,"Million US$, purchasing power parity",28.9
5485,Chile,2015,14,R03-Drugs for obstructive airway diseases,Million of national currency units,46814.6
5486,Chile,2015,14,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,71.6
5487,Chile,2015,14,A02A-Antacids,Million of national currency units,11322.5
5488,Chile,2015,14,R-Respiratory system,Million of national currency units,175733.0
5489,Chile,2015,14,A02A-Antacids,Million US$ at exchange rate,17.3
5490,Chile,2015,14,R-Respiratory system,"Million US$, purchasing power parity",449.2
5491,Chile,2015,14,R-Respiratory system,Million US$ at exchange rate,268.7
5492,Chile,2015,14,R-Respiratory system,"/capita, US$ exchange rate",14.9
5493,Chile,2015,14,A02A-Antacids,"/capita, US$ purchasing power parity",1.6
5494,Chile,2015,14,Products not elsewhere classified,Million US$ at exchange rate,368.8
5495,Chile,2015,14,A02A-Antacids,% of total sales,0.6
5496,Chile,2015,14,J01-Antibacterials for systemic use,Million US$ at exchange rate,121.4
5497,Chile,2015,14,J01-Antibacterials for systemic use,Million of national currency units,79384.9
5498,Chile,2015,14,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",4.0
5499,Chile,2015,14,A02A-Antacids,"/capita, US$ exchange rate",1.0
5500,Chile,2015,14,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",119.7
5501,Chile,2015,14,M-Musculo-skeletal system,Million US$ at exchange rate,188.5
5502,Chile,2015,14,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",6.7
5503,Chile,2015,14,Products not elsewhere classified,Million of national currency units,241259.0
5504,Chile,2015,14,R03-Drugs for obstructive airway diseases,% of total sales,2.6
5505,Chile,2015,14,N02-Analgesics,"Million US$, purchasing power parity",193.2
5506,Chile,2015,14,N02-Analgesics,"/capita, US$ exchange rate",6.4
5507,Chile,2015,14,N02-Analgesics,"/capita, US$ purchasing power parity",10.7
5508,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,30504.0
5509,Chile,2015,14,N02-Analgesics,Million US$ at exchange rate,115.5
5510,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",166.2
5511,Chile,2015,14,J-Antiinfectives for systemic use,Million of national currency units,241797.7
5512,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,99.4
5513,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.2
5514,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.6
5515,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.5
5516,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,46.6
5517,Chile,2015,14,N-Nervous system,Million of national currency units,283661.8
5518,Chile,2015,14,N-Nervous system,Million US$ at exchange rate,433.7
5519,Chile,2015,14,N-Nervous system,% of total sales,15.6
5520,Chile,2015,14,N-Nervous system,"/capita, US$ exchange rate",24.1
5521,Chile,2015,14,N-Nervous system,"Million US$, purchasing power parity",725.1
5522,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.6
5523,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",78.0
5524,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.3
5525,Chile,2015,14,N02-Analgesics,Million of national currency units,75558.7
5526,Chile,2015,14,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7
5527,Chile,2015,14,N05B-Anxiolytics,% of total sales,0.7
5528,Chile,2015,14,N05C-Hypnotics and sedatives,Million of national currency units,9241.4
5529,Chile,2015,14,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.1
5530,Chile,2015,14,N05B-Anxiolytics,"Million US$, purchasing power parity",32.5
5531,Chile,2015,14,N05B-Anxiolytics,Million US$ at exchange rate,19.4
5532,Chile,2015,14,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8
5533,Chile,2015,14,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
5534,Chile,2015,14,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.5
5535,Chile,2015,14,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.5
5536,Chile,2015,14,M-Musculo-skeletal system,"Million US$, purchasing power parity",315.3
5537,Chile,2015,14,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
5538,Chile,2015,14,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",23.6
5539,Chile,2015,14,M-Musculo-skeletal system,% of total sales,6.8
5540,Chile,2015,14,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3
5541,Chile,2015,14,N02-Analgesics,% of total sales,4.1
5542,Chile,2015,14,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.4
5543,Chile,2015,14,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,65023.8
5544,Chile,2015,14,J-Antiinfectives for systemic use,% of total sales,13.3
5545,Chile,2015,14,J-Antiinfectives for systemic use,Million US$ at exchange rate,369.7
5546,Chile,2015,14,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",20.6
5547,Chile,2015,14,N05B-Anxiolytics,Million of national currency units,12721.9
5548,Chile,2015,14,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",618.1
5549,Chile,2014,15,B-Blood and blood forming organs,Million US$ at exchange rate,120.2
5550,Chile,2014,15,G-Genito urinary system and sex hormones,Million of national currency units,145380.0
5551,Chile,2014,15,B-Blood and blood forming organs,Million of national currency units,68583.3
5552,Chile,2014,15,C10-Lipid modifying agents,"Million US$, purchasing power parity",91.7
5553,Chile,2014,15,G-Genito urinary system and sex hormones,Million US$ at exchange rate,254.9
5554,Chile,2014,15,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",395.9
5555,Chile,2014,15,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",10.5
5556,Chile,2014,15,B-Blood and blood forming organs,% of total sales,4.4
5557,Chile,2014,15,B-Blood and blood forming organs,"Million US$, purchasing power parity",186.8
5558,Chile,2014,15,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.8
5559,Chile,2014,15,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.3
5560,Chile,2014,15,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.2
5561,Chile,2014,15,C10-Lipid modifying agents,% of total sales,2.2
5562,Chile,2014,15,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.3
5563,Chile,2014,15,A-Alimentary tract and metabolism,% of total sales,16.8
5564,Chile,2014,15,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7
5565,Chile,2014,15,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
5566,Chile,2014,15,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",708.1
5567,Chile,2014,15,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.8
5568,Chile,2014,15,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.6
5569,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.8
5570,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.8
5571,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
5572,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,38190.1
5573,Chile,2014,15,C01A-Cardiac glycosides,Million of national currency units,247.9
5574,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",104.0
5575,Chile,2014,15,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,67.0
5576,Chile,2014,15,A-Alimentary tract and metabolism,Million US$ at exchange rate,455.9
5577,Chile,2014,15,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.3
5578,Chile,2014,15,G03-Sex hormones and modulators of the genital system,Million of national currency units,102222.0
5579,Chile,2014,15,G-Genito urinary system and sex hormones,% of total sales,9.4
5580,Chile,2014,15,C01A-Cardiac glycosides,% of total sales,0.0
5581,Chile,2014,15,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
5582,Chile,2014,15,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
5583,Chile,2014,15,G03-Sex hormones and modulators of the genital system,% of total sales,6.6
5584,Chile,2014,15,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",15.6
5585,Chile,2014,15,A-Alimentary tract and metabolism,Million of national currency units,260015.0
5586,Chile,2014,15,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",278.4
5587,Chile,2014,15,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,179.2
5588,Chile,2014,15,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.1
5589,Chile,2014,15,C10-Lipid modifying agents,Million US$ at exchange rate,59.0
5590,Chile,2014,15,Total pharmaceutical sales,"/capita, US$ purchasing power parity",236.8
5591,Chile,2014,15,C07-Beta blocking agents,Million of national currency units,15358.9
5592,Chile,2014,15,C07-Beta blocking agents,Million US$ at exchange rate,26.9
5593,Chile,2014,15,Total pharmaceutical sales,Million US$ at exchange rate,2711.4
5594,Chile,2014,15,Total pharmaceutical sales,"Million US$, purchasing power parity",4211.3
5595,Chile,2014,15,Total pharmaceutical sales,"/capita, US$ exchange rate",152.4
5596,Chile,2014,15,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5
5597,Chile,2014,15,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
5598,Chile,2014,15,C02-Antihypertensives,"Million US$, purchasing power parity",8.5
5599,Chile,2014,15,C-Cardiovascular system,% of total sales,8.0
5600,Chile,2014,15,C07-Beta blocking agents,"Million US$, purchasing power parity",41.8
5601,Chile,2014,15,C02-Antihypertensives,% of total sales,0.2
5602,Chile,2014,15,C-Cardiovascular system,Million of national currency units,124399.3
5603,Chile,2014,15,C03-Diuretics,Million US$ at exchange rate,7.9
5604,Chile,2014,15,C03-Diuretics,Million of national currency units,4497.4
5605,Chile,2014,15,C-Cardiovascular system,"/capita, US$ exchange rate",12.3
5606,Chile,2014,15,C-Cardiovascular system,Million US$ at exchange rate,218.1
5607,Chile,2014,15,C-Cardiovascular system,"Million US$, purchasing power parity",338.8
5608,Chile,2014,15,C03-Diuretics,"/capita, US$ purchasing power parity",0.7
5609,Chile,2014,15,C03-Diuretics,% of total sales,0.3
5610,Chile,2014,15,Total pharmaceutical sales,Million of national currency units,1546451.1
5611,Chile,2014,15,C-Cardiovascular system,"/capita, US$ purchasing power parity",19.0
5612,Chile,2014,15,C03-Diuretics,"/capita, US$ exchange rate",0.4
5613,Chile,2014,15,C03-Diuretics,"Million US$, purchasing power parity",12.2
5614,Chile,2014,15,C08-Calcium channel blockers,% of total sales,0.4
5615,Chile,2014,15,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0
5616,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,44854.1
5617,Chile,2014,15,C08-Calcium channel blockers,"Million US$, purchasing power parity",18.0
5618,Chile,2014,15,C08-Calcium channel blockers,Million US$ at exchange rate,11.6
5619,Chile,2014,15,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7
5620,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.9
5621,Chile,2014,15,C10-Lipid modifying agents,Million of national currency units,33677.0
5622,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",6.9
5623,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",122.1
5624,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,78.6
5625,Chile,2014,15,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.4
5626,Chile,2014,15,C02-Antihypertensives,Million US$ at exchange rate,5.5
5627,Chile,2014,15,C02-Antihypertensives,Million of national currency units,3129.0
5628,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
5629,Chile,2014,15,C07-Beta blocking agents,"/capita, US$ exchange rate",1.5
5630,Chile,2014,15,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.4
5631,Chile,2014,15,C07-Beta blocking agents,% of total sales,1.0
5632,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.0
5633,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1688.5
5634,Chile,2014,15,C08-Calcium channel blockers,Million of national currency units,6613.0
5635,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.3
5636,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.6
5637,Chile,2014,15,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2
5638,Chile,2014,15,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.1
5639,Chile,2014,15,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",196.9
5640,Chile,2014,15,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.1
5641,Chile,2014,15,N06A-Antidepressants,% of total sales,3.2
5642,Chile,2014,15,J01-Antibacterials for systemic use,% of total sales,4.7
5643,Chile,2014,15,A10-Drugs used in diabetes,"/capita, US$ exchange rate",6.5
5644,Chile,2014,15,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",10.1
5645,Chile,2014,15,A10-Drugs used in diabetes,% of total sales,4.3
5646,Chile,2014,15,A10-Drugs used in diabetes,Million of national currency units,66175.6
5647,Chile,2014,15,A10-Drugs used in diabetes,Million US$ at exchange rate,116.0
5648,Chile,2014,15,A10-Drugs used in diabetes,"Million US$, purchasing power parity",180.2
5649,Chile,2014,15,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.5
5650,Chile,2014,15,N06A-Antidepressants,Million of national currency units,48805.4
5651,Chile,2014,15,N06A-Antidepressants,Million US$ at exchange rate,85.6
5652,Chile,2014,15,N06A-Antidepressants,"Million US$, purchasing power parity",132.9
5653,Chile,2014,15,M-Musculo-skeletal system,Million of national currency units,107902.8
5654,Chile,2014,15,M-Musculo-skeletal system,Million US$ at exchange rate,189.2
5655,Chile,2014,15,N05C-Hypnotics and sedatives,% of total sales,0.6
5656,Chile,2014,15,Products not elsewhere classified,"Million US$, purchasing power parity",594.8
5657,Chile,2014,15,Products not elsewhere classified,"/capita, US$ exchange rate",21.5
5658,Chile,2014,15,N06A-Antidepressants,"/capita, US$ exchange rate",4.8
5659,Chile,2014,15,Products not elsewhere classified,% of total sales,14.1
5660,Chile,2014,15,Products not elsewhere classified,"/capita, US$ purchasing power parity",33.4
5661,Chile,2014,15,R-Respiratory system,% of total sales,9.9
5662,Chile,2014,15,R-Respiratory system,"/capita, US$ purchasing power parity",23.5
5663,Chile,2014,15,R03-Drugs for obstructive airway diseases,Million of national currency units,37615.6
5664,Chile,2014,15,A02A-Antacids,"Million US$, purchasing power parity",28.3
5665,Chile,2014,15,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,66.0
5666,Chile,2014,15,R-Respiratory system,"/capita, US$ exchange rate",15.2
5667,Chile,2014,15,A02A-Antacids,Million of national currency units,10396.9
5668,Chile,2014,15,R-Respiratory system,Million of national currency units,153706.6
5669,Chile,2014,15,A02A-Antacids,Million US$ at exchange rate,18.2
5670,Chile,2014,15,R-Respiratory system,"Million US$, purchasing power parity",418.6
5671,Chile,2014,15,R-Respiratory system,Million US$ at exchange rate,269.5
5672,Chile,2014,15,A02A-Antacids,"/capita, US$ purchasing power parity",1.6
5673,Chile,2014,15,A02A-Antacids,% of total sales,0.7
5674,Chile,2014,15,Products not elsewhere classified,Million US$ at exchange rate,383.0
5675,Chile,2014,15,J01-Antibacterials for systemic use,Million US$ at exchange rate,126.8
5676,Chile,2014,15,J01-Antibacterials for systemic use,Million of national currency units,72295.7
5677,Chile,2014,15,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",3.7
5678,Chile,2014,15,A02A-Antacids,"/capita, US$ exchange rate",1.0
5679,Chile,2014,15,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",102.4
5680,Chile,2014,15,Products not elsewhere classified,Million of national currency units,218422.5
5681,Chile,2014,15,R03-Drugs for obstructive airway diseases,% of total sales,2.4
5682,Chile,2014,15,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",5.8
5683,Chile,2014,15,N02-Analgesics,"/capita, US$ exchange rate",6.6
5684,Chile,2014,15,N02-Analgesics,"Million US$, purchasing power parity",181.0
5685,Chile,2014,15,N02-Analgesics,"/capita, US$ purchasing power parity",10.2
5686,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,26581.9
5687,Chile,2014,15,N02-Analgesics,Million US$ at exchange rate,116.6
5688,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,46.6
5689,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",157.6
5690,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,101.5
5691,Chile,2014,15,J-Antiinfectives for systemic use,Million of national currency units,180250.2
5692,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.7
5693,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.9
5694,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.7
5695,Chile,2014,15,N-Nervous system,Million US$ at exchange rate,437.6
5696,Chile,2014,15,N-Nervous system,Million of national currency units,249601.3
5697,Chile,2014,15,N-Nervous system,% of total sales,16.1
5698,Chile,2014,15,N-Nervous system,"/capita, US$ exchange rate",24.6
5699,Chile,2014,15,N-Nervous system,"/capita, US$ purchasing power parity",38.2
5700,Chile,2014,15,N-Nervous system,"Million US$, purchasing power parity",679.7
5701,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.6
5702,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",72.4
5703,Chile,2014,15,N02-Analgesics,Million of national currency units,66475.8
5704,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7
5705,Chile,2014,15,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.1
5706,Chile,2014,15,N05B-Anxiolytics,% of total sales,0.8
5707,Chile,2014,15,N05C-Hypnotics and sedatives,Million of national currency units,8655.6
5708,Chile,2014,15,N05C-Hypnotics and sedatives,Million US$ at exchange rate,15.2
5709,Chile,2014,15,N05B-Anxiolytics,"Million US$, purchasing power parity",32.0
5710,Chile,2014,15,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8
5711,Chile,2014,15,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
5712,Chile,2014,15,N05B-Anxiolytics,Million US$ at exchange rate,20.6
5713,Chile,2014,15,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.5
5714,Chile,2014,15,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.6
5715,Chile,2014,15,M-Musculo-skeletal system,"Million US$, purchasing power parity",293.8
5716,Chile,2014,15,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9
5717,Chile,2014,15,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",23.6
5718,Chile,2014,15,M-Musculo-skeletal system,% of total sales,7.0
5719,Chile,2014,15,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3
5720,Chile,2014,15,N02-Analgesics,% of total sales,4.3
5721,Chile,2014,15,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.6
5722,Chile,2014,15,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,57880.5
5723,Chile,2014,15,J-Antiinfectives for systemic use,% of total sales,11.7
5724,Chile,2014,15,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",17.8
5725,Chile,2014,15,N05B-Anxiolytics,Million of national currency units,11744.7
5726,Chile,2014,15,J-Antiinfectives for systemic use,Million US$ at exchange rate,316.0
5727,Chile,2014,15,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",490.9
5728,Chile,2013,16,B-Blood and blood forming organs,Million US$ at exchange rate,151.7
5729,Chile,2013,16,B-Blood and blood forming organs,Million of national currency units,75138.6
5730,Chile,2013,16,G-Genito urinary system and sex hormones,Million of national currency units,134181.4
5731,Chile,2013,16,G-Genito urinary system and sex hormones,Million US$ at exchange rate,270.9
5732,Chile,2013,16,C10-Lipid modifying agents,"Million US$, purchasing power parity",85.8
5733,Chile,2013,16,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",383.7
5734,Chile,2013,16,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.2
5735,Chile,2013,16,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.4
5736,Chile,2013,16,B-Blood and blood forming organs,% of total sales,5.2
5737,Chile,2013,16,B-Blood and blood forming organs,"/capita, US$ exchange rate",8.6
5738,Chile,2013,16,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.9
5739,Chile,2013,16,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.4
5740,Chile,2013,16,B-Blood and blood forming organs,"Million US$, purchasing power parity",214.9
5741,Chile,2013,16,C10-Lipid modifying agents,% of total sales,2.1
5742,Chile,2013,16,A-Alimentary tract and metabolism,% of total sales,15.2
5743,Chile,2013,16,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4
5744,Chile,2013,16,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
5745,Chile,2013,16,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",630.8
5746,Chile,2013,16,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",35.8
5747,Chile,2013,16,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.3
5748,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.9
5749,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.7
5750,Chile,2013,16,C01A-Cardiac glycosides,Million of national currency units,136.0
5751,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6
5752,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,23741.8
5753,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,47.9
5754,Chile,2013,16,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",67.9
5755,Chile,2013,16,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.8
5756,Chile,2013,16,G03-Sex hormones and modulators of the genital system,Million of national currency units,95808.5
5757,Chile,2013,16,G-Genito urinary system and sex hormones,% of total sales,9.3
5758,Chile,2013,16,C01A-Cardiac glycosides,% of total sales,0.0
5759,Chile,2013,16,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
5760,Chile,2013,16,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
5761,Chile,2013,16,G03-Sex hormones and modulators of the genital system,% of total sales,6.6
5762,Chile,2013,16,A-Alimentary tract and metabolism,Million US$ at exchange rate,445.4
5763,Chile,2013,16,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",15.6
5764,Chile,2013,16,A-Alimentary tract and metabolism,Million of national currency units,220594.0
5765,Chile,2013,16,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",274.0
5766,Chile,2013,16,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,193.4
5767,Chile,2013,16,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.0
5768,Chile,2013,16,Total pharmaceutical sales,"/capita, US$ purchasing power parity",235.0
5769,Chile,2013,16,C07-Beta blocking agents,Million of national currency units,12752.7
5770,Chile,2013,16,C07-Beta blocking agents,Million US$ at exchange rate,25.7
5771,Chile,2013,16,Total pharmaceutical sales,Million US$ at exchange rate,2921.6
5772,Chile,2013,16,Total pharmaceutical sales,"Million US$, purchasing power parity",4138.0
5773,Chile,2013,16,Total pharmaceutical sales,"/capita, US$ exchange rate",165.9
5774,Chile,2013,16,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5
5775,Chile,2013,16,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
5776,Chile,2013,16,C02-Antihypertensives,"Million US$, purchasing power parity",8.2
5777,Chile,2013,16,C-Cardiovascular system,% of total sales,7.3
5778,Chile,2013,16,C07-Beta blocking agents,"Million US$, purchasing power parity",36.5
5779,Chile,2013,16,C02-Antihypertensives,% of total sales,0.2
5780,Chile,2013,16,C-Cardiovascular system,Million of national currency units,105559.0
5781,Chile,2013,16,C03-Diuretics,Million of national currency units,3467.2
5782,Chile,2013,16,C03-Diuretics,Million US$ at exchange rate,7.0
5783,Chile,2013,16,C-Cardiovascular system,Million US$ at exchange rate,213.1
5784,Chile,2013,16,C-Cardiovascular system,"/capita, US$ exchange rate",12.1
5785,Chile,2013,16,C-Cardiovascular system,"Million US$, purchasing power parity",301.9
5786,Chile,2013,16,C03-Diuretics,"/capita, US$ purchasing power parity",0.6
5787,Chile,2013,16,C03-Diuretics,% of total sales,0.2
5788,Chile,2013,16,Total pharmaceutical sales,Million of national currency units,1446986.6
5789,Chile,2013,16,C-Cardiovascular system,"/capita, US$ purchasing power parity",17.1
5790,Chile,2013,16,C03-Diuretics,"Million US$, purchasing power parity",9.9
5791,Chile,2013,16,C03-Diuretics,"/capita, US$ exchange rate",0.4
5792,Chile,2013,16,C08-Calcium channel blockers,% of total sales,0.4
5793,Chile,2013,16,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.9
5794,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,36639.5
5795,Chile,2013,16,C08-Calcium channel blockers,"Million US$, purchasing power parity",16.2
5796,Chile,2013,16,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7
5797,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,74.0
5798,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.5
5799,Chile,2013,16,C10-Lipid modifying agents,Million of national currency units,30013.4
5800,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.9
5801,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",104.8
5802,Chile,2013,16,C08-Calcium channel blockers,Million US$ at exchange rate,11.5
5803,Chile,2013,16,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.2
5804,Chile,2013,16,C02-Antihypertensives,Million US$ at exchange rate,5.8
5805,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
5806,Chile,2013,16,C02-Antihypertensives,Million of national currency units,2861.8
5807,Chile,2013,16,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.1
5808,Chile,2013,16,C07-Beta blocking agents,"/capita, US$ exchange rate",1.5
5809,Chile,2013,16,C07-Beta blocking agents,% of total sales,0.9
5810,Chile,2013,16,C10-Lipid modifying agents,Million US$ at exchange rate,60.6
5811,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3
5812,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1625.7
5813,Chile,2013,16,C08-Calcium channel blockers,Million of national currency units,5672.3
5814,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.3
5815,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2
5816,Chile,2013,16,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.6
5817,Chile,2013,16,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.5
5818,Chile,2013,16,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.1
5819,Chile,2013,16,N06A-Antidepressants,% of total sales,2.1
5820,Chile,2013,16,J01-Antibacterials for systemic use,% of total sales,4.9
5821,Chile,2013,16,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",202.3
5822,Chile,2013,16,A10-Drugs used in diabetes,"/capita, US$ exchange rate",5.8
5823,Chile,2013,16,A10-Drugs used in diabetes,% of total sales,3.5
5824,Chile,2013,16,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",8.2
5825,Chile,2013,16,A10-Drugs used in diabetes,Million US$ at exchange rate,101.6
5826,Chile,2013,16,A10-Drugs used in diabetes,Million of national currency units,50330.5
5827,Chile,2013,16,A10-Drugs used in diabetes,"Million US$, purchasing power parity",143.9
5828,Chile,2013,16,N06A-Antidepressants,Million of national currency units,30007.6
5829,Chile,2013,16,N06A-Antidepressants,"Million US$, purchasing power parity",85.8
5830,Chile,2013,16,N06A-Antidepressants,Million US$ at exchange rate,60.6
5831,Chile,2013,16,M-Musculo-skeletal system,Million of national currency units,87138.2
5832,Chile,2013,16,M-Musculo-skeletal system,Million US$ at exchange rate,175.9
5833,Chile,2013,16,N05C-Hypnotics and sedatives,% of total sales,0.5
5834,Chile,2013,16,Products not elsewhere classified,"/capita, US$ exchange rate",27.0
5835,Chile,2013,16,Products not elsewhere classified,"Million US$, purchasing power parity",673.1
5836,Chile,2013,16,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.9
5837,Chile,2013,16,N06A-Antidepressants,"/capita, US$ exchange rate",3.4
5838,Chile,2013,16,Products not elsewhere classified,% of total sales,16.3
5839,Chile,2013,16,Products not elsewhere classified,"/capita, US$ purchasing power parity",38.2
5840,Chile,2013,16,R-Respiratory system,% of total sales,9.7
5841,Chile,2013,16,R-Respiratory system,"/capita, US$ purchasing power parity",22.8
5842,Chile,2013,16,R03-Drugs for obstructive airway diseases,Million of national currency units,30901.9
5843,Chile,2013,16,A02A-Antacids,"Million US$, purchasing power parity",27.9
5844,Chile,2013,16,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,62.4
5845,Chile,2013,16,A02A-Antacids,Million of national currency units,9763.4
5846,Chile,2013,16,R-Respiratory system,Million of national currency units,140586.0
5847,Chile,2013,16,A02A-Antacids,Million US$ at exchange rate,19.7
5848,Chile,2013,16,R-Respiratory system,"Million US$, purchasing power parity",402.0
5849,Chile,2013,16,R-Respiratory system,"/capita, US$ exchange rate",16.1
5850,Chile,2013,16,R-Respiratory system,Million US$ at exchange rate,283.9
5851,Chile,2013,16,A02A-Antacids,"/capita, US$ purchasing power parity",1.6
5852,Chile,2013,16,A02A-Antacids,% of total sales,0.7
5853,Chile,2013,16,J01-Antibacterials for systemic use,Million US$ at exchange rate,142.8
5854,Chile,2013,16,J01-Antibacterials for systemic use,Million of national currency units,70741.0
5855,Chile,2013,16,Products not elsewhere classified,Million US$ at exchange rate,475.2
5856,Chile,2013,16,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",3.5
5857,Chile,2013,16,A02A-Antacids,"/capita, US$ exchange rate",1.1
5858,Chile,2013,16,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",88.4
5859,Chile,2013,16,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",5.0
5860,Chile,2013,16,Products not elsewhere classified,Million of national currency units,235364.6
5861,Chile,2013,16,R03-Drugs for obstructive airway diseases,% of total sales,2.1
5862,Chile,2013,16,N02-Analgesics,"/capita, US$ exchange rate",7.3
5863,Chile,2013,16,N02-Analgesics,"Million US$, purchasing power parity",183.0
5864,Chile,2013,16,N02-Analgesics,"/capita, US$ purchasing power parity",10.4
5865,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,24042.2
5866,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,48.5
5867,Chile,2013,16,N02-Analgesics,Million US$ at exchange rate,129.2
5868,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",154.6
5869,Chile,2013,16,J-Antiinfectives for systemic use,Million of national currency units,209955.4
5870,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,109.2
5871,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.7
5872,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8
5873,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.2
5874,Chile,2013,16,N-Nervous system,Million US$ at exchange rate,433.6
5875,Chile,2013,16,N-Nervous system,% of total sales,14.8
5876,Chile,2013,16,N-Nervous system,Million of national currency units,214727.7
5877,Chile,2013,16,N-Nervous system,"/capita, US$ exchange rate",24.6
5878,Chile,2013,16,N-Nervous system,"/capita, US$ purchasing power parity",34.9
5879,Chile,2013,16,N-Nervous system,"Million US$, purchasing power parity",614.1
5880,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.8
5881,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",68.8
5882,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",3.9
5883,Chile,2013,16,N02-Analgesics,Million of national currency units,63983.2
5884,Chile,2013,16,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7
5885,Chile,2013,16,N05B-Anxiolytics,% of total sales,0.8
5886,Chile,2013,16,N05C-Hypnotics and sedatives,Million of national currency units,7153.9
5887,Chile,2013,16,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.4
5888,Chile,2013,16,N05B-Anxiolytics,"Million US$, purchasing power parity",31.6
5889,Chile,2013,16,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8
5890,Chile,2013,16,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
5891,Chile,2013,16,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.1
5892,Chile,2013,16,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.0
5893,Chile,2013,16,M-Musculo-skeletal system,"Million US$, purchasing power parity",249.2
5894,Chile,2013,16,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
5895,Chile,2013,16,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",20.5
5896,Chile,2013,16,M-Musculo-skeletal system,% of total sales,6.0
5897,Chile,2013,16,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2
5898,Chile,2013,16,N05B-Anxiolytics,Million US$ at exchange rate,22.3
5899,Chile,2013,16,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.1
5900,Chile,2013,16,N02-Analgesics,% of total sales,4.4
5901,Chile,2013,16,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,54075.4
5902,Chile,2013,16,J-Antiinfectives for systemic use,% of total sales,14.5
5903,Chile,2013,16,N05B-Anxiolytics,Million of national currency units,11038.7
5904,Chile,2013,16,J-Antiinfectives for systemic use,Million US$ at exchange rate,423.9
5905,Chile,2013,16,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",24.1
5906,Chile,2013,16,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",600.4
5907,Chile,2012,17,B-Blood and blood forming organs,Million US$ at exchange rate,135.8
5908,Chile,2012,17,B-Blood and blood forming organs,Million of national currency units,66082.9
5909,Chile,2012,17,G-Genito urinary system and sex hormones,Million of national currency units,122348.3
5910,Chile,2012,17,B-Blood and blood forming organs,"Million US$, purchasing power parity",190.3
5911,Chile,2012,17,C10-Lipid modifying agents,"Million US$, purchasing power parity",79.6
5912,Chile,2012,17,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.4
5913,Chile,2012,17,G-Genito urinary system and sex hormones,Million US$ at exchange rate,251.5
5914,Chile,2012,17,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",352.4
5915,Chile,2012,17,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",10.9
5916,Chile,2012,17,B-Blood and blood forming organs,% of total sales,5.3
5917,Chile,2012,17,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.8
5918,Chile,2012,17,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.6
5919,Chile,2012,17,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.3
5920,Chile,2012,17,C10-Lipid modifying agents,% of total sales,2.2
5921,Chile,2012,17,A-Alimentary tract and metabolism,% of total sales,16.3
5922,Chile,2012,17,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
5923,Chile,2012,17,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
5924,Chile,2012,17,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",586.3
5925,Chile,2012,17,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",24.0
5926,Chile,2012,17,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",33.6
5927,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.5
5928,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.2
5929,Chile,2012,17,C01A-Cardiac glycosides,Million of national currency units,185.5
5930,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
5931,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,55.7
5932,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,27115.2
5933,Chile,2012,17,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",78.1
5934,Chile,2012,17,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.2
5935,Chile,2012,17,G-Genito urinary system and sex hormones,% of total sales,9.8
5936,Chile,2012,17,G03-Sex hormones and modulators of the genital system,Million of national currency units,87798.2
5937,Chile,2012,17,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
5938,Chile,2012,17,C01A-Cardiac glycosides,% of total sales,0.0
5939,Chile,2012,17,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
5940,Chile,2012,17,G03-Sex hormones and modulators of the genital system,% of total sales,7.0
5941,Chile,2012,17,A-Alimentary tract and metabolism,Million US$ at exchange rate,418.5
5942,Chile,2012,17,A-Alimentary tract and metabolism,Million of national currency units,203569.3
5943,Chile,2012,17,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",14.5
5944,Chile,2012,17,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",252.9
5945,Chile,2012,17,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,180.5
5946,Chile,2012,17,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.3
5947,Chile,2012,17,C10-Lipid modifying agents,Million US$ at exchange rate,56.8
5948,Chile,2012,17,Total pharmaceutical sales,"/capita, US$ purchasing power parity",206.1
5949,Chile,2012,17,C07-Beta blocking agents,Million of national currency units,11971.2
5950,Chile,2012,17,C07-Beta blocking agents,Million US$ at exchange rate,24.6
5951,Chile,2012,17,Total pharmaceutical sales,Million US$ at exchange rate,2565.9
5952,Chile,2012,17,Total pharmaceutical sales,"Million US$, purchasing power parity",3594.9
5953,Chile,2012,17,Total pharmaceutical sales,"/capita, US$ exchange rate",147.1
5954,Chile,2012,17,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4
5955,Chile,2012,17,C02-Antihypertensives,"Million US$, purchasing power parity",7.3
5956,Chile,2012,17,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
5957,Chile,2012,17,C-Cardiovascular system,% of total sales,8.1
5958,Chile,2012,17,C07-Beta blocking agents,"Million US$, purchasing power parity",34.5
5959,Chile,2012,17,C02-Antihypertensives,% of total sales,0.2
5960,Chile,2012,17,C-Cardiovascular system,Million of national currency units,100837.7
5961,Chile,2012,17,C03-Diuretics,Million of national currency units,3547.9
5962,Chile,2012,17,C03-Diuretics,Million US$ at exchange rate,7.3
5963,Chile,2012,17,C-Cardiovascular system,Million US$ at exchange rate,207.3
5964,Chile,2012,17,C-Cardiovascular system,"/capita, US$ exchange rate",11.9
5965,Chile,2012,17,C-Cardiovascular system,"Million US$, purchasing power parity",290.4
5966,Chile,2012,17,C03-Diuretics,"/capita, US$ purchasing power parity",0.6
5967,Chile,2012,17,C03-Diuretics,% of total sales,0.3
5968,Chile,2012,17,Total pharmaceutical sales,Million of national currency units,1248234.6
5969,Chile,2012,17,C03-Diuretics,"Million US$, purchasing power parity",10.2
5970,Chile,2012,17,C-Cardiovascular system,"/capita, US$ purchasing power parity",16.6
5971,Chile,2012,17,C03-Diuretics,"/capita, US$ exchange rate",0.4
5972,Chile,2012,17,C08-Calcium channel blockers,% of total sales,0.5
5973,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,35202.9
5974,Chile,2012,17,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0
5975,Chile,2012,17,C08-Calcium channel blockers,"Million US$, purchasing power parity",17.0
5976,Chile,2012,17,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7
5977,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,72.4
5978,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.8
5979,Chile,2012,17,C10-Lipid modifying agents,Million of national currency units,27634.2
5980,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.8
5981,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",101.4
5982,Chile,2012,17,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.1
5983,Chile,2012,17,C08-Calcium channel blockers,Million US$ at exchange rate,12.2
5984,Chile,2012,17,C02-Antihypertensives,Million US$ at exchange rate,5.2
5985,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
5986,Chile,2012,17,C02-Antihypertensives,Million of national currency units,2551.3
5987,Chile,2012,17,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.0
5988,Chile,2012,17,C07-Beta blocking agents,"/capita, US$ exchange rate",1.4
5989,Chile,2012,17,C07-Beta blocking agents,% of total sales,1.0
5990,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.0
5991,Chile,2012,17,C08-Calcium channel blockers,Million of national currency units,5913.9
5992,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1457.1
5993,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.2
5994,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.2
5995,Chile,2012,17,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2
5996,Chile,2012,17,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
5997,Chile,2012,17,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.0
5998,Chile,2012,17,N06A-Antidepressants,% of total sales,2.3
5999,Chile,2012,17,J01-Antibacterials for systemic use,% of total sales,5.4
6000,Chile,2012,17,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",195.7
6001,Chile,2012,17,A10-Drugs used in diabetes,"/capita, US$ exchange rate",4.9
6002,Chile,2012,17,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",6.9
6003,Chile,2012,17,A10-Drugs used in diabetes,% of total sales,3.3
6004,Chile,2012,17,A10-Drugs used in diabetes,Million US$ at exchange rate,85.8
6005,Chile,2012,17,A10-Drugs used in diabetes,Million of national currency units,41736.2
6006,Chile,2012,17,A10-Drugs used in diabetes,"Million US$, purchasing power parity",120.2
6007,Chile,2012,17,N06A-Antidepressants,Million of national currency units,28119.5
6008,Chile,2012,17,N06A-Antidepressants,Million US$ at exchange rate,57.8
6009,Chile,2012,17,N06A-Antidepressants,"Million US$, purchasing power parity",81.0
6010,Chile,2012,17,M-Musculo-skeletal system,Million US$ at exchange rate,177.1
6011,Chile,2012,17,M-Musculo-skeletal system,Million of national currency units,86133.7
6012,Chile,2012,17,N05C-Hypnotics and sedatives,% of total sales,0.5
6013,Chile,2012,17,Products not elsewhere classified,"/capita, US$ exchange rate",20.0
6014,Chile,2012,17,N06A-Antidepressants,"/capita, US$ exchange rate",3.3
6015,Chile,2012,17,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.6
6016,Chile,2012,17,Products not elsewhere classified,% of total sales,13.6
6017,Chile,2012,17,Products not elsewhere classified,"/capita, US$ purchasing power parity",28.1
6018,Chile,2012,17,R-Respiratory system,% of total sales,10.7
6019,Chile,2012,17,R-Respiratory system,"/capita, US$ purchasing power parity",22.1
6020,Chile,2012,17,R03-Drugs for obstructive airway diseases,Million of national currency units,29207.1
6021,Chile,2012,17,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",84.1
6022,Chile,2012,17,A02A-Antacids,"Million US$, purchasing power parity",26.5
6023,Chile,2012,17,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,60.0
6024,Chile,2012,17,A02A-Antacids,Million of national currency units,9204.3
6025,Chile,2012,17,R-Respiratory system,Million of national currency units,133945.9
6026,Chile,2012,17,A02A-Antacids,Million US$ at exchange rate,18.9
6027,Chile,2012,17,R-Respiratory system,"Million US$, purchasing power parity",385.8
6028,Chile,2012,17,R-Respiratory system,"/capita, US$ exchange rate",15.8
6029,Chile,2012,17,R-Respiratory system,Million US$ at exchange rate,275.3
6030,Chile,2012,17,A02A-Antacids,"/capita, US$ purchasing power parity",1.5
6031,Chile,2012,17,A02A-Antacids,% of total sales,0.7
6032,Chile,2012,17,Products not elsewhere classified,"Million US$, purchasing power parity",489.5
6033,Chile,2012,17,J01-Antibacterials for systemic use,Million US$ at exchange rate,139.7
6034,Chile,2012,17,J01-Antibacterials for systemic use,Million of national currency units,67944.0
6035,Chile,2012,17,Products not elsewhere classified,Million US$ at exchange rate,349.4
6036,Chile,2012,17,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",3.4
6037,Chile,2012,17,A02A-Antacids,"/capita, US$ exchange rate",1.1
6038,Chile,2012,17,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",4.8
6039,Chile,2012,17,Products not elsewhere classified,Million of national currency units,169953.3
6040,Chile,2012,17,R03-Drugs for obstructive airway diseases,% of total sales,2.3
6041,Chile,2012,17,N02-Analgesics,"/capita, US$ exchange rate",7.5
6042,Chile,2012,17,N02-Analgesics,"Million US$, purchasing power parity",184.5
6043,Chile,2012,17,N02-Analgesics,"/capita, US$ purchasing power parity",10.6
6044,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,22320.2
6045,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,45.9
6046,Chile,2012,17,N02-Analgesics,Million US$ at exchange rate,131.7
6047,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",145.8
6048,Chile,2012,17,J-Antiinfectives for systemic use,Million of national currency units,132266.7
6049,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,104.1
6050,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.1
6051,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.4
6052,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.0
6053,Chile,2012,17,N-Nervous system,Million US$ at exchange rate,423.4
6054,Chile,2012,17,N-Nervous system,Million of national currency units,205981.7
6055,Chile,2012,17,N-Nervous system,% of total sales,16.5
6056,Chile,2012,17,N-Nervous system,"/capita, US$ purchasing power parity",34.0
6057,Chile,2012,17,N-Nervous system,"/capita, US$ exchange rate",24.3
6058,Chile,2012,17,N-Nervous system,"Million US$, purchasing power parity",593.2
6059,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.6
6060,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",64.3
6061,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",3.7
6062,Chile,2012,17,N02-Analgesics,Million of national currency units,64056.5
6063,Chile,2012,17,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8
6064,Chile,2012,17,N05C-Hypnotics and sedatives,Million of national currency units,5909.7
6065,Chile,2012,17,N05B-Anxiolytics,% of total sales,0.9
6066,Chile,2012,17,N05C-Hypnotics and sedatives,Million US$ at exchange rate,12.1
6067,Chile,2012,17,N05B-Anxiolytics,"Million US$, purchasing power parity",30.6
6068,Chile,2012,17,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8
6069,Chile,2012,17,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
6070,Chile,2012,17,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",17.0
6071,Chile,2012,17,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.2
6072,Chile,2012,17,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.2
6073,Chile,2012,17,M-Musculo-skeletal system,"Million US$, purchasing power parity",248.1
6074,Chile,2012,17,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.7
6075,Chile,2012,17,M-Musculo-skeletal system,% of total sales,6.9
6076,Chile,2012,17,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.0
6077,Chile,2012,17,N05B-Anxiolytics,Million US$ at exchange rate,21.9
6078,Chile,2012,17,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,50640.7
6079,Chile,2012,17,J-Antiinfectives for systemic use,% of total sales,10.6
6080,Chile,2012,17,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",21.8
6081,Chile,2012,17,N02-Analgesics,% of total sales,5.1
6082,Chile,2012,17,N05B-Anxiolytics,Million of national currency units,10633.1
6083,Chile,2012,17,J-Antiinfectives for systemic use,Million US$ at exchange rate,271.9
6084,Chile,2012,17,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.6
6085,Chile,2012,17,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",380.9
6086,Chile,2011,18,B-Blood and blood forming organs,Million US$ at exchange rate,114.1
6087,Chile,2011,18,B-Blood and blood forming organs,Million of national currency units,55202.5
6088,Chile,2011,18,G-Genito urinary system and sex hormones,Million of national currency units,111351.6
6089,Chile,2011,18,G-Genito urinary system and sex hormones,Million US$ at exchange rate,230.2
6090,Chile,2011,18,C10-Lipid modifying agents,"Million US$, purchasing power parity",71.9
6091,Chile,2011,18,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.3
6092,Chile,2011,18,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",320.0
6093,Chile,2011,18,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.2
6094,Chile,2011,18,B-Blood and blood forming organs,% of total sales,4.7
6095,Chile,2011,18,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.6
6096,Chile,2011,18,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.2
6097,Chile,2011,18,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.0
6098,Chile,2011,18,B-Blood and blood forming organs,"Million US$, purchasing power parity",158.6
6099,Chile,2011,18,C10-Lipid modifying agents,% of total sales,2.1
6100,Chile,2011,18,C01A-Cardiac glycosides,% of total sales,0.0
6101,Chile,2011,18,A-Alimentary tract and metabolism,% of total sales,15.7
6102,Chile,2011,18,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
6103,Chile,2011,18,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
6104,Chile,2011,18,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",530.5
6105,Chile,2011,18,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",22.1
6106,Chile,2011,18,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",30.7
6107,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.1
6108,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.2
6109,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6
6110,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,38.2
6111,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,18495.4
6112,Chile,2011,18,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",53.1
6113,Chile,2011,18,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.5
6114,Chile,2011,18,G-Genito urinary system and sex hormones,% of total sales,9.4
6115,Chile,2011,18,G03-Sex hormones and modulators of the genital system,Million of national currency units,80168.5
6116,Chile,2011,18,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
6117,Chile,2011,18,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
6118,Chile,2011,18,G03-Sex hormones and modulators of the genital system,% of total sales,6.8
6119,Chile,2011,18,A-Alimentary tract and metabolism,Million US$ at exchange rate,381.7
6120,Chile,2011,18,A-Alimentary tract and metabolism,Million of national currency units,184612.6
6121,Chile,2011,18,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",13.4
6122,Chile,2011,18,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",230.4
6123,Chile,2011,18,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,165.8
6124,Chile,2011,18,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.6
6125,Chile,2011,18,C07-Beta blocking agents,Million of national currency units,10586.3
6126,Chile,2011,18,Total pharmaceutical sales,"/capita, US$ purchasing power parity",196.4
6127,Chile,2011,18,C07-Beta blocking agents,Million US$ at exchange rate,21.9
6128,Chile,2011,18,Total pharmaceutical sales,"Million US$, purchasing power parity",3388.6
6129,Chile,2011,18,Total pharmaceutical sales,Million US$ at exchange rate,2438.2
6130,Chile,2011,18,Total pharmaceutical sales,"/capita, US$ exchange rate",141.3
6131,Chile,2011,18,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4
6132,Chile,2011,18,C02-Antihypertensives,"Million US$, purchasing power parity",6.7
6133,Chile,2011,18,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
6134,Chile,2011,18,C-Cardiovascular system,% of total sales,7.8
6135,Chile,2011,18,C07-Beta blocking agents,"Million US$, purchasing power parity",30.4
6136,Chile,2011,18,C02-Antihypertensives,% of total sales,0.2
6137,Chile,2011,18,C-Cardiovascular system,Million of national currency units,91532.1
6138,Chile,2011,18,C-Cardiovascular system,Million US$ at exchange rate,189.2
6139,Chile,2011,18,C03-Diuretics,Million of national currency units,2756.0
6140,Chile,2011,18,C03-Diuretics,Million US$ at exchange rate,5.7
6141,Chile,2011,18,C-Cardiovascular system,"/capita, US$ exchange rate",11.0
6142,Chile,2011,18,C-Cardiovascular system,"/capita, US$ purchasing power parity",15.2
6143,Chile,2011,18,C-Cardiovascular system,"Million US$, purchasing power parity",263.0
6144,Chile,2011,18,C03-Diuretics,% of total sales,0.2
6145,Chile,2011,18,C03-Diuretics,"/capita, US$ purchasing power parity",0.5
6146,Chile,2011,18,Total pharmaceutical sales,Million of national currency units,1179279.0
6147,Chile,2011,18,C03-Diuretics,"Million US$, purchasing power parity",7.9
6148,Chile,2011,18,C03-Diuretics,"/capita, US$ exchange rate",0.3
6149,Chile,2011,18,C08-Calcium channel blockers,% of total sales,0.5
6150,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,32614.1
6151,Chile,2011,18,C08-Calcium channel blockers,"Million US$, purchasing power parity",16.9
6152,Chile,2011,18,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0
6153,Chile,2011,18,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7
6154,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,67.4
6155,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.8
6156,Chile,2011,18,C10-Lipid modifying agents,Million US$ at exchange rate,51.7
6157,Chile,2011,18,C10-Lipid modifying agents,Million of national currency units,25005.3
6158,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",93.7
6159,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.4
6160,Chile,2011,18,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",3.9
6161,Chile,2011,18,C08-Calcium channel blockers,Million US$ at exchange rate,12.2
6162,Chile,2011,18,C02-Antihypertensives,Million US$ at exchange rate,4.8
6163,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
6164,Chile,2011,18,C02-Antihypertensives,Million of national currency units,2317.9
6165,Chile,2011,18,C07-Beta blocking agents,"/capita, US$ purchasing power parity",1.8
6166,Chile,2011,18,C07-Beta blocking agents,"/capita, US$ exchange rate",1.3
6167,Chile,2011,18,C07-Beta blocking agents,% of total sales,0.9
6168,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,2.8
6169,Chile,2011,18,C08-Calcium channel blockers,Million of national currency units,5881.7
6170,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1341.3
6171,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.2
6172,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.9
6173,Chile,2011,18,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2
6174,Chile,2011,18,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.0
6175,Chile,2011,18,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.2
6176,Chile,2011,18,N06A-Antidepressants,% of total sales,2.2
6177,Chile,2011,18,J01-Antibacterials for systemic use,% of total sales,5.1
6178,Chile,2011,18,A10-Drugs used in diabetes,Million of national currency units,34618.4
6179,Chile,2011,18,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",5.8
6180,Chile,2011,18,A10-Drugs used in diabetes,"/capita, US$ exchange rate",4.1
6181,Chile,2011,18,A10-Drugs used in diabetes,% of total sales,2.9
6182,Chile,2011,18,A10-Drugs used in diabetes,Million US$ at exchange rate,71.6
6183,Chile,2011,18,A10-Drugs used in diabetes,"Million US$, purchasing power parity",99.5
6184,Chile,2011,18,N06A-Antidepressants,Million US$ at exchange rate,53.2
6185,Chile,2011,18,N06A-Antidepressants,Million of national currency units,25714.6
6186,Chile,2011,18,N06A-Antidepressants,"Million US$, purchasing power parity",73.9
6187,Chile,2011,18,M-Musculo-skeletal system,Million US$ at exchange rate,127.2
6188,Chile,2011,18,M-Musculo-skeletal system,Million of national currency units,61502.0
6189,Chile,2011,18,N05C-Hypnotics and sedatives,% of total sales,0.4
6190,Chile,2011,18,Products not elsewhere classified,"/capita, US$ exchange rate",20.0
6191,Chile,2011,18,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.3
6192,Chile,2011,18,N06A-Antidepressants,"/capita, US$ exchange rate",3.1
6193,Chile,2011,18,Products not elsewhere classified,% of total sales,14.1
6194,Chile,2011,18,Products not elsewhere classified,"/capita, US$ purchasing power parity",27.8
6195,Chile,2011,18,R-Respiratory system,% of total sales,10.6
6196,Chile,2011,18,R03-Drugs for obstructive airway diseases,Million of national currency units,26263.5
6197,Chile,2011,18,R-Respiratory system,"/capita, US$ purchasing power parity",20.8
6198,Chile,2011,18,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",75.5
6199,Chile,2011,18,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,54.3
6200,Chile,2011,18,A02A-Antacids,Million of national currency units,9337.8
6201,Chile,2011,18,R-Respiratory system,Million of national currency units,124669.7
6202,Chile,2011,18,A02A-Antacids,Million US$ at exchange rate,19.3
6203,Chile,2011,18,R-Respiratory system,"/capita, US$ exchange rate",14.9
6204,Chile,2011,18,R-Respiratory system,"Million US$, purchasing power parity",358.2
6205,Chile,2011,18,R-Respiratory system,Million US$ at exchange rate,257.8
6206,Chile,2011,18,A02A-Antacids,"/capita, US$ exchange rate",1.1
6207,Chile,2011,18,A02A-Antacids,% of total sales,0.8
6208,Chile,2011,18,A02A-Antacids,"/capita, US$ purchasing power parity",1.6
6209,Chile,2011,18,Products not elsewhere classified,"Million US$, purchasing power parity",479.3
6210,Chile,2011,18,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",173.3
6211,Chile,2011,18,J01-Antibacterials for systemic use,Million US$ at exchange rate,124.7
6212,Chile,2011,18,J01-Antibacterials for systemic use,Million of national currency units,60319.9
6213,Chile,2011,18,Products not elsewhere classified,Million US$ at exchange rate,344.9
6214,Chile,2011,18,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",3.1
6215,Chile,2011,18,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",4.4
6216,Chile,2011,18,Products not elsewhere classified,Million of national currency units,166797.1
6217,Chile,2011,18,R03-Drugs for obstructive airway diseases,% of total sales,2.2
6218,Chile,2011,18,N02-Analgesics,"/capita, US$ exchange rate",7.1
6219,Chile,2011,18,N02-Analgesics,"/capita, US$ purchasing power parity",9.8
6220,Chile,2011,18,N02-Analgesics,"Million US$, purchasing power parity",169.5
6221,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,43.7
6222,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,21124.4
6223,Chile,2011,18,N02-Analgesics,Million US$ at exchange rate,122.0
6224,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",136.3
6225,Chile,2011,18,J-Antiinfectives for systemic use,Million of national currency units,177900.9
6226,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,98.1
6227,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.0
6228,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.7
6229,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.9
6230,Chile,2011,18,N-Nervous system,Million US$ at exchange rate,387.1
6231,Chile,2011,18,N-Nervous system,% of total sales,15.9
6232,Chile,2011,18,N-Nervous system,Million of national currency units,187215.0
6233,Chile,2011,18,N-Nervous system,"/capita, US$ purchasing power parity",31.2
6234,Chile,2011,18,N-Nervous system,"/capita, US$ exchange rate",22.4
6235,Chile,2011,18,N-Nervous system,"Million US$, purchasing power parity",537.9
6236,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.5
6237,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",3.5
6238,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",60.7
6239,Chile,2011,18,N02-Analgesics,Million of national currency units,58995.7
6240,Chile,2011,18,C01A-Cardiac glycosides,Million of national currency units,91.5
6241,Chile,2011,18,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8
6242,Chile,2011,18,N05C-Hypnotics and sedatives,Million of national currency units,5170.6
6243,Chile,2011,18,N05B-Anxiolytics,% of total sales,0.8
6244,Chile,2011,18,N05C-Hypnotics and sedatives,Million US$ at exchange rate,10.7
6245,Chile,2011,18,N05B-Anxiolytics,"Million US$, purchasing power parity",28.1
6246,Chile,2011,18,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6
6247,Chile,2011,18,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
6248,Chile,2011,18,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.2
6249,Chile,2011,18,M-Musculo-skeletal system,"Million US$, purchasing power parity",176.7
6250,Chile,2011,18,M-Musculo-skeletal system,"/capita, US$ exchange rate",7.4
6251,Chile,2011,18,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.9
6252,Chile,2011,18,M-Musculo-skeletal system,% of total sales,5.2
6253,Chile,2011,18,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.6
6254,Chile,2011,18,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.9
6255,Chile,2011,18,A02A-Antacids,"Million US$, purchasing power parity",26.8
6256,Chile,2011,18,N05B-Anxiolytics,Million US$ at exchange rate,20.2
6257,Chile,2011,18,J-Antiinfectives for systemic use,% of total sales,15.1
6258,Chile,2011,18,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.6
6259,Chile,2011,18,N02-Analgesics,% of total sales,5.0
6260,Chile,2011,18,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,47430.8
6261,Chile,2011,18,N05B-Anxiolytics,Million of national currency units,9773.0
6262,Chile,2011,18,J-Antiinfectives for systemic use,Million US$ at exchange rate,367.8
6263,Chile,2011,18,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.3
6264,Chile,2011,18,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",511.2
6265,Chile,2010,20,B-Blood and blood forming organs,Million of national currency units,19663.6
6266,Chile,2010,20,G-Genito urinary system and sex hormones,Million US$ at exchange rate,159.7
6267,Chile,2010,20,B-Blood and blood forming organs,Million US$ at exchange rate,38.5
6268,Chile,2010,20,G-Genito urinary system and sex hormones,Million of national currency units,81496.5
6269,Chile,2010,20,C10-Lipid modifying agents,"Million US$, purchasing power parity",54.0
6270,Chile,2010,20,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.4
6271,Chile,2010,20,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",226.5
6272,Chile,2010,20,B-Blood and blood forming organs,% of total sales,2.4
6273,Chile,2010,20,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",3.2
6274,Chile,2010,20,B-Blood and blood forming organs,"/capita, US$ exchange rate",2.3
6275,Chile,2010,20,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",3.2
6276,Chile,2010,20,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.2
6277,Chile,2010,20,B-Blood and blood forming organs,"Million US$, purchasing power parity",54.6
6278,Chile,2010,20,C10-Lipid modifying agents,% of total sales,2.4
6279,Chile,2010,20,A-Alimentary tract and metabolism,% of total sales,18.3
6280,Chile,2010,20,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
6281,Chile,2010,20,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
6282,Chile,2010,20,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",420.5
6283,Chile,2010,20,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",17.4
6284,Chile,2010,20,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",24.6
6285,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.1
6286,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.5
6287,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.5
6288,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,25.1
6289,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,12798.0
6290,Chile,2010,20,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",35.6
6291,Chile,2010,20,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.3
6292,Chile,2010,20,G-Genito urinary system and sex hormones,% of total sales,9.9
6293,Chile,2010,20,G03-Sex hormones and modulators of the genital system,Million of national currency units,64724.6
6294,Chile,2010,20,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
6295,Chile,2010,20,C01A-Cardiac glycosides,% of total sales,0.0
6296,Chile,2010,20,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
6297,Chile,2010,20,G03-Sex hormones and modulators of the genital system,% of total sales,7.8
6298,Chile,2010,20,A-Alimentary tract and metabolism,Million US$ at exchange rate,296.5
6299,Chile,2010,20,A-Alimentary tract and metabolism,Million of national currency units,151311.4
6300,Chile,2010,20,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.5
6301,Chile,2010,20,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",179.9
6302,Chile,2010,20,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,126.8
6303,Chile,2010,20,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.4
6304,Chile,2010,20,C07-Beta blocking agents,Million of national currency units,8640.2
6305,Chile,2010,20,Total pharmaceutical sales,"/capita, US$ purchasing power parity",134.5
6306,Chile,2010,20,C07-Beta blocking agents,Million US$ at exchange rate,16.9
6307,Chile,2010,20,Total pharmaceutical sales,"Million US$, purchasing power parity",2295.8
6308,Chile,2010,20,Total pharmaceutical sales,Million US$ at exchange rate,1619.0
6309,Chile,2010,20,Total pharmaceutical sales,"/capita, US$ exchange rate",94.9
6310,Chile,2010,20,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3
6311,Chile,2010,20,C02-Antihypertensives,"Million US$, purchasing power parity",4.7
6312,Chile,2010,20,C02-Antihypertensives,"/capita, US$ exchange rate",0.2
6313,Chile,2010,20,C07-Beta blocking agents,"Million US$, purchasing power parity",24.0
6314,Chile,2010,20,C02-Antihypertensives,% of total sales,0.2
6315,Chile,2010,20,C-Cardiovascular system,Million of national currency units,74875.9
6316,Chile,2010,20,C-Cardiovascular system,Million US$ at exchange rate,146.7
6317,Chile,2010,20,C03-Diuretics,Million of national currency units,1770.5
6318,Chile,2010,20,C03-Diuretics,Million US$ at exchange rate,3.5
6319,Chile,2010,20,C-Cardiovascular system,"/capita, US$ exchange rate",8.6
6320,Chile,2010,20,C-Cardiovascular system,"/capita, US$ purchasing power parity",12.2
6321,Chile,2010,20,C-Cardiovascular system,"Million US$, purchasing power parity",208.1
6322,Chile,2010,20,C03-Diuretics,% of total sales,0.2
6323,Chile,2010,20,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
6324,Chile,2010,20,Total pharmaceutical sales,Million of national currency units,826115.8
6325,Chile,2010,20,C03-Diuretics,"Million US$, purchasing power parity",4.9
6326,Chile,2010,20,C-Cardiovascular system,% of total sales,9.1
6327,Chile,2010,20,C03-Diuretics,"/capita, US$ exchange rate",0.2
6328,Chile,2010,20,C08-Calcium channel blockers,% of total sales,0.6
6329,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,28108.5
6330,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,55.1
6331,Chile,2010,20,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.8
6332,Chile,2010,20,C08-Calcium channel blockers,"Million US$, purchasing power parity",13.8
6333,Chile,2010,20,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.6
6334,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.4
6335,Chile,2010,20,C10-Lipid modifying agents,Million US$ at exchange rate,38.1
6336,Chile,2010,20,C10-Lipid modifying agents,Million of national currency units,19420.8
6337,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",78.1
6338,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.6
6339,Chile,2010,20,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",3.2
6340,Chile,2010,20,C08-Calcium channel blockers,Million US$ at exchange rate,9.8
6341,Chile,2010,20,C02-Antihypertensives,Million US$ at exchange rate,3.3
6342,Chile,2010,20,C02-Antihypertensives,Million of national currency units,1699.3
6343,Chile,2010,20,C07-Beta blocking agents,"/capita, US$ purchasing power parity",1.4
6344,Chile,2010,20,C07-Beta blocking agents,"/capita, US$ exchange rate",1.0
6345,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
6346,Chile,2010,20,C07-Beta blocking agents,% of total sales,1.0
6347,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,2.3
6348,Chile,2010,20,C08-Calcium channel blockers,Million of national currency units,4975.3
6349,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1169.2
6350,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.2
6351,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.2
6352,Chile,2010,20,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.1
6353,Chile,2010,20,C01A-Cardiac glycosides,Million of national currency units,49.0
6354,Chile,2010,20,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",6.3
6355,Chile,2010,20,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",4.4
6356,Chile,2010,20,J01-Antibacterials for systemic use,% of total sales,4.7
6357,Chile,2010,20,N06A-Antidepressants,% of total sales,3.9
6358,Chile,2010,20,A02A-Antacids,"Million US$, purchasing power parity",23.2
6359,Chile,2010,20,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",3.5
6360,Chile,2010,20,A10-Drugs used in diabetes,"/capita, US$ exchange rate",2.5
6361,Chile,2010,20,A10-Drugs used in diabetes,% of total sales,2.6
6362,Chile,2010,20,A10-Drugs used in diabetes,Million US$ at exchange rate,42.3
6363,Chile,2010,20,A10-Drugs used in diabetes,"Million US$, purchasing power parity",60.0
6364,Chile,2010,20,A10-Drugs used in diabetes,Million of national currency units,21597.9
6365,Chile,2010,20,N06A-Antidepressants,Million US$ at exchange rate,62.6
6366,Chile,2010,20,N06A-Antidepressants,Million of national currency units,31955.1
6367,Chile,2010,20,N06A-Antidepressants,"Million US$, purchasing power parity",88.8
6368,Chile,2010,20,M-Musculo-skeletal system,Million US$ at exchange rate,134.1
6369,Chile,2010,20,M-Musculo-skeletal system,Million of national currency units,68438.5
6370,Chile,2010,20,N05C-Hypnotics and sedatives,% of total sales,0.4
6371,Chile,2010,20,Products not elsewhere classified,"/capita, US$ exchange rate",11.0
6372,Chile,2010,20,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.2
6373,Chile,2010,20,N06A-Antidepressants,"/capita, US$ exchange rate",3.7
6374,Chile,2010,20,Products not elsewhere classified,% of total sales,11.6
6375,Chile,2010,20,Products not elsewhere classified,"/capita, US$ purchasing power parity",15.6
6376,Chile,2010,20,R-Respiratory system,% of total sales,13.1
6377,Chile,2010,20,R03-Drugs for obstructive airway diseases,Million of national currency units,15206.7
6378,Chile,2010,20,R-Respiratory system,"/capita, US$ purchasing power parity",17.6
6379,Chile,2010,20,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",42.3
6380,Chile,2010,20,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,29.8
6381,Chile,2010,20,R-Respiratory system,Million of national currency units,108206.7
6382,Chile,2010,20,A02A-Antacids,Million of national currency units,8337.3
6383,Chile,2010,20,A02A-Antacids,Million US$ at exchange rate,16.3
6384,Chile,2010,20,R-Respiratory system,"/capita, US$ exchange rate",12.4
6385,Chile,2010,20,R-Respiratory system,"Million US$, purchasing power parity",300.7
6386,Chile,2010,20,R-Respiratory system,Million US$ at exchange rate,212.1
6387,Chile,2010,20,A02A-Antacids,"/capita, US$ exchange rate",1.0
6388,Chile,2010,20,A02A-Antacids,% of total sales,1.0
6389,Chile,2010,20,A02A-Antacids,"/capita, US$ purchasing power parity",1.4
6390,Chile,2010,20,Products not elsewhere classified,"Million US$, purchasing power parity",265.7
6391,Chile,2010,20,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",106.9
6392,Chile,2010,20,J01-Antibacterials for systemic use,Million US$ at exchange rate,75.4
6393,Chile,2010,20,J01-Antibacterials for systemic use,Million of national currency units,38463.8
6394,Chile,2010,20,Products not elsewhere classified,Million US$ at exchange rate,187.4
6395,Chile,2010,20,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.7
6396,Chile,2010,20,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.5
6397,Chile,2010,20,Products not elsewhere classified,Million of national currency units,95614.1
6398,Chile,2010,20,R03-Drugs for obstructive airway diseases,% of total sales,1.8
6399,Chile,2010,20,N02-Analgesics,"/capita, US$ exchange rate",6.2
6400,Chile,2010,20,N02-Analgesics,"/capita, US$ purchasing power parity",8.8
6401,Chile,2010,20,N02-Analgesics,"Million US$, purchasing power parity",150.1
6402,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,31.7
6403,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,16183.9
6404,Chile,2010,20,N02-Analgesics,Million US$ at exchange rate,105.8
6405,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",98.3
6406,Chile,2010,20,J-Antiinfectives for systemic use,Million of national currency units,58760.8
6407,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,69.3
6408,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.3
6409,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.1
6410,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.8
6411,Chile,2010,20,N-Nervous system,Million US$ at exchange rate,303.7
6412,Chile,2010,20,N-Nervous system,% of total sales,18.8
6413,Chile,2010,20,N-Nervous system,Million of national currency units,154950.4
6414,Chile,2010,20,N-Nervous system,"/capita, US$ purchasing power parity",25.2
6415,Chile,2010,20,N-Nervous system,"/capita, US$ exchange rate",17.8
6416,Chile,2010,20,N-Nervous system,"Million US$, purchasing power parity",430.6
6417,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.9
6418,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",2.6
6419,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",45.0
6420,Chile,2010,20,N02-Analgesics,Million of national currency units,54002.2
6421,Chile,2010,20,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0
6422,Chile,2010,20,N05C-Hypnotics and sedatives,Million of national currency units,3361.7
6423,Chile,2010,20,N05B-Anxiolytics,% of total sales,1.0
6424,Chile,2010,20,N05C-Hypnotics and sedatives,Million US$ at exchange rate,6.6
6425,Chile,2010,20,N05B-Anxiolytics,"Million US$, purchasing power parity",23.9
6426,Chile,2010,20,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.4
6427,Chile,2010,20,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0
6428,Chile,2010,20,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",9.3
6429,Chile,2010,20,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.1
6430,Chile,2010,20,M-Musculo-skeletal system,"Million US$, purchasing power parity",190.2
6431,Chile,2010,20,M-Musculo-skeletal system,"/capita, US$ exchange rate",7.9
6432,Chile,2010,20,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.4
6433,Chile,2010,20,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.5
6434,Chile,2010,20,M-Musculo-skeletal system,% of total sales,8.3
6435,Chile,2010,20,J-Antiinfectives for systemic use,% of total sales,7.1
6436,Chile,2010,20,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.6
6437,Chile,2010,20,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,35363.2
6438,Chile,2010,20,N02-Analgesics,% of total sales,6.5
6439,Chile,2010,20,N05B-Anxiolytics,Million of national currency units,8596.0
6440,Chile,2010,20,J-Antiinfectives for systemic use,Million US$ at exchange rate,115.2
6441,Chile,2010,20,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.7
6442,Chile,2010,20,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",163.3
6443,Chile,2010,20,N05B-Anxiolytics,Million US$ at exchange rate,16.8
6444,Chile,2017,13,B-Blood and blood forming organs,Million US$ at exchange rate,143.7
6445,Chile,2017,13,G-Genito urinary system and sex hormones,Million of national currency units,178137.8
6446,Chile,2017,13,B-Blood and blood forming organs,Million of national currency units,93218.1
6447,Chile,2017,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",90.0
6448,Chile,2017,13,C10-Lipid modifying agents,Million US$ at exchange rate,55.1
6449,Chile,2017,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,274.6
6450,Chile,2017,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",447.9
6451,Chile,2017,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.7
6452,Chile,2017,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",234.4
6453,Chile,2017,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.8
6454,Chile,2017,13,B-Blood and blood forming organs,% of total sales,4.5
6455,Chile,2017,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.0
6456,Chile,2017,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.9
6457,Chile,2017,13,C10-Lipid modifying agents,% of total sales,1.7
6458,Chile,2017,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
6459,Chile,2017,13,A-Alimentary tract and metabolism,% of total sales,18.6
6460,Chile,2017,13,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
6461,Chile,2017,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",968.8
6462,Chile,2017,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",52.6
6463,Chile,2017,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",32.2
6464,Chile,2017,13,C01A-Cardiac glycosides,Million of national currency units,198.3
6465,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.6
6466,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6
6467,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
6468,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,55462.8
6469,Chile,2017,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,593.8
6470,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",139.5
6471,Chile,2017,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,85.5
6472,Chile,2017,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.3
6473,Chile,2017,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,124650.7
6474,Chile,2017,13,G-Genito urinary system and sex hormones,% of total sales,8.6
6475,Chile,2017,13,C01A-Cardiac glycosides,% of total sales,0.0
6476,Chile,2017,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.9
6477,Chile,2017,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
6478,Chile,2017,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
6479,Chile,2017,13,G03-Sex hormones and modulators of the genital system,% of total sales,6.0
6480,Chile,2017,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",17.0
6481,Chile,2017,13,A-Alimentary tract and metabolism,Million of national currency units,385291.1
6482,Chile,2017,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,192.1
6483,Chile,2017,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",313.4
6484,Chile,2017,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.4
6485,Chile,2017,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",282.3
6486,Chile,2017,13,C07-Beta blocking agents,Million US$ at exchange rate,28.9
6487,Chile,2017,13,C07-Beta blocking agents,Million of national currency units,18779.6
6488,Chile,2017,13,Total pharmaceutical sales,Million US$ at exchange rate,3187.0
6489,Chile,2017,13,Total pharmaceutical sales,"/capita, US$ exchange rate",173.0
6490,Chile,2017,13,Total pharmaceutical sales,"Million US$, purchasing power parity",5199.6
6491,Chile,2017,13,C02-Antihypertensives,"/capita, US$ exchange rate",0.4
6492,Chile,2017,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.7
6493,Chile,2017,13,C02-Antihypertensives,"Million US$, purchasing power parity",12.4
6494,Chile,2017,13,C07-Beta blocking agents,"Million US$, purchasing power parity",47.2
6495,Chile,2017,13,C-Cardiovascular system,% of total sales,7.1
6496,Chile,2017,13,C02-Antihypertensives,% of total sales,0.2
6497,Chile,2017,13,C-Cardiovascular system,Million of national currency units,146723.5
6498,Chile,2017,13,C03-Diuretics,Million of national currency units,5534.7
6499,Chile,2017,13,C03-Diuretics,Million US$ at exchange rate,8.5
6500,Chile,2017,13,C-Cardiovascular system,"/capita, US$ exchange rate",12.3
6501,Chile,2017,13,C-Cardiovascular system,Million US$ at exchange rate,226.1
6502,Chile,2017,13,C-Cardiovascular system,"Million US$, purchasing power parity",368.9
6503,Chile,2017,13,C03-Diuretics,"/capita, US$ purchasing power parity",0.8
6504,Chile,2017,13,Total pharmaceutical sales,Million of national currency units,2067820.4
6505,Chile,2017,13,C03-Diuretics,% of total sales,0.3
6506,Chile,2017,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",20.0
6507,Chile,2017,13,C03-Diuretics,"/capita, US$ exchange rate",0.5
6508,Chile,2017,13,C03-Diuretics,"Million US$, purchasing power parity",13.9
6509,Chile,2017,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.2
6510,Chile,2017,13,C08-Calcium channel blockers,% of total sales,0.4
6511,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,55530.1
6512,Chile,2017,13,C08-Calcium channel blockers,Million US$ at exchange rate,13.1
6513,Chile,2017,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",21.3
6514,Chile,2017,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.7
6515,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.7
6516,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",7.6
6517,Chile,2017,13,C10-Lipid modifying agents,Million of national currency units,35776.7
6518,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",139.6
6519,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,85.6
6520,Chile,2017,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.6
6521,Chile,2017,13,C02-Antihypertensives,Million US$ at exchange rate,7.6
6522,Chile,2017,13,C02-Antihypertensives,Million of national currency units,4932.3
6523,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
6524,Chile,2017,13,C07-Beta blocking agents,"/capita, US$ exchange rate",1.6
6525,Chile,2017,13,C07-Beta blocking agents,% of total sales,0.9
6526,Chile,2017,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.6
6527,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,2149.5
6528,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3
6529,Chile,2017,13,C08-Calcium channel blockers,Million of national currency units,8473.5
6530,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2
6531,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.3
6532,Chile,2017,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",5.4
6533,Chile,2017,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.9
6534,Chile,2017,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.7
6535,Chile,2017,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",200.6
6536,Chile,2017,13,N06A-Antidepressants,% of total sales,3.0
6537,Chile,2017,13,J01-Antibacterials for systemic use,% of total sales,3.9
6538,Chile,2017,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.6
6539,Chile,2017,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",9.3
6540,Chile,2017,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.2
6541,Chile,2017,13,A10-Drugs used in diabetes,Million of national currency units,111563.3
6542,Chile,2017,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",280.5
6543,Chile,2017,13,A10-Drugs used in diabetes,Million US$ at exchange rate,171.9
6544,Chile,2017,13,N06A-Antidepressants,Million of national currency units,62830.3
6545,Chile,2017,13,N06A-Antidepressants,Million US$ at exchange rate,96.8
6546,Chile,2017,13,M-Musculo-skeletal system,Million of national currency units,116144.0
6547,Chile,2017,13,N05C-Hypnotics and sedatives,% of total sales,0.6
6548,Chile,2017,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.7
6549,Chile,2017,13,N06A-Antidepressants,"Million US$, purchasing power parity",158.0
6550,Chile,2017,13,Products not elsewhere classified,"Million US$, purchasing power parity",820.0
6551,Chile,2017,13,N06A-Antidepressants,"/capita, US$ exchange rate",5.3
6552,Chile,2017,13,Products not elsewhere classified,"/capita, US$ exchange rate",27.3
6553,Chile,2017,13,Products not elsewhere classified,% of total sales,15.8
6554,Chile,2017,13,Products not elsewhere classified,"/capita, US$ purchasing power parity",44.5
6555,Chile,2017,13,A10-Drugs used in diabetes,% of total sales,5.4
6556,Chile,2017,13,R-Respiratory system,% of total sales,9.7
6557,Chile,2017,13,R-Respiratory system,"/capita, US$ purchasing power parity",27.4
6558,Chile,2017,13,A02A-Antacids,"Million US$, purchasing power parity",29.2
6559,Chile,2017,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,86.4
6560,Chile,2017,13,R03-Drugs for obstructive airway diseases,Million of national currency units,56041.0
6561,Chile,2017,13,R-Respiratory system,"/capita, US$ exchange rate",16.8
6562,Chile,2017,13,A02A-Antacids,Million of national currency units,11617.0
6563,Chile,2017,13,A02A-Antacids,Million US$ at exchange rate,17.9
6564,Chile,2017,13,R-Respiratory system,Million of national currency units,200656.9
6565,Chile,2017,13,R-Respiratory system,"Million US$, purchasing power parity",504.6
6566,Chile,2017,13,R-Respiratory system,Million US$ at exchange rate,309.3
6567,Chile,2017,13,A02A-Antacids,"/capita, US$ purchasing power parity",1.6
6568,Chile,2017,13,Products not elsewhere classified,Million US$ at exchange rate,502.6
6569,Chile,2017,13,A02A-Antacids,% of total sales,0.6
6570,Chile,2017,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,123.0
6571,Chile,2017,13,J01-Antibacterials for systemic use,Million of national currency units,79791.6
6572,Chile,2017,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",4.7
6573,Chile,2017,13,A02A-Antacids,"/capita, US$ exchange rate",1.0
6574,Chile,2017,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",140.9
6575,Chile,2017,13,Products not elsewhere classified,Million of national currency units,326087.2
6576,Chile,2017,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",7.7
6577,Chile,2017,13,R03-Drugs for obstructive airway diseases,% of total sales,2.7
6578,Chile,2017,13,N02-Analgesics,"Million US$, purchasing power parity",200.3
6579,Chile,2017,13,M-Musculo-skeletal system,Million US$ at exchange rate,179.0
6580,Chile,2017,13,N02-Analgesics,"/capita, US$ exchange rate",6.7
6581,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,31943.0
6582,Chile,2017,13,N02-Analgesics,Million US$ at exchange rate,122.8
6583,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.8
6584,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,87.9
6585,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",143.4
6586,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.8
6587,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.8
6588,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,49.2
6589,Chile,2017,13,N-Nervous system,Million of national currency units,310804.0
6590,Chile,2017,13,N-Nervous system,Million US$ at exchange rate,479.0
6591,Chile,2017,13,N-Nervous system,"/capita, US$ purchasing power parity",42.4
6592,Chile,2017,13,N-Nervous system,"/capita, US$ exchange rate",26.0
6593,Chile,2017,13,N-Nervous system,"Million US$, purchasing power parity",781.5
6594,Chile,2017,13,N-Nervous system,% of total sales,15.0
6595,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.7
6596,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",80.3
6597,Chile,2017,13,J-Antiinfectives for systemic use,Million of national currency units,255295.0
6598,Chile,2017,13,N02-Analgesics,Million of national currency units,79662.9
6599,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.4
6600,Chile,2017,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
6601,Chile,2017,13,N05B-Anxiolytics,% of total sales,0.8
6602,Chile,2017,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.8
6603,Chile,2017,13,N05C-Hypnotics and sedatives,Million of national currency units,12193.6
6604,Chile,2017,13,N05B-Anxiolytics,"Million US$, purchasing power parity",39.2
6605,Chile,2017,13,N05B-Anxiolytics,Million US$ at exchange rate,24.0
6606,Chile,2017,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
6607,Chile,2017,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.1
6608,Chile,2017,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.7
6609,Chile,2017,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.9
6610,Chile,2017,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",292.0
6611,Chile,2017,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0
6612,Chile,2017,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",30.7
6613,Chile,2017,13,M-Musculo-skeletal system,% of total sales,5.6
6614,Chile,2017,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.9
6615,Chile,2017,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,57012.2
6616,Chile,2017,13,J-Antiinfectives for systemic use,% of total sales,12.3
6617,Chile,2017,13,N02-Analgesics,"/capita, US$ purchasing power parity",10.9
6618,Chile,2017,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.4
6619,Chile,2017,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,393.5
6620,Chile,2017,13,N05B-Anxiolytics,Million of national currency units,15592.8
6621,Chile,2017,13,N02-Analgesics,% of total sales,3.9
6622,Chile,2017,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",641.9
6623,Chile,2016,13,B-Blood and blood forming organs,Million US$ at exchange rate,147.5
6624,Chile,2016,13,G-Genito urinary system and sex hormones,Million of national currency units,191680.8
6625,Chile,2016,13,B-Blood and blood forming organs,Million of national currency units,99840.0
6626,Chile,2016,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",108.0
6627,Chile,2016,13,C10-Lipid modifying agents,Million US$ at exchange rate,63.4
6628,Chile,2016,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,283.2
6629,Chile,2016,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",482.5
6630,Chile,2016,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.8
6631,Chile,2016,13,B-Blood and blood forming organs,% of total sales,4.9
6632,Chile,2016,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",251.3
6633,Chile,2016,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",8.1
6634,Chile,2016,13,N-Nervous system,"/capita, US$ purchasing power parity",42.0
6635,Chile,2016,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.5
6636,Chile,2016,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.9
6637,Chile,2016,13,C10-Lipid modifying agents,% of total sales,2.1
6638,Chile,2016,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.6
6639,Chile,2016,13,A-Alimentary tract and metabolism,% of total sales,17.8
6640,Chile,2016,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.8
6641,Chile,2016,13,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5
6642,Chile,2016,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",909.1
6643,Chile,2016,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.0
6644,Chile,2016,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",29.4
6645,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.1
6646,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.1
6647,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
6648,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,50996.5
6649,Chile,2016,13,C01A-Cardiac glycosides,Million of national currency units,335.1
6650,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",128.4
6651,Chile,2016,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,75.3
6652,Chile,2016,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,533.5
6653,Chile,2016,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.6
6654,Chile,2016,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,139368.4
6655,Chile,2016,13,G-Genito urinary system and sex hormones,% of total sales,9.5
6656,Chile,2016,13,C01A-Cardiac glycosides,% of total sales,0.0
6657,Chile,2016,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
6658,Chile,2016,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
6659,Chile,2016,13,G03-Sex hormones and modulators of the genital system,% of total sales,6.9
6660,Chile,2016,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",19.3
6661,Chile,2016,13,A-Alimentary tract and metabolism,Million of national currency units,361148.7
6662,Chile,2016,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,205.9
6663,Chile,2016,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.3
6664,Chile,2016,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",350.8
6665,Chile,2016,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",280.4
6666,Chile,2016,13,C07-Beta blocking agents,Million US$ at exchange rate,28.2
6667,Chile,2016,13,C07-Beta blocking agents,Million of national currency units,19105.1
6668,Chile,2016,13,Total pharmaceutical sales,Million US$ at exchange rate,2989.7
6669,Chile,2016,13,Total pharmaceutical sales,"/capita, US$ exchange rate",164.6
6670,Chile,2016,13,Total pharmaceutical sales,"Million US$, purchasing power parity",5094.7
6671,Chile,2016,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
6672,Chile,2016,13,C02-Antihypertensives,"/capita, US$ exchange rate",0.4
6673,Chile,2016,13,C02-Antihypertensives,"Million US$, purchasing power parity",11.2
6674,Chile,2016,13,C-Cardiovascular system,% of total sales,7.5
6675,Chile,2016,13,C07-Beta blocking agents,"Million US$, purchasing power parity",48.1
6676,Chile,2016,13,C02-Antihypertensives,% of total sales,0.2
6677,Chile,2016,13,C-Cardiovascular system,Million of national currency units,152031.5
6678,Chile,2016,13,C03-Diuretics,Million US$ at exchange rate,8.9
6679,Chile,2016,13,C03-Diuretics,Million of national currency units,6034.4
6680,Chile,2016,13,C-Cardiovascular system,"/capita, US$ exchange rate",12.4
6681,Chile,2016,13,C-Cardiovascular system,Million US$ at exchange rate,224.6
6682,Chile,2016,13,C-Cardiovascular system,"Million US$, purchasing power parity",382.7
6683,Chile,2016,13,C03-Diuretics,"/capita, US$ purchasing power parity",0.8
6684,Chile,2016,13,Total pharmaceutical sales,Million of national currency units,2023878.4
6685,Chile,2016,13,C03-Diuretics,% of total sales,0.3
6686,Chile,2016,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",21.1
6687,Chile,2016,13,C03-Diuretics,"/capita, US$ exchange rate",0.5
6688,Chile,2016,13,C03-Diuretics,"Million US$, purchasing power parity",15.2
6689,Chile,2016,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.0
6690,Chile,2016,13,C08-Calcium channel blockers,% of total sales,0.3
6691,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,54643.5
6692,Chile,2016,13,C08-Calcium channel blockers,Million US$ at exchange rate,10.3
6693,Chile,2016,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",17.6
6694,Chile,2016,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.6
6695,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.7
6696,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",7.6
6697,Chile,2016,13,C10-Lipid modifying agents,Million of national currency units,42911.6
6698,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",137.6
6699,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,80.7
6700,Chile,2016,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.4
6701,Chile,2016,13,C02-Antihypertensives,Million US$ at exchange rate,6.6
6702,Chile,2016,13,C02-Antihypertensives,Million of national currency units,4456.9
6703,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
6704,Chile,2016,13,C07-Beta blocking agents,"/capita, US$ exchange rate",1.6
6705,Chile,2016,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.6
6706,Chile,2016,13,C07-Beta blocking agents,% of total sales,0.9
6707,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3
6708,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,2214.9
6709,Chile,2016,13,C08-Calcium channel blockers,Million of national currency units,6996.6
6710,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.2
6711,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.3
6712,Chile,2016,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",5.6
6713,Chile,2016,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.6
6714,Chile,2016,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",210.0
6715,Chile,2016,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.8
6716,Chile,2016,13,N06A-Antidepressants,% of total sales,3.0
6717,Chile,2016,13,J01-Antibacterials for systemic use,% of total sales,4.1
6718,Chile,2016,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.9
6719,Chile,2016,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.4
6720,Chile,2016,13,A10-Drugs used in diabetes,Million of national currency units,96716.5
6721,Chile,2016,13,A10-Drugs used in diabetes,Million US$ at exchange rate,142.9
6722,Chile,2016,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",243.5
6723,Chile,2016,13,A10-Drugs used in diabetes,% of total sales,4.8
6724,Chile,2016,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.3
6725,Chile,2016,13,N06A-Antidepressants,Million of national currency units,60183.9
6726,Chile,2016,13,N06A-Antidepressants,Million US$ at exchange rate,88.9
6727,Chile,2016,13,M-Musculo-skeletal system,Million of national currency units,120374.3
6728,Chile,2016,13,N05C-Hypnotics and sedatives,% of total sales,0.5
6729,Chile,2016,13,N06A-Antidepressants,"Million US$, purchasing power parity",151.5
6730,Chile,2016,13,Products not elsewhere classified,"Million US$, purchasing power parity",686.4
6731,Chile,2016,13,Products not elsewhere classified,"/capita, US$ exchange rate",22.2
6732,Chile,2016,13,N06A-Antidepressants,"/capita, US$ exchange rate",4.9
6733,Chile,2016,13,Products not elsewhere classified,% of total sales,13.5
6734,Chile,2016,13,Products not elsewhere classified,"/capita, US$ purchasing power parity",37.8
6735,Chile,2016,13,R-Respiratory system,% of total sales,9.4
6736,Chile,2016,13,R-Respiratory system,"/capita, US$ purchasing power parity",26.4
6737,Chile,2016,13,A02A-Antacids,"Million US$, purchasing power parity",28.4
6738,Chile,2016,13,R03-Drugs for obstructive airway diseases,Million of national currency units,52879.3
6739,Chile,2016,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,78.1
6740,Chile,2016,13,R-Respiratory system,"/capita, US$ exchange rate",15.5
6741,Chile,2016,13,A02A-Antacids,Million of national currency units,11264.6
6742,Chile,2016,13,R-Respiratory system,Million of national currency units,190353.2
6743,Chile,2016,13,A02A-Antacids,Million US$ at exchange rate,16.6
6744,Chile,2016,13,R-Respiratory system,"Million US$, purchasing power parity",479.2
6745,Chile,2016,13,R-Respiratory system,Million US$ at exchange rate,281.2
6746,Chile,2016,13,A02A-Antacids,"/capita, US$ purchasing power parity",1.6
6747,Chile,2016,13,Products not elsewhere classified,Million US$ at exchange rate,402.8
6748,Chile,2016,13,A02A-Antacids,% of total sales,0.6
6749,Chile,2016,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,123.2
6750,Chile,2016,13,J01-Antibacterials for systemic use,Million of national currency units,83434.7
6751,Chile,2016,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",4.3
6752,Chile,2016,13,A02A-Antacids,"/capita, US$ exchange rate",0.9
6753,Chile,2016,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",133.1
6754,Chile,2016,13,Products not elsewhere classified,Million of national currency units,272690.5
6755,Chile,2016,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",7.3
6756,Chile,2016,13,R03-Drugs for obstructive airway diseases,% of total sales,2.6
6757,Chile,2016,13,M-Musculo-skeletal system,Million US$ at exchange rate,177.8
6758,Chile,2016,13,N02-Analgesics,"Million US$, purchasing power parity",216.1
6759,Chile,2016,13,N02-Analgesics,"/capita, US$ purchasing power parity",11.9
6760,Chile,2016,13,N02-Analgesics,"/capita, US$ exchange rate",7.0
6761,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,27671.1
6762,Chile,2016,13,N02-Analgesics,Million US$ at exchange rate,126.8
6763,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",154.1
6764,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,90.4
6765,Chile,2016,13,J-Antiinfectives for systemic use,Million of national currency units,281371.0
6766,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.5
6767,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.0
6768,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.0
6769,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,40.9
6770,Chile,2016,13,N-Nervous system,Million of national currency units,303392.0
6771,Chile,2016,13,N-Nervous system,Million US$ at exchange rate,448.2
6772,Chile,2016,13,N-Nervous system,"/capita, US$ exchange rate",24.7
6773,Chile,2016,13,N-Nervous system,"Million US$, purchasing power parity",763.7
6774,Chile,2016,13,N-Nervous system,% of total sales,15.0
6775,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.2
6776,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",69.7
6777,Chile,2016,13,N02-Analgesics,Million of national currency units,85860.4
6778,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",3.8
6779,Chile,2016,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.4
6780,Chile,2016,13,N05B-Anxiolytics,% of total sales,0.7
6781,Chile,2016,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,16.0
6782,Chile,2016,13,N05C-Hypnotics and sedatives,Million of national currency units,10849.8
6783,Chile,2016,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.9
6784,Chile,2016,13,N05B-Anxiolytics,"Million US$, purchasing power parity",35.2
6785,Chile,2016,13,N05B-Anxiolytics,Million US$ at exchange rate,20.6
6786,Chile,2016,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
6787,Chile,2016,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.8
6788,Chile,2016,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.7
6789,Chile,2016,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",303.0
6790,Chile,2016,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9
6791,Chile,2016,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",27.3
6792,Chile,2016,13,M-Musculo-skeletal system,% of total sales,5.9
6793,Chile,2016,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5
6794,Chile,2016,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",39.0
6795,Chile,2016,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,61219.5
6796,Chile,2016,13,J-Antiinfectives for systemic use,% of total sales,13.9
6797,Chile,2016,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",22.9
6798,Chile,2016,13,N05B-Anxiolytics,Million of national currency units,13974.1
6799,Chile,2016,13,N02-Analgesics,% of total sales,4.2
6800,Chile,2016,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,415.6
6801,Chile,2016,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",708.3
6802,Costa Rica,2016,28,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.3
6803,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.0
6804,Costa Rica,2016,28,C02-Antihypertensives,Million US$ at exchange rate,1.0
6805,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,5.7
6806,Costa Rica,2016,28,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.4
6807,Costa Rica,2016,28,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5
6808,Costa Rica,2016,28,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
6809,Costa Rica,2016,28,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.4
6810,Costa Rica,2016,28,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
6811,Costa Rica,2016,28,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.6
6812,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2
6813,Costa Rica,2016,28,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.0
6814,Costa Rica,2016,28,B-Blood and blood forming organs,"Million US$, purchasing power parity",46.6
6815,Costa Rica,2016,28,C08-Calcium channel blockers,Million of national currency units,298.2
6816,Costa Rica,2016,28,N02-Analgesics,"/capita, US$ exchange rate",1.0
6817,Costa Rica,2016,28,C03-Diuretics,"/capita, US$ exchange rate",0.2
6818,Costa Rica,2016,28,C08-Calcium channel blockers,Million US$ at exchange rate,0.5
6819,Costa Rica,2016,28,N06A-Antidepressants,"/capita, US$ exchange rate",0.6
6820,Costa Rica,2016,28,C-Cardiovascular system,Million of national currency units,5484.2
6821,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1689.2
6822,Costa Rica,2016,28,C-Cardiovascular system,Million US$ at exchange rate,10.1
6823,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",0.9
6824,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.1
6825,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.5
6826,Costa Rica,2016,28,N05B-Anxiolytics,"Million US$, purchasing power parity",1.0
6827,Costa Rica,2016,28,C02-Antihypertensives,Million of national currency units,539.3
6828,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1877.2
6829,Costa Rica,2016,28,J-Antiinfectives for systemic use,Million of national currency units,19042.5
6830,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.6
6831,Costa Rica,2016,28,N02-Analgesics,"Million US$, purchasing power parity",7.7
6832,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",1.9
6833,Costa Rica,2016,28,J-Antiinfectives for systemic use,Million US$ at exchange rate,35.0
6834,Costa Rica,2016,28,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.0
6835,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.4
6836,Costa Rica,2016,28,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
6837,Costa Rica,2016,28,N05B-Anxiolytics,Million US$ at exchange rate,0.7
6838,Costa Rica,2016,28,C02-Antihypertensives,"/capita, US$ exchange rate",0.2
6839,Costa Rica,2016,28,C-Cardiovascular system,"/capita, US$ exchange rate",2.1
6840,Costa Rica,2016,28,C10-Lipid modifying agents,Million US$ at exchange rate,3.1
6841,Costa Rica,2016,28,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.0
6842,Costa Rica,2016,28,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.5
6843,Costa Rica,2016,28,N06A-Antidepressants,"Million US$, purchasing power parity",4.4
6844,Costa Rica,2016,28,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.9
6845,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.8
6846,Costa Rica,2016,28,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.5
6847,Costa Rica,2016,28,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.1
6848,Costa Rica,2016,28,C10-Lipid modifying agents,"Million US$, purchasing power parity",4.9
6849,Costa Rica,2016,28,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
6850,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0
6851,Costa Rica,2016,28,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
6852,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1
6853,Costa Rica,2016,28,C07-Beta blocking agents,Million US$ at exchange rate,1.6
6854,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2333.1
6855,Costa Rica,2016,28,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",1.9
6856,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,Million of national currency units,3104.4
6857,Costa Rica,2016,28,C10-Lipid modifying agents,Million of national currency units,1683.6
6858,Costa Rica,2016,28,A02A-Antacids,Million of national currency units,927.7
6859,Costa Rica,2016,28,B-Blood and blood forming organs,Million of national currency units,15990.6
6860,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.5
6861,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7
6862,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,75.6
6863,Costa Rica,2016,28,A02A-Antacids,Million US$ at exchange rate,1.7
6864,Costa Rica,2016,28,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.6
6865,Costa Rica,2016,28,B-Blood and blood forming organs,Million US$ at exchange rate,29.4
6866,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.4
6867,Costa Rica,2016,28,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
6868,Costa Rica,2016,28,A02A-Antacids,"/capita, US$ exchange rate",0.3
6869,Costa Rica,2016,28,C-Cardiovascular system,"Million US$, purchasing power parity",16.0
6870,Costa Rica,2016,28,C07-Beta blocking agents,Million of national currency units,868.6
6871,Costa Rica,2016,28,C03-Diuretics,"Million US$, purchasing power parity",1.2
6872,Costa Rica,2016,28,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
6873,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
6874,Costa Rica,2016,28,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",11.4
6875,Costa Rica,2016,28,A10-Drugs used in diabetes,"Million US$, purchasing power parity",12.5
6876,Costa Rica,2016,28,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2
6877,Costa Rica,2016,28,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3
6878,Costa Rica,2016,28,N06A-Antidepressants,Million of national currency units,1494.7
6879,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.1
6880,Costa Rica,2016,28,N02-Analgesics,Million of national currency units,2631.2
6881,Costa Rica,2016,28,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.6
6882,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",9.1
6883,Costa Rica,2016,28,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
6884,Costa Rica,2016,28,N02-Analgesics,Million US$ at exchange rate,4.8
6885,Costa Rica,2016,28,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
6886,Costa Rica,2016,28,A10-Drugs used in diabetes,Million US$ at exchange rate,7.9
6887,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.3
6888,Costa Rica,2016,28,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",14.9
6889,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.0
6890,Costa Rica,2016,28,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.6
6891,Costa Rica,2016,28,N06A-Antidepressants,Million US$ at exchange rate,2.7
6892,Costa Rica,2016,28,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.2
6893,Costa Rica,2016,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.3
6894,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.8
6895,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,Million of national currency units,1812.8
6896,Costa Rica,2016,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7
6897,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1357.8
6898,Costa Rica,2016,28,C03-Diuretics,Million US$ at exchange rate,0.8
6899,Costa Rica,2016,28,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3
6900,Costa Rica,2016,28,N05C-Hypnotics and sedatives,Million of national currency units,213.0
6901,Costa Rica,2016,28,J01-Antibacterials for systemic use,Million of national currency units,5106.3
6902,Costa Rica,2016,28,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",55.5
6903,Costa Rica,2016,28,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
6904,Costa Rica,2016,28,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
6905,Costa Rica,2016,28,C01A-Cardiac glycosides,Million of national currency units,201.9
6906,Costa Rica,2016,28,A02A-Antacids,"Million US$, purchasing power parity",2.7
6907,Costa Rica,2016,28,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.5
6908,Costa Rica,2016,28,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
6909,Costa Rica,2016,28,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.3
6910,Costa Rica,2016,28,C03-Diuretics,Million of national currency units,427.5
6911,Costa Rica,2016,28,A10-Drugs used in diabetes,Million of national currency units,4281.7
6912,Costa Rica,2016,28,N05B-Anxiolytics,Million of national currency units,355.5
6913,Costa Rica,2016,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.9
6914,Costa Rica,2016,28,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.9
6915,Costa Rica,2016,28,C02-Antihypertensives,"Million US$, purchasing power parity",1.6
6916,Costa Rica,2016,28,N02-Analgesics,"/capita, US$ purchasing power parity",1.6
6917,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.0
6918,Costa Rica,2015,28,C02-Antihypertensives,Million US$ at exchange rate,1.0
6919,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,6.9
6920,Costa Rica,2015,28,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.4
6921,Costa Rica,2015,28,C07-Beta blocking agents,"Million US$, purchasing power parity",2.3
6922,Costa Rica,2015,28,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
6923,Costa Rica,2015,28,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
6924,Costa Rica,2015,28,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.6
6925,Costa Rica,2015,28,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.2
6926,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2
6927,Costa Rica,2015,28,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.9
6928,Costa Rica,2015,28,B-Blood and blood forming organs,"Million US$, purchasing power parity",47.2
6929,Costa Rica,2015,28,C08-Calcium channel blockers,Million of national currency units,362.9
6930,Costa Rica,2015,28,N02-Analgesics,"/capita, US$ exchange rate",1.0
6931,Costa Rica,2015,28,C03-Diuretics,"/capita, US$ exchange rate",0.2
6932,Costa Rica,2015,28,C08-Calcium channel blockers,Million US$ at exchange rate,0.7
6933,Costa Rica,2015,28,N06A-Antidepressants,"/capita, US$ exchange rate",0.5
6934,Costa Rica,2015,28,C-Cardiovascular system,Million of national currency units,5719.1
6935,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1648.5
6936,Costa Rica,2015,28,C-Cardiovascular system,Million US$ at exchange rate,10.7
6937,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",0.9
6938,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0
6939,Costa Rica,2015,28,C02-Antihypertensives,Million of national currency units,519.3
6940,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.3
6941,Costa Rica,2015,28,N05B-Anxiolytics,"Million US$, purchasing power parity",1.0
6942,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1858.9
6943,Costa Rica,2015,28,J-Antiinfectives for systemic use,Million of national currency units,17281.8
6944,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.6
6945,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.1
6946,Costa Rica,2015,28,N02-Analgesics,"Million US$, purchasing power parity",7.4
6947,Costa Rica,2015,28,J-Antiinfectives for systemic use,Million US$ at exchange rate,32.3
6948,Costa Rica,2015,28,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
6949,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.5
6950,Costa Rica,2015,28,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.5
6951,Costa Rica,2015,28,C02-Antihypertensives,"/capita, US$ exchange rate",0.2
6952,Costa Rica,2015,28,C-Cardiovascular system,"/capita, US$ exchange rate",2.2
6953,Costa Rica,2015,28,C10-Lipid modifying agents,Million US$ at exchange rate,3.2
6954,Costa Rica,2015,28,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.0
6955,Costa Rica,2015,28,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.5
6956,Costa Rica,2015,28,N06A-Antidepressants,"Million US$, purchasing power parity",3.6
6957,Costa Rica,2015,28,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.7
6958,Costa Rica,2015,28,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.8
6959,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.5
6960,Costa Rica,2015,28,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.7
6961,Costa Rica,2015,28,C10-Lipid modifying agents,"Million US$, purchasing power parity",4.8
6962,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0
6963,Costa Rica,2015,28,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
6964,Costa Rica,2015,28,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
6965,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1
6966,Costa Rica,2015,28,C07-Beta blocking agents,Million US$ at exchange rate,1.6
6967,Costa Rica,2015,28,A02A-Antacids,Million US$ at exchange rate,1.7
6968,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2298.6
6969,Costa Rica,2015,28,A02A-Antacids,Million of national currency units,882.4
6970,Costa Rica,2015,28,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",1.9
6971,Costa Rica,2015,28,B-Blood and blood forming organs,Million of national currency units,16694.8
6972,Costa Rica,2015,28,C10-Lipid modifying agents,Million of national currency units,1710.2
6973,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.6
6974,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,Million of national currency units,3675.4
6975,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,64.5
6976,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7
6977,Costa Rica,2015,28,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.3
6978,Costa Rica,2015,28,B-Blood and blood forming organs,Million US$ at exchange rate,31.2
6979,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.3
6980,Costa Rica,2015,28,N05B-Anxiolytics,Million US$ at exchange rate,0.7
6981,Costa Rica,2015,28,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
6982,Costa Rica,2015,28,A02A-Antacids,"/capita, US$ exchange rate",0.3
6983,Costa Rica,2015,28,C07-Beta blocking agents,Million of national currency units,830.8
6984,Costa Rica,2015,28,C-Cardiovascular system,"Million US$, purchasing power parity",16.2
6985,Costa Rica,2015,28,C03-Diuretics,"Million US$, purchasing power parity",1.2
6986,Costa Rica,2015,28,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
6987,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
6988,Costa Rica,2015,28,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.1
6989,Costa Rica,2015,28,A10-Drugs used in diabetes,"Million US$, purchasing power parity",11.4
6990,Costa Rica,2015,28,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.3
6991,Costa Rica,2015,28,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2
6992,Costa Rica,2015,28,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3
6993,Costa Rica,2015,28,N06A-Antidepressants,Million of national currency units,1278.7
6994,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.1
6995,Costa Rica,2015,28,N02-Analgesics,Million of national currency units,2634.7
6996,Costa Rica,2015,28,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.6
6997,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",10.4
6998,Costa Rica,2015,28,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
6999,Costa Rica,2015,28,N02-Analgesics,Million US$ at exchange rate,4.9
7000,Costa Rica,2015,28,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
7001,Costa Rica,2015,28,A10-Drugs used in diabetes,Million US$ at exchange rate,7.5
7002,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.0
7003,Costa Rica,2015,28,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",13.9
7004,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.5
7005,Costa Rica,2015,28,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.7
7006,Costa Rica,2015,28,N06A-Antidepressants,Million US$ at exchange rate,2.4
7007,Costa Rica,2015,28,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.4
7008,Costa Rica,2015,28,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.3
7009,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,Million of national currency units,1760.3
7010,Costa Rica,2015,28,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7
7011,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1579.9
7012,Costa Rica,2015,28,C03-Diuretics,Million US$ at exchange rate,0.8
7013,Costa Rica,2015,28,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3
7014,Costa Rica,2015,28,N05C-Hypnotics and sedatives,Million of national currency units,195.8
7015,Costa Rica,2015,28,J01-Antibacterials for systemic use,Million of national currency units,4904.9
7016,Costa Rica,2015,28,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",48.8
7017,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.9
7018,Costa Rica,2015,28,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
7019,Costa Rica,2015,28,C01A-Cardiac glycosides,Million of national currency units,200.6
7020,Costa Rica,2015,28,C03-Diuretics,"/capita, US$ purchasing power parity",0.2
7021,Costa Rica,2015,28,A02A-Antacids,"Million US$, purchasing power parity",2.5
7022,Costa Rica,2015,28,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.0
7023,Costa Rica,2015,28,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
7024,Costa Rica,2015,28,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.3
7025,Costa Rica,2015,28,C03-Diuretics,Million of national currency units,413.6
7026,Costa Rica,2015,28,A10-Drugs used in diabetes,Million of national currency units,4018.0
7027,Costa Rica,2015,28,N05B-Anxiolytics,Million of national currency units,348.3
7028,Costa Rica,2015,28,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.7
7029,Costa Rica,2015,28,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.0
7030,Costa Rica,2015,28,C02-Antihypertensives,"Million US$, purchasing power parity",1.5
7031,Costa Rica,2015,28,N02-Analgesics,"/capita, US$ purchasing power parity",1.5
7032,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,7.9
7033,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.0
7034,Costa Rica,2014,29,C02-Antihypertensives,Million US$ at exchange rate,0.9
7035,Costa Rica,2014,29,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3
7036,Costa Rica,2014,29,C07-Beta blocking agents,"Million US$, purchasing power parity",1.9
7037,Costa Rica,2014,29,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
7038,Costa Rica,2014,29,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
7039,Costa Rica,2014,29,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.7
7040,Costa Rica,2014,29,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.7
7041,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2
7042,Costa Rica,2014,29,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.4
7043,Costa Rica,2014,29,B-Blood and blood forming organs,"Million US$, purchasing power parity",52.6
7044,Costa Rica,2014,29,C08-Calcium channel blockers,Million of national currency units,319.1
7045,Costa Rica,2014,29,N02-Analgesics,"/capita, US$ exchange rate",1.1
7046,Costa Rica,2014,29,C03-Diuretics,"/capita, US$ exchange rate",0.2
7047,Costa Rica,2014,29,C08-Calcium channel blockers,Million US$ at exchange rate,0.6
7048,Costa Rica,2014,29,N06A-Antidepressants,"/capita, US$ exchange rate",0.4
7049,Costa Rica,2014,29,C-Cardiovascular system,Million of national currency units,6768.8
7050,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1732.8
7051,Costa Rica,2014,29,C-Cardiovascular system,Million US$ at exchange rate,12.6
7052,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.1
7053,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0
7054,Costa Rica,2014,29,C02-Antihypertensives,Million of national currency units,481.8
7055,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.7
7056,Costa Rica,2014,29,N05B-Anxiolytics,"Million US$, purchasing power parity",1.0
7057,Costa Rica,2014,29,C-Cardiovascular system,"/capita, US$ purchasing power parity",4.0
7058,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1674.9
7059,Costa Rica,2014,29,J-Antiinfectives for systemic use,Million of national currency units,16847.2
7060,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.7
7061,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.5
7062,Costa Rica,2014,29,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.3
7063,Costa Rica,2014,29,N02-Analgesics,"Million US$, purchasing power parity",8.0
7064,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.1
7065,Costa Rica,2014,29,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
7066,Costa Rica,2014,29,C-Cardiovascular system,"/capita, US$ exchange rate",2.6
7067,Costa Rica,2014,29,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.2
7068,Costa Rica,2014,29,C02-Antihypertensives,"/capita, US$ exchange rate",0.2
7069,Costa Rica,2014,29,C10-Lipid modifying agents,Million US$ at exchange rate,5.5
7070,Costa Rica,2014,29,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.7
7071,Costa Rica,2014,29,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.4
7072,Costa Rica,2014,29,N06A-Antidepressants,"Million US$, purchasing power parity",3.2
7073,Costa Rica,2014,29,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.7
7074,Costa Rica,2014,29,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.6
7075,Costa Rica,2014,29,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",11.0
7076,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",7.6
7077,Costa Rica,2014,29,C10-Lipid modifying agents,"Million US$, purchasing power parity",8.4
7078,Costa Rica,2014,29,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
7079,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0
7080,Costa Rica,2014,29,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
7081,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1
7082,Costa Rica,2014,29,A02A-Antacids,Million US$ at exchange rate,1.6
7083,Costa Rica,2014,29,C07-Beta blocking agents,Million US$ at exchange rate,1.2
7084,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2700.8
7085,Costa Rica,2014,29,A02A-Antacids,Million of national currency units,864.0
7086,Costa Rica,2014,29,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.2
7087,Costa Rica,2014,29,B-Blood and blood forming organs,Million of national currency units,18566.0
7088,Costa Rica,2014,29,C10-Lipid modifying agents,Million of national currency units,2949.9
7089,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.6
7090,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,Million of national currency units,4275.6
7091,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,71.7
7092,Costa Rica,2014,29,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.5
7093,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7
7094,Costa Rica,2014,29,B-Blood and blood forming organs,Million US$ at exchange rate,34.5
7095,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.6
7096,Costa Rica,2014,29,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
7097,Costa Rica,2014,29,N05B-Anxiolytics,Million US$ at exchange rate,0.7
7098,Costa Rica,2014,29,A02A-Antacids,"/capita, US$ exchange rate",0.3
7099,Costa Rica,2014,29,C-Cardiovascular system,"Million US$, purchasing power parity",19.2
7100,Costa Rica,2014,29,C07-Beta blocking agents,Million of national currency units,656.4
7101,Costa Rica,2014,29,C03-Diuretics,"Million US$, purchasing power parity",1.2
7102,Costa Rica,2014,29,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
7103,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0
7104,Costa Rica,2014,29,A10-Drugs used in diabetes,"Million US$, purchasing power parity",12.1
7105,Costa Rica,2014,29,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.0
7106,Costa Rica,2014,29,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2
7107,Costa Rica,2014,29,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3
7108,Costa Rica,2014,29,N06A-Antidepressants,Million of national currency units,1118.1
7109,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.2
7110,Costa Rica,2014,29,N02-Analgesics,Million of national currency units,2811.6
7111,Costa Rica,2014,29,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.5
7112,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.1
7113,Costa Rica,2014,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
7114,Costa Rica,2014,29,N02-Analgesics,Million US$ at exchange rate,5.2
7115,Costa Rica,2014,29,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
7116,Costa Rica,2014,29,A10-Drugs used in diabetes,Million US$ at exchange rate,7.9
7117,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.0
7118,Costa Rica,2014,29,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",16.3
7119,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.6
7120,Costa Rica,2014,29,C10-Lipid modifying agents,"/capita, US$ exchange rate",1.1
7121,Costa Rica,2014,29,N06A-Antidepressants,Million US$ at exchange rate,2.1
7122,Costa Rica,2014,29,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.7
7123,Costa Rica,2014,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.0
7124,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.0
7125,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,Million of national currency units,1766.7
7126,Costa Rica,2014,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7
7127,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1623.3
7128,Costa Rica,2014,29,C03-Diuretics,Million US$ at exchange rate,0.8
7129,Costa Rica,2014,29,N05C-Hypnotics and sedatives,Million of national currency units,176.3
7130,Costa Rica,2014,29,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3
7131,Costa Rica,2014,29,J01-Antibacterials for systemic use,Million of national currency units,5751.6
7132,Costa Rica,2014,29,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",47.7
7133,Costa Rica,2014,29,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
7134,Costa Rica,2014,29,C01A-Cardiac glycosides,Million of national currency units,227.2
7135,Costa Rica,2014,29,A02A-Antacids,"Million US$, purchasing power parity",2.4
7136,Costa Rica,2014,29,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
7137,Costa Rica,2014,29,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.0
7138,Costa Rica,2014,29,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
7139,Costa Rica,2014,29,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.3
7140,Costa Rica,2014,29,C03-Diuretics,Million of national currency units,427.6
7141,Costa Rica,2014,29,A10-Drugs used in diabetes,Million of national currency units,4269.6
7142,Costa Rica,2014,29,N05B-Anxiolytics,Million of national currency units,351.2
7143,Costa Rica,2014,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.9
7144,Costa Rica,2014,29,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.9
7145,Costa Rica,2014,29,C02-Antihypertensives,"Million US$, purchasing power parity",1.4
7146,Costa Rica,2014,29,N02-Analgesics,"/capita, US$ purchasing power parity",1.7
7147,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.8
7148,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,7.3
7149,Costa Rica,2013,29,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3
7150,Costa Rica,2013,29,C02-Antihypertensives,Million US$ at exchange rate,0.8
7151,Costa Rica,2013,29,C07-Beta blocking agents,"Million US$, purchasing power parity",1.8
7152,Costa Rica,2013,29,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
7153,Costa Rica,2013,29,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
7154,Costa Rica,2013,29,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.5
7155,Costa Rica,2013,29,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.2
7156,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.3
7157,Costa Rica,2013,29,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.1
7158,Costa Rica,2013,29,B-Blood and blood forming organs,"Million US$, purchasing power parity",42.6
7159,Costa Rica,2013,29,C08-Calcium channel blockers,Million of national currency units,276.6
7160,Costa Rica,2013,29,N02-Analgesics,"/capita, US$ exchange rate",0.8
7161,Costa Rica,2013,29,C03-Diuretics,"/capita, US$ exchange rate",0.2
7162,Costa Rica,2013,29,C08-Calcium channel blockers,Million US$ at exchange rate,0.6
7163,Costa Rica,2013,29,N06A-Antidepressants,"/capita, US$ exchange rate",0.4
7164,Costa Rica,2013,29,C-Cardiovascular system,Million of national currency units,5356.4
7165,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1381.1
7166,Costa Rica,2013,29,C-Cardiovascular system,Million US$ at exchange rate,10.7
7167,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.0
7168,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0
7169,Costa Rica,2013,29,C02-Antihypertensives,Million of national currency units,394.0
7170,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.5
7171,Costa Rica,2013,29,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9
7172,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1915.9
7173,Costa Rica,2013,29,J-Antiinfectives for systemic use,Million of national currency units,14080.5
7174,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.6
7175,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.2
7176,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,Million of national currency units,3657.2
7177,Costa Rica,2013,29,N02-Analgesics,"Million US$, purchasing power parity",5.5
7178,Costa Rica,2013,29,J-Antiinfectives for systemic use,Million US$ at exchange rate,28.2
7179,Costa Rica,2013,29,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
7180,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.8
7181,Costa Rica,2013,29,B-Blood and blood forming organs,"/capita, US$ exchange rate",6.3
7182,Costa Rica,2013,29,C-Cardiovascular system,"/capita, US$ exchange rate",2.3
7183,Costa Rica,2013,29,C02-Antihypertensives,"/capita, US$ exchange rate",0.2
7184,Costa Rica,2013,29,C10-Lipid modifying agents,Million US$ at exchange rate,3.9
7185,Costa Rica,2013,29,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.2
7186,Costa Rica,2013,29,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.0
7187,Costa Rica,2013,29,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.4
7188,Costa Rica,2013,29,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.6
7189,Costa Rica,2013,29,N06A-Antidepressants,"Million US$, purchasing power parity",3.0
7190,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.9
7191,Costa Rica,2013,29,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.7
7192,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.1
7193,Costa Rica,2013,29,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
7194,Costa Rica,2013,29,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
7195,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.2
7196,Costa Rica,2013,29,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.0
7197,Costa Rica,2013,29,A02A-Antacids,Million US$ at exchange rate,2.0
7198,Costa Rica,2013,29,C07-Beta blocking agents,Million US$ at exchange rate,1.2
7199,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2416.6
7200,Costa Rica,2013,29,A02A-Antacids,Million of national currency units,975.1
7201,Costa Rica,2013,29,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.2
7202,Costa Rica,2013,29,B-Blood and blood forming organs,Million of national currency units,14811.2
7203,Costa Rica,2013,29,C10-Lipid modifying agents,Million of national currency units,1969.3
7204,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.6
7205,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,114.0
7206,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7
7207,Costa Rica,2013,29,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.2
7208,Costa Rica,2013,29,B-Blood and blood forming organs,Million US$ at exchange rate,29.6
7209,Costa Rica,2013,29,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
7210,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.5
7211,Costa Rica,2013,29,N05B-Anxiolytics,Million US$ at exchange rate,0.6
7212,Costa Rica,2013,29,A02A-Antacids,"/capita, US$ exchange rate",0.4
7213,Costa Rica,2013,29,C07-Beta blocking agents,Million of national currency units,622.3
7214,Costa Rica,2013,29,C-Cardiovascular system,"Million US$, purchasing power parity",15.4
7215,Costa Rica,2013,29,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4
7216,Costa Rica,2013,29,C03-Diuretics,"Million US$, purchasing power parity",1.2
7217,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.2
7218,Costa Rica,2013,29,A10-Drugs used in diabetes,"Million US$, purchasing power parity",10.2
7219,Costa Rica,2013,29,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2
7220,Costa Rica,2013,29,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.6
7221,Costa Rica,2013,29,C02-Antihypertensives,"Million US$, purchasing power parity",1.1
7222,Costa Rica,2013,29,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3
7223,Costa Rica,2013,29,N06A-Antidepressants,Million of national currency units,1043.0
7224,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,2.8
7225,Costa Rica,2013,29,N02-Analgesics,Million of national currency units,1924.0
7226,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",10.5
7227,Costa Rica,2013,29,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.4
7228,Costa Rica,2013,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
7229,Costa Rica,2013,29,N02-Analgesics,Million US$ at exchange rate,3.8
7230,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.9
7231,Costa Rica,2013,29,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
7232,Costa Rica,2013,29,A10-Drugs used in diabetes,Million US$ at exchange rate,7.1
7233,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.8
7234,Costa Rica,2013,29,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",14.6
7235,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.1
7236,Costa Rica,2013,29,N06A-Antidepressants,Million US$ at exchange rate,2.1
7237,Costa Rica,2013,29,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.6
7238,Costa Rica,2013,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.8
7239,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,Million of national currency units,1682.6
7240,Costa Rica,2013,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.8
7241,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1436.0
7242,Costa Rica,2013,29,C03-Diuretics,Million US$ at exchange rate,0.8
7243,Costa Rica,2013,29,J01-Antibacterials for systemic use,Million of national currency units,5081.9
7244,Costa Rica,2013,29,N05C-Hypnotics and sedatives,Million of national currency units,138.7
7245,Costa Rica,2013,29,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.3
7246,Costa Rica,2013,29,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.2
7247,Costa Rica,2013,29,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",40.5
7248,Costa Rica,2013,29,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
7249,Costa Rica,2013,29,C01A-Cardiac glycosides,Million of national currency units,137.7
7250,Costa Rica,2013,29,A02A-Antacids,"Million US$, purchasing power parity",2.8
7251,Costa Rica,2013,29,C03-Diuretics,"/capita, US$ purchasing power parity",0.2
7252,Costa Rica,2013,29,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.9
7253,Costa Rica,2013,29,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
7254,Costa Rica,2013,29,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.4
7255,Costa Rica,2013,29,C03-Diuretics,Million of national currency units,406.6
7256,Costa Rica,2013,29,A10-Drugs used in diabetes,Million of national currency units,3557.3
7257,Costa Rica,2013,29,N05B-Anxiolytics,Million of national currency units,314.0
7258,Costa Rica,2013,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.0
7259,Costa Rica,2013,29,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.8
7260,Costa Rica,2013,29,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.8
7261,Costa Rica,2013,29,N02-Analgesics,"/capita, US$ purchasing power parity",1.2
7262,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,6.4
7263,Costa Rica,2012,29,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3
7264,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.6
7265,Costa Rica,2012,29,C02-Antihypertensives,Million US$ at exchange rate,0.8
7266,Costa Rica,2012,29,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.7
7267,Costa Rica,2012,29,C07-Beta blocking agents,"Million US$, purchasing power parity",1.7
7268,Costa Rica,2012,29,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
7269,Costa Rica,2012,29,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
7270,Costa Rica,2012,29,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.4
7271,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2
7272,Costa Rica,2012,29,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.0
7273,Costa Rica,2012,29,B-Blood and blood forming organs,"Million US$, purchasing power parity",35.5
7274,Costa Rica,2012,29,C08-Calcium channel blockers,Million of national currency units,204.0
7275,Costa Rica,2012,29,C08-Calcium channel blockers,Million US$ at exchange rate,0.4
7276,Costa Rica,2012,29,C03-Diuretics,"/capita, US$ exchange rate",0.2
7277,Costa Rica,2012,29,N02-Analgesics,"/capita, US$ exchange rate",0.7
7278,Costa Rica,2012,29,N06A-Antidepressants,"/capita, US$ exchange rate",0.4
7279,Costa Rica,2012,29,C-Cardiovascular system,Million of national currency units,5057.2
7280,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1000.3
7281,Costa Rica,2012,29,C-Cardiovascular system,Million US$ at exchange rate,10.1
7282,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",0.9
7283,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0
7284,Costa Rica,2012,29,C02-Antihypertensives,Million of national currency units,379.8
7285,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.1
7286,Costa Rica,2012,29,N05B-Anxiolytics,"Million US$, purchasing power parity",0.8
7287,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1763.9
7288,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.4
7289,Costa Rica,2012,29,J-Antiinfectives for systemic use,Million of national currency units,13948.3
7290,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.0
7291,Costa Rica,2012,29,J-Antiinfectives for systemic use,Million US$ at exchange rate,27.7
7292,Costa Rica,2012,29,N02-Analgesics,"Million US$, purchasing power parity",4.9
7293,Costa Rica,2012,29,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
7294,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.5
7295,Costa Rica,2012,29,C-Cardiovascular system,"/capita, US$ exchange rate",2.2
7296,Costa Rica,2012,29,C02-Antihypertensives,"/capita, US$ exchange rate",0.2
7297,Costa Rica,2012,29,B-Blood and blood forming organs,"/capita, US$ exchange rate",5.2
7298,Costa Rica,2012,29,C10-Lipid modifying agents,Million US$ at exchange rate,4.2
7299,Costa Rica,2012,29,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.3
7300,Costa Rica,2012,29,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.0
7301,Costa Rica,2012,29,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.4
7302,Costa Rica,2012,29,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.6
7303,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.4
7304,Costa Rica,2012,29,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.1
7305,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0
7306,Costa Rica,2012,29,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
7307,Costa Rica,2012,29,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
7308,Costa Rica,2012,29,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",7.6
7309,Costa Rica,2012,29,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.1
7310,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1
7311,Costa Rica,2012,29,A02A-Antacids,Million US$ at exchange rate,1.5
7312,Costa Rica,2012,29,C07-Beta blocking agents,Million US$ at exchange rate,1.2
7313,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2194.5
7314,Costa Rica,2012,29,A02A-Antacids,Million of national currency units,765.2
7315,Costa Rica,2012,29,B-Blood and blood forming organs,Million of national currency units,12208.2
7316,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.5
7317,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,74.5
7318,Costa Rica,2012,29,C10-Lipid modifying agents,Million of national currency units,2104.9
7319,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7
7320,Costa Rica,2012,29,B-Blood and blood forming organs,Million US$ at exchange rate,24.3
7321,Costa Rica,2012,29,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
7322,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.4
7323,Costa Rica,2012,29,N05B-Anxiolytics,Million US$ at exchange rate,0.6
7324,Costa Rica,2012,29,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.1
7325,Costa Rica,2012,29,C07-Beta blocking agents,Million of national currency units,591.5
7326,Costa Rica,2012,29,A02A-Antacids,"/capita, US$ exchange rate",0.3
7327,Costa Rica,2012,29,C-Cardiovascular system,"Million US$, purchasing power parity",14.7
7328,Costa Rica,2012,29,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4
7329,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
7330,Costa Rica,2012,29,C03-Diuretics,"Million US$, purchasing power parity",1.1
7331,Costa Rica,2012,29,A10-Drugs used in diabetes,"Million US$, purchasing power parity",9.7
7332,Costa Rica,2012,29,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.7
7333,Costa Rica,2012,29,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.1
7334,Costa Rica,2012,29,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3
7335,Costa Rica,2012,29,N06A-Antidepressants,Million of national currency units,933.3
7336,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,2.0
7337,Costa Rica,2012,29,N02-Analgesics,Million of national currency units,1696.3
7338,Costa Rica,2012,29,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
7339,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",9.3
7340,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.8
7341,Costa Rica,2012,29,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.4
7342,Costa Rica,2012,29,N02-Analgesics,Million US$ at exchange rate,3.4
7343,Costa Rica,2012,29,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
7344,Costa Rica,2012,29,A10-Drugs used in diabetes,Million US$ at exchange rate,6.6
7345,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.6
7346,Costa Rica,2012,29,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",14.1
7347,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.5
7348,Costa Rica,2012,29,N06A-Antidepressants,Million US$ at exchange rate,1.9
7349,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.4
7350,Costa Rica,2012,29,C02-Antihypertensives,"Million US$, purchasing power parity",1.1
7351,Costa Rica,2012,29,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.4
7352,Costa Rica,2012,29,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.8
7353,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,Million of national currency units,1597.4
7354,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1212.1
7355,Costa Rica,2012,29,C03-Diuretics,Million US$ at exchange rate,0.7
7356,Costa Rica,2012,29,J01-Antibacterials for systemic use,Million of national currency units,4854.0
7357,Costa Rica,2012,29,N05C-Hypnotics and sedatives,Million of national currency units,141.2
7358,Costa Rica,2012,29,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.2
7359,Costa Rica,2012,29,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.2
7360,Costa Rica,2012,29,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",40.6
7361,Costa Rica,2012,29,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
7362,Costa Rica,2012,29,C01A-Cardiac glycosides,Million of national currency units,126.1
7363,Costa Rica,2012,29,A02A-Antacids,"Million US$, purchasing power parity",2.2
7364,Costa Rica,2012,29,C03-Diuretics,"/capita, US$ purchasing power parity",0.2
7365,Costa Rica,2012,29,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.4
7366,Costa Rica,2012,29,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
7367,Costa Rica,2012,29,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.2
7368,Costa Rica,2012,29,C03-Diuretics,Million of national currency units,364.4
7369,Costa Rica,2012,29,R03-Drugs for obstructive airway diseases,Million of national currency units,3202.7
7370,Costa Rica,2012,29,N06A-Antidepressants,"Million US$, purchasing power parity",2.7
7371,Costa Rica,2012,29,A10-Drugs used in diabetes,Million of national currency units,3318.6
7372,Costa Rica,2012,29,N05B-Anxiolytics,Million of national currency units,282.2
7373,Costa Rica,2012,29,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",2.9
7374,Costa Rica,2012,29,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.9
7375,Costa Rica,2012,29,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.6
7376,Costa Rica,2012,29,N02-Analgesics,"/capita, US$ purchasing power parity",1.1
7377,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,6.1
7378,Costa Rica,2011,30,C02-Antihypertensives,Million US$ at exchange rate,0.7
7379,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.6
7380,Costa Rica,2011,30,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3
7381,Costa Rica,2011,30,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
7382,Costa Rica,2011,30,C07-Beta blocking agents,"Million US$, purchasing power parity",1.5
7383,Costa Rica,2011,30,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
7384,Costa Rica,2011,30,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.2
7385,Costa Rica,2011,30,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.9
7386,Costa Rica,2011,30,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",3.6
7387,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2
7388,Costa Rica,2011,30,C08-Calcium channel blockers,Million of national currency units,177.2
7389,Costa Rica,2011,30,B-Blood and blood forming organs,"Million US$, purchasing power parity",35.4
7390,Costa Rica,2011,30,C03-Diuretics,"/capita, US$ exchange rate",0.3
7391,Costa Rica,2011,30,N02-Analgesics,"/capita, US$ exchange rate",0.7
7392,Costa Rica,2011,30,N06A-Antidepressants,"/capita, US$ exchange rate",0.6
7393,Costa Rica,2011,30,C08-Calcium channel blockers,Million US$ at exchange rate,0.4
7394,Costa Rica,2011,30,C-Cardiovascular system,Million of national currency units,4872.5
7395,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,886.3
7396,Costa Rica,2011,30,C-Cardiovascular system,Million US$ at exchange rate,9.6
7397,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.0
7398,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.1
7399,Costa Rica,2011,30,C02-Antihypertensives,Million of national currency units,347.1
7400,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.0
7401,Costa Rica,2011,30,N05B-Anxiolytics,"Million US$, purchasing power parity",0.8
7402,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.0
7403,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1662.2
7404,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.4
7405,Costa Rica,2011,30,J-Antiinfectives for systemic use,Million of national currency units,14773.7
7406,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.0
7407,Costa Rica,2011,30,J-Antiinfectives for systemic use,Million US$ at exchange rate,29.2
7408,Costa Rica,2011,30,N02-Analgesics,"Million US$, purchasing power parity",4.6
7409,Costa Rica,2011,30,C02-Antihypertensives,"/capita, US$ exchange rate",0.1
7410,Costa Rica,2011,30,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
7411,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.3
7412,Costa Rica,2011,30,C-Cardiovascular system,"/capita, US$ exchange rate",2.1
7413,Costa Rica,2011,30,B-Blood and blood forming organs,"/capita, US$ exchange rate",5.1
7414,Costa Rica,2011,30,C10-Lipid modifying agents,Million US$ at exchange rate,3.9
7415,Costa Rica,2011,30,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.3
7416,Costa Rica,2011,30,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",6.4
7417,Costa Rica,2011,30,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.3
7418,Costa Rica,2011,30,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.9
7419,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.6
7420,Costa Rica,2011,30,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.9
7421,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0
7422,Costa Rica,2011,30,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
7423,Costa Rica,2011,30,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",7.7
7424,Costa Rica,2011,30,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
7425,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1
7426,Costa Rica,2011,30,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.4
7427,Costa Rica,2011,30,A02A-Antacids,Million US$ at exchange rate,1.5
7428,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2218.4
7429,Costa Rica,2011,30,C07-Beta blocking agents,Million US$ at exchange rate,1.0
7430,Costa Rica,2011,30,A02A-Antacids,Million of national currency units,749.2
7431,Costa Rica,2011,30,B-Blood and blood forming organs,Million of national currency units,11848.0
7432,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.4
7433,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,Million of national currency units,3103.4
7434,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,73.6
7435,Costa Rica,2011,30,C10-Lipid modifying agents,Million of national currency units,1973.1
7436,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7
7437,Costa Rica,2011,30,B-Blood and blood forming organs,Million US$ at exchange rate,23.4
7438,Costa Rica,2011,30,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
7439,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.4
7440,Costa Rica,2011,30,N05B-Anxiolytics,Million US$ at exchange rate,0.5
7441,Costa Rica,2011,30,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",1.8
7442,Costa Rica,2011,30,C07-Beta blocking agents,Million of national currency units,501.3
7443,Costa Rica,2011,30,A02A-Antacids,"/capita, US$ exchange rate",0.3
7444,Costa Rica,2011,30,C-Cardiovascular system,"Million US$, purchasing power parity",14.5
7445,Costa Rica,2011,30,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4
7446,Costa Rica,2011,30,C03-Diuretics,"Million US$, purchasing power parity",2.0
7447,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
7448,Costa Rica,2011,30,A10-Drugs used in diabetes,"Million US$, purchasing power parity",8.5
7449,Costa Rica,2011,30,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.1
7450,Costa Rica,2011,30,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.6
7451,Costa Rica,2011,30,C02-Antihypertensives,"Million US$, purchasing power parity",1.0
7452,Costa Rica,2011,30,N06A-Antidepressants,Million of national currency units,1440.9
7453,Costa Rica,2011,30,C07-Beta blocking agents,"/capita, US$ exchange rate",0.2
7454,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1.8
7455,Costa Rica,2011,30,N02-Analgesics,Million of national currency units,1540.2
7456,Costa Rica,2011,30,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
7457,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",9.3
7458,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",0.6
7459,Costa Rica,2011,30,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.4
7460,Costa Rica,2011,30,N02-Analgesics,Million US$ at exchange rate,3.0
7461,Costa Rica,2011,30,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
7462,Costa Rica,2011,30,A10-Drugs used in diabetes,Million US$ at exchange rate,5.6
7463,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.0
7464,Costa Rica,2011,30,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",16.5
7465,Costa Rica,2011,30,N06A-Antidepressants,Million US$ at exchange rate,2.8
7466,Costa Rica,2011,30,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.3
7467,Costa Rica,2011,30,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.4
7468,Costa Rica,2011,30,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7
7469,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,Million of national currency units,1661.5
7470,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,996.1
7471,Costa Rica,2011,30,C03-Diuretics,Million US$ at exchange rate,1.3
7472,Costa Rica,2011,30,J01-Antibacterials for systemic use,Million of national currency units,5512.1
7473,Costa Rica,2011,30,N05C-Hypnotics and sedatives,Million of national currency units,129.2
7474,Costa Rica,2011,30,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.2
7475,Costa Rica,2011,30,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",44.1
7476,Costa Rica,2011,30,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.2
7477,Costa Rica,2011,30,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
7478,Costa Rica,2011,30,C01A-Cardiac glycosides,Million of national currency units,132.1
7479,Costa Rica,2011,30,A02A-Antacids,"Million US$, purchasing power parity",2.2
7480,Costa Rica,2011,30,C03-Diuretics,"/capita, US$ purchasing power parity",0.4
7481,Costa Rica,2011,30,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.0
7482,Costa Rica,2011,30,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
7483,Costa Rica,2011,30,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.3
7484,Costa Rica,2011,30,C03-Diuretics,Million of national currency units,671.9
7485,Costa Rica,2011,30,N06A-Antidepressants,"Million US$, purchasing power parity",4.3
7486,Costa Rica,2011,30,A10-Drugs used in diabetes,Million of national currency units,2834.0
7487,Costa Rica,2011,30,N05B-Anxiolytics,Million of national currency units,277.6
7488,Costa Rica,2011,30,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",2.6
7489,Costa Rica,2011,30,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.8
7490,Costa Rica,2011,30,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.5
7491,Costa Rica,2011,30,N02-Analgesics,"/capita, US$ purchasing power parity",1.0
7492,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,6.3
7493,Costa Rica,2010,32,C02-Antihypertensives,Million US$ at exchange rate,0.5
7494,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.6
7495,Costa Rica,2010,32,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.3
7496,Costa Rica,2010,32,C07-Beta blocking agents,"Million US$, purchasing power parity",1.0
7497,Costa Rica,2010,32,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
7498,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.4
7499,Costa Rica,2010,32,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
7500,Costa Rica,2010,32,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.1
7501,Costa Rica,2010,32,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.5
7502,Costa Rica,2010,32,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",4.1
7503,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2
7504,Costa Rica,2010,32,C08-Calcium channel blockers,Million of national currency units,175.2
7505,Costa Rica,2010,32,C08-Calcium channel blockers,Million US$ at exchange rate,0.3
7506,Costa Rica,2010,32,C03-Diuretics,"/capita, US$ exchange rate",0.2
7507,Costa Rica,2010,32,N02-Analgesics,"/capita, US$ exchange rate",0.6
7508,Costa Rica,2010,32,N06A-Antidepressants,"/capita, US$ exchange rate",0.7
7509,Costa Rica,2010,32,B-Blood and blood forming organs,"Million US$, purchasing power parity",35.0
7510,Costa Rica,2010,32,C-Cardiovascular system,Million of national currency units,4821.9
7511,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,924.5
7512,Costa Rica,2010,32,C-Cardiovascular system,Million US$ at exchange rate,9.2
7513,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",1.0
7514,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.0
7515,Costa Rica,2010,32,C02-Antihypertensives,Million of national currency units,286.8
7516,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.7
7517,Costa Rica,2010,32,N05B-Anxiolytics,"Million US$, purchasing power parity",0.8
7518,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1530.3
7519,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.4
7520,Costa Rica,2010,32,J-Antiinfectives for systemic use,Million of national currency units,17239.8
7521,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",2.2
7522,Costa Rica,2010,32,J-Antiinfectives for systemic use,Million US$ at exchange rate,32.8
7523,Costa Rica,2010,32,N02-Analgesics,"Million US$, purchasing power parity",4.4
7524,Costa Rica,2010,32,C02-Antihypertensives,"/capita, US$ exchange rate",0.1
7525,Costa Rica,2010,32,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
7526,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,2.9
7527,Costa Rica,2010,32,C-Cardiovascular system,"/capita, US$ exchange rate",2.0
7528,Costa Rica,2010,32,B-Blood and blood forming organs,"/capita, US$ exchange rate",4.8
7529,Costa Rica,2010,32,C10-Lipid modifying agents,Million US$ at exchange rate,3.6
7530,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0
7531,Costa Rica,2010,32,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.3
7532,Costa Rica,2010,32,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.2
7533,Costa Rica,2010,32,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.2
7534,Costa Rica,2010,32,N06A-Antidepressants,"/capita, US$ purchasing power parity",1.1
7535,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",7.1
7536,Costa Rica,2010,32,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.8
7537,Costa Rica,2010,32,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
7538,Costa Rica,2010,32,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
7539,Costa Rica,2010,32,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",7.7
7540,Costa Rica,2010,32,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.5
7541,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1
7542,Costa Rica,2010,32,A02A-Antacids,Million US$ at exchange rate,1.2
7543,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2333.6
7544,Costa Rica,2010,32,C07-Beta blocking agents,Million US$ at exchange rate,0.6
7545,Costa Rica,2010,32,A02A-Antacids,Million of national currency units,649.4
7546,Costa Rica,2010,32,B-Blood and blood forming organs,Million of national currency units,11435.7
7547,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.6
7548,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,55.7
7549,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,Million of national currency units,3327.3
7550,Costa Rica,2010,32,C10-Lipid modifying agents,Million of national currency units,1900.8
7551,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.6
7552,Costa Rica,2010,32,B-Blood and blood forming organs,Million US$ at exchange rate,21.7
7553,Costa Rica,2010,32,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
7554,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.6
7555,Costa Rica,2010,32,N05B-Anxiolytics,Million US$ at exchange rate,0.5
7556,Costa Rica,2010,32,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",1.8
7557,Costa Rica,2010,32,C07-Beta blocking agents,Million of national currency units,314.6
7558,Costa Rica,2010,32,A02A-Antacids,"/capita, US$ exchange rate",0.3
7559,Costa Rica,2010,32,C-Cardiovascular system,"Million US$, purchasing power parity",14.8
7560,Costa Rica,2010,32,C02-Antihypertensives,"Million US$, purchasing power parity",0.9
7561,Costa Rica,2010,32,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
7562,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0
7563,Costa Rica,2010,32,C03-Diuretics,"Million US$, purchasing power parity",1.5
7564,Costa Rica,2010,32,A10-Drugs used in diabetes,"Million US$, purchasing power parity",8.3
7565,Costa Rica,2010,32,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.1
7566,Costa Rica,2010,32,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",11.6
7567,Costa Rica,2010,32,N06A-Antidepressants,Million of national currency units,1617.5
7568,Costa Rica,2010,32,C07-Beta blocking agents,"/capita, US$ exchange rate",0.1
7569,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1.8
7570,Costa Rica,2010,32,N02-Analgesics,Million of national currency units,1450.0
7571,Costa Rica,2010,32,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
7572,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",10.2
7573,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.0
7574,Costa Rica,2010,32,N02-Analgesics,Million US$ at exchange rate,2.8
7575,Costa Rica,2010,32,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.5
7576,Costa Rica,2010,32,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
7577,Costa Rica,2010,32,A10-Drugs used in diabetes,Million US$ at exchange rate,5.2
7578,Costa Rica,2010,32,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.5
7579,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.5
7580,Costa Rica,2010,32,N06A-Antidepressants,Million US$ at exchange rate,3.1
7581,Costa Rica,2010,32,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.4
7582,Costa Rica,2010,32,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.4
7583,Costa Rica,2010,32,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.6
7584,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,Million of national currency units,1471.6
7585,Costa Rica,2010,32,J01-Antibacterials for systemic use,Million of national currency units,6059.1
7586,Costa Rica,2010,32,C03-Diuretics,Million US$ at exchange rate,0.9
7587,Costa Rica,2010,32,N05C-Hypnotics and sedatives,Million of national currency units,166.7
7588,Costa Rica,2010,32,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.3
7589,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1443.7
7590,Costa Rica,2010,32,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",52.7
7591,Costa Rica,2010,32,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.2
7592,Costa Rica,2010,32,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
7593,Costa Rica,2010,32,C01A-Cardiac glycosides,Million of national currency units,157.0
7594,Costa Rica,2010,32,A02A-Antacids,"Million US$, purchasing power parity",2.0
7595,Costa Rica,2010,32,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
7596,Costa Rica,2010,32,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2.7
7597,Costa Rica,2010,32,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
7598,Costa Rica,2010,32,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,2.8
7599,Costa Rica,2010,32,C03-Diuretics,Million of national currency units,488.0
7600,Costa Rica,2010,32,N05B-Anxiolytics,Million of national currency units,272.4
7601,Costa Rica,2010,32,N06A-Antidepressants,"Million US$, purchasing power parity",4.9
7602,Costa Rica,2010,32,A10-Drugs used in diabetes,Million of national currency units,2715.6
7603,Costa Rica,2010,32,C08-Calcium channel blockers,"Million US$, purchasing power parity",0.5
7604,Costa Rica,2010,32,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",2.8
7605,Costa Rica,2010,32,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.8
7606,Costa Rica,2010,32,N02-Analgesics,"/capita, US$ purchasing power parity",1.0
7607,Costa Rica,2017,27,C-Cardiovascular system,"/capita, US$ purchasing power parity",3.8
7608,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.1
7609,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,5.3
7610,Costa Rica,2017,27,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.4
7611,Costa Rica,2017,27,C07-Beta blocking agents,"Million US$, purchasing power parity",2.8
7612,Costa Rica,2017,27,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
7613,Costa Rica,2017,27,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
7614,Costa Rica,2017,27,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.7
7615,Costa Rica,2017,27,A10-Drugs used in diabetes,"/capita, US$ exchange rate",1.6
7616,Costa Rica,2017,27,C02-Antihypertensives,Million US$ at exchange rate,1.1
7617,Costa Rica,2017,27,C-Cardiovascular system,Million US$ at exchange rate,11.4
7618,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.2
7619,Costa Rica,2017,27,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.6
7620,Costa Rica,2017,27,B-Blood and blood forming organs,"Million US$, purchasing power parity",45.0
7621,Costa Rica,2017,27,C08-Calcium channel blockers,Million of national currency units,364.0
7622,Costa Rica,2017,27,N02-Analgesics,"/capita, US$ exchange rate",1.0
7623,Costa Rica,2017,27,C03-Diuretics,"/capita, US$ exchange rate",0.1
7624,Costa Rica,2017,27,C08-Calcium channel blockers,Million US$ at exchange rate,0.6
7625,Costa Rica,2017,27,N06A-Antidepressants,"/capita, US$ exchange rate",0.5
7626,Costa Rica,2017,27,C-Cardiovascular system,Million of national currency units,6494.7
7627,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1838.9
7628,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",0.9
7629,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.2
7630,Costa Rica,2017,27,C02-Antihypertensives,Million of national currency units,625.9
7631,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.6
7632,Costa Rica,2017,27,N05B-Anxiolytics,"Million US$, purchasing power parity",1.2
7633,Costa Rica,2017,27,J-Antiinfectives for systemic use,Million of national currency units,19558.1
7634,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,1901.9
7635,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.7
7636,Costa Rica,2017,27,N02-Analgesics,"Million US$, purchasing power parity",8.2
7637,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",1.8
7638,Costa Rica,2017,27,J-Antiinfectives for systemic use,Million US$ at exchange rate,34.5
7639,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.4
7640,Costa Rica,2017,27,B-Blood and blood forming organs,"/capita, US$ exchange rate",5.5
7641,Costa Rica,2017,27,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
7642,Costa Rica,2017,27,N05B-Anxiolytics,Million US$ at exchange rate,0.7
7643,Costa Rica,2017,27,C02-Antihypertensives,"/capita, US$ exchange rate",0.2
7644,Costa Rica,2017,27,C-Cardiovascular system,"/capita, US$ exchange rate",2.3
7645,Costa Rica,2017,27,C10-Lipid modifying agents,Million US$ at exchange rate,3.4
7646,Costa Rica,2017,27,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.1
7647,Costa Rica,2017,27,N06A-Antidepressants,"Million US$, purchasing power parity",4.2
7648,Costa Rica,2017,27,C07-Beta blocking agents,"/capita, US$ purchasing power parity",0.6
7649,Costa Rica,2017,27,N06A-Antidepressants,"/capita, US$ purchasing power parity",0.8
7650,Costa Rica,2017,27,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.1
7651,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",7.2
7652,Costa Rica,2017,27,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.0
7653,Costa Rica,2017,27,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
7654,Costa Rica,2017,27,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.6
7655,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.0
7656,Costa Rica,2017,27,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
7657,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.1
7658,Costa Rica,2017,27,C07-Beta blocking agents,Million US$ at exchange rate,1.7
7659,Costa Rica,2017,27,C10-Lipid modifying agents,Million of national currency units,1908.2
7660,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2446.5
7661,Costa Rica,2017,27,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",1.6
7662,Costa Rica,2017,27,B-Blood and blood forming organs,Million of national currency units,15352.6
7663,Costa Rica,2017,27,A02A-Antacids,Million of national currency units,1006.5
7664,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",0.7
7665,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",0.7
7666,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,76.7
7667,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,Million of national currency units,3015.6
7668,Costa Rica,2017,27,A02A-Antacids,Million US$ at exchange rate,1.8
7669,Costa Rica,2017,27,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",2.7
7670,Costa Rica,2017,27,B-Blood and blood forming organs,Million US$ at exchange rate,27.1
7671,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",1.5
7672,Costa Rica,2017,27,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
7673,Costa Rica,2017,27,A02A-Antacids,"/capita, US$ exchange rate",0.4
7674,Costa Rica,2017,27,C-Cardiovascular system,"Million US$, purchasing power parity",19.0
7675,Costa Rica,2017,27,C07-Beta blocking agents,Million of national currency units,941.0
7676,Costa Rica,2017,27,C03-Diuretics,"Million US$, purchasing power parity",1.2
7677,Costa Rica,2017,27,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
7678,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
7679,Costa Rica,2017,27,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",11.6
7680,Costa Rica,2017,27,A10-Drugs used in diabetes,"Million US$, purchasing power parity",13.5
7681,Costa Rica,2017,27,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.2
7682,Costa Rica,2017,27,C07-Beta blocking agents,"/capita, US$ exchange rate",0.3
7683,Costa Rica,2017,27,N06A-Antidepressants,Million of national currency units,1423.3
7684,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.2
7685,Costa Rica,2017,27,N02-Analgesics,Million of national currency units,2796.1
7686,Costa Rica,2017,27,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.6
7687,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.8
7688,Costa Rica,2017,27,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.0
7689,Costa Rica,2017,27,N02-Analgesics,Million US$ at exchange rate,4.9
7690,Costa Rica,2017,27,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.1
7691,Costa Rica,2017,27,A10-Drugs used in diabetes,Million US$ at exchange rate,8.1
7692,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.0
7693,Costa Rica,2017,27,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.9
7694,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",5.7
7695,Costa Rica,2017,27,C10-Lipid modifying agents,"/capita, US$ exchange rate",0.7
7696,Costa Rica,2017,27,N06A-Antidepressants,Million US$ at exchange rate,2.5
7697,Costa Rica,2017,27,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",1.1
7698,Costa Rica,2017,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.3
7699,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,Million of national currency units,2033.8
7700,Costa Rica,2017,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",0.7
7701,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1954.6
7702,Costa Rica,2017,27,C03-Diuretics,Million US$ at exchange rate,0.7
7703,Costa Rica,2017,27,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4
7704,Costa Rica,2017,27,N05C-Hypnotics and sedatives,Million of national currency units,212.0
7705,Costa Rica,2017,27,J01-Antibacterials for systemic use,Million of national currency units,4383.7
7706,Costa Rica,2017,27,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",57.4
7707,Costa Rica,2017,27,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
7708,Costa Rica,2017,27,C03-Diuretics,"/capita, US$ purchasing power parity",0.2
7709,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.2
7710,Costa Rica,2017,27,A02A-Antacids,"Million US$, purchasing power parity",3.0
7711,Costa Rica,2017,27,C01A-Cardiac glycosides,Million of national currency units,185.4
7712,Costa Rica,2017,27,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.4
7713,Costa Rica,2017,27,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
7714,Costa Rica,2017,27,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.6
7715,Costa Rica,2017,27,C03-Diuretics,Million of national currency units,405.0
7716,Costa Rica,2017,27,A10-Drugs used in diabetes,Million of national currency units,4591.0
7717,Costa Rica,2017,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",5.4
7718,Costa Rica,2017,27,N05B-Anxiolytics,Million of national currency units,399.9
7719,Costa Rica,2017,27,C02-Antihypertensives,"Million US$, purchasing power parity",1.8
7720,Costa Rica,2017,27,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.1
7721,Costa Rica,2017,27,N02-Analgesics,"/capita, US$ purchasing power parity",1.7
7722,Croatia,2016,7,C07-Beta blocking agents,Million US$ at exchange rate,94.1
7723,Croatia,2016,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,36.5
7724,Croatia,2016,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",859.9
7725,Croatia,2016,7,N-Nervous system,"/capita, US$ exchange rate",225.3
7726,Croatia,2016,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",383.2
7727,Croatia,2016,7,A02A-Antacids,"/capita, US$ exchange rate",2.7
7728,Croatia,2016,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",218.3
7729,Croatia,2016,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",118.3
7730,Croatia,2016,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1724.3
7731,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",4.2
7732,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,116.2
7733,Croatia,2016,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",23.0
7734,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,16.0
7735,Croatia,2016,7,C07-Beta blocking agents,Million of national currency units,85.0
7736,Croatia,2016,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",260.0
7737,Croatia,2016,7,A02A-Antacids,Million of national currency units,10.0
7738,Croatia,2016,7,R-Respiratory system,"Million US$, purchasing power parity",802.0
7739,Croatia,2016,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",58.1
7740,Croatia,2016,7,Total pharmaceutical sales,Million US$ at exchange rate,6424.2
7741,Croatia,2016,7,N02-Analgesics,Million US$ at exchange rate,203.7
7742,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,124.0
7743,Croatia,2016,7,N05B-Anxiolytics,"Million US$, purchasing power parity",205.0
7744,Croatia,2016,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",39.0
7745,Croatia,2016,7,C-Cardiovascular system,Million of national currency units,777.0
7746,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",294.1
7747,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,112.0
7748,Croatia,2016,7,N05C-Hypnotics and sedatives,Million of national currency units,33.0
7749,Croatia,2016,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1084.9
7750,Croatia,2016,7,N-Nervous system,Million of national currency units,849.0
7751,Croatia,2016,7,B-Blood and blood forming organs,Million of national currency units,446.0
7752,Croatia,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",91.8
7753,Croatia,2016,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",52.3
7754,Croatia,2016,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",43.8
7755,Croatia,2016,7,N02-Analgesics,Million of national currency units,184.0
7756,Croatia,2016,7,N06A-Antidepressants,Million of national currency units,82.0
7757,Croatia,2016,7,C02-Antihypertensives,Million of national currency units,43.0
7758,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",728.5
7759,Croatia,2016,7,C10-Lipid modifying agents,Million of national currency units,147.0
7760,Croatia,2016,7,R03-Drugs for obstructive airway diseases,Million of national currency units,219.0
7761,Croatia,2016,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.7
7762,Croatia,2016,7,B-Blood and blood forming organs,Million US$ at exchange rate,493.7
7763,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",135.9
7764,Croatia,2016,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",57.6
7765,Croatia,2016,7,N06A-Antidepressants,Million US$ at exchange rate,90.8
7766,Croatia,2016,7,C03-Diuretics,"Million US$, purchasing power parity",115.8
7767,Croatia,2016,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",49.1
7768,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",86.8
7769,Croatia,2016,7,A02A-Antacids,Million US$ at exchange rate,11.1
7770,Croatia,2016,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",3098.4
7771,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,17.7
7772,Croatia,2016,7,M-Musculo-skeletal system,Million of national currency units,217.0
7773,Croatia,2016,7,C02-Antihypertensives,"Million US$, purchasing power parity",95.8
7774,Croatia,2016,7,N-Nervous system,Million US$ at exchange rate,939.9
7775,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.2
7776,Croatia,2016,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.8
7777,Croatia,2016,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",206.1
7778,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",27.9
7779,Croatia,2016,7,N02-Analgesics,"/capita, US$ purchasing power parity",98.2
7780,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",70.5
7781,Croatia,2016,7,C02-Antihypertensives,Million US$ at exchange rate,47.6
7782,Croatia,2016,7,R-Respiratory system,"/capita, US$ purchasing power parity",192.2
7783,Croatia,2016,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",413.3
7784,Croatia,2016,7,C-Cardiovascular system,Million US$ at exchange rate,860.2
7785,Croatia,2016,7,Total pharmaceutical sales,"/capita, US$ exchange rate",1539.7
7786,Croatia,2016,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",115.9
7787,Croatia,2016,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,242.4
7788,Croatia,2016,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",414.9
7789,Croatia,2016,7,C10-Lipid modifying agents,Million US$ at exchange rate,162.7
7790,Croatia,2016,7,Total pharmaceutical sales,Million of national currency units,5803.0
7791,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",59.8
7792,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,105.0
7793,Croatia,2016,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",79.9
7794,Croatia,2016,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",238.1
7795,Croatia,2016,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",327.5
7796,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,362.0
7797,Croatia,2016,7,A02A-Antacids,"/capita, US$ purchasing power parity",5.3
7798,Croatia,2016,7,C03-Diuretics,Million US$ at exchange rate,57.6
7799,Croatia,2016,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",102.4
7800,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.6
7801,Croatia,2016,7,A10-Drugs used in diabetes,% of total sales,6.7
7802,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.1
7803,Croatia,2016,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",129.2
7804,Croatia,2016,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",116.9
7805,Croatia,2016,7,C01A-Cardiac glycosides,Million US$ at exchange rate,5.5
7806,Croatia,2016,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",205.4
7807,Croatia,2016,7,N02-Analgesics,"Million US$, purchasing power parity",409.9
7808,Croatia,2016,7,C08-Calcium channel blockers,Million of national currency units,98.0
7809,Croatia,2016,7,C03-Diuretics,"/capita, US$ exchange rate",13.8
7810,Croatia,2016,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",45.4
7811,Croatia,2016,7,C-Cardiovascular system,"Million US$, purchasing power parity",1731.0
7812,Croatia,2016,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,333.2
7813,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.5
7814,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",233.9
7815,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",35.0
7816,Croatia,2016,7,N05B-Anxiolytics,"/capita, US$ exchange rate",24.4
7817,Croatia,2016,7,G-Genito urinary system and sex hormones,Million of national currency units,172.0
7818,Croatia,2016,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",17.6
7819,Croatia,2016,7,M-Musculo-skeletal system,% of total sales,3.7
7820,Croatia,2016,7,C10-Lipid modifying agents,% of total sales,2.5
7821,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
7822,Croatia,2016,7,C-Cardiovascular system,% of total sales,13.4
7823,Croatia,2016,7,N06A-Antidepressants,% of total sales,1.4
7824,Croatia,2016,7,N02-Analgesics,% of total sales,3.2
7825,Croatia,2016,7,C02-Antihypertensives,% of total sales,0.7
7826,Croatia,2016,7,C08-Calcium channel blockers,% of total sales,1.7
7827,Croatia,2016,7,G-Genito urinary system and sex hormones,% of total sales,3.0
7828,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3
7829,Croatia,2016,7,A-Alimentary tract and metabolism,% of total sales,13.3
7830,Croatia,2016,7,J-Antiinfectives for systemic use,% of total sales,8.4
7831,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9
7832,Croatia,2016,7,R-Respiratory system,% of total sales,6.2
7833,Croatia,2016,7,B-Blood and blood forming organs,% of total sales,7.7
7834,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
7835,Croatia,2016,7,N05B-Anxiolytics,% of total sales,1.6
7836,Croatia,2016,7,C01A-Cardiac glycosides,% of total sales,0.1
7837,Croatia,2016,7,C03-Diuretics,% of total sales,0.9
7838,Croatia,2016,7,N05C-Hypnotics and sedatives,% of total sales,0.6
7839,Croatia,2016,7,J01-Antibacterials for systemic use,% of total sales,5.2
7840,Croatia,2016,7,N-Nervous system,% of total sales,14.6
7841,Croatia,2016,7,C07-Beta blocking agents,% of total sales,1.5
7842,Croatia,2016,7,R03-Drugs for obstructive airway diseases,% of total sales,3.8
7843,Croatia,2016,7,N05B-Anxiolytics,Million of national currency units,92.0
7844,Croatia,2016,7,A02A-Antacids,% of total sales,0.2
7845,Croatia,2016,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",35.6
7846,Croatia,2016,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",26.0
7847,Croatia,2016,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",73.5
7848,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",32.6
7849,Croatia,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",45.6
7850,Croatia,2016,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",993.6
7851,Croatia,2016,7,N05B-Anxiolytics,Million US$ at exchange rate,101.8
7852,Croatia,2016,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,190.4
7853,Croatia,2016,7,N06A-Antidepressants,"/capita, US$ exchange rate",21.8
7854,Croatia,2016,7,N02-Analgesics,"/capita, US$ exchange rate",48.8
7855,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,146.1
7856,Croatia,2016,7,C02-Antihypertensives,"/capita, US$ exchange rate",11.4
7857,Croatia,2016,7,A10-Drugs used in diabetes,Million US$ at exchange rate,427.3
7858,Croatia,2016,7,N-Nervous system,"/capita, US$ purchasing power parity",453.3
7859,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,327.0
7860,Croatia,2016,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",487.9
7861,Croatia,2016,7,C07-Beta blocking agents,"/capita, US$ exchange rate",22.6
7862,Croatia,2016,7,M-Musculo-skeletal system,Million US$ at exchange rate,240.2
7863,Croatia,2016,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",11.1
7864,Croatia,2016,7,R-Respiratory system,Million US$ at exchange rate,398.5
7865,Croatia,2016,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",160.7
7866,Croatia,2016,7,J01-Antibacterials for systemic use,Million of national currency units,301.0
7867,Croatia,2016,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,856.8
7868,Croatia,2016,7,C07-Beta blocking agents,"Million US$, purchasing power parity",189.4
7869,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,61.0
7870,Croatia,2016,7,Total pharmaceutical sales,"Million US$, purchasing power parity",12928.0
7871,Croatia,2016,7,J-Antiinfectives for systemic use,Million of national currency units,487.0
7872,Croatia,2016,7,A-Alimentary tract and metabolism,Million of national currency units,774.0
7873,Croatia,2016,7,N06A-Antidepressants,"Million US$, purchasing power parity",182.7
7874,Croatia,2016,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,67.5
7875,Croatia,2016,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.3
7876,Croatia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",56.1
7877,Croatia,2016,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",78.5
7878,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",249.5
7879,Croatia,2016,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",483.4
7880,Croatia,2016,7,A10-Drugs used in diabetes,Million of national currency units,386.0
7881,Croatia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,132.0
7882,Croatia,2016,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",670.6
7883,Croatia,2016,7,A02A-Antacids,"Million US$, purchasing power parity",22.3
7884,Croatia,2016,7,C01A-Cardiac glycosides,Million of national currency units,5.0
7885,Croatia,2016,7,C-Cardiovascular system,"/capita, US$ exchange rate",206.2
7886,Croatia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",29.7
7887,Croatia,2016,7,C08-Calcium channel blockers,Million US$ at exchange rate,108.5
7888,Croatia,2016,7,C03-Diuretics,"/capita, US$ purchasing power parity",27.8
7889,Croatia,2016,7,C03-Diuretics,Million of national currency units,52.0
7890,Croatia,2016,7,R-Respiratory system,"/capita, US$ exchange rate",95.5
7891,Croatia,2016,7,R-Respiratory system,Million of national currency units,360.0
7892,Croatia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",174.6
7893,Croatia,2016,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,539.1
7894,Croatia,2016,7,N-Nervous system,"Million US$, purchasing power parity",1891.4
7895,Croatia,2015,8,C07-Beta blocking agents,Million US$ at exchange rate,97.8
7896,Croatia,2015,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",25.0
7897,Croatia,2015,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",737.9
7898,Croatia,2015,8,N-Nervous system,"/capita, US$ exchange rate",212.0
7899,Croatia,2015,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",353.9
7900,Croatia,2015,8,A02A-Antacids,"/capita, US$ exchange rate",2.6
7901,Croatia,2015,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",218.8
7902,Croatia,2015,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",92.7
7903,Croatia,2015,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1544.5
7904,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",4.4
7905,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,106.6
7906,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0
7907,Croatia,2015,8,C07-Beta blocking agents,Million of national currency units,89.0
7908,Croatia,2015,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",209.5
7909,Croatia,2015,8,A02A-Antacids,Million of national currency units,10.0
7910,Croatia,2015,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",56.7
7911,Croatia,2015,8,R-Respiratory system,"Million US$, purchasing power parity",746.5
7912,Croatia,2015,8,Total pharmaceutical sales,Million US$ at exchange rate,5786.3
7913,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,125.2
7914,Croatia,2015,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",43.3
7915,Croatia,2015,8,C-Cardiovascular system,Million of national currency units,782.0
7916,Croatia,2015,8,N05B-Anxiolytics,"Million US$, purchasing power parity",195.2
7917,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,114.0
7918,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",276.7
7919,Croatia,2015,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",881.6
7920,Croatia,2015,8,N-Nervous system,Million of national currency units,812.0
7921,Croatia,2015,8,B-Blood and blood forming organs,Million of national currency units,355.0
7922,Croatia,2015,8,N02-Analgesics,Million US$ at exchange rate,205.4
7923,Croatia,2015,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",52.0
7924,Croatia,2015,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",84.1
7925,Croatia,2015,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",41.3
7926,Croatia,2015,8,N02-Analgesics,Million of national currency units,187.0
7927,Croatia,2015,8,N06A-Antidepressants,Million of national currency units,81.0
7928,Croatia,2015,8,C02-Antihypertensives,Million of national currency units,49.0
7929,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",682.2
7930,Croatia,2015,8,C10-Lipid modifying agents,Million of national currency units,166.0
7931,Croatia,2015,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.5
7932,Croatia,2015,8,B-Blood and blood forming organs,Million US$ at exchange rate,390.0
7933,Croatia,2015,8,R03-Drugs for obstructive airway diseases,Million of national currency units,217.0
7934,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",135.1
7935,Croatia,2015,8,N06A-Antidepressants,Million US$ at exchange rate,89.0
7936,Croatia,2015,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",53.3
7937,Croatia,2015,8,C03-Diuretics,"Million US$, purchasing power parity",103.0
7938,Croatia,2015,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",46.4
7939,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",83.0
7940,Croatia,2015,8,A02A-Antacids,Million US$ at exchange rate,11.0
7941,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,18.7
7942,Croatia,2015,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,34.1
7943,Croatia,2015,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2685.0
7944,Croatia,2015,8,M-Musculo-skeletal system,Million of national currency units,204.0
7945,Croatia,2015,8,C02-Antihypertensives,"Million US$, purchasing power parity",105.1
7946,Croatia,2015,8,N-Nervous system,Million US$ at exchange rate,892.1
7947,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.4
7948,Croatia,2015,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",175.4
7949,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",25.3
7950,Croatia,2015,8,N02-Analgesics,"/capita, US$ purchasing power parity",95.3
7951,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",65.8
7952,Croatia,2015,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",367.0
7953,Croatia,2015,8,C02-Antihypertensives,Million US$ at exchange rate,53.8
7954,Croatia,2015,8,R-Respiratory system,"/capita, US$ purchasing power parity",177.4
7955,Croatia,2015,8,C-Cardiovascular system,Million US$ at exchange rate,859.1
7956,Croatia,2015,8,Total pharmaceutical sales,"/capita, US$ exchange rate",1375.1
7957,Croatia,2015,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",104.0
7958,Croatia,2015,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,238.4
7959,Croatia,2015,8,C10-Lipid modifying agents,Million US$ at exchange rate,182.4
7960,Croatia,2015,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.1
7961,Croatia,2015,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",398.6
7962,Croatia,2015,8,Total pharmaceutical sales,Million of national currency units,5267.0
7963,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",58.1
7964,Croatia,2015,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",77.5
7965,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,97.0
7966,Croatia,2015,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",181.0
7967,Croatia,2015,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",356.1
7968,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,349.4
7969,Croatia,2015,8,A02A-Antacids,"/capita, US$ purchasing power parity",5.1
7970,Croatia,2015,8,C03-Diuretics,Million US$ at exchange rate,52.7
7971,Croatia,2015,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",89.8
7972,Croatia,2015,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",107.3
7973,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0
7974,Croatia,2015,8,A10-Drugs used in diabetes,% of total sales,6.5
7975,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
7976,Croatia,2015,8,C01A-Cardiac glycosides,Million US$ at exchange rate,5.5
7977,Croatia,2015,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",110.6
7978,Croatia,2015,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",188.0
7979,Croatia,2015,8,N02-Analgesics,"Million US$, purchasing power parity",401.1
7980,Croatia,2015,8,C03-Diuretics,"/capita, US$ exchange rate",12.5
7981,Croatia,2015,8,C08-Calcium channel blockers,Million of national currency units,102.0
7982,Croatia,2015,8,C-Cardiovascular system,"Million US$, purchasing power parity",1677.5
7983,Croatia,2015,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",45.4
7984,Croatia,2015,8,N05B-Anxiolytics,Million of national currency units,91.0
7985,Croatia,2015,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,326.3
7986,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.7
7987,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",33.7
7988,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",208.1
7989,Croatia,2015,8,N05B-Anxiolytics,"/capita, US$ exchange rate",23.8
7990,Croatia,2015,8,G-Genito urinary system and sex hormones,Million of national currency units,165.0
7991,Croatia,2015,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",15.8
7992,Croatia,2015,8,M-Musculo-skeletal system,% of total sales,3.9
7993,Croatia,2015,8,C10-Lipid modifying agents,% of total sales,3.2
7994,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
7995,Croatia,2015,8,N06A-Antidepressants,% of total sales,1.5
7996,Croatia,2015,8,C-Cardiovascular system,% of total sales,14.8
7997,Croatia,2015,8,N02-Analgesics,% of total sales,3.6
7998,Croatia,2015,8,C02-Antihypertensives,% of total sales,0.9
7999,Croatia,2015,8,C08-Calcium channel blockers,% of total sales,1.9
8000,Croatia,2015,8,G-Genito urinary system and sex hormones,% of total sales,3.1
8001,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4
8002,Croatia,2015,8,J-Antiinfectives for systemic use,% of total sales,7.8
8003,Croatia,2015,8,A-Alimentary tract and metabolism,% of total sales,13.7
8004,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.2
8005,Croatia,2015,8,R-Respiratory system,% of total sales,6.6
8006,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
8007,Croatia,2015,8,B-Blood and blood forming organs,% of total sales,6.7
8008,Croatia,2015,8,N05B-Anxiolytics,% of total sales,1.7
8009,Croatia,2015,8,C03-Diuretics,% of total sales,0.9
8010,Croatia,2015,8,C01A-Cardiac glycosides,% of total sales,0.1
8011,Croatia,2015,8,N05C-Hypnotics and sedatives,% of total sales,0.6
8012,Croatia,2015,8,J01-Antibacterials for systemic use,% of total sales,5.6
8013,Croatia,2015,8,N-Nervous system,% of total sales,15.4
8014,Croatia,2015,8,R03-Drugs for obstructive airway diseases,% of total sales,4.1
8015,Croatia,2015,8,C07-Beta blocking agents,% of total sales,1.7
8016,Croatia,2015,8,A02A-Antacids,% of total sales,0.2
8017,Croatia,2015,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",36.5
8018,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",32.1
8019,Croatia,2015,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",26.6
8020,Croatia,2015,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",43.1
8021,Croatia,2015,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",761.5
8022,Croatia,2015,8,N05B-Anxiolytics,Million US$ at exchange rate,100.0
8023,Croatia,2015,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",66.5
8024,Croatia,2015,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,181.3
8025,Croatia,2015,8,N02-Analgesics,"/capita, US$ exchange rate",48.8
8026,Croatia,2015,8,N06A-Antidepressants,"/capita, US$ exchange rate",21.1
8027,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,141.7
8028,Croatia,2015,8,C02-Antihypertensives,"/capita, US$ exchange rate",12.8
8029,Croatia,2015,8,A10-Drugs used in diabetes,Million US$ at exchange rate,377.9
8030,Croatia,2015,8,N-Nervous system,"/capita, US$ purchasing power parity",413.9
8031,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,318.0
8032,Croatia,2015,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",465.5
8033,Croatia,2015,8,M-Musculo-skeletal system,Million US$ at exchange rate,224.1
8034,Croatia,2015,8,C07-Beta blocking agents,"/capita, US$ exchange rate",23.2
8035,Croatia,2015,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",10.7
8036,Croatia,2015,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",151.4
8037,Croatia,2015,8,R-Respiratory system,Million US$ at exchange rate,382.3
8038,Croatia,2015,8,J01-Antibacterials for systemic use,Million of national currency units,297.0
8039,Croatia,2015,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,791.0
8040,Croatia,2015,8,C07-Beta blocking agents,"Million US$, purchasing power parity",190.9
8041,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,63.0
8042,Croatia,2015,8,N05C-Hypnotics and sedatives,Million of national currency units,31.0
8043,Croatia,2015,8,Total pharmaceutical sales,"Million US$, purchasing power parity",11298.4
8044,Croatia,2015,8,A-Alimentary tract and metabolism,Million of national currency units,720.0
8045,Croatia,2015,8,J-Antiinfectives for systemic use,Million of national currency units,411.0
8046,Croatia,2015,8,N06A-Antidepressants,"Million US$, purchasing power parity",173.8
8047,Croatia,2015,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,69.2
8048,Croatia,2015,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.3
8049,Croatia,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",49.4
8050,Croatia,2015,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",84.6
8051,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",244.5
8052,Croatia,2015,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",437.6
8053,Croatia,2015,8,A10-Drugs used in diabetes,Million of national currency units,344.0
8054,Croatia,2015,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,129.0
8055,Croatia,2015,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",637.1
8056,Croatia,2015,8,A02A-Antacids,"Million US$, purchasing power parity",21.5
8057,Croatia,2015,8,C01A-Cardiac glycosides,Million of national currency units,5.0
8058,Croatia,2015,8,C-Cardiovascular system,"/capita, US$ exchange rate",204.2
8059,Croatia,2015,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",29.8
8060,Croatia,2015,8,C08-Calcium channel blockers,Million US$ at exchange rate,112.1
8061,Croatia,2015,8,C03-Diuretics,Million of national currency units,48.0
8062,Croatia,2015,8,R-Respiratory system,"/capita, US$ exchange rate",90.9
8063,Croatia,2015,8,R-Respiratory system,Million of national currency units,348.0
8064,Croatia,2015,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",162.1
8065,Croatia,2015,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,451.5
8066,Croatia,2015,8,C03-Diuretics,"/capita, US$ purchasing power parity",24.5
8067,Croatia,2015,8,N-Nervous system,"Million US$, purchasing power parity",1741.8
8068,Croatia,2014,8,C07-Beta blocking agents,Million US$ at exchange rate,119.3
8069,Croatia,2014,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",26.1
8070,Croatia,2014,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",674.0
8071,Croatia,2014,8,N-Nervous system,"/capita, US$ exchange rate",246.0
8072,Croatia,2014,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",340.2
8073,Croatia,2014,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",93.8
8074,Croatia,2014,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1471.4
8075,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",5.0
8076,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,118.0
8077,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,16.0
8078,Croatia,2014,8,C07-Beta blocking agents,Million of national currency units,91.0
8079,Croatia,2014,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",204.8
8080,Croatia,2014,8,A02A-Antacids,Million of national currency units,10.0
8081,Croatia,2014,8,R-Respiratory system,"Million US$, purchasing power parity",686.8
8082,Croatia,2014,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",65.3
8083,Croatia,2014,8,Total pharmaceutical sales,Million US$ at exchange rate,6561.7
8084,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,165.2
8085,Croatia,2014,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",45.8
8086,Croatia,2014,8,C-Cardiovascular system,Million of national currency units,778.0
8087,Croatia,2014,8,N-Nervous system,Million of national currency units,795.0
8088,Croatia,2014,8,N05B-Anxiolytics,"Million US$, purchasing power parity",191.4
8089,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,126.0
8090,Croatia,2014,8,A02A-Antacids,"/capita, US$ exchange rate",3.1
8091,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",267.9
8092,Croatia,2014,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",867.5
8093,Croatia,2014,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",57.2
8094,Croatia,2014,8,B-Blood and blood forming organs,Million of national currency units,303.0
8095,Croatia,2014,8,N02-Analgesics,Million US$ at exchange rate,242.5
8096,Croatia,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",80.3
8097,Croatia,2014,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",41.2
8098,Croatia,2014,8,N02-Analgesics,Million of national currency units,185.0
8099,Croatia,2014,8,N06A-Antidepressants,Million of national currency units,82.0
8100,Croatia,2014,8,C02-Antihypertensives,Million of national currency units,52.0
8101,Croatia,2014,8,R-Respiratory system,"/capita, US$ purchasing power parity",162.1
8102,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",686.8
8103,Croatia,2014,8,C10-Lipid modifying agents,Million of national currency units,148.0
8104,Croatia,2014,8,B-Blood and blood forming organs,Million US$ at exchange rate,397.2
8105,Croatia,2014,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.5
8106,Croatia,2014,8,R03-Drugs for obstructive airway diseases,Million of national currency units,211.0
8107,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",129.7
8108,Croatia,2014,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",61.6
8109,Croatia,2014,8,C03-Diuretics,"Million US$, purchasing power parity",95.7
8110,Croatia,2014,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",45.2
8111,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",99.9
8112,Croatia,2014,8,A02A-Antacids,Million US$ at exchange rate,13.1
8113,Croatia,2014,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,39.3
8114,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.0
8115,Croatia,2014,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2512.8
8116,Croatia,2014,8,M-Musculo-skeletal system,Million of national currency units,199.0
8117,Croatia,2014,8,C02-Antihypertensives,"Million US$, purchasing power parity",110.6
8118,Croatia,2014,8,N-Nervous system,Million US$ at exchange rate,1042.1
8119,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",18.9
8120,Croatia,2014,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",159.1
8121,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",27.8
8122,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",63.2
8123,Croatia,2014,8,N02-Analgesics,"/capita, US$ purchasing power parity",92.9
8124,Croatia,2014,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",242.4
8125,Croatia,2014,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",347.3
8126,Croatia,2014,8,C02-Antihypertensives,Million US$ at exchange rate,68.2
8127,Croatia,2014,8,C-Cardiovascular system,Million US$ at exchange rate,1019.8
8128,Croatia,2014,8,Total pharmaceutical sales,"/capita, US$ exchange rate",1549.0
8129,Croatia,2014,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",99.9
8130,Croatia,2014,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,276.6
8131,Croatia,2014,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.3
8132,Croatia,2014,8,C10-Lipid modifying agents,Million US$ at exchange rate,194.0
8133,Croatia,2014,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",390.5
8134,Croatia,2014,8,Total pharmaceutical sales,Million of national currency units,5006.0
8135,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",63.2
8136,Croatia,2014,8,N06A-Antidepressants,Million US$ at exchange rate,107.5
8137,Croatia,2014,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",89.1
8138,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,90.0
8139,Croatia,2014,8,N05C-Hypnotics and sedatives,Million of national currency units,30.0
8140,Croatia,2014,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",152.1
8141,Croatia,2014,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",314.7
8142,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,423.4
8143,Croatia,2014,8,A02A-Antacids,"/capita, US$ purchasing power parity",5.0
8144,Croatia,2014,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",98.1
8145,Croatia,2014,8,C03-Diuretics,Million US$ at exchange rate,59.0
8146,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.5
8147,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
8148,Croatia,2014,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",105.9
8149,Croatia,2014,8,C01A-Cardiac glycosides,Million US$ at exchange rate,6.6
8150,Croatia,2014,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",126.2
8151,Croatia,2014,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",214.1
8152,Croatia,2014,8,A10-Drugs used in diabetes,% of total sales,6.3
8153,Croatia,2014,8,N02-Analgesics,"Million US$, purchasing power parity",393.4
8154,Croatia,2014,8,C-Cardiovascular system,"Million US$, purchasing power parity",1654.3
8155,Croatia,2014,8,C03-Diuretics,"/capita, US$ exchange rate",13.9
8156,Croatia,2014,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",45.7
8157,Croatia,2014,8,N05B-Anxiolytics,Million of national currency units,90.0
8158,Croatia,2014,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,377.5
8159,Croatia,2014,8,C08-Calcium channel blockers,Million of national currency units,114.0
8160,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.0
8161,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",191.4
8162,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",39.0
8163,Croatia,2014,8,N05B-Anxiolytics,"/capita, US$ exchange rate",27.8
8164,Croatia,2014,8,G-Genito urinary system and sex hormones,Million of national currency units,160.0
8165,Croatia,2014,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",15.1
8166,Croatia,2014,8,M-Musculo-skeletal system,% of total sales,4.0
8167,Croatia,2014,8,C10-Lipid modifying agents,% of total sales,3.0
8168,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
8169,Croatia,2014,8,C-Cardiovascular system,% of total sales,15.5
8170,Croatia,2014,8,N06A-Antidepressants,% of total sales,1.6
8171,Croatia,2014,8,N02-Analgesics,% of total sales,3.7
8172,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5
8173,Croatia,2014,8,C02-Antihypertensives,% of total sales,1.0
8174,Croatia,2014,8,G-Genito urinary system and sex hormones,% of total sales,3.2
8175,Croatia,2014,8,C08-Calcium channel blockers,% of total sales,2.3
8176,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.5
8177,Croatia,2014,8,A-Alimentary tract and metabolism,% of total sales,13.8
8178,Croatia,2014,8,J-Antiinfectives for systemic use,% of total sales,8.2
8179,Croatia,2014,8,R-Respiratory system,% of total sales,6.5
8180,Croatia,2014,8,B-Blood and blood forming organs,% of total sales,6.1
8181,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
8182,Croatia,2014,8,N05B-Anxiolytics,% of total sales,1.8
8183,Croatia,2014,8,C03-Diuretics,% of total sales,0.9
8184,Croatia,2014,8,C01A-Cardiac glycosides,% of total sales,0.1
8185,Croatia,2014,8,N05C-Hypnotics and sedatives,% of total sales,0.6
8186,Croatia,2014,8,J01-Antibacterials for systemic use,% of total sales,5.8
8187,Croatia,2014,8,N-Nervous system,% of total sales,15.9
8188,Croatia,2014,8,R03-Drugs for obstructive airway diseases,% of total sales,4.2
8189,Croatia,2014,8,C07-Beta blocking agents,% of total sales,1.8
8190,Croatia,2014,8,A02A-Antacids,% of total sales,0.2
8191,Croatia,2014,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",34.0
8192,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",30.6
8193,Croatia,2014,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",35.3
8194,Croatia,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",49.5
8195,Croatia,2014,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",644.3
8196,Croatia,2014,8,N05B-Anxiolytics,Million US$ at exchange rate,118.0
8197,Croatia,2014,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,209.7
8198,Croatia,2014,8,N02-Analgesics,"/capita, US$ exchange rate",57.2
8199,Croatia,2014,8,N06A-Antidepressants,"/capita, US$ exchange rate",25.4
8200,Croatia,2014,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",63.8
8201,Croatia,2014,8,C02-Antihypertensives,"/capita, US$ exchange rate",16.1
8202,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,165.2
8203,Croatia,2014,8,A10-Drugs used in diabetes,Million US$ at exchange rate,415.5
8204,Croatia,2014,8,N-Nervous system,"/capita, US$ purchasing power parity",399.0
8205,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,323.0
8206,Croatia,2014,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",448.6
8207,Croatia,2014,8,C07-Beta blocking agents,"/capita, US$ exchange rate",28.2
8208,Croatia,2014,8,M-Musculo-skeletal system,Million US$ at exchange rate,260.8
8209,Croatia,2014,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",10.6
8210,Croatia,2014,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",144.6
8211,Croatia,2014,8,R-Respiratory system,Million US$ at exchange rate,423.4
8212,Croatia,2014,8,J01-Antibacterials for systemic use,Million of national currency units,288.0
8213,Croatia,2014,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,907.0
8214,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,61.0
8215,Croatia,2014,8,C07-Beta blocking agents,"Million US$, purchasing power parity",193.5
8216,Croatia,2014,8,Total pharmaceutical sales,"Million US$, purchasing power parity",10644.2
8217,Croatia,2014,8,J-Antiinfectives for systemic use,Million of national currency units,408.0
8218,Croatia,2014,8,A-Alimentary tract and metabolism,Million of national currency units,692.0
8219,Croatia,2014,8,N06A-Antidepressants,"Million US$, purchasing power parity",174.4
8220,Croatia,2014,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,80.0
8221,Croatia,2014,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.5
8222,Croatia,2014,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",74.3
8223,Croatia,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",45.2
8224,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",267.9
8225,Croatia,2014,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",423.1
8226,Croatia,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,126.0
8227,Croatia,2014,8,A10-Drugs used in diabetes,Million of national currency units,317.0
8228,Croatia,2014,8,R-Respiratory system,"/capita, US$ exchange rate",99.9
8229,Croatia,2014,8,A02A-Antacids,"Million US$, purchasing power parity",21.3
8230,Croatia,2014,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",612.4
8231,Croatia,2014,8,C01A-Cardiac glycosides,Million of national currency units,5.0
8232,Croatia,2014,8,C-Cardiovascular system,"/capita, US$ exchange rate",240.7
8233,Croatia,2014,8,C08-Calcium channel blockers,Million US$ at exchange rate,149.4
8234,Croatia,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",39.0
8235,Croatia,2014,8,C03-Diuretics,Million of national currency units,45.0
8236,Croatia,2014,8,R-Respiratory system,Million of national currency units,323.0
8237,Croatia,2014,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",162.1
8238,Croatia,2014,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,534.8
8239,Croatia,2014,8,C03-Diuretics,"/capita, US$ purchasing power parity",22.6
8240,Croatia,2014,8,N-Nervous system,"Million US$, purchasing power parity",1690.4
8241,Croatia,2013,9,C07-Beta blocking agents,Million US$ at exchange rate,124.1
8242,Croatia,2013,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",26.3
8243,Croatia,2013,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",636.5
8244,Croatia,2013,9,N-Nervous system,"/capita, US$ exchange rate",251.8
8245,Croatia,2013,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",339.3
8246,Croatia,2013,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",89.1
8247,Croatia,2013,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1502.6
8248,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",5.6
8249,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,117.5
8250,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,18.0
8251,Croatia,2013,9,C07-Beta blocking agents,Million of national currency units,94.0
8252,Croatia,2013,9,R-Respiratory system,"Million US$, purchasing power parity",699.7
8253,Croatia,2013,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",212.5
8254,Croatia,2013,9,A02A-Antacids,Million of national currency units,9.0
8255,Croatia,2013,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",63.6
8256,Croatia,2013,9,Total pharmaceutical sales,Million US$ at exchange rate,6845.2
8257,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,215.3
8258,Croatia,2013,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",69.5
8259,Croatia,2013,9,C-Cardiovascular system,Million of national currency units,946.0
8260,Croatia,2013,9,N-Nervous system,Million of national currency units,811.0
8261,Croatia,2013,9,N05B-Anxiolytics,"Million US$, purchasing power parity",185.5
8262,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,163.0
8263,Croatia,2013,9,A02A-Antacids,"/capita, US$ exchange rate",2.8
8264,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",248.7
8265,Croatia,2013,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",904.1
8266,Croatia,2013,9,B-Blood and blood forming organs,Million of national currency units,287.0
8267,Croatia,2013,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",60.9
8268,Croatia,2013,9,N02-Analgesics,Million US$ at exchange rate,249.6
8269,Croatia,2013,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",79.8
8270,Croatia,2013,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",41.6
8271,Croatia,2013,9,N02-Analgesics,Million of national currency units,189.0
8272,Croatia,2013,9,N06A-Antidepressants,Million of national currency units,84.0
8273,Croatia,2013,9,C02-Antihypertensives,Million of national currency units,53.0
8274,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",687.0
8275,Croatia,2013,9,C10-Lipid modifying agents,Million of national currency units,224.0
8276,Croatia,2013,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.0
8277,Croatia,2013,9,B-Blood and blood forming organs,Million US$ at exchange rate,379.0
8278,Croatia,2013,9,R03-Drugs for obstructive airway diseases,Million of national currency units,205.0
8279,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",130.7
8280,Croatia,2013,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",64.6
8281,Croatia,2013,9,C03-Diuretics,"Million US$, purchasing power parity",92.7
8282,Croatia,2013,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",43.6
8283,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",101.2
8284,Croatia,2013,9,A02A-Antacids,Million US$ at exchange rate,11.9
8285,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,23.8
8286,Croatia,2013,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,38.3
8287,Croatia,2013,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2567.4
8288,Croatia,2013,9,M-Musculo-skeletal system,Million of national currency units,208.0
8289,Croatia,2013,9,C02-Antihypertensives,"Million US$, purchasing power parity",111.7
8290,Croatia,2013,9,N-Nervous system,Million US$ at exchange rate,1071.1
8291,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.2
8292,Croatia,2013,9,R-Respiratory system,"/capita, US$ purchasing power parity",164.5
8293,Croatia,2013,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",149.6
8294,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",27.6
8295,Croatia,2013,9,N02-Analgesics,"/capita, US$ purchasing power parity",93.6
8296,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",58.5
8297,Croatia,2013,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",259.2
8298,Croatia,2013,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",353.2
8299,Croatia,2013,9,C02-Antihypertensives,Million US$ at exchange rate,70.0
8300,Croatia,2013,9,C-Cardiovascular system,Million US$ at exchange rate,1249.4
8301,Croatia,2013,9,Total pharmaceutical sales,"/capita, US$ exchange rate",1609.0
8302,Croatia,2013,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",103.0
8303,Croatia,2013,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,270.7
8304,Croatia,2013,9,C10-Lipid modifying agents,Million US$ at exchange rate,295.8
8305,Croatia,2013,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.0
8306,Croatia,2013,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",468.6
8307,Croatia,2013,9,Total pharmaceutical sales,Million of national currency units,5183.0
8308,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",80.7
8309,Croatia,2013,9,N06A-Antidepressants,Million US$ at exchange rate,110.9
8310,Croatia,2013,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",91.6
8311,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,89.0
8312,Croatia,2013,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",472.1
8313,Croatia,2013,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",142.2
8314,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,430.6
8315,Croatia,2013,9,A02A-Antacids,"/capita, US$ purchasing power parity",4.5
8316,Croatia,2013,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",93.7
8317,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3
8318,Croatia,2013,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",101.5
8319,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
8320,Croatia,2013,9,C01A-Cardiac glycosides,Million US$ at exchange rate,5.3
8321,Croatia,2013,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",133.2
8322,Croatia,2013,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",221.3
8323,Croatia,2013,9,N02-Analgesics,"Million US$, purchasing power parity",398.3
8324,Croatia,2013,9,C-Cardiovascular system,"Million US$, purchasing power parity",1993.7
8325,Croatia,2013,9,C03-Diuretics,"/capita, US$ exchange rate",13.7
8326,Croatia,2013,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",46.6
8327,Croatia,2013,9,N05B-Anxiolytics,Million of national currency units,88.0
8328,Croatia,2013,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,389.6
8329,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.9
8330,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",187.6
8331,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",36.6
8332,Croatia,2013,9,C08-Calcium channel blockers,Million of national currency units,123.0
8333,Croatia,2013,9,G-Genito urinary system and sex hormones,Million of national currency units,161.0
8334,Croatia,2013,9,N05B-Anxiolytics,"/capita, US$ exchange rate",27.3
8335,Croatia,2013,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",14.4
8336,Croatia,2013,9,A10-Drugs used in diabetes,% of total sales,5.8
8337,Croatia,2013,9,M-Musculo-skeletal system,% of total sales,4.0
8338,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7
8339,Croatia,2013,9,C10-Lipid modifying agents,% of total sales,4.3
8340,Croatia,2013,9,N06A-Antidepressants,% of total sales,1.6
8341,Croatia,2013,9,C-Cardiovascular system,% of total sales,18.3
8342,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.1
8343,Croatia,2013,9,N02-Analgesics,% of total sales,3.6
8344,Croatia,2013,9,C02-Antihypertensives,% of total sales,1.0
8345,Croatia,2013,9,C08-Calcium channel blockers,% of total sales,2.4
8346,Croatia,2013,9,G-Genito urinary system and sex hormones,% of total sales,3.1
8347,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3
8348,Croatia,2013,9,A-Alimentary tract and metabolism,% of total sales,13.8
8349,Croatia,2013,9,J-Antiinfectives for systemic use,% of total sales,8.3
8350,Croatia,2013,9,R-Respiratory system,% of total sales,6.4
8351,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
8352,Croatia,2013,9,B-Blood and blood forming organs,% of total sales,5.5
8353,Croatia,2013,9,N05B-Anxiolytics,% of total sales,1.7
8354,Croatia,2013,9,C03-Diuretics,% of total sales,0.8
8355,Croatia,2013,9,C01A-Cardiac glycosides,% of total sales,0.1
8356,Croatia,2013,9,N05C-Hypnotics and sedatives,% of total sales,0.6
8357,Croatia,2013,9,J01-Antibacterials for systemic use,% of total sales,5.7
8358,Croatia,2013,9,N-Nervous system,% of total sales,15.6
8359,Croatia,2013,9,R03-Drugs for obstructive airway diseases,% of total sales,4.0
8360,Croatia,2013,9,C07-Beta blocking agents,% of total sales,1.8
8361,Croatia,2013,9,A02A-Antacids,% of total sales,0.2
8362,Croatia,2013,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",37.9
8363,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",30.7
8364,Croatia,2013,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",38.2
8365,Croatia,2013,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",604.8
8366,Croatia,2013,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",50.0
8367,Croatia,2013,9,N05B-Anxiolytics,Million US$ at exchange rate,116.2
8368,Croatia,2013,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",61.1
8369,Croatia,2013,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,212.6
8370,Croatia,2013,9,N02-Analgesics,"/capita, US$ exchange rate",58.7
8371,Croatia,2013,9,N06A-Antidepressants,"/capita, US$ exchange rate",26.1
8372,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,155.8
8373,Croatia,2013,9,C02-Antihypertensives,"/capita, US$ exchange rate",16.5
8374,Croatia,2013,9,A10-Drugs used in diabetes,Million US$ at exchange rate,398.9
8375,Croatia,2013,9,N-Nervous system,"/capita, US$ purchasing power parity",401.7
8376,Croatia,2013,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",432.0
8377,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,326.0
8378,Croatia,2013,9,M-Musculo-skeletal system,Million US$ at exchange rate,274.7
8379,Croatia,2013,9,C07-Beta blocking agents,"/capita, US$ exchange rate",29.2
8380,Croatia,2013,9,N05C-Hypnotics and sedatives,Million of national currency units,29.0
8381,Croatia,2013,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",8.4
8382,Croatia,2013,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",146.1
8383,Croatia,2013,9,J01-Antibacterials for systemic use,Million of national currency units,295.0
8384,Croatia,2013,9,R-Respiratory system,Million US$ at exchange rate,438.5
8385,Croatia,2013,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,941.7
8386,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,62.0
8387,Croatia,2013,9,C07-Beta blocking agents,"Million US$, purchasing power parity",198.1
8388,Croatia,2013,9,Total pharmaceutical sales,"Million US$, purchasing power parity",10923.1
8389,Croatia,2013,9,J-Antiinfectives for systemic use,Million of national currency units,429.0
8390,Croatia,2013,9,A-Alimentary tract and metabolism,Million of national currency units,713.0
8391,Croatia,2013,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,81.9
8392,Croatia,2013,9,N06A-Antidepressants,"Million US$, purchasing power parity",177.0
8393,Croatia,2013,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.2
8394,Croatia,2013,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",111.0
8395,Croatia,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",44.1
8396,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",343.5
8397,Croatia,2013,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",438.4
8398,Croatia,2013,9,A10-Drugs used in diabetes,Million of national currency units,302.0
8399,Croatia,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,118.0
8400,Croatia,2013,9,R-Respiratory system,"/capita, US$ exchange rate",103.1
8401,Croatia,2013,9,A02A-Antacids,"Million US$, purchasing power parity",19.0
8402,Croatia,2013,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",621.7
8403,Croatia,2013,9,C01A-Cardiac glycosides,Million of national currency units,4.0
8404,Croatia,2013,9,C-Cardiovascular system,"/capita, US$ exchange rate",293.7
8405,Croatia,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",50.6
8406,Croatia,2013,9,C08-Calcium channel blockers,Million US$ at exchange rate,162.4
8407,Croatia,2013,9,C03-Diuretics,Million of national currency units,44.0
8408,Croatia,2013,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",161.5
8409,Croatia,2013,9,R-Respiratory system,Million of national currency units,332.0
8410,Croatia,2013,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,566.6
8411,Croatia,2013,9,C03-Diuretics,"/capita, US$ purchasing power parity",21.8
8412,Croatia,2013,9,N-Nervous system,"Million US$, purchasing power parity",1709.2
8413,Croatia,2013,9,C03-Diuretics,Million US$ at exchange rate,58.1
8414,Croatia,2012,8,C07-Beta blocking agents,Million US$ at exchange rate,124.9
8415,Croatia,2012,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",571.6
8416,Croatia,2012,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",24.6
8417,Croatia,2012,8,N-Nervous system,"/capita, US$ exchange rate",246.2
8418,Croatia,2012,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",335.2
8419,Croatia,2012,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",85.1
8420,Croatia,2012,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1455.8
8421,Croatia,2012,8,A02A-Antacids,Million of national currency units,8.0
8422,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",5.1
8423,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,96.6
8424,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,17.0
8425,Croatia,2012,8,C07-Beta blocking agents,Million of national currency units,97.0
8426,Croatia,2012,8,R-Respiratory system,"Million US$, purchasing power parity",664.2
8427,Croatia,2012,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",206.2
8428,Croatia,2012,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",60.6
8429,Croatia,2012,8,Total pharmaceutical sales,Million US$ at exchange rate,6536.0
8430,Croatia,2012,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",74.5
8431,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,258.9
8432,Croatia,2012,8,C-Cardiovascular system,Million of national currency units,1005.0
8433,Croatia,2012,8,N-Nervous system,Million of national currency units,816.0
8434,Croatia,2012,8,N05B-Anxiolytics,"Million US$, purchasing power parity",183.0
8435,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,201.0
8436,Croatia,2012,8,A02A-Antacids,"/capita, US$ exchange rate",2.4
8437,Croatia,2012,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",880.1
8438,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",232.4
8439,Croatia,2012,8,B-Blood and blood forming organs,Million of national currency units,282.0
8440,Croatia,2012,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",66.0
8441,Croatia,2012,8,N02-Analgesics,Million US$ at exchange rate,246.0
8442,Croatia,2012,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",78.5
8443,Croatia,2012,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",41.4
8444,Croatia,2012,8,N02-Analgesics,Million of national currency units,191.0
8445,Croatia,2012,8,N06A-Antidepressants,Million of national currency units,86.0
8446,Croatia,2012,8,C02-Antihypertensives,Million of national currency units,51.0
8447,Croatia,2012,8,R-Respiratory system,"/capita, US$ purchasing power parity",155.6
8448,Croatia,2012,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.4
8449,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",738.2
8450,Croatia,2012,8,C10-Lipid modifying agents,Million of national currency units,247.0
8451,Croatia,2012,8,B-Blood and blood forming organs,Million US$ at exchange rate,363.2
8452,Croatia,2012,8,R03-Drugs for obstructive airway diseases,Million of national currency units,201.0
8453,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",129.5
8454,Croatia,2012,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",61.8
8455,Croatia,2012,8,C03-Diuretics,"Million US$, purchasing power parity",88.4
8456,Croatia,2012,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",42.9
8457,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,21.9
8458,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",108.3
8459,Croatia,2012,8,A02A-Antacids,Million US$ at exchange rate,10.3
8460,Croatia,2012,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,33.5
8461,Croatia,2012,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2444.5
8462,Croatia,2012,8,M-Musculo-skeletal system,Million of national currency units,205.0
8463,Croatia,2012,8,C02-Antihypertensives,"Million US$, purchasing power parity",104.9
8464,Croatia,2012,8,N-Nervous system,Million US$ at exchange rate,1050.9
8465,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.0
8466,Croatia,2012,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",133.9
8467,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",22.6
8468,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",54.4
8469,Croatia,2012,8,N02-Analgesics,"/capita, US$ purchasing power parity",92.0
8470,Croatia,2012,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",281.7
8471,Croatia,2012,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",341.0
8472,Croatia,2012,8,C02-Antihypertensives,Million US$ at exchange rate,65.7
8473,Croatia,2012,8,C-Cardiovascular system,Million US$ at exchange rate,1294.3
8474,Croatia,2012,8,Total pharmaceutical sales,"/capita, US$ exchange rate",1531.0
8475,Croatia,2012,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",98.7
8476,Croatia,2012,8,C10-Lipid modifying agents,Million US$ at exchange rate,318.1
8477,Croatia,2012,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,258.9
8478,Croatia,2012,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.8
8479,Croatia,2012,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",484.1
8480,Croatia,2012,8,Total pharmaceutical sales,Million of national currency units,5075.0
8481,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",96.8
8482,Croatia,2012,8,N06A-Antidepressants,Million US$ at exchange rate,110.8
8483,Croatia,2012,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",88.4
8484,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,75.0
8485,Croatia,2012,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",507.9
8486,Croatia,2012,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",135.8
8487,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,462.4
8488,Croatia,2012,8,A02A-Antacids,"/capita, US$ purchasing power parity",3.9
8489,Croatia,2012,8,C03-Diuretics,Million US$ at exchange rate,55.4
8490,Croatia,2012,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",83.9
8491,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.1
8492,Croatia,2012,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",96.8
8493,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
8494,Croatia,2012,8,C01A-Cardiac glycosides,Million US$ at exchange rate,6.4
8495,Croatia,2012,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",129.1
8496,Croatia,2012,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",213.6
8497,Croatia,2012,8,N02-Analgesics,"Million US$, purchasing power parity",392.7
8498,Croatia,2012,8,C-Cardiovascular system,"Million US$, purchasing power parity",2066.6
8499,Croatia,2012,8,C03-Diuretics,"/capita, US$ exchange rate",13.0
8500,Croatia,2012,8,N05B-Anxiolytics,Million of national currency units,89.0
8501,Croatia,2012,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",46.7
8502,Croatia,2012,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,377.4
8503,Croatia,2012,8,C08-Calcium channel blockers,Million of national currency units,137.0
8504,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.2
8505,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",154.2
8506,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",34.1
8507,Croatia,2012,8,N05B-Anxiolytics,"/capita, US$ exchange rate",26.8
8508,Croatia,2012,8,G-Genito urinary system and sex hormones,Million of national currency units,163.0
8509,Croatia,2012,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",12.5
8510,Croatia,2012,8,A10-Drugs used in diabetes,% of total sales,5.5
8511,Croatia,2012,8,M-Musculo-skeletal system,% of total sales,4.0
8512,Croatia,2012,8,N06A-Antidepressants,% of total sales,1.7
8513,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.5
8514,Croatia,2012,8,C-Cardiovascular system,% of total sales,19.8
8515,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.0
8516,Croatia,2012,8,N02-Analgesics,% of total sales,3.8
8517,Croatia,2012,8,C10-Lipid modifying agents,% of total sales,4.9
8518,Croatia,2012,8,C02-Antihypertensives,% of total sales,1.0
8519,Croatia,2012,8,G-Genito urinary system and sex hormones,% of total sales,3.2
8520,Croatia,2012,8,C08-Calcium channel blockers,% of total sales,2.7
8521,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.2
8522,Croatia,2012,8,A-Alimentary tract and metabolism,% of total sales,14.0
8523,Croatia,2012,8,J-Antiinfectives for systemic use,% of total sales,8.4
8524,Croatia,2012,8,R-Respiratory system,% of total sales,6.4
8525,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
8526,Croatia,2012,8,B-Blood and blood forming organs,% of total sales,5.6
8527,Croatia,2012,8,C03-Diuretics,% of total sales,0.8
8528,Croatia,2012,8,N05B-Anxiolytics,% of total sales,1.8
8529,Croatia,2012,8,C01A-Cardiac glycosides,% of total sales,0.1
8530,Croatia,2012,8,J01-Antibacterials for systemic use,% of total sales,5.8
8531,Croatia,2012,8,N05C-Hypnotics and sedatives,% of total sales,0.5
8532,Croatia,2012,8,N-Nervous system,% of total sales,16.1
8533,Croatia,2012,8,R03-Drugs for obstructive airway diseases,% of total sales,4.0
8534,Croatia,2012,8,C07-Beta blocking agents,% of total sales,1.9
8535,Croatia,2012,8,A02A-Antacids,% of total sales,0.2
8536,Croatia,2012,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",35.0
8537,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",30.3
8538,Croatia,2012,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",41.3
8539,Croatia,2012,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",579.9
8540,Croatia,2012,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",49.2
8541,Croatia,2012,8,N05B-Anxiolytics,Million US$ at exchange rate,114.6
8542,Croatia,2012,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,209.9
8543,Croatia,2012,8,N06A-Antidepressants,"/capita, US$ exchange rate",25.9
8544,Croatia,2012,8,C02-Antihypertensives,"/capita, US$ exchange rate",15.4
8545,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,145.5
8546,Croatia,2012,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",53.5
8547,Croatia,2012,8,A10-Drugs used in diabetes,Million US$ at exchange rate,358.0
8548,Croatia,2012,8,N-Nervous system,"/capita, US$ purchasing power parity",393.0
8549,Croatia,2012,8,M-Musculo-skeletal system,Million US$ at exchange rate,264.0
8550,Croatia,2012,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",413.3
8551,Croatia,2012,8,C07-Beta blocking agents,"/capita, US$ exchange rate",29.3
8552,Croatia,2012,8,N05C-Hypnotics and sedatives,Million of national currency units,26.0
8553,Croatia,2012,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",10.3
8554,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,359.0
8555,Croatia,2012,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",141.1
8556,Croatia,2012,8,R-Respiratory system,Million US$ at exchange rate,416.0
8557,Croatia,2012,8,J01-Antibacterials for systemic use,Million of national currency units,293.0
8558,Croatia,2012,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,911.8
8559,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,63.0
8560,Croatia,2012,8,N02-Analgesics,"/capita, US$ exchange rate",57.6
8561,Croatia,2012,8,C07-Beta blocking agents,"Million US$, purchasing power parity",199.5
8562,Croatia,2012,8,Total pharmaceutical sales,"Million US$, purchasing power parity",10435.6
8563,Croatia,2012,8,J-Antiinfectives for systemic use,Million of national currency units,428.0
8564,Croatia,2012,8,A-Alimentary tract and metabolism,Million of national currency units,708.0
8565,Croatia,2012,8,N06A-Antidepressants,"Million US$, purchasing power parity",176.8
8566,Croatia,2012,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,81.1
8567,Croatia,2012,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.5
8568,Croatia,2012,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",119.0
8569,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",413.3
8570,Croatia,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",36.1
8571,Croatia,2012,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",421.5
8572,Croatia,2012,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,113.0
8573,Croatia,2012,8,A10-Drugs used in diabetes,Million of national currency units,278.0
8574,Croatia,2012,8,R-Respiratory system,"/capita, US$ exchange rate",97.4
8575,Croatia,2012,8,A02A-Antacids,"Million US$, purchasing power parity",16.5
8576,Croatia,2012,8,C01A-Cardiac glycosides,Million of national currency units,5.0
8577,Croatia,2012,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",602.5
8578,Croatia,2012,8,C-Cardiovascular system,"/capita, US$ exchange rate",303.2
8579,Croatia,2012,8,C08-Calcium channel blockers,Million US$ at exchange rate,176.4
8580,Croatia,2012,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",60.6
8581,Croatia,2012,8,C03-Diuretics,Million of national currency units,43.0
8582,Croatia,2012,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",172.9
8583,Croatia,2012,8,R-Respiratory system,Million of national currency units,323.0
8584,Croatia,2012,8,C03-Diuretics,"/capita, US$ purchasing power parity",20.7
8585,Croatia,2012,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,551.2
8586,Croatia,2012,8,N-Nervous system,"Million US$, purchasing power parity",1677.9
8587,Croatia,2011,9,C07-Beta blocking agents,Million US$ at exchange rate,133.9
8588,Croatia,2011,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",520.0
8589,Croatia,2011,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",22.5
8590,Croatia,2011,9,N-Nervous system,"/capita, US$ exchange rate",267.0
8591,Croatia,2011,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",333.3
8592,Croatia,2011,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",85.3
8593,Croatia,2011,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1385.4
8594,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",6.3
8595,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,98.7
8596,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,19.0
8597,Croatia,2011,9,C07-Beta blocking agents,Million of national currency units,95.0
8598,Croatia,2011,9,R-Respiratory system,"Million US$, purchasing power parity",668.6
8599,Croatia,2011,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",217.1
8600,Croatia,2011,9,A02A-Antacids,Million of national currency units,9.0
8601,Croatia,2011,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",64.5
8602,Croatia,2011,9,Total pharmaceutical sales,Million US$ at exchange rate,7145.5
8603,Croatia,2011,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",82.3
8604,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,282.0
8605,Croatia,2011,9,C-Cardiovascular system,Million of national currency units,984.0
8606,Croatia,2011,9,N-Nervous system,Million of national currency units,811.0
8607,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,200.0
8608,Croatia,2011,9,A02A-Antacids,"/capita, US$ exchange rate",3.0
8609,Croatia,2011,9,N05B-Anxiolytics,"Million US$, purchasing power parity",174.7
8610,Croatia,2011,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",929.6
8611,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",220.9
8612,Croatia,2011,9,B-Blood and blood forming organs,Million of national currency units,259.0
8613,Croatia,2011,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",68.0
8614,Croatia,2011,9,N02-Analgesics,Million US$ at exchange rate,273.5
8615,Croatia,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",77.8
8616,Croatia,2011,9,R-Respiratory system,"/capita, US$ purchasing power parity",156.1
8617,Croatia,2011,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",40.8
8618,Croatia,2011,9,N02-Analgesics,Million of national currency units,194.0
8619,Croatia,2011,9,N06A-Antidepressants,Million of national currency units,87.0
8620,Croatia,2011,9,C02-Antihypertensives,Million of national currency units,48.0
8621,Croatia,2011,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",1.9
8622,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",704.7
8623,Croatia,2011,9,C10-Lipid modifying agents,Million of national currency units,250.0
8624,Croatia,2011,9,B-Blood and blood forming organs,Million US$ at exchange rate,365.2
8625,Croatia,2011,9,R03-Drugs for obstructive airway diseases,Million of national currency units,196.0
8626,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",120.5
8627,Croatia,2011,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",68.5
8628,Croatia,2011,9,C03-Diuretics,"Million US$, purchasing power parity",82.3
8629,Croatia,2011,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",40.8
8630,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,26.8
8631,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",115.5
8632,Croatia,2011,9,A02A-Antacids,Million US$ at exchange rate,12.7
8633,Croatia,2011,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,33.8
8634,Croatia,2011,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2375.8
8635,Croatia,2011,9,M-Musculo-skeletal system,Million of national currency units,208.0
8636,Croatia,2011,9,C02-Antihypertensives,"Million US$, purchasing power parity",96.4
8637,Croatia,2011,9,N-Nervous system,Million US$ at exchange rate,1143.5
8638,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.8
8639,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",51.6
8640,Croatia,2011,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",121.4
8641,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",23.0
8642,Croatia,2011,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",291.1
8643,Croatia,2011,9,N02-Analgesics,"/capita, US$ purchasing power parity",90.9
8644,Croatia,2011,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",323.5
8645,Croatia,2011,9,C02-Antihypertensives,Million US$ at exchange rate,67.7
8646,Croatia,2011,9,C-Cardiovascular system,Million US$ at exchange rate,1387.4
8647,Croatia,2011,9,Total pharmaceutical sales,"/capita, US$ exchange rate",1668.4
8648,Croatia,2011,9,C10-Lipid modifying agents,Million US$ at exchange rate,352.5
8649,Croatia,2011,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",97.5
8650,Croatia,2011,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,276.3
8651,Croatia,2011,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.9
8652,Croatia,2011,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",461.3
8653,Croatia,2011,9,Total pharmaceutical sales,Million of national currency units,5068.0
8654,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",93.8
8655,Croatia,2011,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",95.1
8656,Croatia,2011,9,N06A-Antidepressants,Million US$ at exchange rate,122.7
8657,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,70.0
8658,Croatia,2011,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",501.9
8659,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,494.9
8660,Croatia,2011,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",121.4
8661,Croatia,2011,9,A02A-Antacids,"/capita, US$ purchasing power parity",4.2
8662,Croatia,2011,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",85.3
8663,Croatia,2011,9,C03-Diuretics,Million US$ at exchange rate,57.8
8664,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.9
8665,Croatia,2011,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",91.9
8666,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
8667,Croatia,2011,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",152.4
8668,Croatia,2011,9,C01A-Cardiac glycosides,Million US$ at exchange rate,5.6
8669,Croatia,2011,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",227.1
8670,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",140.5
8671,Croatia,2011,9,N02-Analgesics,"Million US$, purchasing power parity",389.5
8672,Croatia,2011,9,C-Cardiovascular system,"Million US$, purchasing power parity",1975.7
8673,Croatia,2011,9,C03-Diuretics,"/capita, US$ exchange rate",13.5
8674,Croatia,2011,9,N05B-Anxiolytics,Million of national currency units,87.0
8675,Croatia,2011,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",44.5
8676,Croatia,2011,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,407.5
8677,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.9
8678,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",36.2
8679,Croatia,2011,9,G-Genito urinary system and sex hormones,Million of national currency units,166.0
8680,Croatia,2011,9,N05B-Anxiolytics,"/capita, US$ exchange rate",28.6
8681,Croatia,2011,9,C08-Calcium channel blockers,Million of national currency units,145.0
8682,Croatia,2011,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",11.3
8683,Croatia,2011,9,A10-Drugs used in diabetes,% of total sales,5.1
8684,Croatia,2011,9,M-Musculo-skeletal system,% of total sales,4.1
8685,Croatia,2011,9,N06A-Antidepressants,% of total sales,1.7
8686,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
8687,Croatia,2011,9,C-Cardiovascular system,% of total sales,19.4
8688,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.9
8689,Croatia,2011,9,N02-Analgesics,% of total sales,3.8
8690,Croatia,2011,9,C02-Antihypertensives,% of total sales,0.9
8691,Croatia,2011,9,G-Genito urinary system and sex hormones,% of total sales,3.3
8692,Croatia,2011,9,C08-Calcium channel blockers,% of total sales,2.9
8693,Croatia,2011,9,C10-Lipid modifying agents,% of total sales,4.9
8694,Croatia,2011,9,A-Alimentary tract and metabolism,% of total sales,13.6
8695,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.2
8696,Croatia,2011,9,J-Antiinfectives for systemic use,% of total sales,9.1
8697,Croatia,2011,9,R-Respiratory system,% of total sales,6.6
8698,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
8699,Croatia,2011,9,B-Blood and blood forming organs,% of total sales,5.1
8700,Croatia,2011,9,N05B-Anxiolytics,% of total sales,1.7
8701,Croatia,2011,9,C03-Diuretics,% of total sales,0.8
8702,Croatia,2011,9,C01A-Cardiac glycosides,% of total sales,0.1
8703,Croatia,2011,9,J01-Antibacterials for systemic use,% of total sales,5.7
8704,Croatia,2011,9,N05C-Hypnotics and sedatives,% of total sales,0.5
8705,Croatia,2011,9,N-Nervous system,% of total sales,16.0
8706,Croatia,2011,9,R03-Drugs for obstructive airway diseases,% of total sales,3.9
8707,Croatia,2011,9,A02A-Antacids,% of total sales,0.2
8708,Croatia,2011,9,C07-Beta blocking agents,% of total sales,1.9
8709,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",28.1
8710,Croatia,2011,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",38.1
8711,Croatia,2011,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",47.7
8712,Croatia,2011,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",520.0
8713,Croatia,2011,9,N05B-Anxiolytics,Million US$ at exchange rate,122.7
8714,Croatia,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",54.6
8715,Croatia,2011,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,234.0
8716,Croatia,2011,9,C02-Antihypertensives,"/capita, US$ exchange rate",15.8
8717,Croatia,2011,9,N06A-Antidepressants,"/capita, US$ exchange rate",28.6
8718,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,155.1
8719,Croatia,2011,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",48.2
8720,Croatia,2011,9,A10-Drugs used in diabetes,Million US$ at exchange rate,365.2
8721,Croatia,2011,9,N-Nervous system,"/capita, US$ purchasing power parity",380.2
8722,Croatia,2011,9,M-Musculo-skeletal system,Million US$ at exchange rate,293.3
8723,Croatia,2011,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",393.5
8724,Croatia,2011,9,C07-Beta blocking agents,"/capita, US$ exchange rate",31.3
8725,Croatia,2011,9,N05C-Hypnotics and sedatives,Million of national currency units,24.0
8726,Croatia,2011,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",8.0
8727,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,351.0
8728,Croatia,2011,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",135.5
8729,Croatia,2011,9,J01-Antibacterials for systemic use,Million of national currency units,289.0
8730,Croatia,2011,9,R-Respiratory system,Million US$ at exchange rate,469.5
8731,Croatia,2011,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,972.9
8732,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,60.0
8733,Croatia,2011,9,C07-Beta blocking agents,"Million US$, purchasing power parity",190.7
8734,Croatia,2011,9,N02-Analgesics,"/capita, US$ exchange rate",63.9
8735,Croatia,2011,9,Total pharmaceutical sales,"Million US$, purchasing power parity",10175.5
8736,Croatia,2011,9,A-Alimentary tract and metabolism,Million of national currency units,690.0
8737,Croatia,2011,9,J-Antiinfectives for systemic use,Million of national currency units,463.0
8738,Croatia,2011,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,84.6
8739,Croatia,2011,9,N06A-Antidepressants,"Million US$, purchasing power parity",174.7
8740,Croatia,2011,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.3
8741,Croatia,2011,9,R-Respiratory system,"/capita, US$ exchange rate",109.6
8742,Croatia,2011,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",117.2
8743,Croatia,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",32.8
8744,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",401.6
8745,Croatia,2011,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",417.6
8746,Croatia,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,110.0
8747,Croatia,2011,9,A10-Drugs used in diabetes,Million of national currency units,259.0
8748,Croatia,2011,9,A02A-Antacids,"Million US$, purchasing power parity",18.1
8749,Croatia,2011,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",580.3
8750,Croatia,2011,9,C01A-Cardiac glycosides,Million of national currency units,4.0
8751,Croatia,2011,9,C-Cardiovascular system,"/capita, US$ exchange rate",323.9
8752,Croatia,2011,9,C08-Calcium channel blockers,Million US$ at exchange rate,204.4
8753,Croatia,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",65.8
8754,Croatia,2011,9,C03-Diuretics,Million of national currency units,41.0
8755,Croatia,2011,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",164.5
8756,Croatia,2011,9,R-Respiratory system,Million of national currency units,333.0
8757,Croatia,2011,9,C03-Diuretics,"/capita, US$ purchasing power parity",19.2
8758,Croatia,2011,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,652.8
8759,Croatia,2011,9,N-Nervous system,"Million US$, purchasing power parity",1628.3
8760,Croatia,2010,9,C07-Beta blocking agents,Million US$ at exchange rate,126.1
8761,Croatia,2010,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",468.8
8762,Croatia,2010,9,N-Nervous system,"/capita, US$ exchange rate",250.1
8763,Croatia,2010,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",19.5
8764,Croatia,2010,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",317.1
8765,Croatia,2010,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1244.9
8766,Croatia,2010,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",85.2
8767,Croatia,2010,9,A02A-Antacids,Million of national currency units,9.0
8768,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",5.7
8769,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,82.2
8770,Croatia,2010,9,C07-Beta blocking agents,Million of national currency units,92.0
8771,Croatia,2010,9,R-Respiratory system,"/capita, US$ purchasing power parity",152.6
8772,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,18.0
8773,Croatia,2010,9,R-Respiratory system,"Million US$, purchasing power parity",655.5
8774,Croatia,2010,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",215.5
8775,Croatia,2010,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",59.0
8776,Croatia,2010,9,Total pharmaceutical sales,Million US$ at exchange rate,6628.7
8777,Croatia,2010,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",77.2
8778,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,270.0
8779,Croatia,2010,9,N-Nervous system,Million of national currency units,784.0
8780,Croatia,2010,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",925.9
8781,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,197.0
8782,Croatia,2010,9,A02A-Antacids,"/capita, US$ exchange rate",2.9
8783,Croatia,2010,9,C-Cardiovascular system,Million of national currency units,975.0
8784,Croatia,2010,9,N05B-Anxiolytics,"Million US$, purchasing power parity",167.3
8785,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",215.9
8786,Croatia,2010,9,B-Blood and blood forming organs,Million of national currency units,267.0
8787,Croatia,2010,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",66.1
8788,Croatia,2010,9,N02-Analgesics,Million US$ at exchange rate,254.9
8789,Croatia,2010,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",73.8
8790,Croatia,2010,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",39.8
8791,Croatia,2010,9,N02-Analgesics,Million of national currency units,186.0
8792,Croatia,2010,9,N06A-Antidepressants,Million of national currency units,88.0
8793,Croatia,2010,9,C02-Antihypertensives,Million of national currency units,43.0
8794,Croatia,2010,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.3
8795,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",663.3
8796,Croatia,2010,9,B-Blood and blood forming organs,Million US$ at exchange rate,365.9
8797,Croatia,2010,9,R03-Drugs for obstructive airway diseases,Million of national currency units,185.0
8798,Croatia,2010,9,C10-Lipid modifying agents,Million of national currency units,242.0
8799,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",120.6
8800,Croatia,2010,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",67.3
8801,Croatia,2010,9,C03-Diuretics,"Million US$, purchasing power parity",75.9
8802,Croatia,2010,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",38.9
8803,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,24.7
8804,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",108.8
8805,Croatia,2010,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,31.5
8806,Croatia,2010,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",2189.9
8807,Croatia,2010,9,A02A-Antacids,Million US$ at exchange rate,12.3
8808,Croatia,2010,9,M-Musculo-skeletal system,Million of national currency units,211.0
8809,Croatia,2010,9,C02-Antihypertensives,"Million US$, purchasing power parity",83.6
8810,Croatia,2010,9,N-Nervous system,Million US$ at exchange rate,1074.4
8811,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.8
8812,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",50.3
8813,Croatia,2010,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",109.1
8814,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",19.1
8815,Croatia,2010,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",284.0
8816,Croatia,2010,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",289.8
8817,Croatia,2010,9,C02-Antihypertensives,Million US$ at exchange rate,58.9
8818,Croatia,2010,9,C-Cardiovascular system,Million US$ at exchange rate,1336.1
8819,Croatia,2010,9,Total pharmaceutical sales,"/capita, US$ exchange rate",1542.9
8820,Croatia,2010,9,N02-Analgesics,"/capita, US$ purchasing power parity",84.2
8821,Croatia,2010,9,C10-Lipid modifying agents,Million US$ at exchange rate,331.6
8822,Croatia,2010,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",95.5
8823,Croatia,2010,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,253.5
8824,Croatia,2010,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.3
8825,Croatia,2010,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",441.4
8826,Croatia,2010,9,Total pharmaceutical sales,Million of national currency units,4837.0
8827,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",89.2
8828,Croatia,2010,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",90.6
8829,Croatia,2010,9,N06A-Antidepressants,Million US$ at exchange rate,120.6
8830,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,60.0
8831,Croatia,2010,9,C-Cardiovascular system,"/capita, US$ exchange rate",311.0
8832,Croatia,2010,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",470.7
8833,Croatia,2010,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",120.9
8834,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,467.3
8835,Croatia,2010,9,A02A-Antacids,"/capita, US$ purchasing power parity",4.1
8836,Croatia,2010,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",76.9
8837,Croatia,2010,9,C03-Diuretics,Million US$ at exchange rate,53.4
8838,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.0
8839,Croatia,2010,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",83.8
8840,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.3
8841,Croatia,2010,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",151.8
8842,Croatia,2010,9,C01A-Cardiac glycosides,Million US$ at exchange rate,6.9
8843,Croatia,2010,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",204.1
8844,Croatia,2010,9,C-Cardiovascular system,"Million US$, purchasing power parity",1896.5
8845,Croatia,2010,9,N02-Analgesics,"Million US$, purchasing power parity",361.8
8846,Croatia,2010,9,C03-Diuretics,"/capita, US$ exchange rate",12.4
8847,Croatia,2010,9,N05B-Anxiolytics,Million of national currency units,86.0
8848,Croatia,2010,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,389.2
8849,Croatia,2010,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",41.7
8850,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",116.7
8851,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.1
8852,Croatia,2010,9,G-Genito urinary system and sex hormones,Million of national currency units,163.0
8853,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",35.4
8854,Croatia,2010,9,N05B-Anxiolytics,"/capita, US$ exchange rate",27.4
8855,Croatia,2010,9,C08-Calcium channel blockers,Million of national currency units,146.0
8856,Croatia,2010,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.4
8857,Croatia,2010,9,M-Musculo-skeletal system,% of total sales,4.4
8858,Croatia,2010,9,N06A-Antidepressants,% of total sales,1.8
8859,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.2
8860,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.1
8861,Croatia,2010,9,C-Cardiovascular system,% of total sales,20.2
8862,Croatia,2010,9,N02-Analgesics,% of total sales,3.8
8863,Croatia,2010,9,C10-Lipid modifying agents,% of total sales,5.0
8864,Croatia,2010,9,C02-Antihypertensives,% of total sales,0.9
8865,Croatia,2010,9,G-Genito urinary system and sex hormones,% of total sales,3.4
8866,Croatia,2010,9,C08-Calcium channel blockers,% of total sales,3.0
8867,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3
8868,Croatia,2010,9,A-Alimentary tract and metabolism,% of total sales,13.2
8869,Croatia,2010,9,J-Antiinfectives for systemic use,% of total sales,9.8
8870,Croatia,2010,9,R-Respiratory system,% of total sales,7.0
8871,Croatia,2010,9,B-Blood and blood forming organs,% of total sales,5.5
8872,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
8873,Croatia,2010,9,C03-Diuretics,% of total sales,0.8
8874,Croatia,2010,9,N05B-Anxiolytics,% of total sales,1.8
8875,Croatia,2010,9,A10-Drugs used in diabetes,% of total sales,5.0
8876,Croatia,2010,9,C01A-Cardiac glycosides,% of total sales,0.1
8877,Croatia,2010,9,J01-Antibacterials for systemic use,% of total sales,5.9
8878,Croatia,2010,9,N-Nervous system,% of total sales,16.2
8879,Croatia,2010,9,N05C-Hypnotics and sedatives,% of total sales,0.5
8880,Croatia,2010,9,R03-Drugs for obstructive airway diseases,% of total sales,3.8
8881,Croatia,2010,9,A02A-Antacids,% of total sales,0.2
8882,Croatia,2010,9,C07-Beta blocking agents,% of total sales,1.9
8883,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",28.1
8884,Croatia,2010,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",35.0
8885,Croatia,2010,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",46.6
8886,Croatia,2010,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",519.3
8887,Croatia,2010,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",52.0
8888,Croatia,2010,9,N05B-Anxiolytics,Million US$ at exchange rate,117.9
8889,Croatia,2010,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,223.4
8890,Croatia,2010,9,C02-Antihypertensives,"/capita, US$ exchange rate",13.7
8891,Croatia,2010,9,N06A-Antidepressants,"/capita, US$ exchange rate",28.1
8892,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,152.1
8893,Croatia,2010,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",44.7
8894,Croatia,2010,9,A10-Drugs used in diabetes,Million US$ at exchange rate,330.3
8895,Croatia,2010,9,N-Nervous system,"/capita, US$ purchasing power parity",354.9
8896,Croatia,2010,9,M-Musculo-skeletal system,Million US$ at exchange rate,289.2
8897,Croatia,2010,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",359.8
8898,Croatia,2010,9,N05C-Hypnotics and sedatives,Million of national currency units,23.0
8899,Croatia,2010,9,C07-Beta blocking agents,"/capita, US$ exchange rate",29.3
8900,Croatia,2010,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",9.7
8901,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,341.0
8902,Croatia,2010,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",128.6
8903,Croatia,2010,9,J01-Antibacterials for systemic use,Million of national currency units,284.0
8904,Croatia,2010,9,R-Respiratory system,Million US$ at exchange rate,461.8
8905,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,62.0
8906,Croatia,2010,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,877.1
8907,Croatia,2010,9,C07-Beta blocking agents,"Million US$, purchasing power parity",179.0
8908,Croatia,2010,9,Total pharmaceutical sales,"Million US$, purchasing power parity",9408.5
8909,Croatia,2010,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,85.0
8910,Croatia,2010,9,A-Alimentary tract and metabolism,Million of national currency units,640.0
8911,Croatia,2010,9,N06A-Antidepressants,"Million US$, purchasing power parity",171.2
8912,Croatia,2010,9,R-Respiratory system,"/capita, US$ exchange rate",107.5
8913,Croatia,2010,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.6
8914,Croatia,2010,9,J-Antiinfectives for systemic use,Million of national currency units,476.0
8915,Croatia,2010,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",109.6
8916,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",383.2
8917,Croatia,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",27.2
8918,Croatia,2010,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",410.4
8919,Croatia,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,111.0
8920,Croatia,2010,9,A10-Drugs used in diabetes,Million of national currency units,241.0
8921,Croatia,2010,9,A02A-Antacids,"Million US$, purchasing power parity",17.5
8922,Croatia,2010,9,C01A-Cardiac glycosides,Million of national currency units,5.0
8923,Croatia,2010,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",552.4
8924,Croatia,2010,9,C08-Calcium channel blockers,Million US$ at exchange rate,200.1
8925,Croatia,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",62.8
8926,Croatia,2010,9,C03-Diuretics,Million of national currency units,39.0
8927,Croatia,2010,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",154.4
8928,Croatia,2010,9,R-Respiratory system,Million of national currency units,337.0
8929,Croatia,2010,9,C03-Diuretics,"/capita, US$ purchasing power parity",17.7
8930,Croatia,2010,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,652.3
8931,Croatia,2010,9,N-Nervous system,"Million US$, purchasing power parity",1525.0
8932,Croatia,2010,9,N02-Analgesics,"/capita, US$ exchange rate",59.3
8933,Croatia,2017,8,C07-Beta blocking agents,Million US$ at exchange rate,99.0
8934,Croatia,2017,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",924.6
8935,Croatia,2017,8,N-Nervous system,"/capita, US$ exchange rate",229.7
8936,Croatia,2017,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",405.7
8937,Croatia,2017,8,A02A-Antacids,"/capita, US$ exchange rate",2.5
8938,Croatia,2017,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",136.6
8939,Croatia,2017,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1810.7
8940,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",4.4
8941,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,129.7
8942,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,16.0
8943,Croatia,2017,8,C07-Beta blocking agents,Million of national currency units,87.0
8944,Croatia,2017,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",60.6
8945,Croatia,2017,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",334.2
8946,Croatia,2017,8,A02A-Antacids,Million of national currency units,9.0
8947,Croatia,2017,8,Total pharmaceutical sales,Million US$ at exchange rate,6975.1
8948,Croatia,2017,8,R-Respiratory system,"Million US$, purchasing power parity",811.3
8949,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,131.9
8950,Croatia,2017,8,N05B-Anxiolytics,"Million US$, purchasing power parity",204.0
8951,Croatia,2017,8,C-Cardiovascular system,Million of national currency units,785.0
8952,Croatia,2017,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",41.0
8953,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",315.0
8954,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,116.0
8955,Croatia,2017,8,N05C-Hypnotics and sedatives,Million of national currency units,35.0
8956,Croatia,2017,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1380.1
8957,Croatia,2017,8,N02-Analgesics,Million US$ at exchange rate,208.2
8958,Croatia,2017,8,N-Nervous system,Million of national currency units,834.0
8959,Croatia,2017,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",188.1
8960,Croatia,2017,8,B-Blood and blood forming organs,Million of national currency units,496.0
8961,Croatia,2017,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",98.2
8962,Croatia,2017,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",45.5
8963,Croatia,2017,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",43.9
8964,Croatia,2017,8,N02-Analgesics,Million of national currency units,183.0
8965,Croatia,2017,8,C02-Antihypertensives,Million of national currency units,47.0
8966,Croatia,2017,8,N06A-Antidepressants,Million of national currency units,80.0
8967,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",713.9
8968,Croatia,2017,8,C10-Lipid modifying agents,Million of national currency units,149.0
8969,Croatia,2017,8,R03-Drugs for obstructive airway diseases,Million of national currency units,220.0
8970,Croatia,2017,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",2.7
8971,Croatia,2017,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",62.8
8972,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",140.5
8973,Croatia,2017,8,C03-Diuretics,"Million US$, purchasing power parity",120.1
8974,Croatia,2017,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",49.4
8975,Croatia,2017,8,B-Blood and blood forming organs,Million US$ at exchange rate,564.2
8976,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",86.8
8977,Croatia,2017,8,A02A-Antacids,Million US$ at exchange rate,10.2
8978,Croatia,2017,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",3364.9
8979,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,18.2
8980,Croatia,2017,8,M-Musculo-skeletal system,Million of national currency units,228.0
8981,Croatia,2017,8,C02-Antihypertensives,"Million US$, purchasing power parity",106.5
8982,Croatia,2017,8,N-Nervous system,Million US$ at exchange rate,948.7
8983,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",17.1
8984,Croatia,2017,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",223.9
8985,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",31.4
8986,Croatia,2017,8,N02-Analgesics,"/capita, US$ purchasing power parity",100.4
8987,Croatia,2017,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",25.8
8988,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",76.3
8989,Croatia,2017,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,39.8
8990,Croatia,2017,8,C02-Antihypertensives,Million US$ at exchange rate,53.5
8991,Croatia,2017,8,R-Respiratory system,"/capita, US$ purchasing power parity",196.5
8992,Croatia,2017,8,C-Cardiovascular system,Million US$ at exchange rate,892.9
8993,Croatia,2017,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",438.4
8994,Croatia,2017,8,Total pharmaceutical sales,"/capita, US$ exchange rate",1688.9
8995,Croatia,2017,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",9.6
8996,Croatia,2017,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",125.1
8997,Croatia,2017,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,250.2
8998,Croatia,2017,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",430.8
8999,Croatia,2017,8,C10-Lipid modifying agents,Million US$ at exchange rate,169.5
9000,Croatia,2017,8,Total pharmaceutical sales,Million of national currency units,6132.0
9001,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",63.7
9002,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,114.0
9003,Croatia,2017,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",85.9
9004,Croatia,2017,8,N06A-Antidepressants,Million US$ at exchange rate,91.0
9005,Croatia,2017,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",272.2
9006,Croatia,2017,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",337.7
9007,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,358.3
9008,Croatia,2017,8,C03-Diuretics,Million US$ at exchange rate,60.3
9009,Croatia,2017,8,A02A-Antacids,"/capita, US$ purchasing power parity",4.9
9010,Croatia,2017,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",112.4
9011,Croatia,2017,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",167.7
9012,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.1
9013,Croatia,2017,8,A10-Drugs used in diabetes,% of total sales,6.7
9014,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.0
9015,Croatia,2017,8,C01A-Cardiac glycosides,Million US$ at exchange rate,5.7
9016,Croatia,2017,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",120.7
9017,Croatia,2017,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",220.1
9018,Croatia,2017,8,N02-Analgesics,"Million US$, purchasing power parity",414.7
9019,Croatia,2017,8,C08-Calcium channel blockers,Million of national currency units,83.0
9020,Croatia,2017,8,C03-Diuretics,"/capita, US$ exchange rate",14.6
9021,Croatia,2017,8,C-Cardiovascular system,"Million US$, purchasing power parity",1779.0
9022,Croatia,2017,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",47.7
9023,Croatia,2017,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,354.9
9024,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",8.8
9025,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",38.3
9026,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",258.4
9027,Croatia,2017,8,N05B-Anxiolytics,"/capita, US$ exchange rate",24.8
9028,Croatia,2017,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",19.2
9029,Croatia,2017,8,G-Genito urinary system and sex hormones,Million of national currency units,179.0
9030,Croatia,2017,8,M-Musculo-skeletal system,% of total sales,3.7
9031,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
9032,Croatia,2017,8,C10-Lipid modifying agents,% of total sales,2.4
9033,Croatia,2017,8,C-Cardiovascular system,% of total sales,12.8
9034,Croatia,2017,8,N06A-Antidepressants,% of total sales,1.3
9035,Croatia,2017,8,N02-Analgesics,% of total sales,3.0
9036,Croatia,2017,8,C08-Calcium channel blockers,% of total sales,1.4
9037,Croatia,2017,8,C02-Antihypertensives,% of total sales,0.8
9038,Croatia,2017,8,G-Genito urinary system and sex hormones,% of total sales,2.9
9039,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3
9040,Croatia,2017,8,J-Antiinfectives for systemic use,% of total sales,9.9
9041,Croatia,2017,8,A-Alimentary tract and metabolism,% of total sales,13.0
9042,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9
9043,Croatia,2017,8,R-Respiratory system,% of total sales,5.8
9044,Croatia,2017,8,B-Blood and blood forming organs,% of total sales,8.1
9045,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
9046,Croatia,2017,8,N05B-Anxiolytics,% of total sales,1.5
9047,Croatia,2017,8,C03-Diuretics,% of total sales,0.9
9048,Croatia,2017,8,C01A-Cardiac glycosides,% of total sales,0.1
9049,Croatia,2017,8,N05C-Hypnotics and sedatives,% of total sales,0.6
9050,Croatia,2017,8,N-Nervous system,% of total sales,13.6
9051,Croatia,2017,8,J01-Antibacterials for systemic use,% of total sales,5.1
9052,Croatia,2017,8,C07-Beta blocking agents,% of total sales,1.4
9053,Croatia,2017,8,R03-Drugs for obstructive airway diseases,% of total sales,3.6
9054,Croatia,2017,8,A02A-Antacids,% of total sales,0.1
9055,Croatia,2017,8,N05B-Anxiolytics,Million of national currency units,90.0
9056,Croatia,2017,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",36.3
9057,Croatia,2017,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",79.3
9058,Croatia,2017,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",22.9
9059,Croatia,2017,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",49.3
9060,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",34.0
9061,Croatia,2017,8,N05B-Anxiolytics,Million US$ at exchange rate,102.4
9062,Croatia,2017,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",1124.1
9063,Croatia,2017,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,203.6
9064,Croatia,2017,8,N02-Analgesics,"/capita, US$ exchange rate",50.4
9065,Croatia,2017,8,N06A-Antidepressants,"/capita, US$ exchange rate",22.0
9066,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,158.1
9067,Croatia,2017,8,C02-Antihypertensives,"/capita, US$ exchange rate",12.9
9068,Croatia,2017,8,A10-Drugs used in diabetes,Million US$ at exchange rate,464.1
9069,Croatia,2017,8,N-Nervous system,"/capita, US$ purchasing power parity",457.7
9070,Croatia,2017,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",498.6
9071,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,315.0
9072,Croatia,2017,8,C07-Beta blocking agents,"/capita, US$ exchange rate",24.0
9073,Croatia,2017,8,M-Musculo-skeletal system,Million US$ at exchange rate,259.3
9074,Croatia,2017,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",11.3
9075,Croatia,2017,8,R-Respiratory system,Million US$ at exchange rate,407.2
9076,Croatia,2017,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",171.2
9077,Croatia,2017,8,J01-Antibacterials for systemic use,Million of national currency units,312.0
9078,Croatia,2017,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,908.8
9079,Croatia,2017,8,C07-Beta blocking agents,"Million US$, purchasing power parity",197.2
9080,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,62.0
9081,Croatia,2017,8,Total pharmaceutical sales,"Million US$, purchasing power parity",13896.6
9082,Croatia,2017,8,A-Alimentary tract and metabolism,Million of national currency units,799.0
9083,Croatia,2017,8,J-Antiinfectives for systemic use,Million of national currency units,609.0
9084,Croatia,2017,8,N06A-Antidepressants,"Million US$, purchasing power parity",181.3
9085,Croatia,2017,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",1.4
9086,Croatia,2017,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,70.5
9087,Croatia,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",62.6
9088,Croatia,2017,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",81.8
9089,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",262.9
9090,Croatia,2017,8,A10-Drugs used in diabetes,Million of national currency units,408.0
9091,Croatia,2017,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",516.7
9092,Croatia,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,139.0
9093,Croatia,2017,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",707.1
9094,Croatia,2017,8,A02A-Antacids,"Million US$, purchasing power parity",20.4
9095,Croatia,2017,8,C01A-Cardiac glycosides,Million of national currency units,5.0
9096,Croatia,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",31.9
9097,Croatia,2017,8,C-Cardiovascular system,"/capita, US$ exchange rate",216.2
9098,Croatia,2017,8,C08-Calcium channel blockers,Million US$ at exchange rate,94.4
9099,Croatia,2017,8,C03-Diuretics,"/capita, US$ purchasing power parity",29.1
9100,Croatia,2017,8,C03-Diuretics,Million of national currency units,53.0
9101,Croatia,2017,8,R-Respiratory system,"/capita, US$ exchange rate",98.6
9102,Croatia,2017,8,R-Respiratory system,Million of national currency units,358.0
9103,Croatia,2017,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,692.7
9104,Croatia,2017,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",172.9
9105,Croatia,2017,8,N-Nervous system,"Million US$, purchasing power parity",1890.0
9106,Denmark,2011,5,Total pharmaceutical sales,Million US$ at exchange rate,3825.9
9107,Denmark,2011,5,R-Respiratory system,"/capita, US$ purchasing power parity",46.0
9108,Denmark,2011,5,M-Musculo-skeletal system,Million US$ at exchange rate,120.3
9109,Denmark,2011,5,Total pharmaceutical sales,Million of national currency units,20540.2
9110,Denmark,2011,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2751.0
9111,Denmark,2011,5,C-Cardiovascular system,Million US$ at exchange rate,264.2
9112,Denmark,2011,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",86.5
9113,Denmark,2011,5,C-Cardiovascular system,Million of national currency units,1418.5
9114,Denmark,2011,5,R-Respiratory system,% of total sales,9.3
9115,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.0
9116,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
9117,Denmark,2011,5,M-Musculo-skeletal system,Million of national currency units,646.0
9118,Denmark,2011,5,J-Antiinfectives for systemic use,Million of national currency units,2036.3
9119,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.6
9120,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,497.6
9121,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,92.7
9122,Denmark,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",66.6
9123,Denmark,2011,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",272.7
9124,Denmark,2011,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,379.3
9125,Denmark,2011,5,R-Respiratory system,Million of national currency units,1913.4
9126,Denmark,2011,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",68.1
9127,Denmark,2011,5,R-Respiratory system,"/capita, US$ exchange rate",64.0
9128,Denmark,2011,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",493.8
9129,Denmark,2011,5,R-Respiratory system,Million US$ at exchange rate,356.4
9130,Denmark,2011,5,C-Cardiovascular system,% of total sales,6.9
9131,Denmark,2011,5,R-Respiratory system,"Million US$, purchasing power parity",256.3
9132,Denmark,2011,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",21.6
9133,Denmark,2011,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.5
9134,Denmark,2011,5,C-Cardiovascular system,"Million US$, purchasing power parity",190.0
9135,Denmark,2011,5,C-Cardiovascular system,"/capita, US$ exchange rate",47.4
9136,Denmark,2011,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",49.0
9137,Denmark,2011,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",34.1
9138,Denmark,2011,5,J-Antiinfectives for systemic use,% of total sales,9.9
9139,Denmark,2011,5,M-Musculo-skeletal system,% of total sales,3.1
9140,Denmark,2011,5,Total pharmaceutical sales,"/capita, US$ exchange rate",686.8
9141,Denmark,2011,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",40.3
9142,Denmark,2011,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",161.5
9143,Denmark,2011,5,Products not elsewhere classified,Million of national currency units,5610.0
9144,Denmark,2011,5,Products not elsewhere classified,Million US$ at exchange rate,1044.9
9145,Denmark,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.7
9146,Denmark,2011,5,G-Genito urinary system and sex hormones,% of total sales,4.6
9147,Denmark,2011,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.3
9148,Denmark,2011,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,313.5
9149,Denmark,2011,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.0
9150,Denmark,2011,5,A-Alimentary tract and metabolism,Million of national currency units,1682.9
9151,Denmark,2011,5,N-Nervous system,"/capita, US$ exchange rate",153.3
9152,Denmark,2011,5,B-Blood and blood forming organs,% of total sales,5.9
9153,Denmark,2011,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",225.4
9154,Denmark,2011,5,N-Nervous system,% of total sales,22.3
9155,Denmark,2011,5,N-Nervous system,"/capita, US$ purchasing power parity",110.2
9156,Denmark,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",31.6
9157,Denmark,2011,5,N-Nervous system,Million US$ at exchange rate,853.7
9158,Denmark,2011,5,G-Genito urinary system and sex hormones,Million of national currency units,946.1
9159,Denmark,2011,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,176.2
9160,Denmark,2011,5,A-Alimentary tract and metabolism,% of total sales,8.2
9161,Denmark,2011,5,N-Nervous system,Million of national currency units,4583.4
9162,Denmark,2011,5,N-Nervous system,"Million US$, purchasing power parity",613.9
9163,Denmark,2011,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.5
9164,Denmark,2011,5,Products not elsewhere classified,"Million US$, purchasing power parity",751.4
9165,Denmark,2011,5,Products not elsewhere classified,"/capita, US$ exchange rate",187.6
9166,Denmark,2011,5,B-Blood and blood forming organs,Million US$ at exchange rate,224.6
9167,Denmark,2011,5,B-Blood and blood forming organs,Million of national currency units,1206.0
9168,Denmark,2011,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",134.9
9169,Denmark,2011,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",126.7
9170,Denmark,2011,5,Products not elsewhere classified,% of total sales,27.3
9171,Denmark,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,3532.1
9172,Denmark,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",46.8
9173,Denmark,2012,5,Total pharmaceutical sales,Million of national currency units,20459.8
9174,Denmark,2012,5,M-Musculo-skeletal system,Million US$ at exchange rate,93.9
9175,Denmark,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2704.8
9176,Denmark,2012,5,C-Cardiovascular system,Million US$ at exchange rate,219.8
9177,Denmark,2012,5,C-Cardiovascular system,Million of national currency units,1273.3
9178,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.4
9179,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
9180,Denmark,2012,5,M-Musculo-skeletal system,Million of national currency units,543.8
9181,Denmark,2012,5,J-Antiinfectives for systemic use,Million of national currency units,2015.8
9182,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.9
9183,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,482.7
9184,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.8
9185,Denmark,2012,5,R-Respiratory system,% of total sales,9.7
9186,Denmark,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,83.3
9187,Denmark,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",266.5
9188,Denmark,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,348.0
9189,Denmark,2012,5,R-Respiratory system,Million of national currency units,1977.5
9190,Denmark,2012,5,C-Cardiovascular system,% of total sales,6.2
9191,Denmark,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",62.2
9192,Denmark,2012,5,R-Respiratory system,"/capita, US$ exchange rate",61.1
9193,Denmark,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",483.7
9194,Denmark,2012,5,R-Respiratory system,Million US$ at exchange rate,341.4
9195,Denmark,2012,5,R-Respiratory system,"Million US$, purchasing power parity",261.4
9196,Denmark,2012,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",16.8
9197,Denmark,2012,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.9
9198,Denmark,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",168.3
9199,Denmark,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",39.3
9200,Denmark,2012,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",71.9
9201,Denmark,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",631.7
9202,Denmark,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",47.7
9203,Denmark,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",30.1
9204,Denmark,2012,5,J-Antiinfectives for systemic use,% of total sales,9.9
9205,Denmark,2012,5,M-Musculo-skeletal system,% of total sales,2.7
9206,Denmark,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",41.5
9207,Denmark,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",177.7
9208,Denmark,2012,5,Products not elsewhere classified,Million of national currency units,5976.8
9209,Denmark,2012,5,Products not elsewhere classified,Million US$ at exchange rate,1031.8
9210,Denmark,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.1
9211,Denmark,2012,5,G-Genito urinary system and sex hormones,% of total sales,4.8
9212,Denmark,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",54.9
9213,Denmark,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,306.8
9214,Denmark,2012,5,A-Alimentary tract and metabolism,Million of national currency units,1777.0
9215,Denmark,2012,5,N-Nervous system,"/capita, US$ exchange rate",126.3
9216,Denmark,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.8
9217,Denmark,2012,5,B-Blood and blood forming organs,% of total sales,6.6
9218,Denmark,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",234.9
9219,Denmark,2012,5,N-Nervous system,% of total sales,20.0
9220,Denmark,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",96.7
9221,Denmark,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",30.2
9222,Denmark,2012,5,N-Nervous system,Million US$ at exchange rate,706.2
9223,Denmark,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,978.0
9224,Denmark,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,168.8
9225,Denmark,2012,5,A-Alimentary tract and metabolism,% of total sales,8.7
9226,Denmark,2012,5,N-Nervous system,Million of national currency units,4090.7
9227,Denmark,2012,5,N-Nervous system,"Million US$, purchasing power parity",540.8
9228,Denmark,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.0
9229,Denmark,2012,5,Products not elsewhere classified,"Million US$, purchasing power parity",790.2
9230,Denmark,2012,5,Products not elsewhere classified,"/capita, US$ exchange rate",184.5
9231,Denmark,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,232.0
9232,Denmark,2012,5,B-Blood and blood forming organs,Million of national currency units,1344.1
9233,Denmark,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",129.3
9234,Denmark,2012,5,Products not elsewhere classified,% of total sales,29.2
9235,Denmark,2012,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",141.3
9236,Denmark,2013,4,Total pharmaceutical sales,Million US$ at exchange rate,3636.2
9237,Denmark,2013,4,Total pharmaceutical sales,Million of national currency units,20422.2
9238,Denmark,2013,4,R-Respiratory system,"/capita, US$ purchasing power parity",46.2
9239,Denmark,2013,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2776.7
9240,Denmark,2013,4,C-Cardiovascular system,Million US$ at exchange rate,200.9
9241,Denmark,2013,4,M-Musculo-skeletal system,Million US$ at exchange rate,98.2
9242,Denmark,2013,4,C-Cardiovascular system,Million of national currency units,1128.6
9243,Denmark,2013,4,R-Respiratory system,% of total sales,9.3
9244,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6
9245,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.9
9246,Denmark,2013,4,M-Musculo-skeletal system,Million of national currency units,551.8
9247,Denmark,2013,4,J-Antiinfectives for systemic use,Million of national currency units,2066.2
9248,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
9249,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,437.0
9250,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",59.4
9251,Denmark,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,77.8
9252,Denmark,2013,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",280.9
9253,Denmark,2013,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,367.9
9254,Denmark,2013,4,Total pharmaceutical sales,"/capita, US$ exchange rate",647.6
9255,Denmark,2013,4,C-Cardiovascular system,% of total sales,5.5
9256,Denmark,2013,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.5
9257,Denmark,2013,4,R-Respiratory system,Million of national currency units,1909.3
9258,Denmark,2013,4,R-Respiratory system,"/capita, US$ exchange rate",60.5
9259,Denmark,2013,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",494.5
9260,Denmark,2013,4,R-Respiratory system,Million US$ at exchange rate,340.0
9261,Denmark,2013,4,R-Respiratory system,"Million US$, purchasing power parity",259.6
9262,Denmark,2013,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.5
9263,Denmark,2013,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.4
9264,Denmark,2013,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",75.0
9265,Denmark,2013,4,C-Cardiovascular system,"Million US$, purchasing power parity",153.4
9266,Denmark,2013,4,C-Cardiovascular system,"/capita, US$ exchange rate",35.8
9267,Denmark,2013,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",50.0
9268,Denmark,2013,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.3
9269,Denmark,2013,4,M-Musculo-skeletal system,% of total sales,2.7
9270,Denmark,2013,4,J-Antiinfectives for systemic use,% of total sales,10.1
9271,Denmark,2013,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",44.6
9272,Denmark,2013,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",191.1
9273,Denmark,2013,4,Products not elsewhere classified,Million of national currency units,6538.7
9274,Denmark,2013,4,Products not elsewhere classified,Million US$ at exchange rate,1164.2
9275,Denmark,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.1
9276,Denmark,2013,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.9
9277,Denmark,2013,4,G-Genito urinary system and sex hormones,% of total sales,4.3
9278,Denmark,2013,4,A-Alimentary tract and metabolism,Million of national currency units,1825.1
9279,Denmark,2013,4,N-Nervous system,"/capita, US$ exchange rate",117.0
9280,Denmark,2013,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.0
9281,Denmark,2013,4,B-Blood and blood forming organs,% of total sales,6.9
9282,Denmark,2013,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",248.2
9283,Denmark,2013,4,N-Nervous system,% of total sales,18.1
9284,Denmark,2013,4,N-Nervous system,"/capita, US$ purchasing power parity",89.3
9285,Denmark,2013,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,325.0
9286,Denmark,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.6
9287,Denmark,2013,4,N-Nervous system,Million US$ at exchange rate,657.0
9288,Denmark,2013,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,155.0
9289,Denmark,2013,4,G-Genito urinary system and sex hormones,Million of national currency units,870.4
9290,Denmark,2013,4,A-Alimentary tract and metabolism,% of total sales,8.9
9291,Denmark,2013,4,N-Nervous system,Million of national currency units,3689.7
9292,Denmark,2013,4,N-Nervous system,"Million US$, purchasing power parity",501.7
9293,Denmark,2013,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.2
9294,Denmark,2013,4,Products not elsewhere classified,% of total sales,32.0
9295,Denmark,2013,4,Products not elsewhere classified,"Million US$, purchasing power parity",889.0
9296,Denmark,2013,4,Products not elsewhere classified,"/capita, US$ exchange rate",207.3
9297,Denmark,2013,4,B-Blood and blood forming organs,Million US$ at exchange rate,250.2
9298,Denmark,2013,4,B-Blood and blood forming organs,Million of national currency units,1405.3
9299,Denmark,2013,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",118.3
9300,Denmark,2013,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",158.3
9301,Denmark,2017,4,Total pharmaceutical sales,Million of national currency units,22941.5
9302,Denmark,2017,4,M-Musculo-skeletal system,Million of national currency units,598.1
9303,Denmark,2017,4,R-Respiratory system,"/capita, US$ purchasing power parity",48.6
9304,Denmark,2017,4,R-Respiratory system,"/capita, US$ exchange rate",50.6
9305,Denmark,2017,4,Total pharmaceutical sales,"Million US$, purchasing power parity",3338.6
9306,Denmark,2017,4,C-Cardiovascular system,Million US$ at exchange rate,163.5
9307,Denmark,2017,4,Total pharmaceutical sales,Million US$ at exchange rate,3474.5
9308,Denmark,2017,4,M-Musculo-skeletal system,Million US$ at exchange rate,90.6
9309,Denmark,2017,4,C-Cardiovascular system,Million of national currency units,1079.3
9310,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.1
9311,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.6
9312,Denmark,2017,4,J-Antiinfectives for systemic use,Million of national currency units,1983.3
9313,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
9314,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,477.8
9315,Denmark,2017,4,R-Respiratory system,% of total sales,8.4
9316,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",69.5
9317,Denmark,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,72.4
9318,Denmark,2017,4,Total pharmaceutical sales,"/capita, US$ exchange rate",602.7
9319,Denmark,2017,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",288.6
9320,Denmark,2017,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,300.4
9321,Denmark,2017,4,C-Cardiovascular system,% of total sales,4.7
9322,Denmark,2017,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",52.1
9323,Denmark,2017,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",579.1
9324,Denmark,2017,4,R-Respiratory system,"Million US$, purchasing power parity",280.2
9325,Denmark,2017,4,R-Respiratory system,Million of national currency units,1925.4
9326,Denmark,2017,4,R-Respiratory system,Million US$ at exchange rate,291.6
9327,Denmark,2017,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",87.0
9328,Denmark,2017,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.7
9329,Denmark,2017,4,C-Cardiovascular system,"Million US$, purchasing power parity",157.1
9330,Denmark,2017,4,C-Cardiovascular system,"/capita, US$ exchange rate",28.4
9331,Denmark,2017,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1
9332,Denmark,2017,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.2
9333,Denmark,2017,4,M-Musculo-skeletal system,% of total sales,2.6
9334,Denmark,2017,4,J-Antiinfectives for systemic use,% of total sales,8.6
9335,Denmark,2017,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",50.1
9336,Denmark,2017,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",52.4
9337,Denmark,2017,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",290.1
9338,Denmark,2017,4,Products not elsewhere classified,Million of national currency units,8416.3
9339,Denmark,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.0
9340,Denmark,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.8
9341,Denmark,2017,4,G-Genito urinary system and sex hormones,% of total sales,3.6
9342,Denmark,2017,4,A-Alimentary tract and metabolism,Million of national currency units,2320.4
9343,Denmark,2017,4,B-Blood and blood forming organs,% of total sales,8.7
9344,Denmark,2017,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",50.3
9345,Denmark,2017,4,N-Nervous system,"/capita, US$ exchange rate",87.1
9346,Denmark,2017,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",337.7
9347,Denmark,2017,4,N-Nervous system,% of total sales,14.5
9348,Denmark,2017,4,N-Nervous system,"/capita, US$ purchasing power parity",83.7
9349,Denmark,2017,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,351.4
9350,Denmark,2017,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.0
9351,Denmark,2017,4,N-Nervous system,Million US$ at exchange rate,502.3
9352,Denmark,2017,4,Products not elsewhere classified,% of total sales,36.7
9353,Denmark,2017,4,G-Genito urinary system and sex hormones,Million of national currency units,830.2
9354,Denmark,2017,4,N-Nervous system,Million of national currency units,3316.9
9355,Denmark,2017,4,A-Alimentary tract and metabolism,% of total sales,10.1
9356,Denmark,2017,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",58.6
9357,Denmark,2017,4,N-Nervous system,"Million US$, purchasing power parity",482.7
9358,Denmark,2017,4,Products not elsewhere classified,"Million US$, purchasing power parity",1224.8
9359,Denmark,2017,4,Products not elsewhere classified,"/capita, US$ exchange rate",221.1
9360,Denmark,2017,4,B-Blood and blood forming organs,Million US$ at exchange rate,302.0
9361,Denmark,2017,4,B-Blood and blood forming organs,Million of national currency units,1993.8
9362,Denmark,2017,4,Products not elsewhere classified,Million US$ at exchange rate,1274.6
9363,Denmark,2017,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",212.5
9364,Denmark,2017,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",120.8
9365,Denmark,2017,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,125.7
9366,Denmark,2015,4,Total pharmaceutical sales,Million US$ at exchange rate,3254.8
9367,Denmark,2015,4,M-Musculo-skeletal system,Million of national currency units,578.9
9368,Denmark,2015,4,Total pharmaceutical sales,Million of national currency units,21897.7
9369,Denmark,2015,4,R-Respiratory system,"/capita, US$ purchasing power parity",47.4
9370,Denmark,2015,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2997.5
9371,Denmark,2015,4,C-Cardiovascular system,Million US$ at exchange rate,171.3
9372,Denmark,2015,4,M-Musculo-skeletal system,Million US$ at exchange rate,86.0
9373,Denmark,2015,4,C-Cardiovascular system,Million of national currency units,1152.3
9374,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.1
9375,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.0
9376,Denmark,2015,4,J-Antiinfectives for systemic use,Million of national currency units,2220.3
9377,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
9378,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,459.2
9379,Denmark,2015,4,R-Respiratory system,% of total sales,9.0
9380,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",62.9
9381,Denmark,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,68.2
9382,Denmark,2015,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",303.9
9383,Denmark,2015,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,330.0
9384,Denmark,2015,4,Total pharmaceutical sales,"/capita, US$ exchange rate",572.7
9385,Denmark,2015,4,C-Cardiovascular system,% of total sales,5.3
9386,Denmark,2015,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",58.1
9387,Denmark,2015,4,R-Respiratory system,Million of national currency units,1968.7
9388,Denmark,2015,4,R-Respiratory system,"/capita, US$ exchange rate",51.5
9389,Denmark,2015,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",527.4
9390,Denmark,2015,4,R-Respiratory system,Million US$ at exchange rate,292.6
9391,Denmark,2015,4,R-Respiratory system,"Million US$, purchasing power parity",269.5
9392,Denmark,2015,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.1
9393,Denmark,2015,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.9
9394,Denmark,2015,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",79.2
9395,Denmark,2015,4,C-Cardiovascular system,"Million US$, purchasing power parity",157.7
9396,Denmark,2015,4,C-Cardiovascular system,"/capita, US$ exchange rate",30.1
9397,Denmark,2015,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",53.5
9398,Denmark,2015,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.8
9399,Denmark,2015,4,M-Musculo-skeletal system,% of total sales,2.6
9400,Denmark,2015,4,J-Antiinfectives for systemic use,% of total sales,10.1
9401,Denmark,2015,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.0
9402,Denmark,2015,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",235.6
9403,Denmark,2015,4,Products not elsewhere classified,Million of national currency units,7278.8
9404,Denmark,2015,4,Products not elsewhere classified,Million US$ at exchange rate,1081.9
9405,Denmark,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.1
9406,Denmark,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.8
9407,Denmark,2015,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",54.6
9408,Denmark,2015,4,G-Genito urinary system and sex hormones,% of total sales,3.8
9409,Denmark,2015,4,A-Alimentary tract and metabolism,Million of national currency units,2086.5
9410,Denmark,2015,4,B-Blood and blood forming organs,% of total sales,7.9
9411,Denmark,2015,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.5
9412,Denmark,2015,4,N-Nervous system,"/capita, US$ exchange rate",94.1
9413,Denmark,2015,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",285.6
9414,Denmark,2015,4,N-Nervous system,% of total sales,16.4
9415,Denmark,2015,4,N-Nervous system,"/capita, US$ purchasing power parity",86.6
9416,Denmark,2015,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,310.1
9417,Denmark,2015,4,N-Nervous system,Million US$ at exchange rate,534.6
9418,Denmark,2015,4,G-Genito urinary system and sex hormones,Million of national currency units,834.9
9419,Denmark,2015,4,N-Nervous system,Million of national currency units,3596.9
9420,Denmark,2015,4,A-Alimentary tract and metabolism,% of total sales,9.5
9421,Denmark,2015,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.3
9422,Denmark,2015,4,N-Nervous system,"Million US$, purchasing power parity",492.4
9423,Denmark,2015,4,Products not elsewhere classified,% of total sales,33.2
9424,Denmark,2015,4,Products not elsewhere classified,"Million US$, purchasing power parity",996.4
9425,Denmark,2015,4,Products not elsewhere classified,"/capita, US$ exchange rate",190.4
9426,Denmark,2015,4,B-Blood and blood forming organs,Million US$ at exchange rate,255.8
9427,Denmark,2015,4,B-Blood and blood forming organs,Million of national currency units,1721.2
9428,Denmark,2015,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",175.3
9429,Denmark,2015,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",114.3
9430,Denmark,2015,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,124.1
9431,Denmark,2016,4,M-Musculo-skeletal system,Million of national currency units,593.4
9432,Denmark,2016,4,Total pharmaceutical sales,Million of national currency units,22110.0
9433,Denmark,2016,4,Total pharmaceutical sales,Million US$ at exchange rate,3284.5
9434,Denmark,2016,4,R-Respiratory system,"/capita, US$ purchasing power parity",48.2
9435,Denmark,2016,4,R-Respiratory system,"/capita, US$ exchange rate",50.7
9436,Denmark,2016,4,Total pharmaceutical sales,"Million US$, purchasing power parity",3122.9
9437,Denmark,2016,4,C-Cardiovascular system,Million US$ at exchange rate,161.1
9438,Denmark,2016,4,M-Musculo-skeletal system,Million US$ at exchange rate,88.1
9439,Denmark,2016,4,C-Cardiovascular system,Million of national currency units,1084.4
9440,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.5
9441,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.1
9442,Denmark,2016,4,J-Antiinfectives for systemic use,Million of national currency units,2066.0
9443,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
9444,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,466.9
9445,Denmark,2016,4,R-Respiratory system,% of total sales,8.8
9446,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",66.0
9447,Denmark,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,69.4
9448,Denmark,2016,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",291.8
9449,Denmark,2016,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,306.9
9450,Denmark,2016,4,Total pharmaceutical sales,"/capita, US$ exchange rate",573.4
9451,Denmark,2016,4,C-Cardiovascular system,% of total sales,4.9
9452,Denmark,2016,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.6
9453,Denmark,2016,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",545.2
9454,Denmark,2016,4,R-Respiratory system,"Million US$, purchasing power parity",276.1
9455,Denmark,2016,4,R-Respiratory system,Million of national currency units,1954.6
9456,Denmark,2016,4,R-Respiratory system,Million US$ at exchange rate,290.4
9457,Denmark,2016,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.4
9458,Denmark,2016,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",83.8
9459,Denmark,2016,4,C-Cardiovascular system,"Million US$, purchasing power parity",153.2
9460,Denmark,2016,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.6
9461,Denmark,2016,4,C-Cardiovascular system,"/capita, US$ exchange rate",28.1
9462,Denmark,2016,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",50.9
9463,Denmark,2016,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",26.7
9464,Denmark,2016,4,M-Musculo-skeletal system,% of total sales,2.7
9465,Denmark,2016,4,J-Antiinfectives for systemic use,% of total sales,9.3
9466,Denmark,2016,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",48.0
9467,Denmark,2016,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",261.6
9468,Denmark,2016,4,Products not elsewhere classified,Million of national currency units,7562.7
9469,Denmark,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.5
9470,Denmark,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.6
9471,Denmark,2016,4,G-Genito urinary system and sex hormones,% of total sales,3.8
9472,Denmark,2016,4,A-Alimentary tract and metabolism,Million of national currency units,2214.3
9473,Denmark,2016,4,B-Blood and blood forming organs,% of total sales,8.4
9474,Denmark,2016,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.7
9475,Denmark,2016,4,N-Nervous system,"/capita, US$ exchange rate",90.4
9476,Denmark,2016,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",312.8
9477,Denmark,2016,4,N-Nervous system,% of total sales,15.8
9478,Denmark,2016,4,N-Nervous system,"/capita, US$ purchasing power parity",85.9
9479,Denmark,2016,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,328.9
9480,Denmark,2016,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.4
9481,Denmark,2016,4,N-Nervous system,Million US$ at exchange rate,517.6
9482,Denmark,2016,4,G-Genito urinary system and sex hormones,Million of national currency units,831.7
9483,Denmark,2016,4,Products not elsewhere classified,% of total sales,34.2
9484,Denmark,2016,4,A-Alimentary tract and metabolism,% of total sales,10.0
9485,Denmark,2016,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",54.6
9486,Denmark,2016,4,N-Nervous system,"Million US$, purchasing power parity",492.1
9487,Denmark,2016,4,N-Nervous system,Million of national currency units,3484.1
9488,Denmark,2016,4,Products not elsewhere classified,"Million US$, purchasing power parity",1068.2
9489,Denmark,2016,4,Products not elsewhere classified,"/capita, US$ exchange rate",196.1
9490,Denmark,2016,4,Products not elsewhere classified,Million US$ at exchange rate,1123.4
9491,Denmark,2016,4,B-Blood and blood forming organs,Million US$ at exchange rate,275.1
9492,Denmark,2016,4,B-Blood and blood forming organs,Million of national currency units,1851.8
9493,Denmark,2016,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",186.5
9494,Denmark,2016,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",117.5
9495,Denmark,2016,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,123.5
9496,Denmark,2010,5,Total pharmaceutical sales,Million US$ at exchange rate,3764.4
9497,Denmark,2010,5,M-Musculo-skeletal system,Million US$ at exchange rate,109.9
9498,Denmark,2010,5,R-Respiratory system,"/capita, US$ purchasing power parity",45.5
9499,Denmark,2010,5,Total pharmaceutical sales,Million of national currency units,21171.2
9500,Denmark,2010,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2788.9
9501,Denmark,2010,5,Total pharmaceutical sales,"/capita, US$ exchange rate",678.6
9502,Denmark,2010,5,R-Respiratory system,% of total sales,9.1
9503,Denmark,2010,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",81.5
9504,Denmark,2010,5,C-Cardiovascular system,Million of national currency units,1722.0
9505,Denmark,2010,5,C-Cardiovascular system,Million US$ at exchange rate,306.2
9506,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
9507,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8
9508,Denmark,2010,5,M-Musculo-skeletal system,Million of national currency units,618.3
9509,Denmark,2010,5,J-Antiinfectives for systemic use,Million of national currency units,2056.7
9510,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.9
9511,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,497.6
9512,Denmark,2010,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,365.7
9513,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,88.5
9514,Denmark,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",65.6
9515,Denmark,2010,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",270.9
9516,Denmark,2010,5,R-Respiratory system,Million of national currency units,1917.9
9517,Denmark,2010,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.9
9518,Denmark,2010,5,R-Respiratory system,"/capita, US$ exchange rate",61.5
9519,Denmark,2010,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",502.7
9520,Denmark,2010,5,R-Respiratory system,Million US$ at exchange rate,341.0
9521,Denmark,2010,5,R-Respiratory system,"Million US$, purchasing power parity",252.7
9522,Denmark,2010,5,C-Cardiovascular system,% of total sales,8.1
9523,Denmark,2010,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.8
9524,Denmark,2010,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.7
9525,Denmark,2010,5,C-Cardiovascular system,"Million US$, purchasing power parity",226.8
9526,Denmark,2010,5,C-Cardiovascular system,"/capita, US$ exchange rate",55.2
9527,Denmark,2010,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",48.8
9528,Denmark,2010,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",40.9
9529,Denmark,2010,5,J-Antiinfectives for systemic use,% of total sales,9.7
9530,Denmark,2010,5,M-Musculo-skeletal system,% of total sales,2.9
9531,Denmark,2010,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.9
9532,Denmark,2010,5,Products not elsewhere classified,Million US$ at exchange rate,1011.3
9533,Denmark,2010,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.5
9534,Denmark,2010,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",163.8
9535,Denmark,2010,5,Products not elsewhere classified,Million of national currency units,5687.4
9536,Denmark,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.7
9537,Denmark,2010,5,G-Genito urinary system and sex hormones,% of total sales,4.9
9538,Denmark,2010,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",55.8
9539,Denmark,2010,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,309.4
9540,Denmark,2010,5,A-Alimentary tract and metabolism,Million of national currency units,1740.0
9541,Denmark,2010,5,B-Blood and blood forming organs,% of total sales,5.9
9542,Denmark,2010,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",229.2
9543,Denmark,2010,5,N-Nervous system,% of total sales,21.9
9544,Denmark,2010,5,N-Nervous system,"/capita, US$ purchasing power parity",110.3
9545,Denmark,2010,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.3
9546,Denmark,2010,5,N-Nervous system,Million US$ at exchange rate,826.1
9547,Denmark,2010,5,G-Genito urinary system and sex hormones,Million of national currency units,1041.8
9548,Denmark,2010,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,185.2
9549,Denmark,2010,5,A-Alimentary tract and metabolism,% of total sales,8.2
9550,Denmark,2010,5,N-Nervous system,"/capita, US$ exchange rate",148.9
9551,Denmark,2010,5,N-Nervous system,Million of national currency units,4646.0
9552,Denmark,2010,5,N-Nervous system,"Million US$, purchasing power parity",612.0
9553,Denmark,2010,5,Products not elsewhere classified,"Million US$, purchasing power parity",749.2
9554,Denmark,2010,5,Products not elsewhere classified,"/capita, US$ exchange rate",182.3
9555,Denmark,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",33.4
9556,Denmark,2010,5,B-Blood and blood forming organs,Million US$ at exchange rate,221.1
9557,Denmark,2010,5,B-Blood and blood forming organs,Million of national currency units,1243.4
9558,Denmark,2010,5,Products not elsewhere classified,% of total sales,26.9
9559,Denmark,2010,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",135.0
9560,Denmark,2010,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",137.2
9561,Denmark,2014,4,Total pharmaceutical sales,Million US$ at exchange rate,3816.2
9562,Denmark,2014,4,M-Musculo-skeletal system,Million of national currency units,534.2
9563,Denmark,2014,4,R-Respiratory system,"/capita, US$ purchasing power parity",47.0
9564,Denmark,2014,4,Total pharmaceutical sales,Million of national currency units,21418.1
9565,Denmark,2014,4,M-Musculo-skeletal system,Million US$ at exchange rate,95.2
9566,Denmark,2014,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2922.5
9567,Denmark,2014,4,C-Cardiovascular system,Million US$ at exchange rate,205.5
9568,Denmark,2014,4,C-Cardiovascular system,Million of national currency units,1153.2
9569,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.3
9570,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.7
9571,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
9572,Denmark,2014,4,J-Antiinfectives for systemic use,Million of national currency units,2107.4
9573,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,465.8
9574,Denmark,2014,4,R-Respiratory system,% of total sales,9.1
9575,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.6
9576,Denmark,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,83.0
9577,Denmark,2014,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",287.6
9578,Denmark,2014,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,375.5
9579,Denmark,2014,4,Total pharmaceutical sales,"/capita, US$ exchange rate",676.2
9580,Denmark,2014,4,C-Cardiovascular system,% of total sales,5.4
9581,Denmark,2014,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.5
9582,Denmark,2014,4,R-Respiratory system,Million of national currency units,1944.7
9583,Denmark,2014,4,R-Respiratory system,"/capita, US$ exchange rate",61.4
9584,Denmark,2014,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",517.9
9585,Denmark,2014,4,R-Respiratory system,Million US$ at exchange rate,346.5
9586,Denmark,2014,4,R-Respiratory system,"Million US$, purchasing power parity",265.4
9587,Denmark,2014,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",16.9
9588,Denmark,2014,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.9
9589,Denmark,2014,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",72.9
9590,Denmark,2014,4,C-Cardiovascular system,"Million US$, purchasing power parity",157.4
9591,Denmark,2014,4,C-Cardiovascular system,"/capita, US$ exchange rate",36.4
9592,Denmark,2014,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",51.0
9593,Denmark,2014,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.9
9594,Denmark,2014,4,M-Musculo-skeletal system,% of total sales,2.5
9595,Denmark,2014,4,J-Antiinfectives for systemic use,% of total sales,9.8
9596,Denmark,2014,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",50.3
9597,Denmark,2014,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",217.5
9598,Denmark,2014,4,Products not elsewhere classified,Million of national currency units,7193.0
9599,Denmark,2014,4,Products not elsewhere classified,Million US$ at exchange rate,1281.6
9600,Denmark,2014,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.7
9601,Denmark,2014,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.7
9602,Denmark,2014,4,G-Genito urinary system and sex hormones,% of total sales,3.8
9603,Denmark,2014,4,A-Alimentary tract and metabolism,Million of national currency units,1954.7
9604,Denmark,2014,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.5
9605,Denmark,2014,4,B-Blood and blood forming organs,% of total sales,7.4
9606,Denmark,2014,4,N-Nervous system,"/capita, US$ exchange rate",115.5
9607,Denmark,2014,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",266.7
9608,Denmark,2014,4,N-Nervous system,% of total sales,17.1
9609,Denmark,2014,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.7
9610,Denmark,2014,4,N-Nervous system,"/capita, US$ purchasing power parity",88.5
9611,Denmark,2014,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,348.3
9612,Denmark,2014,4,N-Nervous system,Million US$ at exchange rate,651.8
9613,Denmark,2014,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,144.9
9614,Denmark,2014,4,G-Genito urinary system and sex hormones,Million of national currency units,813.1
9615,Denmark,2014,4,A-Alimentary tract and metabolism,% of total sales,9.1
9616,Denmark,2014,4,N-Nervous system,Million of national currency units,3658.3
9617,Denmark,2014,4,N-Nervous system,"Million US$, purchasing power parity",499.2
9618,Denmark,2014,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.3
9619,Denmark,2014,4,Products not elsewhere classified,"Million US$, purchasing power parity",981.5
9620,Denmark,2014,4,Products not elsewhere classified,"/capita, US$ exchange rate",227.1
9621,Denmark,2014,4,B-Blood and blood forming organs,Million US$ at exchange rate,284.0
9622,Denmark,2014,4,B-Blood and blood forming organs,Million of national currency units,1593.7
9623,Denmark,2014,4,Products not elsewhere classified,% of total sales,33.6
9624,Denmark,2014,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",173.9
9625,Denmark,2014,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",110.9
9626,Estonia,2016,11,C02-Antihypertensives,"Million US$, purchasing power parity",1.4
9627,Estonia,2016,11,C02-Antihypertensives,"/capita, US$ exchange rate",0.6
9628,Estonia,2016,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0
9629,Estonia,2016,11,N05B-Anxiolytics,% of total sales,0.5
9630,Estonia,2016,11,C02-Antihypertensives,Million US$ at exchange rate,0.8
9631,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3
9632,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.6
9633,Estonia,2016,11,N02-Analgesics,"Million US$, purchasing power parity",14.1
9634,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",7.4
9635,Estonia,2016,11,N02-Analgesics,Million US$ at exchange rate,8.3
9636,Estonia,2016,11,N05B-Anxiolytics,Million US$ at exchange rate,1.5
9637,Estonia,2016,11,N05B-Anxiolytics,Million of national currency units,1.4
9638,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.3
9639,Estonia,2016,11,N02-Analgesics,"/capita, US$ purchasing power parity",10.7
9640,Estonia,2016,11,N02-Analgesics,"/capita, US$ exchange rate",6.3
9641,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.9
9642,Estonia,2016,11,N02-Analgesics,% of total sales,2.6
9643,Estonia,2016,11,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6
9644,Estonia,2016,11,C-Cardiovascular system,"/capita, US$ exchange rate",25.9
9645,Estonia,2016,11,C-Cardiovascular system,"Million US$, purchasing power parity",58.3
9646,Estonia,2016,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
9647,Estonia,2016,11,C02-Antihypertensives,% of total sales,0.3
9648,Estonia,2016,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3
9649,Estonia,2016,11,C-Cardiovascular system,Million US$ at exchange rate,34.1
9650,Estonia,2016,11,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
9651,Estonia,2016,11,N02-Analgesics,Million of national currency units,7.5
9652,Estonia,2016,11,C-Cardiovascular system,Million of national currency units,30.8
9653,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.7
9654,Estonia,2016,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.3
9655,Estonia,2016,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",36.5
9656,Estonia,2016,11,B-Blood and blood forming organs,Million US$ at exchange rate,28.1
9657,Estonia,2016,11,B-Blood and blood forming organs,% of total sales,8.7
9658,Estonia,2016,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",48.0
9659,Estonia,2016,11,R-Respiratory system,"Million US$, purchasing power parity",40.4
9660,Estonia,2016,11,R-Respiratory system,"/capita, US$ exchange rate",17.9
9661,Estonia,2016,11,R-Respiratory system,Million of national currency units,21.3
9662,Estonia,2016,11,R-Respiratory system,Million US$ at exchange rate,23.6
9663,Estonia,2016,11,C10-Lipid modifying agents,% of total sales,1.1
9664,Estonia,2016,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.4
9665,Estonia,2016,11,A02A-Antacids,Million of national currency units,0.4
9666,Estonia,2016,11,A02A-Antacids,"Million US$, purchasing power parity",0.7
9667,Estonia,2016,11,A02A-Antacids,Million US$ at exchange rate,0.4
9668,Estonia,2016,11,C10-Lipid modifying agents,Million US$ at exchange rate,3.4
9669,Estonia,2016,11,C10-Lipid modifying agents,Million of national currency units,3.1
9670,Estonia,2016,11,B-Blood and blood forming organs,Million of national currency units,25.4
9671,Estonia,2016,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.6
9672,Estonia,2016,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.8
9673,Estonia,2016,11,R-Respiratory system,"/capita, US$ purchasing power parity",30.7
9674,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,13.6
9675,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.3
9676,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.2
9677,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.7
9678,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.3
9679,Estonia,2016,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.5
9680,Estonia,2016,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",16.8
9681,Estonia,2016,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.8
9682,Estonia,2016,11,R03-Drugs for obstructive airway diseases,Million of national currency units,8.9
9683,Estonia,2016,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.8
9684,Estonia,2016,11,C08-Calcium channel blockers,Million US$ at exchange rate,2.3
9685,Estonia,2016,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.0
9686,Estonia,2016,11,R-Respiratory system,% of total sales,7.4
9687,Estonia,2016,11,C08-Calcium channel blockers,Million of national currency units,2.1
9688,Estonia,2016,11,R03-Drugs for obstructive airway diseases,% of total sales,3.1
9689,Estonia,2016,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.2
9690,Estonia,2016,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.8
9691,Estonia,2016,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.0
9692,Estonia,2016,11,C08-Calcium channel blockers,% of total sales,0.7
9693,Estonia,2016,11,N05C-Hypnotics and sedatives,Million of national currency units,1.8
9694,Estonia,2016,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.0
9695,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.4
9696,Estonia,2016,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4
9697,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.8
9698,Estonia,2016,11,N05C-Hypnotics and sedatives,% of total sales,0.6
9699,Estonia,2016,11,G-Genito urinary system and sex hormones,% of total sales,4.0
9700,Estonia,2016,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5
9701,Estonia,2016,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.6
9702,Estonia,2016,11,C03-Diuretics,"/capita, US$ exchange rate",1.6
9703,Estonia,2016,11,C03-Diuretics,"/capita, US$ purchasing power parity",2.7
9704,Estonia,2016,11,C03-Diuretics,"Million US$, purchasing power parity",3.6
9705,Estonia,2016,11,C03-Diuretics,Million of national currency units,1.9
9706,Estonia,2016,11,C03-Diuretics,Million US$ at exchange rate,2.1
9707,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.3
9708,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.9
9709,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.0
9710,Estonia,2016,11,C03-Diuretics,% of total sales,0.7
9711,Estonia,2016,11,G03-Sex hormones and modulators of the genital system,% of total sales,2.0
9712,Estonia,2016,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.7
9713,Estonia,2016,11,C07-Beta blocking agents,Million US$ at exchange rate,6.0
9714,Estonia,2016,11,C07-Beta blocking agents,"Million US$, purchasing power parity",10.3
9715,Estonia,2016,11,N06A-Antidepressants,% of total sales,1.1
9716,Estonia,2016,11,C07-Beta blocking agents,Million of national currency units,5.4
9717,Estonia,2016,11,A02A-Antacids,% of total sales,0.1
9718,Estonia,2016,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
9719,Estonia,2016,11,A02A-Antacids,"/capita, US$ exchange rate",0.3
9720,Estonia,2016,11,C07-Beta blocking agents,% of total sales,1.9
9721,Estonia,2016,11,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6
9722,Estonia,2016,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.8
9723,Estonia,2016,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.8
9724,Estonia,2016,11,G-Genito urinary system and sex hormones,Million of national currency units,11.6
9725,Estonia,2016,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.8
9726,Estonia,2016,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",22.0
9727,Estonia,2016,11,N06A-Antidepressants,"/capita, US$ exchange rate",2.7
9728,Estonia,2016,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.7
9729,Estonia,2016,11,N06A-Antidepressants,Million of national currency units,3.3
9730,Estonia,2016,11,N06A-Antidepressants,Million US$ at exchange rate,3.6
9731,Estonia,2016,11,N06A-Antidepressants,"Million US$, purchasing power parity",6.2
9732,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3
9733,Estonia,2016,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,38.0
9734,Estonia,2016,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.9
9735,Estonia,2016,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",65.1
9736,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.3
9737,Estonia,2016,11,A10-Drugs used in diabetes,% of total sales,6.0
9738,Estonia,2016,11,A-Alimentary tract and metabolism,Million of national currency units,34.3
9739,Estonia,2016,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.8
9740,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.1
9741,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",7.0
9742,Estonia,2016,11,N-Nervous system,% of total sales,8.7
9743,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0
9744,Estonia,2016,11,N-Nervous system,"/capita, US$ purchasing power parity",36.4
9745,Estonia,2016,11,N-Nervous system,"Million US$, purchasing power parity",47.9
9746,Estonia,2016,11,N-Nervous system,"/capita, US$ exchange rate",21.3
9747,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
9748,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.4
9749,Estonia,2016,11,A-Alimentary tract and metabolism,% of total sales,11.8
9750,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.8
9751,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1
9752,Estonia,2016,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.4
9753,Estonia,2016,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
9754,Estonia,2016,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
9755,Estonia,2016,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
9756,Estonia,2016,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
9757,Estonia,2016,11,C01A-Cardiac glycosides,Million of national currency units,0.1
9758,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.0
9759,Estonia,2016,11,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
9760,Estonia,2016,11,Total pharmaceutical sales,Million US$ at exchange rate,320.9
9761,Estonia,2016,11,Total pharmaceutical sales,Million of national currency units,289.9
9762,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.3
9763,Estonia,2016,11,C01A-Cardiac glycosides,% of total sales,0.0
9764,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.7
9765,Estonia,2016,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.6
9766,Estonia,2016,11,M-Musculo-skeletal system,% of total sales,5.6
9767,Estonia,2016,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.8
9768,Estonia,2016,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",14.5
9769,Estonia,2016,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",32.7
9770,Estonia,2016,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.1
9771,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,9.5
9772,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.5
9773,Estonia,2016,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",18.0
9774,Estonia,2016,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",31.0
9775,Estonia,2016,11,M-Musculo-skeletal system,Million US$ at exchange rate,18.1
9776,Estonia,2016,11,M-Musculo-skeletal system,Million of national currency units,16.4
9777,Estonia,2016,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,49.1
9778,Estonia,2016,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",13.0
9779,Estonia,2016,11,A10-Drugs used in diabetes,Million US$ at exchange rate,19.1
9780,Estonia,2016,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",63.8
9781,Estonia,2016,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",84.0
9782,Estonia,2016,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.3
9783,Estonia,2016,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.6
9784,Estonia,2016,11,Total pharmaceutical sales,"/capita, US$ exchange rate",243.9
9785,Estonia,2016,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",417.4
9786,Estonia,2016,11,J-Antiinfectives for systemic use,Million of national currency units,44.3
9787,Estonia,2016,11,J01-Antibacterials for systemic use,Million of national currency units,6.9
9788,Estonia,2016,11,A10-Drugs used in diabetes,Million of national currency units,17.3
9789,Estonia,2016,11,N-Nervous system,Million of national currency units,25.3
9790,Estonia,2016,11,N-Nervous system,Million US$ at exchange rate,28.0
9791,Estonia,2016,11,J-Antiinfectives for systemic use,% of total sales,15.3
9792,Estonia,2016,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",44.3
9793,Estonia,2016,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.9
9794,Estonia,2016,11,C02-Antihypertensives,Million of national currency units,0.8
9795,Estonia,2016,11,Total pharmaceutical sales,"Million US$, purchasing power parity",549.2
9796,Estonia,2016,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8
9797,Estonia,2016,11,J01-Antibacterials for systemic use,% of total sales,2.4
9798,Estonia,2016,11,C-Cardiovascular system,% of total sales,10.6
9799,Estonia,2015,10,C02-Antihypertensives,"Million US$, purchasing power parity",1.5
9800,Estonia,2015,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.7
9801,Estonia,2015,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0
9802,Estonia,2015,10,N05B-Anxiolytics,% of total sales,0.5
9803,Estonia,2015,10,C02-Antihypertensives,Million US$ at exchange rate,0.9
9804,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.0
9805,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3
9806,Estonia,2015,10,N02-Analgesics,"Million US$, purchasing power parity",12.7
9807,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.6
9808,Estonia,2015,10,N05B-Anxiolytics,Million US$ at exchange rate,1.6
9809,Estonia,2015,10,N05B-Anxiolytics,Million of national currency units,1.4
9810,Estonia,2015,10,N02-Analgesics,Million US$ at exchange rate,7.6
9811,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,3.9
9812,Estonia,2015,10,N02-Analgesics,"/capita, US$ exchange rate",5.8
9813,Estonia,2015,10,N02-Analgesics,"/capita, US$ purchasing power parity",9.7
9814,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.5
9815,Estonia,2015,10,N02-Analgesics,% of total sales,2.6
9816,Estonia,2015,10,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6
9817,Estonia,2015,10,C-Cardiovascular system,"/capita, US$ exchange rate",26.5
9818,Estonia,2015,10,C-Cardiovascular system,"Million US$, purchasing power parity",58.5
9819,Estonia,2015,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
9820,Estonia,2015,10,C02-Antihypertensives,% of total sales,0.3
9821,Estonia,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.0
9822,Estonia,2015,10,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
9823,Estonia,2015,10,N02-Analgesics,Million of national currency units,6.8
9824,Estonia,2015,10,C-Cardiovascular system,Million US$ at exchange rate,34.9
9825,Estonia,2015,10,C-Cardiovascular system,Million of national currency units,31.5
9826,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.5
9827,Estonia,2015,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.9
9828,Estonia,2015,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",30.1
9829,Estonia,2015,10,B-Blood and blood forming organs,% of total sales,8.0
9830,Estonia,2015,10,B-Blood and blood forming organs,Million US$ at exchange rate,23.6
9831,Estonia,2015,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",39.6
9832,Estonia,2015,10,R-Respiratory system,"Million US$, purchasing power parity",37.9
9833,Estonia,2015,10,R-Respiratory system,"/capita, US$ exchange rate",17.2
9834,Estonia,2015,10,R-Respiratory system,Million of national currency units,20.4
9835,Estonia,2015,10,R-Respiratory system,Million US$ at exchange rate,22.6
9836,Estonia,2015,10,C10-Lipid modifying agents,% of total sales,1.2
9837,Estonia,2015,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.6
9838,Estonia,2015,10,A02A-Antacids,Million of national currency units,0.4
9839,Estonia,2015,10,A02A-Antacids,"Million US$, purchasing power parity",0.7
9840,Estonia,2015,10,A02A-Antacids,Million US$ at exchange rate,0.4
9841,Estonia,2015,10,C10-Lipid modifying agents,Million US$ at exchange rate,3.6
9842,Estonia,2015,10,B-Blood and blood forming organs,Million of national currency units,21.3
9843,Estonia,2015,10,C10-Lipid modifying agents,Million of national currency units,3.2
9844,Estonia,2015,10,R-Respiratory system,"/capita, US$ purchasing power parity",28.8
9845,Estonia,2015,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.7
9846,Estonia,2015,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.0
9847,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,13.7
9848,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.3
9849,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.0
9850,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.5
9851,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.4
9852,Estonia,2015,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.3
9853,Estonia,2015,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.2
9854,Estonia,2015,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",16.0
9855,Estonia,2015,10,R03-Drugs for obstructive airway diseases,Million of national currency units,8.6
9856,Estonia,2015,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.6
9857,Estonia,2015,10,C08-Calcium channel blockers,Million US$ at exchange rate,2.6
9858,Estonia,2015,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.4
9859,Estonia,2015,10,R-Respiratory system,% of total sales,7.7
9860,Estonia,2015,10,C08-Calcium channel blockers,Million of national currency units,2.3
9861,Estonia,2015,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.0
9862,Estonia,2015,10,R03-Drugs for obstructive airway diseases,% of total sales,3.3
9863,Estonia,2015,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.7
9864,Estonia,2015,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.3
9865,Estonia,2015,10,C08-Calcium channel blockers,% of total sales,0.9
9866,Estonia,2015,10,N05C-Hypnotics and sedatives,Million of national currency units,1.8
9867,Estonia,2015,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.9
9868,Estonia,2015,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3
9869,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.6
9870,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.0
9871,Estonia,2015,10,N05C-Hypnotics and sedatives,% of total sales,0.7
9872,Estonia,2015,10,G-Genito urinary system and sex hormones,% of total sales,4.4
9873,Estonia,2015,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5
9874,Estonia,2015,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.5
9875,Estonia,2015,10,C03-Diuretics,"/capita, US$ exchange rate",1.5
9876,Estonia,2015,10,C03-Diuretics,"/capita, US$ purchasing power parity",2.6
9877,Estonia,2015,10,C03-Diuretics,"Million US$, purchasing power parity",3.4
9878,Estonia,2015,10,C03-Diuretics,Million of national currency units,1.8
9879,Estonia,2015,10,C03-Diuretics,Million US$ at exchange rate,2.0
9880,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.5
9881,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.1
9882,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.1
9883,Estonia,2015,10,C03-Diuretics,% of total sales,0.7
9884,Estonia,2015,10,G03-Sex hormones and modulators of the genital system,% of total sales,2.3
9885,Estonia,2015,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.4
9886,Estonia,2015,10,C07-Beta blocking agents,Million US$ at exchange rate,6.2
9887,Estonia,2015,10,C07-Beta blocking agents,"Million US$, purchasing power parity",10.4
9888,Estonia,2015,10,N06A-Antidepressants,% of total sales,1.2
9889,Estonia,2015,10,A02A-Antacids,% of total sales,0.1
9890,Estonia,2015,10,C07-Beta blocking agents,Million of national currency units,5.6
9891,Estonia,2015,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
9892,Estonia,2015,10,A02A-Antacids,"/capita, US$ exchange rate",0.3
9893,Estonia,2015,10,C07-Beta blocking agents,"/capita, US$ exchange rate",4.7
9894,Estonia,2015,10,C07-Beta blocking agents,% of total sales,2.1
9895,Estonia,2015,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9
9896,Estonia,2015,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.9
9897,Estonia,2015,10,G-Genito urinary system and sex hormones,Million of national currency units,11.6
9898,Estonia,2015,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.8
9899,Estonia,2015,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.6
9900,Estonia,2015,10,N06A-Antidepressants,Million of national currency units,3.2
9901,Estonia,2015,10,N06A-Antidepressants,"/capita, US$ exchange rate",2.7
9902,Estonia,2015,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.6
9903,Estonia,2015,10,N06A-Antidepressants,Million US$ at exchange rate,3.6
9904,Estonia,2015,10,N06A-Antidepressants,"Million US$, purchasing power parity",6.0
9905,Estonia,2015,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,36.3
9906,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3
9907,Estonia,2015,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",27.6
9908,Estonia,2015,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",60.9
9909,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.9
9910,Estonia,2015,10,A-Alimentary tract and metabolism,Million of national currency units,32.7
9911,Estonia,2015,10,A10-Drugs used in diabetes,% of total sales,6.2
9912,Estonia,2015,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.1
9913,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.9
9914,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.4
9915,Estonia,2015,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",46.3
9916,Estonia,2015,10,N-Nervous system,% of total sales,9.4
9917,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0
9918,Estonia,2015,10,N-Nervous system,"/capita, US$ purchasing power parity",35.3
9919,Estonia,2015,10,N-Nervous system,"Million US$, purchasing power parity",46.4
9920,Estonia,2015,10,N-Nervous system,"/capita, US$ exchange rate",21.1
9921,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
9922,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.4
9923,Estonia,2015,10,A-Alimentary tract and metabolism,% of total sales,12.3
9924,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.9
9925,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1
9926,Estonia,2015,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
9927,Estonia,2015,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
9928,Estonia,2015,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
9929,Estonia,2015,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
9930,Estonia,2015,10,C01A-Cardiac glycosides,Million of national currency units,0.1
9931,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.8
9932,Estonia,2015,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
9933,Estonia,2015,10,Total pharmaceutical sales,Million US$ at exchange rate,294.2
9934,Estonia,2015,10,Total pharmaceutical sales,Million of national currency units,265.2
9935,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.5
9936,Estonia,2015,10,C01A-Cardiac glycosides,% of total sales,0.1
9937,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.1
9938,Estonia,2015,10,M-Musculo-skeletal system,% of total sales,5.9
9939,Estonia,2015,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.1
9940,Estonia,2015,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.2
9941,Estonia,2015,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",13.8
9942,Estonia,2015,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",30.4
9943,Estonia,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,3.8
9944,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,9.2
9945,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.2
9946,Estonia,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",17.2
9947,Estonia,2015,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",29.1
9948,Estonia,2015,10,M-Musculo-skeletal system,Million of national currency units,15.6
9949,Estonia,2015,10,M-Musculo-skeletal system,Million US$ at exchange rate,17.3
9950,Estonia,2015,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,35.3
9951,Estonia,2015,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.9
9952,Estonia,2015,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",59.2
9953,Estonia,2015,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",45.0
9954,Estonia,2015,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",26.8
9955,Estonia,2015,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.7
9956,Estonia,2015,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",375.0
9957,Estonia,2015,10,Total pharmaceutical sales,"/capita, US$ exchange rate",223.6
9958,Estonia,2015,10,J-Antiinfectives for systemic use,Million of national currency units,31.8
9959,Estonia,2015,10,J01-Antibacterials for systemic use,Million of national currency units,6.9
9960,Estonia,2015,10,A10-Drugs used in diabetes,Million of national currency units,16.4
9961,Estonia,2015,10,A10-Drugs used in diabetes,Million US$ at exchange rate,18.2
9962,Estonia,2015,10,N-Nervous system,Million of national currency units,25.0
9963,Estonia,2015,10,N-Nervous system,Million US$ at exchange rate,27.7
9964,Estonia,2015,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",44.5
9965,Estonia,2015,10,J-Antiinfectives for systemic use,% of total sales,12.0
9966,Estonia,2015,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.8
9967,Estonia,2015,10,C02-Antihypertensives,Million of national currency units,0.8
9968,Estonia,2015,10,Total pharmaceutical sales,"Million US$, purchasing power parity",493.2
9969,Estonia,2015,10,J01-Antibacterials for systemic use,% of total sales,2.6
9970,Estonia,2015,10,C-Cardiovascular system,% of total sales,11.9
9971,Estonia,2015,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.9
9972,Estonia,2014,11,C02-Antihypertensives,"Million US$, purchasing power parity",1.6
9973,Estonia,2014,11,C02-Antihypertensives,"/capita, US$ exchange rate",0.8
9974,Estonia,2014,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0
9975,Estonia,2014,11,N05B-Anxiolytics,% of total sales,0.6
9976,Estonia,2014,11,C02-Antihypertensives,Million US$ at exchange rate,1.1
9977,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.2
9978,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
9979,Estonia,2014,11,N02-Analgesics,"Million US$, purchasing power parity",12.0
9980,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.8
9981,Estonia,2014,11,N05B-Anxiolytics,Million US$ at exchange rate,1.9
9982,Estonia,2014,11,N05B-Anxiolytics,Million of national currency units,1.4
9983,Estonia,2014,11,N05B-Anxiolytics,"Million US$, purchasing power parity",2.7
9984,Estonia,2014,11,N02-Analgesics,"/capita, US$ exchange rate",6.4
9985,Estonia,2014,11,N02-Analgesics,"/capita, US$ purchasing power parity",9.1
9986,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.6
9987,Estonia,2014,11,N02-Analgesics,% of total sales,2.5
9988,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.7
9989,Estonia,2014,11,C-Cardiovascular system,"/capita, US$ exchange rate",32.4
9990,Estonia,2014,11,C-Cardiovascular system,"Million US$, purchasing power parity",60.8
9991,Estonia,2014,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2
9992,Estonia,2014,11,C02-Antihypertensives,% of total sales,0.3
9993,Estonia,2014,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.6
9994,Estonia,2014,11,N02-Analgesics,Million US$ at exchange rate,8.4
9995,Estonia,2014,11,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
9996,Estonia,2014,11,C-Cardiovascular system,Million US$ at exchange rate,42.5
9997,Estonia,2014,11,C-Cardiovascular system,Million of national currency units,32.0
9998,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.4
9999,Estonia,2014,11,N02-Analgesics,Million of national currency units,6.3
10000,Estonia,2014,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.1
10001,Estonia,2014,11,B-Blood and blood forming organs,% of total sales,7.0
10002,Estonia,2014,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.6
10003,Estonia,2014,11,B-Blood and blood forming organs,Million US$ at exchange rate,23.1
10004,Estonia,2014,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",33.0
10005,Estonia,2014,11,R-Respiratory system,"Million US$, purchasing power parity",37.5
10006,Estonia,2014,11,R-Respiratory system,"/capita, US$ exchange rate",20.0
10007,Estonia,2014,11,R-Respiratory system,"/capita, US$ purchasing power parity",28.5
10008,Estonia,2014,11,R-Respiratory system,Million of national currency units,19.7
10009,Estonia,2014,11,R-Respiratory system,Million US$ at exchange rate,26.2
10010,Estonia,2014,11,A02A-Antacids,Million of national currency units,0.4
10011,Estonia,2014,11,C10-Lipid modifying agents,% of total sales,1.3
10012,Estonia,2014,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.7
10013,Estonia,2014,11,A02A-Antacids,"Million US$, purchasing power parity",0.7
10014,Estonia,2014,11,A02A-Antacids,Million US$ at exchange rate,0.5
10015,Estonia,2014,11,C10-Lipid modifying agents,Million US$ at exchange rate,4.3
10016,Estonia,2014,11,C10-Lipid modifying agents,Million of national currency units,3.2
10017,Estonia,2014,11,B-Blood and blood forming organs,Million of national currency units,17.4
10018,Estonia,2014,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.3
10019,Estonia,2014,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.1
10020,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,17.1
10021,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.9
10022,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",24.4
10023,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.6
10024,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.0
10025,Estonia,2014,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",8.8
10026,Estonia,2014,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.6
10027,Estonia,2014,11,R03-Drugs for obstructive airway diseases,Million of national currency units,8.7
10028,Estonia,2014,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",16.6
10029,Estonia,2014,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.6
10030,Estonia,2014,11,C08-Calcium channel blockers,Million US$ at exchange rate,3.4
10031,Estonia,2014,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.9
10032,Estonia,2014,11,R-Respiratory system,% of total sales,7.9
10033,Estonia,2014,11,C08-Calcium channel blockers,Million of national currency units,2.6
10034,Estonia,2014,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6
10035,Estonia,2014,11,R03-Drugs for obstructive airway diseases,% of total sales,3.5
10036,Estonia,2014,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.2
10037,Estonia,2014,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.7
10038,Estonia,2014,11,C08-Calcium channel blockers,% of total sales,1.0
10039,Estonia,2014,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.2
10040,Estonia,2014,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2
10041,Estonia,2014,11,N05C-Hypnotics and sedatives,Million of national currency units,1.7
10042,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.2
10043,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.2
10044,Estonia,2014,11,N05C-Hypnotics and sedatives,% of total sales,0.7
10045,Estonia,2014,11,G-Genito urinary system and sex hormones,% of total sales,4.6
10046,Estonia,2014,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7
10047,Estonia,2014,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.4
10048,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.7
10049,Estonia,2014,11,C03-Diuretics,"/capita, US$ exchange rate",1.8
10050,Estonia,2014,11,C03-Diuretics,"/capita, US$ purchasing power parity",2.5
10051,Estonia,2014,11,C03-Diuretics,"Million US$, purchasing power parity",3.3
10052,Estonia,2014,11,C03-Diuretics,Million of national currency units,1.8
10053,Estonia,2014,11,C03-Diuretics,Million US$ at exchange rate,2.3
10054,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.9
10055,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.2
10056,Estonia,2014,11,C03-Diuretics,% of total sales,0.7
10057,Estonia,2014,11,G03-Sex hormones and modulators of the genital system,% of total sales,2.5
10058,Estonia,2014,11,C07-Beta blocking agents,Million US$ at exchange rate,7.4
10059,Estonia,2014,11,C07-Beta blocking agents,"Million US$, purchasing power parity",10.5
10060,Estonia,2014,11,A02A-Antacids,% of total sales,0.1
10061,Estonia,2014,11,C07-Beta blocking agents,Million of national currency units,5.5
10062,Estonia,2014,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
10063,Estonia,2014,11,A02A-Antacids,"/capita, US$ exchange rate",0.4
10064,Estonia,2014,11,N06A-Antidepressants,% of total sales,1.2
10065,Estonia,2014,11,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6
10066,Estonia,2014,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0
10067,Estonia,2014,11,C07-Beta blocking agents,% of total sales,2.2
10068,Estonia,2014,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.3
10069,Estonia,2014,11,G-Genito urinary system and sex hormones,Million of national currency units,11.5
10070,Estonia,2014,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.6
10071,Estonia,2014,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.6
10072,Estonia,2014,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.8
10073,Estonia,2014,11,N06A-Antidepressants,Million of national currency units,3.0
10074,Estonia,2014,11,N06A-Antidepressants,"/capita, US$ exchange rate",3.1
10075,Estonia,2014,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.4
10076,Estonia,2014,11,N06A-Antidepressants,Million US$ at exchange rate,4.1
10077,Estonia,2014,11,N06A-Antidepressants,"Million US$, purchasing power parity",5.8
10078,Estonia,2014,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,40.8
10079,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3
10080,Estonia,2014,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",31.1
10081,Estonia,2014,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",58.3
10082,Estonia,2014,11,A-Alimentary tract and metabolism,Million of national currency units,30.7
10083,Estonia,2014,11,A10-Drugs used in diabetes,% of total sales,6.2
10084,Estonia,2014,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.2
10085,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.4
10086,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.8
10087,Estonia,2014,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.4
10088,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.4
10089,Estonia,2014,11,N-Nervous system,% of total sales,9.6
10090,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0
10091,Estonia,2014,11,N-Nervous system,"Million US$, purchasing power parity",45.3
10092,Estonia,2014,11,N-Nervous system,"/capita, US$ exchange rate",24.1
10093,Estonia,2014,11,N-Nervous system,"/capita, US$ purchasing power parity",34.5
10094,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.3
10095,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
10096,Estonia,2014,11,A-Alimentary tract and metabolism,% of total sales,12.3
10097,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.4
10098,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.8
10099,Estonia,2014,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
10100,Estonia,2014,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
10101,Estonia,2014,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
10102,Estonia,2014,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
10103,Estonia,2014,11,C01A-Cardiac glycosides,Million of national currency units,0.2
10104,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.8
10105,Estonia,2014,11,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
10106,Estonia,2014,11,Total pharmaceutical sales,Million of national currency units,249.4
10107,Estonia,2014,11,Total pharmaceutical sales,Million US$ at exchange rate,331.4
10108,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.5
10109,Estonia,2014,11,C01A-Cardiac glycosides,% of total sales,0.1
10110,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.5
10111,Estonia,2014,11,M-Musculo-skeletal system,% of total sales,5.8
10112,Estonia,2014,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.7
10113,Estonia,2014,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.5
10114,Estonia,2014,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.5
10115,Estonia,2014,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.5
10116,Estonia,2014,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",29.2
10117,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.7
10118,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,11.5
10119,Estonia,2014,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",16.5
10120,Estonia,2014,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",27.2
10121,Estonia,2014,11,M-Musculo-skeletal system,Million US$ at exchange rate,19.1
10122,Estonia,2014,11,M-Musculo-skeletal system,Million of national currency units,14.3
10123,Estonia,2014,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,37.2
10124,Estonia,2014,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",13.4
10125,Estonia,2014,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",40.5
10126,Estonia,2014,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",53.2
10127,Estonia,2014,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.3
10128,Estonia,2014,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.4
10129,Estonia,2014,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",360.1
10130,Estonia,2014,11,Total pharmaceutical sales,"/capita, US$ exchange rate",252.1
10131,Estonia,2014,11,J-Antiinfectives for systemic use,Million of national currency units,28.0
10132,Estonia,2014,11,J01-Antibacterials for systemic use,Million of national currency units,7.0
10133,Estonia,2014,11,A10-Drugs used in diabetes,Million US$ at exchange rate,20.4
10134,Estonia,2014,11,A10-Drugs used in diabetes,Million of national currency units,15.4
10135,Estonia,2014,11,N-Nervous system,Million of national currency units,23.9
10136,Estonia,2014,11,N-Nervous system,Million US$ at exchange rate,31.7
10137,Estonia,2014,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",46.2
10138,Estonia,2014,11,J-Antiinfectives for systemic use,% of total sales,11.2
10139,Estonia,2014,11,C-Cardiovascular system,% of total sales,12.8
10140,Estonia,2014,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.2
10141,Estonia,2014,11,C02-Antihypertensives,Million of national currency units,0.8
10142,Estonia,2014,11,J01-Antibacterials for systemic use,% of total sales,2.8
10143,Estonia,2014,11,Total pharmaceutical sales,"Million US$, purchasing power parity",473.4
10144,Estonia,2014,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.1
10145,Estonia,2013,10,C02-Antihypertensives,"Million US$, purchasing power parity",1.6
10146,Estonia,2013,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.9
10147,Estonia,2013,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.9
10148,Estonia,2013,10,N05B-Anxiolytics,% of total sales,0.6
10149,Estonia,2013,10,C02-Antihypertensives,Million US$ at exchange rate,1.1
10150,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.8
10151,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
10152,Estonia,2013,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2
10153,Estonia,2013,10,N02-Analgesics,"Million US$, purchasing power parity",11.3
10154,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.3
10155,Estonia,2013,10,N05B-Anxiolytics,"Million US$, purchasing power parity",2.5
10156,Estonia,2013,10,N05B-Anxiolytics,Million US$ at exchange rate,1.8
10157,Estonia,2013,10,N05B-Anxiolytics,Million of national currency units,1.3
10158,Estonia,2013,10,N02-Analgesics,"/capita, US$ exchange rate",6.0
10159,Estonia,2013,10,N02-Analgesics,"/capita, US$ purchasing power parity",8.6
10160,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.4
10161,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.3
10162,Estonia,2013,10,N02-Analgesics,% of total sales,2.6
10163,Estonia,2013,10,C-Cardiovascular system,"/capita, US$ exchange rate",31.9
10164,Estonia,2013,10,C-Cardiovascular system,"Million US$, purchasing power parity",60.7
10165,Estonia,2013,10,C02-Antihypertensives,% of total sales,0.4
10166,Estonia,2013,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3
10167,Estonia,2013,10,N02-Analgesics,Million US$ at exchange rate,7.8
10168,Estonia,2013,10,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
10169,Estonia,2013,10,N02-Analgesics,Million of national currency units,5.9
10170,Estonia,2013,10,C-Cardiovascular system,Million US$ at exchange rate,42.1
10171,Estonia,2013,10,C-Cardiovascular system,Million of national currency units,31.7
10172,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.5
10173,Estonia,2013,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.5
10174,Estonia,2013,10,B-Blood and blood forming organs,% of total sales,6.1
10175,Estonia,2013,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",14.2
10176,Estonia,2013,10,B-Blood and blood forming organs,Million US$ at exchange rate,18.7
10177,Estonia,2013,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",27.0
10178,Estonia,2013,10,R-Respiratory system,"/capita, US$ exchange rate",18.8
10179,Estonia,2013,10,R-Respiratory system,"/capita, US$ purchasing power parity",27.1
10180,Estonia,2013,10,R-Respiratory system,"Million US$, purchasing power parity",35.7
10181,Estonia,2013,10,R-Respiratory system,Million of national currency units,18.6
10182,Estonia,2013,10,R-Respiratory system,Million US$ at exchange rate,24.8
10183,Estonia,2013,10,A02A-Antacids,Million of national currency units,0.3
10184,Estonia,2013,10,C10-Lipid modifying agents,% of total sales,1.5
10185,Estonia,2013,10,A02A-Antacids,"Million US$, purchasing power parity",0.6
10186,Estonia,2013,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.0
10187,Estonia,2013,10,A02A-Antacids,Million US$ at exchange rate,0.4
10188,Estonia,2013,10,C10-Lipid modifying agents,Million US$ at exchange rate,4.6
10189,Estonia,2013,10,C10-Lipid modifying agents,Million of national currency units,3.4
10190,Estonia,2013,10,B-Blood and blood forming organs,Million of national currency units,14.1
10191,Estonia,2013,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.5
10192,Estonia,2013,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.6
10193,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.8
10194,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,16.5
10195,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.4
10196,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.1
10197,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.5
10198,Estonia,2013,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",8.4
10199,Estonia,2013,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.1
10200,Estonia,2013,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",16.0
10201,Estonia,2013,10,R03-Drugs for obstructive airway diseases,Million of national currency units,8.3
10202,Estonia,2013,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.1
10203,Estonia,2013,10,C08-Calcium channel blockers,Million US$ at exchange rate,3.9
10204,Estonia,2013,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.6
10205,Estonia,2013,10,R-Respiratory system,% of total sales,8.1
10206,Estonia,2013,10,C08-Calcium channel blockers,Million of national currency units,2.9
10207,Estonia,2013,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.0
10208,Estonia,2013,10,R03-Drugs for obstructive airway diseases,% of total sales,3.6
10209,Estonia,2013,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4
10210,Estonia,2013,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.3
10211,Estonia,2013,10,C08-Calcium channel blockers,% of total sales,1.3
10212,Estonia,2013,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.1
10213,Estonia,2013,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.0
10214,Estonia,2013,10,N05C-Hypnotics and sedatives,Million of national currency units,1.5
10215,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.5
10216,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.4
10217,Estonia,2013,10,N05C-Hypnotics and sedatives,% of total sales,0.7
10218,Estonia,2013,10,G-Genito urinary system and sex hormones,% of total sales,5.0
10219,Estonia,2013,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
10220,Estonia,2013,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.2
10221,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.2
10222,Estonia,2013,10,C03-Diuretics,"/capita, US$ exchange rate",1.7
10223,Estonia,2013,10,C03-Diuretics,"/capita, US$ purchasing power parity",2.4
10224,Estonia,2013,10,C03-Diuretics,Million of national currency units,1.6
10225,Estonia,2013,10,C03-Diuretics,"Million US$, purchasing power parity",3.2
10226,Estonia,2013,10,C03-Diuretics,Million US$ at exchange rate,2.2
10227,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.3
10228,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.4
10229,Estonia,2013,10,C03-Diuretics,% of total sales,0.7
10230,Estonia,2013,10,G03-Sex hormones and modulators of the genital system,% of total sales,2.8
10231,Estonia,2013,10,C07-Beta blocking agents,Million US$ at exchange rate,7.1
10232,Estonia,2013,10,C07-Beta blocking agents,"Million US$, purchasing power parity",10.2
10233,Estonia,2013,10,A02A-Antacids,% of total sales,0.1
10234,Estonia,2013,10,C07-Beta blocking agents,Million of national currency units,5.3
10235,Estonia,2013,10,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4
10236,Estonia,2013,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
10237,Estonia,2013,10,A02A-Antacids,"/capita, US$ exchange rate",0.3
10238,Estonia,2013,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7
10239,Estonia,2013,10,C07-Beta blocking agents,% of total sales,2.3
10240,Estonia,2013,10,N06A-Antidepressants,% of total sales,1.3
10241,Estonia,2013,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.2
10242,Estonia,2013,10,G-Genito urinary system and sex hormones,Million of national currency units,11.4
10243,Estonia,2013,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.6
10244,Estonia,2013,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.9
10245,Estonia,2013,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.5
10246,Estonia,2013,10,N06A-Antidepressants,Million of national currency units,2.9
10247,Estonia,2013,10,N06A-Antidepressants,"/capita, US$ exchange rate",2.9
10248,Estonia,2013,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.2
10249,Estonia,2013,10,N06A-Antidepressants,Million US$ at exchange rate,3.9
10250,Estonia,2013,10,N06A-Antidepressants,"Million US$, purchasing power parity",5.6
10251,Estonia,2013,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,38.1
10252,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
10253,Estonia,2013,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.9
10254,Estonia,2013,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.7
10255,Estonia,2013,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",54.9
10256,Estonia,2013,10,A-Alimentary tract and metabolism,Million of national currency units,28.7
10257,Estonia,2013,10,A10-Drugs used in diabetes,% of total sales,6.1
10258,Estonia,2013,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.5
10259,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.6
10260,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.1
10261,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.8
10262,Estonia,2013,10,N-Nervous system,% of total sales,10.0
10263,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.9
10264,Estonia,2013,10,N-Nervous system,"/capita, US$ purchasing power parity",33.6
10265,Estonia,2013,10,N-Nervous system,"Million US$, purchasing power parity",44.3
10266,Estonia,2013,10,N-Nervous system,"/capita, US$ exchange rate",23.3
10267,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.2
10268,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
10269,Estonia,2013,10,A-Alimentary tract and metabolism,% of total sales,12.4
10270,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
10271,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7
10272,Estonia,2013,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
10273,Estonia,2013,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
10274,Estonia,2013,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
10275,Estonia,2013,10,C01A-Cardiac glycosides,Million of national currency units,0.2
10276,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.0
10277,Estonia,2013,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
10278,Estonia,2013,10,Total pharmaceutical sales,Million of national currency units,231.0
10279,Estonia,2013,10,Total pharmaceutical sales,Million US$ at exchange rate,306.7
10280,Estonia,2013,10,C01A-Cardiac glycosides,% of total sales,0.1
10281,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.4
10282,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.5
10283,Estonia,2013,10,M-Musculo-skeletal system,% of total sales,5.7
10284,Estonia,2013,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.2
10285,Estonia,2013,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.3
10286,Estonia,2013,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",14.3
10287,Estonia,2013,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.7
10288,Estonia,2013,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",27.1
10289,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.6
10290,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.9
10291,Estonia,2013,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",15.2
10292,Estonia,2013,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",25.3
10293,Estonia,2013,10,M-Musculo-skeletal system,Million of national currency units,13.2
10294,Estonia,2013,10,M-Musculo-skeletal system,Million US$ at exchange rate,17.5
10295,Estonia,2013,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
10296,Estonia,2013,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.8
10297,Estonia,2013,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",14.0
10298,Estonia,2013,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",45.8
10299,Estonia,2013,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",34.7
10300,Estonia,2013,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",24.1
10301,Estonia,2013,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",335.4
10302,Estonia,2013,10,Total pharmaceutical sales,"/capita, US$ exchange rate",232.7
10303,Estonia,2013,10,J-Antiinfectives for systemic use,Million of national currency units,23.9
10304,Estonia,2013,10,J01-Antibacterials for systemic use,Million of national currency units,7.3
10305,Estonia,2013,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.7
10306,Estonia,2013,10,A10-Drugs used in diabetes,Million US$ at exchange rate,18.8
10307,Estonia,2013,10,A10-Drugs used in diabetes,Million of national currency units,14.1
10308,Estonia,2013,10,N-Nervous system,Million of national currency units,23.2
10309,Estonia,2013,10,N-Nervous system,Million US$ at exchange rate,30.8
10310,Estonia,2013,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",46.0
10311,Estonia,2013,10,C-Cardiovascular system,% of total sales,13.7
10312,Estonia,2013,10,J-Antiinfectives for systemic use,% of total sales,10.4
10313,Estonia,2013,10,C02-Antihypertensives,Million of national currency units,0.9
10314,Estonia,2013,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.6
10315,Estonia,2013,10,J01-Antibacterials for systemic use,% of total sales,3.2
10316,Estonia,2013,10,Total pharmaceutical sales,"Million US$, purchasing power parity",442.1
10317,Estonia,2013,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.4
10318,Estonia,2012,12,C02-Antihypertensives,"Million US$, purchasing power parity",1.8
10319,Estonia,2012,12,C02-Antihypertensives,"/capita, US$ exchange rate",0.9
10320,Estonia,2012,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.8
10321,Estonia,2012,12,N05B-Anxiolytics,% of total sales,0.6
10322,Estonia,2012,12,C02-Antihypertensives,Million US$ at exchange rate,1.2
10323,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.4
10324,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
10325,Estonia,2012,12,N02-Analgesics,"Million US$, purchasing power parity",10.6
10326,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.8
10327,Estonia,2012,12,N05B-Anxiolytics,"Million US$, purchasing power parity",2.4
10328,Estonia,2012,12,N05B-Anxiolytics,Million US$ at exchange rate,1.6
10329,Estonia,2012,12,N05B-Anxiolytics,Million of national currency units,1.3
10330,Estonia,2012,12,N02-Analgesics,"/capita, US$ exchange rate",5.4
10331,Estonia,2012,12,N02-Analgesics,"/capita, US$ purchasing power parity",8.0
10332,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,3.0
10333,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,3.9
10334,Estonia,2012,12,N02-Analgesics,% of total sales,2.5
10335,Estonia,2012,12,C-Cardiovascular system,"/capita, US$ exchange rate",31.6
10336,Estonia,2012,12,C-Cardiovascular system,"Million US$, purchasing power parity",62.5
10337,Estonia,2012,12,C02-Antihypertensives,% of total sales,0.4
10338,Estonia,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.9
10339,Estonia,2012,12,N02-Analgesics,Million US$ at exchange rate,7.1
10340,Estonia,2012,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
10341,Estonia,2012,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
10342,Estonia,2012,12,C-Cardiovascular system,Million US$ at exchange rate,41.8
10343,Estonia,2012,12,C-Cardiovascular system,Million of national currency units,32.6
10344,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.4
10345,Estonia,2012,12,N02-Analgesics,Million of national currency units,5.5
10346,Estonia,2012,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.1
10347,Estonia,2012,12,B-Blood and blood forming organs,% of total sales,5.9
10348,Estonia,2012,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",12.8
10349,Estonia,2012,12,B-Blood and blood forming organs,Million US$ at exchange rate,16.9
10350,Estonia,2012,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",25.2
10351,Estonia,2012,12,R-Respiratory system,"/capita, US$ exchange rate",16.2
10352,Estonia,2012,12,R-Respiratory system,"/capita, US$ purchasing power parity",24.2
10353,Estonia,2012,12,R-Respiratory system,"Million US$, purchasing power parity",32.0
10354,Estonia,2012,12,R-Respiratory system,Million of national currency units,16.7
10355,Estonia,2012,12,R-Respiratory system,Million US$ at exchange rate,21.4
10356,Estonia,2012,12,A02A-Antacids,Million of national currency units,0.3
10357,Estonia,2012,12,C10-Lipid modifying agents,% of total sales,1.8
10358,Estonia,2012,12,A02A-Antacids,"Million US$, purchasing power parity",0.6
10359,Estonia,2012,12,A02A-Antacids,Million US$ at exchange rate,0.4
10360,Estonia,2012,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.7
10361,Estonia,2012,12,C10-Lipid modifying agents,Million US$ at exchange rate,5.1
10362,Estonia,2012,12,C10-Lipid modifying agents,Million of national currency units,4.0
10363,Estonia,2012,12,B-Blood and blood forming organs,Million of national currency units,13.1
10364,Estonia,2012,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.8
10365,Estonia,2012,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",7.6
10366,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",22.8
10367,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,15.2
10368,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.2
10369,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.9
10370,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.5
10371,Estonia,2012,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.2
10372,Estonia,2012,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",10.7
10373,Estonia,2012,12,R03-Drugs for obstructive airway diseases,Million of national currency units,7.4
10374,Estonia,2012,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",14.2
10375,Estonia,2012,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.5
10376,Estonia,2012,12,C08-Calcium channel blockers,Million US$ at exchange rate,4.5
10377,Estonia,2012,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",6.7
10378,Estonia,2012,12,R-Respiratory system,% of total sales,7.5
10379,Estonia,2012,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.4
10380,Estonia,2012,12,C08-Calcium channel blockers,Million of national currency units,3.5
10381,Estonia,2012,12,R03-Drugs for obstructive airway diseases,% of total sales,3.3
10382,Estonia,2012,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4
10383,Estonia,2012,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.1
10384,Estonia,2012,12,C08-Calcium channel blockers,% of total sales,1.6
10385,Estonia,2012,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.0
10386,Estonia,2012,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",2.9
10387,Estonia,2012,12,N05C-Hypnotics and sedatives,Million of national currency units,1.5
10388,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.5
10389,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.6
10390,Estonia,2012,12,G-Genito urinary system and sex hormones,% of total sales,5.0
10391,Estonia,2012,12,N05C-Hypnotics and sedatives,% of total sales,0.7
10392,Estonia,2012,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5
10393,Estonia,2012,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.2
10394,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.7
10395,Estonia,2012,12,C03-Diuretics,"/capita, US$ exchange rate",1.7
10396,Estonia,2012,12,C03-Diuretics,"/capita, US$ purchasing power parity",2.5
10397,Estonia,2012,12,C03-Diuretics,Million of national currency units,1.7
10398,Estonia,2012,12,C03-Diuretics,Million US$ at exchange rate,2.2
10399,Estonia,2012,12,C03-Diuretics,"Million US$, purchasing power parity",3.3
10400,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.6
10401,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.4
10402,Estonia,2012,12,C03-Diuretics,% of total sales,0.8
10403,Estonia,2012,12,G03-Sex hormones and modulators of the genital system,% of total sales,3.0
10404,Estonia,2012,12,C07-Beta blocking agents,Million US$ at exchange rate,6.8
10405,Estonia,2012,12,C07-Beta blocking agents,"Million US$, purchasing power parity",10.2
10406,Estonia,2012,12,A02A-Antacids,% of total sales,0.1
10407,Estonia,2012,12,C07-Beta blocking agents,Million of national currency units,5.3
10408,Estonia,2012,12,C07-Beta blocking agents,"/capita, US$ exchange rate",5.2
10409,Estonia,2012,12,A02A-Antacids,"/capita, US$ exchange rate",0.3
10410,Estonia,2012,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
10411,Estonia,2012,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7
10412,Estonia,2012,12,C07-Beta blocking agents,% of total sales,2.4
10413,Estonia,2012,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,14.4
10414,Estonia,2012,12,G-Genito urinary system and sex hormones,Million of national currency units,11.2
10415,Estonia,2012,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.5
10416,Estonia,2012,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.2
10417,Estonia,2012,12,N06A-Antidepressants,Million of national currency units,2.9
10418,Estonia,2012,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.9
10419,Estonia,2012,12,N06A-Antidepressants,"/capita, US$ exchange rate",2.9
10420,Estonia,2012,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.3
10421,Estonia,2012,12,N06A-Antidepressants,% of total sales,1.3
10422,Estonia,2012,12,N06A-Antidepressants,Million US$ at exchange rate,3.8
10423,Estonia,2012,12,N06A-Antidepressants,"Million US$, purchasing power parity",5.6
10424,Estonia,2012,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,34.5
10425,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
10426,Estonia,2012,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",26.1
10427,Estonia,2012,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.0
10428,Estonia,2012,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",51.6
10429,Estonia,2012,12,A-Alimentary tract and metabolism,Million of national currency units,26.9
10430,Estonia,2012,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.4
10431,Estonia,2012,12,A10-Drugs used in diabetes,% of total sales,6.0
10432,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.0
10433,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.3
10434,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.6
10435,Estonia,2012,12,N-Nervous system,% of total sales,10.3
10436,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.9
10437,Estonia,2012,12,N-Nervous system,"Million US$, purchasing power parity",43.9
10438,Estonia,2012,12,N-Nervous system,"/capita, US$ purchasing power parity",33.2
10439,Estonia,2012,12,N-Nervous system,"/capita, US$ exchange rate",22.2
10440,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1
10441,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
10442,Estonia,2012,12,A-Alimentary tract and metabolism,% of total sales,12.1
10443,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
10444,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7
10445,Estonia,2012,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
10446,Estonia,2012,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
10447,Estonia,2012,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
10448,Estonia,2012,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
10449,Estonia,2012,12,C01A-Cardiac glycosides,Million of national currency units,0.2
10450,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.9
10451,Estonia,2012,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
10452,Estonia,2012,12,Total pharmaceutical sales,Million of national currency units,221.7
10453,Estonia,2012,12,Total pharmaceutical sales,Million US$ at exchange rate,284.9
10454,Estonia,2012,12,C01A-Cardiac glycosides,% of total sales,0.1
10455,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2
10456,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.3
10457,Estonia,2012,12,M-Musculo-skeletal system,% of total sales,5.5
10458,Estonia,2012,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.9
10459,Estonia,2012,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.7
10460,Estonia,2012,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",13.0
10461,Estonia,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.4
10462,Estonia,2012,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",25.7
10463,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,9.1
10464,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.1
10465,Estonia,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",13.6
10466,Estonia,2012,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",23.4
10467,Estonia,2012,12,M-Musculo-skeletal system,Million of national currency units,12.2
10468,Estonia,2012,12,M-Musculo-skeletal system,Million US$ at exchange rate,15.7
10469,Estonia,2012,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.5
10470,Estonia,2012,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",47.1
10471,Estonia,2012,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",15.2
10472,Estonia,2012,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.6
10473,Estonia,2012,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",23.8
10474,Estonia,2012,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",321.7
10475,Estonia,2012,12,Total pharmaceutical sales,"/capita, US$ exchange rate",215.4
10476,Estonia,2012,12,J-Antiinfectives for systemic use,Million of national currency units,24.5
10477,Estonia,2012,12,J01-Antibacterials for systemic use,Million of national currency units,7.9
10478,Estonia,2012,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.2
10479,Estonia,2012,12,A10-Drugs used in diabetes,Million of national currency units,13.4
10480,Estonia,2012,12,A10-Drugs used in diabetes,Million US$ at exchange rate,17.2
10481,Estonia,2012,12,N-Nervous system,Million of national currency units,22.9
10482,Estonia,2012,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",47.2
10483,Estonia,2012,12,N-Nervous system,Million US$ at exchange rate,29.4
10484,Estonia,2012,12,C-Cardiovascular system,% of total sales,14.7
10485,Estonia,2012,12,C02-Antihypertensives,Million of national currency units,0.9
10486,Estonia,2012,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.5
10487,Estonia,2012,12,J01-Antibacterials for systemic use,% of total sales,3.6
10488,Estonia,2012,12,Total pharmaceutical sales,"Million US$, purchasing power parity",425.5
10489,Estonia,2012,12,J-Antiinfectives for systemic use,% of total sales,11.1
10490,Estonia,2012,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.7
10491,Estonia,2011,13,C02-Antihypertensives,"Million US$, purchasing power parity",1.7
10492,Estonia,2011,13,C02-Antihypertensives,"/capita, US$ exchange rate",0.9
10493,Estonia,2011,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.7
10494,Estonia,2011,13,N05B-Anxiolytics,% of total sales,0.6
10495,Estonia,2011,13,C02-Antihypertensives,Million US$ at exchange rate,1.2
10496,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.1
10497,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
10498,Estonia,2011,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
10499,Estonia,2011,13,N02-Analgesics,"Million US$, purchasing power parity",10.5
10500,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.5
10501,Estonia,2011,13,N05B-Anxiolytics,"Million US$, purchasing power parity",2.3
10502,Estonia,2011,13,N05B-Anxiolytics,Million US$ at exchange rate,1.6
10503,Estonia,2011,13,N05B-Anxiolytics,Million of national currency units,1.2
10504,Estonia,2011,13,N02-Analgesics,"/capita, US$ exchange rate",5.6
10505,Estonia,2011,13,N02-Analgesics,"/capita, US$ purchasing power parity",7.9
10506,Estonia,2011,13,N02-Analgesics,% of total sales,2.6
10507,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2.8
10508,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,3.9
10509,Estonia,2011,13,C-Cardiovascular system,"/capita, US$ exchange rate",32.7
10510,Estonia,2011,13,C-Cardiovascular system,"Million US$, purchasing power parity",60.9
10511,Estonia,2011,13,C02-Antihypertensives,% of total sales,0.4
10512,Estonia,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.9
10513,Estonia,2011,13,N02-Analgesics,Million US$ at exchange rate,7.5
10514,Estonia,2011,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
10515,Estonia,2011,13,C-Cardiovascular system,Million US$ at exchange rate,43.4
10516,Estonia,2011,13,C-Cardiovascular system,Million of national currency units,31.2
10517,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.2
10518,Estonia,2011,13,N02-Analgesics,Million of national currency units,5.4
10519,Estonia,2011,13,C03-Diuretics,Million of national currency units,1.6
10520,Estonia,2011,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.7
10521,Estonia,2011,13,B-Blood and blood forming organs,% of total sales,5.6
10522,Estonia,2011,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",11.9
10523,Estonia,2011,13,B-Blood and blood forming organs,Million US$ at exchange rate,15.8
10524,Estonia,2011,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",22.2
10525,Estonia,2011,13,R-Respiratory system,"/capita, US$ exchange rate",15.8
10526,Estonia,2011,13,R-Respiratory system,"/capita, US$ purchasing power parity",22.2
10527,Estonia,2011,13,R-Respiratory system,"Million US$, purchasing power parity",29.5
10528,Estonia,2011,13,R-Respiratory system,Million of national currency units,15.1
10529,Estonia,2011,13,R-Respiratory system,Million US$ at exchange rate,21.0
10530,Estonia,2011,13,A02A-Antacids,Million of national currency units,0.3
10531,Estonia,2011,13,C10-Lipid modifying agents,% of total sales,1.9
10532,Estonia,2011,13,A02A-Antacids,"Million US$, purchasing power parity",0.6
10533,Estonia,2011,13,A02A-Antacids,Million US$ at exchange rate,0.4
10534,Estonia,2011,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.8
10535,Estonia,2011,13,C10-Lipid modifying agents,Million US$ at exchange rate,5.5
10536,Estonia,2011,13,C10-Lipid modifying agents,Million of national currency units,3.9
10537,Estonia,2011,13,B-Blood and blood forming organs,Million of national currency units,11.4
10538,Estonia,2011,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",4.1
10539,Estonia,2011,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",7.7
10540,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",21.7
10541,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,15.5
10542,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.4
10543,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.7
10544,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.1
10545,Estonia,2011,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.0
10546,Estonia,2011,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.8
10547,Estonia,2011,13,R03-Drugs for obstructive airway diseases,Million of national currency units,6.7
10548,Estonia,2011,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.3
10549,Estonia,2011,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",13.1
10550,Estonia,2011,13,C08-Calcium channel blockers,Million US$ at exchange rate,5.2
10551,Estonia,2011,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",7.2
10552,Estonia,2011,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9
10553,Estonia,2011,13,R-Respiratory system,% of total sales,7.4
10554,Estonia,2011,13,C08-Calcium channel blockers,Million of national currency units,3.7
10555,Estonia,2011,13,R03-Drugs for obstructive airway diseases,% of total sales,3.3
10556,Estonia,2011,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4
10557,Estonia,2011,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.4
10558,Estonia,2011,13,C08-Calcium channel blockers,% of total sales,1.8
10559,Estonia,2011,13,A02A-Antacids,"/capita, US$ exchange rate",0.3
10560,Estonia,2011,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.0
10561,Estonia,2011,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",2.8
10562,Estonia,2011,13,N05C-Hypnotics and sedatives,Million of national currency units,1.4
10563,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,9.1
10564,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.5
10565,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.8
10566,Estonia,2011,13,G-Genito urinary system and sex hormones,% of total sales,5.3
10567,Estonia,2011,13,N05C-Hypnotics and sedatives,% of total sales,0.7
10568,Estonia,2011,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5
10569,Estonia,2011,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.1
10570,Estonia,2011,13,C03-Diuretics,"/capita, US$ exchange rate",1.6
10571,Estonia,2011,13,C03-Diuretics,"/capita, US$ purchasing power parity",2.3
10572,Estonia,2011,13,C03-Diuretics,Million US$ at exchange rate,2.2
10573,Estonia,2011,13,C03-Diuretics,"Million US$, purchasing power parity",3.1
10574,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.6
10575,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.9
10576,Estonia,2011,13,C03-Diuretics,% of total sales,0.8
10577,Estonia,2011,13,G03-Sex hormones and modulators of the genital system,% of total sales,3.2
10578,Estonia,2011,13,C07-Beta blocking agents,Million US$ at exchange rate,6.6
10579,Estonia,2011,13,C07-Beta blocking agents,"Million US$, purchasing power parity",9.3
10580,Estonia,2011,13,A02A-Antacids,% of total sales,0.1
10581,Estonia,2011,13,C07-Beta blocking agents,Million of national currency units,4.8
10582,Estonia,2011,13,C07-Beta blocking agents,"/capita, US$ exchange rate",5.0
10583,Estonia,2011,13,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
10584,Estonia,2011,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.0
10585,Estonia,2011,13,C07-Beta blocking agents,% of total sales,2.3
10586,Estonia,2011,13,N06A-Antidepressants,% of total sales,1.4
10587,Estonia,2011,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.0
10588,Estonia,2011,13,G-Genito urinary system and sex hormones,Million of national currency units,10.8
10589,Estonia,2011,13,N06A-Antidepressants,Million of national currency units,2.9
10590,Estonia,2011,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.1
10591,Estonia,2011,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.9
10592,Estonia,2011,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3
10593,Estonia,2011,13,N06A-Antidepressants,"/capita, US$ exchange rate",3.1
10594,Estonia,2011,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.3
10595,Estonia,2011,13,N06A-Antidepressants,Million US$ at exchange rate,4.1
10596,Estonia,2011,13,N06A-Antidepressants,"Million US$, purchasing power parity",5.8
10597,Estonia,2011,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,33.9
10598,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6
10599,Estonia,2011,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",35.8
10600,Estonia,2011,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.5
10601,Estonia,2011,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",47.6
10602,Estonia,2011,13,A-Alimentary tract and metabolism,Million of national currency units,24.3
10603,Estonia,2011,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.6
10604,Estonia,2011,13,A10-Drugs used in diabetes,% of total sales,5.8
10605,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.7
10606,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.4
10607,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.3
10608,Estonia,2011,13,N-Nervous system,% of total sales,10.8
10609,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8
10610,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1
10611,Estonia,2011,13,N-Nervous system,"Million US$, purchasing power parity",43.3
10612,Estonia,2011,13,N-Nervous system,"/capita, US$ purchasing power parity",32.6
10613,Estonia,2011,13,N-Nervous system,"/capita, US$ exchange rate",23.2
10614,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
10615,Estonia,2011,13,A-Alimentary tract and metabolism,% of total sales,11.9
10616,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
10617,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.5
10618,Estonia,2011,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
10619,Estonia,2011,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
10620,Estonia,2011,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
10621,Estonia,2011,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
10622,Estonia,2011,13,C01A-Cardiac glycosides,Million of national currency units,0.2
10623,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.6
10624,Estonia,2011,13,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
10625,Estonia,2011,13,Total pharmaceutical sales,"Million US$, purchasing power parity",399.5
10626,Estonia,2011,13,Total pharmaceutical sales,Million of national currency units,204.4
10627,Estonia,2011,13,Total pharmaceutical sales,Million US$ at exchange rate,284.5
10628,Estonia,2011,13,C01A-Cardiac glycosides,% of total sales,0.1
10629,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.3
10630,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1
10631,Estonia,2011,13,M-Musculo-skeletal system,% of total sales,5.4
10632,Estonia,2011,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.6
10633,Estonia,2011,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.3
10634,Estonia,2011,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",12.5
10635,Estonia,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.5
10636,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,8.7
10637,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",12.3
10638,Estonia,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.3
10639,Estonia,2011,13,M-Musculo-skeletal system,Million of national currency units,11.1
10640,Estonia,2011,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",21.6
10641,Estonia,2011,13,M-Musculo-skeletal system,Million US$ at exchange rate,15.4
10642,Estonia,2011,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.1
10643,Estonia,2011,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",43.7
10644,Estonia,2011,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",15.8
10645,Estonia,2011,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",32.9
10646,Estonia,2011,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",23.4
10647,Estonia,2011,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",301.0
10648,Estonia,2011,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",23.3
10649,Estonia,2011,13,J-Antiinfectives for systemic use,Million of national currency units,22.4
10650,Estonia,2011,13,Total pharmaceutical sales,"/capita, US$ exchange rate",214.3
10651,Estonia,2011,13,J01-Antibacterials for systemic use,Million of national currency units,8.1
10652,Estonia,2011,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.2
10653,Estonia,2011,13,A10-Drugs used in diabetes,Million US$ at exchange rate,16.6
10654,Estonia,2011,13,A10-Drugs used in diabetes,Million of national currency units,11.9
10655,Estonia,2011,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.5
10656,Estonia,2011,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",45.9
10657,Estonia,2011,13,N-Nervous system,Million of national currency units,22.1
10658,Estonia,2011,13,N-Nervous system,Million US$ at exchange rate,30.8
10659,Estonia,2011,13,C-Cardiovascular system,% of total sales,15.3
10660,Estonia,2011,13,J-Antiinfectives for systemic use,% of total sales,10.9
10661,Estonia,2011,13,J01-Antibacterials for systemic use,% of total sales,3.9
10662,Estonia,2011,13,C02-Antihypertensives,Million of national currency units,0.9
10663,Estonia,2011,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9
10664,Estonia,2010,11,C02-Antihypertensives,"Million US$, purchasing power parity",1.7
10665,Estonia,2010,11,C02-Antihypertensives,"/capita, US$ exchange rate",0.9
10666,Estonia,2010,11,N05B-Anxiolytics,% of total sales,0.6
10667,Estonia,2010,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.7
10668,Estonia,2010,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
10669,Estonia,2010,11,C02-Antihypertensives,Million US$ at exchange rate,1.2
10670,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.7
10671,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3
10672,Estonia,2010,11,N02-Analgesics,"Million US$, purchasing power parity",10.2
10673,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.9
10674,Estonia,2010,11,N05B-Anxiolytics,"Million US$, purchasing power parity",2.2
10675,Estonia,2010,11,N05B-Anxiolytics,Million US$ at exchange rate,1.5
10676,Estonia,2010,11,N02-Analgesics,"/capita, US$ exchange rate",5.2
10677,Estonia,2010,11,N02-Analgesics,"/capita, US$ purchasing power parity",7.6
10678,Estonia,2010,11,N02-Analgesics,% of total sales,2.7
10679,Estonia,2010,11,N05B-Anxiolytics,Million of national currency units,1.1
10680,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,2.5
10681,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,3.3
10682,Estonia,2010,11,C-Cardiovascular system,"/capita, US$ exchange rate",34.8
10683,Estonia,2010,11,C-Cardiovascular system,"Million US$, purchasing power parity",68.3
10684,Estonia,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.5
10685,Estonia,2010,11,C02-Antihypertensives,% of total sales,0.5
10686,Estonia,2010,11,N02-Analgesics,Million US$ at exchange rate,6.9
10687,Estonia,2010,11,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
10688,Estonia,2010,11,C-Cardiovascular system,Million US$ at exchange rate,46.3
10689,Estonia,2010,11,C-Cardiovascular system,Million of national currency units,35.0
10690,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.6
10691,Estonia,2010,11,N02-Analgesics,Million of national currency units,5.2
10692,Estonia,2010,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",15.2
10693,Estonia,2010,11,B-Blood and blood forming organs,% of total sales,5.3
10694,Estonia,2010,11,B-Blood and blood forming organs,Million US$ at exchange rate,13.7
10695,Estonia,2010,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",10.3
10696,Estonia,2010,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",20.2
10697,Estonia,2010,11,R-Respiratory system,"/capita, US$ exchange rate",14.4
10698,Estonia,2010,11,R-Respiratory system,"/capita, US$ purchasing power parity",21.2
10699,Estonia,2010,11,R-Respiratory system,"Million US$, purchasing power parity",28.2
10700,Estonia,2010,11,R-Respiratory system,Million of national currency units,14.5
10701,Estonia,2010,11,R-Respiratory system,Million US$ at exchange rate,19.2
10702,Estonia,2010,11,A02A-Antacids,Million of national currency units,0.3
10703,Estonia,2010,11,C10-Lipid modifying agents,% of total sales,2.7
10704,Estonia,2010,11,A02A-Antacids,"Million US$, purchasing power parity",0.5
10705,Estonia,2010,11,A02A-Antacids,Million US$ at exchange rate,0.4
10706,Estonia,2010,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.8
10707,Estonia,2010,11,C10-Lipid modifying agents,Million US$ at exchange rate,7.1
10708,Estonia,2010,11,C10-Lipid modifying agents,Million of national currency units,5.3
10709,Estonia,2010,11,B-Blood and blood forming organs,Million of national currency units,10.3
10710,Estonia,2010,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",5.3
10711,Estonia,2010,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",10.4
10712,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",22.8
10713,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,15.5
10714,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.1
10715,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.6
10716,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.7
10717,Estonia,2010,11,R03-Drugs for obstructive airway diseases,Million of national currency units,6.4
10718,Estonia,2010,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",6.4
10719,Estonia,2010,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.4
10720,Estonia,2010,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,8.5
10721,Estonia,2010,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.5
10722,Estonia,2010,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0
10723,Estonia,2010,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",9.7
10724,Estonia,2010,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.9
10725,Estonia,2010,11,C08-Calcium channel blockers,Million US$ at exchange rate,6.6
10726,Estonia,2010,11,R-Respiratory system,% of total sales,7.5
10727,Estonia,2010,11,C08-Calcium channel blockers,Million of national currency units,4.9
10728,Estonia,2010,11,R03-Drugs for obstructive airway diseases,% of total sales,3.3
10729,Estonia,2010,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.3
10730,Estonia,2010,11,C08-Calcium channel blockers,% of total sales,2.6
10731,Estonia,2010,11,C03-Diuretics,Million of national currency units,1.6
10732,Estonia,2010,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.8
10733,Estonia,2010,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",2.7
10734,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.7
10735,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.6
10736,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.5
10737,Estonia,2010,11,N05C-Hypnotics and sedatives,Million of national currency units,1.4
10738,Estonia,2010,11,G-Genito urinary system and sex hormones,% of total sales,5.5
10739,Estonia,2010,11,N05C-Hypnotics and sedatives,% of total sales,0.7
10740,Estonia,2010,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.4
10741,Estonia,2010,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0
10742,Estonia,2010,11,C03-Diuretics,"/capita, US$ exchange rate",1.6
10743,Estonia,2010,11,C03-Diuretics,"/capita, US$ purchasing power parity",2.3
10744,Estonia,2010,11,C03-Diuretics,Million US$ at exchange rate,2.1
10745,Estonia,2010,11,C03-Diuretics,"Million US$, purchasing power parity",3.1
10746,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.5
10747,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.5
10748,Estonia,2010,11,C03-Diuretics,% of total sales,0.8
10749,Estonia,2010,11,G03-Sex hormones and modulators of the genital system,% of total sales,3.4
10750,Estonia,2010,11,C07-Beta blocking agents,Million US$ at exchange rate,7.2
10751,Estonia,2010,11,C07-Beta blocking agents,"Million US$, purchasing power parity",10.7
10752,Estonia,2010,11,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4
10753,Estonia,2010,11,C07-Beta blocking agents,Million of national currency units,5.5
10754,Estonia,2010,11,A02A-Antacids,% of total sales,0.1
10755,Estonia,2010,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
10756,Estonia,2010,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0
10757,Estonia,2010,11,C07-Beta blocking agents,% of total sales,2.8
10758,Estonia,2010,11,A02A-Antacids,"/capita, US$ exchange rate",0.3
10759,Estonia,2010,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,14.1
10760,Estonia,2010,11,G-Genito urinary system and sex hormones,Million of national currency units,10.6
10761,Estonia,2010,11,N06A-Antidepressants,Million of national currency units,3.0
10762,Estonia,2010,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",20.7
10763,Estonia,2010,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.6
10764,Estonia,2010,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.6
10765,Estonia,2010,11,N06A-Antidepressants,"/capita, US$ exchange rate",3.0
10766,Estonia,2010,11,N06A-Antidepressants,% of total sales,1.6
10767,Estonia,2010,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.4
10768,Estonia,2010,11,N06A-Antidepressants,Million US$ at exchange rate,4.0
10769,Estonia,2010,11,N06A-Antidepressants,"Million US$, purchasing power parity",5.9
10770,Estonia,2010,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,31.2
10771,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9
10772,Estonia,2010,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",34.5
10773,Estonia,2010,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",23.4
10774,Estonia,2010,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",46.0
10775,Estonia,2010,11,A-Alimentary tract and metabolism,Million of national currency units,23.5
10776,Estonia,2010,11,A10-Drugs used in diabetes,% of total sales,5.9
10777,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.3
10778,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",7.1
10779,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.6
10780,Estonia,2010,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.8
10781,Estonia,2010,11,N-Nervous system,% of total sales,11.1
10782,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.0
10783,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8
10784,Estonia,2010,11,N-Nervous system,"Million US$, purchasing power parity",42.0
10785,Estonia,2010,11,N-Nervous system,"/capita, US$ exchange rate",21.4
10786,Estonia,2010,11,N-Nervous system,"/capita, US$ purchasing power parity",31.5
10787,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
10788,Estonia,2010,11,A-Alimentary tract and metabolism,% of total sales,12.1
10789,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.5
10790,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
10791,Estonia,2010,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
10792,Estonia,2010,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
10793,Estonia,2010,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
10794,Estonia,2010,11,C01A-Cardiac glycosides,Million of national currency units,0.2
10795,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.1
10796,Estonia,2010,11,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
10797,Estonia,2010,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
10798,Estonia,2010,11,C01A-Cardiac glycosides,% of total sales,0.1
10799,Estonia,2010,11,Total pharmaceutical sales,"Million US$, purchasing power parity",379.0
10800,Estonia,2010,11,Total pharmaceutical sales,Million of national currency units,194.1
10801,Estonia,2010,11,Total pharmaceutical sales,Million US$ at exchange rate,257.2
10802,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2
10803,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.0
10804,Estonia,2010,11,M-Musculo-skeletal system,% of total sales,5.6
10805,Estonia,2010,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.8
10806,Estonia,2010,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.7
10807,Estonia,2010,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.4
10808,Estonia,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.8
10809,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,8.1
10810,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",11.9
10811,Estonia,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.1
10812,Estonia,2010,11,M-Musculo-skeletal system,Million of national currency units,10.8
10813,Estonia,2010,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",21.1
10814,Estonia,2010,11,M-Musculo-skeletal system,Million US$ at exchange rate,14.3
10815,Estonia,2010,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,26.3
10816,Estonia,2010,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",38.7
10817,Estonia,2010,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",15.3
10818,Estonia,2010,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.1
10819,Estonia,2010,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.7
10820,Estonia,2010,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",284.6
10821,Estonia,2010,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",22.4
10822,Estonia,2010,11,J-Antiinfectives for systemic use,Million of national currency units,19.8
10823,Estonia,2010,11,J01-Antibacterials for systemic use,Million of national currency units,7.9
10824,Estonia,2010,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.4
10825,Estonia,2010,11,A10-Drugs used in diabetes,Million of national currency units,11.5
10826,Estonia,2010,11,A10-Drugs used in diabetes,Million US$ at exchange rate,15.2
10827,Estonia,2010,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",51.3
10828,Estonia,2010,11,N-Nervous system,Million of national currency units,21.5
10829,Estonia,2010,11,N-Nervous system,Million US$ at exchange rate,28.5
10830,Estonia,2010,11,C-Cardiovascular system,% of total sales,18.0
10831,Estonia,2010,11,J-Antiinfectives for systemic use,% of total sales,10.2
10832,Estonia,2010,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.8
10833,Estonia,2010,11,Total pharmaceutical sales,"/capita, US$ exchange rate",193.2
10834,Estonia,2010,11,J01-Antibacterials for systemic use,% of total sales,4.0
10835,Estonia,2010,11,C02-Antihypertensives,Million of national currency units,0.9
10836,Estonia,2010,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.5
10837,Estonia,2017,9,C02-Antihypertensives,"Million US$, purchasing power parity",1.7
10838,Estonia,2017,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.8
10839,Estonia,2017,9,C02-Antihypertensives,Million US$ at exchange rate,1.0
10840,Estonia,2017,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0
10841,Estonia,2017,9,N05B-Anxiolytics,% of total sales,0.5
10842,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
10843,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.1
10844,Estonia,2017,9,N02-Analgesics,"/capita, US$ purchasing power parity",11.3
10845,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.9
10846,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",8.1
10847,Estonia,2017,9,N02-Analgesics,Million US$ at exchange rate,9.0
10848,Estonia,2017,9,N05B-Anxiolytics,Million US$ at exchange rate,1.6
10849,Estonia,2017,9,N05B-Anxiolytics,Million of national currency units,1.4
10850,Estonia,2017,9,N02-Analgesics,"Million US$, purchasing power parity",14.9
10851,Estonia,2017,9,N02-Analgesics,"/capita, US$ exchange rate",6.8
10852,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.3
10853,Estonia,2017,9,N02-Analgesics,% of total sales,2.6
10854,Estonia,2017,9,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6
10855,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,3.7
10856,Estonia,2017,9,C-Cardiovascular system,"/capita, US$ exchange rate",25.7
10857,Estonia,2017,9,C-Cardiovascular system,"Million US$, purchasing power parity",56.0
10858,Estonia,2017,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
10859,Estonia,2017,9,C02-Antihypertensives,% of total sales,0.3
10860,Estonia,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.7
10861,Estonia,2017,9,C-Cardiovascular system,Million US$ at exchange rate,33.8
10862,Estonia,2017,9,N02-Analgesics,Million of national currency units,7.9
10863,Estonia,2017,9,N05B-Anxiolytics,"/capita, US$ exchange rate",1.2
10864,Estonia,2017,9,C-Cardiovascular system,Million of national currency units,29.9
10865,Estonia,2017,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.2
10866,Estonia,2017,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.7
10867,Estonia,2017,9,B-Blood and blood forming organs,Million US$ at exchange rate,33.2
10868,Estonia,2017,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",54.9
10869,Estonia,2017,9,B-Blood and blood forming organs,% of total sales,9.8
10870,Estonia,2017,9,R-Respiratory system,"Million US$, purchasing power parity",41.3
10871,Estonia,2017,9,R-Respiratory system,"/capita, US$ exchange rate",18.9
10872,Estonia,2017,9,R-Respiratory system,Million of national currency units,22.1
10873,Estonia,2017,9,R-Respiratory system,Million US$ at exchange rate,25.0
10874,Estonia,2017,9,C10-Lipid modifying agents,% of total sales,1.0
10875,Estonia,2017,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.5
10876,Estonia,2017,9,A02A-Antacids,Million of national currency units,0.4
10877,Estonia,2017,9,A02A-Antacids,"Million US$, purchasing power parity",0.7
10878,Estonia,2017,9,A02A-Antacids,Million US$ at exchange rate,0.4
10879,Estonia,2017,9,C10-Lipid modifying agents,Million of national currency units,3.1
10880,Estonia,2017,9,C10-Lipid modifying agents,Million US$ at exchange rate,3.5
10881,Estonia,2017,9,B-Blood and blood forming organs,Million of national currency units,29.4
10882,Estonia,2017,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.7
10883,Estonia,2017,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",5.9
10884,Estonia,2017,9,R-Respiratory system,"/capita, US$ purchasing power parity",31.4
10885,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,13.3
10886,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.7
10887,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",21.9
10888,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.7
10889,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.1
10890,Estonia,2017,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",17.2
10891,Estonia,2017,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",7.9
10892,Estonia,2017,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",13.1
10893,Estonia,2017,9,R03-Drugs for obstructive airway diseases,Million of national currency units,9.2
10894,Estonia,2017,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.4
10895,Estonia,2017,9,C08-Calcium channel blockers,Million US$ at exchange rate,2.1
10896,Estonia,2017,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",3.5
10897,Estonia,2017,9,R-Respiratory system,% of total sales,7.3
10898,Estonia,2017,9,C08-Calcium channel blockers,Million of national currency units,1.9
10899,Estonia,2017,9,R03-Drugs for obstructive airway diseases,% of total sales,3.1
10900,Estonia,2017,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.9
10901,Estonia,2017,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.6
10902,Estonia,2017,9,C08-Calcium channel blockers,% of total sales,0.6
10903,Estonia,2017,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.7
10904,Estonia,2017,9,N05C-Hypnotics and sedatives,Million of national currency units,2.0
10905,Estonia,2017,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.2
10906,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.1
10907,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.4
10908,Estonia,2017,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.7
10909,Estonia,2017,9,N05C-Hypnotics and sedatives,% of total sales,0.7
10910,Estonia,2017,9,G-Genito urinary system and sex hormones,% of total sales,3.8
10911,Estonia,2017,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7
10912,Estonia,2017,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.8
10913,Estonia,2017,9,C03-Diuretics,"/capita, US$ exchange rate",1.6
10914,Estonia,2017,9,C03-Diuretics,"/capita, US$ purchasing power parity",2.7
10915,Estonia,2017,9,C03-Diuretics,"Million US$, purchasing power parity",3.6
10916,Estonia,2017,9,C03-Diuretics,Million of national currency units,1.9
10917,Estonia,2017,9,C03-Diuretics,Million US$ at exchange rate,2.2
10918,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.6
10919,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.6
10920,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",10.1
10921,Estonia,2017,9,C03-Diuretics,% of total sales,0.6
10922,Estonia,2017,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
10923,Estonia,2017,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.4
10924,Estonia,2017,9,C07-Beta blocking agents,Million US$ at exchange rate,6.2
10925,Estonia,2017,9,C07-Beta blocking agents,"Million US$, purchasing power parity",10.2
10926,Estonia,2017,9,N06A-Antidepressants,% of total sales,1.1
10927,Estonia,2017,9,A02A-Antacids,% of total sales,0.1
10928,Estonia,2017,9,C07-Beta blocking agents,Million of national currency units,5.5
10929,Estonia,2017,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
10930,Estonia,2017,9,A02A-Antacids,"/capita, US$ exchange rate",0.3
10931,Estonia,2017,9,C07-Beta blocking agents,"/capita, US$ exchange rate",4.7
10932,Estonia,2017,9,C07-Beta blocking agents,% of total sales,1.8
10933,Estonia,2017,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7
10934,Estonia,2017,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,13.0
10935,Estonia,2017,9,G-Genito urinary system and sex hormones,Million of national currency units,11.5
10936,Estonia,2017,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.9
10937,Estonia,2017,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",21.6
10938,Estonia,2017,9,N06A-Antidepressants,"/capita, US$ exchange rate",2.8
10939,Estonia,2017,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.6
10940,Estonia,2017,9,N06A-Antidepressants,Million of national currency units,3.2
10941,Estonia,2017,9,N06A-Antidepressants,"Million US$, purchasing power parity",6.0
10942,Estonia,2017,9,N06A-Antidepressants,Million US$ at exchange rate,3.6
10943,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
10944,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2
10945,Estonia,2017,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,40.2
10946,Estonia,2017,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",30.5
10947,Estonia,2017,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",66.5
10948,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.3
10949,Estonia,2017,9,A10-Drugs used in diabetes,% of total sales,6.0
10950,Estonia,2017,9,A-Alimentary tract and metabolism,Million of national currency units,35.6
10951,Estonia,2017,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",25.5
10952,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.2
10953,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.2
10954,Estonia,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",7.0
10955,Estonia,2017,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.5
10956,Estonia,2017,9,N-Nervous system,% of total sales,8.7
10957,Estonia,2017,9,N-Nervous system,"/capita, US$ purchasing power parity",37.2
10958,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8
10959,Estonia,2017,9,N-Nervous system,"Million US$, purchasing power parity",49.0
10960,Estonia,2017,9,N-Nervous system,"/capita, US$ exchange rate",22.5
10961,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
10962,Estonia,2017,9,A-Alimentary tract and metabolism,% of total sales,11.8
10963,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.9
10964,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.5
10965,Estonia,2017,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
10966,Estonia,2017,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
10967,Estonia,2017,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
10968,Estonia,2017,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
10969,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.1
10970,Estonia,2017,9,C01A-Cardiac glycosides,Million of national currency units,0.1
10971,Estonia,2017,9,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
10972,Estonia,2017,9,Total pharmaceutical sales,Million US$ at exchange rate,340.0
10973,Estonia,2017,9,Total pharmaceutical sales,Million of national currency units,301.0
10974,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2
10975,Estonia,2017,9,C01A-Cardiac glycosides,% of total sales,0.0
10976,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.5
10977,Estonia,2017,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.9
10978,Estonia,2017,9,M-Musculo-skeletal system,% of total sales,5.6
10979,Estonia,2017,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.4
10980,Estonia,2017,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.4
10981,Estonia,2017,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",33.6
10982,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,9.5
10983,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",17.8
10984,Estonia,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.7
10985,Estonia,2017,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",31.5
10986,Estonia,2017,9,M-Musculo-skeletal system,Million US$ at exchange rate,19.0
10987,Estonia,2017,9,M-Musculo-skeletal system,Million of national currency units,16.8
10988,Estonia,2017,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,49.4
10989,Estonia,2017,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.4
10990,Estonia,2017,9,J-Antiinfectives for systemic use,Million of national currency units,43.8
10991,Estonia,2017,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.5
10992,Estonia,2017,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",62.1
10993,Estonia,2017,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",81.8
10994,Estonia,2017,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.5
10995,Estonia,2017,9,Total pharmaceutical sales,"/capita, US$ exchange rate",258.1
10996,Estonia,2017,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",427.1
10997,Estonia,2017,9,A10-Drugs used in diabetes,Million US$ at exchange rate,20.3
10998,Estonia,2017,9,J01-Antibacterials for systemic use,Million of national currency units,6.6
10999,Estonia,2017,9,A10-Drugs used in diabetes,Million of national currency units,18.0
11000,Estonia,2017,9,N-Nervous system,Million of national currency units,26.2
11001,Estonia,2017,9,J-Antiinfectives for systemic use,% of total sales,14.5
11002,Estonia,2017,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",42.5
11003,Estonia,2017,9,N-Nervous system,Million US$ at exchange rate,29.6
11004,Estonia,2017,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.4
11005,Estonia,2017,9,C02-Antihypertensives,Million of national currency units,0.9
11006,Estonia,2017,9,Total pharmaceutical sales,"Million US$, purchasing power parity",562.6
11007,Estonia,2017,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.7
11008,Estonia,2017,9,J01-Antibacterials for systemic use,% of total sales,2.2
11009,Estonia,2017,9,C-Cardiovascular system,% of total sales,9.9
11010,Finland,2016,3,C01A-Cardiac glycosides,% of total sales,0.1
11011,Finland,2016,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
11012,Finland,2016,3,C07-Beta blocking agents,"Million US$, purchasing power parity",30.1
11013,Finland,2016,3,C07-Beta blocking agents,Million US$ at exchange rate,29.3
11014,Finland,2016,3,C07-Beta blocking agents,Million of national currency units,26.5
11015,Finland,2016,3,C01A-Cardiac glycosides,Million of national currency units,1.2
11016,Finland,2016,3,C02-Antihypertensives,Million of national currency units,7.6
11017,Finland,2016,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
11018,Finland,2016,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
11019,Finland,2016,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3
11020,Finland,2016,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",62.5
11021,Finland,2016,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.9
11022,Finland,2016,3,A-Alimentary tract and metabolism,% of total sales,13.2
11023,Finland,2016,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,334.7
11024,Finland,2016,3,A-Alimentary tract and metabolism,Million of national currency units,302.4
11025,Finland,2016,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",343.3
11026,Finland,2016,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.7
11027,Finland,2016,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,13.4
11028,Finland,2016,3,N-Nervous system,Million of national currency units,307.0
11029,Finland,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.4
11030,Finland,2016,3,N05C-Hypnotics and sedatives,% of total sales,0.5
11031,Finland,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.5
11032,Finland,2016,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",130.2
11033,Finland,2016,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,127.0
11034,Finland,2016,3,C02-Antihypertensives,Million US$ at exchange rate,8.4
11035,Finland,2016,3,C02-Antihypertensives,"Million US$, purchasing power parity",8.6
11036,Finland,2016,3,G-Genito urinary system and sex hormones,% of total sales,5.0
11037,Finland,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",23.1
11038,Finland,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.7
11039,Finland,2016,3,N-Nervous system,Million US$ at exchange rate,339.8
11040,Finland,2016,3,N-Nervous system,"Million US$, purchasing power parity",348.5
11041,Finland,2016,3,G-Genito urinary system and sex hormones,Million of national currency units,114.7
11042,Finland,2016,3,N-Nervous system,% of total sales,13.4
11043,Finland,2016,3,N-Nervous system,"/capita, US$ purchasing power parity",63.4
11044,Finland,2016,3,N-Nervous system,"/capita, US$ exchange rate",61.8
11045,Finland,2016,3,N06A-Antidepressants,"Million US$, purchasing power parity",35.0
11046,Finland,2016,3,N06A-Antidepressants,Million US$ at exchange rate,34.1
11047,Finland,2016,3,N06A-Antidepressants,Million of national currency units,30.8
11048,Finland,2016,3,N06A-Antidepressants,% of total sales,1.3
11049,Finland,2016,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.4
11050,Finland,2016,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.2
11051,Finland,2016,3,A10-Drugs used in diabetes,Million of national currency units,153.5
11052,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.1
11053,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",40.1
11054,Finland,2016,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",174.3
11055,Finland,2016,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.9
11056,Finland,2016,3,A10-Drugs used in diabetes,Million US$ at exchange rate,169.9
11057,Finland,2016,3,R-Respiratory system,"/capita, US$ exchange rate",30.3
11058,Finland,2016,3,M-Musculo-skeletal system,% of total sales,4.3
11059,Finland,2016,3,R-Respiratory system,Million of national currency units,150.2
11060,Finland,2016,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",111.0
11061,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
11062,Finland,2016,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.2
11063,Finland,2016,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.7
11064,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.3
11065,Finland,2016,3,R-Respiratory system,Million US$ at exchange rate,166.3
11066,Finland,2016,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.7
11067,Finland,2016,3,R-Respiratory system,"Million US$, purchasing power parity",170.5
11068,Finland,2016,3,C08-Calcium channel blockers,% of total sales,0.8
11069,Finland,2016,3,A10-Drugs used in diabetes,% of total sales,6.7
11070,Finland,2016,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.0
11071,Finland,2016,3,M-Musculo-skeletal system,Million US$ at exchange rate,108.3
11072,Finland,2016,3,M-Musculo-skeletal system,Million of national currency units,97.8
11073,Finland,2016,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.5
11074,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
11075,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
11076,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
11077,Finland,2016,3,C07-Beta blocking agents,% of total sales,1.2
11078,Finland,2016,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3
11079,Finland,2016,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5
11080,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.2
11081,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.8
11082,Finland,2016,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.6
11083,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,35.3
11084,Finland,2016,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9
11085,Finland,2016,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.0
11086,Finland,2016,3,C02-Antihypertensives,"/capita, US$ exchange rate",1.5
11087,Finland,2016,3,R-Respiratory system,% of total sales,6.6
11088,Finland,2016,3,R-Respiratory system,"/capita, US$ purchasing power parity",31.0
11089,Finland,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.1
11090,Finland,2016,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",65.5
11091,Finland,2016,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,63.9
11092,Finland,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.6
11093,Finland,2016,3,C08-Calcium channel blockers,Million of national currency units,19.4
11094,Finland,2016,3,C08-Calcium channel blockers,Million US$ at exchange rate,21.5
11095,Finland,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.9
11096,Finland,2016,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,57.7
11097,Finland,2016,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.1
11098,Finland,2016,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",209.0
11099,Finland,2016,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.0
11100,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.5
11101,Finland,2016,3,A02A-Antacids,% of total sales,0.1
11102,Finland,2016,3,J-Antiinfectives for systemic use,Million of national currency units,184.1
11103,Finland,2016,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,203.8
11104,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,54.2
11105,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,60.0
11106,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",61.5
11107,Finland,2016,3,J-Antiinfectives for systemic use,% of total sales,8.0
11108,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.8
11109,Finland,2016,3,C-Cardiovascular system,% of total sales,9.2
11110,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3
11111,Finland,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.2
11112,Finland,2016,3,R03-Drugs for obstructive airway diseases,% of total sales,4.0
11113,Finland,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.7
11114,Finland,2016,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",102.7
11115,Finland,2016,3,R03-Drugs for obstructive airway diseases,Million of national currency units,90.5
11116,Finland,2016,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,100.2
11117,Finland,2016,3,A02A-Antacids,"Million US$, purchasing power parity",3.6
11118,Finland,2016,3,A02A-Antacids,"/capita, US$ exchange rate",0.6
11119,Finland,2016,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
11120,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",59.4
11121,Finland,2016,3,A02A-Antacids,Million US$ at exchange rate,3.5
11122,Finland,2016,3,A02A-Antacids,Million of national currency units,3.2
11123,Finland,2016,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",222.4
11124,Finland,2016,3,B-Blood and blood forming organs,Million US$ at exchange rate,216.8
11125,Finland,2016,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.5
11126,Finland,2016,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.5
11127,Finland,2016,3,N05B-Anxiolytics,Million US$ at exchange rate,8.0
11128,Finland,2016,3,N05B-Anxiolytics,Million of national currency units,7.2
11129,Finland,2016,3,N02-Analgesics,% of total sales,3.2
11130,Finland,2016,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2598.3
11131,Finland,2016,3,Total pharmaceutical sales,Million US$ at exchange rate,2533.5
11132,Finland,2016,3,Total pharmaceutical sales,Million of national currency units,2288.8
11133,Finland,2016,3,B-Blood and blood forming organs,% of total sales,8.6
11134,Finland,2016,3,Total pharmaceutical sales,"/capita, US$ exchange rate",461.0
11135,Finland,2016,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",472.8
11136,Finland,2016,3,C03-Diuretics,"/capita, US$ purchasing power parity",1.7
11137,Finland,2016,3,C03-Diuretics,"Million US$, purchasing power parity",9.1
11138,Finland,2016,3,C03-Diuretics,"/capita, US$ exchange rate",1.6
11139,Finland,2016,3,C03-Diuretics,% of total sales,0.3
11140,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.2
11141,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.9
11142,Finland,2016,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.4
11143,Finland,2016,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5
11144,Finland,2016,3,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
11145,Finland,2016,3,N05B-Anxiolytics,"Million US$, purchasing power parity",8.2
11146,Finland,2016,3,C03-Diuretics,Million US$ at exchange rate,8.9
11147,Finland,2016,3,C03-Diuretics,Million of national currency units,8.0
11148,Finland,2016,3,N05B-Anxiolytics,% of total sales,0.3
11149,Finland,2016,3,B-Blood and blood forming organs,Million of national currency units,195.9
11150,Finland,2016,3,N02-Analgesics,Million US$ at exchange rate,79.9
11151,Finland,2016,3,N02-Analgesics,"Million US$, purchasing power parity",82.0
11152,Finland,2016,3,N05C-Hypnotics and sedatives,Million of national currency units,12.1
11153,Finland,2016,3,C10-Lipid modifying agents,Million of national currency units,66.8
11154,Finland,2016,3,C10-Lipid modifying agents,Million US$ at exchange rate,73.9
11155,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,50.1
11156,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,45.3
11157,Finland,2016,3,N02-Analgesics,"/capita, US$ exchange rate",14.5
11158,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.1
11159,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",51.4
11160,Finland,2016,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",62.7
11161,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.4
11162,Finland,2016,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,61.1
11163,Finland,2016,3,J01-Antibacterials for systemic use,Million of national currency units,55.2
11164,Finland,2016,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.4
11165,Finland,2016,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.1
11166,Finland,2016,3,N02-Analgesics,Million of national currency units,72.2
11167,Finland,2016,3,J01-Antibacterials for systemic use,% of total sales,2.4
11168,Finland,2016,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",13.5
11169,Finland,2016,3,C-Cardiovascular system,"/capita, US$ exchange rate",42.3
11170,Finland,2016,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",43.4
11171,Finland,2016,3,C02-Antihypertensives,% of total sales,0.3
11172,Finland,2016,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.6
11173,Finland,2016,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.8
11174,Finland,2016,3,C10-Lipid modifying agents,% of total sales,2.9
11175,Finland,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
11176,Finland,2016,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",75.8
11177,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,57.9
11178,Finland,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,52.3
11179,Finland,2016,3,N02-Analgesics,"/capita, US$ purchasing power parity",14.9
11180,Finland,2016,3,C-Cardiovascular system,Million of national currency units,210.1
11181,Finland,2016,3,C-Cardiovascular system,Million US$ at exchange rate,232.6
11182,Finland,2016,3,C-Cardiovascular system,"Million US$, purchasing power parity",238.5
11183,Finland,2015,3,C01A-Cardiac glycosides,% of total sales,0.1
11184,Finland,2015,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
11185,Finland,2015,3,C07-Beta blocking agents,"Million US$, purchasing power parity",30.4
11186,Finland,2015,3,C07-Beta blocking agents,Million US$ at exchange rate,30.6
11187,Finland,2015,3,C07-Beta blocking agents,Million of national currency units,27.6
11188,Finland,2015,3,C01A-Cardiac glycosides,Million of national currency units,1.3
11189,Finland,2015,3,C02-Antihypertensives,Million of national currency units,7.1
11190,Finland,2015,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.4
11191,Finland,2015,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
11192,Finland,2015,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
11193,Finland,2015,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",58.9
11194,Finland,2015,3,A-Alimentary tract and metabolism,% of total sales,13.3
11195,Finland,2015,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",59.3
11196,Finland,2015,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,325.1
11197,Finland,2015,3,A-Alimentary tract and metabolism,Million of national currency units,293.0
11198,Finland,2015,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",322.8
11199,Finland,2015,3,N-Nervous system,Million of national currency units,319.8
11200,Finland,2015,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.8
11201,Finland,2015,3,C02-Antihypertensives,"/capita, US$ exchange rate",1.4
11202,Finland,2015,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,13.9
11203,Finland,2015,3,N05C-Hypnotics and sedatives,% of total sales,0.6
11204,Finland,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.5
11205,Finland,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.5
11206,Finland,2015,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",123.4
11207,Finland,2015,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,124.3
11208,Finland,2015,3,C02-Antihypertensives,"Million US$, purchasing power parity",7.8
11209,Finland,2015,3,C02-Antihypertensives,Million US$ at exchange rate,7.9
11210,Finland,2015,3,G-Genito urinary system and sex hormones,% of total sales,5.1
11211,Finland,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.5
11212,Finland,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.7
11213,Finland,2015,3,N-Nervous system,Million US$ at exchange rate,354.8
11214,Finland,2015,3,N-Nervous system,"Million US$, purchasing power parity",352.3
11215,Finland,2015,3,G-Genito urinary system and sex hormones,Million of national currency units,112.0
11216,Finland,2015,3,N-Nervous system,% of total sales,14.5
11217,Finland,2015,3,N-Nervous system,"/capita, US$ purchasing power parity",64.3
11218,Finland,2015,3,N-Nervous system,"/capita, US$ exchange rate",64.8
11219,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6
11220,Finland,2015,3,N06A-Antidepressants,"Million US$, purchasing power parity",35.4
11221,Finland,2015,3,N06A-Antidepressants,Million of national currency units,32.1
11222,Finland,2015,3,N06A-Antidepressants,Million US$ at exchange rate,35.6
11223,Finland,2015,3,N06A-Antidepressants,% of total sales,1.5
11224,Finland,2015,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.5
11225,Finland,2015,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.5
11226,Finland,2015,3,A10-Drugs used in diabetes,Million of national currency units,148.2
11227,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.2
11228,Finland,2015,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.0
11229,Finland,2015,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",163.3
11230,Finland,2015,3,A10-Drugs used in diabetes,Million US$ at exchange rate,164.4
11231,Finland,2015,3,M-Musculo-skeletal system,% of total sales,4.5
11232,Finland,2015,3,R-Respiratory system,Million of national currency units,144.4
11233,Finland,2015,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",108.2
11234,Finland,2015,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.9
11235,Finland,2015,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.7
11236,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.1
11237,Finland,2015,3,R-Respiratory system,Million US$ at exchange rate,160.2
11238,Finland,2015,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",29.8
11239,Finland,2015,3,R-Respiratory system,"/capita, US$ exchange rate",29.2
11240,Finland,2015,3,R-Respiratory system,"Million US$, purchasing power parity",159.1
11241,Finland,2015,3,C08-Calcium channel blockers,% of total sales,0.9
11242,Finland,2015,3,A10-Drugs used in diabetes,% of total sales,6.7
11243,Finland,2015,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8
11244,Finland,2015,3,R-Respiratory system,"/capita, US$ purchasing power parity",29.0
11245,Finland,2015,3,M-Musculo-skeletal system,Million US$ at exchange rate,109.0
11246,Finland,2015,3,M-Musculo-skeletal system,Million of national currency units,98.2
11247,Finland,2015,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.7
11248,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
11249,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
11250,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
11251,Finland,2015,3,C07-Beta blocking agents,% of total sales,1.3
11252,Finland,2015,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6
11253,Finland,2015,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5
11254,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.0
11255,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.4
11256,Finland,2015,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.4
11257,Finland,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.7
11258,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,35.4
11259,Finland,2015,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",20.9
11260,Finland,2015,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.8
11261,Finland,2015,3,R-Respiratory system,% of total sales,6.6
11262,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",39.0
11263,Finland,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.3
11264,Finland,2015,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",64.3
11265,Finland,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.8
11266,Finland,2015,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,64.8
11267,Finland,2015,3,C08-Calcium channel blockers,Million US$ at exchange rate,21.1
11268,Finland,2015,3,C08-Calcium channel blockers,Million of national currency units,19.0
11269,Finland,2015,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,58.4
11270,Finland,2015,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",36.9
11271,Finland,2015,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",200.6
11272,Finland,2015,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",36.6
11273,Finland,2015,3,A02A-Antacids,% of total sales,0.1
11274,Finland,2015,3,J-Antiinfectives for systemic use,Million of national currency units,182.1
11275,Finland,2015,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,202.0
11276,Finland,2015,3,J-Antiinfectives for systemic use,% of total sales,8.3
11277,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,55.0
11278,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,61.0
11279,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",60.6
11280,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.6
11281,Finland,2015,3,C-Cardiovascular system,% of total sales,9.2
11282,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4
11283,Finland,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",17.7
11284,Finland,2015,3,R03-Drugs for obstructive airway diseases,% of total sales,4.0
11285,Finland,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.6
11286,Finland,2015,3,R03-Drugs for obstructive airway diseases,Million of national currency units,87.5
11287,Finland,2015,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",96.4
11288,Finland,2015,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,97.1
11289,Finland,2015,3,A02A-Antacids,"Million US$, purchasing power parity",3.5
11290,Finland,2015,3,A02A-Antacids,"/capita, US$ exchange rate",0.6
11291,Finland,2015,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
11292,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.7
11293,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",57.9
11294,Finland,2015,3,A02A-Antacids,Million of national currency units,3.2
11295,Finland,2015,3,A02A-Antacids,Million US$ at exchange rate,3.6
11296,Finland,2015,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",195.4
11297,Finland,2015,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.7
11298,Finland,2015,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.9
11299,Finland,2015,3,B-Blood and blood forming organs,Million US$ at exchange rate,196.8
11300,Finland,2015,3,N05B-Anxiolytics,Million US$ at exchange rate,8.7
11301,Finland,2015,3,N05B-Anxiolytics,Million of national currency units,7.8
11302,Finland,2015,3,N02-Analgesics,% of total sales,3.3
11303,Finland,2015,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2423.7
11304,Finland,2015,3,Total pharmaceutical sales,Million US$ at exchange rate,2441.0
11305,Finland,2015,3,Total pharmaceutical sales,Million of national currency units,2200.1
11306,Finland,2015,3,B-Blood and blood forming organs,% of total sales,8.1
11307,Finland,2015,3,Total pharmaceutical sales,"/capita, US$ exchange rate",445.5
11308,Finland,2015,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",442.3
11309,Finland,2015,3,C03-Diuretics,"/capita, US$ purchasing power parity",1.8
11310,Finland,2015,3,C03-Diuretics,% of total sales,0.4
11311,Finland,2015,3,C03-Diuretics,"/capita, US$ exchange rate",1.8
11312,Finland,2015,3,C03-Diuretics,"Million US$, purchasing power parity",9.7
11313,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.1
11314,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.1
11315,Finland,2015,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.5
11316,Finland,2015,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6
11317,Finland,2015,3,N05B-Anxiolytics,"Million US$, purchasing power parity",8.6
11318,Finland,2015,3,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6
11319,Finland,2015,3,C03-Diuretics,Million US$ at exchange rate,9.8
11320,Finland,2015,3,N05B-Anxiolytics,% of total sales,0.4
11321,Finland,2015,3,C03-Diuretics,Million of national currency units,8.8
11322,Finland,2015,3,B-Blood and blood forming organs,Million of national currency units,177.4
11323,Finland,2015,3,N02-Analgesics,"/capita, US$ exchange rate",14.6
11324,Finland,2015,3,N02-Analgesics,Million US$ at exchange rate,79.8
11325,Finland,2015,3,N02-Analgesics,"Million US$, purchasing power parity",79.2
11326,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
11327,Finland,2015,3,C10-Lipid modifying agents,Million of national currency units,58.7
11328,Finland,2015,3,C10-Lipid modifying agents,Million US$ at exchange rate,65.1
11329,Finland,2015,3,N05C-Hypnotics and sedatives,Million of national currency units,12.5
11330,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,46.8
11331,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,42.2
11332,Finland,2015,3,N02-Analgesics,Million of national currency units,71.9
11333,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.5
11334,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",46.5
11335,Finland,2015,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",57.1
11336,Finland,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.5
11337,Finland,2015,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,57.5
11338,Finland,2015,3,J01-Antibacterials for systemic use,Million of national currency units,51.8
11339,Finland,2015,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.4
11340,Finland,2015,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.5
11341,Finland,2015,3,J01-Antibacterials for systemic use,% of total sales,2.4
11342,Finland,2015,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.9
11343,Finland,2015,3,C-Cardiovascular system,"/capita, US$ exchange rate",41.1
11344,Finland,2015,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",40.9
11345,Finland,2015,3,C02-Antihypertensives,% of total sales,0.3
11346,Finland,2015,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.4
11347,Finland,2015,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.8
11348,Finland,2015,3,C10-Lipid modifying agents,% of total sales,2.7
11349,Finland,2015,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",64.7
11350,Finland,2015,3,C-Cardiovascular system,Million of national currency units,203.2
11351,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,58.4
11352,Finland,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,52.6
11353,Finland,2015,3,N02-Analgesics,"/capita, US$ purchasing power parity",14.5
11354,Finland,2015,3,C-Cardiovascular system,Million US$ at exchange rate,225.5
11355,Finland,2015,3,C-Cardiovascular system,"Million US$, purchasing power parity",223.9
11356,Finland,2014,3,C01A-Cardiac glycosides,% of total sales,0.1
11357,Finland,2014,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
11358,Finland,2014,3,C07-Beta blocking agents,"Million US$, purchasing power parity",30.4
11359,Finland,2014,3,C07-Beta blocking agents,Million US$ at exchange rate,36.7
11360,Finland,2014,3,C07-Beta blocking agents,Million of national currency units,27.6
11361,Finland,2014,3,C01A-Cardiac glycosides,Million of national currency units,1.1
11362,Finland,2014,3,C02-Antihypertensives,Million of national currency units,6.2
11363,Finland,2014,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
11364,Finland,2014,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2
11365,Finland,2014,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5
11366,Finland,2014,3,G-Genito urinary system and sex hormones,% of total sales,5.3
11367,Finland,2014,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",56.4
11368,Finland,2014,3,A-Alimentary tract and metabolism,% of total sales,13.3
11369,Finland,2014,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,371.1
11370,Finland,2014,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",67.9
11371,Finland,2014,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",307.9
11372,Finland,2014,3,A-Alimentary tract and metabolism,Million of national currency units,279.3
11373,Finland,2014,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.1
11374,Finland,2014,3,C02-Antihypertensives,"/capita, US$ exchange rate",1.5
11375,Finland,2014,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,17.0
11376,Finland,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",3.1
11377,Finland,2014,3,N05C-Hypnotics and sedatives,% of total sales,0.6
11378,Finland,2014,3,N-Nervous system,Million of national currency units,335.5
11379,Finland,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.6
11380,Finland,2014,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",122.8
11381,Finland,2014,3,C02-Antihypertensives,"Million US$, purchasing power parity",6.8
11382,Finland,2014,3,C02-Antihypertensives,Million US$ at exchange rate,8.2
11383,Finland,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.1
11384,Finland,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.5
11385,Finland,2014,3,N-Nervous system,"Million US$, purchasing power parity",369.8
11386,Finland,2014,3,N-Nervous system,Million US$ at exchange rate,445.7
11387,Finland,2014,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,148.0
11388,Finland,2014,3,G-Genito urinary system and sex hormones,Million of national currency units,111.4
11389,Finland,2014,3,N-Nervous system,% of total sales,16.0
11390,Finland,2014,3,N-Nervous system,"/capita, US$ purchasing power parity",67.7
11391,Finland,2014,3,N-Nervous system,"/capita, US$ exchange rate",81.6
11392,Finland,2014,3,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7
11393,Finland,2014,3,N06A-Antidepressants,"Million US$, purchasing power parity",36.3
11394,Finland,2014,3,N06A-Antidepressants,Million US$ at exchange rate,43.7
11395,Finland,2014,3,N06A-Antidepressants,Million of national currency units,32.9
11396,Finland,2014,3,N06A-Antidepressants,% of total sales,1.6
11397,Finland,2014,3,N06A-Antidepressants,"/capita, US$ exchange rate",8.0
11398,Finland,2014,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.6
11399,Finland,2014,3,A10-Drugs used in diabetes,Million of national currency units,140.0
11400,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.0
11401,Finland,2014,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",34.1
11402,Finland,2014,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",154.3
11403,Finland,2014,3,A10-Drugs used in diabetes,Million US$ at exchange rate,186.0
11404,Finland,2014,3,M-Musculo-skeletal system,% of total sales,4.7
11405,Finland,2014,3,R-Respiratory system,Million of national currency units,148.8
11406,Finland,2014,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.0
11407,Finland,2014,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",24.1
11408,Finland,2014,3,R-Respiratory system,Million US$ at exchange rate,197.7
11409,Finland,2014,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",28.3
11410,Finland,2014,3,R-Respiratory system,"/capita, US$ exchange rate",36.2
11411,Finland,2014,3,R-Respiratory system,"Million US$, purchasing power parity",164.0
11412,Finland,2014,3,C08-Calcium channel blockers,% of total sales,0.9
11413,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.7
11414,Finland,2014,3,A10-Drugs used in diabetes,% of total sales,6.7
11415,Finland,2014,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.7
11416,Finland,2014,3,R-Respiratory system,"/capita, US$ purchasing power parity",30.0
11417,Finland,2014,3,M-Musculo-skeletal system,Million US$ at exchange rate,131.4
11418,Finland,2014,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",109.0
11419,Finland,2014,3,M-Musculo-skeletal system,Million of national currency units,98.9
11420,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
11421,Finland,2014,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.8
11422,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
11423,Finland,2014,3,C07-Beta blocking agents,% of total sales,1.3
11424,Finland,2014,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.6
11425,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.6
11426,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.0
11427,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
11428,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6
11429,Finland,2014,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.8
11430,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,33.0
11431,Finland,2014,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.4
11432,Finland,2014,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",20.0
11433,Finland,2014,3,R-Respiratory system,% of total sales,7.1
11434,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,43.8
11435,Finland,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",36.4
11436,Finland,2014,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",63.6
11437,Finland,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.6
11438,Finland,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.0
11439,Finland,2014,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,76.7
11440,Finland,2014,3,C08-Calcium channel blockers,Million US$ at exchange rate,24.0
11441,Finland,2014,3,C08-Calcium channel blockers,Million of national currency units,18.1
11442,Finland,2014,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,57.7
11443,Finland,2014,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",35.4
11444,Finland,2014,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",160.6
11445,Finland,2014,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.4
11446,Finland,2014,3,J-Antiinfectives for systemic use,% of total sales,7.0
11447,Finland,2014,3,J-Antiinfectives for systemic use,Million of national currency units,145.7
11448,Finland,2014,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,193.6
11449,Finland,2014,3,A02A-Antacids,% of total sales,0.1
11450,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,54.5
11451,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,72.4
11452,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",60.1
11453,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.9
11454,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.6
11455,Finland,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.1
11456,Finland,2014,3,R03-Drugs for obstructive airway diseases,% of total sales,4.3
11457,Finland,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.3
11458,Finland,2014,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",100.2
11459,Finland,2014,3,R03-Drugs for obstructive airway diseases,Million of national currency units,90.9
11460,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",59.5
11461,Finland,2014,3,C-Cardiovascular system,% of total sales,9.1
11462,Finland,2014,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,120.8
11463,Finland,2014,3,A02A-Antacids,"/capita, US$ exchange rate",0.8
11464,Finland,2014,3,A02A-Antacids,"Million US$, purchasing power parity",3.4
11465,Finland,2014,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
11466,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.1
11467,Finland,2014,3,A02A-Antacids,Million US$ at exchange rate,4.1
11468,Finland,2014,3,A02A-Antacids,Million of national currency units,3.1
11469,Finland,2014,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",178.7
11470,Finland,2014,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.7
11471,Finland,2014,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.4
11472,Finland,2014,3,N05B-Anxiolytics,Million US$ at exchange rate,10.5
11473,Finland,2014,3,N05B-Anxiolytics,Million of national currency units,7.9
11474,Finland,2014,3,N02-Analgesics,% of total sales,3.4
11475,Finland,2014,3,B-Blood and blood forming organs,Million US$ at exchange rate,215.4
11476,Finland,2014,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2307.6
11477,Finland,2014,3,Total pharmaceutical sales,Million US$ at exchange rate,2781.2
11478,Finland,2014,3,Total pharmaceutical sales,Million of national currency units,2093.5
11479,Finland,2014,3,B-Blood and blood forming organs,% of total sales,7.7
11480,Finland,2014,3,Total pharmaceutical sales,"/capita, US$ exchange rate",509.2
11481,Finland,2014,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",422.5
11482,Finland,2014,3,C03-Diuretics,"/capita, US$ purchasing power parity",1.7
11483,Finland,2014,3,C03-Diuretics,% of total sales,0.4
11484,Finland,2014,3,C03-Diuretics,"/capita, US$ exchange rate",2.1
11485,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.0
11486,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.3
11487,Finland,2014,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.6
11488,Finland,2014,3,C03-Diuretics,"Million US$, purchasing power parity",9.4
11489,Finland,2014,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6
11490,Finland,2014,3,N05B-Anxiolytics,"Million US$, purchasing power parity",8.7
11491,Finland,2014,3,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9
11492,Finland,2014,3,N05B-Anxiolytics,% of total sales,0.4
11493,Finland,2014,3,C03-Diuretics,Million US$ at exchange rate,11.3
11494,Finland,2014,3,C03-Diuretics,Million of national currency units,8.5
11495,Finland,2014,3,B-Blood and blood forming organs,Million of national currency units,162.1
11496,Finland,2014,3,N02-Analgesics,"/capita, US$ exchange rate",17.1
11497,Finland,2014,3,N02-Analgesics,Million US$ at exchange rate,93.5
11498,Finland,2014,3,N02-Analgesics,"Million US$, purchasing power parity",77.6
11499,Finland,2014,3,C10-Lipid modifying agents,Million of national currency units,49.1
11500,Finland,2014,3,C10-Lipid modifying agents,Million US$ at exchange rate,65.2
11501,Finland,2014,3,N05C-Hypnotics and sedatives,Million of national currency units,12.8
11502,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,54.5
11503,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,41.0
11504,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.0
11505,Finland,2014,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",55.4
11506,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.3
11507,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
11508,Finland,2014,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,66.8
11509,Finland,2014,3,J01-Antibacterials for systemic use,Million of national currency units,50.3
11510,Finland,2014,3,N02-Analgesics,Million of national currency units,70.4
11511,Finland,2014,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.2
11512,Finland,2014,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.2
11513,Finland,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",45.2
11514,Finland,2014,3,J01-Antibacterials for systemic use,% of total sales,2.4
11515,Finland,2014,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.9
11516,Finland,2014,3,C-Cardiovascular system,"/capita, US$ exchange rate",46.4
11517,Finland,2014,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",38.5
11518,Finland,2014,3,C02-Antihypertensives,% of total sales,0.3
11519,Finland,2014,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
11520,Finland,2014,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.9
11521,Finland,2014,3,C10-Lipid modifying agents,% of total sales,2.3
11522,Finland,2014,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",54.1
11523,Finland,2014,3,C-Cardiovascular system,Million of national currency units,190.9
11524,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,71.7
11525,Finland,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,54.0
11526,Finland,2014,3,C-Cardiovascular system,Million US$ at exchange rate,253.6
11527,Finland,2014,3,C-Cardiovascular system,"Million US$, purchasing power parity",210.4
11528,Finland,2014,3,N02-Analgesics,"/capita, US$ purchasing power parity",14.2
11529,Finland,2013,4,C01A-Cardiac glycosides,% of total sales,0.0
11530,Finland,2013,4,C07-Beta blocking agents,Million of national currency units,27.1
11531,Finland,2013,4,C07-Beta blocking agents,"Million US$, purchasing power parity",29.9
11532,Finland,2013,4,C07-Beta blocking agents,Million US$ at exchange rate,36.0
11533,Finland,2013,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
11534,Finland,2013,4,C01A-Cardiac glycosides,Million of national currency units,0.6
11535,Finland,2013,4,C02-Antihypertensives,Million of national currency units,5.7
11536,Finland,2013,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
11537,Finland,2013,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
11538,Finland,2013,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.7
11539,Finland,2013,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.8
11540,Finland,2013,4,A-Alimentary tract and metabolism,% of total sales,13.2
11541,Finland,2013,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.7
11542,Finland,2013,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,352.0
11543,Finland,2013,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",292.7
11544,Finland,2013,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.9
11545,Finland,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",3.1
11546,Finland,2013,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.4
11547,Finland,2013,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,16.7
11548,Finland,2013,4,N05C-Hypnotics and sedatives,% of total sales,0.6
11549,Finland,2013,4,N-Nervous system,Million of national currency units,341.2
11550,Finland,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.6
11551,Finland,2013,4,A-Alimentary tract and metabolism,Million of national currency units,265.0
11552,Finland,2013,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",120.3
11553,Finland,2013,4,C02-Antihypertensives,"Million US$, purchasing power parity",6.3
11554,Finland,2013,4,C02-Antihypertensives,Million US$ at exchange rate,7.6
11555,Finland,2013,4,G-Genito urinary system and sex hormones,% of total sales,5.4
11556,Finland,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",26.6
11557,Finland,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.1
11558,Finland,2013,4,N-Nervous system,"Million US$, purchasing power parity",376.9
11559,Finland,2013,4,N-Nervous system,Million US$ at exchange rate,453.2
11560,Finland,2013,4,G-Genito urinary system and sex hormones,Million of national currency units,108.9
11561,Finland,2013,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,144.6
11562,Finland,2013,4,N-Nervous system,% of total sales,17.0
11563,Finland,2013,4,N-Nervous system,"/capita, US$ exchange rate",83.3
11564,Finland,2013,4,N-Nervous system,"/capita, US$ purchasing power parity",69.3
11565,Finland,2013,4,N06A-Antidepressants,"Million US$, purchasing power parity",34.0
11566,Finland,2013,4,N06A-Antidepressants,Million of national currency units,30.8
11567,Finland,2013,4,N06A-Antidepressants,Million US$ at exchange rate,40.9
11568,Finland,2013,4,N06A-Antidepressants,% of total sales,1.5
11569,Finland,2013,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.5
11570,Finland,2013,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.3
11571,Finland,2013,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.4
11572,Finland,2013,4,A10-Drugs used in diabetes,Million of national currency units,131.0
11573,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.8
11574,Finland,2013,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.0
11575,Finland,2013,4,A10-Drugs used in diabetes,Million US$ at exchange rate,174.0
11576,Finland,2013,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",144.7
11577,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6
11578,Finland,2013,4,M-Musculo-skeletal system,% of total sales,4.8
11579,Finland,2013,4,R-Respiratory system,Million of national currency units,146.3
11580,Finland,2013,4,R-Respiratory system,Million US$ at exchange rate,194.3
11581,Finland,2013,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.6
11582,Finland,2013,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.6
11583,Finland,2013,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",26.6
11584,Finland,2013,4,R-Respiratory system,"/capita, US$ exchange rate",35.7
11585,Finland,2013,4,R-Respiratory system,"Million US$, purchasing power parity",161.6
11586,Finland,2013,4,C08-Calcium channel blockers,% of total sales,0.8
11587,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.5
11588,Finland,2013,4,A10-Drugs used in diabetes,% of total sales,6.5
11589,Finland,2013,4,R-Respiratory system,"/capita, US$ purchasing power parity",29.7
11590,Finland,2013,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",106.8
11591,Finland,2013,4,M-Musculo-skeletal system,Million US$ at exchange rate,128.4
11592,Finland,2013,4,M-Musculo-skeletal system,Million of national currency units,96.7
11593,Finland,2013,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.8
11594,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
11595,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
11596,Finland,2013,4,C07-Beta blocking agents,% of total sales,1.3
11597,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7
11598,Finland,2013,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5
11599,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.1
11600,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
11601,Finland,2013,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.9
11602,Finland,2013,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.6
11603,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,32.0
11604,Finland,2013,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",18.7
11605,Finland,2013,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1
11606,Finland,2013,4,R-Respiratory system,% of total sales,7.3
11607,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,42.5
11608,Finland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",35.3
11609,Finland,2013,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",62.8
11610,Finland,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.6
11611,Finland,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.9
11612,Finland,2013,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,75.6
11613,Finland,2013,4,C08-Calcium channel blockers,Million US$ at exchange rate,22.4
11614,Finland,2013,4,C08-Calcium channel blockers,Million of national currency units,16.9
11615,Finland,2013,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,56.9
11616,Finland,2013,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",35.2
11617,Finland,2013,4,J-Antiinfectives for systemic use,% of total sales,7.2
11618,Finland,2013,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.3
11619,Finland,2013,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",159.2
11620,Finland,2013,4,J-Antiinfectives for systemic use,Million of national currency units,144.1
11621,Finland,2013,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,191.4
11622,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,75.8
11623,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,57.1
11624,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",63.1
11625,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.9
11626,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.7
11627,Finland,2013,4,A02A-Antacids,% of total sales,0.1
11628,Finland,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.6
11629,Finland,2013,4,R03-Drugs for obstructive airway diseases,% of total sales,4.6
11630,Finland,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.8
11631,Finland,2013,4,R03-Drugs for obstructive airway diseases,Million of national currency units,92.4
11632,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",59.5
11633,Finland,2013,4,C-Cardiovascular system,% of total sales,9.0
11634,Finland,2013,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",102.1
11635,Finland,2013,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,122.7
11636,Finland,2013,4,A02A-Antacids,"/capita, US$ exchange rate",0.7
11637,Finland,2013,4,A02A-Antacids,"Million US$, purchasing power parity",3.3
11638,Finland,2013,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
11639,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.2
11640,Finland,2013,4,A02A-Antacids,Million of national currency units,3.0
11641,Finland,2013,4,A02A-Antacids,Million US$ at exchange rate,4.0
11642,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.9
11643,Finland,2013,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",172.5
11644,Finland,2013,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.7
11645,Finland,2013,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.1
11646,Finland,2013,4,N05B-Anxiolytics,Million US$ at exchange rate,10.5
11647,Finland,2013,4,N05B-Anxiolytics,Million of national currency units,7.9
11648,Finland,2013,4,N02-Analgesics,% of total sales,3.5
11649,Finland,2013,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2223.1
11650,Finland,2013,4,Total pharmaceutical sales,Million of national currency units,2012.7
11651,Finland,2013,4,Total pharmaceutical sales,Million US$ at exchange rate,2673.1
11652,Finland,2013,4,B-Blood and blood forming organs,% of total sales,7.8
11653,Finland,2013,4,Total pharmaceutical sales,"/capita, US$ exchange rate",491.5
11654,Finland,2013,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",408.7
11655,Finland,2013,4,C03-Diuretics,"/capita, US$ purchasing power parity",1.7
11656,Finland,2013,4,C03-Diuretics,% of total sales,0.4
11657,Finland,2013,4,C03-Diuretics,"/capita, US$ exchange rate",2.0
11658,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.6
11659,Finland,2013,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.8
11660,Finland,2013,4,C03-Diuretics,"Million US$, purchasing power parity",9.2
11661,Finland,2013,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6
11662,Finland,2013,4,N05B-Anxiolytics,"Million US$, purchasing power parity",8.7
11663,Finland,2013,4,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9
11664,Finland,2013,4,N05B-Anxiolytics,% of total sales,0.4
11665,Finland,2013,4,C03-Diuretics,Million US$ at exchange rate,11.0
11666,Finland,2013,4,C03-Diuretics,Million of national currency units,8.3
11667,Finland,2013,4,N02-Analgesics,"/capita, US$ exchange rate",17.0
11668,Finland,2013,4,B-Blood and blood forming organs,Million of national currency units,156.2
11669,Finland,2013,4,B-Blood and blood forming organs,Million US$ at exchange rate,207.5
11670,Finland,2013,4,N02-Analgesics,Million US$ at exchange rate,92.6
11671,Finland,2013,4,N02-Analgesics,"Million US$, purchasing power parity",77.0
11672,Finland,2013,4,C10-Lipid modifying agents,Million of national currency units,41.9
11673,Finland,2013,4,C10-Lipid modifying agents,Million US$ at exchange rate,55.6
11674,Finland,2013,4,N05C-Hypnotics and sedatives,Million of national currency units,12.6
11675,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,51.9
11676,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,39.1
11677,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.5
11678,Finland,2013,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",59.4
11679,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
11680,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.9
11681,Finland,2013,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,71.5
11682,Finland,2013,4,J01-Antibacterials for systemic use,Million of national currency units,53.8
11683,Finland,2013,4,N02-Analgesics,Million of national currency units,69.7
11684,Finland,2013,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.1
11685,Finland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",43.2
11686,Finland,2013,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.9
11687,Finland,2013,4,J01-Antibacterials for systemic use,% of total sales,2.7
11688,Finland,2013,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.2
11689,Finland,2013,4,C-Cardiovascular system,"/capita, US$ exchange rate",44.4
11690,Finland,2013,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.9
11691,Finland,2013,4,C02-Antihypertensives,% of total sales,0.3
11692,Finland,2013,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2
11693,Finland,2013,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.5
11694,Finland,2013,4,C10-Lipid modifying agents,% of total sales,2.1
11695,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,71.6
11696,Finland,2013,4,C-Cardiovascular system,Million of national currency units,181.9
11697,Finland,2013,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",46.3
11698,Finland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,53.9
11699,Finland,2013,4,C-Cardiovascular system,"Million US$, purchasing power parity",200.9
11700,Finland,2013,4,C-Cardiovascular system,Million US$ at exchange rate,241.6
11701,Finland,2013,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.2
11702,Finland,2012,4,C01A-Cardiac glycosides,% of total sales,0.0
11703,Finland,2012,4,C07-Beta blocking agents,"Million US$, purchasing power parity",28.8
11704,Finland,2012,4,C07-Beta blocking agents,Million US$ at exchange rate,33.7
11705,Finland,2012,4,C07-Beta blocking agents,Million of national currency units,26.2
11706,Finland,2012,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
11707,Finland,2012,4,C01A-Cardiac glycosides,Million of national currency units,0.4
11708,Finland,2012,4,C02-Antihypertensives,Million of national currency units,5.4
11709,Finland,2012,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5
11710,Finland,2012,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
11711,Finland,2012,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4
11712,Finland,2012,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.8
11713,Finland,2012,4,A-Alimentary tract and metabolism,% of total sales,13.0
11714,Finland,2012,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,327.2
11715,Finland,2012,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.4
11716,Finland,2012,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",280.4
11717,Finland,2012,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.4
11718,Finland,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.9
11719,Finland,2012,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.3
11720,Finland,2012,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,15.7
11721,Finland,2012,4,N05C-Hypnotics and sedatives,% of total sales,0.6
11722,Finland,2012,4,N-Nervous system,Million of national currency units,350.6
11723,Finland,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.5
11724,Finland,2012,4,A-Alimentary tract and metabolism,Million of national currency units,254.7
11725,Finland,2012,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",115.7
11726,Finland,2012,4,C02-Antihypertensives,Million US$ at exchange rate,6.9
11727,Finland,2012,4,C02-Antihypertensives,"Million US$, purchasing power parity",5.9
11728,Finland,2012,4,G-Genito urinary system and sex hormones,% of total sales,5.3
11729,Finland,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",24.9
11730,Finland,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.4
11731,Finland,2012,4,N-Nervous system,"Million US$, purchasing power parity",385.9
11732,Finland,2012,4,G-Genito urinary system and sex hormones,Million of national currency units,105.1
11733,Finland,2012,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,135.0
11734,Finland,2012,4,N-Nervous system,Million US$ at exchange rate,450.4
11735,Finland,2012,4,N-Nervous system,% of total sales,17.8
11736,Finland,2012,4,N-Nervous system,"/capita, US$ exchange rate",83.2
11737,Finland,2012,4,N-Nervous system,"/capita, US$ purchasing power parity",71.3
11738,Finland,2012,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.2
11739,Finland,2012,4,N06A-Antidepressants,"Million US$, purchasing power parity",32.5
11740,Finland,2012,4,N06A-Antidepressants,Million of national currency units,29.5
11741,Finland,2012,4,N06A-Antidepressants,Million US$ at exchange rate,37.9
11742,Finland,2012,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.0
11743,Finland,2012,4,N06A-Antidepressants,% of total sales,1.5
11744,Finland,2012,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.0
11745,Finland,2012,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.1
11746,Finland,2012,4,A10-Drugs used in diabetes,Million of national currency units,127.2
11747,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.3
11748,Finland,2012,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.2
11749,Finland,2012,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",140.0
11750,Finland,2012,4,A10-Drugs used in diabetes,Million US$ at exchange rate,163.4
11751,Finland,2012,4,R-Respiratory system,Million of national currency units,154.4
11752,Finland,2012,4,M-Musculo-skeletal system,% of total sales,4.9
11753,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6
11754,Finland,2012,4,R-Respiratory system,Million US$ at exchange rate,198.4
11755,Finland,2012,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.8
11756,Finland,2012,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.5
11757,Finland,2012,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",25.9
11758,Finland,2012,4,R-Respiratory system,"Million US$, purchasing power parity",170.0
11759,Finland,2012,4,R-Respiratory system,"/capita, US$ exchange rate",36.6
11760,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.2
11761,Finland,2012,4,C08-Calcium channel blockers,% of total sales,0.8
11762,Finland,2012,4,A10-Drugs used in diabetes,% of total sales,6.5
11763,Finland,2012,4,R-Respiratory system,"/capita, US$ purchasing power parity",31.4
11764,Finland,2012,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",105.8
11765,Finland,2012,4,M-Musculo-skeletal system,Million US$ at exchange rate,123.5
11766,Finland,2012,4,M-Musculo-skeletal system,Million of national currency units,96.1
11767,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
11768,Finland,2012,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.8
11769,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
11770,Finland,2012,4,C07-Beta blocking agents,% of total sales,1.3
11771,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.8
11772,Finland,2012,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.3
11773,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.2
11774,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
11775,Finland,2012,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.9
11776,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,30.7
11777,Finland,2012,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",16.8
11778,Finland,2012,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.6
11779,Finland,2012,4,R-Respiratory system,% of total sales,7.9
11780,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.4
11781,Finland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",33.8
11782,Finland,2012,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",61.2
11783,Finland,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.3
11784,Finland,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.2
11785,Finland,2012,4,C08-Calcium channel blockers,Million US$ at exchange rate,19.7
11786,Finland,2012,4,C08-Calcium channel blockers,Million of national currency units,15.3
11787,Finland,2012,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,71.4
11788,Finland,2012,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,55.6
11789,Finland,2012,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",33.4
11790,Finland,2012,4,J-Antiinfectives for systemic use,% of total sales,7.2
11791,Finland,2012,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.6
11792,Finland,2012,4,J-Antiinfectives for systemic use,Million of national currency units,140.8
11793,Finland,2012,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",155.0
11794,Finland,2012,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,180.9
11795,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,80.9
11796,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,63.0
11797,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",69.3
11798,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.3
11799,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.8
11800,Finland,2012,4,A02A-Antacids,% of total sales,0.2
11801,Finland,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.8
11802,Finland,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.5
11803,Finland,2012,4,R03-Drugs for obstructive airway diseases,% of total sales,4.9
11804,Finland,2012,4,R03-Drugs for obstructive airway diseases,Million of national currency units,95.9
11805,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",61.2
11806,Finland,2012,4,C-Cardiovascular system,% of total sales,9.0
11807,Finland,2012,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",105.6
11808,Finland,2012,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,123.2
11809,Finland,2012,4,A02A-Antacids,"/capita, US$ exchange rate",0.7
11810,Finland,2012,4,A02A-Antacids,"Million US$, purchasing power parity",3.3
11811,Finland,2012,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
11812,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.2
11813,Finland,2012,4,A02A-Antacids,Million of national currency units,3.0
11814,Finland,2012,4,A02A-Antacids,Million US$ at exchange rate,3.9
11815,Finland,2012,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",167.7
11816,Finland,2012,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.0
11817,Finland,2012,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",36.2
11818,Finland,2012,4,N05B-Anxiolytics,Million US$ at exchange rate,10.4
11819,Finland,2012,4,N05B-Anxiolytics,Million of national currency units,8.1
11820,Finland,2012,4,N02-Analgesics,% of total sales,3.6
11821,Finland,2012,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2162.7
11822,Finland,2012,4,Total pharmaceutical sales,Million of national currency units,1964.8
11823,Finland,2012,4,Total pharmaceutical sales,Million US$ at exchange rate,2524.4
11824,Finland,2012,4,Total pharmaceutical sales,"/capita, US$ exchange rate",466.3
11825,Finland,2012,4,B-Blood and blood forming organs,% of total sales,7.8
11826,Finland,2012,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",399.5
11827,Finland,2012,4,C03-Diuretics,"/capita, US$ purchasing power parity",1.7
11828,Finland,2012,4,C03-Diuretics,% of total sales,0.4
11829,Finland,2012,4,C03-Diuretics,"/capita, US$ exchange rate",1.9
11830,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",12.8
11831,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.2
11832,Finland,2012,4,C03-Diuretics,"Million US$, purchasing power parity",9.0
11833,Finland,2012,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.6
11834,Finland,2012,4,N05B-Anxiolytics,"Million US$, purchasing power parity",8.9
11835,Finland,2012,4,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9
11836,Finland,2012,4,N05B-Anxiolytics,% of total sales,0.4
11837,Finland,2012,4,C03-Diuretics,Million US$ at exchange rate,10.5
11838,Finland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.0
11839,Finland,2012,4,C03-Diuretics,Million of national currency units,8.2
11840,Finland,2012,4,N02-Analgesics,"/capita, US$ exchange rate",16.8
11841,Finland,2012,4,B-Blood and blood forming organs,Million of national currency units,152.4
11842,Finland,2012,4,B-Blood and blood forming organs,Million US$ at exchange rate,195.8
11843,Finland,2012,4,N02-Analgesics,Million US$ at exchange rate,91.0
11844,Finland,2012,4,N02-Analgesics,"Million US$, purchasing power parity",77.9
11845,Finland,2012,4,C10-Lipid modifying agents,Million of national currency units,35.2
11846,Finland,2012,4,C10-Lipid modifying agents,Million US$ at exchange rate,45.2
11847,Finland,2012,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",38.7
11848,Finland,2012,4,N05C-Hypnotics and sedatives,Million of national currency units,12.2
11849,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,54.9
11850,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,42.7
11851,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.1
11852,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.7
11853,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
11854,Finland,2012,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",60.5
11855,Finland,2012,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,70.7
11856,Finland,2012,4,J01-Antibacterials for systemic use,Million of national currency units,55.0
11857,Finland,2012,4,N02-Analgesics,Million of national currency units,70.8
11858,Finland,2012,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.1
11859,Finland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",47.0
11860,Finland,2012,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
11861,Finland,2012,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.4
11862,Finland,2012,4,J01-Antibacterials for systemic use,% of total sales,2.8
11863,Finland,2012,4,C-Cardiovascular system,"/capita, US$ exchange rate",41.8
11864,Finland,2012,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",35.8
11865,Finland,2012,4,C02-Antihypertensives,% of total sales,0.3
11866,Finland,2012,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
11867,Finland,2012,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.2
11868,Finland,2012,4,C10-Lipid modifying agents,% of total sales,1.8
11869,Finland,2012,4,C-Cardiovascular system,Million of national currency units,176.2
11870,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,71.4
11871,Finland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,55.6
11872,Finland,2012,4,C-Cardiovascular system,"Million US$, purchasing power parity",193.9
11873,Finland,2012,4,C-Cardiovascular system,Million US$ at exchange rate,226.4
11874,Finland,2012,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.4
11875,Finland,2011,4,C01A-Cardiac glycosides,% of total sales,0.0
11876,Finland,2011,4,C07-Beta blocking agents,Million of national currency units,25.0
11877,Finland,2011,4,C07-Beta blocking agents,"Million US$, purchasing power parity",27.8
11878,Finland,2011,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6
11879,Finland,2011,4,C01A-Cardiac glycosides,Million of national currency units,0.4
11880,Finland,2011,4,C07-Beta blocking agents,Million US$ at exchange rate,34.8
11881,Finland,2011,4,C02-Antihypertensives,Million of national currency units,5.3
11882,Finland,2011,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
11883,Finland,2011,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
11884,Finland,2011,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.4
11885,Finland,2011,4,A-Alimentary tract and metabolism,Million of national currency units,241.9
11886,Finland,2011,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.0
11887,Finland,2011,4,A-Alimentary tract and metabolism,% of total sales,12.5
11888,Finland,2011,4,N-Nervous system,Million US$ at exchange rate,492.5
11889,Finland,2011,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,336.7
11890,Finland,2011,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",62.5
11891,Finland,2011,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",269.4
11892,Finland,2011,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",11.7
11893,Finland,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.7
11894,Finland,2011,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.4
11895,Finland,2011,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.6
11896,Finland,2011,4,N-Nervous system,Million of national currency units,353.8
11897,Finland,2011,4,N05C-Hypnotics and sedatives,% of total sales,0.5
11898,Finland,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.2
11899,Finland,2011,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",116.9
11900,Finland,2011,4,C02-Antihypertensives,"Million US$, purchasing power parity",5.9
11901,Finland,2011,4,C02-Antihypertensives,Million US$ at exchange rate,7.4
11902,Finland,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.1
11903,Finland,2011,4,G-Genito urinary system and sex hormones,% of total sales,5.4
11904,Finland,2011,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.5
11905,Finland,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.7
11906,Finland,2011,4,N-Nervous system,"Million US$, purchasing power parity",394.0
11907,Finland,2011,4,G-Genito urinary system and sex hormones,Million of national currency units,105.0
11908,Finland,2011,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,146.2
11909,Finland,2011,4,N-Nervous system,% of total sales,18.4
11910,Finland,2011,4,N-Nervous system,"/capita, US$ exchange rate",91.4
11911,Finland,2011,4,N-Nervous system,"/capita, US$ purchasing power parity",73.1
11912,Finland,2011,4,N06A-Antidepressants,"Million US$, purchasing power parity",32.7
11913,Finland,2011,4,N06A-Antidepressants,Million of national currency units,29.4
11914,Finland,2011,4,N06A-Antidepressants,Million US$ at exchange rate,40.9
11915,Finland,2011,4,N06A-Antidepressants,% of total sales,1.5
11916,Finland,2011,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.6
11917,Finland,2011,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.1
11918,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.1
11919,Finland,2011,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.1
11920,Finland,2011,4,A10-Drugs used in diabetes,Million of national currency units,117.1
11921,Finland,2011,4,R-Respiratory system,"/capita, US$ purchasing power parity",30.7
11922,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.6
11923,Finland,2011,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.3
11924,Finland,2011,4,A10-Drugs used in diabetes,Million US$ at exchange rate,163.0
11925,Finland,2011,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",130.4
11926,Finland,2011,4,R-Respiratory system,Million of national currency units,148.7
11927,Finland,2011,4,M-Musculo-skeletal system,% of total sales,4.7
11928,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
11929,Finland,2011,4,R-Respiratory system,Million US$ at exchange rate,207.0
11930,Finland,2011,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.5
11931,Finland,2011,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",18.8
11932,Finland,2011,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.2
11933,Finland,2011,4,R-Respiratory system,"/capita, US$ exchange rate",38.4
11934,Finland,2011,4,R-Respiratory system,"Million US$, purchasing power parity",165.6
11935,Finland,2011,4,C08-Calcium channel blockers,% of total sales,0.8
11936,Finland,2011,4,A10-Drugs used in diabetes,% of total sales,6.1
11937,Finland,2011,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",101.3
11938,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
11939,Finland,2011,4,M-Musculo-skeletal system,Million of national currency units,91.0
11940,Finland,2011,4,M-Musculo-skeletal system,Million US$ at exchange rate,126.7
11941,Finland,2011,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.9
11942,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
11943,Finland,2011,4,C07-Beta blocking agents,% of total sales,1.3
11944,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.2
11945,Finland,2011,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.2
11946,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
11947,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.7
11948,Finland,2011,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.8
11949,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,29.4
11950,Finland,2011,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",16.9
11951,Finland,2011,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9
11952,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,40.9
11953,Finland,2011,4,R-Respiratory system,% of total sales,7.7
11954,Finland,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",32.7
11955,Finland,2011,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",62.0
11956,Finland,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.4
11957,Finland,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.5
11958,Finland,2011,4,C08-Calcium channel blockers,Million US$ at exchange rate,21.2
11959,Finland,2011,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,77.5
11960,Finland,2011,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,55.7
11961,Finland,2011,4,C08-Calcium channel blockers,Million of national currency units,15.2
11962,Finland,2011,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.5
11963,Finland,2011,4,J-Antiinfectives for systemic use,% of total sales,7.9
11964,Finland,2011,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.6
11965,Finland,2011,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",170.3
11966,Finland,2011,4,J-Antiinfectives for systemic use,Million of national currency units,152.9
11967,Finland,2011,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,212.8
11968,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,99.4
11969,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,71.4
11970,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",79.5
11971,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.0
11972,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.8
11973,Finland,2011,4,A02A-Antacids,% of total sales,0.1
11974,Finland,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.2
11975,Finland,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.4
11976,Finland,2011,4,R03-Drugs for obstructive airway diseases,% of total sales,4.9
11977,Finland,2011,4,R03-Drugs for obstructive airway diseases,Million of national currency units,93.8
11978,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",59.2
11979,Finland,2011,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",104.4
11980,Finland,2011,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,130.6
11981,Finland,2011,4,A02A-Antacids,"/capita, US$ exchange rate",0.7
11982,Finland,2011,4,A02A-Antacids,"Million US$, purchasing power parity",3.1
11983,Finland,2011,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
11984,Finland,2011,4,A02A-Antacids,Million of national currency units,2.8
11985,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.7
11986,Finland,2011,4,A02A-Antacids,Million US$ at exchange rate,3.9
11987,Finland,2011,4,C-Cardiovascular system,% of total sales,9.2
11988,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",18.4
11989,Finland,2011,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",154.2
11990,Finland,2011,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.8
11991,Finland,2011,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.6
11992,Finland,2011,4,N05B-Anxiolytics,Million US$ at exchange rate,11.4
11993,Finland,2011,4,N02-Analgesics,% of total sales,3.5
11994,Finland,2011,4,N05B-Anxiolytics,Million of national currency units,8.2
11995,Finland,2011,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2146.4
11996,Finland,2011,4,Total pharmaceutical sales,Million of national currency units,1927.6
11997,Finland,2011,4,Total pharmaceutical sales,Million US$ at exchange rate,2683.1
11998,Finland,2011,4,B-Blood and blood forming organs,% of total sales,7.2
11999,Finland,2011,4,Total pharmaceutical sales,"/capita, US$ exchange rate",498.0
12000,Finland,2011,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",398.3
12001,Finland,2011,4,N05B-Anxiolytics,"Million US$, purchasing power parity",9.1
12002,Finland,2011,4,C03-Diuretics,% of total sales,0.5
12003,Finland,2011,4,C03-Diuretics,"/capita, US$ purchasing power parity",1.8
12004,Finland,2011,4,C03-Diuretics,"/capita, US$ exchange rate",2.3
12005,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",14.8
12006,Finland,2011,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.7
12007,Finland,2011,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.7
12008,Finland,2011,4,N05B-Anxiolytics,% of total sales,0.4
12009,Finland,2011,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.1
12010,Finland,2011,4,C03-Diuretics,Million US$ at exchange rate,12.2
12011,Finland,2011,4,C03-Diuretics,"Million US$, purchasing power parity",9.8
12012,Finland,2011,4,C03-Diuretics,Million of national currency units,8.8
12013,Finland,2011,4,N02-Analgesics,"/capita, US$ exchange rate",17.5
12014,Finland,2011,4,B-Blood and blood forming organs,Million of national currency units,138.5
12015,Finland,2011,4,B-Blood and blood forming organs,Million US$ at exchange rate,192.8
12016,Finland,2011,4,N02-Analgesics,Million US$ at exchange rate,94.5
12017,Finland,2011,4,N02-Analgesics,"Million US$, purchasing power parity",75.6
12018,Finland,2011,4,C10-Lipid modifying agents,Million US$ at exchange rate,41.3
12019,Finland,2011,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",33.1
12020,Finland,2011,4,C10-Lipid modifying agents,Million of national currency units,29.7
12021,Finland,2011,4,N05C-Hypnotics and sedatives,Million of national currency units,10.5
12022,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,57.8
12023,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,41.5
12024,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.6
12025,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.7
12026,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
12027,Finland,2011,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",73.0
12028,Finland,2011,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,91.3
12029,Finland,2011,4,J01-Antibacterials for systemic use,Million of national currency units,65.6
12030,Finland,2011,4,N02-Analgesics,Million of national currency units,67.9
12031,Finland,2011,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.9
12032,Finland,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",46.2
12033,Finland,2011,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.6
12034,Finland,2011,4,J01-Antibacterials for systemic use,% of total sales,3.4
12035,Finland,2011,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.7
12036,Finland,2011,4,C-Cardiovascular system,"/capita, US$ exchange rate",46.0
12037,Finland,2011,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.8
12038,Finland,2011,4,C02-Antihypertensives,% of total sales,0.3
12039,Finland,2011,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
12040,Finland,2011,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.1
12041,Finland,2011,4,C10-Lipid modifying agents,% of total sales,1.5
12042,Finland,2011,4,C-Cardiovascular system,Million of national currency units,178.2
12043,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,53.2
12044,Finland,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,74.1
12045,Finland,2011,4,C-Cardiovascular system,"Million US$, purchasing power parity",198.4
12046,Finland,2011,4,C-Cardiovascular system,Million US$ at exchange rate,248.0
12047,Finland,2011,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.0
12048,Finland,2010,4,C01A-Cardiac glycosides,% of total sales,0.0
12049,Finland,2010,4,C07-Beta blocking agents,"/capita, US$ exchange rate",7.4
12050,Finland,2010,4,C07-Beta blocking agents,"Million US$, purchasing power parity",33.1
12051,Finland,2010,4,C07-Beta blocking agents,Million of national currency units,29.8
12052,Finland,2010,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
12053,Finland,2010,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.7
12054,Finland,2010,4,C01A-Cardiac glycosides,Million of national currency units,0.5
12055,Finland,2010,4,C07-Beta blocking agents,Million US$ at exchange rate,39.5
12056,Finland,2010,4,C02-Antihypertensives,Million of national currency units,4.9
12057,Finland,2010,4,C02-Antihypertensives,Million US$ at exchange rate,6.5
12058,Finland,2010,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
12059,Finland,2010,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
12060,Finland,2010,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.1
12061,Finland,2010,4,N-Nervous system,Million US$ at exchange rate,456.0
12062,Finland,2010,4,A-Alimentary tract and metabolism,% of total sales,12.1
12063,Finland,2010,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,301.6
12064,Finland,2010,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.2
12065,Finland,2010,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",252.6
12066,Finland,2010,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",10.9
12067,Finland,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.4
12068,Finland,2010,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.2
12069,Finland,2010,4,N-Nervous system,Million of national currency units,344.0
12070,Finland,2010,4,N05C-Hypnotics and sedatives,% of total sales,0.5
12071,Finland,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0
12072,Finland,2010,4,G-Genito urinary system and sex hormones,Million of national currency units,108.1
12073,Finland,2010,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",120.0
12074,Finland,2010,4,C02-Antihypertensives,"Million US$, purchasing power parity",5.4
12075,Finland,2010,4,G-Genito urinary system and sex hormones,% of total sales,5.7
12076,Finland,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",26.7
12077,Finland,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.4
12078,Finland,2010,4,N-Nervous system,"Million US$, purchasing power parity",382.0
12079,Finland,2010,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,143.3
12080,Finland,2010,4,N-Nervous system,% of total sales,18.3
12081,Finland,2010,4,N-Nervous system,"/capita, US$ exchange rate",85.0
12082,Finland,2010,4,A-Alimentary tract and metabolism,Million of national currency units,227.5
12083,Finland,2010,4,N-Nervous system,"/capita, US$ purchasing power parity",71.2
12084,Finland,2010,4,N06A-Antidepressants,"Million US$, purchasing power parity",35.2
12085,Finland,2010,4,N06A-Antidepressants,Million US$ at exchange rate,42.0
12086,Finland,2010,4,N06A-Antidepressants,Million of national currency units,31.7
12087,Finland,2010,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.8
12088,Finland,2010,4,N06A-Antidepressants,% of total sales,1.7
12089,Finland,2010,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.6
12090,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.9
12091,Finland,2010,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5
12092,Finland,2010,4,A10-Drugs used in diabetes,Million of national currency units,104.6
12093,Finland,2010,4,R-Respiratory system,"/capita, US$ purchasing power parity",30.6
12094,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.2
12095,Finland,2010,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",25.9
12096,Finland,2010,4,A10-Drugs used in diabetes,Million US$ at exchange rate,138.7
12097,Finland,2010,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",116.2
12098,Finland,2010,4,R-Respiratory system,Million of national currency units,147.6
12099,Finland,2010,4,M-Musculo-skeletal system,% of total sales,4.8
12100,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8
12101,Finland,2010,4,R-Respiratory system,Million US$ at exchange rate,195.7
12102,Finland,2010,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.5
12103,Finland,2010,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",18.8
12104,Finland,2010,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.7
12105,Finland,2010,4,R-Respiratory system,"Million US$, purchasing power parity",163.9
12106,Finland,2010,4,R-Respiratory system,"/capita, US$ exchange rate",36.5
12107,Finland,2010,4,C08-Calcium channel blockers,% of total sales,0.9
12108,Finland,2010,4,A10-Drugs used in diabetes,% of total sales,5.6
12109,Finland,2010,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",101.1
12110,Finland,2010,4,C08-Calcium channel blockers,Million of national currency units,17.0
12111,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
12112,Finland,2010,4,M-Musculo-skeletal system,Million US$ at exchange rate,120.6
12113,Finland,2010,4,M-Musculo-skeletal system,Million of national currency units,91.0
12114,Finland,2010,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.9
12115,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
12116,Finland,2010,4,C07-Beta blocking agents,% of total sales,1.6
12117,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.2
12118,Finland,2010,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.2
12119,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
12120,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.6
12121,Finland,2010,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.2
12122,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,33.2
12123,Finland,2010,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.2
12124,Finland,2010,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",18.9
12125,Finland,2010,4,R-Respiratory system,% of total sales,7.9
12126,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,44.0
12127,Finland,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",36.9
12128,Finland,2010,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",60.7
12129,Finland,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.3
12130,Finland,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.5
12131,Finland,2010,4,C08-Calcium channel blockers,Million US$ at exchange rate,22.5
12132,Finland,2010,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,72.5
12133,Finland,2010,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,54.7
12134,Finland,2010,4,J-Antiinfectives for systemic use,% of total sales,7.9
12135,Finland,2010,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.8
12136,Finland,2010,4,J-Antiinfectives for systemic use,Million of national currency units,148.9
12137,Finland,2010,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",165.3
12138,Finland,2010,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,197.4
12139,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,103.1
12140,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,77.8
12141,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",86.4
12142,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.6
12143,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.7
12144,Finland,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.6
12145,Finland,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.8
12146,Finland,2010,4,R03-Drugs for obstructive airway diseases,% of total sales,5.1
12147,Finland,2010,4,R03-Drugs for obstructive airway diseases,Million of national currency units,95.5
12148,Finland,2010,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",106.0
12149,Finland,2010,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,126.6
12150,Finland,2010,4,A02A-Antacids,"/capita, US$ exchange rate",0.7
12151,Finland,2010,4,A02A-Antacids,% of total sales,0.1
12152,Finland,2010,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
12153,Finland,2010,4,A02A-Antacids,"Million US$, purchasing power parity",3.0
12154,Finland,2010,4,A02A-Antacids,Million of national currency units,2.7
12155,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.7
12156,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",19.2
12157,Finland,2010,4,A02A-Antacids,Million US$ at exchange rate,3.6
12158,Finland,2010,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",145.8
12159,Finland,2010,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",32.5
12160,Finland,2010,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.2
12161,Finland,2010,4,N05B-Anxiolytics,Million US$ at exchange rate,11.0
12162,Finland,2010,4,N02-Analgesics,% of total sales,3.5
12163,Finland,2010,4,N05B-Anxiolytics,Million of national currency units,8.3
12164,Finland,2010,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2087.9
12165,Finland,2010,4,Total pharmaceutical sales,Million of national currency units,1880.2
12166,Finland,2010,4,Total pharmaceutical sales,Million US$ at exchange rate,2492.6
12167,Finland,2010,4,Total pharmaceutical sales,"/capita, US$ exchange rate",464.7
12168,Finland,2010,4,B-Blood and blood forming organs,% of total sales,7.0
12169,Finland,2010,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",389.3
12170,Finland,2010,4,N05B-Anxiolytics,"Million US$, purchasing power parity",9.2
12171,Finland,2010,4,C03-Diuretics,% of total sales,0.5
12172,Finland,2010,4,C03-Diuretics,"/capita, US$ purchasing power parity",1.9
12173,Finland,2010,4,C03-Diuretics,"/capita, US$ exchange rate",2.2
12174,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",16.1
12175,Finland,2010,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.1
12176,Finland,2010,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.7
12177,Finland,2010,4,N05B-Anxiolytics,% of total sales,0.4
12178,Finland,2010,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.1
12179,Finland,2010,4,C03-Diuretics,Million US$ at exchange rate,11.9
12180,Finland,2010,4,C03-Diuretics,"Million US$, purchasing power parity",10.0
12181,Finland,2010,4,C03-Diuretics,Million of national currency units,9.0
12182,Finland,2010,4,C-Cardiovascular system,% of total sales,10.4
12183,Finland,2010,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",36.8
12184,Finland,2010,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.9
12185,Finland,2010,4,B-Blood and blood forming organs,Million of national currency units,131.3
12186,Finland,2010,4,N02-Analgesics,"/capita, US$ exchange rate",16.3
12187,Finland,2010,4,B-Blood and blood forming organs,Million US$ at exchange rate,174.1
12188,Finland,2010,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,13.0
12189,Finland,2010,4,N02-Analgesics,Million US$ at exchange rate,87.6
12190,Finland,2010,4,N02-Analgesics,"Million US$, purchasing power parity",73.4
12191,Finland,2010,4,C10-Lipid modifying agents,Million US$ at exchange rate,46.1
12192,Finland,2010,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",38.6
12193,Finland,2010,4,C10-Lipid modifying agents,Million of national currency units,34.8
12194,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,38.7
12195,Finland,2010,4,N05C-Hypnotics and sedatives,Million of national currency units,9.8
12196,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,51.3
12197,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.0
12198,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.6
12199,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
12200,Finland,2010,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",74.5
12201,Finland,2010,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,89.0
12202,Finland,2010,4,J01-Antibacterials for systemic use,Million of national currency units,67.1
12203,Finland,2010,4,N02-Analgesics,Million of national currency units,66.1
12204,Finland,2010,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.6
12205,Finland,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",43.0
12206,Finland,2010,4,J01-Antibacterials for systemic use,% of total sales,3.6
12207,Finland,2010,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.6
12208,Finland,2010,4,C-Cardiovascular system,"/capita, US$ exchange rate",48.2
12209,Finland,2010,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",40.4
12210,Finland,2010,4,C02-Antihypertensives,% of total sales,0.3
12211,Finland,2010,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
12212,Finland,2010,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.2
12213,Finland,2010,4,C10-Lipid modifying agents,% of total sales,1.9
12214,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,68.1
12215,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",57.1
12216,Finland,2010,4,C-Cardiovascular system,Million of national currency units,195.0
12217,Finland,2010,4,C-Cardiovascular system,"Million US$, purchasing power parity",216.5
12218,Finland,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,51.4
12219,Finland,2010,4,C-Cardiovascular system,Million US$ at exchange rate,258.5
12220,Finland,2010,4,N02-Analgesics,"/capita, US$ purchasing power parity",13.7
12221,Finland,2017,3,C07-Beta blocking agents,Million of national currency units,23.5
12222,Finland,2017,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
12223,Finland,2017,3,C01A-Cardiac glycosides,% of total sales,0.1
12224,Finland,2017,3,C07-Beta blocking agents,"Million US$, purchasing power parity",27.2
12225,Finland,2017,3,C07-Beta blocking agents,Million US$ at exchange rate,26.5
12226,Finland,2017,3,C01A-Cardiac glycosides,Million of national currency units,1.2
12227,Finland,2017,3,C02-Antihypertensives,Million of national currency units,6.5
12228,Finland,2017,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
12229,Finland,2017,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
12230,Finland,2017,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.4
12231,Finland,2017,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",62.0
12232,Finland,2017,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.5
12233,Finland,2017,3,A-Alimentary tract and metabolism,% of total sales,12.8
12234,Finland,2017,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,333.4
12235,Finland,2017,3,A-Alimentary tract and metabolism,Million of national currency units,295.1
12236,Finland,2017,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",341.7
12237,Finland,2017,3,N-Nervous system,Million of national currency units,297.2
12238,Finland,2017,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.8
12239,Finland,2017,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.5
12240,Finland,2017,3,N05C-Hypnotics and sedatives,% of total sales,0.6
12241,Finland,2017,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.6
12242,Finland,2017,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.7
12243,Finland,2017,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,127.2
12244,Finland,2017,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",130.4
12245,Finland,2017,3,C02-Antihypertensives,Million US$ at exchange rate,7.3
12246,Finland,2017,3,G-Genito urinary system and sex hormones,% of total sales,4.9
12247,Finland,2017,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.7
12248,Finland,2017,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",23.1
12249,Finland,2017,3,C02-Antihypertensives,"Million US$, purchasing power parity",7.5
12250,Finland,2017,3,N-Nervous system,Million US$ at exchange rate,335.7
12251,Finland,2017,3,N-Nervous system,"Million US$, purchasing power parity",344.1
12252,Finland,2017,3,G-Genito urinary system and sex hormones,Million of national currency units,112.6
12253,Finland,2017,3,N-Nervous system,% of total sales,12.8
12254,Finland,2017,3,N-Nervous system,"/capita, US$ purchasing power parity",62.5
12255,Finland,2017,3,N-Nervous system,"/capita, US$ exchange rate",61.0
12256,Finland,2017,3,N06A-Antidepressants,"Million US$, purchasing power parity",35.1
12257,Finland,2017,3,N06A-Antidepressants,Million US$ at exchange rate,34.2
12258,Finland,2017,3,N06A-Antidepressants,Million of national currency units,30.3
12259,Finland,2017,3,N06A-Antidepressants,% of total sales,1.3
12260,Finland,2017,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.2
12261,Finland,2017,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.4
12262,Finland,2017,3,A10-Drugs used in diabetes,Million of national currency units,148.0
12263,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",39.7
12264,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.0
12265,Finland,2017,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",171.4
12266,Finland,2017,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.4
12267,Finland,2017,3,A10-Drugs used in diabetes,Million US$ at exchange rate,167.2
12268,Finland,2017,3,R-Respiratory system,"/capita, US$ exchange rate",30.8
12269,Finland,2017,3,M-Musculo-skeletal system,% of total sales,4.2
12270,Finland,2017,3,R-Respiratory system,Million of national currency units,150.1
12271,Finland,2017,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",111.3
12272,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
12273,Finland,2017,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.2
12274,Finland,2017,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.7
12275,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.2
12276,Finland,2017,3,R-Respiratory system,Million US$ at exchange rate,169.6
12277,Finland,2017,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.1
12278,Finland,2017,3,R-Respiratory system,"Million US$, purchasing power parity",173.8
12279,Finland,2017,3,C08-Calcium channel blockers,% of total sales,0.8
12280,Finland,2017,3,A10-Drugs used in diabetes,% of total sales,6.4
12281,Finland,2017,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8
12282,Finland,2017,3,M-Musculo-skeletal system,Million US$ at exchange rate,108.6
12283,Finland,2017,3,M-Musculo-skeletal system,Million of national currency units,96.1
12284,Finland,2017,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.5
12285,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
12286,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
12287,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
12288,Finland,2017,3,C07-Beta blocking agents,% of total sales,1.0
12289,Finland,2017,3,C07-Beta blocking agents,"/capita, US$ exchange rate",4.8
12290,Finland,2017,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.9
12291,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.9
12292,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.2
12293,Finland,2017,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.7
12294,Finland,2017,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.1
12295,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,34.3
12296,Finland,2017,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.7
12297,Finland,2017,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",21.1
12298,Finland,2017,3,R-Respiratory system,% of total sales,6.5
12299,Finland,2017,3,R-Respiratory system,"/capita, US$ purchasing power parity",31.6
12300,Finland,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,38.7
12301,Finland,2017,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.8
12302,Finland,2017,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,65.2
12303,Finland,2017,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.8
12304,Finland,2017,3,C08-Calcium channel blockers,Million of national currency units,18.2
12305,Finland,2017,3,C08-Calcium channel blockers,Million US$ at exchange rate,20.6
12306,Finland,2017,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,57.7
12307,Finland,2017,3,C02-Antihypertensives,"/capita, US$ exchange rate",1.3
12308,Finland,2017,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",40.4
12309,Finland,2017,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",228.0
12310,Finland,2017,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",41.4
12311,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.1
12312,Finland,2017,3,A02A-Antacids,% of total sales,0.1
12313,Finland,2017,3,J-Antiinfectives for systemic use,Million of national currency units,196.9
12314,Finland,2017,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,222.4
12315,Finland,2017,3,J-Antiinfectives for systemic use,% of total sales,8.5
12316,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,50.5
12317,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,57.0
12318,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",58.5
12319,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.3
12320,Finland,2017,3,C-Cardiovascular system,% of total sales,8.5
12321,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.1
12322,Finland,2017,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.0
12323,Finland,2017,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",107.0
12324,Finland,2017,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.4
12325,Finland,2017,3,R03-Drugs for obstructive airway diseases,% of total sales,4.0
12326,Finland,2017,3,R03-Drugs for obstructive airway diseases,Million of national currency units,92.4
12327,Finland,2017,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,104.4
12328,Finland,2017,3,A02A-Antacids,"Million US$, purchasing power parity",3.9
12329,Finland,2017,3,A02A-Antacids,"/capita, US$ exchange rate",0.7
12330,Finland,2017,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
12331,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",57.0
12332,Finland,2017,3,A02A-Antacids,Million US$ at exchange rate,3.8
12333,Finland,2017,3,A02A-Antacids,Million of national currency units,3.4
12334,Finland,2017,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",251.8
12335,Finland,2017,3,B-Blood and blood forming organs,Million US$ at exchange rate,245.7
12336,Finland,2017,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",44.6
12337,Finland,2017,3,N05B-Anxiolytics,Million of national currency units,6.6
12338,Finland,2017,3,N05B-Anxiolytics,Million US$ at exchange rate,7.5
12339,Finland,2017,3,N02-Analgesics,% of total sales,2.9
12340,Finland,2017,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.7
12341,Finland,2017,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2679.0
12342,Finland,2017,3,Total pharmaceutical sales,Million US$ at exchange rate,2613.7
12343,Finland,2017,3,Total pharmaceutical sales,Million of national currency units,2313.7
12344,Finland,2017,3,B-Blood and blood forming organs,% of total sales,9.4
12345,Finland,2017,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",486.4
12346,Finland,2017,3,Total pharmaceutical sales,"/capita, US$ exchange rate",474.5
12347,Finland,2017,3,C03-Diuretics,"/capita, US$ purchasing power parity",1.7
12348,Finland,2017,3,C03-Diuretics,"Million US$, purchasing power parity",9.1
12349,Finland,2017,3,C03-Diuretics,"/capita, US$ exchange rate",1.6
12350,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.4
12351,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",10.6
12352,Finland,2017,3,C03-Diuretics,% of total sales,0.3
12353,Finland,2017,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.2
12354,Finland,2017,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.4
12355,Finland,2017,3,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
12356,Finland,2017,3,N05B-Anxiolytics,"Million US$, purchasing power parity",7.6
12357,Finland,2017,3,C03-Diuretics,Million US$ at exchange rate,8.9
12358,Finland,2017,3,N05B-Anxiolytics,% of total sales,0.3
12359,Finland,2017,3,C03-Diuretics,Million of national currency units,7.9
12360,Finland,2017,3,N02-Analgesics,"/capita, US$ purchasing power parity",14.0
12361,Finland,2017,3,B-Blood and blood forming organs,Million of national currency units,217.5
12362,Finland,2017,3,N02-Analgesics,Million US$ at exchange rate,75.2
12363,Finland,2017,3,N02-Analgesics,"Million US$, purchasing power parity",77.1
12364,Finland,2017,3,C10-Lipid modifying agents,Million of national currency units,65.1
12365,Finland,2017,3,C10-Lipid modifying agents,Million US$ at exchange rate,73.5
12366,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,49.9
12367,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,44.2
12368,Finland,2017,3,N02-Analgesics,Million of national currency units,66.6
12369,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.1
12370,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",51.2
12371,Finland,2017,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",60.9
12372,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
12373,Finland,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.3
12374,Finland,2017,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,59.4
12375,Finland,2017,3,J01-Antibacterials for systemic use,Million of national currency units,52.6
12376,Finland,2017,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.8
12377,Finland,2017,3,N02-Analgesics,"/capita, US$ exchange rate",13.7
12378,Finland,2017,3,N05C-Hypnotics and sedatives,Million of national currency units,12.8
12379,Finland,2017,3,J01-Antibacterials for systemic use,% of total sales,2.3
12380,Finland,2017,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.1
12381,Finland,2017,3,C-Cardiovascular system,"/capita, US$ exchange rate",40.5
12382,Finland,2017,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",41.6
12383,Finland,2017,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",13.4
12384,Finland,2017,3,C02-Antihypertensives,% of total sales,0.3
12385,Finland,2017,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.4
12386,Finland,2017,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",13.7
12387,Finland,2017,3,C10-Lipid modifying agents,% of total sales,2.8
12388,Finland,2017,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",75.4
12389,Finland,2017,3,C-Cardiovascular system,Million of national currency units,197.7
12390,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,49.2
12391,Finland,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,55.6
12392,Finland,2017,3,C-Cardiovascular system,Million US$ at exchange rate,223.3
12393,Finland,2017,3,C-Cardiovascular system,"Million US$, purchasing power parity",228.9
12394,France,2013,9,Total pharmaceutical sales,Million of national currency units,26800.0
12395,France,2013,9,Total pharmaceutical sales,Million US$ at exchange rate,35593.6
12396,France,2013,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",502.0
12397,France,2013,9,Total pharmaceutical sales,"/capita, US$ exchange rate",541.2
12398,France,2013,9,Total pharmaceutical sales,"Million US$, purchasing power parity",33019.4
12399,France,2012,9,Total pharmaceutical sales,Million of national currency units,27200.0
12400,France,2012,9,Total pharmaceutical sales,Million US$ at exchange rate,34946.3
12401,France,2012,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",492.3
12402,France,2012,9,Total pharmaceutical sales,"/capita, US$ exchange rate",534.0
12403,France,2012,9,Total pharmaceutical sales,"Million US$, purchasing power parity",32216.0
12404,France,2011,9,B-Blood and blood forming organs,% of total sales,7.7
12405,France,2011,9,N-Nervous system,"Million US$, purchasing power parity",4634.0
12406,France,2011,9,N-Nervous system,Million US$ at exchange rate,5427.1
12407,France,2011,9,N-Nervous system,"/capita, US$ exchange rate",83.3
12408,France,2011,9,N-Nervous system,"/capita, US$ purchasing power parity",71.2
12409,France,2011,9,N-Nervous system,% of total sales,14.1
12410,France,2011,9,M-Musculo-skeletal system,% of total sales,3.4
12411,France,2011,9,C-Cardiovascular system,"/capita, US$ exchange rate",84.1
12412,France,2011,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.1
12413,France,2011,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.0
12414,France,2011,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",1111.1
12415,France,2011,9,M-Musculo-skeletal system,Million of national currency units,934.8
12416,France,2011,9,N-Nervous system,Million of national currency units,3898.9
12417,France,2011,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.8
12418,France,2011,9,M-Musculo-skeletal system,Million US$ at exchange rate,1301.2
12419,France,2011,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.5
12420,France,2011,9,Total pharmaceutical sales,Million of national currency units,27600.0
12421,France,2011,9,B-Blood and blood forming organs,Million US$ at exchange rate,2963.3
12422,France,2011,9,B-Blood and blood forming organs,Million of national currency units,2128.9
12423,France,2011,9,A-Alimentary tract and metabolism,% of total sales,10.7
12424,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
12425,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.2
12426,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.7
12427,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",597.7
12428,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,700.0
12429,France,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,502.9
12430,France,2011,9,A-Alimentary tract and metabolism,Million of national currency units,2952.3
12431,France,2011,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,4109.5
12432,France,2011,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3509.0
12433,France,2011,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",63.1
12434,France,2011,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.9
12435,France,2011,9,Total pharmaceutical sales,Million US$ at exchange rate,38418.0
12436,France,2011,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",2530.3
12437,France,2011,9,G-Genito urinary system and sex hormones,% of total sales,3.7
12438,France,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.9
12439,France,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.1
12440,France,2011,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1228.5
12441,France,2011,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1438.7
12442,France,2011,9,G-Genito urinary system and sex hormones,Million of national currency units,1033.6
12443,France,2011,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.9
12444,France,2011,9,Total pharmaceutical sales,"/capita, US$ exchange rate",589.9
12445,France,2011,9,Total pharmaceutical sales,"Million US$, purchasing power parity",32804.0
12446,France,2011,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",503.7
12447,France,2011,9,C-Cardiovascular system,"Million US$, purchasing power parity",4679.3
12448,France,2011,9,C-Cardiovascular system,Million of national currency units,3937.0
12449,France,2011,9,R-Respiratory system,% of total sales,7.3
12450,France,2011,9,C-Cardiovascular system,% of total sales,14.3
12451,France,2011,9,J-Antiinfectives for systemic use,Million of national currency units,3056.5
12452,France,2011,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,4254.5
12453,France,2011,9,R-Respiratory system,Million of national currency units,2016.0
12454,France,2011,9,R-Respiratory system,Million US$ at exchange rate,2806.2
12455,France,2011,9,R-Respiratory system,"/capita, US$ exchange rate",43.1
12456,France,2011,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3632.8
12457,France,2011,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.3
12458,France,2011,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",55.8
12459,France,2011,9,J-Antiinfectives for systemic use,% of total sales,11.1
12460,France,2011,9,R-Respiratory system,"Million US$, purchasing power parity",2396.1
12461,France,2011,9,C-Cardiovascular system,Million US$ at exchange rate,5480.1
12462,France,2011,9,R-Respiratory system,"/capita, US$ purchasing power parity",36.8
12463,France,2010,9,Total pharmaceutical sales,Million US$ at exchange rate,36508.9
12464,France,2010,9,Total pharmaceutical sales,"Million US$, purchasing power parity",32221.6
12465,France,2010,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",497.1
12466,France,2010,9,Total pharmaceutical sales,"/capita, US$ exchange rate",563.2
12467,France,2010,9,Total pharmaceutical sales,Million of national currency units,27539.0
12468,Germany,2017,7,C-Cardiovascular system,"Million US$, purchasing power parity",5949.9
12469,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.0
12470,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.0
12471,Germany,2017,7,C-Cardiovascular system,Million US$ at exchange rate,5006.1
12472,Germany,2017,7,C08-Calcium channel blockers,Million of national currency units,287.2
12473,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.5
12474,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",26.1
12475,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.3
12476,Germany,2017,7,C-Cardiovascular system,Million of national currency units,4431.4
12477,Germany,2017,7,N-Nervous system,% of total sales,13.5
12478,Germany,2017,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2006.7
12479,Germany,2017,7,N-Nervous system,"/capita, US$ exchange rate",68.4
12480,Germany,2017,7,N-Nervous system,"/capita, US$ purchasing power parity",81.3
12481,Germany,2017,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.9
12482,Germany,2017,7,R03-Drugs for obstructive airway diseases,% of total sales,4.8
12483,Germany,2017,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2385.0
12484,Germany,2017,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.3
12485,Germany,2017,7,N-Nervous system,Million of national currency units,5004.2
12486,Germany,2017,7,Products not elsewhere classified,Million US$ at exchange rate,13284.1
12487,Germany,2017,7,Products not elsewhere classified,Million of national currency units,11759.2
12488,Germany,2017,7,N-Nervous system,Million US$ at exchange rate,5653.1
12489,Germany,2017,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",72.0
12490,Germany,2017,7,R03-Drugs for obstructive airway diseases,Million of national currency units,1776.3
12491,Germany,2017,7,N-Nervous system,"Million US$, purchasing power parity",6719.0
12492,Germany,2017,7,C-Cardiovascular system,"/capita, US$ exchange rate",60.6
12493,Germany,2017,7,R-Respiratory system,Million of national currency units,2146.1
12494,Germany,2017,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.9
12495,Germany,2017,7,R-Respiratory system,"/capita, US$ exchange rate",29.3
12496,Germany,2017,7,R-Respiratory system,"Million US$, purchasing power parity",2881.5
12497,Germany,2017,7,R-Respiratory system,Million US$ at exchange rate,2424.4
12498,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,556.5
12499,Germany,2017,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",604.1
12500,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,628.7
12501,Germany,2017,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.0
12502,Germany,2017,7,C10-Lipid modifying agents,Million US$ at exchange rate,828.7
12503,Germany,2017,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",985.0
12504,Germany,2017,7,C10-Lipid modifying agents,% of total sales,2.0
12505,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
12506,Germany,2017,7,M-Musculo-skeletal system,% of total sales,3.7
12507,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
12508,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",95.6
12509,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
12510,Germany,2017,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.6
12511,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,71.2
12512,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",747.2
12513,Germany,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.6
12514,Germany,2017,7,R-Respiratory system,% of total sales,5.8
12515,Germany,2017,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,80.4
12516,Germany,2017,7,R-Respiratory system,"/capita, US$ purchasing power parity",34.9
12517,Germany,2017,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.7
12518,Germany,2017,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9
12519,Germany,2017,7,C08-Calcium channel blockers,% of total sales,0.8
12520,Germany,2017,7,M-Musculo-skeletal system,Million of national currency units,1390.3
12521,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1609.5
12522,Germany,2017,7,Products not elsewhere classified,"Million US$, purchasing power parity",15788.8
12523,Germany,2017,7,C08-Calcium channel blockers,Million US$ at exchange rate,324.4
12524,Germany,2017,7,Products not elsewhere classified,"/capita, US$ exchange rate",160.7
12525,Germany,2017,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",385.6
12526,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2161.0
12527,Germany,2017,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1818.2
12528,Germany,2017,7,Total pharmaceutical sales,Million US$ at exchange rate,42011.2
12529,Germany,2017,7,Total pharmaceutical sales,Million of national currency units,37188.6
12530,Germany,2017,7,Total pharmaceutical sales,"Million US$, purchasing power parity",49932.1
12531,Germany,2017,7,C-Cardiovascular system,% of total sales,11.9
12532,Germany,2017,7,Total pharmaceutical sales,"/capita, US$ exchange rate",508.3
12533,Germany,2017,7,C10-Lipid modifying agents,Million of national currency units,733.6
12534,Germany,2017,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.0
12535,Germany,2017,7,M-Musculo-skeletal system,Million US$ at exchange rate,1570.6
12536,Germany,2017,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",1866.7
12537,Germany,2017,7,Products not elsewhere classified,% of total sales,31.6
12538,Germany,2017,7,Products not elsewhere classified,"/capita, US$ purchasing power parity",191.0
12539,Germany,2017,7,C07-Beta blocking agents,Million of national currency units,654.9
12540,Germany,2017,7,C01A-Cardiac glycosides,% of total sales,0.1
12541,Germany,2017,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
12542,Germany,2017,7,J-Antiinfectives for systemic use,% of total sales,7.9
12543,Germany,2017,7,C07-Beta blocking agents,Million US$ at exchange rate,739.8
12544,Germany,2017,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.9
12545,Germany,2017,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",47.5
12546,Germany,2017,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
12547,Germany,2017,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3924.2
12548,Germany,2017,7,J-Antiinfectives for systemic use,Million of national currency units,2922.7
12549,Germany,2017,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,3301.7
12550,Germany,2017,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",29.1
12551,Germany,2017,7,C01A-Cardiac glycosides,Million of national currency units,21.7
12552,Germany,2017,7,C01A-Cardiac glycosides,Million US$ at exchange rate,24.5
12553,Germany,2017,7,C07-Beta blocking agents,"Million US$, purchasing power parity",879.3
12554,Germany,2017,7,C03-Diuretics,"/capita, US$ exchange rate",6.1
12555,Germany,2017,7,C03-Diuretics,"Million US$, purchasing power parity",602.2
12556,Germany,2017,7,C03-Diuretics,% of total sales,1.2
12557,Germany,2017,7,C03-Diuretics,"/capita, US$ purchasing power parity",7.3
12558,Germany,2017,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.0
12559,Germany,2017,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
12560,Germany,2017,7,C03-Diuretics,Million of national currency units,448.5
12561,Germany,2017,7,C03-Diuretics,Million US$ at exchange rate,506.7
12562,Germany,2017,7,C07-Beta blocking agents,% of total sales,1.8
12563,Germany,2017,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.6
12564,Germany,2017,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.1
12565,Germany,2017,7,C07-Beta blocking agents,"/capita, US$ exchange rate",9.0
12566,Germany,2017,7,N05B-Anxiolytics,Million US$ at exchange rate,74.1
12567,Germany,2017,7,N05B-Anxiolytics,"Million US$, purchasing power parity",88.1
12568,Germany,2017,7,N05B-Anxiolytics,"/capita, US$ exchange rate",0.9
12569,Germany,2017,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.0
12570,Germany,2017,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9
12571,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1132.0
12572,Germany,2017,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",983.9
12573,Germany,2017,7,C02-Antihypertensives,% of total sales,1.1
12574,Germany,2017,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.4
12575,Germany,2017,7,J01-Antibacterials for systemic use,% of total sales,2.0
12576,Germany,2017,7,N05B-Anxiolytics,% of total sales,0.2
12577,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.0
12578,Germany,2017,7,J01-Antibacterials for systemic use,Million of national currency units,732.8
12579,Germany,2017,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,827.8
12580,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",18.4
12581,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1519.9
12582,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1278.8
12583,Germany,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.5
12584,Germany,2017,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",120.6
12585,Germany,2017,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2
12586,Germany,2017,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,101.4
12587,Germany,2017,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",4254.1
12588,Germany,2017,7,B-Blood and blood forming organs,Million US$ at exchange rate,3579.3
12589,Germany,2017,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5
12590,Germany,2017,7,N05C-Hypnotics and sedatives,% of total sales,0.2
12591,Germany,2017,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",43.3
12592,Germany,2017,7,C02-Antihypertensives,Million US$ at exchange rate,442.0
12593,Germany,2017,7,C02-Antihypertensives,Million of national currency units,391.3
12594,Germany,2017,7,C02-Antihypertensives,"/capita, US$ exchange rate",5.3
12595,Germany,2017,7,C02-Antihypertensives,"Million US$, purchasing power parity",525.4
12596,Germany,2017,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",51.5
12597,Germany,2017,7,B-Blood and blood forming organs,% of total sales,8.5
12598,Germany,2017,7,N05C-Hypnotics and sedatives,Million of national currency units,89.8
12599,Germany,2017,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",3359.4
12600,Germany,2017,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",34.2
12601,Germany,2017,7,A10-Drugs used in diabetes,Million US$ at exchange rate,2826.5
12602,Germany,2017,7,G-Genito urinary system and sex hormones,% of total sales,2.0
12603,Germany,2017,7,A10-Drugs used in diabetes,% of total sales,6.7
12604,Germany,2017,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",40.6
12605,Germany,2017,7,A10-Drugs used in diabetes,Million of national currency units,2502.0
12606,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.5
12607,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.3
12608,Germany,2017,7,N02-Analgesics,"/capita, US$ exchange rate",24.1
12609,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,695.7
12610,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",934.1
12611,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,785.9
12612,Germany,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.2
12613,Germany,2017,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.8
12614,Germany,2017,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.3
12615,Germany,2017,7,N02-Analgesics,"/capita, US$ purchasing power parity",28.7
12616,Germany,2017,7,A-Alimentary tract and metabolism,% of total sales,12.1
12617,Germany,2017,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,5064.7
12618,Germany,2017,7,A-Alimentary tract and metabolism,Million of national currency units,4483.3
12619,Germany,2017,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",6019.6
12620,Germany,2017,7,N02-Analgesics,% of total sales,4.7
12621,Germany,2017,7,B-Blood and blood forming organs,Million of national currency units,3168.4
12622,Germany,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.3
12623,Germany,2017,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,848.4
12624,Germany,2017,7,G-Genito urinary system and sex hormones,Million of national currency units,751.0
12625,Germany,2017,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1008.3
12626,Germany,2017,7,A02A-Antacids,Million US$ at exchange rate,21.6
12627,Germany,2017,7,A02A-Antacids,"Million US$, purchasing power parity",25.6
12628,Germany,2017,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",521.4
12629,Germany,2017,7,A02A-Antacids,% of total sales,0.1
12630,Germany,2017,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.3
12631,Germany,2017,7,N06A-Antidepressants,Million of national currency units,702.5
12632,Germany,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9
12633,Germany,2017,7,N02-Analgesics,Million of national currency units,1763.8
12634,Germany,2017,7,N02-Analgesics,Million US$ at exchange rate,1992.5
12635,Germany,2017,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,438.7
12636,Germany,2017,7,A02A-Antacids,"/capita, US$ exchange rate",0.3
12637,Germany,2017,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,388.3
12638,Germany,2017,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.4
12639,Germany,2017,7,N06A-Antidepressants,"/capita, US$ exchange rate",9.6
12640,Germany,2017,7,N02-Analgesics,"Million US$, purchasing power parity",2368.2
12641,Germany,2017,7,N06A-Antidepressants,% of total sales,1.9
12642,Germany,2017,7,A02A-Antacids,Million of national currency units,19.1
12643,Germany,2017,7,N06A-Antidepressants,"Million US$, purchasing power parity",943.2
12644,Germany,2017,7,N05B-Anxiolytics,Million of national currency units,65.6
12645,Germany,2017,7,N06A-Antidepressants,Million US$ at exchange rate,793.6
12646,Germany,2017,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.3
12647,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.6
12648,Germany,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",5492.2
12649,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.5
12650,Germany,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",58.0
12651,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.0
12652,Germany,2015,5,C-Cardiovascular system,Million US$ at exchange rate,4741.6
12653,Germany,2015,5,C08-Calcium channel blockers,Million of national currency units,284.9
12654,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
12655,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5
12656,Germany,2015,5,C-Cardiovascular system,Million of national currency units,4273.6
12657,Germany,2015,5,N-Nervous system,% of total sales,15.3
12658,Germany,2015,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1883.2
12659,Germany,2015,5,N-Nervous system,"/capita, US$ exchange rate",73.4
12660,Germany,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",85.0
12661,Germany,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.7
12662,Germany,2015,5,R03-Drugs for obstructive airway diseases,% of total sales,4.8
12663,Germany,2015,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2181.3
12664,Germany,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.1
12665,Germany,2015,5,N-Nervous system,Million of national currency units,5401.9
12666,Germany,2015,5,N-Nervous system,Million US$ at exchange rate,5993.5
12667,Germany,2015,5,Products not elsewhere classified,Million of national currency units,9719.6
12668,Germany,2015,5,Products not elsewhere classified,Million US$ at exchange rate,10784.0
12669,Germany,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",67.2
12670,Germany,2015,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1697.3
12671,Germany,2015,5,N-Nervous system,"Million US$, purchasing power parity",6942.2
12672,Germany,2015,5,R-Respiratory system,Million of national currency units,2054.6
12673,Germany,2015,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.4
12674,Germany,2015,5,R-Respiratory system,Million US$ at exchange rate,2279.6
12675,Germany,2015,5,R-Respiratory system,"/capita, US$ exchange rate",27.9
12676,Germany,2015,5,R-Respiratory system,"Million US$, purchasing power parity",2640.5
12677,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,606.3
12678,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,672.7
12679,Germany,2015,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.1
12680,Germany,2015,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",767.1
12681,Germany,2015,5,C10-Lipid modifying agents,Million US$ at exchange rate,662.3
12682,Germany,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",556.1
12683,Germany,2015,5,C10-Lipid modifying agents,% of total sales,1.7
12684,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
12685,Germany,2015,5,M-Musculo-skeletal system,% of total sales,4.0
12686,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",100.1
12687,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
12688,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
12689,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.9
12690,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.2
12691,Germany,2015,5,R-Respiratory system,% of total sales,5.8
12692,Germany,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",32.3
12693,Germany,2015,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,86.4
12694,Germany,2015,5,C08-Calcium channel blockers,% of total sales,0.8
12695,Germany,2015,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.5
12696,Germany,2015,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.9
12697,Germany,2015,5,M-Musculo-skeletal system,Million of national currency units,1397.1
12698,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1590.0
12699,Germany,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",132.0
12700,Germany,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",12491.1
12701,Germany,2015,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",366.1
12702,Germany,2015,5,C08-Calcium channel blockers,Million US$ at exchange rate,316.1
12703,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1764.1
12704,Germany,2015,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2043.4
12705,Germany,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",45429.5
12706,Germany,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,39221.0
12707,Germany,2015,5,Total pharmaceutical sales,Million of national currency units,35349.7
12708,Germany,2015,5,C-Cardiovascular system,% of total sales,12.1
12709,Germany,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",480.1
12710,Germany,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.0
12711,Germany,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1795.5
12712,Germany,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,1550.1
12713,Germany,2015,5,C10-Lipid modifying agents,Million of national currency units,596.9
12714,Germany,2015,5,Products not elsewhere classified,% of total sales,27.5
12715,Germany,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",152.9
12716,Germany,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.0
12717,Germany,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",779.2
12718,Germany,2015,5,C07-Beta blocking agents,Million of national currency units,668.9
12719,Germany,2015,5,C01A-Cardiac glycosides,% of total sales,0.1
12720,Germany,2015,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
12721,Germany,2015,5,C07-Beta blocking agents,Million US$ at exchange rate,742.2
12722,Germany,2015,5,J-Antiinfectives for systemic use,% of total sales,10.6
12723,Germany,2015,5,C07-Beta blocking agents,"Million US$, purchasing power parity",859.6
12724,Germany,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",58.9
12725,Germany,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",4811.3
12726,Germany,2015,5,J-Antiinfectives for systemic use,Million of national currency units,3743.8
12727,Germany,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,4153.8
12728,Germany,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",50.9
12729,Germany,2015,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",33.9
12730,Germany,2015,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4
12731,Germany,2015,5,C01A-Cardiac glycosides,Million of national currency units,26.4
12732,Germany,2015,5,C01A-Cardiac glycosides,Million US$ at exchange rate,29.3
12733,Germany,2015,5,C03-Diuretics,"/capita, US$ exchange rate",6.0
12734,Germany,2015,5,C03-Diuretics,% of total sales,1.3
12735,Germany,2015,5,C03-Diuretics,"/capita, US$ purchasing power parity",7.0
12736,Germany,2015,5,C03-Diuretics,"Million US$, purchasing power parity",569.7
12737,Germany,2015,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
12738,Germany,2015,5,C03-Diuretics,Million of national currency units,443.3
12739,Germany,2015,5,C03-Diuretics,Million US$ at exchange rate,491.8
12740,Germany,2015,5,C07-Beta blocking agents,% of total sales,1.9
12741,Germany,2015,5,C07-Beta blocking agents,"/capita, US$ exchange rate",9.1
12742,Germany,2015,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.5
12743,Germany,2015,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.2
12744,Germany,2015,5,N05B-Anxiolytics,Million US$ at exchange rate,81.3
12745,Germany,2015,5,N05B-Anxiolytics,"Million US$, purchasing power parity",94.2
12746,Germany,2015,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0
12747,Germany,2015,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.5
12748,Germany,2015,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.1
12749,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1111.7
12750,Germany,2015,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",989.2
12751,Germany,2015,5,C02-Antihypertensives,% of total sales,1.1
12752,Germany,2015,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.8
12753,Germany,2015,5,J01-Antibacterials for systemic use,% of total sales,2.2
12754,Germany,2015,5,N05B-Anxiolytics,% of total sales,0.2
12755,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.1
12756,Germany,2015,5,J01-Antibacterials for systemic use,Million of national currency units,769.7
12757,Germany,2015,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,854.0
12758,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1428.7
12759,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1233.4
12760,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",17.5
12761,Germany,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.1
12762,Germany,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3
12763,Germany,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",34.8
12764,Germany,2015,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,104.8
12765,Germany,2015,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",121.4
12766,Germany,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5
12767,Germany,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",3295.4
12768,Germany,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,2845.0
12769,Germany,2015,5,N05C-Hypnotics and sedatives,% of total sales,0.3
12770,Germany,2015,5,C02-Antihypertensives,Million US$ at exchange rate,412.3
12771,Germany,2015,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.0
12772,Germany,2015,5,C02-Antihypertensives,"Million US$, purchasing power parity",477.6
12773,Germany,2015,5,C02-Antihypertensives,Million of national currency units,371.6
12774,Germany,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.4
12775,Germany,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.3
12776,Germany,2015,5,B-Blood and blood forming organs,% of total sales,7.3
12777,Germany,2015,5,N05C-Hypnotics and sedatives,Million of national currency units,94.5
12778,Germany,2015,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2960.3
12779,Germany,2015,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",31.3
12780,Germany,2015,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2555.8
12781,Germany,2015,5,G-Genito urinary system and sex hormones,% of total sales,2.3
12782,Germany,2015,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",36.2
12783,Germany,2015,5,A10-Drugs used in diabetes,% of total sales,6.5
12784,Germany,2015,5,A10-Drugs used in diabetes,Million of national currency units,2303.5
12785,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.8
12786,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.5
12787,Germany,2015,5,N02-Analgesics,"/capita, US$ exchange rate",23.0
12788,Germany,2015,5,B-Blood and blood forming organs,Million of national currency units,2564.2
12789,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,796.2
12790,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1023.2
12791,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,883.4
12792,Germany,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",66.9
12793,Germany,2015,5,A-Alimentary tract and metabolism,% of total sales,12.0
12794,Germany,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.8
12795,Germany,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,4719.0
12796,Germany,2015,5,A-Alimentary tract and metabolism,Million of national currency units,4253.2
12797,Germany,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5466.0
12798,Germany,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,829.9
12799,Germany,2015,5,N02-Analgesics,% of total sales,4.8
12800,Germany,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.1
12801,Germany,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3
12802,Germany,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,920.8
12803,Germany,2015,5,N02-Analgesics,"/capita, US$ purchasing power parity",26.6
12804,Germany,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1066.5
12805,Germany,2015,5,A02A-Antacids,Million US$ at exchange rate,19.7
12806,Germany,2015,5,A02A-Antacids,"Million US$, purchasing power parity",22.9
12807,Germany,2015,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",523.6
12808,Germany,2015,5,A02A-Antacids,% of total sales,0.1
12809,Germany,2015,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.3
12810,Germany,2015,5,N06A-Antidepressants,Million of national currency units,805.8
12811,Germany,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.3
12812,Germany,2015,5,N02-Analgesics,Million US$ at exchange rate,1877.3
12813,Germany,2015,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,452.0
12814,Germany,2015,5,A02A-Antacids,"/capita, US$ exchange rate",0.2
12815,Germany,2015,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,407.4
12816,Germany,2015,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.7
12817,Germany,2015,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.9
12818,Germany,2015,5,N02-Analgesics,"Million US$, purchasing power parity",2174.5
12819,Germany,2015,5,N06A-Antidepressants,% of total sales,2.3
12820,Germany,2015,5,N02-Analgesics,Million of national currency units,1692.0
12821,Germany,2015,5,N05B-Anxiolytics,Million of national currency units,73.3
12822,Germany,2015,5,A02A-Antacids,Million of national currency units,17.8
12823,Germany,2015,5,N06A-Antidepressants,Million US$ at exchange rate,894.0
12824,Germany,2015,5,N06A-Antidepressants,"Million US$, purchasing power parity",1035.6
12825,Germany,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.5
12826,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",28.5
12827,Germany,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",5721.8
12828,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.0
12829,Germany,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",72.2
12830,Germany,2014,5,C08-Calcium channel blockers,Million of national currency units,284.7
12831,Germany,2014,5,C-Cardiovascular system,Million US$ at exchange rate,5845.0
12832,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
12833,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.2
12834,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.9
12835,Germany,2014,5,C-Cardiovascular system,Million of national currency units,4399.7
12836,Germany,2014,5,N-Nervous system,% of total sales,16.9
12837,Germany,2014,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2270.1
12838,Germany,2014,5,N-Nervous system,"/capita, US$ exchange rate",93.1
12839,Germany,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",91.1
12840,Germany,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.4
12841,Germany,2014,5,R03-Drugs for obstructive airway diseases,% of total sales,5.1
12842,Germany,2014,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2222.3
12843,Germany,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.0
12844,Germany,2014,5,N-Nervous system,Million of national currency units,5672.9
12845,Germany,2014,5,N-Nervous system,Million US$ at exchange rate,7536.5
12846,Germany,2014,5,Products not elsewhere classified,Million of national currency units,8741.3
12847,Germany,2014,5,Products not elsewhere classified,Million US$ at exchange rate,11612.8
12848,Germany,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",11368.0
12849,Germany,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.7
12850,Germany,2014,5,C-Cardiovascular system,% of total sales,13.1
12851,Germany,2014,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1708.8
12852,Germany,2014,5,N-Nervous system,"Million US$, purchasing power parity",7377.6
12853,Germany,2014,5,R-Respiratory system,Million of national currency units,2047.5
12854,Germany,2014,5,C10-Lipid modifying agents,% of total sales,1.7
12855,Germany,2014,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.4
12856,Germany,2014,5,R-Respiratory system,Million US$ at exchange rate,2720.1
12857,Germany,2014,5,R-Respiratory system,"/capita, US$ exchange rate",33.6
12858,Germany,2014,5,R-Respiratory system,"Million US$, purchasing power parity",2662.8
12859,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,620.4
12860,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,824.2
12861,Germany,2014,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.6
12862,Germany,2014,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",763.4
12863,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
12864,Germany,2014,5,M-Musculo-skeletal system,% of total sales,4.1
12865,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",104.6
12866,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.3
12867,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
12868,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,80.4
12869,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",806.8
12870,Germany,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.2
12871,Germany,2014,5,R-Respiratory system,% of total sales,6.1
12872,Germany,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",32.9
12873,Germany,2014,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,106.8
12874,Germany,2014,5,C10-Lipid modifying agents,Million US$ at exchange rate,779.8
12875,Germany,2014,5,C08-Calcium channel blockers,% of total sales,0.8
12876,Germany,2014,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6
12877,Germany,2014,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.7
12878,Germany,2014,5,M-Musculo-skeletal system,Million of national currency units,1386.0
12879,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1739.9
12880,Germany,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",143.4
12881,Germany,2014,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",370.3
12882,Germany,2014,5,C08-Calcium channel blockers,Million US$ at exchange rate,378.2
12883,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2311.5
12884,Germany,2014,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2262.7
12885,Germany,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,1841.3
12886,Germany,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",43650.9
12887,Germany,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,44590.9
12888,Germany,2014,5,Total pharmaceutical sales,Million of national currency units,33564.8
12889,Germany,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",539.0
12890,Germany,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",550.6
12891,Germany,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.7
12892,Germany,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1802.5
12893,Germany,2014,5,C10-Lipid modifying agents,Million of national currency units,587.0
12894,Germany,2014,5,Products not elsewhere classified,% of total sales,26.0
12895,Germany,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",140.4
12896,Germany,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.3
12897,Germany,2014,5,C07-Beta blocking agents,Million of national currency units,669.8
12898,Germany,2014,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
12899,Germany,2014,5,C01A-Cardiac glycosides,% of total sales,0.1
12900,Germany,2014,5,C07-Beta blocking agents,Million US$ at exchange rate,889.8
12901,Germany,2014,5,J-Antiinfectives for systemic use,% of total sales,8.8
12902,Germany,2014,5,C07-Beta blocking agents,"Million US$, purchasing power parity",871.1
12903,Germany,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",47.6
12904,Germany,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3857.4
12905,Germany,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",48.7
12906,Germany,2014,5,J-Antiinfectives for systemic use,Million of national currency units,2966.1
12907,Germany,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3940.5
12908,Germany,2014,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",37.3
12909,Germany,2014,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
12910,Germany,2014,5,C01A-Cardiac glycosides,Million of national currency units,28.7
12911,Germany,2014,5,C01A-Cardiac glycosides,Million US$ at exchange rate,38.1
12912,Germany,2014,5,C03-Diuretics,"/capita, US$ exchange rate",7.2
12913,Germany,2014,5,C03-Diuretics,"/capita, US$ purchasing power parity",7.1
12914,Germany,2014,5,C03-Diuretics,% of total sales,1.3
12915,Germany,2014,5,C03-Diuretics,"Million US$, purchasing power parity",572.9
12916,Germany,2014,5,C03-Diuretics,Million of national currency units,440.5
12917,Germany,2014,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
12918,Germany,2014,5,C03-Diuretics,Million US$ at exchange rate,585.2
12919,Germany,2014,5,C07-Beta blocking agents,% of total sales,2.0
12920,Germany,2014,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.8
12921,Germany,2014,5,C07-Beta blocking agents,"/capita, US$ exchange rate",11.0
12922,Germany,2014,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.2
12923,Germany,2014,5,N05B-Anxiolytics,"Million US$, purchasing power parity",99.9
12924,Germany,2014,5,N05B-Anxiolytics,Million US$ at exchange rate,102.0
12925,Germany,2014,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
12926,Germany,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,3079.2
12927,Germany,2014,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.8
12928,Germany,2014,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.6
12929,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1085.5
12930,Germany,2014,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1017.9
12931,Germany,2014,5,C02-Antihypertensives,% of total sales,1.1
12932,Germany,2014,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.7
12933,Germany,2014,5,J01-Antibacterials for systemic use,% of total sales,2.3
12934,Germany,2014,5,N05B-Anxiolytics,% of total sales,0.2
12935,Germany,2014,5,J01-Antibacterials for systemic use,Million of national currency units,782.7
12936,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.2
12937,Germany,2014,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,1039.8
12938,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1411.7
12939,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1442.1
12940,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",17.4
12941,Germany,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",17.8
12942,Germany,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
12943,Germany,2014,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",126.9
12944,Germany,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.0
12945,Germany,2014,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,129.7
12946,Germany,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6
12947,Germany,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",3014.3
12948,Germany,2014,5,N05C-Hypnotics and sedatives,% of total sales,0.3
12949,Germany,2014,5,C02-Antihypertensives,Million US$ at exchange rate,473.6
12950,Germany,2014,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.8
12951,Germany,2014,5,C02-Antihypertensives,"Million US$, purchasing power parity",463.6
12952,Germany,2014,5,C02-Antihypertensives,Million of national currency units,356.5
12953,Germany,2014,5,B-Blood and blood forming organs,% of total sales,6.9
12954,Germany,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.2
12955,Germany,2014,5,N05C-Hypnotics and sedatives,Million of national currency units,97.6
12956,Germany,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
12957,Germany,2014,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2899.6
12958,Germany,2014,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.6
12959,Germany,2014,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2962.0
12960,Germany,2014,5,G-Genito urinary system and sex hormones,% of total sales,2.4
12961,Germany,2014,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.8
12962,Germany,2014,5,A10-Drugs used in diabetes,% of total sales,6.6
12963,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.8
12964,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.1
12965,Germany,2014,5,N02-Analgesics,"/capita, US$ exchange rate",27.5
12966,Germany,2014,5,B-Blood and blood forming organs,Million of national currency units,2317.8
12967,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,795.5
12968,Germany,2014,5,A10-Drugs used in diabetes,Million of national currency units,2229.6
12969,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1034.5
12970,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1056.8
12971,Germany,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",66.4
12972,Germany,2014,5,A-Alimentary tract and metabolism,% of total sales,12.3
12973,Germany,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",67.8
12974,Germany,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,5489.8
12975,Germany,2014,5,A-Alimentary tract and metabolism,Million of national currency units,4132.3
12976,Germany,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5374.0
12977,Germany,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,815.7
12978,Germany,2014,5,N02-Analgesics,% of total sales,5.0
12979,Germany,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.1
12980,Germany,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.4
12981,Germany,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1083.7
12982,Germany,2014,5,N02-Analgesics,"/capita, US$ purchasing power parity",26.9
12983,Germany,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1060.8
12984,Germany,2014,5,A02A-Antacids,"Million US$, purchasing power parity",22.2
12985,Germany,2014,5,A02A-Antacids,Million US$ at exchange rate,22.7
12986,Germany,2014,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.3
12987,Germany,2014,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",513.8
12988,Germany,2014,5,A02A-Antacids,% of total sales,0.1
12989,Germany,2014,5,N06A-Antidepressants,Million of national currency units,832.6
12990,Germany,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
12991,Germany,2014,5,N02-Analgesics,Million US$ at exchange rate,2226.3
12992,Germany,2014,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,524.9
12993,Germany,2014,5,A02A-Antacids,"/capita, US$ exchange rate",0.3
12994,Germany,2014,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,395.1
12995,Germany,2014,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.4
12996,Germany,2014,5,N06A-Antidepressants,"/capita, US$ exchange rate",13.7
12997,Germany,2014,5,N02-Analgesics,"Million US$, purchasing power parity",2179.4
12998,Germany,2014,5,N06A-Antidepressants,% of total sales,2.5
12999,Germany,2014,5,N02-Analgesics,Million of national currency units,1675.8
13000,Germany,2014,5,N05B-Anxiolytics,Million of national currency units,76.8
13001,Germany,2014,5,A02A-Antacids,Million of national currency units,17.1
13002,Germany,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.5
13003,Germany,2014,5,N06A-Antidepressants,Million US$ at exchange rate,1106.1
13004,Germany,2014,5,N06A-Antidepressants,"Million US$, purchasing power parity",1082.8
13005,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
13006,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.6
13007,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.9
13008,Germany,2013,5,C-Cardiovascular system,"/capita, US$ exchange rate",73.4
13009,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.8
13010,Germany,2013,5,C-Cardiovascular system,Million US$ at exchange rate,5918.0
13011,Germany,2013,5,C08-Calcium channel blockers,Million of national currency units,283.4
13012,Germany,2013,5,C-Cardiovascular system,"Million US$, purchasing power parity",5751.2
13013,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9
13014,Germany,2013,5,C-Cardiovascular system,Million of national currency units,4455.9
13015,Germany,2013,5,Products not elsewhere classified,"Million US$, purchasing power parity",10354.8
13016,Germany,2013,5,N-Nervous system,% of total sales,17.1
13017,Germany,2013,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2241.3
13018,Germany,2013,5,N-Nervous system,"/capita, US$ exchange rate",88.6
13019,Germany,2013,5,N-Nervous system,"/capita, US$ purchasing power parity",86.1
13020,Germany,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.0
13021,Germany,2013,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4
13022,Germany,2013,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2178.2
13023,Germany,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.8
13024,Germany,2013,5,N-Nervous system,Million of national currency units,5380.2
13025,Germany,2013,5,N-Nervous system,Million US$ at exchange rate,7145.5
13026,Germany,2013,5,Products not elsewhere classified,Million of national currency units,8022.7
13027,Germany,2013,5,Products not elsewhere classified,Million US$ at exchange rate,10655.1
13028,Germany,2013,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.3
13029,Germany,2013,5,C-Cardiovascular system,% of total sales,14.1
13030,Germany,2013,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1687.6
13031,Germany,2013,5,N-Nervous system,"Million US$, purchasing power parity",6944.1
13032,Germany,2013,5,R-Respiratory system,Million of national currency units,2036.5
13033,Germany,2013,5,C10-Lipid modifying agents,% of total sales,1.9
13034,Germany,2013,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.5
13035,Germany,2013,5,R-Respiratory system,Million US$ at exchange rate,2704.7
13036,Germany,2013,5,R-Respiratory system,"/capita, US$ exchange rate",33.5
13037,Germany,2013,5,R-Respiratory system,"Million US$, purchasing power parity",2628.5
13038,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,820.5
13039,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,617.8
13040,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",797.4
13041,Germany,2013,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.8
13042,Germany,2013,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",766.7
13043,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
13044,Germany,2013,5,M-Musculo-skeletal system,% of total sales,4.3
13045,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",102.1
13046,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
13047,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.3
13048,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,79.1
13049,Germany,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.2
13050,Germany,2013,5,R-Respiratory system,% of total sales,6.5
13051,Germany,2013,5,R-Respiratory system,"/capita, US$ purchasing power parity",32.6
13052,Germany,2013,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,105.1
13053,Germany,2013,5,C08-Calcium channel blockers,% of total sales,0.9
13054,Germany,2013,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.5
13055,Germany,2013,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.7
13056,Germany,2013,5,M-Musculo-skeletal system,Million of national currency units,1361.5
13057,Germany,2013,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",128.4
13058,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1860.4
13059,Germany,2013,5,Products not elsewhere classified,"/capita, US$ exchange rate",132.1
13060,Germany,2013,5,C08-Calcium channel blockers,Million US$ at exchange rate,376.4
13061,Germany,2013,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",365.8
13062,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2470.8
13063,Germany,2013,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2401.2
13064,Germany,2013,5,C10-Lipid modifying agents,Million US$ at exchange rate,788.9
13065,Germany,2013,5,Total pharmaceutical sales,"Million US$, purchasing power parity",40687.6
13066,Germany,2013,5,Total pharmaceutical sales,Million US$ at exchange rate,41867.7
13067,Germany,2013,5,Total pharmaceutical sales,Million of national currency units,31524.1
13068,Germany,2013,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",504.5
13069,Germany,2013,5,Total pharmaceutical sales,"/capita, US$ exchange rate",519.2
13070,Germany,2013,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.4
13071,Germany,2013,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1757.3
13072,Germany,2013,5,M-Musculo-skeletal system,Million US$ at exchange rate,1808.2
13073,Germany,2013,5,C10-Lipid modifying agents,Million of national currency units,594.0
13074,Germany,2013,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.8
13075,Germany,2013,5,Products not elsewhere classified,% of total sales,25.4
13076,Germany,2013,5,C07-Beta blocking agents,Million of national currency units,661.4
13077,Germany,2013,5,C07-Beta blocking agents,Million US$ at exchange rate,878.4
13078,Germany,2013,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
13079,Germany,2013,5,C01A-Cardiac glycosides,% of total sales,0.1
13080,Germany,2013,5,J-Antiinfectives for systemic use,% of total sales,7.6
13081,Germany,2013,5,C07-Beta blocking agents,"Million US$, purchasing power parity",853.7
13082,Germany,2013,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.3
13083,Germany,2013,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3091.6
13084,Germany,2013,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.4
13085,Germany,2013,5,J-Antiinfectives for systemic use,Million of national currency units,2395.3
13086,Germany,2013,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3181.2
13087,Germany,2013,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",39.8
13088,Germany,2013,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
13089,Germany,2013,5,C01A-Cardiac glycosides,Million of national currency units,30.8
13090,Germany,2013,5,C01A-Cardiac glycosides,Million US$ at exchange rate,40.9
13091,Germany,2013,5,C03-Diuretics,"/capita, US$ exchange rate",6.9
13092,Germany,2013,5,C03-Diuretics,% of total sales,1.3
13093,Germany,2013,5,C03-Diuretics,"/capita, US$ purchasing power parity",6.7
13094,Germany,2013,5,C03-Diuretics,"Million US$, purchasing power parity",540.7
13095,Germany,2013,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
13096,Germany,2013,5,C03-Diuretics,Million US$ at exchange rate,556.3
13097,Germany,2013,5,C07-Beta blocking agents,% of total sales,2.1
13098,Germany,2013,5,C07-Beta blocking agents,"/capita, US$ exchange rate",10.9
13099,Germany,2013,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.6
13100,Germany,2013,5,N05B-Anxiolytics,"Million US$, purchasing power parity",99.4
13101,Germany,2013,5,N05B-Anxiolytics,Million US$ at exchange rate,102.3
13102,Germany,2013,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.2
13103,Germany,2013,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
13104,Germany,2013,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.6
13105,Germany,2013,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.3
13106,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1046.4
13107,Germany,2013,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1068.9
13108,Germany,2013,5,C02-Antihypertensives,% of total sales,1.0
13109,Germany,2013,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.2
13110,Germany,2013,5,N05B-Anxiolytics,% of total sales,0.2
13111,Germany,2013,5,J01-Antibacterials for systemic use,% of total sales,2.6
13112,Germany,2013,5,J01-Antibacterials for systemic use,Million of national currency units,828.2
13113,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3
13114,Germany,2013,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,1099.9
13115,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1350.6
13116,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1389.7
13117,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",16.7
13118,Germany,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",17.2
13119,Germany,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
13120,Germany,2013,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,129.4
13121,Germany,2013,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",125.7
13122,Germany,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6
13123,Germany,2013,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",2598.8
13124,Germany,2013,5,N05C-Hypnotics and sedatives,% of total sales,0.3
13125,Germany,2013,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",33.2
13126,Germany,2013,5,C02-Antihypertensives,Million US$ at exchange rate,433.0
13127,Germany,2013,5,C02-Antihypertensives,"Million US$, purchasing power parity",420.8
13128,Germany,2013,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.4
13129,Germany,2013,5,B-Blood and blood forming organs,% of total sales,6.4
13130,Germany,2013,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.2
13131,Germany,2013,5,N05C-Hypnotics and sedatives,Million of national currency units,97.4
13132,Germany,2013,5,C02-Antihypertensives,Million of national currency units,326.0
13133,Germany,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.0
13134,Germany,2013,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.3
13135,Germany,2013,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2843.4
13136,Germany,2013,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2925.8
13137,Germany,2013,5,G-Genito urinary system and sex hormones,% of total sales,2.5
13138,Germany,2013,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.3
13139,Germany,2013,5,A10-Drugs used in diabetes,% of total sales,7.0
13140,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.5
13141,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.8
13142,Germany,2013,5,N02-Analgesics,"/capita, US$ exchange rate",27.2
13143,Germany,2013,5,B-Blood and blood forming organs,Million of national currency units,2013.5
13144,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,778.8
13145,Germany,2013,5,A10-Drugs used in diabetes,Million of national currency units,2203.0
13146,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1005.2
13147,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1034.3
13148,Germany,2013,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",64.5
13149,Germany,2013,5,A-Alimentary tract and metabolism,% of total sales,12.8
13150,Germany,2013,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,5354.4
13151,Germany,2013,5,A-Alimentary tract and metabolism,Million of national currency units,4031.6
13152,Germany,2013,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",66.4
13153,Germany,2013,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5203.5
13154,Germany,2013,5,G-Genito urinary system and sex hormones,Million of national currency units,780.3
13155,Germany,2013,5,N02-Analgesics,% of total sales,5.2
13156,Germany,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.5
13157,Germany,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.9
13158,Germany,2013,5,B-Blood and blood forming organs,Million US$ at exchange rate,2674.2
13159,Germany,2013,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1036.3
13160,Germany,2013,5,N02-Analgesics,"/capita, US$ purchasing power parity",26.5
13161,Germany,2013,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1007.1
13162,Germany,2013,5,A02A-Antacids,"Million US$, purchasing power parity",19.5
13163,Germany,2013,5,A02A-Antacids,Million US$ at exchange rate,20.1
13164,Germany,2013,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.2
13165,Germany,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.2
13166,Germany,2013,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",487.7
13167,Germany,2013,5,A02A-Antacids,% of total sales,0.0
13168,Germany,2013,5,N06A-Antidepressants,Million of national currency units,791.7
13169,Germany,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5
13170,Germany,2013,5,N02-Analgesics,Million US$ at exchange rate,2197.1
13171,Germany,2013,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,501.9
13172,Germany,2013,5,A02A-Antacids,"/capita, US$ exchange rate",0.2
13173,Germany,2013,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,377.9
13174,Germany,2013,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.7
13175,Germany,2013,5,N06A-Antidepressants,"/capita, US$ exchange rate",13.0
13176,Germany,2013,5,N02-Analgesics,"Million US$, purchasing power parity",2135.2
13177,Germany,2013,5,N06A-Antidepressants,% of total sales,2.5
13178,Germany,2013,5,N02-Analgesics,Million of national currency units,1654.3
13179,Germany,2013,5,N05B-Anxiolytics,Million of national currency units,77.0
13180,Germany,2013,5,N06A-Antidepressants,Million US$ at exchange rate,1051.5
13181,Germany,2013,5,N06A-Antidepressants,"Million US$, purchasing power parity",1021.8
13182,Germany,2013,5,C03-Diuretics,Million of national currency units,418.9
13183,Germany,2013,5,A02A-Antacids,Million of national currency units,15.1
13184,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.7
13185,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.3
13186,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
13187,Germany,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",72.4
13188,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",30.3
13189,Germany,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",5753.2
13190,Germany,2012,5,C08-Calcium channel blockers,Million of national currency units,289.6
13191,Germany,2012,5,C-Cardiovascular system,Million US$ at exchange rate,5819.1
13192,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3
13193,Germany,2012,5,C-Cardiovascular system,Million of national currency units,4529.2
13194,Germany,2012,5,N-Nervous system,% of total sales,17.9
13195,Germany,2012,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2088.7
13196,Germany,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",85.9
13197,Germany,2012,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2065.0
13198,Germany,2012,5,R03-Drugs for obstructive airway diseases,% of total sales,5.3
13199,Germany,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.7
13200,Germany,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.0
13201,Germany,2012,5,N-Nervous system,Million of national currency units,5439.9
13202,Germany,2012,5,Products not elsewhere classified,Million of national currency units,7344.1
13203,Germany,2012,5,N-Nervous system,Million US$ at exchange rate,6989.1
13204,Germany,2012,5,Products not elsewhere classified,"Million US$, purchasing power parity",9328.9
13205,Germany,2012,5,Products not elsewhere classified,Million US$ at exchange rate,9435.6
13206,Germany,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.5
13207,Germany,2012,5,C-Cardiovascular system,% of total sales,14.9
13208,Germany,2012,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1625.7
13209,Germany,2012,5,N-Nervous system,"Million US$, purchasing power parity",6910.0
13210,Germany,2012,5,N-Nervous system,"/capita, US$ exchange rate",86.9
13211,Germany,2012,5,R-Respiratory system,Million US$ at exchange rate,2476.9
13212,Germany,2012,5,R-Respiratory system,Million of national currency units,1927.9
13213,Germany,2012,5,C10-Lipid modifying agents,% of total sales,2.1
13214,Germany,2012,5,R-Respiratory system,"/capita, US$ exchange rate",30.8
13215,Germany,2012,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",10.1
13216,Germany,2012,5,R-Respiratory system,"Million US$, purchasing power parity",2448.9
13217,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,759.8
13218,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",751.2
13219,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,591.4
13220,Germany,2012,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.3
13221,Germany,2012,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",815.4
13222,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
13223,Germany,2012,5,M-Musculo-skeletal system,% of total sales,4.4
13224,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",100.7
13225,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.3
13226,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
13227,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,79.3
13228,Germany,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.4
13229,Germany,2012,5,R-Respiratory system,% of total sales,6.3
13230,Germany,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",30.4
13231,Germany,2012,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,101.9
13232,Germany,2012,5,C10-Lipid modifying agents,Million US$ at exchange rate,824.7
13233,Germany,2012,5,C08-Calcium channel blockers,% of total sales,1.0
13234,Germany,2012,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6
13235,Germany,2012,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.6
13236,Germany,2012,5,M-Musculo-skeletal system,Million of national currency units,1338.2
13237,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1919.1
13238,Germany,2012,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",116.0
13239,Germany,2012,5,Products not elsewhere classified,"/capita, US$ exchange rate",117.3
13240,Germany,2012,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",367.9
13241,Germany,2012,5,C08-Calcium channel blockers,Million US$ at exchange rate,372.1
13242,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2465.6
13243,Germany,2012,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2437.7
13244,Germany,2012,5,M-Musculo-skeletal system,Million US$ at exchange rate,1719.3
13245,Germany,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",38669.0
13246,Germany,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,39111.5
13247,Germany,2012,5,Total pharmaceutical sales,Million of national currency units,30442.0
13248,Germany,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",480.8
13249,Germany,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",486.3
13250,Germany,2012,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",21.4
13251,Germany,2012,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1699.8
13252,Germany,2012,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.1
13253,Germany,2012,5,C10-Lipid modifying agents,Million of national currency units,641.9
13254,Germany,2012,5,Products not elsewhere classified,% of total sales,24.1
13255,Germany,2012,5,A-Alimentary tract and metabolism,Million of national currency units,3894.1
13256,Germany,2012,5,C07-Beta blocking agents,Million of national currency units,654.5
13257,Germany,2012,5,C07-Beta blocking agents,Million US$ at exchange rate,840.9
13258,Germany,2012,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
13259,Germany,2012,5,C01A-Cardiac glycosides,% of total sales,0.1
13260,Germany,2012,5,J-Antiinfectives for systemic use,% of total sales,7.9
13261,Germany,2012,5,C07-Beta blocking agents,"Million US$, purchasing power parity",831.4
13262,Germany,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.1
13263,Germany,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3062.8
13264,Germany,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",38.5
13265,Germany,2012,5,J-Antiinfectives for systemic use,Million of national currency units,2411.2
13266,Germany,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3097.9
13267,Germany,2012,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",42.7
13268,Germany,2012,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
13269,Germany,2012,5,C01A-Cardiac glycosides,Million of national currency units,33.6
13270,Germany,2012,5,C01A-Cardiac glycosides,Million US$ at exchange rate,43.2
13271,Germany,2012,5,A02A-Antacids,Million of national currency units,14.9
13272,Germany,2012,5,C03-Diuretics,"/capita, US$ exchange rate",6.4
13273,Germany,2012,5,C03-Diuretics,"/capita, US$ purchasing power parity",6.3
13274,Germany,2012,5,C03-Diuretics,% of total sales,1.3
13275,Germany,2012,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.3
13276,Germany,2012,5,C03-Diuretics,"Million US$, purchasing power parity",509.8
13277,Germany,2012,5,C03-Diuretics,Million US$ at exchange rate,515.6
13278,Germany,2012,5,C07-Beta blocking agents,% of total sales,2.1
13279,Germany,2012,5,N05B-Anxiolytics,% of total sales,0.3
13280,Germany,2012,5,C07-Beta blocking agents,"/capita, US$ exchange rate",10.5
13281,Germany,2012,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.3
13282,Germany,2012,5,N05B-Anxiolytics,"Million US$, purchasing power parity",100.2
13283,Germany,2012,5,N05B-Anxiolytics,Million US$ at exchange rate,101.4
13284,Germany,2012,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.2
13285,Germany,2012,5,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
13286,Germany,2012,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.3
13287,Germany,2012,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.2
13288,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1019.3
13289,Germany,2012,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",981.8
13290,Germany,2012,5,C02-Antihypertensives,% of total sales,1.0
13291,Germany,2012,5,J01-Antibacterials for systemic use,% of total sales,2.5
13292,Germany,2012,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.9
13293,Germany,2012,5,J01-Antibacterials for systemic use,Million of national currency units,772.9
13294,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3
13295,Germany,2012,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,993.0
13296,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1294.8
13297,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1309.6
13298,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",16.1
13299,Germany,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.3
13300,Germany,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
13301,Germany,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6
13302,Germany,2012,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,127.6
13303,Germany,2012,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",126.1
13304,Germany,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",2233.2
13305,Germany,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",28.1
13306,Germany,2012,5,N05C-Hypnotics and sedatives,% of total sales,0.3
13307,Germany,2012,5,C02-Antihypertensives,Million US$ at exchange rate,399.4
13308,Germany,2012,5,C02-Antihypertensives,"Million US$, purchasing power parity",394.9
13309,Germany,2012,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.0
13310,Germany,2012,5,C02-Antihypertensives,Million of national currency units,310.9
13311,Germany,2012,5,B-Blood and blood forming organs,% of total sales,5.8
13312,Germany,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.8
13313,Germany,2012,5,N05C-Hypnotics and sedatives,Million of national currency units,99.3
13314,Germany,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.1
13315,Germany,2012,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.0
13316,Germany,2012,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2658.0
13317,Germany,2012,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2627.9
13318,Germany,2012,5,G-Genito urinary system and sex hormones,% of total sales,2.6
13319,Germany,2012,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",32.7
13320,Germany,2012,5,A10-Drugs used in diabetes,% of total sales,6.8
13321,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.7
13322,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.9
13323,Germany,2012,5,N02-Analgesics,"/capita, US$ exchange rate",26.0
13324,Germany,2012,5,B-Blood and blood forming organs,Million of national currency units,1758.1
13325,Germany,2012,5,A10-Drugs used in diabetes,Million of national currency units,2068.8
13326,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,805.4
13327,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1034.8
13328,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1023.1
13329,Germany,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",61.5
13330,Germany,2012,5,A-Alimentary tract and metabolism,% of total sales,12.8
13331,Germany,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,5003.1
13332,Germany,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",62.2
13333,Germany,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4946.5
13334,Germany,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,779.7
13335,Germany,2012,5,N02-Analgesics,% of total sales,5.4
13336,Germany,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,2258.8
13337,Germany,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.3
13338,Germany,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.5
13339,Germany,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1001.7
13340,Germany,2012,5,N02-Analgesics,"/capita, US$ purchasing power parity",25.7
13341,Germany,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",990.4
13342,Germany,2012,5,A02A-Antacids,"Million US$, purchasing power parity",18.9
13343,Germany,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.1
13344,Germany,2012,5,A02A-Antacids,% of total sales,0.0
13345,Germany,2012,5,N06A-Antidepressants,Million of national currency units,746.5
13346,Germany,2012,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",487.1
13347,Germany,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
13348,Germany,2012,5,N02-Analgesics,Million US$ at exchange rate,2093.0
13349,Germany,2012,5,A02A-Antacids,"/capita, US$ exchange rate",0.2
13350,Germany,2012,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,492.7
13351,Germany,2012,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,383.5
13352,Germany,2012,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.8
13353,Germany,2012,5,N06A-Antidepressants,"/capita, US$ exchange rate",11.9
13354,Germany,2012,5,N06A-Antidepressants,% of total sales,2.5
13355,Germany,2012,5,N02-Analgesics,"Million US$, purchasing power parity",2069.4
13356,Germany,2012,5,A02A-Antacids,Million US$ at exchange rate,19.1
13357,Germany,2012,5,N05B-Anxiolytics,Million of national currency units,78.9
13358,Germany,2012,5,N02-Analgesics,Million of national currency units,1629.1
13359,Germany,2012,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.2
13360,Germany,2012,5,N06A-Antidepressants,Million US$ at exchange rate,959.1
13361,Germany,2012,5,C03-Diuretics,Million of national currency units,401.3
13362,Germany,2012,5,N06A-Antidepressants,"Million US$, purchasing power parity",948.2
13363,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",37.3
13364,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.0
13365,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
13366,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8
13367,Germany,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",83.1
13368,Germany,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",6078.4
13369,Germany,2011,6,C08-Calcium channel blockers,Million of national currency units,292.0
13370,Germany,2011,6,C-Cardiovascular system,Million US$ at exchange rate,6673.5
13371,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.2
13372,Germany,2011,6,C-Cardiovascular system,Million of national currency units,4794.3
13373,Germany,2011,6,N-Nervous system,% of total sales,19.1
13374,Germany,2011,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2325.3
13375,Germany,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",89.7
13376,Germany,2011,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2117.9
13377,Germany,2011,6,R03-Drugs for obstructive airway diseases,% of total sales,5.6
13378,Germany,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.4
13379,Germany,2011,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.0
13380,Germany,2011,6,Products not elsewhere classified,Million of national currency units,6791.6
13381,Germany,2011,6,N-Nervous system,Million of national currency units,5679.2
13382,Germany,2011,6,N-Nervous system,Million US$ at exchange rate,7905.2
13383,Germany,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",8610.7
13384,Germany,2011,6,Products not elsewhere classified,Million US$ at exchange rate,9453.6
13385,Germany,2011,6,C-Cardiovascular system,% of total sales,16.1
13386,Germany,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.7
13387,Germany,2011,6,N-Nervous system,"Million US$, purchasing power parity",7200.4
13388,Germany,2011,6,N-Nervous system,"/capita, US$ exchange rate",98.5
13389,Germany,2011,6,R-Respiratory system,Million US$ at exchange rate,2766.2
13390,Germany,2011,6,R-Respiratory system,Million of national currency units,1987.3
13391,Germany,2011,6,C10-Lipid modifying agents,% of total sales,2.3
13392,Germany,2011,6,R-Respiratory system,"/capita, US$ exchange rate",34.5
13393,Germany,2011,6,R-Respiratory system,"Million US$, purchasing power parity",2519.6
13394,Germany,2011,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",10.6
13395,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,772.5
13396,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",703.7
13397,Germany,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",31.4
13398,Germany,2011,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.7
13399,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,555.0
13400,Germany,2011,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",852.8
13401,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
13402,Germany,2011,6,M-Musculo-skeletal system,% of total sales,4.3
13403,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",111.2
13404,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5
13405,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.4
13406,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,87.7
13407,Germany,2011,6,R03-Drugs for obstructive airway diseases,Million of national currency units,1670.5
13408,Germany,2011,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.6
13409,Germany,2011,6,R-Respiratory system,% of total sales,6.7
13410,Germany,2011,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,122.1
13411,Germany,2011,6,C08-Calcium channel blockers,% of total sales,1.0
13412,Germany,2011,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6
13413,Germany,2011,6,M-Musculo-skeletal system,Million of national currency units,1285.2
13414,Germany,2011,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1
13415,Germany,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",107.3
13416,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,2149.7
13417,Germany,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",117.8
13418,Germany,2011,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",370.2
13419,Germany,2011,6,C08-Calcium channel blockers,Million US$ at exchange rate,406.5
13420,Germany,2011,6,M-Musculo-skeletal system,Million US$ at exchange rate,1788.9
13421,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2992.3
13422,Germany,2011,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2725.5
13423,Germany,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",37675.6
13424,Germany,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,41363.6
13425,Germany,2011,6,Total pharmaceutical sales,Million of national currency units,29716.2
13426,Germany,2011,6,C10-Lipid modifying agents,Million US$ at exchange rate,936.2
13427,Germany,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",469.3
13428,Germany,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",515.3
13429,Germany,2011,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.3
13430,Germany,2011,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",1629.4
13431,Germany,2011,6,C10-Lipid modifying agents,Million of national currency units,672.6
13432,Germany,2011,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.3
13433,Germany,2011,6,Products not elsewhere classified,% of total sales,22.9
13434,Germany,2011,6,C07-Beta blocking agents,Million of national currency units,647.2
13435,Germany,2011,6,C07-Beta blocking agents,Million US$ at exchange rate,900.9
13436,Germany,2011,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.6
13437,Germany,2011,6,C01A-Cardiac glycosides,% of total sales,0.1
13438,Germany,2011,6,J-Antiinfectives for systemic use,% of total sales,7.1
13439,Germany,2011,6,C07-Beta blocking agents,"Million US$, purchasing power parity",820.6
13440,Germany,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",33.1
13441,Germany,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2661.1
13442,Germany,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",36.4
13443,Germany,2011,6,J-Antiinfectives for systemic use,Million of national currency units,2098.9
13444,Germany,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,2921.6
13445,Germany,2011,6,C01A-Cardiac glycosides,Million of national currency units,35.8
13446,Germany,2011,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",45.4
13447,Germany,2011,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.6
13448,Germany,2011,6,C01A-Cardiac glycosides,Million US$ at exchange rate,49.8
13449,Germany,2011,6,C03-Diuretics,"/capita, US$ purchasing power parity",6.1
13450,Germany,2011,6,C03-Diuretics,"/capita, US$ exchange rate",6.7
13451,Germany,2011,6,C03-Diuretics,% of total sales,1.3
13452,Germany,2011,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.3
13453,Germany,2011,6,C03-Diuretics,"Million US$, purchasing power parity",493.3
13454,Germany,2011,6,C03-Diuretics,Million US$ at exchange rate,541.6
13455,Germany,2011,6,C07-Beta blocking agents,% of total sales,2.2
13456,Germany,2011,6,N05B-Anxiolytics,% of total sales,0.3
13457,Germany,2011,6,C07-Beta blocking agents,"/capita, US$ exchange rate",11.2
13458,Germany,2011,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.2
13459,Germany,2011,6,N05B-Anxiolytics,"Million US$, purchasing power parity",101.6
13460,Germany,2011,6,N05B-Anxiolytics,Million US$ at exchange rate,111.5
13461,Germany,2011,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.3
13462,Germany,2011,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
13463,Germany,2011,6,A02A-Antacids,Million of national currency units,14.7
13464,Germany,2011,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
13465,Germany,2011,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.4
13466,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,994.0
13467,Germany,2011,6,C02-Antihypertensives,% of total sales,1.0
13468,Germany,2011,6,J01-Antibacterials for systemic use,% of total sales,2.4
13469,Germany,2011,6,J01-Antibacterials for systemic use,Million of national currency units,712.3
13470,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3
13471,Germany,2011,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",903.1
13472,Germany,2011,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,991.5
13473,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1260.2
13474,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1383.6
13475,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",15.7
13476,Germany,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",17.2
13477,Germany,2011,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.7
13478,Germany,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8
13479,Germany,2011,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6
13480,Germany,2011,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,144.3
13481,Germany,2011,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",131.5
13482,Germany,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",2019.3
13483,Germany,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",27.6
13484,Germany,2011,6,N05C-Hypnotics and sedatives,% of total sales,0.3
13485,Germany,2011,6,C02-Antihypertensives,Million US$ at exchange rate,416.5
13486,Germany,2011,6,C02-Antihypertensives,"Million US$, purchasing power parity",379.3
13487,Germany,2011,6,C02-Antihypertensives,"/capita, US$ exchange rate",5.2
13488,Germany,2011,6,B-Blood and blood forming organs,% of total sales,5.4
13489,Germany,2011,6,A-Alimentary tract and metabolism,Million of national currency units,3704.0
13490,Germany,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.2
13491,Germany,2011,6,C02-Antihypertensives,Million of national currency units,299.2
13492,Germany,2011,6,N05C-Hypnotics and sedatives,Million of national currency units,103.7
13493,Germany,2011,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.8
13494,Germany,2011,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2468.6
13495,Germany,2011,6,A10-Drugs used in diabetes,Million US$ at exchange rate,2710.3
13496,Germany,2011,6,G-Genito urinary system and sex hormones,% of total sales,2.7
13497,Germany,2011,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",30.8
13498,Germany,2011,6,A10-Drugs used in diabetes,% of total sales,6.6
13499,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.6
13500,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.8
13501,Germany,2011,6,N02-Analgesics,"/capita, US$ exchange rate",27.3
13502,Germany,2011,6,B-Blood and blood forming organs,Million of national currency units,1592.7
13503,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,796.7
13504,Germany,2011,6,A10-Drugs used in diabetes,Million of national currency units,1947.1
13505,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1109.0
13506,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1010.1
13507,Germany,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",58.5
13508,Germany,2011,6,A-Alimentary tract and metabolism,% of total sales,12.5
13509,Germany,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,788.7
13510,Germany,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,5155.8
13511,Germany,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.2
13512,Germany,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4696.1
13513,Germany,2011,6,N02-Analgesics,% of total sales,5.3
13514,Germany,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,2217.0
13515,Germany,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.5
13516,Germany,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.7
13517,Germany,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1097.8
13518,Germany,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1000.0
13519,Germany,2011,6,N02-Analgesics,"/capita, US$ purchasing power parity",24.9
13520,Germany,2011,6,A02A-Antacids,"Million US$, purchasing power parity",18.6
13521,Germany,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.9
13522,Germany,2011,6,A02A-Antacids,% of total sales,0.0
13523,Germany,2011,6,N06A-Antidepressants,Million US$ at exchange rate,1065.4
13524,Germany,2011,6,N06A-Antidepressants,Million of national currency units,765.4
13525,Germany,2011,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.7
13526,Germany,2011,6,N02-Analgesics,Million US$ at exchange rate,2192.2
13527,Germany,2011,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",501.3
13528,Germany,2011,6,A02A-Antacids,"/capita, US$ exchange rate",0.3
13529,Germany,2011,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,395.4
13530,Germany,2011,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,550.4
13531,Germany,2011,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.2
13532,Germany,2011,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.1
13533,Germany,2011,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.3
13534,Germany,2011,6,N06A-Antidepressants,% of total sales,2.6
13535,Germany,2011,6,N02-Analgesics,"Million US$, purchasing power parity",1996.7
13536,Germany,2011,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.2
13537,Germany,2011,6,A02A-Antacids,Million US$ at exchange rate,20.5
13538,Germany,2011,6,N02-Analgesics,Million of national currency units,1574.9
13539,Germany,2011,6,N05B-Anxiolytics,Million of national currency units,80.1
13540,Germany,2011,6,N06A-Antidepressants,"Million US$, purchasing power parity",970.4
13541,Germany,2011,6,C03-Diuretics,Million of national currency units,389.1
13542,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",34.8
13543,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",32.6
13544,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
13545,Germany,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",78.9
13546,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.4
13547,Germany,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",6048.6
13548,Germany,2010,6,C08-Calcium channel blockers,Million of national currency units,308.0
13549,Germany,2010,6,C-Cardiovascular system,Million US$ at exchange rate,6455.7
13550,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.2
13551,Germany,2010,6,C-Cardiovascular system,Million of national currency units,4869.6
13552,Germany,2010,6,N-Nervous system,% of total sales,19.1
13553,Germany,2010,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,2284.2
13554,Germany,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",86.4
13555,Germany,2010,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2140.2
13556,Germany,2010,6,R03-Drugs for obstructive airway diseases,% of total sales,5.8
13557,Germany,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.2
13558,Germany,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.9
13559,Germany,2010,6,Products not elsewhere classified,Million of national currency units,6585.2
13560,Germany,2010,6,N-Nervous system,Million of national currency units,5688.1
13561,Germany,2010,6,N-Nervous system,Million US$ at exchange rate,7540.8
13562,Germany,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",8179.5
13563,Germany,2010,6,Products not elsewhere classified,Million US$ at exchange rate,8730.1
13564,Germany,2010,6,C-Cardiovascular system,% of total sales,16.4
13565,Germany,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.0
13566,Germany,2010,6,N-Nervous system,"Million US$, purchasing power parity",7065.3
13567,Germany,2010,6,N-Nervous system,"/capita, US$ exchange rate",92.2
13568,Germany,2010,6,C08-Calcium channel blockers,Million US$ at exchange rate,408.3
13569,Germany,2010,6,R-Respiratory system,Million US$ at exchange rate,2719.7
13570,Germany,2010,6,R-Respiratory system,Million of national currency units,2051.5
13571,Germany,2010,6,C10-Lipid modifying agents,% of total sales,2.4
13572,Germany,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",31.2
13573,Germany,2010,6,R-Respiratory system,"/capita, US$ exchange rate",33.3
13574,Germany,2010,6,R-Respiratory system,"Million US$, purchasing power parity",2548.2
13575,Germany,2010,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",10.8
13576,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,735.9
13577,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",689.5
13578,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,555.1
13579,Germany,2010,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.5
13580,Germany,2010,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",880.3
13581,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
13582,Germany,2010,6,M-Musculo-skeletal system,% of total sales,4.5
13583,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",94.5
13584,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.2
13585,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
13586,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,76.1
13587,Germany,2010,6,R03-Drugs for obstructive airway diseases,Million of national currency units,1723.0
13588,Germany,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.0
13589,Germany,2010,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,100.9
13590,Germany,2010,6,R-Respiratory system,% of total sales,6.9
13591,Germany,2010,6,C08-Calcium channel blockers,% of total sales,1.0
13592,Germany,2010,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.7
13593,Germany,2010,6,M-Musculo-skeletal system,Million US$ at exchange rate,1771.4
13594,Germany,2010,6,M-Musculo-skeletal system,Million of national currency units,1336.2
13595,Germany,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",100.0
13596,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,2144.2
13597,Germany,2010,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.0
13598,Germany,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",106.8
13599,Germany,2010,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",382.6
13600,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2842.6
13601,Germany,2010,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2663.3
13602,Germany,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",36921.4
13603,Germany,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,39406.5
13604,Germany,2010,6,C10-Lipid modifying agents,Million US$ at exchange rate,939.5
13605,Germany,2010,6,Total pharmaceutical sales,Million of national currency units,29724.7
13606,Germany,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",481.9
13607,Germany,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",451.5
13608,Germany,2010,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",21.7
13609,Germany,2010,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",1659.7
13610,Germany,2010,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.3
13611,Germany,2010,6,C10-Lipid modifying agents,Million of national currency units,708.7
13612,Germany,2010,6,Products not elsewhere classified,% of total sales,22.2
13613,Germany,2010,6,A-Alimentary tract and metabolism,Million of national currency units,3714.8
13614,Germany,2010,6,C07-Beta blocking agents,Million of national currency units,666.0
13615,Germany,2010,6,C07-Beta blocking agents,Million US$ at exchange rate,882.9
13616,Germany,2010,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.6
13617,Germany,2010,6,C01A-Cardiac glycosides,% of total sales,0.1
13618,Germany,2010,6,J-Antiinfectives for systemic use,% of total sales,6.8
13619,Germany,2010,6,C07-Beta blocking agents,"Million US$, purchasing power parity",827.2
13620,Germany,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.8
13621,Germany,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2520.2
13622,Germany,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",32.9
13623,Germany,2010,6,J-Antiinfectives for systemic use,Million of national currency units,2029.0
13624,Germany,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,2689.9
13625,Germany,2010,6,C01A-Cardiac glycosides,Million of national currency units,39.3
13626,Germany,2010,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",48.8
13627,Germany,2010,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.6
13628,Germany,2010,6,C01A-Cardiac glycosides,Million US$ at exchange rate,52.1
13629,Germany,2010,6,C03-Diuretics,"/capita, US$ purchasing power parity",6.0
13630,Germany,2010,6,C03-Diuretics,"/capita, US$ exchange rate",6.4
13631,Germany,2010,6,C03-Diuretics,% of total sales,1.3
13632,Germany,2010,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.4
13633,Germany,2010,6,C03-Diuretics,"Million US$, purchasing power parity",487.5
13634,Germany,2010,6,C03-Diuretics,Million US$ at exchange rate,520.3
13635,Germany,2010,6,C07-Beta blocking agents,% of total sales,2.2
13636,Germany,2010,6,N05B-Anxiolytics,% of total sales,0.3
13637,Germany,2010,6,C07-Beta blocking agents,"/capita, US$ exchange rate",10.8
13638,Germany,2010,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.1
13639,Germany,2010,6,N05B-Anxiolytics,"Million US$, purchasing power parity",105.6
13640,Germany,2010,6,N05B-Anxiolytics,Million US$ at exchange rate,112.7
13641,Germany,2010,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.3
13642,Germany,2010,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
13643,Germany,2010,6,A02A-Antacids,Million of national currency units,14.5
13644,Germany,2010,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
13645,Germany,2010,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.0
13646,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,987.2
13647,Germany,2010,6,J01-Antibacterials for systemic use,% of total sales,2.5
13648,Germany,2010,6,C02-Antihypertensives,% of total sales,1.0
13649,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1308.7
13650,Germany,2010,6,J01-Antibacterials for systemic use,Million of national currency units,740.2
13651,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3
13652,Germany,2010,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",919.4
13653,Germany,2010,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,981.3
13654,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1226.2
13655,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",15.0
13656,Germany,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.0
13657,Germany,2010,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.7
13658,Germany,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8
13659,Germany,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.7
13660,Germany,2010,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",137.0
13661,Germany,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",2050.1
13662,Germany,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.8
13663,Germany,2010,6,N05C-Hypnotics and sedatives,% of total sales,0.4
13664,Germany,2010,6,C02-Antihypertensives,"Million US$, purchasing power parity",381.0
13665,Germany,2010,6,C02-Antihypertensives,Million US$ at exchange rate,406.6
13666,Germany,2010,6,C02-Antihypertensives,"/capita, US$ exchange rate",5.0
13667,Germany,2010,6,B-Blood and blood forming organs,% of total sales,5.6
13668,Germany,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.1
13669,Germany,2010,6,C02-Antihypertensives,Million of national currency units,306.7
13670,Germany,2010,6,N05C-Hypnotics and sedatives,Million of national currency units,110.3
13671,Germany,2010,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,146.2
13672,Germany,2010,6,A10-Drugs used in diabetes,Million US$ at exchange rate,2504.1
13673,Germany,2010,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2346.2
13674,Germany,2010,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",28.7
13675,Germany,2010,6,G-Genito urinary system and sex hormones,% of total sales,2.7
13676,Germany,2010,6,A10-Drugs used in diabetes,% of total sales,6.4
13677,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.9
13678,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.8
13679,Germany,2010,6,N02-Analgesics,"/capita, US$ exchange rate",25.3
13680,Germany,2010,6,B-Blood and blood forming organs,Million of national currency units,1650.5
13681,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,912.0
13682,Germany,2010,6,A10-Drugs used in diabetes,Million of national currency units,1888.9
13683,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1209.1
13684,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1132.8
13685,Germany,2010,6,A-Alimentary tract and metabolism,% of total sales,12.5
13686,Germany,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",56.4
13687,Germany,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,812.2
13688,Germany,2010,6,N02-Analgesics,% of total sales,5.3
13689,Germany,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,4924.8
13690,Germany,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.2
13691,Germany,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4614.2
13692,Germany,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,2188.1
13693,Germany,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.3
13694,Germany,2010,6,N02-Analgesics,"/capita, US$ purchasing power parity",23.7
13695,Germany,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1076.7
13696,Germany,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1008.8
13697,Germany,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.2
13698,Germany,2010,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.6
13699,Germany,2010,6,A02A-Antacids,"Million US$, purchasing power parity",18.0
13700,Germany,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.8
13701,Germany,2010,6,A02A-Antacids,% of total sales,0.0
13702,Germany,2010,6,N06A-Antidepressants,Million of national currency units,798.5
13703,Germany,2010,6,N06A-Antidepressants,Million US$ at exchange rate,1058.6
13704,Germany,2010,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",521.4
13705,Germany,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.1
13706,Germany,2010,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.2
13707,Germany,2010,6,N02-Analgesics,Million US$ at exchange rate,2069.6
13708,Germany,2010,6,A02A-Antacids,"/capita, US$ exchange rate",0.2
13709,Germany,2010,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,556.5
13710,Germany,2010,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,419.8
13711,Germany,2010,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.1
13712,Germany,2010,6,N06A-Antidepressants,"/capita, US$ exchange rate",12.9
13713,Germany,2010,6,N06A-Antidepressants,% of total sales,2.7
13714,Germany,2010,6,N02-Analgesics,"Million US$, purchasing power parity",1939.1
13715,Germany,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.4
13716,Germany,2010,6,A02A-Antacids,Million US$ at exchange rate,19.2
13717,Germany,2010,6,N02-Analgesics,Million of national currency units,1561.1
13718,Germany,2010,6,N05B-Anxiolytics,Million of national currency units,85.0
13719,Germany,2010,6,N06A-Antidepressants,"Million US$, purchasing power parity",991.8
13720,Germany,2010,6,C03-Diuretics,Million of national currency units,392.5
13721,Germany,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",5802.0
13722,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.6
13723,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.5
13724,Germany,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",58.7
13725,Germany,2016,5,C-Cardiovascular system,Million US$ at exchange rate,4833.4
13726,Germany,2016,5,C08-Calcium channel blockers,Million of national currency units,285.0
13727,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6
13728,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.9
13729,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.4
13730,Germany,2016,5,C-Cardiovascular system,Million of national currency units,4366.6
13731,Germany,2016,5,N-Nervous system,% of total sales,14.6
13732,Germany,2016,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1929.4
13733,Germany,2016,5,N-Nervous system,"/capita, US$ exchange rate",70.7
13734,Germany,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",84.9
13735,Germany,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",28.1
13736,Germany,2016,5,R03-Drugs for obstructive airway diseases,% of total sales,4.8
13737,Germany,2016,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",2316.1
13738,Germany,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.4
13739,Germany,2016,5,N-Nervous system,Million of national currency units,5260.4
13740,Germany,2016,5,Products not elsewhere classified,Million US$ at exchange rate,11702.7
13741,Germany,2016,5,Products not elsewhere classified,Million of national currency units,10572.5
13742,Germany,2016,5,N-Nervous system,Million US$ at exchange rate,5822.8
13743,Germany,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.5
13744,Germany,2016,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1743.1
13745,Germany,2016,5,N-Nervous system,"Million US$, purchasing power parity",6989.6
13746,Germany,2016,5,R-Respiratory system,Million of national currency units,2134.3
13747,Germany,2016,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",10.7
13748,Germany,2016,5,R-Respiratory system,Million US$ at exchange rate,2362.5
13749,Germany,2016,5,R-Respiratory system,"/capita, US$ exchange rate",28.7
13750,Germany,2016,5,R-Respiratory system,"Million US$, purchasing power parity",2835.9
13751,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,588.8
13752,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,651.7
13753,Germany,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",582.8
13754,Germany,2016,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.9
13755,Germany,2016,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",884.4
13756,Germany,2016,5,C10-Lipid modifying agents,Million US$ at exchange rate,736.8
13757,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
13758,Germany,2016,5,M-Musculo-skeletal system,% of total sales,3.9
13759,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
13760,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",100.3
13761,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
13762,Germany,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7
13763,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,75.5
13764,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",782.3
13765,Germany,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.9
13766,Germany,2016,5,C10-Lipid modifying agents,% of total sales,1.8
13767,Germany,2016,5,R-Respiratory system,% of total sales,5.9
13768,Germany,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",34.4
13769,Germany,2016,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,83.6
13770,Germany,2016,5,C08-Calcium channel blockers,% of total sales,0.8
13771,Germany,2016,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6
13772,Germany,2016,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.8
13773,Germany,2016,5,M-Musculo-skeletal system,Million of national currency units,1405.1
13774,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1604.2
13775,Germany,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",14047.8
13776,Germany,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",142.1
13777,Germany,2016,5,C08-Calcium channel blockers,Million US$ at exchange rate,315.5
13778,Germany,2016,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",378.7
13779,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1775.7
13780,Germany,2016,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2131.5
13781,Germany,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,39979.8
13782,Germany,2016,5,Total pharmaceutical sales,Million of national currency units,36118.6
13783,Germany,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",47991.3
13784,Germany,2016,5,C-Cardiovascular system,% of total sales,12.1
13785,Germany,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",485.5
13786,Germany,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.9
13787,Germany,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",1867.0
13788,Germany,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,1555.3
13789,Germany,2016,5,C10-Lipid modifying agents,Million of national currency units,665.6
13790,Germany,2016,5,Products not elsewhere classified,% of total sales,29.3
13791,Germany,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",170.6
13792,Germany,2016,5,C07-Beta blocking agents,Million of national currency units,659.7
13793,Germany,2016,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
13794,Germany,2016,5,C01A-Cardiac glycosides,% of total sales,0.1
13795,Germany,2016,5,C07-Beta blocking agents,Million US$ at exchange rate,730.2
13796,Germany,2016,5,J-Antiinfectives for systemic use,% of total sales,9.0
13797,Germany,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",43.5
13798,Germany,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",52.3
13799,Germany,2016,5,C07-Beta blocking agents,"Million US$, purchasing power parity",876.6
13800,Germany,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",4302.8
13801,Germany,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3584.5
13802,Germany,2016,5,J-Antiinfectives for systemic use,Million of national currency units,3238.3
13803,Germany,2016,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",31.4
13804,Germany,2016,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
13805,Germany,2016,5,C01A-Cardiac glycosides,Million of national currency units,23.6
13806,Germany,2016,5,C01A-Cardiac glycosides,Million US$ at exchange rate,26.1
13807,Germany,2016,5,C03-Diuretics,"/capita, US$ exchange rate",6.0
13808,Germany,2016,5,C03-Diuretics,"Million US$, purchasing power parity",597.8
13809,Germany,2016,5,C03-Diuretics,% of total sales,1.2
13810,Germany,2016,5,C03-Diuretics,"/capita, US$ purchasing power parity",7.3
13811,Germany,2016,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.1
13812,Germany,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.5
13813,Germany,2016,5,C03-Diuretics,Million of national currency units,449.9
13814,Germany,2016,5,C03-Diuretics,Million US$ at exchange rate,498.0
13815,Germany,2016,5,C07-Beta blocking agents,% of total sales,1.8
13816,Germany,2016,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.6
13817,Germany,2016,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.9
13818,Germany,2016,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.1
13819,Germany,2016,5,N05B-Anxiolytics,Million US$ at exchange rate,76.2
13820,Germany,2016,5,N05B-Anxiolytics,"/capita, US$ exchange rate",0.9
13821,Germany,2016,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.1
13822,Germany,2016,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.2
13823,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1115.3
13824,Germany,2016,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1002.6
13825,Germany,2016,5,C02-Antihypertensives,% of total sales,1.1
13826,Germany,2016,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.3
13827,Germany,2016,5,J01-Antibacterials for systemic use,% of total sales,2.1
13828,Germany,2016,5,N05B-Anxiolytics,% of total sales,0.2
13829,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.1
13830,Germany,2016,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,835.3
13831,Germany,2016,5,J01-Antibacterials for systemic use,Million of national currency units,754.6
13832,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",18.0
13833,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1481.9
13834,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1234.5
13835,Germany,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.0
13836,Germany,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2
13837,Germany,2016,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",120.2
13838,Germany,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.1
13839,Germany,2016,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,100.2
13840,Germany,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",3770.0
13841,Germany,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,3140.6
13842,Germany,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5
13843,Germany,2016,5,N05C-Hypnotics and sedatives,% of total sales,0.3
13844,Germany,2016,5,C02-Antihypertensives,Million US$ at exchange rate,431.8
13845,Germany,2016,5,C02-Antihypertensives,Million of national currency units,390.1
13846,Germany,2016,5,C02-Antihypertensives,"/capita, US$ exchange rate",5.2
13847,Germany,2016,5,C02-Antihypertensives,"Million US$, purchasing power parity",518.3
13848,Germany,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.8
13849,Germany,2016,5,B-Blood and blood forming organs,% of total sales,7.9
13850,Germany,2016,5,N05C-Hypnotics and sedatives,Million of national currency units,90.5
13851,Germany,2016,5,N05B-Anxiolytics,"Million US$, purchasing power parity",91.4
13852,Germany,2016,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",3211.4
13853,Germany,2016,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.5
13854,Germany,2016,5,A10-Drugs used in diabetes,Million US$ at exchange rate,2675.3
13855,Germany,2016,5,G-Genito urinary system and sex hormones,% of total sales,2.2
13856,Germany,2016,5,A10-Drugs used in diabetes,% of total sales,6.7
13857,Germany,2016,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",39.0
13858,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.4
13859,Germany,2016,5,N02-Analgesics,"/capita, US$ exchange rate",23.3
13860,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.5
13861,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,772.4
13862,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1026.3
13863,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,855.0
13864,Germany,2016,5,A10-Drugs used in diabetes,Million of national currency units,2416.9
13865,Germany,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.7
13866,Germany,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",71.1
13867,Germany,2016,5,A-Alimentary tract and metabolism,% of total sales,12.2
13868,Germany,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",59.2
13869,Germany,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,4875.1
13870,Germany,2016,5,A-Alimentary tract and metabolism,Million of national currency units,4404.3
13871,Germany,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5852.1
13872,Germany,2016,5,N02-Analgesics,% of total sales,4.8
13873,Germany,2016,5,B-Blood and blood forming organs,Million of national currency units,2837.3
13874,Germany,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.5
13875,Germany,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,868.3
13876,Germany,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,784.4
13877,Germany,2016,5,N02-Analgesics,"/capita, US$ purchasing power parity",28.0
13878,Germany,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1042.2
13879,Germany,2016,5,A02A-Antacids,Million US$ at exchange rate,21.1
13880,Germany,2016,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",533.1
13881,Germany,2016,5,A02A-Antacids,"Million US$, purchasing power parity",25.4
13882,Germany,2016,5,N02-Analgesics,Million of national currency units,1735.8
13883,Germany,2016,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.3
13884,Germany,2016,5,A02A-Antacids,% of total sales,0.1
13885,Germany,2016,5,N06A-Antidepressants,Million of national currency units,759.1
13886,Germany,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.1
13887,Germany,2016,5,N02-Analgesics,Million US$ at exchange rate,1921.4
13888,Germany,2016,5,A02A-Antacids,"/capita, US$ exchange rate",0.3
13889,Germany,2016,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,444.1
13890,Germany,2016,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,401.2
13891,Germany,2016,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.2
13892,Germany,2016,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.2
13893,Germany,2016,5,N02-Analgesics,"Million US$, purchasing power parity",2306.4
13894,Germany,2016,5,N06A-Antidepressants,% of total sales,2.1
13895,Germany,2016,5,N06A-Antidepressants,"Million US$, purchasing power parity",1008.6
13896,Germany,2016,5,A02A-Antacids,Million of national currency units,19.1
13897,Germany,2016,5,N05B-Anxiolytics,Million of national currency units,68.8
13898,Germany,2016,5,N06A-Antidepressants,Million US$ at exchange rate,840.3
13899,Germany,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.4
13900,Greece,2016,3,N02-Analgesics,Million of national currency units,143.3
13901,Greece,2016,3,N05B-Anxiolytics,Million US$ at exchange rate,23.7
13902,Greece,2016,3,N05B-Anxiolytics,Million of national currency units,21.4
13903,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,66.5
13904,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,73.6
13905,Greece,2016,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4
13906,Greece,2016,3,N05B-Anxiolytics,"Million US$, purchasing power parity",36.4
13907,Greece,2016,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.2
13908,Greece,2016,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.1
13909,Greece,2016,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1076.6
13910,Greece,2016,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,288.1
13911,Greece,2016,3,R03-Drugs for obstructive airway diseases,Million of national currency units,260.3
13912,Greece,2016,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",99.9
13913,Greece,2016,3,N02-Analgesics,"/capita, US$ exchange rate",14.7
13914,Greece,2016,3,N02-Analgesics,"/capita, US$ purchasing power parity",22.6
13915,Greece,2016,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,701.4
13916,Greece,2016,3,J-Antiinfectives for systemic use,Million of national currency units,633.7
13917,Greece,2016,3,N02-Analgesics,"Million US$, purchasing power parity",243.4
13918,Greece,2016,3,B-Blood and blood forming organs,Million US$ at exchange rate,1883.7
13919,Greece,2016,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",2891.3
13920,Greece,2016,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",268.3
13921,Greece,2016,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",174.8
13922,Greece,2016,3,N02-Analgesics,Million US$ at exchange rate,158.6
13923,Greece,2016,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",442.2
13924,Greece,2016,3,B-Blood and blood forming organs,Million of national currency units,1701.7
13925,Greece,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.7
13926,Greece,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",41.0
13927,Greece,2016,3,M-Musculo-skeletal system,Million of national currency units,215.5
13928,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",26.3
13929,Greece,2016,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",366.1
13930,Greece,2016,3,M-Musculo-skeletal system,Million US$ at exchange rate,238.5
13931,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,184.6
13932,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.1
13933,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",283.4
13934,Greece,2016,3,R-Respiratory system,Million of national currency units,405.5
13935,Greece,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.9
13936,Greece,2016,3,R-Respiratory system,"Million US$, purchasing power parity",688.9
13937,Greece,2016,3,R-Respiratory system,Million US$ at exchange rate,448.8
13938,Greece,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,166.8
13939,Greece,2016,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,41.3
13940,Greece,2016,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,37.3
13941,Greece,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.8
13942,Greece,2016,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",63.3
13943,Greece,2016,3,G-Genito urinary system and sex hormones,Million of national currency units,155.4
13944,Greece,2016,3,N-Nervous system,"/capita, US$ purchasing power parity",107.3
13945,Greece,2016,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",264.1
13946,Greece,2016,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,172.1
13947,Greece,2016,3,N-Nervous system,Million US$ at exchange rate,753.0
13948,Greece,2016,3,N-Nervous system,"/capita, US$ exchange rate",69.9
13949,Greece,2016,3,N-Nervous system,"Million US$, purchasing power parity",1155.8
13950,Greece,2016,3,N-Nervous system,Million of national currency units,680.3
13951,Greece,2016,3,N06A-Antidepressants,"Million US$, purchasing power parity",182.8
13952,Greece,2016,3,N06A-Antidepressants,Million of national currency units,107.6
13953,Greece,2016,3,N06A-Antidepressants,"/capita, US$ exchange rate",11.1
13954,Greece,2016,3,N06A-Antidepressants,Million US$ at exchange rate,119.1
13955,Greece,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.0
13956,Greece,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.5
13957,Greece,2016,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.0
13958,Greece,2016,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",393.4
13959,Greece,2016,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",23.8
13960,Greece,2016,3,J01-Antibacterials for systemic use,Million of national currency units,231.5
13961,Greece,2016,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,256.3
13962,Greece,2016,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",40.9
13963,Greece,2016,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",676.5
13964,Greece,2016,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",36.5
13965,Greece,2016,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",62.8
13966,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.5
13967,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",19.3
13968,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",112.9
13969,Greece,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.8
13970,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,135.8
13971,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,122.7
13972,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.6
13973,Greece,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",208.4
13974,Greece,2016,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",35.4
13975,Greece,2016,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",54.4
13976,Greece,2016,3,C10-Lipid modifying agents,Million US$ at exchange rate,381.6
13977,Greece,2016,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",585.7
13978,Greece,2016,3,R-Respiratory system,"/capita, US$ purchasing power parity",63.9
13979,Greece,2016,3,R-Respiratory system,"/capita, US$ exchange rate",41.7
13980,Greece,2016,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",34.0
13981,Greece,2016,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.1
13982,Greece,2016,3,N05C-Hypnotics and sedatives,Million of national currency units,8.2
13983,Greece,2016,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,9.1
13984,Greece,2016,3,A10-Drugs used in diabetes,Million US$ at exchange rate,440.7
13985,Greece,2016,3,A10-Drugs used in diabetes,Million of national currency units,398.2
13986,Greece,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3
13987,Greece,2016,3,C10-Lipid modifying agents,Million of national currency units,344.7
13988,Greece,2016,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.9
13989,Greece,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
13990,Greece,2016,3,C-Cardiovascular system,Million US$ at exchange rate,1039.8
13991,Greece,2016,3,C-Cardiovascular system,"Million US$, purchasing power parity",1596.1
13992,Greece,2016,3,C-Cardiovascular system,"/capita, US$ exchange rate",96.5
13993,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,362.6
13994,Greece,2016,3,C-Cardiovascular system,Million of national currency units,939.4
13995,Greece,2016,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
13996,Greece,2016,3,C03-Diuretics,"/capita, US$ purchasing power parity",5.4
13997,Greece,2016,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",148.1
13998,Greece,2016,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
13999,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.5
14000,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
14001,Greece,2016,3,A-Alimentary tract and metabolism,Million of national currency units,749.2
14002,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.2
14003,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
14004,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",616.1
14005,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,401.4
14006,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",57.2
14007,Greece,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",37.2
14008,Greece,2016,3,C03-Diuretics,"/capita, US$ exchange rate",3.5
14009,Greece,2016,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
14010,Greece,2016,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,829.3
14011,Greece,2016,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1272.9
14012,Greece,2016,3,C07-Beta blocking agents,Million of national currency units,59.7
14013,Greece,2016,3,C02-Antihypertensives,Million of national currency units,26.0
14014,Greece,2016,3,C01A-Cardiac glycosides,Million of national currency units,0.7
14015,Greece,2016,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
14016,Greece,2016,3,C07-Beta blocking agents,"Million US$, purchasing power parity",101.5
14017,Greece,2016,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2
14018,Greece,2016,3,C07-Beta blocking agents,Million US$ at exchange rate,66.1
14019,Greece,2016,3,C02-Antihypertensives,"Million US$, purchasing power parity",44.2
14020,Greece,2016,3,C02-Antihypertensives,Million US$ at exchange rate,28.8
14021,Greece,2016,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.1
14022,Greece,2016,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
14023,Greece,2016,3,A02A-Antacids,"Million US$, purchasing power parity",7.3
14024,Greece,2016,3,A02A-Antacids,Million US$ at exchange rate,4.8
14025,Greece,2016,3,A02A-Antacids,Million of national currency units,4.3
14026,Greece,2016,3,A02A-Antacids,"/capita, US$ exchange rate",0.4
14027,Greece,2016,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",77.0
14028,Greece,2016,3,C03-Diuretics,"Million US$, purchasing power parity",58.6
14029,Greece,2016,3,C03-Diuretics,Million US$ at exchange rate,38.2
14030,Greece,2016,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.9
14031,Greece,2016,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.4
14032,Greece,2016,3,C07-Beta blocking agents,"/capita, US$ exchange rate",6.1
14033,Greece,2016,3,C03-Diuretics,Million of national currency units,34.5
14034,Greece,2016,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",118.1
14035,Greece,2016,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.4
14036,Greece,2016,3,C08-Calcium channel blockers,Million US$ at exchange rate,55.6
14037,Greece,2016,3,C08-Calcium channel blockers,Million of national currency units,50.2
14038,Greece,2016,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",85.3
14039,Greece,2016,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.2
14040,Greece,2015,3,N02-Analgesics,Million of national currency units,84.1
14041,Greece,2015,3,N05B-Anxiolytics,Million US$ at exchange rate,23.0
14042,Greece,2015,3,N05B-Anxiolytics,Million of national currency units,20.7
14043,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,62.4
14044,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,69.3
14045,Greece,2015,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.1
14046,Greece,2015,3,N05B-Anxiolytics,"Million US$, purchasing power parity",34.0
14047,Greece,2015,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.1
14048,Greece,2015,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",55.2
14049,Greece,2015,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",883.7
14050,Greece,2015,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",81.7
14051,Greece,2015,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,234.7
14052,Greece,2015,3,R03-Drugs for obstructive airway diseases,Million of national currency units,211.5
14053,Greece,2015,3,N02-Analgesics,"Million US$, purchasing power parity",138.1
14054,Greece,2015,3,N02-Analgesics,"/capita, US$ exchange rate",8.6
14055,Greece,2015,3,N02-Analgesics,"/capita, US$ purchasing power parity",12.8
14056,Greece,2015,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,597.2
14057,Greece,2015,3,J-Antiinfectives for systemic use,Million of national currency units,538.2
14058,Greece,2015,3,B-Blood and blood forming organs,Million US$ at exchange rate,498.4
14059,Greece,2015,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",737.5
14060,Greece,2015,3,N02-Analgesics,Million US$ at exchange rate,93.4
14061,Greece,2015,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",68.2
14062,Greece,2015,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",46.1
14063,Greece,2015,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",347.3
14064,Greece,2015,3,B-Blood and blood forming organs,Million of national currency units,449.2
14065,Greece,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.7
14066,Greece,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.1
14067,Greece,2015,3,M-Musculo-skeletal system,Million of national currency units,187.1
14068,Greece,2015,3,R-Respiratory system,Million of national currency units,331.4
14069,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",23.5
14070,Greece,2015,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",307.1
14071,Greece,2015,3,M-Musculo-skeletal system,Million US$ at exchange rate,207.5
14072,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,172.0
14073,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",254.6
14074,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.9
14075,Greece,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.1
14076,Greece,2015,3,R-Respiratory system,Million US$ at exchange rate,367.7
14077,Greece,2015,3,R-Respiratory system,"Million US$, purchasing power parity",544.2
14078,Greece,2015,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,37.5
14079,Greece,2015,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,33.8
14080,Greece,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.5
14081,Greece,2015,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",55.5
14082,Greece,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,155.1
14083,Greece,2015,3,G-Genito urinary system and sex hormones,Million of national currency units,125.6
14084,Greece,2015,3,N-Nervous system,"/capita, US$ purchasing power parity",85.7
14085,Greece,2015,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",206.2
14086,Greece,2015,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,139.4
14087,Greece,2015,3,N-Nervous system,Million US$ at exchange rate,626.3
14088,Greece,2015,3,N-Nervous system,"Million US$, purchasing power parity",926.8
14089,Greece,2015,3,N-Nervous system,"/capita, US$ exchange rate",57.9
14090,Greece,2015,3,N-Nervous system,Million of national currency units,564.5
14091,Greece,2015,3,N06A-Antidepressants,"Million US$, purchasing power parity",172.9
14092,Greece,2015,3,N06A-Antidepressants,"/capita, US$ exchange rate",10.8
14093,Greece,2015,3,N06A-Antidepressants,Million of national currency units,105.3
14094,Greece,2015,3,N06A-Antidepressants,Million US$ at exchange rate,116.8
14095,Greece,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.1
14096,Greece,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.9
14097,Greece,2015,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.0
14098,Greece,2015,3,R-Respiratory system,"/capita, US$ exchange rate",34.0
14099,Greece,2015,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",375.1
14100,Greece,2015,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",23.4
14101,Greece,2015,3,J01-Antibacterials for systemic use,Million of national currency units,228.5
14102,Greece,2015,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,253.5
14103,Greece,2015,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.1
14104,Greece,2015,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",465.9
14105,Greece,2015,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",34.7
14106,Greece,2015,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",43.1
14107,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.5
14108,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",15.1
14109,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",102.5
14110,Greece,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.4
14111,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,110.3
14112,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,99.5
14113,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.2
14114,Greece,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",163.3
14115,Greece,2015,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",31.2
14116,Greece,2015,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",46.2
14117,Greece,2015,3,C10-Lipid modifying agents,Million US$ at exchange rate,337.8
14118,Greece,2015,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",499.9
14119,Greece,2015,3,R-Respiratory system,"/capita, US$ purchasing power parity",50.3
14120,Greece,2015,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.4
14121,Greece,2015,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.2
14122,Greece,2015,3,N05C-Hypnotics and sedatives,Million of national currency units,7.4
14123,Greece,2015,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,8.3
14124,Greece,2015,3,A10-Drugs used in diabetes,Million US$ at exchange rate,314.8
14125,Greece,2015,3,A10-Drugs used in diabetes,Million of national currency units,283.8
14126,Greece,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.1
14127,Greece,2015,3,C10-Lipid modifying agents,Million of national currency units,304.5
14128,Greece,2015,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",12.2
14129,Greece,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.8
14130,Greece,2015,3,C-Cardiovascular system,"Million US$, purchasing power parity",1454.5
14131,Greece,2015,3,C-Cardiovascular system,"/capita, US$ exchange rate",90.8
14132,Greece,2015,3,C-Cardiovascular system,Million US$ at exchange rate,982.9
14133,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,331.1
14134,Greece,2015,3,C-Cardiovascular system,Million of national currency units,885.9
14135,Greece,2015,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
14136,Greece,2015,3,C03-Diuretics,"/capita, US$ purchasing power parity",4.7
14137,Greece,2015,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",134.4
14138,Greece,2015,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
14139,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.9
14140,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
14141,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.3
14142,Greece,2015,3,A-Alimentary tract and metabolism,Million of national currency units,594.7
14143,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",543.6
14144,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,367.4
14145,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
14146,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",34.0
14147,Greece,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",50.2
14148,Greece,2015,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,659.8
14149,Greece,2015,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",976.4
14150,Greece,2015,3,C07-Beta blocking agents,Million of national currency units,57.5
14151,Greece,2015,3,C07-Beta blocking agents,Million US$ at exchange rate,63.8
14152,Greece,2015,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
14153,Greece,2015,3,C02-Antihypertensives,Million of national currency units,25.1
14154,Greece,2015,3,C01A-Cardiac glycosides,Million of national currency units,0.7
14155,Greece,2015,3,C07-Beta blocking agents,"Million US$, purchasing power parity",94.4
14156,Greece,2015,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2
14157,Greece,2015,3,A02A-Antacids,Million of national currency units,5.2
14158,Greece,2015,3,C02-Antihypertensives,"Million US$, purchasing power parity",41.3
14159,Greece,2015,3,C02-Antihypertensives,Million US$ at exchange rate,27.9
14160,Greece,2015,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
14161,Greece,2015,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.8
14162,Greece,2015,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.6
14163,Greece,2015,3,A02A-Antacids,"Million US$, purchasing power parity",8.5
14164,Greece,2015,3,A02A-Antacids,Million US$ at exchange rate,5.7
14165,Greece,2015,3,A02A-Antacids,"/capita, US$ exchange rate",0.5
14166,Greece,2015,3,C03-Diuretics,"/capita, US$ exchange rate",3.2
14167,Greece,2015,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.0
14168,Greece,2015,3,C03-Diuretics,"Million US$, purchasing power parity",50.6
14169,Greece,2015,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.6
14170,Greece,2015,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.6
14171,Greece,2015,3,C03-Diuretics,Million US$ at exchange rate,34.2
14172,Greece,2015,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.9
14173,Greece,2015,3,C03-Diuretics,Million of national currency units,30.8
14174,Greece,2015,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.7
14175,Greece,2015,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",90.2
14176,Greece,2015,3,C08-Calcium channel blockers,Million US$ at exchange rate,55.9
14177,Greece,2015,3,C08-Calcium channel blockers,Million of national currency units,50.4
14178,Greece,2015,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",82.7
14179,Greece,2015,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.2
14180,Greece,2014,3,N02-Analgesics,Million of national currency units,89.8
14181,Greece,2014,3,N05B-Anxiolytics,Million US$ at exchange rate,26.8
14182,Greece,2014,3,N05B-Anxiolytics,Million of national currency units,20.2
14183,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,66.0
14184,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,87.7
14185,Greece,2014,3,N05B-Anxiolytics,"Million US$, purchasing power parity",33.1
14186,Greece,2014,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.5
14187,Greece,2014,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.0
14188,Greece,2014,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.9
14189,Greece,2014,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",897.0
14190,Greece,2014,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",82.4
14191,Greece,2014,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,328.5
14192,Greece,2014,3,R03-Drugs for obstructive airway diseases,Million of national currency units,247.3
14193,Greece,2014,3,N02-Analgesics,"Million US$, purchasing power parity",146.9
14194,Greece,2014,3,N02-Analgesics,"/capita, US$ exchange rate",10.9
14195,Greece,2014,3,N02-Analgesics,"/capita, US$ purchasing power parity",13.5
14196,Greece,2014,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,728.3
14197,Greece,2014,3,J-Antiinfectives for systemic use,Million of national currency units,548.2
14198,Greece,2014,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",805.1
14199,Greece,2014,3,B-Blood and blood forming organs,Million US$ at exchange rate,653.6
14200,Greece,2014,3,N02-Analgesics,Million US$ at exchange rate,119.2
14201,Greece,2014,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",73.9
14202,Greece,2014,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",60.0
14203,Greece,2014,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",404.6
14204,Greece,2014,3,B-Blood and blood forming organs,Million of national currency units,492.0
14205,Greece,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.2
14206,Greece,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",37.1
14207,Greece,2014,3,M-Musculo-skeletal system,Million of national currency units,211.4
14208,Greece,2014,3,R-Respiratory system,Million of national currency units,365.1
14209,Greece,2014,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",345.8
14210,Greece,2014,3,M-Musculo-skeletal system,Million US$ at exchange rate,280.8
14211,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",24.3
14212,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,214.6
14213,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",264.3
14214,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",19.7
14215,Greece,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.1
14216,Greece,2014,3,R-Respiratory system,Million US$ at exchange rate,485.1
14217,Greece,2014,3,R-Respiratory system,"Million US$, purchasing power parity",597.5
14218,Greece,2014,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,53.9
14219,Greece,2014,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,40.6
14220,Greece,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.9
14221,Greece,2014,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.4
14222,Greece,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,161.5
14223,Greece,2014,3,G-Genito urinary system and sex hormones,Million of national currency units,152.6
14224,Greece,2014,3,N-Nervous system,"/capita, US$ purchasing power parity",99.9
14225,Greece,2014,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",249.7
14226,Greece,2014,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,202.7
14227,Greece,2014,3,N-Nervous system,Million US$ at exchange rate,883.7
14228,Greece,2014,3,N-Nervous system,"Million US$, purchasing power parity",1088.5
14229,Greece,2014,3,N-Nervous system,"/capita, US$ exchange rate",81.1
14230,Greece,2014,3,N-Nervous system,Million of national currency units,665.2
14231,Greece,2014,3,N06A-Antidepressants,"Million US$, purchasing power parity",195.1
14232,Greece,2014,3,N06A-Antidepressants,"/capita, US$ exchange rate",14.5
14233,Greece,2014,3,N06A-Antidepressants,Million of national currency units,119.2
14234,Greece,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.9
14235,Greece,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.6
14236,Greece,2014,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.9
14237,Greece,2014,3,R-Respiratory system,"/capita, US$ exchange rate",44.5
14238,Greece,2014,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",385.9
14239,Greece,2014,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",28.8
14240,Greece,2014,3,J01-Antibacterials for systemic use,Million of national currency units,235.9
14241,Greece,2014,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,313.3
14242,Greece,2014,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",37.3
14243,Greece,2014,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",500.8
14244,Greece,2014,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",46.0
14245,Greece,2014,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",35.4
14246,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.9
14247,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",17.4
14248,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",108.1
14249,Greece,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.1
14250,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,153.7
14251,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,115.7
14252,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.1
14253,Greece,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",189.3
14254,Greece,2014,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",42.5
14255,Greece,2014,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",52.4
14256,Greece,2014,3,C10-Lipid modifying agents,Million US$ at exchange rate,463.0
14257,Greece,2014,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",570.3
14258,Greece,2014,3,R-Respiratory system,"/capita, US$ purchasing power parity",54.9
14259,Greece,2014,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",31.7
14260,Greece,2014,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.8
14261,Greece,2014,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,11.9
14262,Greece,2014,3,N05C-Hypnotics and sedatives,Million of national currency units,8.9
14263,Greece,2014,3,A10-Drugs used in diabetes,Million US$ at exchange rate,406.6
14264,Greece,2014,3,A10-Drugs used in diabetes,Million of national currency units,306.1
14265,Greece,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3
14266,Greece,2014,3,C10-Lipid modifying agents,Million of national currency units,348.5
14267,Greece,2014,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.6
14268,Greece,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1
14269,Greece,2014,3,N06A-Antidepressants,Million US$ at exchange rate,158.4
14270,Greece,2014,3,C-Cardiovascular system,"Million US$, purchasing power parity",1560.8
14271,Greece,2014,3,C-Cardiovascular system,"/capita, US$ exchange rate",116.3
14272,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,364.8
14273,Greece,2014,3,C-Cardiovascular system,Million US$ at exchange rate,1267.2
14274,Greece,2014,3,C-Cardiovascular system,Million of national currency units,953.9
14275,Greece,2014,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
14276,Greece,2014,3,C03-Diuretics,"/capita, US$ purchasing power parity",5.5
14277,Greece,2014,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",143.3
14278,Greece,2014,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
14279,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.4
14280,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
14281,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.4
14282,Greece,2014,3,A-Alimentary tract and metabolism,Million of national currency units,634.9
14283,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
14284,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",596.9
14285,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,484.6
14286,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",44.5
14287,Greece,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",54.8
14288,Greece,2014,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1038.9
14289,Greece,2014,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,843.5
14290,Greece,2014,3,C07-Beta blocking agents,Million of national currency units,58.7
14291,Greece,2014,3,C07-Beta blocking agents,Million US$ at exchange rate,78.0
14292,Greece,2014,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.2
14293,Greece,2014,3,C01A-Cardiac glycosides,Million of national currency units,0.9
14294,Greece,2014,3,C02-Antihypertensives,Million of national currency units,25.2
14295,Greece,2014,3,C07-Beta blocking agents,"Million US$, purchasing power parity",96.0
14296,Greece,2014,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
14297,Greece,2014,3,C02-Antihypertensives,"Million US$, purchasing power parity",41.2
14298,Greece,2014,3,C02-Antihypertensives,Million US$ at exchange rate,33.5
14299,Greece,2014,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
14300,Greece,2014,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.8
14301,Greece,2014,3,C02-Antihypertensives,"/capita, US$ exchange rate",3.1
14302,Greece,2014,3,A02A-Antacids,Million of national currency units,5.5
14303,Greece,2014,3,A02A-Antacids,"Million US$, purchasing power parity",8.9
14304,Greece,2014,3,A02A-Antacids,Million US$ at exchange rate,7.2
14305,Greece,2014,3,A02A-Antacids,"/capita, US$ exchange rate",0.7
14306,Greece,2014,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",77.4
14307,Greece,2014,3,C03-Diuretics,"Million US$, purchasing power parity",59.5
14308,Greece,2014,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",8.4
14309,Greece,2014,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.4
14310,Greece,2014,3,C03-Diuretics,Million US$ at exchange rate,48.3
14311,Greece,2014,3,C07-Beta blocking agents,"/capita, US$ exchange rate",7.2
14312,Greece,2014,3,C03-Diuretics,"/capita, US$ exchange rate",4.4
14313,Greece,2014,3,C03-Diuretics,Million of national currency units,36.3
14314,Greece,2014,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.8
14315,Greece,2014,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",95.4
14316,Greece,2014,3,C08-Calcium channel blockers,Million US$ at exchange rate,74.3
14317,Greece,2014,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",91.6
14318,Greece,2014,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.8
14319,Greece,2014,3,C08-Calcium channel blockers,Million of national currency units,56.0
14320,Greece,2013,3,N02-Analgesics,Million of national currency units,82.9
14321,Greece,2013,3,N05B-Anxiolytics,Million of national currency units,21.8
14322,Greece,2013,3,N05B-Anxiolytics,Million US$ at exchange rate,29.0
14323,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,67.6
14324,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,89.8
14325,Greece,2013,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.2
14326,Greece,2013,3,N05B-Anxiolytics,"Million US$, purchasing power parity",34.6
14327,Greece,2013,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.6
14328,Greece,2013,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",74.9
14329,Greece,2013,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",62.8
14330,Greece,2013,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",821.3
14331,Greece,2013,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,328.4
14332,Greece,2013,3,R03-Drugs for obstructive airway diseases,Million of national currency units,247.3
14333,Greece,2013,3,N02-Analgesics,"Million US$, purchasing power parity",131.4
14334,Greece,2013,3,N02-Analgesics,"/capita, US$ exchange rate",10.0
14335,Greece,2013,3,N02-Analgesics,"/capita, US$ purchasing power parity",12.0
14336,Greece,2013,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,688.6
14337,Greece,2013,3,J-Antiinfectives for systemic use,Million of national currency units,518.5
14338,Greece,2013,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",734.5
14339,Greece,2013,3,B-Blood and blood forming organs,Million US$ at exchange rate,615.8
14340,Greece,2013,3,N02-Analgesics,Million US$ at exchange rate,110.1
14341,Greece,2013,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",67.0
14342,Greece,2013,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",56.2
14343,Greece,2013,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",391.7
14344,Greece,2013,3,B-Blood and blood forming organs,Million of national currency units,463.7
14345,Greece,2013,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.9
14346,Greece,2013,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",35.7
14347,Greece,2013,3,M-Musculo-skeletal system,Million of national currency units,221.0
14348,Greece,2013,3,R-Respiratory system,Million of national currency units,359.2
14349,Greece,2013,3,M-Musculo-skeletal system,Million US$ at exchange rate,293.6
14350,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",26.0
14351,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,239.0
14352,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",285.1
14353,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.8
14354,Greece,2013,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.6
14355,Greece,2013,3,R-Respiratory system,Million US$ at exchange rate,477.0
14356,Greece,2013,3,R-Respiratory system,"Million US$, purchasing power parity",568.9
14357,Greece,2013,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,51.3
14358,Greece,2013,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,38.6
14359,Greece,2013,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.7
14360,Greece,2013,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",61.2
14361,Greece,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,180.0
14362,Greece,2013,3,G-Genito urinary system and sex hormones,Million of national currency units,149.0
14363,Greece,2013,3,N-Nervous system,"/capita, US$ purchasing power parity",102.1
14364,Greece,2013,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",236.0
14365,Greece,2013,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,197.9
14366,Greece,2013,3,N-Nervous system,Million US$ at exchange rate,938.7
14367,Greece,2013,3,N-Nervous system,"Million US$, purchasing power parity",1119.6
14368,Greece,2013,3,N-Nervous system,"/capita, US$ exchange rate",85.6
14369,Greece,2013,3,N-Nervous system,Million of national currency units,706.8
14370,Greece,2013,3,N06A-Antidepressants,"Million US$, purchasing power parity",213.8
14371,Greece,2013,3,N06A-Antidepressants,"/capita, US$ exchange rate",16.3
14372,Greece,2013,3,N06A-Antidepressants,Million of national currency units,134.9
14373,Greece,2013,3,N06A-Antidepressants,Million US$ at exchange rate,179.2
14374,Greece,2013,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.5
14375,Greece,2013,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.0
14376,Greece,2013,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.5
14377,Greece,2013,3,R-Respiratory system,"/capita, US$ exchange rate",43.5
14378,Greece,2013,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",360.1
14379,Greece,2013,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",27.5
14380,Greece,2013,3,J01-Antibacterials for systemic use,Million of national currency units,227.4
14381,Greece,2013,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,301.9
14382,Greece,2013,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",34.7
14383,Greece,2013,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",453.7
14384,Greece,2013,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",41.4
14385,Greece,2013,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",32.8
14386,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.8
14387,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",16.6
14388,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",107.1
14389,Greece,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.2
14390,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,152.3
14391,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,114.7
14392,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.9
14393,Greece,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",181.7
14394,Greece,2013,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",43.8
14395,Greece,2013,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",52.3
14396,Greece,2013,3,C10-Lipid modifying agents,Million US$ at exchange rate,480.8
14397,Greece,2013,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",573.4
14398,Greece,2013,3,R-Respiratory system,"/capita, US$ purchasing power parity",51.9
14399,Greece,2013,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",31.9
14400,Greece,2013,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",26.8
14401,Greece,2013,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,10.9
14402,Greece,2013,3,N05C-Hypnotics and sedatives,Million of national currency units,8.2
14403,Greece,2013,3,A10-Drugs used in diabetes,Million US$ at exchange rate,380.4
14404,Greece,2013,3,A10-Drugs used in diabetes,Million of national currency units,286.4
14405,Greece,2013,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2
14406,Greece,2013,3,C10-Lipid modifying agents,Million of national currency units,362.0
14407,Greece,2013,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.0
14408,Greece,2013,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0
14409,Greece,2013,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",350.1
14410,Greece,2013,3,C-Cardiovascular system,"Million US$, purchasing power parity",1612.5
14411,Greece,2013,3,C-Cardiovascular system,"/capita, US$ exchange rate",123.3
14412,Greece,2013,3,C-Cardiovascular system,Million US$ at exchange rate,1352.0
14413,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,400.1
14414,Greece,2013,3,C-Cardiovascular system,Million of national currency units,1018.0
14415,Greece,2013,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
14416,Greece,2013,3,C03-Diuretics,"/capita, US$ purchasing power parity",5.5
14417,Greece,2013,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",147.1
14418,Greece,2013,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
14419,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.3
14420,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
14421,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
14422,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.6
14423,Greece,2013,3,A-Alimentary tract and metabolism,Million of national currency units,630.1
14424,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",633.7
14425,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,531.3
14426,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",48.5
14427,Greece,2013,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",57.8
14428,Greece,2013,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",998.1
14429,Greece,2013,3,C08-Calcium channel blockers,Million of national currency units,61.0
14430,Greece,2013,3,C07-Beta blocking agents,Million of national currency units,64.2
14431,Greece,2013,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,836.8
14432,Greece,2013,3,C07-Beta blocking agents,Million US$ at exchange rate,85.2
14433,Greece,2013,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3
14434,Greece,2013,3,C02-Antihypertensives,Million of national currency units,27.0
14435,Greece,2013,3,C01A-Cardiac glycosides,Million of national currency units,1.0
14436,Greece,2013,3,C07-Beta blocking agents,"Million US$, purchasing power parity",101.7
14437,Greece,2013,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
14438,Greece,2013,3,A02A-Antacids,Million of national currency units,5.6
14439,Greece,2013,3,C02-Antihypertensives,"Million US$, purchasing power parity",42.8
14440,Greece,2013,3,C02-Antihypertensives,Million US$ at exchange rate,35.9
14441,Greece,2013,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
14442,Greece,2013,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.9
14443,Greece,2013,3,C02-Antihypertensives,"/capita, US$ exchange rate",3.3
14444,Greece,2013,3,A02A-Antacids,"Million US$, purchasing power parity",8.9
14445,Greece,2013,3,A02A-Antacids,Million US$ at exchange rate,7.4
14446,Greece,2013,3,A02A-Antacids,"/capita, US$ exchange rate",0.7
14447,Greece,2013,3,C03-Diuretics,"/capita, US$ exchange rate",4.6
14448,Greece,2013,3,C03-Diuretics,"Million US$, purchasing power parity",60.5
14449,Greece,2013,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",76.3
14450,Greece,2013,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",8.8
14451,Greece,2013,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.5
14452,Greece,2013,3,C03-Diuretics,Million US$ at exchange rate,50.7
14453,Greece,2013,3,C07-Beta blocking agents,"/capita, US$ exchange rate",7.8
14454,Greece,2013,3,C03-Diuretics,Million of national currency units,38.2
14455,Greece,2013,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.3
14456,Greece,2013,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",91.0
14457,Greece,2013,3,C08-Calcium channel blockers,Million US$ at exchange rate,81.0
14458,Greece,2013,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",96.7
14459,Greece,2013,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.4
14460,Greece,2012,3,N05B-Anxiolytics,Million of national currency units,21.1
14461,Greece,2012,3,N02-Analgesics,Million of national currency units,84.3
14462,Greece,2012,3,N05B-Anxiolytics,Million US$ at exchange rate,27.1
14463,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,74.2
14464,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,95.3
14465,Greece,2012,3,N05B-Anxiolytics,"Million US$, purchasing power parity",30.8
14466,Greece,2012,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.8
14467,Greece,2012,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.5
14468,Greece,2012,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",79.4
14469,Greece,2012,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.9
14470,Greece,2012,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",877.1
14471,Greece,2012,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,356.9
14472,Greece,2012,3,R03-Drugs for obstructive airway diseases,Million of national currency units,277.8
14473,Greece,2012,3,N02-Analgesics,"Million US$, purchasing power parity",123.2
14474,Greece,2012,3,N02-Analgesics,"/capita, US$ exchange rate",9.8
14475,Greece,2012,3,N02-Analgesics,"/capita, US$ purchasing power parity",11.2
14476,Greece,2012,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,771.6
14477,Greece,2012,3,J-Antiinfectives for systemic use,Million of national currency units,600.5
14478,Greece,2012,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",744.8
14479,Greece,2012,3,B-Blood and blood forming organs,Million US$ at exchange rate,655.1
14480,Greece,2012,3,N02-Analgesics,Million US$ at exchange rate,108.4
14481,Greece,2012,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",67.4
14482,Greece,2012,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",59.3
14483,Greece,2012,3,B-Blood and blood forming organs,Million of national currency units,509.9
14484,Greece,2012,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",405.7
14485,Greece,2012,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.3
14486,Greece,2012,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",36.7
14487,Greece,2012,3,A10-Drugs used in diabetes,Million US$ at exchange rate,361.1
14488,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",108.4
14489,Greece,2012,3,M-Musculo-skeletal system,Million of national currency units,245.0
14490,Greece,2012,3,R-Respiratory system,Million of national currency units,398.3
14491,Greece,2012,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",357.8
14492,Greece,2012,3,M-Musculo-skeletal system,Million US$ at exchange rate,314.8
14493,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",29.5
14494,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,286.4
14495,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",325.6
14496,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",25.9
14497,Greece,2012,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.6
14498,Greece,2012,3,R-Respiratory system,Million US$ at exchange rate,511.7
14499,Greece,2012,3,R-Respiratory system,"Million US$, purchasing power parity",581.7
14500,Greece,2012,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,64.5
14501,Greece,2012,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,50.2
14502,Greece,2012,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.8
14503,Greece,2012,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",73.3
14504,Greece,2012,3,G-Genito urinary system and sex hormones,Million of national currency units,161.3
14505,Greece,2012,3,N-Nervous system,"/capita, US$ purchasing power parity",104.5
14506,Greece,2012,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",235.6
14507,Greece,2012,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,207.3
14508,Greece,2012,3,N-Nervous system,Million US$ at exchange rate,1015.0
14509,Greece,2012,3,N-Nervous system,"Million US$, purchasing power parity",1153.9
14510,Greece,2012,3,N-Nervous system,"/capita, US$ exchange rate",91.9
14511,Greece,2012,3,N-Nervous system,Million of national currency units,790.0
14512,Greece,2012,3,R-Respiratory system,"/capita, US$ exchange rate",46.3
14513,Greece,2012,3,N06A-Antidepressants,"Million US$, purchasing power parity",200.0
14514,Greece,2012,3,N06A-Antidepressants,"/capita, US$ exchange rate",15.9
14515,Greece,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,222.9
14516,Greece,2012,3,N06A-Antidepressants,Million of national currency units,137.0
14517,Greece,2012,3,N06A-Antidepressants,Million US$ at exchange rate,176.0
14518,Greece,2012,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.3
14519,Greece,2012,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.8
14520,Greece,2012,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",18.1
14521,Greece,2012,3,A10-Drugs used in diabetes,Million of national currency units,281.1
14522,Greece,2012,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",34.2
14523,Greece,2012,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",429.6
14524,Greece,2012,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,377.9
14525,Greece,2012,3,J01-Antibacterials for systemic use,Million of national currency units,294.1
14526,Greece,2012,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.7
14527,Greece,2012,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.2
14528,Greece,2012,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",38.9
14529,Greece,2012,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",410.6
14530,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",18.0
14531,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.8
14532,Greece,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.6
14533,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,175.2
14534,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,136.4
14535,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.9
14536,Greece,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",199.2
14537,Greece,2012,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",50.6
14538,Greece,2012,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",57.5
14539,Greece,2012,3,C10-Lipid modifying agents,Million US$ at exchange rate,558.8
14540,Greece,2012,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",635.2
14541,Greece,2012,3,R-Respiratory system,"/capita, US$ purchasing power parity",52.7
14542,Greece,2012,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",32.4
14543,Greece,2012,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",28.5
14544,Greece,2012,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,11.4
14545,Greece,2012,3,N05C-Hypnotics and sedatives,Million of national currency units,8.9
14546,Greece,2012,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2
14547,Greece,2012,3,C10-Lipid modifying agents,Million of national currency units,434.9
14548,Greece,2012,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.0
14549,Greece,2012,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0
14550,Greece,2012,3,C08-Calcium channel blockers,Million of national currency units,68.8
14551,Greece,2012,3,C-Cardiovascular system,"Million US$, purchasing power parity",1748.1
14552,Greece,2012,3,C-Cardiovascular system,"/capita, US$ exchange rate",139.2
14553,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,473.3
14554,Greece,2012,3,C-Cardiovascular system,Million of national currency units,1196.9
14555,Greece,2012,3,C-Cardiovascular system,Million US$ at exchange rate,1537.7
14556,Greece,2012,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
14557,Greece,2012,3,C03-Diuretics,"/capita, US$ purchasing power parity",4.9
14558,Greece,2012,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",158.3
14559,Greece,2012,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
14560,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.5
14561,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
14562,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
14563,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.5
14564,Greece,2012,3,A-Alimentary tract and metabolism,Million of national currency units,678.3
14565,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",691.2
14566,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,608.0
14567,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",55.1
14568,Greece,2012,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",62.6
14569,Greece,2012,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",990.7
14570,Greece,2012,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,871.5
14571,Greece,2012,3,C07-Beta blocking agents,Million of national currency units,79.9
14572,Greece,2012,3,C07-Beta blocking agents,Million US$ at exchange rate,102.6
14573,Greece,2012,3,A02A-Antacids,Million of national currency units,5.3
14574,Greece,2012,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5
14575,Greece,2012,3,C02-Antihypertensives,Million of national currency units,32.3
14576,Greece,2012,3,C01A-Cardiac glycosides,Million of national currency units,1.2
14577,Greece,2012,3,C07-Beta blocking agents,"Million US$, purchasing power parity",116.7
14578,Greece,2012,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7
14579,Greece,2012,3,C02-Antihypertensives,"Million US$, purchasing power parity",47.2
14580,Greece,2012,3,C02-Antihypertensives,Million US$ at exchange rate,41.5
14581,Greece,2012,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
14582,Greece,2012,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.3
14583,Greece,2012,3,C02-Antihypertensives,"/capita, US$ exchange rate",3.8
14584,Greece,2012,3,A02A-Antacids,"Million US$, purchasing power parity",7.8
14585,Greece,2012,3,A02A-Antacids,Million US$ at exchange rate,6.9
14586,Greece,2012,3,A02A-Antacids,"/capita, US$ exchange rate",0.6
14587,Greece,2012,3,C03-Diuretics,"Million US$, purchasing power parity",53.9
14588,Greece,2012,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",78.9
14589,Greece,2012,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,5.8
14590,Greece,2012,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.6
14591,Greece,2012,3,C03-Diuretics,Million of national currency units,36.9
14592,Greece,2012,3,C07-Beta blocking agents,"/capita, US$ exchange rate",9.3
14593,Greece,2012,3,C03-Diuretics,Million US$ at exchange rate,47.4
14594,Greece,2012,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",89.7
14595,Greece,2012,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",9.1
14596,Greece,2012,3,C08-Calcium channel blockers,Million US$ at exchange rate,88.4
14597,Greece,2012,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",100.5
14598,Greece,2012,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",8.0
14599,Greece,2012,3,C03-Diuretics,"/capita, US$ exchange rate",4.3
14600,Greece,2011,3,N02-Analgesics,Million of national currency units,80.9
14601,Greece,2011,3,N05B-Anxiolytics,Million US$ at exchange rate,31.4
14602,Greece,2011,3,N05B-Anxiolytics,Million of national currency units,22.6
14603,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,83.3
14604,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,115.9
14605,Greece,2011,3,N05B-Anxiolytics,"Million US$, purchasing power parity",31.7
14606,Greece,2011,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.9
14607,Greece,2011,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.8
14608,Greece,2011,3,N02-Analgesics,Million US$ at exchange rate,112.7
14609,Greece,2011,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",87.6
14610,Greece,2011,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",86.9
14611,Greece,2011,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,438.4
14612,Greece,2011,3,R03-Drugs for obstructive airway diseases,Million of national currency units,315.0
14613,Greece,2011,3,N02-Analgesics,"Million US$, purchasing power parity",113.5
14614,Greece,2011,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",972.4
14615,Greece,2011,3,N02-Analgesics,"/capita, US$ exchange rate",10.1
14616,Greece,2011,3,N02-Analgesics,"/capita, US$ purchasing power parity",10.2
14617,Greece,2011,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,965.3
14618,Greece,2011,3,J-Antiinfectives for systemic use,Million of national currency units,693.5
14619,Greece,2011,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",812.5
14620,Greece,2011,3,B-Blood and blood forming organs,Million US$ at exchange rate,806.5
14621,Greece,2011,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",73.2
14622,Greece,2011,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",72.6
14623,Greece,2011,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",39.5
14624,Greece,2011,3,B-Blood and blood forming organs,Million of national currency units,579.4
14625,Greece,2011,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",441.7
14626,Greece,2011,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",39.8
14627,Greece,2011,3,M-Musculo-skeletal system,Million of national currency units,275.8
14628,Greece,2011,3,R-Respiratory system,Million of national currency units,451.6
14629,Greece,2011,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",386.7
14630,Greece,2011,3,M-Musculo-skeletal system,Million US$ at exchange rate,383.9
14631,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",371.2
14632,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,368.5
14633,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",33.4
14634,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",33.2
14635,Greece,2011,3,R-Respiratory system,Million US$ at exchange rate,628.6
14636,Greece,2011,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.2
14637,Greece,2011,3,R-Respiratory system,"/capita, US$ exchange rate",56.6
14638,Greece,2011,3,R-Respiratory system,"Million US$, purchasing power parity",633.2
14639,Greece,2011,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,90.9
14640,Greece,2011,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,65.3
14641,Greece,2011,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.2
14642,Greece,2011,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",91.6
14643,Greece,2011,3,G-Genito urinary system and sex hormones,Million of national currency units,191.1
14644,Greece,2011,3,N-Nervous system,"/capita, US$ purchasing power parity",115.4
14645,Greece,2011,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",268.0
14646,Greece,2011,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,266.0
14647,Greece,2011,3,N-Nervous system,Million US$ at exchange rate,1272.3
14648,Greece,2011,3,N-Nervous system,"Million US$, purchasing power parity",1281.7
14649,Greece,2011,3,N-Nervous system,"/capita, US$ exchange rate",114.6
14650,Greece,2011,3,N-Nervous system,Million of national currency units,914.1
14651,Greece,2011,3,N06A-Antidepressants,"Million US$, purchasing power parity",218.9
14652,Greece,2011,3,N06A-Antidepressants,"/capita, US$ exchange rate",19.6
14653,Greece,2011,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,264.7
14654,Greece,2011,3,N06A-Antidepressants,Million of national currency units,156.1
14655,Greece,2011,3,N06A-Antidepressants,Million US$ at exchange rate,217.3
14656,Greece,2011,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.1
14657,Greece,2011,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",24.0
14658,Greece,2011,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.7
14659,Greece,2011,3,A10-Drugs used in diabetes,Million of national currency units,277.3
14660,Greece,2011,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",42.7
14661,Greece,2011,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",477.7
14662,Greece,2011,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,474.2
14663,Greece,2011,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",34.8
14664,Greece,2011,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.0
14665,Greece,2011,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",43.0
14666,Greece,2011,3,J01-Antibacterials for systemic use,Million of national currency units,340.7
14667,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",19.8
14668,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.5
14669,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.4
14670,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,218.8
14671,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,157.2
14672,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",19.7
14673,Greece,2011,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",220.4
14674,Greece,2011,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",116.8
14675,Greece,2011,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",388.9
14676,Greece,2011,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",60.2
14677,Greece,2011,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",60.6
14678,Greece,2011,3,C10-Lipid modifying agents,Million US$ at exchange rate,668.5
14679,Greece,2011,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",673.5
14680,Greece,2011,3,R-Respiratory system,"/capita, US$ purchasing power parity",57.0
14681,Greece,2011,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",34.6
14682,Greece,2011,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",34.8
14683,Greece,2011,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.2
14684,Greece,2011,3,N05C-Hypnotics and sedatives,Million of national currency units,10.2
14685,Greece,2011,3,A10-Drugs used in diabetes,Million US$ at exchange rate,386.1
14686,Greece,2011,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3
14687,Greece,2011,3,C10-Lipid modifying agents,Million of national currency units,480.3
14688,Greece,2011,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.3
14689,Greece,2011,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3
14690,Greece,2011,3,C-Cardiovascular system,"Million US$, purchasing power parity",1843.2
14691,Greece,2011,3,C-Cardiovascular system,"/capita, US$ exchange rate",164.8
14692,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,523.1
14693,Greece,2011,3,C-Cardiovascular system,Million of national currency units,1314.5
14694,Greece,2011,3,C-Cardiovascular system,Million US$ at exchange rate,1829.7
14695,Greece,2011,3,C03-Diuretics,"/capita, US$ purchasing power parity",4.5
14696,Greece,2011,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
14697,Greece,2011,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",166.0
14698,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
14699,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
14700,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.7
14701,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.7
14702,Greece,2011,3,A-Alimentary tract and metabolism,Million of national currency units,743.9
14703,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",65.6
14704,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",733.5
14705,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,728.2
14706,Greece,2011,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1043.1
14707,Greece,2011,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",93.2
14708,Greece,2011,3,A02A-Antacids,Million of national currency units,6.0
14709,Greece,2011,3,C07-Beta blocking agents,Million of national currency units,81.7
14710,Greece,2011,3,C07-Beta blocking agents,Million US$ at exchange rate,113.7
14711,Greece,2011,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,1035.5
14712,Greece,2011,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.6
14713,Greece,2011,3,C02-Antihypertensives,Million of national currency units,39.3
14714,Greece,2011,3,C01A-Cardiac glycosides,Million of national currency units,1.2
14715,Greece,2011,3,C07-Beta blocking agents,"Million US$, purchasing power parity",114.5
14716,Greece,2011,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6
14717,Greece,2011,3,C02-Antihypertensives,"Million US$, purchasing power parity",55.1
14718,Greece,2011,3,C02-Antihypertensives,Million US$ at exchange rate,54.7
14719,Greece,2011,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
14720,Greece,2011,3,C02-Antihypertensives,"/capita, US$ exchange rate",4.9
14721,Greece,2011,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.0
14722,Greece,2011,3,A02A-Antacids,"Million US$, purchasing power parity",8.4
14723,Greece,2011,3,A02A-Antacids,Million US$ at exchange rate,8.4
14724,Greece,2011,3,A02A-Antacids,"/capita, US$ exchange rate",0.8
14725,Greece,2011,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
14726,Greece,2011,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",66.1
14727,Greece,2011,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",93.9
14728,Greece,2011,3,C03-Diuretics,"Million US$, purchasing power parity",50.1
14729,Greece,2011,3,C08-Calcium channel blockers,Million of national currency units,77.7
14730,Greece,2011,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,6.2
14731,Greece,2011,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.3
14732,Greece,2011,3,C07-Beta blocking agents,"/capita, US$ exchange rate",10.2
14733,Greece,2011,3,C03-Diuretics,Million of national currency units,35.7
14734,Greece,2011,3,C03-Diuretics,Million US$ at exchange rate,49.7
14735,Greece,2011,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",9.8
14736,Greece,2011,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",9.7
14737,Greece,2011,3,C08-Calcium channel blockers,Million US$ at exchange rate,108.1
14738,Greece,2011,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",108.9
14739,Greece,2011,3,C03-Diuretics,"/capita, US$ exchange rate",4.5
14740,Greece,2010,3,N02-Analgesics,Million of national currency units,76.5
14741,Greece,2010,3,N05B-Anxiolytics,Million US$ at exchange rate,29.5
14742,Greece,2010,3,N05B-Anxiolytics,Million of national currency units,22.3
14743,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,101.4
14744,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,134.5
14745,Greece,2010,3,N05B-Anxiolytics,"Million US$, purchasing power parity",30.8
14746,Greece,2010,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7
14747,Greece,2010,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.8
14748,Greece,2010,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",93.2
14749,Greece,2010,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",89.2
14750,Greece,2010,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,427.1
14751,Greece,2010,3,R03-Drugs for obstructive airway diseases,Million of national currency units,322.2
14752,Greece,2010,3,N02-Analgesics,"Million US$, purchasing power parity",106.0
14753,Greece,2010,3,N02-Analgesics,"/capita, US$ exchange rate",9.1
14754,Greece,2010,3,N02-Analgesics,"/capita, US$ purchasing power parity",9.5
14755,Greece,2010,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1036.8
14756,Greece,2010,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,992.4
14757,Greece,2010,3,J-Antiinfectives for systemic use,Million of national currency units,748.6
14758,Greece,2010,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",891.6
14759,Greece,2010,3,B-Blood and blood forming organs,Million US$ at exchange rate,853.4
14760,Greece,2010,3,N02-Analgesics,Million US$ at exchange rate,101.4
14761,Greece,2010,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",80.2
14762,Greece,2010,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",76.7
14763,Greece,2010,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.4
14764,Greece,2010,3,B-Blood and blood forming organs,Million of national currency units,643.7
14765,Greece,2010,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",446.2
14766,Greece,2010,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",40.1
14767,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",140.5
14768,Greece,2010,3,M-Musculo-skeletal system,Million of national currency units,317.4
14769,Greece,2010,3,R-Respiratory system,Million of national currency units,459.6
14770,Greece,2010,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",439.6
14771,Greece,2010,3,M-Musculo-skeletal system,Million US$ at exchange rate,420.8
14772,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",444.8
14773,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,425.8
14774,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",40.0
14775,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",38.3
14776,Greece,2010,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,67.5
14777,Greece,2010,3,R-Respiratory system,Million US$ at exchange rate,609.3
14778,Greece,2010,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.4
14779,Greece,2010,3,R-Respiratory system,"/capita, US$ exchange rate",54.8
14780,Greece,2010,3,R-Respiratory system,"Million US$, purchasing power parity",636.5
14781,Greece,2010,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,89.4
14782,Greece,2010,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.0
14783,Greece,2010,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",93.4
14784,Greece,2010,3,G-Genito urinary system and sex hormones,Million of national currency units,211.3
14785,Greece,2010,3,N-Nervous system,"/capita, US$ purchasing power parity",130.0
14786,Greece,2010,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",292.6
14787,Greece,2010,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,280.1
14788,Greece,2010,3,N-Nervous system,Million US$ at exchange rate,1383.9
14789,Greece,2010,3,N-Nervous system,"Million US$, purchasing power parity",1445.8
14790,Greece,2010,3,N-Nervous system,"/capita, US$ exchange rate",124.4
14791,Greece,2010,3,N-Nervous system,Million of national currency units,1043.9
14792,Greece,2010,3,N06A-Antidepressants,"Million US$, purchasing power parity",258.4
14793,Greece,2010,3,N06A-Antidepressants,"/capita, US$ exchange rate",22.2
14794,Greece,2010,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,321.2
14795,Greece,2010,3,N06A-Antidepressants,Million of national currency units,186.6
14796,Greece,2010,3,N06A-Antidepressants,Million US$ at exchange rate,247.4
14797,Greece,2010,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.3
14798,Greece,2010,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.2
14799,Greece,2010,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",23.2
14800,Greece,2010,3,A10-Drugs used in diabetes,Million of national currency units,303.2
14801,Greece,2010,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",43.6
14802,Greece,2010,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",507.1
14803,Greece,2010,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,485.4
14804,Greece,2010,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.1
14805,Greece,2010,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",45.6
14806,Greece,2010,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.8
14807,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,169.2
14808,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",21.1
14809,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.6
14810,Greece,2010,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.1
14811,Greece,2010,3,J01-Antibacterials for systemic use,Million of national currency units,366.1
14812,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,224.2
14813,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",20.2
14814,Greece,2010,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",234.3
14815,Greece,2010,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",64.8
14816,Greece,2010,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",67.7
14817,Greece,2010,3,C10-Lipid modifying agents,Million US$ at exchange rate,720.2
14818,Greece,2010,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",752.5
14819,Greece,2010,3,R-Respiratory system,"/capita, US$ purchasing power parity",57.2
14820,Greece,2010,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",37.8
14821,Greece,2010,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",39.5
14822,Greece,2010,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",419.9
14823,Greece,2010,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,14.2
14824,Greece,2010,3,A10-Drugs used in diabetes,Million US$ at exchange rate,401.9
14825,Greece,2010,3,N05C-Hypnotics and sedatives,Million of national currency units,10.7
14826,Greece,2010,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3
14827,Greece,2010,3,C10-Lipid modifying agents,Million of national currency units,543.3
14828,Greece,2010,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.8
14829,Greece,2010,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3
14830,Greece,2010,3,C-Cardiovascular system,"Million US$, purchasing power parity",1974.4
14831,Greece,2010,3,C-Cardiovascular system,"/capita, US$ exchange rate",169.9
14832,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,539.5
14833,Greece,2010,3,C-Cardiovascular system,Million of national currency units,1425.5
14834,Greece,2010,3,C-Cardiovascular system,Million US$ at exchange rate,1889.8
14835,Greece,2010,3,C03-Diuretics,"/capita, US$ purchasing power parity",4.6
14836,Greece,2010,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",177.5
14837,Greece,2010,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
14838,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,715.2
14839,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
14840,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
14841,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",7.6
14842,Greece,2010,3,A-Alimentary tract and metabolism,Million of national currency units,856.0
14843,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",64.3
14844,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",747.1
14845,Greece,2010,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",67.2
14846,Greece,2010,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1185.5
14847,Greece,2010,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",102.0
14848,Greece,2010,3,C07-Beta blocking agents,"/capita, US$ exchange rate",9.7
14849,Greece,2010,3,A02A-Antacids,Million of national currency units,5.8
14850,Greece,2010,3,C07-Beta blocking agents,Million of national currency units,81.2
14851,Greece,2010,3,C07-Beta blocking agents,Million US$ at exchange rate,107.7
14852,Greece,2010,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,1134.8
14853,Greece,2010,3,C01A-Cardiac glycosides,Million US$ at exchange rate,1.6
14854,Greece,2010,3,C02-Antihypertensives,Million of national currency units,41.5
14855,Greece,2010,3,C01A-Cardiac glycosides,Million of national currency units,1.2
14856,Greece,2010,3,C07-Beta blocking agents,"Million US$, purchasing power parity",112.5
14857,Greece,2010,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7
14858,Greece,2010,3,C02-Antihypertensives,"Million US$, purchasing power parity",57.5
14859,Greece,2010,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
14860,Greece,2010,3,C02-Antihypertensives,"/capita, US$ exchange rate",5.0
14861,Greece,2010,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.2
14862,Greece,2010,3,A02A-Antacids,"Million US$, purchasing power parity",8.0
14863,Greece,2010,3,A02A-Antacids,Million US$ at exchange rate,7.7
14864,Greece,2010,3,A02A-Antacids,"/capita, US$ exchange rate",0.7
14865,Greece,2010,3,C02-Antihypertensives,Million US$ at exchange rate,55.1
14866,Greece,2010,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
14867,Greece,2010,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",106.6
14868,Greece,2010,3,C03-Diuretics,"Million US$, purchasing power parity",50.8
14869,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.3
14870,Greece,2010,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,5.5
14871,Greece,2010,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",10.1
14872,Greece,2010,3,C03-Diuretics,Million of national currency units,36.7
14873,Greece,2010,3,C03-Diuretics,Million US$ at exchange rate,48.7
14874,Greece,2010,3,C08-Calcium channel blockers,Million of national currency units,94.3
14875,Greece,2010,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",11.2
14876,Greece,2010,3,C08-Calcium channel blockers,Million US$ at exchange rate,125.0
14877,Greece,2010,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",130.6
14878,Greece,2010,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",11.7
14879,Greece,2010,3,C03-Diuretics,"/capita, US$ exchange rate",4.4
14880,Greece,2017,3,N02-Analgesics,Million of national currency units,141.8
14881,Greece,2017,3,N05B-Anxiolytics,Million of national currency units,22.2
14882,Greece,2017,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.6
14883,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,64.2
14884,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,72.5
14885,Greece,2017,3,N05B-Anxiolytics,Million US$ at exchange rate,25.1
14886,Greece,2017,3,N05B-Anxiolytics,"Million US$, purchasing power parity",38.7
14887,Greece,2017,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.3
14888,Greece,2017,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",68.6
14889,Greece,2017,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1135.8
14890,Greece,2017,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",105.6
14891,Greece,2017,3,R03-Drugs for obstructive airway diseases,Million of national currency units,267.2
14892,Greece,2017,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,301.8
14893,Greece,2017,3,N02-Analgesics,"/capita, US$ exchange rate",14.9
14894,Greece,2017,3,N02-Analgesics,"/capita, US$ purchasing power parity",22.9
14895,Greece,2017,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,737.8
14896,Greece,2017,3,J-Antiinfectives for systemic use,Million of national currency units,653.1
14897,Greece,2017,3,N02-Analgesics,"Million US$, purchasing power parity",246.7
14898,Greece,2017,3,B-Blood and blood forming organs,Million US$ at exchange rate,1157.5
14899,Greece,2017,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",165.7
14900,Greece,2017,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",107.6
14901,Greece,2017,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",1781.9
14902,Greece,2017,3,N02-Analgesics,Million US$ at exchange rate,160.2
14903,Greece,2017,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",464.6
14904,Greece,2017,3,B-Blood and blood forming organs,Million of national currency units,1024.6
14905,Greece,2017,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",43.2
14906,Greece,2017,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.1
14907,Greece,2017,3,M-Musculo-skeletal system,Million of national currency units,212.1
14908,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",24.7
14909,Greece,2017,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",368.9
14910,Greece,2017,3,M-Musculo-skeletal system,Million US$ at exchange rate,239.6
14911,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,172.3
14912,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,152.5
14913,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.0
14914,Greece,2017,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",265.3
14915,Greece,2017,3,R-Respiratory system,Million of national currency units,410.4
14916,Greece,2017,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.1
14917,Greece,2017,3,R-Respiratory system,"Million US$, purchasing power parity",713.8
14918,Greece,2017,3,R-Respiratory system,Million US$ at exchange rate,463.7
14919,Greece,2017,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,42.9
14920,Greece,2017,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,38.0
14921,Greece,2017,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.0
14922,Greece,2017,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",66.1
14923,Greece,2017,3,N-Nervous system,"/capita, US$ purchasing power parity",104.6
14924,Greece,2017,3,G-Genito urinary system and sex hormones,Million of national currency units,166.8
14925,Greece,2017,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,188.4
14926,Greece,2017,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",290.0
14927,Greece,2017,3,N-Nervous system,Million US$ at exchange rate,730.9
14928,Greece,2017,3,N-Nervous system,Million of national currency units,647.0
14929,Greece,2017,3,N-Nervous system,"/capita, US$ exchange rate",68.0
14930,Greece,2017,3,N-Nervous system,"Million US$, purchasing power parity",1125.1
14931,Greece,2017,3,N06A-Antidepressants,"Million US$, purchasing power parity",173.8
14932,Greece,2017,3,N06A-Antidepressants,Million US$ at exchange rate,112.9
14933,Greece,2017,3,N06A-Antidepressants,Million of national currency units,100.0
14934,Greece,2017,3,N06A-Antidepressants,"/capita, US$ exchange rate",10.5
14935,Greece,2017,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.5
14936,Greece,2017,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",27.0
14937,Greece,2017,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2
14938,Greece,2017,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",393.3
14939,Greece,2017,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",23.8
14940,Greece,2017,3,J01-Antibacterials for systemic use,Million of national currency units,226.2
14941,Greece,2017,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,255.5
14942,Greece,2017,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",710.7
14943,Greece,2017,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",36.6
14944,Greece,2017,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",66.1
14945,Greece,2017,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",42.9
14946,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.4
14947,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",20.9
14948,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",111.6
14949,Greece,2017,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.7
14950,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,146.0
14951,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,129.2
14952,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.6
14953,Greece,2017,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",224.7
14954,Greece,2017,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",32.8
14955,Greece,2017,3,C10-Lipid modifying agents,Million US$ at exchange rate,352.4
14956,Greece,2017,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",50.4
14957,Greece,2017,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",542.4
14958,Greece,2017,3,R-Respiratory system,"/capita, US$ purchasing power parity",66.4
14959,Greece,2017,3,R-Respiratory system,"/capita, US$ exchange rate",43.1
14960,Greece,2017,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",34.3
14961,Greece,2017,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.3
14962,Greece,2017,3,N05C-Hypnotics and sedatives,Million of national currency units,8.4
14963,Greece,2017,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,9.5
14964,Greece,2017,3,A10-Drugs used in diabetes,Million US$ at exchange rate,461.7
14965,Greece,2017,3,A10-Drugs used in diabetes,Million of national currency units,408.7
14966,Greece,2017,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.4
14967,Greece,2017,3,C10-Lipid modifying agents,Million of national currency units,311.9
14968,Greece,2017,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.6
14969,Greece,2017,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9
14970,Greece,2017,3,C-Cardiovascular system,Million US$ at exchange rate,987.0
14971,Greece,2017,3,C-Cardiovascular system,"Million US$, purchasing power parity",1519.4
14972,Greece,2017,3,C-Cardiovascular system,"/capita, US$ exchange rate",91.8
14973,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,334.4
14974,Greece,2017,3,C-Cardiovascular system,Million of national currency units,873.7
14975,Greece,2017,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
14976,Greece,2017,3,C03-Diuretics,"/capita, US$ purchasing power parity",5.6
14977,Greece,2017,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",141.3
14978,Greece,2017,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
14979,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",13.2
14980,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
14981,Greece,2017,3,C03-Diuretics,"/capita, US$ exchange rate",3.6
14982,Greece,2017,3,A-Alimentary tract and metabolism,Million of national currency units,760.9
14983,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.6
14984,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",581.5
14985,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,377.7
14986,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
14987,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",54.1
14988,Greece,2017,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.1
14989,Greece,2017,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,859.6
14990,Greece,2017,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1323.2
14991,Greece,2017,3,C07-Beta blocking agents,Million of national currency units,57.6
14992,Greece,2017,3,C07-Beta blocking agents,"Million US$, purchasing power parity",100.1
14993,Greece,2017,3,C02-Antihypertensives,Million of national currency units,24.9
14994,Greece,2017,3,C01A-Cardiac glycosides,Million of national currency units,0.6
14995,Greece,2017,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.7
14996,Greece,2017,3,C07-Beta blocking agents,Million US$ at exchange rate,65.0
14997,Greece,2017,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.0
14998,Greece,2017,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
14999,Greece,2017,3,C02-Antihypertensives,"Million US$, purchasing power parity",43.2
15000,Greece,2017,3,C02-Antihypertensives,Million US$ at exchange rate,28.1
15001,Greece,2017,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.0
15002,Greece,2017,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.6
15003,Greece,2017,3,A02A-Antacids,Million US$ at exchange rate,5.0
15004,Greece,2017,3,A02A-Antacids,Million of national currency units,4.4
15005,Greece,2017,3,A02A-Antacids,"Million US$, purchasing power parity",7.6
15006,Greece,2017,3,A02A-Antacids,"/capita, US$ exchange rate",0.5
15007,Greece,2017,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",79.9
15008,Greece,2017,3,C03-Diuretics,"Million US$, purchasing power parity",60.3
15009,Greece,2017,3,C03-Diuretics,Million US$ at exchange rate,39.2
15010,Greece,2017,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.9
15011,Greece,2017,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,7.6
15012,Greece,2017,3,C07-Beta blocking agents,"/capita, US$ exchange rate",6.0
15013,Greece,2017,3,C03-Diuretics,Million of national currency units,34.7
15014,Greece,2017,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",123.0
15015,Greece,2017,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.3
15016,Greece,2017,3,C08-Calcium channel blockers,Million of national currency units,49.1
15017,Greece,2017,3,C08-Calcium channel blockers,Million US$ at exchange rate,55.5
15018,Greece,2017,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",85.5
15019,Greece,2017,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.2
15020,Hungary,2017,12,A-Alimentary tract and metabolism,Million of national currency units,78667.7
15021,Hungary,2017,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.4
15022,Hungary,2017,12,C10-Lipid modifying agents,% of total sales,3.9
15023,Hungary,2017,12,A10-Drugs used in diabetes,Million US$ at exchange rate,182.3
15024,Hungary,2017,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",367.8
15025,Hungary,2017,12,A10-Drugs used in diabetes,Million of national currency units,50037.2
15026,Hungary,2017,12,C03-Diuretics,"/capita, US$ exchange rate",1.7
15027,Hungary,2017,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.4
15028,Hungary,2017,12,C03-Diuretics,% of total sales,0.9
15029,Hungary,2017,12,C03-Diuretics,Million US$ at exchange rate,16.6
15030,Hungary,2017,12,C03-Diuretics,"Million US$, purchasing power parity",33.4
15031,Hungary,2017,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",140.7
15032,Hungary,2017,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",578.3
15033,Hungary,2017,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,286.7
15034,Hungary,2017,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.1
15035,Hungary,2017,12,N06A-Antidepressants,% of total sales,1.6
15036,Hungary,2017,12,C08-Calcium channel blockers,Million of national currency units,2649.1
15037,Hungary,2017,12,N-Nervous system,"/capita, US$ purchasing power parity",44.9
15038,Hungary,2017,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",19.5
15039,Hungary,2017,12,C08-Calcium channel blockers,Million US$ at exchange rate,9.7
15040,Hungary,2017,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.0
15041,Hungary,2017,12,N06A-Antidepressants,Million US$ at exchange rate,29.2
15042,Hungary,2017,12,N06A-Antidepressants,Million of national currency units,8013.6
15043,Hungary,2017,12,N06A-Antidepressants,"/capita, US$ exchange rate",3.0
15044,Hungary,2017,12,N06A-Antidepressants,"Million US$, purchasing power parity",58.9
15045,Hungary,2017,12,A10-Drugs used in diabetes,% of total sales,10.1
15046,Hungary,2017,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
15047,Hungary,2017,12,C01A-Cardiac glycosides,% of total sales,0.0
15048,Hungary,2017,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.6
15049,Hungary,2017,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.6
15050,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
15051,Hungary,2017,12,N-Nervous system,% of total sales,12.1
15052,Hungary,2017,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.0
15053,Hungary,2017,12,C08-Calcium channel blockers,% of total sales,0.5
15054,Hungary,2017,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.0
15055,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.1
15056,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
15057,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1380.3
15058,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0
15059,Hungary,2017,12,A02A-Antacids,"/capita, US$ exchange rate",0.0
15060,Hungary,2017,12,A02A-Antacids,"Million US$, purchasing power parity",0.0
15061,Hungary,2017,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
15062,Hungary,2017,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
15063,Hungary,2017,12,A02A-Antacids,% of total sales,0.0
15064,Hungary,2017,12,A-Alimentary tract and metabolism,% of total sales,16.0
15065,Hungary,2017,12,R-Respiratory system,"/capita, US$ exchange rate",12.8
15066,Hungary,2017,12,R-Respiratory system,"Million US$, purchasing power parity",253.6
15067,Hungary,2017,12,N02-Analgesics,Million of national currency units,5346.6
15068,Hungary,2017,12,R-Respiratory system,Million of national currency units,34496.8
15069,Hungary,2017,12,R-Respiratory system,Million US$ at exchange rate,125.7
15070,Hungary,2017,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",59.1
15071,Hungary,2017,12,N02-Analgesics,Million US$ at exchange rate,19.5
15072,Hungary,2017,12,R-Respiratory system,"/capita, US$ purchasing power parity",25.9
15073,Hungary,2017,12,N02-Analgesics,"Million US$, purchasing power parity",39.3
15074,Hungary,2017,12,R-Respiratory system,% of total sales,7.0
15075,Hungary,2017,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",216.0
15076,Hungary,2017,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6
15077,Hungary,2017,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.0
15078,Hungary,2017,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",10.9
15079,Hungary,2017,12,C01A-Cardiac glycosides,Million of national currency units,162.2
15080,Hungary,2017,12,J-Antiinfectives for systemic use,Million of national currency units,29379.9
15081,Hungary,2017,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",29.3
15082,Hungary,2017,12,C03-Diuretics,Million of national currency units,4545.2
15083,Hungary,2017,12,A02A-Antacids,Million US$ at exchange rate,0.0
15084,Hungary,2017,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,107.1
15085,Hungary,2017,12,A02A-Antacids,Million of national currency units,0.0
15086,Hungary,2017,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",22.1
15087,Hungary,2017,12,N02-Analgesics,"/capita, US$ exchange rate",2.0
15088,Hungary,2017,12,J-Antiinfectives for systemic use,% of total sales,6.0
15089,Hungary,2017,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
15090,Hungary,2017,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.2
15091,Hungary,2017,12,M-Musculo-skeletal system,% of total sales,3.6
15092,Hungary,2017,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",130.3
15093,Hungary,2017,12,M-Musculo-skeletal system,Million of national currency units,17723.5
15094,Hungary,2017,12,M-Musculo-skeletal system,Million US$ at exchange rate,64.6
15095,Hungary,2017,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.3
15096,Hungary,2017,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",6.6
15097,Hungary,2017,12,N05C-Hypnotics and sedatives,% of total sales,0.0
15098,Hungary,2017,12,C07-Beta blocking agents,% of total sales,2.0
15099,Hungary,2017,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4
15100,Hungary,2017,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0
15101,Hungary,2017,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
15102,Hungary,2017,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
15103,Hungary,2017,12,C07-Beta blocking agents,Million US$ at exchange rate,35.9
15104,Hungary,2017,12,C07-Beta blocking agents,"Million US$, purchasing power parity",72.4
15105,Hungary,2017,12,C07-Beta blocking agents,Million of national currency units,9854.4
15106,Hungary,2017,12,N05B-Anxiolytics,Million of national currency units,2831.3
15107,Hungary,2017,12,C07-Beta blocking agents,"/capita, US$ exchange rate",3.7
15108,Hungary,2017,12,N05B-Anxiolytics,Million US$ at exchange rate,10.3
15109,Hungary,2017,12,C02-Antihypertensives,% of total sales,2.0
15110,Hungary,2017,12,N05C-Hypnotics and sedatives,Million of national currency units,1.0
15111,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.6
15112,Hungary,2017,12,N02-Analgesics,% of total sales,1.1
15113,Hungary,2017,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",7.4
15114,Hungary,2017,12,R03-Drugs for obstructive airway diseases,Million of national currency units,29875.7
15115,Hungary,2017,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.4
15116,Hungary,2017,12,R03-Drugs for obstructive airway diseases,% of total sales,6.1
15117,Hungary,2017,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
15118,Hungary,2017,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,108.9
15119,Hungary,2017,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.1
15120,Hungary,2017,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",219.6
15121,Hungary,2017,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",87.7
15122,Hungary,2017,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",9.0
15123,Hungary,2017,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.4
15124,Hungary,2017,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,43.5
15125,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.3
15126,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
15127,Hungary,2017,12,G-Genito urinary system and sex hormones,Million of national currency units,11937.0
15128,Hungary,2017,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3624.2
15129,Hungary,2017,12,Total pharmaceutical sales,Million US$ at exchange rate,1796.5
15130,Hungary,2017,12,Total pharmaceutical sales,Million of national currency units,493022.1
15131,Hungary,2017,12,G-Genito urinary system and sex hormones,% of total sales,2.4
15132,Hungary,2017,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",370.3
15133,Hungary,2017,12,Total pharmaceutical sales,"/capita, US$ exchange rate",183.5
15134,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,20.5
15135,Hungary,2017,12,N05B-Anxiolytics,"Million US$, purchasing power parity",20.8
15136,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5629.9
15137,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2
15138,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",41.4
15139,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.1
15140,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,20.9
15141,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.1
15142,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",42.2
15143,Hungary,2017,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,5743.2
15144,Hungary,2017,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.1
15145,Hungary,2017,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
15146,Hungary,2017,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1
15147,Hungary,2017,12,N05B-Anxiolytics,% of total sales,0.6
15148,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.0
15149,Hungary,2017,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",93.5
15150,Hungary,2017,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,46.3
15151,Hungary,2017,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",4.7
15152,Hungary,2017,12,J01-Antibacterials for systemic use,% of total sales,2.6
15153,Hungary,2017,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.5
15154,Hungary,2017,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",370.0
15155,Hungary,2017,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.7
15156,Hungary,2017,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.8
15157,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
15158,Hungary,2017,12,J01-Antibacterials for systemic use,Million of national currency units,12714.9
15159,Hungary,2017,12,B-Blood and blood forming organs,Million of national currency units,50338.2
15160,Hungary,2017,12,B-Blood and blood forming organs,Million US$ at exchange rate,183.4
15161,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,39.7
15162,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",80.2
15163,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,10907.7
15164,Hungary,2017,12,C10-Lipid modifying agents,Million US$ at exchange rate,69.7
15165,Hungary,2017,12,C10-Lipid modifying agents,Million of national currency units,19139.1
15166,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.1
15167,Hungary,2017,12,N-Nervous system,Million of national currency units,59790.5
15168,Hungary,2017,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.2
15169,Hungary,2017,12,N-Nervous system,Million US$ at exchange rate,217.9
15170,Hungary,2017,12,N-Nervous system,"/capita, US$ exchange rate",22.3
15171,Hungary,2017,12,N-Nervous system,"Million US$, purchasing power parity",439.5
15172,Hungary,2017,12,C-Cardiovascular system,"Million US$, purchasing power parity",683.4
15173,Hungary,2017,12,C-Cardiovascular system,Million US$ at exchange rate,338.8
15174,Hungary,2017,12,C-Cardiovascular system,% of total sales,18.9
15175,Hungary,2017,12,C-Cardiovascular system,"/capita, US$ exchange rate",34.6
15176,Hungary,2017,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",69.8
15177,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",274.2
15178,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.9
15179,Hungary,2017,12,C-Cardiovascular system,Million of national currency units,92973.4
15180,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,37305.6
15181,Hungary,2017,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,135.9
15182,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.6
15183,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.3
15184,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8825.9
15185,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8
15186,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,32.2
15187,Hungary,2017,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",64.9
15188,Hungary,2017,12,C02-Antihypertensives,Million of national currency units,9804.7
15189,Hungary,2017,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.7
15190,Hungary,2017,12,B-Blood and blood forming organs,% of total sales,10.2
15191,Hungary,2017,12,C02-Antihypertensives,Million US$ at exchange rate,35.7
15192,Hungary,2017,12,C02-Antihypertensives,"Million US$, purchasing power parity",72.1
15193,Hungary,2016,12,A-Alimentary tract and metabolism,Million of national currency units,73066.7
15194,Hungary,2016,12,C10-Lipid modifying agents,% of total sales,3.8
15195,Hungary,2016,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.7
15196,Hungary,2016,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",342.9
15197,Hungary,2016,12,A10-Drugs used in diabetes,Million US$ at exchange rate,160.8
15198,Hungary,2016,12,A10-Drugs used in diabetes,Million of national currency units,45267.9
15199,Hungary,2016,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.5
15200,Hungary,2016,12,C03-Diuretics,% of total sales,0.9
15201,Hungary,2016,12,C03-Diuretics,"/capita, US$ exchange rate",1.6
15202,Hungary,2016,12,C03-Diuretics,Million US$ at exchange rate,16.1
15203,Hungary,2016,12,C03-Diuretics,"Million US$, purchasing power parity",34.3
15204,Hungary,2016,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",553.4
15205,Hungary,2016,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,259.5
15206,Hungary,2016,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.9
15207,Hungary,2016,12,C08-Calcium channel blockers,Million of national currency units,2787.9
15208,Hungary,2016,12,N-Nervous system,"/capita, US$ purchasing power parity",46.1
15209,Hungary,2016,12,N06A-Antidepressants,% of total sales,1.6
15210,Hungary,2016,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",21.1
15211,Hungary,2016,12,C08-Calcium channel blockers,Million US$ at exchange rate,9.9
15212,Hungary,2016,12,N06A-Antidepressants,Million US$ at exchange rate,28.6
15213,Hungary,2016,12,N06A-Antidepressants,Million of national currency units,8047.7
15214,Hungary,2016,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.2
15215,Hungary,2016,12,N06A-Antidepressants,"/capita, US$ exchange rate",2.9
15216,Hungary,2016,12,N06A-Antidepressants,"Million US$, purchasing power parity",61.0
15217,Hungary,2016,12,A10-Drugs used in diabetes,% of total sales,9.1
15218,Hungary,2016,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
15219,Hungary,2016,12,C01A-Cardiac glycosides,% of total sales,0.0
15220,Hungary,2016,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.4
15221,Hungary,2016,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",34.9
15222,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
15223,Hungary,2016,12,N-Nervous system,% of total sales,12.0
15224,Hungary,2016,12,C08-Calcium channel blockers,% of total sales,0.6
15225,Hungary,2016,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.2
15226,Hungary,2016,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.0
15227,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.5
15228,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
15229,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.9
15230,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1384.4
15231,Hungary,2016,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
15232,Hungary,2016,12,A02A-Antacids,"/capita, US$ exchange rate",0.0
15233,Hungary,2016,12,A02A-Antacids,"Million US$, purchasing power parity",0.0
15234,Hungary,2016,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
15235,Hungary,2016,12,A02A-Antacids,% of total sales,0.0
15236,Hungary,2016,12,N02-Analgesics,"Million US$, purchasing power parity",39.7
15237,Hungary,2016,12,A-Alimentary tract and metabolism,% of total sales,14.6
15238,Hungary,2016,12,R-Respiratory system,"Million US$, purchasing power parity",258.8
15239,Hungary,2016,12,R-Respiratory system,"/capita, US$ exchange rate",12.4
15240,Hungary,2016,12,N02-Analgesics,Million of national currency units,5247.3
15241,Hungary,2016,12,R-Respiratory system,Million of national currency units,34173.3
15242,Hungary,2016,12,R-Respiratory system,Million US$ at exchange rate,121.4
15243,Hungary,2016,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",56.4
15244,Hungary,2016,12,N02-Analgesics,Million US$ at exchange rate,18.6
15245,Hungary,2016,12,R-Respiratory system,"/capita, US$ purchasing power parity",26.4
15246,Hungary,2016,12,R-Respiratory system,% of total sales,6.9
15247,Hungary,2016,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",297.0
15248,Hungary,2016,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6
15249,Hungary,2016,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.3
15250,Hungary,2016,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.2
15251,Hungary,2016,12,J-Antiinfectives for systemic use,Million of national currency units,39211.2
15252,Hungary,2016,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",26.4
15253,Hungary,2016,12,C03-Diuretics,Million of national currency units,4527.3
15254,Hungary,2016,12,C01A-Cardiac glycosides,Million of national currency units,174.1
15255,Hungary,2016,12,A02A-Antacids,Million US$ at exchange rate,0.0
15256,Hungary,2016,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,139.3
15257,Hungary,2016,12,A02A-Antacids,Million of national currency units,0.0
15258,Hungary,2016,12,N02-Analgesics,"/capita, US$ exchange rate",1.9
15259,Hungary,2016,12,J-Antiinfectives for systemic use,% of total sales,7.9
15260,Hungary,2016,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",144.1
15261,Hungary,2016,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.0
15262,Hungary,2016,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
15263,Hungary,2016,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.3
15264,Hungary,2016,12,M-Musculo-skeletal system,% of total sales,3.5
15265,Hungary,2016,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",133.8
15266,Hungary,2016,12,M-Musculo-skeletal system,Million US$ at exchange rate,62.7
15267,Hungary,2016,12,M-Musculo-skeletal system,Million of national currency units,17665.2
15268,Hungary,2016,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.6
15269,Hungary,2016,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",6.4
15270,Hungary,2016,12,N05C-Hypnotics and sedatives,% of total sales,0.0
15271,Hungary,2016,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.6
15272,Hungary,2016,12,C07-Beta blocking agents,% of total sales,2.0
15273,Hungary,2016,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0
15274,Hungary,2016,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
15275,Hungary,2016,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
15276,Hungary,2016,12,C07-Beta blocking agents,Million US$ at exchange rate,34.8
15277,Hungary,2016,12,C07-Beta blocking agents,"Million US$, purchasing power parity",74.2
15278,Hungary,2016,12,C07-Beta blocking agents,Million of national currency units,9800.0
15279,Hungary,2016,12,N05B-Anxiolytics,Million of national currency units,2872.5
15280,Hungary,2016,12,C07-Beta blocking agents,"/capita, US$ exchange rate",3.5
15281,Hungary,2016,12,N05B-Anxiolytics,Million US$ at exchange rate,10.2
15282,Hungary,2016,12,C02-Antihypertensives,% of total sales,1.9
15283,Hungary,2016,12,N05C-Hypnotics and sedatives,Million of national currency units,0.9
15284,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.3
15285,Hungary,2016,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",7.2
15286,Hungary,2016,12,N02-Analgesics,% of total sales,1.1
15287,Hungary,2016,12,R03-Drugs for obstructive airway diseases,Million of national currency units,29620.8
15288,Hungary,2016,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.9
15289,Hungary,2016,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
15290,Hungary,2016,12,R03-Drugs for obstructive airway diseases,% of total sales,5.9
15291,Hungary,2016,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,105.2
15292,Hungary,2016,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",10.7
15293,Hungary,2016,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",224.3
15294,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1
15295,Hungary,2016,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",85.2
15296,Hungary,2016,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",8.7
15297,Hungary,2016,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.1
15298,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.2
15299,Hungary,2016,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,40.0
15300,Hungary,2016,12,G-Genito urinary system and sex hormones,Million of national currency units,11251.9
15301,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.1
15302,Hungary,2016,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3778.3
15303,Hungary,2016,12,Total pharmaceutical sales,Million US$ at exchange rate,1772.0
15304,Hungary,2016,12,Total pharmaceutical sales,Million of national currency units,498866.9
15305,Hungary,2016,12,G-Genito urinary system and sex hormones,% of total sales,2.3
15306,Hungary,2016,12,Total pharmaceutical sales,"/capita, US$ exchange rate",180.6
15307,Hungary,2016,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",385.0
15308,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,19.9
15309,Hungary,2016,12,N05B-Anxiolytics,"Million US$, purchasing power parity",21.8
15310,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5595.1
15311,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",42.4
15312,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.3
15313,Hungary,2016,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.0
15314,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,19.3
15315,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.0
15316,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.1
15317,Hungary,2016,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,5426.8
15318,Hungary,2016,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
15319,Hungary,2016,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.0
15320,Hungary,2016,12,N05B-Anxiolytics,% of total sales,0.6
15321,Hungary,2016,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",97.4
15322,Hungary,2016,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,45.7
15323,Hungary,2016,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",4.7
15324,Hungary,2016,12,J01-Antibacterials for systemic use,% of total sales,2.6
15325,Hungary,2016,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.9
15326,Hungary,2016,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",402.8
15327,Hungary,2016,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.3
15328,Hungary,2016,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.0
15329,Hungary,2016,12,B-Blood and blood forming organs,Million of national currency units,53187.8
15330,Hungary,2016,12,J01-Antibacterials for systemic use,Million of national currency units,12865.7
15331,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.1
15332,Hungary,2016,12,B-Blood and blood forming organs,Million US$ at exchange rate,188.9
15333,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
15334,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,37.7
15335,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",80.4
15336,Hungary,2016,12,C10-Lipid modifying agents,Million US$ at exchange rate,67.6
15337,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,10611.0
15338,Hungary,2016,12,C10-Lipid modifying agents,Million of national currency units,19032.0
15339,Hungary,2016,12,N-Nervous system,Million of national currency units,59756.4
15340,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.2
15341,Hungary,2016,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.8
15342,Hungary,2016,12,N-Nervous system,"/capita, US$ exchange rate",21.6
15343,Hungary,2016,12,N-Nervous system,Million US$ at exchange rate,212.3
15344,Hungary,2016,12,N-Nervous system,"Million US$, purchasing power parity",452.6
15345,Hungary,2016,12,C-Cardiovascular system,"Million US$, purchasing power parity",698.1
15346,Hungary,2016,12,C-Cardiovascular system,Million US$ at exchange rate,327.4
15347,Hungary,2016,12,C-Cardiovascular system,"/capita, US$ exchange rate",33.4
15348,Hungary,2016,12,C-Cardiovascular system,% of total sales,18.5
15349,Hungary,2016,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.1
15350,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",275.7
15351,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.2
15352,Hungary,2016,12,C-Cardiovascular system,Million of national currency units,92167.6
15353,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,36400.5
15354,Hungary,2016,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,129.3
15355,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.6
15356,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.1
15357,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8548.3
15358,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7
15359,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,30.4
15360,Hungary,2016,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",64.7
15361,Hungary,2016,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.4
15362,Hungary,2016,12,B-Blood and blood forming organs,% of total sales,10.7
15363,Hungary,2016,12,C02-Antihypertensives,Million US$ at exchange rate,33.1
15364,Hungary,2016,12,C02-Antihypertensives,Million of national currency units,9311.8
15365,Hungary,2016,12,C02-Antihypertensives,"Million US$, purchasing power parity",70.5
15366,Hungary,2015,12,C10-Lipid modifying agents,% of total sales,4.1
15367,Hungary,2015,12,A-Alimentary tract and metabolism,Million of national currency units,67533.0
15368,Hungary,2015,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",305.9
15369,Hungary,2015,12,A10-Drugs used in diabetes,Million US$ at exchange rate,145.2
15370,Hungary,2015,12,A10-Drugs used in diabetes,Million of national currency units,40546.0
15371,Hungary,2015,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.4
15372,Hungary,2015,12,C03-Diuretics,% of total sales,1.0
15373,Hungary,2015,12,C03-Diuretics,Million US$ at exchange rate,16.1
15374,Hungary,2015,12,C03-Diuretics,"/capita, US$ exchange rate",1.6
15375,Hungary,2015,12,C03-Diuretics,"Million US$, purchasing power parity",33.9
15376,Hungary,2015,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",509.5
15377,Hungary,2015,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,241.8
15378,Hungary,2015,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.9
15379,Hungary,2015,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",14.5
15380,Hungary,2015,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",14.7
15381,Hungary,2015,12,C08-Calcium channel blockers,Million of national currency units,2946.5
15382,Hungary,2015,12,N-Nervous system,"/capita, US$ purchasing power parity",46.7
15383,Hungary,2015,12,N06A-Antidepressants,% of total sales,2.0
15384,Hungary,2015,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.2
15385,Hungary,2015,12,C08-Calcium channel blockers,Million US$ at exchange rate,10.5
15386,Hungary,2015,12,N06A-Antidepressants,Million US$ at exchange rate,33.7
15387,Hungary,2015,12,N06A-Antidepressants,Million of national currency units,9404.9
15388,Hungary,2015,12,N06A-Antidepressants,"Million US$, purchasing power parity",71.0
15389,Hungary,2015,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.2
15390,Hungary,2015,12,N06A-Antidepressants,"/capita, US$ exchange rate",3.4
15391,Hungary,2015,12,A10-Drugs used in diabetes,% of total sales,8.7
15392,Hungary,2015,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
15393,Hungary,2015,12,C01A-Cardiac glycosides,% of total sales,0.0
15394,Hungary,2015,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.1
15395,Hungary,2015,12,N-Nervous system,% of total sales,13.1
15396,Hungary,2015,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.1
15397,Hungary,2015,12,C08-Calcium channel blockers,% of total sales,0.6
15398,Hungary,2015,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
15399,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.5
15400,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
15401,Hungary,2015,12,N02-Analgesics,"/capita, US$ exchange rate",1.9
15402,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1391.1
15403,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0
15404,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
15405,Hungary,2015,12,A02A-Antacids,"/capita, US$ exchange rate",0.0
15406,Hungary,2015,12,A02A-Antacids,"Million US$, purchasing power parity",0.0
15407,Hungary,2015,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
15408,Hungary,2015,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
15409,Hungary,2015,12,A02A-Antacids,% of total sales,0.0
15410,Hungary,2015,12,A-Alimentary tract and metabolism,% of total sales,14.5
15411,Hungary,2015,12,R-Respiratory system,"Million US$, purchasing power parity",252.8
15412,Hungary,2015,12,R-Respiratory system,"/capita, US$ exchange rate",12.2
15413,Hungary,2015,12,N02-Analgesics,Million of national currency units,5270.6
15414,Hungary,2015,12,R-Respiratory system,Million of national currency units,33515.8
15415,Hungary,2015,12,R-Respiratory system,Million US$ at exchange rate,120.0
15416,Hungary,2015,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.8
15417,Hungary,2015,12,N02-Analgesics,Million US$ at exchange rate,18.9
15418,Hungary,2015,12,N02-Analgesics,"Million US$, purchasing power parity",39.8
15419,Hungary,2015,12,R-Respiratory system,"/capita, US$ purchasing power parity",25.7
15420,Hungary,2015,12,R-Respiratory system,% of total sales,7.2
15421,Hungary,2015,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",236.2
15422,Hungary,2015,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.7
15423,Hungary,2015,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.0
15424,Hungary,2015,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.4
15425,Hungary,2015,12,J-Antiinfectives for systemic use,Million of national currency units,31313.2
15426,Hungary,2015,12,C03-Diuretics,Million of national currency units,4496.7
15427,Hungary,2015,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",24.6
15428,Hungary,2015,12,C01A-Cardiac glycosides,Million of national currency units,188.4
15429,Hungary,2015,12,A02A-Antacids,Million US$ at exchange rate,0.0
15430,Hungary,2015,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,112.1
15431,Hungary,2015,12,A02A-Antacids,Million of national currency units,0.0
15432,Hungary,2015,12,M-Musculo-skeletal system,Million of national currency units,17492.2
15433,Hungary,2015,12,J-Antiinfectives for systemic use,% of total sales,6.7
15434,Hungary,2015,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.0
15435,Hungary,2015,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
15436,Hungary,2015,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
15437,Hungary,2015,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",132.0
15438,Hungary,2015,12,M-Musculo-skeletal system,Million US$ at exchange rate,62.6
15439,Hungary,2015,12,M-Musculo-skeletal system,% of total sales,3.8
15440,Hungary,2015,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.4
15441,Hungary,2015,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",6.4
15442,Hungary,2015,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",142.8
15443,Hungary,2015,12,G-Genito urinary system and sex hormones,Million of national currency units,10463.8
15444,Hungary,2015,12,N05C-Hypnotics and sedatives,% of total sales,0.0
15445,Hungary,2015,12,C07-Beta blocking agents,% of total sales,2.1
15446,Hungary,2015,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.5
15447,Hungary,2015,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
15448,Hungary,2015,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0
15449,Hungary,2015,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
15450,Hungary,2015,12,C07-Beta blocking agents,Million US$ at exchange rate,34.9
15451,Hungary,2015,12,C07-Beta blocking agents,"Million US$, purchasing power parity",73.5
15452,Hungary,2015,12,C07-Beta blocking agents,Million of national currency units,9746.0
15453,Hungary,2015,12,N05B-Anxiolytics,Million of national currency units,2888.3
15454,Hungary,2015,12,C07-Beta blocking agents,"/capita, US$ exchange rate",3.5
15455,Hungary,2015,12,N05B-Anxiolytics,Million US$ at exchange rate,10.3
15456,Hungary,2015,12,N05B-Anxiolytics,"Million US$, purchasing power parity",21.8
15457,Hungary,2015,12,C02-Antihypertensives,% of total sales,1.9
15458,Hungary,2015,12,N05C-Hypnotics and sedatives,Million of national currency units,1.1
15459,Hungary,2015,12,R03-Drugs for obstructive airway diseases,Million of national currency units,28986.7
15460,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.5
15461,Hungary,2015,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.6
15462,Hungary,2015,12,N02-Analgesics,% of total sales,1.1
15463,Hungary,2015,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.2
15464,Hungary,2015,12,R03-Drugs for obstructive airway diseases,% of total sales,6.2
15465,Hungary,2015,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
15466,Hungary,2015,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,103.8
15467,Hungary,2015,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",10.5
15468,Hungary,2015,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",218.7
15469,Hungary,2015,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",78.9
15470,Hungary,2015,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",8.0
15471,Hungary,2015,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.8
15472,Hungary,2015,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,37.5
15473,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.8
15474,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.1
15475,Hungary,2015,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3518.7
15476,Hungary,2015,12,Total pharmaceutical sales,Million of national currency units,466411.6
15477,Hungary,2015,12,Total pharmaceutical sales,Million US$ at exchange rate,1669.7
15478,Hungary,2015,12,G-Genito urinary system and sex hormones,% of total sales,2.2
15479,Hungary,2015,12,Total pharmaceutical sales,"/capita, US$ exchange rate",169.6
15480,Hungary,2015,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",357.5
15481,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,19.8
15482,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5542.3
15483,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2
15484,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2
15485,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",41.8
15486,Hungary,2015,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.0
15487,Hungary,2015,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.1
15488,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,17.7
15489,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.8
15490,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",37.4
15491,Hungary,2015,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
15492,Hungary,2015,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,4957.9
15493,Hungary,2015,12,N05B-Anxiolytics,% of total sales,0.6
15494,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.0
15495,Hungary,2015,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",102.3
15496,Hungary,2015,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",4.9
15497,Hungary,2015,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,48.6
15498,Hungary,2015,12,J01-Antibacterials for systemic use,% of total sales,2.9
15499,Hungary,2015,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.4
15500,Hungary,2015,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.6
15501,Hungary,2015,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",364.9
15502,Hungary,2015,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.1
15503,Hungary,2015,12,B-Blood and blood forming organs,Million of national currency units,48375.2
15504,Hungary,2015,12,J01-Antibacterials for systemic use,Million of national currency units,13565.6
15505,Hungary,2015,12,B-Blood and blood forming organs,Million US$ at exchange rate,173.2
15506,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
15507,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,35.7
15508,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",75.2
15509,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9969.4
15510,Hungary,2015,12,C10-Lipid modifying agents,Million US$ at exchange rate,67.8
15511,Hungary,2015,12,C10-Lipid modifying agents,Million of national currency units,18929.3
15512,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.6
15513,Hungary,2015,12,N-Nervous system,Million of national currency units,60933.7
15514,Hungary,2015,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6
15515,Hungary,2015,12,N-Nervous system,Million US$ at exchange rate,218.1
15516,Hungary,2015,12,N-Nervous system,"Million US$, purchasing power parity",459.7
15517,Hungary,2015,12,C-Cardiovascular system,"Million US$, purchasing power parity",683.3
15518,Hungary,2015,12,C-Cardiovascular system,Million US$ at exchange rate,324.3
15519,Hungary,2015,12,C-Cardiovascular system,"/capita, US$ exchange rate",32.9
15520,Hungary,2015,12,C-Cardiovascular system,% of total sales,19.4
15521,Hungary,2015,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",69.4
15522,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",265.3
15523,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.8
15524,Hungary,2015,12,C-Cardiovascular system,Million of national currency units,90577.6
15525,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,35167.2
15526,Hungary,2015,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,125.9
15527,Hungary,2015,12,N-Nervous system,"/capita, US$ exchange rate",22.2
15528,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",67.2
15529,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.8
15530,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.2
15531,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.9
15532,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,31.9
15533,Hungary,2015,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8905.5
15534,Hungary,2015,12,C02-Antihypertensives,Million of national currency units,8633.8
15535,Hungary,2015,12,C02-Antihypertensives,Million US$ at exchange rate,30.9
15536,Hungary,2015,12,B-Blood and blood forming organs,% of total sales,10.4
15537,Hungary,2015,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.1
15538,Hungary,2015,12,C02-Antihypertensives,"Million US$, purchasing power parity",65.1
15539,Hungary,2014,12,C10-Lipid modifying agents,% of total sales,4.5
15540,Hungary,2014,12,A-Alimentary tract and metabolism,Million of national currency units,64320.4
15541,Hungary,2014,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",297.4
15542,Hungary,2014,12,A10-Drugs used in diabetes,Million US$ at exchange rate,165.5
15543,Hungary,2014,12,A10-Drugs used in diabetes,Million of national currency units,38486.2
15544,Hungary,2014,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.5
15545,Hungary,2014,12,C03-Diuretics,% of total sales,1.0
15546,Hungary,2014,12,C03-Diuretics,"/capita, US$ exchange rate",2.0
15547,Hungary,2014,12,C03-Diuretics,"Million US$, purchasing power parity",34.8
15548,Hungary,2014,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.0
15549,Hungary,2014,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",497.0
15550,Hungary,2014,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,276.5
15551,Hungary,2014,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.6
15552,Hungary,2014,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",15.5
15553,Hungary,2014,12,A02A-Antacids,Million of national currency units,0.0
15554,Hungary,2014,12,C08-Calcium channel blockers,Million of national currency units,3109.2
15555,Hungary,2014,12,N-Nervous system,"/capita, US$ purchasing power parity",46.8
15556,Hungary,2014,12,N06A-Antidepressants,% of total sales,2.4
15557,Hungary,2014,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",24.0
15558,Hungary,2014,12,C08-Calcium channel blockers,Million US$ at exchange rate,13.4
15559,Hungary,2014,12,N06A-Antidepressants,Million US$ at exchange rate,45.1
15560,Hungary,2014,12,N06A-Antidepressants,Million of national currency units,10500.3
15561,Hungary,2014,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.2
15562,Hungary,2014,12,N06A-Antidepressants,"/capita, US$ exchange rate",4.6
15563,Hungary,2014,12,N06A-Antidepressants,"Million US$, purchasing power parity",81.1
15564,Hungary,2014,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
15565,Hungary,2014,12,C01A-Cardiac glycosides,% of total sales,0.0
15566,Hungary,2014,12,C03-Diuretics,Million US$ at exchange rate,19.4
15567,Hungary,2014,12,A10-Drugs used in diabetes,% of total sales,8.7
15568,Hungary,2014,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8
15569,Hungary,2014,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",30.1
15570,Hungary,2014,12,N-Nervous system,% of total sales,13.5
15571,Hungary,2014,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.4
15572,Hungary,2014,12,C08-Calcium channel blockers,% of total sales,0.7
15573,Hungary,2014,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4
15574,Hungary,2014,12,J-Antiinfectives for systemic use,Million of national currency units,26838.3
15575,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",10.9
15576,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
15577,Hungary,2014,12,N02-Analgesics,"/capita, US$ exchange rate",2.3
15578,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1405.0
15579,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,6.0
15580,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
15581,Hungary,2014,12,A02A-Antacids,"/capita, US$ exchange rate",0.0
15582,Hungary,2014,12,A02A-Antacids,"Million US$, purchasing power parity",0.0
15583,Hungary,2014,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
15584,Hungary,2014,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
15585,Hungary,2014,12,A02A-Antacids,% of total sales,0.0
15586,Hungary,2014,12,A-Alimentary tract and metabolism,% of total sales,14.5
15587,Hungary,2014,12,R-Respiratory system,"Million US$, purchasing power parity",264.3
15588,Hungary,2014,12,R-Respiratory system,"/capita, US$ exchange rate",14.9
15589,Hungary,2014,12,R-Respiratory system,Million of national currency units,34198.5
15590,Hungary,2014,12,R-Respiratory system,Million US$ at exchange rate,147.0
15591,Hungary,2014,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.4
15592,Hungary,2014,12,N02-Analgesics,"Million US$, purchasing power parity",41.0
15593,Hungary,2014,12,N02-Analgesics,Million US$ at exchange rate,22.8
15594,Hungary,2014,12,R-Respiratory system,"/capita, US$ purchasing power parity",26.8
15595,Hungary,2014,12,N02-Analgesics,Million of national currency units,5304.8
15596,Hungary,2014,12,R-Respiratory system,% of total sales,7.7
15597,Hungary,2014,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",207.4
15598,Hungary,2014,12,C01A-Cardiac glycosides,Million US$ at exchange rate,0.9
15599,Hungary,2014,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",21.0
15600,Hungary,2014,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.7
15601,Hungary,2014,12,C03-Diuretics,Million of national currency units,4504.9
15602,Hungary,2014,12,C01A-Cardiac glycosides,Million of national currency units,204.0
15603,Hungary,2014,12,A02A-Antacids,Million US$ at exchange rate,0.0
15604,Hungary,2014,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,115.4
15605,Hungary,2014,12,J-Antiinfectives for systemic use,% of total sales,6.1
15606,Hungary,2014,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.2
15607,Hungary,2014,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
15608,Hungary,2014,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6
15609,Hungary,2014,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",137.2
15610,Hungary,2014,12,M-Musculo-skeletal system,Million US$ at exchange rate,76.3
15611,Hungary,2014,12,M-Musculo-skeletal system,% of total sales,4.0
15612,Hungary,2014,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.9
15613,Hungary,2014,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",7.7
15614,Hungary,2014,12,M-Musculo-skeletal system,Million of national currency units,17751.8
15615,Hungary,2014,12,G-Genito urinary system and sex hormones,Million of national currency units,9549.9
15616,Hungary,2014,12,N05C-Hypnotics and sedatives,% of total sales,0.0
15617,Hungary,2014,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.6
15618,Hungary,2014,12,C07-Beta blocking agents,% of total sales,2.2
15619,Hungary,2014,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
15620,Hungary,2014,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0
15621,Hungary,2014,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
15622,Hungary,2014,12,C07-Beta blocking agents,"Million US$, purchasing power parity",75.1
15623,Hungary,2014,12,C07-Beta blocking agents,Million US$ at exchange rate,41.8
15624,Hungary,2014,12,C07-Beta blocking agents,Million of national currency units,9722.1
15625,Hungary,2014,12,N05B-Anxiolytics,Million of national currency units,2958.9
15626,Hungary,2014,12,C07-Beta blocking agents,"/capita, US$ exchange rate",4.2
15627,Hungary,2014,12,N05B-Anxiolytics,"Million US$, purchasing power parity",22.9
15628,Hungary,2014,12,N05B-Anxiolytics,Million US$ at exchange rate,12.7
15629,Hungary,2014,12,C02-Antihypertensives,% of total sales,1.8
15630,Hungary,2014,12,R03-Drugs for obstructive airway diseases,Million of national currency units,29679.1
15631,Hungary,2014,12,N05C-Hypnotics and sedatives,Million of national currency units,1.1
15632,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.8
15633,Hungary,2014,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.3
15634,Hungary,2014,12,N02-Analgesics,% of total sales,1.2
15635,Hungary,2014,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",153.2
15636,Hungary,2014,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.2
15637,Hungary,2014,12,R03-Drugs for obstructive airway diseases,% of total sales,6.7
15638,Hungary,2014,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
15639,Hungary,2014,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,127.6
15640,Hungary,2014,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",12.9
15641,Hungary,2014,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",229.3
15642,Hungary,2014,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",73.8
15643,Hungary,2014,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",7.5
15644,Hungary,2014,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.2
15645,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.4
15646,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.0
15647,Hungary,2014,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,41.1
15648,Hungary,2014,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3422.7
15649,Hungary,2014,12,Total pharmaceutical sales,Million US$ at exchange rate,1904.3
15650,Hungary,2014,12,Total pharmaceutical sales,Million of national currency units,442945.7
15651,Hungary,2014,12,G-Genito urinary system and sex hormones,% of total sales,2.2
15652,Hungary,2014,12,Total pharmaceutical sales,"/capita, US$ exchange rate",193.0
15653,Hungary,2014,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",346.9
15654,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,23.9
15655,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5568.3
15656,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",43.0
15657,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.4
15658,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.3
15659,Hungary,2014,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.4
15660,Hungary,2014,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
15661,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,18.6
15662,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",33.4
15663,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.9
15664,Hungary,2014,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
15665,Hungary,2014,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,4324.3
15666,Hungary,2014,12,N05B-Anxiolytics,% of total sales,0.7
15667,Hungary,2014,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",102.3
15668,Hungary,2014,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8
15669,Hungary,2014,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,56.9
15670,Hungary,2014,12,J01-Antibacterials for systemic use,% of total sales,3.0
15671,Hungary,2014,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.4
15672,Hungary,2014,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.0
15673,Hungary,2014,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",337.4
15674,Hungary,2014,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.2
15675,Hungary,2014,12,B-Blood and blood forming organs,Million of national currency units,43658.2
15676,Hungary,2014,12,J01-Antibacterials for systemic use,Million of national currency units,13239.1
15677,Hungary,2014,12,B-Blood and blood forming organs,Million US$ at exchange rate,187.7
15678,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
15679,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,38.9
15680,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",70.0
15681,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.9
15682,Hungary,2014,12,C10-Lipid modifying agents,Million US$ at exchange rate,85.3
15683,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9057.8
15684,Hungary,2014,12,C10-Lipid modifying agents,Million of national currency units,19830.2
15685,Hungary,2014,12,N-Nervous system,Million of national currency units,59797.2
15686,Hungary,2014,12,N-Nervous system,Million US$ at exchange rate,257.1
15687,Hungary,2014,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.1
15688,Hungary,2014,12,N-Nervous system,"/capita, US$ exchange rate",26.1
15689,Hungary,2014,12,N-Nervous system,"Million US$, purchasing power parity",462.1
15690,Hungary,2014,12,C-Cardiovascular system,"/capita, US$ exchange rate",39.5
15691,Hungary,2014,12,C-Cardiovascular system,"Million US$, purchasing power parity",700.4
15692,Hungary,2014,12,C-Cardiovascular system,Million US$ at exchange rate,389.7
15693,Hungary,2014,12,C-Cardiovascular system,% of total sales,20.5
15694,Hungary,2014,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",71.0
15695,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",265.4
15696,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",26.9
15697,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.0
15698,Hungary,2014,12,C-Cardiovascular system,Million of national currency units,90647.4
15699,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,34341.3
15700,Hungary,2014,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,147.6
15701,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.9
15702,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8814.9
15703,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0
15704,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.8
15705,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,37.9
15706,Hungary,2014,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",68.1
15707,Hungary,2014,12,C02-Antihypertensives,Million US$ at exchange rate,34.8
15708,Hungary,2014,12,C02-Antihypertensives,Million of national currency units,8102.4
15709,Hungary,2014,12,B-Blood and blood forming organs,% of total sales,9.9
15710,Hungary,2014,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.5
15711,Hungary,2014,12,C02-Antihypertensives,"Million US$, purchasing power parity",62.6
15712,Hungary,2013,12,C10-Lipid modifying agents,% of total sales,5.3
15713,Hungary,2013,12,A-Alimentary tract and metabolism,Million of national currency units,60613.7
15714,Hungary,2013,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",284.5
15715,Hungary,2013,12,A10-Drugs used in diabetes,Million US$ at exchange rate,159.0
15716,Hungary,2013,12,A10-Drugs used in diabetes,Million of national currency units,35559.7
15717,Hungary,2013,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,271.0
15718,Hungary,2013,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.8
15719,Hungary,2013,12,C03-Diuretics,% of total sales,1.1
15720,Hungary,2013,12,C03-Diuretics,"Million US$, purchasing power parity",37.1
15721,Hungary,2013,12,C03-Diuretics,"/capita, US$ exchange rate",2.1
15722,Hungary,2013,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",27.4
15723,Hungary,2013,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",485.0
15724,Hungary,2013,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.3
15725,Hungary,2013,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",18.5
15726,Hungary,2013,12,A02A-Antacids,Million of national currency units,0.0
15727,Hungary,2013,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.1
15728,Hungary,2013,12,C08-Calcium channel blockers,Million of national currency units,3769.8
15729,Hungary,2013,12,N-Nervous system,"/capita, US$ purchasing power parity",47.6
15730,Hungary,2013,12,N06A-Antidepressants,% of total sales,2.5
15731,Hungary,2013,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",30.2
15732,Hungary,2013,12,C08-Calcium channel blockers,Million US$ at exchange rate,16.9
15733,Hungary,2013,12,N06A-Antidepressants,Million US$ at exchange rate,47.9
15734,Hungary,2013,12,N06A-Antidepressants,"Million US$, purchasing power parity",85.8
15735,Hungary,2013,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.7
15736,Hungary,2013,12,N06A-Antidepressants,"/capita, US$ exchange rate",4.8
15737,Hungary,2013,12,C01A-Cardiac glycosides,% of total sales,0.1
15738,Hungary,2013,12,N06A-Antidepressants,Million of national currency units,10723.6
15739,Hungary,2013,12,A10-Drugs used in diabetes,% of total sales,8.3
15740,Hungary,2013,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",28.8
15741,Hungary,2013,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
15742,Hungary,2013,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.7
15743,Hungary,2013,12,N-Nervous system,% of total sales,13.7
15744,Hungary,2013,12,C08-Calcium channel blockers,% of total sales,0.9
15745,Hungary,2013,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.0
15746,Hungary,2013,12,C03-Diuretics,Million US$ at exchange rate,20.8
15747,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.3
15748,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
15749,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
15750,Hungary,2013,12,N02-Analgesics,"/capita, US$ exchange rate",2.4
15751,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1406.9
15752,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,6.3
15753,Hungary,2013,12,A02A-Antacids,"/capita, US$ exchange rate",0.0
15754,Hungary,2013,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
15755,Hungary,2013,12,A02A-Antacids,"Million US$, purchasing power parity",0.0
15756,Hungary,2013,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
15757,Hungary,2013,12,A02A-Antacids,% of total sales,0.0
15758,Hungary,2013,12,A-Alimentary tract and metabolism,% of total sales,14.1
15759,Hungary,2013,12,R-Respiratory system,"Million US$, purchasing power parity",274.3
15760,Hungary,2013,12,R-Respiratory system,"/capita, US$ exchange rate",15.5
15761,Hungary,2013,12,R-Respiratory system,Million of national currency units,34278.8
15762,Hungary,2013,12,R-Respiratory system,Million US$ at exchange rate,153.2
15763,Hungary,2013,12,N02-Analgesics,Million US$ at exchange rate,23.4
15764,Hungary,2013,12,N02-Analgesics,"Million US$, purchasing power parity",41.8
15765,Hungary,2013,12,R-Respiratory system,"/capita, US$ purchasing power parity",27.7
15766,Hungary,2013,12,R-Respiratory system,% of total sales,8.0
15767,Hungary,2013,12,N02-Analgesics,Million of national currency units,5228.6
15768,Hungary,2013,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",192.7
15769,Hungary,2013,12,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0
15770,Hungary,2013,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",10.9
15771,Hungary,2013,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.5
15772,Hungary,2013,12,J-Antiinfectives for systemic use,Million of national currency units,24081.3
15773,Hungary,2013,12,C03-Diuretics,Million of national currency units,4641.7
15774,Hungary,2013,12,C01A-Cardiac glycosides,Million of national currency units,219.9
15775,Hungary,2013,12,A02A-Antacids,Million US$ at exchange rate,0.0
15776,Hungary,2013,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,107.7
15777,Hungary,2013,12,M-Musculo-skeletal system,Million of national currency units,18632.7
15778,Hungary,2013,12,J-Antiinfectives for systemic use,% of total sales,5.6
15779,Hungary,2013,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.2
15780,Hungary,2013,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
15781,Hungary,2013,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.8
15782,Hungary,2013,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",149.1
15783,Hungary,2013,12,M-Musculo-skeletal system,Million US$ at exchange rate,83.3
15784,Hungary,2013,12,M-Musculo-skeletal system,% of total sales,4.3
15785,Hungary,2013,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1
15786,Hungary,2013,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.4
15787,Hungary,2013,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.0
15788,Hungary,2013,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",182.7
15789,Hungary,2013,12,G-Genito urinary system and sex hormones,Million of national currency units,9141.6
15790,Hungary,2013,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.1
15791,Hungary,2013,12,C07-Beta blocking agents,% of total sales,2.3
15792,Hungary,2013,12,N05C-Hypnotics and sedatives,% of total sales,0.0
15793,Hungary,2013,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
15794,Hungary,2013,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0
15795,Hungary,2013,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
15796,Hungary,2013,12,C07-Beta blocking agents,"Million US$, purchasing power parity",79.6
15797,Hungary,2013,12,C07-Beta blocking agents,Million US$ at exchange rate,44.5
15798,Hungary,2013,12,C07-Beta blocking agents,Million of national currency units,9953.6
15799,Hungary,2013,12,N05B-Anxiolytics,Million US$ at exchange rate,13.3
15800,Hungary,2013,12,C07-Beta blocking agents,"/capita, US$ exchange rate",4.5
15801,Hungary,2013,12,N05B-Anxiolytics,"Million US$, purchasing power parity",23.8
15802,Hungary,2013,12,N02-Analgesics,% of total sales,1.2
15803,Hungary,2013,12,C02-Antihypertensives,% of total sales,1.8
15804,Hungary,2013,12,R03-Drugs for obstructive airway diseases,Million of national currency units,29536.7
15805,Hungary,2013,12,N05C-Hypnotics and sedatives,Million of national currency units,0.8
15806,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.2
15807,Hungary,2013,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.1
15808,Hungary,2013,12,R03-Drugs for obstructive airway diseases,% of total sales,6.9
15809,Hungary,2013,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.9
15810,Hungary,2013,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
15811,Hungary,2013,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,132.0
15812,Hungary,2013,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",236.3
15813,Hungary,2013,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.3
15814,Hungary,2013,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",73.1
15815,Hungary,2013,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.1
15816,Hungary,2013,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",7.4
15817,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,% of total sales,1.0
15818,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.3
15819,Hungary,2013,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,40.9
15820,Hungary,2013,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3441.9
15821,Hungary,2013,12,Total pharmaceutical sales,Million of national currency units,430163.5
15822,Hungary,2013,12,Total pharmaceutical sales,Million US$ at exchange rate,1923.0
15823,Hungary,2013,12,G-Genito urinary system and sex hormones,% of total sales,2.1
15824,Hungary,2013,12,Total pharmaceutical sales,"/capita, US$ exchange rate",194.4
15825,Hungary,2013,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",347.9
15826,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,23.5
15827,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",42.0
15828,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5250.0
15829,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2
15830,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2
15831,Hungary,2013,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.4
15832,Hungary,2013,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
15833,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,18.4
15834,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.9
15835,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",32.9
15836,Hungary,2013,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
15837,Hungary,2013,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,4108.8
15838,Hungary,2013,12,N05B-Anxiolytics,% of total sales,0.7
15839,Hungary,2013,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8
15840,Hungary,2013,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",103.5
15841,Hungary,2013,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,57.8
15842,Hungary,2013,12,J01-Antibacterials for systemic use,% of total sales,3.0
15843,Hungary,2013,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.5
15844,Hungary,2013,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.6
15845,Hungary,2013,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",311.8
15846,Hungary,2013,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.5
15847,Hungary,2013,12,B-Blood and blood forming organs,Million of national currency units,38973.8
15848,Hungary,2013,12,J01-Antibacterials for systemic use,Million of national currency units,12938.1
15849,Hungary,2013,12,B-Blood and blood forming organs,Million US$ at exchange rate,174.2
15850,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,37.1
15851,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.8
15852,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",66.5
15853,Hungary,2013,12,C10-Lipid modifying agents,Million US$ at exchange rate,102.1
15854,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,8307.2
15855,Hungary,2013,12,C10-Lipid modifying agents,Million of national currency units,22838.1
15856,Hungary,2013,12,N-Nervous system,Million of national currency units,58867.3
15857,Hungary,2013,12,N-Nervous system,Million US$ at exchange rate,263.2
15858,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
15859,Hungary,2013,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.7
15860,Hungary,2013,12,N-Nervous system,"/capita, US$ exchange rate",26.6
15861,Hungary,2013,12,N-Nervous system,"Million US$, purchasing power parity",471.0
15862,Hungary,2013,12,C-Cardiovascular system,"/capita, US$ exchange rate",43.1
15863,Hungary,2013,12,C-Cardiovascular system,"Million US$, purchasing power parity",763.3
15864,Hungary,2013,12,C-Cardiovascular system,Million US$ at exchange rate,426.5
15865,Hungary,2013,12,C-Cardiovascular system,% of total sales,22.2
15866,Hungary,2013,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",77.2
15867,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",281.9
15868,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.9
15869,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.5
15870,Hungary,2013,12,C-Cardiovascular system,Million of national currency units,95396.2
15871,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,35227.6
15872,Hungary,2013,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,157.5
15873,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.3
15874,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,9057.7
15875,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.1
15876,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",4.1
15877,Hungary,2013,12,N05B-Anxiolytics,Million of national currency units,2974.6
15878,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,40.5
15879,Hungary,2013,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",72.5
15880,Hungary,2013,12,C02-Antihypertensives,Million US$ at exchange rate,33.9
15881,Hungary,2013,12,B-Blood and blood forming organs,% of total sales,9.1
15882,Hungary,2013,12,C02-Antihypertensives,Million of national currency units,7583.8
15883,Hungary,2013,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.4
15884,Hungary,2013,12,C02-Antihypertensives,"Million US$, purchasing power parity",60.7
15885,Hungary,2012,12,A-Alimentary tract and metabolism,Million of national currency units,64446.7
15886,Hungary,2012,12,C10-Lipid modifying agents,% of total sales,6.3
15887,Hungary,2012,12,A10-Drugs used in diabetes,"Million US$, purchasing power parity",273.7
15888,Hungary,2012,12,A10-Drugs used in diabetes,Million of national currency units,34389.1
15889,Hungary,2012,12,A10-Drugs used in diabetes,Million US$ at exchange rate,152.8
15890,Hungary,2012,12,C03-Diuretics,"/capita, US$ purchasing power parity",3.9
15891,Hungary,2012,12,C03-Diuretics,% of total sales,1.1
15892,Hungary,2012,12,C03-Diuretics,"Million US$, purchasing power parity",38.5
15893,Hungary,2012,12,C03-Diuretics,"/capita, US$ exchange rate",2.2
15894,Hungary,2012,12,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.9
15895,Hungary,2012,12,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",513.0
15896,Hungary,2012,12,A02A-Antacids,Million of national currency units,0.0
15897,Hungary,2012,12,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.5
15898,Hungary,2012,12,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.4
15899,Hungary,2012,12,A-Alimentary tract and metabolism,Million US$ at exchange rate,286.3
15900,Hungary,2012,12,N-Nervous system,"/capita, US$ purchasing power parity",47.0
15901,Hungary,2012,12,N06A-Antidepressants,% of total sales,2.5
15902,Hungary,2012,12,C08-Calcium channel blockers,"Million US$, purchasing power parity",44.0
15903,Hungary,2012,12,C08-Calcium channel blockers,Million US$ at exchange rate,24.6
15904,Hungary,2012,12,C08-Calcium channel blockers,Million of national currency units,5530.2
15905,Hungary,2012,12,N06A-Antidepressants,Million US$ at exchange rate,49.2
15906,Hungary,2012,12,N06A-Antidepressants,"Million US$, purchasing power parity",88.1
15907,Hungary,2012,12,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.9
15908,Hungary,2012,12,N06A-Antidepressants,"/capita, US$ exchange rate",5.0
15909,Hungary,2012,12,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.4
15910,Hungary,2012,12,C01A-Cardiac glycosides,% of total sales,0.1
15911,Hungary,2012,12,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",27.6
15912,Hungary,2012,12,N06A-Antidepressants,Million of national currency units,11070.4
15913,Hungary,2012,12,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
15914,Hungary,2012,12,A10-Drugs used in diabetes,% of total sales,7.7
15915,Hungary,2012,12,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.5
15916,Hungary,2012,12,N-Nervous system,% of total sales,13.2
15917,Hungary,2012,12,C08-Calcium channel blockers,% of total sales,1.2
15918,Hungary,2012,12,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4
15919,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.4
15920,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
15921,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.1
15922,Hungary,2012,12,N02-Analgesics,"/capita, US$ exchange rate",2.4
15923,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1427.3
15924,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,6.3
15925,Hungary,2012,12,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
15926,Hungary,2012,12,A02A-Antacids,"/capita, US$ exchange rate",0.0
15927,Hungary,2012,12,A02A-Antacids,"Million US$, purchasing power parity",0.0
15928,Hungary,2012,12,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
15929,Hungary,2012,12,A02A-Antacids,% of total sales,0.0
15930,Hungary,2012,12,A-Alimentary tract and metabolism,% of total sales,14.5
15931,Hungary,2012,12,R-Respiratory system,"Million US$, purchasing power parity",268.8
15932,Hungary,2012,12,R-Respiratory system,"/capita, US$ exchange rate",15.1
15933,Hungary,2012,12,R-Respiratory system,Million of national currency units,33762.7
15934,Hungary,2012,12,R-Respiratory system,Million US$ at exchange rate,150.0
15935,Hungary,2012,12,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.7
15936,Hungary,2012,12,N02-Analgesics,Million US$ at exchange rate,23.4
15937,Hungary,2012,12,N02-Analgesics,"Million US$, purchasing power parity",42.0
15938,Hungary,2012,12,R-Respiratory system,"/capita, US$ purchasing power parity",27.1
15939,Hungary,2012,12,R-Respiratory system,% of total sales,7.6
15940,Hungary,2012,12,N02-Analgesics,Million of national currency units,5276.2
15941,Hungary,2012,12,C03-Diuretics,Million US$ at exchange rate,21.5
15942,Hungary,2012,12,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",169.0
15943,Hungary,2012,12,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0
15944,Hungary,2012,12,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.0
15945,Hungary,2012,12,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.5
15946,Hungary,2012,12,J-Antiinfectives for systemic use,Million of national currency units,21233.6
15947,Hungary,2012,12,C03-Diuretics,Million of national currency units,4833.0
15948,Hungary,2012,12,C01A-Cardiac glycosides,Million of national currency units,234.3
15949,Hungary,2012,12,A02A-Antacids,Million US$ at exchange rate,0.0
15950,Hungary,2012,12,J-Antiinfectives for systemic use,Million US$ at exchange rate,94.3
15951,Hungary,2012,12,M-Musculo-skeletal system,Million of national currency units,19341.8
15952,Hungary,2012,12,J-Antiinfectives for systemic use,% of total sales,4.8
15953,Hungary,2012,12,N02-Analgesics,"/capita, US$ purchasing power parity",4.2
15954,Hungary,2012,12,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
15955,Hungary,2012,12,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.9
15956,Hungary,2012,12,M-Musculo-skeletal system,"Million US$, purchasing power parity",154.0
15957,Hungary,2012,12,M-Musculo-skeletal system,Million US$ at exchange rate,85.9
15958,Hungary,2012,12,M-Musculo-skeletal system,% of total sales,4.4
15959,Hungary,2012,12,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.5
15960,Hungary,2012,12,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.7
15961,Hungary,2012,12,G-Genito urinary system and sex hormones,Million of national currency units,8098.7
15962,Hungary,2012,12,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.3
15963,Hungary,2012,12,C07-Beta blocking agents,% of total sales,2.3
15964,Hungary,2012,12,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
15965,Hungary,2012,12,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0
15966,Hungary,2012,12,N05C-Hypnotics and sedatives,% of total sales,0.0
15967,Hungary,2012,12,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
15968,Hungary,2012,12,C07-Beta blocking agents,"Million US$, purchasing power parity",82.6
15969,Hungary,2012,12,C07-Beta blocking agents,Million of national currency units,10376.8
15970,Hungary,2012,12,C07-Beta blocking agents,Million US$ at exchange rate,46.1
15971,Hungary,2012,12,N05B-Anxiolytics,Million US$ at exchange rate,13.1
15972,Hungary,2012,12,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6
15973,Hungary,2012,12,N05B-Anxiolytics,"Million US$, purchasing power parity",23.5
15974,Hungary,2012,12,N02-Analgesics,% of total sales,1.2
15975,Hungary,2012,12,C02-Antihypertensives,% of total sales,1.7
15976,Hungary,2012,12,R03-Drugs for obstructive airway diseases,Million of national currency units,28440.2
15977,Hungary,2012,12,N05C-Hypnotics and sedatives,Million of national currency units,0.5
15978,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.5
15979,Hungary,2012,12,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.9
15980,Hungary,2012,12,R03-Drugs for obstructive airway diseases,% of total sales,6.4
15981,Hungary,2012,12,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.8
15982,Hungary,2012,12,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
15983,Hungary,2012,12,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,126.3
15984,Hungary,2012,12,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",226.4
15985,Hungary,2012,12,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",12.7
15986,Hungary,2012,12,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",64.5
15987,Hungary,2012,12,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.5
15988,Hungary,2012,12,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.6
15989,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,% of total sales,0.8
15990,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.7
15991,Hungary,2012,12,G-Genito urinary system and sex hormones,Million US$ at exchange rate,36.0
15992,Hungary,2012,12,Total pharmaceutical sales,"Million US$, purchasing power parity",3538.7
15993,Hungary,2012,12,Total pharmaceutical sales,Million of national currency units,444548.6
15994,Hungary,2012,12,Total pharmaceutical sales,Million US$ at exchange rate,1974.9
15995,Hungary,2012,12,Total pharmaceutical sales,"/capita, US$ exchange rate",199.1
15996,Hungary,2012,12,G-Genito urinary system and sex hormones,% of total sales,1.8
15997,Hungary,2012,12,Total pharmaceutical sales,"/capita, US$ purchasing power parity",356.7
15998,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,23.0
15999,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",41.2
16000,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5181.6
16001,Hungary,2012,12,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
16002,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2
16003,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2
16004,Hungary,2012,12,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.3
16005,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,15.2
16006,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",27.3
16007,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.5
16008,Hungary,2012,12,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
16009,Hungary,2012,12,G03-Sex hormones and modulators of the genital system,Million of national currency units,3423.8
16010,Hungary,2012,12,N05B-Anxiolytics,% of total sales,0.7
16011,Hungary,2012,12,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8
16012,Hungary,2012,12,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",102.9
16013,Hungary,2012,12,J01-Antibacterials for systemic use,Million US$ at exchange rate,57.4
16014,Hungary,2012,12,J01-Antibacterials for systemic use,% of total sales,2.9
16015,Hungary,2012,12,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.4
16016,Hungary,2012,12,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.5
16017,Hungary,2012,12,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.4
16018,Hungary,2012,12,B-Blood and blood forming organs,"Million US$, purchasing power parity",311.0
16019,Hungary,2012,12,B-Blood and blood forming organs,Million of national currency units,39070.0
16020,Hungary,2012,12,J01-Antibacterials for systemic use,Million of national currency units,12925.5
16021,Hungary,2012,12,B-Blood and blood forming organs,Million US$ at exchange rate,173.6
16022,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,36.4
16023,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.7
16024,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",65.2
16025,Hungary,2012,12,C10-Lipid modifying agents,Million US$ at exchange rate,124.2
16026,Hungary,2012,12,C10-Lipid modifying agents,"Million US$, purchasing power parity",222.6
16027,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,8192.9
16028,Hungary,2012,12,C10-Lipid modifying agents,Million of national currency units,27959.9
16029,Hungary,2012,12,N-Nervous system,Million of national currency units,58615.1
16030,Hungary,2012,12,N-Nervous system,Million US$ at exchange rate,260.4
16031,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
16032,Hungary,2012,12,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.6
16033,Hungary,2012,12,N-Nervous system,"/capita, US$ exchange rate",26.2
16034,Hungary,2012,12,N-Nervous system,"Million US$, purchasing power parity",466.6
16035,Hungary,2012,12,B-Blood and blood forming organs,% of total sales,8.8
16036,Hungary,2012,12,C-Cardiovascular system,"/capita, US$ exchange rate",47.4
16037,Hungary,2012,12,C-Cardiovascular system,"Million US$, purchasing power parity",843.0
16038,Hungary,2012,12,C-Cardiovascular system,Million US$ at exchange rate,470.4
16039,Hungary,2012,12,C-Cardiovascular system,% of total sales,23.8
16040,Hungary,2012,12,C-Cardiovascular system,"/capita, US$ purchasing power parity",85.0
16041,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",302.3
16042,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",17.0
16043,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",30.5
16044,Hungary,2012,12,C-Cardiovascular system,Million of national currency units,105895.0
16045,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,37976.3
16046,Hungary,2012,12,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,168.7
16047,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.2
16048,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,12740.4
16049,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.9
16050,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.7
16051,Hungary,2012,12,N05B-Anxiolytics,Million of national currency units,2947.0
16052,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,56.6
16053,Hungary,2012,12,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",101.4
16054,Hungary,2012,12,C02-Antihypertensives,Million US$ at exchange rate,32.8
16055,Hungary,2012,12,C02-Antihypertensives,Million of national currency units,7380.4
16056,Hungary,2012,12,C02-Antihypertensives,"/capita, US$ exchange rate",3.3
16057,Hungary,2012,12,C02-Antihypertensives,"Million US$, purchasing power parity",58.8
16058,Hungary,2010,13,A-Alimentary tract and metabolism,Million of national currency units,64095.7
16059,Hungary,2010,13,C10-Lipid modifying agents,% of total sales,7.5
16060,Hungary,2010,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",241.8
16061,Hungary,2010,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,308.2
16062,Hungary,2010,13,A10-Drugs used in diabetes,Million of national currency units,30573.8
16063,Hungary,2010,13,A10-Drugs used in diabetes,Million US$ at exchange rate,147.0
16064,Hungary,2010,13,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
16065,Hungary,2010,13,C03-Diuretics,% of total sales,0.9
16066,Hungary,2010,13,C03-Diuretics,"Million US$, purchasing power parity",36.7
16067,Hungary,2010,13,C03-Diuretics,"/capita, US$ exchange rate",2.2
16068,Hungary,2010,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",30.8
16069,Hungary,2010,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",507.0
16070,Hungary,2010,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",14.7
16071,Hungary,2010,13,A02A-Antacids,Million of national currency units,0.0
16072,Hungary,2010,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.9
16073,Hungary,2010,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",29.4
16074,Hungary,2010,13,N-Nervous system,"/capita, US$ purchasing power parity",49.1
16075,Hungary,2010,13,N06A-Antidepressants,% of total sales,2.4
16076,Hungary,2010,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",55.1
16077,Hungary,2010,13,C08-Calcium channel blockers,Million US$ at exchange rate,33.5
16078,Hungary,2010,13,N06A-Antidepressants,"Million US$, purchasing power parity",94.5
16079,Hungary,2010,13,N06A-Antidepressants,Million US$ at exchange rate,57.5
16080,Hungary,2010,13,C08-Calcium channel blockers,Million of national currency units,6967.9
16081,Hungary,2010,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.5
16082,Hungary,2010,13,N06A-Antidepressants,"/capita, US$ exchange rate",5.7
16083,Hungary,2010,13,C01A-Cardiac glycosides,% of total sales,0.1
16084,Hungary,2010,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.2
16085,Hungary,2010,13,N06A-Antidepressants,Million of national currency units,11947.1
16086,Hungary,2010,13,A10-Drugs used in diabetes,% of total sales,6.1
16087,Hungary,2010,13,N-Nervous system,% of total sales,12.5
16088,Hungary,2010,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.4
16089,Hungary,2010,13,C08-Calcium channel blockers,% of total sales,1.4
16090,Hungary,2010,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.5
16091,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.0
16092,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
16093,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
16094,Hungary,2010,13,N02-Analgesics,"/capita, US$ exchange rate",2.6
16095,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1511.2
16096,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.3
16097,Hungary,2010,13,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
16098,Hungary,2010,13,A02A-Antacids,"Million US$, purchasing power parity",0.0
16099,Hungary,2010,13,A02A-Antacids,"/capita, US$ exchange rate",0.0
16100,Hungary,2010,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
16101,Hungary,2010,13,A02A-Antacids,% of total sales,0.0
16102,Hungary,2010,13,R-Respiratory system,"Million US$, purchasing power parity",269.1
16103,Hungary,2010,13,R-Respiratory system,"/capita, US$ exchange rate",16.4
16104,Hungary,2010,13,R-Respiratory system,Million of national currency units,34020.0
16105,Hungary,2010,13,R-Respiratory system,Million US$ at exchange rate,163.6
16106,Hungary,2010,13,N02-Analgesics,Million US$ at exchange rate,25.8
16107,Hungary,2010,13,N02-Analgesics,"Million US$, purchasing power parity",42.4
16108,Hungary,2010,13,A-Alimentary tract and metabolism,% of total sales,12.9
16109,Hungary,2010,13,R-Respiratory system,"/capita, US$ purchasing power parity",26.9
16110,Hungary,2010,13,R-Respiratory system,% of total sales,6.8
16111,Hungary,2010,13,N02-Analgesics,Million of national currency units,5356.6
16112,Hungary,2010,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",175.0
16113,Hungary,2010,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.2
16114,Hungary,2010,13,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3
16115,Hungary,2010,13,M-Musculo-skeletal system,Million of national currency units,22271.6
16116,Hungary,2010,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.7
16117,Hungary,2010,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",10.6
16118,Hungary,2010,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.5
16119,Hungary,2010,13,J-Antiinfectives for systemic use,Million of national currency units,22127.8
16120,Hungary,2010,13,C03-Diuretics,Million of national currency units,4641.1
16121,Hungary,2010,13,C03-Diuretics,Million US$ at exchange rate,22.3
16122,Hungary,2010,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,106.4
16123,Hungary,2010,13,C01A-Cardiac glycosides,Million of national currency units,279.1
16124,Hungary,2010,13,A02A-Antacids,Million US$ at exchange rate,0.0
16125,Hungary,2010,13,J-Antiinfectives for systemic use,% of total sales,4.4
16126,Hungary,2010,13,N02-Analgesics,"/capita, US$ purchasing power parity",4.2
16127,Hungary,2010,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
16128,Hungary,2010,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
16129,Hungary,2010,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",176.2
16130,Hungary,2010,13,M-Musculo-skeletal system,Million US$ at exchange rate,107.1
16131,Hungary,2010,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.7
16132,Hungary,2010,13,M-Musculo-skeletal system,% of total sales,4.5
16133,Hungary,2010,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.6
16134,Hungary,2010,13,G-Genito urinary system and sex hormones,Million of national currency units,7875.0
16135,Hungary,2010,13,C07-Beta blocking agents,% of total sales,2.4
16136,Hungary,2010,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.5
16137,Hungary,2010,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
16138,Hungary,2010,13,N05C-Hypnotics and sedatives,% of total sales,0.0
16139,Hungary,2010,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
16140,Hungary,2010,13,C07-Beta blocking agents,"Million US$, purchasing power parity",95.5
16141,Hungary,2010,13,C07-Beta blocking agents,Million of national currency units,12071.4
16142,Hungary,2010,13,C07-Beta blocking agents,Million US$ at exchange rate,58.1
16143,Hungary,2010,13,N05B-Anxiolytics,Million US$ at exchange rate,14.0
16144,Hungary,2010,13,C07-Beta blocking agents,"/capita, US$ exchange rate",5.8
16145,Hungary,2010,13,N05B-Anxiolytics,"Million US$, purchasing power parity",23.0
16146,Hungary,2010,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.1
16147,Hungary,2010,13,N02-Analgesics,% of total sales,1.1
16148,Hungary,2010,13,C02-Antihypertensives,% of total sales,1.5
16149,Hungary,2010,13,R03-Drugs for obstructive airway diseases,Million of national currency units,27620.8
16150,Hungary,2010,13,N05C-Hypnotics and sedatives,Million of national currency units,9.8
16151,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.7
16152,Hungary,2010,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.8
16153,Hungary,2010,13,R03-Drugs for obstructive airway diseases,% of total sales,5.5
16154,Hungary,2010,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.8
16155,Hungary,2010,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
16156,Hungary,2010,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,132.8
16157,Hungary,2010,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",218.5
16158,Hungary,2010,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.3
16159,Hungary,2010,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",62.3
16160,Hungary,2010,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.8
16161,Hungary,2010,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.2
16162,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,% of total sales,0.7
16163,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.7
16164,Hungary,2010,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,37.9
16165,Hungary,2010,13,Total pharmaceutical sales,"Million US$, purchasing power parity",3940.5
16166,Hungary,2010,13,Total pharmaceutical sales,Million of national currency units,498140.3
16167,Hungary,2010,13,Total pharmaceutical sales,Million US$ at exchange rate,2395.5
16168,Hungary,2010,13,Total pharmaceutical sales,"/capita, US$ exchange rate",239.6
16169,Hungary,2010,13,G-Genito urinary system and sex hormones,% of total sales,1.6
16170,Hungary,2010,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",394.0
16171,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,31.0
16172,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.0
16173,Hungary,2010,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
16174,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6442.7
16175,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.3
16176,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.1
16177,Hungary,2010,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.1
16178,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",26.5
16179,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,16.1
16180,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.6
16181,Hungary,2010,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
16182,Hungary,2010,13,N05B-Anxiolytics,% of total sales,0.6
16183,Hungary,2010,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,3352.5
16184,Hungary,2010,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.9
16185,Hungary,2010,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,69.0
16186,Hungary,2010,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",113.4
16187,Hungary,2010,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.3
16188,Hungary,2010,13,J01-Antibacterials for systemic use,% of total sales,2.9
16189,Hungary,2010,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.9
16190,Hungary,2010,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.1
16191,Hungary,2010,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",311.2
16192,Hungary,2010,13,B-Blood and blood forming organs,Million of national currency units,39342.1
16193,Hungary,2010,13,J01-Antibacterials for systemic use,Million of national currency units,14338.6
16194,Hungary,2010,13,B-Blood and blood forming organs,Million US$ at exchange rate,189.2
16195,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,33.4
16196,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3
16197,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",54.9
16198,Hungary,2010,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",294.2
16199,Hungary,2010,13,C10-Lipid modifying agents,Million US$ at exchange rate,178.8
16200,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,6945.0
16201,Hungary,2010,13,C10-Lipid modifying agents,Million of national currency units,37190.0
16202,Hungary,2010,13,N-Nervous system,Million US$ at exchange rate,298.7
16203,Hungary,2010,13,N-Nervous system,Million of national currency units,62105.9
16204,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
16205,Hungary,2010,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.5
16206,Hungary,2010,13,N-Nervous system,"/capita, US$ exchange rate",29.9
16207,Hungary,2010,13,N-Nervous system,"Million US$, purchasing power parity",491.3
16208,Hungary,2010,13,B-Blood and blood forming organs,% of total sales,7.9
16209,Hungary,2010,13,C-Cardiovascular system,"/capita, US$ exchange rate",62.5
16210,Hungary,2010,13,C-Cardiovascular system,Million US$ at exchange rate,625.1
16211,Hungary,2010,13,C-Cardiovascular system,"Million US$, purchasing power parity",1028.2
16212,Hungary,2010,13,C-Cardiovascular system,% of total sales,26.1
16213,Hungary,2010,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",102.8
16214,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",380.3
16215,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.1
16216,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",38.0
16217,Hungary,2010,13,C-Cardiovascular system,Million of national currency units,129978.7
16218,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,48076.5
16219,Hungary,2010,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,231.2
16220,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.8
16221,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.8
16222,Hungary,2010,13,N05B-Anxiolytics,Million of national currency units,2903.2
16223,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,89.9
16224,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.0
16225,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",147.8
16226,Hungary,2010,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,18687.7
16227,Hungary,2010,13,C02-Antihypertensives,Million US$ at exchange rate,35.3
16228,Hungary,2010,13,C02-Antihypertensives,Million of national currency units,7338.5
16229,Hungary,2010,13,C02-Antihypertensives,"/capita, US$ exchange rate",3.5
16230,Hungary,2010,13,C02-Antihypertensives,"Million US$, purchasing power parity",58.0
16231,Hungary,2011,13,A-Alimentary tract and metabolism,Million of national currency units,68963.5
16232,Hungary,2011,13,C10-Lipid modifying agents,% of total sales,7.2
16233,Hungary,2011,13,A10-Drugs used in diabetes,"Million US$, purchasing power parity",268.9
16234,Hungary,2011,13,A10-Drugs used in diabetes,Million of national currency units,33416.2
16235,Hungary,2011,13,A10-Drugs used in diabetes,Million US$ at exchange rate,166.2
16236,Hungary,2011,13,A-Alimentary tract and metabolism,Million US$ at exchange rate,343.0
16237,Hungary,2011,13,C03-Diuretics,"/capita, US$ purchasing power parity",3.9
16238,Hungary,2011,13,C03-Diuretics,% of total sales,0.9
16239,Hungary,2011,13,C03-Diuretics,"Million US$, purchasing power parity",39.1
16240,Hungary,2011,13,C03-Diuretics,"/capita, US$ exchange rate",2.4
16241,Hungary,2011,13,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",34.4
16242,Hungary,2011,13,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",554.9
16243,Hungary,2011,13,A02A-Antacids,Million of national currency units,0.0
16244,Hungary,2011,13,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.5
16245,Hungary,2011,13,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",29.9
16246,Hungary,2011,13,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.7
16247,Hungary,2011,13,N-Nervous system,"/capita, US$ purchasing power parity",52.0
16248,Hungary,2011,13,N06A-Antidepressants,% of total sales,2.4
16249,Hungary,2011,13,C08-Calcium channel blockers,"Million US$, purchasing power parity",54.7
16250,Hungary,2011,13,C08-Calcium channel blockers,Million US$ at exchange rate,33.8
16251,Hungary,2011,13,N06A-Antidepressants,"Million US$, purchasing power parity",101.1
16252,Hungary,2011,13,N06A-Antidepressants,Million US$ at exchange rate,62.5
16253,Hungary,2011,13,C08-Calcium channel blockers,Million of national currency units,6798.9
16254,Hungary,2011,13,N06A-Antidepressants,"/capita, US$ purchasing power parity",10.1
16255,Hungary,2011,13,N06A-Antidepressants,"/capita, US$ exchange rate",6.3
16256,Hungary,2011,13,N-Nervous system,% of total sales,12.5
16257,Hungary,2011,13,C01A-Cardiac glycosides,% of total sales,0.1
16258,Hungary,2011,13,A10-Drugs used in diabetes,% of total sales,6.5
16259,Hungary,2011,13,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",27.0
16260,Hungary,2011,13,N06A-Antidepressants,Million of national currency units,12569.5
16261,Hungary,2011,13,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.4
16262,Hungary,2011,13,C08-Calcium channel blockers,% of total sales,1.3
16263,Hungary,2011,13,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.5
16264,Hungary,2011,13,C03-Diuretics,Million US$ at exchange rate,24.2
16265,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.3
16266,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
16267,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
16268,Hungary,2011,13,N02-Analgesics,"/capita, US$ exchange rate",2.7
16269,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1522.8
16270,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.6
16271,Hungary,2011,13,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
16272,Hungary,2011,13,A02A-Antacids,"/capita, US$ exchange rate",0.0
16273,Hungary,2011,13,A02A-Antacids,"Million US$, purchasing power parity",0.0
16274,Hungary,2011,13,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
16275,Hungary,2011,13,A02A-Antacids,% of total sales,0.0
16276,Hungary,2011,13,A-Alimentary tract and metabolism,% of total sales,13.4
16277,Hungary,2011,13,R-Respiratory system,"Million US$, purchasing power parity",287.5
16278,Hungary,2011,13,R-Respiratory system,"/capita, US$ exchange rate",17.8
16279,Hungary,2011,13,R-Respiratory system,Million of national currency units,35728.1
16280,Hungary,2011,13,R-Respiratory system,Million US$ at exchange rate,177.7
16281,Hungary,2011,13,N02-Analgesics,Million US$ at exchange rate,27.1
16282,Hungary,2011,13,N02-Analgesics,"Million US$, purchasing power parity",43.8
16283,Hungary,2011,13,R-Respiratory system,"/capita, US$ purchasing power parity",28.8
16284,Hungary,2011,13,R-Respiratory system,% of total sales,6.9
16285,Hungary,2011,13,N02-Analgesics,Million of national currency units,5439.1
16286,Hungary,2011,13,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",180.3
16287,Hungary,2011,13,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3
16288,Hungary,2011,13,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.2
16289,Hungary,2011,13,M-Musculo-skeletal system,Million of national currency units,21144.6
16290,Hungary,2011,13,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",55.7
16291,Hungary,2011,13,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.1
16292,Hungary,2011,13,J-Antiinfectives for systemic use,Million of national currency units,22409.7
16293,Hungary,2011,13,C03-Diuretics,Million of national currency units,4864.6
16294,Hungary,2011,13,J-Antiinfectives for systemic use,Million US$ at exchange rate,111.5
16295,Hungary,2011,13,C01A-Cardiac glycosides,Million of national currency units,260.8
16296,Hungary,2011,13,A02A-Antacids,Million US$ at exchange rate,0.0
16297,Hungary,2011,13,J-Antiinfectives for systemic use,% of total sales,4.3
16298,Hungary,2011,13,N02-Analgesics,"/capita, US$ purchasing power parity",4.4
16299,Hungary,2011,13,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
16300,Hungary,2011,13,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
16301,Hungary,2011,13,C01A-Cardiac glycosides,"Million US$, purchasing power parity",2.1
16302,Hungary,2011,13,M-Musculo-skeletal system,"Million US$, purchasing power parity",170.1
16303,Hungary,2011,13,M-Musculo-skeletal system,Million US$ at exchange rate,105.2
16304,Hungary,2011,13,M-Musculo-skeletal system,% of total sales,4.1
16305,Hungary,2011,13,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.5
16306,Hungary,2011,13,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.1
16307,Hungary,2011,13,G-Genito urinary system and sex hormones,Million of national currency units,8316.0
16308,Hungary,2011,13,C07-Beta blocking agents,"/capita, US$ purchasing power parity",9.8
16309,Hungary,2011,13,C07-Beta blocking agents,% of total sales,2.4
16310,Hungary,2011,13,N05C-Hypnotics and sedatives,% of total sales,0.0
16311,Hungary,2011,13,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.0
16312,Hungary,2011,13,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.0
16313,Hungary,2011,13,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.0
16314,Hungary,2011,13,C07-Beta blocking agents,"Million US$, purchasing power parity",98.1
16315,Hungary,2011,13,C07-Beta blocking agents,Million US$ at exchange rate,60.6
16316,Hungary,2011,13,C07-Beta blocking agents,Million of national currency units,12185.1
16317,Hungary,2011,13,N05B-Anxiolytics,Million US$ at exchange rate,15.2
16318,Hungary,2011,13,C07-Beta blocking agents,"/capita, US$ exchange rate",6.1
16319,Hungary,2011,13,N05B-Anxiolytics,"Million US$, purchasing power parity",24.6
16320,Hungary,2011,13,N02-Analgesics,% of total sales,1.1
16321,Hungary,2011,13,C02-Antihypertensives,% of total sales,1.5
16322,Hungary,2011,13,R03-Drugs for obstructive airway diseases,Million of national currency units,29340.5
16323,Hungary,2011,13,N05C-Hypnotics and sedatives,Million of national currency units,3.3
16324,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.9
16325,Hungary,2011,13,C02-Antihypertensives,"/capita, US$ purchasing power parity",6.2
16326,Hungary,2011,13,R03-Drugs for obstructive airway diseases,% of total sales,5.7
16327,Hungary,2011,13,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.7
16328,Hungary,2011,13,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.0
16329,Hungary,2011,13,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,145.9
16330,Hungary,2011,13,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",236.1
16331,Hungary,2011,13,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.6
16332,Hungary,2011,13,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",66.9
16333,Hungary,2011,13,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.1
16334,Hungary,2011,13,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",6.7
16335,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,% of total sales,0.7
16336,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.8
16337,Hungary,2011,13,G-Genito urinary system and sex hormones,Million US$ at exchange rate,41.4
16338,Hungary,2011,13,Total pharmaceutical sales,"Million US$, purchasing power parity",4146.5
16339,Hungary,2011,13,Total pharmaceutical sales,Million of national currency units,515299.2
16340,Hungary,2011,13,Total pharmaceutical sales,Million US$ at exchange rate,2563.0
16341,Hungary,2011,13,G-Genito urinary system and sex hormones,% of total sales,1.6
16342,Hungary,2011,13,Total pharmaceutical sales,"/capita, US$ exchange rate",257.0
16343,Hungary,2011,13,Total pharmaceutical sales,"/capita, US$ purchasing power parity",415.8
16344,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,28.2
16345,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",45.6
16346,Hungary,2011,13,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
16347,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5672.5
16348,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1
16349,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.6
16350,Hungary,2011,13,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",2.8
16351,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,17.3
16352,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",28.0
16353,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7
16354,Hungary,2011,13,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
16355,Hungary,2011,13,G03-Sex hormones and modulators of the genital system,Million of national currency units,3483.0
16356,Hungary,2011,13,N05B-Anxiolytics,% of total sales,0.6
16357,Hungary,2011,13,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.1
16358,Hungary,2011,13,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",114.9
16359,Hungary,2011,13,J01-Antibacterials for systemic use,Million US$ at exchange rate,71.0
16360,Hungary,2011,13,J01-Antibacterials for systemic use,% of total sales,2.8
16361,Hungary,2011,13,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.5
16362,Hungary,2011,13,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.1
16363,Hungary,2011,13,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.5
16364,Hungary,2011,13,B-Blood and blood forming organs,Million of national currency units,40274.7
16365,Hungary,2011,13,J01-Antibacterials for systemic use,Million of national currency units,14278.5
16366,Hungary,2011,13,B-Blood and blood forming organs,"Million US$, purchasing power parity",324.1
16367,Hungary,2011,13,B-Blood and blood forming organs,Million US$ at exchange rate,200.3
16368,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,39.2
16369,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",63.4
16370,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.9
16371,Hungary,2011,13,C10-Lipid modifying agents,Million US$ at exchange rate,184.0
16372,Hungary,2011,13,C10-Lipid modifying agents,"Million US$, purchasing power parity",297.7
16373,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,7875.2
16374,Hungary,2011,13,C10-Lipid modifying agents,Million of national currency units,37000.6
16375,Hungary,2011,13,N-Nervous system,Million US$ at exchange rate,320.4
16376,Hungary,2011,13,N-Nervous system,Million of national currency units,64409.0
16377,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.4
16378,Hungary,2011,13,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.5
16379,Hungary,2011,13,N-Nervous system,"/capita, US$ exchange rate",32.1
16380,Hungary,2011,13,N-Nervous system,"Million US$, purchasing power parity",518.3
16381,Hungary,2011,13,C-Cardiovascular system,"/capita, US$ exchange rate",63.6
16382,Hungary,2011,13,C-Cardiovascular system,"Million US$, purchasing power parity",1025.6
16383,Hungary,2011,13,C-Cardiovascular system,Million US$ at exchange rate,633.9
16384,Hungary,2011,13,C-Cardiovascular system,% of total sales,24.7
16385,Hungary,2011,13,C-Cardiovascular system,"/capita, US$ purchasing power parity",102.9
16386,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",367.8
16387,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.8
16388,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",36.9
16389,Hungary,2011,13,C-Cardiovascular system,Million of national currency units,127453.0
16390,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,45712.3
16391,Hungary,2011,13,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,227.4
16392,Hungary,2011,13,B-Blood and blood forming organs,% of total sales,7.8
16393,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.9
16394,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6
16395,Hungary,2011,13,N05B-Anxiolytics,Million of national currency units,3057.1
16396,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,92.1
16397,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.2
16398,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",148.9
16399,Hungary,2011,13,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,18507.6
16400,Hungary,2011,13,C02-Antihypertensives,Million US$ at exchange rate,38.3
16401,Hungary,2011,13,C02-Antihypertensives,Million of national currency units,7703.6
16402,Hungary,2011,13,C02-Antihypertensives,"/capita, US$ exchange rate",3.8
16403,Hungary,2011,13,C02-Antihypertensives,"Million US$, purchasing power parity",62.0
16404,Iceland,2010,5,N05C-Hypnotics and sedatives,Million of national currency units,461.2
16405,Iceland,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",35.4
16406,Iceland,2010,5,G-Genito urinary system and sex hormones,% of total sales,6.0
16407,Iceland,2010,5,N-Nervous system,"Million US$, purchasing power parity",51.0
16408,Iceland,2010,5,N-Nervous system,Million US$ at exchange rate,55.5
16409,Iceland,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.9
16410,Iceland,2010,5,N-Nervous system,"/capita, US$ exchange rate",174.5
16411,Iceland,2010,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.5
16412,Iceland,2010,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8
16413,Iceland,2010,5,N-Nervous system,Million of national currency units,6783.8
16414,Iceland,2010,5,N05C-Hypnotics and sedatives,% of total sales,1.8
16415,Iceland,2010,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.9
16416,Iceland,2010,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.9
16417,Iceland,2010,5,C02-Antihypertensives,Million of national currency units,37.6
16418,Iceland,2010,5,C02-Antihypertensives,% of total sales,0.2
16419,Iceland,2010,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.4
16420,Iceland,2010,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7
16421,Iceland,2010,5,C07-Beta blocking agents,% of total sales,1.3
16422,Iceland,2010,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.1
16423,Iceland,2010,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.7
16424,Iceland,2010,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",24.2
16425,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,7.0
16426,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.4
16427,Iceland,2010,5,J01-Antibacterials for systemic use,Million of national currency units,942.2
16428,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,853.4
16429,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,% of total sales,3.4
16430,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",20.0
16431,Iceland,2010,5,C02-Antihypertensives,"/capita, US$ exchange rate",1.0
16432,Iceland,2010,5,C02-Antihypertensives,Million US$ at exchange rate,0.3
16433,Iceland,2010,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.3
16434,Iceland,2010,5,C07-Beta blocking agents,Million of national currency units,327.2
16435,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,846.9
16436,Iceland,2010,5,C07-Beta blocking agents,Million US$ at exchange rate,2.7
16437,Iceland,2010,5,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5
16438,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.8
16439,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.4
16440,Iceland,2010,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.9
16441,Iceland,2010,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.0
16442,Iceland,2010,5,A-Alimentary tract and metabolism,% of total sales,8.3
16443,Iceland,2010,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.3
16444,Iceland,2010,5,A02A-Antacids,"Million US$, purchasing power parity",0.4
16445,Iceland,2010,5,A02A-Antacids,Million US$ at exchange rate,0.4
16446,Iceland,2010,5,A02A-Antacids,"/capita, US$ exchange rate",1.4
16447,Iceland,2010,5,N-Nervous system,% of total sales,27.1
16448,Iceland,2010,5,N-Nervous system,"/capita, US$ purchasing power parity",160.5
16449,Iceland,2010,5,A-Alimentary tract and metabolism,Million of national currency units,2071.3
16450,Iceland,2010,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,16.9
16451,Iceland,2010,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",15.6
16452,Iceland,2010,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.3
16453,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",20.2
16454,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.4
16455,Iceland,2010,5,N06A-Antidepressants,Million of national currency units,1101.8
16456,Iceland,2010,5,J01-Antibacterials for systemic use,% of total sales,3.8
16457,Iceland,2010,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.3
16458,Iceland,2010,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.0
16459,Iceland,2010,5,N06A-Antidepressants,% of total sales,4.4
16460,Iceland,2010,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",26.1
16461,Iceland,2010,5,A02A-Antacids,Million of national currency units,53.9
16462,Iceland,2010,5,N06A-Antidepressants,Million US$ at exchange rate,9.0
16463,Iceland,2010,5,N06A-Antidepressants,"Million US$, purchasing power parity",8.3
16464,Iceland,2010,5,N06A-Antidepressants,"/capita, US$ exchange rate",28.3
16465,Iceland,2010,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.7
16466,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.8
16467,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.4
16468,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.9
16469,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.1
16470,Iceland,2010,5,Products not elsewhere classified,Million of national currency units,5683.3
16471,Iceland,2010,5,Products not elsewhere classified,"/capita, US$ exchange rate",146.2
16472,Iceland,2010,5,Products not elsewhere classified,"Million US$, purchasing power parity",42.8
16473,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,585.4
16474,Iceland,2010,5,Products not elsewhere classified,Million US$ at exchange rate,46.5
16475,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.6
16476,Iceland,2010,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",33.8
16477,Iceland,2010,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.1
16478,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",21.4
16479,Iceland,2010,5,B-Blood and blood forming organs,Million of national currency units,1316.0
16480,Iceland,2010,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
16481,Iceland,2010,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",134.5
16482,Iceland,2010,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",9.9
16483,Iceland,2010,5,B-Blood and blood forming organs,Million US$ at exchange rate,10.8
16484,Iceland,2010,5,A10-Drugs used in diabetes,% of total sales,2.4
16485,Iceland,2010,5,C03-Diuretics,"/capita, US$ exchange rate",5.3
16486,Iceland,2010,5,C03-Diuretics,% of total sales,0.8
16487,Iceland,2010,5,C03-Diuretics,"/capita, US$ purchasing power parity",4.8
16488,Iceland,2010,5,A10-Drugs used in diabetes,Million US$ at exchange rate,5.0
16489,Iceland,2010,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",4.6
16490,Iceland,2010,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.5
16491,Iceland,2010,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.8
16492,Iceland,2010,5,C10-Lipid modifying agents,Million US$ at exchange rate,2.7
16493,Iceland,2010,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.5
16494,Iceland,2010,5,Products not elsewhere classified,% of total sales,22.7
16495,Iceland,2010,5,C10-Lipid modifying agents,Million of national currency units,335.4
16496,Iceland,2010,5,C10-Lipid modifying agents,% of total sales,1.3
16497,Iceland,2010,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.6
16498,Iceland,2010,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.9
16499,Iceland,2010,5,N05B-Anxiolytics,Million US$ at exchange rate,2.1
16500,Iceland,2010,5,N05B-Anxiolytics,Million of national currency units,262.1
16501,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,903.3
16502,Iceland,2010,5,N05B-Anxiolytics,"/capita, US$ exchange rate",6.7
16503,Iceland,2010,5,N05B-Anxiolytics,"Million US$, purchasing power parity",2.0
16504,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",23.2
16505,Iceland,2010,5,R03-Drugs for obstructive airway diseases,% of total sales,4.5
16506,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,7.4
16507,Iceland,2010,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.8
16508,Iceland,2010,5,Total pharmaceutical sales,"/capita, US$ exchange rate",643.3
16509,Iceland,2010,5,Total pharmaceutical sales,"Million US$, purchasing power parity",188.2
16510,Iceland,2010,5,Total pharmaceutical sales,Million of national currency units,25011.6
16511,Iceland,2010,5,Total pharmaceutical sales,Million US$ at exchange rate,204.6
16512,Iceland,2010,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",591.8
16513,Iceland,2010,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",6.2
16514,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.2
16515,Iceland,2010,5,N05B-Anxiolytics,% of total sales,1.0
16516,Iceland,2010,5,C-Cardiovascular system,"Million US$, purchasing power parity",14.3
16517,Iceland,2010,5,C-Cardiovascular system,Million US$ at exchange rate,15.6
16518,Iceland,2010,5,C-Cardiovascular system,"/capita, US$ exchange rate",49.0
16519,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,543.8
16520,Iceland,2010,5,C-Cardiovascular system,Million of national currency units,1906.8
16521,Iceland,2010,5,B-Blood and blood forming organs,% of total sales,5.3
16522,Iceland,2010,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",45.1
16523,Iceland,2010,5,C-Cardiovascular system,% of total sales,7.6
16524,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,4.4
16525,Iceland,2010,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.4
16526,Iceland,2010,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.1
16527,Iceland,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.4
16528,Iceland,2010,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.7
16529,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.0
16530,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",4.1
16531,Iceland,2010,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1114.5
16532,Iceland,2010,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",12.9
16533,Iceland,2010,5,A10-Drugs used in diabetes,Million of national currency units,612.6
16534,Iceland,2010,5,C01A-Cardiac glycosides,Million of national currency units,9.4
16535,Iceland,2010,5,C08-Calcium channel blockers,% of total sales,0.9
16536,Iceland,2010,5,M-Musculo-skeletal system,Million of national currency units,1220.1
16537,Iceland,2010,5,M-Musculo-skeletal system,Million US$ at exchange rate,10.0
16538,Iceland,2010,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.3
16539,Iceland,2010,5,C08-Calcium channel blockers,Million US$ at exchange rate,1.8
16540,Iceland,2010,5,C08-Calcium channel blockers,Million of national currency units,223.5
16541,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,61.4
16542,Iceland,2010,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.7
16543,Iceland,2010,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",9.2
16544,Iceland,2010,5,R-Respiratory system,"Million US$, purchasing power parity",13.3
16545,Iceland,2010,5,R-Respiratory system,Million US$ at exchange rate,14.4
16546,Iceland,2010,5,R-Respiratory system,"/capita, US$ purchasing power parity",41.7
16547,Iceland,2010,5,R-Respiratory system,"/capita, US$ exchange rate",45.3
16548,Iceland,2010,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.9
16549,Iceland,2010,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",31.4
16550,Iceland,2010,5,R-Respiratory system,Million of national currency units,1762.5
16551,Iceland,2010,5,M-Musculo-skeletal system,% of total sales,4.9
16552,Iceland,2010,5,N02-Analgesics,"Million US$, purchasing power parity",7.6
16553,Iceland,2010,5,N02-Analgesics,Million US$ at exchange rate,8.3
16554,Iceland,2010,5,N02-Analgesics,"/capita, US$ purchasing power parity",23.9
16555,Iceland,2010,5,N02-Analgesics,"/capita, US$ exchange rate",26.0
16556,Iceland,2010,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",11.3
16557,Iceland,2010,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",38.5
16558,Iceland,2010,5,N02-Analgesics,Million of national currency units,1011.6
16559,Iceland,2010,5,G-Genito urinary system and sex hormones,Million of national currency units,1497.1
16560,Iceland,2010,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.2
16561,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6
16562,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.5
16563,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.5
16564,Iceland,2010,5,N02-Analgesics,% of total sales,4.0
16565,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.5
16566,Iceland,2010,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
16567,Iceland,2010,5,A02A-Antacids,% of total sales,0.2
16568,Iceland,2010,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
16569,Iceland,2010,5,J-Antiinfectives for systemic use,Million of national currency units,2185.2
16570,Iceland,2010,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
16571,Iceland,2010,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
16572,Iceland,2010,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
16573,Iceland,2010,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,17.9
16574,Iceland,2010,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",51.7
16575,Iceland,2010,5,J-Antiinfectives for systemic use,% of total sales,8.7
16576,Iceland,2010,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",16.4
16577,Iceland,2010,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",56.2
16578,Iceland,2010,5,C01A-Cardiac glycosides,% of total sales,0.0
16579,Iceland,2010,5,C03-Diuretics,"Million US$, purchasing power parity",1.5
16580,Iceland,2010,5,C03-Diuretics,Million of national currency units,204.5
16581,Iceland,2010,5,R-Respiratory system,% of total sales,7.0
16582,Iceland,2010,5,C03-Diuretics,Million US$ at exchange rate,1.7
16583,Iceland,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",27.5
16584,Iceland,2017,4,G-Genito urinary system and sex hormones,% of total sales,4.9
16585,Iceland,2017,4,N05C-Hypnotics and sedatives,Million of national currency units,509.2
16586,Iceland,2017,4,N-Nervous system,Million US$ at exchange rate,49.3
16587,Iceland,2017,4,N-Nervous system,Million of national currency units,5265.0
16588,Iceland,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",13.9
16589,Iceland,2017,4,N-Nervous system,"Million US$, purchasing power parity",38.1
16590,Iceland,2017,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.8
16591,Iceland,2017,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.7
16592,Iceland,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.7
16593,Iceland,2017,4,N05C-Hypnotics and sedatives,% of total sales,1.9
16594,Iceland,2017,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
16595,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.5
16596,Iceland,2017,4,C02-Antihypertensives,% of total sales,0.2
16597,Iceland,2017,4,C07-Beta blocking agents,% of total sales,1.3
16598,Iceland,2017,4,C07-Beta blocking agents,"/capita, US$ exchange rate",9.5
16599,Iceland,2017,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4
16600,Iceland,2017,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.0
16601,Iceland,2017,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.7
16602,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.9
16603,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,626.3
16604,Iceland,2017,4,J01-Antibacterials for systemic use,Million of national currency units,1066.3
16605,Iceland,2017,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5
16606,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.7
16607,Iceland,2017,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.4
16608,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",14.9
16609,Iceland,2017,4,C02-Antihypertensives,Million of national currency units,51.0
16610,Iceland,2017,4,C02-Antihypertensives,Million US$ at exchange rate,0.5
16611,Iceland,2017,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.4
16612,Iceland,2017,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",29.1
16613,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.2
16614,Iceland,2017,4,C07-Beta blocking agents,Million of national currency units,349.6
16615,Iceland,2017,4,C07-Beta blocking agents,Million US$ at exchange rate,3.3
16616,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,705.6
16617,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.1
16618,Iceland,2017,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.6
16619,Iceland,2017,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.5
16620,Iceland,2017,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",15.6
16621,Iceland,2017,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",58.9
16622,Iceland,2017,4,A02A-Antacids,Million US$ at exchange rate,0.0
16623,Iceland,2017,4,A-Alimentary tract and metabolism,% of total sales,8.1
16624,Iceland,2017,4,A02A-Antacids,"Million US$, purchasing power parity",0.0
16625,Iceland,2017,4,N-Nervous system,% of total sales,19.9
16626,Iceland,2017,4,N-Nervous system,"/capita, US$ purchasing power parity",110.9
16627,Iceland,2017,4,N-Nervous system,"/capita, US$ exchange rate",143.5
16628,Iceland,2017,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,20.2
16629,Iceland,2017,4,A02A-Antacids,"/capita, US$ exchange rate",0.0
16630,Iceland,2017,4,A-Alimentary tract and metabolism,Million of national currency units,2159.5
16631,Iceland,2017,4,A02A-Antacids,Million of national currency units,0.0
16632,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.2
16633,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
16634,Iceland,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.1
16635,Iceland,2017,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.5
16636,Iceland,2017,4,J01-Antibacterials for systemic use,% of total sales,4.0
16637,Iceland,2017,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2
16638,Iceland,2017,4,N06A-Antidepressants,% of total sales,2.9
16639,Iceland,2017,4,N06A-Antidepressants,Million of national currency units,769.4
16640,Iceland,2017,4,N06A-Antidepressants,Million US$ at exchange rate,7.2
16641,Iceland,2017,4,N06A-Antidepressants,"Million US$, purchasing power parity",5.6
16642,Iceland,2017,4,N06A-Antidepressants,"/capita, US$ exchange rate",21.0
16643,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.5
16644,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,690.2
16645,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",18.8
16646,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.0
16647,Iceland,2017,4,Products not elsewhere classified,"Million US$, purchasing power parity",58.1
16648,Iceland,2017,4,Products not elsewhere classified,"/capita, US$ exchange rate",218.8
16649,Iceland,2017,4,Products not elsewhere classified,Million of national currency units,8027.6
16650,Iceland,2017,4,Products not elsewhere classified,Million US$ at exchange rate,75.1
16651,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.1
16652,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6
16653,Iceland,2017,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",48.2
16654,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.8
16655,Iceland,2017,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",12.8
16656,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
16657,Iceland,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5
16658,Iceland,2017,4,B-Blood and blood forming organs,Million of national currency units,1768.1
16659,Iceland,2017,4,B-Blood and blood forming organs,Million US$ at exchange rate,16.5
16660,Iceland,2017,4,A10-Drugs used in diabetes,% of total sales,3.2
16661,Iceland,2017,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.8
16662,Iceland,2017,4,C03-Diuretics,"/capita, US$ purchasing power parity",4.6
16663,Iceland,2017,4,C03-Diuretics,"/capita, US$ exchange rate",5.9
16664,Iceland,2017,4,A10-Drugs used in diabetes,Million US$ at exchange rate,7.9
16665,Iceland,2017,4,A10-Drugs used in diabetes,Million of national currency units,845.8
16666,Iceland,2017,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.1
16667,Iceland,2017,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",6.1
16668,Iceland,2017,4,C10-Lipid modifying agents,Million of national currency units,344.3
16669,Iceland,2017,4,C10-Lipid modifying agents,Million US$ at exchange rate,3.2
16670,Iceland,2017,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",169.1
16671,Iceland,2017,4,Products not elsewhere classified,% of total sales,30.3
16672,Iceland,2017,4,C10-Lipid modifying agents,% of total sales,1.3
16673,Iceland,2017,4,C03-Diuretics,% of total sales,0.8
16674,Iceland,2017,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.3
16675,Iceland,2017,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.4
16676,Iceland,2017,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.2
16677,Iceland,2017,4,N05B-Anxiolytics,Million of national currency units,276.7
16678,Iceland,2017,4,N05B-Anxiolytics,Million US$ at exchange rate,2.6
16679,Iceland,2017,4,N05B-Anxiolytics,"Million US$, purchasing power parity",2.0
16680,Iceland,2017,4,N05B-Anxiolytics,"/capita, US$ exchange rate",7.5
16681,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,431.6
16682,Iceland,2017,4,R03-Drugs for obstructive airway diseases,% of total sales,4.3
16683,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.1
16684,Iceland,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,4.0
16685,Iceland,2017,4,Total pharmaceutical sales,"Million US$, purchasing power parity",191.8
16686,Iceland,2017,4,Total pharmaceutical sales,"/capita, US$ exchange rate",722.9
16687,Iceland,2017,4,Total pharmaceutical sales,Million of national currency units,26522.3
16688,Iceland,2017,4,Total pharmaceutical sales,Million US$ at exchange rate,248.2
16689,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.7
16690,Iceland,2017,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.8
16691,Iceland,2017,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",558.5
16692,Iceland,2017,4,N05B-Anxiolytics,% of total sales,1.0
16693,Iceland,2017,4,C-Cardiovascular system,Million US$ at exchange rate,17.1
16694,Iceland,2017,4,C-Cardiovascular system,"Million US$, purchasing power parity",13.2
16695,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,454.9
16696,Iceland,2017,4,C-Cardiovascular system,Million of national currency units,1827.3
16697,Iceland,2017,4,C-Cardiovascular system,% of total sales,6.9
16698,Iceland,2017,4,B-Blood and blood forming organs,% of total sales,6.7
16699,Iceland,2017,4,C-Cardiovascular system,"/capita, US$ exchange rate",49.8
16700,Iceland,2017,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",38.5
16701,Iceland,2017,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.6
16702,Iceland,2017,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.2
16703,Iceland,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.9
16704,Iceland,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.0
16705,Iceland,2017,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1136.8
16706,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.3
16707,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,4.3
16708,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.6
16709,Iceland,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.4
16710,Iceland,2017,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.5
16711,Iceland,2017,4,C03-Diuretics,"Million US$, purchasing power parity",1.6
16712,Iceland,2017,4,C08-Calcium channel blockers,% of total sales,0.6
16713,Iceland,2017,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5
16714,Iceland,2017,4,M-Musculo-skeletal system,Million US$ at exchange rate,6.5
16715,Iceland,2017,4,M-Musculo-skeletal system,Million of national currency units,698.3
16716,Iceland,2017,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.5
16717,Iceland,2017,4,C08-Calcium channel blockers,Million of national currency units,164.6
16718,Iceland,2017,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5
16719,Iceland,2017,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.2
16720,Iceland,2017,4,R-Respiratory system,Million US$ at exchange rate,14.3
16721,Iceland,2017,4,R-Respiratory system,Million of national currency units,1532.7
16722,Iceland,2017,4,R-Respiratory system,"Million US$, purchasing power parity",11.1
16723,Iceland,2017,4,R-Respiratory system,"/capita, US$ purchasing power parity",32.3
16724,Iceland,2017,4,R-Respiratory system,"/capita, US$ exchange rate",41.8
16725,Iceland,2017,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.0
16726,Iceland,2017,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.1
16727,Iceland,2017,4,M-Musculo-skeletal system,% of total sales,2.6
16728,Iceland,2017,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.7
16729,Iceland,2017,4,N02-Analgesics,Million US$ at exchange rate,8.5
16730,Iceland,2017,4,N02-Analgesics,Million of national currency units,903.0
16731,Iceland,2017,4,N02-Analgesics,"Million US$, purchasing power parity",6.5
16732,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
16733,Iceland,2017,4,N02-Analgesics,"/capita, US$ exchange rate",24.6
16734,Iceland,2017,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.5
16735,Iceland,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",35.7
16736,Iceland,2017,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.2
16737,Iceland,2017,4,G-Genito urinary system and sex hormones,Million of national currency units,1308.1
16738,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
16739,Iceland,2017,4,N02-Analgesics,% of total sales,3.4
16740,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,83.5
16741,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8
16742,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",2.3
16743,Iceland,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8
16744,Iceland,2017,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
16745,Iceland,2017,4,N02-Analgesics,"/capita, US$ purchasing power parity",19.0
16746,Iceland,2017,4,A02A-Antacids,% of total sales,0.0
16747,Iceland,2017,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
16748,Iceland,2017,4,C01A-Cardiac glycosides,Million of national currency units,11.3
16749,Iceland,2017,4,J-Antiinfectives for systemic use,Million of national currency units,3067.9
16750,Iceland,2017,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
16751,Iceland,2017,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
16752,Iceland,2017,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
16753,Iceland,2017,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",64.6
16754,Iceland,2017,4,J-Antiinfectives for systemic use,% of total sales,11.6
16755,Iceland,2017,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",83.6
16756,Iceland,2017,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,28.7
16757,Iceland,2017,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",22.2
16758,Iceland,2017,4,C01A-Cardiac glycosides,% of total sales,0.0
16759,Iceland,2017,4,R-Respiratory system,% of total sales,5.8
16760,Iceland,2017,4,C03-Diuretics,Million US$ at exchange rate,2.0
16761,Iceland,2017,4,C03-Diuretics,Million of national currency units,216.6
16762,Iceland,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",28.4
16763,Iceland,2016,4,G-Genito urinary system and sex hormones,% of total sales,5.3
16764,Iceland,2016,4,N05C-Hypnotics and sedatives,Million of national currency units,471.8
16765,Iceland,2016,4,N-Nervous system,Million US$ at exchange rate,46.0
16766,Iceland,2016,4,N-Nervous system,Million of national currency units,5561.3
16767,Iceland,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.6
16768,Iceland,2016,4,N-Nervous system,"Million US$, purchasing power parity",39.7
16769,Iceland,2016,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4
16770,Iceland,2016,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.9
16771,Iceland,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.0
16772,Iceland,2016,4,N05C-Hypnotics and sedatives,% of total sales,1.9
16773,Iceland,2016,4,N06A-Antidepressants,Million US$ at exchange rate,6.2
16774,Iceland,2016,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
16775,Iceland,2016,4,C02-Antihypertensives,% of total sales,0.2
16776,Iceland,2016,4,C07-Beta blocking agents,% of total sales,1.3
16777,Iceland,2016,4,C07-Beta blocking agents,"/capita, US$ exchange rate",8.4
16778,Iceland,2016,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2
16779,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.3
16780,Iceland,2016,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.8
16781,Iceland,2016,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.2
16782,Iceland,2016,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.6
16783,Iceland,2016,4,J01-Antibacterials for systemic use,Million of national currency units,1062.7
16784,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.9
16785,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,596.9
16786,Iceland,2016,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.4
16787,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.9
16788,Iceland,2016,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.2
16789,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",15.5
16790,Iceland,2016,4,C02-Antihypertensives,Million of national currency units,49.0
16791,Iceland,2016,4,C02-Antihypertensives,Million US$ at exchange rate,0.4
16792,Iceland,2016,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.3
16793,Iceland,2016,4,C07-Beta blocking agents,Million of national currency units,340.2
16794,Iceland,2016,4,C07-Beta blocking agents,Million US$ at exchange rate,2.8
16795,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",18.0
16796,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.2
16797,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.0
16798,Iceland,2016,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,729.9
16799,Iceland,2016,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",46.6
16800,Iceland,2016,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",15.6
16801,Iceland,2016,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",54.0
16802,Iceland,2016,4,A-Alimentary tract and metabolism,% of total sales,8.6
16803,Iceland,2016,4,A02A-Antacids,Million US$ at exchange rate,0.0
16804,Iceland,2016,4,A02A-Antacids,"Million US$, purchasing power parity",0.0
16805,Iceland,2016,4,N-Nervous system,% of total sales,21.9
16806,Iceland,2016,4,N-Nervous system,"/capita, US$ exchange rate",137.2
16807,Iceland,2016,4,N-Nervous system,"/capita, US$ purchasing power parity",118.4
16808,Iceland,2016,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,18.1
16809,Iceland,2016,4,A02A-Antacids,"/capita, US$ exchange rate",0.0
16810,Iceland,2016,4,A-Alimentary tract and metabolism,Million of national currency units,2188.8
16811,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.7
16812,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
16813,Iceland,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.7
16814,Iceland,2016,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.6
16815,Iceland,2016,4,J01-Antibacterials for systemic use,% of total sales,4.2
16816,Iceland,2016,4,N06A-Antidepressants,Million of national currency units,744.1
16817,Iceland,2016,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.8
16818,Iceland,2016,4,A02A-Antacids,Million of national currency units,0.0
16819,Iceland,2016,4,N06A-Antidepressants,% of total sales,2.9
16820,Iceland,2016,4,N06A-Antidepressants,"/capita, US$ exchange rate",18.4
16821,Iceland,2016,4,N06A-Antidepressants,"Million US$, purchasing power parity",5.3
16822,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.5
16823,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,670.4
16824,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.5
16825,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.8
16826,Iceland,2016,4,Products not elsewhere classified,"Million US$, purchasing power parity",52.4
16827,Iceland,2016,4,Products not elsewhere classified,"/capita, US$ exchange rate",181.2
16828,Iceland,2016,4,Products not elsewhere classified,Million of national currency units,7341.2
16829,Iceland,2016,4,Products not elsewhere classified,Million US$ at exchange rate,60.8
16830,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
16831,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.2
16832,Iceland,2016,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",47.4
16833,Iceland,2016,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",13.7
16834,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
16835,Iceland,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.3
16836,Iceland,2016,4,B-Blood and blood forming organs,Million of national currency units,1922.6
16837,Iceland,2016,4,B-Blood and blood forming organs,Million US$ at exchange rate,15.9
16838,Iceland,2016,4,A10-Drugs used in diabetes,% of total sales,3.3
16839,Iceland,2016,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.8
16840,Iceland,2016,4,C03-Diuretics,"/capita, US$ purchasing power parity",4.4
16841,Iceland,2016,4,C03-Diuretics,"/capita, US$ exchange rate",5.1
16842,Iceland,2016,4,A10-Drugs used in diabetes,Million US$ at exchange rate,6.9
16843,Iceland,2016,4,A10-Drugs used in diabetes,Million of national currency units,838.3
16844,Iceland,2016,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.7
16845,Iceland,2016,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",6.0
16846,Iceland,2016,4,C10-Lipid modifying agents,Million of national currency units,326.4
16847,Iceland,2016,4,C10-Lipid modifying agents,Million US$ at exchange rate,2.7
16848,Iceland,2016,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",156.3
16849,Iceland,2016,4,Products not elsewhere classified,% of total sales,28.9
16850,Iceland,2016,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.3
16851,Iceland,2016,4,C10-Lipid modifying agents,% of total sales,1.3
16852,Iceland,2016,4,C03-Diuretics,% of total sales,0.8
16853,Iceland,2016,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.9
16854,Iceland,2016,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.1
16855,Iceland,2016,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.9
16856,Iceland,2016,4,N05B-Anxiolytics,Million of national currency units,265.2
16857,Iceland,2016,4,N05B-Anxiolytics,Million US$ at exchange rate,2.2
16858,Iceland,2016,4,N05B-Anxiolytics,"/capita, US$ exchange rate",6.5
16859,Iceland,2016,4,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9
16860,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.7
16861,Iceland,2016,4,R03-Drugs for obstructive airway diseases,% of total sales,4.5
16862,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.1
16863,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,431.9
16864,Iceland,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.6
16865,Iceland,2016,4,Total pharmaceutical sales,"Million US$, purchasing power parity",181.3
16866,Iceland,2016,4,Total pharmaceutical sales,"/capita, US$ exchange rate",626.4
16867,Iceland,2016,4,Total pharmaceutical sales,Million of national currency units,25384.8
16868,Iceland,2016,4,Total pharmaceutical sales,Million US$ at exchange rate,210.1
16869,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8
16870,Iceland,2016,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.6
16871,Iceland,2016,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",540.4
16872,Iceland,2016,4,N05B-Anxiolytics,% of total sales,1.0
16873,Iceland,2016,4,C-Cardiovascular system,Million US$ at exchange rate,14.4
16874,Iceland,2016,4,C-Cardiovascular system,"Million US$, purchasing power parity",12.4
16875,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,448.0
16876,Iceland,2016,4,C-Cardiovascular system,Million of national currency units,1734.6
16877,Iceland,2016,4,C-Cardiovascular system,% of total sales,6.8
16878,Iceland,2016,4,B-Blood and blood forming organs,% of total sales,7.6
16879,Iceland,2016,4,C-Cardiovascular system,"/capita, US$ exchange rate",42.8
16880,Iceland,2016,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.9
16881,Iceland,2016,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.4
16882,Iceland,2016,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.1
16883,Iceland,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",24.3
16884,Iceland,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.2
16885,Iceland,2016,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1141.2
16886,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.2
16887,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.7
16888,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.5
16889,Iceland,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.1
16890,Iceland,2016,4,C08-Calcium channel blockers,% of total sales,0.7
16891,Iceland,2016,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5
16892,Iceland,2016,4,M-Musculo-skeletal system,Million US$ at exchange rate,5.8
16893,Iceland,2016,4,M-Musculo-skeletal system,Million of national currency units,697.1
16894,Iceland,2016,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.4
16895,Iceland,2016,4,C08-Calcium channel blockers,Million of national currency units,165.6
16896,Iceland,2016,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1
16897,Iceland,2016,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.2
16898,Iceland,2016,4,R-Respiratory system,"Million US$, purchasing power parity",10.8
16899,Iceland,2016,4,R-Respiratory system,Million US$ at exchange rate,12.5
16900,Iceland,2016,4,R-Respiratory system,"/capita, US$ purchasing power parity",32.1
16901,Iceland,2016,4,R-Respiratory system,"/capita, US$ exchange rate",37.2
16902,Iceland,2016,4,R-Respiratory system,Million of national currency units,1508.4
16903,Iceland,2016,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.2
16904,Iceland,2016,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.0
16905,Iceland,2016,4,M-Musculo-skeletal system,% of total sales,2.7
16906,Iceland,2016,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.8
16907,Iceland,2016,4,N02-Analgesics,"Million US$, purchasing power parity",6.2
16908,Iceland,2016,4,N02-Analgesics,Million US$ at exchange rate,7.2
16909,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
16910,Iceland,2016,4,N02-Analgesics,"/capita, US$ exchange rate",21.6
16911,Iceland,2016,4,N02-Analgesics,Million of national currency units,873.8
16912,Iceland,2016,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.5
16913,Iceland,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",32.9
16914,Iceland,2016,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,11.1
16915,Iceland,2016,4,G-Genito urinary system and sex hormones,Million of national currency units,1335.0
16916,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
16917,Iceland,2016,4,N02-Analgesics,% of total sales,3.4
16918,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9
16919,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.9
16920,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
16921,Iceland,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
16922,Iceland,2016,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
16923,Iceland,2016,4,N02-Analgesics,"/capita, US$ purchasing power parity",18.6
16924,Iceland,2016,4,A02A-Antacids,% of total sales,0.0
16925,Iceland,2016,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
16926,Iceland,2016,4,C01A-Cardiac glycosides,Million of national currency units,11.5
16927,Iceland,2016,4,J-Antiinfectives for systemic use,Million of national currency units,3055.4
16928,Iceland,2016,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
16929,Iceland,2016,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
16930,Iceland,2016,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
16931,Iceland,2016,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",65.0
16932,Iceland,2016,4,J-Antiinfectives for systemic use,% of total sales,12.0
16933,Iceland,2016,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,25.3
16934,Iceland,2016,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",75.4
16935,Iceland,2016,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",21.8
16936,Iceland,2016,4,C01A-Cardiac glycosides,% of total sales,0.0
16937,Iceland,2016,4,R-Respiratory system,% of total sales,5.9
16938,Iceland,2016,4,C03-Diuretics,"Million US$, purchasing power parity",1.5
16939,Iceland,2016,4,C03-Diuretics,Million US$ at exchange rate,1.7
16940,Iceland,2016,4,C03-Diuretics,Million of national currency units,205.6
16941,Iceland,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",28.0
16942,Iceland,2015,4,N05C-Hypnotics and sedatives,Million of national currency units,460.4
16943,Iceland,2015,4,G-Genito urinary system and sex hormones,% of total sales,5.4
16944,Iceland,2015,4,N-Nervous system,Million US$ at exchange rate,40.5
16945,Iceland,2015,4,N-Nervous system,Million of national currency units,5341.2
16946,Iceland,2015,4,N-Nervous system,"Million US$, purchasing power parity",37.6
16947,Iceland,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",10.5
16948,Iceland,2015,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2
16949,Iceland,2015,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.5
16950,Iceland,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",9.8
16951,Iceland,2015,4,N05C-Hypnotics and sedatives,% of total sales,1.9
16952,Iceland,2015,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
16953,Iceland,2015,4,C02-Antihypertensives,% of total sales,0.2
16954,Iceland,2015,4,C07-Beta blocking agents,"/capita, US$ exchange rate",7.8
16955,Iceland,2015,4,C07-Beta blocking agents,% of total sales,1.4
16956,Iceland,2015,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2
16957,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.0
16958,Iceland,2015,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.9
16959,Iceland,2015,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",23.8
16960,Iceland,2015,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.3
16961,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.3
16962,Iceland,2015,4,J01-Antibacterials for systemic use,Million of national currency units,1040.8
16963,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,561.1
16964,Iceland,2015,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.4
16965,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,% of total sales,3.0
16966,Iceland,2015,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.2
16967,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",15.4
16968,Iceland,2015,4,C02-Antihypertensives,Million US$ at exchange rate,0.4
16969,Iceland,2015,4,C02-Antihypertensives,Million of national currency units,50.5
16970,Iceland,2015,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.4
16971,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",16.6
16972,Iceland,2015,4,C07-Beta blocking agents,Million of national currency units,339.2
16973,Iceland,2015,4,C07-Beta blocking agents,Million US$ at exchange rate,2.6
16974,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,723.6
16975,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.1
16976,Iceland,2015,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,5.5
16977,Iceland,2015,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.7
16978,Iceland,2015,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",45.9
16979,Iceland,2015,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",14.1
16980,Iceland,2015,4,A02A-Antacids,Million US$ at exchange rate,0.0
16981,Iceland,2015,4,A02A-Antacids,"Million US$, purchasing power parity",0.0
16982,Iceland,2015,4,A-Alimentary tract and metabolism,% of total sales,8.2
16983,Iceland,2015,4,N-Nervous system,% of total sales,21.9
16984,Iceland,2015,4,N-Nervous system,"/capita, US$ exchange rate",122.4
16985,Iceland,2015,4,N-Nervous system,"/capita, US$ purchasing power parity",113.7
16986,Iceland,2015,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,15.2
16987,Iceland,2015,4,A02A-Antacids,"/capita, US$ exchange rate",0.0
16988,Iceland,2015,4,A-Alimentary tract and metabolism,Million of national currency units,2003.7
16989,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.9
16990,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.3
16991,Iceland,2015,4,N06A-Antidepressants,Million of national currency units,759.2
16992,Iceland,2015,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.2
16993,Iceland,2015,4,J01-Antibacterials for systemic use,% of total sales,4.3
16994,Iceland,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.9
16995,Iceland,2015,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2
16996,Iceland,2015,4,A02A-Antacids,Million of national currency units,0.0
16997,Iceland,2015,4,N06A-Antidepressants,% of total sales,3.1
16998,Iceland,2015,4,N06A-Antidepressants,Million US$ at exchange rate,5.8
16999,Iceland,2015,4,N06A-Antidepressants,"/capita, US$ exchange rate",17.4
17000,Iceland,2015,4,N06A-Antidepressants,"Million US$, purchasing power parity",5.3
17001,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.8
17002,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,636.0
17003,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.6
17004,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.5
17005,Iceland,2015,4,Products not elsewhere classified,"Million US$, purchasing power parity",48.4
17006,Iceland,2015,4,Products not elsewhere classified,"/capita, US$ exchange rate",157.4
17007,Iceland,2015,4,Products not elsewhere classified,Million of national currency units,6869.4
17008,Iceland,2015,4,Products not elsewhere classified,Million US$ at exchange rate,52.1
17009,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.5
17010,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
17011,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.2
17012,Iceland,2015,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",36.1
17013,Iceland,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
17014,Iceland,2015,4,B-Blood and blood forming organs,Million of national currency units,1575.9
17015,Iceland,2015,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",11.1
17016,Iceland,2015,4,B-Blood and blood forming organs,Million US$ at exchange rate,11.9
17017,Iceland,2015,4,A10-Drugs used in diabetes,% of total sales,3.0
17018,Iceland,2015,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.6
17019,Iceland,2015,4,C03-Diuretics,"/capita, US$ purchasing power parity",4.0
17020,Iceland,2015,4,C03-Diuretics,"/capita, US$ exchange rate",4.3
17021,Iceland,2015,4,A10-Drugs used in diabetes,Million US$ at exchange rate,5.5
17022,Iceland,2015,4,A10-Drugs used in diabetes,Million of national currency units,731.1
17023,Iceland,2015,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8
17024,Iceland,2015,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",5.1
17025,Iceland,2015,4,C10-Lipid modifying agents,Million US$ at exchange rate,2.3
17026,Iceland,2015,4,C10-Lipid modifying agents,Million of national currency units,308.6
17027,Iceland,2015,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",146.3
17028,Iceland,2015,4,Products not elsewhere classified,% of total sales,28.1
17029,Iceland,2015,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.2
17030,Iceland,2015,4,C10-Lipid modifying agents,% of total sales,1.3
17031,Iceland,2015,4,C03-Diuretics,% of total sales,0.8
17032,Iceland,2015,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.6
17033,Iceland,2015,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.1
17034,Iceland,2015,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",33.6
17035,Iceland,2015,4,N05B-Anxiolytics,Million of national currency units,268.0
17036,Iceland,2015,4,N05B-Anxiolytics,Million US$ at exchange rate,2.0
17037,Iceland,2015,4,N05B-Anxiolytics,"/capita, US$ exchange rate",6.1
17038,Iceland,2015,4,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9
17039,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,430.1
17040,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.9
17041,Iceland,2015,4,R03-Drugs for obstructive airway diseases,% of total sales,4.4
17042,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.3
17043,Iceland,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.0
17044,Iceland,2015,4,Total pharmaceutical sales,"Million US$, purchasing power parity",171.9
17045,Iceland,2015,4,Total pharmaceutical sales,"/capita, US$ exchange rate",559.2
17046,Iceland,2015,4,Total pharmaceutical sales,Million of national currency units,24403.4
17047,Iceland,2015,4,Total pharmaceutical sales,Million US$ at exchange rate,185.0
17048,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8
17049,Iceland,2015,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.7
17050,Iceland,2015,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",519.6
17051,Iceland,2015,4,N05B-Anxiolytics,% of total sales,1.1
17052,Iceland,2015,4,C-Cardiovascular system,Million US$ at exchange rate,13.0
17053,Iceland,2015,4,C-Cardiovascular system,"Million US$, purchasing power parity",12.1
17054,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,438.0
17055,Iceland,2015,4,C-Cardiovascular system,Million of national currency units,1713.3
17056,Iceland,2015,4,C-Cardiovascular system,% of total sales,7.0
17057,Iceland,2015,4,B-Blood and blood forming organs,% of total sales,6.5
17058,Iceland,2015,4,C-Cardiovascular system,"/capita, US$ exchange rate",39.3
17059,Iceland,2015,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.5
17060,Iceland,2015,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",7.6
17061,Iceland,2015,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,8.2
17062,Iceland,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.1
17063,Iceland,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.9
17064,Iceland,2015,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1085.7
17065,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.1
17066,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.3
17067,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.3
17068,Iceland,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.0
17069,Iceland,2015,4,C08-Calcium channel blockers,% of total sales,0.6
17070,Iceland,2015,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.3
17071,Iceland,2015,4,M-Musculo-skeletal system,Million US$ at exchange rate,4.9
17072,Iceland,2015,4,M-Musculo-skeletal system,Million of national currency units,645.8
17073,Iceland,2015,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.2
17074,Iceland,2015,4,C08-Calcium channel blockers,Million of national currency units,156.8
17075,Iceland,2015,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.6
17076,Iceland,2015,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.1
17077,Iceland,2015,4,R-Respiratory system,"Million US$, purchasing power parity",10.2
17078,Iceland,2015,4,R-Respiratory system,Million US$ at exchange rate,11.0
17079,Iceland,2015,4,R-Respiratory system,"/capita, US$ purchasing power parity",30.8
17080,Iceland,2015,4,R-Respiratory system,"/capita, US$ exchange rate",33.1
17081,Iceland,2015,4,R-Respiratory system,Million of national currency units,1444.8
17082,Iceland,2015,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.8
17083,Iceland,2015,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",4.5
17084,Iceland,2015,4,M-Musculo-skeletal system,% of total sales,2.6
17085,Iceland,2015,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.7
17086,Iceland,2015,4,N02-Analgesics,"Million US$, purchasing power parity",5.9
17087,Iceland,2015,4,N02-Analgesics,Million US$ at exchange rate,6.4
17088,Iceland,2015,4,N02-Analgesics,"/capita, US$ exchange rate",19.3
17089,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
17090,Iceland,2015,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.3
17091,Iceland,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",30.1
17092,Iceland,2015,4,N02-Analgesics,Million of national currency units,841.5
17093,Iceland,2015,4,G-Genito urinary system and sex hormones,Million of national currency units,1315.4
17094,Iceland,2015,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.0
17095,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6
17096,Iceland,2015,4,N02-Analgesics,% of total sales,3.4
17097,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.5
17098,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,69.1
17099,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.5
17100,Iceland,2015,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
17101,Iceland,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.5
17102,Iceland,2015,4,N02-Analgesics,"/capita, US$ purchasing power parity",17.9
17103,Iceland,2015,4,A02A-Antacids,% of total sales,0.0
17104,Iceland,2015,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
17105,Iceland,2015,4,C01A-Cardiac glycosides,Million of national currency units,11.7
17106,Iceland,2015,4,J-Antiinfectives for systemic use,Million of national currency units,2857.9
17107,Iceland,2015,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
17108,Iceland,2015,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
17109,Iceland,2015,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
17110,Iceland,2015,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",60.8
17111,Iceland,2015,4,J-Antiinfectives for systemic use,% of total sales,11.7
17112,Iceland,2015,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.5
17113,Iceland,2015,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,21.7
17114,Iceland,2015,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",20.1
17115,Iceland,2015,4,C01A-Cardiac glycosides,% of total sales,0.0
17116,Iceland,2015,4,R-Respiratory system,% of total sales,5.9
17117,Iceland,2015,4,C03-Diuretics,"Million US$, purchasing power parity",1.3
17118,Iceland,2015,4,C03-Diuretics,Million US$ at exchange rate,1.4
17119,Iceland,2015,4,C03-Diuretics,Million of national currency units,186.4
17120,Iceland,2014,5,N05C-Hypnotics and sedatives,Million of national currency units,451.9
17121,Iceland,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",29.6
17122,Iceland,2014,5,G-Genito urinary system and sex hormones,% of total sales,5.7
17123,Iceland,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.8
17124,Iceland,2014,5,N-Nervous system,Million US$ at exchange rate,45.5
17125,Iceland,2014,5,N-Nervous system,Million of national currency units,5314.4
17126,Iceland,2014,5,N-Nervous system,"Million US$, purchasing power parity",38.4
17127,Iceland,2014,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3
17128,Iceland,2014,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.9
17129,Iceland,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.0
17130,Iceland,2014,5,N05C-Hypnotics and sedatives,% of total sales,1.9
17131,Iceland,2014,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
17132,Iceland,2014,5,C02-Antihypertensives,% of total sales,0.2
17133,Iceland,2014,5,C07-Beta blocking agents,"/capita, US$ exchange rate",8.9
17134,Iceland,2014,5,C07-Beta blocking agents,% of total sales,1.4
17135,Iceland,2014,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.5
17136,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.1
17137,Iceland,2014,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.5
17138,Iceland,2014,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.1
17139,Iceland,2014,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.2
17140,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.9
17141,Iceland,2014,5,J01-Antibacterials for systemic use,Million of national currency units,997.1
17142,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,569.9
17143,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,% of total sales,3.2
17144,Iceland,2014,5,C02-Antihypertensives,"/capita, US$ exchange rate",1.2
17145,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",16.6
17146,Iceland,2014,5,C02-Antihypertensives,Million US$ at exchange rate,0.4
17147,Iceland,2014,5,C02-Antihypertensives,Million of national currency units,45.3
17148,Iceland,2014,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.3
17149,Iceland,2014,5,C07-Beta blocking agents,Million of national currency units,342.1
17150,Iceland,2014,5,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5
17151,Iceland,2014,5,C07-Beta blocking agents,Million US$ at exchange rate,2.9
17152,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,754.3
17153,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",5.4
17154,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",19.7
17155,Iceland,2014,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.5
17156,Iceland,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.8
17157,Iceland,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.6
17158,Iceland,2014,5,A-Alimentary tract and metabolism,% of total sales,8.0
17159,Iceland,2014,5,A02A-Antacids,Million US$ at exchange rate,0.0
17160,Iceland,2014,5,A02A-Antacids,"Million US$, purchasing power parity",0.0
17161,Iceland,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",13.7
17162,Iceland,2014,5,N-Nervous system,% of total sales,22.4
17163,Iceland,2014,5,N-Nervous system,"/capita, US$ exchange rate",139.0
17164,Iceland,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",117.2
17165,Iceland,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,16.2
17166,Iceland,2014,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
17167,Iceland,2014,5,A-Alimentary tract and metabolism,Million of national currency units,1897.2
17168,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",12.6
17169,Iceland,2014,5,N06A-Antidepressants,Million of national currency units,730.7
17170,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
17171,Iceland,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.9
17172,Iceland,2014,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.0
17173,Iceland,2014,5,J01-Antibacterials for systemic use,% of total sales,4.2
17174,Iceland,2014,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.1
17175,Iceland,2014,5,A02A-Antacids,Million of national currency units,0.0
17176,Iceland,2014,5,N06A-Antidepressants,% of total sales,3.1
17177,Iceland,2014,5,N06A-Antidepressants,Million US$ at exchange rate,6.3
17178,Iceland,2014,5,N06A-Antidepressants,"/capita, US$ exchange rate",19.1
17179,Iceland,2014,5,N06A-Antidepressants,"Million US$, purchasing power parity",5.3
17180,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.6
17181,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,656.6
17182,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",17.2
17183,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.7
17184,Iceland,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",45.4
17185,Iceland,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",164.5
17186,Iceland,2014,5,Products not elsewhere classified,Million of national currency units,6288.7
17187,Iceland,2014,5,Products not elsewhere classified,Million US$ at exchange rate,53.9
17188,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5
17189,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
17190,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.8
17191,Iceland,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.9
17192,Iceland,2014,5,B-Blood and blood forming organs,Million of national currency units,1526.6
17193,Iceland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.8
17194,Iceland,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",11.0
17195,Iceland,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,13.1
17196,Iceland,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",33.7
17197,Iceland,2014,5,A10-Drugs used in diabetes,% of total sales,3.1
17198,Iceland,2014,5,C03-Diuretics,"/capita, US$ purchasing power parity",4.6
17199,Iceland,2014,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.0
17200,Iceland,2014,5,C03-Diuretics,"/capita, US$ exchange rate",5.4
17201,Iceland,2014,5,A10-Drugs used in diabetes,Million US$ at exchange rate,6.2
17202,Iceland,2014,5,A10-Drugs used in diabetes,Million of national currency units,726.7
17203,Iceland,2014,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.0
17204,Iceland,2014,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",5.2
17205,Iceland,2014,5,C03-Diuretics,% of total sales,0.9
17206,Iceland,2014,5,C10-Lipid modifying agents,Million US$ at exchange rate,2.9
17207,Iceland,2014,5,C10-Lipid modifying agents,Million of national currency units,333.6
17208,Iceland,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",138.6
17209,Iceland,2014,5,Products not elsewhere classified,% of total sales,26.5
17210,Iceland,2014,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.4
17211,Iceland,2014,5,C10-Lipid modifying agents,% of total sales,1.4
17212,Iceland,2014,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.7
17213,Iceland,2014,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.4
17214,Iceland,2014,5,N05B-Anxiolytics,Million US$ at exchange rate,2.3
17215,Iceland,2014,5,N05B-Anxiolytics,Million of national currency units,263.5
17216,Iceland,2014,5,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9
17217,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,446.0
17218,Iceland,2014,5,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9
17219,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.7
17220,Iceland,2014,5,R03-Drugs for obstructive airway diseases,% of total sales,4.9
17221,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.8
17222,Iceland,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.2
17223,Iceland,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",171.0
17224,Iceland,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",619.7
17225,Iceland,2014,5,Total pharmaceutical sales,Million of national currency units,23689.8
17226,Iceland,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,202.9
17227,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.9
17228,Iceland,2014,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.8
17229,Iceland,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",522.3
17230,Iceland,2014,5,N05B-Anxiolytics,% of total sales,1.1
17231,Iceland,2014,5,C-Cardiovascular system,Million US$ at exchange rate,15.3
17232,Iceland,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",12.9
17233,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,439.8
17234,Iceland,2014,5,C-Cardiovascular system,Million of national currency units,1783.8
17235,Iceland,2014,5,B-Blood and blood forming organs,% of total sales,6.4
17236,Iceland,2014,5,C-Cardiovascular system,% of total sales,7.5
17237,Iceland,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",46.7
17238,Iceland,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",39.3
17239,Iceland,2014,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.4
17240,Iceland,2014,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.0
17241,Iceland,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.7
17242,Iceland,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.5
17243,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.2
17244,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.8
17245,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.5
17246,Iceland,2014,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1164.2
17247,Iceland,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.7
17248,Iceland,2014,5,C08-Calcium channel blockers,% of total sales,0.8
17249,Iceland,2014,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.1
17250,Iceland,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,6.0
17251,Iceland,2014,5,C01A-Cardiac glycosides,Million of national currency units,11.6
17252,Iceland,2014,5,M-Musculo-skeletal system,Million of national currency units,699.9
17253,Iceland,2014,5,C08-Calcium channel blockers,Million US$ at exchange rate,1.6
17254,Iceland,2014,5,C08-Calcium channel blockers,Million of national currency units,185.1
17255,Iceland,2014,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.8
17256,Iceland,2014,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.3
17257,Iceland,2014,5,R-Respiratory system,"Million US$, purchasing power parity",10.9
17258,Iceland,2014,5,R-Respiratory system,Million US$ at exchange rate,13.0
17259,Iceland,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",33.4
17260,Iceland,2014,5,R-Respiratory system,"/capita, US$ exchange rate",39.7
17261,Iceland,2014,5,R-Respiratory system,Million of national currency units,1516.1
17262,Iceland,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.3
17263,Iceland,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.1
17264,Iceland,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.4
17265,Iceland,2014,5,M-Musculo-skeletal system,% of total sales,3.0
17266,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,73.0
17267,Iceland,2014,5,N02-Analgesics,"Million US$, purchasing power parity",6.1
17268,Iceland,2014,5,N02-Analgesics,Million US$ at exchange rate,7.2
17269,Iceland,2014,5,N02-Analgesics,"/capita, US$ exchange rate",22.1
17270,Iceland,2014,5,N02-Analgesics,Million of national currency units,843.8
17271,Iceland,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.7
17272,Iceland,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",35.1
17273,Iceland,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,1343.4
17274,Iceland,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,11.5
17275,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
17276,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9
17277,Iceland,2014,5,N02-Analgesics,% of total sales,3.6
17278,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.5
17279,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
17280,Iceland,2014,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
17281,Iceland,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.6
17282,Iceland,2014,5,N02-Analgesics,"/capita, US$ purchasing power parity",18.6
17283,Iceland,2014,5,A02A-Antacids,% of total sales,0.0
17284,Iceland,2014,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
17285,Iceland,2014,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
17286,Iceland,2014,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
17287,Iceland,2014,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
17288,Iceland,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",58.7
17289,Iceland,2014,5,J-Antiinfectives for systemic use,% of total sales,11.2
17290,Iceland,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,22.8
17291,Iceland,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",19.2
17292,Iceland,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.7
17293,Iceland,2014,5,J-Antiinfectives for systemic use,Million of national currency units,2663.1
17294,Iceland,2014,5,C01A-Cardiac glycosides,% of total sales,0.0
17295,Iceland,2014,5,R-Respiratory system,% of total sales,6.4
17296,Iceland,2014,5,C03-Diuretics,"Million US$, purchasing power parity",1.5
17297,Iceland,2014,5,C03-Diuretics,Million US$ at exchange rate,1.8
17298,Iceland,2014,5,C03-Diuretics,Million of national currency units,206.8
17299,Iceland,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.8
17300,Iceland,2013,4,N05C-Hypnotics and sedatives,Million of national currency units,449.1
17301,Iceland,2013,4,G-Genito urinary system and sex hormones,% of total sales,5.8
17302,Iceland,2013,4,N-Nervous system,Million US$ at exchange rate,52.6
17303,Iceland,2013,4,N-Nervous system,"Million US$, purchasing power parity",46.9
17304,Iceland,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.4
17305,Iceland,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.1
17306,Iceland,2013,4,N-Nervous system,Million of national currency units,6429.3
17307,Iceland,2013,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3
17308,Iceland,2013,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.7
17309,Iceland,2013,4,N05C-Hypnotics and sedatives,% of total sales,1.7
17310,Iceland,2013,4,N-Nervous system,"/capita, US$ exchange rate",162.5
17311,Iceland,2013,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
17312,Iceland,2013,4,C02-Antihypertensives,% of total sales,0.2
17313,Iceland,2013,4,C07-Beta blocking agents,"/capita, US$ exchange rate",8.9
17314,Iceland,2013,4,C07-Beta blocking agents,% of total sales,1.4
17315,Iceland,2013,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0
17316,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.5
17317,Iceland,2013,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.6
17318,Iceland,2013,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.6
17319,Iceland,2013,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.5
17320,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.1
17321,Iceland,2013,4,J01-Antibacterials for systemic use,Million of national currency units,1047.8
17322,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,621.0
17323,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,% of total sales,3.3
17324,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",19.2
17325,Iceland,2013,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.3
17326,Iceland,2013,4,C02-Antihypertensives,Million US$ at exchange rate,0.4
17327,Iceland,2013,4,C02-Antihypertensives,Million of national currency units,50.8
17328,Iceland,2013,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.4
17329,Iceland,2013,4,C07-Beta blocking agents,Million of national currency units,353.3
17330,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,853.4
17331,Iceland,2013,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.6
17332,Iceland,2013,4,C07-Beta blocking agents,Million US$ at exchange rate,2.9
17333,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.2
17334,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.6
17335,Iceland,2013,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.0
17336,Iceland,2013,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",48.1
17337,Iceland,2013,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.9
17338,Iceland,2013,4,A-Alimentary tract and metabolism,% of total sales,8.2
17339,Iceland,2013,4,A02A-Antacids,Million US$ at exchange rate,0.0
17340,Iceland,2013,4,A02A-Antacids,"Million US$, purchasing power parity",0.0
17341,Iceland,2013,4,N-Nervous system,% of total sales,24.7
17342,Iceland,2013,4,N-Nervous system,"/capita, US$ purchasing power parity",144.9
17343,Iceland,2013,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",15.6
17344,Iceland,2013,4,A-Alimentary tract and metabolism,Million of national currency units,2134.0
17345,Iceland,2013,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,17.5
17346,Iceland,2013,4,A02A-Antacids,"/capita, US$ exchange rate",0.0
17347,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.0
17348,Iceland,2013,4,N06A-Antidepressants,Million of national currency units,767.5
17349,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
17350,Iceland,2013,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",23.6
17351,Iceland,2013,4,J01-Antibacterials for systemic use,% of total sales,4.0
17352,Iceland,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.7
17353,Iceland,2013,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.3
17354,Iceland,2013,4,N06A-Antidepressants,% of total sales,2.9
17355,Iceland,2013,4,A02A-Antacids,Million of national currency units,0.0
17356,Iceland,2013,4,N06A-Antidepressants,Million US$ at exchange rate,6.3
17357,Iceland,2013,4,N06A-Antidepressants,"/capita, US$ exchange rate",19.4
17358,Iceland,2013,4,N06A-Antidepressants,"Million US$, purchasing power parity",5.6
17359,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.4
17360,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,665.0
17361,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.9
17362,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.8
17363,Iceland,2013,4,Products not elsewhere classified,"Million US$, purchasing power parity",47.6
17364,Iceland,2013,4,Products not elsewhere classified,"/capita, US$ exchange rate",164.9
17365,Iceland,2013,4,Products not elsewhere classified,Million of national currency units,6524.4
17366,Iceland,2013,4,Products not elsewhere classified,Million US$ at exchange rate,53.4
17367,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",15.0
17368,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.5
17369,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",14.4
17370,Iceland,2013,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.1
17371,Iceland,2013,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.4
17372,Iceland,2013,4,B-Blood and blood forming organs,Million of national currency units,1557.0
17373,Iceland,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
17374,Iceland,2013,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",11.4
17375,Iceland,2013,4,B-Blood and blood forming organs,Million US$ at exchange rate,12.7
17376,Iceland,2013,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",147.1
17377,Iceland,2013,4,A10-Drugs used in diabetes,% of total sales,2.8
17378,Iceland,2013,4,C03-Diuretics,"/capita, US$ purchasing power parity",5.1
17379,Iceland,2013,4,C03-Diuretics,"/capita, US$ exchange rate",5.7
17380,Iceland,2013,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.6
17381,Iceland,2013,4,A10-Drugs used in diabetes,Million US$ at exchange rate,6.0
17382,Iceland,2013,4,A10-Drugs used in diabetes,Million of national currency units,738.0
17383,Iceland,2013,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.7
17384,Iceland,2013,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",5.4
17385,Iceland,2013,4,C03-Diuretics,% of total sales,0.9
17386,Iceland,2013,4,C10-Lipid modifying agents,Million US$ at exchange rate,2.5
17387,Iceland,2013,4,C10-Lipid modifying agents,Million of national currency units,308.7
17388,Iceland,2013,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.3
17389,Iceland,2013,4,Products not elsewhere classified,% of total sales,25.1
17390,Iceland,2013,4,C10-Lipid modifying agents,% of total sales,1.2
17391,Iceland,2013,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.8
17392,Iceland,2013,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.0
17393,Iceland,2013,4,N05B-Anxiolytics,Million US$ at exchange rate,2.2
17394,Iceland,2013,4,N05B-Anxiolytics,Million of national currency units,270.4
17395,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,638.8
17396,Iceland,2013,4,N05B-Anxiolytics,"/capita, US$ exchange rate",6.8
17397,Iceland,2013,4,N05B-Anxiolytics,"Million US$, purchasing power parity",2.0
17398,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",16.1
17399,Iceland,2013,4,R03-Drugs for obstructive airway diseases,% of total sales,4.7
17400,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.2
17401,Iceland,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.7
17402,Iceland,2013,4,Total pharmaceutical sales,"Million US$, purchasing power parity",189.9
17403,Iceland,2013,4,Total pharmaceutical sales,"/capita, US$ exchange rate",657.9
17404,Iceland,2013,4,Total pharmaceutical sales,Million of national currency units,26023.1
17405,Iceland,2013,4,Total pharmaceutical sales,Million US$ at exchange rate,213.0
17406,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.6
17407,Iceland,2013,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",6.1
17408,Iceland,2013,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",586.6
17409,Iceland,2013,4,N05B-Anxiolytics,% of total sales,1.0
17410,Iceland,2013,4,C-Cardiovascular system,Million US$ at exchange rate,14.8
17411,Iceland,2013,4,C-Cardiovascular system,"Million US$, purchasing power parity",13.2
17412,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,417.9
17413,Iceland,2013,4,C-Cardiovascular system,Million of national currency units,1814.0
17414,Iceland,2013,4,C-Cardiovascular system,"/capita, US$ exchange rate",45.9
17415,Iceland,2013,4,B-Blood and blood forming organs,% of total sales,6.0
17416,Iceland,2013,4,C-Cardiovascular system,% of total sales,7.0
17417,Iceland,2013,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",40.9
17418,Iceland,2013,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.9
17419,Iceland,2013,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.9
17420,Iceland,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.4
17421,Iceland,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.7
17422,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.0
17423,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.4
17424,Iceland,2013,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1215.5
17425,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.6
17426,Iceland,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.4
17427,Iceland,2013,4,C08-Calcium channel blockers,% of total sales,0.8
17428,Iceland,2013,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.5
17429,Iceland,2013,4,C01A-Cardiac glycosides,Million of national currency units,11.3
17430,Iceland,2013,4,M-Musculo-skeletal system,Million US$ at exchange rate,7.7
17431,Iceland,2013,4,M-Musculo-skeletal system,Million of national currency units,945.5
17432,Iceland,2013,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.6
17433,Iceland,2013,4,C08-Calcium channel blockers,Million of national currency units,198.8
17434,Iceland,2013,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.0
17435,Iceland,2013,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.5
17436,Iceland,2013,4,R-Respiratory system,"Million US$, purchasing power parity",13.4
17437,Iceland,2013,4,R-Respiratory system,Million US$ at exchange rate,15.0
17438,Iceland,2013,4,R-Respiratory system,"/capita, US$ purchasing power parity",41.4
17439,Iceland,2013,4,R-Respiratory system,"/capita, US$ exchange rate",46.4
17440,Iceland,2013,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.9
17441,Iceland,2013,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",6.9
17442,Iceland,2013,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.3
17443,Iceland,2013,4,R-Respiratory system,Million of national currency units,1836.6
17444,Iceland,2013,4,M-Musculo-skeletal system,% of total sales,3.6
17445,Iceland,2013,4,N02-Analgesics,"Million US$, purchasing power parity",7.3
17446,Iceland,2013,4,N02-Analgesics,Million US$ at exchange rate,8.2
17447,Iceland,2013,4,N02-Analgesics,"/capita, US$ exchange rate",25.3
17448,Iceland,2013,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.9
17449,Iceland,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",37.9
17450,Iceland,2013,4,N02-Analgesics,Million of national currency units,998.9
17451,Iceland,2013,4,G-Genito urinary system and sex hormones,Million of national currency units,1498.7
17452,Iceland,2013,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.3
17453,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
17454,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",2.0
17455,Iceland,2013,4,N02-Analgesics,% of total sales,3.8
17456,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
17457,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
17458,Iceland,2013,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
17459,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8
17460,Iceland,2013,4,N02-Analgesics,"/capita, US$ purchasing power parity",22.5
17461,Iceland,2013,4,A02A-Antacids,% of total sales,0.0
17462,Iceland,2013,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,79.2
17463,Iceland,2013,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
17464,Iceland,2013,4,J-Antiinfectives for systemic use,Million of national currency units,2618.6
17465,Iceland,2013,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
17466,Iceland,2013,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
17467,Iceland,2013,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
17468,Iceland,2013,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",59.0
17469,Iceland,2013,4,J-Antiinfectives for systemic use,% of total sales,10.1
17470,Iceland,2013,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,21.4
17471,Iceland,2013,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.2
17472,Iceland,2013,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",19.1
17473,Iceland,2013,4,R-Respiratory system,% of total sales,7.1
17474,Iceland,2013,4,C01A-Cardiac glycosides,% of total sales,0.0
17475,Iceland,2013,4,C03-Diuretics,Million US$ at exchange rate,1.8
17476,Iceland,2013,4,C03-Diuretics,"Million US$, purchasing power parity",1.6
17477,Iceland,2013,4,C03-Diuretics,Million of national currency units,225.0
17478,Iceland,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.6
17479,Iceland,2012,4,N05C-Hypnotics and sedatives,Million of national currency units,463.9
17480,Iceland,2012,4,G-Genito urinary system and sex hormones,% of total sales,6.1
17481,Iceland,2012,4,N-Nervous system,Million US$ at exchange rate,45.3
17482,Iceland,2012,4,N-Nervous system,"Million US$, purchasing power parity",41.4
17483,Iceland,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",11.6
17484,Iceland,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.6
17485,Iceland,2012,4,N-Nervous system,Million of national currency units,5666.6
17486,Iceland,2012,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4
17487,Iceland,2012,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.7
17488,Iceland,2012,4,N05C-Hypnotics and sedatives,% of total sales,1.9
17489,Iceland,2012,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
17490,Iceland,2012,4,C02-Antihypertensives,Million of national currency units,57.7
17491,Iceland,2012,4,C02-Antihypertensives,% of total sales,0.2
17492,Iceland,2012,4,C07-Beta blocking agents,"/capita, US$ exchange rate",8.6
17493,Iceland,2012,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9
17494,Iceland,2012,4,C07-Beta blocking agents,% of total sales,1.4
17495,Iceland,2012,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.2
17496,Iceland,2012,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.5
17497,Iceland,2012,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",25.7
17498,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.6
17499,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.2
17500,Iceland,2012,4,J01-Antibacterials for systemic use,Million of national currency units,1031.1
17501,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,581.0
17502,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,% of total sales,3.6
17503,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",19.7
17504,Iceland,2012,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.4
17505,Iceland,2012,4,C02-Antihypertensives,Million US$ at exchange rate,0.5
17506,Iceland,2012,4,C02-Antihypertensives,"Million US$, purchasing power parity",0.4
17507,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,865.6
17508,Iceland,2012,4,C07-Beta blocking agents,Million of national currency units,345.8
17509,Iceland,2012,4,C07-Beta blocking agents,"Million US$, purchasing power parity",2.5
17510,Iceland,2012,4,C07-Beta blocking agents,Million US$ at exchange rate,2.8
17511,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.3
17512,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",21.6
17513,Iceland,2012,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.9
17514,Iceland,2012,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",38.7
17515,Iceland,2012,4,A-Alimentary tract and metabolism,% of total sales,7.0
17516,Iceland,2012,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",42.4
17517,Iceland,2012,4,A02A-Antacids,Million US$ at exchange rate,0.0
17518,Iceland,2012,4,A02A-Antacids,"Million US$, purchasing power parity",0.0
17519,Iceland,2012,4,A02A-Antacids,"/capita, US$ exchange rate",0.0
17520,Iceland,2012,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",12.4
17521,Iceland,2012,4,N-Nervous system,% of total sales,23.3
17522,Iceland,2012,4,N-Nervous system,"/capita, US$ purchasing power parity",129.0
17523,Iceland,2012,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,13.6
17524,Iceland,2012,4,A-Alimentary tract and metabolism,Million of national currency units,1700.3
17525,Iceland,2012,4,N-Nervous system,"/capita, US$ exchange rate",141.3
17526,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.2
17527,Iceland,2012,4,N06A-Antidepressants,Million of national currency units,842.3
17528,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
17529,Iceland,2012,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",23.5
17530,Iceland,2012,4,J01-Antibacterials for systemic use,% of total sales,4.2
17531,Iceland,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.5
17532,Iceland,2012,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.2
17533,Iceland,2012,4,N06A-Antidepressants,% of total sales,3.5
17534,Iceland,2012,4,A02A-Antacids,Million of national currency units,0.0
17535,Iceland,2012,4,N06A-Antidepressants,Million US$ at exchange rate,6.7
17536,Iceland,2012,4,N06A-Antidepressants,"Million US$, purchasing power parity",6.1
17537,Iceland,2012,4,N06A-Antidepressants,"/capita, US$ exchange rate",21.0
17538,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,4.9
17539,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.5
17540,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,617.7
17541,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.4
17542,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.1
17543,Iceland,2012,4,Products not elsewhere classified,"/capita, US$ exchange rate",174.1
17544,Iceland,2012,4,Products not elsewhere classified,"Million US$, purchasing power parity",51.0
17545,Iceland,2012,4,Products not elsewhere classified,Million of national currency units,6983.5
17546,Iceland,2012,4,Products not elsewhere classified,Million US$ at exchange rate,55.8
17547,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
17548,Iceland,2012,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",30.2
17549,Iceland,2012,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",33.0
17550,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.0
17551,Iceland,2012,4,B-Blood and blood forming organs,Million of national currency units,1325.5
17552,Iceland,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
17553,Iceland,2012,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",9.7
17554,Iceland,2012,4,B-Blood and blood forming organs,Million US$ at exchange rate,10.6
17555,Iceland,2012,4,A10-Drugs used in diabetes,% of total sales,2.8
17556,Iceland,2012,4,C03-Diuretics,"/capita, US$ exchange rate",5.5
17557,Iceland,2012,4,C03-Diuretics,"/capita, US$ purchasing power parity",5.0
17558,Iceland,2012,4,A10-Drugs used in diabetes,Million US$ at exchange rate,5.4
17559,Iceland,2012,4,A10-Drugs used in diabetes,Million of national currency units,673.1
17560,Iceland,2012,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",4.9
17561,Iceland,2012,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.3
17562,Iceland,2012,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8
17563,Iceland,2012,4,C03-Diuretics,% of total sales,0.9
17564,Iceland,2012,4,C10-Lipid modifying agents,Million US$ at exchange rate,2.9
17565,Iceland,2012,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.7
17566,Iceland,2012,4,C10-Lipid modifying agents,Million of national currency units,367.8
17567,Iceland,2012,4,Products not elsewhere classified,% of total sales,28.8
17568,Iceland,2012,4,C10-Lipid modifying agents,% of total sales,1.5
17569,Iceland,2012,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",159.0
17570,Iceland,2012,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.2
17571,Iceland,2012,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.4
17572,Iceland,2012,4,N05B-Anxiolytics,Million US$ at exchange rate,2.1
17573,Iceland,2012,4,N05B-Anxiolytics,Million of national currency units,256.8
17574,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,482.3
17575,Iceland,2012,4,N05B-Anxiolytics,"/capita, US$ exchange rate",6.4
17576,Iceland,2012,4,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9
17577,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.0
17578,Iceland,2012,4,R03-Drugs for obstructive airway diseases,% of total sales,4.9
17579,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,3.9
17580,Iceland,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.5
17581,Iceland,2012,4,Total pharmaceutical sales,"Million US$, purchasing power parity",177.3
17582,Iceland,2012,4,Total pharmaceutical sales,"/capita, US$ exchange rate",605.2
17583,Iceland,2012,4,Total pharmaceutical sales,Million of national currency units,24278.0
17584,Iceland,2012,4,Total pharmaceutical sales,Million US$ at exchange rate,194.1
17585,Iceland,2012,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",552.7
17586,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8
17587,Iceland,2012,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.8
17588,Iceland,2012,4,N05B-Anxiolytics,% of total sales,1.1
17589,Iceland,2012,4,C-Cardiovascular system,"Million US$, purchasing power parity",13.6
17590,Iceland,2012,4,C-Cardiovascular system,Million US$ at exchange rate,14.9
17591,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,435.6
17592,Iceland,2012,4,C-Cardiovascular system,Million of national currency units,1866.2
17593,Iceland,2012,4,C-Cardiovascular system,"/capita, US$ exchange rate",46.5
17594,Iceland,2012,4,B-Blood and blood forming organs,% of total sales,5.5
17595,Iceland,2012,4,C-Cardiovascular system,% of total sales,7.7
17596,Iceland,2012,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",42.5
17597,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,3.5
17598,Iceland,2012,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.7
17599,Iceland,2012,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,9.6
17600,Iceland,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.2
17601,Iceland,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.8
17602,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.2
17603,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.9
17604,Iceland,2012,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1196.5
17605,Iceland,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.9
17606,Iceland,2012,4,C08-Calcium channel blockers,% of total sales,0.9
17607,Iceland,2012,4,M-Musculo-skeletal system,Million US$ at exchange rate,6.1
17608,Iceland,2012,4,M-Musculo-skeletal system,Million of national currency units,765.0
17609,Iceland,2012,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8
17610,Iceland,2012,4,C08-Calcium channel blockers,Million US$ at exchange rate,1.7
17611,Iceland,2012,4,C08-Calcium channel blockers,Million of national currency units,211.5
17612,Iceland,2012,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.3
17613,Iceland,2012,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.5
17614,Iceland,2012,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.6
17615,Iceland,2012,4,R-Respiratory system,"Million US$, purchasing power parity",11.6
17616,Iceland,2012,4,R-Respiratory system,Million US$ at exchange rate,12.7
17617,Iceland,2012,4,R-Respiratory system,"/capita, US$ purchasing power parity",36.0
17618,Iceland,2012,4,R-Respiratory system,"/capita, US$ exchange rate",39.5
17619,Iceland,2012,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.1
17620,Iceland,2012,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.4
17621,Iceland,2012,4,R-Respiratory system,Million of national currency units,1582.6
17622,Iceland,2012,4,M-Musculo-skeletal system,% of total sales,3.2
17623,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.4
17624,Iceland,2012,4,N02-Analgesics,"Million US$, purchasing power parity",5.7
17625,Iceland,2012,4,N02-Analgesics,Million US$ at exchange rate,6.3
17626,Iceland,2012,4,N02-Analgesics,"/capita, US$ exchange rate",19.6
17627,Iceland,2012,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.8
17628,Iceland,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",36.8
17629,Iceland,2012,4,N02-Analgesics,Million of national currency units,787.5
17630,Iceland,2012,4,G-Genito urinary system and sex hormones,Million of national currency units,1476.1
17631,Iceland,2012,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,11.8
17632,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
17633,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9
17634,Iceland,2012,4,N02-Analgesics,% of total sales,3.2
17635,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
17636,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
17637,Iceland,2012,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
17638,Iceland,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8
17639,Iceland,2012,4,N02-Analgesics,"/capita, US$ purchasing power parity",17.9
17640,Iceland,2012,4,A02A-Antacids,% of total sales,0.0
17641,Iceland,2012,4,C01A-Cardiac glycosides,Million of national currency units,10.6
17642,Iceland,2012,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
17643,Iceland,2012,4,J-Antiinfectives for systemic use,Million of national currency units,2794.5
17644,Iceland,2012,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
17645,Iceland,2012,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
17646,Iceland,2012,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
17647,Iceland,2012,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",63.6
17648,Iceland,2012,4,J-Antiinfectives for systemic use,% of total sales,11.5
17649,Iceland,2012,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,22.3
17650,Iceland,2012,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",20.4
17651,Iceland,2012,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",69.7
17652,Iceland,2012,4,C03-Diuretics,Million of national currency units,221.6
17653,Iceland,2012,4,C01A-Cardiac glycosides,% of total sales,0.0
17654,Iceland,2012,4,C03-Diuretics,Million US$ at exchange rate,1.8
17655,Iceland,2012,4,R-Respiratory system,% of total sales,6.5
17656,Iceland,2012,4,C03-Diuretics,"Million US$, purchasing power parity",1.6
17657,Iceland,2011,5,N05C-Hypnotics and sedatives,Million of national currency units,466.6
17658,Iceland,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.3
17659,Iceland,2011,5,G-Genito urinary system and sex hormones,% of total sales,5.5
17660,Iceland,2011,5,N-Nervous system,"Million US$, purchasing power parity",42.2
17661,Iceland,2011,5,N-Nervous system,Million US$ at exchange rate,49.2
17662,Iceland,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",10.8
17663,Iceland,2011,5,N-Nervous system,"/capita, US$ exchange rate",154.2
17664,Iceland,2011,5,N-Nervous system,Million of national currency units,5703.4
17665,Iceland,2011,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.5
17666,Iceland,2011,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.0
17667,Iceland,2011,5,N05C-Hypnotics and sedatives,% of total sales,1.8
17668,Iceland,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",12.6
17669,Iceland,2011,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.1
17670,Iceland,2011,5,C02-Antihypertensives,% of total sales,0.2
17671,Iceland,2011,5,C02-Antihypertensives,Million of national currency units,48.9
17672,Iceland,2011,5,C07-Beta blocking agents,"/capita, US$ exchange rate",9.4
17673,Iceland,2011,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0
17674,Iceland,2011,5,C07-Beta blocking agents,% of total sales,1.3
17675,Iceland,2011,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.3
17676,Iceland,2011,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.2
17677,Iceland,2011,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.1
17678,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,7.0
17679,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",6.0
17680,Iceland,2011,5,J01-Antibacterials for systemic use,Million of national currency units,966.8
17681,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,808.1
17682,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,% of total sales,3.2
17683,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",19.6
17684,Iceland,2011,5,C02-Antihypertensives,Million US$ at exchange rate,0.4
17685,Iceland,2011,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.4
17686,Iceland,2011,5,C02-Antihypertensives,"/capita, US$ exchange rate",1.3
17687,Iceland,2011,5,C07-Beta blocking agents,Million of national currency units,346.8
17688,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,845.0
17689,Iceland,2011,5,C07-Beta blocking agents,Million US$ at exchange rate,3.0
17690,Iceland,2011,5,C07-Beta blocking agents,"Million US$, purchasing power parity",2.6
17691,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",22.8
17692,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",6.3
17693,Iceland,2011,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.3
17694,Iceland,2011,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.9
17695,Iceland,2011,5,A-Alimentary tract and metabolism,% of total sales,7.3
17696,Iceland,2011,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.2
17697,Iceland,2011,5,A02A-Antacids,"Million US$, purchasing power parity",0.0
17698,Iceland,2011,5,A02A-Antacids,Million US$ at exchange rate,0.0
17699,Iceland,2011,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
17700,Iceland,2011,5,N-Nervous system,% of total sales,21.9
17701,Iceland,2011,5,N-Nervous system,"/capita, US$ purchasing power parity",132.3
17702,Iceland,2011,5,A-Alimentary tract and metabolism,Million of national currency units,1894.8
17703,Iceland,2011,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,16.3
17704,Iceland,2011,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",14.0
17705,Iceland,2011,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
17706,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",18.7
17707,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.1
17708,Iceland,2011,5,N06A-Antidepressants,Million of national currency units,865.8
17709,Iceland,2011,5,J01-Antibacterials for systemic use,% of total sales,3.7
17710,Iceland,2011,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.4
17711,Iceland,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.8
17712,Iceland,2011,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.1
17713,Iceland,2011,5,N06A-Antidepressants,% of total sales,3.3
17714,Iceland,2011,5,A02A-Antacids,Million of national currency units,0.0
17715,Iceland,2011,5,N06A-Antidepressants,Million US$ at exchange rate,7.5
17716,Iceland,2011,5,N06A-Antidepressants,"Million US$, purchasing power parity",6.4
17717,Iceland,2011,5,N06A-Antidepressants,"/capita, US$ exchange rate",23.4
17718,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.4
17719,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.6
17720,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5
17721,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.9
17722,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,623.4
17723,Iceland,2011,5,Products not elsewhere classified,"/capita, US$ exchange rate",223.3
17724,Iceland,2011,5,Products not elsewhere classified,"Million US$, purchasing power parity",61.1
17725,Iceland,2011,5,Products not elsewhere classified,Million of national currency units,8260.8
17726,Iceland,2011,5,Products not elsewhere classified,Million US$ at exchange rate,71.2
17727,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
17728,Iceland,2011,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",34.7
17729,Iceland,2011,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.8
17730,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.3
17731,Iceland,2011,5,B-Blood and blood forming organs,Million of national currency units,1283.9
17732,Iceland,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
17733,Iceland,2011,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",9.5
17734,Iceland,2011,5,B-Blood and blood forming organs,Million US$ at exchange rate,11.1
17735,Iceland,2011,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",191.6
17736,Iceland,2011,5,A10-Drugs used in diabetes,% of total sales,2.5
17737,Iceland,2011,5,C03-Diuretics,"/capita, US$ exchange rate",5.9
17738,Iceland,2011,5,C03-Diuretics,"/capita, US$ purchasing power parity",5.1
17739,Iceland,2011,5,C03-Diuretics,% of total sales,0.8
17740,Iceland,2011,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.0
17741,Iceland,2011,5,A10-Drugs used in diabetes,Million US$ at exchange rate,5.6
17742,Iceland,2011,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",4.8
17743,Iceland,2011,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.4
17744,Iceland,2011,5,C10-Lipid modifying agents,Million US$ at exchange rate,3.2
17745,Iceland,2011,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",2.7
17746,Iceland,2011,5,Products not elsewhere classified,% of total sales,31.7
17747,Iceland,2011,5,C10-Lipid modifying agents,Million of national currency units,366.0
17748,Iceland,2011,5,C10-Lipid modifying agents,% of total sales,1.4
17749,Iceland,2011,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.9
17750,Iceland,2011,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.5
17751,Iceland,2011,5,N05B-Anxiolytics,Million US$ at exchange rate,1.9
17752,Iceland,2011,5,N05B-Anxiolytics,Million of national currency units,214.7
17753,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,485.5
17754,Iceland,2011,5,N05B-Anxiolytics,"/capita, US$ exchange rate",5.8
17755,Iceland,2011,5,N05B-Anxiolytics,"Million US$, purchasing power parity",1.6
17756,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",13.1
17757,Iceland,2011,5,R03-Drugs for obstructive airway diseases,% of total sales,4.5
17758,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,4.2
17759,Iceland,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",3.6
17760,Iceland,2011,5,Total pharmaceutical sales,"/capita, US$ exchange rate",705.1
17761,Iceland,2011,5,Total pharmaceutical sales,"Million US$, purchasing power parity",193.0
17762,Iceland,2011,5,Total pharmaceutical sales,Million of national currency units,26083.5
17763,Iceland,2011,5,Total pharmaceutical sales,Million US$ at exchange rate,224.9
17764,Iceland,2011,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",605.0
17765,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.0
17766,Iceland,2011,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.0
17767,Iceland,2011,5,N05B-Anxiolytics,% of total sales,0.8
17768,Iceland,2011,5,C-Cardiovascular system,"Million US$, purchasing power parity",14.4
17769,Iceland,2011,5,C-Cardiovascular system,Million US$ at exchange rate,16.8
17770,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,520.4
17771,Iceland,2011,5,C-Cardiovascular system,Million of national currency units,1946.3
17772,Iceland,2011,5,C-Cardiovascular system,"/capita, US$ exchange rate",52.6
17773,Iceland,2011,5,B-Blood and blood forming organs,% of total sales,4.9
17774,Iceland,2011,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",45.1
17775,Iceland,2011,5,C-Cardiovascular system,% of total sales,7.5
17776,Iceland,2011,5,A10-Drugs used in diabetes,Million of national currency units,645.2
17777,Iceland,2011,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",8.7
17778,Iceland,2011,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.2
17779,Iceland,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",27.4
17780,Iceland,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.9
17781,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.1
17782,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",3.9
17783,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,4.5
17784,Iceland,2011,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1180.2
17785,Iceland,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",12.1
17786,Iceland,2011,5,C01A-Cardiac glycosides,Million of national currency units,10.0
17787,Iceland,2011,5,C08-Calcium channel blockers,% of total sales,0.9
17788,Iceland,2011,5,M-Musculo-skeletal system,Million US$ at exchange rate,6.6
17789,Iceland,2011,5,M-Musculo-skeletal system,Million of national currency units,760.9
17790,Iceland,2011,5,C08-Calcium channel blockers,Million US$ at exchange rate,2.0
17791,Iceland,2011,5,C08-Calcium channel blockers,Million of national currency units,229.8
17792,Iceland,2011,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.3
17793,Iceland,2011,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.2
17794,Iceland,2011,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",1.7
17795,Iceland,2011,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",5.6
17796,Iceland,2011,5,R-Respiratory system,"Million US$, purchasing power parity",11.5
17797,Iceland,2011,5,R-Respiratory system,Million US$ at exchange rate,13.4
17798,Iceland,2011,5,R-Respiratory system,"/capita, US$ purchasing power parity",36.1
17799,Iceland,2011,5,R-Respiratory system,"/capita, US$ exchange rate",42.1
17800,Iceland,2011,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.6
17801,Iceland,2011,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.6
17802,Iceland,2011,5,R-Respiratory system,Million of national currency units,1558.2
17803,Iceland,2011,5,M-Musculo-skeletal system,% of total sales,2.9
17804,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,69.6
17805,Iceland,2011,5,N02-Analgesics,"Million US$, purchasing power parity",5.8
17806,Iceland,2011,5,N02-Analgesics,Million US$ at exchange rate,6.8
17807,Iceland,2011,5,N02-Analgesics,"/capita, US$ purchasing power parity",18.3
17808,Iceland,2011,5,N02-Analgesics,"/capita, US$ exchange rate",21.4
17809,Iceland,2011,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.6
17810,Iceland,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",38.8
17811,Iceland,2011,5,N02-Analgesics,Million of national currency units,789.8
17812,Iceland,2011,5,G-Genito urinary system and sex hormones,Million of national currency units,1436.1
17813,Iceland,2011,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,12.4
17814,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.9
17815,Iceland,2011,5,N02-Analgesics,% of total sales,3.0
17816,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
17817,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.5
17818,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.6
17819,Iceland,2011,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
17820,Iceland,2011,5,A02A-Antacids,% of total sales,0.0
17821,Iceland,2011,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
17822,Iceland,2011,5,J-Antiinfectives for systemic use,Million of national currency units,2615.7
17823,Iceland,2011,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
17824,Iceland,2011,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
17825,Iceland,2011,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
17826,Iceland,2011,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",60.7
17827,Iceland,2011,5,J-Antiinfectives for systemic use,% of total sales,10.0
17828,Iceland,2011,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,22.6
17829,Iceland,2011,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",19.4
17830,Iceland,2011,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",70.7
17831,Iceland,2011,5,C01A-Cardiac glycosides,% of total sales,0.0
17832,Iceland,2011,5,C03-Diuretics,"Million US$, purchasing power parity",1.6
17833,Iceland,2011,5,C03-Diuretics,Million of national currency units,219.2
17834,Iceland,2011,5,R-Respiratory system,% of total sales,6.0
17835,Iceland,2011,5,C03-Diuretics,Million US$ at exchange rate,1.9
17836,Ireland,2017,5,N02-Analgesics,"Million US$, purchasing power parity",69.0
17837,Ireland,2017,5,C03-Diuretics,"/capita, US$ exchange rate",3.4
17838,Ireland,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.6
17839,Ireland,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.6
17840,Ireland,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",142.4
17841,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.5
17842,Ireland,2017,5,N05B-Anxiolytics,% of total sales,0.4
17843,Ireland,2017,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
17844,Ireland,2017,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
17845,Ireland,2017,5,B-Blood and blood forming organs,% of total sales,5.3
17846,Ireland,2017,5,N05B-Anxiolytics,"/capita, US$ exchange rate",2.1
17847,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
17848,Ireland,2017,5,C02-Antihypertensives,Million of national currency units,17.8
17849,Ireland,2017,5,N05B-Anxiolytics,Million US$ at exchange rate,10.2
17850,Ireland,2017,5,N05B-Anxiolytics,"Million US$, purchasing power parity",11.3
17851,Ireland,2017,5,N05B-Anxiolytics,Million of national currency units,9.0
17852,Ireland,2017,5,N02-Analgesics,Million of national currency units,54.8
17853,Ireland,2017,5,N02-Analgesics,Million US$ at exchange rate,61.9
17854,Ireland,2017,5,C03-Diuretics,Million of national currency units,14.3
17855,Ireland,2017,5,C03-Diuretics,Million US$ at exchange rate,16.1
17856,Ireland,2017,5,C03-Diuretics,"Million US$, purchasing power parity",18.0
17857,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
17858,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,51.7
17859,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.0
17860,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.5
17861,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.1
17862,Ireland,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",143.0
17863,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.5
17864,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,58.4
17865,Ireland,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",65.1
17866,Ireland,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.7
17867,Ireland,2017,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.7
17868,Ireland,2017,5,C02-Antihypertensives,% of total sales,0.8
17869,Ireland,2017,5,J-Antiinfectives for systemic use,% of total sales,5.3
17870,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,62.7
17871,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",69.9
17872,Ireland,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",26.7
17873,Ireland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,55.5
17874,Ireland,2017,5,N02-Analgesics,% of total sales,2.6
17875,Ireland,2017,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",23.1
17876,Ireland,2017,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.7
17877,Ireland,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.8
17878,Ireland,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.3
17879,Ireland,2017,5,C02-Antihypertensives,"Million US$, purchasing power parity",22.4
17880,Ireland,2017,5,C02-Antihypertensives,Million US$ at exchange rate,20.1
17881,Ireland,2017,5,N05C-Hypnotics and sedatives,Million of national currency units,18.3
17882,Ireland,2017,5,C02-Antihypertensives,"/capita, US$ exchange rate",4.2
17883,Ireland,2017,5,N05C-Hypnotics and sedatives,% of total sales,0.9
17884,Ireland,2017,5,B-Blood and blood forming organs,Million of national currency units,113.1
17885,Ireland,2017,5,N02-Analgesics,"/capita, US$ exchange rate",12.9
17886,Ireland,2017,5,N02-Analgesics,"/capita, US$ purchasing power parity",14.4
17887,Ireland,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,127.8
17888,Ireland,2017,5,C03-Diuretics,% of total sales,0.7
17889,Ireland,2017,5,J-Antiinfectives for systemic use,Million of national currency units,113.6
17890,Ireland,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,128.3
17891,Ireland,2017,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
17892,Ireland,2017,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
17893,Ireland,2017,5,C01A-Cardiac glycosides,% of total sales,0.1
17894,Ireland,2017,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
17895,Ireland,2017,5,C01A-Cardiac glycosides,Million US$ at exchange rate,1.2
17896,Ireland,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.7
17897,Ireland,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.9
17898,Ireland,2017,5,C01A-Cardiac glycosides,Million of national currency units,1.1
17899,Ireland,2017,5,M-Musculo-skeletal system,% of total sales,3.2
17900,Ireland,2017,5,C10-Lipid modifying agents,Million US$ at exchange rate,74.8
17901,Ireland,2017,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",83.3
17902,Ireland,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",205.2
17903,Ireland,2017,5,Products not elsewhere classified,% of total sales,36.9
17904,Ireland,2017,5,C10-Lipid modifying agents,Million of national currency units,66.2
17905,Ireland,2017,5,A10-Drugs used in diabetes,Million US$ at exchange rate,110.5
17906,Ireland,2017,5,A10-Drugs used in diabetes,Million of national currency units,97.8
17907,Ireland,2017,5,C10-Lipid modifying agents,% of total sales,3.1
17908,Ireland,2017,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.6
17909,Ireland,2017,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",17.3
17910,Ireland,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",85.0
17911,Ireland,2017,5,C08-Calcium channel blockers,Million US$ at exchange rate,19.9
17912,Ireland,2017,5,C08-Calcium channel blockers,Million of national currency units,17.6
17913,Ireland,2017,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.2
17914,Ireland,2017,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.6
17915,Ireland,2017,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1
17916,Ireland,2017,5,A02A-Antacids,Million US$ at exchange rate,0.0
17917,Ireland,2017,5,A02A-Antacids,Million of national currency units,0.0
17918,Ireland,2017,5,A02A-Antacids,"Million US$, purchasing power parity",0.0
17919,Ireland,2017,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
17920,Ireland,2017,5,A02A-Antacids,"/capita, US$ exchange rate",0.0
17921,Ireland,2017,5,R-Respiratory system,"/capita, US$ exchange rate",42.7
17922,Ireland,2017,5,R-Respiratory system,% of total sales,8.6
17923,Ireland,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",47.6
17924,Ireland,2017,5,M-Musculo-skeletal system,Million of national currency units,67.5
17925,Ireland,2017,5,C08-Calcium channel blockers,% of total sales,0.8
17926,Ireland,2017,5,R-Respiratory system,Million US$ at exchange rate,205.3
17927,Ireland,2017,5,R-Respiratory system,Million of national currency units,181.8
17928,Ireland,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,76.2
17929,Ireland,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",26.9
17930,Ireland,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.2
17931,Ireland,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",556.3
17932,Ireland,2017,5,R03-Drugs for obstructive airway diseases,% of total sales,4.8
17933,Ireland,2017,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",129.4
17934,Ireland,2017,5,C-Cardiovascular system,Million of national currency units,211.3
17935,Ireland,2017,5,C-Cardiovascular system,Million US$ at exchange rate,238.7
17936,Ireland,2017,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,116.1
17937,Ireland,2017,5,R03-Drugs for obstructive airway diseases,Million of national currency units,102.8
17938,Ireland,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",499.2
17939,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.5
17940,Ireland,2017,5,Total pharmaceutical sales,Million of national currency units,2124.4
17941,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",13.9
17942,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.5
17943,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",66.9
17944,Ireland,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,2399.9
17945,Ireland,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",2674.3
17946,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,60.0
17947,Ireland,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,53.1
17948,Ireland,2017,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",123.2
17949,Ireland,2017,5,A02A-Antacids,% of total sales,0.0
17950,Ireland,2017,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.0
17951,Ireland,2017,5,A10-Drugs used in diabetes,% of total sales,4.6
17952,Ireland,2017,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",25.6
17953,Ireland,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",986.5
17954,Ireland,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",184.2
17955,Ireland,2017,5,Products not elsewhere classified,Million of national currency units,783.7
17956,Ireland,2017,5,Products not elsewhere classified,Million US$ at exchange rate,885.3
17957,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,17.8
17958,Ireland,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",266.0
17959,Ireland,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",49.7
17960,Ireland,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",55.3
17961,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.7
17962,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
17963,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.2
17964,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,20.1
17965,Ireland,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",22.4
17966,Ireland,2017,5,C-Cardiovascular system,% of total sales,9.9
17967,Ireland,2017,5,R-Respiratory system,"Million US$, purchasing power parity",228.8
17968,Ireland,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",81.5
17969,Ireland,2017,5,J01-Antibacterials for systemic use,Million of national currency units,42.9
17970,Ireland,2017,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.1
17971,Ireland,2017,5,N-Nervous system,% of total sales,14.7
17972,Ireland,2017,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",54.0
17973,Ireland,2017,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
17974,Ireland,2017,5,N-Nervous system,"/capita, US$ exchange rate",73.1
17975,Ireland,2017,5,G-Genito urinary system and sex hormones,% of total sales,3.3
17976,Ireland,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.7
17977,Ireland,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.6
17978,Ireland,2017,5,N-Nervous system,"Million US$, purchasing power parity",391.8
17979,Ireland,2017,5,N-Nervous system,Million of national currency units,311.2
17980,Ireland,2017,5,N-Nervous system,Million US$ at exchange rate,351.6
17981,Ireland,2017,5,N06A-Antidepressants,Million US$ at exchange rate,50.1
17982,Ireland,2017,5,N06A-Antidepressants,"Million US$, purchasing power parity",55.8
17983,Ireland,2017,5,A-Alimentary tract and metabolism,% of total sales,10.1
17984,Ireland,2017,5,N06A-Antidepressants,Million of national currency units,44.4
17985,Ireland,2017,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.4
17986,Ireland,2017,5,N06A-Antidepressants,% of total sales,2.1
17987,Ireland,2017,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.6
17988,Ireland,2017,5,A-Alimentary tract and metabolism,Million of national currency units,215.6
17989,Ireland,2017,5,J01-Antibacterials for systemic use,% of total sales,2.0
17990,Ireland,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,243.5
17991,Ireland,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",50.7
17992,Ireland,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",56.4
17993,Ireland,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",271.4
17994,Ireland,2017,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,48.5
17995,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.3
17996,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,37.0
17997,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.7
17998,Ireland,2017,5,C07-Beta blocking agents,Million of national currency units,22.5
17999,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,32.8
18000,Ireland,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.6
18001,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
18002,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
18003,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.1
18004,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.4
18005,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.8
18006,Ireland,2017,5,C07-Beta blocking agents,Million US$ at exchange rate,25.4
18007,Ireland,2017,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
18008,Ireland,2017,5,C07-Beta blocking agents,% of total sales,1.1
18009,Ireland,2017,5,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3
18010,Ireland,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,80.4
18011,Ireland,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",89.6
18012,Ireland,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,71.2
18013,Ireland,2017,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.9
18014,Ireland,2017,5,C07-Beta blocking agents,"Million US$, purchasing power parity",28.3
18015,Ireland,2016,6,N02-Analgesics,"Million US$, purchasing power parity",73.0
18016,Ireland,2016,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.8
18017,Ireland,2016,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",24.4
18018,Ireland,2016,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",132.1
18019,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
18020,Ireland,2016,6,C02-Antihypertensives,Million of national currency units,18.3
18021,Ireland,2016,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.9
18022,Ireland,2016,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
18023,Ireland,2016,6,N05B-Anxiolytics,% of total sales,0.4
18024,Ireland,2016,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.2
18025,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5
18026,Ireland,2016,6,N05B-Anxiolytics,Million US$ at exchange rate,10.3
18027,Ireland,2016,6,N05B-Anxiolytics,Million of national currency units,9.3
18028,Ireland,2016,6,B-Blood and blood forming organs,% of total sales,5.1
18029,Ireland,2016,6,C03-Diuretics,"/capita, US$ exchange rate",3.4
18030,Ireland,2016,6,N02-Analgesics,Million of national currency units,58.0
18031,Ireland,2016,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.8
18032,Ireland,2016,6,N02-Analgesics,Million US$ at exchange rate,64.2
18033,Ireland,2016,6,C03-Diuretics,Million of national currency units,14.7
18034,Ireland,2016,6,C03-Diuretics,Million US$ at exchange rate,16.3
18035,Ireland,2016,6,C03-Diuretics,"Million US$, purchasing power parity",18.6
18036,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
18037,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,52.4
18038,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.0
18039,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.8
18040,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.9
18041,Ireland,2016,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",129.4
18042,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.2
18043,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,58.0
18044,Ireland,2016,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",66.0
18045,Ireland,2016,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.2
18046,Ireland,2016,6,J-Antiinfectives for systemic use,% of total sales,5.0
18047,Ireland,2016,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.9
18048,Ireland,2016,6,C02-Antihypertensives,% of total sales,0.9
18049,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,61.7
18050,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",70.2
18051,Ireland,2016,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",23.9
18052,Ireland,2016,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,55.7
18053,Ireland,2016,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",23.6
18054,Ireland,2016,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.8
18055,Ireland,2016,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.4
18056,Ireland,2016,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",5.0
18057,Ireland,2016,6,C02-Antihypertensives,"Million US$, purchasing power parity",23.1
18058,Ireland,2016,6,C02-Antihypertensives,Million US$ at exchange rate,20.3
18059,Ireland,2016,6,N05C-Hypnotics and sedatives,Million of national currency units,18.8
18060,Ireland,2016,6,C02-Antihypertensives,"/capita, US$ exchange rate",4.3
18061,Ireland,2016,6,N05C-Hypnotics and sedatives,% of total sales,0.9
18062,Ireland,2016,6,B-Blood and blood forming organs,Million of national currency units,104.9
18063,Ireland,2016,6,B-Blood and blood forming organs,Million US$ at exchange rate,116.1
18064,Ireland,2016,6,N02-Analgesics,"/capita, US$ exchange rate",13.5
18065,Ireland,2016,6,N02-Analgesics,% of total sales,2.8
18066,Ireland,2016,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.4
18067,Ireland,2016,6,C03-Diuretics,% of total sales,0.7
18068,Ireland,2016,6,J-Antiinfectives for systemic use,Million of national currency units,102.8
18069,Ireland,2016,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,113.8
18070,Ireland,2016,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
18071,Ireland,2016,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6
18072,Ireland,2016,6,C01A-Cardiac glycosides,% of total sales,0.1
18073,Ireland,2016,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
18074,Ireland,2016,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.4
18075,Ireland,2016,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.9
18076,Ireland,2016,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.7
18077,Ireland,2016,6,C01A-Cardiac glycosides,Million of national currency units,1.2
18078,Ireland,2016,6,M-Musculo-skeletal system,% of total sales,3.2
18079,Ireland,2016,6,C10-Lipid modifying agents,Million US$ at exchange rate,72.4
18080,Ireland,2016,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",82.3
18081,Ireland,2016,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",194.1
18082,Ireland,2016,6,Products not elsewhere classified,% of total sales,35.3
18083,Ireland,2016,6,C10-Lipid modifying agents,Million of national currency units,65.4
18084,Ireland,2016,6,A10-Drugs used in diabetes,Million US$ at exchange rate,104.0
18085,Ireland,2016,6,A10-Drugs used in diabetes,Million of national currency units,94.0
18086,Ireland,2016,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.2
18087,Ireland,2016,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",17.3
18088,Ireland,2016,6,C10-Lipid modifying agents,% of total sales,3.1
18089,Ireland,2016,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",84.9
18090,Ireland,2016,6,C08-Calcium channel blockers,Million US$ at exchange rate,20.0
18091,Ireland,2016,6,C08-Calcium channel blockers,Million of national currency units,18.1
18092,Ireland,2016,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.7
18093,Ireland,2016,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8
18094,Ireland,2016,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.2
18095,Ireland,2016,6,A02A-Antacids,Million US$ at exchange rate,0.0
18096,Ireland,2016,6,A02A-Antacids,Million of national currency units,0.0
18097,Ireland,2016,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
18098,Ireland,2016,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
18099,Ireland,2016,6,A02A-Antacids,"Million US$, purchasing power parity",0.1
18100,Ireland,2016,6,R-Respiratory system,"/capita, US$ exchange rate",39.1
18101,Ireland,2016,6,R-Respiratory system,"Million US$, purchasing power parity",211.3
18102,Ireland,2016,6,R-Respiratory system,% of total sales,8.1
18103,Ireland,2016,6,R-Respiratory system,"/capita, US$ purchasing power parity",44.4
18104,Ireland,2016,6,R-Respiratory system,Million US$ at exchange rate,185.7
18105,Ireland,2016,6,M-Musculo-skeletal system,Million of national currency units,67.5
18106,Ireland,2016,6,C08-Calcium channel blockers,% of total sales,0.9
18107,Ireland,2016,6,M-Musculo-skeletal system,Million US$ at exchange rate,74.7
18108,Ireland,2016,6,R-Respiratory system,Million of national currency units,167.8
18109,Ireland,2016,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",29.5
18110,Ireland,2016,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",25.9
18111,Ireland,2016,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",549.6
18112,Ireland,2016,6,R03-Drugs for obstructive airway diseases,% of total sales,5.4
18113,Ireland,2016,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",140.2
18114,Ireland,2016,6,C-Cardiovascular system,Million of national currency units,218.3
18115,Ireland,2016,6,C-Cardiovascular system,Million US$ at exchange rate,241.6
18116,Ireland,2016,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,123.2
18117,Ireland,2016,6,R03-Drugs for obstructive airway diseases,Million of national currency units,111.3
18118,Ireland,2016,6,Total pharmaceutical sales,"/capita, US$ exchange rate",483.2
18119,Ireland,2016,6,Total pharmaceutical sales,Million US$ at exchange rate,2298.0
18120,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.8
18121,Ireland,2016,6,Total pharmaceutical sales,Million of national currency units,2076.0
18122,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",15.7
18123,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.9
18124,Ireland,2016,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2613.7
18125,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",74.5
18126,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,65.5
18127,Ireland,2016,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,59.2
18128,Ireland,2016,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.9
18129,Ireland,2016,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",118.3
18130,Ireland,2016,6,A10-Drugs used in diabetes,% of total sales,4.5
18131,Ireland,2016,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.9
18132,Ireland,2016,6,A02A-Antacids,% of total sales,0.0
18133,Ireland,2016,6,Products not elsewhere classified,"Million US$, purchasing power parity",923.2
18134,Ireland,2016,6,Products not elsewhere classified,"/capita, US$ exchange rate",170.7
18135,Ireland,2016,6,Products not elsewhere classified,Million US$ at exchange rate,811.7
18136,Ireland,2016,6,Products not elsewhere classified,Million of national currency units,733.3
18137,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,19.2
18138,Ireland,2016,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",57.8
18139,Ireland,2016,6,C-Cardiovascular system,"Million US$, purchasing power parity",274.8
18140,Ireland,2016,6,C-Cardiovascular system,"/capita, US$ exchange rate",50.8
18141,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,21.2
18142,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.1
18143,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9
18144,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.5
18145,Ireland,2016,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",24.1
18146,Ireland,2016,6,C-Cardiovascular system,% of total sales,10.5
18147,Ireland,2016,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,49.7
18148,Ireland,2016,6,N-Nervous system,"/capita, US$ purchasing power parity",89.7
18149,Ireland,2016,6,J01-Antibacterials for systemic use,Million of national currency units,44.9
18150,Ireland,2016,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.4
18151,Ireland,2016,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9
18152,Ireland,2016,6,N-Nervous system,% of total sales,16.3
18153,Ireland,2016,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",56.5
18154,Ireland,2016,6,G-Genito urinary system and sex hormones,% of total sales,3.7
18155,Ireland,2016,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.3
18156,Ireland,2016,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.8
18157,Ireland,2016,6,N-Nervous system,"Million US$, purchasing power parity",426.5
18158,Ireland,2016,6,N-Nervous system,"/capita, US$ exchange rate",78.9
18159,Ireland,2016,6,N-Nervous system,Million of national currency units,338.8
18160,Ireland,2016,6,N-Nervous system,Million US$ at exchange rate,375.0
18161,Ireland,2016,6,N06A-Antidepressants,Million US$ at exchange rate,55.0
18162,Ireland,2016,6,N06A-Antidepressants,"Million US$, purchasing power parity",62.5
18163,Ireland,2016,6,A-Alimentary tract and metabolism,% of total sales,10.1
18164,Ireland,2016,6,N06A-Antidepressants,Million of national currency units,49.7
18165,Ireland,2016,6,N06A-Antidepressants,"/capita, US$ exchange rate",11.6
18166,Ireland,2016,6,N06A-Antidepressants,% of total sales,2.4
18167,Ireland,2016,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.2
18168,Ireland,2016,6,A-Alimentary tract and metabolism,Million of national currency units,210.4
18169,Ireland,2016,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,232.9
18170,Ireland,2016,6,J01-Antibacterials for systemic use,% of total sales,2.2
18171,Ireland,2016,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.0
18172,Ireland,2016,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",55.7
18173,Ireland,2016,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",264.9
18174,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",44.4
18175,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,39.0
18176,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.2
18177,Ireland,2016,6,C07-Beta blocking agents,Million of national currency units,22.9
18178,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,35.3
18179,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
18180,Ireland,2016,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.3
18181,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
18182,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
18183,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.4
18184,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.1
18185,Ireland,2016,6,C07-Beta blocking agents,Million US$ at exchange rate,25.4
18186,Ireland,2016,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.9
18187,Ireland,2016,6,C07-Beta blocking agents,% of total sales,1.1
18188,Ireland,2016,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.1
18189,Ireland,2016,6,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3
18190,Ireland,2016,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",96.5
18191,Ireland,2016,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,84.8
18192,Ireland,2016,6,G-Genito urinary system and sex hormones,Million of national currency units,76.6
18193,Ireland,2016,6,C07-Beta blocking agents,"Million US$, purchasing power parity",28.9
18194,Ireland,2015,6,N02-Analgesics,"Million US$, purchasing power parity",71.0
18195,Ireland,2015,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.0
18196,Ireland,2015,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",117.5
18197,Ireland,2015,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",22.5
18198,Ireland,2015,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.6
18199,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
18200,Ireland,2015,6,C02-Antihypertensives,Million of national currency units,17.2
18201,Ireland,2015,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.0
18202,Ireland,2015,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
18203,Ireland,2015,6,N05B-Anxiolytics,% of total sales,0.5
18204,Ireland,2015,6,B-Blood and blood forming organs,% of total sales,4.8
18205,Ireland,2015,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.2
18206,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.8
18207,Ireland,2015,6,N05B-Anxiolytics,Million US$ at exchange rate,10.4
18208,Ireland,2015,6,N05B-Anxiolytics,Million of national currency units,9.4
18209,Ireland,2015,6,C03-Diuretics,"/capita, US$ exchange rate",3.6
18210,Ireland,2015,6,N02-Analgesics,Million of national currency units,57.5
18211,Ireland,2015,6,N02-Analgesics,Million US$ at exchange rate,63.7
18212,Ireland,2015,6,C03-Diuretics,Million of national currency units,15.4
18213,Ireland,2015,6,C03-Diuretics,Million US$ at exchange rate,17.1
18214,Ireland,2015,6,C03-Diuretics,"Million US$, purchasing power parity",19.0
18215,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
18216,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,55.6
18217,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.6
18218,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",14.0
18219,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,61.7
18220,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.6
18221,Ireland,2015,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",110.7
18222,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.1
18223,Ireland,2015,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",68.6
18224,Ireland,2015,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.5
18225,Ireland,2015,6,J-Antiinfectives for systemic use,% of total sales,4.5
18226,Ireland,2015,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.5
18227,Ireland,2015,6,C02-Antihypertensives,% of total sales,0.9
18228,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,59.2
18229,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",65.9
18230,Ireland,2015,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.2
18231,Ireland,2015,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,53.4
18232,Ireland,2015,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.6
18233,Ireland,2015,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,20.3
18234,Ireland,2015,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.3
18235,Ireland,2015,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.8
18236,Ireland,2015,6,N05C-Hypnotics and sedatives,% of total sales,0.9
18237,Ireland,2015,6,C02-Antihypertensives,"Million US$, purchasing power parity",21.2
18238,Ireland,2015,6,C02-Antihypertensives,Million US$ at exchange rate,19.1
18239,Ireland,2015,6,N05C-Hypnotics and sedatives,Million of national currency units,18.3
18240,Ireland,2015,6,C02-Antihypertensives,"/capita, US$ exchange rate",4.1
18241,Ireland,2015,6,B-Blood and blood forming organs,Million of national currency units,95.2
18242,Ireland,2015,6,N02-Analgesics,"/capita, US$ exchange rate",13.6
18243,Ireland,2015,6,B-Blood and blood forming organs,Million US$ at exchange rate,105.6
18244,Ireland,2015,6,N02-Analgesics,% of total sales,2.9
18245,Ireland,2015,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.1
18246,Ireland,2015,6,C03-Diuretics,% of total sales,0.8
18247,Ireland,2015,6,J-Antiinfectives for systemic use,Million of national currency units,89.6
18248,Ireland,2015,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,99.5
18249,Ireland,2015,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.3
18250,Ireland,2015,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7
18251,Ireland,2015,6,C01A-Cardiac glycosides,% of total sales,0.1
18252,Ireland,2015,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
18253,Ireland,2015,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5
18254,Ireland,2015,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.4
18255,Ireland,2015,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.6
18256,Ireland,2015,6,C01A-Cardiac glycosides,Million of national currency units,1.3
18257,Ireland,2015,6,M-Musculo-skeletal system,% of total sales,3.3
18258,Ireland,2015,6,C10-Lipid modifying agents,Million US$ at exchange rate,72.7
18259,Ireland,2015,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",80.9
18260,Ireland,2015,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",174.4
18261,Ireland,2015,6,Products not elsewhere classified,% of total sales,33.4
18262,Ireland,2015,6,C10-Lipid modifying agents,Million of national currency units,65.5
18263,Ireland,2015,6,A10-Drugs used in diabetes,Million US$ at exchange rate,99.1
18264,Ireland,2015,6,A10-Drugs used in diabetes,Million of national currency units,89.3
18265,Ireland,2015,6,C10-Lipid modifying agents,% of total sales,3.3
18266,Ireland,2015,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.5
18267,Ireland,2015,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",17.2
18268,Ireland,2015,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.2
18269,Ireland,2015,6,C08-Calcium channel blockers,Million US$ at exchange rate,20.0
18270,Ireland,2015,6,C08-Calcium channel blockers,Million of national currency units,18.0
18271,Ireland,2015,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.7
18272,Ireland,2015,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.2
18273,Ireland,2015,6,A02A-Antacids,Million US$ at exchange rate,0.1
18274,Ireland,2015,6,A02A-Antacids,Million of national currency units,0.1
18275,Ireland,2015,6,A02A-Antacids,"Million US$, purchasing power parity",0.1
18276,Ireland,2015,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
18277,Ireland,2015,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
18278,Ireland,2015,6,R-Respiratory system,"/capita, US$ exchange rate",40.0
18279,Ireland,2015,6,R-Respiratory system,"Million US$, purchasing power parity",209.4
18280,Ireland,2015,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",81.8
18281,Ireland,2015,6,R-Respiratory system,% of total sales,8.5
18282,Ireland,2015,6,R-Respiratory system,"/capita, US$ purchasing power parity",44.5
18283,Ireland,2015,6,M-Musculo-skeletal system,Million of national currency units,66.2
18284,Ireland,2015,6,C08-Calcium channel blockers,% of total sales,0.9
18285,Ireland,2015,6,R-Respiratory system,Million US$ at exchange rate,188.1
18286,Ireland,2015,6,R-Respiratory system,Million of national currency units,169.5
18287,Ireland,2015,6,M-Musculo-skeletal system,Million US$ at exchange rate,73.5
18288,Ireland,2015,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.3
18289,Ireland,2015,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.2
18290,Ireland,2015,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",521.4
18291,Ireland,2015,6,R03-Drugs for obstructive airway diseases,% of total sales,5.8
18292,Ireland,2015,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",142.5
18293,Ireland,2015,6,C-Cardiovascular system,Million of national currency units,217.8
18294,Ireland,2015,6,C-Cardiovascular system,Million US$ at exchange rate,241.7
18295,Ireland,2015,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,128.0
18296,Ireland,2015,6,R03-Drugs for obstructive airway diseases,Million of national currency units,115.4
18297,Ireland,2015,6,Total pharmaceutical sales,Million US$ at exchange rate,2202.5
18298,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.0
18299,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",15.6
18300,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.0
18301,Ireland,2015,6,Total pharmaceutical sales,Million of national currency units,1985.1
18302,Ireland,2015,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2451.7
18303,Ireland,2015,6,Total pharmaceutical sales,"/capita, US$ exchange rate",468.4
18304,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,59.5
18305,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",73.4
18306,Ireland,2015,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,66.0
18307,Ireland,2015,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.1
18308,Ireland,2015,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",110.3
18309,Ireland,2015,6,A10-Drugs used in diabetes,% of total sales,4.5
18310,Ireland,2015,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.5
18311,Ireland,2015,6,A02A-Antacids,% of total sales,0.0
18312,Ireland,2015,6,Products not elsewhere classified,"Million US$, purchasing power parity",819.8
18313,Ireland,2015,6,Products not elsewhere classified,"/capita, US$ exchange rate",156.6
18314,Ireland,2015,6,Products not elsewhere classified,Million of national currency units,663.8
18315,Ireland,2015,6,Products not elsewhere classified,Million US$ at exchange rate,736.5
18316,Ireland,2015,6,C-Cardiovascular system,% of total sales,11.0
18317,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,19.7
18318,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,21.9
18319,Ireland,2015,6,C-Cardiovascular system,"Million US$, purchasing power parity",269.0
18320,Ireland,2015,6,C-Cardiovascular system,"/capita, US$ exchange rate",51.4
18321,Ireland,2015,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",57.2
18322,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.2
18323,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0
18324,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",24.4
18325,Ireland,2015,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.7
18326,Ireland,2015,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,53.0
18327,Ireland,2015,6,N-Nervous system,"/capita, US$ purchasing power parity",91.7
18328,Ireland,2015,6,J01-Antibacterials for systemic use,Million of national currency units,47.7
18329,Ireland,2015,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.3
18330,Ireland,2015,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.5
18331,Ireland,2015,6,N-Nervous system,% of total sales,17.6
18332,Ireland,2015,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",58.9
18333,Ireland,2015,6,G-Genito urinary system and sex hormones,% of total sales,3.7
18334,Ireland,2015,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.5
18335,Ireland,2015,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.5
18336,Ireland,2015,6,N-Nervous system,Million of national currency units,349.3
18337,Ireland,2015,6,N-Nervous system,"Million US$, purchasing power parity",431.4
18338,Ireland,2015,6,N-Nervous system,"/capita, US$ exchange rate",82.4
18339,Ireland,2015,6,N-Nervous system,Million US$ at exchange rate,387.5
18340,Ireland,2015,6,N06A-Antidepressants,Million US$ at exchange rate,62.3
18341,Ireland,2015,6,N06A-Antidepressants,"Million US$, purchasing power parity",69.4
18342,Ireland,2015,6,A-Alimentary tract and metabolism,% of total sales,10.4
18343,Ireland,2015,6,N06A-Antidepressants,Million of national currency units,56.2
18344,Ireland,2015,6,N06A-Antidepressants,"/capita, US$ exchange rate",13.3
18345,Ireland,2015,6,N06A-Antidepressants,% of total sales,2.8
18346,Ireland,2015,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.8
18347,Ireland,2015,6,A-Alimentary tract and metabolism,Million of national currency units,206.0
18348,Ireland,2015,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,228.6
18349,Ireland,2015,6,J01-Antibacterials for systemic use,% of total sales,2.4
18350,Ireland,2015,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",54.1
18351,Ireland,2015,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",48.6
18352,Ireland,2015,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",254.4
18353,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",42.4
18354,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,38.1
18355,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.1
18356,Ireland,2015,6,C07-Beta blocking agents,Million of national currency units,22.7
18357,Ireland,2015,6,C07-Beta blocking agents,Million US$ at exchange rate,25.2
18358,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,34.3
18359,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
18360,Ireland,2015,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.0
18361,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
18362,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
18363,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3
18364,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.0
18365,Ireland,2015,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.7
18366,Ireland,2015,6,C07-Beta blocking agents,% of total sales,1.1
18367,Ireland,2015,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.0
18368,Ireland,2015,6,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4
18369,Ireland,2015,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",91.7
18370,Ireland,2015,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,82.4
18371,Ireland,2015,6,G-Genito urinary system and sex hormones,Million of national currency units,74.3
18372,Ireland,2015,6,C07-Beta blocking agents,"Million US$, purchasing power parity",28.0
18373,Ireland,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.7
18374,Ireland,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",110.5
18375,Ireland,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.8
18376,Ireland,2014,6,N02-Analgesics,"Million US$, purchasing power parity",67.1
18377,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
18378,Ireland,2014,6,C02-Antihypertensives,Million of national currency units,16.6
18379,Ireland,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.2
18380,Ireland,2014,6,B-Blood and blood forming organs,% of total sales,4.7
18381,Ireland,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
18382,Ireland,2014,6,N05B-Anxiolytics,% of total sales,0.5
18383,Ireland,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.6
18384,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.5
18385,Ireland,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.3
18386,Ireland,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,12.3
18387,Ireland,2014,6,N05B-Anxiolytics,Million of national currency units,9.3
18388,Ireland,2014,6,C03-Diuretics,"/capita, US$ exchange rate",4.5
18389,Ireland,2014,6,N02-Analgesics,Million of national currency units,54.9
18390,Ireland,2014,6,N02-Analgesics,Million US$ at exchange rate,73.0
18391,Ireland,2014,6,C03-Diuretics,Million of national currency units,15.9
18392,Ireland,2014,6,C03-Diuretics,Million US$ at exchange rate,21.2
18393,Ireland,2014,6,C03-Diuretics,"Million US$, purchasing power parity",19.5
18394,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,66.3
18395,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
18396,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.7
18397,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.5
18398,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",17.4
18399,Ireland,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",83.6
18400,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,88.1
18401,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",18.9
18402,Ireland,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",81.0
18403,Ireland,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.0
18404,Ireland,2014,6,J-Antiinfectives for systemic use,% of total sales,3.6
18405,Ireland,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.3
18406,Ireland,2014,6,C02-Antihypertensives,% of total sales,0.9
18407,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,68.4
18408,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",62.9
18409,Ireland,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.5
18410,Ireland,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,51.5
18411,Ireland,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.9
18412,Ireland,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.9
18413,Ireland,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.4
18414,Ireland,2014,6,N05C-Hypnotics and sedatives,% of total sales,1.0
18415,Ireland,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.9
18416,Ireland,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",20.2
18417,Ireland,2014,6,C02-Antihypertensives,Million US$ at exchange rate,22.0
18418,Ireland,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,18.8
18419,Ireland,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",4.7
18420,Ireland,2014,6,N02-Analgesics,"/capita, US$ exchange rate",15.7
18421,Ireland,2014,6,B-Blood and blood forming organs,Million of national currency units,90.5
18422,Ireland,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,120.2
18423,Ireland,2014,6,N02-Analgesics,% of total sales,2.9
18424,Ireland,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.4
18425,Ireland,2014,6,C03-Diuretics,% of total sales,0.8
18426,Ireland,2014,6,J-Antiinfectives for systemic use,Million of national currency units,68.5
18427,Ireland,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,91.0
18428,Ireland,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4
18429,Ireland,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7
18430,Ireland,2014,6,C01A-Cardiac glycosides,% of total sales,0.1
18431,Ireland,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
18432,Ireland,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,1.9
18433,Ireland,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.3
18434,Ireland,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.8
18435,Ireland,2014,6,C01A-Cardiac glycosides,Million of national currency units,1.4
18436,Ireland,2014,6,M-Musculo-skeletal system,% of total sales,3.4
18437,Ireland,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,92.2
18438,Ireland,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",84.7
18439,Ireland,2014,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",158.5
18440,Ireland,2014,6,Products not elsewhere classified,% of total sales,31.6
18441,Ireland,2014,6,C10-Lipid modifying agents,Million of national currency units,69.4
18442,Ireland,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,111.1
18443,Ireland,2014,6,A10-Drugs used in diabetes,Million of national currency units,83.6
18444,Ireland,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",19.8
18445,Ireland,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",18.2
18446,Ireland,2014,6,C10-Lipid modifying agents,% of total sales,3.6
18447,Ireland,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",27.3
18448,Ireland,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,29.7
18449,Ireland,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.9
18450,Ireland,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.4
18451,Ireland,2014,6,C08-Calcium channel blockers,Million of national currency units,22.3
18452,Ireland,2014,6,A02A-Antacids,Million US$ at exchange rate,0.1
18453,Ireland,2014,6,A02A-Antacids,Million of national currency units,0.1
18454,Ireland,2014,6,A02A-Antacids,"Million US$, purchasing power parity",0.1
18455,Ireland,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
18456,Ireland,2014,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
18457,Ireland,2014,6,R-Respiratory system,"/capita, US$ exchange rate",47.1
18458,Ireland,2014,6,R-Respiratory system,"Million US$, purchasing power parity",201.5
18459,Ireland,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",80.5
18460,Ireland,2014,6,R-Respiratory system,% of total sales,8.6
18461,Ireland,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",43.3
18462,Ireland,2014,6,M-Musculo-skeletal system,Million of national currency units,66.0
18463,Ireland,2014,6,C08-Calcium channel blockers,% of total sales,1.2
18464,Ireland,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,87.6
18465,Ireland,2014,6,R-Respiratory system,Million US$ at exchange rate,219.3
18466,Ireland,2014,6,R-Respiratory system,Million of national currency units,165.0
18467,Ireland,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",29.7
18468,Ireland,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.4
18469,Ireland,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",501.7
18470,Ireland,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,5.9
18471,Ireland,2014,6,C-Cardiovascular system,Million of national currency units,233.7
18472,Ireland,2014,6,C-Cardiovascular system,Million US$ at exchange rate,310.5
18473,Ireland,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",138.5
18474,Ireland,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,150.7
18475,Ireland,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,113.5
18476,Ireland,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,2542.4
18477,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",19.2
18478,Ireland,2014,6,Total pharmaceutical sales,Million of national currency units,1913.8
18479,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.6
18480,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.5
18481,Ireland,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2336.6
18482,Ireland,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",545.9
18483,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",82.0
18484,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,89.2
18485,Ireland,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,67.2
18486,Ireland,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",285.4
18487,Ireland,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.8
18488,Ireland,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",102.1
18489,Ireland,2014,6,A10-Drugs used in diabetes,% of total sales,4.4
18490,Ireland,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.9
18491,Ireland,2014,6,A02A-Antacids,% of total sales,0.0
18492,Ireland,2014,6,Products not elsewhere classified,"Million US$, purchasing power parity",738.3
18493,Ireland,2014,6,Products not elsewhere classified,"/capita, US$ exchange rate",172.5
18494,Ireland,2014,6,Products not elsewhere classified,Million of national currency units,604.7
18495,Ireland,2014,6,Products not elsewhere classified,Million US$ at exchange rate,803.3
18496,Ireland,2014,6,C-Cardiovascular system,% of total sales,12.2
18497,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,19.9
18498,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,26.4
18499,Ireland,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",66.7
18500,Ireland,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",61.3
18501,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.2
18502,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.0
18503,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.7
18504,Ireland,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",24.3
18505,Ireland,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,63.8
18506,Ireland,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",92.4
18507,Ireland,2014,6,J01-Antibacterials for systemic use,Million of national currency units,48.0
18508,Ireland,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.7
18509,Ireland,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.6
18510,Ireland,2014,6,N-Nervous system,% of total sales,18.4
18511,Ireland,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",58.6
18512,Ireland,2014,6,G-Genito urinary system and sex hormones,% of total sales,3.9
18513,Ireland,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.2
18514,Ireland,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.4
18515,Ireland,2014,6,N-Nervous system,Million of national currency units,352.3
18516,Ireland,2014,6,N-Nervous system,"Million US$, purchasing power parity",430.2
18517,Ireland,2014,6,N-Nervous system,"/capita, US$ exchange rate",100.5
18518,Ireland,2014,6,N-Nervous system,Million US$ at exchange rate,468.1
18519,Ireland,2014,6,N06A-Antidepressants,Million US$ at exchange rate,93.1
18520,Ireland,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",85.6
18521,Ireland,2014,6,A-Alimentary tract and metabolism,% of total sales,10.8
18522,Ireland,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",20.0
18523,Ireland,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",18.4
18524,Ireland,2014,6,N06A-Antidepressants,% of total sales,3.7
18525,Ireland,2014,6,A-Alimentary tract and metabolism,Million of national currency units,207.4
18526,Ireland,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,275.5
18527,Ireland,2014,6,J01-Antibacterials for systemic use,% of total sales,2.5
18528,Ireland,2014,6,N06A-Antidepressants,Million of national currency units,70.1
18529,Ireland,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",54.4
18530,Ireland,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",59.1
18531,Ireland,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",253.2
18532,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",40.0
18533,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.3
18534,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,43.5
18535,Ireland,2014,6,C07-Beta blocking agents,Million of national currency units,23.4
18536,Ireland,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,31.0
18537,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,32.8
18538,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
18539,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
18540,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
18541,Ireland,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.6
18542,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.0
18543,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,2.3
18544,Ireland,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",2.8
18545,Ireland,2014,6,C07-Beta blocking agents,% of total sales,1.2
18546,Ireland,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7
18547,Ireland,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.1
18548,Ireland,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",90.6
18549,Ireland,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,74.2
18550,Ireland,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,98.6
18551,Ireland,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",28.5
18552,Ireland,2013,6,N02-Analgesics,"Million US$, purchasing power parity",67.5
18553,Ireland,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.9
18554,Ireland,2013,6,B-Blood and blood forming organs,% of total sales,4.6
18555,Ireland,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.8
18556,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
18557,Ireland,2013,6,C02-Antihypertensives,Million of national currency units,16.9
18558,Ireland,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.4
18559,Ireland,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
18560,Ireland,2013,6,N05B-Anxiolytics,% of total sales,0.5
18561,Ireland,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7
18562,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.8
18563,Ireland,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.7
18564,Ireland,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,12.6
18565,Ireland,2013,6,N05B-Anxiolytics,Million of national currency units,9.5
18566,Ireland,2013,6,C03-Diuretics,Million of national currency units,16.4
18567,Ireland,2013,6,C03-Diuretics,"/capita, US$ exchange rate",4.7
18568,Ireland,2013,6,N02-Analgesics,Million of national currency units,54.7
18569,Ireland,2013,6,N02-Analgesics,Million US$ at exchange rate,72.7
18570,Ireland,2013,6,C03-Diuretics,Million US$ at exchange rate,21.8
18571,Ireland,2013,6,C03-Diuretics,"Million US$, purchasing power parity",20.2
18572,Ireland,2013,6,C02-Antihypertensives,Million US$ at exchange rate,22.4
18573,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,95.0
18574,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
18575,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.4
18576,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.4
18577,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,126.2
18578,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",25.3
18579,Ireland,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",79.3
18580,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",117.2
18581,Ireland,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",27.3
18582,Ireland,2013,6,J-Antiinfectives for systemic use,% of total sales,3.3
18583,Ireland,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.2
18584,Ireland,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.5
18585,Ireland,2013,6,C02-Antihypertensives,% of total sales,0.9
18586,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,66.6
18587,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",61.8
18588,Ireland,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.5
18589,Ireland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,50.1
18590,Ireland,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.2
18591,Ireland,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.5
18592,Ireland,2013,6,N05C-Hypnotics and sedatives,% of total sales,0.9
18593,Ireland,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.9
18594,Ireland,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.2
18595,Ireland,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",20.8
18596,Ireland,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,18.2
18597,Ireland,2013,6,J-Antiinfectives for systemic use,Million of national currency units,64.3
18598,Ireland,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",4.8
18599,Ireland,2013,6,N02-Analgesics,"/capita, US$ exchange rate",15.7
18600,Ireland,2013,6,B-Blood and blood forming organs,Million of national currency units,89.7
18601,Ireland,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,119.2
18602,Ireland,2013,6,N02-Analgesics,% of total sales,2.8
18603,Ireland,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.6
18604,Ireland,2013,6,C03-Diuretics,% of total sales,0.8
18605,Ireland,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",110.6
18606,Ireland,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,85.4
18607,Ireland,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4
18608,Ireland,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.9
18609,Ireland,2013,6,C01A-Cardiac glycosides,% of total sales,0.1
18610,Ireland,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
18611,Ireland,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.9
18612,Ireland,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.3
18613,Ireland,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0
18614,Ireland,2013,6,C01A-Cardiac glycosides,Million of national currency units,1.5
18615,Ireland,2013,6,M-Musculo-skeletal system,% of total sales,3.4
18616,Ireland,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,149.2
18617,Ireland,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",138.5
18618,Ireland,2013,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",150.8
18619,Ireland,2013,6,Products not elsewhere classified,% of total sales,28.9
18620,Ireland,2013,6,C10-Lipid modifying agents,Million of national currency units,112.4
18621,Ireland,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",32.3
18622,Ireland,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,108.9
18623,Ireland,2013,6,A10-Drugs used in diabetes,Million of national currency units,82.0
18624,Ireland,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.0
18625,Ireland,2013,6,C10-Lipid modifying agents,% of total sales,5.7
18626,Ireland,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",29.6
18627,Ireland,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,31.8
18628,Ireland,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.4
18629,Ireland,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.9
18630,Ireland,2013,6,C08-Calcium channel blockers,Million of national currency units,24.0
18631,Ireland,2013,6,A02A-Antacids,"Million US$, purchasing power parity",0.1
18632,Ireland,2013,6,A02A-Antacids,Million US$ at exchange rate,0.1
18633,Ireland,2013,6,A02A-Antacids,Million of national currency units,0.1
18634,Ireland,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
18635,Ireland,2013,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
18636,Ireland,2013,6,R-Respiratory system,"/capita, US$ exchange rate",47.0
18637,Ireland,2013,6,R-Respiratory system,"Million US$, purchasing power parity",201.5
18638,Ireland,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",82.7
18639,Ireland,2013,6,R-Respiratory system,% of total sales,8.3
18640,Ireland,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",43.6
18641,Ireland,2013,6,M-Musculo-skeletal system,Million of national currency units,67.1
18642,Ireland,2013,6,C08-Calcium channel blockers,% of total sales,1.2
18643,Ireland,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,89.1
18644,Ireland,2013,6,R-Respiratory system,Million US$ at exchange rate,217.1
18645,Ireland,2013,6,R-Respiratory system,Million of national currency units,163.5
18646,Ireland,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",31.7
18647,Ireland,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",34.2
18648,Ireland,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",522.4
18649,Ireland,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,6.1
18650,Ireland,2013,6,C-Cardiovascular system,Million of national currency units,288.4
18651,Ireland,2013,6,C-Cardiovascular system,Million US$ at exchange rate,383.0
18652,Ireland,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,119.0
18653,Ireland,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",146.7
18654,Ireland,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,158.1
18655,Ireland,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,2602.6
18656,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.1
18657,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",20.5
18658,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.9
18659,Ireland,2013,6,Total pharmaceutical sales,Million of national currency units,1959.6
18660,Ireland,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2415.6
18661,Ireland,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",562.9
18662,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,76.8
18663,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",94.7
18664,Ireland,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,102.0
18665,Ireland,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",23.5
18666,Ireland,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",101.0
18667,Ireland,2013,6,A10-Drugs used in diabetes,% of total sales,4.2
18668,Ireland,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.9
18669,Ireland,2013,6,A02A-Antacids,% of total sales,0.0
18670,Ireland,2013,6,Products not elsewhere classified,"Million US$, purchasing power parity",697.2
18671,Ireland,2013,6,Products not elsewhere classified,"/capita, US$ exchange rate",162.5
18672,Ireland,2013,6,Products not elsewhere classified,Million of national currency units,565.6
18673,Ireland,2013,6,Products not elsewhere classified,Million US$ at exchange rate,751.2
18674,Ireland,2013,6,C-Cardiovascular system,% of total sales,14.7
18675,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,21.3
18676,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,28.3
18677,Ireland,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",82.8
18678,Ireland,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",76.9
18679,Ireland,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",355.5
18680,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.7
18681,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.1
18682,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",26.3
18683,Ireland,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.1
18684,Ireland,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,63.8
18685,Ireland,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",95.4
18686,Ireland,2013,6,J01-Antibacterials for systemic use,Million of national currency units,48.1
18687,Ireland,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.8
18688,Ireland,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.8
18689,Ireland,2013,6,N-Nervous system,% of total sales,18.3
18690,Ireland,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",59.2
18691,Ireland,2013,6,G-Genito urinary system and sex hormones,% of total sales,4.1
18692,Ireland,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.9
18693,Ireland,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.2
18694,Ireland,2013,6,N-Nervous system,Million of national currency units,357.7
18695,Ireland,2013,6,N-Nervous system,"Million US$, purchasing power parity",441.0
18696,Ireland,2013,6,N-Nervous system,"/capita, US$ exchange rate",102.8
18697,Ireland,2013,6,N-Nervous system,Million US$ at exchange rate,475.1
18698,Ireland,2013,6,N06A-Antidepressants,Million US$ at exchange rate,96.6
18699,Ireland,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",89.7
18700,Ireland,2013,6,A-Alimentary tract and metabolism,% of total sales,11.9
18701,Ireland,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",20.9
18702,Ireland,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.4
18703,Ireland,2013,6,N06A-Antidepressants,% of total sales,3.7
18704,Ireland,2013,6,A-Alimentary tract and metabolism,Million of national currency units,233.4
18705,Ireland,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,310.0
18706,Ireland,2013,6,N06A-Antidepressants,Million of national currency units,72.7
18707,Ireland,2013,6,J01-Antibacterials for systemic use,% of total sales,2.5
18708,Ireland,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",62.2
18709,Ireland,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",67.0
18710,Ireland,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",287.7
18711,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.8
18712,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.7
18713,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,45.0
18714,Ireland,2013,6,C07-Beta blocking agents,Million of national currency units,23.6
18715,Ireland,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,31.3
18716,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,33.9
18717,Ireland,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.0
18718,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.0
18719,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
18720,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
18721,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
18722,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.9
18723,Ireland,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.6
18724,Ireland,2013,6,C07-Beta blocking agents,% of total sales,1.2
18725,Ireland,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.3
18726,Ireland,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.8
18727,Ireland,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",98.2
18728,Ireland,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,105.8
18729,Ireland,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,79.7
18730,Ireland,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",29.0
18731,Ireland,2012,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.2
18732,Ireland,2012,6,B-Blood and blood forming organs,% of total sales,4.5
18733,Ireland,2012,6,N02-Analgesics,"Million US$, purchasing power parity",71.9
18734,Ireland,2012,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.6
18735,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
18736,Ireland,2012,6,J-Antiinfectives for systemic use,Million of national currency units,69.6
18737,Ireland,2012,6,C02-Antihypertensives,Million of national currency units,21.1
18738,Ireland,2012,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.3
18739,Ireland,2012,6,N05B-Anxiolytics,% of total sales,0.5
18740,Ireland,2012,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7
18741,Ireland,2012,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.6
18742,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.3
18743,Ireland,2012,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.8
18744,Ireland,2012,6,N05B-Anxiolytics,Million US$ at exchange rate,12.5
18745,Ireland,2012,6,N05B-Anxiolytics,Million of national currency units,9.7
18746,Ireland,2012,6,N02-Analgesics,Million of national currency units,59.2
18747,Ireland,2012,6,C03-Diuretics,"/capita, US$ exchange rate",4.6
18748,Ireland,2012,6,N02-Analgesics,Million US$ at exchange rate,76.0
18749,Ireland,2012,6,C03-Diuretics,Million US$ at exchange rate,21.1
18750,Ireland,2012,6,C03-Diuretics,Million of national currency units,16.4
18751,Ireland,2012,6,C03-Diuretics,"Million US$, purchasing power parity",20.0
18752,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,108.5
18753,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,139.4
18754,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
18755,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.8
18756,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",28.7
18757,Ireland,2012,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",84.6
18758,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",131.8
18759,Ireland,2012,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",30.3
18760,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.6
18761,Ireland,2012,6,J-Antiinfectives for systemic use,% of total sales,3.4
18762,Ireland,2012,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.4
18763,Ireland,2012,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.6
18764,Ireland,2012,6,C02-Antihypertensives,% of total sales,1.0
18765,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,62.4
18766,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",59.0
18767,Ireland,2012,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.5
18768,Ireland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,48.6
18769,Ireland,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.9
18770,Ireland,2012,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",21.5
18771,Ireland,2012,6,N05C-Hypnotics and sedatives,% of total sales,0.9
18772,Ireland,2012,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.7
18773,Ireland,2012,6,C02-Antihypertensives,"Million US$, purchasing power parity",25.7
18774,Ireland,2012,6,C02-Antihypertensives,Million US$ at exchange rate,27.1
18775,Ireland,2012,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,22.7
18776,Ireland,2012,6,N05C-Hypnotics and sedatives,Million of national currency units,17.7
18777,Ireland,2012,6,C02-Antihypertensives,"/capita, US$ exchange rate",5.9
18778,Ireland,2012,6,N02-Analgesics,"/capita, US$ exchange rate",16.5
18779,Ireland,2012,6,B-Blood and blood forming organs,Million of national currency units,91.6
18780,Ireland,2012,6,B-Blood and blood forming organs,Million US$ at exchange rate,117.7
18781,Ireland,2012,6,N02-Analgesics,% of total sales,2.9
18782,Ireland,2012,6,N02-Analgesics,"/capita, US$ purchasing power parity",15.6
18783,Ireland,2012,6,C03-Diuretics,% of total sales,0.8
18784,Ireland,2012,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",111.3
18785,Ireland,2012,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,89.5
18786,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.6
18787,Ireland,2012,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.4
18788,Ireland,2012,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.9
18789,Ireland,2012,6,C01A-Cardiac glycosides,% of total sales,0.1
18790,Ireland,2012,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
18791,Ireland,2012,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.8
18792,Ireland,2012,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.9
18793,Ireland,2012,6,M-Musculo-skeletal system,% of total sales,3.7
18794,Ireland,2012,6,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0
18795,Ireland,2012,6,C01A-Cardiac glycosides,Million of national currency units,1.5
18796,Ireland,2012,6,C10-Lipid modifying agents,Million US$ at exchange rate,187.3
18797,Ireland,2012,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",177.2
18798,Ireland,2012,6,Products not elsewhere classified,% of total sales,26.6
18799,Ireland,2012,6,C10-Lipid modifying agents,Million of national currency units,145.8
18800,Ireland,2012,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",40.7
18801,Ireland,2012,6,A10-Drugs used in diabetes,Million US$ at exchange rate,104.5
18802,Ireland,2012,6,A10-Drugs used in diabetes,Million of national currency units,81.4
18803,Ireland,2012,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",38.5
18804,Ireland,2012,6,C10-Lipid modifying agents,% of total sales,7.1
18805,Ireland,2012,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",30.6
18806,Ireland,2012,6,C08-Calcium channel blockers,Million US$ at exchange rate,32.4
18807,Ireland,2012,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.7
18808,Ireland,2012,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.0
18809,Ireland,2012,6,C08-Calcium channel blockers,Million of national currency units,25.2
18810,Ireland,2012,6,A02A-Antacids,"Million US$, purchasing power parity",0.1
18811,Ireland,2012,6,A02A-Antacids,Million US$ at exchange rate,0.1
18812,Ireland,2012,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
18813,Ireland,2012,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
18814,Ireland,2012,6,R-Respiratory system,"/capita, US$ exchange rate",43.6
18815,Ireland,2012,6,R-Respiratory system,"Million US$, purchasing power parity",189.5
18816,Ireland,2012,6,R-Respiratory system,"/capita, US$ purchasing power parity",41.2
18817,Ireland,2012,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",90.9
18818,Ireland,2012,6,R-Respiratory system,% of total sales,7.6
18819,Ireland,2012,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",143.7
18820,Ireland,2012,6,M-Musculo-skeletal system,Million US$ at exchange rate,96.2
18821,Ireland,2012,6,M-Musculo-skeletal system,Million of national currency units,74.9
18822,Ireland,2012,6,C08-Calcium channel blockers,% of total sales,1.2
18823,Ireland,2012,6,R-Respiratory system,Million US$ at exchange rate,200.4
18824,Ireland,2012,6,R-Respiratory system,Million of national currency units,156.0
18825,Ireland,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",35.0
18826,Ireland,2012,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",37.0
18827,Ireland,2012,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",540.1
18828,Ireland,2012,6,R03-Drugs for obstructive airway diseases,% of total sales,6.5
18829,Ireland,2012,6,C-Cardiovascular system,Million of national currency units,337.5
18830,Ireland,2012,6,C-Cardiovascular system,Million US$ at exchange rate,433.6
18831,Ireland,2012,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",161.0
18832,Ireland,2012,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,170.2
18833,Ireland,2012,6,R03-Drugs for obstructive airway diseases,Million of national currency units,132.5
18834,Ireland,2012,6,Total pharmaceutical sales,Million US$ at exchange rate,2627.1
18835,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.9
18836,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.2
18837,Ireland,2012,6,Total pharmaceutical sales,Million of national currency units,2044.7
18838,Ireland,2012,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2484.3
18839,Ireland,2012,6,Total pharmaceutical sales,"/capita, US$ exchange rate",571.2
18840,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,85.7
18841,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",104.1
18842,Ireland,2012,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,110.1
18843,Ireland,2012,6,A02A-Antacids,Million of national currency units,0.1
18844,Ireland,2012,6,C-Cardiovascular system,"Million US$, purchasing power parity",410.0
18845,Ireland,2012,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.7
18846,Ireland,2012,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",98.8
18847,Ireland,2012,6,A10-Drugs used in diabetes,% of total sales,4.0
18848,Ireland,2012,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.5
18849,Ireland,2012,6,Products not elsewhere classified,"Million US$, purchasing power parity",661.1
18850,Ireland,2012,6,Products not elsewhere classified,"/capita, US$ exchange rate",152.0
18851,Ireland,2012,6,A02A-Antacids,% of total sales,0.0
18852,Ireland,2012,6,Products not elsewhere classified,Million of national currency units,544.1
18853,Ireland,2012,6,Products not elsewhere classified,Million US$ at exchange rate,699.1
18854,Ireland,2012,6,C-Cardiovascular system,% of total sales,16.5
18855,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,27.8
18856,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,35.7
18857,Ireland,2012,6,C-Cardiovascular system,"/capita, US$ exchange rate",94.3
18858,Ireland,2012,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",89.1
18859,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.3
18860,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.4
18861,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",33.8
18862,Ireland,2012,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.8
18863,Ireland,2012,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,69.6
18864,Ireland,2012,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",65.8
18865,Ireland,2012,6,N-Nervous system,"/capita, US$ purchasing power parity",102.5
18866,Ireland,2012,6,J01-Antibacterials for systemic use,Million of national currency units,54.2
18867,Ireland,2012,6,N-Nervous system,% of total sales,19.0
18868,Ireland,2012,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.1
18869,Ireland,2012,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",14.3
18870,Ireland,2012,6,G-Genito urinary system and sex hormones,% of total sales,4.2
18871,Ireland,2012,6,N-Nervous system,Million of national currency units,387.9
18872,Ireland,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",24.0
18873,Ireland,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.7
18874,Ireland,2012,6,N-Nervous system,"Million US$, purchasing power parity",471.3
18875,Ireland,2012,6,N-Nervous system,"/capita, US$ exchange rate",108.4
18876,Ireland,2012,6,N-Nervous system,Million US$ at exchange rate,498.4
18877,Ireland,2012,6,N06A-Antidepressants,"Million US$, purchasing power parity",88.5
18878,Ireland,2012,6,N06A-Antidepressants,Million US$ at exchange rate,93.6
18879,Ireland,2012,6,N06A-Antidepressants,"/capita, US$ exchange rate",20.3
18880,Ireland,2012,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",19.2
18881,Ireland,2012,6,N06A-Antidepressants,% of total sales,3.6
18882,Ireland,2012,6,A-Alimentary tract and metabolism,% of total sales,12.2
18883,Ireland,2012,6,A-Alimentary tract and metabolism,Million of national currency units,248.8
18884,Ireland,2012,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,319.6
18885,Ireland,2012,6,J01-Antibacterials for systemic use,% of total sales,2.6
18886,Ireland,2012,6,N06A-Antidepressants,Million of national currency units,72.8
18887,Ireland,2012,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",65.7
18888,Ireland,2012,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",302.3
18889,Ireland,2012,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",69.5
18890,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",42.2
18891,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.7
18892,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.2
18893,Ireland,2012,6,C07-Beta blocking agents,Million US$ at exchange rate,30.4
18894,Ireland,2012,6,C07-Beta blocking agents,Million of national currency units,23.7
18895,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,34.7
18896,Ireland,2012,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,44.6
18897,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.1
18898,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
18899,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
18900,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
18901,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.9
18902,Ireland,2012,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.7
18903,Ireland,2012,6,C07-Beta blocking agents,% of total sales,1.2
18904,Ireland,2012,6,C07-Beta blocking agents,"/capita, US$ exchange rate",6.6
18905,Ireland,2012,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.2
18906,Ireland,2012,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",104.2
18907,Ireland,2012,6,G-Genito urinary system and sex hormones,Million of national currency units,85.8
18908,Ireland,2012,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,110.2
18909,Ireland,2012,6,C07-Beta blocking agents,"Million US$, purchasing power parity",28.7
18910,Ireland,2010,6,N02-Analgesics,"Million US$, purchasing power parity",64.9
18911,Ireland,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.2
18912,Ireland,2010,6,B-Blood and blood forming organs,% of total sales,4.6
18913,Ireland,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",27.3
18914,Ireland,2010,6,C03-Diuretics,"/capita, US$ purchasing power parity",4.0
18915,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
18916,Ireland,2010,6,J-Antiinfectives for systemic use,Million of national currency units,66.1
18917,Ireland,2010,6,C02-Antihypertensives,Million of national currency units,21.1
18918,Ireland,2010,6,N05B-Anxiolytics,% of total sales,0.5
18919,Ireland,2010,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
18920,Ireland,2010,6,N05B-Anxiolytics,"/capita, US$ exchange rate",2.8
18921,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,6.6
18922,Ireland,2010,6,N05B-Anxiolytics,"Million US$, purchasing power parity",11.5
18923,Ireland,2010,6,N05B-Anxiolytics,Million US$ at exchange rate,12.9
18924,Ireland,2010,6,N05B-Anxiolytics,Million of national currency units,9.7
18925,Ireland,2010,6,C03-Diuretics,Million of national currency units,15.7
18926,Ireland,2010,6,N02-Analgesics,Million of national currency units,55.1
18927,Ireland,2010,6,N02-Analgesics,Million US$ at exchange rate,73.1
18928,Ireland,2010,6,C03-Diuretics,"/capita, US$ exchange rate",4.6
18929,Ireland,2010,6,C03-Diuretics,Million US$ at exchange rate,20.8
18930,Ireland,2010,6,C03-Diuretics,"Million US$, purchasing power parity",18.4
18931,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,135.0
18932,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,178.9
18933,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.4
18934,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
18935,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",34.8
18936,Ireland,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",77.8
18937,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",158.9
18938,Ireland,2010,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",39.2
18939,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.9
18940,Ireland,2010,6,J-Antiinfectives for systemic use,% of total sales,3.2
18941,Ireland,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.1
18942,Ireland,2010,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.4
18943,Ireland,2010,6,C02-Antihypertensives,% of total sales,1.0
18944,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",52.1
18945,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,58.7
18946,Ireland,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.2
18947,Ireland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,44.3
18948,Ireland,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.9
18949,Ireland,2010,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",19.7
18950,Ireland,2010,6,N05C-Hypnotics and sedatives,% of total sales,0.8
18951,Ireland,2010,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.3
18952,Ireland,2010,6,C02-Antihypertensives,"Million US$, purchasing power parity",24.8
18953,Ireland,2010,6,C02-Antihypertensives,Million US$ at exchange rate,28.0
18954,Ireland,2010,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,22.2
18955,Ireland,2010,6,C02-Antihypertensives,"/capita, US$ exchange rate",6.1
18956,Ireland,2010,6,N05C-Hypnotics and sedatives,Million of national currency units,16.8
18957,Ireland,2010,6,B-Blood and blood forming organs,Million of national currency units,93.9
18958,Ireland,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,124.5
18959,Ireland,2010,6,N02-Analgesics,% of total sales,2.7
18960,Ireland,2010,6,N02-Analgesics,"/capita, US$ purchasing power parity",14.2
18961,Ireland,2010,6,C03-Diuretics,% of total sales,0.8
18962,Ireland,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",110.6
18963,Ireland,2010,6,N02-Analgesics,"/capita, US$ exchange rate",16.0
18964,Ireland,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,87.7
18965,Ireland,2010,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
18966,Ireland,2010,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.8
18967,Ireland,2010,6,C01A-Cardiac glycosides,% of total sales,0.1
18968,Ireland,2010,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
18969,Ireland,2010,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7
18970,Ireland,2010,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.6
18971,Ireland,2010,6,M-Musculo-skeletal system,% of total sales,4.3
18972,Ireland,2010,6,C01A-Cardiac glycosides,Million US$ at exchange rate,2.1
18973,Ireland,2010,6,C01A-Cardiac glycosides,Million of national currency units,1.6
18974,Ireland,2010,6,A10-Drugs used in diabetes,Million of national currency units,68.0
18975,Ireland,2010,6,C10-Lipid modifying agents,Million US$ at exchange rate,256.6
18976,Ireland,2010,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",227.8
18977,Ireland,2010,6,Products not elsewhere classified,% of total sales,24.8
18978,Ireland,2010,6,C10-Lipid modifying agents,Million of national currency units,193.6
18979,Ireland,2010,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",56.3
18980,Ireland,2010,6,A10-Drugs used in diabetes,Million US$ at exchange rate,90.1
18981,Ireland,2010,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",50.0
18982,Ireland,2010,6,C10-Lipid modifying agents,% of total sales,9.4
18983,Ireland,2010,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",31.5
18984,Ireland,2010,6,C08-Calcium channel blockers,Million US$ at exchange rate,35.5
18985,Ireland,2010,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.9
18986,Ireland,2010,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.8
18987,Ireland,2010,6,A02A-Antacids,"Million US$, purchasing power parity",0.2
18988,Ireland,2010,6,A02A-Antacids,Million US$ at exchange rate,0.2
18989,Ireland,2010,6,C08-Calcium channel blockers,Million of national currency units,26.8
18990,Ireland,2010,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
18991,Ireland,2010,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
18992,Ireland,2010,6,C08-Calcium channel blockers,% of total sales,1.3
18993,Ireland,2010,6,R-Respiratory system,"/capita, US$ exchange rate",46.1
18994,Ireland,2010,6,R-Respiratory system,"Million US$, purchasing power parity",186.6
18995,Ireland,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",40.9
18996,Ireland,2010,6,R-Respiratory system,% of total sales,7.7
18997,Ireland,2010,6,M-Musculo-skeletal system,Million US$ at exchange rate,116.8
18998,Ireland,2010,6,M-Musculo-skeletal system,Million of national currency units,88.1
18999,Ireland,2010,6,R-Respiratory system,Million US$ at exchange rate,210.2
19000,Ireland,2010,6,R-Respiratory system,Million of national currency units,158.6
19001,Ireland,2010,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",103.7
19002,Ireland,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",131.1
19003,Ireland,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",34.8
19004,Ireland,2010,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",39.1
19005,Ireland,2010,6,R03-Drugs for obstructive airway diseases,% of total sales,6.6
19006,Ireland,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",529.1
19007,Ireland,2010,6,C-Cardiovascular system,Million of national currency units,398.5
19008,Ireland,2010,6,C-Cardiovascular system,Million US$ at exchange rate,528.2
19009,Ireland,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",469.0
19010,Ireland,2010,6,R03-Drugs for obstructive airway diseases,Million of national currency units,134.6
19011,Ireland,2010,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",158.5
19012,Ireland,2010,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,178.5
19013,Ireland,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,2717.7
19014,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.7
19015,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.9
19016,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.7
19017,Ireland,2010,6,Total pharmaceutical sales,Million of national currency units,2050.0
19018,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,95.8
19019,Ireland,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",2413.0
19020,Ireland,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",596.0
19021,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",112.8
19022,Ireland,2010,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,127.0
19023,Ireland,2010,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.8
19024,Ireland,2010,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",80.0
19025,Ireland,2010,6,A10-Drugs used in diabetes,% of total sales,3.3
19026,Ireland,2010,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.5
19027,Ireland,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",597.6
19028,Ireland,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",147.6
19029,Ireland,2010,6,A02A-Antacids,% of total sales,0.0
19030,Ireland,2010,6,Products not elsewhere classified,Million of national currency units,507.7
19031,Ireland,2010,6,Products not elsewhere classified,Million US$ at exchange rate,673.1
19032,Ireland,2010,6,C-Cardiovascular system,% of total sales,19.4
19033,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,34.3
19034,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,45.4
19035,Ireland,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",115.8
19036,Ireland,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",102.9
19037,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8
19038,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
19039,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",40.4
19040,Ireland,2010,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.0
19041,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,2.6
19042,Ireland,2010,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",56.8
19043,Ireland,2010,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,64.0
19044,Ireland,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",89.1
19045,Ireland,2010,6,N-Nervous system,% of total sales,16.8
19046,Ireland,2010,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.5
19047,Ireland,2010,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.0
19048,Ireland,2010,6,G-Genito urinary system and sex hormones,% of total sales,4.1
19049,Ireland,2010,6,N-Nervous system,Million of national currency units,345.2
19050,Ireland,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.7
19051,Ireland,2010,6,N-Nervous system,"/capita, US$ exchange rate",100.4
19052,Ireland,2010,6,N-Nervous system,"Million US$, purchasing power parity",406.3
19053,Ireland,2010,6,N-Nervous system,Million US$ at exchange rate,457.6
19054,Ireland,2010,6,N06A-Antidepressants,"Million US$, purchasing power parity",79.1
19055,Ireland,2010,6,N06A-Antidepressants,Million US$ at exchange rate,89.1
19056,Ireland,2010,6,A02A-Antacids,Million of national currency units,0.1
19057,Ireland,2010,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.4
19058,Ireland,2010,6,N06A-Antidepressants,"/capita, US$ exchange rate",19.5
19059,Ireland,2010,6,N06A-Antidepressants,% of total sales,3.3
19060,Ireland,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,349.2
19061,Ireland,2010,6,A-Alimentary tract and metabolism,Million of national currency units,263.4
19062,Ireland,2010,6,J01-Antibacterials for systemic use,% of total sales,2.4
19063,Ireland,2010,6,N06A-Antidepressants,Million of national currency units,67.2
19064,Ireland,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",68.0
19065,Ireland,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",310.0
19066,Ireland,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",76.6
19067,Ireland,2010,6,A-Alimentary tract and metabolism,% of total sales,12.8
19068,Ireland,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",24.5
19069,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.3
19070,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.0
19071,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.2
19072,Ireland,2010,6,C07-Beta blocking agents,Million US$ at exchange rate,36.3
19073,Ireland,2010,6,C07-Beta blocking agents,Million of national currency units,27.4
19074,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,46.5
19075,Ireland,2010,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,35.1
19076,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
19077,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
19078,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.4
19079,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
19080,Ireland,2010,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.1
19081,Ireland,2010,6,C07-Beta blocking agents,% of total sales,1.3
19082,Ireland,2010,6,C07-Beta blocking agents,"/capita, US$ exchange rate",8.0
19083,Ireland,2010,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.1
19084,Ireland,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",99.1
19085,Ireland,2010,6,J01-Antibacterials for systemic use,Million of national currency units,48.2
19086,Ireland,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,84.2
19087,Ireland,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,111.6
19088,Ireland,2010,6,C07-Beta blocking agents,"Million US$, purchasing power parity",32.2
19089,Ireland,2011,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.6
19090,Ireland,2011,7,B-Blood and blood forming organs,% of total sales,4.6
19091,Ireland,2011,7,N02-Analgesics,"Million US$, purchasing power parity",68.6
19092,Ireland,2011,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",27.3
19093,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
19094,Ireland,2011,7,J-Antiinfectives for systemic use,Million of national currency units,60.3
19095,Ireland,2011,7,C02-Antihypertensives,Million of national currency units,21.4
19096,Ireland,2011,7,C03-Diuretics,"/capita, US$ purchasing power parity",4.1
19097,Ireland,2011,7,N05B-Anxiolytics,% of total sales,0.5
19098,Ireland,2011,7,N02-Analgesics,Million US$ at exchange rate,79.4
19099,Ireland,2011,7,N05B-Anxiolytics,"/capita, US$ exchange rate",2.9
19100,Ireland,2011,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
19101,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.5
19102,Ireland,2011,7,N05B-Anxiolytics,"Million US$, purchasing power parity",11.5
19103,Ireland,2011,7,N05B-Anxiolytics,Million US$ at exchange rate,13.4
19104,Ireland,2011,7,N05B-Anxiolytics,Million of national currency units,9.6
19105,Ireland,2011,7,C03-Diuretics,Million of national currency units,15.8
19106,Ireland,2011,7,N02-Analgesics,Million of national currency units,57.1
19107,Ireland,2011,7,C03-Diuretics,"/capita, US$ exchange rate",4.8
19108,Ireland,2011,7,C03-Diuretics,Million US$ at exchange rate,22.0
19109,Ireland,2011,7,C03-Diuretics,"Million US$, purchasing power parity",19.0
19110,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",22.4
19111,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,107.7
19112,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,150.0
19113,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.0
19114,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
19115,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",28.3
19116,Ireland,2011,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",72.5
19117,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",129.6
19118,Ireland,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",32.7
19119,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.9
19120,Ireland,2011,7,J-Antiinfectives for systemic use,% of total sales,3.1
19121,Ireland,2011,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.8
19122,Ireland,2011,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.6
19123,Ireland,2011,7,C02-Antihypertensives,% of total sales,1.1
19124,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,63.8
19125,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",55.1
19126,Ireland,2011,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.3
19127,Ireland,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,45.8
19128,Ireland,2011,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.2
19129,Ireland,2011,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",20.4
19130,Ireland,2011,7,N05C-Hypnotics and sedatives,% of total sales,0.9
19131,Ireland,2011,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.5
19132,Ireland,2011,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,23.6
19133,Ireland,2011,7,C02-Antihypertensives,"Million US$, purchasing power parity",25.7
19134,Ireland,2011,7,C02-Antihypertensives,Million US$ at exchange rate,29.8
19135,Ireland,2011,7,C02-Antihypertensives,"/capita, US$ exchange rate",6.5
19136,Ireland,2011,7,N05C-Hypnotics and sedatives,Million of national currency units,17.0
19137,Ireland,2011,7,N02-Analgesics,"/capita, US$ exchange rate",17.3
19138,Ireland,2011,7,B-Blood and blood forming organs,Million of national currency units,89.8
19139,Ireland,2011,7,B-Blood and blood forming organs,Million US$ at exchange rate,124.9
19140,Ireland,2011,7,N02-Analgesics,% of total sales,2.9
19141,Ireland,2011,7,N02-Analgesics,"/capita, US$ purchasing power parity",15.0
19142,Ireland,2011,7,C03-Diuretics,% of total sales,0.8
19143,Ireland,2011,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",107.9
19144,Ireland,2011,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,83.9
19145,Ireland,2011,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
19146,Ireland,2011,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.9
19147,Ireland,2011,7,C01A-Cardiac glycosides,% of total sales,0.1
19148,Ireland,2011,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
19149,Ireland,2011,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.7
19150,Ireland,2011,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.8
19151,Ireland,2011,7,C01A-Cardiac glycosides,Million US$ at exchange rate,2.1
19152,Ireland,2011,7,C01A-Cardiac glycosides,Million of national currency units,1.5
19153,Ireland,2011,7,M-Musculo-skeletal system,% of total sales,3.8
19154,Ireland,2011,7,C10-Lipid modifying agents,Million US$ at exchange rate,209.8
19155,Ireland,2011,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",181.3
19156,Ireland,2011,7,Products not elsewhere classified,% of total sales,26.3
19157,Ireland,2011,7,C10-Lipid modifying agents,Million of national currency units,150.8
19158,Ireland,2011,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",45.8
19159,Ireland,2011,7,A10-Drugs used in diabetes,Million US$ at exchange rate,102.2
19160,Ireland,2011,7,A10-Drugs used in diabetes,Million of national currency units,73.5
19161,Ireland,2011,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",39.6
19162,Ireland,2011,7,C10-Lipid modifying agents,% of total sales,7.7
19163,Ireland,2011,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",29.8
19164,Ireland,2011,7,C08-Calcium channel blockers,Million US$ at exchange rate,34.5
19165,Ireland,2011,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.5
19166,Ireland,2011,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.5
19167,Ireland,2011,7,C08-Calcium channel blockers,Million of national currency units,24.8
19168,Ireland,2011,7,A02A-Antacids,"Million US$, purchasing power parity",0.1
19169,Ireland,2011,7,A02A-Antacids,Million US$ at exchange rate,0.2
19170,Ireland,2011,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
19171,Ireland,2011,7,A02A-Antacids,"/capita, US$ exchange rate",0.0
19172,Ireland,2011,7,C08-Calcium channel blockers,% of total sales,1.3
19173,Ireland,2011,7,R-Respiratory system,"/capita, US$ exchange rate",45.9
19174,Ireland,2011,7,R-Respiratory system,"Million US$, purchasing power parity",181.6
19175,Ireland,2011,7,R-Respiratory system,% of total sales,7.7
19176,Ireland,2011,7,R-Respiratory system,"/capita, US$ purchasing power parity",39.7
19177,Ireland,2011,7,M-Musculo-skeletal system,Million US$ at exchange rate,104.3
19178,Ireland,2011,7,M-Musculo-skeletal system,Million of national currency units,74.9
19179,Ireland,2011,7,R-Respiratory system,Million US$ at exchange rate,210.2
19180,Ireland,2011,7,R-Respiratory system,Million of national currency units,151.0
19181,Ireland,2011,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",90.1
19182,Ireland,2011,7,Products not elsewhere classified,"/capita, US$ purchasing power parity",135.2
19183,Ireland,2011,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",33.9
19184,Ireland,2011,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",39.3
19185,Ireland,2011,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",513.8
19186,Ireland,2011,7,R03-Drugs for obstructive airway diseases,% of total sales,6.6
19187,Ireland,2011,7,C-Cardiovascular system,Million of national currency units,339.9
19188,Ireland,2011,7,C-Cardiovascular system,Million US$ at exchange rate,473.1
19189,Ireland,2011,7,R03-Drugs for obstructive airway diseases,Million of national currency units,129.2
19190,Ireland,2011,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",155.4
19191,Ireland,2011,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,179.8
19192,Ireland,2011,7,Total pharmaceutical sales,Million US$ at exchange rate,2723.5
19193,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.9
19194,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.4
19195,Ireland,2011,7,Total pharmaceutical sales,Million of national currency units,1956.6
19196,Ireland,2011,7,C-Cardiovascular system,"Million US$, purchasing power parity",408.7
19197,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,85.1
19198,Ireland,2011,7,Total pharmaceutical sales,"Million US$, purchasing power parity",2353.1
19199,Ireland,2011,7,Total pharmaceutical sales,"/capita, US$ exchange rate",594.6
19200,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",102.4
19201,Ireland,2011,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,118.5
19202,Ireland,2011,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.3
19203,Ireland,2011,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",88.3
19204,Ireland,2011,7,A10-Drugs used in diabetes,% of total sales,3.8
19205,Ireland,2011,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.3
19206,Ireland,2011,7,Products not elsewhere classified,"Million US$, purchasing power parity",619.1
19207,Ireland,2011,7,Products not elsewhere classified,"/capita, US$ exchange rate",156.4
19208,Ireland,2011,7,A02A-Antacids,% of total sales,0.0
19209,Ireland,2011,7,Products not elsewhere classified,Million of national currency units,514.8
19210,Ireland,2011,7,Products not elsewhere classified,Million US$ at exchange rate,716.6
19211,Ireland,2011,7,C-Cardiovascular system,% of total sales,17.4
19212,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,29.9
19213,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,41.6
19214,Ireland,2011,7,C-Cardiovascular system,"/capita, US$ exchange rate",103.3
19215,Ireland,2011,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",89.2
19216,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.9
19217,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.5
19218,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",36.0
19219,Ireland,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.1
19220,Ireland,2011,7,A02A-Antacids,Million of national currency units,0.1
19221,Ireland,2011,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,61.6
19222,Ireland,2011,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",53.2
19223,Ireland,2011,7,N-Nervous system,"/capita, US$ purchasing power parity",94.1
19224,Ireland,2011,7,N-Nervous system,% of total sales,18.3
19225,Ireland,2011,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.6
19226,Ireland,2011,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.5
19227,Ireland,2011,7,G-Genito urinary system and sex hormones,% of total sales,4.2
19228,Ireland,2011,7,N-Nervous system,Million of national currency units,358.3
19229,Ireland,2011,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.8
19230,Ireland,2011,7,N-Nervous system,"/capita, US$ exchange rate",108.9
19231,Ireland,2011,7,N-Nervous system,"Million US$, purchasing power parity",430.9
19232,Ireland,2011,7,N-Nervous system,Million US$ at exchange rate,498.7
19233,Ireland,2011,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.2
19234,Ireland,2011,7,N06A-Antidepressants,"Million US$, purchasing power parity",80.6
19235,Ireland,2011,7,N06A-Antidepressants,Million US$ at exchange rate,93.3
19236,Ireland,2011,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.6
19237,Ireland,2011,7,N06A-Antidepressants,"/capita, US$ exchange rate",20.4
19238,Ireland,2011,7,N06A-Antidepressants,% of total sales,3.4
19239,Ireland,2011,7,A-Alimentary tract and metabolism,% of total sales,12.2
19240,Ireland,2011,7,A-Alimentary tract and metabolism,Million of national currency units,239.0
19241,Ireland,2011,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,332.6
19242,Ireland,2011,7,J01-Antibacterials for systemic use,% of total sales,2.3
19243,Ireland,2011,7,N06A-Antidepressants,Million of national currency units,67.1
19244,Ireland,2011,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",62.7
19245,Ireland,2011,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",287.4
19246,Ireland,2011,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",72.6
19247,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",41.1
19248,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.0
19249,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.4
19250,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,47.6
19251,Ireland,2011,7,C07-Beta blocking agents,Million US$ at exchange rate,32.4
19252,Ireland,2011,7,C07-Beta blocking agents,Million of national currency units,23.3
19253,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.3
19254,Ireland,2011,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,34.2
19255,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
19256,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
19257,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.6
19258,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
19259,Ireland,2011,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.9
19260,Ireland,2011,7,C07-Beta blocking agents,% of total sales,1.2
19261,Ireland,2011,7,C07-Beta blocking agents,"/capita, US$ exchange rate",7.1
19262,Ireland,2011,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.1
19263,Ireland,2011,7,J01-Antibacterials for systemic use,Million of national currency units,44.3
19264,Ireland,2011,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",99.7
19265,Ireland,2011,7,G-Genito urinary system and sex hormones,Million of national currency units,82.9
19266,Ireland,2011,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,115.4
19267,Ireland,2011,7,C07-Beta blocking agents,"Million US$, purchasing power parity",28.0
19268,Italy,2016,2,C03-Diuretics,"/capita, US$ exchange rate",2.0
19269,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,195.1
19270,Italy,2016,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.6
19271,Italy,2016,2,C02-Antihypertensives,"Million US$, purchasing power parity",324.7
19272,Italy,2016,2,C02-Antihypertensives,Million of national currency units,227.5
19273,Italy,2016,2,C02-Antihypertensives,Million US$ at exchange rate,251.8
19274,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",278.5
19275,Italy,2016,2,C03-Diuretics,Million US$ at exchange rate,121.7
19276,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.6
19277,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.6
19278,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,216.0
19279,Italy,2016,2,C03-Diuretics,"Million US$, purchasing power parity",156.9
19280,Italy,2016,2,C03-Diuretics,% of total sales,0.5
19281,Italy,2016,2,B-Blood and blood forming organs,Million of national currency units,2027.0
19282,Italy,2016,2,B-Blood and blood forming organs,Million US$ at exchange rate,2243.7
19283,Italy,2016,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,978.7
19284,Italy,2016,2,J01-Antibacterials for systemic use,Million of national currency units,884.2
19285,Italy,2016,2,Total pharmaceutical sales,Million US$ at exchange rate,25215.9
19286,Italy,2016,2,Total pharmaceutical sales,Million of national currency units,22780.6
19287,Italy,2016,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",536.4
19288,Italy,2016,2,Total pharmaceutical sales,"/capita, US$ exchange rate",415.9
19289,Italy,2016,2,Total pharmaceutical sales,"Million US$, purchasing power parity",32518.4
19290,Italy,2016,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.3
19291,Italy,2016,2,N05B-Anxiolytics,Million US$ at exchange rate,3.4
19292,Italy,2016,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
19293,Italy,2016,2,N05B-Anxiolytics,% of total sales,0.0
19294,Italy,2016,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
19295,Italy,2016,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.1
19296,Italy,2016,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1262.1
19297,Italy,2016,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",20.8
19298,Italy,2016,2,N05B-Anxiolytics,Million of national currency units,3.0
19299,Italy,2016,2,J01-Antibacterials for systemic use,% of total sales,3.9
19300,Italy,2016,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9
19301,Italy,2016,2,J-Antiinfectives for systemic use,Million of national currency units,4413.6
19302,Italy,2016,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,4885.4
19303,Italy,2016,2,M-Musculo-skeletal system,Million of national currency units,467.9
19304,Italy,2016,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",103.9
19305,Italy,2016,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",80.6
19306,Italy,2016,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",6300.2
19307,Italy,2016,2,M-Musculo-skeletal system,% of total sales,2.1
19308,Italy,2016,2,N-Nervous system,Million US$ at exchange rate,2000.6
19309,Italy,2016,2,N-Nervous system,Million of national currency units,1807.4
19310,Italy,2016,2,M-Musculo-skeletal system,Million US$ at exchange rate,517.9
19311,Italy,2016,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",667.9
19312,Italy,2016,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.0
19313,Italy,2016,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.5
19314,Italy,2016,2,N02-Analgesics,"Million US$, purchasing power parity",511.2
19315,Italy,2016,2,N02-Analgesics,Million US$ at exchange rate,396.4
19316,Italy,2016,2,N02-Analgesics,"/capita, US$ exchange rate",6.5
19317,Italy,2016,2,N02-Analgesics,"/capita, US$ purchasing power parity",8.4
19318,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.7
19319,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,86.0
19320,Italy,2016,2,N02-Analgesics,Million of national currency units,358.1
19321,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.8
19322,Italy,2016,2,J-Antiinfectives for systemic use,% of total sales,19.4
19323,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
19324,Italy,2016,2,N02-Analgesics,% of total sales,1.6
19325,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.4
19326,Italy,2016,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",110.9
19327,Italy,2016,2,C02-Antihypertensives,% of total sales,1.0
19328,Italy,2016,2,A-Alimentary tract and metabolism,% of total sales,11.8
19329,Italy,2016,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.4
19330,Italy,2016,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3847.5
19331,Italy,2016,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.2
19332,Italy,2016,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",63.5
19333,Italy,2016,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.2
19334,Italy,2016,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.1
19335,Italy,2016,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.4
19336,Italy,2016,2,A10-Drugs used in diabetes,% of total sales,3.9
19337,Italy,2016,2,A10-Drugs used in diabetes,Million US$ at exchange rate,994.2
19338,Italy,2016,2,A10-Drugs used in diabetes,Million of national currency units,898.2
19339,Italy,2016,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1282.1
19340,Italy,2016,2,C01A-Cardiac glycosides,Million US$ at exchange rate,7.2
19341,Italy,2016,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
19342,Italy,2016,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",9.3
19343,Italy,2016,2,C01A-Cardiac glycosides,Million of national currency units,6.5
19344,Italy,2016,2,N-Nervous system,"Million US$, purchasing power parity",2579.9
19345,Italy,2016,2,N-Nervous system,"/capita, US$ exchange rate",33.0
19346,Italy,2016,2,N-Nervous system,"/capita, US$ purchasing power parity",42.6
19347,Italy,2016,2,A-Alimentary tract and metabolism,Million of national currency units,2695.4
19348,Italy,2016,2,C03-Diuretics,Million of national currency units,109.9
19349,Italy,2016,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,2983.5
19350,Italy,2016,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
19351,Italy,2016,2,C01A-Cardiac glycosides,% of total sales,0.0
19352,Italy,2016,2,N-Nervous system,% of total sales,7.9
19353,Italy,2016,2,R-Respiratory system,"/capita, US$ purchasing power parity",26.1
19354,Italy,2016,2,R-Respiratory system,% of total sales,4.9
19355,Italy,2016,2,R-Respiratory system,"Million US$, purchasing power parity",1580.8
19356,Italy,2016,2,R-Respiratory system,"/capita, US$ exchange rate",20.2
19357,Italy,2016,2,B-Blood and blood forming organs,% of total sales,8.9
19358,Italy,2016,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2893.5
19359,Italy,2016,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",37.0
19360,Italy,2016,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",47.7
19361,Italy,2016,2,C10-Lipid modifying agents,% of total sales,4.6
19362,Italy,2016,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",423.1
19363,Italy,2016,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.4
19364,Italy,2016,2,C08-Calcium channel blockers,Million US$ at exchange rate,328.1
19365,Italy,2016,2,N05C-Hypnotics and sedatives,Million of national currency units,7.1
19366,Italy,2016,2,C08-Calcium channel blockers,Million of national currency units,296.4
19367,Italy,2016,2,R-Respiratory system,Million of national currency units,1107.4
19368,Italy,2016,2,R-Respiratory system,Million US$ at exchange rate,1225.8
19369,Italy,2016,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.0
19370,Italy,2016,2,C08-Calcium channel blockers,% of total sales,1.3
19371,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,489.7
19372,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,542.1
19373,Italy,2016,2,A02A-Antacids,% of total sales,0.1
19374,Italy,2016,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
19375,Italy,2016,2,A02A-Antacids,"/capita, US$ exchange rate",0.5
19376,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.5
19377,Italy,2016,2,C-Cardiovascular system,% of total sales,15.9
19378,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",699.0
19379,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.9
19380,Italy,2016,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1483.7
19381,Italy,2016,2,C10-Lipid modifying agents,Million US$ at exchange rate,1150.5
19382,Italy,2016,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.5
19383,Italy,2016,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",19.0
19384,Italy,2016,2,A02A-Antacids,Million US$ at exchange rate,28.0
19385,Italy,2016,2,A02A-Antacids,"Million US$, purchasing power parity",36.1
19386,Italy,2016,2,C10-Lipid modifying agents,Million of national currency units,1039.4
19387,Italy,2016,2,A02A-Antacids,Million of national currency units,25.3
19388,Italy,2016,2,G-Genito urinary system and sex hormones,Million of national currency units,560.9
19389,Italy,2016,2,C07-Beta blocking agents,% of total sales,1.5
19390,Italy,2016,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,620.9
19391,Italy,2016,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",800.7
19392,Italy,2016,2,C07-Beta blocking agents,"Million US$, purchasing power parity",489.9
19393,Italy,2016,2,C07-Beta blocking agents,Million US$ at exchange rate,379.9
19394,Italy,2016,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.1
19395,Italy,2016,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.3
19396,Italy,2016,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.2
19397,Italy,2016,2,N06A-Antidepressants,"/capita, US$ exchange rate",6.6
19398,Italy,2016,2,N06A-Antidepressants,"Million US$, purchasing power parity",512.7
19399,Italy,2016,2,N06A-Antidepressants,% of total sales,1.6
19400,Italy,2016,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.5
19401,Italy,2016,2,G-Genito urinary system and sex hormones,% of total sales,2.5
19402,Italy,2016,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.2
19403,Italy,2016,2,N06A-Antidepressants,Million US$ at exchange rate,397.6
19404,Italy,2016,2,N06A-Antidepressants,Million of national currency units,359.2
19405,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",21.4
19406,Italy,2016,2,N05C-Hypnotics and sedatives,% of total sales,0.0
19407,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1294.9
19408,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.6
19409,Italy,2016,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",10.2
19410,Italy,2016,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,7.9
19411,Italy,2016,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
19412,Italy,2016,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
19413,Italy,2016,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,150.6
19414,Italy,2016,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",194.3
19415,Italy,2016,2,C07-Beta blocking agents,Million of national currency units,343.2
19416,Italy,2016,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,136.1
19417,Italy,2016,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.5
19418,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,907.1
19419,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1004.1
19420,Italy,2016,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.2
19421,Italy,2016,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.6
19422,Italy,2016,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
19423,Italy,2016,2,R03-Drugs for obstructive airway diseases,Million of national currency units,991.3
19424,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9
19425,Italy,2016,2,C-Cardiovascular system,"Million US$, purchasing power parity",5181.0
19426,Italy,2016,2,C-Cardiovascular system,Million US$ at exchange rate,4017.5
19427,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1916.4
19428,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1486.1
19429,Italy,2016,2,C-Cardiovascular system,Million of national currency units,3629.5
19430,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",31.6
19431,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",24.5
19432,Italy,2016,2,C-Cardiovascular system,"/capita, US$ exchange rate",66.3
19433,Italy,2016,2,R03-Drugs for obstructive airway diseases,% of total sales,4.4
19434,Italy,2016,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.3
19435,Italy,2016,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",85.5
19436,Italy,2016,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.0
19437,Italy,2016,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.1
19438,Italy,2016,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1415.1
19439,Italy,2016,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1097.3
19440,Italy,2016,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1342.6
19441,Italy,2015,2,C03-Diuretics,"/capita, US$ exchange rate",2.1
19442,Italy,2015,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.1
19443,Italy,2015,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.6
19444,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,209.1
19445,Italy,2015,2,C02-Antihypertensives,Million of national currency units,224.1
19446,Italy,2015,2,C02-Antihypertensives,"Million US$, purchasing power parity",303.3
19447,Italy,2015,2,C02-Antihypertensives,Million US$ at exchange rate,248.6
19448,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",283.1
19449,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.8
19450,Italy,2015,2,C03-Diuretics,Million US$ at exchange rate,127.0
19451,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.7
19452,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,232.0
19453,Italy,2015,2,C03-Diuretics,"Million US$, purchasing power parity",155.0
19454,Italy,2015,2,C03-Diuretics,% of total sales,0.5
19455,Italy,2015,2,B-Blood and blood forming organs,Million of national currency units,1981.9
19456,Italy,2015,2,B-Blood and blood forming organs,Million US$ at exchange rate,2198.9
19457,Italy,2015,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9
19458,Italy,2015,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1060.9
19459,Italy,2015,2,J01-Antibacterials for systemic use,Million of national currency units,956.2
19460,Italy,2015,2,Total pharmaceutical sales,Million US$ at exchange rate,25092.0
19461,Italy,2015,2,Total pharmaceutical sales,Million of national currency units,22615.3
19462,Italy,2015,2,Total pharmaceutical sales,"Million US$, purchasing power parity",30615.3
19463,Italy,2015,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",504.1
19464,Italy,2015,2,Total pharmaceutical sales,"/capita, US$ exchange rate",413.2
19465,Italy,2015,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.1
19466,Italy,2015,2,N05B-Anxiolytics,Million US$ at exchange rate,3.4
19467,Italy,2015,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
19468,Italy,2015,2,N05B-Anxiolytics,% of total sales,0.0
19469,Italy,2015,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
19470,Italy,2015,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",21.3
19471,Italy,2015,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",17.5
19472,Italy,2015,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1294.4
19473,Italy,2015,2,N05B-Anxiolytics,Million of national currency units,3.0
19474,Italy,2015,2,J01-Antibacterials for systemic use,% of total sales,4.2
19475,Italy,2015,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,4852.6
19476,Italy,2015,2,J-Antiinfectives for systemic use,Million of national currency units,4373.6
19477,Italy,2015,2,M-Musculo-skeletal system,Million of national currency units,485.2
19478,Italy,2015,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",97.5
19479,Italy,2015,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",79.9
19480,Italy,2015,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",5920.7
19481,Italy,2015,2,M-Musculo-skeletal system,Million US$ at exchange rate,538.4
19482,Italy,2015,2,M-Musculo-skeletal system,% of total sales,2.1
19483,Italy,2015,2,N-Nervous system,Million of national currency units,1902.0
19484,Italy,2015,2,N-Nervous system,Million US$ at exchange rate,2110.3
19485,Italy,2015,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",656.9
19486,Italy,2015,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.8
19487,Italy,2015,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.9
19488,Italy,2015,2,N02-Analgesics,"Million US$, purchasing power parity",456.4
19489,Italy,2015,2,N02-Analgesics,"/capita, US$ purchasing power parity",7.5
19490,Italy,2015,2,N02-Analgesics,"/capita, US$ exchange rate",6.2
19491,Italy,2015,2,N02-Analgesics,Million US$ at exchange rate,374.0
19492,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,77.1
19493,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,85.5
19494,Italy,2015,2,N02-Analgesics,Million of national currency units,337.1
19495,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
19496,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
19497,Italy,2015,2,J-Antiinfectives for systemic use,% of total sales,19.3
19498,Italy,2015,2,N02-Analgesics,% of total sales,1.5
19499,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.4
19500,Italy,2015,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",104.3
19501,Italy,2015,2,C02-Antihypertensives,% of total sales,1.0
19502,Italy,2015,2,A-Alimentary tract and metabolism,% of total sales,11.7
19503,Italy,2015,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.0
19504,Italy,2015,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3594.0
19505,Italy,2015,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",48.5
19506,Italy,2015,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",59.2
19507,Italy,2015,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.4
19508,Italy,2015,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.9
19509,Italy,2015,2,A10-Drugs used in diabetes,% of total sales,3.8
19510,Italy,2015,2,A10-Drugs used in diabetes,Million US$ at exchange rate,965.1
19511,Italy,2015,2,A10-Drugs used in diabetes,Million of national currency units,869.9
19512,Italy,2015,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1177.6
19513,Italy,2015,2,C01A-Cardiac glycosides,Million US$ at exchange rate,8.0
19514,Italy,2015,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
19515,Italy,2015,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",9.8
19516,Italy,2015,2,N-Nervous system,"Million US$, purchasing power parity",2574.8
19517,Italy,2015,2,N-Nervous system,"/capita, US$ exchange rate",34.7
19518,Italy,2015,2,C01A-Cardiac glycosides,Million of national currency units,7.2
19519,Italy,2015,2,N-Nervous system,"/capita, US$ purchasing power parity",42.4
19520,Italy,2015,2,A-Alimentary tract and metabolism,Million of national currency units,2654.9
19521,Italy,2015,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,2945.6
19522,Italy,2015,2,C03-Diuretics,Million of national currency units,114.5
19523,Italy,2015,2,C01A-Cardiac glycosides,% of total sales,0.0
19524,Italy,2015,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
19525,Italy,2015,2,N-Nervous system,% of total sales,8.4
19526,Italy,2015,2,R-Respiratory system,"/capita, US$ purchasing power parity",25.1
19527,Italy,2015,2,R-Respiratory system,% of total sales,5.0
19528,Italy,2015,2,R-Respiratory system,"Million US$, purchasing power parity",1523.6
19529,Italy,2015,2,R-Respiratory system,"/capita, US$ exchange rate",20.6
19530,Italy,2015,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2683.0
19531,Italy,2015,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",36.2
19532,Italy,2015,2,B-Blood and blood forming organs,% of total sales,8.8
19533,Italy,2015,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",44.2
19534,Italy,2015,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",408.7
19535,Italy,2015,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5
19536,Italy,2015,2,N05C-Hypnotics and sedatives,Million of national currency units,4.1
19537,Italy,2015,2,C08-Calcium channel blockers,Million US$ at exchange rate,335.0
19538,Italy,2015,2,C08-Calcium channel blockers,Million of national currency units,301.9
19539,Italy,2015,2,R-Respiratory system,Million of national currency units,1125.4
19540,Italy,2015,2,R-Respiratory system,Million US$ at exchange rate,1248.7
19541,Italy,2015,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.7
19542,Italy,2015,2,C08-Calcium channel blockers,% of total sales,1.3
19543,Italy,2015,2,C10-Lipid modifying agents,% of total sales,4.5
19544,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,481.1
19545,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,533.8
19546,Italy,2015,2,A02A-Antacids,% of total sales,0.1
19547,Italy,2015,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
19548,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.7
19549,Italy,2015,2,C-Cardiovascular system,% of total sales,16.0
19550,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",651.3
19551,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.8
19552,Italy,2015,2,A02A-Antacids,"/capita, US$ exchange rate",0.5
19553,Italy,2015,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1370.3
19554,Italy,2015,2,C10-Lipid modifying agents,Million US$ at exchange rate,1123.1
19555,Italy,2015,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.6
19556,Italy,2015,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.5
19557,Italy,2015,2,A02A-Antacids,Million US$ at exchange rate,27.3
19558,Italy,2015,2,A02A-Antacids,"Million US$, purchasing power parity",33.4
19559,Italy,2015,2,C10-Lipid modifying agents,Million of national currency units,1012.2
19560,Italy,2015,2,A02A-Antacids,Million of national currency units,24.6
19561,Italy,2015,2,G-Genito urinary system and sex hormones,Million of national currency units,548.0
19562,Italy,2015,2,C07-Beta blocking agents,% of total sales,1.5
19563,Italy,2015,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,608.1
19564,Italy,2015,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",741.9
19565,Italy,2015,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.0
19566,Italy,2015,2,C07-Beta blocking agents,"Million US$, purchasing power parity",451.2
19567,Italy,2015,2,C07-Beta blocking agents,Million US$ at exchange rate,369.8
19568,Italy,2015,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.4
19569,Italy,2015,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.1
19570,Italy,2015,2,N06A-Antidepressants,"/capita, US$ exchange rate",7.4
19571,Italy,2015,2,N06A-Antidepressants,"Million US$, purchasing power parity",550.0
19572,Italy,2015,2,N06A-Antidepressants,% of total sales,1.8
19573,Italy,2015,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.1
19574,Italy,2015,2,G-Genito urinary system and sex hormones,% of total sales,2.4
19575,Italy,2015,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.2
19576,Italy,2015,2,N06A-Antidepressants,Million US$ at exchange rate,450.8
19577,Italy,2015,2,N06A-Antidepressants,Million of national currency units,406.3
19578,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",21.9
19579,Italy,2015,2,N05C-Hypnotics and sedatives,% of total sales,0.0
19580,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1328.9
19581,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",17.9
19582,Italy,2015,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.5
19583,Italy,2015,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.5
19584,Italy,2015,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
19585,Italy,2015,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
19586,Italy,2015,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",202.4
19587,Italy,2015,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.7
19588,Italy,2015,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,165.9
19589,Italy,2015,2,C07-Beta blocking agents,Million of national currency units,333.3
19590,Italy,2015,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,149.5
19591,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,981.7
19592,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1089.2
19593,Italy,2015,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.3
19594,Italy,2015,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.7
19595,Italy,2015,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
19596,Italy,2015,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1020.1
19597,Italy,2015,2,C-Cardiovascular system,"Million US$, purchasing power parity",4897.1
19598,Italy,2015,2,C-Cardiovascular system,Million US$ at exchange rate,4013.6
19599,Italy,2015,2,C-Cardiovascular system,"/capita, US$ exchange rate",66.1
19600,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.1
19601,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1865.8
19602,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1529.2
19603,Italy,2015,2,C-Cardiovascular system,Million of national currency units,3617.5
19604,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",30.7
19605,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.2
19606,Italy,2015,2,R03-Drugs for obstructive airway diseases,% of total sales,4.5
19607,Italy,2015,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.7
19608,Italy,2015,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",80.6
19609,Italy,2015,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.3
19610,Italy,2015,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1380.9
19611,Italy,2015,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.6
19612,Italy,2015,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1131.8
19613,Italy,2015,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1378.2
19614,Italy,2014,2,C03-Diuretics,"/capita, US$ exchange rate",2.5
19615,Italy,2014,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.3
19616,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,232.6
19617,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2
19618,Italy,2014,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.6
19619,Italy,2014,2,C02-Antihypertensives,Million of national currency units,197.8
19620,Italy,2014,2,C02-Antihypertensives,Million US$ at exchange rate,262.8
19621,Italy,2014,2,C02-Antihypertensives,"Million US$, purchasing power parity",267.4
19622,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",314.5
19623,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.1
19624,Italy,2014,2,C03-Diuretics,Million US$ at exchange rate,153.9
19625,Italy,2014,2,C03-Diuretics,"Million US$, purchasing power parity",156.7
19626,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.2
19627,Italy,2014,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,309.0
19628,Italy,2014,2,C03-Diuretics,% of total sales,0.6
19629,Italy,2014,2,B-Blood and blood forming organs,Million US$ at exchange rate,2462.9
19630,Italy,2014,2,B-Blood and blood forming organs,Million of national currency units,1853.9
19631,Italy,2014,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1294.3
19632,Italy,2014,2,J01-Antibacterials for systemic use,Million of national currency units,974.3
19633,Italy,2014,2,Total pharmaceutical sales,Million of national currency units,19887.5
19634,Italy,2014,2,Total pharmaceutical sales,Million US$ at exchange rate,26420.6
19635,Italy,2014,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",442.3
19636,Italy,2014,2,Total pharmaceutical sales,"/capita, US$ exchange rate",434.6
19637,Italy,2014,2,Total pharmaceutical sales,"Million US$, purchasing power parity",26888.0
19638,Italy,2014,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1317.2
19639,Italy,2014,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
19640,Italy,2014,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7
19641,Italy,2014,2,N05B-Anxiolytics,Million US$ at exchange rate,4.7
19642,Italy,2014,2,N05B-Anxiolytics,% of total sales,0.0
19643,Italy,2014,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
19644,Italy,2014,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",21.7
19645,Italy,2014,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",21.3
19646,Italy,2014,2,N05B-Anxiolytics,Million of national currency units,3.5
19647,Italy,2014,2,J01-Antibacterials for systemic use,% of total sales,4.9
19648,Italy,2014,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3251.5
19649,Italy,2014,2,J-Antiinfectives for systemic use,Million of national currency units,2447.5
19650,Italy,2014,2,M-Musculo-skeletal system,Million of national currency units,505.9
19651,Italy,2014,2,M-Musculo-skeletal system,Million US$ at exchange rate,672.1
19652,Italy,2014,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",54.4
19653,Italy,2014,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3309.0
19654,Italy,2014,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.5
19655,Italy,2014,2,M-Musculo-skeletal system,% of total sales,2.5
19656,Italy,2014,2,N-Nervous system,Million of national currency units,1881.8
19657,Italy,2014,2,N-Nervous system,Million US$ at exchange rate,2499.9
19658,Italy,2014,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",683.9
19659,Italy,2014,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.3
19660,Italy,2014,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.1
19661,Italy,2014,2,N02-Analgesics,"Million US$, purchasing power parity",468.5
19662,Italy,2014,2,N02-Analgesics,"/capita, US$ purchasing power parity",7.7
19663,Italy,2014,2,N02-Analgesics,"/capita, US$ exchange rate",7.6
19664,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,75.7
19665,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,100.5
19666,Italy,2014,2,N02-Analgesics,Million US$ at exchange rate,460.3
19667,Italy,2014,2,N02-Analgesics,Million of national currency units,346.5
19668,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
19669,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
19670,Italy,2014,2,J-Antiinfectives for systemic use,% of total sales,12.3
19671,Italy,2014,2,N02-Analgesics,% of total sales,1.7
19672,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.7
19673,Italy,2014,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",102.3
19674,Italy,2014,2,C02-Antihypertensives,% of total sales,1.0
19675,Italy,2014,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.4
19676,Italy,2014,2,A-Alimentary tract and metabolism,% of total sales,13.0
19677,Italy,2014,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.5
19678,Italy,2014,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3494.1
19679,Italy,2014,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",57.5
19680,Italy,2014,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.0
19681,Italy,2014,2,A10-Drugs used in diabetes,% of total sales,4.1
19682,Italy,2014,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.7
19683,Italy,2014,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1075.6
19684,Italy,2014,2,A10-Drugs used in diabetes,Million of national currency units,809.7
19685,Italy,2014,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1094.7
19686,Italy,2014,2,C01A-Cardiac glycosides,Million US$ at exchange rate,10.7
19687,Italy,2014,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",10.9
19688,Italy,2014,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
19689,Italy,2014,2,N-Nervous system,"/capita, US$ exchange rate",41.1
19690,Italy,2014,2,N-Nervous system,"Million US$, purchasing power parity",2544.1
19691,Italy,2014,2,C01A-Cardiac glycosides,Million of national currency units,8.1
19692,Italy,2014,2,N-Nervous system,"/capita, US$ purchasing power parity",41.9
19693,Italy,2014,2,A-Alimentary tract and metabolism,Million of national currency units,2584.4
19694,Italy,2014,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3433.3
19695,Italy,2014,2,C03-Diuretics,Million of national currency units,115.9
19696,Italy,2014,2,C01A-Cardiac glycosides,% of total sales,0.0
19697,Italy,2014,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
19698,Italy,2014,2,N-Nervous system,% of total sales,9.5
19699,Italy,2014,2,R-Respiratory system,% of total sales,5.5
19700,Italy,2014,2,R-Respiratory system,"/capita, US$ purchasing power parity",24.5
19701,Italy,2014,2,R-Respiratory system,"Million US$, purchasing power parity",1491.4
19702,Italy,2014,2,R-Respiratory system,"/capita, US$ exchange rate",24.1
19703,Italy,2014,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",40.5
19704,Italy,2014,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2506.4
19705,Italy,2014,2,B-Blood and blood forming organs,% of total sales,9.3
19706,Italy,2014,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",41.2
19707,Italy,2014,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",430.3
19708,Italy,2014,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.0
19709,Italy,2014,2,C08-Calcium channel blockers,Million US$ at exchange rate,422.8
19710,Italy,2014,2,N05C-Hypnotics and sedatives,Million of national currency units,2.5
19711,Italy,2014,2,C08-Calcium channel blockers,Million of national currency units,318.3
19712,Italy,2014,2,R-Respiratory system,Million of national currency units,1103.1
19713,Italy,2014,2,R-Respiratory system,Million US$ at exchange rate,1465.4
19714,Italy,2014,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.1
19715,Italy,2014,2,C08-Calcium channel blockers,% of total sales,1.6
19716,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,488.9
19717,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,649.5
19718,Italy,2014,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
19719,Italy,2014,2,A02A-Antacids,% of total sales,0.1
19720,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.9
19721,Italy,2014,2,C-Cardiovascular system,% of total sales,18.2
19722,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",661.0
19723,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.7
19724,Italy,2014,2,C10-Lipid modifying agents,% of total sales,5.1
19725,Italy,2014,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1363.1
19726,Italy,2014,2,C10-Lipid modifying agents,Million US$ at exchange rate,1339.4
19727,Italy,2014,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",22.0
19728,Italy,2014,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.4
19729,Italy,2014,2,A02A-Antacids,"/capita, US$ exchange rate",0.5
19730,Italy,2014,2,A02A-Antacids,Million US$ at exchange rate,32.2
19731,Italy,2014,2,A02A-Antacids,"Million US$, purchasing power parity",32.7
19732,Italy,2014,2,C10-Lipid modifying agents,Million of national currency units,1008.2
19733,Italy,2014,2,A02A-Antacids,Million of national currency units,24.2
19734,Italy,2014,2,G-Genito urinary system and sex hormones,Million of national currency units,532.6
19735,Italy,2014,2,C07-Beta blocking agents,% of total sales,1.6
19736,Italy,2014,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,707.6
19737,Italy,2014,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.6
19738,Italy,2014,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",720.1
19739,Italy,2014,2,C07-Beta blocking agents,"Million US$, purchasing power parity",437.1
19740,Italy,2014,2,C07-Beta blocking agents,Million US$ at exchange rate,429.5
19741,Italy,2014,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2
19742,Italy,2014,2,C07-Beta blocking agents,"/capita, US$ exchange rate",7.1
19743,Italy,2014,2,N06A-Antidepressants,"/capita, US$ exchange rate",10.2
19744,Italy,2014,2,N06A-Antidepressants,"Million US$, purchasing power parity",628.0
19745,Italy,2014,2,N06A-Antidepressants,% of total sales,2.3
19746,Italy,2014,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",10.3
19747,Italy,2014,2,G-Genito urinary system and sex hormones,% of total sales,2.7
19748,Italy,2014,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.8
19749,Italy,2014,2,N06A-Antidepressants,Million US$ at exchange rate,617.1
19750,Italy,2014,2,N06A-Antidepressants,Million of national currency units,464.5
19751,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",23.1
19752,Italy,2014,2,N05C-Hypnotics and sedatives,% of total sales,0.0
19753,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1402.0
19754,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.7
19755,Italy,2014,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4
19756,Italy,2014,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3
19757,Italy,2014,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
19758,Italy,2014,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
19759,Italy,2014,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",209.1
19760,Italy,2014,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.4
19761,Italy,2014,2,C07-Beta blocking agents,Million of national currency units,323.3
19762,Italy,2014,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,205.5
19763,Italy,2014,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,154.7
19764,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,1037.0
19765,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1377.7
19766,Italy,2014,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.4
19767,Italy,2014,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.8
19768,Italy,2014,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
19769,Italy,2014,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1009.2
19770,Italy,2014,2,C-Cardiovascular system,"/capita, US$ exchange rate",79.2
19771,Italy,2014,2,C-Cardiovascular system,"Million US$, purchasing power parity",4899.6
19772,Italy,2014,2,C-Cardiovascular system,Million US$ at exchange rate,4814.5
19773,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1890.3
19774,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1857.5
19775,Italy,2014,2,C-Cardiovascular system,Million of national currency units,3624.0
19776,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.0
19777,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",31.1
19778,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",30.6
19779,Italy,2014,2,R03-Drugs for obstructive airway diseases,% of total sales,5.1
19780,Italy,2014,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.4
19781,Italy,2014,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",80.6
19782,Italy,2014,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.2
19783,Italy,2014,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1364.4
19784,Italy,2014,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1340.7
19785,Italy,2014,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.1
19786,Italy,2014,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1398.2
19787,Italy,2013,2,C03-Diuretics,"/capita, US$ exchange rate",2.4
19788,Italy,2013,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.2
19789,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,235.2
19790,Italy,2013,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.5
19791,Italy,2013,2,C02-Antihypertensives,Million US$ at exchange rate,251.4
19792,Italy,2013,2,C02-Antihypertensives,"Million US$, purchasing power parity",256.7
19793,Italy,2013,2,C03-Diuretics,"Million US$, purchasing power parity",149.4
19794,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",319.0
19795,Italy,2013,2,C03-Diuretics,Million US$ at exchange rate,146.3
19796,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.3
19797,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2
19798,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,312.4
19799,Italy,2013,2,C03-Diuretics,% of total sales,0.6
19800,Italy,2013,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.2
19801,Italy,2013,2,B-Blood and blood forming organs,Million US$ at exchange rate,2280.7
19802,Italy,2013,2,C02-Antihypertensives,Million of national currency units,189.3
19803,Italy,2013,2,B-Blood and blood forming organs,Million of national currency units,1717.3
19804,Italy,2013,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1300.7
19805,Italy,2013,2,J01-Antibacterials for systemic use,Million of national currency units,979.4
19806,Italy,2013,2,Total pharmaceutical sales,Million of national currency units,19445.0
19807,Italy,2013,2,Total pharmaceutical sales,Million US$ at exchange rate,25825.3
19808,Italy,2013,2,Total pharmaceutical sales,"Million US$, purchasing power parity",26373.3
19809,Italy,2013,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",437.8
19810,Italy,2013,2,Total pharmaceutical sales,"/capita, US$ exchange rate",428.7
19811,Italy,2013,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
19812,Italy,2013,2,N05B-Anxiolytics,"Million US$, purchasing power parity",5.4
19813,Italy,2013,2,N05B-Anxiolytics,% of total sales,0.0
19814,Italy,2013,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
19815,Italy,2013,2,N05B-Anxiolytics,Million US$ at exchange rate,5.3
19816,Italy,2013,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.1
19817,Italy,2013,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",21.6
19818,Italy,2013,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1328.3
19819,Italy,2013,2,N05B-Anxiolytics,Million of national currency units,4.0
19820,Italy,2013,2,J01-Antibacterials for systemic use,% of total sales,5.0
19821,Italy,2013,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3234.2
19822,Italy,2013,2,J-Antiinfectives for systemic use,Million of national currency units,2435.2
19823,Italy,2013,2,M-Musculo-skeletal system,Million US$ at exchange rate,732.0
19824,Italy,2013,2,M-Musculo-skeletal system,Million of national currency units,551.2
19825,Italy,2013,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",54.8
19826,Italy,2013,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3302.9
19827,Italy,2013,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.7
19828,Italy,2013,2,M-Musculo-skeletal system,% of total sales,2.8
19829,Italy,2013,2,N-Nervous system,Million of national currency units,1897.9
19830,Italy,2013,2,N-Nervous system,Million US$ at exchange rate,2520.6
19831,Italy,2013,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",747.6
19832,Italy,2013,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.4
19833,Italy,2013,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.2
19834,Italy,2013,2,J-Antiinfectives for systemic use,% of total sales,12.5
19835,Italy,2013,2,N02-Analgesics,"Million US$, purchasing power parity",442.8
19836,Italy,2013,2,N02-Analgesics,"/capita, US$ purchasing power parity",7.4
19837,Italy,2013,2,N02-Analgesics,"/capita, US$ exchange rate",7.2
19838,Italy,2013,2,N02-Analgesics,Million US$ at exchange rate,433.6
19839,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,99.3
19840,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,74.8
19841,Italy,2013,2,N02-Analgesics,Million of national currency units,326.5
19842,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
19843,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
19844,Italy,2013,2,N02-Analgesics,% of total sales,1.7
19845,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6
19846,Italy,2013,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",101.4
19847,Italy,2013,2,C02-Antihypertensives,% of total sales,1.0
19848,Italy,2013,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.3
19849,Italy,2013,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",54.7
19850,Italy,2013,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3361.9
19851,Italy,2013,2,A-Alimentary tract and metabolism,% of total sales,12.7
19852,Italy,2013,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",55.8
19853,Italy,2013,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.3
19854,Italy,2013,2,A10-Drugs used in diabetes,% of total sales,4.2
19855,Italy,2013,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.9
19856,Italy,2013,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1078.4
19857,Italy,2013,2,A10-Drugs used in diabetes,Million of national currency units,812.0
19858,Italy,2013,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1101.3
19859,Italy,2013,2,C01A-Cardiac glycosides,Million US$ at exchange rate,11.7
19860,Italy,2013,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",11.9
19861,Italy,2013,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
19862,Italy,2013,2,N-Nervous system,"/capita, US$ exchange rate",41.8
19863,Italy,2013,2,N-Nervous system,"Million US$, purchasing power parity",2574.1
19864,Italy,2013,2,C01A-Cardiac glycosides,Million of national currency units,8.8
19865,Italy,2013,2,N-Nervous system,"/capita, US$ purchasing power parity",42.7
19866,Italy,2013,2,A-Alimentary tract and metabolism,Million of national currency units,2478.7
19867,Italy,2013,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3292.0
19868,Italy,2013,2,C03-Diuretics,Million of national currency units,110.2
19869,Italy,2013,2,C01A-Cardiac glycosides,% of total sales,0.0
19870,Italy,2013,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
19871,Italy,2013,2,N-Nervous system,% of total sales,9.8
19872,Italy,2013,2,R-Respiratory system,% of total sales,5.5
19873,Italy,2013,2,R-Respiratory system,"Million US$, purchasing power parity",1459.8
19874,Italy,2013,2,R-Respiratory system,"/capita, US$ purchasing power parity",24.2
19875,Italy,2013,2,R-Respiratory system,"/capita, US$ exchange rate",23.7
19876,Italy,2013,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",37.9
19877,Italy,2013,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2329.1
19878,Italy,2013,2,B-Blood and blood forming organs,% of total sales,8.8
19879,Italy,2013,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.7
19880,Italy,2013,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",438.5
19881,Italy,2013,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.1
19882,Italy,2013,2,N05C-Hypnotics and sedatives,Million of national currency units,3.1
19883,Italy,2013,2,C08-Calcium channel blockers,Million of national currency units,323.3
19884,Italy,2013,2,C08-Calcium channel blockers,Million US$ at exchange rate,429.4
19885,Italy,2013,2,R-Respiratory system,Million of national currency units,1076.3
19886,Italy,2013,2,R-Respiratory system,Million US$ at exchange rate,1429.5
19887,Italy,2013,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.3
19888,Italy,2013,2,C08-Calcium channel blockers,% of total sales,1.7
19889,Italy,2013,2,C10-Lipid modifying agents,% of total sales,5.3
19890,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,484.7
19891,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,643.7
19892,Italy,2013,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
19893,Italy,2013,2,A02A-Antacids,% of total sales,0.1
19894,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.9
19895,Italy,2013,2,C-Cardiovascular system,% of total sales,19.4
19896,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",657.4
19897,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.7
19898,Italy,2013,2,A02A-Antacids,"/capita, US$ exchange rate",0.5
19899,Italy,2013,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1401.2
19900,Italy,2013,2,C10-Lipid modifying agents,Million US$ at exchange rate,1372.1
19901,Italy,2013,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",22.8
19902,Italy,2013,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",23.3
19903,Italy,2013,2,A02A-Antacids,"Million US$, purchasing power parity",30.0
19904,Italy,2013,2,A02A-Antacids,Million US$ at exchange rate,29.4
19905,Italy,2013,2,C10-Lipid modifying agents,Million of national currency units,1033.1
19906,Italy,2013,2,A02A-Antacids,Million of national currency units,22.1
19907,Italy,2013,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,686.0
19908,Italy,2013,2,G-Genito urinary system and sex hormones,Million of national currency units,516.5
19909,Italy,2013,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.4
19910,Italy,2013,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",700.6
19911,Italy,2013,2,C07-Beta blocking agents,% of total sales,1.6
19912,Italy,2013,2,C07-Beta blocking agents,"Million US$, purchasing power parity",410.7
19913,Italy,2013,2,C07-Beta blocking agents,Million US$ at exchange rate,402.1
19914,Italy,2013,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8
19915,Italy,2013,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7
19916,Italy,2013,2,N06A-Antidepressants,"/capita, US$ exchange rate",10.9
19917,Italy,2013,2,N06A-Antidepressants,"Million US$, purchasing power parity",668.9
19918,Italy,2013,2,N06A-Antidepressants,% of total sales,2.5
19919,Italy,2013,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.1
19920,Italy,2013,2,G-Genito urinary system and sex hormones,% of total sales,2.7
19921,Italy,2013,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.6
19922,Italy,2013,2,N06A-Antidepressants,Million US$ at exchange rate,655.0
19923,Italy,2013,2,N06A-Antidepressants,Million of national currency units,493.2
19924,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",22.5
19925,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.1
19926,Italy,2013,2,N05C-Hypnotics and sedatives,% of total sales,0.0
19927,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1352.6
19928,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.0
19929,Italy,2013,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.2
19930,Italy,2013,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.1
19931,Italy,2013,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
19932,Italy,2013,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
19933,Italy,2013,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",222.1
19934,Italy,2013,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.6
19935,Italy,2013,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,217.5
19936,Italy,2013,2,C07-Beta blocking agents,Million of national currency units,302.8
19937,Italy,2013,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,163.8
19938,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,997.3
19939,Italy,2013,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1324.5
19940,Italy,2013,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.7
19941,Italy,2013,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.8
19942,Italy,2013,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
19943,Italy,2013,2,R03-Drugs for obstructive airway diseases,Million of national currency units,986.1
19944,Italy,2013,2,C-Cardiovascular system,Million of national currency units,3769.3
19945,Italy,2013,2,C-Cardiovascular system,"Million US$, purchasing power parity",5112.3
19946,Italy,2013,2,C-Cardiovascular system,Million US$ at exchange rate,5006.1
19947,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.0
19948,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2104.9
19949,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2061.2
19950,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.9
19951,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",34.2
19952,Italy,2013,2,C-Cardiovascular system,"/capita, US$ exchange rate",83.1
19953,Italy,2013,2,R03-Drugs for obstructive airway diseases,% of total sales,5.1
19954,Italy,2013,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.2
19955,Italy,2013,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",84.9
19956,Italy,2013,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1337.4
19957,Italy,2013,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1309.6
19958,Italy,2013,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.7
19959,Italy,2013,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1551.9
19960,Italy,2012,2,C03-Diuretics,"/capita, US$ exchange rate",2.3
19961,Italy,2012,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.2
19962,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,234.5
19963,Italy,2012,2,C02-Antihypertensives,Million US$ at exchange rate,249.9
19964,Italy,2012,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.4
19965,Italy,2012,2,C02-Antihypertensives,"Million US$, purchasing power parity",260.2
19966,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,301.3
19967,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.1
19968,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",313.6
19969,Italy,2012,2,C03-Diuretics,"Million US$, purchasing power parity",145.0
19970,Italy,2012,2,C03-Diuretics,Million US$ at exchange rate,139.3
19971,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.3
19972,Italy,2012,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.2
19973,Italy,2012,2,C03-Diuretics,% of total sales,0.6
19974,Italy,2012,2,B-Blood and blood forming organs,Million US$ at exchange rate,2267.4
19975,Italy,2012,2,C02-Antihypertensives,Million of national currency units,194.5
19976,Italy,2012,2,B-Blood and blood forming organs,Million of national currency units,1764.8
19977,Italy,2012,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1282.4
19978,Italy,2012,2,J01-Antibacterials for systemic use,Million of national currency units,998.1
19979,Italy,2012,2,Total pharmaceutical sales,Million of national currency units,19077.9
19980,Italy,2012,2,Total pharmaceutical sales,Million US$ at exchange rate,24511.0
19981,Italy,2012,2,Total pharmaceutical sales,"Million US$, purchasing power parity",25514.3
19982,Italy,2012,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",428.5
19983,Italy,2012,2,Total pharmaceutical sales,"/capita, US$ exchange rate",411.7
19984,Italy,2012,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1334.9
19985,Italy,2012,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
19986,Italy,2012,2,N05B-Anxiolytics,"Million US$, purchasing power parity",5.2
19987,Italy,2012,2,N05B-Anxiolytics,% of total sales,0.0
19988,Italy,2012,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
19989,Italy,2012,2,N05B-Anxiolytics,Million US$ at exchange rate,5.0
19990,Italy,2012,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",22.4
19991,Italy,2012,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",21.5
19992,Italy,2012,2,N05B-Anxiolytics,Million of national currency units,3.9
19993,Italy,2012,2,J01-Antibacterials for systemic use,% of total sales,5.2
19994,Italy,2012,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3027.7
19995,Italy,2012,2,J-Antiinfectives for systemic use,Million of national currency units,2356.5
19996,Italy,2012,2,M-Musculo-skeletal system,Million US$ at exchange rate,757.3
19997,Italy,2012,2,M-Musculo-skeletal system,Million of national currency units,589.4
19998,Italy,2012,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",52.9
19999,Italy,2012,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3151.6
20000,Italy,2012,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",50.9
20001,Italy,2012,2,M-Musculo-skeletal system,% of total sales,3.1
20002,Italy,2012,2,N-Nervous system,Million of national currency units,1936.9
20003,Italy,2012,2,N-Nervous system,Million US$ at exchange rate,2488.5
20004,Italy,2012,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",788.3
20005,Italy,2012,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.7
20006,Italy,2012,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.2
20007,Italy,2012,2,J-Antiinfectives for systemic use,% of total sales,12.4
20008,Italy,2012,2,N02-Analgesics,"Million US$, purchasing power parity",409.5
20009,Italy,2012,2,N02-Analgesics,"/capita, US$ purchasing power parity",6.9
20010,Italy,2012,2,N02-Analgesics,"/capita, US$ exchange rate",6.6
20011,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,94.3
20012,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,73.4
20013,Italy,2012,2,N02-Analgesics,Million US$ at exchange rate,393.4
20014,Italy,2012,2,N02-Analgesics,Million of national currency units,306.2
20015,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.6
20016,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
20017,Italy,2012,2,N02-Analgesics,% of total sales,1.6
20018,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",98.1
20019,Italy,2012,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6
20020,Italy,2012,2,C02-Antihypertensives,% of total sales,1.0
20021,Italy,2012,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.4
20022,Italy,2012,2,A-Alimentary tract and metabolism,% of total sales,12.4
20023,Italy,2012,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.0
20024,Italy,2012,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3160.4
20025,Italy,2012,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.1
20026,Italy,2012,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.5
20027,Italy,2012,2,A10-Drugs used in diabetes,% of total sales,4.1
20028,Italy,2012,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.8
20029,Italy,2012,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1001.8
20030,Italy,2012,2,A10-Drugs used in diabetes,Million of national currency units,779.7
20031,Italy,2012,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1042.8
20032,Italy,2012,2,C01A-Cardiac glycosides,Million US$ at exchange rate,12.5
20033,Italy,2012,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",13.0
20034,Italy,2012,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
20035,Italy,2012,2,N-Nervous system,"/capita, US$ exchange rate",41.8
20036,Italy,2012,2,N-Nervous system,"Million US$, purchasing power parity",2590.3
20037,Italy,2012,2,C01A-Cardiac glycosides,Million of national currency units,9.7
20038,Italy,2012,2,N-Nervous system,"/capita, US$ purchasing power parity",43.5
20039,Italy,2012,2,A-Alimentary tract and metabolism,Million of national currency units,2363.1
20040,Italy,2012,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3036.1
20041,Italy,2012,2,C03-Diuretics,Million of national currency units,108.5
20042,Italy,2012,2,C01A-Cardiac glycosides,% of total sales,0.1
20043,Italy,2012,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
20044,Italy,2012,2,N-Nervous system,% of total sales,10.2
20045,Italy,2012,2,R-Respiratory system,% of total sales,5.8
20046,Italy,2012,2,R-Respiratory system,"/capita, US$ purchasing power parity",24.9
20047,Italy,2012,2,R-Respiratory system,"/capita, US$ exchange rate",23.9
20048,Italy,2012,2,R-Respiratory system,"Million US$, purchasing power parity",1484.1
20049,Italy,2012,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.1
20050,Italy,2012,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2360.2
20051,Italy,2012,2,B-Blood and blood forming organs,% of total sales,9.3
20052,Italy,2012,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",39.6
20053,Italy,2012,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",444.8
20054,Italy,2012,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.2
20055,Italy,2012,2,N05C-Hypnotics and sedatives,Million of national currency units,3.8
20056,Italy,2012,2,C08-Calcium channel blockers,Million of national currency units,332.6
20057,Italy,2012,2,C08-Calcium channel blockers,Million US$ at exchange rate,427.3
20058,Italy,2012,2,R-Respiratory system,Million of national currency units,1109.7
20059,Italy,2012,2,R-Respiratory system,Million US$ at exchange rate,1425.7
20060,Italy,2012,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.5
20061,Italy,2012,2,C08-Calcium channel blockers,% of total sales,1.7
20062,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,478.2
20063,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,614.3
20064,Italy,2012,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
20065,Italy,2012,2,A02A-Antacids,% of total sales,0.1
20066,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.7
20067,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",639.5
20068,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.3
20069,Italy,2012,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1531.3
20070,Italy,2012,2,C10-Lipid modifying agents,Million US$ at exchange rate,1471.1
20071,Italy,2012,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",24.7
20072,Italy,2012,2,C10-Lipid modifying agents,% of total sales,6.0
20073,Italy,2012,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.7
20074,Italy,2012,2,A02A-Antacids,"Million US$, purchasing power parity",29.1
20075,Italy,2012,2,A02A-Antacids,"/capita, US$ exchange rate",0.5
20076,Italy,2012,2,C10-Lipid modifying agents,Million of national currency units,1145.0
20077,Italy,2012,2,A02A-Antacids,Million US$ at exchange rate,27.9
20078,Italy,2012,2,A02A-Antacids,Million of national currency units,21.7
20079,Italy,2012,2,C-Cardiovascular system,% of total sales,20.8
20080,Italy,2012,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,643.1
20081,Italy,2012,2,G-Genito urinary system and sex hormones,Million of national currency units,500.5
20082,Italy,2012,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.8
20083,Italy,2012,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",669.4
20084,Italy,2012,2,C07-Beta blocking agents,"Million US$, purchasing power parity",387.4
20085,Italy,2012,2,C07-Beta blocking agents,Million US$ at exchange rate,372.2
20086,Italy,2012,2,C07-Beta blocking agents,% of total sales,1.5
20087,Italy,2012,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.3
20088,Italy,2012,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.5
20089,Italy,2012,2,N06A-Antidepressants,"/capita, US$ exchange rate",10.6
20090,Italy,2012,2,N06A-Antidepressants,"Million US$, purchasing power parity",659.4
20091,Italy,2012,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.1
20092,Italy,2012,2,N06A-Antidepressants,% of total sales,2.6
20093,Italy,2012,2,G-Genito urinary system and sex hormones,% of total sales,2.6
20094,Italy,2012,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.2
20095,Italy,2012,2,N06A-Antidepressants,Million US$ at exchange rate,633.4
20096,Italy,2012,2,N06A-Antidepressants,Million of national currency units,493.0
20097,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",22.0
20098,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.1
20099,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1310.5
20100,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.1
20101,Italy,2012,2,N05C-Hypnotics and sedatives,% of total sales,0.0
20102,Italy,2012,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.1
20103,Italy,2012,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.9
20104,Italy,2012,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
20105,Italy,2012,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
20106,Italy,2012,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",227.0
20107,Italy,2012,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.7
20108,Italy,2012,2,C07-Beta blocking agents,Million of national currency units,289.7
20109,Italy,2012,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,169.7
20110,Italy,2012,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,218.0
20111,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,979.9
20112,Italy,2012,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1259.0
20113,Italy,2012,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.8
20114,Italy,2012,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.9
20115,Italy,2012,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
20116,Italy,2012,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1008.3
20117,Italy,2012,2,C-Cardiovascular system,Million of national currency units,3968.6
20118,Italy,2012,2,C-Cardiovascular system,"/capita, US$ exchange rate",85.6
20119,Italy,2012,2,C-Cardiovascular system,"Million US$, purchasing power parity",5307.5
20120,Italy,2012,2,C-Cardiovascular system,Million US$ at exchange rate,5098.8
20121,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2201.1
20122,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.6
20123,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",37.0
20124,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.5
20125,Italy,2012,2,R03-Drugs for obstructive airway diseases,% of total sales,5.3
20126,Italy,2012,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.6
20127,Italy,2012,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",89.1
20128,Italy,2012,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1348.5
20129,Italy,2012,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1295.5
20130,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2114.6
20131,Italy,2012,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",21.8
20132,Italy,2012,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1645.8
20133,Italy,2017,2,C03-Diuretics,"/capita, US$ exchange rate",2.1
20134,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",3.3
20135,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,174.7
20136,Italy,2017,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.7
20137,Italy,2017,2,C02-Antihypertensives,Million of national currency units,221.7
20138,Italy,2017,2,C02-Antihypertensives,"Million US$, purchasing power parity",321.3
20139,Italy,2017,2,C02-Antihypertensives,Million US$ at exchange rate,250.4
20140,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",253.2
20141,Italy,2017,2,C03-Diuretics,Million US$ at exchange rate,127.7
20142,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,197.3
20143,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",4.2
20144,Italy,2017,2,C03-Diuretics,"Million US$, purchasing power parity",163.8
20145,Italy,2017,2,C03-Diuretics,% of total sales,0.5
20146,Italy,2017,2,J01-Antibacterials for systemic use,% of total sales,3.9
20147,Italy,2017,2,B-Blood and blood forming organs,Million of national currency units,2088.3
20148,Italy,2017,2,B-Blood and blood forming organs,Million US$ at exchange rate,2359.1
20149,Italy,2017,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,983.9
20150,Italy,2017,2,J01-Antibacterials for systemic use,Million of national currency units,871.0
20151,Italy,2017,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",541.6
20152,Italy,2017,2,Total pharmaceutical sales,Million US$ at exchange rate,25552.0
20153,Italy,2017,2,Total pharmaceutical sales,Million of national currency units,22618.8
20154,Italy,2017,2,Total pharmaceutical sales,"/capita, US$ exchange rate",422.1
20155,Italy,2017,2,Total pharmaceutical sales,"Million US$, purchasing power parity",32785.9
20156,Italy,2017,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.8
20157,Italy,2017,2,N05B-Anxiolytics,Million US$ at exchange rate,3.7
20158,Italy,2017,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
20159,Italy,2017,2,N05B-Anxiolytics,% of total sales,0.0
20160,Italy,2017,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
20161,Italy,2017,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.3
20162,Italy,2017,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1262.5
20163,Italy,2017,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",20.9
20164,Italy,2017,2,N05B-Anxiolytics,Million of national currency units,3.3
20165,Italy,2017,2,J-Antiinfectives for systemic use,Million of national currency units,3501.5
20166,Italy,2017,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3955.6
20167,Italy,2017,2,M-Musculo-skeletal system,Million of national currency units,462.0
20168,Italy,2017,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",83.8
20169,Italy,2017,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",65.3
20170,Italy,2017,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",5075.4
20171,Italy,2017,2,M-Musculo-skeletal system,Million US$ at exchange rate,521.9
20172,Italy,2017,2,M-Musculo-skeletal system,% of total sales,2.0
20173,Italy,2017,2,N-Nervous system,Million US$ at exchange rate,2019.4
20174,Italy,2017,2,N-Nervous system,Million of national currency units,1787.6
20175,Italy,2017,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.1
20176,Italy,2017,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",669.7
20177,Italy,2017,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.6
20178,Italy,2017,2,N02-Analgesics,"Million US$, purchasing power parity",540.3
20179,Italy,2017,2,N02-Analgesics,Million US$ at exchange rate,421.1
20180,Italy,2017,2,N02-Analgesics,"/capita, US$ exchange rate",7.0
20181,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,79.0
20182,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,89.2
20183,Italy,2017,2,N02-Analgesics,Million of national currency units,372.7
20184,Italy,2017,2,N02-Analgesics,"/capita, US$ purchasing power parity",8.9
20185,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.9
20186,Italy,2017,2,J-Antiinfectives for systemic use,% of total sales,15.5
20187,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
20188,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5
20189,Italy,2017,2,N02-Analgesics,% of total sales,1.6
20190,Italy,2017,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",114.5
20191,Italy,2017,2,C02-Antihypertensives,% of total sales,1.0
20192,Italy,2017,2,A-Alimentary tract and metabolism,% of total sales,12.2
20193,Italy,2017,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",5.3
20194,Italy,2017,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3992.0
20195,Italy,2017,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.4
20196,Italy,2017,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",65.9
20197,Italy,2017,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.1
20198,Italy,2017,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.6
20199,Italy,2017,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.9
20200,Italy,2017,2,A10-Drugs used in diabetes,% of total sales,4.0
20201,Italy,2017,2,A10-Drugs used in diabetes,Million of national currency units,904.1
20202,Italy,2017,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1021.3
20203,Italy,2017,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1310.5
20204,Italy,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
20205,Italy,2017,2,C01A-Cardiac glycosides,Million US$ at exchange rate,6.7
20206,Italy,2017,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
20207,Italy,2017,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",8.6
20208,Italy,2017,2,N-Nervous system,"Million US$, purchasing power parity",2591.1
20209,Italy,2017,2,N-Nervous system,"/capita, US$ exchange rate",33.4
20210,Italy,2017,2,C01A-Cardiac glycosides,Million of national currency units,5.9
20211,Italy,2017,2,A-Alimentary tract and metabolism,Million of national currency units,2754.0
20212,Italy,2017,2,C03-Diuretics,Million of national currency units,113.0
20213,Italy,2017,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3111.2
20214,Italy,2017,2,N-Nervous system,% of total sales,7.9
20215,Italy,2017,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
20216,Italy,2017,2,C01A-Cardiac glycosides,% of total sales,0.0
20217,Italy,2017,2,N-Nervous system,"/capita, US$ purchasing power parity",42.8
20218,Italy,2017,2,R-Respiratory system,"/capita, US$ purchasing power parity",26.8
20219,Italy,2017,2,R-Respiratory system,% of total sales,5.0
20220,Italy,2017,2,R-Respiratory system,"Million US$, purchasing power parity",1623.1
20221,Italy,2017,2,R-Respiratory system,"/capita, US$ exchange rate",20.9
20222,Italy,2017,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",3027.0
20223,Italy,2017,2,C10-Lipid modifying agents,% of total sales,4.8
20224,Italy,2017,2,B-Blood and blood forming organs,% of total sales,9.2
20225,Italy,2017,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.0
20226,Italy,2017,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",50.0
20227,Italy,2017,2,C08-Calcium channel blockers,Million US$ at exchange rate,323.9
20228,Italy,2017,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",415.5
20229,Italy,2017,2,N05C-Hypnotics and sedatives,Million of national currency units,10.1
20230,Italy,2017,2,C08-Calcium channel blockers,Million of national currency units,286.7
20231,Italy,2017,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.3
20232,Italy,2017,2,R-Respiratory system,Million of national currency units,1119.8
20233,Italy,2017,2,R-Respiratory system,Million US$ at exchange rate,1265.0
20234,Italy,2017,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.9
20235,Italy,2017,2,C08-Calcium channel blockers,% of total sales,1.3
20236,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,509.2
20237,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,575.2
20238,Italy,2017,2,A02A-Antacids,% of total sales,0.1
20239,Italy,2017,2,A02A-Antacids,"/capita, US$ exchange rate",0.5
20240,Italy,2017,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
20241,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.2
20242,Italy,2017,2,C-Cardiovascular system,% of total sales,15.7
20243,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",738.0
20244,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.5
20245,Italy,2017,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1583.1
20246,Italy,2017,2,C10-Lipid modifying agents,Million US$ at exchange rate,1233.8
20247,Italy,2017,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",26.2
20248,Italy,2017,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.4
20249,Italy,2017,2,A02A-Antacids,Million US$ at exchange rate,28.7
20250,Italy,2017,2,A02A-Antacids,"Million US$, purchasing power parity",36.9
20251,Italy,2017,2,C10-Lipid modifying agents,Million of national currency units,1092.2
20252,Italy,2017,2,A02A-Antacids,Million of national currency units,25.4
20253,Italy,2017,2,G-Genito urinary system and sex hormones,Million of national currency units,514.6
20254,Italy,2017,2,C07-Beta blocking agents,% of total sales,1.5
20255,Italy,2017,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",746.0
20256,Italy,2017,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,581.4
20257,Italy,2017,2,C07-Beta blocking agents,"Million US$, purchasing power parity",504.0
20258,Italy,2017,2,C07-Beta blocking agents,Million US$ at exchange rate,392.8
20259,Italy,2017,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.3
20260,Italy,2017,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.5
20261,Italy,2017,2,N06A-Antidepressants,"/capita, US$ exchange rate",6.9
20262,Italy,2017,2,N06A-Antidepressants,"Million US$, purchasing power parity",534.9
20263,Italy,2017,2,N06A-Antidepressants,% of total sales,1.6
20264,Italy,2017,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.8
20265,Italy,2017,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.6
20266,Italy,2017,2,G-Genito urinary system and sex hormones,% of total sales,2.3
20267,Italy,2017,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.3
20268,Italy,2017,2,N06A-Antidepressants,Million US$ at exchange rate,416.9
20269,Italy,2017,2,N06A-Antidepressants,Million of national currency units,369.0
20270,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",21.3
20271,Italy,2017,2,N05C-Hypnotics and sedatives,% of total sales,0.0
20272,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1289.8
20273,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.6
20274,Italy,2017,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.6
20275,Italy,2017,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,11.4
20276,Italy,2017,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
20277,Italy,2017,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.2
20278,Italy,2017,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,139.8
20279,Italy,2017,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",179.3
20280,Italy,2017,2,C07-Beta blocking agents,Million of national currency units,347.7
20281,Italy,2017,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,123.7
20282,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,889.8
20283,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1005.2
20284,Italy,2017,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.3
20285,Italy,2017,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.5
20286,Italy,2017,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.0
20287,Italy,2017,2,R03-Drugs for obstructive airway diseases,Million of national currency units,988.2
20288,Italy,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
20289,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.4
20290,Italy,2017,2,C-Cardiovascular system,"Million US$, purchasing power parity",5145.2
20291,Italy,2017,2,C-Cardiovascular system,Million US$ at exchange rate,4010.0
20292,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1757.8
20293,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1370.0
20294,Italy,2017,2,C-Cardiovascular system,Million of national currency units,3549.6
20295,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.0
20296,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.6
20297,Italy,2017,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.7
20298,Italy,2017,2,C-Cardiovascular system,"/capita, US$ exchange rate",66.2
20299,Italy,2017,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",18.4
20300,Italy,2017,2,R03-Drugs for obstructive airway diseases,% of total sales,4.4
20301,Italy,2017,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",85.0
20302,Italy,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.9
20303,Italy,2017,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1432.4
20304,Italy,2017,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1116.4
20305,Italy,2017,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1212.7
20306,Italy,2011,2,C03-Diuretics,"/capita, US$ exchange rate",2.5
20307,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,250.0
20308,Italy,2011,2,C02-Antihypertensives,"/capita, US$ exchange rate",4.6
20309,Italy,2011,2,C02-Antihypertensives,Million US$ at exchange rate,274.6
20310,Italy,2011,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.4
20311,Italy,2011,2,C02-Antihypertensives,"Million US$, purchasing power parity",260.1
20312,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,347.9
20313,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.9
20314,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",329.5
20315,Italy,2011,2,C03-Diuretics,Million US$ at exchange rate,151.3
20316,Italy,2011,2,C03-Diuretics,"Million US$, purchasing power parity",143.3
20317,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.5
20318,Italy,2011,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.3
20319,Italy,2011,2,C03-Diuretics,% of total sales,0.6
20320,Italy,2011,2,B-Blood and blood forming organs,Million US$ at exchange rate,2471.4
20321,Italy,2011,2,C02-Antihypertensives,Million of national currency units,197.3
20322,Italy,2011,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,1565.3
20323,Italy,2011,2,J01-Antibacterials for systemic use,Million of national currency units,1124.5
20324,Italy,2011,2,B-Blood and blood forming organs,Million of national currency units,1775.5
20325,Italy,2011,2,Total pharmaceutical sales,"Million US$, purchasing power parity",25720.8
20326,Italy,2011,2,Total pharmaceutical sales,Million of national currency units,19514.0
20327,Italy,2011,2,Total pharmaceutical sales,Million US$ at exchange rate,27162.7
20328,Italy,2011,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",1482.2
20329,Italy,2011,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",433.2
20330,Italy,2011,2,Total pharmaceutical sales,"/capita, US$ exchange rate",457.4
20331,Italy,2011,2,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
20332,Italy,2011,2,N05B-Anxiolytics,"Million US$, purchasing power parity",4.8
20333,Italy,2011,2,N05B-Anxiolytics,% of total sales,0.0
20334,Italy,2011,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
20335,Italy,2011,2,N05B-Anxiolytics,Million US$ at exchange rate,5.1
20336,Italy,2011,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",25.0
20337,Italy,2011,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",26.4
20338,Italy,2011,2,N05B-Anxiolytics,Million of national currency units,3.7
20339,Italy,2011,2,J01-Antibacterials for systemic use,% of total sales,5.8
20340,Italy,2011,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,3335.7
20341,Italy,2011,2,M-Musculo-skeletal system,Million US$ at exchange rate,891.0
20342,Italy,2011,2,M-Musculo-skeletal system,Million of national currency units,640.1
20343,Italy,2011,2,J-Antiinfectives for systemic use,Million of national currency units,2396.4
20344,Italy,2011,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",53.2
20345,Italy,2011,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3158.6
20346,Italy,2011,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",56.2
20347,Italy,2011,2,N-Nervous system,Million of national currency units,1995.7
20348,Italy,2011,2,M-Musculo-skeletal system,% of total sales,3.3
20349,Italy,2011,2,N-Nervous system,Million US$ at exchange rate,2778.0
20350,Italy,2011,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",843.7
20351,Italy,2011,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.0
20352,Italy,2011,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.2
20353,Italy,2011,2,J-Antiinfectives for systemic use,% of total sales,12.3
20354,Italy,2011,2,N02-Analgesics,"Million US$, purchasing power parity",375.6
20355,Italy,2011,2,N02-Analgesics,"/capita, US$ exchange rate",6.7
20356,Italy,2011,2,N02-Analgesics,"/capita, US$ purchasing power parity",6.3
20357,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,104.8
20358,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,75.3
20359,Italy,2011,2,N02-Analgesics,Million US$ at exchange rate,396.7
20360,Italy,2011,2,N02-Analgesics,Million of national currency units,285.0
20361,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
20362,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.7
20363,Italy,2011,2,N02-Analgesics,% of total sales,1.5
20364,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.8
20365,Italy,2011,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",99.2
20366,Italy,2011,2,N-Nervous system,"Million US$, purchasing power parity",2630.5
20367,Italy,2011,2,C02-Antihypertensives,% of total sales,1.0
20368,Italy,2011,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.4
20369,Italy,2011,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.5
20370,Italy,2011,2,A-Alimentary tract and metabolism,% of total sales,11.7
20371,Italy,2011,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.7
20372,Italy,2011,2,A10-Drugs used in diabetes,Million of national currency units,742.4
20373,Italy,2011,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.5
20374,Italy,2011,2,A10-Drugs used in diabetes,% of total sales,3.8
20375,Italy,2011,2,A10-Drugs used in diabetes,Million US$ at exchange rate,1033.4
20376,Italy,2011,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.4
20377,Italy,2011,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",978.5
20378,Italy,2011,2,C01A-Cardiac glycosides,Million US$ at exchange rate,14.7
20379,Italy,2011,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",14.0
20380,Italy,2011,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
20381,Italy,2011,2,N-Nervous system,"/capita, US$ exchange rate",46.8
20382,Italy,2011,2,C01A-Cardiac glycosides,Million of national currency units,10.6
20383,Italy,2011,2,N-Nervous system,"/capita, US$ purchasing power parity",44.3
20384,Italy,2011,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,3176.3
20385,Italy,2011,2,A-Alimentary tract and metabolism,Million of national currency units,2281.9
20386,Italy,2011,2,C03-Diuretics,Million of national currency units,108.7
20387,Italy,2011,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3007.7
20388,Italy,2011,2,C01A-Cardiac glycosides,% of total sales,0.1
20389,Italy,2011,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
20390,Italy,2011,2,N-Nervous system,% of total sales,10.2
20391,Italy,2011,2,R-Respiratory system,Million of national currency units,1136.7
20392,Italy,2011,2,R-Respiratory system,% of total sales,5.8
20393,Italy,2011,2,R-Respiratory system,"/capita, US$ exchange rate",26.6
20394,Italy,2011,2,R-Respiratory system,"/capita, US$ purchasing power parity",25.2
20395,Italy,2011,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",41.6
20396,Italy,2011,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",2340.2
20397,Italy,2011,2,B-Blood and blood forming organs,% of total sales,9.1
20398,Italy,2011,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",39.4
20399,Italy,2011,2,R-Respiratory system,"Million US$, purchasing power parity",1498.3
20400,Italy,2011,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",512.7
20401,Italy,2011,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",9.1
20402,Italy,2011,2,N05C-Hypnotics and sedatives,Million of national currency units,3.1
20403,Italy,2011,2,C08-Calcium channel blockers,Million of national currency units,389.0
20404,Italy,2011,2,C08-Calcium channel blockers,Million US$ at exchange rate,541.5
20405,Italy,2011,2,R-Respiratory system,Million US$ at exchange rate,1582.3
20406,Italy,2011,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",8.6
20407,Italy,2011,2,C08-Calcium channel blockers,% of total sales,2.0
20408,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,462.9
20409,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,644.4
20410,Italy,2011,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
20411,Italy,2011,2,A02A-Antacids,% of total sales,0.1
20412,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.3
20413,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
20414,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",610.2
20415,Italy,2011,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.9
20416,Italy,2011,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",32.3
20417,Italy,2011,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",1815.3
20418,Italy,2011,2,C10-Lipid modifying agents,% of total sales,7.1
20419,Italy,2011,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.6
20420,Italy,2011,2,C10-Lipid modifying agents,Million US$ at exchange rate,1917.0
20421,Italy,2011,2,A02A-Antacids,"Million US$, purchasing power parity",28.9
20422,Italy,2011,2,A02A-Antacids,"/capita, US$ exchange rate",0.5
20423,Italy,2011,2,A02A-Antacids,Million US$ at exchange rate,30.5
20424,Italy,2011,2,C10-Lipid modifying agents,Million of national currency units,1377.2
20425,Italy,2011,2,A02A-Antacids,Million of national currency units,21.9
20426,Italy,2011,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,700.8
20427,Italy,2011,2,G-Genito urinary system and sex hormones,Million of national currency units,503.5
20428,Italy,2011,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.8
20429,Italy,2011,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",663.6
20430,Italy,2011,2,C07-Beta blocking agents,% of total sales,1.5
20431,Italy,2011,2,C07-Beta blocking agents,"Million US$, purchasing power parity",375.0
20432,Italy,2011,2,C07-Beta blocking agents,Million US$ at exchange rate,396.0
20433,Italy,2011,2,C07-Beta blocking agents,"/capita, US$ exchange rate",6.7
20434,Italy,2011,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.3
20435,Italy,2011,2,N06A-Antidepressants,"/capita, US$ exchange rate",11.7
20436,Italy,2011,2,N06A-Antidepressants,"Million US$, purchasing power parity",655.6
20437,Italy,2011,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.0
20438,Italy,2011,2,N06A-Antidepressants,% of total sales,2.5
20439,Italy,2011,2,G-Genito urinary system and sex hormones,% of total sales,2.6
20440,Italy,2011,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.2
20441,Italy,2011,2,N06A-Antidepressants,Million US$ at exchange rate,692.4
20442,Italy,2011,2,N06A-Antidepressants,Million of national currency units,497.4
20443,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.1
20444,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",21.9
20445,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",1301.5
20446,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",23.1
20447,Italy,2011,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1
20448,Italy,2011,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.3
20449,Italy,2011,2,N05C-Hypnotics and sedatives,% of total sales,0.0
20450,Italy,2011,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.1
20451,Italy,2011,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.1
20452,Italy,2011,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",232.5
20453,Italy,2011,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.1
20454,Italy,2011,2,C07-Beta blocking agents,Million of national currency units,284.5
20455,Italy,2011,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,176.4
20456,Italy,2011,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,245.5
20457,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,987.4
20458,Italy,2011,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,1374.5
20459,Italy,2011,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.9
20460,Italy,2011,2,G03-Sex hormones and modulators of the genital system,% of total sales,0.9
20461,Italy,2011,2,C-Cardiovascular system,% of total sales,23.3
20462,Italy,2011,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1030.5
20463,Italy,2011,2,C-Cardiovascular system,Million of national currency units,4542.7
20464,Italy,2011,2,C-Cardiovascular system,"/capita, US$ exchange rate",106.5
20465,Italy,2011,2,C-Cardiovascular system,"Million US$, purchasing power parity",5987.5
20466,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",2546.9
20467,Italy,2011,2,C-Cardiovascular system,Million US$ at exchange rate,6323.2
20468,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.9
20469,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",42.9
20470,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",45.3
20471,Italy,2011,2,R03-Drugs for obstructive airway diseases,% of total sales,5.3
20472,Italy,2011,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.9
20473,Italy,2011,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",100.8
20474,Italy,2011,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1358.2
20475,Italy,2011,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1434.4
20476,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,2689.7
20477,Italy,2011,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.2
20478,Italy,2011,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1932.3
20479,Japan,2016,5,Products not elsewhere classified,% of total sales,50.4
20480,Japan,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",62773.8
20481,Japan,2016,5,Products not elsewhere classified,Million US$ at exchange rate,30673.2
20482,Japan,2016,5,Products not elsewhere classified,Million of national currency units,3337024.0
20483,Japan,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",241.6
20484,Japan,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",31624.7
20485,Japan,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.2
20486,Japan,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1989.1
20487,Japan,2016,5,J-Antiinfectives for systemic use,% of total sales,3.2
20488,Japan,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.7
20489,Japan,2016,5,R-Respiratory system,"Million US$, purchasing power parity",1133.6
20490,Japan,2016,5,R-Respiratory system,Million US$ at exchange rate,1099.5
20491,Japan,2016,5,R-Respiratory system,Million of national currency units,119619.0
20492,Japan,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",479.7
20493,Japan,2016,5,R-Respiratory system,% of total sales,1.8
20494,Japan,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",249.1
20495,Japan,2016,5,R-Respiratory system,"/capita, US$ exchange rate",8.7
20496,Japan,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",8.9
20497,Japan,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3793.9
20498,Japan,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,3679.7
20499,Japan,2016,5,A-Alimentary tract and metabolism,Million of national currency units,400328.0
20500,Japan,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",29.0
20501,Japan,2016,5,G-Genito urinary system and sex hormones,% of total sales,2.0
20502,Japan,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.0
20503,Japan,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",29.9
20504,Japan,2016,5,N-Nervous system,"Million US$, purchasing power parity",7865.8
20505,Japan,2016,5,N-Nervous system,"/capita, US$ exchange rate",60.1
20506,Japan,2016,5,N-Nervous system,Million US$ at exchange rate,7629.2
20507,Japan,2016,5,N-Nervous system,% of total sales,12.5
20508,Japan,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",62.0
20509,Japan,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,60885.0
20510,Japan,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",9550.3
20511,Japan,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.2
20512,Japan,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",73.0
20513,Japan,2016,5,Total pharmaceutical sales,Million of national currency units,6623860.0
20514,Japan,2016,5,C-Cardiovascular system,Million US$ at exchange rate,9263.0
20515,Japan,2016,5,C-Cardiovascular system,Million of national currency units,1007745.0
20516,Japan,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1274.6
20517,Japan,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1236.2
20518,Japan,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.7
20519,Japan,2016,5,A-Alimentary tract and metabolism,% of total sales,6.0
20520,Japan,2016,5,C-Cardiovascular system,% of total sales,15.2
20521,Japan,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,134491.0
20522,Japan,2016,5,N-Nervous system,Million of national currency units,830000.0
20523,Japan,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",494.5
20524,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,159150.0
20525,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1508.3
20526,Japan,2016,5,B-Blood and blood forming organs,Million of national currency units,425618.0
20527,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
20528,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.9
20529,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.5
20530,Japan,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.8
20531,Japan,2016,5,B-Blood and blood forming organs,% of total sales,6.4
20532,Japan,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.8
20533,Japan,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1462.9
20534,Japan,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,1929.2
20535,Japan,2016,5,J-Antiinfectives for systemic use,Million of national currency units,209885.0
20536,Japan,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,3912.2
20537,Japan,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4033.5
20538,Japan,2015,5,Products not elsewhere classified,% of total sales,48.2
20539,Japan,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",65218.5
20540,Japan,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",438.6
20541,Japan,2015,5,Products not elsewhere classified,Million US$ at exchange rate,26853.0
20542,Japan,2015,5,Products not elsewhere classified,Million of national currency units,3250399.0
20543,Japan,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",211.3
20544,Japan,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",31414.1
20545,Japan,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.3
20546,Japan,2015,5,J-Antiinfectives for systemic use,% of total sales,3.3
20547,Japan,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.7
20548,Japan,2015,5,R-Respiratory system,"Million US$, purchasing power parity",1150.3
20549,Japan,2015,5,R-Respiratory system,Million US$ at exchange rate,983.3
20550,Japan,2015,5,R-Respiratory system,Million of national currency units,119017.0
20551,Japan,2015,5,R-Respiratory system,"/capita, US$ exchange rate",7.7
20552,Japan,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",247.2
20553,Japan,2015,5,R-Respiratory system,% of total sales,1.8
20554,Japan,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",9.1
20555,Japan,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,55749.3
20556,Japan,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4485.1
20557,Japan,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",30.2
20558,Japan,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,3833.9
20559,Japan,2015,5,G-Genito urinary system and sex hormones,% of total sales,2.2
20560,Japan,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",35.3
20561,Japan,2015,5,A-Alimentary tract and metabolism,Million of national currency units,464073.0
20562,Japan,2015,5,N-Nervous system,"Million US$, purchasing power parity",7869.6
20563,Japan,2015,5,N-Nervous system,"/capita, US$ exchange rate",52.9
20564,Japan,2015,5,N-Nervous system,Million US$ at exchange rate,6727.0
20565,Japan,2015,5,N-Nervous system,Million of national currency units,814267.0
20566,Japan,2015,5,N-Nervous system,% of total sales,12.1
20567,Japan,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.2
20568,Japan,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",61.9
20569,Japan,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",10519.8
20570,Japan,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",70.8
20571,Japan,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",82.8
20572,Japan,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2121.2
20573,Japan,2015,5,Total pharmaceutical sales,Million of national currency units,6748121.0
20574,Japan,2015,5,C-Cardiovascular system,Million of national currency units,1088475.0
20575,Japan,2015,5,C-Cardiovascular system,Million US$ at exchange rate,8992.4
20576,Japan,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1427.3
20577,Japan,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1220.1
20578,Japan,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.6
20579,Japan,2015,5,C-Cardiovascular system,% of total sales,16.1
20580,Japan,2015,5,A-Alimentary tract and metabolism,% of total sales,6.9
20581,Japan,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,147680.0
20582,Japan,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",513.1
20583,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1767.7
20584,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,182902.0
20585,Japan,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.1
20586,Japan,2015,5,B-Blood and blood forming organs,Million of national currency units,461825.0
20587,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
20588,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.9
20589,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.9
20590,Japan,2015,5,B-Blood and blood forming organs,% of total sales,6.8
20591,Japan,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1511.0
20592,Japan,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,1813.2
20593,Japan,2015,5,J-Antiinfectives for systemic use,Million of national currency units,219483.0
20594,Japan,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,3815.3
20595,Japan,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.0
20596,Japan,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4463.4
20597,Japan,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",488.9
20598,Japan,2014,5,Products not elsewhere classified,% of total sales,46.0
20599,Japan,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",63945.9
20600,Japan,2014,5,R-Respiratory system,"Million US$, purchasing power parity",951.6
20601,Japan,2014,5,Products not elsewhere classified,Million US$ at exchange rate,28623.7
20602,Japan,2014,5,Products not elsewhere classified,Million of national currency units,3032529.0
20603,Japan,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",225.0
20604,Japan,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",29427.2
20605,Japan,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",17.5
20606,Japan,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.0
20607,Japan,2014,5,J-Antiinfectives for systemic use,% of total sales,3.6
20608,Japan,2014,5,R-Respiratory system,Million US$ at exchange rate,925.6
20609,Japan,2014,5,R-Respiratory system,Million of national currency units,98066.0
20610,Japan,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",231.3
20611,Japan,2014,5,R-Respiratory system,% of total sales,1.5
20612,Japan,2014,5,R-Respiratory system,"/capita, US$ exchange rate",7.3
20613,Japan,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",7.5
20614,Japan,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",4699.9
20615,Japan,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",35.9
20616,Japan,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,4571.5
20617,Japan,2014,5,G-Genito urinary system and sex hormones,% of total sales,2.3
20618,Japan,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",36.9
20619,Japan,2014,5,A-Alimentary tract and metabolism,Million of national currency units,484331.0
20620,Japan,2014,5,N-Nervous system,"Million US$, purchasing power parity",7970.7
20621,Japan,2014,5,N-Nervous system,"/capita, US$ exchange rate",60.9
20622,Japan,2014,5,N-Nervous system,Million US$ at exchange rate,7753.0
20623,Japan,2014,5,N-Nervous system,Million of national currency units,821393.0
20624,Japan,2014,5,N-Nervous system,% of total sales,12.5
20625,Japan,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",62.6
20626,Japan,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.6
20627,Japan,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",11229.5
20628,Japan,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",85.8
20629,Japan,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",88.3
20630,Japan,2014,5,Total pharmaceutical sales,Million of national currency units,6589762.0
20631,Japan,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,62200.0
20632,Japan,2014,5,C-Cardiovascular system,Million US$ at exchange rate,10922.9
20633,Japan,2014,5,C-Cardiovascular system,Million of national currency units,1157221.0
20634,Japan,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1477.3
20635,Japan,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1437.0
20636,Japan,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3
20637,Japan,2014,5,C-Cardiovascular system,% of total sales,17.6
20638,Japan,2014,5,A-Alimentary tract and metabolism,% of total sales,7.3
20639,Japan,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,152239.0
20640,Japan,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2293.1
20641,Japan,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",502.6
20642,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,158691.0
20643,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1539.9
20644,Japan,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.2
20645,Japan,2014,5,B-Blood and blood forming organs,Million of national currency units,448987.0
20646,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
20647,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.1
20648,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.8
20649,Japan,2014,5,B-Blood and blood forming organs,% of total sales,6.8
20650,Japan,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1497.9
20651,Japan,2014,5,J-Antiinfectives for systemic use,Million of national currency units,236305.0
20652,Japan,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,2230.5
20653,Japan,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,4237.9
20654,Japan,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4356.9
20655,Japan,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",33.3
20656,Japan,2013,5,Total pharmaceutical sales,"/capita, US$ exchange rate",554.4
20657,Japan,2013,5,Total pharmaceutical sales,"Million US$, purchasing power parity",68053.6
20658,Japan,2013,5,Products not elsewhere classified,Million US$ at exchange rate,31664.9
20659,Japan,2013,5,Products not elsewhere classified,"Million US$, purchasing power parity",30506.2
20660,Japan,2013,5,Products not elsewhere classified,"/capita, US$ exchange rate",248.5
20661,Japan,2013,5,Products not elsewhere classified,Million of national currency units,3090356.0
20662,Japan,2013,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.9
20663,Japan,2013,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.2
20664,Japan,2013,5,J-Antiinfectives for systemic use,% of total sales,3.4
20665,Japan,2013,5,R-Respiratory system,"Million US$, purchasing power parity",1168.8
20666,Japan,2013,5,R-Respiratory system,Million US$ at exchange rate,1213.2
20667,Japan,2013,5,R-Respiratory system,Million of national currency units,118406.0
20668,Japan,2013,5,R-Respiratory system,"/capita, US$ exchange rate",9.5
20669,Japan,2013,5,Products not elsewhere classified,% of total sales,44.8
20670,Japan,2013,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",239.4
20671,Japan,2013,5,R-Respiratory system,% of total sales,1.7
20672,Japan,2013,5,R-Respiratory system,"/capita, US$ purchasing power parity",9.2
20673,Japan,2013,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5257.4
20674,Japan,2013,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",42.8
20675,Japan,2013,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,5457.1
20676,Japan,2013,5,G-Genito urinary system and sex hormones,% of total sales,2.4
20677,Japan,2013,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.3
20678,Japan,2013,5,A-Alimentary tract and metabolism,Million of national currency units,532593.0
20679,Japan,2013,5,N-Nervous system,"Million US$, purchasing power parity",8200.2
20680,Japan,2013,5,N-Nervous system,"/capita, US$ exchange rate",66.8
20681,Japan,2013,5,N-Nervous system,Million US$ at exchange rate,8511.7
20682,Japan,2013,5,N-Nervous system,Million of national currency units,830706.0
20683,Japan,2013,5,N-Nervous system,% of total sales,12.0
20684,Japan,2013,5,N-Nervous system,"/capita, US$ purchasing power parity",64.4
20685,Japan,2013,5,C-Cardiovascular system,"/capita, US$ exchange rate",100.9
20686,Japan,2013,5,C-Cardiovascular system,"Million US$, purchasing power parity",12388.8
20687,Japan,2013,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",97.2
20688,Japan,2013,5,Total pharmaceutical sales,Million of national currency units,6894014.0
20689,Japan,2013,5,Total pharmaceutical sales,Million US$ at exchange rate,70638.5
20690,Japan,2013,5,C-Cardiovascular system,Million of national currency units,1255017.0
20691,Japan,2013,5,C-Cardiovascular system,Million US$ at exchange rate,12859.4
20692,Japan,2013,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1658.5
20693,Japan,2013,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1721.5
20694,Japan,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.5
20695,Japan,2013,5,C-Cardiovascular system,% of total sales,18.2
20696,Japan,2013,5,A-Alimentary tract and metabolism,% of total sales,7.7
20697,Japan,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.0
20698,Japan,2013,5,G-Genito urinary system and sex hormones,Million of national currency units,168011.0
20699,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,166912.0
20700,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1647.7
20701,Japan,2013,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",534.1
20702,Japan,2013,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.5
20703,Japan,2013,5,B-Blood and blood forming organs,Million of national currency units,497196.0
20704,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
20705,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.9
20706,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.4
20707,Japan,2013,5,B-Blood and blood forming organs,% of total sales,7.2
20708,Japan,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1710.2
20709,Japan,2013,5,J-Antiinfectives for systemic use,Million of national currency units,234817.0
20710,Japan,2013,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,2406.0
20711,Japan,2013,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4908.0
20712,Japan,2013,5,B-Blood and blood forming organs,Million US$ at exchange rate,5094.4
20713,Japan,2013,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",40.0
20714,Japan,2013,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2318.0
20715,Japan,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",685.3
20716,Japan,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",66907.5
20717,Japan,2012,5,Products not elsewhere classified,Million US$ at exchange rate,37641.3
20718,Japan,2012,5,Products not elsewhere classified,"/capita, US$ exchange rate",295.0
20719,Japan,2012,5,Products not elsewhere classified,"Million US$, purchasing power parity",28803.1
20720,Japan,2012,5,Products not elsewhere classified,Million of national currency units,3003413.0
20721,Japan,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",24.7
20722,Japan,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.9
20723,Japan,2012,5,J-Antiinfectives for systemic use,% of total sales,3.6
20724,Japan,2012,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",225.7
20725,Japan,2012,5,R-Respiratory system,"Million US$, purchasing power parity",1221.6
20726,Japan,2012,5,R-Respiratory system,Million of national currency units,127386.0
20727,Japan,2012,5,R-Respiratory system,"/capita, US$ exchange rate",12.5
20728,Japan,2012,5,R-Respiratory system,Million US$ at exchange rate,1596.5
20729,Japan,2012,5,Products not elsewhere classified,% of total sales,43.0
20730,Japan,2012,5,R-Respiratory system,% of total sales,1.8
20731,Japan,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",9.6
20732,Japan,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5488.9
20733,Japan,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",56.2
20734,Japan,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,7173.2
20735,Japan,2012,5,G-Genito urinary system and sex hormones,% of total sales,2.5
20736,Japan,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.0
20737,Japan,2012,5,N-Nervous system,"/capita, US$ exchange rate",86.9
20738,Japan,2012,5,N-Nervous system,"Million US$, purchasing power parity",8481.0
20739,Japan,2012,5,N-Nervous system,Million US$ at exchange rate,11083.3
20740,Japan,2012,5,N-Nervous system,Million of national currency units,884343.0
20741,Japan,2012,5,A-Alimentary tract and metabolism,Million of national currency units,572354.0
20742,Japan,2012,5,N-Nervous system,% of total sales,12.7
20743,Japan,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",66.5
20744,Japan,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.3
20745,Japan,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",127.4
20746,Japan,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",12438.7
20747,Japan,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",97.5
20748,Japan,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,87437.9
20749,Japan,2012,5,C-Cardiovascular system,Million of national currency units,1297037.0
20750,Japan,2012,5,C-Cardiovascular system,Million US$ at exchange rate,16255.5
20751,Japan,2012,5,C-Cardiovascular system,% of total sales,18.6
20752,Japan,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1695.6
20753,Japan,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.4
20754,Japan,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,2215.9
20755,Japan,2012,5,A-Alimentary tract and metabolism,% of total sales,8.2
20756,Japan,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,176807.0
20757,Japan,2012,5,Total pharmaceutical sales,Million of national currency units,6976712.0
20758,Japan,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2412.6
20759,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,152914.0
20760,Japan,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.4
20761,Japan,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",524.4
20762,Japan,2012,5,B-Blood and blood forming organs,Million of national currency units,510891.0
20763,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.0
20764,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
20765,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.5
20766,Japan,2012,5,B-Blood and blood forming organs,% of total sales,7.3
20767,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1916.4
20768,Japan,2012,5,J-Antiinfectives for systemic use,Million of national currency units,251567.0
20769,Japan,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,3152.8
20770,Japan,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1466.5
20771,Japan,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4899.5
20772,Japan,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,6402.9
20773,Japan,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",50.2
20774,Japan,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",684.9
20775,Japan,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",65026.4
20776,Japan,2011,6,Products not elsewhere classified,Million US$ at exchange rate,37960.1
20777,Japan,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",28193.3
20778,Japan,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",296.9
20779,Japan,2011,6,Products not elsewhere classified,Million of national currency units,3029486.0
20780,Japan,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",26.1
20781,Japan,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.4
20782,Japan,2011,6,J-Antiinfectives for systemic use,% of total sales,3.8
20783,Japan,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",220.5
20784,Japan,2011,6,R-Respiratory system,"Million US$, purchasing power parity",1152.4
20785,Japan,2011,6,R-Respiratory system,"/capita, US$ exchange rate",12.1
20786,Japan,2011,6,R-Respiratory system,Million of national currency units,123835.0
20787,Japan,2011,6,R-Respiratory system,Million US$ at exchange rate,1551.7
20788,Japan,2011,6,Products not elsewhere classified,% of total sales,43.4
20789,Japan,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",9.0
20790,Japan,2011,6,R-Respiratory system,% of total sales,1.8
20791,Japan,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",55.9
20792,Japan,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5305.8
20793,Japan,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,7143.9
20794,Japan,2011,6,G-Genito urinary system and sex hormones,% of total sales,2.2
20795,Japan,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.5
20796,Japan,2011,6,N-Nervous system,"/capita, US$ exchange rate",87.2
20797,Japan,2011,6,N-Nervous system,"Million US$, purchasing power parity",8282.7
20798,Japan,2011,6,N-Nervous system,Million US$ at exchange rate,11152.0
20799,Japan,2011,6,N-Nervous system,Million of national currency units,890011.0
20800,Japan,2011,6,A-Alimentary tract and metabolism,Million of national currency units,570135.0
20801,Japan,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",64.8
20802,Japan,2011,6,N-Nervous system,% of total sales,12.7
20803,Japan,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",132.1
20804,Japan,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",12544.8
20805,Japan,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",98.1
20806,Japan,2011,6,C-Cardiovascular system,Million of national currency units,1347996.0
20807,Japan,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,87553.3
20808,Japan,2011,6,C-Cardiovascular system,Million US$ at exchange rate,16890.7
20809,Japan,2011,6,C-Cardiovascular system,% of total sales,19.3
20810,Japan,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1452.9
20811,Japan,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.4
20812,Japan,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.3
20813,Japan,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1956.2
20814,Japan,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,156118.0
20815,Japan,2011,6,Total pharmaceutical sales,Million of national currency units,6987367.0
20816,Japan,2011,6,A-Alimentary tract and metabolism,% of total sales,8.2
20817,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,139935.0
20818,Japan,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",508.7
20819,Japan,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",33.8
20820,Japan,2011,6,B-Blood and blood forming organs,Million of national currency units,463919.0
20821,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.7
20822,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
20823,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.2
20824,Japan,2011,6,B-Blood and blood forming organs,% of total sales,6.6
20825,Japan,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,5813.0
20826,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1753.4
20827,Japan,2011,6,J-Antiinfectives for systemic use,Million of national currency units,265932.0
20828,Japan,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1302.3
20829,Japan,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2474.8
20830,Japan,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,3332.2
20831,Japan,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",4317.4
20832,Japan,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.5
20833,Japan,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",603.1
20834,Japan,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",60685.0
20835,Japan,2010,6,C-Cardiovascular system,Million of national currency units,1401736.0
20836,Japan,2010,6,Products not elsewhere classified,Million US$ at exchange rate,33031.6
20837,Japan,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",25955.8
20838,Japan,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",257.9
20839,Japan,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.8
20840,Japan,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.4
20841,Japan,2010,6,Products not elsewhere classified,Million of national currency units,2899512.0
20842,Japan,2010,6,J-Antiinfectives for systemic use,% of total sales,3.5
20843,Japan,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",202.7
20844,Japan,2010,6,R-Respiratory system,"Million US$, purchasing power parity",1102.5
20845,Japan,2010,6,R-Respiratory system,"/capita, US$ exchange rate",11.0
20846,Japan,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",473.9
20847,Japan,2010,6,R-Respiratory system,Million of national currency units,123160.0
20848,Japan,2010,6,R-Respiratory system,Million US$ at exchange rate,1403.1
20849,Japan,2010,6,Products not elsewhere classified,% of total sales,42.8
20850,Japan,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",8.6
20851,Japan,2010,6,R-Respiratory system,% of total sales,1.8
20852,Japan,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.8
20853,Japan,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",5209.6
20854,Japan,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,6629.8
20855,Japan,2010,6,G-Genito urinary system and sex hormones,% of total sales,2.3
20856,Japan,2010,6,A-Alimentary tract and metabolism,% of total sales,8.6
20857,Japan,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.7
20858,Japan,2010,6,N-Nervous system,"/capita, US$ exchange rate",72.3
20859,Japan,2010,6,N-Nervous system,Million US$ at exchange rate,9253.3
20860,Japan,2010,6,N-Nervous system,"Million US$, purchasing power parity",7271.1
20861,Japan,2010,6,N-Nervous system,Million of national currency units,812255.0
20862,Japan,2010,6,A-Alimentary tract and metabolism,Million of national currency units,581966.0
20863,Japan,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",56.8
20864,Japan,2010,6,N-Nervous system,% of total sales,12.0
20865,Japan,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",124.7
20866,Japan,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",12548.0
20867,Japan,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",98.0
20868,Japan,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,77228.4
20869,Japan,2010,6,C-Cardiovascular system,Million US$ at exchange rate,15968.8
20870,Japan,2010,6,C-Cardiovascular system,% of total sales,20.7
20871,Japan,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1419.4
20872,Japan,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",11.1
20873,Japan,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.1
20874,Japan,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1806.3
20875,Japan,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,158560.0
20876,Japan,2010,6,Total pharmaceutical sales,Million of national currency units,6779099.0
20877,Japan,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.2
20878,Japan,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,5088.9
20879,Japan,2010,6,B-Blood and blood forming organs,Million of national currency units,446699.0
20880,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.2
20881,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7
20882,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.0
20883,Japan,2010,6,B-Blood and blood forming organs,% of total sales,6.6
20884,Japan,2010,6,J-Antiinfectives for systemic use,Million of national currency units,240226.0
20885,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,114985.0
20886,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1309.9
20887,Japan,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1029.3
20888,Japan,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2150.5
20889,Japan,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,2736.7
20890,Japan,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",3998.8
20891,Japan,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",39.7
20892,Japan,2017,5,N-Nervous system,Million of national currency units,779318.0
20893,Japan,2017,5,Products not elsewhere classified,% of total sales,52.7
20894,Japan,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",63950.5
20895,Japan,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",472.9
20896,Japan,2017,5,Products not elsewhere classified,Million US$ at exchange rate,31572.7
20897,Japan,2017,5,Products not elsewhere classified,Million of national currency units,3541392.0
20898,Japan,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",249.2
20899,Japan,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",33694.8
20900,Japan,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.9
20901,Japan,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1609.2
20902,Japan,2017,5,J-Antiinfectives for systemic use,% of total sales,2.5
20903,Japan,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",12.7
20904,Japan,2017,5,R-Respiratory system,Million US$ at exchange rate,1204.0
20905,Japan,2017,5,R-Respiratory system,"Million US$, purchasing power parity",1285.0
20906,Japan,2017,5,R-Respiratory system,Million of national currency units,135053.0
20907,Japan,2017,5,R-Respiratory system,% of total sales,2.0
20908,Japan,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",265.9
20909,Japan,2017,5,R-Respiratory system,"/capita, US$ exchange rate",9.5
20910,Japan,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",10.1
20911,Japan,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,59922.9
20912,Japan,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3839.1
20913,Japan,2017,5,A-Alimentary tract and metabolism,Million of national currency units,403493.0
20914,Japan,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,3597.3
20915,Japan,2017,5,G-Genito urinary system and sex hormones,% of total sales,2.4
20916,Japan,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.2
20917,Japan,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.4
20918,Japan,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",30.3
20919,Japan,2017,5,N-Nervous system,"Million US$, purchasing power parity",7414.9
20920,Japan,2017,5,N-Nervous system,Million US$ at exchange rate,6947.9
20921,Japan,2017,5,N-Nervous system,"/capita, US$ exchange rate",54.8
20922,Japan,2017,5,N-Nervous system,% of total sales,11.6
20923,Japan,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",58.5
20924,Japan,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",8890.8
20925,Japan,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",65.7
20926,Japan,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",70.2
20927,Japan,2017,5,Total pharmaceutical sales,Million of national currency units,6721317.0
20928,Japan,2017,5,C-Cardiovascular system,Million US$ at exchange rate,8330.8
20929,Japan,2017,5,C-Cardiovascular system,Million of national currency units,934437.0
20930,Japan,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1448.0
20931,Japan,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1545.3
20932,Japan,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.4
20933,Japan,2017,5,A-Alimentary tract and metabolism,% of total sales,6.0
20934,Japan,2017,5,C-Cardiovascular system,% of total sales,13.9
20935,Japan,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,162419.0
20936,Japan,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",504.7
20937,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,175173.0
20938,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",1666.7
20939,Japan,2017,5,B-Blood and blood forming organs,Million of national currency units,420896.0
20940,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
20941,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.2
20942,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.3
20943,Japan,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.6
20944,Japan,2017,5,B-Blood and blood forming organs,% of total sales,6.3
20945,Japan,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,1561.7
20946,Japan,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,1507.9
20947,Japan,2017,5,J-Antiinfectives for systemic use,Million of national currency units,169135.0
20948,Japan,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",29.6
20949,Japan,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,3752.4
20950,Japan,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",4004.6
20951,Latvia,2010,26,A-Alimentary tract and metabolism,Million of national currency units,35.8
20952,Latvia,2010,26,A02A-Antacids,Million of national currency units,0.4
20953,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.5
20954,Latvia,2010,26,C01A-Cardiac glycosides,% of total sales,0.0
20955,Latvia,2010,26,Total pharmaceutical sales,Million of national currency units,276.2
20956,Latvia,2010,26,N05B-Anxiolytics,% of total sales,0.8
20957,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,% of total sales,2.1
20958,Latvia,2010,26,N-Nervous system,% of total sales,12.0
20959,Latvia,2010,26,M-Musculo-skeletal system,% of total sales,6.6
20960,Latvia,2010,26,A02A-Antacids,% of total sales,0.1
20961,Latvia,2010,26,J01-Antibacterials for systemic use,% of total sales,3.4
20962,Latvia,2010,26,R03-Drugs for obstructive airway diseases,% of total sales,3.1
20963,Latvia,2010,26,B-Blood and blood forming organs,% of total sales,6.8
20964,Latvia,2010,26,N02-Analgesics,% of total sales,2.6
20965,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7
20966,Latvia,2010,26,C-Cardiovascular system,% of total sales,18.9
20967,Latvia,2010,26,C10-Lipid modifying agents,% of total sales,2.6
20968,Latvia,2010,26,N05C-Hypnotics and sedatives,% of total sales,0.9
20969,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
20970,Latvia,2010,26,C07-Beta blocking agents,% of total sales,2.4
20971,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
20972,Latvia,2010,26,N06A-Antidepressants,% of total sales,0.8
20973,Latvia,2010,26,R-Respiratory system,% of total sales,7.4
20974,Latvia,2010,26,C03-Diuretics,% of total sales,0.8
20975,Latvia,2010,26,A-Alimentary tract and metabolism,% of total sales,13.0
20976,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.7
20977,Latvia,2010,26,A10-Drugs used in diabetes,% of total sales,5.5
20978,Latvia,2010,26,C02-Antihypertensives,% of total sales,0.9
20979,Latvia,2010,26,C08-Calcium channel blockers,% of total sales,1.5
20980,Latvia,2010,26,J-Antiinfectives for systemic use,% of total sales,9.3
20981,Latvia,2010,26,G-Genito urinary system and sex hormones,% of total sales,4.5
20982,Latvia,2010,26,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.8
20983,Latvia,2010,26,C10-Lipid modifying agents,"/capita, US$ exchange rate",4.6
20984,Latvia,2010,26,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
20985,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.6
20986,Latvia,2010,26,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.4
20987,Latvia,2010,26,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.0
20988,Latvia,2010,26,C03-Diuretics,"/capita, US$ purchasing power parity",2.1
20989,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.4
20990,Latvia,2010,26,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5
20991,Latvia,2010,26,R-Respiratory system,Million US$ at exchange rate,27.3
20992,Latvia,2010,26,N06A-Antidepressants,Million US$ at exchange rate,3.0
20993,Latvia,2010,26,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.2
20994,Latvia,2010,26,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",73.5
20995,Latvia,2010,26,Total pharmaceutical sales,"Million US$, purchasing power parity",567.2
20996,Latvia,2010,26,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.3
20997,Latvia,2010,26,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.9
20998,Latvia,2010,26,C-Cardiovascular system,"/capita, US$ purchasing power parity",51.2
20999,Latvia,2010,26,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
21000,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.1
21001,Latvia,2010,26,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.2
21002,Latvia,2010,26,Total pharmaceutical sales,"/capita, US$ exchange rate",174.5
21003,Latvia,2010,26,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",22.6
21004,Latvia,2010,26,A02A-Antacids,"/capita, US$ exchange rate",0.2
21005,Latvia,2010,26,N05B-Anxiolytics,Million US$ at exchange rate,2.8
21006,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,13.7
21007,Latvia,2010,26,M-Musculo-skeletal system,Million US$ at exchange rate,24.1
21008,Latvia,2010,26,N02-Analgesics,Million US$ at exchange rate,9.5
21009,Latvia,2010,26,N-Nervous system,Million US$ at exchange rate,43.8
21010,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.6
21011,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.5
21012,Latvia,2010,26,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.2
21013,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.6
21014,Latvia,2010,26,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.1
21015,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.4
21016,Latvia,2010,26,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6
21017,Latvia,2010,26,C07-Beta blocking agents,"/capita, US$ exchange rate",4.1
21018,Latvia,2010,26,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",25.0
21019,Latvia,2010,26,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2
21020,Latvia,2010,26,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.4
21021,Latvia,2010,26,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",17.3
21022,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.5
21023,Latvia,2010,26,N-Nervous system,"/capita, US$ exchange rate",20.9
21024,Latvia,2010,26,N02-Analgesics,"Million US$, purchasing power parity",14.7
21025,Latvia,2010,26,N05B-Anxiolytics,"/capita, US$ exchange rate",1.3
21026,Latvia,2010,26,N02-Analgesics,"/capita, US$ exchange rate",4.5
21027,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",21.2
21028,Latvia,2010,26,M-Musculo-skeletal system,"Million US$, purchasing power parity",37.4
21029,Latvia,2010,26,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.5
21030,Latvia,2010,26,N-Nervous system,"Million US$, purchasing power parity",67.9
21031,Latvia,2010,26,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.3
21032,Latvia,2010,26,Total pharmaceutical sales,"/capita, US$ purchasing power parity",270.4
21033,Latvia,2010,26,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.5
21034,Latvia,2010,26,N06A-Antidepressants,"/capita, US$ exchange rate",1.4
21035,Latvia,2010,26,R-Respiratory system,"/capita, US$ exchange rate",13.0
21036,Latvia,2010,26,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.0
21037,Latvia,2010,26,N05B-Anxiolytics,"Million US$, purchasing power parity",4.3
21038,Latvia,2010,26,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",35.0
21039,Latvia,2010,26,R-Respiratory system,"Million US$, purchasing power parity",42.3
21040,Latvia,2010,26,N06A-Antidepressants,"Million US$, purchasing power parity",4.7
21041,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.8
21042,Latvia,2010,26,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
21043,Latvia,2010,26,C02-Antihypertensives,"Million US$, purchasing power parity",5.3
21044,Latvia,2010,26,C07-Beta blocking agents,"Million US$, purchasing power parity",13.4
21045,Latvia,2010,26,C03-Diuretics,"Million US$, purchasing power parity",4.4
21046,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.7
21047,Latvia,2010,26,A02A-Antacids,"Million US$, purchasing power parity",0.8
21048,Latvia,2010,26,A10-Drugs used in diabetes,"Million US$, purchasing power parity",31.2
21049,Latvia,2010,26,C-Cardiovascular system,"Million US$, purchasing power parity",107.3
21050,Latvia,2010,26,B-Blood and blood forming organs,"Million US$, purchasing power parity",38.5
21051,Latvia,2010,26,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.9
21052,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.7
21053,Latvia,2010,26,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.2
21054,Latvia,2010,26,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",52.5
21055,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",9.4
21056,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",36.9
21057,Latvia,2010,26,C08-Calcium channel blockers,"Million US$, purchasing power parity",8.3
21058,Latvia,2010,26,C10-Lipid modifying agents,"Million US$, purchasing power parity",14.9
21059,Latvia,2010,26,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",25.5
21060,Latvia,2010,26,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",16.2
21061,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.9
21062,Latvia,2010,26,N02-Analgesics,Million of national currency units,7.2
21063,Latvia,2010,26,N-Nervous system,Million of national currency units,33.1
21064,Latvia,2010,26,N05C-Hypnotics and sedatives,Million of national currency units,2.4
21065,Latvia,2010,26,N05B-Anxiolytics,Million of national currency units,2.1
21066,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,10.3
21067,Latvia,2010,26,J-Antiinfectives for systemic use,Million of national currency units,25.6
21068,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.6
21069,Latvia,2010,26,M-Musculo-skeletal system,Million of national currency units,18.2
21070,Latvia,2010,26,J01-Antibacterials for systemic use,Million of national currency units,9.4
21071,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.6
21072,Latvia,2010,26,A02A-Antacids,Million US$ at exchange rate,0.5
21073,Latvia,2010,26,A10-Drugs used in diabetes,Million US$ at exchange rate,20.1
21074,Latvia,2010,26,C-Cardiovascular system,Million US$ at exchange rate,69.2
21075,Latvia,2010,26,B-Blood and blood forming organs,Million US$ at exchange rate,24.8
21076,Latvia,2010,26,R-Respiratory system,Million of national currency units,20.6
21077,Latvia,2010,26,N06A-Antidepressants,Million of national currency units,2.3
21078,Latvia,2010,26,R03-Drugs for obstructive airway diseases,Million of national currency units,8.4
21079,Latvia,2010,26,A-Alimentary tract and metabolism,Million US$ at exchange rate,47.4
21080,Latvia,2010,26,Total pharmaceutical sales,Million US$ at exchange rate,365.9
21081,Latvia,2010,26,C03-Diuretics,"/capita, US$ exchange rate",1.3
21082,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.4
21083,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.3
21084,Latvia,2010,26,C02-Antihypertensives,"/capita, US$ exchange rate",1.6
21085,Latvia,2010,26,A10-Drugs used in diabetes,Million of national currency units,15.2
21086,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.2
21087,Latvia,2010,26,C01A-Cardiac glycosides,Million of national currency units,0.1
21088,Latvia,2010,26,C-Cardiovascular system,Million of national currency units,52.3
21089,Latvia,2010,26,B-Blood and blood forming organs,Million of national currency units,18.7
21090,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,18.0
21091,Latvia,2010,26,C08-Calcium channel blockers,Million of national currency units,4.0
21092,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.7
21093,Latvia,2010,26,G-Genito urinary system and sex hormones,Million of national currency units,12.4
21094,Latvia,2010,26,C10-Lipid modifying agents,Million of national currency units,7.3
21095,Latvia,2010,26,C-Cardiovascular system,"/capita, US$ exchange rate",33.0
21096,Latvia,2010,26,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
21097,Latvia,2010,26,C02-Antihypertensives,Million of national currency units,2.6
21098,Latvia,2010,26,C07-Beta blocking agents,Million of national currency units,6.5
21099,Latvia,2010,26,C03-Diuretics,Million of national currency units,2.1
21100,Latvia,2010,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.7
21101,Latvia,2010,26,C02-Antihypertensives,Million US$ at exchange rate,3.4
21102,Latvia,2010,26,R-Respiratory system,"/capita, US$ purchasing power parity",20.1
21103,Latvia,2010,26,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",8.3
21104,Latvia,2010,26,C07-Beta blocking agents,Million US$ at exchange rate,8.7
21105,Latvia,2010,26,C03-Diuretics,Million US$ at exchange rate,2.8
21106,Latvia,2010,26,A10-Drugs used in diabetes,"/capita, US$ exchange rate",9.6
21107,Latvia,2010,26,N-Nervous system,"/capita, US$ purchasing power parity",32.4
21108,Latvia,2010,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.1
21109,Latvia,2010,26,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.5
21110,Latvia,2010,26,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.8
21111,Latvia,2010,26,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.4
21112,Latvia,2010,26,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.2
21113,Latvia,2010,26,N02-Analgesics,"/capita, US$ purchasing power parity",7.0
21114,Latvia,2010,26,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.0
21115,Latvia,2010,26,J-Antiinfectives for systemic use,Million US$ at exchange rate,33.9
21116,Latvia,2010,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.0
21117,Latvia,2010,26,B-Blood and blood forming organs,"/capita, US$ exchange rate",11.8
21118,Latvia,2010,26,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
21119,Latvia,2010,26,C10-Lipid modifying agents,Million US$ at exchange rate,9.6
21120,Latvia,2010,26,C08-Calcium channel blockers,Million US$ at exchange rate,5.4
21121,Latvia,2010,26,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,23.8
21122,Latvia,2010,26,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.6
21123,Latvia,2010,26,G-Genito urinary system and sex hormones,Million US$ at exchange rate,16.5
21124,Latvia,2016,26,A-Alimentary tract and metabolism,Million of national currency units,49.1
21125,Latvia,2016,26,A02A-Antacids,% of total sales,0.1
21126,Latvia,2016,26,A02A-Antacids,Million of national currency units,0.4
21127,Latvia,2016,26,Total pharmaceutical sales,Million of national currency units,369.2
21128,Latvia,2016,26,C01A-Cardiac glycosides,% of total sales,0.0
21129,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.1
21130,Latvia,2016,26,N05B-Anxiolytics,% of total sales,0.8
21131,Latvia,2016,26,N-Nervous system,% of total sales,9.6
21132,Latvia,2016,26,N06A-Antidepressants,% of total sales,0.7
21133,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
21134,Latvia,2016,26,J01-Antibacterials for systemic use,% of total sales,2.7
21135,Latvia,2016,26,N05C-Hypnotics and sedatives,% of total sales,0.8
21136,Latvia,2016,26,R03-Drugs for obstructive airway diseases,% of total sales,2.5
21137,Latvia,2016,26,B-Blood and blood forming organs,% of total sales,6.7
21138,Latvia,2016,26,A-Alimentary tract and metabolism,% of total sales,13.3
21139,Latvia,2016,26,C10-Lipid modifying agents,% of total sales,1.5
21140,Latvia,2016,26,N02-Analgesics,% of total sales,2.1
21141,Latvia,2016,26,C-Cardiovascular system,% of total sales,14.9
21142,Latvia,2016,26,M-Musculo-skeletal system,% of total sales,6.2
21143,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.4
21144,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6
21145,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
21146,Latvia,2016,26,C07-Beta blocking agents,% of total sales,2.1
21147,Latvia,2016,26,C03-Diuretics,% of total sales,0.6
21148,Latvia,2016,26,A10-Drugs used in diabetes,% of total sales,5.7
21149,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.0
21150,Latvia,2016,26,R-Respiratory system,% of total sales,7.0
21151,Latvia,2016,26,C02-Antihypertensives,% of total sales,1.0
21152,Latvia,2016,26,C08-Calcium channel blockers,% of total sales,0.7
21153,Latvia,2016,26,J-Antiinfectives for systemic use,% of total sales,15.0
21154,Latvia,2016,26,G-Genito urinary system and sex hormones,% of total sales,3.8
21155,Latvia,2016,26,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.0
21156,Latvia,2016,26,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.1
21157,Latvia,2016,26,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",19.1
21158,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.5
21159,Latvia,2016,26,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
21160,Latvia,2016,26,C-Cardiovascular system,"/capita, US$ purchasing power parity",57.9
21161,Latvia,2016,26,C03-Diuretics,"/capita, US$ purchasing power parity",2.4
21162,Latvia,2016,26,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.3
21163,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
21164,Latvia,2016,26,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.7
21165,Latvia,2016,26,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.7
21166,Latvia,2016,26,R-Respiratory system,Million US$ at exchange rate,28.4
21167,Latvia,2016,26,N06A-Antidepressants,Million US$ at exchange rate,2.9
21168,Latvia,2016,26,Total pharmaceutical sales,"Million US$, purchasing power parity",762.0
21169,Latvia,2016,26,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.3
21170,Latvia,2016,26,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.7
21171,Latvia,2016,26,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.2
21172,Latvia,2016,26,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.0
21173,Latvia,2016,26,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
21174,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.4
21175,Latvia,2016,26,A02A-Antacids,"/capita, US$ exchange rate",0.2
21176,Latvia,2016,26,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3
21177,Latvia,2016,26,N05B-Anxiolytics,Million US$ at exchange rate,3.1
21178,Latvia,2016,26,Total pharmaceutical sales,"/capita, US$ exchange rate",208.6
21179,Latvia,2016,26,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",27.7
21180,Latvia,2016,26,M-Musculo-skeletal system,Million US$ at exchange rate,25.3
21181,Latvia,2016,26,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.1
21182,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,16.4
21183,Latvia,2016,26,N02-Analgesics,Million US$ at exchange rate,8.8
21184,Latvia,2016,26,N-Nervous system,Million US$ at exchange rate,39.1
21185,Latvia,2016,26,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.9
21186,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.6
21187,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.8
21188,Latvia,2016,26,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.9
21189,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.4
21190,Latvia,2016,26,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.5
21191,Latvia,2016,26,C07-Beta blocking agents,"/capita, US$ exchange rate",4.5
21192,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.6
21193,Latvia,2016,26,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",58.5
21194,Latvia,2016,26,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.6
21195,Latvia,2016,26,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",101.3
21196,Latvia,2016,26,N-Nervous system,"/capita, US$ exchange rate",19.9
21197,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.4
21198,Latvia,2016,26,R-Respiratory system,"Million US$, purchasing power parity",53.0
21199,Latvia,2016,26,N02-Analgesics,"/capita, US$ exchange rate",4.5
21200,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",30.7
21201,Latvia,2016,26,M-Musculo-skeletal system,"Million US$, purchasing power parity",47.1
21202,Latvia,2016,26,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",20.8
21203,Latvia,2016,26,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.9
21204,Latvia,2016,26,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.7
21205,Latvia,2016,26,N-Nervous system,"Million US$, purchasing power parity",72.8
21206,Latvia,2016,26,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6
21207,Latvia,2016,26,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.2
21208,Latvia,2016,26,N06A-Antidepressants,"/capita, US$ exchange rate",1.5
21209,Latvia,2016,26,R-Respiratory system,"/capita, US$ exchange rate",14.5
21210,Latvia,2016,26,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7
21211,Latvia,2016,26,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",6.2
21212,Latvia,2016,26,N05B-Anxiolytics,"Million US$, purchasing power parity",5.8
21213,Latvia,2016,26,N02-Analgesics,"Million US$, purchasing power parity",16.4
21214,Latvia,2016,26,N06A-Antidepressants,"Million US$, purchasing power parity",5.4
21215,Latvia,2016,26,Total pharmaceutical sales,"/capita, US$ purchasing power parity",388.9
21216,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.6
21217,Latvia,2016,26,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
21218,Latvia,2016,26,C03-Diuretics,"Million US$, purchasing power parity",4.8
21219,Latvia,2016,26,C02-Antihypertensives,"Million US$, purchasing power parity",7.3
21220,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",10.5
21221,Latvia,2016,26,A02A-Antacids,"Million US$, purchasing power parity",0.8
21222,Latvia,2016,26,B-Blood and blood forming organs,"Million US$, purchasing power parity",50.9
21223,Latvia,2016,26,A10-Drugs used in diabetes,"Million US$, purchasing power parity",43.6
21224,Latvia,2016,26,C-Cardiovascular system,"Million US$, purchasing power parity",113.4
21225,Latvia,2016,26,C07-Beta blocking agents,"Million US$, purchasing power parity",16.3
21226,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.9
21227,Latvia,2016,26,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",31.4
21228,Latvia,2016,26,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",114.6
21229,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.5
21230,Latvia,2016,26,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",29.2
21231,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",38.9
21232,Latvia,2016,26,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.3
21233,Latvia,2016,26,C10-Lipid modifying agents,"Million US$, purchasing power parity",11.5
21234,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.4
21235,Latvia,2016,26,N-Nervous system,Million of national currency units,35.3
21236,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,14.9
21237,Latvia,2016,26,N02-Analgesics,Million of national currency units,7.9
21238,Latvia,2016,26,N05C-Hypnotics and sedatives,Million of national currency units,3.0
21239,Latvia,2016,26,N05B-Anxiolytics,Million of national currency units,2.8
21240,Latvia,2016,26,J-Antiinfectives for systemic use,Million of national currency units,55.5
21241,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,6.0
21242,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.3
21243,Latvia,2016,26,M-Musculo-skeletal system,Million of national currency units,22.8
21244,Latvia,2016,26,J01-Antibacterials for systemic use,Million of national currency units,10.1
21245,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.6
21246,Latvia,2016,26,A02A-Antacids,Million US$ at exchange rate,0.5
21247,Latvia,2016,26,B-Blood and blood forming organs,Million US$ at exchange rate,27.3
21248,Latvia,2016,26,A10-Drugs used in diabetes,Million US$ at exchange rate,23.4
21249,Latvia,2016,26,R-Respiratory system,Million of national currency units,25.7
21250,Latvia,2016,26,N06A-Antidepressants,Million of national currency units,2.6
21251,Latvia,2016,26,A-Alimentary tract and metabolism,Million US$ at exchange rate,54.4
21252,Latvia,2016,26,Total pharmaceutical sales,Million US$ at exchange rate,408.7
21253,Latvia,2016,26,R03-Drugs for obstructive airway diseases,Million of national currency units,9.3
21254,Latvia,2016,26,C03-Diuretics,"/capita, US$ exchange rate",1.3
21255,Latvia,2016,26,C01A-Cardiac glycosides,Million of national currency units,0.1
21256,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4
21257,Latvia,2016,26,C02-Antihypertensives,"/capita, US$ exchange rate",2.0
21258,Latvia,2016,26,A10-Drugs used in diabetes,Million of national currency units,21.1
21259,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,5.1
21260,Latvia,2016,26,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
21261,Latvia,2016,26,C-Cardiovascular system,Million of national currency units,54.9
21262,Latvia,2016,26,B-Blood and blood forming organs,Million of national currency units,24.6
21263,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,18.8
21264,Latvia,2016,26,C08-Calcium channel blockers,Million of national currency units,2.6
21265,Latvia,2016,26,G-Genito urinary system and sex hormones,Million of national currency units,14.2
21266,Latvia,2016,26,C10-Lipid modifying agents,Million of national currency units,5.6
21267,Latvia,2016,26,C07-Beta blocking agents,Million of national currency units,7.9
21268,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8
21269,Latvia,2016,26,C-Cardiovascular system,"/capita, US$ exchange rate",31.0
21270,Latvia,2016,26,C03-Diuretics,Million of national currency units,2.3
21271,Latvia,2016,26,C02-Antihypertensives,Million of national currency units,3.6
21272,Latvia,2016,26,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.8
21273,Latvia,2016,26,C02-Antihypertensives,Million US$ at exchange rate,3.9
21274,Latvia,2016,26,R-Respiratory system,"/capita, US$ purchasing power parity",27.0
21275,Latvia,2016,26,C03-Diuretics,Million US$ at exchange rate,2.6
21276,Latvia,2016,26,C07-Beta blocking agents,Million US$ at exchange rate,8.7
21277,Latvia,2016,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.9
21278,Latvia,2016,26,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.9
21279,Latvia,2016,26,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.7
21280,Latvia,2016,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",15.7
21281,Latvia,2016,26,N-Nervous system,"/capita, US$ purchasing power parity",37.2
21282,Latvia,2016,26,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8
21283,Latvia,2016,26,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",24.0
21284,Latvia,2016,26,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.2
21285,Latvia,2016,26,N02-Analgesics,"/capita, US$ purchasing power parity",8.4
21286,Latvia,2016,26,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.9
21287,Latvia,2016,26,J-Antiinfectives for systemic use,Million US$ at exchange rate,61.5
21288,Latvia,2016,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.7
21289,Latvia,2016,26,C-Cardiovascular system,Million US$ at exchange rate,60.8
21290,Latvia,2016,26,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
21291,Latvia,2016,26,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.9
21292,Latvia,2016,26,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,20.8
21293,Latvia,2016,26,C08-Calcium channel blockers,Million US$ at exchange rate,2.9
21294,Latvia,2016,26,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.9
21295,Latvia,2016,26,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.7
21296,Latvia,2016,26,C10-Lipid modifying agents,Million US$ at exchange rate,6.2
21297,Latvia,2015,23,A-Alimentary tract and metabolism,Million of national currency units,45.6
21298,Latvia,2015,23,A02A-Antacids,% of total sales,0.1
21299,Latvia,2015,23,A02A-Antacids,Million of national currency units,0.4
21300,Latvia,2015,23,C01A-Cardiac glycosides,% of total sales,0.0
21301,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.6
21302,Latvia,2015,23,N05B-Anxiolytics,% of total sales,0.8
21303,Latvia,2015,23,Total pharmaceutical sales,Million of national currency units,331.6
21304,Latvia,2015,23,N-Nervous system,% of total sales,10.5
21305,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,% of total sales,1.9
21306,Latvia,2015,23,N06A-Antidepressants,% of total sales,0.8
21307,Latvia,2015,23,J01-Antibacterials for systemic use,% of total sales,3.0
21308,Latvia,2015,23,N05C-Hypnotics and sedatives,% of total sales,0.9
21309,Latvia,2015,23,R03-Drugs for obstructive airway diseases,% of total sales,2.8
21310,Latvia,2015,23,B-Blood and blood forming organs,% of total sales,7.0
21311,Latvia,2015,23,C10-Lipid modifying agents,% of total sales,1.6
21312,Latvia,2015,23,N02-Analgesics,% of total sales,2.3
21313,Latvia,2015,23,C-Cardiovascular system,% of total sales,16.2
21314,Latvia,2015,23,M-Musculo-skeletal system,% of total sales,6.6
21315,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
21316,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
21317,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
21318,Latvia,2015,23,C07-Beta blocking agents,% of total sales,2.3
21319,Latvia,2015,23,C03-Diuretics,% of total sales,0.7
21320,Latvia,2015,23,A10-Drugs used in diabetes,% of total sales,6.0
21321,Latvia,2015,23,R-Respiratory system,% of total sales,7.3
21322,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.2
21323,Latvia,2015,23,C02-Antihypertensives,% of total sales,1.0
21324,Latvia,2015,23,C08-Calcium channel blockers,% of total sales,0.9
21325,Latvia,2015,23,J-Antiinfectives for systemic use,% of total sales,10.6
21326,Latvia,2015,23,G-Genito urinary system and sex hormones,% of total sales,4.3
21327,Latvia,2015,23,A-Alimentary tract and metabolism,% of total sales,13.7
21328,Latvia,2015,23,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",7.9
21329,Latvia,2015,23,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.0
21330,Latvia,2015,23,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
21331,Latvia,2015,23,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",18.4
21332,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.5
21333,Latvia,2015,23,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
21334,Latvia,2015,23,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.9
21335,Latvia,2015,23,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7
21336,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
21337,Latvia,2015,23,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.3
21338,Latvia,2015,23,C-Cardiovascular system,"/capita, US$ purchasing power parity",54.5
21339,Latvia,2015,23,R-Respiratory system,Million US$ at exchange rate,26.9
21340,Latvia,2015,23,N06A-Antidepressants,Million US$ at exchange rate,2.8
21341,Latvia,2015,23,Total pharmaceutical sales,"Million US$, purchasing power parity",666.4
21342,Latvia,2015,23,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.2
21343,Latvia,2015,23,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.1
21344,Latvia,2015,23,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.5
21345,Latvia,2015,23,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
21346,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.0
21347,Latvia,2015,23,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",46.3
21348,Latvia,2015,23,A02A-Antacids,"/capita, US$ exchange rate",0.2
21349,Latvia,2015,23,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.2
21350,Latvia,2015,23,N05B-Anxiolytics,Million US$ at exchange rate,3.0
21351,Latvia,2015,23,Total pharmaceutical sales,"/capita, US$ exchange rate",186.0
21352,Latvia,2015,23,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.6
21353,Latvia,2015,23,M-Musculo-skeletal system,Million US$ at exchange rate,24.1
21354,Latvia,2015,23,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.0
21355,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,15.5
21356,Latvia,2015,23,N02-Analgesics,Million US$ at exchange rate,8.5
21357,Latvia,2015,23,N-Nervous system,Million US$ at exchange rate,38.5
21358,Latvia,2015,23,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.4
21359,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.0
21360,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
21361,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.0
21362,Latvia,2015,23,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.4
21363,Latvia,2015,23,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.6
21364,Latvia,2015,23,C07-Beta blocking agents,"/capita, US$ exchange rate",4.3
21365,Latvia,2015,23,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",91.6
21366,Latvia,2015,23,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.9
21367,Latvia,2015,23,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.1
21368,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.5
21369,Latvia,2015,23,N-Nervous system,"/capita, US$ exchange rate",19.5
21370,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.8
21371,Latvia,2015,23,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
21372,Latvia,2015,23,N02-Analgesics,"/capita, US$ exchange rate",4.3
21373,Latvia,2015,23,R-Respiratory system,"Million US$, purchasing power parity",48.8
21374,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",28.0
21375,Latvia,2015,23,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.9
21376,Latvia,2015,23,M-Musculo-skeletal system,"Million US$, purchasing power parity",43.7
21377,Latvia,2015,23,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.2
21378,Latvia,2015,23,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.6
21379,Latvia,2015,23,N-Nervous system,"Million US$, purchasing power parity",69.8
21380,Latvia,2015,23,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.1
21381,Latvia,2015,23,N06A-Antidepressants,"/capita, US$ exchange rate",1.4
21382,Latvia,2015,23,R-Respiratory system,"/capita, US$ exchange rate",13.6
21383,Latvia,2015,23,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
21384,Latvia,2015,23,Total pharmaceutical sales,"/capita, US$ purchasing power parity",337.0
21385,Latvia,2015,23,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.7
21386,Latvia,2015,23,N02-Analgesics,"Million US$, purchasing power parity",15.4
21387,Latvia,2015,23,N05B-Anxiolytics,"Million US$, purchasing power parity",5.5
21388,Latvia,2015,23,N06A-Antidepressants,"Million US$, purchasing power parity",5.0
21389,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.4
21390,Latvia,2015,23,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
21391,Latvia,2015,23,C03-Diuretics,"Million US$, purchasing power parity",4.4
21392,Latvia,2015,23,C02-Antihypertensives,"Million US$, purchasing power parity",6.6
21393,Latvia,2015,23,C07-Beta blocking agents,"Million US$, purchasing power parity",15.3
21394,Latvia,2015,23,C-Cardiovascular system,"Million US$, purchasing power parity",107.7
21395,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.9
21396,Latvia,2015,23,A02A-Antacids,"Million US$, purchasing power parity",0.8
21397,Latvia,2015,23,B-Blood and blood forming organs,"Million US$, purchasing power parity",46.5
21398,Latvia,2015,23,A10-Drugs used in diabetes,"Million US$, purchasing power parity",39.8
21399,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.5
21400,Latvia,2015,23,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.8
21401,Latvia,2015,23,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",70.9
21402,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",11.8
21403,Latvia,2015,23,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",28.4
21404,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",37.6
21405,Latvia,2015,23,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.8
21406,Latvia,2015,23,C10-Lipid modifying agents,"Million US$, purchasing power parity",10.7
21407,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.3
21408,Latvia,2015,23,N-Nervous system,Million of national currency units,34.7
21409,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,13.9
21410,Latvia,2015,23,N02-Analgesics,Million of national currency units,7.7
21411,Latvia,2015,23,N05C-Hypnotics and sedatives,Million of national currency units,2.8
21412,Latvia,2015,23,N05B-Anxiolytics,Million of national currency units,2.7
21413,Latvia,2015,23,J-Antiinfectives for systemic use,Million of national currency units,35.3
21414,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.9
21415,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.2
21416,Latvia,2015,23,M-Musculo-skeletal system,Million of national currency units,21.7
21417,Latvia,2015,23,J01-Antibacterials for systemic use,Million of national currency units,9.9
21418,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.5
21419,Latvia,2015,23,A02A-Antacids,Million US$ at exchange rate,0.5
21420,Latvia,2015,23,B-Blood and blood forming organs,Million US$ at exchange rate,25.7
21421,Latvia,2015,23,A10-Drugs used in diabetes,Million US$ at exchange rate,22.0
21422,Latvia,2015,23,A-Alimentary tract and metabolism,Million US$ at exchange rate,50.6
21423,Latvia,2015,23,R-Respiratory system,Million of national currency units,24.3
21424,Latvia,2015,23,N06A-Antidepressants,Million of national currency units,2.5
21425,Latvia,2015,23,Total pharmaceutical sales,Million US$ at exchange rate,367.9
21426,Latvia,2015,23,R03-Drugs for obstructive airway diseases,Million of national currency units,9.2
21427,Latvia,2015,23,C03-Diuretics,"/capita, US$ exchange rate",1.2
21428,Latvia,2015,23,C01A-Cardiac glycosides,Million of national currency units,0.1
21429,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4
21430,Latvia,2015,23,C02-Antihypertensives,"/capita, US$ exchange rate",1.8
21431,Latvia,2015,23,A10-Drugs used in diabetes,Million of national currency units,19.8
21432,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.9
21433,Latvia,2015,23,C-Cardiovascular system,Million of national currency units,53.6
21434,Latvia,2015,23,B-Blood and blood forming organs,Million of national currency units,23.1
21435,Latvia,2015,23,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
21436,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,18.7
21437,Latvia,2015,23,C08-Calcium channel blockers,Million of national currency units,2.9
21438,Latvia,2015,23,G-Genito urinary system and sex hormones,Million of national currency units,14.2
21439,Latvia,2015,23,C10-Lipid modifying agents,Million of national currency units,5.3
21440,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.7
21441,Latvia,2015,23,C-Cardiovascular system,"/capita, US$ exchange rate",30.1
21442,Latvia,2015,23,C07-Beta blocking agents,Million of national currency units,7.6
21443,Latvia,2015,23,C03-Diuretics,Million of national currency units,2.2
21444,Latvia,2015,23,C02-Antihypertensives,Million of national currency units,3.3
21445,Latvia,2015,23,C02-Antihypertensives,Million US$ at exchange rate,3.6
21446,Latvia,2015,23,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.3
21447,Latvia,2015,23,R-Respiratory system,"/capita, US$ purchasing power parity",24.7
21448,Latvia,2015,23,C03-Diuretics,Million US$ at exchange rate,2.4
21449,Latvia,2015,23,C07-Beta blocking agents,Million US$ at exchange rate,8.4
21450,Latvia,2015,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.8
21451,Latvia,2015,23,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.1
21452,Latvia,2015,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",14.2
21453,Latvia,2015,23,N-Nervous system,"/capita, US$ purchasing power parity",35.3
21454,Latvia,2015,23,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8
21455,Latvia,2015,23,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.1
21456,Latvia,2015,23,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.9
21457,Latvia,2015,23,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.5
21458,Latvia,2015,23,N02-Analgesics,"/capita, US$ purchasing power parity",7.8
21459,Latvia,2015,23,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.8
21460,Latvia,2015,23,J-Antiinfectives for systemic use,Million US$ at exchange rate,39.1
21461,Latvia,2015,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.5
21462,Latvia,2015,23,C-Cardiovascular system,Million US$ at exchange rate,59.5
21463,Latvia,2015,23,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
21464,Latvia,2015,23,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.0
21465,Latvia,2015,23,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,6.9
21466,Latvia,2015,23,C08-Calcium channel blockers,Million US$ at exchange rate,3.2
21467,Latvia,2015,23,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,20.7
21468,Latvia,2015,23,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.7
21469,Latvia,2015,23,C10-Lipid modifying agents,Million US$ at exchange rate,5.9
21470,Latvia,2014,24,A-Alimentary tract and metabolism,Million of national currency units,42.6
21471,Latvia,2014,24,A02A-Antacids,% of total sales,0.1
21472,Latvia,2014,24,A02A-Antacids,Million of national currency units,0.4
21473,Latvia,2014,24,Total pharmaceutical sales,Million of national currency units,315.9
21474,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.1
21475,Latvia,2014,24,C01A-Cardiac glycosides,% of total sales,0.0
21476,Latvia,2014,24,N05B-Anxiolytics,% of total sales,0.8
21477,Latvia,2014,24,N-Nervous system,% of total sales,10.7
21478,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,% of total sales,2.0
21479,Latvia,2014,24,N06A-Antidepressants,% of total sales,0.7
21480,Latvia,2014,24,J01-Antibacterials for systemic use,% of total sales,3.1
21481,Latvia,2014,24,N05C-Hypnotics and sedatives,% of total sales,0.9
21482,Latvia,2014,24,R03-Drugs for obstructive airway diseases,% of total sales,3.0
21483,Latvia,2014,24,B-Blood and blood forming organs,% of total sales,7.0
21484,Latvia,2014,24,A-Alimentary tract and metabolism,% of total sales,13.5
21485,Latvia,2014,24,C10-Lipid modifying agents,% of total sales,1.8
21486,Latvia,2014,24,N02-Analgesics,% of total sales,2.3
21487,Latvia,2014,24,C-Cardiovascular system,% of total sales,17.2
21488,Latvia,2014,24,M-Musculo-skeletal system,% of total sales,6.6
21489,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
21490,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.8
21491,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
21492,Latvia,2014,24,C07-Beta blocking agents,% of total sales,2.4
21493,Latvia,2014,24,C03-Diuretics,% of total sales,0.7
21494,Latvia,2014,24,A10-Drugs used in diabetes,% of total sales,5.7
21495,Latvia,2014,24,R-Respiratory system,% of total sales,7.6
21496,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.1
21497,Latvia,2014,24,C02-Antihypertensives,% of total sales,1.0
21498,Latvia,2014,24,C08-Calcium channel blockers,% of total sales,1.0
21499,Latvia,2014,24,J-Antiinfectives for systemic use,% of total sales,9.9
21500,Latvia,2014,24,G-Genito urinary system and sex hormones,% of total sales,4.5
21501,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,17.3
21502,Latvia,2014,24,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.5
21503,Latvia,2014,24,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.7
21504,Latvia,2014,24,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
21505,Latvia,2014,24,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",19.2
21506,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.1
21507,Latvia,2014,24,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
21508,Latvia,2014,24,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.6
21509,Latvia,2014,24,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.2
21510,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
21511,Latvia,2014,24,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.2
21512,Latvia,2014,24,R-Respiratory system,Million US$ at exchange rate,31.8
21513,Latvia,2014,24,N06A-Antidepressants,Million US$ at exchange rate,3.0
21514,Latvia,2014,24,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",85.7
21515,Latvia,2014,24,Total pharmaceutical sales,"Million US$, purchasing power parity",634.9
21516,Latvia,2014,24,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,12.7
21517,Latvia,2014,24,C-Cardiovascular system,"/capita, US$ purchasing power parity",54.6
21518,Latvia,2014,24,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.0
21519,Latvia,2014,24,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.2
21520,Latvia,2014,24,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",22.3
21521,Latvia,2014,24,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
21522,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.9
21523,Latvia,2014,24,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.6
21524,Latvia,2014,24,A02A-Antacids,"/capita, US$ exchange rate",0.3
21525,Latvia,2014,24,N05B-Anxiolytics,Million US$ at exchange rate,3.4
21526,Latvia,2014,24,Total pharmaceutical sales,"/capita, US$ exchange rate",210.5
21527,Latvia,2014,24,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.4
21528,Latvia,2014,24,M-Musculo-skeletal system,Million US$ at exchange rate,27.6
21529,Latvia,2014,24,J01-Antibacterials for systemic use,Million US$ at exchange rate,13.0
21530,Latvia,2014,24,N02-Analgesics,Million US$ at exchange rate,9.8
21531,Latvia,2014,24,N-Nervous system,Million US$ at exchange rate,44.8
21532,Latvia,2014,24,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.4
21533,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
21534,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.8
21535,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.3
21536,Latvia,2014,24,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.7
21537,Latvia,2014,24,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.1
21538,Latvia,2014,24,C07-Beta blocking agents,"/capita, US$ exchange rate",5.0
21539,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.7
21540,Latvia,2014,24,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.4
21541,Latvia,2014,24,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.9
21542,Latvia,2014,24,N-Nervous system,"/capita, US$ exchange rate",22.5
21543,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.7
21544,Latvia,2014,24,N05B-Anxiolytics,"/capita, US$ exchange rate",1.7
21545,Latvia,2014,24,N02-Analgesics,"/capita, US$ exchange rate",4.9
21546,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",26.1
21547,Latvia,2014,24,M-Musculo-skeletal system,"Million US$, purchasing power parity",41.8
21548,Latvia,2014,24,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.9
21549,Latvia,2014,24,N-Nervous system,"Million US$, purchasing power parity",67.7
21550,Latvia,2014,24,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.7
21551,Latvia,2014,24,N02-Analgesics,"Million US$, purchasing power parity",14.9
21552,Latvia,2014,24,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",6.4
21553,Latvia,2014,24,N06A-Antidepressants,"/capita, US$ exchange rate",1.5
21554,Latvia,2014,24,R-Respiratory system,"/capita, US$ exchange rate",16.0
21555,Latvia,2014,24,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8
21556,Latvia,2014,24,Total pharmaceutical sales,"/capita, US$ purchasing power parity",318.5
21557,Latvia,2014,24,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.5
21558,Latvia,2014,24,N05B-Anxiolytics,"Million US$, purchasing power parity",5.2
21559,Latvia,2014,24,R-Respiratory system,"Million US$, purchasing power parity",48.2
21560,Latvia,2014,24,N06A-Antidepressants,"Million US$, purchasing power parity",4.6
21561,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.3
21562,Latvia,2014,24,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
21563,Latvia,2014,24,C07-Beta blocking agents,"Million US$, purchasing power parity",15.1
21564,Latvia,2014,24,C03-Diuretics,"Million US$, purchasing power parity",4.4
21565,Latvia,2014,24,C02-Antihypertensives,"Million US$, purchasing power parity",6.3
21566,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.8
21567,Latvia,2014,24,A02A-Antacids,"Million US$, purchasing power parity",0.8
21568,Latvia,2014,24,C-Cardiovascular system,"Million US$, purchasing power parity",108.9
21569,Latvia,2014,24,B-Blood and blood forming organs,"Million US$, purchasing power parity",44.4
21570,Latvia,2014,24,A10-Drugs used in diabetes,"Million US$, purchasing power parity",36.3
21571,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.5
21572,Latvia,2014,24,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.5
21573,Latvia,2014,24,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",20.7
21574,Latvia,2014,24,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",62.6
21575,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",11.5
21576,Latvia,2014,24,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",28.7
21577,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",38.4
21578,Latvia,2014,24,C08-Calcium channel blockers,"Million US$, purchasing power parity",6.4
21579,Latvia,2014,24,C10-Lipid modifying agents,"Million US$, purchasing power parity",11.3
21580,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.8
21581,Latvia,2014,24,N-Nervous system,Million of national currency units,33.7
21582,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,13.0
21583,Latvia,2014,24,N02-Analgesics,Million of national currency units,7.4
21584,Latvia,2014,24,N05C-Hypnotics and sedatives,Million of national currency units,2.7
21585,Latvia,2014,24,N05B-Anxiolytics,Million of national currency units,2.6
21586,Latvia,2014,24,J-Antiinfectives for systemic use,Million of national currency units,31.1
21587,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.7
21588,Latvia,2014,24,M-Musculo-skeletal system,Million of national currency units,20.8
21589,Latvia,2014,24,J01-Antibacterials for systemic use,Million of national currency units,9.8
21590,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,6.4
21591,Latvia,2014,24,A02A-Antacids,Million US$ at exchange rate,0.5
21592,Latvia,2014,24,B-Blood and blood forming organs,Million US$ at exchange rate,29.3
21593,Latvia,2014,24,A10-Drugs used in diabetes,Million US$ at exchange rate,24.0
21594,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.2
21595,Latvia,2014,24,R-Respiratory system,Million of national currency units,24.0
21596,Latvia,2014,24,N06A-Antidepressants,Million of national currency units,2.3
21597,Latvia,2014,24,A-Alimentary tract and metabolism,Million US$ at exchange rate,56.6
21598,Latvia,2014,24,Total pharmaceutical sales,Million US$ at exchange rate,419.7
21599,Latvia,2014,24,R03-Drugs for obstructive airway diseases,Million of national currency units,9.6
21600,Latvia,2014,24,C03-Diuretics,"/capita, US$ exchange rate",1.5
21601,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
21602,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4
21603,Latvia,2014,24,C02-Antihypertensives,"/capita, US$ exchange rate",2.1
21604,Latvia,2014,24,C01A-Cardiac glycosides,Million of national currency units,0.1
21605,Latvia,2014,24,A10-Drugs used in diabetes,Million of national currency units,18.1
21606,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.9
21607,Latvia,2014,24,C-Cardiovascular system,Million of national currency units,54.2
21608,Latvia,2014,24,B-Blood and blood forming organs,Million of national currency units,22.1
21609,Latvia,2014,24,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
21610,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,19.1
21611,Latvia,2014,24,C08-Calcium channel blockers,Million of national currency units,3.2
21612,Latvia,2014,24,G-Genito urinary system and sex hormones,Million of national currency units,14.3
21613,Latvia,2014,24,C10-Lipid modifying agents,Million of national currency units,5.6
21614,Latvia,2014,24,C07-Beta blocking agents,Million of national currency units,7.5
21615,Latvia,2014,24,C-Cardiovascular system,"/capita, US$ exchange rate",36.1
21616,Latvia,2014,24,C03-Diuretics,Million of national currency units,2.2
21617,Latvia,2014,24,C02-Antihypertensives,Million of national currency units,3.1
21618,Latvia,2014,24,C02-Antihypertensives,Million US$ at exchange rate,4.2
21619,Latvia,2014,24,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.2
21620,Latvia,2014,24,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.6
21621,Latvia,2014,24,R-Respiratory system,"/capita, US$ purchasing power parity",24.2
21622,Latvia,2014,24,C03-Diuretics,Million US$ at exchange rate,2.9
21623,Latvia,2014,24,C07-Beta blocking agents,Million US$ at exchange rate,10.0
21624,Latvia,2014,24,A10-Drugs used in diabetes,"/capita, US$ exchange rate",12.0
21625,Latvia,2014,24,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.1
21626,Latvia,2014,24,N-Nervous system,"/capita, US$ purchasing power parity",34.0
21627,Latvia,2014,24,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.9
21628,Latvia,2014,24,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.0
21629,Latvia,2014,24,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.8
21630,Latvia,2014,24,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.3
21631,Latvia,2014,24,N02-Analgesics,"/capita, US$ purchasing power parity",7.4
21632,Latvia,2014,24,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.6
21633,Latvia,2014,24,J-Antiinfectives for systemic use,Million US$ at exchange rate,41.4
21634,Latvia,2014,24,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,7.6
21635,Latvia,2014,24,C-Cardiovascular system,Million US$ at exchange rate,72.0
21636,Latvia,2014,24,B-Blood and blood forming organs,"/capita, US$ exchange rate",14.7
21637,Latvia,2014,24,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
21638,Latvia,2014,24,C08-Calcium channel blockers,Million US$ at exchange rate,4.2
21639,Latvia,2014,24,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,25.4
21640,Latvia,2014,24,G-Genito urinary system and sex hormones,Million US$ at exchange rate,19.0
21641,Latvia,2014,24,C10-Lipid modifying agents,Million US$ at exchange rate,7.5
21642,Latvia,2014,24,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.3
21643,Latvia,2013,27,A-Alimentary tract and metabolism,Million of national currency units,40.5
21644,Latvia,2013,27,A02A-Antacids,% of total sales,0.1
21645,Latvia,2013,27,A02A-Antacids,Million of national currency units,0.4
21646,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3
21647,Latvia,2013,27,C01A-Cardiac glycosides,% of total sales,0.0
21648,Latvia,2013,27,Total pharmaceutical sales,Million of national currency units,307.6
21649,Latvia,2013,27,N05B-Anxiolytics,% of total sales,0.8
21650,Latvia,2013,27,N05C-Hypnotics and sedatives,% of total sales,0.8
21651,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,% of total sales,2.0
21652,Latvia,2013,27,N-Nervous system,% of total sales,10.8
21653,Latvia,2013,27,J01-Antibacterials for systemic use,% of total sales,3.1
21654,Latvia,2013,27,R03-Drugs for obstructive airway diseases,% of total sales,3.0
21655,Latvia,2013,27,B-Blood and blood forming organs,% of total sales,6.7
21656,Latvia,2013,27,C10-Lipid modifying agents,% of total sales,2.2
21657,Latvia,2013,27,N02-Analgesics,% of total sales,2.4
21658,Latvia,2013,27,C-Cardiovascular system,% of total sales,18.0
21659,Latvia,2013,27,M-Musculo-skeletal system,% of total sales,6.5
21660,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
21661,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
21662,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
21663,Latvia,2013,27,N06A-Antidepressants,% of total sales,0.7
21664,Latvia,2013,27,C07-Beta blocking agents,% of total sales,2.4
21665,Latvia,2013,27,C03-Diuretics,% of total sales,0.7
21666,Latvia,2013,27,A10-Drugs used in diabetes,% of total sales,5.6
21667,Latvia,2013,27,R-Respiratory system,% of total sales,7.6
21668,Latvia,2013,27,A-Alimentary tract and metabolism,% of total sales,13.2
21669,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.0
21670,Latvia,2013,27,C02-Antihypertensives,% of total sales,1.0
21671,Latvia,2013,27,C08-Calcium channel blockers,% of total sales,1.1
21672,Latvia,2013,27,J-Antiinfectives for systemic use,% of total sales,10.4
21673,Latvia,2013,27,G-Genito urinary system and sex hormones,% of total sales,4.5
21674,Latvia,2013,27,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",9.1
21675,Latvia,2013,27,C10-Lipid modifying agents,"/capita, US$ exchange rate",4.5
21676,Latvia,2013,27,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
21677,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.0
21678,Latvia,2013,27,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2
21679,Latvia,2013,27,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
21680,Latvia,2013,27,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.4
21681,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
21682,Latvia,2013,27,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.0
21683,Latvia,2013,27,C-Cardiovascular system,"/capita, US$ purchasing power parity",55.0
21684,Latvia,2013,27,R-Respiratory system,Million US$ at exchange rate,30.9
21685,Latvia,2013,27,N06A-Antidepressants,Million US$ at exchange rate,3.0
21686,Latvia,2013,27,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",81.2
21687,Latvia,2013,27,Total pharmaceutical sales,"Million US$, purchasing power parity",616.0
21688,Latvia,2013,27,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,12.4
21689,Latvia,2013,27,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.2
21690,Latvia,2013,27,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.4
21691,Latvia,2013,27,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
21692,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.6
21693,Latvia,2013,27,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.5
21694,Latvia,2013,27,N05B-Anxiolytics,Million US$ at exchange rate,3.2
21695,Latvia,2013,27,A02A-Antacids,"/capita, US$ exchange rate",0.3
21696,Latvia,2013,27,Total pharmaceutical sales,"/capita, US$ exchange rate",202.9
21697,Latvia,2013,27,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",26.7
21698,Latvia,2013,27,M-Musculo-skeletal system,Million US$ at exchange rate,26.7
21699,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,16.4
21700,Latvia,2013,27,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.7
21701,Latvia,2013,27,N02-Analgesics,Million US$ at exchange rate,9.9
21702,Latvia,2013,27,N-Nervous system,Million US$ at exchange rate,44.2
21703,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.1
21704,Latvia,2013,27,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",13.8
21705,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.1
21706,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",19.4
21707,Latvia,2013,27,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.8
21708,Latvia,2013,27,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.3
21709,Latvia,2013,27,C07-Beta blocking agents,"/capita, US$ exchange rate",4.8
21710,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.8
21711,Latvia,2013,27,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.8
21712,Latvia,2013,27,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.5
21713,Latvia,2013,27,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",18.7
21714,Latvia,2013,27,N-Nervous system,"/capita, US$ exchange rate",22.0
21715,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.1
21716,Latvia,2013,27,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6
21717,Latvia,2013,27,N02-Analgesics,"/capita, US$ exchange rate",4.9
21718,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",24.7
21719,Latvia,2013,27,M-Musculo-skeletal system,"Million US$, purchasing power parity",40.2
21720,Latvia,2013,27,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.2
21721,Latvia,2013,27,N-Nervous system,"Million US$, purchasing power parity",66.7
21722,Latvia,2013,27,Total pharmaceutical sales,"/capita, US$ purchasing power parity",306.1
21723,Latvia,2013,27,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",6.2
21724,Latvia,2013,27,N06A-Antidepressants,"/capita, US$ exchange rate",1.5
21725,Latvia,2013,27,R-Respiratory system,"/capita, US$ exchange rate",15.3
21726,Latvia,2013,27,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7
21727,Latvia,2013,27,N02-Analgesics,"Million US$, purchasing power parity",14.9
21728,Latvia,2013,27,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.2
21729,Latvia,2013,27,N05B-Anxiolytics,"Million US$, purchasing power parity",4.9
21730,Latvia,2013,27,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.3
21731,Latvia,2013,27,R-Respiratory system,"Million US$, purchasing power parity",46.6
21732,Latvia,2013,27,N06A-Antidepressants,"Million US$, purchasing power parity",4.5
21733,Latvia,2013,27,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.1
21734,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.2
21735,Latvia,2013,27,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
21736,Latvia,2013,27,C07-Beta blocking agents,"Million US$, purchasing power parity",14.5
21737,Latvia,2013,27,C03-Diuretics,"Million US$, purchasing power parity",4.4
21738,Latvia,2013,27,C02-Antihypertensives,"Million US$, purchasing power parity",6.1
21739,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.3
21740,Latvia,2013,27,A02A-Antacids,"Million US$, purchasing power parity",0.8
21741,Latvia,2013,27,C-Cardiovascular system,"Million US$, purchasing power parity",110.6
21742,Latvia,2013,27,B-Blood and blood forming organs,"Million US$, purchasing power parity",41.1
21743,Latvia,2013,27,A10-Drugs used in diabetes,"Million US$, purchasing power parity",34.5
21744,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.2
21745,Latvia,2013,27,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.3
21746,Latvia,2013,27,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.1
21747,Latvia,2013,27,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",64.0
21748,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.3
21749,Latvia,2013,27,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",27.7
21750,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",39.0
21751,Latvia,2013,27,C08-Calcium channel blockers,"Million US$, purchasing power parity",6.9
21752,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.0
21753,Latvia,2013,27,C10-Lipid modifying agents,"Million US$, purchasing power parity",13.7
21754,Latvia,2013,27,N02-Analgesics,Million of national currency units,7.4
21755,Latvia,2013,27,N-Nervous system,Million of national currency units,33.3
21756,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,12.3
21757,Latvia,2013,27,N05C-Hypnotics and sedatives,Million of national currency units,2.6
21758,Latvia,2013,27,N05B-Anxiolytics,Million of national currency units,2.4
21759,Latvia,2013,27,J-Antiinfectives for systemic use,Million of national currency units,32.0
21760,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,6.1
21761,Latvia,2013,27,M-Musculo-skeletal system,Million of national currency units,20.1
21762,Latvia,2013,27,J01-Antibacterials for systemic use,Million of national currency units,9.5
21763,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,6.2
21764,Latvia,2013,27,A02A-Antacids,Million US$ at exchange rate,0.5
21765,Latvia,2013,27,B-Blood and blood forming organs,Million US$ at exchange rate,27.2
21766,Latvia,2013,27,A10-Drugs used in diabetes,Million US$ at exchange rate,22.9
21767,Latvia,2013,27,R-Respiratory system,Million of national currency units,23.3
21768,Latvia,2013,27,N06A-Antidepressants,Million of national currency units,2.2
21769,Latvia,2013,27,R03-Drugs for obstructive airway diseases,Million of national currency units,9.3
21770,Latvia,2013,27,A-Alimentary tract and metabolism,Million US$ at exchange rate,53.8
21771,Latvia,2013,27,Total pharmaceutical sales,Million US$ at exchange rate,408.3
21772,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.1
21773,Latvia,2013,27,C03-Diuretics,"/capita, US$ exchange rate",1.4
21774,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
21775,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4
21776,Latvia,2013,27,C02-Antihypertensives,"/capita, US$ exchange rate",2.0
21777,Latvia,2013,27,C01A-Cardiac glycosides,Million of national currency units,0.1
21778,Latvia,2013,27,A10-Drugs used in diabetes,Million of national currency units,17.2
21779,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.7
21780,Latvia,2013,27,C-Cardiovascular system,Million of national currency units,55.2
21781,Latvia,2013,27,B-Blood and blood forming organs,Million of national currency units,20.5
21782,Latvia,2013,27,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
21783,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,19.5
21784,Latvia,2013,27,C08-Calcium channel blockers,Million of national currency units,3.4
21785,Latvia,2013,27,G-Genito urinary system and sex hormones,Million of national currency units,13.8
21786,Latvia,2013,27,C10-Lipid modifying agents,Million of national currency units,6.9
21787,Latvia,2013,27,C-Cardiovascular system,"/capita, US$ exchange rate",36.4
21788,Latvia,2013,27,C07-Beta blocking agents,Million of national currency units,7.2
21789,Latvia,2013,27,C03-Diuretics,Million of national currency units,2.2
21790,Latvia,2013,27,C02-Antihypertensives,Million of national currency units,3.0
21791,Latvia,2013,27,C-Cardiovascular system,Million US$ at exchange rate,73.3
21792,Latvia,2013,27,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.1
21793,Latvia,2013,27,C02-Antihypertensives,Million US$ at exchange rate,4.0
21794,Latvia,2013,27,R-Respiratory system,"/capita, US$ purchasing power parity",23.2
21795,Latvia,2013,27,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",9.3
21796,Latvia,2013,27,C03-Diuretics,Million US$ at exchange rate,2.9
21797,Latvia,2013,27,C07-Beta blocking agents,Million US$ at exchange rate,9.6
21798,Latvia,2013,27,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.4
21799,Latvia,2013,27,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.3
21800,Latvia,2013,27,N-Nervous system,"/capita, US$ purchasing power parity",33.1
21801,Latvia,2013,27,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8
21802,Latvia,2013,27,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",20.0
21803,Latvia,2013,27,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.6
21804,Latvia,2013,27,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.2
21805,Latvia,2013,27,N02-Analgesics,"/capita, US$ purchasing power parity",7.4
21806,Latvia,2013,27,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
21807,Latvia,2013,27,J-Antiinfectives for systemic use,Million US$ at exchange rate,42.4
21808,Latvia,2013,27,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,8.1
21809,Latvia,2013,27,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
21810,Latvia,2013,27,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.5
21811,Latvia,2013,27,C08-Calcium channel blockers,Million US$ at exchange rate,4.6
21812,Latvia,2013,27,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,25.8
21813,Latvia,2013,27,G-Genito urinary system and sex hormones,Million US$ at exchange rate,18.4
21814,Latvia,2013,27,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.1
21815,Latvia,2013,27,C10-Lipid modifying agents,Million US$ at exchange rate,9.1
21816,Latvia,2012,23,A-Alimentary tract and metabolism,Million of national currency units,38.9
21817,Latvia,2012,23,A02A-Antacids,Million of national currency units,0.4
21818,Latvia,2012,23,A02A-Antacids,% of total sales,0.1
21819,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.4
21820,Latvia,2012,23,C01A-Cardiac glycosides,% of total sales,0.0
21821,Latvia,2012,23,Total pharmaceutical sales,Million of national currency units,295.4
21822,Latvia,2012,23,N05B-Anxiolytics,% of total sales,0.8
21823,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,% of total sales,2.0
21824,Latvia,2012,23,N-Nervous system,% of total sales,11.3
21825,Latvia,2012,23,N05C-Hypnotics and sedatives,% of total sales,0.8
21826,Latvia,2012,23,J01-Antibacterials for systemic use,% of total sales,3.2
21827,Latvia,2012,23,R03-Drugs for obstructive airway diseases,% of total sales,3.1
21828,Latvia,2012,23,B-Blood and blood forming organs,% of total sales,6.6
21829,Latvia,2012,23,C10-Lipid modifying agents,% of total sales,2.6
21830,Latvia,2012,23,N02-Analgesics,% of total sales,2.5
21831,Latvia,2012,23,C-Cardiovascular system,% of total sales,18.6
21832,Latvia,2012,23,M-Musculo-skeletal system,% of total sales,6.6
21833,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.6
21834,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
21835,Latvia,2012,23,C07-Beta blocking agents,% of total sales,2.4
21836,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
21837,Latvia,2012,23,N06A-Antidepressants,% of total sales,0.8
21838,Latvia,2012,23,R-Respiratory system,% of total sales,7.6
21839,Latvia,2012,23,C03-Diuretics,% of total sales,0.7
21840,Latvia,2012,23,A-Alimentary tract and metabolism,% of total sales,13.2
21841,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9
21842,Latvia,2012,23,A10-Drugs used in diabetes,% of total sales,5.7
21843,Latvia,2012,23,C02-Antihypertensives,% of total sales,1.0
21844,Latvia,2012,23,C08-Calcium channel blockers,% of total sales,1.2
21845,Latvia,2012,23,J-Antiinfectives for systemic use,% of total sales,9.9
21846,Latvia,2012,23,G-Genito urinary system and sex hormones,% of total sales,4.4
21847,Latvia,2012,23,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.3
21848,Latvia,2012,23,C10-Lipid modifying agents,"/capita, US$ exchange rate",4.8
21849,Latvia,2012,23,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
21850,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.7
21851,Latvia,2012,23,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8
21852,Latvia,2012,23,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.6
21853,Latvia,2012,23,C03-Diuretics,"/capita, US$ purchasing power parity",2.1
21854,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.5
21855,Latvia,2012,23,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.9
21856,Latvia,2012,23,R-Respiratory system,Million US$ at exchange rate,28.7
21857,Latvia,2012,23,N06A-Antidepressants,Million US$ at exchange rate,2.9
21858,Latvia,2012,23,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",76.8
21859,Latvia,2012,23,Total pharmaceutical sales,"Million US$, purchasing power parity",583.5
21860,Latvia,2012,23,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.7
21861,Latvia,2012,23,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.2
21862,Latvia,2012,23,C-Cardiovascular system,"/capita, US$ purchasing power parity",53.5
21863,Latvia,2012,23,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.0
21864,Latvia,2012,23,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
21865,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.5
21866,Latvia,2012,23,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.2
21867,Latvia,2012,23,N05B-Anxiolytics,Million US$ at exchange rate,3.0
21868,Latvia,2012,23,A02A-Antacids,"/capita, US$ exchange rate",0.3
21869,Latvia,2012,23,Total pharmaceutical sales,"/capita, US$ exchange rate",186.6
21870,Latvia,2012,23,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",24.6
21871,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,14.8
21872,Latvia,2012,23,M-Musculo-skeletal system,Million US$ at exchange rate,24.9
21873,Latvia,2012,23,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.2
21874,Latvia,2012,23,N02-Analgesics,Million US$ at exchange rate,9.4
21875,Latvia,2012,23,N-Nervous system,Million US$ at exchange rate,43.0
21876,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.7
21877,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",5.3
21878,Latvia,2012,23,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.8
21879,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.5
21880,Latvia,2012,23,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.4
21881,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.0
21882,Latvia,2012,23,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.3
21883,Latvia,2012,23,C07-Beta blocking agents,"/capita, US$ exchange rate",4.4
21884,Latvia,2012,23,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.4
21885,Latvia,2012,23,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2
21886,Latvia,2012,23,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",18.0
21887,Latvia,2012,23,N-Nervous system,"/capita, US$ exchange rate",21.2
21888,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.3
21889,Latvia,2012,23,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
21890,Latvia,2012,23,N02-Analgesics,"/capita, US$ exchange rate",4.6
21891,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",22.8
21892,Latvia,2012,23,M-Musculo-skeletal system,"Million US$, purchasing power parity",38.3
21893,Latvia,2012,23,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.2
21894,Latvia,2012,23,N-Nervous system,"Million US$, purchasing power parity",66.2
21895,Latvia,2012,23,N02-Analgesics,"Million US$, purchasing power parity",14.5
21896,Latvia,2012,23,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.7
21897,Latvia,2012,23,Total pharmaceutical sales,"/capita, US$ purchasing power parity",286.8
21898,Latvia,2012,23,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
21899,Latvia,2012,23,N06A-Antidepressants,"/capita, US$ exchange rate",1.4
21900,Latvia,2012,23,R-Respiratory system,"/capita, US$ exchange rate",14.1
21901,Latvia,2012,23,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.9
21902,Latvia,2012,23,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7
21903,Latvia,2012,23,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",37.7
21904,Latvia,2012,23,R-Respiratory system,"Million US$, purchasing power parity",44.1
21905,Latvia,2012,23,N06A-Antidepressants,"Million US$, purchasing power parity",4.5
21906,Latvia,2012,23,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.8
21907,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.0
21908,Latvia,2012,23,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
21909,Latvia,2012,23,C07-Beta blocking agents,"Million US$, purchasing power parity",13.9
21910,Latvia,2012,23,C03-Diuretics,"Million US$, purchasing power parity",4.3
21911,Latvia,2012,23,C02-Antihypertensives,"Million US$, purchasing power parity",5.8
21912,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.1
21913,Latvia,2012,23,A02A-Antacids,"Million US$, purchasing power parity",0.8
21914,Latvia,2012,23,C-Cardiovascular system,"Million US$, purchasing power parity",108.8
21915,Latvia,2012,23,B-Blood and blood forming organs,"Million US$, purchasing power parity",38.6
21916,Latvia,2012,23,A10-Drugs used in diabetes,"Million US$, purchasing power parity",33.0
21917,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.6
21918,Latvia,2012,23,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.0
21919,Latvia,2012,23,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",57.8
21920,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",10.8
21921,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",37.6
21922,Latvia,2012,23,C08-Calcium channel blockers,"Million US$, purchasing power parity",7.3
21923,Latvia,2012,23,C10-Lipid modifying agents,"Million US$, purchasing power parity",15.0
21924,Latvia,2012,23,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",25.9
21925,Latvia,2012,23,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.5
21926,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.5
21927,Latvia,2012,23,N02-Analgesics,Million of national currency units,7.3
21928,Latvia,2012,23,N-Nervous system,Million of national currency units,33.5
21929,Latvia,2012,23,N05C-Hypnotics and sedatives,Million of national currency units,2.5
21930,Latvia,2012,23,N05B-Anxiolytics,Million of national currency units,2.4
21931,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,11.6
21932,Latvia,2012,23,J-Antiinfectives for systemic use,Million of national currency units,29.3
21933,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.5
21934,Latvia,2012,23,M-Musculo-skeletal system,Million of national currency units,19.4
21935,Latvia,2012,23,J01-Antibacterials for systemic use,Million of national currency units,9.5
21936,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.9
21937,Latvia,2012,23,A02A-Antacids,Million US$ at exchange rate,0.5
21938,Latvia,2012,23,B-Blood and blood forming organs,Million US$ at exchange rate,25.1
21939,Latvia,2012,23,A10-Drugs used in diabetes,Million US$ at exchange rate,21.5
21940,Latvia,2012,23,R-Respiratory system,Million of national currency units,22.3
21941,Latvia,2012,23,N06A-Antidepressants,Million of national currency units,2.3
21942,Latvia,2012,23,A-Alimentary tract and metabolism,Million US$ at exchange rate,49.9
21943,Latvia,2012,23,Total pharmaceutical sales,Million US$ at exchange rate,379.6
21944,Latvia,2012,23,R03-Drugs for obstructive airway diseases,Million of national currency units,9.1
21945,Latvia,2012,23,C-Cardiovascular system,Million US$ at exchange rate,70.8
21946,Latvia,2012,23,C03-Diuretics,"/capita, US$ exchange rate",1.4
21947,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.5
21948,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.3
21949,Latvia,2012,23,C02-Antihypertensives,"/capita, US$ exchange rate",1.9
21950,Latvia,2012,23,C01A-Cardiac glycosides,Million of national currency units,0.1
21951,Latvia,2012,23,A10-Drugs used in diabetes,Million of national currency units,16.7
21952,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.6
21953,Latvia,2012,23,C-Cardiovascular system,Million of national currency units,55.1
21954,Latvia,2012,23,B-Blood and blood forming organs,Million of national currency units,19.5
21955,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,19.0
21956,Latvia,2012,23,C08-Calcium channel blockers,Million of national currency units,3.7
21957,Latvia,2012,23,G-Genito urinary system and sex hormones,Million of national currency units,13.1
21958,Latvia,2012,23,C10-Lipid modifying agents,Million of national currency units,7.6
21959,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.9
21960,Latvia,2012,23,C-Cardiovascular system,"/capita, US$ exchange rate",34.8
21961,Latvia,2012,23,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
21962,Latvia,2012,23,C02-Antihypertensives,Million of national currency units,3.0
21963,Latvia,2012,23,C07-Beta blocking agents,Million of national currency units,7.0
21964,Latvia,2012,23,C03-Diuretics,Million of national currency units,2.2
21965,Latvia,2012,23,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.9
21966,Latvia,2012,23,C02-Antihypertensives,Million US$ at exchange rate,3.8
21967,Latvia,2012,23,R-Respiratory system,"/capita, US$ purchasing power parity",21.7
21968,Latvia,2012,23,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",8.8
21969,Latvia,2012,23,C03-Diuretics,Million US$ at exchange rate,2.8
21970,Latvia,2012,23,C07-Beta blocking agents,Million US$ at exchange rate,9.0
21971,Latvia,2012,23,A10-Drugs used in diabetes,"/capita, US$ exchange rate",10.6
21972,Latvia,2012,23,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.2
21973,Latvia,2012,23,N-Nervous system,"/capita, US$ purchasing power parity",32.5
21974,Latvia,2012,23,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.7
21975,Latvia,2012,23,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",18.8
21976,Latvia,2012,23,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.4
21977,Latvia,2012,23,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.2
21978,Latvia,2012,23,N02-Analgesics,"/capita, US$ purchasing power parity",7.1
21979,Latvia,2012,23,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
21980,Latvia,2012,23,J-Antiinfectives for systemic use,Million US$ at exchange rate,37.6
21981,Latvia,2012,23,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,7.0
21982,Latvia,2012,23,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
21983,Latvia,2012,23,B-Blood and blood forming organs,"/capita, US$ exchange rate",12.3
21984,Latvia,2012,23,C10-Lipid modifying agents,Million US$ at exchange rate,9.8
21985,Latvia,2012,23,C08-Calcium channel blockers,Million US$ at exchange rate,4.7
21986,Latvia,2012,23,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,24.5
21987,Latvia,2012,23,G-Genito urinary system and sex hormones,Million US$ at exchange rate,16.9
21988,Latvia,2012,23,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.5
21989,Latvia,2011,26,A-Alimentary tract and metabolism,Million of national currency units,38.1
21990,Latvia,2011,26,A02A-Antacids,Million of national currency units,0.4
21991,Latvia,2011,26,C01A-Cardiac glycosides,% of total sales,0.0
21992,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.3
21993,Latvia,2011,26,Total pharmaceutical sales,Million of national currency units,289.9
21994,Latvia,2011,26,N05B-Anxiolytics,% of total sales,0.8
21995,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,% of total sales,2.0
21996,Latvia,2011,26,N-Nervous system,% of total sales,11.6
21997,Latvia,2011,26,A02A-Antacids,% of total sales,0.1
21998,Latvia,2011,26,J01-Antibacterials for systemic use,% of total sales,3.3
21999,Latvia,2011,26,R03-Drugs for obstructive airway diseases,% of total sales,3.1
22000,Latvia,2011,26,B-Blood and blood forming organs,% of total sales,6.5
22001,Latvia,2011,26,J-Antiinfectives for systemic use,% of total sales,9.2
22002,Latvia,2011,26,N02-Analgesics,% of total sales,2.6
22003,Latvia,2011,26,N05C-Hypnotics and sedatives,% of total sales,0.9
22004,Latvia,2011,26,C10-Lipid modifying agents,% of total sales,2.7
22005,Latvia,2011,26,C-Cardiovascular system,% of total sales,18.6
22006,Latvia,2011,26,M-Musculo-skeletal system,% of total sales,6.6
22007,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
22008,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.7
22009,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
22010,Latvia,2011,26,C07-Beta blocking agents,% of total sales,2.4
22011,Latvia,2011,26,N06A-Antidepressants,% of total sales,0.8
22012,Latvia,2011,26,R-Respiratory system,% of total sales,7.4
22013,Latvia,2011,26,C03-Diuretics,% of total sales,0.7
22014,Latvia,2011,26,A-Alimentary tract and metabolism,% of total sales,13.1
22015,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9
22016,Latvia,2011,26,A10-Drugs used in diabetes,% of total sales,5.8
22017,Latvia,2011,26,C02-Antihypertensives,% of total sales,1.0
22018,Latvia,2011,26,C08-Calcium channel blockers,% of total sales,1.3
22019,Latvia,2011,26,G-Genito urinary system and sex hormones,% of total sales,4.5
22020,Latvia,2011,26,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.8
22021,Latvia,2011,26,C10-Lipid modifying agents,"/capita, US$ exchange rate",5.2
22022,Latvia,2011,26,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
22023,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.0
22024,Latvia,2011,26,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.7
22025,Latvia,2011,26,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8
22026,Latvia,2011,26,C03-Diuretics,"/capita, US$ purchasing power parity",2.1
22027,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.4
22028,Latvia,2011,26,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.8
22029,Latvia,2011,26,R-Respiratory system,Million US$ at exchange rate,30.0
22030,Latvia,2011,26,N06A-Antidepressants,Million US$ at exchange rate,3.2
22031,Latvia,2011,26,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,12.5
22032,Latvia,2011,26,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",76.4
22033,Latvia,2011,26,Total pharmaceutical sales,"Million US$, purchasing power parity",581.5
22034,Latvia,2011,26,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.4
22035,Latvia,2011,26,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.5
22036,Latvia,2011,26,C-Cardiovascular system,"/capita, US$ purchasing power parity",52.5
22037,Latvia,2011,26,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
22038,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",4.3
22039,Latvia,2011,26,N05B-Anxiolytics,Million US$ at exchange rate,3.1
22040,Latvia,2011,26,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.5
22041,Latvia,2011,26,A02A-Antacids,"/capita, US$ exchange rate",0.3
22042,Latvia,2011,26,Total pharmaceutical sales,"/capita, US$ exchange rate",197.3
22043,Latvia,2011,26,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",25.9
22044,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,15.8
22045,Latvia,2011,26,J01-Antibacterials for systemic use,Million US$ at exchange rate,13.4
22046,Latvia,2011,26,M-Musculo-skeletal system,Million US$ at exchange rate,26.8
22047,Latvia,2011,26,N02-Analgesics,Million US$ at exchange rate,10.4
22048,Latvia,2011,26,N-Nervous system,Million US$ at exchange rate,47.0
22049,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.7
22050,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.9
22051,Latvia,2011,26,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",12.7
22052,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.9
22053,Latvia,2011,26,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.5
22054,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",12.5
22055,Latvia,2011,26,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6
22056,Latvia,2011,26,C07-Beta blocking agents,"/capita, US$ exchange rate",4.7
22057,Latvia,2011,26,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",26.1
22058,Latvia,2011,26,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.3
22059,Latvia,2011,26,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",17.9
22060,Latvia,2011,26,N-Nervous system,"/capita, US$ exchange rate",22.8
22061,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.7
22062,Latvia,2011,26,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
22063,Latvia,2011,26,N02-Analgesics,"/capita, US$ exchange rate",5.0
22064,Latvia,2011,26,N02-Analgesics,"Million US$, purchasing power parity",14.8
22065,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",22.5
22066,Latvia,2011,26,M-Musculo-skeletal system,"Million US$, purchasing power parity",38.3
22067,Latvia,2011,26,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.0
22068,Latvia,2011,26,N-Nervous system,"Million US$, purchasing power parity",67.3
22069,Latvia,2011,26,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",6.1
22070,Latvia,2011,26,Total pharmaceutical sales,"/capita, US$ purchasing power parity",282.3
22071,Latvia,2011,26,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.7
22072,Latvia,2011,26,N06A-Antidepressants,"/capita, US$ exchange rate",1.6
22073,Latvia,2011,26,R-Respiratory system,"/capita, US$ exchange rate",14.6
22074,Latvia,2011,26,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",5.0
22075,Latvia,2011,26,N05B-Anxiolytics,"Million US$, purchasing power parity",4.5
22076,Latvia,2011,26,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",37.1
22077,Latvia,2011,26,R-Respiratory system,"Million US$, purchasing power parity",43.0
22078,Latvia,2011,26,N06A-Antidepressants,"Million US$, purchasing power parity",4.6
22079,Latvia,2011,26,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.2
22080,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.9
22081,Latvia,2011,26,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
22082,Latvia,2011,26,C02-Antihypertensives,"Million US$, purchasing power parity",5.7
22083,Latvia,2011,26,C07-Beta blocking agents,"Million US$, purchasing power parity",13.9
22084,Latvia,2011,26,C03-Diuretics,"Million US$, purchasing power parity",4.2
22085,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.8
22086,Latvia,2011,26,A02A-Antacids,"Million US$, purchasing power parity",0.8
22087,Latvia,2011,26,A10-Drugs used in diabetes,"Million US$, purchasing power parity",33.7
22088,Latvia,2011,26,C-Cardiovascular system,"Million US$, purchasing power parity",108.2
22089,Latvia,2011,26,B-Blood and blood forming organs,"Million US$, purchasing power parity",38.0
22090,Latvia,2011,26,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.5
22091,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",11.8
22092,Latvia,2011,26,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",53.7
22093,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",10.0
22094,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",36.8
22095,Latvia,2011,26,C08-Calcium channel blockers,"Million US$, purchasing power parity",7.7
22096,Latvia,2011,26,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",26.1
22097,Latvia,2011,26,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.2
22098,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.4
22099,Latvia,2011,26,C10-Lipid modifying agents,"Million US$, purchasing power parity",15.4
22100,Latvia,2011,26,N02-Analgesics,Million of national currency units,7.4
22101,Latvia,2011,26,N-Nervous system,Million of national currency units,33.5
22102,Latvia,2011,26,N05C-Hypnotics and sedatives,Million of national currency units,2.5
22103,Latvia,2011,26,N05B-Anxiolytics,Million of national currency units,2.2
22104,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,11.2
22105,Latvia,2011,26,J-Antiinfectives for systemic use,Million of national currency units,26.8
22106,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.0
22107,Latvia,2011,26,M-Musculo-skeletal system,Million of national currency units,19.1
22108,Latvia,2011,26,J01-Antibacterials for systemic use,Million of national currency units,9.6
22109,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,6.2
22110,Latvia,2011,26,A02A-Antacids,Million US$ at exchange rate,0.5
22111,Latvia,2011,26,C-Cardiovascular system,Million US$ at exchange rate,75.6
22112,Latvia,2011,26,B-Blood and blood forming organs,Million US$ at exchange rate,26.6
22113,Latvia,2011,26,A10-Drugs used in diabetes,Million US$ at exchange rate,23.5
22114,Latvia,2011,26,R-Respiratory system,Million of national currency units,21.4
22115,Latvia,2011,26,N06A-Antidepressants,Million of national currency units,2.3
22116,Latvia,2011,26,R03-Drugs for obstructive airway diseases,Million of national currency units,8.9
22117,Latvia,2011,26,A-Alimentary tract and metabolism,Million US$ at exchange rate,53.4
22118,Latvia,2011,26,Total pharmaceutical sales,Million US$ at exchange rate,406.4
22119,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,Million of national currency units,5.9
22120,Latvia,2011,26,C03-Diuretics,"/capita, US$ exchange rate",1.4
22121,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.5
22122,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.3
22123,Latvia,2011,26,C02-Antihypertensives,"/capita, US$ exchange rate",1.9
22124,Latvia,2011,26,C01A-Cardiac glycosides,Million of national currency units,0.1
22125,Latvia,2011,26,A10-Drugs used in diabetes,Million of national currency units,16.8
22126,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,4.4
22127,Latvia,2011,26,C-Cardiovascular system,Million of national currency units,53.9
22128,Latvia,2011,26,B-Blood and blood forming organs,Million of national currency units,18.9
22129,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,18.4
22130,Latvia,2011,26,C08-Calcium channel blockers,Million of national currency units,3.9
22131,Latvia,2011,26,G-Genito urinary system and sex hormones,Million of national currency units,13.0
22132,Latvia,2011,26,C10-Lipid modifying agents,Million of national currency units,7.7
22133,Latvia,2011,26,C-Cardiovascular system,"/capita, US$ exchange rate",36.7
22134,Latvia,2011,26,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
22135,Latvia,2011,26,C07-Beta blocking agents,Million of national currency units,6.9
22136,Latvia,2011,26,C03-Diuretics,Million of national currency units,2.1
22137,Latvia,2011,26,C02-Antihypertensives,Million of national currency units,2.9
22138,Latvia,2011,26,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.0
22139,Latvia,2011,26,C02-Antihypertensives,Million US$ at exchange rate,4.0
22140,Latvia,2011,26,R-Respiratory system,"/capita, US$ purchasing power parity",20.9
22141,Latvia,2011,26,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",8.7
22142,Latvia,2011,26,C03-Diuretics,Million US$ at exchange rate,3.0
22143,Latvia,2011,26,C07-Beta blocking agents,Million US$ at exchange rate,9.7
22144,Latvia,2011,26,A10-Drugs used in diabetes,"/capita, US$ exchange rate",11.4
22145,Latvia,2011,26,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.9
22146,Latvia,2011,26,N-Nervous system,"/capita, US$ purchasing power parity",32.7
22147,Latvia,2011,26,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
22148,Latvia,2011,26,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",18.6
22149,Latvia,2011,26,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.4
22150,Latvia,2011,26,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.2
22151,Latvia,2011,26,N02-Analgesics,"/capita, US$ purchasing power parity",7.2
22152,Latvia,2011,26,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
22153,Latvia,2011,26,J-Antiinfectives for systemic use,Million US$ at exchange rate,37.5
22154,Latvia,2011,26,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,7.0
22155,Latvia,2011,26,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
22156,Latvia,2011,26,B-Blood and blood forming organs,"/capita, US$ exchange rate",12.9
22157,Latvia,2011,26,C10-Lipid modifying agents,Million US$ at exchange rate,10.8
22158,Latvia,2011,26,C08-Calcium channel blockers,Million US$ at exchange rate,5.4
22159,Latvia,2011,26,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,25.7
22160,Latvia,2011,26,G-Genito urinary system and sex hormones,Million US$ at exchange rate,18.2
22161,Latvia,2011,26,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.2
22162,Latvia,2017,19,A-Alimentary tract and metabolism,Million of national currency units,50.4
22163,Latvia,2017,19,A02A-Antacids,Million of national currency units,0.4
22164,Latvia,2017,19,Total pharmaceutical sales,Million of national currency units,392.8
22165,Latvia,2017,19,C01A-Cardiac glycosides,% of total sales,0.0
22166,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.0
22167,Latvia,2017,19,N05B-Anxiolytics,% of total sales,0.7
22168,Latvia,2017,19,N-Nervous system,% of total sales,9.5
22169,Latvia,2017,19,A-Alimentary tract and metabolism,% of total sales,12.8
22170,Latvia,2017,19,N06A-Antidepressants,% of total sales,0.7
22171,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
22172,Latvia,2017,19,R03-Drugs for obstructive airway diseases,% of total sales,2.5
22173,Latvia,2017,19,J01-Antibacterials for systemic use,% of total sales,2.7
22174,Latvia,2017,19,N05C-Hypnotics and sedatives,% of total sales,0.8
22175,Latvia,2017,19,B-Blood and blood forming organs,% of total sales,7.2
22176,Latvia,2017,19,C10-Lipid modifying agents,% of total sales,1.6
22177,Latvia,2017,19,N02-Analgesics,% of total sales,2.1
22178,Latvia,2017,19,A02A-Antacids,% of total sales,0.1
22179,Latvia,2017,19,M-Musculo-skeletal system,% of total sales,6.3
22180,Latvia,2017,19,C-Cardiovascular system,% of total sales,14.5
22181,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3
22182,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.6
22183,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
22184,Latvia,2017,19,C07-Beta blocking agents,% of total sales,2.0
22185,Latvia,2017,19,C03-Diuretics,% of total sales,0.6
22186,Latvia,2017,19,A10-Drugs used in diabetes,% of total sales,5.7
22187,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9
22188,Latvia,2017,19,R-Respiratory system,% of total sales,7.1
22189,Latvia,2017,19,C02-Antihypertensives,% of total sales,1.0
22190,Latvia,2017,19,C08-Calcium channel blockers,% of total sales,0.6
22191,Latvia,2017,19,J-Antiinfectives for systemic use,% of total sales,15.4
22192,Latvia,2017,19,G-Genito urinary system and sex hormones,% of total sales,3.8
22193,Latvia,2017,19,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.7
22194,Latvia,2017,19,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.6
22195,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.5
22196,Latvia,2017,19,C-Cardiovascular system,"/capita, US$ purchasing power parity",60.3
22197,Latvia,2017,19,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",20.1
22198,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.8
22199,Latvia,2017,19,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
22200,Latvia,2017,19,C03-Diuretics,"/capita, US$ purchasing power parity",2.6
22201,Latvia,2017,19,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.3
22202,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
22203,Latvia,2017,19,C02-Antihypertensives,"/capita, US$ purchasing power parity",4.0
22204,Latvia,2017,19,R-Respiratory system,Million US$ at exchange rate,31.3
22205,Latvia,2017,19,N06A-Antidepressants,Million US$ at exchange rate,3.2
22206,Latvia,2017,19,Total pharmaceutical sales,"Million US$, purchasing power parity",810.6
22207,Latvia,2017,19,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.0
22208,Latvia,2017,19,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.8
22209,Latvia,2017,19,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",30.1
22210,Latvia,2017,19,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.6
22211,Latvia,2017,19,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
22212,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.5
22213,Latvia,2017,19,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.5
22214,Latvia,2017,19,A02A-Antacids,"/capita, US$ exchange rate",0.3
22215,Latvia,2017,19,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.5
22216,Latvia,2017,19,N05B-Anxiolytics,Million US$ at exchange rate,3.3
22217,Latvia,2017,19,Total pharmaceutical sales,"/capita, US$ exchange rate",228.5
22218,Latvia,2017,19,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",29.3
22219,Latvia,2017,19,M-Musculo-skeletal system,Million US$ at exchange rate,27.7
22220,Latvia,2017,19,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.0
22221,Latvia,2017,19,N02-Analgesics,Million US$ at exchange rate,9.4
22222,Latvia,2017,19,N-Nervous system,Million US$ at exchange rate,42.2
22223,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,17.4
22224,Latvia,2017,19,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.9
22225,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.9
22226,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",21.1
22227,Latvia,2017,19,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.6
22228,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.5
22229,Latvia,2017,19,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.4
22230,Latvia,2017,19,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6
22231,Latvia,2017,19,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",64.3
22232,Latvia,2017,19,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.3
22233,Latvia,2017,19,N-Nervous system,"/capita, US$ exchange rate",21.7
22234,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.0
22235,Latvia,2017,19,R-Respiratory system,"Million US$, purchasing power parity",57.2
22236,Latvia,2017,19,N02-Analgesics,"/capita, US$ exchange rate",4.9
22237,Latvia,2017,19,M-Musculo-skeletal system,"Million US$, purchasing power parity",50.7
22238,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",31.8
22239,Latvia,2017,19,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",21.9
22240,Latvia,2017,19,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.3
22241,Latvia,2017,19,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.2
22242,Latvia,2017,19,N-Nervous system,"Million US$, purchasing power parity",77.1
22243,Latvia,2017,19,N05B-Anxiolytics,"/capita, US$ exchange rate",1.7
22244,Latvia,2017,19,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",5.7
22245,Latvia,2017,19,N06A-Antidepressants,"/capita, US$ exchange rate",1.7
22246,Latvia,2017,19,R-Respiratory system,"/capita, US$ exchange rate",16.1
22247,Latvia,2017,19,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8
22248,Latvia,2017,19,Total pharmaceutical sales,"/capita, US$ purchasing power parity",417.4
22249,Latvia,2017,19,N05B-Anxiolytics,"Million US$, purchasing power parity",6.0
22250,Latvia,2017,19,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",6.4
22251,Latvia,2017,19,N02-Analgesics,"Million US$, purchasing power parity",17.2
22252,Latvia,2017,19,N06A-Antidepressants,"Million US$, purchasing power parity",5.9
22253,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7
22254,Latvia,2017,19,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
22255,Latvia,2017,19,C03-Diuretics,"Million US$, purchasing power parity",5.1
22256,Latvia,2017,19,C02-Antihypertensives,"Million US$, purchasing power parity",7.7
22257,Latvia,2017,19,C-Cardiovascular system,"Million US$, purchasing power parity",117.2
22258,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",10.7
22259,Latvia,2017,19,A02A-Antacids,"Million US$, purchasing power parity",0.9
22260,Latvia,2017,19,B-Blood and blood forming organs,"Million US$, purchasing power parity",58.4
22261,Latvia,2017,19,A10-Drugs used in diabetes,"Million US$, purchasing power parity",46.1
22262,Latvia,2017,19,C07-Beta blocking agents,"Million US$, purchasing power parity",16.2
22263,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",13.5
22264,Latvia,2017,19,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",35.2
22265,Latvia,2017,19,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",30.8
22266,Latvia,2017,19,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",124.9
22267,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.6
22268,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",40.9
22269,Latvia,2017,19,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.0
22270,Latvia,2017,19,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",104.0
22271,Latvia,2017,19,C10-Lipid modifying agents,"Million US$, purchasing power parity",12.9
22272,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.5
22273,Latvia,2017,19,N-Nervous system,Million of national currency units,37.4
22274,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,15.4
22275,Latvia,2017,19,N05C-Hypnotics and sedatives,Million of national currency units,3.1
22276,Latvia,2017,19,N05B-Anxiolytics,Million of national currency units,2.9
22277,Latvia,2017,19,N02-Analgesics,Million of national currency units,8.3
22278,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,6.1
22279,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,Million of national currency units,6.5
22280,Latvia,2017,19,J-Antiinfectives for systemic use,Million of national currency units,60.5
22281,Latvia,2017,19,M-Musculo-skeletal system,Million of national currency units,24.6
22282,Latvia,2017,19,J01-Antibacterials for systemic use,Million of national currency units,10.6
22283,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.9
22284,Latvia,2017,19,A02A-Antacids,Million US$ at exchange rate,0.5
22285,Latvia,2017,19,B-Blood and blood forming organs,Million US$ at exchange rate,32.0
22286,Latvia,2017,19,A10-Drugs used in diabetes,Million US$ at exchange rate,25.3
22287,Latvia,2017,19,A-Alimentary tract and metabolism,Million US$ at exchange rate,57.0
22288,Latvia,2017,19,R-Respiratory system,Million of national currency units,27.7
22289,Latvia,2017,19,N06A-Antidepressants,Million of national currency units,2.8
22290,Latvia,2017,19,Total pharmaceutical sales,Million US$ at exchange rate,443.7
22291,Latvia,2017,19,R03-Drugs for obstructive airway diseases,Million of national currency units,9.8
22292,Latvia,2017,19,C03-Diuretics,"/capita, US$ exchange rate",1.4
22293,Latvia,2017,19,C01A-Cardiac glycosides,Million of national currency units,0.1
22294,Latvia,2017,19,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
22295,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
22296,Latvia,2017,19,C02-Antihypertensives,"/capita, US$ exchange rate",2.2
22297,Latvia,2017,19,A10-Drugs used in diabetes,Million of national currency units,22.4
22298,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,5.2
22299,Latvia,2017,19,C-Cardiovascular system,Million of national currency units,56.8
22300,Latvia,2017,19,B-Blood and blood forming organs,Million of national currency units,28.3
22301,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,19.8
22302,Latvia,2017,19,C08-Calcium channel blockers,Million of national currency units,2.4
22303,Latvia,2017,19,C07-Beta blocking agents,Million of national currency units,7.9
22304,Latvia,2017,19,G-Genito urinary system and sex hormones,Million of national currency units,14.9
22305,Latvia,2017,19,C10-Lipid modifying agents,Million of national currency units,6.2
22306,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.8
22307,Latvia,2017,19,C-Cardiovascular system,"/capita, US$ exchange rate",33.0
22308,Latvia,2017,19,C03-Diuretics,Million of national currency units,2.5
22309,Latvia,2017,19,C02-Antihypertensives,Million of national currency units,3.8
22310,Latvia,2017,19,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",10.4
22311,Latvia,2017,19,R-Respiratory system,"/capita, US$ purchasing power parity",29.4
22312,Latvia,2017,19,C02-Antihypertensives,Million US$ at exchange rate,4.2
22313,Latvia,2017,19,C03-Diuretics,Million US$ at exchange rate,2.8
22314,Latvia,2017,19,C07-Beta blocking agents,Million US$ at exchange rate,8.9
22315,Latvia,2017,19,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",3.0
22316,Latvia,2017,19,A10-Drugs used in diabetes,"/capita, US$ exchange rate",13.0
22317,Latvia,2017,19,N06A-Antidepressants,"/capita, US$ purchasing power parity",3.0
22318,Latvia,2017,19,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.4
22319,Latvia,2017,19,N-Nervous system,"/capita, US$ purchasing power parity",39.7
22320,Latvia,2017,19,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.9
22321,Latvia,2017,19,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",26.1
22322,Latvia,2017,19,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.3
22323,Latvia,2017,19,N02-Analgesics,"/capita, US$ purchasing power parity",8.9
22324,Latvia,2017,19,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.1
22325,Latvia,2017,19,J-Antiinfectives for systemic use,Million US$ at exchange rate,68.4
22326,Latvia,2017,19,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.9
22327,Latvia,2017,19,C-Cardiovascular system,Million US$ at exchange rate,64.2
22328,Latvia,2017,19,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
22329,Latvia,2017,19,B-Blood and blood forming organs,"/capita, US$ exchange rate",16.5
22330,Latvia,2017,19,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,7.4
22331,Latvia,2017,19,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,22.4
22332,Latvia,2017,19,C08-Calcium channel blockers,Million US$ at exchange rate,2.7
22333,Latvia,2017,19,G-Genito urinary system and sex hormones,Million US$ at exchange rate,16.9
22334,Latvia,2017,19,C10-Lipid modifying agents,Million US$ at exchange rate,7.0
22335,Luxembourg,2016,5,N05B-Anxiolytics,Million US$ at exchange rate,2.8
22336,Luxembourg,2016,5,N05B-Anxiolytics,Million of national currency units,2.5
22337,Luxembourg,2016,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.5
22338,Luxembourg,2016,5,N05B-Anxiolytics,% of total sales,1.3
22339,Luxembourg,2016,5,N05B-Anxiolytics,"Million US$, purchasing power parity",2.9
22340,Luxembourg,2016,5,N05B-Anxiolytics,"/capita, US$ exchange rate",5.2
22341,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.3
22342,Luxembourg,2016,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
22343,Luxembourg,2016,5,A02A-Antacids,% of total sales,0.2
22344,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",16.2
22345,Luxembourg,2016,5,A02A-Antacids,"/capita, US$ exchange rate",0.8
22346,Luxembourg,2016,5,A02A-Antacids,"Million US$, purchasing power parity",0.4
22347,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.2
22348,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.7
22349,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.3
22350,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,8.1
22351,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,% of total sales,5.1
22352,Luxembourg,2016,5,A02A-Antacids,Million US$ at exchange rate,0.4
22353,Luxembourg,2016,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.5
22354,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",11.7
22355,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.9
22356,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,Million of national currency units,10.0
22357,Luxembourg,2016,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.0
22358,Luxembourg,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",76.6
22359,Luxembourg,2016,5,N05C-Hypnotics and sedatives,% of total sales,1.8
22360,Luxembourg,2016,5,A-Alimentary tract and metabolism,% of total sales,17.6
22361,Luxembourg,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",72.2
22362,Luxembourg,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,38.0
22363,Luxembourg,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",40.3
22364,Luxembourg,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.2
22365,Luxembourg,2016,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.0
22366,Luxembourg,2016,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8
22367,Luxembourg,2016,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.7
22368,Luxembourg,2016,5,A-Alimentary tract and metabolism,Million of national currency units,34.4
22369,Luxembourg,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",70.9
22370,Luxembourg,2016,5,N-Nervous system,"/capita, US$ exchange rate",66.8
22371,Luxembourg,2016,5,N-Nervous system,% of total sales,16.3
22372,Luxembourg,2016,5,N-Nervous system,Million of national currency units,31.8
22373,Luxembourg,2016,5,N-Nervous system,Million US$ at exchange rate,35.2
22374,Luxembourg,2016,5,N-Nervous system,"Million US$, purchasing power parity",37.3
22375,Luxembourg,2016,5,N06A-Antidepressants,Million US$ at exchange rate,5.9
22376,Luxembourg,2016,5,N06A-Antidepressants,Million of national currency units,5.4
22377,Luxembourg,2016,5,N06A-Antidepressants,"Million US$, purchasing power parity",6.3
22378,Luxembourg,2016,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.9
22379,Luxembourg,2016,5,N06A-Antidepressants,% of total sales,2.7
22380,Luxembourg,2016,5,N06A-Antidepressants,"/capita, US$ exchange rate",11.2
22381,Luxembourg,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,215.7
22382,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.0
22383,Luxembourg,2016,5,Total pharmaceutical sales,Million of national currency units,194.9
22384,Luxembourg,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",434.3
22385,Luxembourg,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",228.8
22386,Luxembourg,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",409.6
22387,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.6
22388,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.9
22389,Luxembourg,2016,5,A02A-Antacids,Million of national currency units,0.4
22390,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.2
22391,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.5
22392,Luxembourg,2016,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",7.0
22393,Luxembourg,2016,5,R-Respiratory system,% of total sales,7.2
22394,Luxembourg,2016,5,N02-Analgesics,"/capita, US$ exchange rate",16.3
22395,Luxembourg,2016,5,N02-Analgesics,"Million US$, purchasing power parity",9.1
22396,Luxembourg,2016,5,N02-Analgesics,"/capita, US$ purchasing power parity",17.3
22397,Luxembourg,2016,5,N02-Analgesics,Million of national currency units,7.8
22398,Luxembourg,2016,5,N05C-Hypnotics and sedatives,Million of national currency units,3.4
22399,Luxembourg,2016,5,N02-Analgesics,Million US$ at exchange rate,8.6
22400,Luxembourg,2016,5,R-Respiratory system,"/capita, US$ exchange rate",29.6
22401,Luxembourg,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",31.4
22402,Luxembourg,2016,5,R-Respiratory system,"Million US$, purchasing power parity",16.5
22403,Luxembourg,2016,5,R-Respiratory system,Million of national currency units,14.1
22404,Luxembourg,2016,5,N02-Analgesics,% of total sales,4.0
22405,Luxembourg,2016,5,R-Respiratory system,Million US$ at exchange rate,15.6
22406,Luxembourg,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",16.9
22407,Luxembourg,2016,5,B-Blood and blood forming organs,Million of national currency units,14.4
22408,Luxembourg,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,15.9
22409,Luxembourg,2016,5,B-Blood and blood forming organs,% of total sales,7.4
22410,Luxembourg,2016,5,C02-Antihypertensives,% of total sales,0.2
22411,Luxembourg,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.3
22412,Luxembourg,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.1
22413,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.7
22414,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.1
22415,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
22416,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.3
22417,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.8
22418,Luxembourg,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.2
22419,Luxembourg,2016,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
22420,Luxembourg,2016,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.0
22421,Luxembourg,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.5
22422,Luxembourg,2016,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0
22423,Luxembourg,2016,5,M-Musculo-skeletal system,% of total sales,5.7
22424,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.5
22425,Luxembourg,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",25.0
22426,Luxembourg,2016,5,J-Antiinfectives for systemic use,% of total sales,4.6
22427,Luxembourg,2016,5,M-Musculo-skeletal system,Million of national currency units,11.2
22428,Luxembourg,2016,5,C10-Lipid modifying agents,% of total sales,6.5
22429,Luxembourg,2016,5,C01A-Cardiac glycosides,Million of national currency units,0.0
22430,Luxembourg,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,12.4
22431,Luxembourg,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",13.1
22432,Luxembourg,2016,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
22433,Luxembourg,2016,5,C10-Lipid modifying agents,Million of national currency units,12.6
22434,Luxembourg,2016,5,C03-Diuretics,Million of national currency units,1.6
22435,Luxembourg,2016,5,C10-Lipid modifying agents,Million US$ at exchange rate,13.9
22436,Luxembourg,2016,5,C03-Diuretics,"/capita, US$ exchange rate",3.3
22437,Luxembourg,2016,5,C03-Diuretics,Million US$ at exchange rate,1.7
22438,Luxembourg,2016,5,C03-Diuretics,"Million US$, purchasing power parity",1.8
22439,Luxembourg,2016,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.5
22440,Luxembourg,2016,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.5
22441,Luxembourg,2016,5,C02-Antihypertensives,Million of national currency units,0.5
22442,Luxembourg,2016,5,C02-Antihypertensives,Million US$ at exchange rate,0.5
22443,Luxembourg,2016,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",14.8
22444,Luxembourg,2016,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",26.5
22445,Luxembourg,2016,5,C02-Antihypertensives,"/capita, US$ exchange rate",0.9
22446,Luxembourg,2016,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",28.1
22447,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
22448,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
22449,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
22450,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.5
22451,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
22452,Luxembourg,2016,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
22453,Luxembourg,2016,5,J-Antiinfectives for systemic use,Million of national currency units,9.0
22454,Luxembourg,2016,5,C03-Diuretics,% of total sales,0.8
22455,Luxembourg,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,10.0
22456,Luxembourg,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",19.0
22457,Luxembourg,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.1
22458,Luxembourg,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",10.6
22459,Luxembourg,2016,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,6.4
22460,Luxembourg,2016,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",6.7
22461,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.8
22462,Luxembourg,2016,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
22463,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
22464,Luxembourg,2016,5,J01-Antibacterials for systemic use,Million of national currency units,5.8
22465,Luxembourg,2016,5,C01A-Cardiac glycosides,% of total sales,0.0
22466,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.5
22467,Luxembourg,2016,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.1
22468,Luxembourg,2016,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.8
22469,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.1
22470,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.4
22471,Luxembourg,2016,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.9
22472,Luxembourg,2016,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.3
22473,Luxembourg,2016,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.3
22474,Luxembourg,2016,5,A10-Drugs used in diabetes,% of total sales,8.1
22475,Luxembourg,2016,5,A10-Drugs used in diabetes,Million of national currency units,15.8
22476,Luxembourg,2016,5,A10-Drugs used in diabetes,Million US$ at exchange rate,17.5
22477,Luxembourg,2016,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",18.6
22478,Luxembourg,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.2
22479,Luxembourg,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.2
22480,Luxembourg,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3
22481,Luxembourg,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,8.7
22482,Luxembourg,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,9.6
22483,Luxembourg,2016,5,C-Cardiovascular system,% of total sales,16.7
22484,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",12.5
22485,Luxembourg,2016,5,C07-Beta blocking agents,% of total sales,1.9
22486,Luxembourg,2016,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.2
22487,Luxembourg,2016,5,C08-Calcium channel blockers,% of total sales,0.9
22488,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,10.7
22489,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,11.8
22490,Luxembourg,2016,5,C07-Beta blocking agents,Million of national currency units,3.7
22491,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.4
22492,Luxembourg,2016,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.7
22493,Luxembourg,2016,5,C07-Beta blocking agents,"Million US$, purchasing power parity",4.3
22494,Luxembourg,2016,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.7
22495,Luxembourg,2016,5,C07-Beta blocking agents,Million US$ at exchange rate,4.1
22496,Luxembourg,2016,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.1
22497,Luxembourg,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",38.1
22498,Luxembourg,2016,5,C-Cardiovascular system,Million US$ at exchange rate,36.0
22499,Luxembourg,2016,5,C-Cardiovascular system,Million of national currency units,32.5
22500,Luxembourg,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",68.3
22501,Luxembourg,2016,5,G-Genito urinary system and sex hormones,% of total sales,4.4
22502,Luxembourg,2016,5,J01-Antibacterials for systemic use,% of total sales,3.0
22503,Luxembourg,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",72.4
22504,Luxembourg,2016,5,C08-Calcium channel blockers,Million US$ at exchange rate,2.0
22505,Luxembourg,2016,5,C08-Calcium channel blockers,Million of national currency units,1.8
22506,Luxembourg,2016,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.8
22507,Luxembourg,2016,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.1
22508,Luxembourg,2015,5,N05B-Anxiolytics,Million of national currency units,2.4
22509,Luxembourg,2015,5,N05B-Anxiolytics,Million US$ at exchange rate,2.7
22510,Luxembourg,2015,5,N05B-Anxiolytics,"Million US$, purchasing power parity",2.7
22511,Luxembourg,2015,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.2
22512,Luxembourg,2015,5,N05B-Anxiolytics,% of total sales,1.2
22513,Luxembourg,2015,5,N05B-Anxiolytics,"/capita, US$ exchange rate",5.1
22514,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.5
22515,Luxembourg,2015,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
22516,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.9
22517,Luxembourg,2015,5,A02A-Antacids,% of total sales,0.2
22518,Luxembourg,2015,5,A02A-Antacids,"Million US$, purchasing power parity",0.4
22519,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.9
22520,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.8
22521,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.2
22522,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.2
22523,Luxembourg,2015,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,8.0
22524,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4
22525,Luxembourg,2015,5,A02A-Antacids,"/capita, US$ exchange rate",0.8
22526,Luxembourg,2015,5,A02A-Antacids,Million US$ at exchange rate,0.4
22527,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",22.4
22528,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",11.9
22529,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,Million of national currency units,10.5
22530,Luxembourg,2015,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,11.6
22531,Luxembourg,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.9
22532,Luxembourg,2015,5,A-Alimentary tract and metabolism,% of total sales,17.3
22533,Luxembourg,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,36.9
22534,Luxembourg,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",71.2
22535,Luxembourg,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",37.8
22536,Luxembourg,2015,5,N05C-Hypnotics and sedatives,% of total sales,1.8
22537,Luxembourg,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.3
22538,Luxembourg,2015,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8
22539,Luxembourg,2015,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.9
22540,Luxembourg,2015,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.5
22541,Luxembourg,2015,5,A-Alimentary tract and metabolism,Million of national currency units,33.3
22542,Luxembourg,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",72.7
22543,Luxembourg,2015,5,N-Nervous system,"/capita, US$ exchange rate",71.1
22544,Luxembourg,2015,5,N-Nervous system,% of total sales,17.2
22545,Luxembourg,2015,5,N-Nervous system,Million US$ at exchange rate,36.8
22546,Luxembourg,2015,5,N-Nervous system,Million of national currency units,33.2
22547,Luxembourg,2015,5,N-Nervous system,"Million US$, purchasing power parity",37.7
22548,Luxembourg,2015,5,N06A-Antidepressants,Million US$ at exchange rate,6.3
22549,Luxembourg,2015,5,N06A-Antidepressants,"Million US$, purchasing power parity",6.5
22550,Luxembourg,2015,5,N06A-Antidepressants,Million of national currency units,5.7
22551,Luxembourg,2015,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.5
22552,Luxembourg,2015,5,N06A-Antidepressants,% of total sales,3.0
22553,Luxembourg,2015,5,N06A-Antidepressants,"/capita, US$ exchange rate",12.2
22554,Luxembourg,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,213.7
22555,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1
22556,Luxembourg,2015,5,Total pharmaceutical sales,Million of national currency units,192.6
22557,Luxembourg,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",421.8
22558,Luxembourg,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",218.6
22559,Luxembourg,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",412.5
22560,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.5
22561,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.9
22562,Luxembourg,2015,5,A02A-Antacids,Million of national currency units,0.4
22563,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.9
22564,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.7
22565,Luxembourg,2015,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.6
22566,Luxembourg,2015,5,N02-Analgesics,"/capita, US$ exchange rate",16.6
22567,Luxembourg,2015,5,N02-Analgesics,"Million US$, purchasing power parity",8.8
22568,Luxembourg,2015,5,N02-Analgesics,"/capita, US$ purchasing power parity",16.9
22569,Luxembourg,2015,5,N02-Analgesics,Million of national currency units,7.7
22570,Luxembourg,2015,5,N05C-Hypnotics and sedatives,Million of national currency units,3.4
22571,Luxembourg,2015,5,N02-Analgesics,Million US$ at exchange rate,8.6
22572,Luxembourg,2015,5,N02-Analgesics,% of total sales,4.0
22573,Luxembourg,2015,5,R-Respiratory system,"/capita, US$ exchange rate",31.1
22574,Luxembourg,2015,5,R-Respiratory system,% of total sales,7.5
22575,Luxembourg,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",31.8
22576,Luxembourg,2015,5,R-Respiratory system,Million of national currency units,14.5
22577,Luxembourg,2015,5,R-Respiratory system,Million US$ at exchange rate,16.1
22578,Luxembourg,2015,5,R-Respiratory system,"Million US$, purchasing power parity",16.5
22579,Luxembourg,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",14.8
22580,Luxembourg,2015,5,B-Blood and blood forming organs,Million of national currency units,13.0
22581,Luxembourg,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,14.5
22582,Luxembourg,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",27.9
22583,Luxembourg,2015,5,B-Blood and blood forming organs,% of total sales,6.8
22584,Luxembourg,2015,5,C02-Antihypertensives,% of total sales,0.2
22585,Luxembourg,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.6
22586,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.2
22587,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.0
22588,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
22589,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.1
22590,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.7
22591,Luxembourg,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.8
22592,Luxembourg,2015,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
22593,Luxembourg,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.0
22594,Luxembourg,2015,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.0
22595,Luxembourg,2015,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0
22596,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.7
22597,Luxembourg,2015,5,M-Musculo-skeletal system,% of total sales,5.6
22598,Luxembourg,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.5
22599,Luxembourg,2015,5,J-Antiinfectives for systemic use,% of total sales,4.9
22600,Luxembourg,2015,5,M-Musculo-skeletal system,Million of national currency units,10.8
22601,Luxembourg,2015,5,C10-Lipid modifying agents,% of total sales,6.6
22602,Luxembourg,2015,5,C01A-Cardiac glycosides,Million of national currency units,0.0
22603,Luxembourg,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,11.9
22604,Luxembourg,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",12.2
22605,Luxembourg,2015,5,C03-Diuretics,Million of national currency units,1.6
22606,Luxembourg,2015,5,C10-Lipid modifying agents,Million US$ at exchange rate,14.1
22607,Luxembourg,2015,5,C03-Diuretics,Million US$ at exchange rate,1.8
22608,Luxembourg,2015,5,C03-Diuretics,"/capita, US$ exchange rate",3.4
22609,Luxembourg,2015,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.5
22610,Luxembourg,2015,5,C03-Diuretics,"Million US$, purchasing power parity",1.8
22611,Luxembourg,2015,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",14.4
22612,Luxembourg,2015,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.5
22613,Luxembourg,2015,5,C02-Antihypertensives,Million of national currency units,0.4
22614,Luxembourg,2015,5,C02-Antihypertensives,Million US$ at exchange rate,0.5
22615,Luxembourg,2015,5,C02-Antihypertensives,"/capita, US$ exchange rate",0.9
22616,Luxembourg,2015,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",27.1
22617,Luxembourg,2015,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.7
22618,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
22619,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.2
22620,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
22621,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
22622,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
22623,Luxembourg,2015,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
22624,Luxembourg,2015,5,J-Antiinfectives for systemic use,Million of national currency units,9.4
22625,Luxembourg,2015,5,C03-Diuretics,% of total sales,0.8
22626,Luxembourg,2015,5,C10-Lipid modifying agents,Million of national currency units,12.7
22627,Luxembourg,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,10.4
22628,Luxembourg,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",20.0
22629,Luxembourg,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.5
22630,Luxembourg,2015,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.9
22631,Luxembourg,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",10.6
22632,Luxembourg,2015,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,6.4
22633,Luxembourg,2015,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",6.6
22634,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.5
22635,Luxembourg,2015,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
22636,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
22637,Luxembourg,2015,5,J01-Antibacterials for systemic use,Million of national currency units,5.8
22638,Luxembourg,2015,5,C01A-Cardiac glycosides,% of total sales,0.0
22639,Luxembourg,2015,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.4
22640,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.4
22641,Luxembourg,2015,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.7
22642,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",3.9
22643,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.3
22644,Luxembourg,2015,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.8
22645,Luxembourg,2015,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",33.1
22646,Luxembourg,2015,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.4
22647,Luxembourg,2015,5,A10-Drugs used in diabetes,% of total sales,7.8
22648,Luxembourg,2015,5,A10-Drugs used in diabetes,Million US$ at exchange rate,16.8
22649,Luxembourg,2015,5,A10-Drugs used in diabetes,Million of national currency units,15.1
22650,Luxembourg,2015,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",17.2
22651,Luxembourg,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.8
22652,Luxembourg,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.4
22653,Luxembourg,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.2
22654,Luxembourg,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,8.3
22655,Luxembourg,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,9.2
22656,Luxembourg,2015,5,C-Cardiovascular system,% of total sales,17.1
22657,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",12.5
22658,Luxembourg,2015,5,C07-Beta blocking agents,% of total sales,1.9
22659,Luxembourg,2015,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9
22660,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,12.2
22661,Luxembourg,2015,5,C08-Calcium channel blockers,% of total sales,1.0
22662,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.0
22663,Luxembourg,2015,5,C07-Beta blocking agents,Million of national currency units,3.6
22664,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.6
22665,Luxembourg,2015,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.1
22666,Luxembourg,2015,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.7
22667,Luxembourg,2015,5,C07-Beta blocking agents,"Million US$, purchasing power parity",4.1
22668,Luxembourg,2015,5,C07-Beta blocking agents,Million US$ at exchange rate,4.0
22669,Luxembourg,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",37.4
22670,Luxembourg,2015,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.2
22671,Luxembourg,2015,5,C-Cardiovascular system,Million US$ at exchange rate,36.6
22672,Luxembourg,2015,5,G-Genito urinary system and sex hormones,% of total sales,4.3
22673,Luxembourg,2015,5,J01-Antibacterials for systemic use,% of total sales,3.0
22674,Luxembourg,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",70.6
22675,Luxembourg,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",72.2
22676,Luxembourg,2015,5,C-Cardiovascular system,Million of national currency units,33.0
22677,Luxembourg,2015,5,C08-Calcium channel blockers,Million US$ at exchange rate,2.1
22678,Luxembourg,2015,5,C08-Calcium channel blockers,Million of national currency units,1.9
22679,Luxembourg,2015,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.2
22680,Luxembourg,2015,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1
22681,Luxembourg,2014,6,N05B-Anxiolytics,Million of national currency units,2.4
22682,Luxembourg,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,3.2
22683,Luxembourg,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.3
22684,Luxembourg,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",2.7
22685,Luxembourg,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",6.2
22686,Luxembourg,2014,6,N05B-Anxiolytics,% of total sales,1.2
22687,Luxembourg,2014,6,A02A-Antacids,"/capita, US$ exchange rate",0.9
22688,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",21.6
22689,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",18.4
22690,Luxembourg,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
22691,Luxembourg,2014,6,A02A-Antacids,% of total sales,0.2
22692,Luxembourg,2014,6,A02A-Antacids,"Million US$, purchasing power parity",0.4
22693,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.4
22694,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.5
22695,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8.3
22696,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.1
22697,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,5.5
22698,Luxembourg,2014,6,A02A-Antacids,Million US$ at exchange rate,0.5
22699,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.5
22700,Luxembourg,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.4
22701,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.0
22702,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,10.6
22703,Luxembourg,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,14.1
22704,Luxembourg,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.8
22705,Luxembourg,2014,6,A-Alimentary tract and metabolism,% of total sales,17.2
22706,Luxembourg,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,43.7
22707,Luxembourg,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",85.5
22708,Luxembourg,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",37.2
22709,Luxembourg,2014,6,N05C-Hypnotics and sedatives,% of total sales,1.6
22710,Luxembourg,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.2
22711,Luxembourg,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.6
22712,Luxembourg,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.2
22713,Luxembourg,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.0
22714,Luxembourg,2014,6,A-Alimentary tract and metabolism,Million of national currency units,32.9
22715,Luxembourg,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",70.5
22716,Luxembourg,2014,6,N-Nervous system,"/capita, US$ exchange rate",82.8
22717,Luxembourg,2014,6,N-Nervous system,% of total sales,16.6
22718,Luxembourg,2014,6,N-Nervous system,Million US$ at exchange rate,42.3
22719,Luxembourg,2014,6,N-Nervous system,Million of national currency units,31.8
22720,Luxembourg,2014,6,N-Nervous system,"Million US$, purchasing power parity",36.0
22721,Luxembourg,2014,6,N06A-Antidepressants,Million US$ at exchange rate,8.3
22722,Luxembourg,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",7.1
22723,Luxembourg,2014,6,N06A-Antidepressants,Million of national currency units,6.3
22724,Luxembourg,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",13.8
22725,Luxembourg,2014,6,N06A-Antidepressants,% of total sales,3.3
22726,Luxembourg,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",16.3
22727,Luxembourg,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,254.1
22728,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2
22729,Luxembourg,2014,6,Total pharmaceutical sales,Million of national currency units,191.3
22730,Luxembourg,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",216.3
22731,Luxembourg,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",423.6
22732,Luxembourg,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",497.5
22733,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,8.1
22734,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.1
22735,Luxembourg,2014,6,A02A-Antacids,Million of national currency units,0.4
22736,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.6
22737,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.9
22738,Luxembourg,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.9
22739,Luxembourg,2014,6,N02-Analgesics,"/capita, US$ exchange rate",19.8
22740,Luxembourg,2014,6,N02-Analgesics,"Million US$, purchasing power parity",8.6
22741,Luxembourg,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",16.8
22742,Luxembourg,2014,6,N02-Analgesics,Million of national currency units,7.6
22743,Luxembourg,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,3.1
22744,Luxembourg,2014,6,N02-Analgesics,Million US$ at exchange rate,10.1
22745,Luxembourg,2014,6,N02-Analgesics,% of total sales,4.0
22746,Luxembourg,2014,6,R-Respiratory system,"/capita, US$ exchange rate",38.4
22747,Luxembourg,2014,6,R-Respiratory system,% of total sales,7.7
22748,Luxembourg,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",32.7
22749,Luxembourg,2014,6,R-Respiratory system,"Million US$, purchasing power parity",16.7
22750,Luxembourg,2014,6,R-Respiratory system,Million of national currency units,14.8
22751,Luxembourg,2014,6,R-Respiratory system,Million US$ at exchange rate,19.6
22752,Luxembourg,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",13.4
22753,Luxembourg,2014,6,B-Blood and blood forming organs,Million of national currency units,11.9
22754,Luxembourg,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",30.8
22755,Luxembourg,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,15.7
22756,Luxembourg,2014,6,B-Blood and blood forming organs,% of total sales,6.2
22757,Luxembourg,2014,6,C02-Antihypertensives,% of total sales,0.2
22758,Luxembourg,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.2
22759,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8
22760,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.8
22761,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.8
22762,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.3
22763,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,7.1
22764,Luxembourg,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.0
22765,Luxembourg,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
22766,Luxembourg,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
22767,Luxembourg,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0
22768,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0
22769,Luxembourg,2014,6,M-Musculo-skeletal system,% of total sales,5.6
22770,Luxembourg,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.7
22771,Luxembourg,2014,6,J-Antiinfectives for systemic use,% of total sales,4.9
22772,Luxembourg,2014,6,C10-Lipid modifying agents,% of total sales,6.9
22773,Luxembourg,2014,6,M-Musculo-skeletal system,Million of national currency units,10.7
22774,Luxembourg,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",27.9
22775,Luxembourg,2014,6,C01A-Cardiac glycosides,Million of national currency units,0.0
22776,Luxembourg,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,14.2
22777,Luxembourg,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",12.1
22778,Luxembourg,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
22779,Luxembourg,2014,6,C03-Diuretics,Million of national currency units,1.7
22780,Luxembourg,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,17.4
22781,Luxembourg,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",14.8
22782,Luxembourg,2014,6,C03-Diuretics,"/capita, US$ exchange rate",4.3
22783,Luxembourg,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
22784,Luxembourg,2014,6,C03-Diuretics,Million US$ at exchange rate,2.2
22785,Luxembourg,2014,6,C03-Diuretics,"Million US$, purchasing power parity",1.9
22786,Luxembourg,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",0.5
22787,Luxembourg,2014,6,C02-Antihypertensives,Million of national currency units,0.4
22788,Luxembourg,2014,6,C02-Antihypertensives,Million US$ at exchange rate,0.6
22789,Luxembourg,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",34.1
22790,Luxembourg,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",1.1
22791,Luxembourg,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",29.1
22792,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
22793,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5
22794,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
22795,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
22796,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8
22797,Luxembourg,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
22798,Luxembourg,2014,6,J-Antiinfectives for systemic use,Million of national currency units,9.4
22799,Luxembourg,2014,6,C03-Diuretics,% of total sales,0.9
22800,Luxembourg,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,12.5
22801,Luxembourg,2014,6,C10-Lipid modifying agents,Million of national currency units,13.1
22802,Luxembourg,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",24.6
22803,Luxembourg,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.9
22804,Luxembourg,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",10.7
22805,Luxembourg,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",6.7
22806,Luxembourg,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,7.9
22807,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.6
22808,Luxembourg,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
22809,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
22810,Luxembourg,2014,6,C01A-Cardiac glycosides,% of total sales,0.0
22811,Luxembourg,2014,6,J01-Antibacterials for systemic use,Million of national currency units,6.0
22812,Luxembourg,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.5
22813,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.4
22814,Luxembourg,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.2
22815,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.9
22816,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",3.9
22817,Luxembourg,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,4.5
22818,Luxembourg,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",30.7
22819,Luxembourg,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.0
22820,Luxembourg,2014,6,A10-Drugs used in diabetes,% of total sales,7.2
22821,Luxembourg,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,18.4
22822,Luxembourg,2014,6,A10-Drugs used in diabetes,Million of national currency units,13.8
22823,Luxembourg,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",15.7
22824,Luxembourg,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,8.2
22825,Luxembourg,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.4
22826,Luxembourg,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.3
22827,Luxembourg,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.2
22828,Luxembourg,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.9
22829,Luxembourg,2014,6,C-Cardiovascular system,% of total sales,17.9
22830,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",12.9
22831,Luxembourg,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.0
22832,Luxembourg,2014,6,C07-Beta blocking agents,% of total sales,1.9
22833,Luxembourg,2014,6,C08-Calcium channel blockers,% of total sales,1.1
22834,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,15.1
22835,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.4
22836,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",29.6
22837,Luxembourg,2014,6,C07-Beta blocking agents,Million of national currency units,3.6
22838,Luxembourg,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",25.2
22839,Luxembourg,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",9.4
22840,Luxembourg,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",4.1
22841,Luxembourg,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,4.8
22842,Luxembourg,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.7
22843,Luxembourg,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",38.7
22844,Luxembourg,2014,6,C-Cardiovascular system,Million US$ at exchange rate,45.4
22845,Luxembourg,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",88.9
22846,Luxembourg,2014,6,G-Genito urinary system and sex hormones,% of total sales,4.3
22847,Luxembourg,2014,6,J01-Antibacterials for systemic use,% of total sales,3.1
22848,Luxembourg,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.7
22849,Luxembourg,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,2.8
22850,Luxembourg,2014,6,C-Cardiovascular system,Million of national currency units,34.2
22851,Luxembourg,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.4
22852,Luxembourg,2014,6,C08-Calcium channel blockers,Million of national currency units,2.1
22853,Luxembourg,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5
22854,Luxembourg,2013,6,N05B-Anxiolytics,Million of national currency units,2.3
22855,Luxembourg,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,3.1
22856,Luxembourg,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6
22857,Luxembourg,2013,6,N05B-Anxiolytics,% of total sales,1.2
22858,Luxembourg,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.2
22859,Luxembourg,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",6.2
22860,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",23.6
22861,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.9
22862,Luxembourg,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
22863,Luxembourg,2013,6,A02A-Antacids,% of total sales,0.2
22864,Luxembourg,2013,6,A02A-Antacids,"/capita, US$ exchange rate",0.8
22865,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.6
22866,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.4
22867,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8.9
22868,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.8
22869,Luxembourg,2013,6,A02A-Antacids,"Million US$, purchasing power parity",0.4
22870,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,5.9
22871,Luxembourg,2013,6,A02A-Antacids,Million US$ at exchange rate,0.4
22872,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,11.4
22873,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",30.2
22874,Luxembourg,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",10.0
22875,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.7
22876,Luxembourg,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,15.2
22877,Luxembourg,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.3
22878,Luxembourg,2013,6,A-Alimentary tract and metabolism,% of total sales,16.2
22879,Luxembourg,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,42.0
22880,Luxembourg,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",83.6
22881,Luxembourg,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",35.3
22882,Luxembourg,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.0
22883,Luxembourg,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.0
22884,Luxembourg,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.4
22885,Luxembourg,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",6.7
22886,Luxembourg,2013,6,N05C-Hypnotics and sedatives,% of total sales,1.6
22887,Luxembourg,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",70.4
22888,Luxembourg,2013,6,N-Nervous system,"/capita, US$ exchange rate",83.7
22889,Luxembourg,2013,6,N-Nervous system,% of total sales,16.2
22890,Luxembourg,2013,6,N-Nervous system,Million US$ at exchange rate,42.0
22891,Luxembourg,2013,6,N-Nervous system,Million of national currency units,31.7
22892,Luxembourg,2013,6,N-Nervous system,"Million US$, purchasing power parity",35.4
22893,Luxembourg,2013,6,N06A-Antidepressants,Million US$ at exchange rate,8.7
22894,Luxembourg,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",7.3
22895,Luxembourg,2013,6,A-Alimentary tract and metabolism,Million of national currency units,31.6
22896,Luxembourg,2013,6,N06A-Antidepressants,Million of national currency units,6.5
22897,Luxembourg,2013,6,N06A-Antidepressants,% of total sales,3.3
22898,Luxembourg,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",14.5
22899,Luxembourg,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",17.3
22900,Luxembourg,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,258.9
22901,Luxembourg,2013,6,Total pharmaceutical sales,Million of national currency units,194.9
22902,Luxembourg,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",217.7
22903,Luxembourg,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",433.8
22904,Luxembourg,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",515.8
22905,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2
22906,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,8.2
22907,Luxembourg,2013,6,A02A-Antacids,Million of national currency units,0.3
22908,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.2
22909,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.7
22910,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.9
22911,Luxembourg,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",16.3
22912,Luxembourg,2013,6,N02-Analgesics,"/capita, US$ exchange rate",20.2
22913,Luxembourg,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",17.0
22914,Luxembourg,2013,6,N02-Analgesics,"Million US$, purchasing power parity",8.5
22915,Luxembourg,2013,6,N02-Analgesics,Million of national currency units,7.6
22916,Luxembourg,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,3.0
22917,Luxembourg,2013,6,N02-Analgesics,Million US$ at exchange rate,10.1
22918,Luxembourg,2013,6,N02-Analgesics,% of total sales,3.9
22919,Luxembourg,2013,6,R-Respiratory system,"/capita, US$ exchange rate",41.4
22920,Luxembourg,2013,6,R-Respiratory system,% of total sales,8.0
22921,Luxembourg,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",34.8
22922,Luxembourg,2013,6,R-Respiratory system,Million of national currency units,15.6
22923,Luxembourg,2013,6,R-Respiratory system,"Million US$, purchasing power parity",17.5
22924,Luxembourg,2013,6,R-Respiratory system,Million US$ at exchange rate,20.8
22925,Luxembourg,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
22926,Luxembourg,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",12.1
22927,Luxembourg,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",28.6
22928,Luxembourg,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,14.4
22929,Luxembourg,2013,6,B-Blood and blood forming organs,Million of national currency units,10.8
22930,Luxembourg,2013,6,C02-Antihypertensives,% of total sales,0.2
22931,Luxembourg,2013,6,B-Blood and blood forming organs,% of total sales,5.6
22932,Luxembourg,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.1
22933,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.5
22934,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.6
22935,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
22936,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.8
22937,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.2
22938,Luxembourg,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.8
22939,Luxembourg,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
22940,Luxembourg,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
22941,Luxembourg,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
22942,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.8
22943,Luxembourg,2013,6,M-Musculo-skeletal system,% of total sales,5.4
22944,Luxembourg,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.4
22945,Luxembourg,2013,6,J-Antiinfectives for systemic use,% of total sales,5.4
22946,Luxembourg,2013,6,C10-Lipid modifying agents,% of total sales,8.0
22947,Luxembourg,2013,6,M-Musculo-skeletal system,Million of national currency units,10.5
22948,Luxembourg,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",27.8
22949,Luxembourg,2013,6,C01A-Cardiac glycosides,Million of national currency units,0.1
22950,Luxembourg,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,13.9
22951,Luxembourg,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",11.7
22952,Luxembourg,2013,6,C03-Diuretics,Million of national currency units,1.6
22953,Luxembourg,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",17.4
22954,Luxembourg,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,20.7
22955,Luxembourg,2013,6,C03-Diuretics,Million US$ at exchange rate,2.2
22956,Luxembourg,2013,6,C03-Diuretics,"/capita, US$ exchange rate",4.3
22957,Luxembourg,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",3.6
22958,Luxembourg,2013,6,C03-Diuretics,"Million US$, purchasing power parity",1.8
22959,Luxembourg,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",0.5
22960,Luxembourg,2013,6,C02-Antihypertensives,Million of national currency units,0.4
22961,Luxembourg,2013,6,C02-Antihypertensives,Million US$ at exchange rate,0.5
22962,Luxembourg,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",1.1
22963,Luxembourg,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",41.3
22964,Luxembourg,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",34.7
22965,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
22966,Luxembourg,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.9
22967,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5
22968,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
22969,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8
22970,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
22971,Luxembourg,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
22972,Luxembourg,2013,6,J-Antiinfectives for systemic use,Million of national currency units,10.4
22973,Luxembourg,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,13.9
22974,Luxembourg,2013,6,C10-Lipid modifying agents,Million of national currency units,15.6
22975,Luxembourg,2013,6,C03-Diuretics,% of total sales,0.8
22976,Luxembourg,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",27.6
22977,Luxembourg,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.2
22978,Luxembourg,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",11.7
22979,Luxembourg,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.0
22980,Luxembourg,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.4
22981,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.4
22982,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
22983,Luxembourg,2013,6,C01A-Cardiac glycosides,% of total sales,0.0
22984,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.3
22985,Luxembourg,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",14.0
22986,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.8
22987,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",3.7
22988,Luxembourg,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,4.4
22989,Luxembourg,2013,6,J01-Antibacterials for systemic use,Million of national currency units,6.3
22990,Luxembourg,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",26.9
22991,Luxembourg,2013,6,A10-Drugs used in diabetes,% of total sales,6.2
22992,Luxembourg,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.0
22993,Luxembourg,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,16.1
22994,Luxembourg,2013,6,A10-Drugs used in diabetes,Million of national currency units,12.1
22995,Luxembourg,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",13.5
22996,Luxembourg,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,8.0
22997,Luxembourg,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.2
22998,Luxembourg,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",9.0
22999,Luxembourg,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",17.9
23000,Luxembourg,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.7
23001,Luxembourg,2013,6,C-Cardiovascular system,% of total sales,19.8
23002,Luxembourg,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.6
23003,Luxembourg,2013,6,J01-Antibacterials for systemic use,% of total sales,3.2
23004,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",14.8
23005,Luxembourg,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.1
23006,Luxembourg,2013,6,C07-Beta blocking agents,% of total sales,1.9
23007,Luxembourg,2013,6,C08-Calcium channel blockers,% of total sales,1.2
23008,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,17.6
23009,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,13.3
23010,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.1
23011,Luxembourg,2013,6,C07-Beta blocking agents,Million of national currency units,3.7
23012,Luxembourg,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.5
23013,Luxembourg,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",9.7
23014,Luxembourg,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,4.9
23015,Luxembourg,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",4.1
23016,Luxembourg,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",43.2
23017,Luxembourg,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",102.4
23018,Luxembourg,2013,6,C-Cardiovascular system,Million US$ at exchange rate,51.4
23019,Luxembourg,2013,6,G-Genito urinary system and sex hormones,% of total sales,4.1
23020,Luxembourg,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",86.1
23021,Luxembourg,2013,6,C-Cardiovascular system,Million of national currency units,38.7
23022,Luxembourg,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,3.0
23023,Luxembourg,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.5
23024,Luxembourg,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.0
23025,Luxembourg,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.0
23026,Luxembourg,2013,6,C08-Calcium channel blockers,Million of national currency units,2.3
23027,Luxembourg,2012,7,N05B-Anxiolytics,Million of national currency units,2.3
23028,Luxembourg,2012,7,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6
23029,Luxembourg,2012,7,N05B-Anxiolytics,% of total sales,1.2
23030,Luxembourg,2012,7,N05B-Anxiolytics,"/capita, US$ exchange rate",6.1
23031,Luxembourg,2012,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.2
23032,Luxembourg,2012,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
23033,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",22.8
23034,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.6
23035,Luxembourg,2012,7,A02A-Antacids,% of total sales,0.2
23036,Luxembourg,2012,7,A02A-Antacids,"/capita, US$ exchange rate",0.9
23037,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.5
23038,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.0
23039,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.2
23040,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8.8
23041,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,% of total sales,5.7
23042,Luxembourg,2012,7,A02A-Antacids,Million US$ at exchange rate,0.4
23043,Luxembourg,2012,7,A02A-Antacids,"Million US$, purchasing power parity",0.4
23044,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.2
23045,Luxembourg,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.6
23046,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.3
23047,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,Million of national currency units,11.2
23048,Luxembourg,2012,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,14.4
23049,Luxembourg,2012,7,R-Respiratory system,"Million US$, purchasing power parity",16.7
23050,Luxembourg,2012,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",66.9
23051,Luxembourg,2012,7,A-Alimentary tract and metabolism,% of total sales,15.3
23052,Luxembourg,2012,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,38.4
23053,Luxembourg,2012,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",78.0
23054,Luxembourg,2012,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",33.0
23055,Luxembourg,2012,7,N05C-Hypnotics and sedatives,% of total sales,1.5
23056,Luxembourg,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.8
23057,Luxembourg,2012,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.9
23058,Luxembourg,2012,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3
23059,Luxembourg,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",6.7
23060,Luxembourg,2012,7,N-Nervous system,"/capita, US$ purchasing power parity",73.6
23061,Luxembourg,2012,7,N-Nervous system,% of total sales,16.8
23062,Luxembourg,2012,7,N-Nervous system,"/capita, US$ exchange rate",85.7
23063,Luxembourg,2012,7,N-Nervous system,Million US$ at exchange rate,42.2
23064,Luxembourg,2012,7,N-Nervous system,Million of national currency units,32.9
23065,Luxembourg,2012,7,N-Nervous system,"Million US$, purchasing power parity",36.2
23066,Luxembourg,2012,7,N06A-Antidepressants,Million US$ at exchange rate,8.6
23067,Luxembourg,2012,7,N06A-Antidepressants,"Million US$, purchasing power parity",7.4
23068,Luxembourg,2012,7,A-Alimentary tract and metabolism,Million of national currency units,29.9
23069,Luxembourg,2012,7,N05B-Anxiolytics,Million US$ at exchange rate,3.0
23070,Luxembourg,2012,7,N06A-Antidepressants,Million of national currency units,6.7
23071,Luxembourg,2012,7,N06A-Antidepressants,% of total sales,3.4
23072,Luxembourg,2012,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.1
23073,Luxembourg,2012,7,N06A-Antidepressants,"/capita, US$ exchange rate",17.6
23074,Luxembourg,2012,7,Total pharmaceutical sales,Million US$ at exchange rate,251.5
23075,Luxembourg,2012,7,Total pharmaceutical sales,Million of national currency units,195.8
23076,Luxembourg,2012,7,Total pharmaceutical sales,"Million US$, purchasing power parity",215.9
23077,Luxembourg,2012,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",438.3
23078,Luxembourg,2012,7,Total pharmaceutical sales,"/capita, US$ exchange rate",510.7
23079,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1
23080,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,7.7
23081,Luxembourg,2012,7,A02A-Antacids,Million of national currency units,0.3
23082,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.0
23083,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",13.4
23084,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.6
23085,Luxembourg,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.7
23086,Luxembourg,2012,7,N02-Analgesics,"/capita, US$ exchange rate",19.5
23087,Luxembourg,2012,7,N02-Analgesics,"/capita, US$ purchasing power parity",16.7
23088,Luxembourg,2012,7,N02-Analgesics,"Million US$, purchasing power parity",8.2
23089,Luxembourg,2012,7,N02-Analgesics,Million of national currency units,7.5
23090,Luxembourg,2012,7,N05C-Hypnotics and sedatives,Million of national currency units,3.0
23091,Luxembourg,2012,7,N02-Analgesics,Million US$ at exchange rate,9.6
23092,Luxembourg,2012,7,N02-Analgesics,% of total sales,3.8
23093,Luxembourg,2012,7,R-Respiratory system,"/capita, US$ exchange rate",39.4
23094,Luxembourg,2012,7,R-Respiratory system,% of total sales,7.7
23095,Luxembourg,2012,7,R-Respiratory system,"/capita, US$ purchasing power parity",33.9
23096,Luxembourg,2012,7,R-Respiratory system,Million of national currency units,15.1
23097,Luxembourg,2012,7,R-Respiratory system,Million US$ at exchange rate,19.4
23098,Luxembourg,2012,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",11.1
23099,Luxembourg,2012,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.2
23100,Luxembourg,2012,7,B-Blood and blood forming organs,Million US$ at exchange rate,12.9
23101,Luxembourg,2012,7,C02-Antihypertensives,% of total sales,0.2
23102,Luxembourg,2012,7,B-Blood and blood forming organs,% of total sales,5.1
23103,Luxembourg,2012,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",22.5
23104,Luxembourg,2012,7,B-Blood and blood forming organs,Million of national currency units,10.1
23105,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.9
23106,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
23107,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.7
23108,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.2
23109,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.9
23110,Luxembourg,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",5.3
23111,Luxembourg,2012,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
23112,Luxembourg,2012,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
23113,Luxembourg,2012,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
23114,Luxembourg,2012,7,M-Musculo-skeletal system,% of total sales,5.0
23115,Luxembourg,2012,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.9
23116,Luxembourg,2012,7,J-Antiinfectives for systemic use,% of total sales,5.6
23117,Luxembourg,2012,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
23118,Luxembourg,2012,7,M-Musculo-skeletal system,Million of national currency units,9.8
23119,Luxembourg,2012,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.6
23120,Luxembourg,2012,7,C01A-Cardiac glycosides,Million of national currency units,0.1
23121,Luxembourg,2012,7,M-Musculo-skeletal system,Million US$ at exchange rate,12.6
23122,Luxembourg,2012,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",10.8
23123,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.4
23124,Luxembourg,2012,7,C03-Diuretics,Million of national currency units,1.6
23125,Luxembourg,2012,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",19.3
23126,Luxembourg,2012,7,C03-Diuretics,Million US$ at exchange rate,2.0
23127,Luxembourg,2012,7,C10-Lipid modifying agents,Million US$ at exchange rate,22.4
23128,Luxembourg,2012,7,C03-Diuretics,"/capita, US$ exchange rate",4.1
23129,Luxembourg,2012,7,C03-Diuretics,"/capita, US$ purchasing power parity",3.5
23130,Luxembourg,2012,7,C03-Diuretics,"Million US$, purchasing power parity",1.7
23131,Luxembourg,2012,7,C02-Antihypertensives,"Million US$, purchasing power parity",0.4
23132,Luxembourg,2012,7,C02-Antihypertensives,Million of national currency units,0.4
23133,Luxembourg,2012,7,C02-Antihypertensives,"/capita, US$ exchange rate",1.0
23134,Luxembourg,2012,7,C02-Antihypertensives,Million US$ at exchange rate,0.5
23135,Luxembourg,2012,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",45.5
23136,Luxembourg,2012,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",39.1
23137,Luxembourg,2012,7,C10-Lipid modifying agents,% of total sales,8.9
23138,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
23139,Luxembourg,2012,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.9
23140,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
23141,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.5
23142,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.7
23143,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
23144,Luxembourg,2012,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
23145,Luxembourg,2012,7,J-Antiinfectives for systemic use,Million of national currency units,11.1
23146,Luxembourg,2012,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,14.2
23147,Luxembourg,2012,7,C10-Lipid modifying agents,Million of national currency units,17.5
23148,Luxembourg,2012,7,C03-Diuretics,% of total sales,0.8
23149,Luxembourg,2012,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.8
23150,Luxembourg,2012,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.8
23151,Luxembourg,2012,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",12.2
23152,Luxembourg,2012,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.1
23153,Luxembourg,2012,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,8.3
23154,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.9
23155,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
23156,Luxembourg,2012,7,C01A-Cardiac glycosides,% of total sales,0.0
23157,Luxembourg,2012,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.9
23158,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.5
23159,Luxembourg,2012,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",14.5
23160,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.2
23161,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",3.9
23162,Luxembourg,2012,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,4.5
23163,Luxembourg,2012,7,J01-Antibacterials for systemic use,Million of national currency units,6.5
23164,Luxembourg,2012,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",24.7
23165,Luxembourg,2012,7,A10-Drugs used in diabetes,% of total sales,5.6
23166,Luxembourg,2012,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",28.8
23167,Luxembourg,2012,7,A10-Drugs used in diabetes,Million US$ at exchange rate,14.2
23168,Luxembourg,2012,7,A10-Drugs used in diabetes,Million of national currency units,11.0
23169,Luxembourg,2012,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",12.2
23170,Luxembourg,2012,7,G-Genito urinary system and sex hormones,Million of national currency units,8.1
23171,Luxembourg,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",21.0
23172,Luxembourg,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.0
23173,Luxembourg,2012,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",8.9
23174,Luxembourg,2012,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.3
23175,Luxembourg,2012,7,C-Cardiovascular system,% of total sales,21.3
23176,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",15.9
23177,Luxembourg,2012,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9
23178,Luxembourg,2012,7,C07-Beta blocking agents,% of total sales,1.8
23179,Luxembourg,2012,7,C08-Calcium channel blockers,% of total sales,1.2
23180,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,18.6
23181,Luxembourg,2012,7,J01-Antibacterials for systemic use,% of total sales,3.3
23182,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,14.4
23183,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",37.7
23184,Luxembourg,2012,7,C07-Beta blocking agents,Million of national currency units,3.5
23185,Luxembourg,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",32.3
23186,Luxembourg,2012,7,C07-Beta blocking agents,"/capita, US$ exchange rate",9.2
23187,Luxembourg,2012,7,C07-Beta blocking agents,"Million US$, purchasing power parity",3.9
23188,Luxembourg,2012,7,C07-Beta blocking agents,Million US$ at exchange rate,4.5
23189,Luxembourg,2012,7,C-Cardiovascular system,"Million US$, purchasing power parity",46.0
23190,Luxembourg,2012,7,C-Cardiovascular system,"/capita, US$ exchange rate",108.8
23191,Luxembourg,2012,7,C-Cardiovascular system,Million US$ at exchange rate,53.6
23192,Luxembourg,2012,7,G-Genito urinary system and sex hormones,% of total sales,4.1
23193,Luxembourg,2012,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",93.4
23194,Luxembourg,2012,7,C08-Calcium channel blockers,Million US$ at exchange rate,3.1
23195,Luxembourg,2012,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.6
23196,Luxembourg,2012,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.4
23197,Luxembourg,2012,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.2
23198,Luxembourg,2012,7,C-Cardiovascular system,Million of national currency units,41.7
23199,Luxembourg,2012,7,C08-Calcium channel blockers,Million of national currency units,2.4
23200,Luxembourg,2011,8,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6
23201,Luxembourg,2011,8,N05B-Anxiolytics,Million of national currency units,2.4
23202,Luxembourg,2011,8,N05B-Anxiolytics,% of total sales,1.3
23203,Luxembourg,2011,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.5
23204,Luxembourg,2011,8,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9
23205,Luxembourg,2011,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
23206,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",25.0
23207,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.8
23208,Luxembourg,2011,8,A02A-Antacids,% of total sales,0.2
23209,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,% of total sales,5.8
23210,Luxembourg,2011,8,A02A-Antacids,"/capita, US$ exchange rate",0.9
23211,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.5
23212,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.1
23213,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,12.0
23214,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,8.6
23215,Luxembourg,2011,8,A02A-Antacids,"Million US$, purchasing power parity",0.3
23216,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,Million of national currency units,11.0
23217,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.6
23218,Luxembourg,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",9.5
23219,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,15.2
23220,Luxembourg,2011,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",12.1
23221,Luxembourg,2011,8,N-Nervous system,Million of national currency units,33.5
23222,Luxembourg,2011,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",65.1
23223,Luxembourg,2011,8,A-Alimentary tract and metabolism,% of total sales,14.9
23224,Luxembourg,2011,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,39.5
23225,Luxembourg,2011,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",31.4
23226,Luxembourg,2011,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",82.0
23227,Luxembourg,2011,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.7
23228,Luxembourg,2011,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.2
23229,Luxembourg,2011,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.3
23230,Luxembourg,2011,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",6.9
23231,Luxembourg,2011,8,N05C-Hypnotics and sedatives,% of total sales,1.6
23232,Luxembourg,2011,8,N-Nervous system,"/capita, US$ purchasing power parity",76.8
23233,Luxembourg,2011,8,N-Nervous system,% of total sales,17.6
23234,Luxembourg,2011,8,N-Nervous system,"/capita, US$ exchange rate",96.8
23235,Luxembourg,2011,8,N-Nervous system,Million US$ at exchange rate,46.6
23236,Luxembourg,2011,8,N-Nervous system,"Million US$, purchasing power parity",37.0
23237,Luxembourg,2011,8,N06A-Antidepressants,"Million US$, purchasing power parity",7.5
23238,Luxembourg,2011,8,N06A-Antidepressants,Million US$ at exchange rate,9.5
23239,Luxembourg,2011,8,A-Alimentary tract and metabolism,Million of national currency units,28.4
23240,Luxembourg,2011,8,N06A-Antidepressants,Million of national currency units,6.8
23241,Luxembourg,2011,8,N06A-Antidepressants,% of total sales,3.6
23242,Luxembourg,2011,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.6
23243,Luxembourg,2011,8,N06A-Antidepressants,"/capita, US$ exchange rate",19.6
23244,Luxembourg,2011,8,Total pharmaceutical sales,Million US$ at exchange rate,265.0
23245,Luxembourg,2011,8,Total pharmaceutical sales,"Million US$, purchasing power parity",210.4
23246,Luxembourg,2011,8,Total pharmaceutical sales,Million of national currency units,190.4
23247,Luxembourg,2011,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",436.5
23248,Luxembourg,2011,8,Total pharmaceutical sales,"/capita, US$ exchange rate",549.9
23249,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.9
23250,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,7.7
23251,Luxembourg,2011,8,A02A-Antacids,Million of national currency units,0.3
23252,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.5
23253,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.1
23254,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.6
23255,Luxembourg,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.9
23256,Luxembourg,2011,8,A02A-Antacids,Million US$ at exchange rate,0.4
23257,Luxembourg,2011,8,N02-Analgesics,"/capita, US$ exchange rate",21.0
23258,Luxembourg,2011,8,N02-Analgesics,% of total sales,3.8
23259,Luxembourg,2011,8,N02-Analgesics,"/capita, US$ purchasing power parity",16.7
23260,Luxembourg,2011,8,N02-Analgesics,"Million US$, purchasing power parity",8.0
23261,Luxembourg,2011,8,N02-Analgesics,Million of national currency units,7.3
23262,Luxembourg,2011,8,N05C-Hypnotics and sedatives,Million of national currency units,3.0
23263,Luxembourg,2011,8,N02-Analgesics,Million US$ at exchange rate,10.1
23264,Luxembourg,2011,8,R-Respiratory system,"/capita, US$ exchange rate",43.2
23265,Luxembourg,2011,8,R-Respiratory system,"/capita, US$ purchasing power parity",34.3
23266,Luxembourg,2011,8,R-Respiratory system,% of total sales,7.9
23267,Luxembourg,2011,8,R-Respiratory system,Million of national currency units,15.0
23268,Luxembourg,2011,8,R-Respiratory system,"Million US$, purchasing power parity",16.5
23269,Luxembourg,2011,8,R-Respiratory system,Million US$ at exchange rate,20.8
23270,Luxembourg,2011,8,N05B-Anxiolytics,Million US$ at exchange rate,3.3
23271,Luxembourg,2011,8,A10-Drugs used in diabetes,Million of national currency units,10.3
23272,Luxembourg,2011,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",10.1
23273,Luxembourg,2011,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.4
23274,Luxembourg,2011,8,B-Blood and blood forming organs,Million US$ at exchange rate,12.7
23275,Luxembourg,2011,8,C02-Antihypertensives,% of total sales,0.2
23276,Luxembourg,2011,8,B-Blood and blood forming organs,% of total sales,4.8
23277,Luxembourg,2011,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.0
23278,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.9
23279,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
23280,Luxembourg,2011,8,B-Blood and blood forming organs,Million of national currency units,9.2
23281,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.0
23282,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.3
23283,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.4
23284,Luxembourg,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.8
23285,Luxembourg,2011,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
23286,Luxembourg,2011,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.1
23287,Luxembourg,2011,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.1
23288,Luxembourg,2011,8,C02-Antihypertensives,Million of national currency units,0.4
23289,Luxembourg,2011,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",21.2
23290,Luxembourg,2011,8,M-Musculo-skeletal system,% of total sales,4.8
23291,Luxembourg,2011,8,J-Antiinfectives for systemic use,% of total sales,5.6
23292,Luxembourg,2011,8,M-Musculo-skeletal system,Million of national currency units,9.2
23293,Luxembourg,2011,8,M-Musculo-skeletal system,Million US$ at exchange rate,12.8
23294,Luxembourg,2011,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",26.7
23295,Luxembourg,2011,8,C01A-Cardiac glycosides,Million of national currency units,0.1
23296,Luxembourg,2011,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",10.2
23297,Luxembourg,2011,8,C03-Diuretics,Million of national currency units,1.6
23298,Luxembourg,2011,8,C03-Diuretics,Million US$ at exchange rate,2.3
23299,Luxembourg,2011,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",19.3
23300,Luxembourg,2011,8,C10-Lipid modifying agents,Million US$ at exchange rate,24.3
23301,Luxembourg,2011,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
23302,Luxembourg,2011,8,C03-Diuretics,"/capita, US$ exchange rate",4.7
23303,Luxembourg,2011,8,C03-Diuretics,"Million US$, purchasing power parity",1.8
23304,Luxembourg,2011,8,C02-Antihypertensives,"Million US$, purchasing power parity",0.5
23305,Luxembourg,2011,8,C02-Antihypertensives,"/capita, US$ exchange rate",1.2
23306,Luxembourg,2011,8,C02-Antihypertensives,Million US$ at exchange rate,0.6
23307,Luxembourg,2011,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",50.3
23308,Luxembourg,2011,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",40.0
23309,Luxembourg,2011,8,C10-Lipid modifying agents,% of total sales,9.2
23310,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
23311,Luxembourg,2011,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
23312,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
23313,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.8
23314,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
23315,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6
23316,Luxembourg,2011,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
23317,Luxembourg,2011,8,J-Antiinfectives for systemic use,Million of national currency units,10.6
23318,Luxembourg,2011,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,14.8
23319,Luxembourg,2011,8,C10-Lipid modifying agents,Million of national currency units,17.4
23320,Luxembourg,2011,8,C03-Diuretics,% of total sales,0.9
23321,Luxembourg,2011,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.3
23322,Luxembourg,2011,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",11.7
23323,Luxembourg,2011,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",30.6
23324,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.7
23325,Luxembourg,2011,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.5
23326,Luxembourg,2011,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.5
23327,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.7
23328,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.3
23329,Luxembourg,2011,8,C01A-Cardiac glycosides,% of total sales,0.0
23330,Luxembourg,2011,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",19.7
23331,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,2.5
23332,Luxembourg,2011,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.6
23333,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.1
23334,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.4
23335,Luxembourg,2011,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",2.7
23336,Luxembourg,2011,8,J01-Antibacterials for systemic use,Million of national currency units,6.8
23337,Luxembourg,2011,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.6
23338,Luxembourg,2011,8,A10-Drugs used in diabetes,% of total sales,5.4
23339,Luxembourg,2011,8,G-Genito urinary system and sex hormones,Million of national currency units,6.8
23340,Luxembourg,2011,8,A10-Drugs used in diabetes,Million US$ at exchange rate,14.4
23341,Luxembourg,2011,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",11.4
23342,Luxembourg,2011,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.8
23343,Luxembourg,2011,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.7
23344,Luxembourg,2011,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.6
23345,Luxembourg,2011,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",7.5
23346,Luxembourg,2011,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,9.5
23347,Luxembourg,2011,8,C-Cardiovascular system,% of total sales,22.0
23348,Luxembourg,2011,8,J01-Antibacterials for systemic use,% of total sales,3.6
23349,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",16.1
23350,Luxembourg,2011,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.6
23351,Luxembourg,2011,8,C07-Beta blocking agents,% of total sales,1.7
23352,Luxembourg,2011,8,C08-Calcium channel blockers,% of total sales,1.4
23353,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,14.6
23354,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,20.3
23355,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",42.2
23356,Luxembourg,2011,8,C07-Beta blocking agents,Million of national currency units,3.3
23357,Luxembourg,2011,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",33.5
23358,Luxembourg,2011,8,C07-Beta blocking agents,"/capita, US$ exchange rate",9.6
23359,Luxembourg,2011,8,C07-Beta blocking agents,Million US$ at exchange rate,4.6
23360,Luxembourg,2011,8,C07-Beta blocking agents,"Million US$, purchasing power parity",3.7
23361,Luxembourg,2011,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
23362,Luxembourg,2011,8,C-Cardiovascular system,"Million US$, purchasing power parity",46.3
23363,Luxembourg,2011,8,C-Cardiovascular system,"/capita, US$ exchange rate",121.2
23364,Luxembourg,2011,8,C-Cardiovascular system,Million US$ at exchange rate,58.4
23365,Luxembourg,2011,8,G-Genito urinary system and sex hormones,% of total sales,3.6
23366,Luxembourg,2011,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",96.2
23367,Luxembourg,2011,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.9
23368,Luxembourg,2011,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.9
23369,Luxembourg,2011,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.5
23370,Luxembourg,2011,8,C08-Calcium channel blockers,Million US$ at exchange rate,3.6
23371,Luxembourg,2011,8,C-Cardiovascular system,Million of national currency units,42.0
23372,Luxembourg,2011,8,C08-Calcium channel blockers,Million of national currency units,2.6
23373,Luxembourg,2010,8,N05B-Anxiolytics,"Million US$, purchasing power parity",2.6
23374,Luxembourg,2010,8,N05B-Anxiolytics,Million of national currency units,2.4
23375,Luxembourg,2010,8,N05B-Anxiolytics,Million US$ at exchange rate,3.2
23376,Luxembourg,2010,8,N05B-Anxiolytics,"/capita, US$ exchange rate",6.7
23377,Luxembourg,2010,8,N05B-Anxiolytics,% of total sales,1.3
23378,Luxembourg,2010,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.5
23379,Luxembourg,2010,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
23380,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",24.1
23381,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",29.6
23382,Luxembourg,2010,8,A02A-Antacids,% of total sales,0.1
23383,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,% of total sales,5.6
23384,Luxembourg,2010,8,A02A-Antacids,"/capita, US$ exchange rate",0.8
23385,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.6
23386,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",24.3
23387,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,14.0
23388,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,10.6
23389,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,Million of national currency units,10.7
23390,Luxembourg,2010,8,A02A-Antacids,"Million US$, purchasing power parity",0.3
23391,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.8
23392,Luxembourg,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",11.4
23393,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,14.1
23394,Luxembourg,2010,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",11.5
23395,Luxembourg,2010,8,A02A-Antacids,Million US$ at exchange rate,0.4
23396,Luxembourg,2010,8,A-Alimentary tract and metabolism,% of total sales,15.1
23397,Luxembourg,2010,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",65.1
23398,Luxembourg,2010,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,37.8
23399,Luxembourg,2010,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",30.8
23400,Luxembourg,2010,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",79.9
23401,Luxembourg,2010,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",8.4
23402,Luxembourg,2010,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",3.2
23403,Luxembourg,2010,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",6.8
23404,Luxembourg,2010,8,N05C-Hypnotics and sedatives,% of total sales,1.6
23405,Luxembourg,2010,8,N-Nervous system,"/capita, US$ purchasing power parity",74.7
23406,Luxembourg,2010,8,N-Nervous system,% of total sales,17.3
23407,Luxembourg,2010,8,N-Nervous system,"/capita, US$ exchange rate",91.7
23408,Luxembourg,2010,8,N-Nervous system,Million US$ at exchange rate,43.4
23409,Luxembourg,2010,8,N-Nervous system,"Million US$, purchasing power parity",35.3
23410,Luxembourg,2010,8,N06A-Antidepressants,"Million US$, purchasing power parity",7.6
23411,Luxembourg,2010,8,N06A-Antidepressants,Million US$ at exchange rate,9.4
23412,Luxembourg,2010,8,A-Alimentary tract and metabolism,Million of national currency units,28.5
23413,Luxembourg,2010,8,N06A-Antidepressants,Million of national currency units,7.1
23414,Luxembourg,2010,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,4.0
23415,Luxembourg,2010,8,N06A-Antidepressants,% of total sales,3.7
23416,Luxembourg,2010,8,N06A-Antidepressants,"/capita, US$ exchange rate",19.8
23417,Luxembourg,2010,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2
23418,Luxembourg,2010,8,Total pharmaceutical sales,Million US$ at exchange rate,251.1
23419,Luxembourg,2010,8,Total pharmaceutical sales,"Million US$, purchasing power parity",204.6
23420,Luxembourg,2010,8,Total pharmaceutical sales,Million of national currency units,189.4
23421,Luxembourg,2010,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",432.5
23422,Luxembourg,2010,8,Total pharmaceutical sales,"/capita, US$ exchange rate",530.7
23423,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.9
23424,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,7.3
23425,Luxembourg,2010,8,A02A-Antacids,Million of national currency units,0.3
23426,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.5
23427,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.6
23428,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.5
23429,Luxembourg,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.0
23430,Luxembourg,2010,8,N02-Analgesics,"/capita, US$ exchange rate",19.1
23431,Luxembourg,2010,8,N02-Analgesics,% of total sales,3.6
23432,Luxembourg,2010,8,N02-Analgesics,"/capita, US$ purchasing power parity",15.6
23433,Luxembourg,2010,8,N02-Analgesics,Million of national currency units,6.8
23434,Luxembourg,2010,8,N05C-Hypnotics and sedatives,Million of national currency units,3.0
23435,Luxembourg,2010,8,N02-Analgesics,"Million US$, purchasing power parity",7.4
23436,Luxembourg,2010,8,N02-Analgesics,Million US$ at exchange rate,9.0
23437,Luxembourg,2010,8,R-Respiratory system,"/capita, US$ exchange rate",42.9
23438,Luxembourg,2010,8,R-Respiratory system,"/capita, US$ purchasing power parity",34.9
23439,Luxembourg,2010,8,R-Respiratory system,% of total sales,8.1
23440,Luxembourg,2010,8,R-Respiratory system,Million of national currency units,15.3
23441,Luxembourg,2010,8,N-Nervous system,Million of national currency units,32.7
23442,Luxembourg,2010,8,R-Respiratory system,"Million US$, purchasing power parity",16.5
23443,Luxembourg,2010,8,R-Respiratory system,Million US$ at exchange rate,20.3
23444,Luxembourg,2010,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",10.4
23445,Luxembourg,2010,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.9
23446,Luxembourg,2010,8,B-Blood and blood forming organs,Million US$ at exchange rate,12.7
23447,Luxembourg,2010,8,C02-Antihypertensives,% of total sales,0.2
23448,Luxembourg,2010,8,B-Blood and blood forming organs,% of total sales,5.1
23449,Luxembourg,2010,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.9
23450,Luxembourg,2010,8,B-Blood and blood forming organs,Million of national currency units,9.6
23451,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.4
23452,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
23453,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.5
23454,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,5.4
23455,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,4.1
23456,Luxembourg,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",4.4
23457,Luxembourg,2010,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
23458,Luxembourg,2010,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
23459,Luxembourg,2010,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0
23460,Luxembourg,2010,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.0
23461,Luxembourg,2010,8,M-Musculo-skeletal system,% of total sales,5.1
23462,Luxembourg,2010,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.0
23463,Luxembourg,2010,8,J-Antiinfectives for systemic use,% of total sales,5.6
23464,Luxembourg,2010,8,M-Musculo-skeletal system,Million of national currency units,9.7
23465,Luxembourg,2010,8,M-Musculo-skeletal system,Million US$ at exchange rate,12.8
23466,Luxembourg,2010,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",27.0
23467,Luxembourg,2010,8,C01A-Cardiac glycosides,Million of national currency units,0.0
23468,Luxembourg,2010,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",10.4
23469,Luxembourg,2010,8,C03-Diuretics,Million of national currency units,1.7
23470,Luxembourg,2010,8,C03-Diuretics,Million US$ at exchange rate,2.3
23471,Luxembourg,2010,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",17.1
23472,Luxembourg,2010,8,C10-Lipid modifying agents,Million US$ at exchange rate,21.0
23473,Luxembourg,2010,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.9
23474,Luxembourg,2010,8,C03-Diuretics,"/capita, US$ exchange rate",4.8
23475,Luxembourg,2010,8,C03-Diuretics,"Million US$, purchasing power parity",1.8
23476,Luxembourg,2010,8,C02-Antihypertensives,"Million US$, purchasing power parity",0.5
23477,Luxembourg,2010,8,C02-Antihypertensives,"/capita, US$ exchange rate",1.3
23478,Luxembourg,2010,8,C02-Antihypertensives,Million US$ at exchange rate,0.6
23479,Luxembourg,2010,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",44.4
23480,Luxembourg,2010,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",36.1
23481,Luxembourg,2010,8,C10-Lipid modifying agents,% of total sales,8.4
23482,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.3
23483,Luxembourg,2010,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
23484,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
23485,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.6
23486,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.7
23487,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.6
23488,Luxembourg,2010,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
23489,Luxembourg,2010,8,J-Antiinfectives for systemic use,Million of national currency units,10.7
23490,Luxembourg,2010,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,14.1
23491,Luxembourg,2010,8,C10-Lipid modifying agents,Million of national currency units,15.8
23492,Luxembourg,2010,8,C03-Diuretics,% of total sales,0.9
23493,Luxembourg,2010,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.3
23494,Luxembourg,2010,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",29.8
23495,Luxembourg,2010,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",11.5
23496,Luxembourg,2010,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",7.7
23497,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.5
23498,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,% of total sales,1.3
23499,Luxembourg,2010,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,9.4
23500,Luxembourg,2010,8,C01A-Cardiac glycosides,% of total sales,0.0
23501,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.9
23502,Luxembourg,2010,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",19.9
23503,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,2.4
23504,Luxembourg,2010,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",16.2
23505,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.8
23506,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,3.2
23507,Luxembourg,2010,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",2.6
23508,Luxembourg,2010,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.9
23509,Luxembourg,2010,8,G-Genito urinary system and sex hormones,Million of national currency units,6.8
23510,Luxembourg,2010,8,A10-Drugs used in diabetes,Million of national currency units,9.1
23511,Luxembourg,2010,8,A10-Drugs used in diabetes,% of total sales,4.8
23512,Luxembourg,2010,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",25.6
23513,Luxembourg,2010,8,A10-Drugs used in diabetes,Million US$ at exchange rate,12.1
23514,Luxembourg,2010,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",9.9
23515,Luxembourg,2010,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.1
23516,Luxembourg,2010,8,J01-Antibacterials for systemic use,Million of national currency units,7.1
23517,Luxembourg,2010,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.5
23518,Luxembourg,2010,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",7.3
23519,Luxembourg,2010,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,9.0
23520,Luxembourg,2010,8,C-Cardiovascular system,% of total sales,21.7
23521,Luxembourg,2010,8,J01-Antibacterials for systemic use,% of total sales,3.7
23522,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",16.1
23523,Luxembourg,2010,8,C07-Beta blocking agents,% of total sales,1.8
23524,Luxembourg,2010,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.8
23525,Luxembourg,2010,8,C08-Calcium channel blockers,% of total sales,1.5
23526,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,14.9
23527,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,19.8
23528,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",41.8
23529,Luxembourg,2010,8,C07-Beta blocking agents,Million of national currency units,3.4
23530,Luxembourg,2010,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.0
23531,Luxembourg,2010,8,C07-Beta blocking agents,"/capita, US$ exchange rate",9.6
23532,Luxembourg,2010,8,C07-Beta blocking agents,Million US$ at exchange rate,4.5
23533,Luxembourg,2010,8,C07-Beta blocking agents,"Million US$, purchasing power parity",3.7
23534,Luxembourg,2010,8,C-Cardiovascular system,"Million US$, purchasing power parity",44.4
23535,Luxembourg,2010,8,C-Cardiovascular system,"/capita, US$ exchange rate",115.1
23536,Luxembourg,2010,8,C-Cardiovascular system,Million US$ at exchange rate,54.4
23537,Luxembourg,2010,8,G-Genito urinary system and sex hormones,% of total sales,3.6
23538,Luxembourg,2010,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",93.8
23539,Luxembourg,2010,8,C02-Antihypertensives,Million of national currency units,0.5
23540,Luxembourg,2010,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",3.0
23541,Luxembourg,2010,8,C08-Calcium channel blockers,Million US$ at exchange rate,3.6
23542,Luxembourg,2010,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.3
23543,Luxembourg,2010,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",7.7
23544,Luxembourg,2010,8,C08-Calcium channel blockers,Million of national currency units,2.8
23545,Luxembourg,2010,8,C-Cardiovascular system,Million of national currency units,41.1
23546,Luxembourg,2017,5,N05B-Anxiolytics,Million of national currency units,2.6
23547,Luxembourg,2017,5,N05B-Anxiolytics,Million US$ at exchange rate,2.9
23548,Luxembourg,2017,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",5.6
23549,Luxembourg,2017,5,N05B-Anxiolytics,% of total sales,1.3
23550,Luxembourg,2017,5,N05B-Anxiolytics,"Million US$, purchasing power parity",3.0
23551,Luxembourg,2017,5,N05B-Anxiolytics,"/capita, US$ exchange rate",5.4
23552,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.8
23553,Luxembourg,2017,5,A02A-Antacids,% of total sales,0.2
23554,Luxembourg,2017,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
23555,Luxembourg,2017,5,A02A-Antacids,"/capita, US$ exchange rate",0.8
23556,Luxembourg,2017,5,A02A-Antacids,"Million US$, purchasing power parity",0.4
23557,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.7
23558,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.4
23559,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6
23560,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.3
23561,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.0
23562,Luxembourg,2017,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,7.9
23563,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,% of total sales,4.9
23564,Luxembourg,2017,5,A02A-Antacids,Million US$ at exchange rate,0.4
23565,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",11.1
23566,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",19.9
23567,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,Million of national currency units,9.4
23568,Luxembourg,2017,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,10.6
23569,Luxembourg,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",77.5
23570,Luxembourg,2017,5,N05C-Hypnotics and sedatives,% of total sales,1.8
23571,Luxembourg,2017,5,A-Alimentary tract and metabolism,% of total sales,18.2
23572,Luxembourg,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",74.3
23573,Luxembourg,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,39.8
23574,Luxembourg,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",41.5
23575,Luxembourg,2017,5,A-Alimentary tract and metabolism,Million of national currency units,35.2
23576,Luxembourg,2017,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.0
23577,Luxembourg,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",7.2
23578,Luxembourg,2017,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.9
23579,Luxembourg,2017,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",7.5
23580,Luxembourg,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",69.3
23581,Luxembourg,2017,5,N-Nervous system,"/capita, US$ exchange rate",66.4
23582,Luxembourg,2017,5,N-Nervous system,% of total sales,16.2
23583,Luxembourg,2017,5,N-Nervous system,Million of national currency units,31.5
23584,Luxembourg,2017,5,N-Nervous system,Million US$ at exchange rate,35.6
23585,Luxembourg,2017,5,N-Nervous system,"Million US$, purchasing power parity",37.2
23586,Luxembourg,2017,5,N06A-Antidepressants,Million US$ at exchange rate,5.8
23587,Luxembourg,2017,5,N06A-Antidepressants,Million of national currency units,5.1
23588,Luxembourg,2017,5,N06A-Antidepressants,"Million US$, purchasing power parity",6.0
23589,Luxembourg,2017,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.3
23590,Luxembourg,2017,5,N06A-Antidepressants,% of total sales,2.6
23591,Luxembourg,2017,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.8
23592,Luxembourg,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,219.2
23593,Luxembourg,2017,5,Total pharmaceutical sales,Million of national currency units,194.1
23594,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.8
23595,Luxembourg,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",426.8
23596,Luxembourg,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",228.8
23597,Luxembourg,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",409.0
23598,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,5.5
23599,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.2
23600,Luxembourg,2017,5,A02A-Antacids,Million of national currency units,0.4
23601,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",12.0
23602,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.5
23603,Luxembourg,2017,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",6.4
23604,Luxembourg,2017,5,N02-Analgesics,"/capita, US$ exchange rate",16.3
23605,Luxembourg,2017,5,N02-Analgesics,"Million US$, purchasing power parity",9.1
23606,Luxembourg,2017,5,N02-Analgesics,"/capita, US$ purchasing power parity",17.0
23607,Luxembourg,2017,5,N05C-Hypnotics and sedatives,Million of national currency units,3.4
23608,Luxembourg,2017,5,N02-Analgesics,Million of national currency units,7.7
23609,Luxembourg,2017,5,N02-Analgesics,Million US$ at exchange rate,8.7
23610,Luxembourg,2017,5,R-Respiratory system,"/capita, US$ exchange rate",27.7
23611,Luxembourg,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",28.9
23612,Luxembourg,2017,5,R-Respiratory system,"Million US$, purchasing power parity",15.5
23613,Luxembourg,2017,5,R-Respiratory system,% of total sales,6.8
23614,Luxembourg,2017,5,R-Respiratory system,Million of national currency units,13.2
23615,Luxembourg,2017,5,N02-Analgesics,% of total sales,4.0
23616,Luxembourg,2017,5,R-Respiratory system,Million US$ at exchange rate,14.9
23617,Luxembourg,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",18.4
23618,Luxembourg,2017,5,B-Blood and blood forming organs,Million of national currency units,15.6
23619,Luxembourg,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,17.6
23620,Luxembourg,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",32.9
23621,Luxembourg,2017,5,B-Blood and blood forming organs,% of total sales,8.0
23622,Luxembourg,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.4
23623,Luxembourg,2017,5,C02-Antihypertensives,% of total sales,0.2
23624,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.7
23625,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.3
23626,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.8
23627,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,5.3
23628,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,6.0
23629,Luxembourg,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",6.3
23630,Luxembourg,2017,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
23631,Luxembourg,2017,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.0
23632,Luxembourg,2017,5,C01A-Cardiac glycosides,Million US$ at exchange rate,0.0
23633,Luxembourg,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.5
23634,Luxembourg,2017,5,M-Musculo-skeletal system,% of total sales,5.5
23635,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.0
23636,Luxembourg,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",23.5
23637,Luxembourg,2017,5,J-Antiinfectives for systemic use,% of total sales,4.6
23638,Luxembourg,2017,5,M-Musculo-skeletal system,Million of national currency units,10.7
23639,Luxembourg,2017,5,C10-Lipid modifying agents,% of total sales,6.0
23640,Luxembourg,2017,5,C01A-Cardiac glycosides,Million of national currency units,0.0
23641,Luxembourg,2017,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.0
23642,Luxembourg,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",12.6
23643,Luxembourg,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,12.1
23644,Luxembourg,2017,5,C10-Lipid modifying agents,Million of national currency units,11.6
23645,Luxembourg,2017,5,C03-Diuretics,Million of national currency units,1.4
23646,Luxembourg,2017,5,C10-Lipid modifying agents,Million US$ at exchange rate,13.1
23647,Luxembourg,2017,5,C03-Diuretics,"/capita, US$ exchange rate",3.0
23648,Luxembourg,2017,5,C03-Diuretics,Million US$ at exchange rate,1.6
23649,Luxembourg,2017,5,C03-Diuretics,"Million US$, purchasing power parity",1.7
23650,Luxembourg,2017,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",13.7
23651,Luxembourg,2017,5,C02-Antihypertensives,"Million US$, purchasing power parity",0.5
23652,Luxembourg,2017,5,C02-Antihypertensives,Million US$ at exchange rate,0.5
23653,Luxembourg,2017,5,C02-Antihypertensives,Million of national currency units,0.4
23654,Luxembourg,2017,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",24.5
23655,Luxembourg,2017,5,C02-Antihypertensives,"/capita, US$ exchange rate",0.9
23656,Luxembourg,2017,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.5
23657,Luxembourg,2017,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.1
23658,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
23659,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.1
23660,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
23661,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,0.5
23662,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,0.6
23663,Luxembourg,2017,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",0.6
23664,Luxembourg,2017,5,J-Antiinfectives for systemic use,Million of national currency units,8.9
23665,Luxembourg,2017,5,C03-Diuretics,% of total sales,0.7
23666,Luxembourg,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,10.0
23667,Luxembourg,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.7
23668,Luxembourg,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.5
23669,Luxembourg,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",10.4
23670,Luxembourg,2017,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,6.2
23671,Luxembourg,2017,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",6.4
23672,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.0
23673,Luxembourg,2017,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
23674,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,% of total sales,1.9
23675,Luxembourg,2017,5,J01-Antibacterials for systemic use,Million of national currency units,5.5
23676,Luxembourg,2017,5,C01A-Cardiac glycosides,% of total sales,0.0
23677,Luxembourg,2017,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.5
23678,Luxembourg,2017,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",12.0
23679,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,3.6
23680,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",4.3
23681,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",7.7
23682,Luxembourg,2017,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,4.1
23683,Luxembourg,2017,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.6
23684,Luxembourg,2017,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",36.0
23685,Luxembourg,2017,5,A10-Drugs used in diabetes,% of total sales,8.8
23686,Luxembourg,2017,5,A10-Drugs used in diabetes,Million of national currency units,17.1
23687,Luxembourg,2017,5,A10-Drugs used in diabetes,Million US$ at exchange rate,19.3
23688,Luxembourg,2017,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",20.1
23689,Luxembourg,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",10.4
23690,Luxembourg,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",18.7
23691,Luxembourg,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.5
23692,Luxembourg,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,8.9
23693,Luxembourg,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,10.0
23694,Luxembourg,2017,5,C-Cardiovascular system,% of total sales,15.6
23695,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",11.5
23696,Luxembourg,2017,5,C07-Beta blocking agents,% of total sales,1.8
23697,Luxembourg,2017,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.9
23698,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,11.0
23699,Luxembourg,2017,5,C08-Calcium channel blockers,% of total sales,0.9
23700,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,9.8
23701,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.6
23702,Luxembourg,2017,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",21.5
23703,Luxembourg,2017,5,C07-Beta blocking agents,Million of national currency units,3.6
23704,Luxembourg,2017,5,C07-Beta blocking agents,"Million US$, purchasing power parity",4.2
23705,Luxembourg,2017,5,C07-Beta blocking agents,"/capita, US$ exchange rate",7.6
23706,Luxembourg,2017,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.8
23707,Luxembourg,2017,5,C07-Beta blocking agents,Million US$ at exchange rate,4.1
23708,Luxembourg,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",35.6
23709,Luxembourg,2017,5,C-Cardiovascular system,Million of national currency units,30.2
23710,Luxembourg,2017,5,C-Cardiovascular system,Million US$ at exchange rate,34.2
23711,Luxembourg,2017,5,G-Genito urinary system and sex hormones,% of total sales,4.6
23712,Luxembourg,2017,5,J01-Antibacterials for systemic use,% of total sales,2.8
23713,Luxembourg,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",63.7
23714,Luxembourg,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",66.5
23715,Luxembourg,2017,5,C08-Calcium channel blockers,Million US$ at exchange rate,2.0
23716,Luxembourg,2017,5,C08-Calcium channel blockers,Million of national currency units,1.7
23717,Luxembourg,2017,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.6
23718,Luxembourg,2017,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",2.0
23719,Mexico,2016,34,M-Musculo-skeletal system,Million of national currency units,2604.0
23720,Mexico,2016,34,R-Respiratory system,Million of national currency units,6149.0
23721,Mexico,2016,34,M-Musculo-skeletal system,"/capita, US$ exchange rate",1.1
23722,Mexico,2016,34,M-Musculo-skeletal system,Million US$ at exchange rate,139.5
23723,Mexico,2016,34,M-Musculo-skeletal system,"Million US$, purchasing power parity",308.3
23724,Mexico,2016,34,C-Cardiovascular system,"/capita, US$ exchange rate",5.2
23725,Mexico,2016,34,C-Cardiovascular system,"Million US$, purchasing power parity",1402.6
23726,Mexico,2016,34,C-Cardiovascular system,Million US$ at exchange rate,634.7
23727,Mexico,2016,34,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.2
23728,Mexico,2016,34,C-Cardiovascular system,"/capita, US$ purchasing power parity",11.4
23729,Mexico,2016,34,Products not elsewhere classified,"/capita, US$ exchange rate",8.4
23730,Mexico,2016,34,Products not elsewhere classified,"Million US$, purchasing power parity",2270.2
23731,Mexico,2016,34,Products not elsewhere classified,"/capita, US$ purchasing power parity",18.5
23732,Mexico,2016,34,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.1
23733,Mexico,2016,34,Products not elsewhere classified,Million of national currency units,19174.5
23734,Mexico,2016,34,C-Cardiovascular system,Million of national currency units,11846.0
23735,Mexico,2016,34,Products not elsewhere classified,Million US$ at exchange rate,1027.3
23736,Mexico,2016,34,N-Nervous system,Million of national currency units,15668.0
23737,Mexico,2016,34,N-Nervous system,Million US$ at exchange rate,839.5
23738,Mexico,2016,34,R-Respiratory system,"/capita, US$ purchasing power parity",5.9
23739,Mexico,2016,34,R-Respiratory system,"Million US$, purchasing power parity",728.0
23740,Mexico,2016,34,R-Respiratory system,Million US$ at exchange rate,329.5
23741,Mexico,2016,34,R-Respiratory system,"/capita, US$ exchange rate",2.7
23742,Mexico,2016,34,N-Nervous system,"Million US$, purchasing power parity",1855.1
23743,Mexico,2016,34,J-Antiinfectives for systemic use,Million US$ at exchange rate,1122.0
23744,Mexico,2016,34,J-Antiinfectives for systemic use,Million of national currency units,20942.0
23745,Mexico,2016,34,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2479.5
23746,Mexico,2016,34,N-Nervous system,"/capita, US$ exchange rate",6.8
23747,Mexico,2016,34,N-Nervous system,"/capita, US$ purchasing power parity",15.1
23748,Mexico,2016,34,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",2.5
23749,Mexico,2016,34,B-Blood and blood forming organs,Million of national currency units,1766.0
23750,Mexico,2016,34,B-Blood and blood forming organs,Million US$ at exchange rate,94.6
23751,Mexico,2016,34,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",1.7
23752,Mexico,2016,34,B-Blood and blood forming organs,"Million US$, purchasing power parity",209.1
23753,Mexico,2016,34,B-Blood and blood forming organs,"/capita, US$ exchange rate",0.8
23754,Mexico,2015,36,M-Musculo-skeletal system,Million of national currency units,3283.0
23755,Mexico,2015,36,R-Respiratory system,Million of national currency units,5656.0
23756,Mexico,2015,36,M-Musculo-skeletal system,"/capita, US$ exchange rate",1.7
23757,Mexico,2015,36,M-Musculo-skeletal system,Million US$ at exchange rate,207.2
23758,Mexico,2015,36,M-Musculo-skeletal system,"Million US$, purchasing power parity",394.2
23759,Mexico,2015,36,R-Respiratory system,Million US$ at exchange rate,356.9
23760,Mexico,2015,36,C-Cardiovascular system,"/capita, US$ exchange rate",5.0
23761,Mexico,2015,36,C-Cardiovascular system,"Million US$, purchasing power parity",1150.8
23762,Mexico,2015,36,C-Cardiovascular system,Million US$ at exchange rate,604.7
23763,Mexico,2015,36,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.8
23764,Mexico,2015,36,C-Cardiovascular system,"/capita, US$ purchasing power parity",9.5
23765,Mexico,2015,36,Products not elsewhere classified,"/capita, US$ exchange rate",9.1
23766,Mexico,2015,36,Products not elsewhere classified,"Million US$, purchasing power parity",2108.6
23767,Mexico,2015,36,Products not elsewhere classified,"/capita, US$ purchasing power parity",17.4
23768,Mexico,2015,36,Products not elsewhere classified,Million of national currency units,17559.7
23769,Mexico,2015,36,C-Cardiovascular system,Million of national currency units,9583.0
23770,Mexico,2015,36,Products not elsewhere classified,Million US$ at exchange rate,1108.0
23771,Mexico,2015,36,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.9
23772,Mexico,2015,36,N-Nervous system,Million of national currency units,14984.0
23773,Mexico,2015,36,N-Nervous system,Million US$ at exchange rate,945.5
23774,Mexico,2015,36,R-Respiratory system,"Million US$, purchasing power parity",679.2
23775,Mexico,2015,36,R-Respiratory system,"/capita, US$ purchasing power parity",5.6
23776,Mexico,2015,36,R-Respiratory system,"/capita, US$ exchange rate",2.9
23777,Mexico,2015,36,J-Antiinfectives for systemic use,Million US$ at exchange rate,1200.3
23778,Mexico,2015,36,J-Antiinfectives for systemic use,Million of national currency units,19023.0
23779,Mexico,2015,36,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2284.3
23780,Mexico,2015,36,N-Nervous system,"Million US$, purchasing power parity",1799.3
23781,Mexico,2015,36,N-Nervous system,"/capita, US$ exchange rate",7.8
23782,Mexico,2015,36,N-Nervous system,"/capita, US$ purchasing power parity",14.8
23783,Mexico,2015,36,B-Blood and blood forming organs,Million of national currency units,2320.0
23784,Mexico,2015,36,B-Blood and blood forming organs,Million US$ at exchange rate,146.4
23785,Mexico,2015,36,B-Blood and blood forming organs,"Million US$, purchasing power parity",278.6
23786,Mexico,2015,36,B-Blood and blood forming organs,"/capita, US$ exchange rate",1.2
23787,Mexico,2015,36,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",2.3
23788,Mexico,2015,36,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.2
23789,Mexico,2014,38,M-Musculo-skeletal system,Million of national currency units,3091.0
23790,Mexico,2014,38,R-Respiratory system,Million of national currency units,6950.0
23791,Mexico,2014,38,M-Musculo-skeletal system,"/capita, US$ exchange rate",1.9
23792,Mexico,2014,38,M-Musculo-skeletal system,Million US$ at exchange rate,232.5
23793,Mexico,2014,38,M-Musculo-skeletal system,"Million US$, purchasing power parity",384.2
23794,Mexico,2014,38,C-Cardiovascular system,"/capita, US$ exchange rate",5.3
23795,Mexico,2014,38,C-Cardiovascular system,"Million US$, purchasing power parity",1042.6
23796,Mexico,2014,38,C-Cardiovascular system,Million US$ at exchange rate,631.0
23797,Mexico,2014,38,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",18.4
23798,Mexico,2014,38,C-Cardiovascular system,"/capita, US$ purchasing power parity",8.7
23799,Mexico,2014,38,Products not elsewhere classified,"/capita, US$ exchange rate",10.7
23800,Mexico,2014,38,Products not elsewhere classified,"Million US$, purchasing power parity",2126.5
23801,Mexico,2014,38,Products not elsewhere classified,"/capita, US$ purchasing power parity",17.7
23802,Mexico,2014,38,Products not elsewhere classified,Million of national currency units,17108.4
23803,Mexico,2014,38,C-Cardiovascular system,Million of national currency units,8388.0
23804,Mexico,2014,38,Products not elsewhere classified,Million US$ at exchange rate,1287.1
23805,Mexico,2014,38,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",11.1
23806,Mexico,2014,38,N-Nervous system,Million of national currency units,14128.0
23807,Mexico,2014,38,N-Nervous system,Million US$ at exchange rate,1062.9
23808,Mexico,2014,38,R-Respiratory system,"/capita, US$ purchasing power parity",7.2
23809,Mexico,2014,38,R-Respiratory system,"Million US$, purchasing power parity",863.9
23810,Mexico,2014,38,R-Respiratory system,"/capita, US$ exchange rate",4.4
23811,Mexico,2014,38,R-Respiratory system,Million US$ at exchange rate,522.9
23812,Mexico,2014,38,N-Nervous system,"Million US$, purchasing power parity",1756.1
23813,Mexico,2014,38,J-Antiinfectives for systemic use,Million US$ at exchange rate,1333.1
23814,Mexico,2014,38,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2202.5
23815,Mexico,2014,38,J-Antiinfectives for systemic use,Million of national currency units,17720.0
23816,Mexico,2014,38,N-Nervous system,"/capita, US$ exchange rate",8.9
23817,Mexico,2014,38,N-Nervous system,"/capita, US$ purchasing power parity",14.6
23818,Mexico,2014,38,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.2
23819,Mexico,2014,38,B-Blood and blood forming organs,"Million US$, purchasing power parity",270.5
23820,Mexico,2014,38,B-Blood and blood forming organs,Million US$ at exchange rate,163.7
23821,Mexico,2014,38,B-Blood and blood forming organs,Million of national currency units,2176.0
23822,Mexico,2014,38,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",2.3
23823,Mexico,2014,38,B-Blood and blood forming organs,"/capita, US$ exchange rate",1.4
23824,Mexico,2013,39,M-Musculo-skeletal system,Million of national currency units,3553.0
23825,Mexico,2013,39,R-Respiratory system,Million of national currency units,7254.0
23826,Mexico,2013,39,R-Respiratory system,Million US$ at exchange rate,568.0
23827,Mexico,2013,39,M-Musculo-skeletal system,Million US$ at exchange rate,278.2
23828,Mexico,2013,39,M-Musculo-skeletal system,"/capita, US$ exchange rate",2.3
23829,Mexico,2013,39,M-Musculo-skeletal system,"Million US$, purchasing power parity",450.6
23830,Mexico,2013,39,C-Cardiovascular system,"/capita, US$ exchange rate",6.6
23831,Mexico,2013,39,C-Cardiovascular system,"Million US$, purchasing power parity",1258.9
23832,Mexico,2013,39,C-Cardiovascular system,Million US$ at exchange rate,777.2
23833,Mexico,2013,39,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.5
23834,Mexico,2013,39,J-Antiinfectives for systemic use,% of total sales,12.8
23835,Mexico,2013,39,C-Cardiovascular system,"/capita, US$ purchasing power parity",10.6
23836,Mexico,2013,39,C-Cardiovascular system,% of total sales,7.0
23837,Mexico,2013,39,Products not elsewhere classified,"/capita, US$ exchange rate",11.8
23838,Mexico,2013,39,Products not elsewhere classified,% of total sales,12.6
23839,Mexico,2013,39,Products not elsewhere classified,"/capita, US$ purchasing power parity",19.1
23840,Mexico,2013,39,Products not elsewhere classified,"Million US$, purchasing power parity",2258.6
23841,Mexico,2013,39,Products not elsewhere classified,Million of national currency units,17807.7
23842,Mexico,2013,39,C-Cardiovascular system,Million of national currency units,9926.0
23843,Mexico,2013,39,Products not elsewhere classified,Million US$ at exchange rate,1394.3
23844,Mexico,2013,39,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.0
23845,Mexico,2013,39,N-Nervous system,Million of national currency units,13836.0
23846,Mexico,2013,39,R-Respiratory system,% of total sales,5.1
23847,Mexico,2013,39,N-Nervous system,Million US$ at exchange rate,1083.3
23848,Mexico,2013,39,N-Nervous system,"Million US$, purchasing power parity",1754.9
23849,Mexico,2013,39,R-Respiratory system,"Million US$, purchasing power parity",920.0
23850,Mexico,2013,39,R-Respiratory system,"/capita, US$ purchasing power parity",7.8
23851,Mexico,2013,39,R-Respiratory system,"/capita, US$ exchange rate",4.8
23852,Mexico,2013,39,J-Antiinfectives for systemic use,Million US$ at exchange rate,1426.0
23853,Mexico,2013,39,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2310.0
23854,Mexico,2013,39,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.8
23855,Mexico,2013,39,N-Nervous system,"/capita, US$ exchange rate",9.1
23856,Mexico,2013,39,J-Antiinfectives for systemic use,Million of national currency units,18213.0
23857,Mexico,2013,39,N-Nervous system,% of total sales,9.8
23858,Mexico,2013,39,N-Nervous system,"/capita, US$ purchasing power parity",14.8
23859,Mexico,2013,39,B-Blood and blood forming organs,"Million US$, purchasing power parity",281.3
23860,Mexico,2013,39,B-Blood and blood forming organs,Million US$ at exchange rate,173.7
23861,Mexico,2013,39,Total pharmaceutical sales,"/capita, US$ purchasing power parity",151.8
23862,Mexico,2013,39,Total pharmaceutical sales,"/capita, US$ exchange rate",93.7
23863,Mexico,2013,39,Total pharmaceutical sales,"Million US$, purchasing power parity",17978.4
23864,Mexico,2013,39,Total pharmaceutical sales,Million US$ at exchange rate,11098.4
23865,Mexico,2013,39,Total pharmaceutical sales,Million of national currency units,141748.4
23866,Mexico,2013,39,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",2.4
23867,Mexico,2013,39,B-Blood and blood forming organs,"/capita, US$ exchange rate",1.5
23868,Mexico,2013,39,B-Blood and blood forming organs,Million of national currency units,2218.0
23869,Mexico,2013,39,B-Blood and blood forming organs,% of total sales,1.6
23870,Mexico,2013,39,M-Musculo-skeletal system,% of total sales,2.5
23871,Mexico,2012,41,M-Musculo-skeletal system,Million of national currency units,4445.0
23872,Mexico,2012,41,R-Respiratory system,Million US$ at exchange rate,607.4
23873,Mexico,2012,41,R-Respiratory system,Million of national currency units,7999.0
23874,Mexico,2012,41,M-Musculo-skeletal system,Million US$ at exchange rate,337.5
23875,Mexico,2012,41,M-Musculo-skeletal system,"/capita, US$ exchange rate",2.9
23876,Mexico,2012,41,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",4.8
23877,Mexico,2012,41,M-Musculo-skeletal system,"Million US$, purchasing power parity",565.6
23878,Mexico,2012,41,C-Cardiovascular system,"/capita, US$ exchange rate",6.3
23879,Mexico,2012,41,C-Cardiovascular system,Million US$ at exchange rate,740.1
23880,Mexico,2012,41,C-Cardiovascular system,"Million US$, purchasing power parity",1240.3
23881,Mexico,2012,41,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",13.2
23882,Mexico,2012,41,C-Cardiovascular system,"/capita, US$ purchasing power parity",10.6
23883,Mexico,2012,41,Products not elsewhere classified,"/capita, US$ exchange rate",10.4
23884,Mexico,2012,41,Products not elsewhere classified,"/capita, US$ purchasing power parity",17.4
23885,Mexico,2012,41,Products not elsewhere classified,Million of national currency units,15972.0
23886,Mexico,2012,41,C-Cardiovascular system,Million of national currency units,9747.0
23887,Mexico,2012,41,Products not elsewhere classified,"Million US$, purchasing power parity",2032.4
23888,Mexico,2012,41,Products not elsewhere classified,Million US$ at exchange rate,1212.8
23889,Mexico,2012,41,N-Nervous system,Million of national currency units,12804.0
23890,Mexico,2012,41,N-Nervous system,"Million US$, purchasing power parity",1629.3
23891,Mexico,2012,41,N-Nervous system,Million US$ at exchange rate,972.2
23892,Mexico,2012,41,R-Respiratory system,"Million US$, purchasing power parity",1017.9
23893,Mexico,2012,41,R-Respiratory system,"/capita, US$ purchasing power parity",8.7
23894,Mexico,2012,41,R-Respiratory system,"/capita, US$ exchange rate",5.2
23895,Mexico,2012,41,J-Antiinfectives for systemic use,Million US$ at exchange rate,924.3
23896,Mexico,2012,41,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.9
23897,Mexico,2012,41,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1549.0
23898,Mexico,2012,41,J-Antiinfectives for systemic use,Million of national currency units,12173.0
23899,Mexico,2012,41,N-Nervous system,"/capita, US$ exchange rate",8.3
23900,Mexico,2012,41,N-Nervous system,"/capita, US$ purchasing power parity",13.9
23901,Mexico,2012,41,B-Blood and blood forming organs,"Million US$, purchasing power parity",530.9
23902,Mexico,2012,41,B-Blood and blood forming organs,Million US$ at exchange rate,316.8
23903,Mexico,2012,41,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",4.5
23904,Mexico,2012,41,B-Blood and blood forming organs,"/capita, US$ exchange rate",2.7
23905,Mexico,2012,41,B-Blood and blood forming organs,Million of national currency units,4172.0
23906,Mexico,2011,43,M-Musculo-skeletal system,Million of national currency units,4208.0
23907,Mexico,2011,43,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",4.8
23908,Mexico,2011,43,R-Respiratory system,Million of national currency units,7354.0
23909,Mexico,2011,43,R-Respiratory system,Million US$ at exchange rate,592.0
23910,Mexico,2011,43,M-Musculo-skeletal system,Million US$ at exchange rate,338.7
23911,Mexico,2011,43,M-Musculo-skeletal system,"/capita, US$ exchange rate",2.9
23912,Mexico,2011,43,M-Musculo-skeletal system,"Million US$, purchasing power parity",548.4
23913,Mexico,2011,43,C-Cardiovascular system,"/capita, US$ exchange rate",7.2
23914,Mexico,2011,43,C-Cardiovascular system,Million US$ at exchange rate,827.2
23915,Mexico,2011,43,C-Cardiovascular system,"Million US$, purchasing power parity",1339.4
23916,Mexico,2011,43,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.0
23917,Mexico,2011,43,C-Cardiovascular system,"/capita, US$ purchasing power parity",11.6
23918,Mexico,2011,43,Products not elsewhere classified,"/capita, US$ exchange rate",11.9
23919,Mexico,2011,43,Products not elsewhere classified,"/capita, US$ purchasing power parity",19.2
23920,Mexico,2011,43,Products not elsewhere classified,"Million US$, purchasing power parity",2217.4
23921,Mexico,2011,43,Products not elsewhere classified,Million of national currency units,17014.0
23922,Mexico,2011,43,C-Cardiovascular system,Million of national currency units,10277.0
23923,Mexico,2011,43,Products not elsewhere classified,Million US$ at exchange rate,1369.5
23924,Mexico,2011,43,N-Nervous system,Million of national currency units,12584.0
23925,Mexico,2011,43,N-Nervous system,"Million US$, purchasing power parity",1640.0
23926,Mexico,2011,43,N-Nervous system,Million US$ at exchange rate,1012.9
23927,Mexico,2011,43,R-Respiratory system,"Million US$, purchasing power parity",958.4
23928,Mexico,2011,43,R-Respiratory system,"/capita, US$ purchasing power parity",8.3
23929,Mexico,2011,43,R-Respiratory system,"/capita, US$ exchange rate",5.1
23930,Mexico,2011,43,J-Antiinfectives for systemic use,Million US$ at exchange rate,638.8
23931,Mexico,2011,43,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",5.5
23932,Mexico,2011,43,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",1034.3
23933,Mexico,2011,43,N-Nervous system,"/capita, US$ exchange rate",8.8
23934,Mexico,2011,43,J-Antiinfectives for systemic use,Million of national currency units,7936.0
23935,Mexico,2011,43,N-Nervous system,"/capita, US$ purchasing power parity",14.2
23936,Mexico,2011,43,B-Blood and blood forming organs,"Million US$, purchasing power parity",290.8
23937,Mexico,2011,43,B-Blood and blood forming organs,Million US$ at exchange rate,179.6
23938,Mexico,2011,43,B-Blood and blood forming organs,"/capita, US$ exchange rate",1.6
23939,Mexico,2011,43,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",2.5
23940,Mexico,2011,43,B-Blood and blood forming organs,Million of national currency units,2231.0
23941,Mexico,2010,46,M-Musculo-skeletal system,Million of national currency units,5495.0
23942,Mexico,2010,46,M-Musculo-skeletal system,Million US$ at exchange rate,434.9
23943,Mexico,2010,46,R-Respiratory system,Million of national currency units,8936.0
23944,Mexico,2010,46,R-Respiratory system,Million US$ at exchange rate,707.2
23945,Mexico,2010,46,M-Musculo-skeletal system,"/capita, US$ exchange rate",3.8
23946,Mexico,2010,46,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",6.3
23947,Mexico,2010,46,M-Musculo-skeletal system,"Million US$, purchasing power parity",715.5
23948,Mexico,2010,46,C-Cardiovascular system,"/capita, US$ exchange rate",7.0
23949,Mexico,2010,46,C-Cardiovascular system,Million US$ at exchange rate,801.1
23950,Mexico,2010,46,C-Cardiovascular system,"Million US$, purchasing power parity",1318.2
23951,Mexico,2010,46,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.6
23952,Mexico,2010,46,C-Cardiovascular system,"/capita, US$ purchasing power parity",11.6
23953,Mexico,2010,46,Products not elsewhere classified,"/capita, US$ exchange rate",12.0
23954,Mexico,2010,46,Products not elsewhere classified,"/capita, US$ purchasing power parity",19.7
23955,Mexico,2010,46,Products not elsewhere classified,Million of national currency units,17216.0
23956,Mexico,2010,46,C-Cardiovascular system,Million of national currency units,10123.0
23957,Mexico,2010,46,Products not elsewhere classified,"Million US$, purchasing power parity",2241.8
23958,Mexico,2010,46,Products not elsewhere classified,Million US$ at exchange rate,1362.5
23959,Mexico,2010,46,N-Nervous system,Million of national currency units,14077.0
23960,Mexico,2010,46,N-Nervous system,"Million US$, purchasing power parity",1833.0
23961,Mexico,2010,46,N-Nervous system,Million US$ at exchange rate,1114.0
23962,Mexico,2010,46,R-Respiratory system,"Million US$, purchasing power parity",1163.6
23963,Mexico,2010,46,R-Respiratory system,"/capita, US$ exchange rate",6.2
23964,Mexico,2010,46,R-Respiratory system,"/capita, US$ purchasing power parity",10.2
23965,Mexico,2010,46,J-Antiinfectives for systemic use,Million US$ at exchange rate,591.8
23966,Mexico,2010,46,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",5.2
23967,Mexico,2010,46,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",973.7
23968,Mexico,2010,46,N-Nervous system,"/capita, US$ exchange rate",9.8
23969,Mexico,2010,46,N-Nervous system,"/capita, US$ purchasing power parity",16.1
23970,Mexico,2010,46,J-Antiinfectives for systemic use,Million of national currency units,7478.0
23971,Mexico,2010,46,B-Blood and blood forming organs,"Million US$, purchasing power parity",511.7
23972,Mexico,2010,46,B-Blood and blood forming organs,Million US$ at exchange rate,311.0
23973,Mexico,2010,46,B-Blood and blood forming organs,"/capita, US$ exchange rate",2.7
23974,Mexico,2010,46,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",4.5
23975,Mexico,2010,46,B-Blood and blood forming organs,Million of national currency units,3930.0
23976,Mexico,2017,33,M-Musculo-skeletal system,Million of national currency units,2708.0
23977,Mexico,2017,33,R-Respiratory system,Million of national currency units,5570.0
23978,Mexico,2017,33,M-Musculo-skeletal system,"/capita, US$ exchange rate",1.2
23979,Mexico,2017,33,M-Musculo-skeletal system,Million US$ at exchange rate,143.1
23980,Mexico,2017,33,M-Musculo-skeletal system,"Million US$, purchasing power parity",303.8
23981,Mexico,2017,33,N-Nervous system,"/capita, US$ exchange rate",7.1
23982,Mexico,2017,33,C-Cardiovascular system,"Million US$, purchasing power parity",1176.9
23983,Mexico,2017,33,C-Cardiovascular system,"/capita, US$ exchange rate",4.5
23984,Mexico,2017,33,C-Cardiovascular system,Million US$ at exchange rate,554.2
23985,Mexico,2017,33,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.4
23986,Mexico,2017,33,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.6
23987,Mexico,2017,33,C-Cardiovascular system,"/capita, US$ purchasing power parity",9.5
23988,Mexico,2017,33,Products not elsewhere classified,"/capita, US$ exchange rate",8.4
23989,Mexico,2017,33,Products not elsewhere classified,"Million US$, purchasing power parity",2221.4
23990,Mexico,2017,33,Products not elsewhere classified,"/capita, US$ purchasing power parity",17.9
23991,Mexico,2017,33,Products not elsewhere classified,Million of national currency units,19800.8
23992,Mexico,2017,33,C-Cardiovascular system,Million of national currency units,10490.0
23993,Mexico,2017,33,Products not elsewhere classified,Million US$ at exchange rate,1046.2
23994,Mexico,2017,33,N-Nervous system,Million of national currency units,16565.0
23995,Mexico,2017,33,R-Respiratory system,"/capita, US$ purchasing power parity",5.0
23996,Mexico,2017,33,N-Nervous system,Million US$ at exchange rate,875.2
23997,Mexico,2017,33,R-Respiratory system,"Million US$, purchasing power parity",624.9
23998,Mexico,2017,33,R-Respiratory system,Million US$ at exchange rate,294.3
23999,Mexico,2017,33,R-Respiratory system,"/capita, US$ exchange rate",2.4
24000,Mexico,2017,33,J-Antiinfectives for systemic use,Million US$ at exchange rate,1192.2
24001,Mexico,2017,33,J-Antiinfectives for systemic use,Million of national currency units,22564.0
24002,Mexico,2017,33,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2531.4
24003,Mexico,2017,33,N-Nervous system,"Million US$, purchasing power parity",1858.4
24004,Mexico,2017,33,N-Nervous system,"/capita, US$ purchasing power parity",15.0
24005,Mexico,2017,33,B-Blood and blood forming organs,Million US$ at exchange rate,86.7
24006,Mexico,2017,33,B-Blood and blood forming organs,Million of national currency units,1640.0
24007,Mexico,2017,33,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",1.5
24008,Mexico,2017,33,B-Blood and blood forming organs,"Million US$, purchasing power parity",184.0
24009,Mexico,2017,33,B-Blood and blood forming organs,"/capita, US$ exchange rate",0.7
24010,Mexico,2017,33,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",2.4
24011,Netherlands,2016,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",334.6
24012,Netherlands,2016,6,Total pharmaceutical sales,"Million US$, purchasing power parity",5697.7
24013,Netherlands,2016,6,Total pharmaceutical sales,Million of national currency units,4532.2
24014,Netherlands,2016,6,Total pharmaceutical sales,Million US$ at exchange rate,5016.8
24015,Netherlands,2016,6,Total pharmaceutical sales,"/capita, US$ exchange rate",294.6
24016,Netherlands,2015,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",325.3
24017,Netherlands,2015,6,Total pharmaceutical sales,"Million US$, purchasing power parity",5510.4
24018,Netherlands,2015,6,Total pharmaceutical sales,Million US$ at exchange rate,4952.1
24019,Netherlands,2015,6,Total pharmaceutical sales,Million of national currency units,4463.3
24020,Netherlands,2015,6,Total pharmaceutical sales,"/capita, US$ exchange rate",292.3
24021,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.4
24022,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.6
24023,Netherlands,2014,6,J-Antiinfectives for systemic use,Million of national currency units,387.7
24024,Netherlands,2014,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,515.0
24025,Netherlands,2014,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",479.3
24026,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,% of total sales,9.6
24027,Netherlands,2014,6,B-Blood and blood forming organs,Million of national currency units,267.6
24028,Netherlands,2014,6,N06A-Antidepressants,% of total sales,2.3
24029,Netherlands,2014,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.6
24030,Netherlands,2014,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.1
24031,Netherlands,2014,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",330.9
24032,Netherlands,2014,6,B-Blood and blood forming organs,Million US$ at exchange rate,355.5
24033,Netherlands,2014,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",30.5
24034,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,141.1
24035,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",512.0
24036,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,550.2
24037,Netherlands,2014,6,R03-Drugs for obstructive airway diseases,Million of national currency units,414.1
24038,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,187.5
24039,Netherlands,2014,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.4
24040,Netherlands,2014,6,J-Antiinfectives for systemic use,% of total sales,9.0
24041,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.3
24042,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",10.3
24043,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",11.1
24044,Netherlands,2014,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",174.5
24045,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,9.6
24046,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,12.8
24047,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.9
24048,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,129.9
24049,Netherlands,2014,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",317.3
24050,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.2
24051,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.5
24052,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.0
24053,Netherlands,2014,6,C03-Diuretics,% of total sales,1.9
24054,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",160.6
24055,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
24056,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
24057,Netherlands,2014,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
24058,Netherlands,2014,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,172.6
24059,Netherlands,2014,6,Total pharmaceutical sales,"Million US$, purchasing power parity",5351.6
24060,Netherlands,2014,6,Total pharmaceutical sales,Million of national currency units,4328.4
24061,Netherlands,2014,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.3
24062,Netherlands,2014,6,Total pharmaceutical sales,Million US$ at exchange rate,5750.2
24063,Netherlands,2014,6,N-Nervous system,% of total sales,13.2
24064,Netherlands,2014,6,N-Nervous system,Million of national currency units,571.7
24065,Netherlands,2014,6,Total pharmaceutical sales,"/capita, US$ exchange rate",341.0
24066,Netherlands,2014,6,N-Nervous system,Million US$ at exchange rate,759.6
24067,Netherlands,2014,6,N-Nervous system,"/capita, US$ purchasing power parity",41.9
24068,Netherlands,2014,6,N-Nervous system,"Million US$, purchasing power parity",706.9
24069,Netherlands,2014,6,N-Nervous system,"/capita, US$ exchange rate",45.0
24070,Netherlands,2014,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.5
24071,Netherlands,2014,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.1
24072,Netherlands,2014,6,C-Cardiovascular system,Million US$ at exchange rate,906.2
24073,Netherlands,2014,6,C-Cardiovascular system,Million of national currency units,682.1
24074,Netherlands,2014,6,C01A-Cardiac glycosides,% of total sales,0.1
24075,Netherlands,2014,6,B-Blood and blood forming organs,% of total sales,6.2
24076,Netherlands,2014,6,J01-Antibacterials for systemic use,Million of national currency units,102.9
24077,Netherlands,2014,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,136.7
24078,Netherlands,2014,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",127.2
24079,Netherlands,2014,6,C-Cardiovascular system,"Million US$, purchasing power parity",843.4
24080,Netherlands,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.0
24081,Netherlands,2014,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1
24082,Netherlands,2014,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",17.2
24083,Netherlands,2014,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,18.5
24084,Netherlands,2014,6,C-Cardiovascular system,"/capita, US$ exchange rate",53.7
24085,Netherlands,2014,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",50.0
24086,Netherlands,2014,6,C-Cardiovascular system,% of total sales,15.8
24087,Netherlands,2014,6,J01-Antibacterials for systemic use,% of total sales,2.4
24088,Netherlands,2014,6,N05C-Hypnotics and sedatives,% of total sales,0.3
24089,Netherlands,2014,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.7
24090,Netherlands,2014,6,A10-Drugs used in diabetes,% of total sales,6.2
24091,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,% of total sales,0.6
24092,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.1
24093,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.2
24094,Netherlands,2014,6,A10-Drugs used in diabetes,Million of national currency units,268.1
24095,Netherlands,2014,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.1
24096,Netherlands,2014,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",331.5
24097,Netherlands,2014,6,A10-Drugs used in diabetes,Million US$ at exchange rate,356.2
24098,Netherlands,2014,6,C01A-Cardiac glycosides,Million US$ at exchange rate,7.9
24099,Netherlands,2014,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",7.4
24100,Netherlands,2014,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
24101,Netherlands,2014,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
24102,Netherlands,2014,6,C01A-Cardiac glycosides,Million of national currency units,6.0
24103,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",34.7
24104,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,37.3
24105,Netherlands,2014,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,28.1
24106,Netherlands,2014,6,N05C-Hypnotics and sedatives,Million of national currency units,13.9
24107,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,69.0
24108,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,91.6
24109,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",85.3
24110,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.4
24111,Netherlands,2014,6,N06A-Antidepressants,"Million US$, purchasing power parity",123.3
24112,Netherlands,2014,6,A02A-Antacids,"Million US$, purchasing power parity",0.0
24113,Netherlands,2014,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
24114,Netherlands,2014,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
24115,Netherlands,2014,6,A02A-Antacids,% of total sales,0.0
24116,Netherlands,2014,6,C07-Beta blocking agents,Million US$ at exchange rate,123.9
24117,Netherlands,2014,6,C07-Beta blocking agents,Million of national currency units,93.3
24118,Netherlands,2014,6,N06A-Antidepressants,"/capita, US$ exchange rate",7.9
24119,Netherlands,2014,6,C07-Beta blocking agents,"Million US$, purchasing power parity",115.3
24120,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",5.1
24121,Netherlands,2014,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.6
24122,Netherlands,2014,6,C07-Beta blocking agents,% of total sales,2.2
24123,Netherlands,2014,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8
24124,Netherlands,2014,6,C07-Beta blocking agents,"/capita, US$ exchange rate",7.3
24125,Netherlands,2014,6,C08-Calcium channel blockers,Million US$ at exchange rate,87.5
24126,Netherlands,2014,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",81.4
24127,Netherlands,2014,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.2
24128,Netherlands,2014,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8
24129,Netherlands,2014,6,C08-Calcium channel blockers,Million of national currency units,65.8
24130,Netherlands,2014,6,N06A-Antidepressants,Million of national currency units,99.7
24131,Netherlands,2014,6,N06A-Antidepressants,Million US$ at exchange rate,132.4
24132,Netherlands,2014,6,N02-Analgesics,"/capita, US$ purchasing power parity",10.5
24133,Netherlands,2014,6,N02-Analgesics,% of total sales,3.3
24134,Netherlands,2014,6,A02A-Antacids,Million of national currency units,0.0
24135,Netherlands,2014,6,A02A-Antacids,Million US$ at exchange rate,0.0
24136,Netherlands,2014,6,N02-Analgesics,"/capita, US$ exchange rate",11.3
24137,Netherlands,2014,6,C08-Calcium channel blockers,% of total sales,1.5
24138,Netherlands,2014,6,N02-Analgesics,Million of national currency units,143.6
24139,Netherlands,2014,6,N02-Analgesics,Million US$ at exchange rate,190.8
24140,Netherlands,2014,6,N02-Analgesics,"Million US$, purchasing power parity",177.6
24141,Netherlands,2014,6,C03-Diuretics,"/capita, US$ purchasing power parity",5.9
24142,Netherlands,2014,6,N05B-Anxiolytics,Million of national currency units,20.4
24143,Netherlands,2014,6,R-Respiratory system,Million US$ at exchange rate,686.1
24144,Netherlands,2014,6,R-Respiratory system,Million of national currency units,516.5
24145,Netherlands,2014,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5
24146,Netherlands,2014,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6
24147,Netherlands,2014,6,N05B-Anxiolytics,"Million US$, purchasing power parity",25.2
24148,Netherlands,2014,6,N05B-Anxiolytics,Million US$ at exchange rate,27.1
24149,Netherlands,2014,6,G-Genito urinary system and sex hormones,% of total sales,2.4
24150,Netherlands,2014,6,R-Respiratory system,% of total sales,11.9
24151,Netherlands,2014,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",129.8
24152,Netherlands,2014,6,R-Respiratory system,"/capita, US$ purchasing power parity",37.9
24153,Netherlands,2014,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,139.5
24154,Netherlands,2014,6,G-Genito urinary system and sex hormones,Million of national currency units,105.0
24155,Netherlands,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",7.7
24156,Netherlands,2014,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",8.3
24157,Netherlands,2014,6,R-Respiratory system,"Million US$, purchasing power parity",638.6
24158,Netherlands,2014,6,R-Respiratory system,"/capita, US$ exchange rate",40.7
24159,Netherlands,2014,6,N05B-Anxiolytics,% of total sales,0.5
24160,Netherlands,2014,6,C02-Antihypertensives,% of total sales,0.8
24161,Netherlands,2014,6,C10-Lipid modifying agents,Million of national currency units,213.7
24162,Netherlands,2014,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.6
24163,Netherlands,2014,6,C10-Lipid modifying agents,Million US$ at exchange rate,283.9
24164,Netherlands,2014,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",264.2
24165,Netherlands,2014,6,C02-Antihypertensives,"Million US$, purchasing power parity",43.3
24166,Netherlands,2014,6,C02-Antihypertensives,Million US$ at exchange rate,46.6
24167,Netherlands,2014,6,C02-Antihypertensives,Million of national currency units,35.0
24168,Netherlands,2014,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.8
24169,Netherlands,2014,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",805.6
24170,Netherlands,2014,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,865.6
24171,Netherlands,2014,6,A-Alimentary tract and metabolism,Million of national currency units,651.6
24172,Netherlands,2014,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.3
24173,Netherlands,2014,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",16.8
24174,Netherlands,2014,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",15.7
24175,Netherlands,2014,6,C10-Lipid modifying agents,% of total sales,4.9
24176,Netherlands,2014,6,A-Alimentary tract and metabolism,% of total sales,15.1
24177,Netherlands,2014,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.8
24178,Netherlands,2014,6,M-Musculo-skeletal system,Million of national currency units,121.1
24179,Netherlands,2014,6,C03-Diuretics,"/capita, US$ exchange rate",6.3
24180,Netherlands,2014,6,C03-Diuretics,"Million US$, purchasing power parity",99.5
24181,Netherlands,2014,6,C03-Diuretics,Million US$ at exchange rate,106.9
24182,Netherlands,2014,6,M-Musculo-skeletal system,Million US$ at exchange rate,160.9
24183,Netherlands,2014,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.9
24184,Netherlands,2014,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.5
24185,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",144.8
24186,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.2
24187,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.6
24188,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.7
24189,Netherlands,2014,6,C03-Diuretics,Million of national currency units,80.5
24190,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,117.1
24191,Netherlands,2014,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,155.6
24192,Netherlands,2014,6,M-Musculo-skeletal system,% of total sales,2.8
24193,Netherlands,2014,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",149.7
24194,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.1
24195,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",34.0
24196,Netherlands,2013,6,J-Antiinfectives for systemic use,Million of national currency units,393.7
24197,Netherlands,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,522.8
24198,Netherlands,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",493.2
24199,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,% of total sales,10.0
24200,Netherlands,2013,6,B-Blood and blood forming organs,Million of national currency units,258.1
24201,Netherlands,2013,6,N06A-Antidepressants,% of total sales,2.3
24202,Netherlands,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.2
24203,Netherlands,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.4
24204,Netherlands,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",323.4
24205,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,222.7
24206,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,167.6
24207,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",538.9
24208,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,571.3
24209,Netherlands,2013,6,R03-Drugs for obstructive airway diseases,Million of national currency units,430.1
24210,Netherlands,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",31.1
24211,Netherlands,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,342.8
24212,Netherlands,2013,6,J-Antiinfectives for systemic use,% of total sales,9.2
24213,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.9
24214,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",12.5
24215,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.2
24216,Netherlands,2013,6,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",210.0
24217,Netherlands,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",29.3
24218,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,9.7
24219,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,12.9
24220,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.2
24221,Netherlands,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",320.7
24222,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,127.9
24223,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
24224,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.1
24225,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.5
24226,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.0
24227,Netherlands,2013,6,C03-Diuretics,% of total sales,1.9
24228,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",160.2
24229,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
24230,Netherlands,2013,6,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
24231,Netherlands,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,169.8
24232,Netherlands,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",5388.7
24233,Netherlands,2013,6,Total pharmaceutical sales,Million of national currency units,4301.1
24234,Netherlands,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,5712.3
24235,Netherlands,2013,6,N-Nervous system,% of total sales,13.2
24236,Netherlands,2013,6,N-Nervous system,Million of national currency units,568.2
24237,Netherlands,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",339.9
24238,Netherlands,2013,6,N-Nervous system,Million US$ at exchange rate,754.7
24239,Netherlands,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",42.4
24240,Netherlands,2013,6,N-Nervous system,"/capita, US$ exchange rate",44.9
24241,Netherlands,2013,6,N-Nervous system,"Million US$, purchasing power parity",711.9
24242,Netherlands,2013,6,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.3
24243,Netherlands,2013,6,N06A-Antidepressants,"/capita, US$ exchange rate",7.8
24244,Netherlands,2013,6,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.0
24245,Netherlands,2013,6,C-Cardiovascular system,Million of national currency units,714.1
24246,Netherlands,2013,6,C-Cardiovascular system,Million US$ at exchange rate,948.4
24247,Netherlands,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",894.7
24248,Netherlands,2013,6,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.5
24249,Netherlands,2013,6,J01-Antibacterials for systemic use,Million of national currency units,120.2
24250,Netherlands,2013,6,J01-Antibacterials for systemic use,Million US$ at exchange rate,159.6
24251,Netherlands,2013,6,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",150.6
24252,Netherlands,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.9
24253,Netherlands,2013,6,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0
24254,Netherlands,2013,6,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",16.0
24255,Netherlands,2013,6,N05C-Hypnotics and sedatives,Million US$ at exchange rate,16.9
24256,Netherlands,2013,6,N05C-Hypnotics and sedatives,% of total sales,0.3
24257,Netherlands,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",56.4
24258,Netherlands,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",53.2
24259,Netherlands,2013,6,C-Cardiovascular system,% of total sales,16.6
24260,Netherlands,2013,6,J01-Antibacterials for systemic use,% of total sales,2.8
24261,Netherlands,2013,6,C01A-Cardiac glycosides,% of total sales,0.1
24262,Netherlands,2013,6,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.1
24263,Netherlands,2013,6,A10-Drugs used in diabetes,% of total sales,6.3
24264,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.5
24265,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,% of total sales,1.4
24266,Netherlands,2013,6,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.3
24267,Netherlands,2013,6,A10-Drugs used in diabetes,Million of national currency units,269.8
24268,Netherlands,2013,6,A10-Drugs used in diabetes,Million US$ at exchange rate,358.3
24269,Netherlands,2013,6,A10-Drugs used in diabetes,"Million US$, purchasing power parity",338.0
24270,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.7
24271,Netherlands,2013,6,C01A-Cardiac glycosides,Million US$ at exchange rate,8.6
24272,Netherlands,2013,6,C01A-Cardiac glycosides,"Million US$, purchasing power parity",8.1
24273,Netherlands,2013,6,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
24274,Netherlands,2013,6,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
24275,Netherlands,2013,6,C01A-Cardiac glycosides,Million of national currency units,6.4
24276,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",75.1
24277,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,79.6
24278,Netherlands,2013,6,G03-Sex hormones and modulators of the genital system,Million of national currency units,59.9
24279,Netherlands,2013,6,N05C-Hypnotics and sedatives,Million of national currency units,12.7
24280,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,80.9
24281,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,107.5
24282,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",101.4
24283,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.4
24284,Netherlands,2013,6,A02A-Antacids,"/capita, US$ exchange rate",0.0
24285,Netherlands,2013,6,A02A-Antacids,% of total sales,0.0
24286,Netherlands,2013,6,N06A-Antidepressants,"Million US$, purchasing power parity",123.2
24287,Netherlands,2013,6,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
24288,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.0
24289,Netherlands,2013,6,C07-Beta blocking agents,Million US$ at exchange rate,124.7
24290,Netherlands,2013,6,C07-Beta blocking agents,"Million US$, purchasing power parity",117.7
24291,Netherlands,2013,6,C07-Beta blocking agents,Million of national currency units,93.9
24292,Netherlands,2013,6,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
24293,Netherlands,2013,6,C07-Beta blocking agents,% of total sales,2.2
24294,Netherlands,2013,6,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.0
24295,Netherlands,2013,6,C07-Beta blocking agents,"/capita, US$ exchange rate",7.4
24296,Netherlands,2013,6,A02A-Antacids,"Million US$, purchasing power parity",0.0
24297,Netherlands,2013,6,C08-Calcium channel blockers,Million US$ at exchange rate,86.2
24298,Netherlands,2013,6,C08-Calcium channel blockers,"Million US$, purchasing power parity",81.3
24299,Netherlands,2013,6,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1
24300,Netherlands,2013,6,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8
24301,Netherlands,2013,6,C08-Calcium channel blockers,Million of national currency units,64.9
24302,Netherlands,2013,6,B-Blood and blood forming organs,% of total sales,6.0
24303,Netherlands,2013,6,N06A-Antidepressants,Million of national currency units,98.3
24304,Netherlands,2013,6,N06A-Antidepressants,Million US$ at exchange rate,130.6
24305,Netherlands,2013,6,C08-Calcium channel blockers,% of total sales,1.5
24306,Netherlands,2013,6,N02-Analgesics,"/capita, US$ purchasing power parity",11.1
24307,Netherlands,2013,6,N02-Analgesics,% of total sales,3.5
24308,Netherlands,2013,6,A02A-Antacids,Million of national currency units,0.0
24309,Netherlands,2013,6,A02A-Antacids,Million US$ at exchange rate,0.0
24310,Netherlands,2013,6,N02-Analgesics,"/capita, US$ exchange rate",11.8
24311,Netherlands,2013,6,N02-Analgesics,Million of national currency units,148.9
24312,Netherlands,2013,6,N02-Analgesics,Million US$ at exchange rate,197.7
24313,Netherlands,2013,6,N02-Analgesics,"Million US$, purchasing power parity",186.5
24314,Netherlands,2013,6,N05B-Anxiolytics,Million of national currency units,20.1
24315,Netherlands,2013,6,R-Respiratory system,Million of national currency units,540.6
24316,Netherlands,2013,6,R-Respiratory system,Million US$ at exchange rate,718.0
24317,Netherlands,2013,6,N05B-Anxiolytics,Million US$ at exchange rate,26.7
24318,Netherlands,2013,6,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5
24319,Netherlands,2013,6,N05B-Anxiolytics,"/capita, US$ exchange rate",1.6
24320,Netherlands,2013,6,N05B-Anxiolytics,"Million US$, purchasing power parity",25.2
24321,Netherlands,2013,6,R-Respiratory system,"Million US$, purchasing power parity",677.3
24322,Netherlands,2013,6,N05B-Anxiolytics,% of total sales,0.5
24323,Netherlands,2013,6,R-Respiratory system,% of total sales,12.6
24324,Netherlands,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",171.4
24325,Netherlands,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,181.7
24326,Netherlands,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,136.8
24327,Netherlands,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",40.3
24328,Netherlands,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.2
24329,Netherlands,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",10.8
24330,Netherlands,2013,6,R-Respiratory system,"/capita, US$ exchange rate",42.7
24331,Netherlands,2013,6,G-Genito urinary system and sex hormones,% of total sales,3.2
24332,Netherlands,2013,6,C02-Antihypertensives,% of total sales,0.8
24333,Netherlands,2013,6,C10-Lipid modifying agents,Million of national currency units,213.2
24334,Netherlands,2013,6,C10-Lipid modifying agents,Million US$ at exchange rate,283.2
24335,Netherlands,2013,6,C10-Lipid modifying agents,"Million US$, purchasing power parity",267.1
24336,Netherlands,2013,6,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.6
24337,Netherlands,2013,6,C02-Antihypertensives,"Million US$, purchasing power parity",42.9
24338,Netherlands,2013,6,C02-Antihypertensives,Million US$ at exchange rate,45.5
24339,Netherlands,2013,6,C02-Antihypertensives,Million of national currency units,34.2
24340,Netherlands,2013,6,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
24341,Netherlands,2013,6,C10-Lipid modifying agents,"/capita, US$ exchange rate",16.9
24342,Netherlands,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",816.6
24343,Netherlands,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,865.6
24344,Netherlands,2013,6,A-Alimentary tract and metabolism,Million of national currency units,651.8
24345,Netherlands,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.5
24346,Netherlands,2013,6,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",15.9
24347,Netherlands,2013,6,C10-Lipid modifying agents,% of total sales,5.0
24348,Netherlands,2013,6,A-Alimentary tract and metabolism,% of total sales,15.2
24349,Netherlands,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",48.6
24350,Netherlands,2013,6,M-Musculo-skeletal system,Million of national currency units,133.3
24351,Netherlands,2013,6,C03-Diuretics,"/capita, US$ exchange rate",6.4
24352,Netherlands,2013,6,C03-Diuretics,"Million US$, purchasing power parity",102.2
24353,Netherlands,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,177.1
24354,Netherlands,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.9
24355,Netherlands,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.5
24356,Netherlands,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",167.1
24357,Netherlands,2013,6,C03-Diuretics,Million US$ at exchange rate,108.3
24358,Netherlands,2013,6,M-Musculo-skeletal system,% of total sales,3.1
24359,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.4
24360,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",148.3
24361,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.8
24362,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.8
24363,Netherlands,2013,6,C03-Diuretics,Million of national currency units,81.5
24364,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,118.4
24365,Netherlands,2013,6,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,157.3
24366,Netherlands,2013,6,C03-Diuretics,"/capita, US$ purchasing power parity",6.1
24367,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.2
24368,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",34.2
24369,Netherlands,2012,7,J-Antiinfectives for systemic use,Million of national currency units,375.5
24370,Netherlands,2012,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,482.5
24371,Netherlands,2012,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",455.5
24372,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,% of total sales,9.7
24373,Netherlands,2012,7,B-Blood and blood forming organs,Million of national currency units,244.3
24374,Netherlands,2012,7,B-Blood and blood forming organs,Million US$ at exchange rate,313.9
24375,Netherlands,2012,7,N06A-Antidepressants,% of total sales,2.1
24376,Netherlands,2012,7,B-Blood and blood forming organs,% of total sales,5.3
24377,Netherlands,2012,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.7
24378,Netherlands,2012,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.7
24379,Netherlands,2012,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.8
24380,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,265.6
24381,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,206.8
24382,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",540.2
24383,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,572.2
24384,Netherlands,2012,7,R03-Drugs for obstructive airway diseases,Million of national currency units,445.4
24385,Netherlands,2012,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",296.4
24386,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",250.8
24387,Netherlands,2012,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.2
24388,Netherlands,2012,7,J-Antiinfectives for systemic use,% of total sales,8.1
24389,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5
24390,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",15.0
24391,Netherlands,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.9
24392,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,9.7
24393,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,12.5
24394,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",11.8
24395,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,223.8
24396,Netherlands,2012,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",333.6
24397,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,174.2
24398,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
24399,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.4
24400,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.6
24401,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.8
24402,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
24403,Netherlands,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",211.3
24404,Netherlands,2012,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
24405,Netherlands,2012,7,Total pharmaceutical sales,"Million US$, purchasing power parity",5589.9
24406,Netherlands,2012,7,Total pharmaceutical sales,Million of national currency units,4608.3
24407,Netherlands,2012,7,Total pharmaceutical sales,Million US$ at exchange rate,5920.7
24408,Netherlands,2012,7,N-Nervous system,Million US$ at exchange rate,761.8
24409,Netherlands,2012,7,N-Nervous system,Million of national currency units,592.9
24410,Netherlands,2012,7,Total pharmaceutical sales,"/capita, US$ exchange rate",353.4
24411,Netherlands,2012,7,N-Nervous system,% of total sales,12.9
24412,Netherlands,2012,7,N-Nervous system,"/capita, US$ purchasing power parity",42.9
24413,Netherlands,2012,7,N-Nervous system,"/capita, US$ exchange rate",45.5
24414,Netherlands,2012,7,N-Nervous system,"Million US$, purchasing power parity",719.2
24415,Netherlands,2012,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.7
24416,Netherlands,2012,7,C-Cardiovascular system,Million of national currency units,776.6
24417,Netherlands,2012,7,C-Cardiovascular system,Million US$ at exchange rate,997.8
24418,Netherlands,2012,7,C-Cardiovascular system,"Million US$, purchasing power parity",942.0
24419,Netherlands,2012,7,J01-Antibacterials for systemic use,Million of national currency units,120.6
24420,Netherlands,2012,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.3
24421,Netherlands,2012,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",146.3
24422,Netherlands,2012,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,155.0
24423,Netherlands,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.9
24424,Netherlands,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0
24425,Netherlands,2012,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",15.1
24426,Netherlands,2012,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,16.0
24427,Netherlands,2012,7,N05C-Hypnotics and sedatives,% of total sales,0.3
24428,Netherlands,2012,7,C-Cardiovascular system,"/capita, US$ exchange rate",59.6
24429,Netherlands,2012,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",56.2
24430,Netherlands,2012,7,C-Cardiovascular system,% of total sales,16.9
24431,Netherlands,2012,7,J01-Antibacterials for systemic use,% of total sales,2.6
24432,Netherlands,2012,7,C01A-Cardiac glycosides,% of total sales,0.1
24433,Netherlands,2012,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.8
24434,Netherlands,2012,7,A10-Drugs used in diabetes,% of total sales,5.6
24435,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.5
24436,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",4.9
24437,Netherlands,2012,7,A10-Drugs used in diabetes,Million of national currency units,260.2
24438,Netherlands,2012,7,A10-Drugs used in diabetes,Million US$ at exchange rate,334.2
24439,Netherlands,2012,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",315.6
24440,Netherlands,2012,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.9
24441,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.2
24442,Netherlands,2012,7,C01A-Cardiac glycosides,Million US$ at exchange rate,8.3
24443,Netherlands,2012,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",7.8
24444,Netherlands,2012,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
24445,Netherlands,2012,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
24446,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",82.7
24447,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,87.6
24448,Netherlands,2012,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,68.2
24449,Netherlands,2012,7,C01A-Cardiac glycosides,Million of national currency units,6.5
24450,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,83.9
24451,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,107.8
24452,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",101.8
24453,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.4
24454,Netherlands,2012,7,A02A-Antacids,"/capita, US$ exchange rate",0.0
24455,Netherlands,2012,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
24456,Netherlands,2012,7,A02A-Antacids,% of total sales,0.0
24457,Netherlands,2012,7,N06A-Antidepressants,"Million US$, purchasing power parity",115.1
24458,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.1
24459,Netherlands,2012,7,C07-Beta blocking agents,"Million US$, purchasing power parity",113.9
24460,Netherlands,2012,7,C07-Beta blocking agents,Million US$ at exchange rate,120.7
24461,Netherlands,2012,7,C07-Beta blocking agents,Million of national currency units,93.9
24462,Netherlands,2012,7,N06A-Antidepressants,"/capita, US$ exchange rate",7.3
24463,Netherlands,2012,7,C03-Diuretics,% of total sales,1.7
24464,Netherlands,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
24465,Netherlands,2012,7,C07-Beta blocking agents,% of total sales,2.0
24466,Netherlands,2012,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.8
24467,Netherlands,2012,7,C07-Beta blocking agents,"/capita, US$ exchange rate",7.2
24468,Netherlands,2012,7,A02A-Antacids,"Million US$, purchasing power parity",0.0
24469,Netherlands,2012,7,C08-Calcium channel blockers,Million US$ at exchange rate,78.2
24470,Netherlands,2012,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",73.9
24471,Netherlands,2012,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.7
24472,Netherlands,2012,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4
24473,Netherlands,2012,7,N05C-Hypnotics and sedatives,Million of national currency units,12.4
24474,Netherlands,2012,7,N06A-Antidepressants,Million of national currency units,94.9
24475,Netherlands,2012,7,N06A-Antidepressants,Million US$ at exchange rate,121.9
24476,Netherlands,2012,7,C08-Calcium channel blockers,Million of national currency units,60.9
24477,Netherlands,2012,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.9
24478,Netherlands,2012,7,N02-Analgesics,"/capita, US$ purchasing power parity",11.8
24479,Netherlands,2012,7,N02-Analgesics,% of total sales,3.5
24480,Netherlands,2012,7,A02A-Antacids,Million of national currency units,0.0
24481,Netherlands,2012,7,A02A-Antacids,Million US$ at exchange rate,0.0
24482,Netherlands,2012,7,N02-Analgesics,Million of national currency units,162.5
24483,Netherlands,2012,7,N02-Analgesics,Million US$ at exchange rate,208.8
24484,Netherlands,2012,7,N02-Analgesics,"Million US$, purchasing power parity",197.1
24485,Netherlands,2012,7,N02-Analgesics,"/capita, US$ exchange rate",12.5
24486,Netherlands,2012,7,C08-Calcium channel blockers,% of total sales,1.3
24487,Netherlands,2012,7,N05B-Anxiolytics,Million of national currency units,19.6
24488,Netherlands,2012,7,R-Respiratory system,Million of national currency units,559.6
24489,Netherlands,2012,7,R-Respiratory system,Million US$ at exchange rate,719.0
24490,Netherlands,2012,7,R-Respiratory system,"Million US$, purchasing power parity",678.8
24491,Netherlands,2012,7,N05B-Anxiolytics,Million US$ at exchange rate,25.1
24492,Netherlands,2012,7,N05B-Anxiolytics,% of total sales,0.4
24493,Netherlands,2012,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.4
24494,Netherlands,2012,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
24495,Netherlands,2012,7,N05B-Anxiolytics,"Million US$, purchasing power parity",23.7
24496,Netherlands,2012,7,G-Genito urinary system and sex hormones,% of total sales,3.2
24497,Netherlands,2012,7,R-Respiratory system,% of total sales,12.1
24498,Netherlands,2012,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",179.2
24499,Netherlands,2012,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,189.8
24500,Netherlands,2012,7,G-Genito urinary system and sex hormones,Million of national currency units,147.7
24501,Netherlands,2012,7,R-Respiratory system,"/capita, US$ purchasing power parity",40.5
24502,Netherlands,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.7
24503,Netherlands,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",11.3
24504,Netherlands,2012,7,R-Respiratory system,"/capita, US$ exchange rate",42.9
24505,Netherlands,2012,7,C10-Lipid modifying agents,Million of national currency units,242.3
24506,Netherlands,2012,7,C10-Lipid modifying agents,Million US$ at exchange rate,311.4
24507,Netherlands,2012,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",294.0
24508,Netherlands,2012,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5
24509,Netherlands,2012,7,C02-Antihypertensives,"Million US$, purchasing power parity",42.1
24510,Netherlands,2012,7,C02-Antihypertensives,Million US$ at exchange rate,44.6
24511,Netherlands,2012,7,C02-Antihypertensives,Million of national currency units,34.7
24512,Netherlands,2012,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
24513,Netherlands,2012,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.6
24514,Netherlands,2012,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.6
24515,Netherlands,2012,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",784.3
24516,Netherlands,2012,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,830.8
24517,Netherlands,2012,7,A-Alimentary tract and metabolism,Million of national currency units,646.6
24518,Netherlands,2012,7,C02-Antihypertensives,% of total sales,0.8
24519,Netherlands,2012,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",17.5
24520,Netherlands,2012,7,C10-Lipid modifying agents,% of total sales,5.3
24521,Netherlands,2012,7,A-Alimentary tract and metabolism,% of total sales,14.0
24522,Netherlands,2012,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",46.8
24523,Netherlands,2012,7,M-Musculo-skeletal system,Million US$ at exchange rate,175.4
24524,Netherlands,2012,7,C03-Diuretics,"/capita, US$ exchange rate",6.1
24525,Netherlands,2012,7,C03-Diuretics,"Million US$, purchasing power parity",95.9
24526,Netherlands,2012,7,M-Musculo-skeletal system,% of total sales,3.0
24527,Netherlands,2012,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.9
24528,Netherlands,2012,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.5
24529,Netherlands,2012,7,M-Musculo-skeletal system,Million of national currency units,136.5
24530,Netherlands,2012,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",165.6
24531,Netherlands,2012,7,C03-Diuretics,Million US$ at exchange rate,101.5
24532,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.6
24533,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.7
24534,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",9.1
24535,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",152.6
24536,Netherlands,2012,7,C03-Diuretics,Million of national currency units,79.0
24537,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,125.8
24538,Netherlands,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,161.7
24539,Netherlands,2012,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.7
24540,Netherlands,2011,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",290.3
24541,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.8
24542,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.1
24543,Netherlands,2011,7,J-Antiinfectives for systemic use,Million of national currency units,358.2
24544,Netherlands,2011,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,498.6
24545,Netherlands,2011,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",428.5
24546,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,% of total sales,8.8
24547,Netherlands,2011,7,B-Blood and blood forming organs,Million of national currency units,242.7
24548,Netherlands,2011,7,B-Blood and blood forming organs,Million US$ at exchange rate,337.8
24549,Netherlands,2011,7,N06A-Antidepressants,% of total sales,1.8
24550,Netherlands,2011,7,B-Blood and blood forming organs,% of total sales,4.7
24551,Netherlands,2011,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.4
24552,Netherlands,2011,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.2
24553,Netherlands,2011,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",29.9
24554,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,356.5
24555,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,256.1
24556,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",546.7
24557,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,636.3
24558,Netherlands,2011,7,R03-Drugs for obstructive airway diseases,Million of national currency units,457.1
24559,Netherlands,2011,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",25.7
24560,Netherlands,2011,7,J-Antiinfectives for systemic use,% of total sales,6.9
24561,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.9
24562,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.4
24563,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.4
24564,Netherlands,2011,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",306.4
24565,Netherlands,2011,7,Total pharmaceutical sales,Million of national currency units,5210.0
24566,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,10.2
24567,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,14.3
24568,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.3
24569,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,242.8
24570,Netherlands,2011,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",373.3
24571,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,174.4
24572,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
24573,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",12.5
24574,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3
24575,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.5
24576,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
24577,Netherlands,2011,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
24578,Netherlands,2011,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",208.6
24579,Netherlands,2011,7,Total pharmaceutical sales,"Million US$, purchasing power parity",6231.5
24580,Netherlands,2011,7,Total pharmaceutical sales,Million US$ at exchange rate,7252.1
24581,Netherlands,2011,7,Total pharmaceutical sales,"/capita, US$ exchange rate",434.4
24582,Netherlands,2011,7,N-Nervous system,Million US$ at exchange rate,877.2
24583,Netherlands,2011,7,N-Nervous system,Million of national currency units,630.2
24584,Netherlands,2011,7,N-Nervous system,"Million US$, purchasing power parity",753.8
24585,Netherlands,2011,7,N-Nervous system,% of total sales,12.1
24586,Netherlands,2011,7,N-Nervous system,"/capita, US$ purchasing power parity",45.2
24587,Netherlands,2011,7,N-Nervous system,"/capita, US$ exchange rate",52.6
24588,Netherlands,2011,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.9
24589,Netherlands,2011,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.1
24590,Netherlands,2011,7,C-Cardiovascular system,Million of national currency units,896.2
24591,Netherlands,2011,7,C-Cardiovascular system,Million US$ at exchange rate,1247.4
24592,Netherlands,2011,7,C-Cardiovascular system,"Million US$, purchasing power parity",1071.9
24593,Netherlands,2011,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.6
24594,Netherlands,2011,7,J01-Antibacterials for systemic use,Million of national currency units,126.9
24595,Netherlands,2011,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,176.7
24596,Netherlands,2011,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",151.8
24597,Netherlands,2011,7,C-Cardiovascular system,"/capita, US$ exchange rate",74.7
24598,Netherlands,2011,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.9
24599,Netherlands,2011,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.0
24600,Netherlands,2011,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",14.8
24601,Netherlands,2011,7,N05C-Hypnotics and sedatives,% of total sales,0.2
24602,Netherlands,2011,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",64.2
24603,Netherlands,2011,7,C-Cardiovascular system,% of total sales,17.2
24604,Netherlands,2011,7,J01-Antibacterials for systemic use,% of total sales,2.4
24605,Netherlands,2011,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,17.3
24606,Netherlands,2011,7,A10-Drugs used in diabetes,% of total sales,4.8
24607,Netherlands,2011,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",18.1
24608,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.4
24609,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",5.2
24610,Netherlands,2011,7,A10-Drugs used in diabetes,Million of national currency units,252.0
24611,Netherlands,2011,7,A10-Drugs used in diabetes,Million US$ at exchange rate,350.8
24612,Netherlands,2011,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",301.5
24613,Netherlands,2011,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.0
24614,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.0
24615,Netherlands,2011,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",7.7
24616,Netherlands,2011,7,C01A-Cardiac glycosides,Million US$ at exchange rate,9.0
24617,Netherlands,2011,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.5
24618,Netherlands,2011,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
24619,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",86.3
24620,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,100.4
24621,Netherlands,2011,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,72.2
24622,Netherlands,2011,7,C01A-Cardiac glycosides,Million of national currency units,6.5
24623,Netherlands,2011,7,C01A-Cardiac glycosides,% of total sales,0.1
24624,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,127.6
24625,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,91.7
24626,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.6
24627,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",109.6
24628,Netherlands,2011,7,A02A-Antacids,"/capita, US$ exchange rate",0.0
24629,Netherlands,2011,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
24630,Netherlands,2011,7,A02A-Antacids,% of total sales,0.0
24631,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.6
24632,Netherlands,2011,7,C07-Beta blocking agents,"Million US$, purchasing power parity",115.5
24633,Netherlands,2011,7,C07-Beta blocking agents,Million US$ at exchange rate,134.4
24634,Netherlands,2011,7,C07-Beta blocking agents,Million of national currency units,96.6
24635,Netherlands,2011,7,N06A-Antidepressants,"/capita, US$ exchange rate",8.0
24636,Netherlands,2011,7,C07-Beta blocking agents,"/capita, US$ exchange rate",8.1
24637,Netherlands,2011,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
24638,Netherlands,2011,7,C07-Beta blocking agents,% of total sales,1.9
24639,Netherlands,2011,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.9
24640,Netherlands,2011,7,A02A-Antacids,"Million US$, purchasing power parity",0.0
24641,Netherlands,2011,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",72.8
24642,Netherlands,2011,7,C08-Calcium channel blockers,Million US$ at exchange rate,84.7
24643,Netherlands,2011,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4
24644,Netherlands,2011,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1
24645,Netherlands,2011,7,N05C-Hypnotics and sedatives,Million of national currency units,12.4
24646,Netherlands,2011,7,N06A-Antidepressants,Million of national currency units,95.7
24647,Netherlands,2011,7,N06A-Antidepressants,Million US$ at exchange rate,133.3
24648,Netherlands,2011,7,N06A-Antidepressants,"Million US$, purchasing power parity",114.5
24649,Netherlands,2011,7,C08-Calcium channel blockers,Million of national currency units,60.9
24650,Netherlands,2011,7,C08-Calcium channel blockers,% of total sales,1.2
24651,Netherlands,2011,7,N02-Analgesics,% of total sales,3.1
24652,Netherlands,2011,7,N02-Analgesics,"/capita, US$ purchasing power parity",11.4
24653,Netherlands,2011,7,A02A-Antacids,Million US$ at exchange rate,0.0
24654,Netherlands,2011,7,A02A-Antacids,Million of national currency units,0.0
24655,Netherlands,2011,7,N02-Analgesics,Million of national currency units,159.7
24656,Netherlands,2011,7,N02-Analgesics,Million US$ at exchange rate,222.3
24657,Netherlands,2011,7,N02-Analgesics,"Million US$, purchasing power parity",191.1
24658,Netherlands,2011,7,N02-Analgesics,"/capita, US$ exchange rate",13.3
24659,Netherlands,2011,7,C03-Diuretics,% of total sales,1.5
24660,Netherlands,2011,7,N05B-Anxiolytics,Million of national currency units,20.3
24661,Netherlands,2011,7,R-Respiratory system,Million of national currency units,586.7
24662,Netherlands,2011,7,R-Respiratory system,Million US$ at exchange rate,816.7
24663,Netherlands,2011,7,R-Respiratory system,"Million US$, purchasing power parity",701.8
24664,Netherlands,2011,7,N05B-Anxiolytics,Million US$ at exchange rate,28.3
24665,Netherlands,2011,7,N05B-Anxiolytics,% of total sales,0.4
24666,Netherlands,2011,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5
24667,Netherlands,2011,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.7
24668,Netherlands,2011,7,N05B-Anxiolytics,"Million US$, purchasing power parity",24.3
24669,Netherlands,2011,7,R-Respiratory system,% of total sales,11.3
24670,Netherlands,2011,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",179.2
24671,Netherlands,2011,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,208.5
24672,Netherlands,2011,7,R-Respiratory system,"/capita, US$ purchasing power parity",42.0
24673,Netherlands,2011,7,G-Genito urinary system and sex hormones,% of total sales,2.9
24674,Netherlands,2011,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",10.7
24675,Netherlands,2011,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.5
24676,Netherlands,2011,7,R-Respiratory system,"/capita, US$ exchange rate",48.9
24677,Netherlands,2011,7,C02-Antihypertensives,% of total sales,0.7
24678,Netherlands,2011,7,C10-Lipid modifying agents,Million of national currency units,309.8
24679,Netherlands,2011,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",370.5
24680,Netherlands,2011,7,C10-Lipid modifying agents,Million US$ at exchange rate,431.2
24681,Netherlands,2011,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5
24682,Netherlands,2011,7,C02-Antihypertensives,"Million US$, purchasing power parity",41.4
24683,Netherlands,2011,7,C02-Antihypertensives,Million US$ at exchange rate,48.2
24684,Netherlands,2011,7,C02-Antihypertensives,Million of national currency units,34.6
24685,Netherlands,2011,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",25.8
24686,Netherlands,2011,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.1
24687,Netherlands,2011,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",818.5
24688,Netherlands,2011,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,952.6
24689,Netherlands,2011,7,A-Alimentary tract and metabolism,Million of national currency units,684.3
24690,Netherlands,2011,7,G-Genito urinary system and sex hormones,Million of national currency units,149.8
24691,Netherlands,2011,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.0
24692,Netherlands,2011,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.2
24693,Netherlands,2011,7,C10-Lipid modifying agents,% of total sales,5.9
24694,Netherlands,2011,7,A-Alimentary tract and metabolism,% of total sales,13.1
24695,Netherlands,2011,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.9
24696,Netherlands,2011,7,M-Musculo-skeletal system,Million US$ at exchange rate,206.6
24697,Netherlands,2011,7,C03-Diuretics,"Million US$, purchasing power parity",93.2
24698,Netherlands,2011,7,C03-Diuretics,"/capita, US$ exchange rate",6.5
24699,Netherlands,2011,7,M-Musculo-skeletal system,% of total sales,2.8
24700,Netherlands,2011,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.6
24701,Netherlands,2011,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.4
24702,Netherlands,2011,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",177.5
24703,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.4
24704,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.3
24705,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6
24706,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",221.5
24707,Netherlands,2011,7,C03-Diuretics,Million of national currency units,78.0
24708,Netherlands,2011,7,M-Musculo-skeletal system,Million of national currency units,148.4
24709,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,185.2
24710,Netherlands,2011,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,257.8
24711,Netherlands,2011,7,C03-Diuretics,Million US$ at exchange rate,108.5
24712,Netherlands,2011,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.6
24713,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,% of total sales,8.4
24714,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.7
24715,Netherlands,2010,7,J-Antiinfectives for systemic use,Million of national currency units,350.8
24716,Netherlands,2010,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,465.1
24717,Netherlands,2010,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",410.8
24718,Netherlands,2010,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",28.0
24719,Netherlands,2010,7,B-Blood and blood forming organs,Million US$ at exchange rate,325.8
24720,Netherlands,2010,7,N06A-Antidepressants,% of total sales,1.8
24721,Netherlands,2010,7,B-Blood and blood forming organs,% of total sales,4.7
24722,Netherlands,2010,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",17.3
24723,Netherlands,2010,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.6
24724,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,352.0
24725,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,265.5
24726,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",34.8
24727,Netherlands,2010,7,B-Blood and blood forming organs,Million of national currency units,245.7
24728,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",510.5
24729,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,578.0
24730,Netherlands,2010,7,R03-Drugs for obstructive airway diseases,Million of national currency units,436.0
24731,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",310.9
24732,Netherlands,2010,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.7
24733,Netherlands,2010,7,J-Antiinfectives for systemic use,% of total sales,6.7
24734,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.1
24735,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.7
24736,Netherlands,2010,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.2
24737,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,10.7
24738,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,14.1
24739,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",12.5
24740,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
24741,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,169.1
24742,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,224.1
24743,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.9
24744,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.2
24745,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.5
24746,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
24747,Netherlands,2010,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
24748,Netherlands,2010,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",367.4
24749,Netherlands,2010,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",197.9
24750,Netherlands,2010,7,Total pharmaceutical sales,Million of national currency units,5213.1
24751,Netherlands,2010,7,Total pharmaceutical sales,"Million US$, purchasing power parity",6103.7
24752,Netherlands,2010,7,Total pharmaceutical sales,"/capita, US$ exchange rate",415.9
24753,Netherlands,2010,7,Total pharmaceutical sales,Million US$ at exchange rate,6911.1
24754,Netherlands,2010,7,N-Nervous system,Million US$ at exchange rate,793.6
24755,Netherlands,2010,7,N-Nervous system,Million of national currency units,598.6
24756,Netherlands,2010,7,N-Nervous system,"Million US$, purchasing power parity",700.9
24757,Netherlands,2010,7,N-Nervous system,% of total sales,11.5
24758,Netherlands,2010,7,N-Nervous system,"/capita, US$ purchasing power parity",42.2
24759,Netherlands,2010,7,N-Nervous system,"/capita, US$ exchange rate",47.8
24760,Netherlands,2010,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.3
24761,Netherlands,2010,7,C-Cardiovascular system,Million of national currency units,906.4
24762,Netherlands,2010,7,C-Cardiovascular system,Million US$ at exchange rate,1201.6
24763,Netherlands,2010,7,C-Cardiovascular system,"Million US$, purchasing power parity",1061.2
24764,Netherlands,2010,7,J01-Antibacterials for systemic use,Million of national currency units,131.9
24765,Netherlands,2010,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,174.8
24766,Netherlands,2010,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",154.4
24767,Netherlands,2010,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.5
24768,Netherlands,2010,7,C-Cardiovascular system,"/capita, US$ exchange rate",72.3
24769,Netherlands,2010,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.8
24770,Netherlands,2010,7,N05C-Hypnotics and sedatives,% of total sales,0.2
24771,Netherlands,2010,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",13.7
24772,Netherlands,2010,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.9
24773,Netherlands,2010,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.9
24774,Netherlands,2010,7,C-Cardiovascular system,% of total sales,17.4
24775,Netherlands,2010,7,J01-Antibacterials for systemic use,% of total sales,2.5
24776,Netherlands,2010,7,C01A-Cardiac glycosides,% of total sales,0.1
24777,Netherlands,2010,7,A10-Drugs used in diabetes,% of total sales,4.6
24778,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
24779,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",8.6
24780,Netherlands,2010,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.1
24781,Netherlands,2010,7,A10-Drugs used in diabetes,Million of national currency units,242.2
24782,Netherlands,2010,7,A10-Drugs used in diabetes,Million US$ at exchange rate,321.1
24783,Netherlands,2010,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",283.6
24784,Netherlands,2010,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.3
24785,Netherlands,2010,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",7.4
24786,Netherlands,2010,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.5
24787,Netherlands,2010,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.4
24788,Netherlands,2010,7,C01A-Cardiac glycosides,Million US$ at exchange rate,8.4
24789,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.8
24790,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",143.7
24791,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,162.7
24792,Netherlands,2010,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,122.7
24793,Netherlands,2010,7,C01A-Cardiac glycosides,Million of national currency units,6.4
24794,Netherlands,2010,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,15.5
24795,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,125.0
24796,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",110.4
24797,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",7.5
24798,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.6
24799,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,94.3
24800,Netherlands,2010,7,A02A-Antacids,"/capita, US$ exchange rate",0.0
24801,Netherlands,2010,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
24802,Netherlands,2010,7,N06A-Antidepressants,"/capita, US$ exchange rate",7.3
24803,Netherlands,2010,7,A02A-Antacids,% of total sales,0.0
24804,Netherlands,2010,7,C07-Beta blocking agents,"Million US$, purchasing power parity",129.3
24805,Netherlands,2010,7,C07-Beta blocking agents,Million US$ at exchange rate,146.4
24806,Netherlands,2010,7,C07-Beta blocking agents,Million of national currency units,110.5
24807,Netherlands,2010,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.5
24808,Netherlands,2010,7,C07-Beta blocking agents,"/capita, US$ exchange rate",8.8
24809,Netherlands,2010,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
24810,Netherlands,2010,7,C07-Beta blocking agents,% of total sales,2.1
24811,Netherlands,2010,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.8
24812,Netherlands,2010,7,A02A-Antacids,"Million US$, purchasing power parity",0.0
24813,Netherlands,2010,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",72.9
24814,Netherlands,2010,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.0
24815,Netherlands,2010,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.4
24816,Netherlands,2010,7,C08-Calcium channel blockers,Million US$ at exchange rate,82.5
24817,Netherlands,2010,7,N05C-Hypnotics and sedatives,Million of national currency units,11.7
24818,Netherlands,2010,7,N06A-Antidepressants,Million of national currency units,91.7
24819,Netherlands,2010,7,N06A-Antidepressants,Million US$ at exchange rate,121.6
24820,Netherlands,2010,7,N06A-Antidepressants,"Million US$, purchasing power parity",107.4
24821,Netherlands,2010,7,C08-Calcium channel blockers,Million of national currency units,62.2
24822,Netherlands,2010,7,C08-Calcium channel blockers,% of total sales,1.2
24823,Netherlands,2010,7,N02-Analgesics,% of total sales,2.8
24824,Netherlands,2010,7,A02A-Antacids,Million of national currency units,0.0
24825,Netherlands,2010,7,A02A-Antacids,Million US$ at exchange rate,0.0
24826,Netherlands,2010,7,N02-Analgesics,"/capita, US$ purchasing power parity",10.3
24827,Netherlands,2010,7,N02-Analgesics,Million of national currency units,146.5
24828,Netherlands,2010,7,N02-Analgesics,Million US$ at exchange rate,194.2
24829,Netherlands,2010,7,N02-Analgesics,"Million US$, purchasing power parity",171.5
24830,Netherlands,2010,7,N02-Analgesics,"/capita, US$ exchange rate",11.7
24831,Netherlands,2010,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",287.7
24832,Netherlands,2010,7,N05B-Anxiolytics,Million of national currency units,21.3
24833,Netherlands,2010,7,R-Respiratory system,Million of national currency units,566.5
24834,Netherlands,2010,7,N05B-Anxiolytics,Million US$ at exchange rate,28.3
24835,Netherlands,2010,7,R-Respiratory system,Million US$ at exchange rate,751.0
24836,Netherlands,2010,7,R-Respiratory system,"Million US$, purchasing power parity",663.2
24837,Netherlands,2010,7,N05B-Anxiolytics,% of total sales,0.4
24838,Netherlands,2010,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",1.5
24839,Netherlands,2010,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.7
24840,Netherlands,2010,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.8
24841,Netherlands,2010,7,R-Respiratory system,% of total sales,10.9
24842,Netherlands,2010,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,273.1
24843,Netherlands,2010,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",241.2
24844,Netherlands,2010,7,G-Genito urinary system and sex hormones,% of total sales,4.0
24845,Netherlands,2010,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.5
24846,Netherlands,2010,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.4
24847,Netherlands,2010,7,R-Respiratory system,"/capita, US$ exchange rate",45.2
24848,Netherlands,2010,7,R-Respiratory system,"/capita, US$ purchasing power parity",39.9
24849,Netherlands,2010,7,C02-Antihypertensives,% of total sales,0.7
24850,Netherlands,2010,7,C03-Diuretics,% of total sales,1.4
24851,Netherlands,2010,7,C10-Lipid modifying agents,Million of national currency units,298.9
24852,Netherlands,2010,7,C10-Lipid modifying agents,Million US$ at exchange rate,396.2
24853,Netherlands,2010,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",349.9
24854,Netherlands,2010,7,C02-Antihypertensives,"Million US$, purchasing power parity",41.6
24855,Netherlands,2010,7,C02-Antihypertensives,Million US$ at exchange rate,47.1
24856,Netherlands,2010,7,C02-Antihypertensives,Million of national currency units,35.6
24857,Netherlands,2010,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5
24858,Netherlands,2010,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",23.8
24859,Netherlands,2010,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.3
24860,Netherlands,2010,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",782.1
24861,Netherlands,2010,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,885.6
24862,Netherlands,2010,7,A-Alimentary tract and metabolism,Million of national currency units,668.0
24863,Netherlands,2010,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",21.1
24864,Netherlands,2010,7,C10-Lipid modifying agents,% of total sales,5.7
24865,Netherlands,2010,7,A-Alimentary tract and metabolism,% of total sales,12.8
24866,Netherlands,2010,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.1
24867,Netherlands,2010,7,G-Genito urinary system and sex hormones,Million of national currency units,206.0
24868,Netherlands,2010,7,N05B-Anxiolytics,"Million US$, purchasing power parity",25.0
24869,Netherlands,2010,7,M-Musculo-skeletal system,Million US$ at exchange rate,212.2
24870,Netherlands,2010,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.3
24871,Netherlands,2010,7,C03-Diuretics,"/capita, US$ exchange rate",5.9
24872,Netherlands,2010,7,C03-Diuretics,"Million US$, purchasing power parity",87.3
24873,Netherlands,2010,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",187.4
24874,Netherlands,2010,7,M-Musculo-skeletal system,% of total sales,3.1
24875,Netherlands,2010,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",11.3
24876,Netherlands,2010,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",12.8
24877,Netherlands,2010,7,C03-Diuretics,Million US$ at exchange rate,98.8
24878,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.1
24879,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.2
24880,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.9
24881,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",236.7
24882,Netherlands,2010,7,C03-Diuretics,Million of national currency units,74.5
24883,Netherlands,2010,7,M-Musculo-skeletal system,Million of national currency units,160.1
24884,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,202.1
24885,Netherlands,2010,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,268.0
24886,Netherlands,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",340.4
24887,Netherlands,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",5831.7
24888,Netherlands,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,5152.7
24889,Netherlands,2017,5,Total pharmaceutical sales,Million of national currency units,4561.2
24890,Netherlands,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",300.8
24891,New Zealand,2011,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.6
24892,New Zealand,2011,10,N05C-Hypnotics and sedatives,Million of national currency units,1.7
24893,New Zealand,2011,10,Products not elsewhere classified,Million US$ at exchange rate,160.0
24894,New Zealand,2011,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.3
24895,New Zealand,2011,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.0
24896,New Zealand,2011,10,C08-Calcium channel blockers,Million US$ at exchange rate,11.7
24897,New Zealand,2011,10,Products not elsewhere classified,"/capita, US$ exchange rate",36.5
24898,New Zealand,2011,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",36.0
24899,New Zealand,2011,10,C10-Lipid modifying agents,Million US$ at exchange rate,42.3
24900,New Zealand,2011,10,Products not elsewhere classified,"Million US$, purchasing power parity",136.3
24901,New Zealand,2011,10,C10-Lipid modifying agents,Million of national currency units,53.5
24902,New Zealand,2011,10,C08-Calcium channel blockers,Million of national currency units,14.8
24903,New Zealand,2011,10,N02-Analgesics,"/capita, US$ purchasing power parity",4.6
24904,New Zealand,2011,10,N02-Analgesics,"Million US$, purchasing power parity",20.1
24905,New Zealand,2011,10,N02-Analgesics,"/capita, US$ exchange rate",5.4
24906,New Zealand,2011,10,Products not elsewhere classified,% of total sales,24.8
24907,New Zealand,2011,10,N02-Analgesics,% of total sales,3.7
24908,New Zealand,2011,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
24909,New Zealand,2011,10,C08-Calcium channel blockers,% of total sales,1.8
24910,New Zealand,2011,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.7
24911,New Zealand,2011,10,N02-Analgesics,Million US$ at exchange rate,23.6
24912,New Zealand,2011,10,N02-Analgesics,Million of national currency units,29.8
24913,New Zealand,2011,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",31.1
24914,New Zealand,2011,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,16.8
24915,New Zealand,2011,10,B-Blood and blood forming organs,Million of national currency units,26.3
24916,New Zealand,2011,10,G-Genito urinary system and sex hormones,Million of national currency units,21.3
24917,New Zealand,2011,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",4.7
24918,New Zealand,2011,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",17.7
24919,New Zealand,2011,10,B-Blood and blood forming organs,Million US$ at exchange rate,20.7
24920,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.6
24921,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",8.9
24922,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.4
24923,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.0
24924,New Zealand,2011,10,C10-Lipid modifying agents,% of total sales,6.6
24925,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.2
24926,New Zealand,2011,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,10.5
24927,New Zealand,2011,10,N05C-Hypnotics and sedatives,% of total sales,0.2
24928,New Zealand,2011,10,B-Blood and blood forming organs,% of total sales,3.2
24929,New Zealand,2011,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
24930,New Zealand,2011,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.1
24931,New Zealand,2011,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.3
24932,New Zealand,2011,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",4.0
24933,New Zealand,2011,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",14.3
24934,New Zealand,2011,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.8
24935,New Zealand,2011,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.2
24936,New Zealand,2011,10,Products not elsewhere classified,Million of national currency units,202.6
24937,New Zealand,2011,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.3
24938,New Zealand,2011,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",33.6
24939,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.3
24940,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.2
24941,New Zealand,2011,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,39.5
24942,New Zealand,2011,10,R-Respiratory system,Million US$ at exchange rate,65.7
24943,New Zealand,2011,10,R-Respiratory system,"Million US$, purchasing power parity",56.0
24944,New Zealand,2011,10,J-Antiinfectives for systemic use,Million of national currency units,50.0
24945,New Zealand,2011,10,R-Respiratory system,Million of national currency units,83.2
24946,New Zealand,2011,10,N05B-Anxiolytics,Million of national currency units,1.2
24947,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
24948,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,Million of national currency units,73.3
24949,New Zealand,2011,10,N05B-Anxiolytics,Million US$ at exchange rate,0.9
24950,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,34.6
24951,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",6.2
24952,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.3
24953,New Zealand,2011,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,27.3
24954,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.9
24955,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
24956,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,11.9
24957,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,14.7
24958,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.4
24959,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.6
24960,New Zealand,2011,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,18.7
24961,New Zealand,2011,10,R-Respiratory system,% of total sales,10.2
24962,New Zealand,2011,10,R-Respiratory system,"/capita, US$ purchasing power parity",12.8
24963,New Zealand,2011,10,R-Respiratory system,"/capita, US$ exchange rate",15.0
24964,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.0
24965,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,9.4
24966,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.8
24967,New Zealand,2011,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.1
24968,New Zealand,2011,10,N06A-Antidepressants,Million US$ at exchange rate,25.4
24969,New Zealand,2011,10,N06A-Antidepressants,"Million US$, purchasing power parity",21.7
24970,New Zealand,2011,10,N06A-Antidepressants,Million of national currency units,32.2
24971,New Zealand,2011,10,N06A-Antidepressants,% of total sales,3.9
24972,New Zealand,2011,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2
24973,New Zealand,2011,10,N06A-Antidepressants,"/capita, US$ exchange rate",5.8
24974,New Zealand,2011,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.9
24975,New Zealand,2011,10,G-Genito urinary system and sex hormones,% of total sales,2.6
24976,New Zealand,2011,10,A02A-Antacids,Million of national currency units,0.3
24977,New Zealand,2011,10,A02A-Antacids,Million US$ at exchange rate,0.2
24978,New Zealand,2011,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
24979,New Zealand,2011,10,N05B-Anxiolytics,% of total sales,0.1
24980,New Zealand,2011,10,N05B-Anxiolytics,"Million US$, purchasing power parity",0.8
24981,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,% of total sales,9.0
24982,New Zealand,2011,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",7.7
24983,New Zealand,2011,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.0
24984,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",49.4
24985,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,57.9
24986,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",11.3
24987,New Zealand,2011,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.2
24988,New Zealand,2011,10,A02A-Antacids,"/capita, US$ exchange rate",0.0
24989,New Zealand,2011,10,A02A-Antacids,"Million US$, purchasing power parity",0.2
24990,New Zealand,2011,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
24991,New Zealand,2011,10,J-Antiinfectives for systemic use,% of total sales,6.1
24992,New Zealand,2011,10,A02A-Antacids,% of total sales,0.0
24993,New Zealand,2011,10,C07-Beta blocking agents,Million US$ at exchange rate,14.4
24994,New Zealand,2011,10,C07-Beta blocking agents,Million of national currency units,18.2
24995,New Zealand,2011,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",20.7
24996,New Zealand,2011,10,C07-Beta blocking agents,"/capita, US$ exchange rate",3.3
24997,New Zealand,2011,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.8
24998,New Zealand,2011,10,C07-Beta blocking agents,"Million US$, purchasing power parity",12.3
24999,New Zealand,2011,10,M-Musculo-skeletal system,% of total sales,3.2
25000,New Zealand,2011,10,C03-Diuretics,Million US$ at exchange rate,1.8
25001,New Zealand,2011,10,C-Cardiovascular system,% of total sales,16.5
25002,New Zealand,2011,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.7
25003,New Zealand,2011,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",4.0
25004,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.4
25005,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.2
25006,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.2
25007,New Zealand,2011,10,M-Musculo-skeletal system,Million of national currency units,26.2
25008,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.5
25009,New Zealand,2011,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",17.6
25010,New Zealand,2011,10,C07-Beta blocking agents,% of total sales,2.2
25011,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
25012,New Zealand,2011,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0
25013,New Zealand,2011,10,M-Musculo-skeletal system,Million US$ at exchange rate,20.7
25014,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.8
25015,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.8
25016,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.2
25017,New Zealand,2011,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",125.4
25018,New Zealand,2011,10,Total pharmaceutical sales,"/capita, US$ exchange rate",147.2
25019,New Zealand,2011,10,N-Nervous system,% of total sales,22.3
25020,New Zealand,2011,10,C02-Antihypertensives,Million US$ at exchange rate,2.4
25021,New Zealand,2011,10,C02-Antihypertensives,Million of national currency units,3.0
25022,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.6
25023,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
25024,New Zealand,2011,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
25025,New Zealand,2011,10,N-Nervous system,Million of national currency units,182.6
25026,New Zealand,2011,10,C03-Diuretics,% of total sales,0.3
25027,New Zealand,2011,10,Total pharmaceutical sales,Million of national currency units,817.0
25028,New Zealand,2011,10,C03-Diuretics,"Million US$, purchasing power parity",1.5
25029,New Zealand,2011,10,C03-Diuretics,"/capita, US$ exchange rate",0.4
25030,New Zealand,2011,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.4
25031,New Zealand,2011,10,Total pharmaceutical sales,Million US$ at exchange rate,645.4
25032,New Zealand,2011,10,N-Nervous system,"/capita, US$ purchasing power parity",28.0
25033,New Zealand,2011,10,Total pharmaceutical sales,"Million US$, purchasing power parity",549.8
25034,New Zealand,2011,10,N-Nervous system,"Million US$, purchasing power parity",122.9
25035,New Zealand,2011,10,N-Nervous system,Million US$ at exchange rate,144.2
25036,New Zealand,2011,10,N-Nervous system,"/capita, US$ exchange rate",32.9
25037,New Zealand,2011,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",3.4
25038,New Zealand,2011,10,J01-Antibacterials for systemic use,% of total sales,2.3
25039,New Zealand,2011,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.9
25040,New Zealand,2011,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,14.9
25041,New Zealand,2011,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.7
25042,New Zealand,2011,10,C-Cardiovascular system,"/capita, US$ exchange rate",24.2
25043,New Zealand,2011,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
25044,New Zealand,2011,10,C01A-Cardiac glycosides,Million of national currency units,0.4
25045,New Zealand,2011,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
25046,New Zealand,2011,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
25047,New Zealand,2011,10,A10-Drugs used in diabetes,Million US$ at exchange rate,25.6
25048,New Zealand,2011,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",21.8
25049,New Zealand,2011,10,C02-Antihypertensives,% of total sales,0.4
25050,New Zealand,2011,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5
25051,New Zealand,2011,10,A10-Drugs used in diabetes,Million of national currency units,32.4
25052,New Zealand,2011,10,J01-Antibacterials for systemic use,Million of national currency units,18.9
25053,New Zealand,2011,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",5.8
25054,New Zealand,2011,10,C-Cardiovascular system,Million of national currency units,134.6
25055,New Zealand,2011,10,C-Cardiovascular system,"Million US$, purchasing power parity",90.6
25056,New Zealand,2011,10,C-Cardiovascular system,Million US$ at exchange rate,106.3
25057,New Zealand,2011,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",5.0
25058,New Zealand,2011,10,A10-Drugs used in diabetes,% of total sales,4.0
25059,New Zealand,2011,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",12.9
25060,New Zealand,2011,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",48.2
25061,New Zealand,2011,10,A-Alimentary tract and metabolism,% of total sales,8.8
25062,New Zealand,2011,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",11.0
25063,New Zealand,2011,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
25064,New Zealand,2011,10,C02-Antihypertensives,"Million US$, purchasing power parity",2.0
25065,New Zealand,2011,10,C03-Diuretics,Million of national currency units,2.3
25066,New Zealand,2011,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,56.6
25067,New Zealand,2011,10,A-Alimentary tract and metabolism,Million of national currency units,71.7
25068,New Zealand,2011,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
25069,New Zealand,2011,10,C01A-Cardiac glycosides,% of total sales,0.0
25070,New Zealand,2017,9,C08-Calcium channel blockers,Million of national currency units,5.8
25071,New Zealand,2017,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",6.4
25072,New Zealand,2017,9,N05C-Hypnotics and sedatives,Million of national currency units,1.1
25073,New Zealand,2017,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,0.8
25074,New Zealand,2017,9,C08-Calcium channel blockers,Million US$ at exchange rate,4.1
25075,New Zealand,2017,9,Products not elsewhere classified,"Million US$, purchasing power parity",456.5
25076,New Zealand,2017,9,C10-Lipid modifying agents,Million US$ at exchange rate,6.5
25077,New Zealand,2017,9,Products not elsewhere classified,Million US$ at exchange rate,464.1
25078,New Zealand,2017,9,C10-Lipid modifying agents,Million of national currency units,9.1
25079,New Zealand,2017,9,N02-Analgesics,"/capita, US$ exchange rate",2.5
25080,New Zealand,2017,9,N02-Analgesics,"/capita, US$ purchasing power parity",2.5
25081,New Zealand,2017,9,N02-Analgesics,"Million US$, purchasing power parity",11.8
25082,New Zealand,2017,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",94.8
25083,New Zealand,2017,9,Products not elsewhere classified,% of total sales,51.7
25084,New Zealand,2017,9,N02-Analgesics,% of total sales,1.3
25085,New Zealand,2017,9,N02-Analgesics,Million US$ at exchange rate,12.0
25086,New Zealand,2017,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.8
25087,New Zealand,2017,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.0
25088,New Zealand,2017,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.8
25089,New Zealand,2017,9,N02-Analgesics,Million of national currency units,16.9
25090,New Zealand,2017,9,C08-Calcium channel blockers,% of total sales,0.5
25091,New Zealand,2017,9,Products not elsewhere classified,"/capita, US$ exchange rate",96.4
25092,New Zealand,2017,9,G-Genito urinary system and sex hormones,Million of national currency units,20.2
25093,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,% of total sales,0.9
25094,New Zealand,2017,9,B-Blood and blood forming organs,Million of national currency units,68.3
25095,New Zealand,2017,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",47.7
25096,New Zealand,2017,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,14.3
25097,New Zealand,2017,9,B-Blood and blood forming organs,Million US$ at exchange rate,48.5
25098,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",7.9
25099,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.7
25100,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.1
25101,New Zealand,2017,9,C10-Lipid modifying agents,% of total sales,0.7
25102,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.6
25103,New Zealand,2017,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,11.4
25104,New Zealand,2017,9,N05C-Hypnotics and sedatives,% of total sales,0.1
25105,New Zealand,2017,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",1.3
25106,New Zealand,2017,9,B-Blood and blood forming organs,% of total sales,5.4
25107,New Zealand,2017,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",0.8
25108,New Zealand,2017,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
25109,New Zealand,2017,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.2
25110,New Zealand,2017,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",10.1
25111,New Zealand,2017,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",14.1
25112,New Zealand,2017,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",9.9
25113,New Zealand,2017,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.3
25114,New Zealand,2017,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.0
25115,New Zealand,2017,9,Products not elsewhere classified,Million of national currency units,653.2
25116,New Zealand,2017,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,121.0
25117,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,0.9
25118,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.7
25119,New Zealand,2017,9,R-Respiratory system,Million US$ at exchange rate,69.3
25120,New Zealand,2017,9,R-Respiratory system,Million of national currency units,97.6
25121,New Zealand,2017,9,J-Antiinfectives for systemic use,Million of national currency units,170.3
25122,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.9
25123,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,Million of national currency units,89.1
25124,New Zealand,2017,9,N05B-Anxiolytics,Million of national currency units,1.2
25125,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",8.2
25126,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",1.7
25127,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,11.8
25128,New Zealand,2017,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,8.4
25129,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.6
25130,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.7
25131,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,5.9
25132,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
25133,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,25.0
25134,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,17.8
25135,New Zealand,2017,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",17.5
25136,New Zealand,2017,9,R-Respiratory system,"/capita, US$ purchasing power parity",14.2
25137,New Zealand,2017,9,R-Respiratory system,% of total sales,7.7
25138,New Zealand,2017,9,R-Respiratory system,"Million US$, purchasing power parity",68.2
25139,New Zealand,2017,9,R-Respiratory system,"/capita, US$ exchange rate",14.4
25140,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.2
25141,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.1
25142,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.9
25143,New Zealand,2017,9,N06A-Antidepressants,Million US$ at exchange rate,9.6
25144,New Zealand,2017,9,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9
25145,New Zealand,2017,9,N06A-Antidepressants,Million of national currency units,13.5
25146,New Zealand,2017,9,N06A-Antidepressants,"Million US$, purchasing power parity",9.4
25147,New Zealand,2017,9,N06A-Antidepressants,% of total sales,1.1
25148,New Zealand,2017,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.0
25149,New Zealand,2017,9,N06A-Antidepressants,"/capita, US$ exchange rate",2.0
25150,New Zealand,2017,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",2.9
25151,New Zealand,2017,9,G-Genito urinary system and sex hormones,% of total sales,1.6
25152,New Zealand,2017,9,A02A-Antacids,Million of national currency units,0.3
25153,New Zealand,2017,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
25154,New Zealand,2017,9,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2
25155,New Zealand,2017,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.5
25156,New Zealand,2017,9,N05B-Anxiolytics,% of total sales,0.1
25157,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,% of total sales,7.1
25158,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.9
25159,New Zealand,2017,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",119.0
25160,New Zealand,2017,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",25.1
25161,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,63.3
25162,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",62.2
25163,New Zealand,2017,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.1
25164,New Zealand,2017,9,A02A-Antacids,"Million US$, purchasing power parity",0.2
25165,New Zealand,2017,9,A02A-Antacids,"/capita, US$ exchange rate",0.0
25166,New Zealand,2017,9,N05B-Anxiolytics,Million US$ at exchange rate,0.9
25167,New Zealand,2017,9,A02A-Antacids,Million US$ at exchange rate,0.2
25168,New Zealand,2017,9,J-Antiinfectives for systemic use,% of total sales,13.5
25169,New Zealand,2017,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.7
25170,New Zealand,2017,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
25171,New Zealand,2017,9,A02A-Antacids,% of total sales,0.0
25172,New Zealand,2017,9,C07-Beta blocking agents,Million of national currency units,12.1
25173,New Zealand,2017,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",7.5
25174,New Zealand,2017,9,C07-Beta blocking agents,Million US$ at exchange rate,8.6
25175,New Zealand,2017,9,C07-Beta blocking agents,"/capita, US$ exchange rate",1.8
25176,New Zealand,2017,9,C07-Beta blocking agents,"Million US$, purchasing power parity",8.5
25177,New Zealand,2017,9,M-Musculo-skeletal system,% of total sales,1.7
25178,New Zealand,2017,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.1
25179,New Zealand,2017,9,C03-Diuretics,Million of national currency units,2.3
25180,New Zealand,2017,9,C-Cardiovascular system,% of total sales,4.1
25181,New Zealand,2017,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",3.2
25182,New Zealand,2017,9,C03-Diuretics,Million US$ at exchange rate,1.7
25183,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.0
25184,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.9
25185,New Zealand,2017,9,C02-Antihypertensives,Million US$ at exchange rate,1.6
25186,New Zealand,2017,9,M-Musculo-skeletal system,Million of national currency units,21.7
25187,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.0
25188,New Zealand,2017,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",15.2
25189,New Zealand,2017,9,C07-Beta blocking agents,% of total sales,1.0
25190,New Zealand,2017,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",1.8
25191,New Zealand,2017,9,M-Musculo-skeletal system,Million US$ at exchange rate,15.4
25192,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0
25193,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.6
25194,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.1
25195,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,2.9
25196,New Zealand,2017,9,N-Nervous system,% of total sales,13.3
25197,New Zealand,2017,9,Total pharmaceutical sales,"/capita, US$ exchange rate",186.3
25198,New Zealand,2017,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",183.2
25199,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
25200,New Zealand,2017,9,C02-Antihypertensives,Million of national currency units,2.2
25201,New Zealand,2017,9,C03-Diuretics,% of total sales,0.2
25202,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
25203,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",2.9
25204,New Zealand,2017,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
25205,New Zealand,2017,9,N-Nervous system,Million of national currency units,167.6
25206,New Zealand,2017,9,Total pharmaceutical sales,Million of national currency units,1262.2
25207,New Zealand,2017,9,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
25208,New Zealand,2017,9,C03-Diuretics,"Million US$, purchasing power parity",1.6
25209,New Zealand,2017,9,C03-Diuretics,"/capita, US$ exchange rate",0.3
25210,New Zealand,2017,9,N-Nervous system,"/capita, US$ purchasing power parity",24.3
25211,New Zealand,2017,9,Total pharmaceutical sales,"Million US$, purchasing power parity",882.1
25212,New Zealand,2017,9,Total pharmaceutical sales,Million US$ at exchange rate,896.8
25213,New Zealand,2017,9,N-Nervous system,Million US$ at exchange rate,119.1
25214,New Zealand,2017,9,N-Nervous system,"/capita, US$ exchange rate",24.7
25215,New Zealand,2017,9,N-Nervous system,"Million US$, purchasing power parity",117.1
25216,New Zealand,2017,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.0
25217,New Zealand,2017,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.3
25218,New Zealand,2017,9,J01-Antibacterials for systemic use,Million of national currency units,15.3
25219,New Zealand,2017,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,10.9
25220,New Zealand,2017,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",10.7
25221,New Zealand,2017,9,C-Cardiovascular system,"Million US$, purchasing power parity",36.1
25222,New Zealand,2017,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
25223,New Zealand,2017,9,C-Cardiovascular system,"/capita, US$ exchange rate",7.6
25224,New Zealand,2017,9,J01-Antibacterials for systemic use,% of total sales,1.2
25225,New Zealand,2017,9,C01A-Cardiac glycosides,Million of national currency units,0.4
25226,New Zealand,2017,9,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
25227,New Zealand,2017,9,A10-Drugs used in diabetes,Million US$ at exchange rate,37.8
25228,New Zealand,2017,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",37.2
25229,New Zealand,2017,9,A10-Drugs used in diabetes,Million of national currency units,53.2
25230,New Zealand,2017,9,C02-Antihypertensives,% of total sales,0.2
25231,New Zealand,2017,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.3
25232,New Zealand,2017,9,C-Cardiovascular system,Million of national currency units,51.6
25233,New Zealand,2017,9,C-Cardiovascular system,Million US$ at exchange rate,36.7
25234,New Zealand,2017,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.9
25235,New Zealand,2017,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",7.7
25236,New Zealand,2017,9,A10-Drugs used in diabetes,% of total sales,4.2
25237,New Zealand,2017,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.2
25238,New Zealand,2017,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.1
25239,New Zealand,2017,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",62.0
25240,New Zealand,2017,9,A-Alimentary tract and metabolism,% of total sales,7.0
25241,New Zealand,2017,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",12.9
25242,New Zealand,2017,9,C02-Antihypertensives,"Million US$, purchasing power parity",1.6
25243,New Zealand,2017,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
25244,New Zealand,2017,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,63.0
25245,New Zealand,2017,9,A-Alimentary tract and metabolism,Million of national currency units,88.7
25246,New Zealand,2017,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
25247,New Zealand,2017,9,C01A-Cardiac glycosides,% of total sales,0.0
25248,New Zealand,2017,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
25249,New Zealand,2016,10,N05C-Hypnotics and sedatives,Million of national currency units,1.8
25250,New Zealand,2016,10,C08-Calcium channel blockers,Million of national currency units,5.7
25251,New Zealand,2016,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",8.1
25252,New Zealand,2016,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.2
25253,New Zealand,2016,10,C08-Calcium channel blockers,Million US$ at exchange rate,4.0
25254,New Zealand,2016,10,C10-Lipid modifying agents,Million US$ at exchange rate,8.1
25255,New Zealand,2016,10,Products not elsewhere classified,"Million US$, purchasing power parity",266.2
25256,New Zealand,2016,10,Products not elsewhere classified,Million US$ at exchange rate,267.0
25257,New Zealand,2016,10,C10-Lipid modifying agents,Million of national currency units,11.7
25258,New Zealand,2016,10,N02-Analgesics,"/capita, US$ exchange rate",2.9
25259,New Zealand,2016,10,N02-Analgesics,"/capita, US$ purchasing power parity",2.9
25260,New Zealand,2016,10,N02-Analgesics,"Million US$, purchasing power parity",13.6
25261,New Zealand,2016,10,Products not elsewhere classified,% of total sales,35.8
25262,New Zealand,2016,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",56.5
25263,New Zealand,2016,10,N02-Analgesics,% of total sales,1.8
25264,New Zealand,2016,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",0.8
25265,New Zealand,2016,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",4.0
25266,New Zealand,2016,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",0.8
25267,New Zealand,2016,10,N02-Analgesics,Million of national currency units,19.6
25268,New Zealand,2016,10,N02-Analgesics,Million US$ at exchange rate,13.7
25269,New Zealand,2016,10,C08-Calcium channel blockers,% of total sales,0.5
25270,New Zealand,2016,10,Products not elsewhere classified,"/capita, US$ exchange rate",56.6
25271,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
25272,New Zealand,2016,10,G-Genito urinary system and sex hormones,Million of national currency units,21.6
25273,New Zealand,2016,10,B-Blood and blood forming organs,Million of national currency units,84.8
25274,New Zealand,2016,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",58.8
25275,New Zealand,2016,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.0
25276,New Zealand,2016,10,B-Blood and blood forming organs,Million US$ at exchange rate,59.0
25277,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",8.8
25278,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.9
25279,New Zealand,2016,10,C10-Lipid modifying agents,% of total sales,1.1
25280,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.8
25281,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,12.6
25282,New Zealand,2016,10,N05C-Hypnotics and sedatives,% of total sales,0.2
25283,New Zealand,2016,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",1.7
25284,New Zealand,2016,10,B-Blood and blood forming organs,% of total sales,7.9
25285,New Zealand,2016,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.2
25286,New Zealand,2016,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
25287,New Zealand,2016,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.3
25288,New Zealand,2016,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9
25289,New Zealand,2016,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",12.5
25290,New Zealand,2016,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",12.5
25291,New Zealand,2016,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",15.0
25292,New Zealand,2016,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",1.7
25293,New Zealand,2016,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.2
25294,New Zealand,2016,10,Products not elsewhere classified,Million of national currency units,383.6
25295,New Zealand,2016,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,80.0
25296,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.1
25297,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",1.8
25298,New Zealand,2016,10,R-Respiratory system,Million US$ at exchange rate,71.9
25299,New Zealand,2016,10,J-Antiinfectives for systemic use,Million of national currency units,114.9
25300,New Zealand,2016,10,R-Respiratory system,Million of national currency units,103.2
25301,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.9
25302,New Zealand,2016,10,N05B-Anxiolytics,Million of national currency units,2.7
25303,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,Million of national currency units,92.7
25304,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",8.5
25305,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",1.8
25306,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,12.3
25307,New Zealand,2016,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,8.6
25308,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.1
25309,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,6.0
25310,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
25311,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.2
25312,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,28.2
25313,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,19.6
25314,New Zealand,2016,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",19.6
25315,New Zealand,2016,10,R-Respiratory system,"/capita, US$ purchasing power parity",15.2
25316,New Zealand,2016,10,R-Respiratory system,% of total sales,9.6
25317,New Zealand,2016,10,R-Respiratory system,"Million US$, purchasing power parity",71.6
25318,New Zealand,2016,10,R-Respiratory system,"/capita, US$ exchange rate",15.2
25319,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.2
25320,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.2
25321,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",0.9
25322,New Zealand,2016,10,N06A-Antidepressants,Million US$ at exchange rate,9.5
25323,New Zealand,2016,10,N06A-Antidepressants,"Million US$, purchasing power parity",9.5
25324,New Zealand,2016,10,N05B-Anxiolytics,"Million US$, purchasing power parity",1.9
25325,New Zealand,2016,10,N06A-Antidepressants,Million of national currency units,13.7
25326,New Zealand,2016,10,N06A-Antidepressants,% of total sales,1.3
25327,New Zealand,2016,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.0
25328,New Zealand,2016,10,N06A-Antidepressants,"/capita, US$ exchange rate",2.0
25329,New Zealand,2016,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.2
25330,New Zealand,2016,10,G-Genito urinary system and sex hormones,% of total sales,2.0
25331,New Zealand,2016,10,A02A-Antacids,Million US$ at exchange rate,0.3
25332,New Zealand,2016,10,A02A-Antacids,Million of national currency units,0.4
25333,New Zealand,2016,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.4
25334,New Zealand,2016,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.4
25335,New Zealand,2016,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.6
25336,New Zealand,2016,10,N05B-Anxiolytics,% of total sales,0.3
25337,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,% of total sales,8.7
25338,New Zealand,2016,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",79.8
25339,New Zealand,2016,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",17.0
25340,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",13.7
25341,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,64.6
25342,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",64.4
25343,New Zealand,2016,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.7
25344,New Zealand,2016,10,A02A-Antacids,"/capita, US$ exchange rate",0.1
25345,New Zealand,2016,10,A02A-Antacids,"Million US$, purchasing power parity",0.3
25346,New Zealand,2016,10,N05B-Anxiolytics,Million US$ at exchange rate,1.9
25347,New Zealand,2016,10,J-Antiinfectives for systemic use,% of total sales,10.7
25348,New Zealand,2016,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.9
25349,New Zealand,2016,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
25350,New Zealand,2016,10,A02A-Antacids,% of total sales,0.0
25351,New Zealand,2016,10,C07-Beta blocking agents,Million of national currency units,7.9
25352,New Zealand,2016,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",7.5
25353,New Zealand,2016,10,C07-Beta blocking agents,Million US$ at exchange rate,5.5
25354,New Zealand,2016,10,C07-Beta blocking agents,"/capita, US$ exchange rate",1.2
25355,New Zealand,2016,10,C07-Beta blocking agents,"Million US$, purchasing power parity",5.5
25356,New Zealand,2016,10,M-Musculo-skeletal system,% of total sales,2.0
25357,New Zealand,2016,10,C03-Diuretics,Million US$ at exchange rate,1.6
25358,New Zealand,2016,10,C03-Diuretics,Million of national currency units,2.2
25359,New Zealand,2016,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.2
25360,New Zealand,2016,10,C-Cardiovascular system,% of total sales,4.8
25361,New Zealand,2016,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",3.2
25362,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.5
25363,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.2
25364,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.5
25365,New Zealand,2016,10,C02-Antihypertensives,Million US$ at exchange rate,1.8
25366,New Zealand,2016,10,M-Musculo-skeletal system,Million of national currency units,21.7
25367,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.9
25368,New Zealand,2016,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",15.1
25369,New Zealand,2016,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",1.2
25370,New Zealand,2016,10,C07-Beta blocking agents,% of total sales,0.7
25371,New Zealand,2016,10,M-Musculo-skeletal system,Million US$ at exchange rate,15.1
25372,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.2
25373,New Zealand,2016,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.7
25374,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.7
25375,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3
25376,New Zealand,2016,10,N-Nervous system,% of total sales,16.0
25377,New Zealand,2016,10,Total pharmaceutical sales,"/capita, US$ exchange rate",158.3
25378,New Zealand,2016,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",157.8
25379,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.3
25380,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.4
25381,New Zealand,2016,10,C03-Diuretics,% of total sales,0.2
25382,New Zealand,2016,10,C02-Antihypertensives,Million of national currency units,2.6
25383,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
25384,New Zealand,2016,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
25385,New Zealand,2016,10,N-Nervous system,Million of national currency units,171.8
25386,New Zealand,2016,10,Total pharmaceutical sales,Million of national currency units,1072.1
25387,New Zealand,2016,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
25388,New Zealand,2016,10,C03-Diuretics,"Million US$, purchasing power parity",1.6
25389,New Zealand,2016,10,C03-Diuretics,"/capita, US$ exchange rate",0.3
25390,New Zealand,2016,10,N-Nervous system,"/capita, US$ purchasing power parity",25.3
25391,New Zealand,2016,10,Total pharmaceutical sales,Million US$ at exchange rate,746.3
25392,New Zealand,2016,10,Total pharmaceutical sales,"Million US$, purchasing power parity",744.0
25393,New Zealand,2016,10,N-Nervous system,Million US$ at exchange rate,119.6
25394,New Zealand,2016,10,N-Nervous system,"/capita, US$ exchange rate",25.4
25395,New Zealand,2016,10,N-Nervous system,"Million US$, purchasing power parity",119.2
25396,New Zealand,2016,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.7
25397,New Zealand,2016,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.7
25398,New Zealand,2016,10,J01-Antibacterials for systemic use,Million of national currency units,18.5
25399,New Zealand,2016,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.8
25400,New Zealand,2016,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.9
25401,New Zealand,2016,10,J01-Antibacterials for systemic use,% of total sales,1.7
25402,New Zealand,2016,10,C-Cardiovascular system,"Million US$, purchasing power parity",35.4
25403,New Zealand,2016,10,C-Cardiovascular system,"/capita, US$ exchange rate",7.5
25404,New Zealand,2016,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
25405,New Zealand,2016,10,C01A-Cardiac glycosides,Million of national currency units,0.3
25406,New Zealand,2016,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
25407,New Zealand,2016,10,A10-Drugs used in diabetes,Million US$ at exchange rate,34.8
25408,New Zealand,2016,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",34.7
25409,New Zealand,2016,10,C02-Antihypertensives,% of total sales,0.2
25410,New Zealand,2016,10,A10-Drugs used in diabetes,Million of national currency units,50.0
25411,New Zealand,2016,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4
25412,New Zealand,2016,10,C-Cardiovascular system,Million of national currency units,51.0
25413,New Zealand,2016,10,C-Cardiovascular system,Million US$ at exchange rate,35.5
25414,New Zealand,2016,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.4
25415,New Zealand,2016,10,A10-Drugs used in diabetes,% of total sales,4.7
25416,New Zealand,2016,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",7.4
25417,New Zealand,2016,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.5
25418,New Zealand,2016,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",63.2
25419,New Zealand,2016,10,A-Alimentary tract and metabolism,% of total sales,8.5
25420,New Zealand,2016,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",13.4
25421,New Zealand,2016,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.4
25422,New Zealand,2016,10,C02-Antihypertensives,"Million US$, purchasing power parity",1.8
25423,New Zealand,2016,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,63.4
25424,New Zealand,2016,10,A-Alimentary tract and metabolism,Million of national currency units,91.1
25425,New Zealand,2016,10,C01A-Cardiac glycosides,% of total sales,0.0
25426,New Zealand,2016,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.0
25427,New Zealand,2016,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.0
25428,New Zealand,2015,10,N05C-Hypnotics and sedatives,Million of national currency units,1.7
25429,New Zealand,2015,10,C08-Calcium channel blockers,Million of national currency units,8.2
25430,New Zealand,2015,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",11.8
25431,New Zealand,2015,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.2
25432,New Zealand,2015,10,C08-Calcium channel blockers,Million US$ at exchange rate,5.7
25433,New Zealand,2015,10,C10-Lipid modifying agents,Million US$ at exchange rate,12.2
25434,New Zealand,2015,10,Products not elsewhere classified,Million US$ at exchange rate,239.3
25435,New Zealand,2015,10,Products not elsewhere classified,"Million US$, purchasing power parity",232.1
25436,New Zealand,2015,10,Products not elsewhere classified,"/capita, US$ exchange rate",51.9
25437,New Zealand,2015,10,C10-Lipid modifying agents,Million of national currency units,17.4
25438,New Zealand,2015,10,N02-Analgesics,"/capita, US$ exchange rate",3.1
25439,New Zealand,2015,10,N02-Analgesics,"/capita, US$ purchasing power parity",3.0
25440,New Zealand,2015,10,N02-Analgesics,"Million US$, purchasing power parity",13.8
25441,New Zealand,2015,10,Products not elsewhere classified,% of total sales,34.7
25442,New Zealand,2015,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",50.4
25443,New Zealand,2015,10,N02-Analgesics,% of total sales,2.1
25444,New Zealand,2015,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.2
25445,New Zealand,2015,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.5
25446,New Zealand,2015,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.2
25447,New Zealand,2015,10,C08-Calcium channel blockers,% of total sales,0.8
25448,New Zealand,2015,10,N02-Analgesics,Million of national currency units,20.4
25449,New Zealand,2015,10,N02-Analgesics,Million US$ at exchange rate,14.2
25450,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9
25451,New Zealand,2015,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,15.6
25452,New Zealand,2015,10,B-Blood and blood forming organs,Million of national currency units,99.0
25453,New Zealand,2015,10,G-Genito urinary system and sex hormones,Million of national currency units,22.4
25454,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.3
25455,New Zealand,2015,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",67.0
25456,New Zealand,2015,10,B-Blood and blood forming organs,Million US$ at exchange rate,69.1
25457,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",8.7
25458,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",1.9
25459,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,9.0
25460,New Zealand,2015,10,C10-Lipid modifying agents,% of total sales,1.8
25461,New Zealand,2015,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,12.9
25462,New Zealand,2015,10,N05C-Hypnotics and sedatives,% of total sales,0.2
25463,New Zealand,2015,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",2.6
25464,New Zealand,2015,10,B-Blood and blood forming organs,% of total sales,10.0
25465,New Zealand,2015,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.1
25466,New Zealand,2015,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
25467,New Zealand,2015,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
25468,New Zealand,2015,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.0
25469,New Zealand,2015,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",14.5
25470,New Zealand,2015,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",15.2
25471,New Zealand,2015,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.4
25472,New Zealand,2015,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",2.6
25473,New Zealand,2015,10,Products not elsewhere classified,Million of national currency units,343.1
25474,New Zealand,2015,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",74.4
25475,New Zealand,2015,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,76.7
25476,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.4
25477,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",2.0
25478,New Zealand,2015,10,R-Respiratory system,Million US$ at exchange rate,70.2
25479,New Zealand,2015,10,R-Respiratory system,Million of national currency units,100.6
25480,New Zealand,2015,10,J-Antiinfectives for systemic use,Million of national currency units,109.9
25481,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",0.9
25482,New Zealand,2015,10,N05B-Anxiolytics,Million of national currency units,2.5
25483,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,Million of national currency units,90.5
25484,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",9.1
25485,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",2.0
25486,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,13.4
25487,New Zealand,2015,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,9.4
25488,New Zealand,2015,10,R-Respiratory system,"Million US$, purchasing power parity",68.1
25489,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.2
25490,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,6.3
25491,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.9
25492,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.3
25493,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,28.5
25494,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,19.9
25495,New Zealand,2015,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",19.3
25496,New Zealand,2015,10,R-Respiratory system,"/capita, US$ purchasing power parity",14.8
25497,New Zealand,2015,10,R-Respiratory system,% of total sales,10.2
25498,New Zealand,2015,10,R-Respiratory system,"/capita, US$ exchange rate",15.2
25499,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.3
25500,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,4.4
25501,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.0
25502,New Zealand,2015,10,N06A-Antidepressants,Million US$ at exchange rate,10.8
25503,New Zealand,2015,10,N06A-Antidepressants,"Million US$, purchasing power parity",10.5
25504,New Zealand,2015,10,N06A-Antidepressants,Million of national currency units,15.6
25505,New Zealand,2015,10,N06A-Antidepressants,% of total sales,1.6
25506,New Zealand,2015,10,N05B-Anxiolytics,"Million US$, purchasing power parity",1.7
25507,New Zealand,2015,10,N06A-Antidepressants,"/capita, US$ exchange rate",2.4
25508,New Zealand,2015,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.3
25509,New Zealand,2015,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.3
25510,New Zealand,2015,10,G-Genito urinary system and sex hormones,% of total sales,2.3
25511,New Zealand,2015,10,A02A-Antacids,Million US$ at exchange rate,0.3
25512,New Zealand,2015,10,A02A-Antacids,Million of national currency units,0.4
25513,New Zealand,2015,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.4
25514,New Zealand,2015,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.4
25515,New Zealand,2015,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.6
25516,New Zealand,2015,10,N05B-Anxiolytics,% of total sales,0.3
25517,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,% of total sales,9.2
25518,New Zealand,2015,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",16.6
25519,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",13.3
25520,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",61.2
25521,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,63.1
25522,New Zealand,2015,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.7
25523,New Zealand,2015,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.1
25524,New Zealand,2015,10,A02A-Antacids,"/capita, US$ exchange rate",0.1
25525,New Zealand,2015,10,A02A-Antacids,"Million US$, purchasing power parity",0.3
25526,New Zealand,2015,10,N05B-Anxiolytics,Million US$ at exchange rate,1.8
25527,New Zealand,2015,10,J-Antiinfectives for systemic use,% of total sales,11.1
25528,New Zealand,2015,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.1
25529,New Zealand,2015,10,A02A-Antacids,% of total sales,0.0
25530,New Zealand,2015,10,C07-Beta blocking agents,Million of national currency units,14.1
25531,New Zealand,2015,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",9.8
25532,New Zealand,2015,10,C07-Beta blocking agents,Million US$ at exchange rate,9.9
25533,New Zealand,2015,10,C07-Beta blocking agents,"/capita, US$ exchange rate",2.1
25534,New Zealand,2015,10,C07-Beta blocking agents,"Million US$, purchasing power parity",9.6
25535,New Zealand,2015,10,M-Musculo-skeletal system,% of total sales,2.2
25536,New Zealand,2015,10,C03-Diuretics,Million US$ at exchange rate,1.5
25537,New Zealand,2015,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.2
25538,New Zealand,2015,10,C-Cardiovascular system,% of total sales,6.7
25539,New Zealand,2015,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",3.3
25540,New Zealand,2015,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.1
25541,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.4
25542,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.2
25543,New Zealand,2015,10,C03-Diuretics,% of total sales,0.2
25544,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.2
25545,New Zealand,2015,10,M-Musculo-skeletal system,Million of national currency units,21.9
25546,New Zealand,2015,10,C02-Antihypertensives,Million US$ at exchange rate,2.5
25547,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.7
25548,New Zealand,2015,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",14.8
25549,New Zealand,2015,10,C07-Beta blocking agents,% of total sales,1.4
25550,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
25551,New Zealand,2015,10,M-Musculo-skeletal system,Million US$ at exchange rate,15.3
25552,New Zealand,2015,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
25553,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.6
25554,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.2
25555,New Zealand,2015,10,Total pharmaceutical sales,"/capita, US$ exchange rate",149.4
25556,New Zealand,2015,10,N-Nervous system,% of total sales,17.0
25557,New Zealand,2015,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",145.0
25558,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.5
25559,New Zealand,2015,10,C02-Antihypertensives,Million of national currency units,3.5
25560,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
25561,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
25562,New Zealand,2015,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.1
25563,New Zealand,2015,10,N-Nervous system,Million of national currency units,167.5
25564,New Zealand,2015,10,Total pharmaceutical sales,Million of national currency units,987.6
25565,New Zealand,2015,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
25566,New Zealand,2015,10,C03-Diuretics,"Million US$, purchasing power parity",1.5
25567,New Zealand,2015,10,C03-Diuretics,"/capita, US$ exchange rate",0.3
25568,New Zealand,2015,10,N-Nervous system,"/capita, US$ purchasing power parity",24.6
25569,New Zealand,2015,10,Total pharmaceutical sales,Million US$ at exchange rate,688.7
25570,New Zealand,2015,10,Total pharmaceutical sales,"Million US$, purchasing power parity",668.2
25571,New Zealand,2015,10,N-Nervous system,Million US$ at exchange rate,116.8
25572,New Zealand,2015,10,N-Nervous system,"Million US$, purchasing power parity",113.4
25573,New Zealand,2015,10,N-Nervous system,"/capita, US$ exchange rate",25.3
25574,New Zealand,2015,10,C03-Diuretics,Million of national currency units,2.2
25575,New Zealand,2015,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.6
25576,New Zealand,2015,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.5
25577,New Zealand,2015,10,J01-Antibacterials for systemic use,Million of national currency units,17.0
25578,New Zealand,2015,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,11.9
25579,New Zealand,2015,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",11.5
25580,New Zealand,2015,10,C-Cardiovascular system,"Million US$, purchasing power parity",45.1
25581,New Zealand,2015,10,C-Cardiovascular system,"/capita, US$ exchange rate",10.1
25582,New Zealand,2015,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.2
25583,New Zealand,2015,10,J01-Antibacterials for systemic use,% of total sales,1.7
25584,New Zealand,2015,10,C01A-Cardiac glycosides,Million of national currency units,0.4
25585,New Zealand,2015,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.2
25586,New Zealand,2015,10,A10-Drugs used in diabetes,Million US$ at exchange rate,32.3
25587,New Zealand,2015,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",31.4
25588,New Zealand,2015,10,A10-Drugs used in diabetes,Million of national currency units,46.4
25589,New Zealand,2015,10,C02-Antihypertensives,% of total sales,0.4
25590,New Zealand,2015,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5
25591,New Zealand,2015,10,C-Cardiovascular system,Million of national currency units,66.6
25592,New Zealand,2015,10,C-Cardiovascular system,Million US$ at exchange rate,46.5
25593,New Zealand,2015,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.0
25594,New Zealand,2015,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",6.8
25595,New Zealand,2015,10,A10-Drugs used in diabetes,% of total sales,4.7
25596,New Zealand,2015,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.6
25597,New Zealand,2015,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",61.0
25598,New Zealand,2015,10,A-Alimentary tract and metabolism,% of total sales,9.1
25599,New Zealand,2015,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",13.2
25600,New Zealand,2015,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
25601,New Zealand,2015,10,C02-Antihypertensives,"Million US$, purchasing power parity",2.4
25602,New Zealand,2015,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,62.9
25603,New Zealand,2015,10,A-Alimentary tract and metabolism,Million of national currency units,90.2
25604,New Zealand,2015,10,C01A-Cardiac glycosides,% of total sales,0.0
25605,New Zealand,2015,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
25606,New Zealand,2015,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
25607,New Zealand,2014,10,N05C-Hypnotics and sedatives,Million of national currency units,1.6
25608,New Zealand,2014,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",12.1
25609,New Zealand,2014,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.3
25610,New Zealand,2014,10,C08-Calcium channel blockers,Million US$ at exchange rate,6.8
25611,New Zealand,2014,10,C10-Lipid modifying agents,Million US$ at exchange rate,14.5
25612,New Zealand,2014,10,Products not elsewhere classified,Million US$ at exchange rate,268.0
25613,New Zealand,2014,10,Products not elsewhere classified,"/capita, US$ exchange rate",59.3
25614,New Zealand,2014,10,Products not elsewhere classified,"Million US$, purchasing power parity",224.3
25615,New Zealand,2014,10,C08-Calcium channel blockers,Million of national currency units,8.3
25616,New Zealand,2014,10,C10-Lipid modifying agents,Million of national currency units,17.5
25617,New Zealand,2014,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",5.7
25618,New Zealand,2014,10,N02-Analgesics,"/capita, US$ exchange rate",3.9
25619,New Zealand,2014,10,N02-Analgesics,"/capita, US$ purchasing power parity",3.3
25620,New Zealand,2014,10,N02-Analgesics,"Million US$, purchasing power parity",14.7
25621,New Zealand,2014,10,Products not elsewhere classified,% of total sales,33.7
25622,New Zealand,2014,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",49.7
25623,New Zealand,2014,10,N02-Analgesics,% of total sales,2.2
25624,New Zealand,2014,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.3
25625,New Zealand,2014,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.5
25626,New Zealand,2014,10,N02-Analgesics,Million of national currency units,21.2
25627,New Zealand,2014,10,N02-Analgesics,Million US$ at exchange rate,17.6
25628,New Zealand,2014,10,C08-Calcium channel blockers,% of total sales,0.9
25629,New Zealand,2014,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,17.5
25630,New Zealand,2014,10,B-Blood and blood forming organs,Million of national currency units,87.1
25631,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
25632,New Zealand,2014,10,G-Genito urinary system and sex hormones,Million of national currency units,21.1
25633,New Zealand,2014,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",60.5
25634,New Zealand,2014,10,B-Blood and blood forming organs,Million US$ at exchange rate,72.3
25635,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",7.7
25636,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.7
25637,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.0
25638,New Zealand,2014,10,C10-Lipid modifying agents,% of total sales,1.8
25639,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,9.2
25640,New Zealand,2014,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,11.1
25641,New Zealand,2014,10,N05C-Hypnotics and sedatives,% of total sales,0.2
25642,New Zealand,2014,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",3.2
25643,New Zealand,2014,10,B-Blood and blood forming organs,% of total sales,9.1
25644,New Zealand,2014,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.1
25645,New Zealand,2014,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
25646,New Zealand,2014,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
25647,New Zealand,2014,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",16.0
25648,New Zealand,2014,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.4
25649,New Zealand,2014,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.9
25650,New Zealand,2014,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",14.6
25651,New Zealand,2014,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",2.7
25652,New Zealand,2014,10,Products not elsewhere classified,Million of national currency units,323.1
25653,New Zealand,2014,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",70.6
25654,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",2.3
25655,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.5
25656,New Zealand,2014,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,84.4
25657,New Zealand,2014,10,R-Respiratory system,Million US$ at exchange rate,76.4
25658,New Zealand,2014,10,J-Antiinfectives for systemic use,Million of national currency units,101.7
25659,New Zealand,2014,10,R-Respiratory system,Million of national currency units,92.1
25660,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.1
25661,New Zealand,2014,10,N05B-Anxiolytics,Million of national currency units,1.3
25662,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,Million of national currency units,84.7
25663,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,14.7
25664,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",10.2
25665,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",2.7
25666,New Zealand,2014,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,12.2
25667,New Zealand,2014,10,R-Respiratory system,"Million US$, purchasing power parity",63.9
25668,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.8
25669,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.0
25670,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
25671,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.5
25672,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,24.5
25673,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,20.3
25674,New Zealand,2014,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",17.0
25675,New Zealand,2014,10,R-Respiratory system,"/capita, US$ purchasing power parity",14.2
25676,New Zealand,2014,10,R-Respiratory system,% of total sales,9.6
25677,New Zealand,2014,10,R-Respiratory system,"/capita, US$ exchange rate",16.9
25678,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.8
25679,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.8
25680,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.3
25681,New Zealand,2014,10,N06A-Antidepressants,Million US$ at exchange rate,14.5
25682,New Zealand,2014,10,N06A-Antidepressants,"Million US$, purchasing power parity",12.1
25683,New Zealand,2014,10,N06A-Antidepressants,Million of national currency units,17.5
25684,New Zealand,2014,10,N06A-Antidepressants,% of total sales,1.8
25685,New Zealand,2014,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",2.7
25686,New Zealand,2014,10,N06A-Antidepressants,"/capita, US$ exchange rate",3.2
25687,New Zealand,2014,10,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9
25688,New Zealand,2014,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2
25689,New Zealand,2014,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.2
25690,New Zealand,2014,10,G-Genito urinary system and sex hormones,% of total sales,2.2
25691,New Zealand,2014,10,A02A-Antacids,Million US$ at exchange rate,0.2
25692,New Zealand,2014,10,A02A-Antacids,Million of national currency units,0.3
25693,New Zealand,2014,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
25694,New Zealand,2014,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.7
25695,New Zealand,2014,10,N05B-Anxiolytics,% of total sales,0.1
25696,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,% of total sales,8.8
25697,New Zealand,2014,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.7
25698,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",13.0
25699,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",58.8
25700,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,70.3
25701,New Zealand,2014,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",15.6
25702,New Zealand,2014,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.6
25703,New Zealand,2014,10,A02A-Antacids,"/capita, US$ exchange rate",0.1
25704,New Zealand,2014,10,N05B-Anxiolytics,Million US$ at exchange rate,1.1
25705,New Zealand,2014,10,A02A-Antacids,"Million US$, purchasing power parity",0.2
25706,New Zealand,2014,10,J-Antiinfectives for systemic use,% of total sales,10.6
25707,New Zealand,2014,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
25708,New Zealand,2014,10,A02A-Antacids,% of total sales,0.0
25709,New Zealand,2014,10,C07-Beta blocking agents,Million of national currency units,14.7
25710,New Zealand,2014,10,C07-Beta blocking agents,Million US$ at exchange rate,12.2
25711,New Zealand,2014,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",10.7
25712,New Zealand,2014,10,C07-Beta blocking agents,"/capita, US$ exchange rate",2.7
25713,New Zealand,2014,10,C07-Beta blocking agents,"Million US$, purchasing power parity",10.2
25714,New Zealand,2014,10,M-Musculo-skeletal system,% of total sales,2.6
25715,New Zealand,2014,10,C03-Diuretics,Million US$ at exchange rate,1.8
25716,New Zealand,2014,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.8
25717,New Zealand,2014,10,C-Cardiovascular system,% of total sales,7.3
25718,New Zealand,2014,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.6
25719,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.2
25720,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.2
25721,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.4
25722,New Zealand,2014,10,M-Musculo-skeletal system,Million of national currency units,24.8
25723,New Zealand,2014,10,C02-Antihypertensives,Million US$ at exchange rate,3.2
25724,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.5
25725,New Zealand,2014,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.3
25726,New Zealand,2014,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",17.2
25727,New Zealand,2014,10,C07-Beta blocking agents,% of total sales,1.5
25728,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
25729,New Zealand,2014,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
25730,New Zealand,2014,10,M-Musculo-skeletal system,Million US$ at exchange rate,20.6
25731,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,5.1
25732,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.2
25733,New Zealand,2014,10,Total pharmaceutical sales,"/capita, US$ exchange rate",176.2
25734,New Zealand,2014,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",147.5
25735,New Zealand,2014,10,N-Nervous system,% of total sales,14.2
25736,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.5
25737,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.5
25738,New Zealand,2014,10,C02-Antihypertensives,Million of national currency units,3.9
25739,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
25740,New Zealand,2014,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
25741,New Zealand,2014,10,N-Nervous system,Million of national currency units,136.0
25742,New Zealand,2014,10,Total pharmaceutical sales,Million of national currency units,959.5
25743,New Zealand,2014,10,C03-Diuretics,"Million US$, purchasing power parity",1.5
25744,New Zealand,2014,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
25745,New Zealand,2014,10,C03-Diuretics,"/capita, US$ exchange rate",0.4
25746,New Zealand,2014,10,N-Nervous system,"/capita, US$ purchasing power parity",20.9
25747,New Zealand,2014,10,Total pharmaceutical sales,Million US$ at exchange rate,796.0
25748,New Zealand,2014,10,Total pharmaceutical sales,"Million US$, purchasing power parity",666.0
25749,New Zealand,2014,10,N-Nervous system,Million US$ at exchange rate,112.9
25750,New Zealand,2014,10,N-Nervous system,"Million US$, purchasing power parity",94.4
25751,New Zealand,2014,10,N-Nervous system,"/capita, US$ exchange rate",25.0
25752,New Zealand,2014,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.8
25753,New Zealand,2014,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.3
25754,New Zealand,2014,10,C03-Diuretics,Million of national currency units,2.2
25755,New Zealand,2014,10,J01-Antibacterials for systemic use,Million of national currency units,15.0
25756,New Zealand,2014,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.4
25757,New Zealand,2014,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",10.4
25758,New Zealand,2014,10,J01-Antibacterials for systemic use,% of total sales,1.6
25759,New Zealand,2014,10,C-Cardiovascular system,"/capita, US$ exchange rate",12.8
25760,New Zealand,2014,10,C-Cardiovascular system,"Million US$, purchasing power parity",48.5
25761,New Zealand,2014,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
25762,New Zealand,2014,10,C01A-Cardiac glycosides,Million of national currency units,0.4
25763,New Zealand,2014,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
25764,New Zealand,2014,10,A10-Drugs used in diabetes,Million US$ at exchange rate,35.3
25765,New Zealand,2014,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",29.5
25766,New Zealand,2014,10,C02-Antihypertensives,% of total sales,0.4
25767,New Zealand,2014,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
25768,New Zealand,2014,10,A10-Drugs used in diabetes,Million of national currency units,42.5
25769,New Zealand,2014,10,C-Cardiovascular system,Million of national currency units,69.9
25770,New Zealand,2014,10,C-Cardiovascular system,Million US$ at exchange rate,58.0
25771,New Zealand,2014,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.8
25772,New Zealand,2014,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",6.5
25773,New Zealand,2014,10,A10-Drugs used in diabetes,% of total sales,4.4
25774,New Zealand,2014,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
25775,New Zealand,2014,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",14.5
25776,New Zealand,2014,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",55.0
25777,New Zealand,2014,10,A-Alimentary tract and metabolism,% of total sales,8.3
25778,New Zealand,2014,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",12.2
25779,New Zealand,2014,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.7
25780,New Zealand,2014,10,C02-Antihypertensives,"Million US$, purchasing power parity",2.7
25781,New Zealand,2014,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,65.7
25782,New Zealand,2014,10,A-Alimentary tract and metabolism,Million of national currency units,79.2
25783,New Zealand,2014,10,C03-Diuretics,% of total sales,0.2
25784,New Zealand,2014,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
25785,New Zealand,2014,10,C01A-Cardiac glycosides,% of total sales,0.0
25786,New Zealand,2013,9,C10-Lipid modifying agents,Million US$ at exchange rate,24.7
25787,New Zealand,2013,9,N05C-Hypnotics and sedatives,Million of national currency units,1.5
25788,New Zealand,2013,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.3
25789,New Zealand,2013,9,C08-Calcium channel blockers,Million US$ at exchange rate,7.8
25790,New Zealand,2013,9,Products not elsewhere classified,"/capita, US$ exchange rate",57.5
25791,New Zealand,2013,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",20.8
25792,New Zealand,2013,9,Products not elsewhere classified,Million US$ at exchange rate,255.2
25793,New Zealand,2013,9,C08-Calcium channel blockers,Million of national currency units,9.6
25794,New Zealand,2013,9,C10-Lipid modifying agents,Million of national currency units,30.1
25795,New Zealand,2013,9,Products not elsewhere classified,"Million US$, purchasing power parity",215.2
25796,New Zealand,2013,9,N02-Analgesics,"/capita, US$ exchange rate",4.4
25797,New Zealand,2013,9,N02-Analgesics,"/capita, US$ purchasing power parity",3.7
25798,New Zealand,2013,9,N02-Analgesics,"Million US$, purchasing power parity",16.5
25799,New Zealand,2013,9,Products not elsewhere classified,% of total sales,33.7
25800,New Zealand,2013,9,N02-Analgesics,% of total sales,2.6
25801,New Zealand,2013,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",48.5
25802,New Zealand,2013,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",6.6
25803,New Zealand,2013,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",1.5
25804,New Zealand,2013,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",1.8
25805,New Zealand,2013,9,C08-Calcium channel blockers,% of total sales,1.0
25806,New Zealand,2013,9,N02-Analgesics,Million of national currency units,23.9
25807,New Zealand,2013,9,N02-Analgesics,Million US$ at exchange rate,19.6
25808,New Zealand,2013,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,17.2
25809,New Zealand,2013,9,B-Blood and blood forming organs,Million of national currency units,48.2
25810,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,% of total sales,1.2
25811,New Zealand,2013,9,G-Genito urinary system and sex hormones,Million of national currency units,21.0
25812,New Zealand,2013,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",33.3
25813,New Zealand,2013,9,B-Blood and blood forming organs,Million US$ at exchange rate,39.5
25814,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",7.9
25815,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.8
25816,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.1
25817,New Zealand,2013,9,C10-Lipid modifying agents,% of total sales,3.3
25818,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,9.4
25819,New Zealand,2013,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,11.4
25820,New Zealand,2013,9,N05C-Hypnotics and sedatives,% of total sales,0.2
25821,New Zealand,2013,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",5.6
25822,New Zealand,2013,9,B-Blood and blood forming organs,% of total sales,5.2
25823,New Zealand,2013,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.1
25824,New Zealand,2013,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
25825,New Zealand,2013,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",7.5
25826,New Zealand,2013,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",8.9
25827,New Zealand,2013,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.9
25828,New Zealand,2013,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",14.5
25829,New Zealand,2013,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",4.7
25830,New Zealand,2013,9,Products not elsewhere classified,Million of national currency units,311.2
25831,New Zealand,2013,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
25832,New Zealand,2013,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",67.9
25833,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",2.8
25834,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.9
25835,New Zealand,2013,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,80.5
25836,New Zealand,2013,9,R-Respiratory system,Million US$ at exchange rate,73.8
25837,New Zealand,2013,9,J-Antiinfectives for systemic use,Million of national currency units,98.1
25838,New Zealand,2013,9,R-Respiratory system,Million of national currency units,90.0
25839,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.7
25840,New Zealand,2013,9,N05B-Anxiolytics,Million of national currency units,1.2
25841,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.1
25842,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,Million of national currency units,79.6
25843,New Zealand,2013,9,N05B-Anxiolytics,Million US$ at exchange rate,1.0
25844,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,17.8
25845,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",12.3
25846,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",3.3
25847,New Zealand,2013,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,14.6
25848,New Zealand,2013,9,R-Respiratory system,"Million US$, purchasing power parity",62.3
25849,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.5
25850,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,6.9
25851,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
25852,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",4.2
25853,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,18.6
25854,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,22.7
25855,New Zealand,2013,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",15.7
25856,New Zealand,2013,9,R-Respiratory system,"/capita, US$ purchasing power parity",14.0
25857,New Zealand,2013,9,R-Respiratory system,% of total sales,9.8
25858,New Zealand,2013,9,R-Respiratory system,"/capita, US$ exchange rate",16.6
25859,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",4.8
25860,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,5.7
25861,New Zealand,2013,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.3
25862,New Zealand,2013,9,N06A-Antidepressants,Million US$ at exchange rate,24.0
25863,New Zealand,2013,9,N06A-Antidepressants,"Million US$, purchasing power parity",20.2
25864,New Zealand,2013,9,N06A-Antidepressants,Million of national currency units,29.2
25865,New Zealand,2013,9,N06A-Antidepressants,% of total sales,3.2
25866,New Zealand,2013,9,N06A-Antidepressants,"/capita, US$ exchange rate",5.4
25867,New Zealand,2013,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.5
25868,New Zealand,2013,9,G-Genito urinary system and sex hormones,% of total sales,2.3
25869,New Zealand,2013,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.3
25870,New Zealand,2013,9,A02A-Antacids,Million of national currency units,0.3
25871,New Zealand,2013,9,A02A-Antacids,Million US$ at exchange rate,0.2
25872,New Zealand,2013,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
25873,New Zealand,2013,9,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2
25874,New Zealand,2013,9,N05B-Anxiolytics,% of total sales,0.1
25875,New Zealand,2013,9,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9
25876,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,% of total sales,8.6
25877,New Zealand,2013,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",18.1
25878,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",12.4
25879,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",55.0
25880,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,65.2
25881,New Zealand,2013,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.7
25882,New Zealand,2013,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.3
25883,New Zealand,2013,9,A02A-Antacids,"/capita, US$ exchange rate",0.1
25884,New Zealand,2013,9,A02A-Antacids,"Million US$, purchasing power parity",0.2
25885,New Zealand,2013,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
25886,New Zealand,2013,9,J-Antiinfectives for systemic use,% of total sales,10.6
25887,New Zealand,2013,9,A02A-Antacids,% of total sales,0.0
25888,New Zealand,2013,9,C07-Beta blocking agents,Million of national currency units,14.4
25889,New Zealand,2013,9,C07-Beta blocking agents,Million US$ at exchange rate,11.8
25890,New Zealand,2013,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",13.5
25891,New Zealand,2013,9,C07-Beta blocking agents,"/capita, US$ exchange rate",2.7
25892,New Zealand,2013,9,C07-Beta blocking agents,"Million US$, purchasing power parity",10.0
25893,New Zealand,2013,9,M-Musculo-skeletal system,% of total sales,2.6
25894,New Zealand,2013,9,C03-Diuretics,Million US$ at exchange rate,1.8
25895,New Zealand,2013,9,C-Cardiovascular system,% of total sales,9.4
25896,New Zealand,2013,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.8
25897,New Zealand,2013,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.5
25898,New Zealand,2013,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.2
25899,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",5.1
25900,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,6.0
25901,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.4
25902,New Zealand,2013,9,M-Musculo-skeletal system,Million of national currency units,24.3
25903,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.3
25904,New Zealand,2013,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",16.8
25905,New Zealand,2013,9,C07-Beta blocking agents,% of total sales,1.6
25906,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
25907,New Zealand,2013,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
25908,New Zealand,2013,9,M-Musculo-skeletal system,Million US$ at exchange rate,19.9
25909,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,5.0
25910,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.1
25911,New Zealand,2013,9,Total pharmaceutical sales,"/capita, US$ exchange rate",170.4
25912,New Zealand,2013,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",143.7
25913,New Zealand,2013,9,N-Nervous system,% of total sales,16.0
25914,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.5
25915,New Zealand,2013,9,C02-Antihypertensives,Million US$ at exchange rate,3.1
25916,New Zealand,2013,9,C02-Antihypertensives,Million of national currency units,3.8
25917,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.5
25918,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
25919,New Zealand,2013,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
25920,New Zealand,2013,9,N-Nervous system,Million of national currency units,147.4
25921,New Zealand,2013,9,C03-Diuretics,% of total sales,0.2
25922,New Zealand,2013,9,Total pharmaceutical sales,Million of national currency units,922.9
25923,New Zealand,2013,9,C03-Diuretics,"Million US$, purchasing power parity",1.5
25924,New Zealand,2013,9,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
25925,New Zealand,2013,9,C03-Diuretics,"/capita, US$ exchange rate",0.4
25926,New Zealand,2013,9,Total pharmaceutical sales,Million US$ at exchange rate,756.8
25927,New Zealand,2013,9,N-Nervous system,"/capita, US$ purchasing power parity",22.9
25928,New Zealand,2013,9,Total pharmaceutical sales,"Million US$, purchasing power parity",638.2
25929,New Zealand,2013,9,N-Nervous system,Million US$ at exchange rate,120.9
25930,New Zealand,2013,9,N-Nervous system,"Million US$, purchasing power parity",101.9
25931,New Zealand,2013,9,N-Nervous system,"/capita, US$ exchange rate",27.2
25932,New Zealand,2013,9,C03-Diuretics,Million of national currency units,2.2
25933,New Zealand,2013,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.9
25934,New Zealand,2013,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.5
25935,New Zealand,2013,9,J01-Antibacterials for systemic use,% of total sales,1.7
25936,New Zealand,2013,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,13.0
25937,New Zealand,2013,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",11.0
25938,New Zealand,2013,9,J01-Antibacterials for systemic use,Million of national currency units,15.9
25939,New Zealand,2013,9,C-Cardiovascular system,"/capita, US$ exchange rate",16.0
25940,New Zealand,2013,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
25941,New Zealand,2013,9,C-Cardiovascular system,"Million US$, purchasing power parity",59.8
25942,New Zealand,2013,9,C01A-Cardiac glycosides,Million of national currency units,0.4
25943,New Zealand,2013,9,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
25944,New Zealand,2013,9,A10-Drugs used in diabetes,Million US$ at exchange rate,32.1
25945,New Zealand,2013,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",27.0
25946,New Zealand,2013,9,C02-Antihypertensives,% of total sales,0.4
25947,New Zealand,2013,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
25948,New Zealand,2013,9,A10-Drugs used in diabetes,Million of national currency units,39.1
25949,New Zealand,2013,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",7.2
25950,New Zealand,2013,9,C-Cardiovascular system,Million of national currency units,86.4
25951,New Zealand,2013,9,C-Cardiovascular system,Million US$ at exchange rate,70.9
25952,New Zealand,2013,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",6.1
25953,New Zealand,2013,9,A10-Drugs used in diabetes,% of total sales,4.2
25954,New Zealand,2013,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.9
25955,New Zealand,2013,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",52.0
25956,New Zealand,2013,9,A-Alimentary tract and metabolism,% of total sales,8.1
25957,New Zealand,2013,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",11.7
25958,New Zealand,2013,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
25959,New Zealand,2013,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.7
25960,New Zealand,2013,9,C02-Antihypertensives,"Million US$, purchasing power parity",2.6
25961,New Zealand,2013,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,61.7
25962,New Zealand,2013,9,A-Alimentary tract and metabolism,Million of national currency units,75.2
25963,New Zealand,2013,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
25964,New Zealand,2013,9,C01A-Cardiac glycosides,% of total sales,0.0
25965,New Zealand,2012,10,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.1
25966,New Zealand,2012,10,N05C-Hypnotics and sedatives,Million of national currency units,1.4
25967,New Zealand,2012,10,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.2
25968,New Zealand,2012,10,C08-Calcium channel blockers,Million US$ at exchange rate,10.9
25969,New Zealand,2012,10,Products not elsewhere classified,Million US$ at exchange rate,234.9
25970,New Zealand,2012,10,Products not elsewhere classified,"/capita, US$ exchange rate",53.3
25971,New Zealand,2012,10,C10-Lipid modifying agents,"Million US$, purchasing power parity",51.2
25972,New Zealand,2012,10,C10-Lipid modifying agents,Million US$ at exchange rate,62.0
25973,New Zealand,2012,10,Products not elsewhere classified,"Million US$, purchasing power parity",193.9
25974,New Zealand,2012,10,C08-Calcium channel blockers,Million of national currency units,13.5
25975,New Zealand,2012,10,C10-Lipid modifying agents,Million of national currency units,76.5
25976,New Zealand,2012,10,C08-Calcium channel blockers,"Million US$, purchasing power parity",9.0
25977,New Zealand,2012,10,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.0
25978,New Zealand,2012,10,N02-Analgesics,"/capita, US$ purchasing power parity",4.4
25979,New Zealand,2012,10,N02-Analgesics,"/capita, US$ exchange rate",5.3
25980,New Zealand,2012,10,N02-Analgesics,"Million US$, purchasing power parity",19.2
25981,New Zealand,2012,10,Products not elsewhere classified,"/capita, US$ purchasing power parity",44.0
25982,New Zealand,2012,10,Products not elsewhere classified,% of total sales,31.4
25983,New Zealand,2012,10,N02-Analgesics,% of total sales,3.1
25984,New Zealand,2012,10,C08-Calcium channel blockers,% of total sales,1.5
25985,New Zealand,2012,10,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.5
25986,New Zealand,2012,10,N02-Analgesics,Million US$ at exchange rate,23.2
25987,New Zealand,2012,10,N02-Analgesics,Million of national currency units,28.7
25988,New Zealand,2012,10,G-Genito urinary system and sex hormones,Million US$ at exchange rate,18.5
25989,New Zealand,2012,10,B-Blood and blood forming organs,Million of national currency units,42.8
25990,New Zealand,2012,10,G-Genito urinary system and sex hormones,Million of national currency units,22.8
25991,New Zealand,2012,10,B-Blood and blood forming organs,"/capita, US$ exchange rate",7.9
25992,New Zealand,2012,10,B-Blood and blood forming organs,"Million US$, purchasing power parity",28.6
25993,New Zealand,2012,10,B-Blood and blood forming organs,Million US$ at exchange rate,34.7
25994,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,% of total sales,1.5
25995,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",9.1
25996,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",2.1
25997,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.5
25998,New Zealand,2012,10,C10-Lipid modifying agents,% of total sales,8.3
25999,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,11.0
26000,New Zealand,2012,10,G03-Sex hormones and modulators of the genital system,Million of national currency units,13.6
26001,New Zealand,2012,10,N05C-Hypnotics and sedatives,% of total sales,0.2
26002,New Zealand,2012,10,B-Blood and blood forming organs,% of total sales,4.6
26003,New Zealand,2012,10,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.3
26004,New Zealand,2012,10,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.0
26005,New Zealand,2012,10,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
26006,New Zealand,2012,10,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",6.5
26007,New Zealand,2012,10,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",4.2
26008,New Zealand,2012,10,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",15.2
26009,New Zealand,2012,10,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.6
26010,New Zealand,2012,10,Products not elsewhere classified,Million of national currency units,290.0
26011,New Zealand,2012,10,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",35.5
26012,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.8
26013,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.4
26014,New Zealand,2012,10,J-Antiinfectives for systemic use,Million US$ at exchange rate,43.1
26015,New Zealand,2012,10,R-Respiratory system,Million US$ at exchange rate,71.9
26016,New Zealand,2012,10,J-Antiinfectives for systemic use,Million of national currency units,53.1
26017,New Zealand,2012,10,R-Respiratory system,Million of national currency units,88.7
26018,New Zealand,2012,10,R-Respiratory system,"Million US$, purchasing power parity",59.3
26019,New Zealand,2012,10,N05B-Anxiolytics,Million of national currency units,1.3
26020,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,0.8
26021,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,Million of national currency units,77.2
26022,New Zealand,2012,10,N05B-Anxiolytics,Million US$ at exchange rate,1.0
26023,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,31.7
26024,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",21.2
26025,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",5.8
26026,New Zealand,2012,10,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,25.7
26027,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.2
26028,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
26029,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,7.8
26030,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,17.2
26031,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,21.2
26032,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.9
26033,New Zealand,2012,10,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",14.2
26034,New Zealand,2012,10,R-Respiratory system,% of total sales,9.6
26035,New Zealand,2012,10,R-Respiratory system,"/capita, US$ purchasing power parity",13.5
26036,New Zealand,2012,10,R-Respiratory system,"/capita, US$ exchange rate",16.3
26037,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",5.2
26038,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,6.3
26039,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.2
26040,New Zealand,2012,10,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",1.4
26041,New Zealand,2012,10,N06A-Antidepressants,Million US$ at exchange rate,26.6
26042,New Zealand,2012,10,N06A-Antidepressants,"Million US$, purchasing power parity",22.0
26043,New Zealand,2012,10,N06A-Antidepressants,Million of national currency units,32.9
26044,New Zealand,2012,10,N06A-Antidepressants,% of total sales,3.6
26045,New Zealand,2012,10,N06A-Antidepressants,"/capita, US$ exchange rate",6.0
26046,New Zealand,2012,10,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.0
26047,New Zealand,2012,10,N05B-Anxiolytics,"/capita, US$ exchange rate",0.2
26048,New Zealand,2012,10,G-Genito urinary system and sex hormones,% of total sales,2.5
26049,New Zealand,2012,10,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",3.5
26050,New Zealand,2012,10,A02A-Antacids,Million of national currency units,0.3
26051,New Zealand,2012,10,A02A-Antacids,Million US$ at exchange rate,0.2
26052,New Zealand,2012,10,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.2
26053,New Zealand,2012,10,N05B-Anxiolytics,% of total sales,0.1
26054,New Zealand,2012,10,N05B-Anxiolytics,"Million US$, purchasing power parity",0.9
26055,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,% of total sales,8.3
26056,New Zealand,2012,10,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.8
26057,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",51.6
26058,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,62.5
26059,New Zealand,2012,10,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.1
26060,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",11.7
26061,New Zealand,2012,10,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.2
26062,New Zealand,2012,10,A02A-Antacids,"/capita, US$ exchange rate",0.1
26063,New Zealand,2012,10,A02A-Antacids,"Million US$, purchasing power parity",0.2
26064,New Zealand,2012,10,J-Antiinfectives for systemic use,% of total sales,5.8
26065,New Zealand,2012,10,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
26066,New Zealand,2012,10,A02A-Antacids,% of total sales,0.0
26067,New Zealand,2012,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",140.2
26068,New Zealand,2012,10,C07-Beta blocking agents,Million of national currency units,18.5
26069,New Zealand,2012,10,C07-Beta blocking agents,Million US$ at exchange rate,15.0
26070,New Zealand,2012,10,C-Cardiovascular system,"/capita, US$ purchasing power parity",23.3
26071,New Zealand,2012,10,C07-Beta blocking agents,"/capita, US$ exchange rate",3.4
26072,New Zealand,2012,10,C07-Beta blocking agents,"Million US$, purchasing power parity",12.4
26073,New Zealand,2012,10,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.8
26074,New Zealand,2012,10,M-Musculo-skeletal system,% of total sales,2.5
26075,New Zealand,2012,10,C03-Diuretics,Million US$ at exchange rate,1.9
26076,New Zealand,2012,10,C-Cardiovascular system,% of total sales,16.6
26077,New Zealand,2012,10,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",3.5
26078,New Zealand,2012,10,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.3
26079,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.8
26080,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,5.8
26081,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.3
26082,New Zealand,2012,10,M-Musculo-skeletal system,Million of national currency units,23.3
26083,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.2
26084,New Zealand,2012,10,M-Musculo-skeletal system,"Million US$, purchasing power parity",15.6
26085,New Zealand,2012,10,C07-Beta blocking agents,% of total sales,2.0
26086,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.1
26087,New Zealand,2012,10,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.8
26088,New Zealand,2012,10,M-Musculo-skeletal system,Million US$ at exchange rate,18.9
26089,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.9
26090,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.3
26091,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.9
26092,New Zealand,2012,10,Total pharmaceutical sales,"/capita, US$ exchange rate",169.8
26093,New Zealand,2012,10,N-Nervous system,% of total sales,17.0
26094,New Zealand,2012,10,C02-Antihypertensives,Million US$ at exchange rate,2.3
26095,New Zealand,2012,10,C02-Antihypertensives,Million of national currency units,2.9
26096,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.5
26097,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
26098,New Zealand,2012,10,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
26099,New Zealand,2012,10,N-Nervous system,Million of national currency units,156.7
26100,New Zealand,2012,10,C03-Diuretics,% of total sales,0.2
26101,New Zealand,2012,10,Total pharmaceutical sales,Million of national currency units,924.1
26102,New Zealand,2012,10,C03-Diuretics,"Million US$, purchasing power parity",1.5
26103,New Zealand,2012,10,C03-Diuretics,"/capita, US$ exchange rate",0.4
26104,New Zealand,2012,10,C03-Diuretics,"/capita, US$ purchasing power parity",0.3
26105,New Zealand,2012,10,Total pharmaceutical sales,Million US$ at exchange rate,748.7
26106,New Zealand,2012,10,N-Nervous system,"/capita, US$ purchasing power parity",23.8
26107,New Zealand,2012,10,Total pharmaceutical sales,"Million US$, purchasing power parity",617.9
26108,New Zealand,2012,10,N-Nervous system,"Million US$, purchasing power parity",104.8
26109,New Zealand,2012,10,N-Nervous system,Million US$ at exchange rate,126.9
26110,New Zealand,2012,10,N-Nervous system,"/capita, US$ exchange rate",28.8
26111,New Zealand,2012,10,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",3.5
26112,New Zealand,2012,10,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.9
26113,New Zealand,2012,10,J01-Antibacterials for systemic use,% of total sales,2.0
26114,New Zealand,2012,10,J01-Antibacterials for systemic use,Million US$ at exchange rate,15.3
26115,New Zealand,2012,10,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",12.6
26116,New Zealand,2012,10,C-Cardiovascular system,"/capita, US$ exchange rate",28.2
26117,New Zealand,2012,10,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
26118,New Zealand,2012,10,C01A-Cardiac glycosides,Million of national currency units,0.4
26119,New Zealand,2012,10,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
26120,New Zealand,2012,10,J01-Antibacterials for systemic use,Million of national currency units,18.8
26121,New Zealand,2012,10,A10-Drugs used in diabetes,Million US$ at exchange rate,28.7
26122,New Zealand,2012,10,A10-Drugs used in diabetes,"Million US$, purchasing power parity",23.7
26123,New Zealand,2012,10,C02-Antihypertensives,% of total sales,0.3
26124,New Zealand,2012,10,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4
26125,New Zealand,2012,10,A10-Drugs used in diabetes,Million of national currency units,35.5
26126,New Zealand,2012,10,C-Cardiovascular system,Million of national currency units,153.7
26127,New Zealand,2012,10,C-Cardiovascular system,Million US$ at exchange rate,124.5
26128,New Zealand,2012,10,C-Cardiovascular system,"Million US$, purchasing power parity",102.8
26129,New Zealand,2012,10,A10-Drugs used in diabetes,"/capita, US$ exchange rate",6.5
26130,New Zealand,2012,10,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",5.4
26131,New Zealand,2012,10,A10-Drugs used in diabetes,% of total sales,3.8
26132,New Zealand,2012,10,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
26133,New Zealand,2012,10,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",13.2
26134,New Zealand,2012,10,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",48.0
26135,New Zealand,2012,10,A-Alimentary tract and metabolism,% of total sales,7.8
26136,New Zealand,2012,10,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",10.9
26137,New Zealand,2012,10,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
26138,New Zealand,2012,10,C02-Antihypertensives,"Million US$, purchasing power parity",1.9
26139,New Zealand,2012,10,C03-Diuretics,Million of national currency units,2.3
26140,New Zealand,2012,10,A-Alimentary tract and metabolism,Million US$ at exchange rate,58.1
26141,New Zealand,2012,10,A-Alimentary tract and metabolism,Million of national currency units,71.7
26142,New Zealand,2012,10,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
26143,New Zealand,2012,10,C01A-Cardiac glycosides,% of total sales,0.0
26144,New Zealand,2010,11,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.3
26145,New Zealand,2010,11,N05C-Hypnotics and sedatives,Million of national currency units,1.5
26146,New Zealand,2010,11,N05C-Hypnotics and sedatives,Million US$ at exchange rate,1.0
26147,New Zealand,2010,11,C08-Calcium channel blockers,"Million US$, purchasing power parity",8.9
26148,New Zealand,2010,11,C08-Calcium channel blockers,Million US$ at exchange rate,9.6
26149,New Zealand,2010,11,Products not elsewhere classified,"/capita, US$ exchange rate",30.9
26150,New Zealand,2010,11,C10-Lipid modifying agents,"Million US$, purchasing power parity",25.3
26151,New Zealand,2010,11,C10-Lipid modifying agents,Million US$ at exchange rate,27.3
26152,New Zealand,2010,11,Products not elsewhere classified,"Million US$, purchasing power parity",124.5
26153,New Zealand,2010,11,C08-Calcium channel blockers,Million of national currency units,13.3
26154,New Zealand,2010,11,C10-Lipid modifying agents,Million of national currency units,37.9
26155,New Zealand,2010,11,N02-Analgesics,"/capita, US$ purchasing power parity",4.6
26156,New Zealand,2010,11,N02-Analgesics,"/capita, US$ exchange rate",4.9
26157,New Zealand,2010,11,N02-Analgesics,"Million US$, purchasing power parity",19.9
26158,New Zealand,2010,11,Products not elsewhere classified,% of total sales,24.9
26159,New Zealand,2010,11,N02-Analgesics,% of total sales,4.0
26160,New Zealand,2010,11,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.0
26161,New Zealand,2010,11,C08-Calcium channel blockers,% of total sales,1.8
26162,New Zealand,2010,11,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.2
26163,New Zealand,2010,11,N02-Analgesics,Million US$ at exchange rate,21.4
26164,New Zealand,2010,11,N02-Analgesics,Million of national currency units,29.7
26165,New Zealand,2010,11,Products not elsewhere classified,"/capita, US$ purchasing power parity",28.6
26166,New Zealand,2010,11,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",1.0
26167,New Zealand,2010,11,G-Genito urinary system and sex hormones,Million US$ at exchange rate,13.0
26168,New Zealand,2010,11,B-Blood and blood forming organs,Million of national currency units,26.2
26169,New Zealand,2010,11,G-Genito urinary system and sex hormones,Million of national currency units,18.0
26170,New Zealand,2010,11,B-Blood and blood forming organs,"/capita, US$ exchange rate",4.3
26171,New Zealand,2010,11,B-Blood and blood forming organs,"Million US$, purchasing power parity",17.5
26172,New Zealand,2010,11,B-Blood and blood forming organs,Million US$ at exchange rate,18.9
26173,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,% of total sales,1.6
26174,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",8.1
26175,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.0
26176,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",1.9
26177,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,Million of national currency units,12.1
26178,New Zealand,2010,11,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.7
26179,New Zealand,2010,11,B-Blood and blood forming organs,% of total sales,3.5
26180,New Zealand,2010,11,N05C-Hypnotics and sedatives,% of total sales,0.2
26181,New Zealand,2010,11,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",0.2
26182,New Zealand,2010,11,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",0.2
26183,New Zealand,2010,11,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",4.0
26184,New Zealand,2010,11,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",12.0
26185,New Zealand,2010,11,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",3.0
26186,New Zealand,2010,11,Products not elsewhere classified,Million US$ at exchange rate,134.3
26187,New Zealand,2010,11,C10-Lipid modifying agents,% of total sales,5.1
26188,New Zealand,2010,11,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.8
26189,New Zealand,2010,11,Products not elsewhere classified,Million of national currency units,186.3
26190,New Zealand,2010,11,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",28.8
26191,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.3
26192,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.6
26193,New Zealand,2010,11,R-Respiratory system,Million US$ at exchange rate,54.4
26194,New Zealand,2010,11,R-Respiratory system,"Million US$, purchasing power parity",50.4
26195,New Zealand,2010,11,J-Antiinfectives for systemic use,Million US$ at exchange rate,31.1
26196,New Zealand,2010,11,J-Antiinfectives for systemic use,Million of national currency units,43.2
26197,New Zealand,2010,11,R-Respiratory system,Million of national currency units,75.5
26198,New Zealand,2010,11,N05B-Anxiolytics,Million of national currency units,0.9
26199,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.7
26200,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,34.5
26201,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,Million of national currency units,68.3
26202,New Zealand,2010,11,N05B-Anxiolytics,Million US$ at exchange rate,0.6
26203,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",5.7
26204,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",23.0
26205,New Zealand,2010,11,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,24.8
26206,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",2.9
26207,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
26208,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,12.5
26209,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,13.4
26210,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,18.7
26211,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.1
26212,New Zealand,2010,11,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",12.5
26213,New Zealand,2010,11,R-Respiratory system,% of total sales,10.1
26214,New Zealand,2010,11,R-Respiratory system,"/capita, US$ exchange rate",12.5
26215,New Zealand,2010,11,R-Respiratory system,"/capita, US$ purchasing power parity",11.6
26216,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",8.4
26217,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,9.0
26218,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",1.9
26219,New Zealand,2010,11,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",2.1
26220,New Zealand,2010,11,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",2.8
26221,New Zealand,2010,11,N06A-Antidepressants,"Million US$, purchasing power parity",19.7
26222,New Zealand,2010,11,N06A-Antidepressants,Million US$ at exchange rate,21.2
26223,New Zealand,2010,11,N05B-Anxiolytics,"/capita, US$ exchange rate",0.1
26224,New Zealand,2010,11,N06A-Antidepressants,Million of national currency units,29.5
26225,New Zealand,2010,11,N06A-Antidepressants,% of total sales,3.9
26226,New Zealand,2010,11,N06A-Antidepressants,"/capita, US$ exchange rate",4.9
26227,New Zealand,2010,11,N06A-Antidepressants,"/capita, US$ purchasing power parity",4.5
26228,New Zealand,2010,11,G-Genito urinary system and sex hormones,% of total sales,2.4
26229,New Zealand,2010,11,A02A-Antacids,Million of national currency units,0.2
26230,New Zealand,2010,11,A02A-Antacids,Million US$ at exchange rate,0.2
26231,New Zealand,2010,11,N05B-Anxiolytics,"/capita, US$ purchasing power parity",0.1
26232,New Zealand,2010,11,N05B-Anxiolytics,% of total sales,0.1
26233,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,% of total sales,9.1
26234,New Zealand,2010,11,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",6.6
26235,New Zealand,2010,11,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.1
26236,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",45.6
26237,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,49.2
26238,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",10.5
26239,New Zealand,2010,11,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.3
26240,New Zealand,2010,11,A02A-Antacids,"/capita, US$ exchange rate",0.0
26241,New Zealand,2010,11,A02A-Antacids,"/capita, US$ purchasing power parity",0.0
26242,New Zealand,2010,11,N05B-Anxiolytics,"Million US$, purchasing power parity",0.6
26243,New Zealand,2010,11,A02A-Antacids,"Million US$, purchasing power parity",0.2
26244,New Zealand,2010,11,J-Antiinfectives for systemic use,% of total sales,5.8
26245,New Zealand,2010,11,A02A-Antacids,% of total sales,0.0
26246,New Zealand,2010,11,C07-Beta blocking agents,Million US$ at exchange rate,16.8
26247,New Zealand,2010,11,C07-Beta blocking agents,Million of national currency units,23.3
26248,New Zealand,2010,11,C-Cardiovascular system,"/capita, US$ purchasing power parity",18.8
26249,New Zealand,2010,11,C07-Beta blocking agents,"/capita, US$ exchange rate",3.9
26250,New Zealand,2010,11,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6
26251,New Zealand,2010,11,C07-Beta blocking agents,"Million US$, purchasing power parity",15.6
26252,New Zealand,2010,11,C-Cardiovascular system,% of total sales,16.3
26253,New Zealand,2010,11,M-Musculo-skeletal system,% of total sales,3.4
26254,New Zealand,2010,11,C03-Diuretics,Million US$ at exchange rate,2.0
26255,New Zealand,2010,11,M-Musculo-skeletal system,"/capita, US$ exchange rate",4.3
26256,New Zealand,2010,11,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",4.0
26257,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",4.4
26258,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",1.1
26259,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,4.7
26260,New Zealand,2010,11,M-Musculo-skeletal system,Million of national currency units,25.8
26261,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,6.5
26262,New Zealand,2010,11,M-Musculo-skeletal system,"Million US$, purchasing power parity",17.2
26263,New Zealand,2010,11,C07-Beta blocking agents,% of total sales,3.1
26264,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,0.9
26265,New Zealand,2010,11,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",1.0
26266,New Zealand,2010,11,M-Musculo-skeletal system,Million US$ at exchange rate,18.6
26267,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.6
26268,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.1
26269,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,3.3
26270,New Zealand,2010,11,Total pharmaceutical sales,"/capita, US$ purchasing power parity",115.0
26271,New Zealand,2010,11,Total pharmaceutical sales,"/capita, US$ exchange rate",124.0
26272,New Zealand,2010,11,N-Nervous system,% of total sales,22.0
26273,New Zealand,2010,11,C02-Antihypertensives,Million US$ at exchange rate,2.0
26274,New Zealand,2010,11,C02-Antihypertensives,Million of national currency units,2.8
26275,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
26276,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.6
26277,New Zealand,2010,11,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
26278,New Zealand,2010,11,N-Nervous system,Million of national currency units,164.5
26279,New Zealand,2010,11,Total pharmaceutical sales,Million of national currency units,748.7
26280,New Zealand,2010,11,C03-Diuretics,% of total sales,0.4
26281,New Zealand,2010,11,Total pharmaceutical sales,Million US$ at exchange rate,539.5
26282,New Zealand,2010,11,C03-Diuretics,"Million US$, purchasing power parity",1.8
26283,New Zealand,2010,11,C03-Diuretics,"/capita, US$ exchange rate",0.5
26284,New Zealand,2010,11,C03-Diuretics,"/capita, US$ purchasing power parity",0.4
26285,New Zealand,2010,11,N-Nervous system,Million US$ at exchange rate,118.5
26286,New Zealand,2010,11,N-Nervous system,"/capita, US$ purchasing power parity",25.3
26287,New Zealand,2010,11,Total pharmaceutical sales,"Million US$, purchasing power parity",500.2
26288,New Zealand,2010,11,C02-Antihypertensives,"Million US$, purchasing power parity",1.9
26289,New Zealand,2010,11,N-Nervous system,"Million US$, purchasing power parity",109.9
26290,New Zealand,2010,11,N-Nervous system,"/capita, US$ exchange rate",27.2
26291,New Zealand,2010,11,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",2.8
26292,New Zealand,2010,11,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",2.6
26293,New Zealand,2010,11,J01-Antibacterials for systemic use,% of total sales,2.2
26294,New Zealand,2010,11,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.0
26295,New Zealand,2010,11,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",11.1
26296,New Zealand,2010,11,C-Cardiovascular system,"/capita, US$ exchange rate",20.3
26297,New Zealand,2010,11,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
26298,New Zealand,2010,11,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
26299,New Zealand,2010,11,C01A-Cardiac glycosides,Million of national currency units,0.4
26300,New Zealand,2010,11,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
26301,New Zealand,2010,11,J01-Antibacterials for systemic use,Million of national currency units,16.7
26302,New Zealand,2010,11,A10-Drugs used in diabetes,Million US$ at exchange rate,21.4
26303,New Zealand,2010,11,A10-Drugs used in diabetes,"Million US$, purchasing power parity",19.8
26304,New Zealand,2010,11,A10-Drugs used in diabetes,"/capita, US$ exchange rate",4.9
26305,New Zealand,2010,11,C02-Antihypertensives,% of total sales,0.4
26306,New Zealand,2010,11,A10-Drugs used in diabetes,Million of national currency units,29.7
26307,New Zealand,2010,11,C-Cardiovascular system,Million of national currency units,122.4
26308,New Zealand,2010,11,C-Cardiovascular system,Million US$ at exchange rate,88.2
26309,New Zealand,2010,11,C-Cardiovascular system,"Million US$, purchasing power parity",81.8
26310,New Zealand,2010,11,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",4.6
26311,New Zealand,2010,11,A10-Drugs used in diabetes,% of total sales,4.0
26312,New Zealand,2010,11,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",11.3
26313,New Zealand,2010,11,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",45.6
26314,New Zealand,2010,11,A-Alimentary tract and metabolism,% of total sales,9.1
26315,New Zealand,2010,11,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",10.5
26316,New Zealand,2010,11,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
26317,New Zealand,2010,11,C03-Diuretics,Million of national currency units,2.7
26318,New Zealand,2010,11,A-Alimentary tract and metabolism,Million US$ at exchange rate,49.2
26319,New Zealand,2010,11,A-Alimentary tract and metabolism,Million of national currency units,68.2
26320,New Zealand,2010,11,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.4
26321,New Zealand,2010,11,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
26322,New Zealand,2010,11,C01A-Cardiac glycosides,% of total sales,0.1
26323,Norway,2011,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",69.4
26324,Norway,2011,4,M-Musculo-skeletal system,Million US$ at exchange rate,112.4
26325,Norway,2011,4,C10-Lipid modifying agents,Million US$ at exchange rate,72.3
26326,Norway,2011,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",44.6
26327,Norway,2011,4,C10-Lipid modifying agents,Million of national currency units,405.0
26328,Norway,2011,4,A-Alimentary tract and metabolism,% of total sales,10.4
26329,Norway,2011,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.9
26330,Norway,2011,4,G-Genito urinary system and sex hormones,Million of national currency units,925.0
26331,Norway,2011,4,C02-Antihypertensives,Million of national currency units,56.0
26332,Norway,2011,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,165.0
26333,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,79.8
26334,Norway,2011,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.0
26335,Norway,2011,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.7
26336,Norway,2011,4,M-Musculo-skeletal system,% of total sales,3.5
26337,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
26338,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",49.2
26339,Norway,2011,4,C10-Lipid modifying agents,% of total sales,2.2
26340,Norway,2011,4,N05B-Anxiolytics,"/capita, US$ exchange rate",4.3
26341,Norway,2011,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",67.9
26342,Norway,2011,4,M-Musculo-skeletal system,Million of national currency units,630.0
26343,Norway,2011,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",207.6
26344,Norway,2011,4,N05B-Anxiolytics,Million US$ at exchange rate,21.1
26345,Norway,2011,4,N05B-Anxiolytics,"Million US$, purchasing power parity",13.0
26346,Norway,2011,4,A-Alimentary tract and metabolism,Million of national currency units,1886.0
26347,Norway,2011,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,336.5
26348,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",9.9
26349,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5
26350,Norway,2011,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.6
26351,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.1
26352,Norway,2011,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.6
26353,Norway,2011,4,N05B-Anxiolytics,Million of national currency units,118.0
26354,Norway,2011,4,N05B-Anxiolytics,% of total sales,0.6
26355,Norway,2011,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.0
26356,Norway,2011,4,N05C-Hypnotics and sedatives,% of total sales,0.9
26357,Norway,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.8
26358,Norway,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.2
26359,Norway,2011,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",18.9
26360,Norway,2011,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",43.3
26361,Norway,2011,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.7
26362,Norway,2011,4,B-Blood and blood forming organs,% of total sales,6.6
26363,Norway,2011,4,C01A-Cardiac glycosides,% of total sales,0.0
26364,Norway,2011,4,N06A-Antidepressants,Million of national currency units,266.0
26365,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,437.0
26366,Norway,2011,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,30.7
26367,Norway,2011,4,N05C-Hypnotics and sedatives,Million of national currency units,172.0
26368,Norway,2011,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
26369,Norway,2011,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
26370,Norway,2011,4,A10-Drugs used in diabetes,Million of national currency units,556.0
26371,Norway,2011,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,436.0
26372,Norway,2011,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
26373,Norway,2011,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",61.2
26374,Norway,2011,4,A10-Drugs used in diabetes,Million US$ at exchange rate,99.2
26375,Norway,2011,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",48.0
26376,Norway,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.7
26377,Norway,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",15.7
26378,Norway,2011,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",132.4
26379,Norway,2011,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
26380,Norway,2011,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5
26381,Norway,2011,4,B-Blood and blood forming organs,Million of national currency units,1203.0
26382,Norway,2011,4,B-Blood and blood forming organs,Million US$ at exchange rate,214.6
26383,Norway,2011,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",12.4
26384,Norway,2011,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.0
26385,Norway,2011,4,C01A-Cardiac glycosides,Million of national currency units,3.0
26386,Norway,2011,4,A10-Drugs used in diabetes,% of total sales,3.1
26387,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.2
26388,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.0
26389,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,79.4
26390,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,445.0
26391,Norway,2011,4,Total pharmaceutical sales,"Million US$, purchasing power parity",2003.8
26392,Norway,2011,4,Total pharmaceutical sales,Million US$ at exchange rate,3247.3
26393,Norway,2011,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",404.6
26394,Norway,2011,4,Total pharmaceutical sales,"/capita, US$ exchange rate",655.6
26395,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
26396,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
26397,Norway,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,447.0
26398,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
26399,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.0
26400,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",49.0
26401,Norway,2011,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.2
26402,Norway,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.9
26403,Norway,2011,4,N06A-Antidepressants,% of total sales,1.5
26404,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,78.0
26405,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",48.1
26406,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.7
26407,Norway,2011,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.9
26408,Norway,2011,4,N06A-Antidepressants,Million US$ at exchange rate,47.5
26409,Norway,2011,4,N06A-Antidepressants,"Million US$, purchasing power parity",29.3
26410,Norway,2011,4,N06A-Antidepressants,"/capita, US$ exchange rate",9.6
26411,Norway,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",33.3
26412,Norway,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.6
26413,Norway,2011,4,Total pharmaceutical sales,Million of national currency units,18200.0
26414,Norway,2011,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",101.8
26415,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.7
26416,Norway,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4
26417,Norway,2011,4,G-Genito urinary system and sex hormones,% of total sales,5.1
26418,Norway,2011,4,C02-Antihypertensives,Million US$ at exchange rate,10.0
26419,Norway,2011,4,R03-Drugs for obstructive airway diseases,% of total sales,6.2
26420,Norway,2011,4,A02A-Antacids,Million US$ at exchange rate,5.0
26421,Norway,2011,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",51.4
26422,Norway,2011,4,A02A-Antacids,Million of national currency units,28.0
26423,Norway,2011,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",125.1
26424,Norway,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.3
26425,Norway,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",40.9
26426,Norway,2011,4,C07-Beta blocking agents,Million of national currency units,166.0
26427,Norway,2011,4,C-Cardiovascular system,Million of national currency units,1797.0
26428,Norway,2011,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.1
26429,Norway,2011,4,C08-Calcium channel blockers,% of total sales,0.8
26430,Norway,2011,4,C-Cardiovascular system,"/capita, US$ exchange rate",64.7
26431,Norway,2011,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",39.9
26432,Norway,2011,4,C-Cardiovascular system,Million US$ at exchange rate,320.6
26433,Norway,2011,4,C-Cardiovascular system,"Million US$, purchasing power parity",197.8
26434,Norway,2011,4,C03-Diuretics,Million US$ at exchange rate,18.2
26435,Norway,2011,4,C03-Diuretics,Million of national currency units,102.0
26436,Norway,2011,4,C03-Diuretics,"/capita, US$ exchange rate",3.7
26437,Norway,2011,4,C03-Diuretics,"Million US$, purchasing power parity",11.2
26438,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",86.1
26439,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,139.5
26440,Norway,2011,4,N-Nervous system,% of total sales,19.0
26441,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,782.0
26442,Norway,2011,4,J-Antiinfectives for systemic use,Million of national currency units,1426.0
26443,Norway,2011,4,C-Cardiovascular system,% of total sales,9.9
26444,Norway,2011,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,254.4
26445,Norway,2011,4,C03-Diuretics,% of total sales,0.6
26446,Norway,2011,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.3
26447,Norway,2011,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,202.7
26448,Norway,2011,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1136.0
26449,Norway,2011,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",157.0
26450,Norway,2011,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.0
26451,Norway,2011,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,77.8
26452,Norway,2011,4,C08-Calcium channel blockers,Million of national currency units,141.0
26453,Norway,2011,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",49.3
26454,Norway,2011,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",16.1
26455,Norway,2011,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.1
26456,Norway,2011,4,C08-Calcium channel blockers,Million US$ at exchange rate,25.2
26457,Norway,2011,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",15.5
26458,Norway,2011,4,Products not elsewhere classified,"Million US$, purchasing power parity",495.2
26459,Norway,2011,4,Products not elsewhere classified,"/capita, US$ exchange rate",162.0
26460,Norway,2011,4,Products not elsewhere classified,Million of national currency units,4498.0
26461,Norway,2011,4,Products not elsewhere classified,Million US$ at exchange rate,802.6
26462,Norway,2011,4,J01-Antibacterials for systemic use,Million of national currency units,448.0
26463,Norway,2011,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,79.9
26464,Norway,2011,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",100.0
26465,Norway,2011,4,Products not elsewhere classified,% of total sales,24.7
26466,Norway,2011,4,J-Antiinfectives for systemic use,% of total sales,7.8
26467,Norway,2011,4,N02-Analgesics,Million US$ at exchange rate,217.5
26468,Norway,2011,4,N02-Analgesics,"Million US$, purchasing power parity",134.2
26469,Norway,2011,4,C07-Beta blocking agents,Million US$ at exchange rate,29.6
26470,Norway,2011,4,N02-Analgesics,Million of national currency units,1219.0
26471,Norway,2011,4,N02-Analgesics,% of total sales,6.7
26472,Norway,2011,4,N02-Analgesics,"/capita, US$ exchange rate",43.9
26473,Norway,2011,4,N02-Analgesics,"/capita, US$ purchasing power parity",27.1
26474,Norway,2011,4,J01-Antibacterials for systemic use,% of total sales,2.5
26475,Norway,2011,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.7
26476,Norway,2011,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.0
26477,Norway,2011,4,C07-Beta blocking agents,"Million US$, purchasing power parity",18.3
26478,Norway,2011,4,C07-Beta blocking agents,% of total sales,0.9
26479,Norway,2011,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.7
26480,Norway,2011,4,R-Respiratory system,Million US$ at exchange rate,339.4
26481,Norway,2011,4,R-Respiratory system,Million of national currency units,1902.0
26482,Norway,2011,4,R-Respiratory system,"/capita, US$ exchange rate",68.5
26483,Norway,2011,4,R-Respiratory system,"Million US$, purchasing power parity",209.4
26484,Norway,2011,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2
26485,Norway,2011,4,N-Nervous system,"Million US$, purchasing power parity",380.7
26486,Norway,2011,4,N-Nervous system,Million US$ at exchange rate,617.0
26487,Norway,2011,4,C02-Antihypertensives,% of total sales,0.3
26488,Norway,2011,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
26489,Norway,2011,4,A02A-Antacids,"/capita, US$ exchange rate",1.0
26490,Norway,2011,4,A02A-Antacids,% of total sales,0.2
26491,Norway,2011,4,R-Respiratory system,"/capita, US$ purchasing power parity",42.3
26492,Norway,2011,4,N-Nervous system,Million of national currency units,3458.0
26493,Norway,2011,4,R-Respiratory system,% of total sales,10.5
26494,Norway,2011,4,A02A-Antacids,"Million US$, purchasing power parity",3.1
26495,Norway,2011,4,N-Nervous system,"/capita, US$ purchasing power parity",76.9
26496,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",28.2
26497,Norway,2011,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.0
26498,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.3
26499,Norway,2011,4,C02-Antihypertensives,"Million US$, purchasing power parity",6.2
26500,Norway,2011,4,N-Nervous system,"/capita, US$ exchange rate",124.6
26501,Norway,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",17.4
26502,Norway,2012,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",73.1
26503,Norway,2012,3,M-Musculo-skeletal system,Million US$ at exchange rate,113.6
26504,Norway,2012,3,C10-Lipid modifying agents,Million US$ at exchange rate,64.5
26505,Norway,2012,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",41.5
26506,Norway,2012,3,N05B-Anxiolytics,% of total sales,0.6
26507,Norway,2012,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.1
26508,Norway,2012,3,C10-Lipid modifying agents,Million of national currency units,375.0
26509,Norway,2012,3,A-Alimentary tract and metabolism,% of total sales,10.2
26510,Norway,2012,3,N05B-Anxiolytics,"Million US$, purchasing power parity",12.8
26511,Norway,2012,3,G-Genito urinary system and sex hormones,Million of national currency units,948.0
26512,Norway,2012,3,C02-Antihypertensives,Million of national currency units,61.0
26513,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,71.2
26514,Norway,2012,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,163.0
26515,Norway,2012,3,M-Musculo-skeletal system,% of total sales,3.5
26516,Norway,2012,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.6
26517,Norway,2012,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.6
26518,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
26519,Norway,2012,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",211.4
26520,Norway,2012,3,C10-Lipid modifying agents,% of total sales,2.0
26521,Norway,2012,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",65.4
26522,Norway,2012,3,N05B-Anxiolytics,"/capita, US$ exchange rate",4.0
26523,Norway,2012,3,M-Musculo-skeletal system,Million of national currency units,661.0
26524,Norway,2012,3,N05B-Anxiolytics,Million US$ at exchange rate,19.9
26525,Norway,2012,3,A-Alimentary tract and metabolism,Million of national currency units,1910.0
26526,Norway,2012,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,328.3
26527,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",9.1
26528,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.2
26529,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",45.8
26530,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",14.2
26531,Norway,2012,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.6
26532,Norway,2012,3,N05B-Anxiolytics,Million of national currency units,116.0
26533,Norway,2012,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.8
26534,Norway,2012,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.3
26535,Norway,2012,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.3
26536,Norway,2012,3,N05C-Hypnotics and sedatives,% of total sales,1.0
26537,Norway,2012,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",21.5
26538,Norway,2012,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.6
26539,Norway,2012,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",43.6
26540,Norway,2012,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.1
26541,Norway,2012,3,B-Blood and blood forming organs,% of total sales,6.8
26542,Norway,2012,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.3
26543,Norway,2012,3,C01A-Cardiac glycosides,% of total sales,0.0
26544,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,446.0
26545,Norway,2012,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
26546,Norway,2012,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,33.3
26547,Norway,2012,3,N05C-Hypnotics and sedatives,Million of national currency units,194.0
26548,Norway,2012,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
26549,Norway,2012,3,N06A-Antidepressants,Million of national currency units,266.0
26550,Norway,2012,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",141.0
26551,Norway,2012,3,A10-Drugs used in diabetes,Million of national currency units,596.0
26552,Norway,2012,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,441.0
26553,Norway,2012,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",66.0
26554,Norway,2012,3,A10-Drugs used in diabetes,Million US$ at exchange rate,102.4
26555,Norway,2012,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",48.8
26556,Norway,2012,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,75.8
26557,Norway,2012,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.7
26558,Norway,2012,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",15.1
26559,Norway,2012,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.3
26560,Norway,2012,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.5
26561,Norway,2012,3,B-Blood and blood forming organs,Million of national currency units,1274.0
26562,Norway,2012,3,B-Blood and blood forming organs,Million US$ at exchange rate,219.0
26563,Norway,2012,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.1
26564,Norway,2012,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.4
26565,Norway,2012,3,C01A-Cardiac glycosides,Million of national currency units,3.0
26566,Norway,2012,3,A10-Drugs used in diabetes,% of total sales,3.2
26567,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0
26568,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.0
26569,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,80.4
26570,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,468.0
26571,Norway,2012,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2080.3
26572,Norway,2012,3,Total pharmaceutical sales,Million US$ at exchange rate,3231.6
26573,Norway,2012,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",414.5
26574,Norway,2012,3,Total pharmaceutical sales,"/capita, US$ exchange rate",643.9
26575,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
26576,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
26577,Norway,2012,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,414.0
26578,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
26579,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.0
26580,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",51.8
26581,Norway,2012,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.2
26582,Norway,2012,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.3
26583,Norway,2012,3,N06A-Antidepressants,% of total sales,1.4
26584,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,76.7
26585,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",49.4
26586,Norway,2012,3,N06A-Antidepressants,Million US$ at exchange rate,45.7
26587,Norway,2012,3,N06A-Antidepressants,"Million US$, purchasing power parity",29.4
26588,Norway,2012,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.9
26589,Norway,2012,3,N06A-Antidepressants,"/capita, US$ exchange rate",9.1
26590,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.3
26591,Norway,2012,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",32.5
26592,Norway,2012,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.9
26593,Norway,2012,3,Total pharmaceutical sales,Million of national currency units,18800.0
26594,Norway,2012,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",104.9
26595,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.8
26596,Norway,2012,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4
26597,Norway,2012,3,G-Genito urinary system and sex hormones,% of total sales,5.0
26598,Norway,2012,3,R03-Drugs for obstructive airway diseases,% of total sales,6.0
26599,Norway,2012,3,A02A-Antacids,Million of national currency units,28.0
26600,Norway,2012,3,A02A-Antacids,Million US$ at exchange rate,4.8
26601,Norway,2012,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",123.8
26602,Norway,2012,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,192.4
26603,Norway,2012,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",24.7
26604,Norway,2012,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",38.3
26605,Norway,2012,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.0
26606,Norway,2012,3,C07-Beta blocking agents,Million of national currency units,165.0
26607,Norway,2012,3,C-Cardiovascular system,Million of national currency units,1631.0
26608,Norway,2012,3,C08-Calcium channel blockers,% of total sales,0.7
26609,Norway,2012,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.9
26610,Norway,2012,3,C-Cardiovascular system,"/capita, US$ exchange rate",55.9
26611,Norway,2012,3,C-Cardiovascular system,Million US$ at exchange rate,280.4
26612,Norway,2012,3,C-Cardiovascular system,"Million US$, purchasing power parity",180.5
26613,Norway,2012,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",169.7
26614,Norway,2012,3,C03-Diuretics,Million US$ at exchange rate,17.0
26615,Norway,2012,3,C03-Diuretics,Million of national currency units,99.0
26616,Norway,2012,3,C03-Diuretics,"/capita, US$ exchange rate",3.4
26617,Norway,2012,3,C03-Diuretics,"Million US$, purchasing power parity",11.0
26618,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,111.2
26619,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",71.6
26620,Norway,2012,3,N-Nervous system,% of total sales,19.1
26621,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,647.0
26622,Norway,2012,3,J-Antiinfectives for systemic use,Million of national currency units,1534.0
26623,Norway,2012,3,C-Cardiovascular system,% of total sales,8.7
26624,Norway,2012,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,263.7
26625,Norway,2012,3,C03-Diuretics,% of total sales,0.5
26626,Norway,2012,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
26627,Norway,2012,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1119.0
26628,Norway,2012,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.5
26629,Norway,2012,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.1
26630,Norway,2012,3,C08-Calcium channel blockers,Million of national currency units,132.0
26631,Norway,2012,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.7
26632,Norway,2012,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",50.7
26633,Norway,2012,3,J-Antiinfectives for systemic use,% of total sales,8.2
26634,Norway,2012,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",14.6
26635,Norway,2012,3,C08-Calcium channel blockers,Million US$ at exchange rate,22.7
26636,Norway,2012,3,Products not elsewhere classified,"Million US$, purchasing power parity",535.8
26637,Norway,2012,3,Products not elsewhere classified,"/capita, US$ exchange rate",165.8
26638,Norway,2012,3,Products not elsewhere classified,Million of national currency units,4842.0
26639,Norway,2012,3,Products not elsewhere classified,Million US$ at exchange rate,832.3
26640,Norway,2012,3,J01-Antibacterials for systemic use,Million of national currency units,458.0
26641,Norway,2012,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,78.7
26642,Norway,2012,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",106.8
26643,Norway,2012,3,Products not elsewhere classified,% of total sales,25.8
26644,Norway,2012,3,N02-Analgesics,Million US$ at exchange rate,215.9
26645,Norway,2012,3,N02-Analgesics,"Million US$, purchasing power parity",139.0
26646,Norway,2012,3,C07-Beta blocking agents,Million US$ at exchange rate,28.4
26647,Norway,2012,3,N02-Analgesics,Million of national currency units,1256.0
26648,Norway,2012,3,N02-Analgesics,% of total sales,6.7
26649,Norway,2012,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.7
26650,Norway,2012,3,N02-Analgesics,"/capita, US$ exchange rate",43.0
26651,Norway,2012,3,J01-Antibacterials for systemic use,% of total sales,2.4
26652,Norway,2012,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",33.8
26653,Norway,2012,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",52.5
26654,Norway,2012,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.7
26655,Norway,2012,3,C07-Beta blocking agents,"Million US$, purchasing power parity",18.3
26656,Norway,2012,3,C07-Beta blocking agents,% of total sales,0.9
26657,Norway,2012,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6
26658,Norway,2012,3,R-Respiratory system,Million US$ at exchange rate,331.4
26659,Norway,2012,3,R-Respiratory system,Million of national currency units,1928.0
26660,Norway,2012,3,R-Respiratory system,"/capita, US$ exchange rate",66.0
26661,Norway,2012,3,R-Respiratory system,"Million US$, purchasing power parity",213.3
26662,Norway,2012,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
26663,Norway,2012,3,N-Nervous system,Million US$ at exchange rate,618.7
26664,Norway,2012,3,C02-Antihypertensives,% of total sales,0.3
26665,Norway,2012,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
26666,Norway,2012,3,A02A-Antacids,"/capita, US$ exchange rate",1.0
26667,Norway,2012,3,A02A-Antacids,% of total sales,0.1
26668,Norway,2012,3,N-Nervous system,"Million US$, purchasing power parity",398.2
26669,Norway,2012,3,R-Respiratory system,"/capita, US$ purchasing power parity",42.5
26670,Norway,2012,3,N-Nervous system,Million of national currency units,3599.0
26671,Norway,2012,3,A02A-Antacids,"Million US$, purchasing power parity",3.1
26672,Norway,2012,3,R-Respiratory system,% of total sales,10.3
26673,Norway,2012,3,N-Nervous system,"/capita, US$ purchasing power parity",79.4
26674,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.2
26675,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,3.4
26676,Norway,2012,3,C02-Antihypertensives,"Million US$, purchasing power parity",6.7
26677,Norway,2012,3,N-Nervous system,"/capita, US$ exchange rate",123.3
26678,Norway,2012,3,C02-Antihypertensives,Million US$ at exchange rate,10.5
26679,Norway,2012,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",14.3
26680,Norway,2012,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.1
26681,Norway,2013,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",79.1
26682,Norway,2013,3,M-Musculo-skeletal system,Million US$ at exchange rate,121.5
26683,Norway,2013,3,N05B-Anxiolytics,% of total sales,0.6
26684,Norway,2013,3,C10-Lipid modifying agents,Million US$ at exchange rate,66.6
26685,Norway,2013,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",43.3
26686,Norway,2013,3,C10-Lipid modifying agents,Million of national currency units,391.0
26687,Norway,2013,3,A-Alimentary tract and metabolism,% of total sales,9.9
26688,Norway,2013,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.8
26689,Norway,2013,3,G-Genito urinary system and sex hormones,Million of national currency units,983.0
26690,Norway,2013,3,C02-Antihypertensives,Million of national currency units,69.0
26691,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,65.9
26692,Norway,2013,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,167.3
26693,Norway,2013,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.6
26694,Norway,2013,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.9
26695,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
26696,Norway,2013,3,M-Musculo-skeletal system,% of total sales,3.7
26697,Norway,2013,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",212.1
26698,Norway,2013,3,C10-Lipid modifying agents,% of total sales,2.0
26699,Norway,2013,3,N05B-Anxiolytics,"/capita, US$ exchange rate",3.8
26700,Norway,2013,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.2
26701,Norway,2013,3,M-Musculo-skeletal system,Million of national currency units,714.0
26702,Norway,2013,3,N05B-Anxiolytics,Million US$ at exchange rate,19.4
26703,Norway,2013,3,A-Alimentary tract and metabolism,Million of national currency units,1915.0
26704,Norway,2013,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,326.0
26705,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.4
26706,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0
26707,Norway,2013,3,N05B-Anxiolytics,"Million US$, purchasing power parity",12.6
26708,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",42.9
26709,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",13.0
26710,Norway,2013,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
26711,Norway,2013,3,N05B-Anxiolytics,Million of national currency units,114.0
26712,Norway,2013,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",13.1
26713,Norway,2013,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.5
26714,Norway,2013,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.2
26715,Norway,2013,3,N05C-Hypnotics and sedatives,% of total sales,1.0
26716,Norway,2013,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",21.2
26717,Norway,2013,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.4
26718,Norway,2013,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",50.2
26719,Norway,2013,3,B-Blood and blood forming organs,% of total sales,7.8
26720,Norway,2013,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.7
26721,Norway,2013,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",165.9
26722,Norway,2013,3,C01A-Cardiac glycosides,% of total sales,0.0
26723,Norway,2013,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
26724,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,464.0
26725,Norway,2013,3,N05C-Hypnotics and sedatives,Million of national currency units,191.0
26726,Norway,2013,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,32.5
26727,Norway,2013,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
26728,Norway,2013,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
26729,Norway,2013,3,A10-Drugs used in diabetes,Million of national currency units,601.0
26730,Norway,2013,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,454.0
26731,Norway,2013,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",66.6
26732,Norway,2013,3,A10-Drugs used in diabetes,Million US$ at exchange rate,102.3
26733,Norway,2013,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",50.3
26734,Norway,2013,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,77.3
26735,Norway,2013,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.9
26736,Norway,2013,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",15.2
26737,Norway,2013,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
26738,Norway,2013,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.9
26739,Norway,2013,3,B-Blood and blood forming organs,Million of national currency units,1498.0
26740,Norway,2013,3,B-Blood and blood forming organs,Million US$ at exchange rate,255.0
26741,Norway,2013,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",13.1
26742,Norway,2013,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.1
26743,Norway,2013,3,C01A-Cardiac glycosides,Million of national currency units,5.0
26744,Norway,2013,3,A10-Drugs used in diabetes,% of total sales,3.1
26745,Norway,2013,3,N06A-Antidepressants,Million of national currency units,261.0
26746,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.3
26747,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,31.0
26748,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,82.6
26749,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,485.0
26750,Norway,2013,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2137.5
26751,Norway,2013,3,Total pharmaceutical sales,Million US$ at exchange rate,3285.1
26752,Norway,2013,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",420.8
26753,Norway,2013,3,Total pharmaceutical sales,"/capita, US$ exchange rate",646.7
26754,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
26755,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
26756,Norway,2013,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,387.0
26757,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
26758,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",16.3
26759,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",53.7
26760,Norway,2013,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.4
26761,Norway,2013,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6
26762,Norway,2013,3,N06A-Antidepressants,% of total sales,1.4
26763,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,79.0
26764,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.4
26765,Norway,2013,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.7
26766,Norway,2013,3,N06A-Antidepressants,Million US$ at exchange rate,44.4
26767,Norway,2013,3,N06A-Antidepressants,"Million US$, purchasing power parity",28.9
26768,Norway,2013,3,N06A-Antidepressants,"/capita, US$ exchange rate",8.7
26769,Norway,2013,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",32.9
26770,Norway,2013,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.4
26771,Norway,2013,3,Total pharmaceutical sales,Million of national currency units,19300.0
26772,Norway,2013,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",108.9
26773,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",15.5
26774,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.1
26775,Norway,2013,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4
26776,Norway,2013,3,G-Genito urinary system and sex hormones,% of total sales,5.1
26777,Norway,2013,3,R03-Drugs for obstructive airway diseases,% of total sales,5.4
26778,Norway,2013,3,A02A-Antacids,Million of national currency units,29.0
26779,Norway,2013,3,A02A-Antacids,Million US$ at exchange rate,4.9
26780,Norway,2013,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",115.7
26781,Norway,2013,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,177.9
26782,Norway,2013,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.8
26783,Norway,2013,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",35.0
26784,Norway,2013,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",32.3
26785,Norway,2013,3,C08-Calcium channel blockers,% of total sales,0.7
26786,Norway,2013,3,C07-Beta blocking agents,Million of national currency units,167.0
26787,Norway,2013,3,C-Cardiovascular system,Million of national currency units,1481.0
26788,Norway,2013,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.8
26789,Norway,2013,3,C-Cardiovascular system,"/capita, US$ exchange rate",49.6
26790,Norway,2013,3,C-Cardiovascular system,Million US$ at exchange rate,252.1
26791,Norway,2013,3,C-Cardiovascular system,"Million US$, purchasing power parity",164.0
26792,Norway,2013,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",167.7
26793,Norway,2013,3,C03-Diuretics,Million US$ at exchange rate,16.7
26794,Norway,2013,3,C03-Diuretics,Million of national currency units,98.0
26795,Norway,2013,3,C03-Diuretics,"/capita, US$ exchange rate",3.3
26796,Norway,2013,3,C03-Diuretics,"Million US$, purchasing power parity",10.9
26797,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,80.2
26798,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",52.2
26799,Norway,2013,3,N-Nervous system,% of total sales,18.5
26800,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,471.0
26801,Norway,2013,3,C-Cardiovascular system,% of total sales,7.7
26802,Norway,2013,3,J-Antiinfectives for systemic use,Million of national currency units,1514.0
26803,Norway,2013,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,257.7
26804,Norway,2013,3,C03-Diuretics,% of total sales,0.5
26805,Norway,2013,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.1
26806,Norway,2013,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1045.0
26807,Norway,2013,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3
26808,Norway,2013,3,C08-Calcium channel blockers,Million of national currency units,128.0
26809,Norway,2013,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2
26810,Norway,2013,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",46.8
26811,Norway,2013,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.2
26812,Norway,2013,3,J-Antiinfectives for systemic use,% of total sales,7.8
26813,Norway,2013,3,C08-Calcium channel blockers,Million US$ at exchange rate,21.8
26814,Norway,2013,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",14.2
26815,Norway,2013,3,Products not elsewhere classified,"Million US$, purchasing power parity",580.7
26816,Norway,2013,3,Products not elsewhere classified,"/capita, US$ exchange rate",175.7
26817,Norway,2013,3,Products not elsewhere classified,Million of national currency units,5243.0
26818,Norway,2013,3,Products not elsewhere classified,Million US$ at exchange rate,892.4
26819,Norway,2013,3,J01-Antibacterials for systemic use,Million of national currency units,423.0
26820,Norway,2013,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,72.0
26821,Norway,2013,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",114.3
26822,Norway,2013,3,Products not elsewhere classified,% of total sales,27.2
26823,Norway,2013,3,N02-Analgesics,Million US$ at exchange rate,213.6
26824,Norway,2013,3,N02-Analgesics,"Million US$, purchasing power parity",139.0
26825,Norway,2013,3,C07-Beta blocking agents,Million US$ at exchange rate,28.4
26826,Norway,2013,3,N02-Analgesics,Million of national currency units,1255.0
26827,Norway,2013,3,N02-Analgesics,% of total sales,6.5
26828,Norway,2013,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.4
26829,Norway,2013,3,N02-Analgesics,"/capita, US$ exchange rate",42.1
26830,Norway,2013,3,J01-Antibacterials for systemic use,% of total sales,2.2
26831,Norway,2013,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",50.7
26832,Norway,2013,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",33.0
26833,Norway,2013,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6
26834,Norway,2013,3,C07-Beta blocking agents,"Million US$, purchasing power parity",18.5
26835,Norway,2013,3,C07-Beta blocking agents,% of total sales,0.9
26836,Norway,2013,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6
26837,Norway,2013,3,R-Respiratory system,Million US$ at exchange rate,316.4
26838,Norway,2013,3,R-Respiratory system,Million of national currency units,1859.0
26839,Norway,2013,3,R-Respiratory system,"Million US$, purchasing power parity",205.9
26840,Norway,2013,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.5
26841,Norway,2013,3,N-Nervous system,Million US$ at exchange rate,607.7
26842,Norway,2013,3,C02-Antihypertensives,% of total sales,0.4
26843,Norway,2013,3,R-Respiratory system,"/capita, US$ exchange rate",62.3
26844,Norway,2013,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
26845,Norway,2013,3,A02A-Antacids,"/capita, US$ exchange rate",1.0
26846,Norway,2013,3,A02A-Antacids,% of total sales,0.2
26847,Norway,2013,3,R-Respiratory system,"/capita, US$ purchasing power parity",40.5
26848,Norway,2013,3,N-Nervous system,Million of national currency units,3570.0
26849,Norway,2013,3,A02A-Antacids,"Million US$, purchasing power parity",3.2
26850,Norway,2013,3,R-Respiratory system,% of total sales,9.6
26851,Norway,2013,3,N-Nervous system,"Million US$, purchasing power parity",395.4
26852,Norway,2013,3,N-Nervous system,"/capita, US$ purchasing power parity",77.8
26853,Norway,2013,3,N-Nervous system,"/capita, US$ exchange rate",119.6
26854,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.8
26855,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.4
26856,Norway,2013,3,C02-Antihypertensives,"Million US$, purchasing power parity",7.6
26857,Norway,2013,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
26858,Norway,2013,3,C02-Antihypertensives,Million US$ at exchange rate,11.7
26859,Norway,2013,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",10.3
26860,Norway,2017,2,N05B-Anxiolytics,% of total sales,0.4
26861,Norway,2017,2,M-Musculo-skeletal system,Million of national currency units,998.0
26862,Norway,2017,2,M-Musculo-skeletal system,"Million US$, purchasing power parity",102.4
26863,Norway,2017,2,M-Musculo-skeletal system,Million US$ at exchange rate,120.7
26864,Norway,2017,2,C10-Lipid modifying agents,Million of national currency units,504.0
26865,Norway,2017,2,C10-Lipid modifying agents,Million US$ at exchange rate,60.9
26866,Norway,2017,2,A-Alimentary tract and metabolism,% of total sales,10.4
26867,Norway,2017,2,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.9
26868,Norway,2017,2,G-Genito urinary system and sex hormones,Million of national currency units,1228.0
26869,Norway,2017,2,M-Musculo-skeletal system,% of total sales,3.7
26870,Norway,2017,2,C02-Antihypertensives,Million of national currency units,110.0
26871,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.9
26872,Norway,2017,2,G-Genito urinary system and sex hormones,Million US$ at exchange rate,148.5
26873,Norway,2017,2,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.4
26874,Norway,2017,2,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.9
26875,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6
26876,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
26877,Norway,2017,2,C10-Lipid modifying agents,"Million US$, purchasing power parity",51.7
26878,Norway,2017,2,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",284.6
26879,Norway,2017,2,C10-Lipid modifying agents,% of total sales,1.9
26880,Norway,2017,2,N05B-Anxiolytics,Million of national currency units,116.0
26881,Norway,2017,2,N05B-Anxiolytics,Million US$ at exchange rate,14.0
26882,Norway,2017,2,N05B-Anxiolytics,"Million US$, purchasing power parity",11.9
26883,Norway,2017,2,A-Alimentary tract and metabolism,Million US$ at exchange rate,335.5
26884,Norway,2017,2,A-Alimentary tract and metabolism,Million of national currency units,2775.0
26885,Norway,2017,2,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7
26886,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.4
26887,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2
26888,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.6
26889,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",33.8
26890,Norway,2017,2,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
26891,Norway,2017,2,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",63.6
26892,Norway,2017,2,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.5
26893,Norway,2017,2,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.8
26894,Norway,2017,2,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",5.0
26895,Norway,2017,2,N05C-Hypnotics and sedatives,% of total sales,1.0
26896,Norway,2017,2,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",26.4
26897,Norway,2017,2,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.9
26898,Norway,2017,2,B-Blood and blood forming organs,"/capita, US$ exchange rate",53.4
26899,Norway,2017,2,B-Blood and blood forming organs,"Million US$, purchasing power parity",239.0
26900,Norway,2017,2,B-Blood and blood forming organs,% of total sales,8.7
26901,Norway,2017,2,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",45.3
26902,Norway,2017,2,C01A-Cardiac glycosides,% of total sales,0.0
26903,Norway,2017,2,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
26904,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,550.0
26905,Norway,2017,2,G03-Sex hormones and modulators of the genital system,% of total sales,2.1
26906,Norway,2017,2,N05C-Hypnotics and sedatives,Million of national currency units,257.0
26907,Norway,2017,2,N05C-Hypnotics and sedatives,Million US$ at exchange rate,31.1
26908,Norway,2017,2,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
26909,Norway,2017,2,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
26910,Norway,2017,2,G03-Sex hormones and modulators of the genital system,Million of national currency units,562.0
26911,Norway,2017,2,A10-Drugs used in diabetes,Million of national currency units,1001.0
26912,Norway,2017,2,A10-Drugs used in diabetes,Million US$ at exchange rate,121.0
26913,Norway,2017,2,A10-Drugs used in diabetes,"Million US$, purchasing power parity",102.7
26914,Norway,2017,2,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",57.6
26915,Norway,2017,2,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,67.9
26916,Norway,2017,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.9
26917,Norway,2017,2,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",12.9
26918,Norway,2017,2,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6
26919,Norway,2017,2,B-Blood and blood forming organs,Million US$ at exchange rate,281.7
26920,Norway,2017,2,B-Blood and blood forming organs,Million of national currency units,2330.0
26921,Norway,2017,2,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.9
26922,Norway,2017,2,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.5
26923,Norway,2017,2,C01A-Cardiac glycosides,Million of national currency units,5.0
26924,Norway,2017,2,A10-Drugs used in diabetes,% of total sales,3.8
26925,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,41.0
26926,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0
26927,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,65.6
26928,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,543.0
26929,Norway,2017,2,Total pharmaceutical sales,"/capita, US$ purchasing power parity",518.0
26930,Norway,2017,2,Total pharmaceutical sales,Million US$ at exchange rate,3221.8
26931,Norway,2017,2,Total pharmaceutical sales,"Million US$, purchasing power parity",2733.4
26932,Norway,2017,2,Total pharmaceutical sales,"/capita, US$ exchange rate",610.5
26933,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
26934,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
26935,Norway,2017,2,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,330.0
26936,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
26937,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",55.7
26938,Norway,2017,2,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.4
26939,Norway,2017,2,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.2
26940,Norway,2017,2,N06A-Antidepressants,% of total sales,1.0
26941,Norway,2017,2,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.4
26942,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",56.4
26943,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,66.5
26944,Norway,2017,2,N06A-Antidepressants,Million US$ at exchange rate,33.5
26945,Norway,2017,2,N06A-Antidepressants,Million of national currency units,277.0
26946,Norway,2017,2,N06A-Antidepressants,"/capita, US$ exchange rate",6.3
26947,Norway,2017,2,N06A-Antidepressants,"Million US$, purchasing power parity",28.4
26948,Norway,2017,2,Total pharmaceutical sales,Million of national currency units,26650.0
26949,Norway,2017,2,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",28.1
26950,Norway,2017,2,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",23.9
26951,Norway,2017,2,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",126.0
26952,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.7
26953,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.6
26954,Norway,2017,2,G-Genito urinary system and sex hormones,% of total sales,4.6
26955,Norway,2017,2,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.1
26956,Norway,2017,2,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",241.2
26957,Norway,2017,2,R03-Drugs for obstructive airway diseases,% of total sales,4.6
26958,Norway,2017,2,A02A-Antacids,Million of national currency units,29.0
26959,Norway,2017,2,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.6
26960,Norway,2017,2,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",124.5
26961,Norway,2017,2,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,146.8
26962,Norway,2017,2,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.8
26963,Norway,2017,2,C08-Calcium channel blockers,% of total sales,0.5
26964,Norway,2017,2,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.9
26965,Norway,2017,2,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.5
26966,Norway,2017,2,C-Cardiovascular system,Million of national currency units,1708.0
26967,Norway,2017,2,C-Cardiovascular system,"Million US$, purchasing power parity",175.2
26968,Norway,2017,2,C-Cardiovascular system,"/capita, US$ exchange rate",39.1
26969,Norway,2017,2,C-Cardiovascular system,Million US$ at exchange rate,206.5
26970,Norway,2017,2,C03-Diuretics,Million US$ at exchange rate,14.7
26971,Norway,2017,2,C03-Diuretics,Million of national currency units,122.0
26972,Norway,2017,2,C03-Diuretics,"Million US$, purchasing power parity",12.5
26973,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,54.5
26974,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",46.3
26975,Norway,2017,2,N-Nervous system,% of total sales,16.0
26976,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,451.0
26977,Norway,2017,2,C03-Diuretics,"/capita, US$ exchange rate",2.8
26978,Norway,2017,2,C-Cardiovascular system,"/capita, US$ purchasing power parity",33.2
26979,Norway,2017,2,C-Cardiovascular system,% of total sales,6.4
26980,Norway,2017,2,J-Antiinfectives for systemic use,Million US$ at exchange rate,284.3
26981,Norway,2017,2,J-Antiinfectives for systemic use,Million of national currency units,2352.0
26982,Norway,2017,2,C03-Diuretics,"/capita, US$ purchasing power parity",2.4
26983,Norway,2017,2,R03-Drugs for obstructive airway diseases,Million of national currency units,1214.0
26984,Norway,2017,2,C03-Diuretics,% of total sales,0.5
26985,Norway,2017,2,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.9
26986,Norway,2017,2,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.4
26987,Norway,2017,2,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",44.5
26988,Norway,2017,2,J01-Antibacterials for systemic use,Million US$ at exchange rate,52.5
26989,Norway,2017,2,C08-Calcium channel blockers,Million of national currency units,128.0
26990,Norway,2017,2,C08-Calcium channel blockers,"Million US$, purchasing power parity",13.1
26991,Norway,2017,2,J-Antiinfectives for systemic use,% of total sales,8.8
26992,Norway,2017,2,C08-Calcium channel blockers,Million US$ at exchange rate,15.5
26993,Norway,2017,2,Products not elsewhere classified,"Million US$, purchasing power parity",822.4
26994,Norway,2017,2,Products not elsewhere classified,"/capita, US$ exchange rate",183.7
26995,Norway,2017,2,Products not elsewhere classified,Million of national currency units,8018.0
26996,Norway,2017,2,Products not elsewhere classified,Million US$ at exchange rate,969.3
26997,Norway,2017,2,J01-Antibacterials for systemic use,Million of national currency units,434.0
26998,Norway,2017,2,Products not elsewhere classified,% of total sales,30.1
26999,Norway,2017,2,Products not elsewhere classified,"/capita, US$ purchasing power parity",155.8
27000,Norway,2017,2,N02-Analgesics,Million US$ at exchange rate,179.2
27001,Norway,2017,2,N02-Analgesics,Million of national currency units,1482.0
27002,Norway,2017,2,C07-Beta blocking agents,Million US$ at exchange rate,22.1
27003,Norway,2017,2,C07-Beta blocking agents,Million of national currency units,183.0
27004,Norway,2017,2,N02-Analgesics,"/capita, US$ purchasing power parity",28.8
27005,Norway,2017,2,N02-Analgesics,% of total sales,5.6
27006,Norway,2017,2,N02-Analgesics,"Million US$, purchasing power parity",152.0
27007,Norway,2017,2,N02-Analgesics,"/capita, US$ exchange rate",34.0
27008,Norway,2017,2,J01-Antibacterials for systemic use,% of total sales,1.6
27009,Norway,2017,2,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",45.7
27010,Norway,2017,2,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.9
27011,Norway,2017,2,C07-Beta blocking agents,% of total sales,0.7
27012,Norway,2017,2,C07-Beta blocking agents,"Million US$, purchasing power parity",18.8
27013,Norway,2017,2,C07-Beta blocking agents,"/capita, US$ exchange rate",4.2
27014,Norway,2017,2,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6
27015,Norway,2017,2,R-Respiratory system,Million of national currency units,2421.0
27016,Norway,2017,2,R-Respiratory system,Million US$ at exchange rate,292.7
27017,Norway,2017,2,R-Respiratory system,"Million US$, purchasing power parity",248.3
27018,Norway,2017,2,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1
27019,Norway,2017,2,N-Nervous system,Million US$ at exchange rate,517.1
27020,Norway,2017,2,N-Nervous system,Million of national currency units,4277.0
27021,Norway,2017,2,C02-Antihypertensives,% of total sales,0.4
27022,Norway,2017,2,A02A-Antacids,"/capita, US$ exchange rate",0.7
27023,Norway,2017,2,A02A-Antacids,% of total sales,0.1
27024,Norway,2017,2,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
27025,Norway,2017,2,A02A-Antacids,"Million US$, purchasing power parity",3.0
27026,Norway,2017,2,R-Respiratory system,"/capita, US$ purchasing power parity",47.1
27027,Norway,2017,2,R-Respiratory system,"/capita, US$ exchange rate",55.5
27028,Norway,2017,2,A02A-Antacids,Million US$ at exchange rate,3.5
27029,Norway,2017,2,R-Respiratory system,% of total sales,9.1
27030,Norway,2017,2,N-Nervous system,"/capita, US$ purchasing power parity",83.1
27031,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.3
27032,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.7
27033,Norway,2017,2,N-Nervous system,"/capita, US$ exchange rate",98.0
27034,Norway,2017,2,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",8.8
27035,Norway,2017,2,C02-Antihypertensives,"Million US$, purchasing power parity",11.3
27036,Norway,2017,2,C02-Antihypertensives,"/capita, US$ exchange rate",2.5
27037,Norway,2017,2,N-Nervous system,"Million US$, purchasing power parity",438.7
27038,Norway,2017,2,C02-Antihypertensives,Million US$ at exchange rate,13.3
27039,Norway,2015,3,N05B-Anxiolytics,% of total sales,0.5
27040,Norway,2015,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",83.9
27041,Norway,2015,3,M-Musculo-skeletal system,Million US$ at exchange rate,103.3
27042,Norway,2015,3,C10-Lipid modifying agents,Million of national currency units,406.0
27043,Norway,2015,3,C10-Lipid modifying agents,Million US$ at exchange rate,50.3
27044,Norway,2015,3,A-Alimentary tract and metabolism,% of total sales,9.8
27045,Norway,2015,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.2
27046,Norway,2015,3,G-Genito urinary system and sex hormones,Million of national currency units,1082.0
27047,Norway,2015,3,C02-Antihypertensives,Million of national currency units,91.0
27048,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.7
27049,Norway,2015,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,134.2
27050,Norway,2015,3,M-Musculo-skeletal system,% of total sales,3.7
27051,Norway,2015,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.2
27052,Norway,2015,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.9
27053,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
27054,Norway,2015,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",40.9
27055,Norway,2015,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",223.9
27056,Norway,2015,3,C10-Lipid modifying agents,% of total sales,1.8
27057,Norway,2015,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7
27058,Norway,2015,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.2
27059,Norway,2015,3,M-Musculo-skeletal system,Million of national currency units,833.0
27060,Norway,2015,3,N05B-Anxiolytics,Million US$ at exchange rate,14.3
27061,Norway,2015,3,N05B-Anxiolytics,"Million US$, purchasing power parity",11.6
27062,Norway,2015,3,A-Alimentary tract and metabolism,Million of national currency units,2224.0
27063,Norway,2015,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,275.8
27064,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.2
27065,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.4
27066,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.6
27067,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",32.2
27068,Norway,2015,3,N05B-Anxiolytics,Million of national currency units,115.0
27069,Norway,2015,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
27070,Norway,2015,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.7
27071,Norway,2015,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.9
27072,Norway,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.3
27073,Norway,2015,3,N05C-Hypnotics and sedatives,% of total sales,1.0
27074,Norway,2015,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.4
27075,Norway,2015,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.3
27076,Norway,2015,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",44.1
27077,Norway,2015,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",185.9
27078,Norway,2015,3,B-Blood and blood forming organs,% of total sales,8.1
27079,Norway,2015,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.8
27080,Norway,2015,3,C01A-Cardiac glycosides,% of total sales,0.0
27081,Norway,2015,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.2
27082,Norway,2015,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
27083,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,515.0
27084,Norway,2015,3,N05C-Hypnotics and sedatives,Million of national currency units,222.0
27085,Norway,2015,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,27.5
27086,Norway,2015,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
27087,Norway,2015,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
27088,Norway,2015,3,A10-Drugs used in diabetes,Million of national currency units,786.0
27089,Norway,2015,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,512.0
27090,Norway,2015,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",79.1
27091,Norway,2015,3,A10-Drugs used in diabetes,Million US$ at exchange rate,97.5
27092,Norway,2015,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",51.5
27093,Norway,2015,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,63.5
27094,Norway,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.9
27095,Norway,2015,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",12.2
27096,Norway,2015,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6
27097,Norway,2015,3,B-Blood and blood forming organs,Million US$ at exchange rate,228.9
27098,Norway,2015,3,B-Blood and blood forming organs,Million of national currency units,1846.0
27099,Norway,2015,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.3
27100,Norway,2015,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.8
27101,Norway,2015,3,C01A-Cardiac glycosides,Million of national currency units,5.0
27102,Norway,2015,3,A10-Drugs used in diabetes,% of total sales,3.5
27103,Norway,2015,3,N06A-Antidepressants,Million of national currency units,264.0
27104,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,36.0
27105,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.5
27106,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,68.1
27107,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,549.0
27108,Norway,2015,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",441.8
27109,Norway,2015,3,Total pharmaceutical sales,Million US$ at exchange rate,2823.5
27110,Norway,2015,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2292.4
27111,Norway,2015,3,Total pharmaceutical sales,"/capita, US$ exchange rate",544.2
27112,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
27113,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
27114,Norway,2015,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,320.0
27115,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
27116,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.1
27117,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",55.3
27118,Norway,2015,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.6
27119,Norway,2015,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.7
27120,Norway,2015,3,N06A-Antidepressants,% of total sales,1.2
27121,Norway,2015,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.1
27122,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.8
27123,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,63.9
27124,Norway,2015,3,N06A-Antidepressants,Million US$ at exchange rate,32.7
27125,Norway,2015,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.3
27126,Norway,2015,3,N06A-Antidepressants,"Million US$, purchasing power parity",26.6
27127,Norway,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.9
27128,Norway,2015,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.0
27129,Norway,2015,3,Total pharmaceutical sales,Million of national currency units,22769.0
27130,Norway,2015,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",108.9
27131,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.0
27132,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.3
27133,Norway,2015,3,G-Genito urinary system and sex hormones,% of total sales,4.8
27134,Norway,2015,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3
27135,Norway,2015,3,R03-Drugs for obstructive airway diseases,% of total sales,4.9
27136,Norway,2015,3,A02A-Antacids,Million of national currency units,28.0
27137,Norway,2015,3,A02A-Antacids,Million US$ at exchange rate,3.5
27138,Norway,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",21.5
27139,Norway,2015,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",111.6
27140,Norway,2015,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,137.4
27141,Norway,2015,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",222.9
27142,Norway,2015,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.5
27143,Norway,2015,3,C08-Calcium channel blockers,% of total sales,0.5
27144,Norway,2015,3,C07-Beta blocking agents,Million of national currency units,174.0
27145,Norway,2015,3,C-Cardiovascular system,Million of national currency units,1508.0
27146,Norway,2015,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
27147,Norway,2015,3,C-Cardiovascular system,"/capita, US$ exchange rate",36.0
27148,Norway,2015,3,C-Cardiovascular system,"Million US$, purchasing power parity",151.8
27149,Norway,2015,3,C-Cardiovascular system,Million US$ at exchange rate,187.0
27150,Norway,2015,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.9
27151,Norway,2015,3,C03-Diuretics,Million US$ at exchange rate,13.6
27152,Norway,2015,3,C03-Diuretics,Million of national currency units,110.0
27153,Norway,2015,3,C03-Diuretics,"Million US$, purchasing power parity",11.1
27154,Norway,2015,3,C03-Diuretics,"/capita, US$ exchange rate",2.6
27155,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,52.1
27156,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",42.3
27157,Norway,2015,3,N-Nervous system,% of total sales,17.3
27158,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,420.0
27159,Norway,2015,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",29.3
27160,Norway,2015,3,C-Cardiovascular system,% of total sales,6.6
27161,Norway,2015,3,J-Antiinfectives for systemic use,Million of national currency units,2214.0
27162,Norway,2015,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,274.5
27163,Norway,2015,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.1
27164,Norway,2015,3,C03-Diuretics,% of total sales,0.5
27165,Norway,2015,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1108.0
27166,Norway,2015,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.0
27167,Norway,2015,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.9
27168,Norway,2015,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",46.3
27169,Norway,2015,3,C08-Calcium channel blockers,Million of national currency units,121.0
27170,Norway,2015,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",12.2
27171,Norway,2015,3,J-Antiinfectives for systemic use,% of total sales,9.7
27172,Norway,2015,3,C08-Calcium channel blockers,Million US$ at exchange rate,15.0
27173,Norway,2015,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,57.0
27174,Norway,2015,3,Products not elsewhere classified,"Million US$, purchasing power parity",653.5
27175,Norway,2015,3,Products not elsewhere classified,"/capita, US$ exchange rate",155.1
27176,Norway,2015,3,Products not elsewhere classified,Million of national currency units,6491.0
27177,Norway,2015,3,Products not elsewhere classified,Million US$ at exchange rate,804.9
27178,Norway,2015,3,J01-Antibacterials for systemic use,Million of national currency units,460.0
27179,Norway,2015,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",126.0
27180,Norway,2015,3,Products not elsewhere classified,% of total sales,28.5
27181,Norway,2015,3,N02-Analgesics,Million US$ at exchange rate,172.5
27182,Norway,2015,3,N02-Analgesics,Million of national currency units,1391.0
27183,Norway,2015,3,C07-Beta blocking agents,Million US$ at exchange rate,21.6
27184,Norway,2015,3,N02-Analgesics,"Million US$, purchasing power parity",140.0
27185,Norway,2015,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.0
27186,Norway,2015,3,N02-Analgesics,% of total sales,6.1
27187,Norway,2015,3,N02-Analgesics,"/capita, US$ exchange rate",33.2
27188,Norway,2015,3,J01-Antibacterials for systemic use,% of total sales,2.0
27189,Norway,2015,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",43.0
27190,Norway,2015,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",52.9
27191,Norway,2015,3,C07-Beta blocking agents,% of total sales,0.8
27192,Norway,2015,3,C07-Beta blocking agents,"/capita, US$ exchange rate",4.2
27193,Norway,2015,3,C07-Beta blocking agents,"Million US$, purchasing power parity",17.5
27194,Norway,2015,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.4
27195,Norway,2015,3,R-Respiratory system,Million US$ at exchange rate,259.5
27196,Norway,2015,3,R-Respiratory system,Million of national currency units,2093.0
27197,Norway,2015,3,R-Respiratory system,"Million US$, purchasing power parity",210.7
27198,Norway,2015,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.8
27199,Norway,2015,3,N-Nervous system,Million of national currency units,3929.0
27200,Norway,2015,3,N-Nervous system,Million US$ at exchange rate,487.2
27201,Norway,2015,3,C02-Antihypertensives,% of total sales,0.4
27202,Norway,2015,3,R-Respiratory system,"/capita, US$ exchange rate",50.0
27203,Norway,2015,3,A02A-Antacids,"/capita, US$ exchange rate",0.7
27204,Norway,2015,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
27205,Norway,2015,3,A02A-Antacids,% of total sales,0.1
27206,Norway,2015,3,A02A-Antacids,"Million US$, purchasing power parity",2.8
27207,Norway,2015,3,R-Respiratory system,"/capita, US$ purchasing power parity",40.6
27208,Norway,2015,3,R-Respiratory system,% of total sales,9.2
27209,Norway,2015,3,N-Nervous system,"Million US$, purchasing power parity",395.6
27210,Norway,2015,3,N-Nervous system,"/capita, US$ purchasing power parity",76.2
27211,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.0
27212,Norway,2015,3,N-Nervous system,"/capita, US$ exchange rate",93.9
27213,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8
27214,Norway,2015,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",8.1
27215,Norway,2015,3,C02-Antihypertensives,"Million US$, purchasing power parity",9.2
27216,Norway,2015,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.2
27217,Norway,2015,3,C02-Antihypertensives,Million US$ at exchange rate,11.3
27218,Norway,2016,3,N05B-Anxiolytics,% of total sales,0.5
27219,Norway,2016,3,M-Musculo-skeletal system,Million of national currency units,922.0
27220,Norway,2016,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",91.8
27221,Norway,2016,3,M-Musculo-skeletal system,Million US$ at exchange rate,109.8
27222,Norway,2016,3,C10-Lipid modifying agents,Million of national currency units,473.0
27223,Norway,2016,3,C10-Lipid modifying agents,Million US$ at exchange rate,56.3
27224,Norway,2016,3,A-Alimentary tract and metabolism,% of total sales,10.3
27225,Norway,2016,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",48.7
27226,Norway,2016,3,G-Genito urinary system and sex hormones,Million of national currency units,1162.0
27227,Norway,2016,3,M-Musculo-skeletal system,% of total sales,3.7
27228,Norway,2016,3,C02-Antihypertensives,Million of national currency units,103.0
27229,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,39.2
27230,Norway,2016,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,138.3
27231,Norway,2016,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.5
27232,Norway,2016,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",21.0
27233,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.8
27234,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
27235,Norway,2016,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",254.8
27236,Norway,2016,3,C10-Lipid modifying agents,% of total sales,1.9
27237,Norway,2016,3,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7
27238,Norway,2016,3,N05B-Anxiolytics,Million of national currency units,119.0
27239,Norway,2016,3,N05B-Anxiolytics,Million US$ at exchange rate,14.2
27240,Norway,2016,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,304.6
27241,Norway,2016,3,N05B-Anxiolytics,"Million US$, purchasing power parity",11.9
27242,Norway,2016,3,A-Alimentary tract and metabolism,Million of national currency units,2559.0
27243,Norway,2016,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",47.1
27244,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.3
27245,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3
27246,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.5
27247,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",32.8
27248,Norway,2016,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
27249,Norway,2016,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",58.2
27250,Norway,2016,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.0
27251,Norway,2016,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.8
27252,Norway,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.8
27253,Norway,2016,3,N05C-Hypnotics and sedatives,% of total sales,1.0
27254,Norway,2016,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",25.3
27255,Norway,2016,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.8
27256,Norway,2016,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",48.4
27257,Norway,2016,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",211.8
27258,Norway,2016,3,B-Blood and blood forming organs,% of total sales,8.6
27259,Norway,2016,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.5
27260,Norway,2016,3,C01A-Cardiac glycosides,% of total sales,0.0
27261,Norway,2016,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
27262,Norway,2016,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.2
27263,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,537.0
27264,Norway,2016,3,N05C-Hypnotics and sedatives,Million of national currency units,254.0
27265,Norway,2016,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,30.2
27266,Norway,2016,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
27267,Norway,2016,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
27268,Norway,2016,3,A10-Drugs used in diabetes,Million of national currency units,913.0
27269,Norway,2016,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,545.0
27270,Norway,2016,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",90.9
27271,Norway,2016,3,A10-Drugs used in diabetes,Million US$ at exchange rate,108.7
27272,Norway,2016,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",54.3
27273,Norway,2016,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,64.9
27274,Norway,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.4
27275,Norway,2016,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",12.4
27276,Norway,2016,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.6
27277,Norway,2016,3,B-Blood and blood forming organs,Million US$ at exchange rate,253.2
27278,Norway,2016,3,B-Blood and blood forming organs,Million of national currency units,2127.0
27279,Norway,2016,3,C01A-Cardiac glycosides,Million of national currency units,5.0
27280,Norway,2016,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",20.8
27281,Norway,2016,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.4
27282,Norway,2016,3,A10-Drugs used in diabetes,% of total sales,3.7
27283,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,38.0
27284,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.5
27285,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,67.9
27286,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,570.0
27287,Norway,2016,3,Total pharmaceutical sales,Million US$ at exchange rate,2948.7
27288,Norway,2016,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2466.6
27289,Norway,2016,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",471.2
27290,Norway,2016,3,Total pharmaceutical sales,"/capita, US$ exchange rate",563.3
27291,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
27292,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
27293,Norway,2016,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,329.0
27294,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
27295,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.0
27296,Norway,2016,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",56.8
27297,Norway,2016,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.8
27298,Norway,2016,3,Total pharmaceutical sales,Million of national currency units,24769.0
27299,Norway,2016,3,N06A-Antidepressants,% of total sales,1.1
27300,Norway,2016,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.1
27301,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",53.5
27302,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,63.9
27303,Norway,2016,3,N06A-Antidepressants,Million US$ at exchange rate,31.8
27304,Norway,2016,3,N06A-Antidepressants,Million of national currency units,267.0
27305,Norway,2016,3,N06A-Antidepressants,"/capita, US$ exchange rate",6.1
27306,Norway,2016,3,N06A-Antidepressants,"Million US$, purchasing power parity",26.6
27307,Norway,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",26.4
27308,Norway,2016,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",22.1
27309,Norway,2016,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",115.7
27310,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.2
27311,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.2
27312,Norway,2016,3,G-Genito urinary system and sex hormones,% of total sales,4.7
27313,Norway,2016,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.2
27314,Norway,2016,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",226.9
27315,Norway,2016,3,R03-Drugs for obstructive airway diseases,% of total sales,4.8
27316,Norway,2016,3,A02A-Antacids,Million of national currency units,30.0
27317,Norway,2016,3,A02A-Antacids,Million US$ at exchange rate,3.6
27318,Norway,2016,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",118.1
27319,Norway,2016,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,141.2
27320,Norway,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.6
27321,Norway,2016,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.0
27322,Norway,2016,3,C08-Calcium channel blockers,% of total sales,0.5
27323,Norway,2016,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.9
27324,Norway,2016,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4
27325,Norway,2016,3,C-Cardiovascular system,Million of national currency units,1632.0
27326,Norway,2016,3,C-Cardiovascular system,"/capita, US$ exchange rate",37.1
27327,Norway,2016,3,C-Cardiovascular system,"Million US$, purchasing power parity",162.5
27328,Norway,2016,3,C-Cardiovascular system,Million US$ at exchange rate,194.3
27329,Norway,2016,3,C03-Diuretics,Million US$ at exchange rate,13.3
27330,Norway,2016,3,C03-Diuretics,Million of national currency units,112.0
27331,Norway,2016,3,C03-Diuretics,"Million US$, purchasing power parity",11.2
27332,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,52.4
27333,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",43.8
27334,Norway,2016,3,N-Nervous system,% of total sales,16.7
27335,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,440.0
27336,Norway,2016,3,C03-Diuretics,"/capita, US$ exchange rate",2.5
27337,Norway,2016,3,C-Cardiovascular system,% of total sales,6.6
27338,Norway,2016,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,271.3
27339,Norway,2016,3,J-Antiinfectives for systemic use,Million of national currency units,2279.0
27340,Norway,2016,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.1
27341,Norway,2016,3,C03-Diuretics,% of total sales,0.5
27342,Norway,2016,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1186.0
27343,Norway,2016,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.7
27344,Norway,2016,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.9
27345,Norway,2016,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",46.7
27346,Norway,2016,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",12.5
27347,Norway,2016,3,J-Antiinfectives for systemic use,% of total sales,9.2
27348,Norway,2016,3,C08-Calcium channel blockers,Million of national currency units,126.0
27349,Norway,2016,3,C08-Calcium channel blockers,Million US$ at exchange rate,15.0
27350,Norway,2016,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,55.8
27351,Norway,2016,3,Products not elsewhere classified,"Million US$, purchasing power parity",708.2
27352,Norway,2016,3,Products not elsewhere classified,"/capita, US$ exchange rate",161.7
27353,Norway,2016,3,Products not elsewhere classified,Million of national currency units,7112.0
27354,Norway,2016,3,Products not elsewhere classified,Million US$ at exchange rate,846.7
27355,Norway,2016,3,J01-Antibacterials for systemic use,Million of national currency units,469.0
27356,Norway,2016,3,Products not elsewhere classified,% of total sales,28.7
27357,Norway,2016,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",135.3
27358,Norway,2016,3,N02-Analgesics,Million US$ at exchange rate,174.4
27359,Norway,2016,3,C07-Beta blocking agents,Million US$ at exchange rate,21.4
27360,Norway,2016,3,N02-Analgesics,Million of national currency units,1465.0
27361,Norway,2016,3,C07-Beta blocking agents,Million of national currency units,180.0
27362,Norway,2016,3,N02-Analgesics,"Million US$, purchasing power parity",145.9
27363,Norway,2016,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.9
27364,Norway,2016,3,N02-Analgesics,% of total sales,5.9
27365,Norway,2016,3,N02-Analgesics,"/capita, US$ exchange rate",33.3
27366,Norway,2016,3,J01-Antibacterials for systemic use,% of total sales,1.9
27367,Norway,2016,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",43.4
27368,Norway,2016,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",51.8
27369,Norway,2016,3,C07-Beta blocking agents,% of total sales,0.7
27370,Norway,2016,3,C07-Beta blocking agents,"/capita, US$ exchange rate",4.1
27371,Norway,2016,3,C07-Beta blocking agents,"Million US$, purchasing power parity",17.9
27372,Norway,2016,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.4
27373,Norway,2016,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",31.0
27374,Norway,2016,3,R-Respiratory system,Million US$ at exchange rate,270.6
27375,Norway,2016,3,R-Respiratory system,Million of national currency units,2273.0
27376,Norway,2016,3,R-Respiratory system,"Million US$, purchasing power parity",226.4
27377,Norway,2016,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.0
27378,Norway,2016,3,N-Nervous system,Million US$ at exchange rate,492.0
27379,Norway,2016,3,N-Nervous system,Million of national currency units,4133.0
27380,Norway,2016,3,C02-Antihypertensives,% of total sales,0.4
27381,Norway,2016,3,R-Respiratory system,"/capita, US$ exchange rate",51.7
27382,Norway,2016,3,A02A-Antacids,"/capita, US$ exchange rate",0.7
27383,Norway,2016,3,A02A-Antacids,% of total sales,0.1
27384,Norway,2016,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
27385,Norway,2016,3,R-Respiratory system,"/capita, US$ purchasing power parity",43.2
27386,Norway,2016,3,R-Respiratory system,% of total sales,9.2
27387,Norway,2016,3,A02A-Antacids,"Million US$, purchasing power parity",3.0
27388,Norway,2016,3,N-Nervous system,"/capita, US$ purchasing power parity",78.6
27389,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",10.0
27390,Norway,2016,3,N-Nervous system,"/capita, US$ exchange rate",94.0
27391,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.8
27392,Norway,2016,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",8.4
27393,Norway,2016,3,C02-Antihypertensives,"Million US$, purchasing power parity",10.3
27394,Norway,2016,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
27395,Norway,2016,3,N-Nervous system,"Million US$, purchasing power parity",411.6
27396,Norway,2016,3,C02-Antihypertensives,Million US$ at exchange rate,12.3
27397,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",50.2
27398,Norway,2010,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",66.5
27399,Norway,2010,4,M-Musculo-skeletal system,Million US$ at exchange rate,100.8
27400,Norway,2010,4,C10-Lipid modifying agents,Million of national currency units,440.0
27401,Norway,2010,4,C10-Lipid modifying agents,Million US$ at exchange rate,72.8
27402,Norway,2010,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",48.1
27403,Norway,2010,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",40.9
27404,Norway,2010,4,A-Alimentary tract and metabolism,% of total sales,10.2
27405,Norway,2010,4,G-Genito urinary system and sex hormones,Million of national currency units,914.0
27406,Norway,2010,4,C02-Antihypertensives,Million of national currency units,54.0
27407,Norway,2010,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,151.2
27408,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,75.9
27409,Norway,2010,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.6
27410,Norway,2010,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.6
27411,Norway,2010,4,M-Musculo-skeletal system,% of total sales,3.4
27412,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
27413,Norway,2010,4,C10-Lipid modifying agents,% of total sales,2.5
27414,Norway,2010,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",61.9
27415,Norway,2010,4,N05B-Anxiolytics,"/capita, US$ exchange rate",4.1
27416,Norway,2010,4,M-Musculo-skeletal system,Million of national currency units,609.0
27417,Norway,2010,4,N05B-Anxiolytics,Million US$ at exchange rate,20.2
27418,Norway,2010,4,N05B-Anxiolytics,"Million US$, purchasing power parity",13.3
27419,Norway,2010,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",199.9
27420,Norway,2010,4,A-Alimentary tract and metabolism,Million of national currency units,1829.0
27421,Norway,2010,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,302.6
27422,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.3
27423,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
27424,Norway,2010,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",14.9
27425,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",15.5
27426,Norway,2010,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.7
27427,Norway,2010,4,N05B-Anxiolytics,Million of national currency units,122.0
27428,Norway,2010,4,N05B-Anxiolytics,% of total sales,0.7
27429,Norway,2010,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.8
27430,Norway,2010,4,N05C-Hypnotics and sedatives,% of total sales,1.0
27431,Norway,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.8
27432,Norway,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.8
27433,Norway,2010,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",40.2
27434,Norway,2010,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.6
27435,Norway,2010,4,B-Blood and blood forming organs,% of total sales,6.6
27436,Norway,2010,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",18.8
27437,Norway,2010,4,C01A-Cardiac glycosides,% of total sales,0.0
27438,Norway,2010,4,N06A-Antidepressants,Million of national currency units,324.0
27439,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,70.3
27440,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,425.0
27441,Norway,2010,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,28.5
27442,Norway,2010,4,N05C-Hypnotics and sedatives,Million of national currency units,172.0
27443,Norway,2010,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
27444,Norway,2010,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
27445,Norway,2010,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",129.8
27446,Norway,2010,4,A10-Drugs used in diabetes,Million of national currency units,517.0
27447,Norway,2010,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,433.0
27448,Norway,2010,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",56.5
27449,Norway,2010,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
27450,Norway,2010,4,A10-Drugs used in diabetes,Million US$ at exchange rate,85.5
27451,Norway,2010,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",47.3
27452,Norway,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.7
27453,Norway,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.7
27454,Norway,2010,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
27455,Norway,2010,4,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
27456,Norway,2010,4,B-Blood and blood forming organs,Million of national currency units,1188.0
27457,Norway,2010,4,B-Blood and blood forming organs,Million US$ at exchange rate,196.6
27458,Norway,2010,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",11.6
27459,Norway,2010,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.5
27460,Norway,2010,4,C01A-Cardiac glycosides,Million of national currency units,5.0
27461,Norway,2010,4,A10-Drugs used in diabetes,% of total sales,2.9
27462,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.1
27463,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,25.0
27464,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,72.8
27465,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,440.0
27466,Norway,2010,4,Total pharmaceutical sales,"Million US$, purchasing power parity",1954.8
27467,Norway,2010,4,Total pharmaceutical sales,Million US$ at exchange rate,2959.9
27468,Norway,2010,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",399.8
27469,Norway,2010,4,Total pharmaceutical sales,"/capita, US$ exchange rate",605.4
27470,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
27471,Norway,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,459.0
27472,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
27473,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
27474,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.9
27475,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",48.1
27476,Norway,2010,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",2.7
27477,Norway,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.8
27478,Norway,2010,4,N06A-Antidepressants,% of total sales,1.8
27479,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",14.4
27480,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",46.4
27481,Norway,2010,4,N06A-Antidepressants,"Million US$, purchasing power parity",35.4
27482,Norway,2010,4,N06A-Antidepressants,Million US$ at exchange rate,53.6
27483,Norway,2010,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.2
27484,Norway,2010,4,N06A-Antidepressants,"/capita, US$ exchange rate",11.0
27485,Norway,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.4
27486,Norway,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",30.9
27487,Norway,2010,4,Total pharmaceutical sales,Million of national currency units,17890.0
27488,Norway,2010,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",99.9
27489,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.5
27490,Norway,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4
27491,Norway,2010,4,G-Genito urinary system and sex hormones,% of total sales,5.1
27492,Norway,2010,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,71.6
27493,Norway,2010,4,R03-Drugs for obstructive airway diseases,% of total sales,6.5
27494,Norway,2010,4,A02A-Antacids,Million US$ at exchange rate,4.6
27495,Norway,2010,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",42.5
27496,Norway,2010,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",126.3
27497,Norway,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.8
27498,Norway,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",39.1
27499,Norway,2010,4,A02A-Antacids,Million of national currency units,28.0
27500,Norway,2010,4,C07-Beta blocking agents,Million of national currency units,168.0
27501,Norway,2010,4,C-Cardiovascular system,Million of national currency units,1869.0
27502,Norway,2010,4,C08-Calcium channel blockers,% of total sales,0.9
27503,Norway,2010,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.6
27504,Norway,2010,4,C-Cardiovascular system,"/capita, US$ exchange rate",63.2
27505,Norway,2010,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",41.8
27506,Norway,2010,4,C-Cardiovascular system,Million US$ at exchange rate,309.2
27507,Norway,2010,4,C-Cardiovascular system,"Million US$, purchasing power parity",204.2
27508,Norway,2010,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",137.2
27509,Norway,2010,4,C03-Diuretics,Million US$ at exchange rate,16.4
27510,Norway,2010,4,C03-Diuretics,Million of national currency units,99.0
27511,Norway,2010,4,C03-Diuretics,"/capita, US$ exchange rate",3.4
27512,Norway,2010,4,C03-Diuretics,"Million US$, purchasing power parity",10.8
27513,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",88.3
27514,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,808.0
27515,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,133.7
27516,Norway,2010,4,J-Antiinfectives for systemic use,Million of national currency units,1256.0
27517,Norway,2010,4,C02-Antihypertensives,Million US$ at exchange rate,8.9
27518,Norway,2010,4,C-Cardiovascular system,% of total sales,10.4
27519,Norway,2010,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,207.8
27520,Norway,2010,4,C03-Diuretics,% of total sales,0.6
27521,Norway,2010,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
27522,Norway,2010,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,191.3
27523,Norway,2010,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1156.0
27524,Norway,2010,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.1
27525,Norway,2010,4,C08-Calcium channel blockers,Million of national currency units,159.0
27526,Norway,2010,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",49.6
27527,Norway,2010,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.4
27528,Norway,2010,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.4
27529,Norway,2010,4,C08-Calcium channel blockers,Million US$ at exchange rate,26.3
27530,Norway,2010,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",17.4
27531,Norway,2010,4,Products not elsewhere classified,"Million US$, purchasing power parity",481.1
27532,Norway,2010,4,Products not elsewhere classified,"/capita, US$ exchange rate",149.0
27533,Norway,2010,4,Products not elsewhere classified,Million of national currency units,4403.0
27534,Norway,2010,4,Products not elsewhere classified,Million US$ at exchange rate,728.5
27535,Norway,2010,4,J01-Antibacterials for systemic use,Million of national currency units,454.0
27536,Norway,2010,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,75.1
27537,Norway,2010,4,Products not elsewhere classified,"/capita, US$ purchasing power parity",98.4
27538,Norway,2010,4,Products not elsewhere classified,% of total sales,24.6
27539,Norway,2010,4,J-Antiinfectives for systemic use,% of total sales,7.0
27540,Norway,2010,4,N02-Analgesics,Million US$ at exchange rate,197.5
27541,Norway,2010,4,N02-Analgesics,"Million US$, purchasing power parity",130.5
27542,Norway,2010,4,C07-Beta blocking agents,Million US$ at exchange rate,27.8
27543,Norway,2010,4,N02-Analgesics,Million of national currency units,1194.0
27544,Norway,2010,4,N02-Analgesics,% of total sales,6.7
27545,Norway,2010,4,N02-Analgesics,"/capita, US$ exchange rate",40.4
27546,Norway,2010,4,N02-Analgesics,"/capita, US$ purchasing power parity",26.7
27547,Norway,2010,4,J01-Antibacterials for systemic use,% of total sales,2.5
27548,Norway,2010,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.1
27549,Norway,2010,4,C07-Beta blocking agents,"/capita, US$ exchange rate",5.7
27550,Norway,2010,4,C07-Beta blocking agents,"Million US$, purchasing power parity",18.4
27551,Norway,2010,4,C07-Beta blocking agents,% of total sales,0.9
27552,Norway,2010,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.8
27553,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.3
27554,Norway,2010,4,R-Respiratory system,Million US$ at exchange rate,317.2
27555,Norway,2010,4,R-Respiratory system,Million of national currency units,1917.0
27556,Norway,2010,4,R-Respiratory system,"/capita, US$ exchange rate",64.9
27557,Norway,2010,4,R-Respiratory system,"Million US$, purchasing power parity",209.5
27558,Norway,2010,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2
27559,Norway,2010,4,N-Nervous system,"Million US$, purchasing power parity",378.4
27560,Norway,2010,4,C02-Antihypertensives,% of total sales,0.3
27561,Norway,2010,4,N-Nervous system,Million US$ at exchange rate,572.9
27562,Norway,2010,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
27563,Norway,2010,4,A02A-Antacids,"/capita, US$ exchange rate",0.9
27564,Norway,2010,4,A02A-Antacids,% of total sales,0.2
27565,Norway,2010,4,R-Respiratory system,"/capita, US$ purchasing power parity",42.8
27566,Norway,2010,4,N-Nervous system,Million of national currency units,3463.0
27567,Norway,2010,4,A02A-Antacids,"Million US$, purchasing power parity",3.1
27568,Norway,2010,4,R-Respiratory system,% of total sales,10.7
27569,Norway,2010,4,N-Nervous system,"/capita, US$ purchasing power parity",77.4
27570,Norway,2010,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.8
27571,Norway,2010,4,N-Nervous system,% of total sales,19.4
27572,Norway,2010,4,C02-Antihypertensives,"Million US$, purchasing power parity",5.9
27573,Norway,2010,4,N-Nervous system,"/capita, US$ exchange rate",117.2
27574,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,4.5
27575,Norway,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",18.1
27576,Norway,2014,3,M-Musculo-skeletal system,Million US$ at exchange rate,119.7
27577,Norway,2014,3,M-Musculo-skeletal system,"Million US$, purchasing power parity",81.3
27578,Norway,2014,3,N05B-Anxiolytics,% of total sales,0.6
27579,Norway,2014,3,C10-Lipid modifying agents,Million of national currency units,377.0
27580,Norway,2014,3,C10-Lipid modifying agents,Million US$ at exchange rate,59.8
27581,Norway,2014,3,A-Alimentary tract and metabolism,% of total sales,9.8
27582,Norway,2014,3,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.2
27583,Norway,2014,3,G-Genito urinary system and sex hormones,Million of national currency units,1015.0
27584,Norway,2014,3,C02-Antihypertensives,Million of national currency units,74.0
27585,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,59.2
27586,Norway,2014,3,G-Genito urinary system and sex hormones,Million US$ at exchange rate,161.1
27587,Norway,2014,3,M-Musculo-skeletal system,% of total sales,3.6
27588,Norway,2014,3,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.8
27589,Norway,2014,3,C10-Lipid modifying agents,"Million US$, purchasing power parity",40.6
27590,Norway,2014,3,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.3
27591,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
27592,Norway,2014,3,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",222.1
27593,Norway,2014,3,C10-Lipid modifying agents,% of total sales,1.8
27594,Norway,2014,3,N05B-Anxiolytics,"/capita, US$ exchange rate",3.7
27595,Norway,2014,3,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",63.7
27596,Norway,2014,3,M-Musculo-skeletal system,Million of national currency units,754.0
27597,Norway,2014,3,N05B-Anxiolytics,Million US$ at exchange rate,19.2
27598,Norway,2014,3,N05B-Anxiolytics,"Million US$, purchasing power parity",13.0
27599,Norway,2014,3,A-Alimentary tract and metabolism,Million of national currency units,2061.0
27600,Norway,2014,3,A-Alimentary tract and metabolism,Million US$ at exchange rate,327.1
27601,Norway,2014,3,N05B-Anxiolytics,Million of national currency units,121.0
27602,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",7.8
27603,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.8
27604,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",40.2
27605,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",11.5
27606,Norway,2014,3,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.5
27607,Norway,2014,3,C10-Lipid modifying agents,"/capita, US$ exchange rate",11.6
27608,Norway,2014,3,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",7.9
27609,Norway,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.4
27610,Norway,2014,3,N05C-Hypnotics and sedatives,% of total sales,1.0
27611,Norway,2014,3,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",22.7
27612,Norway,2014,3,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.5
27613,Norway,2014,3,B-Blood and blood forming organs,"/capita, US$ exchange rate",51.1
27614,Norway,2014,3,B-Blood and blood forming organs,"Million US$, purchasing power parity",178.3
27615,Norway,2014,3,B-Blood and blood forming organs,% of total sales,7.8
27616,Norway,2014,3,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",34.7
27617,Norway,2014,3,C01A-Cardiac glycosides,% of total sales,0.0
27618,Norway,2014,3,G03-Sex hormones and modulators of the genital system,% of total sales,2.2
27619,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,474.0
27620,Norway,2014,3,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
27621,Norway,2014,3,N05C-Hypnotics and sedatives,Million of national currency units,211.0
27622,Norway,2014,3,N05C-Hypnotics and sedatives,Million US$ at exchange rate,33.5
27623,Norway,2014,3,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
27624,Norway,2014,3,A10-Drugs used in diabetes,Million of national currency units,683.0
27625,Norway,2014,3,G03-Sex hormones and modulators of the genital system,Million of national currency units,471.0
27626,Norway,2014,3,A10-Drugs used in diabetes,"Million US$, purchasing power parity",73.6
27627,Norway,2014,3,A10-Drugs used in diabetes,Million US$ at exchange rate,108.4
27628,Norway,2014,3,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",50.8
27629,Norway,2014,3,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,74.7
27630,Norway,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",9.9
27631,Norway,2014,3,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.5
27632,Norway,2014,3,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
27633,Norway,2014,3,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
27634,Norway,2014,3,B-Blood and blood forming organs,Million US$ at exchange rate,262.5
27635,Norway,2014,3,B-Blood and blood forming organs,Million of national currency units,1654.0
27636,Norway,2014,3,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",14.3
27637,Norway,2014,3,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.1
27638,Norway,2014,3,C01A-Cardiac glycosides,Million of national currency units,5.0
27639,Norway,2014,3,A10-Drugs used in diabetes,% of total sales,3.2
27640,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,33.0
27641,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.2
27642,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,81.9
27643,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,516.0
27644,Norway,2014,3,Total pharmaceutical sales,"Million US$, purchasing power parity",2271.6
27645,Norway,2014,3,Total pharmaceutical sales,Million US$ at exchange rate,3344.7
27646,Norway,2014,3,Total pharmaceutical sales,"/capita, US$ purchasing power parity",442.2
27647,Norway,2014,3,Total pharmaceutical sales,"/capita, US$ exchange rate",651.1
27648,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
27649,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
27650,Norway,2014,3,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,373.0
27651,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
27652,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.9
27653,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",55.6
27654,Norway,2014,3,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",3.6
27655,Norway,2014,3,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.8
27656,Norway,2014,3,N06A-Antidepressants,Million of national currency units,263.0
27657,Norway,2014,3,N06A-Antidepressants,% of total sales,1.2
27658,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,75.2
27659,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",51.1
27660,Norway,2014,3,N06A-Antidepressants,"/capita, US$ purchasing power parity",5.5
27661,Norway,2014,3,N06A-Antidepressants,Million US$ at exchange rate,41.7
27662,Norway,2014,3,N06A-Antidepressants,"Million US$, purchasing power parity",28.3
27663,Norway,2014,3,N06A-Antidepressants,"/capita, US$ exchange rate",8.1
27664,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",14.6
27665,Norway,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",31.4
27666,Norway,2014,3,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.3
27667,Norway,2014,3,Total pharmaceutical sales,Million of national currency units,21077.0
27668,Norway,2014,3,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",109.4
27669,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.9
27670,Norway,2014,3,G-Genito urinary system and sex hormones,% of total sales,4.8
27671,Norway,2014,3,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.2
27672,Norway,2014,3,R03-Drugs for obstructive airway diseases,% of total sales,5.2
27673,Norway,2014,3,A02A-Antacids,Million of national currency units,28.0
27674,Norway,2014,3,A02A-Antacids,Million US$ at exchange rate,4.4
27675,Norway,2014,3,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",118.3
27676,Norway,2014,3,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,174.2
27677,Norway,2014,3,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",197.2
27678,Norway,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.0
27679,Norway,2014,3,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",33.9
27680,Norway,2014,3,C08-Calcium channel blockers,% of total sales,0.6
27681,Norway,2014,3,C-Cardiovascular system,Million of national currency units,1477.0
27682,Norway,2014,3,C07-Beta blocking agents,Million of national currency units,172.0
27683,Norway,2014,3,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.7
27684,Norway,2014,3,C-Cardiovascular system,"/capita, US$ exchange rate",45.6
27685,Norway,2014,3,C-Cardiovascular system,"Million US$, purchasing power parity",159.2
27686,Norway,2014,3,C-Cardiovascular system,Million US$ at exchange rate,234.4
27687,Norway,2014,3,C03-Diuretics,Million US$ at exchange rate,16.7
27688,Norway,2014,3,C03-Diuretics,Million of national currency units,105.0
27689,Norway,2014,3,C03-Diuretics,"/capita, US$ exchange rate",3.2
27690,Norway,2014,3,C03-Diuretics,"Million US$, purchasing power parity",11.3
27691,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,70.3
27692,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",47.7
27693,Norway,2014,3,N-Nervous system,% of total sales,17.8
27694,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,443.0
27695,Norway,2014,3,C-Cardiovascular system,"/capita, US$ purchasing power parity",31.0
27696,Norway,2014,3,C-Cardiovascular system,% of total sales,7.0
27697,Norway,2014,3,J-Antiinfectives for systemic use,Million US$ at exchange rate,290.4
27698,Norway,2014,3,J-Antiinfectives for systemic use,Million of national currency units,1830.0
27699,Norway,2014,3,C03-Diuretics,"/capita, US$ purchasing power parity",2.2
27700,Norway,2014,3,C03-Diuretics,% of total sales,0.5
27701,Norway,2014,3,R03-Drugs for obstructive airway diseases,Million of national currency units,1098.0
27702,Norway,2014,3,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.0
27703,Norway,2014,3,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.5
27704,Norway,2014,3,C08-Calcium channel blockers,Million of national currency units,130.0
27705,Norway,2014,3,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.0
27706,Norway,2014,3,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",48.9
27707,Norway,2014,3,J-Antiinfectives for systemic use,% of total sales,8.7
27708,Norway,2014,3,C08-Calcium channel blockers,"Million US$, purchasing power parity",14.0
27709,Norway,2014,3,C08-Calcium channel blockers,Million US$ at exchange rate,20.6
27710,Norway,2014,3,J01-Antibacterials for systemic use,Million US$ at exchange rate,72.0
27711,Norway,2014,3,Products not elsewhere classified,"Million US$, purchasing power parity",648.2
27712,Norway,2014,3,Products not elsewhere classified,"/capita, US$ exchange rate",185.8
27713,Norway,2014,3,Products not elsewhere classified,Million of national currency units,6014.0
27714,Norway,2014,3,Products not elsewhere classified,Million US$ at exchange rate,954.4
27715,Norway,2014,3,J01-Antibacterials for systemic use,Million of national currency units,454.0
27716,Norway,2014,3,Products not elsewhere classified,"/capita, US$ purchasing power parity",126.2
27717,Norway,2014,3,Products not elsewhere classified,% of total sales,28.5
27718,Norway,2014,3,N02-Analgesics,Million US$ at exchange rate,209.0
27719,Norway,2014,3,C07-Beta blocking agents,Million US$ at exchange rate,27.3
27720,Norway,2014,3,N02-Analgesics,Million of national currency units,1317.0
27721,Norway,2014,3,N02-Analgesics,"Million US$, purchasing power parity",141.9
27722,Norway,2014,3,N02-Analgesics,% of total sales,6.2
27723,Norway,2014,3,N02-Analgesics,"/capita, US$ purchasing power parity",27.6
27724,Norway,2014,3,N02-Analgesics,"/capita, US$ exchange rate",40.7
27725,Norway,2014,3,J01-Antibacterials for systemic use,% of total sales,2.2
27726,Norway,2014,3,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.4
27727,Norway,2014,3,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",56.5
27728,Norway,2014,3,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3
27729,Norway,2014,3,C07-Beta blocking agents,"Million US$, purchasing power parity",18.5
27730,Norway,2014,3,C07-Beta blocking agents,% of total sales,0.8
27731,Norway,2014,3,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.6
27732,Norway,2014,3,R-Respiratory system,Million US$ at exchange rate,317.5
27733,Norway,2014,3,R-Respiratory system,Million of national currency units,2001.0
27734,Norway,2014,3,R-Respiratory system,"Million US$, purchasing power parity",215.7
27735,Norway,2014,3,N-Nervous system,Million of national currency units,3753.0
27736,Norway,2014,3,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.6
27737,Norway,2014,3,N-Nervous system,Million US$ at exchange rate,595.6
27738,Norway,2014,3,C02-Antihypertensives,% of total sales,0.4
27739,Norway,2014,3,R-Respiratory system,"/capita, US$ exchange rate",61.8
27740,Norway,2014,3,A02A-Antacids,"/capita, US$ exchange rate",0.9
27741,Norway,2014,3,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
27742,Norway,2014,3,A02A-Antacids,% of total sales,0.1
27743,Norway,2014,3,R-Respiratory system,"/capita, US$ purchasing power parity",42.0
27744,Norway,2014,3,A02A-Antacids,"Million US$, purchasing power parity",3.0
27745,Norway,2014,3,R-Respiratory system,% of total sales,9.5
27746,Norway,2014,3,N-Nervous system,"/capita, US$ purchasing power parity",78.7
27747,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",13.7
27748,Norway,2014,3,N-Nervous system,"/capita, US$ exchange rate",115.9
27749,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.1
27750,Norway,2014,3,C02-Antihypertensives,"Million US$, purchasing power parity",8.0
27751,Norway,2014,3,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
27752,Norway,2014,3,N-Nervous system,"Million US$, purchasing power parity",404.5
27753,Norway,2014,3,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",9.3
27754,Norway,2014,3,C02-Antihypertensives,Million US$ at exchange rate,11.7
27755,Portugal,2011,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
27756,Portugal,2011,9,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3
27757,Portugal,2011,9,C01A-Cardiac glycosides,Million of national currency units,0.9
27758,Portugal,2011,9,C02-Antihypertensives,"Million US$, purchasing power parity",6.6
27759,Portugal,2011,9,R-Respiratory system,% of total sales,7.3
27760,Portugal,2011,9,C02-Antihypertensives,% of total sales,0.1
27761,Portugal,2011,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
27762,Portugal,2011,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
27763,Portugal,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.2
27764,Portugal,2011,9,G-Genito urinary system and sex hormones,% of total sales,5.9
27765,Portugal,2011,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.9
27766,Portugal,2011,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.7
27767,Portugal,2011,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",276.6
27768,Portugal,2011,9,C01A-Cardiac glycosides,% of total sales,0.0
27769,Portugal,2011,9,R-Respiratory system,"/capita, US$ purchasing power parity",32.4
27770,Portugal,2011,9,A02A-Antacids,% of total sales,0.2
27771,Portugal,2011,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
27772,Portugal,2011,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
27773,Portugal,2011,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",169.6
27774,Portugal,2011,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.1
27775,Portugal,2011,9,B-Blood and blood forming organs,% of total sales,3.6
27776,Portugal,2011,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.9
27777,Portugal,2011,9,C07-Beta blocking agents,"/capita, US$ exchange rate",4.1
27778,Portugal,2011,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
27779,Portugal,2011,9,C07-Beta blocking agents,% of total sales,1.1
27780,Portugal,2011,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.8
27781,Portugal,2011,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
27782,Portugal,2011,9,C02-Antihypertensives,Million of national currency units,4.1
27783,Portugal,2011,9,C07-Beta blocking agents,"Million US$, purchasing power parity",50.3
27784,Portugal,2011,9,Products not elsewhere classified,% of total sales,0.0
27785,Portugal,2011,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
27786,Portugal,2011,9,A-Alimentary tract and metabolism,Million of national currency units,455.8
27787,Portugal,2011,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,634.4
27788,Portugal,2011,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",731.5
27789,Portugal,2011,9,R-Respiratory system,Million US$ at exchange rate,297.0
27790,Portugal,2011,9,B-Blood and blood forming organs,Million of national currency units,105.7
27791,Portugal,2011,9,C07-Beta blocking agents,Million of national currency units,31.4
27792,Portugal,2011,9,R-Respiratory system,Million of national currency units,213.4
27793,Portugal,2011,9,B-Blood and blood forming organs,Million US$ at exchange rate,147.1
27794,Portugal,2011,9,R-Respiratory system,"/capita, US$ exchange rate",28.1
27795,Portugal,2011,9,R-Respiratory system,"Million US$, purchasing power parity",342.5
27796,Portugal,2011,9,Products not elsewhere classified,Million of national currency units,0.0
27797,Portugal,2011,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.1
27798,Portugal,2011,9,C02-Antihypertensives,Million US$ at exchange rate,5.8
27799,Portugal,2011,9,Products not elsewhere classified,Million US$ at exchange rate,0.0
27800,Portugal,2011,9,C07-Beta blocking agents,Million US$ at exchange rate,43.6
27801,Portugal,2011,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",69.3
27802,Portugal,2011,9,A-Alimentary tract and metabolism,% of total sales,15.5
27803,Portugal,2011,9,C-Cardiovascular system,"Million US$, purchasing power parity",1254.5
27804,Portugal,2011,9,Total pharmaceutical sales,"/capita, US$ exchange rate",388.0
27805,Portugal,2011,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",447.3
27806,Portugal,2011,9,C-Cardiovascular system,% of total sales,26.6
27807,Portugal,2011,9,C-Cardiovascular system,"/capita, US$ exchange rate",103.1
27808,Portugal,2011,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",118.8
27809,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",56.9
27810,Portugal,2011,9,C-Cardiovascular system,Million of national currency units,781.6
27811,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,12.7
27812,Portugal,2011,9,Total pharmaceutical sales,Million US$ at exchange rate,4096.0
27813,Portugal,2011,9,Total pharmaceutical sales,"Million US$, purchasing power parity",4722.6
27814,Portugal,2011,9,C-Cardiovascular system,Million US$ at exchange rate,1088.0
27815,Portugal,2011,9,Total pharmaceutical sales,Million of national currency units,2942.6
27816,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
27817,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.9
27818,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.9
27819,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
27820,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,521.2
27821,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,374.4
27822,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
27823,Portugal,2011,9,C03-Diuretics,"/capita, US$ exchange rate",3.3
27824,Portugal,2011,9,C03-Diuretics,"Million US$, purchasing power parity",39.9
27825,Portugal,2011,9,C03-Diuretics,% of total sales,0.8
27826,Portugal,2011,9,C03-Diuretics,"/capita, US$ purchasing power parity",3.8
27827,Portugal,2011,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.3
27828,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",600.9
27829,Portugal,2011,9,C03-Diuretics,Million US$ at exchange rate,34.6
27830,Portugal,2011,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",49.4
27831,Portugal,2011,9,C03-Diuretics,Million of national currency units,24.9
27832,Portugal,2011,9,A02A-Antacids,Million of national currency units,6.0
27833,Portugal,2011,9,C10-Lipid modifying agents,Million of national currency units,202.3
27834,Portugal,2011,9,N06A-Antidepressants,Million of national currency units,140.4
27835,Portugal,2011,9,A02A-Antacids,"Million US$, purchasing power parity",9.7
27836,Portugal,2011,9,A02A-Antacids,Million US$ at exchange rate,8.4
27837,Portugal,2011,9,N06A-Antidepressants,"/capita, US$ exchange rate",18.5
27838,Portugal,2011,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",21.3
27839,Portugal,2011,9,N06A-Antidepressants,Million US$ at exchange rate,195.4
27840,Portugal,2011,9,N06A-Antidepressants,"Million US$, purchasing power parity",225.3
27841,Portugal,2011,9,C08-Calcium channel blockers,Million US$ at exchange rate,61.8
27842,Portugal,2011,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",71.2
27843,Portugal,2011,9,A02A-Antacids,"/capita, US$ exchange rate",0.8
27844,Portugal,2011,9,C08-Calcium channel blockers,Million of national currency units,44.4
27845,Portugal,2011,9,C08-Calcium channel blockers,% of total sales,1.5
27846,Portugal,2011,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.7
27847,Portugal,2011,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.9
27848,Portugal,2011,9,G-Genito urinary system and sex hormones,Million of national currency units,172.4
27849,Portugal,2011,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,183.9
27850,Portugal,2011,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,239.9
27851,Portugal,2011,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",212.0
27852,Portugal,2011,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.8
27853,Portugal,2011,9,C10-Lipid modifying agents,% of total sales,6.9
27854,Portugal,2011,9,R03-Drugs for obstructive airway diseases,Million of national currency units,132.1
27855,Portugal,2011,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",26.7
27856,Portugal,2011,9,C10-Lipid modifying agents,Million US$ at exchange rate,281.6
27857,Portugal,2011,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",324.7
27858,Portugal,2011,9,N06A-Antidepressants,% of total sales,4.8
27859,Portugal,2011,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",17.4
27860,Portugal,2011,9,R03-Drugs for obstructive airway diseases,% of total sales,4.5
27861,Portugal,2011,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.1
27862,Portugal,2011,9,N02-Analgesics,% of total sales,3.7
27863,Portugal,2011,9,J01-Antibacterials for systemic use,Million of national currency units,91.4
27864,Portugal,2011,9,N-Nervous system,"/capita, US$ exchange rate",85.1
27865,Portugal,2011,9,N02-Analgesics,"/capita, US$ exchange rate",14.3
27866,Portugal,2011,9,N02-Analgesics,"/capita, US$ purchasing power parity",16.4
27867,Portugal,2011,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,127.2
27868,Portugal,2011,9,N05B-Anxiolytics,Million US$ at exchange rate,80.1
27869,Portugal,2011,9,N05B-Anxiolytics,"Million US$, purchasing power parity",92.4
27870,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,112.3
27871,Portugal,2011,9,N05B-Anxiolytics,Million of national currency units,57.6
27872,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8
27873,Portugal,2011,9,N-Nervous system,"Million US$, purchasing power parity",1035.5
27874,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.2
27875,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.8
27876,Portugal,2011,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.3
27877,Portugal,2011,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",33.8
27878,Portugal,2011,9,A10-Drugs used in diabetes,% of total sales,7.6
27879,Portugal,2011,9,J-Antiinfectives for systemic use,Million of national currency units,163.6
27880,Portugal,2011,9,N-Nervous system,Million of national currency units,645.2
27881,Portugal,2011,9,N-Nervous system,Million US$ at exchange rate,898.1
27882,Portugal,2011,9,N02-Analgesics,Million of national currency units,108.1
27883,Portugal,2011,9,N02-Analgesics,Million US$ at exchange rate,150.5
27884,Portugal,2011,9,N02-Analgesics,"Million US$, purchasing power parity",173.5
27885,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,156.3
27886,Portugal,2011,9,N-Nervous system,"/capita, US$ purchasing power parity",98.1
27887,Portugal,2011,9,N-Nervous system,% of total sales,21.9
27888,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.4
27889,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",199.9
27890,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",17.1
27891,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",180.2
27892,Portugal,2011,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",14.8
27893,Portugal,2011,9,J01-Antibacterials for systemic use,% of total sales,3.1
27894,Portugal,2011,9,N05B-Anxiolytics,% of total sales,2.0
27895,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",18.9
27896,Portugal,2011,9,N05B-Anxiolytics,"/capita, US$ exchange rate",7.6
27897,Portugal,2011,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.8
27898,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.7
27899,Portugal,2011,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",13.9
27900,Portugal,2011,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",146.6
27901,Portugal,2011,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.0
27902,Portugal,2011,9,M-Musculo-skeletal system,Million of national currency units,226.7
27903,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.0
27904,Portugal,2011,9,M-Musculo-skeletal system,Million US$ at exchange rate,315.5
27905,Portugal,2011,9,N05C-Hypnotics and sedatives,% of total sales,0.6
27906,Portugal,2011,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",262.5
27907,Portugal,2011,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,227.7
27908,Portugal,2011,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",28.5
27909,Portugal,2011,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.7
27910,Portugal,2011,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.7
27911,Portugal,2011,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.3
27912,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.5
27913,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,173.4
27914,Portugal,2011,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,124.6
27915,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,22.7
27916,Portugal,2011,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",21.6
27917,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",36.5
27918,Portugal,2011,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",356.8
27919,Portugal,2011,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,31.7
27920,Portugal,2011,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",363.8
27921,Portugal,2011,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",34.5
27922,Portugal,2011,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.9
27923,Portugal,2011,9,A10-Drugs used in diabetes,Million US$ at exchange rate,309.5
27924,Portugal,2011,9,A10-Drugs used in diabetes,Million of national currency units,222.3
27925,Portugal,2011,9,M-Musculo-skeletal system,% of total sales,7.7
27926,Portugal,2011,9,J-Antiinfectives for systemic use,% of total sales,5.6
27927,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.9
27928,Portugal,2011,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",29.9
27929,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,108.9
27930,Portugal,2011,9,N05C-Hypnotics and sedatives,Million of national currency units,17.8
27931,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,78.3
27932,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.3
27933,Portugal,2011,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",125.6
27934,Portugal,2012,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
27935,Portugal,2012,9,C01A-Cardiac glycosides,Million of national currency units,0.9
27936,Portugal,2012,9,C01A-Cardiac glycosides,Million US$ at exchange rate,1.1
27937,Portugal,2012,9,C02-Antihypertensives,"Million US$, purchasing power parity",6.4
27938,Portugal,2012,9,R-Respiratory system,"/capita, US$ purchasing power parity",33.7
27939,Portugal,2012,9,R-Respiratory system,% of total sales,8.2
27940,Portugal,2012,9,C02-Antihypertensives,% of total sales,0.1
27941,Portugal,2012,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
27942,Portugal,2012,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
27943,Portugal,2012,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.0
27944,Portugal,2012,9,G-Genito urinary system and sex hormones,% of total sales,6.1
27945,Portugal,2012,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.4
27946,Portugal,2012,9,A02A-Antacids,"/capita, US$ purchasing power parity",1.0
27947,Portugal,2012,9,C01A-Cardiac glycosides,% of total sales,0.0
27948,Portugal,2012,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",262.9
27949,Portugal,2012,9,A02A-Antacids,% of total sales,0.2
27950,Portugal,2012,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
27951,Portugal,2012,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
27952,Portugal,2012,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",144.4
27953,Portugal,2012,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.7
27954,Portugal,2012,9,B-Blood and blood forming organs,% of total sales,3.3
27955,Portugal,2012,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",10.7
27956,Portugal,2012,9,C07-Beta blocking agents,"/capita, US$ exchange rate",3.6
27957,Portugal,2012,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
27958,Portugal,2012,9,C07-Beta blocking agents,% of total sales,1.1
27959,Portugal,2012,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.6
27960,Portugal,2012,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
27961,Portugal,2012,9,C02-Antihypertensives,Million of national currency units,3.9
27962,Portugal,2012,9,C07-Beta blocking agents,"Million US$, purchasing power parity",48.6
27963,Portugal,2012,9,Products not elsewhere classified,% of total sales,0.0
27964,Portugal,2012,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
27965,Portugal,2012,9,A-Alimentary tract and metabolism,Million of national currency units,400.8
27966,Portugal,2012,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",662.1
27967,Portugal,2012,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,515.0
27968,Portugal,2012,9,R-Respiratory system,Million US$ at exchange rate,275.9
27969,Portugal,2012,9,B-Blood and blood forming organs,Million of national currency units,87.4
27970,Portugal,2012,9,C07-Beta blocking agents,Million of national currency units,29.4
27971,Portugal,2012,9,R-Respiratory system,Million of national currency units,214.8
27972,Portugal,2012,9,B-Blood and blood forming organs,Million US$ at exchange rate,112.3
27973,Portugal,2012,9,R-Respiratory system,"/capita, US$ exchange rate",26.2
27974,Portugal,2012,9,R-Respiratory system,"Million US$, purchasing power parity",354.8
27975,Portugal,2012,9,Products not elsewhere classified,Million of national currency units,0.0
27976,Portugal,2012,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.0
27977,Portugal,2012,9,C02-Antihypertensives,Million US$ at exchange rate,5.0
27978,Portugal,2012,9,Products not elsewhere classified,Million US$ at exchange rate,0.0
27979,Portugal,2012,9,C07-Beta blocking agents,Million US$ at exchange rate,37.8
27980,Portugal,2012,9,A-Alimentary tract and metabolism,% of total sales,15.3
27981,Portugal,2012,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",63.0
27982,Portugal,2012,9,C-Cardiovascular system,"Million US$, purchasing power parity",1104.8
27983,Portugal,2012,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",410.6
27984,Portugal,2012,9,Total pharmaceutical sales,"/capita, US$ exchange rate",319.4
27985,Portugal,2012,9,C-Cardiovascular system,% of total sales,25.6
27986,Portugal,2012,9,C-Cardiovascular system,"/capita, US$ exchange rate",81.7
27987,Portugal,2012,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",105.1
27988,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",50.3
27989,Portugal,2012,9,C-Cardiovascular system,Million of national currency units,668.8
27990,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,12.3
27991,Portugal,2012,9,Total pharmaceutical sales,Million US$ at exchange rate,3358.4
27992,Portugal,2012,9,Total pharmaceutical sales,"Million US$, purchasing power parity",4317.7
27993,Portugal,2012,9,C-Cardiovascular system,Million US$ at exchange rate,859.3
27994,Portugal,2012,9,Total pharmaceutical sales,Million of national currency units,2614.0
27995,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
27996,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.3
27997,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.9
27998,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
27999,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
28000,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,411.4
28001,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,320.2
28002,Portugal,2012,9,C03-Diuretics,"/capita, US$ exchange rate",2.9
28003,Portugal,2012,9,C03-Diuretics,"Million US$, purchasing power parity",39.3
28004,Portugal,2012,9,C03-Diuretics,% of total sales,0.9
28005,Portugal,2012,9,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
28006,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",529.0
28007,Portugal,2012,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.2
28008,Portugal,2012,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",39.1
28009,Portugal,2012,9,C03-Diuretics,Million US$ at exchange rate,30.6
28010,Portugal,2012,9,C03-Diuretics,Million of national currency units,23.8
28011,Portugal,2012,9,A02A-Antacids,Million of national currency units,6.1
28012,Portugal,2012,9,C10-Lipid modifying agents,Million of national currency units,163.9
28013,Portugal,2012,9,N06A-Antidepressants,Million of national currency units,116.6
28014,Portugal,2012,9,A02A-Antacids,"Million US$, purchasing power parity",10.0
28015,Portugal,2012,9,A02A-Antacids,Million US$ at exchange rate,7.8
28016,Portugal,2012,9,N06A-Antidepressants,"/capita, US$ exchange rate",14.3
28017,Portugal,2012,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",18.3
28018,Portugal,2012,9,N06A-Antidepressants,Million US$ at exchange rate,149.9
28019,Portugal,2012,9,N06A-Antidepressants,"Million US$, purchasing power parity",192.7
28020,Portugal,2012,9,C08-Calcium channel blockers,Million US$ at exchange rate,45.1
28021,Portugal,2012,9,A02A-Antacids,"/capita, US$ exchange rate",0.7
28022,Portugal,2012,9,C08-Calcium channel blockers,Million of national currency units,35.1
28023,Portugal,2012,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",58.0
28024,Portugal,2012,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.5
28025,Portugal,2012,9,C08-Calcium channel blockers,% of total sales,1.3
28026,Portugal,2012,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3
28027,Portugal,2012,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,167.9
28028,Portugal,2012,9,G-Genito urinary system and sex hormones,Million of national currency units,159.2
28029,Portugal,2012,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",270.7
28030,Portugal,2012,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,204.5
28031,Portugal,2012,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.7
28032,Portugal,2012,9,C10-Lipid modifying agents,% of total sales,6.3
28033,Portugal,2012,9,R03-Drugs for obstructive airway diseases,Million of national currency units,130.7
28034,Portugal,2012,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.0
28035,Portugal,2012,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",215.9
28036,Portugal,2012,9,C10-Lipid modifying agents,Million US$ at exchange rate,210.6
28037,Portugal,2012,9,N06A-Antidepressants,% of total sales,4.5
28038,Portugal,2012,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",16.0
28039,Portugal,2012,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.5
28040,Portugal,2012,9,R03-Drugs for obstructive airway diseases,% of total sales,5.0
28041,Portugal,2012,9,N02-Analgesics,% of total sales,4.3
28042,Portugal,2012,9,J01-Antibacterials for systemic use,Million of national currency units,75.9
28043,Portugal,2012,9,N02-Analgesics,"/capita, US$ exchange rate",13.7
28044,Portugal,2012,9,N02-Analgesics,"/capita, US$ purchasing power parity",17.6
28045,Portugal,2012,9,N05B-Anxiolytics,Million US$ at exchange rate,72.1
28046,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,105.0
28047,Portugal,2012,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,97.5
28048,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8
28049,Portugal,2012,9,N05B-Anxiolytics,Million of national currency units,56.1
28050,Portugal,2012,9,N-Nervous system,"Million US$, purchasing power parity",944.4
28051,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
28052,Portugal,2012,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",27.4
28053,Portugal,2012,9,J-Antiinfectives for systemic use,Million of national currency units,130.0
28054,Portugal,2012,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",35.2
28055,Portugal,2012,9,A10-Drugs used in diabetes,% of total sales,8.6
28056,Portugal,2012,9,N-Nervous system,Million of national currency units,571.7
28057,Portugal,2012,9,N-Nervous system,Million US$ at exchange rate,734.5
28058,Portugal,2012,9,N02-Analgesics,Million of national currency units,111.8
28059,Portugal,2012,9,N02-Analgesics,Million US$ at exchange rate,143.7
28060,Portugal,2012,9,N02-Analgesics,"Million US$, purchasing power parity",184.7
28061,Portugal,2012,9,N-Nervous system,"/capita, US$ exchange rate",69.9
28062,Portugal,2012,9,N-Nervous system,"/capita, US$ purchasing power parity",89.8
28063,Portugal,2012,9,N-Nervous system,% of total sales,21.9
28064,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.2
28065,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",110.5
28066,Portugal,2012,9,J01-Antibacterials for systemic use,% of total sales,2.9
28067,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.5
28068,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.8
28069,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",173.5
28070,Portugal,2012,9,N05B-Anxiolytics,% of total sales,2.1
28071,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.5
28072,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,135.0
28073,Portugal,2012,9,N05B-Anxiolytics,"Million US$, purchasing power parity",92.7
28074,Portugal,2012,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.8
28075,Portugal,2012,9,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9
28076,Portugal,2012,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9
28077,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.9
28078,Portugal,2012,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",125.3
28079,Portugal,2012,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.3
28080,Portugal,2012,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.0
28081,Portugal,2012,9,M-Musculo-skeletal system,Million US$ at exchange rate,262.5
28082,Portugal,2012,9,N05C-Hypnotics and sedatives,% of total sales,0.7
28083,Portugal,2012,9,M-Musculo-skeletal system,Million of national currency units,204.3
28084,Portugal,2012,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,167.0
28085,Portugal,2012,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",30.9
28086,Portugal,2012,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.0
28087,Portugal,2012,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.9
28088,Portugal,2012,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.3
28089,Portugal,2012,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",214.7
28090,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.5
28091,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,86.0
28092,Portugal,2012,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,66.9
28093,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.2
28094,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,20.6
28095,Portugal,2012,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.9
28096,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",34.1
28097,Portugal,2012,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",370.4
28098,Portugal,2012,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,26.5
28099,Portugal,2012,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",32.1
28100,Portugal,2012,9,A10-Drugs used in diabetes,Million US$ at exchange rate,288.1
28101,Portugal,2012,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.4
28102,Portugal,2012,9,A10-Drugs used in diabetes,Million of national currency units,224.2
28103,Portugal,2012,9,M-Musculo-skeletal system,% of total sales,7.8
28104,Portugal,2012,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",25.0
28105,Portugal,2012,9,J-Antiinfectives for systemic use,% of total sales,5.0
28106,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.7
28107,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,95.9
28108,Portugal,2012,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",337.5
28109,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,74.7
28110,Portugal,2012,9,N05C-Hypnotics and sedatives,Million of national currency units,18.7
28111,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",9.1
28112,Portugal,2012,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",123.3
28113,Portugal,2013,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
28114,Portugal,2013,8,C01A-Cardiac glycosides,Million of national currency units,0.8
28115,Portugal,2013,8,C01A-Cardiac glycosides,Million US$ at exchange rate,1.1
28116,Portugal,2013,8,C02-Antihypertensives,Million US$ at exchange rate,4.8
28117,Portugal,2013,8,C02-Antihypertensives,"Million US$, purchasing power parity",6.1
28118,Portugal,2013,8,R-Respiratory system,"/capita, US$ purchasing power parity",33.1
28119,Portugal,2013,8,R-Respiratory system,% of total sales,8.4
28120,Portugal,2013,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
28121,Portugal,2013,8,C02-Antihypertensives,% of total sales,0.1
28122,Portugal,2013,8,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
28123,Portugal,2013,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",24.5
28124,Portugal,2013,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.0
28125,Portugal,2013,8,G-Genito urinary system and sex hormones,% of total sales,6.2
28126,Portugal,2013,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
28127,Portugal,2013,8,C01A-Cardiac glycosides,% of total sales,0.0
28128,Portugal,2013,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",255.8
28129,Portugal,2013,8,A02A-Antacids,% of total sales,0.2
28130,Portugal,2013,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
28131,Portugal,2013,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
28132,Portugal,2013,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",15.0
28133,Portugal,2013,8,B-Blood and blood forming organs,% of total sales,3.8
28134,Portugal,2013,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",157.3
28135,Portugal,2013,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",11.7
28136,Portugal,2013,8,C07-Beta blocking agents,"/capita, US$ exchange rate",3.8
28137,Portugal,2013,8,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
28138,Portugal,2013,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.9
28139,Portugal,2013,8,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
28140,Portugal,2013,8,C02-Antihypertensives,Million of national currency units,3.6
28141,Portugal,2013,8,C07-Beta blocking agents,"Million US$, purchasing power parity",51.6
28142,Portugal,2013,8,C07-Beta blocking agents,% of total sales,1.2
28143,Portugal,2013,8,Products not elsewhere classified,% of total sales,0.0
28144,Portugal,2013,8,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
28145,Portugal,2013,8,A-Alimentary tract and metabolism,Million of national currency units,396.1
28146,Portugal,2013,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",678.6
28147,Portugal,2013,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,526.0
28148,Portugal,2013,8,R-Respiratory system,Million US$ at exchange rate,268.2
28149,Portugal,2013,8,B-Blood and blood forming organs,Million of national currency units,91.8
28150,Portugal,2013,8,C07-Beta blocking agents,Million of national currency units,30.1
28151,Portugal,2013,8,R-Respiratory system,Million of national currency units,201.9
28152,Portugal,2013,8,B-Blood and blood forming organs,Million US$ at exchange rate,121.9
28153,Portugal,2013,8,R-Respiratory system,"/capita, US$ exchange rate",25.6
28154,Portugal,2013,8,R-Respiratory system,"Million US$, purchasing power parity",346.0
28155,Portugal,2013,8,Products not elsewhere classified,Million of national currency units,0.0
28156,Portugal,2013,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",50.3
28157,Portugal,2013,8,Products not elsewhere classified,Million US$ at exchange rate,0.0
28158,Portugal,2013,8,C07-Beta blocking agents,Million US$ at exchange rate,40.0
28159,Portugal,2013,8,A-Alimentary tract and metabolism,% of total sales,16.4
28160,Portugal,2013,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",64.9
28161,Portugal,2013,8,C-Cardiovascular system,"Million US$, purchasing power parity",1013.0
28162,Portugal,2013,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",394.8
28163,Portugal,2013,8,Total pharmaceutical sales,"/capita, US$ exchange rate",306.0
28164,Portugal,2013,8,C-Cardiovascular system,% of total sales,24.5
28165,Portugal,2013,8,C-Cardiovascular system,"/capita, US$ exchange rate",75.1
28166,Portugal,2013,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",96.9
28167,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",44.0
28168,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",34.1
28169,Portugal,2013,8,C-Cardiovascular system,Million of national currency units,591.2
28170,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,11.1
28171,Portugal,2013,8,Total pharmaceutical sales,Million US$ at exchange rate,3200.1
28172,Portugal,2013,8,Total pharmaceutical sales,"Million US$, purchasing power parity",4128.6
28173,Portugal,2013,8,C-Cardiovascular system,Million US$ at exchange rate,785.2
28174,Portugal,2013,8,Total pharmaceutical sales,Million of national currency units,2409.5
28175,Portugal,2013,8,C03-Diuretics,% of total sales,0.9
28176,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
28177,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.6
28178,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.1
28179,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
28180,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,356.4
28181,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
28182,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,268.4
28183,Portugal,2013,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.8
28184,Portugal,2013,8,C03-Diuretics,"/capita, US$ exchange rate",2.9
28185,Portugal,2013,8,C03-Diuretics,"Million US$, purchasing power parity",38.8
28186,Portugal,2013,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
28187,Portugal,2013,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",459.8
28188,Portugal,2013,8,C03-Diuretics,Million US$ at exchange rate,30.0
28189,Portugal,2013,8,C03-Diuretics,Million of national currency units,22.6
28190,Portugal,2013,8,A02A-Antacids,Million of national currency units,5.1
28191,Portugal,2013,8,C10-Lipid modifying agents,Million of national currency units,153.4
28192,Portugal,2013,8,N06A-Antidepressants,Million of national currency units,97.7
28193,Portugal,2013,8,A02A-Antacids,"Million US$, purchasing power parity",8.8
28194,Portugal,2013,8,A02A-Antacids,Million US$ at exchange rate,6.8
28195,Portugal,2013,8,N06A-Antidepressants,"/capita, US$ exchange rate",12.4
28196,Portugal,2013,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.0
28197,Portugal,2013,8,N06A-Antidepressants,Million US$ at exchange rate,129.8
28198,Portugal,2013,8,N06A-Antidepressants,"Million US$, purchasing power parity",167.4
28199,Portugal,2013,8,C08-Calcium channel blockers,Million US$ at exchange rate,38.9
28200,Portugal,2013,8,C08-Calcium channel blockers,Million of national currency units,29.3
28201,Portugal,2013,8,A02A-Antacids,"/capita, US$ exchange rate",0.7
28202,Portugal,2013,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.8
28203,Portugal,2013,8,C08-Calcium channel blockers,% of total sales,1.2
28204,Portugal,2013,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",50.2
28205,Portugal,2013,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.7
28206,Portugal,2013,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,165.1
28207,Portugal,2013,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",262.8
28208,Portugal,2013,8,G-Genito urinary system and sex hormones,Million of national currency units,149.3
28209,Portugal,2013,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,198.3
28210,Portugal,2013,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",25.1
28211,Portugal,2013,8,C10-Lipid modifying agents,% of total sales,6.4
28212,Portugal,2013,8,R03-Drugs for obstructive airway diseases,Million of national currency units,124.3
28213,Portugal,2013,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",19.5
28214,Portugal,2013,8,C10-Lipid modifying agents,Million US$ at exchange rate,203.7
28215,Portugal,2013,8,N06A-Antidepressants,% of total sales,4.1
28216,Portugal,2013,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",212.9
28217,Portugal,2013,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",15.8
28218,Portugal,2013,8,R03-Drugs for obstructive airway diseases,% of total sales,5.2
28219,Portugal,2013,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.4
28220,Portugal,2013,8,N02-Analgesics,% of total sales,4.5
28221,Portugal,2013,8,J01-Antibacterials for systemic use,Million of national currency units,68.6
28222,Portugal,2013,8,N02-Analgesics,"/capita, US$ exchange rate",13.8
28223,Portugal,2013,8,N02-Analgesics,"/capita, US$ purchasing power parity",17.8
28224,Portugal,2013,8,N-Nervous system,"Million US$, purchasing power parity",877.7
28225,Portugal,2013,8,N05B-Anxiolytics,Million US$ at exchange rate,71.8
28226,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,99.8
28227,Portugal,2013,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,91.1
28228,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.8
28229,Portugal,2013,8,N05B-Anxiolytics,Million of national currency units,54.1
28230,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
28231,Portugal,2013,8,J-Antiinfectives for systemic use,Million of national currency units,116.1
28232,Portugal,2013,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.0
28233,Portugal,2013,8,A10-Drugs used in diabetes,% of total sales,9.5
28234,Portugal,2013,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.4
28235,Portugal,2013,8,N-Nervous system,Million of national currency units,512.2
28236,Portugal,2013,8,N-Nervous system,Million US$ at exchange rate,680.3
28237,Portugal,2013,8,N02-Analgesics,Million of national currency units,108.8
28238,Portugal,2013,8,N02-Analgesics,"Million US$, purchasing power parity",186.5
28239,Portugal,2013,8,N02-Analgesics,Million US$ at exchange rate,144.5
28240,Portugal,2013,8,N-Nervous system,"/capita, US$ exchange rate",65.1
28241,Portugal,2013,8,N-Nervous system,"/capita, US$ purchasing power parity",83.9
28242,Portugal,2013,8,N-Nervous system,% of total sales,21.3
28243,Portugal,2013,8,J01-Antibacterials for systemic use,% of total sales,2.8
28244,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.9
28245,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",107.2
28246,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.1
28247,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.4
28248,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",171.0
28249,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.7
28250,Portugal,2013,8,N05B-Anxiolytics,% of total sales,2.2
28251,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.3
28252,Portugal,2013,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,132.6
28253,Portugal,2013,8,N05B-Anxiolytics,"Million US$, purchasing power parity",92.6
28254,Portugal,2013,8,N05B-Anxiolytics,"/capita, US$ exchange rate",6.9
28255,Portugal,2013,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.9
28256,Portugal,2013,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
28257,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.8
28258,Portugal,2013,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",117.5
28259,Portugal,2013,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.7
28260,Portugal,2013,8,N05C-Hypnotics and sedatives,% of total sales,0.8
28261,Portugal,2013,8,M-Musculo-skeletal system,Million US$ at exchange rate,245.5
28262,Portugal,2013,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,154.2
28263,Portugal,2013,8,M-Musculo-skeletal system,Million of national currency units,184.9
28264,Portugal,2013,8,A10-Drugs used in diabetes,Million US$ at exchange rate,303.4
28265,Portugal,2013,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",34.5
28266,Portugal,2013,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,26.7
28267,Portugal,2013,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.3
28268,Portugal,2013,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.6
28269,Portugal,2013,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",198.9
28270,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.5
28271,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,83.1
28272,Portugal,2013,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,62.6
28273,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.3
28274,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,20.0
28275,Portugal,2013,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.7
28276,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",34.3
28277,Portugal,2013,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",391.4
28278,Portugal,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,26.6
28279,Portugal,2013,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",30.3
28280,Portugal,2013,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",23.5
28281,Portugal,2013,8,A10-Drugs used in diabetes,Million of national currency units,228.4
28282,Portugal,2013,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.0
28283,Portugal,2013,8,M-Musculo-skeletal system,% of total sales,7.7
28284,Portugal,2013,8,J-Antiinfectives for systemic use,% of total sales,4.8
28285,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.0
28286,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,88.9
28287,Portugal,2013,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",316.7
28288,Portugal,2013,8,N05C-Hypnotics and sedatives,Million of national currency units,20.1
28289,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,66.9
28290,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.5
28291,Portugal,2013,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",114.6
28292,Portugal,2017,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.8
28293,Portugal,2017,8,C01A-Cardiac glycosides,Million of national currency units,0.7
28294,Portugal,2017,8,C02-Antihypertensives,% of total sales,0.1
28295,Portugal,2017,8,C02-Antihypertensives,Million US$ at exchange rate,3.5
28296,Portugal,2017,8,R-Respiratory system,"/capita, US$ purchasing power parity",37.5
28297,Portugal,2017,8,R-Respiratory system,% of total sales,8.7
28298,Portugal,2017,8,C02-Antihypertensives,"Million US$, purchasing power parity",5.4
28299,Portugal,2017,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5
28300,Portugal,2017,8,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
28301,Portugal,2017,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.8
28302,Portugal,2017,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.4
28303,Portugal,2017,8,G-Genito urinary system and sex hormones,% of total sales,6.2
28304,Portugal,2017,8,B-Blood and blood forming organs,% of total sales,7.5
28305,Portugal,2017,8,C01A-Cardiac glycosides,% of total sales,0.0
28306,Portugal,2017,8,A02A-Antacids,"/capita, US$ purchasing power parity",1.0
28307,Portugal,2017,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",276.2
28308,Portugal,2017,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
28309,Portugal,2017,8,A02A-Antacids,% of total sales,0.2
28310,Portugal,2017,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
28311,Portugal,2017,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",32.4
28312,Portugal,2017,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",333.6
28313,Portugal,2017,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.1
28314,Portugal,2017,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.3
28315,Portugal,2017,8,C07-Beta blocking agents,"/capita, US$ exchange rate",3.6
28316,Portugal,2017,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5
28317,Portugal,2017,8,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
28318,Portugal,2017,8,C02-Antihypertensives,Million of national currency units,3.1
28319,Portugal,2017,8,C07-Beta blocking agents,Million US$ at exchange rate,37.0
28320,Portugal,2017,8,C07-Beta blocking agents,"Million US$, purchasing power parity",56.9
28321,Portugal,2017,8,Products not elsewhere classified,% of total sales,0.0
28322,Portugal,2017,8,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
28323,Portugal,2017,8,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
28324,Portugal,2017,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",830.4
28325,Portugal,2017,8,A-Alimentary tract and metabolism,Million of national currency units,478.0
28326,Portugal,2017,8,C07-Beta blocking agents,% of total sales,1.3
28327,Portugal,2017,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,540.0
28328,Portugal,2017,8,B-Blood and blood forming organs,Million of national currency units,192.1
28329,Portugal,2017,8,R-Respiratory system,Million of national currency units,222.4
28330,Portugal,2017,8,R-Respiratory system,"Million US$, purchasing power parity",386.3
28331,Portugal,2017,8,R-Respiratory system,"/capita, US$ exchange rate",24.4
28332,Portugal,2017,8,B-Blood and blood forming organs,Million US$ at exchange rate,217.0
28333,Portugal,2017,8,R-Respiratory system,Million US$ at exchange rate,251.2
28334,Portugal,2017,8,C07-Beta blocking agents,Million of national currency units,32.8
28335,Portugal,2017,8,Products not elsewhere classified,Million of national currency units,0.0
28336,Portugal,2017,8,Products not elsewhere classified,Million US$ at exchange rate,0.0
28337,Portugal,2017,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",52.4
28338,Portugal,2017,8,A-Alimentary tract and metabolism,% of total sales,18.7
28339,Portugal,2017,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",80.6
28340,Portugal,2017,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",430.9
28341,Portugal,2017,8,C-Cardiovascular system,"Million US$, purchasing power parity",902.5
28342,Portugal,2017,8,Total pharmaceutical sales,"/capita, US$ exchange rate",280.2
28343,Portugal,2017,8,C-Cardiovascular system,% of total sales,20.3
28344,Portugal,2017,8,C03-Diuretics,% of total sales,0.9
28345,Portugal,2017,8,Total pharmaceutical sales,"Million US$, purchasing power parity",4438.6
28346,Portugal,2017,8,C-Cardiovascular system,"/capita, US$ exchange rate",57.0
28347,Portugal,2017,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",87.6
28348,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",22.2
28349,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.2
28350,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.9
28351,Portugal,2017,8,C-Cardiovascular system,Million of national currency units,519.6
28352,Portugal,2017,8,Total pharmaceutical sales,Million US$ at exchange rate,2886.6
28353,Portugal,2017,8,Total pharmaceutical sales,Million of national currency units,2555.3
28354,Portugal,2017,8,C-Cardiovascular system,Million US$ at exchange rate,587.0
28355,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.4
28356,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4
28357,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7
28358,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.2
28359,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,228.9
28360,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
28361,Portugal,2017,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
28362,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,202.7
28363,Portugal,2017,8,C03-Diuretics,"Million US$, purchasing power parity",37.8
28364,Portugal,2017,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
28365,Portugal,2017,8,C03-Diuretics,"/capita, US$ exchange rate",2.4
28366,Portugal,2017,8,C03-Diuretics,Million US$ at exchange rate,24.6
28367,Portugal,2017,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",352.0
28368,Portugal,2017,8,C03-Diuretics,Million of national currency units,21.8
28369,Portugal,2017,8,C10-Lipid modifying agents,% of total sales,6.3
28370,Portugal,2017,8,N06A-Antidepressants,Million of national currency units,96.0
28371,Portugal,2017,8,A02A-Antacids,Million of national currency units,6.0
28372,Portugal,2017,8,A02A-Antacids,Million US$ at exchange rate,6.8
28373,Portugal,2017,8,N06A-Antidepressants,"/capita, US$ exchange rate",10.5
28374,Portugal,2017,8,N06A-Antidepressants,Million US$ at exchange rate,108.4
28375,Portugal,2017,8,N06A-Antidepressants,"Million US$, purchasing power parity",166.8
28376,Portugal,2017,8,C08-Calcium channel blockers,Million of national currency units,24.3
28377,Portugal,2017,8,C08-Calcium channel blockers,Million US$ at exchange rate,27.5
28378,Portugal,2017,8,A02A-Antacids,"/capita, US$ exchange rate",0.7
28379,Portugal,2017,8,A02A-Antacids,"Million US$, purchasing power parity",10.5
28380,Portugal,2017,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.1
28381,Portugal,2017,8,C08-Calcium channel blockers,% of total sales,1.0
28382,Portugal,2017,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",42.2
28383,Portugal,2017,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.7
28384,Portugal,2017,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2
28385,Portugal,2017,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,148.9
28386,Portugal,2017,8,R03-Drugs for obstructive airway diseases,Million of national currency units,131.8
28387,Portugal,2017,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,179.6
28388,Portugal,2017,8,G-Genito urinary system and sex hormones,Million of national currency units,159.0
28389,Portugal,2017,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",278.4
28390,Portugal,2017,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.0
28391,Portugal,2017,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.6
28392,Portugal,2017,8,C10-Lipid modifying agents,Million of national currency units,160.3
28393,Portugal,2017,8,C10-Lipid modifying agents,Million US$ at exchange rate,181.0
28394,Portugal,2017,8,N06A-Antidepressants,% of total sales,3.8
28395,Portugal,2017,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.5
28396,Portugal,2017,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",228.9
28397,Portugal,2017,8,R03-Drugs for obstructive airway diseases,% of total sales,5.2
28398,Portugal,2017,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.2
28399,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",107.0
28400,Portugal,2017,8,N02-Analgesics,% of total sales,4.9
28401,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.4
28402,Portugal,2017,8,J01-Antibacterials for systemic use,Million of national currency units,59.9
28403,Portugal,2017,8,N02-Analgesics,"/capita, US$ purchasing power parity",21.1
28404,Portugal,2017,8,N-Nervous system,"Million US$, purchasing power parity",898.4
28405,Portugal,2017,8,N02-Analgesics,"/capita, US$ exchange rate",13.7
28406,Portugal,2017,8,N05B-Anxiolytics,Million US$ at exchange rate,58.0
28407,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,93.0
28408,Portugal,2017,8,N05B-Anxiolytics,Million of national currency units,51.4
28409,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.0
28410,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.3
28411,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
28412,Portugal,2017,8,J-Antiinfectives for systemic use,Million of national currency units,116.6
28413,Portugal,2017,8,A10-Drugs used in diabetes,% of total sales,11.4
28414,Portugal,2017,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",32.0
28415,Portugal,2017,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",49.2
28416,Portugal,2017,8,N-Nervous system,Million of national currency units,517.2
28417,Portugal,2017,8,N-Nervous system,Million US$ at exchange rate,584.3
28418,Portugal,2017,8,N02-Analgesics,"Million US$, purchasing power parity",217.1
28419,Portugal,2017,8,N02-Analgesics,Million of national currency units,125.0
28420,Portugal,2017,8,N02-Analgesics,Million US$ at exchange rate,141.2
28421,Portugal,2017,8,N-Nervous system,"/capita, US$ exchange rate",56.7
28422,Portugal,2017,8,N-Nervous system,"/capita, US$ purchasing power parity",87.2
28423,Portugal,2017,8,J01-Antibacterials for systemic use,% of total sales,2.3
28424,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",107.0
28425,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.6
28426,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",15.7
28427,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.2
28428,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,105.1
28429,Portugal,2017,8,N-Nervous system,% of total sales,20.2
28430,Portugal,2017,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",161.6
28431,Portugal,2017,8,N05B-Anxiolytics,% of total sales,2.0
28432,Portugal,2017,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,67.7
28433,Portugal,2017,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.7
28434,Portugal,2017,8,N05B-Anxiolytics,"Million US$, purchasing power parity",89.2
28435,Portugal,2017,8,N05B-Anxiolytics,"/capita, US$ exchange rate",5.6
28436,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.8
28437,Portugal,2017,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.1
28438,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.4
28439,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
28440,Portugal,2017,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",104.1
28441,Portugal,2017,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.6
28442,Portugal,2017,8,M-Musculo-skeletal system,Million of national currency units,161.1
28443,Portugal,2017,8,N05C-Hypnotics and sedatives,% of total sales,0.7
28444,Portugal,2017,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,131.8
28445,Portugal,2017,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,21.4
28446,Portugal,2017,8,M-Musculo-skeletal system,Million US$ at exchange rate,182.0
28447,Portugal,2017,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",32.9
28448,Portugal,2017,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.2
28449,Portugal,2017,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.1
28450,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.8
28451,Portugal,2017,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",506.9
28452,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,69.6
28453,Portugal,2017,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,61.6
28454,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",44.6
28455,Portugal,2017,8,A10-Drugs used in diabetes,Million US$ at exchange rate,329.7
28456,Portugal,2017,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",202.6
28457,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,25.7
28458,Portugal,2017,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,29.0
28459,Portugal,2017,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.2
28460,Portugal,2017,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.8
28461,Portugal,2017,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.7
28462,Portugal,2017,8,A10-Drugs used in diabetes,Million of national currency units,291.8
28463,Portugal,2017,8,J-Antiinfectives for systemic use,% of total sales,4.6
28464,Portugal,2017,8,M-Musculo-skeletal system,% of total sales,6.3
28465,Portugal,2017,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.7
28466,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.8
28467,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,69.6
28468,Portugal,2017,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",279.8
28469,Portugal,2017,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,61.6
28470,Portugal,2017,8,N05C-Hypnotics and sedatives,Million of national currency units,19.0
28471,Portugal,2015,9,C01A-Cardiac glycosides,Million of national currency units,0.9
28472,Portugal,2015,9,C01A-Cardiac glycosides,Million US$ at exchange rate,1.0
28473,Portugal,2015,9,C02-Antihypertensives,Million US$ at exchange rate,4.0
28474,Portugal,2015,9,R-Respiratory system,"/capita, US$ purchasing power parity",35.4
28475,Portugal,2015,9,R-Respiratory system,% of total sales,8.6
28476,Portugal,2015,9,C02-Antihypertensives,"Million US$, purchasing power parity",6.1
28477,Portugal,2015,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
28478,Portugal,2015,9,C02-Antihypertensives,% of total sales,0.1
28479,Portugal,2015,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
28480,Portugal,2015,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.4
28481,Portugal,2015,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.0
28482,Portugal,2015,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.2
28483,Portugal,2015,9,G-Genito urinary system and sex hormones,% of total sales,6.1
28484,Portugal,2015,9,C01A-Cardiac glycosides,% of total sales,0.0
28485,Portugal,2015,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.9
28486,Portugal,2015,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",259.0
28487,Portugal,2015,9,B-Blood and blood forming organs,% of total sales,5.6
28488,Portugal,2015,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
28489,Portugal,2015,9,A02A-Antacids,% of total sales,0.2
28490,Portugal,2015,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
28491,Portugal,2015,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.2
28492,Portugal,2015,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",240.3
28493,Portugal,2015,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.1
28494,Portugal,2015,9,C07-Beta blocking agents,"/capita, US$ exchange rate",3.4
28495,Portugal,2015,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.2
28496,Portugal,2015,9,C07-Beta blocking agents,Million US$ at exchange rate,35.0
28497,Portugal,2015,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
28498,Portugal,2015,9,C02-Antihypertensives,Million of national currency units,3.6
28499,Portugal,2015,9,C07-Beta blocking agents,"Million US$, purchasing power parity",53.9
28500,Portugal,2015,9,Products not elsewhere classified,% of total sales,0.0
28501,Portugal,2015,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
28502,Portugal,2015,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
28503,Portugal,2015,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",752.2
28504,Portugal,2015,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,488.2
28505,Portugal,2015,9,C07-Beta blocking agents,% of total sales,1.3
28506,Portugal,2015,9,B-Blood and blood forming organs,Million of national currency units,140.5
28507,Portugal,2015,9,C07-Beta blocking agents,Million of national currency units,31.5
28508,Portugal,2015,9,R-Respiratory system,Million of national currency units,214.3
28509,Portugal,2015,9,R-Respiratory system,"/capita, US$ exchange rate",23.0
28510,Portugal,2015,9,R-Respiratory system,"Million US$, purchasing power parity",366.4
28511,Portugal,2015,9,B-Blood and blood forming organs,Million US$ at exchange rate,155.9
28512,Portugal,2015,9,R-Respiratory system,Million US$ at exchange rate,237.8
28513,Portugal,2015,9,Products not elsewhere classified,Million of national currency units,0.0
28514,Portugal,2015,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",47.1
28515,Portugal,2015,9,Products not elsewhere classified,Million US$ at exchange rate,0.0
28516,Portugal,2015,9,A-Alimentary tract and metabolism,% of total sales,17.7
28517,Portugal,2015,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",72.6
28518,Portugal,2015,9,C-Cardiovascular system,"Million US$, purchasing power parity",947.9
28519,Portugal,2015,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",411.2
28520,Portugal,2015,9,Total pharmaceutical sales,"/capita, US$ exchange rate",266.9
28521,Portugal,2015,9,C-Cardiovascular system,% of total sales,22.3
28522,Portugal,2015,9,C-Cardiovascular system,"/capita, US$ exchange rate",59.4
28523,Portugal,2015,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",91.5
28524,Portugal,2015,9,Total pharmaceutical sales,"Million US$, purchasing power parity",4259.0
28525,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.0
28526,Portugal,2015,9,C-Cardiovascular system,Million of national currency units,554.5
28527,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",38.5
28528,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.4
28529,Portugal,2015,9,Total pharmaceutical sales,Million US$ at exchange rate,2764.1
28530,Portugal,2015,9,C-Cardiovascular system,Million US$ at exchange rate,615.2
28531,Portugal,2015,9,Total pharmaceutical sales,Million of national currency units,2491.3
28532,Portugal,2015,9,C03-Diuretics,% of total sales,0.9
28533,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.3
28534,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4
28535,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.1
28536,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,258.7
28537,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
28538,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
28539,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,233.2
28540,Portugal,2015,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7
28541,Portugal,2015,9,C03-Diuretics,"/capita, US$ exchange rate",2.4
28542,Portugal,2015,9,C03-Diuretics,"Million US$, purchasing power parity",38.0
28543,Portugal,2015,9,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
28544,Portugal,2015,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",398.6
28545,Portugal,2015,9,C03-Diuretics,Million US$ at exchange rate,24.7
28546,Portugal,2015,9,C03-Diuretics,Million of national currency units,22.3
28547,Portugal,2015,9,A02A-Antacids,Million of national currency units,5.6
28548,Portugal,2015,9,C10-Lipid modifying agents,Million of national currency units,161.0
28549,Portugal,2015,9,N06A-Antidepressants,Million of national currency units,92.9
28550,Portugal,2015,9,A02A-Antacids,Million US$ at exchange rate,6.2
28551,Portugal,2015,9,N06A-Antidepressants,"/capita, US$ exchange rate",10.0
28552,Portugal,2015,9,N06A-Antidepressants,Million US$ at exchange rate,103.1
28553,Portugal,2015,9,N06A-Antidepressants,"Million US$, purchasing power parity",158.8
28554,Portugal,2015,9,A02A-Antacids,"Million US$, purchasing power parity",9.6
28555,Portugal,2015,9,C08-Calcium channel blockers,Million US$ at exchange rate,28.8
28556,Portugal,2015,9,C08-Calcium channel blockers,Million of national currency units,26.0
28557,Portugal,2015,9,A02A-Antacids,"/capita, US$ exchange rate",0.6
28558,Portugal,2015,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.3
28559,Portugal,2015,9,C08-Calcium channel blockers,% of total sales,1.0
28560,Portugal,2015,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",44.4
28561,Portugal,2015,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.8
28562,Portugal,2015,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.3
28563,Portugal,2015,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,138.0
28564,Portugal,2015,9,G-Genito urinary system and sex hormones,Million of national currency units,151.5
28565,Portugal,2015,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,168.1
28566,Portugal,2015,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",275.3
28567,Portugal,2015,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",26.6
28568,Portugal,2015,9,C10-Lipid modifying agents,% of total sales,6.5
28569,Portugal,2015,9,R03-Drugs for obstructive airway diseases,Million of national currency units,124.4
28570,Portugal,2015,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.3
28571,Portugal,2015,9,C10-Lipid modifying agents,Million US$ at exchange rate,178.7
28572,Portugal,2015,9,N06A-Antidepressants,% of total sales,3.7
28573,Portugal,2015,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.3
28574,Portugal,2015,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",212.7
28575,Portugal,2015,9,R03-Drugs for obstructive airway diseases,% of total sales,5.0
28576,Portugal,2015,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.5
28577,Portugal,2015,9,A-Alimentary tract and metabolism,Million of national currency units,440.0
28578,Portugal,2015,9,N02-Analgesics,% of total sales,4.9
28579,Portugal,2015,9,J01-Antibacterials for systemic use,Million of national currency units,66.8
28580,Portugal,2015,9,N-Nervous system,"Million US$, purchasing power parity",870.6
28581,Portugal,2015,9,N02-Analgesics,"/capita, US$ exchange rate",13.1
28582,Portugal,2015,9,N02-Analgesics,"/capita, US$ purchasing power parity",20.2
28583,Portugal,2015,9,N05B-Anxiolytics,Million US$ at exchange rate,60.3
28584,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,97.4
28585,Portugal,2015,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,74.1
28586,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.9
28587,Portugal,2015,9,N05B-Anxiolytics,Million of national currency units,54.4
28588,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5
28589,Portugal,2015,9,J-Antiinfectives for systemic use,Million of national currency units,133.5
28590,Portugal,2015,9,A10-Drugs used in diabetes,% of total sales,10.6
28591,Portugal,2015,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",28.4
28592,Portugal,2015,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",43.7
28593,Portugal,2015,9,N-Nervous system,Million of national currency units,509.2
28594,Portugal,2015,9,N-Nervous system,Million US$ at exchange rate,565.0
28595,Portugal,2015,9,N02-Analgesics,"Million US$, purchasing power parity",209.1
28596,Portugal,2015,9,N02-Analgesics,Million of national currency units,122.3
28597,Portugal,2015,9,N02-Analgesics,Million US$ at exchange rate,135.7
28598,Portugal,2015,9,N-Nervous system,"/capita, US$ exchange rate",54.5
28599,Portugal,2015,9,N-Nervous system,"/capita, US$ purchasing power parity",84.0
28600,Portugal,2015,9,J01-Antibacterials for systemic use,% of total sales,2.7
28601,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.7
28602,Portugal,2015,9,N-Nervous system,% of total sales,20.4
28603,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",107.3
28604,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9
28605,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.1
28606,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.4
28607,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,108.1
28608,Portugal,2015,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",166.5
28609,Portugal,2015,9,N05B-Anxiolytics,% of total sales,2.2
28610,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.4
28611,Portugal,2015,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",9.0
28612,Portugal,2015,9,N05B-Anxiolytics,"Million US$, purchasing power parity",92.9
28613,Portugal,2015,9,N05B-Anxiolytics,"/capita, US$ exchange rate",5.8
28614,Portugal,2015,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.0
28615,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.1
28616,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
28617,Portugal,2015,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",114.1
28618,Portugal,2015,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.2
28619,Portugal,2015,9,N05C-Hypnotics and sedatives,% of total sales,0.8
28620,Portugal,2015,9,M-Musculo-skeletal system,Million of national currency units,169.1
28621,Portugal,2015,9,A10-Drugs used in diabetes,Million US$ at exchange rate,294.0
28622,Portugal,2015,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,148.1
28623,Portugal,2015,9,M-Musculo-skeletal system,Million US$ at exchange rate,187.6
28624,Portugal,2015,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",35.5
28625,Portugal,2015,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,23.1
28626,Portugal,2015,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.4
28627,Portugal,2015,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.2
28628,Portugal,2015,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",228.3
28629,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.5
28630,Portugal,2015,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",453.0
28631,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,69.6
28632,Portugal,2015,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,62.8
28633,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.9
28634,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,23.4
28635,Portugal,2015,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.3
28636,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,25.9
28637,Portugal,2015,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",39.9
28638,Portugal,2015,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",27.9
28639,Portugal,2015,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.1
28640,Portugal,2015,9,A10-Drugs used in diabetes,Million of national currency units,265.0
28641,Portugal,2015,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",22.0
28642,Portugal,2015,9,J-Antiinfectives for systemic use,% of total sales,5.4
28643,Portugal,2015,9,M-Musculo-skeletal system,% of total sales,6.8
28644,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.5
28645,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,67.6
28646,Portugal,2015,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",289.1
28647,Portugal,2015,9,N05C-Hypnotics and sedatives,Million of national currency units,20.8
28648,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,60.9
28649,Portugal,2015,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",104.1
28650,Portugal,2016,9,C01A-Cardiac glycosides,Million US$ at exchange rate,0.9
28651,Portugal,2016,9,C01A-Cardiac glycosides,Million of national currency units,0.8
28652,Portugal,2016,9,C02-Antihypertensives,% of total sales,0.1
28653,Portugal,2016,9,C02-Antihypertensives,Million US$ at exchange rate,3.5
28654,Portugal,2016,9,R-Respiratory system,% of total sales,8.8
28655,Portugal,2016,9,R-Respiratory system,"/capita, US$ purchasing power parity",37.8
28656,Portugal,2016,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.5
28657,Portugal,2016,9,C02-Antihypertensives,"Million US$, purchasing power parity",5.5
28658,Portugal,2016,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.3
28659,Portugal,2016,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
28660,Portugal,2016,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",26.7
28661,Portugal,2016,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.9
28662,Portugal,2016,9,G-Genito urinary system and sex hormones,% of total sales,6.2
28663,Portugal,2016,9,C01A-Cardiac glycosides,% of total sales,0.0
28664,Portugal,2016,9,A02A-Antacids,"/capita, US$ purchasing power parity",0.9
28665,Portugal,2016,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",275.6
28666,Portugal,2016,9,B-Blood and blood forming organs,% of total sales,6.9
28667,Portugal,2016,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
28668,Portugal,2016,9,A02A-Antacids,% of total sales,0.2
28669,Portugal,2016,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
28670,Portugal,2016,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",29.7
28671,Portugal,2016,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",307.2
28672,Portugal,2016,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.8
28673,Portugal,2016,9,C07-Beta blocking agents,"/capita, US$ exchange rate",3.5
28674,Portugal,2016,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.5
28675,Portugal,2016,9,C07-Beta blocking agents,Million US$ at exchange rate,36.0
28676,Portugal,2016,9,C02-Antihypertensives,Million of national currency units,3.1
28677,Portugal,2016,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
28678,Portugal,2016,9,C07-Beta blocking agents,"Million US$, purchasing power parity",57.0
28679,Portugal,2016,9,C07-Beta blocking agents,% of total sales,1.3
28680,Portugal,2016,9,Products not elsewhere classified,% of total sales,0.0
28681,Portugal,2016,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
28682,Portugal,2016,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
28683,Portugal,2016,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",806.0
28684,Portugal,2016,9,A-Alimentary tract and metabolism,Million of national currency units,460.6
28685,Portugal,2016,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,509.8
28686,Portugal,2016,9,B-Blood and blood forming organs,Million of national currency units,175.5
28687,Portugal,2016,9,R-Respiratory system,Million of national currency units,222.8
28688,Portugal,2016,9,R-Respiratory system,"/capita, US$ exchange rate",23.9
28689,Portugal,2016,9,R-Respiratory system,"Million US$, purchasing power parity",389.8
28690,Portugal,2016,9,B-Blood and blood forming organs,Million US$ at exchange rate,194.3
28691,Portugal,2016,9,R-Respiratory system,Million US$ at exchange rate,246.6
28692,Portugal,2016,9,C07-Beta blocking agents,Million of national currency units,32.5
28693,Portugal,2016,9,Products not elsewhere classified,Million of national currency units,0.0
28694,Portugal,2016,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.4
28695,Portugal,2016,9,Products not elsewhere classified,Million US$ at exchange rate,0.0
28696,Portugal,2016,9,A-Alimentary tract and metabolism,% of total sales,18.2
28697,Portugal,2016,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",78.1
28698,Portugal,2016,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",428.9
28699,Portugal,2016,9,C-Cardiovascular system,"Million US$, purchasing power parity",944.9
28700,Portugal,2016,9,Total pharmaceutical sales,"/capita, US$ exchange rate",271.3
28701,Portugal,2016,9,C-Cardiovascular system,% of total sales,21.3
28702,Portugal,2016,9,C-Cardiovascular system,"/capita, US$ exchange rate",57.9
28703,Portugal,2016,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",91.5
28704,Portugal,2016,9,Total pharmaceutical sales,"Million US$, purchasing power parity",4428.3
28705,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",23.3
28706,Portugal,2016,9,C-Cardiovascular system,Million of national currency units,539.9
28707,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.6
28708,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",36.8
28709,Portugal,2016,9,C03-Diuretics,% of total sales,0.9
28710,Portugal,2016,9,Total pharmaceutical sales,Million US$ at exchange rate,2800.9
28711,Portugal,2016,9,Total pharmaceutical sales,Million of national currency units,2530.4
28712,Portugal,2016,9,C-Cardiovascular system,Million US$ at exchange rate,597.6
28713,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.5
28714,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.4
28715,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,4.1
28716,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7
28717,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
28718,Portugal,2016,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
28719,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,240.2
28720,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,217.0
28721,Portugal,2016,9,C03-Diuretics,"Million US$, purchasing power parity",38.4
28722,Portugal,2016,9,C03-Diuretics,"/capita, US$ exchange rate",2.4
28723,Portugal,2016,9,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
28724,Portugal,2016,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",379.7
28725,Portugal,2016,9,C03-Diuretics,Million US$ at exchange rate,24.3
28726,Portugal,2016,9,C03-Diuretics,Million of national currency units,21.9
28727,Portugal,2016,9,A02A-Antacids,Million of national currency units,5.3
28728,Portugal,2016,9,N06A-Antidepressants,Million of national currency units,93.6
28729,Portugal,2016,9,A02A-Antacids,Million US$ at exchange rate,5.9
28730,Portugal,2016,9,N06A-Antidepressants,"/capita, US$ exchange rate",10.0
28731,Portugal,2016,9,N06A-Antidepressants,"Million US$, purchasing power parity",163.7
28732,Portugal,2016,9,N06A-Antidepressants,Million US$ at exchange rate,103.6
28733,Portugal,2016,9,C08-Calcium channel blockers,Million of national currency units,25.1
28734,Portugal,2016,9,C08-Calcium channel blockers,Million US$ at exchange rate,27.8
28735,Portugal,2016,9,A02A-Antacids,"/capita, US$ exchange rate",0.6
28736,Portugal,2016,9,A02A-Antacids,"Million US$, purchasing power parity",9.3
28737,Portugal,2016,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.3
28738,Portugal,2016,9,C08-Calcium channel blockers,% of total sales,1.0
28739,Portugal,2016,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",43.9
28740,Portugal,2016,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.7
28741,Portugal,2016,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,144.6
28742,Portugal,2016,9,R03-Drugs for obstructive airway diseases,Million of national currency units,130.7
28743,Portugal,2016,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,174.3
28744,Portugal,2016,9,G-Genito urinary system and sex hormones,Million of national currency units,157.5
28745,Portugal,2016,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",28.2
28746,Portugal,2016,9,C10-Lipid modifying agents,% of total sales,6.6
28747,Portugal,2016,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",291.0
28748,Portugal,2016,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",17.8
28749,Portugal,2016,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.9
28750,Portugal,2016,9,C10-Lipid modifying agents,Million of national currency units,166.3
28751,Portugal,2016,9,C10-Lipid modifying agents,Million US$ at exchange rate,184.0
28752,Portugal,2016,9,N06A-Antidepressants,% of total sales,3.7
28753,Portugal,2016,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.0
28754,Portugal,2016,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",228.7
28755,Portugal,2016,9,R03-Drugs for obstructive airway diseases,% of total sales,5.2
28756,Portugal,2016,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.1
28757,Portugal,2016,9,N02-Analgesics,% of total sales,4.7
28758,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",11.0
28759,Portugal,2016,9,J01-Antibacterials for systemic use,Million of national currency units,63.4
28760,Portugal,2016,9,N02-Analgesics,"/capita, US$ purchasing power parity",20.2
28761,Portugal,2016,9,N-Nervous system,"Million US$, purchasing power parity",887.0
28762,Portugal,2016,9,N02-Analgesics,"/capita, US$ exchange rate",12.8
28763,Portugal,2016,9,N05B-Anxiolytics,Million US$ at exchange rate,58.2
28764,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,96.9
28765,Portugal,2016,9,N05B-Anxiolytics,Million of national currency units,52.6
28766,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.0
28767,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",4.1
28768,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
28769,Portugal,2016,9,J-Antiinfectives for systemic use,Million of national currency units,118.1
28770,Portugal,2016,9,A10-Drugs used in diabetes,% of total sales,11.0
28771,Portugal,2016,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.9
28772,Portugal,2016,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",47.3
28773,Portugal,2016,9,N-Nervous system,Million of national currency units,506.8
28774,Portugal,2016,9,N-Nervous system,Million US$ at exchange rate,561.0
28775,Portugal,2016,9,N02-Analgesics,Million of national currency units,119.1
28776,Portugal,2016,9,N02-Analgesics,"Million US$, purchasing power parity",208.5
28777,Portugal,2016,9,N02-Analgesics,Million US$ at exchange rate,131.9
28778,Portugal,2016,9,N-Nervous system,"/capita, US$ exchange rate",54.3
28779,Portugal,2016,9,N-Nervous system,"/capita, US$ purchasing power parity",85.9
28780,Portugal,2016,9,J01-Antibacterials for systemic use,% of total sales,2.5
28781,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",113.4
28782,Portugal,2016,9,N-Nervous system,% of total sales,20.0
28783,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.8
28784,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.4
28785,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.4
28786,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,107.2
28787,Portugal,2016,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",169.5
28788,Portugal,2016,9,N05B-Anxiolytics,% of total sales,2.1
28789,Portugal,2016,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,70.2
28790,Portugal,2016,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",8.9
28791,Portugal,2016,9,N05B-Anxiolytics,"Million US$, purchasing power parity",92.0
28792,Portugal,2016,9,N05B-Anxiolytics,"/capita, US$ exchange rate",5.6
28793,Portugal,2016,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.7
28794,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.3
28795,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
28796,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.9
28797,Portugal,2016,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",110.9
28798,Portugal,2016,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.8
28799,Portugal,2016,9,M-Musculo-skeletal system,Million of national currency units,167.0
28800,Portugal,2016,9,N05C-Hypnotics and sedatives,% of total sales,0.8
28801,Portugal,2016,9,A10-Drugs used in diabetes,Million US$ at exchange rate,309.1
28802,Portugal,2016,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,130.7
28803,Portugal,2016,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,22.0
28804,Portugal,2016,9,M-Musculo-skeletal system,Million US$ at exchange rate,184.8
28805,Portugal,2016,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",34.7
28806,Portugal,2016,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.4
28807,Portugal,2016,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.1
28808,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.6
28809,Portugal,2016,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",488.7
28810,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,71.7
28811,Portugal,2016,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,64.8
28812,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",42.8
28813,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,24.5
28814,Portugal,2016,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",206.6
28815,Portugal,2016,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,27.1
28816,Portugal,2016,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.3
28817,Portugal,2016,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.7
28818,Portugal,2016,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.9
28819,Portugal,2016,9,A10-Drugs used in diabetes,Million of national currency units,279.2
28820,Portugal,2016,9,J-Antiinfectives for systemic use,% of total sales,4.7
28821,Portugal,2016,9,M-Musculo-skeletal system,% of total sales,6.6
28822,Portugal,2016,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",20.0
28823,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.5
28824,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,67.5
28825,Portugal,2016,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",292.2
28826,Portugal,2016,9,N05C-Hypnotics and sedatives,Million of national currency units,19.8
28827,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,61.0
28828,Portugal,2016,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",106.8
28829,Portugal,2010,9,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6
28830,Portugal,2010,9,C01A-Cardiac glycosides,Million of national currency units,1.0
28831,Portugal,2010,9,C01A-Cardiac glycosides,Million US$ at exchange rate,1.3
28832,Portugal,2010,9,C02-Antihypertensives,"Million US$, purchasing power parity",7.2
28833,Portugal,2010,9,R-Respiratory system,% of total sales,6.6
28834,Portugal,2010,9,C02-Antihypertensives,% of total sales,0.1
28835,Portugal,2010,9,C02-Antihypertensives,"/capita, US$ exchange rate",0.6
28836,Portugal,2010,9,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.7
28837,Portugal,2010,9,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",27.3
28838,Portugal,2010,9,G-Genito urinary system and sex hormones,% of total sales,5.6
28839,Portugal,2010,9,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",22.6
28840,Portugal,2010,9,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",289.1
28841,Portugal,2010,9,C01A-Cardiac glycosides,% of total sales,0.0
28842,Portugal,2010,9,A02A-Antacids,% of total sales,0.2
28843,Portugal,2010,9,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
28844,Portugal,2010,9,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
28845,Portugal,2010,9,B-Blood and blood forming organs,"Million US$, purchasing power parity",193.4
28846,Portugal,2010,9,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.3
28847,Portugal,2010,9,B-Blood and blood forming organs,% of total sales,3.7
28848,Portugal,2010,9,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.1
28849,Portugal,2010,9,R-Respiratory system,"/capita, US$ purchasing power parity",32.6
28850,Portugal,2010,9,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
28851,Portugal,2010,9,C07-Beta blocking agents,"/capita, US$ exchange rate",4.3
28852,Portugal,2010,9,C07-Beta blocking agents,% of total sales,1.1
28853,Portugal,2010,9,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.2
28854,Portugal,2010,9,C02-Antihypertensives,Million of national currency units,4.5
28855,Portugal,2010,9,C07-Beta blocking agents,"Million US$, purchasing power parity",55.2
28856,Portugal,2010,9,Products not elsewhere classified,% of total sales,0.0
28857,Portugal,2010,9,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
28858,Portugal,2010,9,A-Alimentary tract and metabolism,Million of national currency units,511.4
28859,Portugal,2010,9,A-Alimentary tract and metabolism,Million US$ at exchange rate,677.9
28860,Portugal,2010,9,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",820.6
28861,Portugal,2010,9,C02-Antihypertensives,Million US$ at exchange rate,6.0
28862,Portugal,2010,9,B-Blood and blood forming organs,Million of national currency units,120.5
28863,Portugal,2010,9,R-Respiratory system,Million US$ at exchange rate,284.6
28864,Portugal,2010,9,B-Blood and blood forming organs,Million US$ at exchange rate,159.8
28865,Portugal,2010,9,C07-Beta blocking agents,Million of national currency units,34.4
28866,Portugal,2010,9,R-Respiratory system,Million of national currency units,214.6
28867,Portugal,2010,9,R-Respiratory system,"/capita, US$ exchange rate",26.9
28868,Portugal,2010,9,R-Respiratory system,"Million US$, purchasing power parity",344.5
28869,Portugal,2010,9,Products not elsewhere classified,Million of national currency units,0.0
28870,Portugal,2010,9,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",64.1
28871,Portugal,2010,9,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
28872,Portugal,2010,9,Products not elsewhere classified,Million US$ at exchange rate,0.0
28873,Portugal,2010,9,A02A-Antacids,"/capita, US$ purchasing power parity",1.0
28874,Portugal,2010,9,C07-Beta blocking agents,Million US$ at exchange rate,45.6
28875,Portugal,2010,9,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",77.6
28876,Portugal,2010,9,A-Alimentary tract and metabolism,% of total sales,15.8
28877,Portugal,2010,9,C-Cardiovascular system,"Million US$, purchasing power parity",1431.7
28878,Portugal,2010,9,Total pharmaceutical sales,"/capita, US$ exchange rate",406.0
28879,Portugal,2010,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",491.4
28880,Portugal,2010,9,C-Cardiovascular system,"/capita, US$ exchange rate",111.9
28881,Portugal,2010,9,C-Cardiovascular system,% of total sales,27.6
28882,Portugal,2010,9,C-Cardiovascular system,"/capita, US$ purchasing power parity",135.4
28883,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",60.4
28884,Portugal,2010,9,C-Cardiovascular system,Million of national currency units,892.1
28885,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,% of total sales,12.3
28886,Portugal,2010,9,Total pharmaceutical sales,Million US$ at exchange rate,4292.5
28887,Portugal,2010,9,Total pharmaceutical sales,"Million US$, purchasing power parity",5195.9
28888,Portugal,2010,9,C-Cardiovascular system,Million US$ at exchange rate,1182.7
28889,Portugal,2010,9,Total pharmaceutical sales,Million of national currency units,3237.9
28890,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
28891,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,6.4
28892,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",7.7
28893,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
28894,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,527.3
28895,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,397.7
28896,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
28897,Portugal,2010,9,C03-Diuretics,"/capita, US$ exchange rate",3.6
28898,Portugal,2010,9,C03-Diuretics,"Million US$, purchasing power parity",46.3
28899,Portugal,2010,9,C03-Diuretics,% of total sales,0.9
28900,Portugal,2010,9,C03-Diuretics,"/capita, US$ purchasing power parity",4.4
28901,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",638.2
28902,Portugal,2010,9,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,4.8
28903,Portugal,2010,9,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",49.9
28904,Portugal,2010,9,C03-Diuretics,Million US$ at exchange rate,38.3
28905,Portugal,2010,9,C03-Diuretics,Million of national currency units,28.9
28906,Portugal,2010,9,A02A-Antacids,Million of national currency units,6.4
28907,Portugal,2010,9,C10-Lipid modifying agents,Million of national currency units,256.5
28908,Portugal,2010,9,N06A-Antidepressants,Million of national currency units,158.3
28909,Portugal,2010,9,A02A-Antacids,"Million US$, purchasing power parity",10.2
28910,Portugal,2010,9,A02A-Antacids,Million US$ at exchange rate,8.5
28911,Portugal,2010,9,N06A-Antidepressants,"/capita, US$ exchange rate",19.9
28912,Portugal,2010,9,N06A-Antidepressants,"/capita, US$ purchasing power parity",24.0
28913,Portugal,2010,9,N06A-Antidepressants,Million US$ at exchange rate,209.9
28914,Portugal,2010,9,N06A-Antidepressants,"Million US$, purchasing power parity",254.1
28915,Portugal,2010,9,C08-Calcium channel blockers,Million US$ at exchange rate,72.1
28916,Portugal,2010,9,C08-Calcium channel blockers,"Million US$, purchasing power parity",87.2
28917,Portugal,2010,9,A02A-Antacids,"/capita, US$ exchange rate",0.8
28918,Portugal,2010,9,C08-Calcium channel blockers,Million of national currency units,54.4
28919,Portugal,2010,9,C08-Calcium channel blockers,% of total sales,1.7
28920,Portugal,2010,9,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.8
28921,Portugal,2010,9,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",8.3
28922,Portugal,2010,9,G-Genito urinary system and sex hormones,Million of national currency units,180.2
28923,Portugal,2010,9,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,174.3
28924,Portugal,2010,9,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",211.0
28925,Portugal,2010,9,G-Genito urinary system and sex hormones,Million US$ at exchange rate,238.8
28926,Portugal,2010,9,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",38.9
28927,Portugal,2010,9,C10-Lipid modifying agents,% of total sales,7.9
28928,Portugal,2010,9,R03-Drugs for obstructive airway diseases,Million of national currency units,131.5
28929,Portugal,2010,9,C10-Lipid modifying agents,"/capita, US$ exchange rate",32.2
28930,Portugal,2010,9,C10-Lipid modifying agents,Million US$ at exchange rate,340.1
28931,Portugal,2010,9,C10-Lipid modifying agents,"Million US$, purchasing power parity",411.6
28932,Portugal,2010,9,N06A-Antidepressants,% of total sales,4.9
28933,Portugal,2010,9,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",16.5
28934,Portugal,2010,9,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",20.0
28935,Portugal,2010,9,R03-Drugs for obstructive airway diseases,% of total sales,4.1
28936,Portugal,2010,9,N02-Analgesics,% of total sales,3.4
28937,Portugal,2010,9,J01-Antibacterials for systemic use,Million of national currency units,102.5
28938,Portugal,2010,9,N-Nervous system,"/capita, US$ exchange rate",87.8
28939,Portugal,2010,9,N02-Analgesics,"/capita, US$ exchange rate",13.8
28940,Portugal,2010,9,N02-Analgesics,"/capita, US$ purchasing power parity",16.7
28941,Portugal,2010,9,N05B-Anxiolytics,Million US$ at exchange rate,81.2
28942,Portugal,2010,9,N05B-Anxiolytics,"Million US$, purchasing power parity",98.3
28943,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,127.9
28944,Portugal,2010,9,J01-Antibacterials for systemic use,Million US$ at exchange rate,135.8
28945,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.7
28946,Portugal,2010,9,N05B-Anxiolytics,Million of national currency units,61.2
28947,Portugal,2010,9,N-Nervous system,"Million US$, purchasing power parity",1124.0
28948,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.8
28949,Portugal,2010,9,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",31.7
28950,Portugal,2010,9,A10-Drugs used in diabetes,% of total sales,6.4
28951,Portugal,2010,9,J-Antiinfectives for systemic use,Million of national currency units,182.1
28952,Portugal,2010,9,N02-Analgesics,Million of national currency units,110.3
28953,Portugal,2010,9,N-Nervous system,Million of national currency units,700.4
28954,Portugal,2010,9,N-Nervous system,Million US$ at exchange rate,928.6
28955,Portugal,2010,9,N02-Analgesics,Million US$ at exchange rate,146.2
28956,Portugal,2010,9,N02-Analgesics,"Million US$, purchasing power parity",176.9
28957,Portugal,2010,9,M-Musculo-skeletal system,Million of national currency units,252.5
28958,Portugal,2010,9,N-Nervous system,"/capita, US$ purchasing power parity",106.3
28959,Portugal,2010,9,N-Nervous system,% of total sales,21.6
28960,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",299.3
28961,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",23.4
28962,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",19.4
28963,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.9
28964,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",205.2
28965,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",16.0
28966,Portugal,2010,9,N05B-Anxiolytics,% of total sales,1.9
28967,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",28.3
28968,Portugal,2010,9,N05B-Anxiolytics,"/capita, US$ exchange rate",7.7
28969,Portugal,2010,9,N05B-Anxiolytics,"/capita, US$ purchasing power parity",9.3
28970,Portugal,2010,9,J01-Antibacterials for systemic use,% of total sales,3.2
28971,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,% of total sales,2.5
28972,Portugal,2010,9,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,169.5
28973,Portugal,2010,9,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",164.4
28974,Portugal,2010,9,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",15.6
28975,Portugal,2010,9,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",12.8
28976,Portugal,2010,9,M-Musculo-skeletal system,Million US$ at exchange rate,334.8
28977,Portugal,2010,9,N05C-Hypnotics and sedatives,% of total sales,0.6
28978,Portugal,2010,9,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",292.3
28979,Portugal,2010,9,J-Antiinfectives for systemic use,Million US$ at exchange rate,241.5
28980,Portugal,2010,9,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",29.6
28981,Portugal,2010,9,N05C-Hypnotics and sedatives,Million US$ at exchange rate,24.4
28982,Portugal,2010,9,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.8
28983,Portugal,2010,9,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.3
28984,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",3.0
28985,Portugal,2010,9,A10-Drugs used in diabetes,"/capita, US$ exchange rate",26.2
28986,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.6
28987,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,247.2
28988,Portugal,2010,9,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,186.5
28989,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,24.0
28990,Portugal,2010,9,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",22.8
28991,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",38.5
28992,Portugal,2010,9,A10-Drugs used in diabetes,"Million US$, purchasing power parity",334.7
28993,Portugal,2010,9,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,31.8
28994,Portugal,2010,9,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",38.3
28995,Portugal,2010,9,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",27.6
28996,Portugal,2010,9,A10-Drugs used in diabetes,Million US$ at exchange rate,276.5
28997,Portugal,2010,9,M-Musculo-skeletal system,"Million US$, purchasing power parity",405.2
28998,Portugal,2010,9,A10-Drugs used in diabetes,Million of national currency units,208.6
28999,Portugal,2010,9,M-Musculo-skeletal system,% of total sales,7.8
29000,Portugal,2010,9,J-Antiinfectives for systemic use,% of total sales,5.6
29001,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",12.4
29002,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,108.0
29003,Portugal,2010,9,M-Musculo-skeletal system,"/capita, US$ exchange rate",31.7
29004,Portugal,2010,9,N05C-Hypnotics and sedatives,Million of national currency units,18.4
29005,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,Million of national currency units,81.5
29006,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.2
29007,Portugal,2010,9,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",130.7
29008,Portugal,2014,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6
29009,Portugal,2014,8,C01A-Cardiac glycosides,Million US$ at exchange rate,1.2
29010,Portugal,2014,8,C01A-Cardiac glycosides,Million of national currency units,0.9
29011,Portugal,2014,8,C02-Antihypertensives,Million US$ at exchange rate,4.8
29012,Portugal,2014,8,C02-Antihypertensives,"Million US$, purchasing power parity",6.3
29013,Portugal,2014,8,R-Respiratory system,"/capita, US$ purchasing power parity",31.9
29014,Portugal,2014,8,R-Respiratory system,% of total sales,8.0
29015,Portugal,2014,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",0.6
29016,Portugal,2014,8,C02-Antihypertensives,% of total sales,0.2
29017,Portugal,2014,8,C02-Antihypertensives,"/capita, US$ exchange rate",0.5
29018,Portugal,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",25.1
29019,Portugal,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.3
29020,Portugal,2014,8,G-Genito urinary system and sex hormones,% of total sales,6.3
29021,Portugal,2014,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
29022,Portugal,2014,8,C01A-Cardiac glycosides,% of total sales,0.0
29023,Portugal,2014,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",261.1
29024,Portugal,2014,8,B-Blood and blood forming organs,% of total sales,4.6
29025,Portugal,2014,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
29026,Portugal,2014,8,A02A-Antacids,% of total sales,0.2
29027,Portugal,2014,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
29028,Portugal,2014,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.4
29029,Portugal,2014,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",191.7
29030,Portugal,2014,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",14.2
29031,Portugal,2014,8,C07-Beta blocking agents,"/capita, US$ exchange rate",3.9
29032,Portugal,2014,8,Products not elsewhere classified,"/capita, US$ exchange rate",0.0
29033,Portugal,2014,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.1
29034,Portugal,2014,8,Products not elsewhere classified,"Million US$, purchasing power parity",0.0
29035,Portugal,2014,8,C02-Antihypertensives,Million of national currency units,3.6
29036,Portugal,2014,8,C07-Beta blocking agents,"Million US$, purchasing power parity",52.5
29037,Portugal,2014,8,C07-Beta blocking agents,% of total sales,1.3
29038,Portugal,2014,8,Products not elsewhere classified,% of total sales,0.0
29039,Portugal,2014,8,Products not elsewhere classified,"/capita, US$ purchasing power parity",0.0
29040,Portugal,2014,8,A-Alimentary tract and metabolism,Million of national currency units,404.8
29041,Portugal,2014,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",699.3
29042,Portugal,2014,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,537.8
29043,Portugal,2014,8,R-Respiratory system,Million US$ at exchange rate,255.4
29044,Portugal,2014,8,B-Blood and blood forming organs,Million of national currency units,110.9
29045,Portugal,2014,8,C07-Beta blocking agents,Million of national currency units,30.4
29046,Portugal,2014,8,R-Respiratory system,Million of national currency units,192.3
29047,Portugal,2014,8,R-Respiratory system,"/capita, US$ exchange rate",24.6
29048,Portugal,2014,8,R-Respiratory system,"Million US$, purchasing power parity",332.1
29049,Portugal,2014,8,B-Blood and blood forming organs,Million US$ at exchange rate,147.4
29050,Portugal,2014,8,Products not elsewhere classified,Million of national currency units,0.0
29051,Portugal,2014,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.7
29052,Portugal,2014,8,Products not elsewhere classified,Million US$ at exchange rate,0.0
29053,Portugal,2014,8,C07-Beta blocking agents,Million US$ at exchange rate,40.4
29054,Portugal,2014,8,A-Alimentary tract and metabolism,% of total sales,16.9
29055,Portugal,2014,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",67.2
29056,Portugal,2014,8,C-Cardiovascular system,"Million US$, purchasing power parity",981.9
29057,Portugal,2014,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",398.2
29058,Portugal,2014,8,Total pharmaceutical sales,"/capita, US$ exchange rate",306.2
29059,Portugal,2014,8,C-Cardiovascular system,% of total sales,23.7
29060,Portugal,2014,8,C-Cardiovascular system,"/capita, US$ exchange rate",72.6
29061,Portugal,2014,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",94.4
29062,Portugal,2014,8,Total pharmaceutical sales,"Million US$, purchasing power parity",4141.9
29063,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",41.5
29064,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",31.9
29065,Portugal,2014,8,C-Cardiovascular system,Million of national currency units,568.4
29066,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,10.4
29067,Portugal,2014,8,Total pharmaceutical sales,Million US$ at exchange rate,3185.2
29068,Portugal,2014,8,C-Cardiovascular system,Million US$ at exchange rate,755.1
29069,Portugal,2014,8,Total pharmaceutical sales,Million of national currency units,2397.6
29070,Portugal,2014,8,C03-Diuretics,% of total sales,0.9
29071,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.5
29072,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
29073,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0
29074,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
29075,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
29076,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,332.1
29077,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,250.0
29078,Portugal,2014,8,C03-Diuretics,"/capita, US$ exchange rate",2.9
29079,Portugal,2014,8,C03-Diuretics,"Million US$, purchasing power parity",38.8
29080,Portugal,2014,8,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
29081,Portugal,2014,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,3.7
29082,Portugal,2014,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",431.9
29083,Portugal,2014,8,C03-Diuretics,Million US$ at exchange rate,29.8
29084,Portugal,2014,8,C03-Diuretics,Million of national currency units,22.5
29085,Portugal,2014,8,A02A-Antacids,Million of national currency units,4.7
29086,Portugal,2014,8,N06A-Antidepressants,Million of national currency units,95.4
29087,Portugal,2014,8,C10-Lipid modifying agents,Million of national currency units,157.8
29088,Portugal,2014,8,A02A-Antacids,Million US$ at exchange rate,6.2
29089,Portugal,2014,8,A02A-Antacids,"Million US$, purchasing power parity",8.1
29090,Portugal,2014,8,N06A-Antidepressants,"/capita, US$ exchange rate",12.2
29091,Portugal,2014,8,N06A-Antidepressants,Million US$ at exchange rate,126.7
29092,Portugal,2014,8,N06A-Antidepressants,"Million US$, purchasing power parity",164.8
29093,Portugal,2014,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.8
29094,Portugal,2014,8,C08-Calcium channel blockers,Million US$ at exchange rate,35.8
29095,Portugal,2014,8,A02A-Antacids,"/capita, US$ exchange rate",0.6
29096,Portugal,2014,8,C08-Calcium channel blockers,Million of national currency units,27.0
29097,Portugal,2014,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",46.6
29098,Portugal,2014,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.5
29099,Portugal,2014,8,C08-Calcium channel blockers,% of total sales,1.1
29100,Portugal,2014,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.4
29101,Portugal,2014,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,155.6
29102,Portugal,2014,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",272.7
29103,Portugal,2014,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,200.8
29104,Portugal,2014,8,G-Genito urinary system and sex hormones,Million of national currency units,151.1
29105,Portugal,2014,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",26.2
29106,Portugal,2014,8,C10-Lipid modifying agents,% of total sales,6.6
29107,Portugal,2014,8,R03-Drugs for obstructive airway diseases,Million of national currency units,117.1
29108,Portugal,2014,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.2
29109,Portugal,2014,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",202.3
29110,Portugal,2014,8,C10-Lipid modifying agents,Million US$ at exchange rate,209.7
29111,Portugal,2014,8,N06A-Antidepressants,% of total sales,4.0
29112,Portugal,2014,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",15.0
29113,Portugal,2014,8,R03-Drugs for obstructive airway diseases,% of total sales,4.9
29114,Portugal,2014,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.4
29115,Portugal,2014,8,N02-Analgesics,% of total sales,5.1
29116,Portugal,2014,8,J01-Antibacterials for systemic use,Million of national currency units,64.8
29117,Portugal,2014,8,N-Nervous system,"Million US$, purchasing power parity",882.9
29118,Portugal,2014,8,N02-Analgesics,"/capita, US$ purchasing power parity",20.2
29119,Portugal,2014,8,N02-Analgesics,"/capita, US$ exchange rate",15.5
29120,Portugal,2014,8,N05B-Anxiolytics,Million US$ at exchange rate,72.8
29121,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,98.3
29122,Portugal,2014,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,86.1
29123,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,0.9
29124,Portugal,2014,8,N05B-Anxiolytics,Million of national currency units,54.8
29125,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
29126,Portugal,2014,8,J-Antiinfectives for systemic use,Million of national currency units,119.0
29127,Portugal,2014,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.5
29128,Portugal,2014,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",39.7
29129,Portugal,2014,8,A10-Drugs used in diabetes,% of total sales,10.0
29130,Portugal,2014,8,N-Nervous system,Million of national currency units,511.1
29131,Portugal,2014,8,N-Nervous system,Million US$ at exchange rate,678.9
29132,Portugal,2014,8,N02-Analgesics,Million of national currency units,121.6
29133,Portugal,2014,8,N02-Analgesics,Million US$ at exchange rate,161.5
29134,Portugal,2014,8,N02-Analgesics,"Million US$, purchasing power parity",210.0
29135,Portugal,2014,8,N-Nervous system,"/capita, US$ exchange rate",65.3
29136,Portugal,2014,8,N-Nervous system,"/capita, US$ purchasing power parity",84.9
29137,Portugal,2014,8,N-Nervous system,% of total sales,21.3
29138,Portugal,2014,8,J01-Antibacterials for systemic use,% of total sales,2.7
29139,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.0
29140,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",108.4
29141,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,4.1
29142,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",16.3
29143,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",12.6
29144,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,130.6
29145,Portugal,2014,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",169.9
29146,Portugal,2014,8,N05B-Anxiolytics,% of total sales,2.3
29147,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.4
29148,Portugal,2014,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",9.1
29149,Portugal,2014,8,N05B-Anxiolytics,"Million US$, purchasing power parity",94.6
29150,Portugal,2014,8,N05B-Anxiolytics,"/capita, US$ exchange rate",7.0
29151,Portugal,2014,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.8
29152,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.6
29153,Portugal,2014,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",112.0
29154,Portugal,2014,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.3
29155,Portugal,2014,8,N05C-Hypnotics and sedatives,% of total sales,0.9
29156,Portugal,2014,8,M-Musculo-skeletal system,Million of national currency units,172.5
29157,Portugal,2014,8,A10-Drugs used in diabetes,Million US$ at exchange rate,317.3
29158,Portugal,2014,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,158.1
29159,Portugal,2014,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",36.7
29160,Portugal,2014,8,M-Musculo-skeletal system,Million US$ at exchange rate,229.1
29161,Portugal,2014,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,28.3
29162,Portugal,2014,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.5
29163,Portugal,2014,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",2.7
29164,Portugal,2014,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",205.6
29165,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",2.7
29166,Portugal,2014,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",412.6
29167,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,83.3
29168,Portugal,2014,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,62.7
29169,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",3.6
29170,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",37.1
29171,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,21.5
29172,Portugal,2014,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.2
29173,Portugal,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,28.6
29174,Portugal,2014,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",28.6
29175,Portugal,2014,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.0
29176,Portugal,2014,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",19.8
29177,Portugal,2014,8,J-Antiinfectives for systemic use,% of total sales,5.0
29178,Portugal,2014,8,M-Musculo-skeletal system,% of total sales,7.2
29179,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.5
29180,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",8.1
29181,Portugal,2014,8,A10-Drugs used in diabetes,Million of national currency units,238.9
29182,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,84.1
29183,Portugal,2014,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",298.0
29184,Portugal,2014,8,N05C-Hypnotics and sedatives,Million of national currency units,21.3
29185,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,63.3
29186,Portugal,2014,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",109.3
29187,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",38.5
29188,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,Million of national currency units,22.2
29189,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,24.6
29190,Slovenia,2016,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.7
29191,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.9
29192,Slovenia,2016,7,C-Cardiovascular system,Million US$ at exchange rate,83.7
29193,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.6
29194,Slovenia,2016,7,N02-Analgesics,"/capita, US$ purchasing power parity",15.6
29195,Slovenia,2016,7,N02-Analgesics,% of total sales,4.0
29196,Slovenia,2016,7,N02-Analgesics,"Million US$, purchasing power parity",32.2
29197,Slovenia,2016,7,N02-Analgesics,"/capita, US$ exchange rate",10.0
29198,Slovenia,2016,7,C02-Antihypertensives,"Million US$, purchasing power parity",5.5
29199,Slovenia,2016,7,C08-Calcium channel blockers,% of total sales,1.3
29200,Slovenia,2016,7,C-Cardiovascular system,"Million US$, purchasing power parity",130.9
29201,Slovenia,2016,7,R03-Drugs for obstructive airway diseases,% of total sales,4.8
29202,Slovenia,2016,7,C02-Antihypertensives,"/capita, US$ exchange rate",1.7
29203,Slovenia,2016,7,R-Respiratory system,Million US$ at exchange rate,30.1
29204,Slovenia,2016,7,C08-Calcium channel blockers,Million US$ at exchange rate,6.6
29205,Slovenia,2016,7,R-Respiratory system,"/capita, US$ exchange rate",14.6
29206,Slovenia,2016,7,R-Respiratory system,"Million US$, purchasing power parity",47.1
29207,Slovenia,2016,7,R-Respiratory system,Million of national currency units,27.2
29208,Slovenia,2016,7,C02-Antihypertensives,Million US$ at exchange rate,3.5
29209,Slovenia,2016,7,C08-Calcium channel blockers,Million of national currency units,6.0
29210,Slovenia,2016,7,C02-Antihypertensives,Million of national currency units,3.2
29211,Slovenia,2016,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.0
29212,Slovenia,2016,7,C-Cardiovascular system,Million of national currency units,75.6
29213,Slovenia,2016,7,J01-Antibacterials for systemic use,% of total sales,2.4
29214,Slovenia,2016,7,R-Respiratory system,% of total sales,5.8
29215,Slovenia,2016,7,R-Respiratory system,"/capita, US$ purchasing power parity",22.8
29216,Slovenia,2016,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2
29217,Slovenia,2016,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.3
29218,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,10.8
29219,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.9
29220,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.0
29221,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.3
29222,Slovenia,2016,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",33.6
29223,Slovenia,2016,7,B-Blood and blood forming organs,% of total sales,8.6
29224,Slovenia,2016,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",69.3
29225,Slovenia,2016,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.4
29226,Slovenia,2016,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.5
29227,Slovenia,2016,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.4
29228,Slovenia,2016,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.4
29229,Slovenia,2016,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.0
29230,Slovenia,2016,7,B-Blood and blood forming organs,Million US$ at exchange rate,44.3
29231,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.8
29232,Slovenia,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",18.7
29233,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",48.8
29234,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,31.2
29235,Slovenia,2016,7,A-Alimentary tract and metabolism,% of total sales,12.0
29236,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.1
29237,Slovenia,2016,7,N02-Analgesics,Million of national currency units,18.6
29238,Slovenia,2016,7,N02-Analgesics,Million US$ at exchange rate,20.6
29239,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,28.2
29240,Slovenia,2016,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.1
29241,Slovenia,2016,7,C-Cardiovascular system,"/capita, US$ exchange rate",40.5
29242,Slovenia,2016,7,A-Alimentary tract and metabolism,Million of national currency units,56.1
29243,Slovenia,2016,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,62.1
29244,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.0
29245,Slovenia,2016,7,J01-Antibacterials for systemic use,Million of national currency units,11.2
29246,Slovenia,2016,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",30.1
29247,Slovenia,2016,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",97.3
29248,Slovenia,2016,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",23.6
29249,Slovenia,2016,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
29250,Slovenia,2016,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7
29251,Slovenia,2016,7,N05B-Anxiolytics,% of total sales,0.6
29252,Slovenia,2016,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
29253,Slovenia,2016,7,N06A-Antidepressants,Million of national currency units,11.2
29254,Slovenia,2016,7,N06A-Antidepressants,Million US$ at exchange rate,12.4
29255,Slovenia,2016,7,N05B-Anxiolytics,Million US$ at exchange rate,3.0
29256,Slovenia,2016,7,N05B-Anxiolytics,Million of national currency units,2.7
29257,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,7.5
29258,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.3
29259,Slovenia,2016,7,N-Nervous system,"/capita, US$ exchange rate",34.9
29260,Slovenia,2016,7,N-Nervous system,"/capita, US$ purchasing power parity",54.7
29261,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
29262,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.6
29263,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",13.0
29264,Slovenia,2016,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.0
29265,Slovenia,2016,7,A02A-Antacids,Million of national currency units,0.7
29266,Slovenia,2016,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
29267,Slovenia,2016,7,A02A-Antacids,Million US$ at exchange rate,0.8
29268,Slovenia,2016,7,A02A-Antacids,"Million US$, purchasing power parity",1.3
29269,Slovenia,2016,7,C10-Lipid modifying agents,% of total sales,3.0
29270,Slovenia,2016,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.8
29271,Slovenia,2016,7,C01A-Cardiac glycosides,% of total sales,0.1
29272,Slovenia,2016,7,Total pharmaceutical sales,Million of national currency units,466.7
29273,Slovenia,2016,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.4
29274,Slovenia,2016,7,N06A-Antidepressants,% of total sales,2.4
29275,Slovenia,2016,7,N06A-Antidepressants,"Million US$, purchasing power parity",19.4
29276,Slovenia,2016,7,N06A-Antidepressants,"/capita, US$ exchange rate",6.0
29277,Slovenia,2016,7,A02A-Antacids,"/capita, US$ exchange rate",0.4
29278,Slovenia,2016,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
29279,Slovenia,2016,7,A02A-Antacids,% of total sales,0.2
29280,Slovenia,2016,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0
29281,Slovenia,2016,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3
29282,Slovenia,2016,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1
29283,Slovenia,2016,7,N05C-Hypnotics and sedatives,% of total sales,0.5
29284,Slovenia,2016,7,C03-Diuretics,Million US$ at exchange rate,7.0
29285,Slovenia,2016,7,C03-Diuretics,"Million US$, purchasing power parity",11.0
29286,Slovenia,2016,7,C03-Diuretics,Million of national currency units,6.4
29287,Slovenia,2016,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.4
29288,Slovenia,2016,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",27.0
29289,Slovenia,2016,7,M-Musculo-skeletal system,% of total sales,3.3
29290,Slovenia,2016,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.1
29291,Slovenia,2016,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.6
29292,Slovenia,2016,7,N05C-Hypnotics and sedatives,Million of national currency units,2.4
29293,Slovenia,2016,7,M-Musculo-skeletal system,Million of national currency units,15.6
29294,Slovenia,2016,7,M-Musculo-skeletal system,Million US$ at exchange rate,17.3
29295,Slovenia,2016,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
29296,Slovenia,2016,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
29297,Slovenia,2016,7,C03-Diuretics,% of total sales,1.4
29298,Slovenia,2016,7,C01A-Cardiac glycosides,Million of national currency units,0.3
29299,Slovenia,2016,7,N-Nervous system,Million US$ at exchange rate,72.1
29300,Slovenia,2016,7,N-Nervous system,"Million US$, purchasing power parity",112.9
29301,Slovenia,2016,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
29302,Slovenia,2016,7,N-Nervous system,Million of national currency units,65.1
29303,Slovenia,2016,7,G-Genito urinary system and sex hormones,Million of national currency units,23.5
29304,Slovenia,2016,7,G-Genito urinary system and sex hormones,% of total sales,5.0
29305,Slovenia,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.7
29306,Slovenia,2016,7,C03-Diuretics,"/capita, US$ exchange rate",3.4
29307,Slovenia,2016,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.3
29308,Slovenia,2016,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,26.0
29309,Slovenia,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.6
29310,Slovenia,2016,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",40.7
29311,Slovenia,2016,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.4
29312,Slovenia,2016,7,C07-Beta blocking agents,% of total sales,2.2
29313,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,9.5
29314,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",14.9
29315,Slovenia,2016,7,A10-Drugs used in diabetes,Million of national currency units,30.4
29316,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,10.6
29317,Slovenia,2016,7,C07-Beta blocking agents,Million US$ at exchange rate,11.1
29318,Slovenia,2016,7,C07-Beta blocking agents,Million of national currency units,10.1
29319,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.7
29320,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.6
29321,Slovenia,2016,7,C07-Beta blocking agents,"Million US$, purchasing power parity",17.4
29322,Slovenia,2016,7,A10-Drugs used in diabetes,Million US$ at exchange rate,33.6
29323,Slovenia,2016,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4
29324,Slovenia,2016,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",15.8
29325,Slovenia,2016,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,32.7
29326,Slovenia,2016,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",51.1
29327,Slovenia,2016,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",24.8
29328,Slovenia,2016,7,A10-Drugs used in diabetes,% of total sales,6.5
29329,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
29330,Slovenia,2016,7,J-Antiinfectives for systemic use,% of total sales,6.3
29331,Slovenia,2016,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.3
29332,Slovenia,2016,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",25.5
29333,Slovenia,2016,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",52.6
29334,Slovenia,2016,7,J-Antiinfectives for systemic use,Million of national currency units,29.5
29335,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.2
29336,Slovenia,2016,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.6
29337,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",18.3
29338,Slovenia,2016,7,C-Cardiovascular system,% of total sales,16.2
29339,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
29340,Slovenia,2016,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",63.4
29341,Slovenia,2016,7,Total pharmaceutical sales,"Million US$, purchasing power parity",808.7
29342,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
29343,Slovenia,2016,7,C10-Lipid modifying agents,Million US$ at exchange rate,15.6
29344,Slovenia,2016,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.5
29345,Slovenia,2016,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",24.4
29346,Slovenia,2016,7,B-Blood and blood forming organs,Million of national currency units,40.0
29347,Slovenia,2016,7,Total pharmaceutical sales,Million US$ at exchange rate,516.6
29348,Slovenia,2016,7,C10-Lipid modifying agents,Million of national currency units,14.1
29349,Slovenia,2016,7,Total pharmaceutical sales,"/capita, US$ exchange rate",250.2
29350,Slovenia,2016,7,N-Nervous system,% of total sales,14.0
29351,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.3
29352,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.7
29353,Slovenia,2016,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.9
29354,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1
29355,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0
29356,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7
29357,Slovenia,2016,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
29358,Slovenia,2016,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",391.6
29359,Slovenia,2016,7,C02-Antihypertensives,% of total sales,0.7
29360,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",35.8
29361,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,Million of national currency units,21.3
29362,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,23.6
29363,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,% of total sales,4.8
29364,Slovenia,2015,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.8
29365,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.5
29366,Slovenia,2015,7,C-Cardiovascular system,Million US$ at exchange rate,85.5
29367,Slovenia,2015,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.3
29368,Slovenia,2015,7,C-Cardiovascular system,"Million US$, purchasing power parity",129.4
29369,Slovenia,2015,7,N02-Analgesics,"/capita, US$ purchasing power parity",15.0
29370,Slovenia,2015,7,N02-Analgesics,% of total sales,4.1
29371,Slovenia,2015,7,N02-Analgesics,"Million US$, purchasing power parity",30.9
29372,Slovenia,2015,7,N02-Analgesics,"/capita, US$ exchange rate",9.9
29373,Slovenia,2015,7,C08-Calcium channel blockers,% of total sales,1.4
29374,Slovenia,2015,7,C02-Antihypertensives,"/capita, US$ exchange rate",1.8
29375,Slovenia,2015,7,R-Respiratory system,Million US$ at exchange rate,29.3
29376,Slovenia,2015,7,C08-Calcium channel blockers,Million US$ at exchange rate,6.8
29377,Slovenia,2015,7,R-Respiratory system,"/capita, US$ exchange rate",14.2
29378,Slovenia,2015,7,R-Respiratory system,"Million US$, purchasing power parity",44.4
29379,Slovenia,2015,7,C02-Antihypertensives,"Million US$, purchasing power parity",5.7
29380,Slovenia,2015,7,C02-Antihypertensives,Million US$ at exchange rate,3.8
29381,Slovenia,2015,7,C08-Calcium channel blockers,Million of national currency units,6.2
29382,Slovenia,2015,7,C-Cardiovascular system,Million of national currency units,77.0
29383,Slovenia,2015,7,C02-Antihypertensives,Million of national currency units,3.4
29384,Slovenia,2015,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.0
29385,Slovenia,2015,7,R-Respiratory system,Million of national currency units,26.4
29386,Slovenia,2015,7,J01-Antibacterials for systemic use,% of total sales,2.6
29387,Slovenia,2015,7,R-Respiratory system,% of total sales,5.9
29388,Slovenia,2015,7,R-Respiratory system,"/capita, US$ purchasing power parity",21.5
29389,Slovenia,2015,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.3
29390,Slovenia,2015,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.3
29391,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.0
29392,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9.9
29393,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.1
29394,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
29395,Slovenia,2015,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",28.5
29396,Slovenia,2015,7,B-Blood and blood forming organs,% of total sales,7.8
29397,Slovenia,2015,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",58.8
29398,Slovenia,2015,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.8
29399,Slovenia,2015,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.2
29400,Slovenia,2015,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.1
29401,Slovenia,2015,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.3
29402,Slovenia,2015,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.6
29403,Slovenia,2015,7,B-Blood and blood forming organs,Million US$ at exchange rate,38.8
29404,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.3
29405,Slovenia,2015,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",16.7
29406,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",50.4
29407,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,33.3
29408,Slovenia,2015,7,A-Alimentary tract and metabolism,% of total sales,11.8
29409,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",16.1
29410,Slovenia,2015,7,N02-Analgesics,Million of national currency units,18.4
29411,Slovenia,2015,7,N02-Analgesics,Million US$ at exchange rate,20.4
29412,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,30.0
29413,Slovenia,2015,7,C-Cardiovascular system,"/capita, US$ exchange rate",41.4
29414,Slovenia,2015,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.0
29415,Slovenia,2015,7,A-Alimentary tract and metabolism,Million of national currency units,52.8
29416,Slovenia,2015,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,58.5
29417,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.7
29418,Slovenia,2015,7,J01-Antibacterials for systemic use,Million of national currency units,11.4
29419,Slovenia,2015,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",28.4
29420,Slovenia,2015,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",88.6
29421,Slovenia,2015,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.4
29422,Slovenia,2015,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.5
29423,Slovenia,2015,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.6
29424,Slovenia,2015,7,N05B-Anxiolytics,% of total sales,0.6
29425,Slovenia,2015,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
29426,Slovenia,2015,7,N06A-Antidepressants,Million of national currency units,11.7
29427,Slovenia,2015,7,N06A-Antidepressants,Million US$ at exchange rate,13.0
29428,Slovenia,2015,7,N05B-Anxiolytics,Million of national currency units,2.7
29429,Slovenia,2015,7,N05B-Anxiolytics,Million US$ at exchange rate,3.1
29430,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,7.7
29431,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.5
29432,Slovenia,2015,7,N-Nervous system,"/capita, US$ exchange rate",35.4
29433,Slovenia,2015,7,N-Nervous system,"/capita, US$ purchasing power parity",53.7
29434,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
29435,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.7
29436,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",12.9
29437,Slovenia,2015,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.1
29438,Slovenia,2015,7,A02A-Antacids,Million of national currency units,0.7
29439,Slovenia,2015,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
29440,Slovenia,2015,7,A02A-Antacids,"Million US$, purchasing power parity",1.1
29441,Slovenia,2015,7,A02A-Antacids,Million US$ at exchange rate,0.7
29442,Slovenia,2015,7,C10-Lipid modifying agents,% of total sales,3.1
29443,Slovenia,2015,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.4
29444,Slovenia,2015,7,C01A-Cardiac glycosides,% of total sales,0.1
29445,Slovenia,2015,7,Total pharmaceutical sales,Million of national currency units,446.0
29446,Slovenia,2015,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.5
29447,Slovenia,2015,7,N06A-Antidepressants,% of total sales,2.6
29448,Slovenia,2015,7,N06A-Antidepressants,"Million US$, purchasing power parity",19.6
29449,Slovenia,2015,7,N06A-Antidepressants,"/capita, US$ exchange rate",6.3
29450,Slovenia,2015,7,A02A-Antacids,"/capita, US$ exchange rate",0.4
29451,Slovenia,2015,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
29452,Slovenia,2015,7,A02A-Antacids,% of total sales,0.1
29453,Slovenia,2015,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0
29454,Slovenia,2015,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1
29455,Slovenia,2015,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3
29456,Slovenia,2015,7,C03-Diuretics,"Million US$, purchasing power parity",10.5
29457,Slovenia,2015,7,C03-Diuretics,Million US$ at exchange rate,7.0
29458,Slovenia,2015,7,N05C-Hypnotics and sedatives,% of total sales,0.6
29459,Slovenia,2015,7,C03-Diuretics,Million of national currency units,6.3
29460,Slovenia,2015,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.7
29461,Slovenia,2015,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.4
29462,Slovenia,2015,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",26.3
29463,Slovenia,2015,7,M-Musculo-skeletal system,% of total sales,3.5
29464,Slovenia,2015,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.8
29465,Slovenia,2015,7,N05C-Hypnotics and sedatives,Million of national currency units,2.5
29466,Slovenia,2015,7,M-Musculo-skeletal system,Million US$ at exchange rate,17.4
29467,Slovenia,2015,7,M-Musculo-skeletal system,Million of national currency units,15.7
29468,Slovenia,2015,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.3
29469,Slovenia,2015,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
29470,Slovenia,2015,7,C03-Diuretics,% of total sales,1.4
29471,Slovenia,2015,7,C01A-Cardiac glycosides,Million of national currency units,0.3
29472,Slovenia,2015,7,N-Nervous system,Million US$ at exchange rate,73.2
29473,Slovenia,2015,7,N-Nervous system,"Million US$, purchasing power parity",110.8
29474,Slovenia,2015,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
29475,Slovenia,2015,7,N-Nervous system,Million of national currency units,65.9
29476,Slovenia,2015,7,G-Genito urinary system and sex hormones,Million of national currency units,22.6
29477,Slovenia,2015,7,G-Genito urinary system and sex hormones,% of total sales,5.1
29478,Slovenia,2015,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",18.4
29479,Slovenia,2015,7,C03-Diuretics,"/capita, US$ exchange rate",3.4
29480,Slovenia,2015,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.1
29481,Slovenia,2015,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,25.1
29482,Slovenia,2015,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",38.0
29483,Slovenia,2015,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.2
29484,Slovenia,2015,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.7
29485,Slovenia,2015,7,C07-Beta blocking agents,% of total sales,2.1
29486,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,9.9
29487,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",15.0
29488,Slovenia,2015,7,A10-Drugs used in diabetes,Million of national currency units,28.8
29489,Slovenia,2015,7,A10-Drugs used in diabetes,Million US$ at exchange rate,32.0
29490,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,10.7
29491,Slovenia,2015,7,C07-Beta blocking agents,Million US$ at exchange rate,10.5
29492,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,11.9
29493,Slovenia,2015,7,C07-Beta blocking agents,Million of national currency units,9.5
29494,Slovenia,2015,7,C07-Beta blocking agents,"Million US$, purchasing power parity",15.9
29495,Slovenia,2015,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.1
29496,Slovenia,2015,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.3
29497,Slovenia,2015,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",44.7
29498,Slovenia,2015,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",21.6
29499,Slovenia,2015,7,A10-Drugs used in diabetes,% of total sales,6.5
29500,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
29501,Slovenia,2015,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,29.5
29502,Slovenia,2015,7,J-Antiinfectives for systemic use,% of total sales,6.0
29503,Slovenia,2015,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",15.5
29504,Slovenia,2015,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.5
29505,Slovenia,2015,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",48.4
29506,Slovenia,2015,7,J-Antiinfectives for systemic use,Million of national currency units,26.6
29507,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.3
29508,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.8
29509,Slovenia,2015,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.9
29510,Slovenia,2015,7,C-Cardiovascular system,% of total sales,17.3
29511,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
29512,Slovenia,2015,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",62.7
29513,Slovenia,2015,7,Total pharmaceutical sales,"Million US$, purchasing power parity",749.3
29514,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
29515,Slovenia,2015,7,C10-Lipid modifying agents,Million US$ at exchange rate,15.5
29516,Slovenia,2015,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",23.5
29517,Slovenia,2015,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.5
29518,Slovenia,2015,7,B-Blood and blood forming organs,Million of national currency units,35.0
29519,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",18.0
29520,Slovenia,2015,7,C10-Lipid modifying agents,Million of national currency units,14.0
29521,Slovenia,2015,7,Total pharmaceutical sales,Million US$ at exchange rate,494.9
29522,Slovenia,2015,7,Total pharmaceutical sales,"/capita, US$ exchange rate",239.8
29523,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.4
29524,Slovenia,2015,7,N-Nervous system,% of total sales,14.8
29525,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.7
29526,Slovenia,2015,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.7
29527,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.2
29528,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0
29529,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
29530,Slovenia,2015,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",363.1
29531,Slovenia,2015,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7
29532,Slovenia,2015,7,C02-Antihypertensives,% of total sales,0.8
29533,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",36.1
29534,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,Million of national currency units,21.3
29535,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,28.3
29536,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",13.7
29537,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,% of total sales,4.9
29538,Slovenia,2014,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.3
29539,Slovenia,2014,7,C-Cardiovascular system,Million US$ at exchange rate,107.8
29540,Slovenia,2014,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.5
29541,Slovenia,2014,7,N02-Analgesics,"/capita, US$ purchasing power parity",14.6
29542,Slovenia,2014,7,N02-Analgesics,% of total sales,4.1
29543,Slovenia,2014,7,N02-Analgesics,"Million US$, purchasing power parity",30.1
29544,Slovenia,2014,7,N02-Analgesics,"/capita, US$ exchange rate",11.5
29545,Slovenia,2014,7,C08-Calcium channel blockers,% of total sales,1.5
29546,Slovenia,2014,7,C-Cardiovascular system,"Million US$, purchasing power parity",137.3
29547,Slovenia,2014,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.6
29548,Slovenia,2014,7,R-Respiratory system,Million US$ at exchange rate,35.4
29549,Slovenia,2014,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.8
29550,Slovenia,2014,7,C08-Calcium channel blockers,Million US$ at exchange rate,8.5
29551,Slovenia,2014,7,R-Respiratory system,"/capita, US$ exchange rate",17.2
29552,Slovenia,2014,7,R-Respiratory system,"Million US$, purchasing power parity",45.1
29553,Slovenia,2014,7,C02-Antihypertensives,"Million US$, purchasing power parity",6.8
29554,Slovenia,2014,7,C08-Calcium channel blockers,Million of national currency units,6.4
29555,Slovenia,2014,7,C02-Antihypertensives,Million US$ at exchange rate,5.3
29556,Slovenia,2014,7,C-Cardiovascular system,Million of national currency units,81.2
29557,Slovenia,2014,7,C02-Antihypertensives,Million of national currency units,4.0
29558,Slovenia,2014,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.2
29559,Slovenia,2014,7,J01-Antibacterials for systemic use,% of total sales,2.6
29560,Slovenia,2014,7,R-Respiratory system,% of total sales,6.2
29561,Slovenia,2014,7,R-Respiratory system,"/capita, US$ purchasing power parity",21.9
29562,Slovenia,2014,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.1
29563,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,12.3
29564,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9.3
29565,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6
29566,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
29567,Slovenia,2014,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.6
29568,Slovenia,2014,7,B-Blood and blood forming organs,% of total sales,7.2
29569,Slovenia,2014,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",52.9
29570,Slovenia,2014,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",20.1
29571,Slovenia,2014,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.9
29572,Slovenia,2014,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2
29573,Slovenia,2014,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.2
29574,Slovenia,2014,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,14.8
29575,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",15.7
29576,Slovenia,2014,7,B-Blood and blood forming organs,Million US$ at exchange rate,41.5
29577,Slovenia,2014,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.0
29578,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",57.1
29579,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.8
29580,Slovenia,2014,7,A-Alimentary tract and metabolism,% of total sales,11.6
29581,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,44.9
29582,Slovenia,2014,7,N02-Analgesics,Million of national currency units,17.8
29583,Slovenia,2014,7,N02-Analgesics,Million US$ at exchange rate,23.6
29584,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,33.8
29585,Slovenia,2014,7,C-Cardiovascular system,"/capita, US$ exchange rate",52.3
29586,Slovenia,2014,7,A-Alimentary tract and metabolism,Million of national currency units,50.1
29587,Slovenia,2014,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,66.6
29588,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.8
29589,Slovenia,2014,7,J01-Antibacterials for systemic use,Million of national currency units,11.2
29590,Slovenia,2014,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",32.3
29591,Slovenia,2014,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",84.8
29592,Slovenia,2014,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.1
29593,Slovenia,2014,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",27.7
29594,Slovenia,2014,7,R-Respiratory system,Million of national currency units,26.6
29595,Slovenia,2014,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.8
29596,Slovenia,2014,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.8
29597,Slovenia,2014,7,N05B-Anxiolytics,% of total sales,0.7
29598,Slovenia,2014,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
29599,Slovenia,2014,7,N06A-Antidepressants,Million of national currency units,13.5
29600,Slovenia,2014,7,N06A-Antidepressants,Million US$ at exchange rate,17.9
29601,Slovenia,2014,7,N05B-Anxiolytics,Million US$ at exchange rate,3.7
29602,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,8.1
29603,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,10.8
29604,Slovenia,2014,7,N-Nervous system,"/capita, US$ exchange rate",44.9
29605,Slovenia,2014,7,N-Nervous system,"/capita, US$ purchasing power parity",57.1
29606,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.7
29607,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.9
29608,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",13.7
29609,Slovenia,2014,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.2
29610,Slovenia,2014,7,A02A-Antacids,Million of national currency units,0.6
29611,Slovenia,2014,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
29612,Slovenia,2014,7,A02A-Antacids,"Million US$, purchasing power parity",1.0
29613,Slovenia,2014,7,A02A-Antacids,Million US$ at exchange rate,0.8
29614,Slovenia,2014,7,C10-Lipid modifying agents,% of total sales,3.3
29615,Slovenia,2014,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",11.8
29616,Slovenia,2014,7,C01A-Cardiac glycosides,% of total sales,0.1
29617,Slovenia,2014,7,Total pharmaceutical sales,Million of national currency units,432.3
29618,Slovenia,2014,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.1
29619,Slovenia,2014,7,N06A-Antidepressants,% of total sales,3.1
29620,Slovenia,2014,7,N06A-Antidepressants,"Million US$, purchasing power parity",22.8
29621,Slovenia,2014,7,N06A-Antidepressants,"/capita, US$ exchange rate",8.7
29622,Slovenia,2014,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
29623,Slovenia,2014,7,A02A-Antacids,"/capita, US$ exchange rate",0.4
29624,Slovenia,2014,7,N05B-Anxiolytics,Million of national currency units,2.8
29625,Slovenia,2014,7,A02A-Antacids,% of total sales,0.1
29626,Slovenia,2014,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0
29627,Slovenia,2014,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
29628,Slovenia,2014,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1
29629,Slovenia,2014,7,N05C-Hypnotics and sedatives,% of total sales,0.6
29630,Slovenia,2014,7,C03-Diuretics,"Million US$, purchasing power parity",10.3
29631,Slovenia,2014,7,C03-Diuretics,Million US$ at exchange rate,8.1
29632,Slovenia,2014,7,C03-Diuretics,Million of national currency units,6.1
29633,Slovenia,2014,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.1
29634,Slovenia,2014,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",12.9
29635,Slovenia,2014,7,M-Musculo-skeletal system,% of total sales,3.6
29636,Slovenia,2014,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",26.6
29637,Slovenia,2014,7,N05C-Hypnotics and sedatives,Million of national currency units,2.4
29638,Slovenia,2014,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.2
29639,Slovenia,2014,7,M-Musculo-skeletal system,Million of national currency units,15.7
29640,Slovenia,2014,7,M-Musculo-skeletal system,Million US$ at exchange rate,20.9
29641,Slovenia,2014,7,C03-Diuretics,"/capita, US$ exchange rate",3.9
29642,Slovenia,2014,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
29643,Slovenia,2014,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
29644,Slovenia,2014,7,C01A-Cardiac glycosides,Million of national currency units,0.3
29645,Slovenia,2014,7,N-Nervous system,Million US$ at exchange rate,92.5
29646,Slovenia,2014,7,N-Nervous system,"Million US$, purchasing power parity",117.8
29647,Slovenia,2014,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
29648,Slovenia,2014,7,N-Nervous system,Million of national currency units,69.6
29649,Slovenia,2014,7,G-Genito urinary system and sex hormones,Million of national currency units,23.8
29650,Slovenia,2014,7,C03-Diuretics,% of total sales,1.4
29651,Slovenia,2014,7,G-Genito urinary system and sex hormones,% of total sales,5.5
29652,Slovenia,2014,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.0
29653,Slovenia,2014,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.5
29654,Slovenia,2014,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,31.6
29655,Slovenia,2014,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",40.2
29656,Slovenia,2014,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.3
29657,Slovenia,2014,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.3
29658,Slovenia,2014,7,C07-Beta blocking agents,% of total sales,2.1
29659,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",14.5
29660,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,11.4
29661,Slovenia,2014,7,A10-Drugs used in diabetes,Million of national currency units,28.3
29662,Slovenia,2014,7,A10-Drugs used in diabetes,Million US$ at exchange rate,37.6
29663,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,14.5
29664,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,10.9
29665,Slovenia,2014,7,C07-Beta blocking agents,Million US$ at exchange rate,11.9
29666,Slovenia,2014,7,C07-Beta blocking agents,Million of national currency units,8.9
29667,Slovenia,2014,7,C07-Beta blocking agents,"Million US$, purchasing power parity",15.1
29668,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.5
29669,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
29670,Slovenia,2014,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.8
29671,Slovenia,2014,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.8
29672,Slovenia,2014,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",16.3
29673,Slovenia,2014,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",33.6
29674,Slovenia,2014,7,A10-Drugs used in diabetes,% of total sales,6.5
29675,Slovenia,2014,7,J-Antiinfectives for systemic use,% of total sales,4.6
29676,Slovenia,2014,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,26.4
29677,Slovenia,2014,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.2
29678,Slovenia,2014,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.2
29679,Slovenia,2014,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",47.9
29680,Slovenia,2014,7,J-Antiinfectives for systemic use,Million of national currency units,19.9
29681,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.5
29682,Slovenia,2014,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.0
29683,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",18.5
29684,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
29685,Slovenia,2014,7,C-Cardiovascular system,% of total sales,18.8
29686,Slovenia,2014,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",66.6
29687,Slovenia,2014,7,Total pharmaceutical sales,"Million US$, purchasing power parity",731.2
29688,Slovenia,2014,7,Total pharmaceutical sales,"/capita, US$ exchange rate",278.5
29689,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
29690,Slovenia,2014,7,C10-Lipid modifying agents,Million US$ at exchange rate,19.1
29691,Slovenia,2014,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",9.3
29692,Slovenia,2014,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",24.3
29693,Slovenia,2014,7,B-Blood and blood forming organs,Million of national currency units,31.3
29694,Slovenia,2014,7,C10-Lipid modifying agents,Million of national currency units,14.4
29695,Slovenia,2014,7,Total pharmaceutical sales,Million US$ at exchange rate,574.3
29696,Slovenia,2014,7,N-Nervous system,% of total sales,16.1
29697,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.5
29698,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.0
29699,Slovenia,2014,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.9
29700,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.4
29701,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.8
29702,Slovenia,2014,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",354.6
29703,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
29704,Slovenia,2014,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0
29705,Slovenia,2014,7,C02-Antihypertensives,% of total sales,0.9
29706,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",37.4
29707,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,Million of national currency units,22.1
29708,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,29.3
29709,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,% of total sales,4.9
29710,Slovenia,2013,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.6
29711,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.2
29712,Slovenia,2013,7,C-Cardiovascular system,Million US$ at exchange rate,133.7
29713,Slovenia,2013,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.2
29714,Slovenia,2013,7,N02-Analgesics,"/capita, US$ purchasing power parity",14.2
29715,Slovenia,2013,7,N02-Analgesics,% of total sales,3.8
29716,Slovenia,2013,7,N02-Analgesics,"Million US$, purchasing power parity",29.2
29717,Slovenia,2013,7,N02-Analgesics,"/capita, US$ exchange rate",11.1
29718,Slovenia,2013,7,C08-Calcium channel blockers,% of total sales,1.5
29719,Slovenia,2013,7,C-Cardiovascular system,"Million US$, purchasing power parity",170.5
29720,Slovenia,2013,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.8
29721,Slovenia,2013,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",11.2
29722,Slovenia,2013,7,C08-Calcium channel blockers,Million US$ at exchange rate,8.8
29723,Slovenia,2013,7,R-Respiratory system,"/capita, US$ exchange rate",17.6
29724,Slovenia,2013,7,R-Respiratory system,"Million US$, purchasing power parity",46.1
29725,Slovenia,2013,7,C02-Antihypertensives,"Million US$, purchasing power parity",7.4
29726,Slovenia,2013,7,R-Respiratory system,Million US$ at exchange rate,36.2
29727,Slovenia,2013,7,C08-Calcium channel blockers,Million of national currency units,6.6
29728,Slovenia,2013,7,C02-Antihypertensives,Million US$ at exchange rate,5.8
29729,Slovenia,2013,7,C-Cardiovascular system,Million of national currency units,100.7
29730,Slovenia,2013,7,C02-Antihypertensives,Million of national currency units,4.4
29731,Slovenia,2013,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.5
29732,Slovenia,2013,7,J01-Antibacterials for systemic use,% of total sales,2.6
29733,Slovenia,2013,7,R-Respiratory system,% of total sales,6.0
29734,Slovenia,2013,7,R-Respiratory system,"/capita, US$ purchasing power parity",22.4
29735,Slovenia,2013,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.3
29736,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.7
29737,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,8.8
29738,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.3
29739,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
29740,Slovenia,2013,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.6
29741,Slovenia,2013,7,B-Blood and blood forming organs,% of total sales,6.4
29742,Slovenia,2013,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",48.5
29743,Slovenia,2013,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",18.5
29744,Slovenia,2013,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.6
29745,Slovenia,2013,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.5
29746,Slovenia,2013,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.5
29747,Slovenia,2013,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,15.4
29748,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",15.0
29749,Slovenia,2013,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.7
29750,Slovenia,2013,7,B-Blood and blood forming organs,Million US$ at exchange rate,38.1
29751,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",72.0
29752,Slovenia,2013,7,A-Alimentary tract and metabolism,% of total sales,11.1
29753,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",27.4
29754,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,56.5
29755,Slovenia,2013,7,N02-Analgesics,Million US$ at exchange rate,22.9
29756,Slovenia,2013,7,N02-Analgesics,Million of national currency units,17.2
29757,Slovenia,2013,7,C-Cardiovascular system,"/capita, US$ exchange rate",64.9
29758,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,42.5
29759,Slovenia,2013,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.0
29760,Slovenia,2013,7,A-Alimentary tract and metabolism,Million of national currency units,49.9
29761,Slovenia,2013,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,66.3
29762,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.4
29763,Slovenia,2013,7,J01-Antibacterials for systemic use,Million of national currency units,11.6
29764,Slovenia,2013,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",32.2
29765,Slovenia,2013,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",84.5
29766,Slovenia,2013,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",35.0
29767,Slovenia,2013,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9
29768,Slovenia,2013,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
29769,Slovenia,2013,7,N05B-Anxiolytics,% of total sales,0.7
29770,Slovenia,2013,7,N05B-Anxiolytics,"Million US$, purchasing power parity",5.0
29771,Slovenia,2013,7,N06A-Antidepressants,Million of national currency units,14.5
29772,Slovenia,2013,7,N06A-Antidepressants,Million US$ at exchange rate,19.3
29773,Slovenia,2013,7,N05B-Anxiolytics,Million US$ at exchange rate,3.9
29774,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,10.9
29775,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,8.2
29776,Slovenia,2013,7,N-Nervous system,"/capita, US$ exchange rate",46.3
29777,Slovenia,2013,7,N-Nervous system,"/capita, US$ purchasing power parity",59.1
29778,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.8
29779,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.8
29780,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",14.0
29781,Slovenia,2013,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.3
29782,Slovenia,2013,7,A02A-Antacids,Million of national currency units,0.5
29783,Slovenia,2013,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
29784,Slovenia,2013,7,A02A-Antacids,"Million US$, purchasing power parity",0.9
29785,Slovenia,2013,7,A02A-Antacids,Million US$ at exchange rate,0.7
29786,Slovenia,2013,7,C10-Lipid modifying agents,% of total sales,5.5
29787,Slovenia,2013,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.3
29788,Slovenia,2013,7,C01A-Cardiac glycosides,% of total sales,0.1
29789,Slovenia,2013,7,Total pharmaceutical sales,Million of national currency units,451.1
29790,Slovenia,2013,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.9
29791,Slovenia,2013,7,N06A-Antidepressants,% of total sales,3.2
29792,Slovenia,2013,7,N06A-Antidepressants,"Million US$, purchasing power parity",24.6
29793,Slovenia,2013,7,N06A-Antidepressants,"/capita, US$ exchange rate",9.3
29794,Slovenia,2013,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
29795,Slovenia,2013,7,A02A-Antacids,"/capita, US$ exchange rate",0.4
29796,Slovenia,2013,7,N05B-Anxiolytics,Million of national currency units,3.0
29797,Slovenia,2013,7,A02A-Antacids,% of total sales,0.1
29798,Slovenia,2013,7,R-Respiratory system,Million of national currency units,27.2
29799,Slovenia,2013,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.1
29800,Slovenia,2013,7,N05C-Hypnotics and sedatives,% of total sales,0.6
29801,Slovenia,2013,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.3
29802,Slovenia,2013,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
29803,Slovenia,2013,7,C03-Diuretics,"Million US$, purchasing power parity",10.5
29804,Slovenia,2013,7,C03-Diuretics,Million of national currency units,6.2
29805,Slovenia,2013,7,C03-Diuretics,Million US$ at exchange rate,8.2
29806,Slovenia,2013,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.2
29807,Slovenia,2013,7,M-Musculo-skeletal system,% of total sales,3.9
29808,Slovenia,2013,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.3
29809,Slovenia,2013,7,N05C-Hypnotics and sedatives,Million of national currency units,2.5
29810,Slovenia,2013,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3
29811,Slovenia,2013,7,M-Musculo-skeletal system,Million of national currency units,17.4
29812,Slovenia,2013,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",29.4
29813,Slovenia,2013,7,M-Musculo-skeletal system,Million US$ at exchange rate,23.1
29814,Slovenia,2013,7,C03-Diuretics,"/capita, US$ exchange rate",4.0
29815,Slovenia,2013,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
29816,Slovenia,2013,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
29817,Slovenia,2013,7,C01A-Cardiac glycosides,Million of national currency units,0.3
29818,Slovenia,2013,7,G-Genito urinary system and sex hormones,Million of national currency units,23.5
29819,Slovenia,2013,7,N-Nervous system,Million US$ at exchange rate,95.5
29820,Slovenia,2013,7,N-Nervous system,"Million US$, purchasing power parity",121.8
29821,Slovenia,2013,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
29822,Slovenia,2013,7,N-Nervous system,Million of national currency units,71.9
29823,Slovenia,2013,7,G-Genito urinary system and sex hormones,% of total sales,5.2
29824,Slovenia,2013,7,C03-Diuretics,% of total sales,1.4
29825,Slovenia,2013,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.1
29826,Slovenia,2013,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3
29827,Slovenia,2013,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,31.1
29828,Slovenia,2013,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",39.7
29829,Slovenia,2013,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.1
29830,Slovenia,2013,7,C07-Beta blocking agents,% of total sales,1.9
29831,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",13.9
29832,Slovenia,2013,7,A10-Drugs used in diabetes,Million of national currency units,28.0
29833,Slovenia,2013,7,A10-Drugs used in diabetes,Million US$ at exchange rate,37.1
29834,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,15.5
29835,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,11.7
29836,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.9
29837,Slovenia,2013,7,C07-Beta blocking agents,Million US$ at exchange rate,11.6
29838,Slovenia,2013,7,C07-Beta blocking agents,Million of national currency units,8.7
29839,Slovenia,2013,7,C07-Beta blocking agents,"Million US$, purchasing power parity",14.7
29840,Slovenia,2013,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",7.2
29841,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.2
29842,Slovenia,2013,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6
29843,Slovenia,2013,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",13.7
29844,Slovenia,2013,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",17.5
29845,Slovenia,2013,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",36.0
29846,Slovenia,2013,7,A10-Drugs used in diabetes,% of total sales,6.2
29847,Slovenia,2013,7,J-Antiinfectives for systemic use,% of total sales,4.7
29848,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",19.8
29849,Slovenia,2013,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.0
29850,Slovenia,2013,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.0
29851,Slovenia,2013,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",47.4
29852,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.3
29853,Slovenia,2013,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,28.2
29854,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.8
29855,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
29856,Slovenia,2013,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",82.8
29857,Slovenia,2013,7,C-Cardiovascular system,% of total sales,22.3
29858,Slovenia,2013,7,Total pharmaceutical sales,"Million US$, purchasing power parity",764.0
29859,Slovenia,2013,7,Total pharmaceutical sales,"/capita, US$ exchange rate",290.8
29860,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
29861,Slovenia,2013,7,C10-Lipid modifying agents,Million US$ at exchange rate,32.8
29862,Slovenia,2013,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",41.8
29863,Slovenia,2013,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.9
29864,Slovenia,2013,7,B-Blood and blood forming organs,Million of national currency units,28.7
29865,Slovenia,2013,7,C10-Lipid modifying agents,Million of national currency units,24.7
29866,Slovenia,2013,7,Total pharmaceutical sales,Million US$ at exchange rate,599.1
29867,Slovenia,2013,7,N-Nervous system,% of total sales,15.9
29868,Slovenia,2013,7,J-Antiinfectives for systemic use,Million of national currency units,21.2
29869,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.6
29870,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.5
29871,Slovenia,2013,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",9.6
29872,Slovenia,2013,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
29873,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.8
29874,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.5
29875,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
29876,Slovenia,2013,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.1
29877,Slovenia,2013,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",370.9
29878,Slovenia,2013,7,C02-Antihypertensives,% of total sales,1.0
29879,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,29.3
29880,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",37.6
29881,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.3
29882,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,% of total sales,5.0
29883,Slovenia,2012,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.5
29884,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,Million of national currency units,22.8
29885,Slovenia,2012,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.3
29886,Slovenia,2012,7,C-Cardiovascular system,Million US$ at exchange rate,135.4
29887,Slovenia,2012,7,N02-Analgesics,"/capita, US$ purchasing power parity",12.8
29888,Slovenia,2012,7,N02-Analgesics,% of total sales,3.5
29889,Slovenia,2012,7,N02-Analgesics,"/capita, US$ exchange rate",10.0
29890,Slovenia,2012,7,C08-Calcium channel blockers,% of total sales,1.5
29891,Slovenia,2012,7,C-Cardiovascular system,"Million US$, purchasing power parity",173.6
29892,Slovenia,2012,7,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
29893,Slovenia,2012,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",11.0
29894,Slovenia,2012,7,C08-Calcium channel blockers,Million US$ at exchange rate,8.6
29895,Slovenia,2012,7,R-Respiratory system,"/capita, US$ exchange rate",17.6
29896,Slovenia,2012,7,R-Respiratory system,"Million US$, purchasing power parity",46.5
29897,Slovenia,2012,7,C02-Antihypertensives,"Million US$, purchasing power parity",7.1
29898,Slovenia,2012,7,R-Respiratory system,Million US$ at exchange rate,36.2
29899,Slovenia,2012,7,C08-Calcium channel blockers,Million of national currency units,6.7
29900,Slovenia,2012,7,C02-Antihypertensives,Million US$ at exchange rate,5.5
29901,Slovenia,2012,7,C-Cardiovascular system,Million of national currency units,105.4
29902,Slovenia,2012,7,C02-Antihypertensives,Million of national currency units,4.3
29903,Slovenia,2012,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.3
29904,Slovenia,2012,7,J01-Antibacterials for systemic use,% of total sales,2.5
29905,Slovenia,2012,7,N02-Analgesics,"Million US$, purchasing power parity",26.4
29906,Slovenia,2012,7,R-Respiratory system,% of total sales,6.2
29907,Slovenia,2012,7,R-Respiratory system,"/capita, US$ purchasing power parity",22.6
29908,Slovenia,2012,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",4.2
29909,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.5
29910,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,8.9
29911,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.2
29912,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
29913,Slovenia,2012,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.3
29914,Slovenia,2012,7,B-Blood and blood forming organs,% of total sales,5.6
29915,Slovenia,2012,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",41.9
29916,Slovenia,2012,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.9
29917,Slovenia,2012,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.8
29918,Slovenia,2012,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.1
29919,Slovenia,2012,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2
29920,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",14.7
29921,Slovenia,2012,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,14.7
29922,Slovenia,2012,7,B-Blood and blood forming organs,Million US$ at exchange rate,32.6
29923,Slovenia,2012,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.6
29924,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",77.4
29925,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",29.3
29926,Slovenia,2012,7,A-Alimentary tract and metabolism,% of total sales,11.4
29927,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,60.3
29928,Slovenia,2012,7,N02-Analgesics,Million US$ at exchange rate,20.6
29929,Slovenia,2012,7,N02-Analgesics,Million of national currency units,16.0
29930,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,47.0
29931,Slovenia,2012,7,C-Cardiovascular system,"/capita, US$ exchange rate",65.8
29932,Slovenia,2012,7,A-Alimentary tract and metabolism,Million of national currency units,51.8
29933,Slovenia,2012,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,66.6
29934,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,10.3
29935,Slovenia,2012,7,J01-Antibacterials for systemic use,Million of national currency units,11.4
29936,Slovenia,2012,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",32.4
29937,Slovenia,2012,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.5
29938,Slovenia,2012,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",85.4
29939,Slovenia,2012,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",37.6
29940,Slovenia,2012,7,R-Respiratory system,Million of national currency units,28.2
29941,Slovenia,2012,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.8
29942,Slovenia,2012,7,N05B-Anxiolytics,% of total sales,0.6
29943,Slovenia,2012,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
29944,Slovenia,2012,7,N06A-Antidepressants,Million US$ at exchange rate,18.8
29945,Slovenia,2012,7,N06A-Antidepressants,Million of national currency units,14.6
29946,Slovenia,2012,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7
29947,Slovenia,2012,7,N05B-Anxiolytics,Million US$ at exchange rate,3.7
29948,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,11.6
29949,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,9.1
29950,Slovenia,2012,7,N-Nervous system,"/capita, US$ exchange rate",46.3
29951,Slovenia,2012,7,N-Nervous system,"/capita, US$ purchasing power parity",59.4
29952,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",14.9
29953,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.3
29954,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,% of total sales,2.0
29955,Slovenia,2012,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",5.7
29956,Slovenia,2012,7,A02A-Antacids,Million of national currency units,0.5
29957,Slovenia,2012,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
29958,Slovenia,2012,7,A02A-Antacids,"Million US$, purchasing power parity",0.8
29959,Slovenia,2012,7,A02A-Antacids,Million US$ at exchange rate,0.6
29960,Slovenia,2012,7,C01A-Cardiac glycosides,% of total sales,0.1
29961,Slovenia,2012,7,C10-Lipid modifying agents,% of total sales,5.6
29962,Slovenia,2012,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.3
29963,Slovenia,2012,7,Total pharmaceutical sales,Million of national currency units,454.4
29964,Slovenia,2012,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.7
29965,Slovenia,2012,7,N06A-Antidepressants,% of total sales,3.2
29966,Slovenia,2012,7,N06A-Antidepressants,"Million US$, purchasing power parity",24.1
29967,Slovenia,2012,7,N06A-Antidepressants,"/capita, US$ exchange rate",9.1
29968,Slovenia,2012,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
29969,Slovenia,2012,7,A02A-Antacids,"/capita, US$ exchange rate",0.3
29970,Slovenia,2012,7,N05B-Anxiolytics,Million of national currency units,2.9
29971,Slovenia,2012,7,A02A-Antacids,% of total sales,0.1
29972,Slovenia,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.1
29973,Slovenia,2012,7,N05C-Hypnotics and sedatives,% of total sales,0.6
29974,Slovenia,2012,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.2
29975,Slovenia,2012,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.6
29976,Slovenia,2012,7,C03-Diuretics,"Million US$, purchasing power parity",10.0
29977,Slovenia,2012,7,C03-Diuretics,Million US$ at exchange rate,7.8
29978,Slovenia,2012,7,C03-Diuretics,Million of national currency units,6.0
29979,Slovenia,2012,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.6
29980,Slovenia,2012,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.9
29981,Slovenia,2012,7,M-Musculo-skeletal system,% of total sales,4.1
29982,Slovenia,2012,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",30.6
29983,Slovenia,2012,7,M-Musculo-skeletal system,Million of national currency units,18.6
29984,Slovenia,2012,7,N05C-Hypnotics and sedatives,Million of national currency units,2.6
29985,Slovenia,2012,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.3
29986,Slovenia,2012,7,M-Musculo-skeletal system,Million US$ at exchange rate,23.9
29987,Slovenia,2012,7,C03-Diuretics,"/capita, US$ exchange rate",3.8
29988,Slovenia,2012,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
29989,Slovenia,2012,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
29990,Slovenia,2012,7,G-Genito urinary system and sex hormones,Million of national currency units,24.7
29991,Slovenia,2012,7,C01A-Cardiac glycosides,Million of national currency units,0.3
29992,Slovenia,2012,7,N-Nervous system,Million US$ at exchange rate,95.2
29993,Slovenia,2012,7,N-Nervous system,"Million US$, purchasing power parity",122.2
29994,Slovenia,2012,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
29995,Slovenia,2012,7,N-Nervous system,Million of national currency units,74.1
29996,Slovenia,2012,7,G-Genito urinary system and sex hormones,% of total sales,5.4
29997,Slovenia,2012,7,C03-Diuretics,% of total sales,1.3
29998,Slovenia,2012,7,C03-Diuretics,"/capita, US$ purchasing power parity",4.8
29999,Slovenia,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.8
30000,Slovenia,2012,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,31.7
30001,Slovenia,2012,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",40.7
30002,Slovenia,2012,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.4
30003,Slovenia,2012,7,C07-Beta blocking agents,% of total sales,1.8
30004,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",12.9
30005,Slovenia,2012,7,A10-Drugs used in diabetes,Million of national currency units,28.2
30006,Slovenia,2012,7,A10-Drugs used in diabetes,Million US$ at exchange rate,36.2
30007,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,17.3
30008,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,13.4
30009,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,10.1
30010,Slovenia,2012,7,C07-Beta blocking agents,Million US$ at exchange rate,10.7
30011,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",22.1
30012,Slovenia,2012,7,C07-Beta blocking agents,Million of national currency units,8.3
30013,Slovenia,2012,7,C07-Beta blocking agents,"Million US$, purchasing power parity",13.8
30014,Slovenia,2012,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.7
30015,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,7.8
30016,Slovenia,2012,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.2
30017,Slovenia,2012,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.4
30018,Slovenia,2012,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.9
30019,Slovenia,2012,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",32.7
30020,Slovenia,2012,7,A10-Drugs used in diabetes,% of total sales,6.2
30021,Slovenia,2012,7,J-Antiinfectives for systemic use,% of total sales,4.4
30022,Slovenia,2012,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,25.5
30023,Slovenia,2012,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",22.6
30024,Slovenia,2012,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",46.4
30025,Slovenia,2012,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.6
30026,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
30027,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.9
30028,Slovenia,2012,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.3
30029,Slovenia,2012,7,C-Cardiovascular system,% of total sales,23.2
30030,Slovenia,2012,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",84.4
30031,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
30032,Slovenia,2012,7,Total pharmaceutical sales,"Million US$, purchasing power parity",748.8
30033,Slovenia,2012,7,Total pharmaceutical sales,"/capita, US$ exchange rate",283.8
30034,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
30035,Slovenia,2012,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",41.8
30036,Slovenia,2012,7,C10-Lipid modifying agents,Million US$ at exchange rate,32.6
30037,Slovenia,2012,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",15.8
30038,Slovenia,2012,7,B-Blood and blood forming organs,Million of national currency units,25.4
30039,Slovenia,2012,7,C10-Lipid modifying agents,Million of national currency units,25.3
30040,Slovenia,2012,7,Total pharmaceutical sales,Million US$ at exchange rate,583.8
30041,Slovenia,2012,7,J-Antiinfectives for systemic use,Million of national currency units,19.9
30042,Slovenia,2012,7,N-Nervous system,% of total sales,16.3
30043,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.4
30044,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",10.8
30045,Slovenia,2012,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.0
30046,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.4
30047,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
30048,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.9
30049,Slovenia,2012,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.1
30050,Slovenia,2012,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",364.0
30051,Slovenia,2012,7,C02-Antihypertensives,% of total sales,0.9
30052,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",36.9
30053,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",15.6
30054,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,32.0
30055,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,% of total sales,4.9
30056,Slovenia,2011,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.5
30057,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",18.0
30058,Slovenia,2011,8,R03-Drugs for obstructive airway diseases,Million of national currency units,23.0
30059,Slovenia,2011,8,N02-Analgesics,"/capita, US$ purchasing power parity",13.0
30060,Slovenia,2011,8,N02-Analgesics,% of total sales,3.5
30061,Slovenia,2011,8,N02-Analgesics,"/capita, US$ exchange rate",11.3
30062,Slovenia,2011,8,C-Cardiovascular system,"Million US$, purchasing power parity",182.1
30063,Slovenia,2011,8,C08-Calcium channel blockers,% of total sales,1.7
30064,Slovenia,2011,8,C02-Antihypertensives,"/capita, US$ exchange rate",3.0
30065,Slovenia,2011,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",13.1
30066,Slovenia,2011,8,C08-Calcium channel blockers,Million US$ at exchange rate,11.4
30067,Slovenia,2011,8,R-Respiratory system,"/capita, US$ exchange rate",19.8
30068,Slovenia,2011,8,R-Respiratory system,"Million US$, purchasing power parity",46.8
30069,Slovenia,2011,8,C02-Antihypertensives,"Million US$, purchasing power parity",7.2
30070,Slovenia,2011,8,R-Respiratory system,Million US$ at exchange rate,40.6
30071,Slovenia,2011,8,C08-Calcium channel blockers,Million of national currency units,8.2
30072,Slovenia,2011,8,C02-Antihypertensives,Million US$ at exchange rate,6.2
30073,Slovenia,2011,8,C-Cardiovascular system,Million of national currency units,113.7
30074,Slovenia,2011,8,C02-Antihypertensives,Million of national currency units,4.5
30075,Slovenia,2011,8,C-Cardiovascular system,Million US$ at exchange rate,158.2
30076,Slovenia,2011,8,J01-Antibacterials for systemic use,% of total sales,2.5
30077,Slovenia,2011,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",6.4
30078,Slovenia,2011,8,R-Respiratory system,% of total sales,6.2
30079,Slovenia,2011,8,R-Respiratory system,"/capita, US$ purchasing power parity",22.8
30080,Slovenia,2011,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.5
30081,Slovenia,2011,8,N02-Analgesics,"Million US$, purchasing power parity",26.7
30082,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,12.8
30083,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9.2
30084,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.2
30085,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
30086,Slovenia,2011,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.6
30087,Slovenia,2011,8,B-Blood and blood forming organs,% of total sales,5.4
30088,Slovenia,2011,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",40.3
30089,Slovenia,2011,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.1
30090,Slovenia,2011,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.0
30091,Slovenia,2011,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.8
30092,Slovenia,2011,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.2
30093,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",14.7
30094,Slovenia,2011,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,16.4
30095,Slovenia,2011,8,B-Blood and blood forming organs,Million US$ at exchange rate,35.0
30096,Slovenia,2011,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.2
30097,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",82.6
30098,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.0
30099,Slovenia,2011,8,A-Alimentary tract and metabolism,% of total sales,11.7
30100,Slovenia,2011,8,N02-Analgesics,Million US$ at exchange rate,23.1
30101,Slovenia,2011,8,N02-Analgesics,Million of national currency units,16.6
30102,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,71.8
30103,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,51.6
30104,Slovenia,2011,8,C-Cardiovascular system,"/capita, US$ exchange rate",77.1
30105,Slovenia,2011,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,76.8
30106,Slovenia,2011,8,A-Alimentary tract and metabolism,Million of national currency units,55.2
30107,Slovenia,2011,8,J01-Antibacterials for systemic use,Million of national currency units,11.7
30108,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,11.0
30109,Slovenia,2011,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",37.4
30110,Slovenia,2011,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",43.1
30111,Slovenia,2011,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",88.4
30112,Slovenia,2011,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",40.2
30113,Slovenia,2011,8,N05B-Anxiolytics,"/capita, US$ exchange rate",2.0
30114,Slovenia,2011,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
30115,Slovenia,2011,8,N05B-Anxiolytics,% of total sales,0.6
30116,Slovenia,2011,8,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7
30117,Slovenia,2011,8,N06A-Antidepressants,Million US$ at exchange rate,22.1
30118,Slovenia,2011,8,N06A-Antidepressants,Million of national currency units,15.9
30119,Slovenia,2011,8,N05B-Anxiolytics,Million US$ at exchange rate,4.1
30120,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,13.7
30121,Slovenia,2011,8,N-Nervous system,"/capita, US$ exchange rate",54.2
30122,Slovenia,2011,8,N-Nervous system,"/capita, US$ purchasing power parity",62.4
30123,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,9.8
30124,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.1
30125,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.7
30126,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",15.7
30127,Slovenia,2011,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.7
30128,Slovenia,2011,8,N06A-Antidepressants,"Million US$, purchasing power parity",25.5
30129,Slovenia,2011,8,A02A-Antacids,Million of national currency units,0.4
30130,Slovenia,2011,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
30131,Slovenia,2011,8,A02A-Antacids,"Million US$, purchasing power parity",0.7
30132,Slovenia,2011,8,A02A-Antacids,Million US$ at exchange rate,0.6
30133,Slovenia,2011,8,C10-Lipid modifying agents,% of total sales,5.9
30134,Slovenia,2011,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",21.7
30135,Slovenia,2011,8,C01A-Cardiac glycosides,% of total sales,0.1
30136,Slovenia,2011,8,Total pharmaceutical sales,Million of national currency units,470.0
30137,Slovenia,2011,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",12.4
30138,Slovenia,2011,8,N06A-Antidepressants,% of total sales,3.4
30139,Slovenia,2011,8,N06A-Antidepressants,"/capita, US$ exchange rate",10.8
30140,Slovenia,2011,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.3
30141,Slovenia,2011,8,A02A-Antacids,"/capita, US$ exchange rate",0.3
30142,Slovenia,2011,8,N05B-Anxiolytics,Million of national currency units,2.9
30143,Slovenia,2011,8,A02A-Antacids,% of total sales,0.1
30144,Slovenia,2011,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.1
30145,Slovenia,2011,8,N05C-Hypnotics and sedatives,% of total sales,0.6
30146,Slovenia,2011,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.3
30147,Slovenia,2011,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.8
30148,Slovenia,2011,8,C03-Diuretics,"Million US$, purchasing power parity",9.8
30149,Slovenia,2011,8,C03-Diuretics,Million of national currency units,6.1
30150,Slovenia,2011,8,C03-Diuretics,Million US$ at exchange rate,8.5
30151,Slovenia,2011,8,C03-Diuretics,"/capita, US$ exchange rate",4.1
30152,Slovenia,2011,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.1
30153,Slovenia,2011,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1
30154,Slovenia,2011,8,M-Musculo-skeletal system,% of total sales,4.1
30155,Slovenia,2011,8,M-Musculo-skeletal system,Million of national currency units,19.3
30156,Slovenia,2011,8,N05C-Hypnotics and sedatives,Million of national currency units,2.7
30157,Slovenia,2011,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8
30158,Slovenia,2011,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",31.0
30159,Slovenia,2011,8,M-Musculo-skeletal system,Million US$ at exchange rate,26.9
30160,Slovenia,2011,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
30161,Slovenia,2011,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
30162,Slovenia,2011,8,G-Genito urinary system and sex hormones,Million of national currency units,26.3
30163,Slovenia,2011,8,C01A-Cardiac glycosides,Million of national currency units,0.3
30164,Slovenia,2011,8,N-Nervous system,Million US$ at exchange rate,111.2
30165,Slovenia,2011,8,N-Nervous system,"Million US$, purchasing power parity",128.1
30166,Slovenia,2011,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
30167,Slovenia,2011,8,N-Nervous system,Million of national currency units,79.9
30168,Slovenia,2011,8,G-Genito urinary system and sex hormones,% of total sales,5.6
30169,Slovenia,2011,8,C03-Diuretics,"/capita, US$ purchasing power parity",4.8
30170,Slovenia,2011,8,C03-Diuretics,% of total sales,1.3
30171,Slovenia,2011,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",42.2
30172,Slovenia,2011,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,36.7
30173,Slovenia,2011,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.6
30174,Slovenia,2011,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.9
30175,Slovenia,2011,8,C07-Beta blocking agents,% of total sales,1.7
30176,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",13.3
30177,Slovenia,2011,8,A10-Drugs used in diabetes,Million US$ at exchange rate,37.5
30178,Slovenia,2011,8,A10-Drugs used in diabetes,Million of national currency units,26.9
30179,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,17.9
30180,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,24.9
30181,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,11.6
30182,Slovenia,2011,8,C07-Beta blocking agents,Million US$ at exchange rate,10.9
30183,Slovenia,2011,8,C07-Beta blocking agents,"Million US$, purchasing power parity",12.6
30184,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",28.7
30185,Slovenia,2011,8,C07-Beta blocking agents,Million of national currency units,7.8
30186,Slovenia,2011,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.1
30187,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.3
30188,Slovenia,2011,8,C07-Beta blocking agents,"/capita, US$ exchange rate",5.3
30189,Slovenia,2011,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",13.3
30190,Slovenia,2011,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",15.3
30191,Slovenia,2011,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",31.5
30192,Slovenia,2011,8,A10-Drugs used in diabetes,% of total sales,5.7
30193,Slovenia,2011,8,J-Antiinfectives for systemic use,% of total sales,4.2
30194,Slovenia,2011,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",21.0
30195,Slovenia,2011,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.3
30196,Slovenia,2011,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",43.2
30197,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.8
30198,Slovenia,2011,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,27.3
30199,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",5.6
30200,Slovenia,2011,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",6.5
30201,Slovenia,2011,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",88.7
30202,Slovenia,2011,8,C-Cardiovascular system,% of total sales,24.2
30203,Slovenia,2011,8,Total pharmaceutical sales,"Million US$, purchasing power parity",753.3
30204,Slovenia,2011,8,Total pharmaceutical sales,"/capita, US$ exchange rate",318.7
30205,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
30206,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
30207,Slovenia,2011,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",44.5
30208,Slovenia,2011,8,C10-Lipid modifying agents,Million US$ at exchange rate,38.7
30209,Slovenia,2011,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.8
30210,Slovenia,2011,8,R-Respiratory system,Million of national currency units,29.2
30211,Slovenia,2011,8,C10-Lipid modifying agents,Million of national currency units,27.8
30212,Slovenia,2011,8,Total pharmaceutical sales,Million US$ at exchange rate,654.3
30213,Slovenia,2011,8,B-Blood and blood forming organs,Million of national currency units,25.2
30214,Slovenia,2011,8,J-Antiinfectives for systemic use,Million of national currency units,19.6
30215,Slovenia,2011,8,N-Nervous system,% of total sales,17.0
30216,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.8
30217,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.1
30218,Slovenia,2011,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.0
30219,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",2.0
30220,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.7
30221,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
30222,Slovenia,2011,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",367.0
30223,Slovenia,2011,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.2
30224,Slovenia,2011,8,C02-Antihypertensives,% of total sales,1.0
30225,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",14.9
30226,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,30.5
30227,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",36.0
30228,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,% of total sales,4.8
30229,Slovenia,2010,8,C02-Antihypertensives,"/capita, US$ purchasing power parity",3.2
30230,Slovenia,2010,8,C02-Antihypertensives,% of total sales,0.9
30231,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.6
30232,Slovenia,2010,8,N02-Analgesics,% of total sales,3.6
30233,Slovenia,2010,8,N02-Analgesics,"/capita, US$ purchasing power parity",13.1
30234,Slovenia,2010,8,N02-Analgesics,"/capita, US$ exchange rate",11.1
30235,Slovenia,2010,8,C-Cardiovascular system,"Million US$, purchasing power parity",192.0
30236,Slovenia,2010,8,C08-Calcium channel blockers,% of total sales,2.1
30237,Slovenia,2010,8,R03-Drugs for obstructive airway diseases,Million of national currency units,23.0
30238,Slovenia,2010,8,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
30239,Slovenia,2010,8,C08-Calcium channel blockers,"Million US$, purchasing power parity",15.8
30240,Slovenia,2010,8,R-Respiratory system,"/capita, US$ exchange rate",18.9
30241,Slovenia,2010,8,R-Respiratory system,"Million US$, purchasing power parity",45.9
30242,Slovenia,2010,8,C08-Calcium channel blockers,Million US$ at exchange rate,13.3
30243,Slovenia,2010,8,C02-Antihypertensives,"Million US$, purchasing power parity",6.5
30244,Slovenia,2010,8,R-Respiratory system,Million US$ at exchange rate,38.8
30245,Slovenia,2010,8,C08-Calcium channel blockers,Million of national currency units,10.0
30246,Slovenia,2010,8,C02-Antihypertensives,Million US$ at exchange rate,5.5
30247,Slovenia,2010,8,C-Cardiovascular system,Million of national currency units,122.5
30248,Slovenia,2010,8,C02-Antihypertensives,Million of national currency units,4.1
30249,Slovenia,2010,8,C-Cardiovascular system,Million US$ at exchange rate,162.4
30250,Slovenia,2010,8,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.7
30251,Slovenia,2010,8,R-Respiratory system,% of total sales,6.2
30252,Slovenia,2010,8,R-Respiratory system,"/capita, US$ purchasing power parity",22.4
30253,Slovenia,2010,8,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.5
30254,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,11.9
30255,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,9.0
30256,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.9
30257,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
30258,Slovenia,2010,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.5
30259,Slovenia,2010,8,B-Blood and blood forming organs,% of total sales,5.4
30260,Slovenia,2010,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",39.9
30261,Slovenia,2010,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",16.5
30262,Slovenia,2010,8,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.6
30263,Slovenia,2010,8,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",18.5
30264,Slovenia,2010,8,J01-Antibacterials for systemic use,% of total sales,2.5
30265,Slovenia,2010,8,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.0
30266,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",14.1
30267,Slovenia,2010,8,J01-Antibacterials for systemic use,Million US$ at exchange rate,15.6
30268,Slovenia,2010,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.8
30269,Slovenia,2010,8,B-Blood and blood forming organs,Million US$ at exchange rate,33.8
30270,Slovenia,2010,8,N02-Analgesics,"Million US$, purchasing power parity",26.9
30271,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.5
30272,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",86.1
30273,Slovenia,2010,8,A-Alimentary tract and metabolism,% of total sales,11.7
30274,Slovenia,2010,8,N02-Analgesics,Million US$ at exchange rate,22.7
30275,Slovenia,2010,8,N02-Analgesics,Million of national currency units,17.2
30276,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,72.8
30277,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,54.9
30278,Slovenia,2010,8,C-Cardiovascular system,"/capita, US$ exchange rate",79.3
30279,Slovenia,2010,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,73.5
30280,Slovenia,2010,8,A-Alimentary tract and metabolism,Million of national currency units,55.5
30281,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,% of total sales,11.6
30282,Slovenia,2010,8,J01-Antibacterials for systemic use,Million of national currency units,11.8
30283,Slovenia,2010,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",86.9
30284,Slovenia,2010,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",35.9
30285,Slovenia,2010,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",42.4
30286,Slovenia,2010,8,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",42.0
30287,Slovenia,2010,8,N05B-Anxiolytics,"/capita, US$ exchange rate",1.9
30288,Slovenia,2010,8,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
30289,Slovenia,2010,8,N05B-Anxiolytics,% of total sales,0.6
30290,Slovenia,2010,8,N06A-Antidepressants,Million US$ at exchange rate,20.6
30291,Slovenia,2010,8,N05B-Anxiolytics,"Million US$, purchasing power parity",4.7
30292,Slovenia,2010,8,N05B-Anxiolytics,Million US$ at exchange rate,4.0
30293,Slovenia,2010,8,N06A-Antidepressants,Million of national currency units,15.6
30294,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,13.4
30295,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,Million of national currency units,10.1
30296,Slovenia,2010,8,N-Nervous system,"/capita, US$ exchange rate",52.0
30297,Slovenia,2010,8,N-Nervous system,"/capita, US$ purchasing power parity",61.5
30298,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",15.9
30299,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,% of total sales,2.1
30300,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",7.8
30301,Slovenia,2010,8,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",6.6
30302,Slovenia,2010,8,N06A-Antidepressants,"Million US$, purchasing power parity",24.4
30303,Slovenia,2010,8,A02A-Antacids,Million of national currency units,0.3
30304,Slovenia,2010,8,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
30305,Slovenia,2010,8,A02A-Antacids,"Million US$, purchasing power parity",0.5
30306,Slovenia,2010,8,A02A-Antacids,Million US$ at exchange rate,0.5
30307,Slovenia,2010,8,C01A-Cardiac glycosides,% of total sales,0.1
30308,Slovenia,2010,8,C10-Lipid modifying agents,% of total sales,6.5
30309,Slovenia,2010,8,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",23.7
30310,Slovenia,2010,8,Total pharmaceutical sales,Million of national currency units,474.4
30311,Slovenia,2010,8,N06A-Antidepressants,% of total sales,3.3
30312,Slovenia,2010,8,N06A-Antidepressants,"/capita, US$ purchasing power parity",11.9
30313,Slovenia,2010,8,N06A-Antidepressants,"/capita, US$ exchange rate",10.1
30314,Slovenia,2010,8,A02A-Antacids,"/capita, US$ purchasing power parity",0.3
30315,Slovenia,2010,8,A02A-Antacids,"/capita, US$ exchange rate",0.2
30316,Slovenia,2010,8,N05B-Anxiolytics,Million of national currency units,3.0
30317,Slovenia,2010,8,A02A-Antacids,% of total sales,0.1
30318,Slovenia,2010,8,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.2
30319,Slovenia,2010,8,N05C-Hypnotics and sedatives,% of total sales,0.6
30320,Slovenia,2010,8,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.5
30321,Slovenia,2010,8,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.9
30322,Slovenia,2010,8,C03-Diuretics,"Million US$, purchasing power parity",9.9
30323,Slovenia,2010,8,C03-Diuretics,"/capita, US$ exchange rate",4.1
30324,Slovenia,2010,8,C03-Diuretics,Million of national currency units,6.3
30325,Slovenia,2010,8,C03-Diuretics,Million US$ at exchange rate,8.4
30326,Slovenia,2010,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.1
30327,Slovenia,2010,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",13.6
30328,Slovenia,2010,8,M-Musculo-skeletal system,% of total sales,4.4
30329,Slovenia,2010,8,M-Musculo-skeletal system,Million of national currency units,21.0
30330,Slovenia,2010,8,N05C-Hypnotics and sedatives,Million of national currency units,2.9
30331,Slovenia,2010,8,N05C-Hypnotics and sedatives,Million US$ at exchange rate,3.8
30332,Slovenia,2010,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",32.9
30333,Slovenia,2010,8,M-Musculo-skeletal system,Million US$ at exchange rate,27.8
30334,Slovenia,2010,8,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.5
30335,Slovenia,2010,8,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
30336,Slovenia,2010,8,G-Genito urinary system and sex hormones,Million of national currency units,26.3
30337,Slovenia,2010,8,C01A-Cardiac glycosides,Million of national currency units,0.3
30338,Slovenia,2010,8,N-Nervous system,"Million US$, purchasing power parity",126.0
30339,Slovenia,2010,8,N-Nervous system,Million US$ at exchange rate,106.5
30340,Slovenia,2010,8,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
30341,Slovenia,2010,8,N-Nervous system,Million of national currency units,80.4
30342,Slovenia,2010,8,G-Genito urinary system and sex hormones,% of total sales,5.5
30343,Slovenia,2010,8,C03-Diuretics,% of total sales,1.3
30344,Slovenia,2010,8,C03-Diuretics,"/capita, US$ purchasing power parity",4.8
30345,Slovenia,2010,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",41.2
30346,Slovenia,2010,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,34.9
30347,Slovenia,2010,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.1
30348,Slovenia,2010,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.0
30349,Slovenia,2010,8,C07-Beta blocking agents,% of total sales,1.8
30350,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",14.5
30351,Slovenia,2010,8,A10-Drugs used in diabetes,Million US$ at exchange rate,34.0
30352,Slovenia,2010,8,A10-Drugs used in diabetes,Million of national currency units,25.6
30353,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,26.4
30354,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,19.9
30355,Slovenia,2010,8,C07-Beta blocking agents,Million US$ at exchange rate,11.1
30356,Slovenia,2010,8,C07-Beta blocking agents,"Million US$, purchasing power parity",13.1
30357,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",31.2
30358,Slovenia,2010,8,C07-Beta blocking agents,Million of national currency units,8.4
30359,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,9.2
30360,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,12.2
30361,Slovenia,2010,8,C07-Beta blocking agents,"/capita, US$ purchasing power parity",6.4
30362,Slovenia,2010,8,C07-Beta blocking agents,"/capita, US$ exchange rate",5.4
30363,Slovenia,2010,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",12.3
30364,Slovenia,2010,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",14.6
30365,Slovenia,2010,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",29.8
30366,Slovenia,2010,8,A10-Drugs used in diabetes,% of total sales,5.4
30367,Slovenia,2010,8,J-Antiinfectives for systemic use,% of total sales,4.0
30368,Slovenia,2010,8,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.6
30369,Slovenia,2010,8,A10-Drugs used in diabetes,"Million US$, purchasing power parity",40.2
30370,Slovenia,2010,8,A10-Drugs used in diabetes,"/capita, US$ exchange rate",16.6
30371,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
30372,Slovenia,2010,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,25.2
30373,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.0
30374,Slovenia,2010,8,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.1
30375,Slovenia,2010,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",93.7
30376,Slovenia,2010,8,C-Cardiovascular system,% of total sales,25.8
30377,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
30378,Slovenia,2010,8,Total pharmaceutical sales,"/capita, US$ exchange rate",307.0
30379,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
30380,Slovenia,2010,8,C10-Lipid modifying agents,"Million US$, purchasing power parity",48.6
30381,Slovenia,2010,8,C10-Lipid modifying agents,Million US$ at exchange rate,41.1
30382,Slovenia,2010,8,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.1
30383,Slovenia,2010,8,Total pharmaceutical sales,"Million US$, purchasing power parity",743.6
30384,Slovenia,2010,8,R-Respiratory system,Million of national currency units,29.3
30385,Slovenia,2010,8,B-Blood and blood forming organs,Million of national currency units,25.5
30386,Slovenia,2010,8,C10-Lipid modifying agents,Million of national currency units,31.0
30387,Slovenia,2010,8,Total pharmaceutical sales,Million US$ at exchange rate,628.9
30388,Slovenia,2010,8,J-Antiinfectives for systemic use,Million of national currency units,19.0
30389,Slovenia,2010,8,N-Nervous system,% of total sales,16.9
30390,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.9
30391,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.2
30392,Slovenia,2010,8,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",15.2
30393,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7
30394,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.4
30395,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
30396,Slovenia,2010,8,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.1
30397,Slovenia,2010,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",363.0
30398,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",36.2
30399,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,Million of national currency units,20.6
30400,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,23.3
30401,Slovenia,2017,7,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.7
30402,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",11.3
30403,Slovenia,2017,7,C-Cardiovascular system,Million US$ at exchange rate,85.7
30404,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",17.5
30405,Slovenia,2017,7,N02-Analgesics,"/capita, US$ purchasing power parity",15.5
30406,Slovenia,2017,7,N02-Analgesics,% of total sales,3.8
30407,Slovenia,2017,7,N02-Analgesics,"Million US$, purchasing power parity",32.1
30408,Slovenia,2017,7,N02-Analgesics,"/capita, US$ exchange rate",10.0
30409,Slovenia,2017,7,C08-Calcium channel blockers,% of total sales,1.2
30410,Slovenia,2017,7,C02-Antihypertensives,"Million US$, purchasing power parity",5.6
30411,Slovenia,2017,7,C-Cardiovascular system,"Million US$, purchasing power parity",133.1
30412,Slovenia,2017,7,C02-Antihypertensives,"/capita, US$ exchange rate",1.7
30413,Slovenia,2017,7,R03-Drugs for obstructive airway diseases,% of total sales,4.3
30414,Slovenia,2017,7,R-Respiratory system,Million US$ at exchange rate,28.9
30415,Slovenia,2017,7,C08-Calcium channel blockers,Million US$ at exchange rate,6.6
30416,Slovenia,2017,7,R-Respiratory system,"/capita, US$ exchange rate",14.0
30417,Slovenia,2017,7,R-Respiratory system,"Million US$, purchasing power parity",44.8
30418,Slovenia,2017,7,R-Respiratory system,Million of national currency units,25.6
30419,Slovenia,2017,7,C02-Antihypertensives,Million US$ at exchange rate,3.6
30420,Slovenia,2017,7,C08-Calcium channel blockers,Million of national currency units,5.8
30421,Slovenia,2017,7,C02-Antihypertensives,Million of national currency units,3.2
30422,Slovenia,2017,7,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",4.9
30423,Slovenia,2017,7,C-Cardiovascular system,Million of national currency units,75.9
30424,Slovenia,2017,7,J01-Antibacterials for systemic use,% of total sales,2.3
30425,Slovenia,2017,7,R-Respiratory system,"/capita, US$ purchasing power parity",21.7
30426,Slovenia,2017,7,R-Respiratory system,% of total sales,5.3
30427,Slovenia,2017,7,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2
30428,Slovenia,2017,7,C08-Calcium channel blockers,"Million US$, purchasing power parity",10.2
30429,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,10.8
30430,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,12.2
30431,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.2
30432,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.2
30433,Slovenia,2017,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",39.6
30434,Slovenia,2017,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",81.8
30435,Slovenia,2017,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",25.5
30436,Slovenia,2017,7,B-Blood and blood forming organs,% of total sales,9.6
30437,Slovenia,2017,7,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",19.8
30438,Slovenia,2017,7,J01-Antibacterials for systemic use,Million US$ at exchange rate,12.7
30439,Slovenia,2017,7,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.6
30440,Slovenia,2017,7,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.2
30441,Slovenia,2017,7,B-Blood and blood forming organs,Million US$ at exchange rate,52.7
30442,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.9
30443,Slovenia,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",19.0
30444,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",49.8
30445,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,32.1
30446,Slovenia,2017,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",49.0
30447,Slovenia,2017,7,A-Alimentary tract and metabolism,% of total sales,11.9
30448,Slovenia,2017,7,N02-Analgesics,Million of national currency units,18.3
30449,Slovenia,2017,7,N02-Analgesics,Million US$ at exchange rate,20.7
30450,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,28.4
30451,Slovenia,2017,7,C-Cardiovascular system,"/capita, US$ exchange rate",41.5
30452,Slovenia,2017,7,A-Alimentary tract and metabolism,Million of national currency units,57.8
30453,Slovenia,2017,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,65.3
30454,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,% of total sales,5.9
30455,Slovenia,2017,7,J01-Antibacterials for systemic use,Million of national currency units,11.3
30456,Slovenia,2017,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",31.6
30457,Slovenia,2017,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",101.3
30458,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",24.1
30459,Slovenia,2017,7,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",15.5
30460,Slovenia,2017,7,N05B-Anxiolytics,"/capita, US$ exchange rate",1.4
30461,Slovenia,2017,7,N05B-Anxiolytics,"Million US$, purchasing power parity",4.6
30462,Slovenia,2017,7,N05B-Anxiolytics,% of total sales,0.5
30463,Slovenia,2017,7,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
30464,Slovenia,2017,7,N06A-Antidepressants,Million of national currency units,10.6
30465,Slovenia,2017,7,N06A-Antidepressants,Million US$ at exchange rate,11.9
30466,Slovenia,2017,7,N05B-Anxiolytics,Million US$ at exchange rate,3.0
30467,Slovenia,2017,7,N05B-Anxiolytics,Million of national currency units,2.6
30468,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,Million of national currency units,7.5
30469,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,8.4
30470,Slovenia,2017,7,N-Nervous system,"/capita, US$ exchange rate",34.6
30471,Slovenia,2017,7,N-Nervous system,"/capita, US$ purchasing power parity",53.7
30472,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",6.3
30473,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,% of total sales,1.5
30474,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",13.1
30475,Slovenia,2017,7,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",4.1
30476,Slovenia,2017,7,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.3
30477,Slovenia,2017,7,A02A-Antacids,Million of national currency units,0.8
30478,Slovenia,2017,7,A02A-Antacids,Million US$ at exchange rate,0.9
30479,Slovenia,2017,7,C10-Lipid modifying agents,% of total sales,3.0
30480,Slovenia,2017,7,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",12.1
30481,Slovenia,2017,7,C01A-Cardiac glycosides,% of total sales,0.1
30482,Slovenia,2017,7,Total pharmaceutical sales,Million of national currency units,484.2
30483,Slovenia,2017,7,A02A-Antacids,"Million US$, purchasing power parity",1.3
30484,Slovenia,2017,7,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.0
30485,Slovenia,2017,7,N06A-Antidepressants,% of total sales,2.2
30486,Slovenia,2017,7,N06A-Antidepressants,"Million US$, purchasing power parity",18.5
30487,Slovenia,2017,7,N06A-Antidepressants,"/capita, US$ exchange rate",5.8
30488,Slovenia,2017,7,A02A-Antacids,"/capita, US$ exchange rate",0.4
30489,Slovenia,2017,7,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
30490,Slovenia,2017,7,A02A-Antacids,% of total sales,0.2
30491,Slovenia,2017,7,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",2.0
30492,Slovenia,2017,7,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3
30493,Slovenia,2017,7,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",4.1
30494,Slovenia,2017,7,C03-Diuretics,Million US$ at exchange rate,7.1
30495,Slovenia,2017,7,C03-Diuretics,"Million US$, purchasing power parity",11.0
30496,Slovenia,2017,7,N05C-Hypnotics and sedatives,% of total sales,0.5
30497,Slovenia,2017,7,C03-Diuretics,Million of national currency units,6.3
30498,Slovenia,2017,7,N05C-Hypnotics and sedatives,Million US$ at exchange rate,2.6
30499,Slovenia,2017,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.0
30500,Slovenia,2017,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",28.7
30501,Slovenia,2017,7,M-Musculo-skeletal system,% of total sales,3.4
30502,Slovenia,2017,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",13.9
30503,Slovenia,2017,7,N05C-Hypnotics and sedatives,Million of national currency units,2.3
30504,Slovenia,2017,7,M-Musculo-skeletal system,Million US$ at exchange rate,18.5
30505,Slovenia,2017,7,M-Musculo-skeletal system,Million of national currency units,16.4
30506,Slovenia,2017,7,C01A-Cardiac glycosides,Million US$ at exchange rate,0.4
30507,Slovenia,2017,7,C01A-Cardiac glycosides,"Million US$, purchasing power parity",0.6
30508,Slovenia,2017,7,C03-Diuretics,% of total sales,1.3
30509,Slovenia,2017,7,C01A-Cardiac glycosides,Million of national currency units,0.3
30510,Slovenia,2017,7,N-Nervous system,Million US$ at exchange rate,71.4
30511,Slovenia,2017,7,N-Nervous system,"Million US$, purchasing power parity",110.9
30512,Slovenia,2017,7,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
30513,Slovenia,2017,7,N-Nervous system,Million of national currency units,63.2
30514,Slovenia,2017,7,G-Genito urinary system and sex hormones,% of total sales,4.9
30515,Slovenia,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.2
30516,Slovenia,2017,7,C03-Diuretics,"/capita, US$ exchange rate",3.4
30517,Slovenia,2017,7,C03-Diuretics,"/capita, US$ purchasing power parity",5.3
30518,Slovenia,2017,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,26.9
30519,Slovenia,2017,7,G-Genito urinary system and sex hormones,Million of national currency units,23.8
30520,Slovenia,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.0
30521,Slovenia,2017,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",41.7
30522,Slovenia,2017,7,C07-Beta blocking agents,"/capita, US$ purchasing power parity",8.7
30523,Slovenia,2017,7,C07-Beta blocking agents,% of total sales,2.1
30524,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,9.5
30525,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",14.7
30526,Slovenia,2017,7,A10-Drugs used in diabetes,Million of national currency units,31.5
30527,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,9.5
30528,Slovenia,2017,7,C07-Beta blocking agents,Million US$ at exchange rate,11.5
30529,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,10.8
30530,Slovenia,2017,7,C07-Beta blocking agents,Million of national currency units,10.2
30531,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,8.4
30532,Slovenia,2017,7,C07-Beta blocking agents,"Million US$, purchasing power parity",17.9
30533,Slovenia,2017,7,C07-Beta blocking agents,"/capita, US$ exchange rate",5.6
30534,Slovenia,2017,7,A10-Drugs used in diabetes,Million US$ at exchange rate,35.6
30535,Slovenia,2017,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",14.9
30536,Slovenia,2017,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,30.8
30537,Slovenia,2017,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",47.8
30538,Slovenia,2017,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",23.1
30539,Slovenia,2017,7,A10-Drugs used in diabetes,% of total sales,6.5
30540,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
30541,Slovenia,2017,7,J-Antiinfectives for systemic use,% of total sales,5.6
30542,Slovenia,2017,7,A10-Drugs used in diabetes,"/capita, US$ exchange rate",17.2
30543,Slovenia,2017,7,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",26.7
30544,Slovenia,2017,7,A10-Drugs used in diabetes,"Million US$, purchasing power parity",55.2
30545,Slovenia,2017,7,J-Antiinfectives for systemic use,Million of national currency units,27.2
30546,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",7.1
30547,Slovenia,2017,7,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",4.6
30548,Slovenia,2017,7,C-Cardiovascular system,% of total sales,15.7
30549,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
30550,Slovenia,2017,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",64.4
30551,Slovenia,2017,7,Total pharmaceutical sales,"Million US$, purchasing power parity",849.3
30552,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
30553,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
30554,Slovenia,2017,7,C10-Lipid modifying agents,Million US$ at exchange rate,16.1
30555,Slovenia,2017,7,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.8
30556,Slovenia,2017,7,C10-Lipid modifying agents,"Million US$, purchasing power parity",25.1
30557,Slovenia,2017,7,B-Blood and blood forming organs,Million of national currency units,46.7
30558,Slovenia,2017,7,Total pharmaceutical sales,Million US$ at exchange rate,547.0
30559,Slovenia,2017,7,C10-Lipid modifying agents,Million of national currency units,14.3
30560,Slovenia,2017,7,N-Nervous system,% of total sales,13.1
30561,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0
30562,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.2
30563,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",16.7
30564,Slovenia,2017,7,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.1
30565,Slovenia,2017,7,Total pharmaceutical sales,"/capita, US$ exchange rate",264.7
30566,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,1.1
30567,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,1.0
30568,Slovenia,2017,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",411.0
30569,Slovenia,2017,7,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",1.7
30570,Slovenia,2017,7,C02-Antihypertensives,% of total sales,0.7
30571,Spain,2011,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.8
30572,Spain,2011,4,J01-Antibacterials for systemic use,Million of national currency units,260.9
30573,Spain,2011,4,J01-Antibacterials for systemic use,% of total sales,2.1
30574,Spain,2011,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,363.1
30575,Spain,2011,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",365.3
30576,Spain,2011,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.8
30577,Spain,2011,4,C02-Antihypertensives,"Million US$, purchasing power parity",63.1
30578,Spain,2011,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
30579,Spain,2011,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.3
30580,Spain,2011,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",5.6
30581,Spain,2011,4,C02-Antihypertensives,% of total sales,0.4
30582,Spain,2011,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",5.6
30583,Spain,2011,4,C08-Calcium channel blockers,% of total sales,1.5
30584,Spain,2011,4,C-Cardiovascular system,"Million US$, purchasing power parity",3628.2
30585,Spain,2011,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",9.3
30586,Spain,2011,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.3
30587,Spain,2011,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,433.6
30588,Spain,2011,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",436.2
30589,Spain,2011,4,C03-Diuretics,Million US$ at exchange rate,167.4
30590,Spain,2011,4,C03-Diuretics,"Million US$, purchasing power parity",168.4
30591,Spain,2011,4,J-Antiinfectives for systemic use,% of total sales,2.5
30592,Spain,2011,4,C03-Diuretics,Million of national currency units,120.2
30593,Spain,2011,4,C07-Beta blocking agents,% of total sales,0.7
30594,Spain,2011,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.5
30595,Spain,2011,4,N-Nervous system,Million of national currency units,3080.3
30596,Spain,2011,4,N-Nervous system,Million US$ at exchange rate,4287.7
30597,Spain,2011,4,C07-Beta blocking agents,Million US$ at exchange rate,118.1
30598,Spain,2011,4,C07-Beta blocking agents,Million of national currency units,84.9
30599,Spain,2011,4,J-Antiinfectives for systemic use,Million of national currency units,311.5
30600,Spain,2011,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.5
30601,Spain,2011,4,C07-Beta blocking agents,"Million US$, purchasing power parity",118.8
30602,Spain,2011,4,N-Nervous system,"/capita, US$ purchasing power parity",92.3
30603,Spain,2011,4,N-Nervous system,"/capita, US$ exchange rate",91.7
30604,Spain,2011,4,N-Nervous system,% of total sales,24.9
30605,Spain,2011,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",261.8
30606,Spain,2011,4,C-Cardiovascular system,Million US$ at exchange rate,3606.5
30607,Spain,2011,4,C-Cardiovascular system,Million of national currency units,2591.0
30608,Spain,2011,4,N-Nervous system,"Million US$, purchasing power parity",4313.4
30609,Spain,2011,4,C03-Diuretics,% of total sales,1.0
30610,Spain,2011,4,C03-Diuretics,"/capita, US$ exchange rate",3.6
30611,Spain,2011,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.6
30612,Spain,2011,4,C-Cardiovascular system,% of total sales,21.0
30613,Spain,2011,4,C08-Calcium channel blockers,Million of national currency units,187.0
30614,Spain,2011,4,C08-Calcium channel blockers,Million US$ at exchange rate,260.2
30615,Spain,2011,4,C-Cardiovascular system,"/capita, US$ exchange rate",77.2
30616,Spain,2011,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",77.6
30617,Spain,2011,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1051.7
30618,Spain,2011,4,C10-Lipid modifying agents,Million US$ at exchange rate,1045.5
30619,Spain,2011,4,C10-Lipid modifying agents,Million of national currency units,751.1
30620,Spain,2011,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",22.5
30621,Spain,2011,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",22.4
30622,Spain,2011,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",22.6
30623,Spain,2011,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",1063.0
30624,Spain,2011,4,M-Musculo-skeletal system,% of total sales,6.1
30625,Spain,2011,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",22.7
30626,Spain,2011,4,Total pharmaceutical sales,Million of national currency units,12356.1
30627,Spain,2011,4,Total pharmaceutical sales,Million US$ at exchange rate,17199.1
30628,Spain,2011,4,B-Blood and blood forming organs,% of total sales,4.3
30629,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1
30630,Spain,2011,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",370.2
30631,Spain,2011,4,C10-Lipid modifying agents,% of total sales,6.1
30632,Spain,2011,4,Total pharmaceutical sales,"Million US$, purchasing power parity",17302.4
30633,Spain,2011,4,Total pharmaceutical sales,"/capita, US$ exchange rate",368.0
30634,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.5
30635,Spain,2011,4,M-Musculo-skeletal system,Million of national currency units,759.1
30636,Spain,2011,4,R-Respiratory system,Million of national currency units,1311.5
30637,Spain,2011,4,R-Respiratory system,Million US$ at exchange rate,1825.5
30638,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
30639,Spain,2011,4,M-Musculo-skeletal system,Million US$ at exchange rate,1056.6
30640,Spain,2011,4,R-Respiratory system,"/capita, US$ purchasing power parity",39.3
30641,Spain,2011,4,R-Respiratory system,% of total sales,10.6
30642,Spain,2011,4,R-Respiratory system,"Million US$, purchasing power parity",1836.5
30643,Spain,2011,4,R-Respiratory system,"/capita, US$ exchange rate",39.1
30644,Spain,2011,4,N05B-Anxiolytics,"Million US$, purchasing power parity",158.8
30645,Spain,2011,4,N05B-Anxiolytics,Million US$ at exchange rate,157.9
30646,Spain,2011,4,N05B-Anxiolytics,% of total sales,0.9
30647,Spain,2011,4,N05B-Anxiolytics,"/capita, US$ exchange rate",3.4
30648,Spain,2011,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4
30649,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",362.5
30650,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.7
30651,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.8
30652,Spain,2011,4,N05B-Anxiolytics,Million of national currency units,113.4
30653,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,258.9
30654,Spain,2011,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,360.3
30655,Spain,2011,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",5.2
30656,Spain,2011,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
30657,Spain,2011,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",15.9
30658,Spain,2011,4,C01A-Cardiac glycosides,Million of national currency units,3.7
30659,Spain,2011,4,C01A-Cardiac glycosides,Million US$ at exchange rate,5.2
30660,Spain,2011,4,G-Genito urinary system and sex hormones,% of total sales,4.1
30661,Spain,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.1
30662,Spain,2011,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
30663,Spain,2011,4,C01A-Cardiac glycosides,% of total sales,0.0
30664,Spain,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2
30665,Spain,2011,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",57.6
30666,Spain,2011,4,N05C-Hypnotics and sedatives,% of total sales,0.3
30667,Spain,2011,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2
30668,Spain,2011,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",741.7
30669,Spain,2011,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.8
30670,Spain,2011,4,B-Blood and blood forming organs,Million US$ at exchange rate,737.2
30671,Spain,2011,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,57.3
30672,Spain,2011,4,N05C-Hypnotics and sedatives,Million of national currency units,41.2
30673,Spain,2011,4,B-Blood and blood forming organs,Million of national currency units,529.6
30674,Spain,2011,4,N06A-Antidepressants,"/capita, US$ exchange rate",17.6
30675,Spain,2011,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.7
30676,Spain,2011,4,N06A-Antidepressants,Million US$ at exchange rate,821.9
30677,Spain,2011,4,N06A-Antidepressants,"Million US$, purchasing power parity",826.8
30678,Spain,2011,4,N06A-Antidepressants,% of total sales,4.8
30679,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",539.0
30680,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.5
30681,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,385.0
30682,Spain,2011,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,535.8
30683,Spain,2011,4,G-Genito urinary system and sex hormones,Million of national currency units,502.5
30684,Spain,2011,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,114.8
30685,Spain,2011,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,159.7
30686,Spain,2011,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",15.0
30687,Spain,2011,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,699.4
30688,Spain,2011,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",703.6
30689,Spain,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.4
30690,Spain,2011,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.9
30691,Spain,2011,4,N06A-Antidepressants,Million of national currency units,590.4
30692,Spain,2011,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",160.7
30693,Spain,2011,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.4
30694,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,33.6
30695,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",16.9
30696,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.6
30697,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",788.1
30698,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",16.8
30699,Spain,2011,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2489.0
30700,Spain,2011,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",52.9
30701,Spain,2011,4,A-Alimentary tract and metabolism,Million of national currency units,1777.5
30702,Spain,2011,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2474.2
30703,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",33.9
30704,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",34.1
30705,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.2
30706,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1592.6
30707,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,562.8
30708,Spain,2011,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,783.4
30709,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1137.3
30710,Spain,2011,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1583.1
30711,Spain,2011,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.4
30712,Spain,2011,4,N02-Analgesics,"/capita, US$ exchange rate",14.4
30713,Spain,2011,4,N02-Analgesics,% of total sales,3.9
30714,Spain,2011,4,N02-Analgesics,Million of national currency units,482.3
30715,Spain,2011,4,C02-Antihypertensives,Million of national currency units,45.0
30716,Spain,2011,4,C02-Antihypertensives,Million US$ at exchange rate,62.7
30717,Spain,2011,4,N02-Analgesics,"Million US$, purchasing power parity",675.4
30718,Spain,2011,4,N02-Analgesics,Million US$ at exchange rate,671.3
30719,Spain,2011,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1063.0
30720,Spain,2011,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1479.7
30721,Spain,2011,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.2
30722,Spain,2011,4,A-Alimentary tract and metabolism,% of total sales,14.4
30723,Spain,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",31.8
30724,Spain,2011,4,R03-Drugs for obstructive airway diseases,% of total sales,8.6
30725,Spain,2011,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1488.5
30726,Spain,2011,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.7
30727,Spain,2011,4,A02A-Antacids,Million US$ at exchange rate,24.9
30728,Spain,2011,4,A02A-Antacids,Million of national currency units,17.9
30729,Spain,2011,4,A10-Drugs used in diabetes,Million of national currency units,890.8
30730,Spain,2011,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1239.9
30731,Spain,2011,4,A02A-Antacids,"Million US$, purchasing power parity",25.0
30732,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
30733,Spain,2011,4,A02A-Antacids,% of total sales,0.1
30734,Spain,2011,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.5
30735,Spain,2011,4,A02A-Antacids,"/capita, US$ exchange rate",0.5
30736,Spain,2011,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",26.7
30737,Spain,2011,4,A10-Drugs used in diabetes,% of total sales,7.2
30738,Spain,2011,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1247.4
30739,Spain,2011,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",26.5
30740,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",47.1
30741,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
30742,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,46.8
30743,Spain,2011,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
30744,Spain,2012,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.0
30745,Spain,2012,4,J01-Antibacterials for systemic use,% of total sales,2.1
30746,Spain,2012,4,J01-Antibacterials for systemic use,Million of national currency units,227.4
30747,Spain,2012,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.2
30748,Spain,2012,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,292.1
30749,Spain,2012,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",327.1
30750,Spain,2012,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.5
30751,Spain,2012,4,C02-Antihypertensives,"Million US$, purchasing power parity",58.4
30752,Spain,2012,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.2
30753,Spain,2012,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.1
30754,Spain,2012,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.9
30755,Spain,2012,4,C02-Antihypertensives,% of total sales,0.4
30756,Spain,2012,4,C08-Calcium channel blockers,% of total sales,1.1
30757,Spain,2012,4,C03-Diuretics,"/capita, US$ exchange rate",3.1
30758,Spain,2012,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.5
30759,Spain,2012,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.5
30760,Spain,2012,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,353.1
30761,Spain,2012,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",395.5
30762,Spain,2012,4,C03-Diuretics,Million US$ at exchange rate,143.3
30763,Spain,2012,4,C03-Diuretics,"Million US$, purchasing power parity",160.5
30764,Spain,2012,4,J-Antiinfectives for systemic use,% of total sales,2.5
30765,Spain,2012,4,C03-Diuretics,Million of national currency units,111.6
30766,Spain,2012,4,C07-Beta blocking agents,% of total sales,0.7
30767,Spain,2012,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.4
30768,Spain,2012,4,N-Nervous system,Million of national currency units,2838.9
30769,Spain,2012,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.2
30770,Spain,2012,4,J-Antiinfectives for systemic use,Million of national currency units,274.8
30771,Spain,2012,4,C07-Beta blocking agents,Million of national currency units,79.1
30772,Spain,2012,4,C07-Beta blocking agents,Million US$ at exchange rate,101.6
30773,Spain,2012,4,C07-Beta blocking agents,"Million US$, purchasing power parity",113.8
30774,Spain,2012,4,N-Nervous system,"/capita, US$ purchasing power parity",87.3
30775,Spain,2012,4,N-Nervous system,"/capita, US$ exchange rate",78.0
30776,Spain,2012,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",182.3
30777,Spain,2012,4,N-Nervous system,% of total sales,25.6
30778,Spain,2012,4,C-Cardiovascular system,Million US$ at exchange rate,2838.9
30779,Spain,2012,4,C-Cardiovascular system,Million of national currency units,2209.6
30780,Spain,2012,4,N-Nervous system,"Million US$, purchasing power parity",4084.9
30781,Spain,2012,4,N-Nervous system,Million US$ at exchange rate,3647.4
30782,Spain,2012,4,C-Cardiovascular system,"Million US$, purchasing power parity",3179.4
30783,Spain,2012,4,C03-Diuretics,% of total sales,1.0
30784,Spain,2012,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.4
30785,Spain,2012,4,C-Cardiovascular system,% of total sales,20.0
30786,Spain,2012,4,C08-Calcium channel blockers,Million of national currency units,126.7
30787,Spain,2012,4,C08-Calcium channel blockers,Million US$ at exchange rate,162.8
30788,Spain,2012,4,C-Cardiovascular system,"/capita, US$ exchange rate",60.7
30789,Spain,2012,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",68.0
30790,Spain,2012,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",952.6
30791,Spain,2012,4,C10-Lipid modifying agents,Million US$ at exchange rate,850.6
30792,Spain,2012,4,C10-Lipid modifying agents,Million of national currency units,662.0
30793,Spain,2012,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.4
30794,Spain,2012,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.2
30795,Spain,2012,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.5
30796,Spain,2012,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",914.2
30797,Spain,2012,4,M-Musculo-skeletal system,% of total sales,5.7
30798,Spain,2012,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",19.5
30799,Spain,2012,4,B-Blood and blood forming organs,% of total sales,4.5
30800,Spain,2012,4,Total pharmaceutical sales,Million of national currency units,11072.0
30801,Spain,2012,4,Total pharmaceutical sales,Million US$ at exchange rate,14225.2
30802,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.8
30803,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.2
30804,Spain,2012,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",340.6
30805,Spain,2012,4,C10-Lipid modifying agents,% of total sales,6.0
30806,Spain,2012,4,Total pharmaceutical sales,"Million US$, purchasing power parity",15931.5
30807,Spain,2012,4,Total pharmaceutical sales,"/capita, US$ exchange rate",304.1
30808,Spain,2012,4,M-Musculo-skeletal system,Million of national currency units,635.4
30809,Spain,2012,4,R-Respiratory system,Million of national currency units,1201.6
30810,Spain,2012,4,R-Respiratory system,Million US$ at exchange rate,1543.8
30811,Spain,2012,4,M-Musculo-skeletal system,Million US$ at exchange rate,816.3
30812,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
30813,Spain,2012,4,R-Respiratory system,"/capita, US$ purchasing power parity",37.0
30814,Spain,2012,4,R-Respiratory system,% of total sales,10.9
30815,Spain,2012,4,R-Respiratory system,"Million US$, purchasing power parity",1729.0
30816,Spain,2012,4,R-Respiratory system,"/capita, US$ exchange rate",33.0
30817,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.3
30818,Spain,2012,4,N05B-Anxiolytics,"Million US$, purchasing power parity",141.3
30819,Spain,2012,4,N05B-Anxiolytics,Million US$ at exchange rate,126.2
30820,Spain,2012,4,N05B-Anxiolytics,% of total sales,0.9
30821,Spain,2012,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.0
30822,Spain,2012,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.7
30823,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",339.1
30824,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.5
30825,Spain,2012,4,N05B-Anxiolytics,Million of national currency units,98.2
30826,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,235.7
30827,Spain,2012,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,302.8
30828,Spain,2012,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.8
30829,Spain,2012,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
30830,Spain,2012,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",15.4
30831,Spain,2012,4,C01A-Cardiac glycosides,Million of national currency units,3.4
30832,Spain,2012,4,C01A-Cardiac glycosides,Million US$ at exchange rate,4.3
30833,Spain,2012,4,G-Genito urinary system and sex hormones,% of total sales,4.3
30834,Spain,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",14.7
30835,Spain,2012,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
30836,Spain,2012,4,C01A-Cardiac glycosides,% of total sales,0.0
30837,Spain,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1
30838,Spain,2012,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",57.7
30839,Spain,2012,4,N05C-Hypnotics and sedatives,% of total sales,0.4
30840,Spain,2012,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2
30841,Spain,2012,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,51.5
30842,Spain,2012,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",722.0
30843,Spain,2012,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",13.8
30844,Spain,2012,4,B-Blood and blood forming organs,Million US$ at exchange rate,644.7
30845,Spain,2012,4,N05C-Hypnotics and sedatives,Million of national currency units,40.1
30846,Spain,2012,4,B-Blood and blood forming organs,Million of national currency units,501.8
30847,Spain,2012,4,N06A-Antidepressants,"/capita, US$ exchange rate",13.4
30848,Spain,2012,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.0
30849,Spain,2012,4,N06A-Antidepressants,Million US$ at exchange rate,627.9
30850,Spain,2012,4,N06A-Antidepressants,"Million US$, purchasing power parity",703.2
30851,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",507.1
30852,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.7
30853,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,352.4
30854,Spain,2012,4,N06A-Antidepressants,% of total sales,4.4
30855,Spain,2012,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,452.8
30856,Spain,2012,4,N06A-Antidepressants,Million of national currency units,488.7
30857,Spain,2012,4,G-Genito urinary system and sex hormones,Million of national currency units,478.2
30858,Spain,2012,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,125.1
30859,Spain,2012,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,160.7
30860,Spain,2012,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.1
30861,Spain,2012,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",688.0
30862,Spain,2012,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,614.3
30863,Spain,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.8
30864,Spain,2012,4,G03-Sex hormones and modulators of the genital system,% of total sales,1.1
30865,Spain,2012,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",179.9
30866,Spain,2012,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.4
30867,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.8
30868,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,4.1
30869,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",646.3
30870,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.3
30871,Spain,2012,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2415.6
30872,Spain,2012,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",46.1
30873,Spain,2012,4,A-Alimentary tract and metabolism,Million of national currency units,1678.8
30874,Spain,2012,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2156.9
30875,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.5
30876,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,31.2
30877,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.7
30878,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1385.6
30879,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.6
30880,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,449.2
30881,Spain,2012,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,577.1
30882,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,963.0
30883,Spain,2012,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1237.2
30884,Spain,2012,4,N02-Analgesics,"/capita, US$ exchange rate",12.9
30885,Spain,2012,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.4
30886,Spain,2012,4,N02-Analgesics,% of total sales,4.2
30887,Spain,2012,4,N02-Analgesics,Million of national currency units,468.8
30888,Spain,2012,4,C02-Antihypertensives,Million of national currency units,40.6
30889,Spain,2012,4,C02-Antihypertensives,Million US$ at exchange rate,52.2
30890,Spain,2012,4,N02-Analgesics,"Million US$, purchasing power parity",674.6
30891,Spain,2012,4,N02-Analgesics,Million US$ at exchange rate,602.3
30892,Spain,2012,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1009.0
30893,Spain,2012,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1296.3
30894,Spain,2012,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.6
30895,Spain,2012,4,A-Alimentary tract and metabolism,% of total sales,15.2
30896,Spain,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",31.0
30897,Spain,2012,4,R03-Drugs for obstructive airway diseases,% of total sales,9.1
30898,Spain,2012,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1451.8
30899,Spain,2012,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",27.7
30900,Spain,2012,4,A02A-Antacids,Million US$ at exchange rate,15.0
30901,Spain,2012,4,A02A-Antacids,Million of national currency units,11.7
30902,Spain,2012,4,A10-Drugs used in diabetes,Million of national currency units,941.9
30903,Spain,2012,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1210.1
30904,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
30905,Spain,2012,4,A02A-Antacids,% of total sales,0.1
30906,Spain,2012,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.4
30907,Spain,2012,4,A02A-Antacids,"/capita, US$ exchange rate",0.3
30908,Spain,2012,4,A02A-Antacids,"Million US$, purchasing power parity",16.8
30909,Spain,2012,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",29.0
30910,Spain,2012,4,A10-Drugs used in diabetes,% of total sales,8.5
30911,Spain,2012,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1355.3
30912,Spain,2012,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",25.9
30913,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",44.9
30914,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
30915,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,40.1
30916,Spain,2012,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
30917,Spain,2013,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.2
30918,Spain,2013,4,J01-Antibacterials for systemic use,% of total sales,2.1
30919,Spain,2013,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,302.5
30920,Spain,2013,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",337.5
30921,Spain,2013,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.5
30922,Spain,2013,4,J01-Antibacterials for systemic use,Million of national currency units,227.8
30923,Spain,2013,4,C-Cardiovascular system,"Million US$, purchasing power parity",3080.4
30924,Spain,2013,4,C02-Antihypertensives,"Million US$, purchasing power parity",59.4
30925,Spain,2013,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
30926,Spain,2013,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5
30927,Spain,2013,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2
30928,Spain,2013,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.1
30929,Spain,2013,4,C02-Antihypertensives,% of total sales,0.4
30930,Spain,2013,4,C08-Calcium channel blockers,% of total sales,1.0
30931,Spain,2013,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.8
30932,Spain,2013,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,364.5
30933,Spain,2013,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",406.7
30934,Spain,2013,4,C03-Diuretics,Million US$ at exchange rate,135.0
30935,Spain,2013,4,C03-Diuretics,"Million US$, purchasing power parity",150.6
30936,Spain,2013,4,J-Antiinfectives for systemic use,% of total sales,2.6
30937,Spain,2013,4,C03-Diuretics,Million of national currency units,101.6
30938,Spain,2013,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.6
30939,Spain,2013,4,C07-Beta blocking agents,% of total sales,0.8
30940,Spain,2013,4,N-Nervous system,Million of national currency units,2862.9
30941,Spain,2013,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.3
30942,Spain,2013,4,C07-Beta blocking agents,Million of national currency units,80.7
30943,Spain,2013,4,J-Antiinfectives for systemic use,Million of national currency units,274.4
30944,Spain,2013,4,C07-Beta blocking agents,Million US$ at exchange rate,107.2
30945,Spain,2013,4,C07-Beta blocking agents,"Million US$, purchasing power parity",119.6
30946,Spain,2013,4,N-Nervous system,"/capita, US$ purchasing power parity",91.0
30947,Spain,2013,4,N-Nervous system,"/capita, US$ exchange rate",81.6
30948,Spain,2013,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",164.3
30949,Spain,2013,4,N-Nervous system,% of total sales,26.8
30950,Spain,2013,4,C-Cardiovascular system,Million US$ at exchange rate,2760.7
30951,Spain,2013,4,C-Cardiovascular system,Million of national currency units,2078.7
30952,Spain,2013,4,N-Nervous system,"Million US$, purchasing power parity",4242.6
30953,Spain,2013,4,N-Nervous system,Million US$ at exchange rate,3802.2
30954,Spain,2013,4,C03-Diuretics,% of total sales,1.0
30955,Spain,2013,4,C-Cardiovascular system,% of total sales,19.5
30956,Spain,2013,4,C03-Diuretics,"/capita, US$ exchange rate",2.9
30957,Spain,2013,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.2
30958,Spain,2013,4,C08-Calcium channel blockers,Million of national currency units,110.8
30959,Spain,2013,4,C08-Calcium channel blockers,Million US$ at exchange rate,147.2
30960,Spain,2013,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",66.1
30961,Spain,2013,4,C-Cardiovascular system,"/capita, US$ exchange rate",59.2
30962,Spain,2013,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",8.7
30963,Spain,2013,4,C10-Lipid modifying agents,Million US$ at exchange rate,864.0
30964,Spain,2013,4,C10-Lipid modifying agents,Million of national currency units,650.6
30965,Spain,2013,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",964.1
30966,Spain,2013,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",20.7
30967,Spain,2013,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.5
30968,Spain,2013,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",15.6
30969,Spain,2013,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",812.4
30970,Spain,2013,4,M-Musculo-skeletal system,% of total sales,5.1
30971,Spain,2013,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.4
30972,Spain,2013,4,B-Blood and blood forming organs,% of total sales,4.9
30973,Spain,2013,4,Total pharmaceutical sales,Million of national currency units,10669.9
30974,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.6
30975,Spain,2013,4,Total pharmaceutical sales,Million US$ at exchange rate,14170.8
30976,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.1
30977,Spain,2013,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",339.2
30978,Spain,2013,4,C10-Lipid modifying agents,% of total sales,6.1
30979,Spain,2013,4,Total pharmaceutical sales,"Million US$, purchasing power parity",15811.9
30980,Spain,2013,4,Total pharmaceutical sales,"/capita, US$ exchange rate",304.0
30981,Spain,2013,4,N05B-Anxiolytics,% of total sales,0.9
30982,Spain,2013,4,M-Musculo-skeletal system,Million of national currency units,548.2
30983,Spain,2013,4,R-Respiratory system,Million of national currency units,1092.6
30984,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
30985,Spain,2013,4,M-Musculo-skeletal system,Million US$ at exchange rate,728.1
30986,Spain,2013,4,R-Respiratory system,Million US$ at exchange rate,1451.1
30987,Spain,2013,4,R-Respiratory system,"/capita, US$ purchasing power parity",34.7
30988,Spain,2013,4,R-Respiratory system,% of total sales,10.2
30989,Spain,2013,4,R-Respiratory system,"Million US$, purchasing power parity",1619.2
30990,Spain,2013,4,R-Respiratory system,"/capita, US$ exchange rate",31.1
30991,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.6
30992,Spain,2013,4,N05B-Anxiolytics,"Million US$, purchasing power parity",145.6
30993,Spain,2013,4,N05B-Anxiolytics,Million US$ at exchange rate,130.5
30994,Spain,2013,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.1
30995,Spain,2013,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.8
30996,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",305.5
30997,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.9
30998,Spain,2013,4,N05B-Anxiolytics,Million of national currency units,98.3
30999,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,206.1
31000,Spain,2013,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,273.8
31001,Spain,2013,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.6
31002,Spain,2013,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
31003,Spain,2013,4,C01A-Cardiac glycosides,Million US$ at exchange rate,4.1
31004,Spain,2013,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.7
31005,Spain,2013,4,C01A-Cardiac glycosides,Million of national currency units,3.1
31006,Spain,2013,4,G-Genito urinary system and sex hormones,% of total sales,4.6
31007,Spain,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.5
31008,Spain,2013,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
31009,Spain,2013,4,C01A-Cardiac glycosides,% of total sales,0.0
31010,Spain,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2
31011,Spain,2013,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",62.1
31012,Spain,2013,4,N05C-Hypnotics and sedatives,% of total sales,0.4
31013,Spain,2013,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.3
31014,Spain,2013,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",780.7
31015,Spain,2013,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.0
31016,Spain,2013,4,B-Blood and blood forming organs,Million US$ at exchange rate,699.7
31017,Spain,2013,4,N05C-Hypnotics and sedatives,Million of national currency units,41.9
31018,Spain,2013,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,55.7
31019,Spain,2013,4,B-Blood and blood forming organs,Million of national currency units,526.8
31020,Spain,2013,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.9
31021,Spain,2013,4,N06A-Antidepressants,"/capita, US$ exchange rate",14.3
31022,Spain,2013,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.9
31023,Spain,2013,4,N06A-Antidepressants,Million US$ at exchange rate,664.9
31024,Spain,2013,4,N06A-Antidepressants,"Million US$, purchasing power parity",741.9
31025,Spain,2013,4,N06A-Antidepressants,% of total sales,4.7
31026,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",493.0
31027,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.5
31028,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,332.7
31029,Spain,2013,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,441.9
31030,Spain,2013,4,G-Genito urinary system and sex hormones,Million of national currency units,487.0
31031,Spain,2013,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,121.7
31032,Spain,2013,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,161.7
31033,Spain,2013,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",721.6
31034,Spain,2013,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,646.7
31035,Spain,2013,4,N06A-Antidepressants,Million of national currency units,500.6
31036,Spain,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.9
31037,Spain,2013,4,G03-Sex hormones and modulators of the genital system,% of total sales,1.1
31038,Spain,2013,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",180.4
31039,Spain,2013,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.5
31040,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,31.7
31041,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.3
31042,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.9
31043,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",621.4
31044,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",11.9
31045,Spain,2013,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2497.4
31046,Spain,2013,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",48.0
31047,Spain,2013,4,A-Alimentary tract and metabolism,Million of national currency units,1685.3
31048,Spain,2013,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2238.2
31049,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",26.3
31050,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1367.8
31051,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,8.7
31052,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.3
31053,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,419.3
31054,Spain,2013,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,556.9
31055,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1225.8
31056,Spain,2013,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,923.0
31057,Spain,2013,4,N02-Analgesics,"/capita, US$ exchange rate",13.9
31058,Spain,2013,4,N02-Analgesics,"/capita, US$ purchasing power parity",15.6
31059,Spain,2013,4,N02-Analgesics,% of total sales,4.6
31060,Spain,2013,4,N02-Analgesics,"Million US$, purchasing power parity",725.0
31061,Spain,2013,4,C02-Antihypertensives,Million of national currency units,40.1
31062,Spain,2013,4,C02-Antihypertensives,Million US$ at exchange rate,53.2
31063,Spain,2013,4,N02-Analgesics,Million of national currency units,489.2
31064,Spain,2013,4,N02-Analgesics,Million US$ at exchange rate,649.7
31065,Spain,2013,4,R03-Drugs for obstructive airway diseases,Million of national currency units,945.0
31066,Spain,2013,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1255.1
31067,Spain,2013,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",53.6
31068,Spain,2013,4,A-Alimentary tract and metabolism,% of total sales,15.8
31069,Spain,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.0
31070,Spain,2013,4,R03-Drugs for obstructive airway diseases,% of total sales,8.9
31071,Spain,2013,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1400.5
31072,Spain,2013,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",26.9
31073,Spain,2013,4,A10-Drugs used in diabetes,Million of national currency units,1024.7
31074,Spain,2013,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1361.0
31075,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
31076,Spain,2013,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",32.6
31077,Spain,2013,4,A10-Drugs used in diabetes,% of total sales,9.6
31078,Spain,2013,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1518.6
31079,Spain,2013,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",29.2
31080,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",47.0
31081,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
31082,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,42.1
31083,Spain,2013,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
31084,Spain,2010,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",9.0
31085,Spain,2010,4,J01-Antibacterials for systemic use,Million of national currency units,305.1
31086,Spain,2010,4,J01-Antibacterials for systemic use,% of total sales,2.3
31087,Spain,2010,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,404.5
31088,Spain,2010,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",419.7
31089,Spain,2010,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.7
31090,Spain,2010,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",6.8
31091,Spain,2010,4,C02-Antihypertensives,"Million US$, purchasing power parity",81.5
31092,Spain,2010,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.7
31093,Spain,2010,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.7
31094,Spain,2010,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",7.0
31095,Spain,2010,4,C02-Antihypertensives,% of total sales,0.4
31096,Spain,2010,4,C08-Calcium channel blockers,% of total sales,1.8
31097,Spain,2010,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",10.4
31098,Spain,2010,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.8
31099,Spain,2010,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,485.0
31100,Spain,2010,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",503.3
31101,Spain,2010,4,C03-Diuretics,Million US$ at exchange rate,165.2
31102,Spain,2010,4,C03-Diuretics,"Million US$, purchasing power parity",171.4
31103,Spain,2010,4,J-Antiinfectives for systemic use,% of total sales,2.8
31104,Spain,2010,4,C03-Diuretics,Million of national currency units,124.6
31105,Spain,2010,4,C07-Beta blocking agents,% of total sales,0.7
31106,Spain,2010,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.9
31107,Spain,2010,4,N-Nervous system,Million of national currency units,3140.7
31108,Spain,2010,4,N-Nervous system,Million US$ at exchange rate,4163.7
31109,Spain,2010,4,C07-Beta blocking agents,Million US$ at exchange rate,131.3
31110,Spain,2010,4,C07-Beta blocking agents,Million of national currency units,99.0
31111,Spain,2010,4,J-Antiinfectives for systemic use,Million of national currency units,365.9
31112,Spain,2010,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.8
31113,Spain,2010,4,C07-Beta blocking agents,"Million US$, purchasing power parity",136.2
31114,Spain,2010,4,N-Nervous system,"/capita, US$ purchasing power parity",92.8
31115,Spain,2010,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",327.9
31116,Spain,2010,4,N-Nervous system,% of total sales,23.7
31117,Spain,2010,4,N-Nervous system,"/capita, US$ exchange rate",89.4
31118,Spain,2010,4,C-Cardiovascular system,Million US$ at exchange rate,4080.1
31119,Spain,2010,4,C-Cardiovascular system,"Million US$, purchasing power parity",4233.6
31120,Spain,2010,4,N-Nervous system,"Million US$, purchasing power parity",4320.3
31121,Spain,2010,4,C-Cardiovascular system,Million of national currency units,3077.7
31122,Spain,2010,4,C03-Diuretics,% of total sales,0.9
31123,Spain,2010,4,C03-Diuretics,"/capita, US$ exchange rate",3.5
31124,Spain,2010,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.7
31125,Spain,2010,4,C-Cardiovascular system,% of total sales,23.2
31126,Spain,2010,4,C08-Calcium channel blockers,Million of national currency units,238.3
31127,Spain,2010,4,C08-Calcium channel blockers,Million US$ at exchange rate,316.0
31128,Spain,2010,4,C-Cardiovascular system,"/capita, US$ exchange rate",87.6
31129,Spain,2010,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",90.9
31130,Spain,2010,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1408.7
31131,Spain,2010,4,C10-Lipid modifying agents,Million US$ at exchange rate,1357.6
31132,Spain,2010,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",30.2
31133,Spain,2010,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",29.1
31134,Spain,2010,4,C10-Lipid modifying agents,Million of national currency units,1024.0
31135,Spain,2010,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",24.1
31136,Spain,2010,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",1163.2
31137,Spain,2010,4,M-Musculo-skeletal system,% of total sales,6.4
31138,Spain,2010,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",25.0
31139,Spain,2010,4,Total pharmaceutical sales,Million of national currency units,13238.8
31140,Spain,2010,4,Total pharmaceutical sales,Million US$ at exchange rate,17550.9
31141,Spain,2010,4,B-Blood and blood forming organs,% of total sales,4.6
31142,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,3.0
31143,Spain,2010,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",391.0
31144,Spain,2010,4,C10-Lipid modifying agents,% of total sales,7.7
31145,Spain,2010,4,Total pharmaceutical sales,"Million US$, purchasing power parity",18211.2
31146,Spain,2010,4,Total pharmaceutical sales,"/capita, US$ exchange rate",376.8
31147,Spain,2010,4,M-Musculo-skeletal system,Million of national currency units,845.6
31148,Spain,2010,4,R-Respiratory system,Million of national currency units,1304.6
31149,Spain,2010,4,R-Respiratory system,Million US$ at exchange rate,1729.5
31150,Spain,2010,4,M-Musculo-skeletal system,Million US$ at exchange rate,1121.0
31151,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.9
31152,Spain,2010,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.5
31153,Spain,2010,4,R-Respiratory system,% of total sales,9.9
31154,Spain,2010,4,R-Respiratory system,"Million US$, purchasing power parity",1794.5
31155,Spain,2010,4,R-Respiratory system,"/capita, US$ exchange rate",37.1
31156,Spain,2010,4,N05B-Anxiolytics,"Million US$, purchasing power parity",167.9
31157,Spain,2010,4,N05B-Anxiolytics,"/capita, US$ exchange rate",3.5
31158,Spain,2010,4,N05B-Anxiolytics,% of total sales,0.9
31159,Spain,2010,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.6
31160,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",7.3
31161,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6
31162,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",353.3
31163,Spain,2010,4,N05B-Anxiolytics,Million of national currency units,122.0
31164,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,256.8
31165,Spain,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,340.5
31166,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",11.9
31167,Spain,2010,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",5.4
31168,Spain,2010,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
31169,Spain,2010,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.1
31170,Spain,2010,4,C01A-Cardiac glycosides,Million of national currency units,4.0
31171,Spain,2010,4,C01A-Cardiac glycosides,Million US$ at exchange rate,5.2
31172,Spain,2010,4,G-Genito urinary system and sex hormones,% of total sales,3.9
31173,Spain,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.1
31174,Spain,2010,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
31175,Spain,2010,4,C01A-Cardiac glycosides,% of total sales,0.0
31176,Spain,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2
31177,Spain,2010,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",57.9
31178,Spain,2010,4,N05C-Hypnotics and sedatives,% of total sales,0.3
31179,Spain,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.2
31180,Spain,2010,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",842.7
31181,Spain,2010,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.4
31182,Spain,2010,4,B-Blood and blood forming organs,Million US$ at exchange rate,812.1
31183,Spain,2010,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,55.8
31184,Spain,2010,4,B-Blood and blood forming organs,Million of national currency units,612.6
31185,Spain,2010,4,N05C-Hypnotics and sedatives,Million of national currency units,42.1
31186,Spain,2010,4,N06A-Antidepressants,"/capita, US$ exchange rate",19.6
31187,Spain,2010,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",20.3
31188,Spain,2010,4,N06A-Antidepressants,Million US$ at exchange rate,911.0
31189,Spain,2010,4,N06A-Antidepressants,% of total sales,5.2
31190,Spain,2010,4,N06A-Antidepressants,"Million US$, purchasing power parity",945.2
31191,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",554.4
31192,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.5
31193,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,403.0
31194,Spain,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,534.3
31195,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,22.8
31196,Spain,2010,4,G-Genito urinary system and sex hormones,Million of national currency units,512.2
31197,Spain,2010,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,124.8
31198,Spain,2010,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,165.5
31199,Spain,2010,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,679.0
31200,Spain,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.6
31201,Spain,2010,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",704.5
31202,Spain,2010,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.9
31203,Spain,2010,4,N06A-Antidepressants,Million of national currency units,687.2
31204,Spain,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.7
31205,Spain,2010,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",171.7
31206,Spain,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.6
31207,Spain,2010,4,N05B-Anxiolytics,Million US$ at exchange rate,161.8
31208,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,5.0
31209,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",19.4
31210,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",18.7
31211,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",901.5
31212,Spain,2010,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2446.7
31213,Spain,2010,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",50.6
31214,Spain,2010,4,A-Alimentary tract and metabolism,Million of national currency units,1778.6
31215,Spain,2010,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2358.0
31216,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",35.5
31217,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,9.4
31218,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1714.3
31219,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,655.4
31220,Spain,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,868.9
31221,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,1246.3
31222,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1652.2
31223,Spain,2010,4,N02-Analgesics,"/capita, US$ purchasing power parity",14.3
31224,Spain,2010,4,N02-Analgesics,"/capita, US$ exchange rate",13.8
31225,Spain,2010,4,N02-Analgesics,% of total sales,3.7
31226,Spain,2010,4,N02-Analgesics,Million of national currency units,485.0
31227,Spain,2010,4,C02-Antihypertensives,Million of national currency units,59.2
31228,Spain,2010,4,C02-Antihypertensives,Million US$ at exchange rate,78.5
31229,Spain,2010,4,N02-Analgesics,"Million US$, purchasing power parity",667.2
31230,Spain,2010,4,N02-Analgesics,Million US$ at exchange rate,643.0
31231,Spain,2010,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1043.8
31232,Spain,2010,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1383.8
31233,Spain,2010,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",52.5
31234,Spain,2010,4,A-Alimentary tract and metabolism,% of total sales,13.4
31235,Spain,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",30.8
31236,Spain,2010,4,R03-Drugs for obstructive airway diseases,% of total sales,7.9
31237,Spain,2010,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1435.9
31238,Spain,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.7
31239,Spain,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",36.8
31240,Spain,2010,4,A02A-Antacids,Million US$ at exchange rate,25.6
31241,Spain,2010,4,A02A-Antacids,Million of national currency units,19.3
31242,Spain,2010,4,A10-Drugs used in diabetes,Million of national currency units,802.4
31243,Spain,2010,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1063.8
31244,Spain,2010,4,A02A-Antacids,"Million US$, purchasing power parity",26.6
31245,Spain,2010,4,A02A-Antacids,"/capita, US$ exchange rate",0.6
31246,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
31247,Spain,2010,4,A02A-Antacids,% of total sales,0.1
31248,Spain,2010,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.6
31249,Spain,2010,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",23.7
31250,Spain,2010,4,A10-Drugs used in diabetes,% of total sales,6.1
31251,Spain,2010,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1103.8
31252,Spain,2010,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",22.8
31253,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",31.4
31254,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.6
31255,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
31256,Spain,2010,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,30.2
31257,Spain,2015,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.1
31258,Spain,2015,4,J01-Antibacterials for systemic use,% of total sales,2.2
31259,Spain,2015,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",6.0
31260,Spain,2015,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,277.1
31261,Spain,2015,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",375.7
31262,Spain,2015,4,J01-Antibacterials for systemic use,Million of national currency units,249.7
31263,Spain,2015,4,C02-Antihypertensives,"Million US$, purchasing power parity",61.6
31264,Spain,2015,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
31265,Spain,2015,4,C-Cardiovascular system,"Million US$, purchasing power parity",3237.1
31266,Spain,2015,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.0
31267,Spain,2015,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.5
31268,Spain,2015,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6
31269,Spain,2015,4,C02-Antihypertensives,% of total sales,0.4
31270,Spain,2015,4,C08-Calcium channel blockers,% of total sales,0.9
31271,Spain,2015,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.2
31272,Spain,2015,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.8
31273,Spain,2015,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,335.6
31274,Spain,2015,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",455.0
31275,Spain,2015,4,C03-Diuretics,Million US$ at exchange rate,102.8
31276,Spain,2015,4,C03-Diuretics,"Million US$, purchasing power parity",139.4
31277,Spain,2015,4,J-Antiinfectives for systemic use,% of total sales,2.7
31278,Spain,2015,4,C03-Diuretics,Million of national currency units,92.6
31279,Spain,2015,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.7
31280,Spain,2015,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.0
31281,Spain,2015,4,C07-Beta blocking agents,% of total sales,0.7
31282,Spain,2015,4,N-Nervous system,Million of national currency units,2946.2
31283,Spain,2015,4,C07-Beta blocking agents,Million of national currency units,82.9
31284,Spain,2015,4,J-Antiinfectives for systemic use,Million of national currency units,302.5
31285,Spain,2015,4,C07-Beta blocking agents,"Million US$, purchasing power parity",124.6
31286,Spain,2015,4,C07-Beta blocking agents,Million US$ at exchange rate,91.9
31287,Spain,2015,4,N-Nervous system,"/capita, US$ purchasing power parity",95.4
31288,Spain,2015,4,N-Nervous system,"/capita, US$ exchange rate",70.4
31289,Spain,2015,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",162.8
31290,Spain,2015,4,N-Nervous system,% of total sales,25.8
31291,Spain,2015,4,C-Cardiovascular system,Million of national currency units,2151.8
31292,Spain,2015,4,C-Cardiovascular system,Million US$ at exchange rate,2387.5
31293,Spain,2015,4,N-Nervous system,"Million US$, purchasing power parity",4432.1
31294,Spain,2015,4,N-Nervous system,Million US$ at exchange rate,3268.8
31295,Spain,2015,4,C08-Calcium channel blockers,Million US$ at exchange rate,120.1
31296,Spain,2015,4,C03-Diuretics,% of total sales,0.8
31297,Spain,2015,4,C-Cardiovascular system,% of total sales,18.9
31298,Spain,2015,4,C03-Diuretics,"/capita, US$ exchange rate",2.2
31299,Spain,2015,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.0
31300,Spain,2015,4,C08-Calcium channel blockers,Million of national currency units,108.2
31301,Spain,2015,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",69.7
31302,Spain,2015,4,C-Cardiovascular system,"/capita, US$ exchange rate",51.4
31303,Spain,2015,4,C02-Antihypertensives,Million US$ at exchange rate,45.4
31304,Spain,2015,4,C10-Lipid modifying agents,Million US$ at exchange rate,849.1
31305,Spain,2015,4,C10-Lipid modifying agents,Million of national currency units,765.3
31306,Spain,2015,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",24.8
31307,Spain,2015,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",18.3
31308,Spain,2015,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1151.3
31309,Spain,2015,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",694.3
31310,Spain,2015,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.0
31311,Spain,2015,4,M-Musculo-skeletal system,% of total sales,4.0
31312,Spain,2015,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.9
31313,Spain,2015,4,B-Blood and blood forming organs,% of total sales,5.7
31314,Spain,2015,4,Total pharmaceutical sales,Million of national currency units,11403.6
31315,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8
31316,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.4
31317,Spain,2015,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",369.4
31318,Spain,2015,4,C10-Lipid modifying agents,% of total sales,6.7
31319,Spain,2015,4,Total pharmaceutical sales,"Million US$, purchasing power parity",17155.0
31320,Spain,2015,4,Total pharmaceutical sales,Million US$ at exchange rate,12652.5
31321,Spain,2015,4,Total pharmaceutical sales,"/capita, US$ exchange rate",272.4
31322,Spain,2015,4,N05B-Anxiolytics,% of total sales,0.9
31323,Spain,2015,4,M-Musculo-skeletal system,Million of national currency units,461.5
31324,Spain,2015,4,R-Respiratory system,Million of national currency units,1182.8
31325,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
31326,Spain,2015,4,M-Musculo-skeletal system,Million US$ at exchange rate,512.1
31327,Spain,2015,4,R-Respiratory system,Million US$ at exchange rate,1312.3
31328,Spain,2015,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.3
31329,Spain,2015,4,R-Respiratory system,% of total sales,10.4
31330,Spain,2015,4,R-Respiratory system,"Million US$, purchasing power parity",1779.3
31331,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.4
31332,Spain,2015,4,R-Respiratory system,"/capita, US$ exchange rate",28.3
31333,Spain,2015,4,N05B-Anxiolytics,"Million US$, purchasing power parity",151.4
31334,Spain,2015,4,N05B-Anxiolytics,Million US$ at exchange rate,111.7
31335,Spain,2015,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.3
31336,Spain,2015,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.4
31337,Spain,2015,4,N05B-Anxiolytics,Million of national currency units,100.7
31338,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",343.8
31339,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.5
31340,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,228.5
31341,Spain,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,253.5
31342,Spain,2015,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.5
31343,Spain,2015,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
31344,Spain,2015,4,C01A-Cardiac glycosides,Million US$ at exchange rate,3.3
31345,Spain,2015,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",21.1
31346,Spain,2015,4,C01A-Cardiac glycosides,Million of national currency units,3.0
31347,Spain,2015,4,G-Genito urinary system and sex hormones,% of total sales,4.7
31348,Spain,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",17.3
31349,Spain,2015,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
31350,Spain,2015,4,C01A-Cardiac glycosides,% of total sales,0.0
31351,Spain,2015,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.6
31352,Spain,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1
31353,Spain,2015,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",68.6
31354,Spain,2015,4,N05C-Hypnotics and sedatives,% of total sales,0.4
31355,Spain,2015,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,50.6
31356,Spain,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5
31357,Spain,2015,4,B-Blood and blood forming organs,Million US$ at exchange rate,724.3
31358,Spain,2015,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",982.0
31359,Spain,2015,4,N05C-Hypnotics and sedatives,Million of national currency units,45.6
31360,Spain,2015,4,B-Blood and blood forming organs,Million of national currency units,652.8
31361,Spain,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",12.8
31362,Spain,2015,4,N06A-Antidepressants,"/capita, US$ exchange rate",11.6
31363,Spain,2015,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",15.7
31364,Spain,2015,4,N06A-Antidepressants,Million US$ at exchange rate,537.7
31365,Spain,2015,4,N06A-Antidepressants,"Million US$, purchasing power parity",729.0
31366,Spain,2015,4,N06A-Antidepressants,Million of national currency units,484.6
31367,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",409.4
31368,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.5
31369,Spain,2015,4,N06A-Antidepressants,% of total sales,4.2
31370,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,302.0
31371,Spain,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,272.2
31372,Spain,2015,4,G-Genito urinary system and sex hormones,Million of national currency units,534.8
31373,Spain,2015,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,96.6
31374,Spain,2015,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",804.6
31375,Spain,2015,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,593.4
31376,Spain,2015,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,107.1
31377,Spain,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.1
31378,Spain,2015,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.8
31379,Spain,2015,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",145.3
31380,Spain,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.3
31381,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.4
31382,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6
31383,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",623.5
31384,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.9
31385,Spain,2015,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2945.5
31386,Spain,2015,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",46.8
31387,Spain,2015,4,A-Alimentary tract and metabolism,Million of national currency units,1958.0
31388,Spain,2015,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2172.4
31389,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.8
31390,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1308.9
31391,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.6
31392,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.2
31393,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,414.5
31394,Spain,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,459.8
31395,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,965.3
31396,Spain,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,870.1
31397,Spain,2015,4,N02-Analgesics,"/capita, US$ exchange rate",14.8
31398,Spain,2015,4,N02-Analgesics,"/capita, US$ purchasing power parity",20.1
31399,Spain,2015,4,N02-Analgesics,% of total sales,5.4
31400,Spain,2015,4,N02-Analgesics,"Million US$, purchasing power parity",932.7
31401,Spain,2015,4,C02-Antihypertensives,Million of national currency units,40.9
31402,Spain,2015,4,N02-Analgesics,Million of national currency units,620.0
31403,Spain,2015,4,N02-Analgesics,Million US$ at exchange rate,687.9
31404,Spain,2015,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1007.5
31405,Spain,2015,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1117.9
31406,Spain,2015,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",63.4
31407,Spain,2015,4,A-Alimentary tract and metabolism,% of total sales,17.2
31408,Spain,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.6
31409,Spain,2015,4,R03-Drugs for obstructive airway diseases,% of total sales,8.8
31410,Spain,2015,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1515.7
31411,Spain,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",24.1
31412,Spain,2015,4,A10-Drugs used in diabetes,Million of national currency units,1269.7
31413,Spain,2015,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1408.7
31414,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
31415,Spain,2015,4,A10-Drugs used in diabetes,% of total sales,11.1
31416,Spain,2015,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",41.1
31417,Spain,2015,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1910.0
31418,Spain,2015,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",30.3
31419,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,40.7
31420,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",55.2
31421,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,36.7
31422,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
31423,Spain,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
31424,Spain,2016,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.1
31425,Spain,2016,4,J01-Antibacterials for systemic use,% of total sales,2.1
31426,Spain,2016,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,268.9
31427,Spain,2016,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",378.1
31428,Spain,2016,4,J01-Antibacterials for systemic use,Million of national currency units,243.0
31429,Spain,2016,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8
31430,Spain,2016,4,C02-Antihypertensives,"Million US$, purchasing power parity",64.0
31431,Spain,2016,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.4
31432,Spain,2016,4,C-Cardiovascular system,"Million US$, purchasing power parity",3478.8
31433,Spain,2016,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.0
31434,Spain,2016,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.6
31435,Spain,2016,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6
31436,Spain,2016,4,C02-Antihypertensives,% of total sales,0.3
31437,Spain,2016,4,C08-Calcium channel blockers,% of total sales,0.9
31438,Spain,2016,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.1
31439,Spain,2016,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.0
31440,Spain,2016,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,329.7
31441,Spain,2016,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",463.5
31442,Spain,2016,4,C03-Diuretics,Million US$ at exchange rate,104.6
31443,Spain,2016,4,C03-Diuretics,"Million US$, purchasing power parity",147.1
31444,Spain,2016,4,J-Antiinfectives for systemic use,% of total sales,2.5
31445,Spain,2016,4,C03-Diuretics,Million of national currency units,94.5
31446,Spain,2016,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.9
31447,Spain,2016,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.0
31448,Spain,2016,4,N-Nervous system,Million of national currency units,3022.3
31449,Spain,2016,4,C07-Beta blocking agents,% of total sales,0.7
31450,Spain,2016,4,C07-Beta blocking agents,Million of national currency units,85.9
31451,Spain,2016,4,J-Antiinfectives for systemic use,Million of national currency units,297.9
31452,Spain,2016,4,C07-Beta blocking agents,"Million US$, purchasing power parity",133.7
31453,Spain,2016,4,C07-Beta blocking agents,Million US$ at exchange rate,95.1
31454,Spain,2016,4,N-Nervous system,"/capita, US$ purchasing power parity",101.2
31455,Spain,2016,4,N-Nervous system,"/capita, US$ exchange rate",72.0
31456,Spain,2016,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",168.9
31457,Spain,2016,4,N-Nervous system,% of total sales,25.5
31458,Spain,2016,4,C-Cardiovascular system,Million of national currency units,2235.6
31459,Spain,2016,4,C-Cardiovascular system,Million US$ at exchange rate,2474.6
31460,Spain,2016,4,N-Nervous system,"Million US$, purchasing power parity",4702.9
31461,Spain,2016,4,N-Nervous system,Million US$ at exchange rate,3345.4
31462,Spain,2016,4,C03-Diuretics,% of total sales,0.8
31463,Spain,2016,4,C-Cardiovascular system,% of total sales,18.9
31464,Spain,2016,4,C03-Diuretics,"/capita, US$ exchange rate",2.3
31465,Spain,2016,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.2
31466,Spain,2016,4,C08-Calcium channel blockers,Million of national currency units,108.6
31467,Spain,2016,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.8
31468,Spain,2016,4,C-Cardiovascular system,"/capita, US$ exchange rate",53.2
31469,Spain,2016,4,C08-Calcium channel blockers,Million US$ at exchange rate,120.2
31470,Spain,2016,4,C10-Lipid modifying agents,Million US$ at exchange rate,915.8
31471,Spain,2016,4,C10-Lipid modifying agents,Million of national currency units,827.3
31472,Spain,2016,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1287.4
31473,Spain,2016,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",27.7
31474,Spain,2016,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",19.7
31475,Spain,2016,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",724.2
31476,Spain,2016,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",11.1
31477,Spain,2016,4,M-Musculo-skeletal system,% of total sales,3.9
31478,Spain,2016,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.6
31479,Spain,2016,4,B-Blood and blood forming organs,% of total sales,6.2
31480,Spain,2016,4,Total pharmaceutical sales,Million of national currency units,11833.0
31481,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.0
31482,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.3
31483,Spain,2016,4,N05B-Anxiolytics,% of total sales,0.9
31484,Spain,2016,4,Total pharmaceutical sales,Million US$ at exchange rate,13098.0
31485,Spain,2016,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",396.1
31486,Spain,2016,4,C10-Lipid modifying agents,% of total sales,7.0
31487,Spain,2016,4,Total pharmaceutical sales,"Million US$, purchasing power parity",18412.9
31488,Spain,2016,4,Total pharmaceutical sales,"/capita, US$ exchange rate",281.8
31489,Spain,2016,4,M-Musculo-skeletal system,Million of national currency units,465.4
31490,Spain,2016,4,R-Respiratory system,Million of national currency units,1161.6
31491,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.9
31492,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
31493,Spain,2016,4,M-Musculo-skeletal system,Million US$ at exchange rate,515.2
31494,Spain,2016,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.9
31495,Spain,2016,4,R-Respiratory system,% of total sales,9.8
31496,Spain,2016,4,R-Respiratory system,Million US$ at exchange rate,1285.8
31497,Spain,2016,4,R-Respiratory system,"Million US$, purchasing power parity",1807.6
31498,Spain,2016,4,R-Respiratory system,"/capita, US$ exchange rate",27.7
31499,Spain,2016,4,N05B-Anxiolytics,"Million US$, purchasing power parity",157.0
31500,Spain,2016,4,N05B-Anxiolytics,Million US$ at exchange rate,111.7
31501,Spain,2016,4,C02-Antihypertensives,Million US$ at exchange rate,45.5
31502,Spain,2016,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4
31503,Spain,2016,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.4
31504,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",368.2
31505,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",5.6
31506,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,236.6
31507,Spain,2016,4,N05B-Anxiolytics,Million of national currency units,100.9
31508,Spain,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,261.9
31509,Spain,2016,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.3
31510,Spain,2016,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
31511,Spain,2016,4,C01A-Cardiac glycosides,Million US$ at exchange rate,3.1
31512,Spain,2016,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",24.4
31513,Spain,2016,4,C01A-Cardiac glycosides,Million of national currency units,2.8
31514,Spain,2016,4,G-Genito urinary system and sex hormones,% of total sales,4.8
31515,Spain,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.1
31516,Spain,2016,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
31517,Spain,2016,4,C01A-Cardiac glycosides,% of total sales,0.0
31518,Spain,2016,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.4
31519,Spain,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.1
31520,Spain,2016,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",73.0
31521,Spain,2016,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,51.9
31522,Spain,2016,4,N05C-Hypnotics and sedatives,% of total sales,0.4
31523,Spain,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6
31524,Spain,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",13.6
31525,Spain,2016,4,B-Blood and blood forming organs,Million US$ at exchange rate,806.9
31526,Spain,2016,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",1134.4
31527,Spain,2016,4,N05C-Hypnotics and sedatives,Million of national currency units,46.9
31528,Spain,2016,4,B-Blood and blood forming organs,Million of national currency units,729.0
31529,Spain,2016,4,N06A-Antidepressants,"/capita, US$ exchange rate",11.5
31530,Spain,2016,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",16.2
31531,Spain,2016,4,N06A-Antidepressants,Million of national currency units,483.9
31532,Spain,2016,4,N06A-Antidepressants,Million US$ at exchange rate,535.6
31533,Spain,2016,4,N06A-Antidepressants,"Million US$, purchasing power parity",753.0
31534,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",420.0
31535,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.4
31536,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,298.7
31537,Spain,2016,4,N06A-Antidepressants,% of total sales,4.1
31538,Spain,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,269.9
31539,Spain,2016,4,G-Genito urinary system and sex hormones,Million of national currency units,571.4
31540,Spain,2016,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,99.3
31541,Spain,2016,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",889.2
31542,Spain,2016,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,632.5
31543,Spain,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.3
31544,Spain,2016,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.8
31545,Spain,2016,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",154.6
31546,Spain,2016,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,110.0
31547,Spain,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.4
31548,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.2
31549,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.6
31550,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",657.9
31551,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.1
31552,Spain,2016,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3274.4
31553,Spain,2016,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",50.1
31554,Spain,2016,4,A-Alimentary tract and metabolism,Million of national currency units,2104.3
31555,Spain,2016,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2329.2
31556,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",21.1
31557,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1375.6
31558,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.5
31559,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.6
31560,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,422.8
31561,Spain,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,468.0
31562,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,978.5
31563,Spain,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,884.0
31564,Spain,2016,4,N02-Analgesics,"/capita, US$ exchange rate",16.4
31565,Spain,2016,4,N02-Analgesics,% of total sales,5.8
31566,Spain,2016,4,N02-Analgesics,"Million US$, purchasing power parity",1069.4
31567,Spain,2016,4,N02-Analgesics,"/capita, US$ purchasing power parity",23.0
31568,Spain,2016,4,C02-Antihypertensives,Million of national currency units,41.1
31569,Spain,2016,4,N02-Analgesics,Million of national currency units,687.3
31570,Spain,2016,4,N02-Analgesics,Million US$ at exchange rate,760.7
31571,Spain,2016,4,R03-Drugs for obstructive airway diseases,Million of national currency units,981.7
31572,Spain,2016,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1086.6
31573,Spain,2016,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",70.4
31574,Spain,2016,4,A-Alimentary tract and metabolism,% of total sales,17.8
31575,Spain,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.9
31576,Spain,2016,4,R03-Drugs for obstructive airway diseases,% of total sales,8.3
31577,Spain,2016,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1527.5
31578,Spain,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.4
31579,Spain,2016,4,A10-Drugs used in diabetes,Million of national currency units,1383.9
31580,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
31581,Spain,2016,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1531.8
31582,Spain,2016,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",46.3
31583,Spain,2016,4,A10-Drugs used in diabetes,% of total sales,11.7
31584,Spain,2016,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2153.4
31585,Spain,2016,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.0
31586,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
31587,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,39.2
31588,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",55.1
31589,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,35.4
31590,Spain,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
31591,Spain,2017,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.1
31592,Spain,2017,4,J01-Antibacterials for systemic use,% of total sales,2.0
31593,Spain,2017,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",5.8
31594,Spain,2017,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,268.2
31595,Spain,2017,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",376.3
31596,Spain,2017,4,J01-Antibacterials for systemic use,Million of national currency units,237.4
31597,Spain,2017,4,C02-Antihypertensives,"Million US$, purchasing power parity",71.7
31598,Spain,2017,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.5
31599,Spain,2017,4,C-Cardiovascular system,"Million US$, purchasing power parity",3491.4
31600,Spain,2017,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.1
31601,Spain,2017,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.7
31602,Spain,2017,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.6
31603,Spain,2017,4,C02-Antihypertensives,% of total sales,0.4
31604,Spain,2017,4,C08-Calcium channel blockers,% of total sales,0.9
31605,Spain,2017,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",7.1
31606,Spain,2017,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",10.0
31607,Spain,2017,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,331.2
31608,Spain,2017,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",464.8
31609,Spain,2017,4,C03-Diuretics,Million US$ at exchange rate,108.5
31610,Spain,2017,4,C03-Diuretics,"Million US$, purchasing power parity",152.2
31611,Spain,2017,4,J-Antiinfectives for systemic use,% of total sales,2.4
31612,Spain,2017,4,C03-Diuretics,Million of national currency units,96.0
31613,Spain,2017,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",3.0
31614,Spain,2017,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.1
31615,Spain,2017,4,N-Nervous system,Million of national currency units,3070.2
31616,Spain,2017,4,C07-Beta blocking agents,% of total sales,0.7
31617,Spain,2017,4,C07-Beta blocking agents,Million of national currency units,88.5
31618,Spain,2017,4,J-Antiinfectives for systemic use,Million of national currency units,293.2
31619,Spain,2017,4,C07-Beta blocking agents,"Million US$, purchasing power parity",140.4
31620,Spain,2017,4,C07-Beta blocking agents,Million US$ at exchange rate,100.0
31621,Spain,2017,4,N-Nervous system,"/capita, US$ purchasing power parity",104.5
31622,Spain,2017,4,N-Nervous system,"/capita, US$ exchange rate",74.4
31623,Spain,2017,4,N-Nervous system,% of total sales,25.4
31624,Spain,2017,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",170.7
31625,Spain,2017,4,C-Cardiovascular system,Million of national currency units,2202.5
31626,Spain,2017,4,C-Cardiovascular system,Million US$ at exchange rate,2488.1
31627,Spain,2017,4,N-Nervous system,"Million US$, purchasing power parity",4866.9
31628,Spain,2017,4,N-Nervous system,Million US$ at exchange rate,3468.4
31629,Spain,2017,4,C08-Calcium channel blockers,Million US$ at exchange rate,121.6
31630,Spain,2017,4,C03-Diuretics,% of total sales,0.8
31631,Spain,2017,4,C-Cardiovascular system,% of total sales,18.3
31632,Spain,2017,4,C03-Diuretics,"/capita, US$ exchange rate",2.3
31633,Spain,2017,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.3
31634,Spain,2017,4,C08-Calcium channel blockers,Million of national currency units,107.7
31635,Spain,2017,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.9
31636,Spain,2017,4,C-Cardiovascular system,"/capita, US$ exchange rate",53.4
31637,Spain,2017,4,C02-Antihypertensives,Million US$ at exchange rate,51.1
31638,Spain,2017,4,C10-Lipid modifying agents,Million US$ at exchange rate,969.4
31639,Spain,2017,4,C10-Lipid modifying agents,Million of national currency units,858.1
31640,Spain,2017,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",29.2
31641,Spain,2017,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.8
31642,Spain,2017,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1360.3
31643,Spain,2017,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",710.4
31644,Spain,2017,4,N05B-Anxiolytics,% of total sales,0.8
31645,Spain,2017,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.9
31646,Spain,2017,4,M-Musculo-skeletal system,% of total sales,3.7
31647,Spain,2017,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.2
31648,Spain,2017,4,B-Blood and blood forming organs,% of total sales,6.7
31649,Spain,2017,4,Total pharmaceutical sales,Million of national currency units,12064.9
31650,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.4
31651,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
31652,Spain,2017,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.4
31653,Spain,2017,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",410.5
31654,Spain,2017,4,C10-Lipid modifying agents,% of total sales,7.1
31655,Spain,2017,4,Total pharmaceutical sales,Million US$ at exchange rate,13629.5
31656,Spain,2017,4,Total pharmaceutical sales,"Million US$, purchasing power parity",19125.2
31657,Spain,2017,4,Total pharmaceutical sales,"/capita, US$ exchange rate",292.5
31658,Spain,2017,4,M-Musculo-skeletal system,Million of national currency units,448.2
31659,Spain,2017,4,R-Respiratory system,Million of national currency units,1134.8
31660,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.4
31661,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.1
31662,Spain,2017,4,M-Musculo-skeletal system,Million US$ at exchange rate,506.3
31663,Spain,2017,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.6
31664,Spain,2017,4,R-Respiratory system,% of total sales,9.4
31665,Spain,2017,4,R-Respiratory system,Million US$ at exchange rate,1281.9
31666,Spain,2017,4,R-Respiratory system,"/capita, US$ exchange rate",27.5
31667,Spain,2017,4,R-Respiratory system,"Million US$, purchasing power parity",1798.8
31668,Spain,2017,4,N05B-Anxiolytics,"Million US$, purchasing power parity",159.1
31669,Spain,2017,4,N05B-Anxiolytics,Million US$ at exchange rate,113.4
31670,Spain,2017,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4
31671,Spain,2017,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.4
31672,Spain,2017,4,N05B-Anxiolytics,Million of national currency units,100.4
31673,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",392.1
31674,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.0
31675,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,247.3
31676,Spain,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,279.4
31677,Spain,2017,4,C01A-Cardiac glycosides,Million US$ at exchange rate,2.9
31678,Spain,2017,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.0
31679,Spain,2017,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
31680,Spain,2017,4,C01A-Cardiac glycosides,Million of national currency units,2.5
31681,Spain,2017,4,G-Genito urinary system and sex hormones,% of total sales,5.0
31682,Spain,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.4
31683,Spain,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.5
31684,Spain,2017,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
31685,Spain,2017,4,C01A-Cardiac glycosides,% of total sales,0.0
31686,Spain,2017,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.5
31687,Spain,2017,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",75.5
31688,Spain,2017,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,53.8
31689,Spain,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.2
31690,Spain,2017,4,N05C-Hypnotics and sedatives,% of total sales,0.4
31691,Spain,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.6
31692,Spain,2017,4,B-Blood and blood forming organs,Million US$ at exchange rate,910.7
31693,Spain,2017,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",1277.9
31694,Spain,2017,4,N05C-Hypnotics and sedatives,Million of national currency units,47.6
31695,Spain,2017,4,B-Blood and blood forming organs,Million of national currency units,806.2
31696,Spain,2017,4,N06A-Antidepressants,"/capita, US$ exchange rate",12.1
31697,Spain,2017,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.0
31698,Spain,2017,4,N06A-Antidepressants,Million of national currency units,500.8
31699,Spain,2017,4,N06A-Antidepressants,"Million US$, purchasing power parity",793.8
31700,Spain,2017,4,N06A-Antidepressants,Million US$ at exchange rate,565.7
31701,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",391.1
31702,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",6.0
31703,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,278.7
31704,Spain,2017,4,N06A-Antidepressants,% of total sales,4.2
31705,Spain,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,246.7
31706,Spain,2017,4,G-Genito urinary system and sex hormones,Million of national currency units,600.1
31707,Spain,2017,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,107.7
31708,Spain,2017,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",951.3
31709,Spain,2017,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,677.9
31710,Spain,2017,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,121.7
31711,Spain,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.7
31712,Spain,2017,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.9
31713,Spain,2017,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",170.7
31714,Spain,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",2.6
31715,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",14.4
31716,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.5
31717,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",671.5
31718,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.3
31719,Spain,2017,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",3512.0
31720,Spain,2017,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.7
31721,Spain,2017,4,A-Alimentary tract and metabolism,Million of national currency units,2215.5
31722,Spain,2017,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2502.8
31723,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",20.3
31724,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1328.0
31725,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,6.9
31726,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",28.5
31727,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,423.6
31728,Spain,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,478.6
31729,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,946.4
31730,Spain,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,837.8
31731,Spain,2017,4,N02-Analgesics,"/capita, US$ exchange rate",17.4
31732,Spain,2017,4,N02-Analgesics,"Million US$, purchasing power parity",1138.5
31733,Spain,2017,4,N02-Analgesics,% of total sales,6.0
31734,Spain,2017,4,N02-Analgesics,"/capita, US$ purchasing power parity",24.4
31735,Spain,2017,4,C02-Antihypertensives,Million of national currency units,45.2
31736,Spain,2017,4,N02-Analgesics,Million US$ at exchange rate,811.4
31737,Spain,2017,4,N02-Analgesics,Million of national currency units,718.2
31738,Spain,2017,4,R03-Drugs for obstructive airway diseases,% of total sales,8.0
31739,Spain,2017,4,R03-Drugs for obstructive airway diseases,Million of national currency units,961.2
31740,Spain,2017,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",75.4
31741,Spain,2017,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1085.8
31742,Spain,2017,4,A-Alimentary tract and metabolism,% of total sales,18.4
31743,Spain,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.7
31744,Spain,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",23.3
31745,Spain,2017,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1523.6
31746,Spain,2017,4,A10-Drugs used in diabetes,Million of national currency units,1467.1
31747,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
31748,Spain,2017,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",49.9
31749,Spain,2017,4,A10-Drugs used in diabetes,% of total sales,12.2
31750,Spain,2017,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1657.4
31751,Spain,2017,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",2325.7
31752,Spain,2017,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",35.6
31753,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,33.5
31754,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",47.0
31755,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.0
31756,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.7
31757,Spain,2017,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,29.6
31758,Spain,2014,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.1
31759,Spain,2014,4,J01-Antibacterials for systemic use,% of total sales,2.2
31760,Spain,2014,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,333.1
31761,Spain,2014,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",378.6
31762,Spain,2014,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",7.2
31763,Spain,2014,4,J01-Antibacterials for systemic use,Million of national currency units,250.8
31764,Spain,2014,4,C02-Antihypertensives,"/capita, US$ exchange rate",1.2
31765,Spain,2014,4,C02-Antihypertensives,"Million US$, purchasing power parity",62.4
31766,Spain,2014,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.3
31767,Spain,2014,4,C-Cardiovascular system,"Million US$, purchasing power parity",3232.1
31768,Spain,2014,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",3.7
31769,Spain,2014,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2
31770,Spain,2014,4,C02-Antihypertensives,% of total sales,0.4
31771,Spain,2014,4,C08-Calcium channel blockers,% of total sales,1.0
31772,Spain,2014,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",8.6
31773,Spain,2014,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",9.8
31774,Spain,2014,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,401.5
31775,Spain,2014,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",456.2
31776,Spain,2014,4,C03-Diuretics,Million US$ at exchange rate,136.6
31777,Spain,2014,4,C03-Diuretics,"Million US$, purchasing power parity",155.2
31778,Spain,2014,4,J-Antiinfectives for systemic use,% of total sales,2.7
31779,Spain,2014,4,C03-Diuretics,Million of national currency units,102.8
31780,Spain,2014,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",2.7
31781,Spain,2014,4,N-Nervous system,Million of national currency units,3043.9
31782,Spain,2014,4,C07-Beta blocking agents,% of total sales,0.7
31783,Spain,2014,4,C07-Beta blocking agents,"/capita, US$ exchange rate",2.4
31784,Spain,2014,4,C07-Beta blocking agents,Million of national currency units,84.4
31785,Spain,2014,4,J-Antiinfectives for systemic use,Million of national currency units,302.2
31786,Spain,2014,4,C07-Beta blocking agents,Million US$ at exchange rate,112.1
31787,Spain,2014,4,C07-Beta blocking agents,"Million US$, purchasing power parity",127.4
31788,Spain,2014,4,N-Nervous system,"/capita, US$ purchasing power parity",98.9
31789,Spain,2014,4,N-Nervous system,"/capita, US$ exchange rate",87.0
31790,Spain,2014,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",169.9
31791,Spain,2014,4,N-Nervous system,% of total sales,26.9
31792,Spain,2014,4,C-Cardiovascular system,Million of national currency units,2140.8
31793,Spain,2014,4,C-Cardiovascular system,Million US$ at exchange rate,2844.1
31794,Spain,2014,4,N-Nervous system,"Million US$, purchasing power parity",4595.6
31795,Spain,2014,4,N-Nervous system,Million US$ at exchange rate,4043.9
31796,Spain,2014,4,C03-Diuretics,% of total sales,0.9
31797,Spain,2014,4,C-Cardiovascular system,% of total sales,18.9
31798,Spain,2014,4,C03-Diuretics,"/capita, US$ exchange rate",2.9
31799,Spain,2014,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.3
31800,Spain,2014,4,C08-Calcium channel blockers,Million of national currency units,112.6
31801,Spain,2014,4,C08-Calcium channel blockers,Million US$ at exchange rate,149.5
31802,Spain,2014,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",69.5
31803,Spain,2014,4,C-Cardiovascular system,"/capita, US$ exchange rate",61.2
31804,Spain,2014,4,C10-Lipid modifying agents,Million US$ at exchange rate,950.3
31805,Spain,2014,4,C10-Lipid modifying agents,Million of national currency units,715.3
31806,Spain,2014,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",1080.0
31807,Spain,2014,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",23.2
31808,Spain,2014,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",20.4
31809,Spain,2014,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",14.6
31810,Spain,2014,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",769.1
31811,Spain,2014,4,M-Musculo-skeletal system,% of total sales,4.5
31812,Spain,2014,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",16.5
31813,Spain,2014,4,B-Blood and blood forming organs,% of total sales,5.3
31814,Spain,2014,4,Total pharmaceutical sales,Million of national currency units,11302.6
31815,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",10.0
31816,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.7
31817,Spain,2014,4,Total pharmaceutical sales,Million US$ at exchange rate,15015.6
31818,Spain,2014,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",367.1
31819,Spain,2014,4,C10-Lipid modifying agents,% of total sales,6.3
31820,Spain,2014,4,Total pharmaceutical sales,"Million US$, purchasing power parity",17064.2
31821,Spain,2014,4,Total pharmaceutical sales,"/capita, US$ exchange rate",323.0
31822,Spain,2014,4,M-Musculo-skeletal system,Million of national currency units,509.4
31823,Spain,2014,4,R-Respiratory system,Million of national currency units,1150.2
31824,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.0
31825,Spain,2014,4,M-Musculo-skeletal system,Million US$ at exchange rate,676.7
31826,Spain,2014,4,R-Respiratory system,Million US$ at exchange rate,1528.0
31827,Spain,2014,4,R-Respiratory system,"/capita, US$ purchasing power parity",37.4
31828,Spain,2014,4,R-Respiratory system,% of total sales,10.2
31829,Spain,2014,4,R-Respiratory system,"Million US$, purchasing power parity",1736.5
31830,Spain,2014,4,R-Respiratory system,"/capita, US$ exchange rate",32.9
31831,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.3
31832,Spain,2014,4,N05B-Anxiolytics,"Million US$, purchasing power parity",156.8
31833,Spain,2014,4,N05B-Anxiolytics,Million US$ at exchange rate,137.9
31834,Spain,2014,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",3.4
31835,Spain,2014,4,N05B-Anxiolytics,"/capita, US$ exchange rate",3.0
31836,Spain,2014,4,N05B-Anxiolytics,% of total sales,0.9
31837,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",338.9
31838,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",6.4
31839,Spain,2014,4,N05B-Anxiolytics,Million of national currency units,103.8
31840,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,224.5
31841,Spain,2014,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,298.2
31842,Spain,2014,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",4.8
31843,Spain,2014,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
31844,Spain,2014,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",19.3
31845,Spain,2014,4,C01A-Cardiac glycosides,Million of national currency units,3.2
31846,Spain,2014,4,C01A-Cardiac glycosides,Million US$ at exchange rate,4.2
31847,Spain,2014,4,G-Genito urinary system and sex hormones,% of total sales,4.6
31848,Spain,2014,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.7
31849,Spain,2014,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
31850,Spain,2014,4,C01A-Cardiac glycosides,% of total sales,0.0
31851,Spain,2014,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",1.3
31852,Spain,2014,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",67.6
31853,Spain,2014,4,N05C-Hypnotics and sedatives,% of total sales,0.4
31854,Spain,2014,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",1.5
31855,Spain,2014,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,59.4
31856,Spain,2014,4,B-Blood and blood forming organs,Million US$ at exchange rate,788.8
31857,Spain,2014,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",896.4
31858,Spain,2014,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",17.0
31859,Spain,2014,4,N05C-Hypnotics and sedatives,Million of national currency units,44.7
31860,Spain,2014,4,B-Blood and blood forming organs,Million of national currency units,593.7
31861,Spain,2014,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.7
31862,Spain,2014,4,N06A-Antidepressants,"/capita, US$ exchange rate",15.3
31863,Spain,2014,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",17.4
31864,Spain,2014,4,N06A-Antidepressants,Million US$ at exchange rate,711.2
31865,Spain,2014,4,N06A-Antidepressants,"Million US$, purchasing power parity",808.2
31866,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",467.0
31867,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.8
31868,Spain,2014,4,N06A-Antidepressants,% of total sales,4.7
31869,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,309.3
31870,Spain,2014,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,410.9
31871,Spain,2014,4,N06A-Antidepressants,Million of national currency units,535.3
31872,Spain,2014,4,G-Genito urinary system and sex hormones,Million of national currency units,515.1
31873,Spain,2014,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,103.4
31874,Spain,2014,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",777.6
31875,Spain,2014,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,137.4
31876,Spain,2014,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,684.3
31877,Spain,2014,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",3.4
31878,Spain,2014,4,G03-Sex hormones and modulators of the genital system,% of total sales,0.9
31879,Spain,2014,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",156.1
31880,Spain,2014,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",3.0
31881,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",13.7
31882,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,3.7
31883,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",635.4
31884,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",12.0
31885,Spain,2014,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2796.7
31886,Spain,2014,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",52.9
31887,Spain,2014,4,A-Alimentary tract and metabolism,Million of national currency units,1852.4
31888,Spain,2014,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,2460.9
31889,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",25.6
31890,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",1350.6
31891,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,7.9
31892,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",29.1
31893,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,420.8
31894,Spain,2014,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,559.1
31895,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,1188.4
31896,Spain,2014,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,894.6
31897,Spain,2014,4,N02-Analgesics,"/capita, US$ exchange rate",16.3
31898,Spain,2014,4,N02-Analgesics,"/capita, US$ purchasing power parity",18.5
31899,Spain,2014,4,N02-Analgesics,% of total sales,5.0
31900,Spain,2014,4,C02-Antihypertensives,Million of national currency units,41.3
31901,Spain,2014,4,C02-Antihypertensives,Million US$ at exchange rate,54.9
31902,Spain,2014,4,N02-Analgesics,Million of national currency units,570.2
31903,Spain,2014,4,N02-Analgesics,"Million US$, purchasing power parity",860.9
31904,Spain,2014,4,N02-Analgesics,Million US$ at exchange rate,757.6
31905,Spain,2014,4,R03-Drugs for obstructive airway diseases,Million of national currency units,985.8
31906,Spain,2014,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,1309.6
31907,Spain,2014,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",60.2
31908,Spain,2014,4,A-Alimentary tract and metabolism,% of total sales,16.4
31909,Spain,2014,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",32.0
31910,Spain,2014,4,R03-Drugs for obstructive airway diseases,% of total sales,8.7
31911,Spain,2014,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",1488.3
31912,Spain,2014,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.2
31913,Spain,2014,4,A10-Drugs used in diabetes,Million of national currency units,1167.2
31914,Spain,2014,4,A10-Drugs used in diabetes,Million US$ at exchange rate,1550.7
31915,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.3
31916,Spain,2014,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",37.9
31917,Spain,2014,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",1762.2
31918,Spain,2014,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",33.4
31919,Spain,2014,4,A10-Drugs used in diabetes,% of total sales,10.3
31920,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",53.5
31921,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,47.1
31922,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,35.5
31923,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",1.0
31924,Spain,2014,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",1.2
31925,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.9
31926,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
31927,Sweden,2017,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",78.4
31928,Sweden,2017,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",521.7
31929,Sweden,2017,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,81.2
31930,Sweden,2017,4,C03-Diuretics,"Million US$, purchasing power parity",25.0
31931,Sweden,2017,4,C03-Diuretics,Million US$ at exchange rate,25.9
31932,Sweden,2017,4,C03-Diuretics,Million of national currency units,221.4
31933,Sweden,2017,4,C03-Diuretics,% of total sales,0.5
31934,Sweden,2017,4,C-Cardiovascular system,Million US$ at exchange rate,294.2
31935,Sweden,2017,4,C03-Diuretics,"/capita, US$ exchange rate",2.6
31936,Sweden,2017,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.5
31937,Sweden,2017,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",51.9
31938,Sweden,2017,4,A-Alimentary tract and metabolism,% of total sales,10.6
31939,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,80.9
31940,Sweden,2017,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",53.7
31941,Sweden,2017,4,C02-Antihypertensives,Million of national currency units,226.1
31942,Sweden,2017,4,J01-Antibacterials for systemic use,Million of national currency units,694.2
31943,Sweden,2017,4,C02-Antihypertensives,"Million US$, purchasing power parity",25.5
31944,Sweden,2017,4,C02-Antihypertensives,Million US$ at exchange rate,26.5
31945,Sweden,2017,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
31946,Sweden,2017,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
31947,Sweden,2017,4,C-Cardiovascular system,Million of national currency units,2515.4
31948,Sweden,2017,4,C01A-Cardiac glycosides,% of total sales,0.0
31949,Sweden,2017,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
31950,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",9.1
31951,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,9.5
31952,Sweden,2017,4,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5
31953,Sweden,2017,4,C01A-Cardiac glycosides,Million of national currency units,12.5
31954,Sweden,2017,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5
31955,Sweden,2017,4,A10-Drugs used in diabetes,Million US$ at exchange rate,217.0
31956,Sweden,2017,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.6
31957,Sweden,2017,4,Total pharmaceutical sales,Million US$ at exchange rate,5112.2
31958,Sweden,2017,4,Total pharmaceutical sales,Million of national currency units,43703.1
31959,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.7
31960,Sweden,2017,4,C02-Antihypertensives,% of total sales,0.5
31961,Sweden,2017,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",209.6
31962,Sweden,2017,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.6
31963,Sweden,2017,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",180.2
31964,Sweden,2017,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.6
31965,Sweden,2017,4,M-Musculo-skeletal system,Million of national currency units,1595.2
31966,Sweden,2017,4,M-Musculo-skeletal system,Million US$ at exchange rate,186.6
31967,Sweden,2017,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.9
31968,Sweden,2017,4,Total pharmaceutical sales,"/capita, US$ exchange rate",508.3
31969,Sweden,2017,4,Total pharmaceutical sales,"Million US$, purchasing power parity",4937.0
31970,Sweden,2017,4,M-Musculo-skeletal system,% of total sales,3.7
31971,Sweden,2017,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",490.9
31972,Sweden,2017,4,C-Cardiovascular system,"/capita, US$ exchange rate",29.3
31973,Sweden,2017,4,C-Cardiovascular system,"Million US$, purchasing power parity",284.2
31974,Sweden,2017,4,A10-Drugs used in diabetes,% of total sales,4.2
31975,Sweden,2017,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",28.3
31976,Sweden,2017,4,J01-Antibacterials for systemic use,% of total sales,1.6
31977,Sweden,2017,4,A-Alimentary tract and metabolism,Million of national currency units,4618.1
31978,Sweden,2017,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",7.8
31979,Sweden,2017,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.1
31980,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",86.0
31981,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,89.0
31982,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",8.9
31983,Sweden,2017,4,A10-Drugs used in diabetes,Million of national currency units,1855.0
31984,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.6
31985,Sweden,2017,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,540.2
31986,Sweden,2017,4,C-Cardiovascular system,% of total sales,5.8
31987,Sweden,2017,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",20.8
31988,Sweden,2017,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,761.3
31989,Sweden,2017,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
31990,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.0
31991,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.9
31992,Sweden,2017,4,A02A-Antacids,Million of national currency units,98.3
31993,Sweden,2017,4,A02A-Antacids,"Million US$, purchasing power parity",11.1
31994,Sweden,2017,4,A02A-Antacids,Million US$ at exchange rate,11.5
31995,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,440.6
31996,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,56.5
31997,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,482.8
31998,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",49.8
31999,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",5.1
32000,Sweden,2017,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,51.5
32001,Sweden,2017,4,A02A-Antacids,"/capita, US$ exchange rate",1.1
32002,Sweden,2017,4,R-Respiratory system,Million of national currency units,3523.8
32003,Sweden,2017,4,R-Respiratory system,Million US$ at exchange rate,412.2
32004,Sweden,2017,4,R-Respiratory system,"Million US$, purchasing power parity",398.1
32005,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.3
32006,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8
32007,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
32008,Sweden,2017,4,A02A-Antacids,% of total sales,0.2
32009,Sweden,2017,4,A02A-Antacids,"/capita, US$ purchasing power parity",1.1
32010,Sweden,2017,4,R-Respiratory system,% of total sales,8.1
32011,Sweden,2017,4,R-Respiratory system,"/capita, US$ exchange rate",41.0
32012,Sweden,2017,4,R-Respiratory system,"/capita, US$ purchasing power parity",39.6
32013,Sweden,2017,4,N02-Analgesics,Million US$ at exchange rate,230.4
32014,Sweden,2017,4,C08-Calcium channel blockers,% of total sales,0.5
32015,Sweden,2017,4,N02-Analgesics,Million of national currency units,1969.4
32016,Sweden,2017,4,N02-Analgesics,"/capita, US$ exchange rate",22.9
32017,Sweden,2017,4,N02-Analgesics,"/capita, US$ purchasing power parity",22.1
32018,Sweden,2017,4,N02-Analgesics,"Million US$, purchasing power parity",222.5
32019,Sweden,2017,4,C08-Calcium channel blockers,Million US$ at exchange rate,23.6
32020,Sweden,2017,4,C08-Calcium channel blockers,Million of national currency units,202.1
32021,Sweden,2017,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
32022,Sweden,2017,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.8
32023,Sweden,2017,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.4
32024,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.1
32025,Sweden,2017,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1731.2
32026,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.4
32027,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",54.5
32028,Sweden,2017,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.6
32029,Sweden,2017,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,202.5
32030,Sweden,2017,4,R03-Drugs for obstructive airway diseases,% of total sales,4.0
32031,Sweden,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.4
32032,Sweden,2017,4,N02-Analgesics,% of total sales,4.5
32033,Sweden,2017,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",195.6
32034,Sweden,2017,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.1
32035,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",104.7
32036,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.4
32037,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.8
32038,Sweden,2017,4,G-Genito urinary system and sex hormones,Million of national currency units,1719.5
32039,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,927.0
32040,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,108.4
32041,Sweden,2017,4,N06A-Antidepressants,"Million US$, purchasing power parity",69.9
32042,Sweden,2017,4,N06A-Antidepressants,"/capita, US$ exchange rate",7.2
32043,Sweden,2017,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.1
32044,Sweden,2017,4,N06A-Antidepressants,Million of national currency units,618.9
32045,Sweden,2017,4,N06A-Antidepressants,Million US$ at exchange rate,72.4
32046,Sweden,2017,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",59.2
32047,Sweden,2017,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,61.3
32048,Sweden,2017,4,N05C-Hypnotics and sedatives,% of total sales,1.2
32049,Sweden,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",6.1
32050,Sweden,2017,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",5.9
32051,Sweden,2017,4,N05C-Hypnotics and sedatives,Million of national currency units,523.8
32052,Sweden,2017,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",194.2
32053,Sweden,2017,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,201.1
32054,Sweden,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",20.0
32055,Sweden,2017,4,G-Genito urinary system and sex hormones,% of total sales,3.9
32056,Sweden,2017,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3
32057,Sweden,2017,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.0
32058,Sweden,2017,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
32059,Sweden,2017,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.3
32060,Sweden,2017,4,C10-Lipid modifying agents,Million US$ at exchange rate,68.7
32061,Sweden,2017,4,C10-Lipid modifying agents,Million of national currency units,587.3
32062,Sweden,2017,4,N05B-Anxiolytics,% of total sales,0.5
32063,Sweden,2017,4,N05B-Anxiolytics,"Million US$, purchasing power parity",22.3
32064,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,123.4
32065,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1054.6
32066,Sweden,2017,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",119.1
32067,Sweden,2017,4,N05B-Anxiolytics,Million US$ at exchange rate,23.0
32068,Sweden,2017,4,N05B-Anxiolytics,Million of national currency units,197.0
32069,Sweden,2017,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",485.1
32070,Sweden,2017,4,B-Blood and blood forming organs,Million US$ at exchange rate,502.3
32071,Sweden,2017,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",49.9
32072,Sweden,2017,4,N06A-Antidepressants,% of total sales,1.4
32073,Sweden,2017,4,B-Blood and blood forming organs,Million of national currency units,4294.4
32074,Sweden,2017,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.6
32075,Sweden,2017,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.8
32076,Sweden,2017,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",66.3
32077,Sweden,2017,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",48.2
32078,Sweden,2017,4,B-Blood and blood forming organs,% of total sales,9.8
32079,Sweden,2017,4,C10-Lipid modifying agents,% of total sales,1.3
32080,Sweden,2017,4,J-Antiinfectives for systemic use,Million of national currency units,3285.5
32081,Sweden,2017,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",38.2
32082,Sweden,2017,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",36.9
32083,Sweden,2017,4,N-Nervous system,"/capita, US$ exchange rate",88.1
32084,Sweden,2017,4,N-Nervous system,"/capita, US$ purchasing power parity",85.1
32085,Sweden,2017,4,C07-Beta blocking agents,Million of national currency units,397.1
32086,Sweden,2017,4,N-Nervous system,% of total sales,17.3
32087,Sweden,2017,4,C07-Beta blocking agents,Million US$ at exchange rate,46.4
32088,Sweden,2017,4,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6
32089,Sweden,2017,4,J-Antiinfectives for systemic use,% of total sales,7.5
32090,Sweden,2017,4,C07-Beta blocking agents,"Million US$, purchasing power parity",44.9
32091,Sweden,2017,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.5
32092,Sweden,2017,4,C07-Beta blocking agents,% of total sales,0.9
32093,Sweden,2017,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,384.3
32094,Sweden,2017,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",371.1
32095,Sweden,2017,4,N-Nervous system,Million of national currency units,7573.2
32096,Sweden,2017,4,N-Nervous system,Million US$ at exchange rate,885.9
32097,Sweden,2017,4,N-Nervous system,"Million US$, purchasing power parity",855.5
32098,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
32099,Sweden,2011,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",415.6
32100,Sweden,2011,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",105.6
32101,Sweden,2011,5,C03-Diuretics,"Million US$, purchasing power parity",30.0
32102,Sweden,2011,5,C03-Diuretics,Million of national currency units,265.3
32103,Sweden,2011,5,C03-Diuretics,"/capita, US$ exchange rate",4.3
32104,Sweden,2011,5,C03-Diuretics,Million US$ at exchange rate,40.9
32105,Sweden,2011,5,C-Cardiovascular system,"Million US$, purchasing power parity",343.3
32106,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
32107,Sweden,2011,5,C03-Diuretics,% of total sales,0.7
32108,Sweden,2011,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.2
32109,Sweden,2011,5,A-Alimentary tract and metabolism,% of total sales,10.0
32110,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,49.4
32111,Sweden,2011,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",59.9
32112,Sweden,2011,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.0
32113,Sweden,2011,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.4
32114,Sweden,2011,5,C02-Antihypertensives,Million of national currency units,145.3
32115,Sweden,2011,5,J01-Antibacterials for systemic use,Million of national currency units,934.3
32116,Sweden,2011,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,143.9
32117,Sweden,2011,5,C02-Antihypertensives,"Million US$, purchasing power parity",16.4
32118,Sweden,2011,5,C02-Antihypertensives,Million US$ at exchange rate,22.4
32119,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.6
32120,Sweden,2011,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
32121,Sweden,2011,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
32122,Sweden,2011,5,C-Cardiovascular system,Million US$ at exchange rate,467.5
32123,Sweden,2011,5,C-Cardiovascular system,Million of national currency units,3035.7
32124,Sweden,2011,5,C01A-Cardiac glycosides,% of total sales,0.0
32125,Sweden,2011,5,C01A-Cardiac glycosides,Million of national currency units,13.1
32126,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",5.6
32127,Sweden,2011,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
32128,Sweden,2011,5,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0
32129,Sweden,2011,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.7
32130,Sweden,2011,5,Total pharmaceutical sales,Million US$ at exchange rate,5664.4
32131,Sweden,2011,5,Total pharmaceutical sales,Million of national currency units,36781.9
32132,Sweden,2011,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",149.5
32133,Sweden,2011,5,C02-Antihypertensives,% of total sales,0.4
32134,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
32135,Sweden,2011,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.6
32136,Sweden,2011,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.8
32137,Sweden,2011,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.3
32138,Sweden,2011,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.1
32139,Sweden,2011,5,M-Musculo-skeletal system,Million US$ at exchange rate,182.0
32140,Sweden,2011,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",133.6
32141,Sweden,2011,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",440.1
32142,Sweden,2011,5,Total pharmaceutical sales,"/capita, US$ exchange rate",599.5
32143,Sweden,2011,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4158.9
32144,Sweden,2011,5,M-Musculo-skeletal system,% of total sales,3.2
32145,Sweden,2011,5,A10-Drugs used in diabetes,Million US$ at exchange rate,203.7
32146,Sweden,2011,5,C-Cardiovascular system,"/capita, US$ exchange rate",49.5
32147,Sweden,2011,5,A10-Drugs used in diabetes,% of total sales,3.6
32148,Sweden,2011,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.3
32149,Sweden,2011,5,A-Alimentary tract and metabolism,Million of national currency units,3675.8
32150,Sweden,2011,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,566.1
32151,Sweden,2011,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",15.2
32152,Sweden,2011,5,J01-Antibacterials for systemic use,% of total sales,2.5
32153,Sweden,2011,5,M-Musculo-skeletal system,Million of national currency units,1181.9
32154,Sweden,2011,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.2
32155,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.6
32156,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",80.3
32157,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.5
32158,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,109.3
32159,Sweden,2011,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
32160,Sweden,2011,5,C-Cardiovascular system,% of total sales,8.3
32161,Sweden,2011,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,710.0
32162,Sweden,2011,5,A10-Drugs used in diabetes,Million of national currency units,1322.4
32163,Sweden,2011,5,N-Nervous system,Million of national currency units,7595.8
32164,Sweden,2011,5,A02A-Antacids,Million of national currency units,70.7
32165,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.4
32166,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",10.6
32167,Sweden,2011,5,A02A-Antacids,"/capita, US$ exchange rate",1.2
32168,Sweden,2011,5,A02A-Antacids,"Million US$, purchasing power parity",8.0
32169,Sweden,2011,5,A02A-Antacids,Million US$ at exchange rate,10.9
32170,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,560.8
32171,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,885.6
32172,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,86.4
32173,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,136.4
32174,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.4
32175,Sweden,2011,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",100.1
32176,Sweden,2011,5,R-Respiratory system,Million US$ at exchange rate,530.9
32177,Sweden,2011,5,R-Respiratory system,"Million US$, purchasing power parity",389.8
32178,Sweden,2011,5,R-Respiratory system,Million of national currency units,3447.6
32179,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.2
32180,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
32181,Sweden,2011,5,A02A-Antacids,% of total sales,0.2
32182,Sweden,2011,5,R-Respiratory system,"/capita, US$ purchasing power parity",41.3
32183,Sweden,2011,5,R-Respiratory system,"/capita, US$ exchange rate",56.2
32184,Sweden,2011,5,R-Respiratory system,% of total sales,9.4
32185,Sweden,2011,5,N02-Analgesics,Million US$ at exchange rate,310.5
32186,Sweden,2011,5,N02-Analgesics,Million of national currency units,2016.5
32187,Sweden,2011,5,N02-Analgesics,"Million US$, purchasing power parity",228.0
32188,Sweden,2011,5,N02-Analgesics,"/capita, US$ purchasing power parity",24.1
32189,Sweden,2011,5,N02-Analgesics,"/capita, US$ exchange rate",32.9
32190,Sweden,2011,5,C08-Calcium channel blockers,% of total sales,0.5
32191,Sweden,2011,5,C08-Calcium channel blockers,Million US$ at exchange rate,30.2
32192,Sweden,2011,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.1
32193,Sweden,2011,5,J-Antiinfectives for systemic use,Million of national currency units,2551.0
32194,Sweden,2011,5,C08-Calcium channel blockers,Million of national currency units,195.8
32195,Sweden,2011,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
32196,Sweden,2011,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2
32197,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
32198,Sweden,2011,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,308.0
32199,Sweden,2011,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1999.8
32200,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",9.1
32201,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",63.4
32202,Sweden,2011,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.7
32203,Sweden,2011,5,R03-Drugs for obstructive airway diseases,% of total sales,5.4
32204,Sweden,2011,5,N02-Analgesics,% of total sales,5.5
32205,Sweden,2011,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",226.1
32206,Sweden,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.9
32207,Sweden,2011,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.6
32208,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.2
32209,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.6
32210,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",101.6
32211,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.8
32212,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,898.8
32213,Sweden,2011,5,G-Genito urinary system and sex hormones,Million of national currency units,1722.7
32214,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,138.4
32215,Sweden,2011,5,N06A-Antidepressants,"Million US$, purchasing power parity",74.7
32216,Sweden,2011,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.8
32217,Sweden,2011,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.9
32218,Sweden,2011,5,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
32219,Sweden,2011,5,N06A-Antidepressants,Million of national currency units,660.8
32220,Sweden,2011,5,N06A-Antidepressants,Million US$ at exchange rate,101.8
32221,Sweden,2011,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",31.7
32222,Sweden,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.6
32223,Sweden,2011,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,43.2
32224,Sweden,2011,5,N05C-Hypnotics and sedatives,% of total sales,0.8
32225,Sweden,2011,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.4
32226,Sweden,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",28.1
32227,Sweden,2011,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,265.3
32228,Sweden,2011,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",194.8
32229,Sweden,2011,5,N05C-Hypnotics and sedatives,Million of national currency units,280.4
32230,Sweden,2011,5,G-Genito urinary system and sex hormones,% of total sales,4.7
32231,Sweden,2011,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.6
32232,Sweden,2011,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
32233,Sweden,2011,5,N05B-Anxiolytics,% of total sales,0.5
32234,Sweden,2011,5,N05B-Anxiolytics,"/capita, US$ exchange rate",3.1
32235,Sweden,2011,5,C10-Lipid modifying agents,Million US$ at exchange rate,118.2
32236,Sweden,2011,5,C10-Lipid modifying agents,Million of national currency units,767.3
32237,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,144.0
32238,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",105.7
32239,Sweden,2011,5,N05B-Anxiolytics,"Million US$, purchasing power parity",21.5
32240,Sweden,2011,5,N05B-Anxiolytics,Million US$ at exchange rate,29.3
32241,Sweden,2011,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,934.9
32242,Sweden,2011,5,N05B-Anxiolytics,Million of national currency units,190.1
32243,Sweden,2011,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",86.8
32244,Sweden,2011,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",358.4
32245,Sweden,2011,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",51.7
32246,Sweden,2011,5,N06A-Antidepressants,% of total sales,1.8
32247,Sweden,2011,5,B-Blood and blood forming organs,Million US$ at exchange rate,488.1
32248,Sweden,2011,5,B-Blood and blood forming organs,Million of national currency units,3169.6
32249,Sweden,2011,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",37.9
32250,Sweden,2011,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",9.2
32251,Sweden,2011,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",12.5
32252,Sweden,2011,5,B-Blood and blood forming organs,% of total sales,8.6
32253,Sweden,2011,5,C10-Lipid modifying agents,% of total sales,2.1
32254,Sweden,2011,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.8
32255,Sweden,2011,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.5
32256,Sweden,2011,5,N-Nervous system,% of total sales,20.7
32257,Sweden,2011,5,J-Antiinfectives for systemic use,% of total sales,6.9
32258,Sweden,2011,5,N-Nervous system,"/capita, US$ exchange rate",123.8
32259,Sweden,2011,5,N-Nervous system,"/capita, US$ purchasing power parity",90.9
32260,Sweden,2011,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",41.6
32261,Sweden,2011,5,C07-Beta blocking agents,Million US$ at exchange rate,62.1
32262,Sweden,2011,5,C07-Beta blocking agents,Million of national currency units,403.0
32263,Sweden,2011,5,C07-Beta blocking agents,"/capita, US$ exchange rate",6.6
32264,Sweden,2011,5,C07-Beta blocking agents,"Million US$, purchasing power parity",45.6
32265,Sweden,2011,5,C07-Beta blocking agents,% of total sales,1.1
32266,Sweden,2011,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.8
32267,Sweden,2011,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",288.4
32268,Sweden,2011,5,N-Nervous system,Million US$ at exchange rate,1169.7
32269,Sweden,2011,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,392.9
32270,Sweden,2011,5,N-Nervous system,"Million US$, purchasing power parity",858.9
32271,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.6
32272,Sweden,2012,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",431.2
32273,Sweden,2012,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",98.3
32274,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
32275,Sweden,2012,5,C03-Diuretics,"Million US$, purchasing power parity",29.9
32276,Sweden,2012,5,C03-Diuretics,Million of national currency units,259.0
32277,Sweden,2012,5,C03-Diuretics,Million US$ at exchange rate,38.2
32278,Sweden,2012,5,C03-Diuretics,"/capita, US$ exchange rate",4.0
32279,Sweden,2012,5,C-Cardiovascular system,"Million US$, purchasing power parity",293.9
32280,Sweden,2012,5,C03-Diuretics,% of total sales,0.7
32281,Sweden,2012,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.1
32282,Sweden,2012,5,A-Alimentary tract and metabolism,% of total sales,10.3
32283,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,50.6
32284,Sweden,2012,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.3
32285,Sweden,2012,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.3
32286,Sweden,2012,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.9
32287,Sweden,2012,5,C02-Antihypertensives,Million of national currency units,147.5
32288,Sweden,2012,5,J01-Antibacterials for systemic use,Million of national currency units,850.4
32289,Sweden,2012,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,125.5
32290,Sweden,2012,5,C02-Antihypertensives,"Million US$, purchasing power parity",17.0
32291,Sweden,2012,5,C02-Antihypertensives,Million US$ at exchange rate,21.8
32292,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.5
32293,Sweden,2012,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
32294,Sweden,2012,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
32295,Sweden,2012,5,C-Cardiovascular system,Million US$ at exchange rate,375.4
32296,Sweden,2012,5,C-Cardiovascular system,Million of national currency units,2543.6
32297,Sweden,2012,5,C01A-Cardiac glycosides,% of total sales,0.0
32298,Sweden,2012,5,C01A-Cardiac glycosides,Million of national currency units,13.4
32299,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",5.8
32300,Sweden,2012,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
32301,Sweden,2012,5,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0
32302,Sweden,2012,5,M-Musculo-skeletal system,Million of national currency units,1188.3
32303,Sweden,2012,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.8
32304,Sweden,2012,5,Total pharmaceutical sales,Million US$ at exchange rate,5330.8
32305,Sweden,2012,5,Total pharmaceutical sales,Million of national currency units,36116.2
32306,Sweden,2012,5,C02-Antihypertensives,% of total sales,0.4
32307,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
32308,Sweden,2012,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",159.9
32309,Sweden,2012,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.5
32310,Sweden,2012,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4173.0
32311,Sweden,2012,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.4
32312,Sweden,2012,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.4
32313,Sweden,2012,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",137.3
32314,Sweden,2012,5,M-Musculo-skeletal system,Million US$ at exchange rate,175.4
32315,Sweden,2012,5,Total pharmaceutical sales,"/capita, US$ exchange rate",560.0
32316,Sweden,2012,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",438.4
32317,Sweden,2012,5,M-Musculo-skeletal system,% of total sales,3.3
32318,Sweden,2012,5,A10-Drugs used in diabetes,Million US$ at exchange rate,204.3
32319,Sweden,2012,5,C-Cardiovascular system,"/capita, US$ exchange rate",39.4
32320,Sweden,2012,5,A10-Drugs used in diabetes,% of total sales,3.8
32321,Sweden,2012,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",30.9
32322,Sweden,2012,5,A-Alimentary tract and metabolism,Million of national currency units,3732.0
32323,Sweden,2012,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,550.8
32324,Sweden,2012,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",13.2
32325,Sweden,2012,5,J01-Antibacterials for systemic use,% of total sales,2.4
32326,Sweden,2012,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",10.3
32327,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.2
32328,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",83.4
32329,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.8
32330,Sweden,2012,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
32331,Sweden,2012,5,C-Cardiovascular system,% of total sales,7.0
32332,Sweden,2012,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.8
32333,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,106.6
32334,Sweden,2012,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,722.2
32335,Sweden,2012,5,A10-Drugs used in diabetes,Million of national currency units,1384.0
32336,Sweden,2012,5,A02A-Antacids,Million of national currency units,70.3
32337,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",7.6
32338,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.7
32339,Sweden,2012,5,A02A-Antacids,"Million US$, purchasing power parity",8.1
32340,Sweden,2012,5,A02A-Antacids,"/capita, US$ exchange rate",1.1
32341,Sweden,2012,5,A02A-Antacids,Million US$ at exchange rate,10.4
32342,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,536.8
32343,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,627.9
32344,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,79.2
32345,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",9.7
32346,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,92.7
32347,Sweden,2012,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",72.5
32348,Sweden,2012,5,R-Respiratory system,Million US$ at exchange rate,527.3
32349,Sweden,2012,5,R-Respiratory system,Million of national currency units,3572.8
32350,Sweden,2012,5,R-Respiratory system,"Million US$, purchasing power parity",412.8
32351,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.7
32352,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
32353,Sweden,2012,5,A02A-Antacids,% of total sales,0.2
32354,Sweden,2012,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.9
32355,Sweden,2012,5,R-Respiratory system,"/capita, US$ exchange rate",55.4
32356,Sweden,2012,5,R-Respiratory system,"/capita, US$ purchasing power parity",43.4
32357,Sweden,2012,5,R-Respiratory system,% of total sales,9.9
32358,Sweden,2012,5,N02-Analgesics,Million US$ at exchange rate,285.8
32359,Sweden,2012,5,N02-Analgesics,Million of national currency units,1936.1
32360,Sweden,2012,5,N02-Analgesics,"/capita, US$ purchasing power parity",23.5
32361,Sweden,2012,5,N02-Analgesics,"Million US$, purchasing power parity",223.7
32362,Sweden,2012,5,N02-Analgesics,"/capita, US$ exchange rate",30.0
32363,Sweden,2012,5,C08-Calcium channel blockers,% of total sales,0.5
32364,Sweden,2012,5,C08-Calcium channel blockers,Million US$ at exchange rate,28.5
32365,Sweden,2012,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.3
32366,Sweden,2012,5,J-Antiinfectives for systemic use,Million of national currency units,2540.3
32367,Sweden,2012,5,C08-Calcium channel blockers,Million of national currency units,193.0
32368,Sweden,2012,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
32369,Sweden,2012,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.0
32370,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.5
32371,Sweden,2012,5,R03-Drugs for obstructive airway diseases,Million of national currency units,2058.9
32372,Sweden,2012,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,303.9
32373,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",62.0
32374,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.3
32375,Sweden,2012,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.5
32376,Sweden,2012,5,R03-Drugs for obstructive airway diseases,% of total sales,5.7
32377,Sweden,2012,5,N02-Analgesics,% of total sales,5.4
32378,Sweden,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",25.0
32379,Sweden,2012,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",237.9
32380,Sweden,2012,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",31.9
32381,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.0
32382,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.3
32383,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",106.6
32384,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.2
32385,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,922.9
32386,Sweden,2012,5,G-Genito urinary system and sex hormones,Million of national currency units,1757.1
32387,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,136.2
32388,Sweden,2012,5,N06A-Antidepressants,"Million US$, purchasing power parity",78.4
32389,Sweden,2012,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.2
32390,Sweden,2012,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.5
32391,Sweden,2012,5,G03-Sex hormones and modulators of the genital system,% of total sales,2.6
32392,Sweden,2012,5,N06A-Antidepressants,Million of national currency units,678.8
32393,Sweden,2012,5,N06A-Antidepressants,Million US$ at exchange rate,100.2
32394,Sweden,2012,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",34.5
32395,Sweden,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.6
32396,Sweden,2012,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,44.0
32397,Sweden,2012,5,N05C-Hypnotics and sedatives,% of total sales,0.8
32398,Sweden,2012,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.6
32399,Sweden,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.2
32400,Sweden,2012,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",203.0
32401,Sweden,2012,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,259.3
32402,Sweden,2012,5,N05C-Hypnotics and sedatives,Million of national currency units,298.3
32403,Sweden,2012,5,G-Genito urinary system and sex hormones,% of total sales,4.9
32404,Sweden,2012,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",21.3
32405,Sweden,2012,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
32406,Sweden,2012,5,N05B-Anxiolytics,"/capita, US$ exchange rate",3.0
32407,Sweden,2012,5,N05B-Anxiolytics,% of total sales,0.5
32408,Sweden,2012,5,C10-Lipid modifying agents,Million US$ at exchange rate,82.4
32409,Sweden,2012,5,C10-Lipid modifying agents,Million of national currency units,558.3
32410,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,142.5
32411,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",111.6
32412,Sweden,2012,5,N05B-Anxiolytics,Million US$ at exchange rate,28.3
32413,Sweden,2012,5,N05B-Anxiolytics,"Million US$, purchasing power parity",22.1
32414,Sweden,2012,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,965.5
32415,Sweden,2012,5,N05B-Anxiolytics,Million of national currency units,191.6
32416,Sweden,2012,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",64.5
32417,Sweden,2012,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",366.5
32418,Sweden,2012,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",49.2
32419,Sweden,2012,5,B-Blood and blood forming organs,Million US$ at exchange rate,468.2
32420,Sweden,2012,5,N06A-Antidepressants,% of total sales,1.9
32421,Sweden,2012,5,B-Blood and blood forming organs,Million of national currency units,3172.3
32422,Sweden,2012,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.8
32423,Sweden,2012,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",8.7
32424,Sweden,2012,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.5
32425,Sweden,2012,5,B-Blood and blood forming organs,% of total sales,8.8
32426,Sweden,2012,5,C10-Lipid modifying agents,% of total sales,1.5
32427,Sweden,2012,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",30.8
32428,Sweden,2012,5,N-Nervous system,% of total sales,20.0
32429,Sweden,2012,5,J-Antiinfectives for systemic use,% of total sales,7.0
32430,Sweden,2012,5,N-Nervous system,"/capita, US$ exchange rate",112.2
32431,Sweden,2012,5,N-Nervous system,"/capita, US$ purchasing power parity",87.8
32432,Sweden,2012,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.4
32433,Sweden,2012,5,C07-Beta blocking agents,Million US$ at exchange rate,58.0
32434,Sweden,2012,5,C07-Beta blocking agents,Million of national currency units,393.0
32435,Sweden,2012,5,C07-Beta blocking agents,"/capita, US$ exchange rate",6.1
32436,Sweden,2012,5,C07-Beta blocking agents,"Million US$, purchasing power parity",45.4
32437,Sweden,2012,5,C07-Beta blocking agents,% of total sales,1.1
32438,Sweden,2012,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.8
32439,Sweden,2012,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",293.5
32440,Sweden,2012,5,N-Nervous system,Million US$ at exchange rate,1067.8
32441,Sweden,2012,5,N-Nervous system,Million of national currency units,7234.7
32442,Sweden,2012,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,374.9
32443,Sweden,2012,5,N-Nervous system,"Million US$, purchasing power parity",835.9
32444,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
32445,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
32446,Sweden,2016,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,84.6
32447,Sweden,2016,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",82.1
32448,Sweden,2016,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",498.4
32449,Sweden,2016,4,C03-Diuretics,"Million US$, purchasing power parity",25.3
32450,Sweden,2016,4,C03-Diuretics,Million US$ at exchange rate,26.0
32451,Sweden,2016,4,C03-Diuretics,Million of national currency units,223.0
32452,Sweden,2016,4,C03-Diuretics,% of total sales,0.5
32453,Sweden,2016,4,C03-Diuretics,"/capita, US$ exchange rate",2.6
32454,Sweden,2016,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.5
32455,Sweden,2016,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",50.2
32456,Sweden,2016,4,A-Alimentary tract and metabolism,% of total sales,10.4
32457,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,74.4
32458,Sweden,2016,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",51.8
32459,Sweden,2016,4,C02-Antihypertensives,Million of national currency units,211.9
32460,Sweden,2016,4,J01-Antibacterials for systemic use,Million of national currency units,724.5
32461,Sweden,2016,4,C02-Antihypertensives,"Million US$, purchasing power parity",24.0
32462,Sweden,2016,4,C02-Antihypertensives,Million US$ at exchange rate,24.7
32463,Sweden,2016,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.1
32464,Sweden,2016,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.1
32465,Sweden,2016,4,C-Cardiovascular system,Million of national currency units,2398.2
32466,Sweden,2016,4,C01A-Cardiac glycosides,% of total sales,0.0
32467,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",8.4
32468,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.7
32469,Sweden,2016,4,C-Cardiovascular system,Million US$ at exchange rate,280.1
32470,Sweden,2016,4,C01A-Cardiac glycosides,Million of national currency units,12.7
32471,Sweden,2016,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.4
32472,Sweden,2016,4,C01A-Cardiac glycosides,Million US$ at exchange rate,1.5
32473,Sweden,2016,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,513.6
32474,Sweden,2016,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.4
32475,Sweden,2016,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.5
32476,Sweden,2016,4,A10-Drugs used in diabetes,Million US$ at exchange rate,197.1
32477,Sweden,2016,4,Total pharmaceutical sales,Million US$ at exchange rate,4945.8
32478,Sweden,2016,4,Total pharmaceutical sales,Million of national currency units,42346.3
32479,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
32480,Sweden,2016,4,C02-Antihypertensives,% of total sales,0.5
32481,Sweden,2016,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",191.3
32482,Sweden,2016,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.9
32483,Sweden,2016,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",170.3
32484,Sweden,2016,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",17.7
32485,Sweden,2016,4,M-Musculo-skeletal system,Million of national currency units,1502.6
32486,Sweden,2016,4,M-Musculo-skeletal system,Million US$ at exchange rate,175.5
32487,Sweden,2016,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",17.2
32488,Sweden,2016,4,Total pharmaceutical sales,"/capita, US$ exchange rate",498.4
32489,Sweden,2016,4,Total pharmaceutical sales,"Million US$, purchasing power parity",4799.8
32490,Sweden,2016,4,M-Musculo-skeletal system,% of total sales,3.5
32491,Sweden,2016,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",483.7
32492,Sweden,2016,4,C-Cardiovascular system,"/capita, US$ exchange rate",28.2
32493,Sweden,2016,4,C-Cardiovascular system,"Million US$, purchasing power parity",271.8
32494,Sweden,2016,4,A10-Drugs used in diabetes,% of total sales,4.0
32495,Sweden,2016,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.4
32496,Sweden,2016,4,J01-Antibacterials for systemic use,% of total sales,1.7
32497,Sweden,2016,4,A-Alimentary tract and metabolism,Million of national currency units,4397.3
32498,Sweden,2016,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.3
32499,Sweden,2016,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",8.5
32500,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",90.7
32501,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,93.5
32502,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",9.1
32503,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.4
32504,Sweden,2016,4,C-Cardiovascular system,% of total sales,5.7
32505,Sweden,2016,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",19.3
32506,Sweden,2016,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
32507,Sweden,2016,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,800.6
32508,Sweden,2016,4,A10-Drugs used in diabetes,Million of national currency units,1687.7
32509,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.0
32510,Sweden,2016,4,A02A-Antacids,Million of national currency units,95.9
32511,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.7
32512,Sweden,2016,4,A02A-Antacids,"Million US$, purchasing power parity",10.9
32513,Sweden,2016,4,A02A-Antacids,Million US$ at exchange rate,11.2
32514,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,414.0
32515,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,493.9
32516,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,57.7
32517,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",4.9
32518,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",46.9
32519,Sweden,2016,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,48.4
32520,Sweden,2016,4,R-Respiratory system,Million of national currency units,3456.4
32521,Sweden,2016,4,R-Respiratory system,"Million US$, purchasing power parity",391.8
32522,Sweden,2016,4,R-Respiratory system,Million US$ at exchange rate,403.7
32523,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.7
32524,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.1
32525,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
32526,Sweden,2016,4,A02A-Antacids,% of total sales,0.2
32527,Sweden,2016,4,A02A-Antacids,"/capita, US$ purchasing power parity",1.1
32528,Sweden,2016,4,A02A-Antacids,"/capita, US$ exchange rate",1.1
32529,Sweden,2016,4,R-Respiratory system,"/capita, US$ exchange rate",40.7
32530,Sweden,2016,4,R-Respiratory system,% of total sales,8.2
32531,Sweden,2016,4,R-Respiratory system,"/capita, US$ purchasing power parity",39.5
32532,Sweden,2016,4,N02-Analgesics,Million US$ at exchange rate,235.9
32533,Sweden,2016,4,N02-Analgesics,Million of national currency units,2020.0
32534,Sweden,2016,4,C08-Calcium channel blockers,% of total sales,0.5
32535,Sweden,2016,4,N02-Analgesics,"/capita, US$ purchasing power parity",23.1
32536,Sweden,2016,4,N02-Analgesics,"/capita, US$ exchange rate",23.8
32537,Sweden,2016,4,N02-Analgesics,"Million US$, purchasing power parity",229.0
32538,Sweden,2016,4,C08-Calcium channel blockers,Million US$ at exchange rate,23.4
32539,Sweden,2016,4,C08-Calcium channel blockers,Million of national currency units,200.3
32540,Sweden,2016,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.7
32541,Sweden,2016,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
32542,Sweden,2016,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.4
32543,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2
32544,Sweden,2016,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1741.7
32545,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",56.0
32546,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.6
32547,Sweden,2016,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",5.8
32548,Sweden,2016,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,203.4
32549,Sweden,2016,4,R03-Drugs for obstructive airway diseases,% of total sales,4.1
32550,Sweden,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.9
32551,Sweden,2016,4,N02-Analgesics,% of total sales,4.8
32552,Sweden,2016,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",197.4
32553,Sweden,2016,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.5
32554,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",104.8
32555,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",10.9
32556,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.6
32557,Sweden,2016,4,G-Genito urinary system and sex hormones,Million of national currency units,1693.7
32558,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,924.5
32559,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,108.0
32560,Sweden,2016,4,N06A-Antidepressants,"Million US$, purchasing power parity",66.9
32561,Sweden,2016,4,N06A-Antidepressants,"/capita, US$ exchange rate",6.9
32562,Sweden,2016,4,N06A-Antidepressants,Million US$ at exchange rate,68.9
32563,Sweden,2016,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.2
32564,Sweden,2016,4,N06A-Antidepressants,Million of national currency units,590.1
32565,Sweden,2016,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",49.1
32566,Sweden,2016,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,50.6
32567,Sweden,2016,4,N05C-Hypnotics and sedatives,% of total sales,1.0
32568,Sweden,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.1
32569,Sweden,2016,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",5.0
32570,Sweden,2016,4,N05C-Hypnotics and sedatives,Million of national currency units,433.4
32571,Sweden,2016,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",192.0
32572,Sweden,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",19.9
32573,Sweden,2016,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,197.8
32574,Sweden,2016,4,G-Genito urinary system and sex hormones,% of total sales,4.0
32575,Sweden,2016,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3
32576,Sweden,2016,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",6.7
32577,Sweden,2016,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
32578,Sweden,2016,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.3
32579,Sweden,2016,4,C10-Lipid modifying agents,Million US$ at exchange rate,61.0
32580,Sweden,2016,4,N05B-Anxiolytics,% of total sales,0.5
32581,Sweden,2016,4,C10-Lipid modifying agents,Million of national currency units,522.1
32582,Sweden,2016,4,N05B-Anxiolytics,"Million US$, purchasing power parity",22.5
32583,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,119.9
32584,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",116.4
32585,Sweden,2016,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,1026.8
32586,Sweden,2016,4,N05B-Anxiolytics,Million US$ at exchange rate,23.2
32587,Sweden,2016,4,N05B-Anxiolytics,Million of national currency units,198.3
32588,Sweden,2016,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",440.6
32589,Sweden,2016,4,B-Blood and blood forming organs,Million US$ at exchange rate,454.0
32590,Sweden,2016,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.8
32591,Sweden,2016,4,N06A-Antidepressants,% of total sales,1.4
32592,Sweden,2016,4,B-Blood and blood forming organs,Million of national currency units,3887.5
32593,Sweden,2016,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",6.0
32594,Sweden,2016,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",6.1
32595,Sweden,2016,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",59.2
32596,Sweden,2016,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",44.4
32597,Sweden,2016,4,B-Blood and blood forming organs,% of total sales,9.2
32598,Sweden,2016,4,C10-Lipid modifying agents,% of total sales,1.2
32599,Sweden,2016,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",44.4
32600,Sweden,2016,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",45.8
32601,Sweden,2016,4,N-Nervous system,"/capita, US$ exchange rate",87.2
32602,Sweden,2016,4,N-Nervous system,"/capita, US$ purchasing power parity",84.7
32603,Sweden,2016,4,J-Antiinfectives for systemic use,% of total sales,9.2
32604,Sweden,2016,4,C07-Beta blocking agents,Million of national currency units,394.3
32605,Sweden,2016,4,N-Nervous system,% of total sales,17.5
32606,Sweden,2016,4,C07-Beta blocking agents,Million US$ at exchange rate,46.0
32607,Sweden,2016,4,C07-Beta blocking agents,"/capita, US$ exchange rate",4.6
32608,Sweden,2016,4,C07-Beta blocking agents,"Million US$, purchasing power parity",44.7
32609,Sweden,2016,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.5
32610,Sweden,2016,4,C07-Beta blocking agents,% of total sales,0.9
32611,Sweden,2016,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,454.2
32612,Sweden,2016,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",440.8
32613,Sweden,2016,4,J-Antiinfectives for systemic use,Million of national currency units,3888.6
32614,Sweden,2016,4,N-Nervous system,Million of national currency units,7411.8
32615,Sweden,2016,4,N-Nervous system,"Million US$, purchasing power parity",840.1
32616,Sweden,2016,4,N-Nervous system,Million US$ at exchange rate,865.7
32617,Sweden,2014,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",81.4
32618,Sweden,2014,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,103.5
32619,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
32620,Sweden,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",440.2
32621,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
32622,Sweden,2014,5,C03-Diuretics,"Million US$, purchasing power parity",29.2
32623,Sweden,2014,5,C03-Diuretics,Million US$ at exchange rate,37.2
32624,Sweden,2014,5,C03-Diuretics,Million of national currency units,255.1
32625,Sweden,2014,5,C03-Diuretics,"/capita, US$ exchange rate",3.8
32626,Sweden,2014,5,C03-Diuretics,% of total sales,0.7
32627,Sweden,2014,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.0
32628,Sweden,2014,5,A-Alimentary tract and metabolism,% of total sales,10.2
32629,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,60.5
32630,Sweden,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.4
32631,Sweden,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",57.8
32632,Sweden,2014,5,C02-Antihypertensives,Million of national currency units,181.4
32633,Sweden,2014,5,J01-Antibacterials for systemic use,Million of national currency units,710.3
32634,Sweden,2014,5,C02-Antihypertensives,"Million US$, purchasing power parity",20.8
32635,Sweden,2014,5,C02-Antihypertensives,Million US$ at exchange rate,26.4
32636,Sweden,2014,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
32637,Sweden,2014,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
32638,Sweden,2014,5,C-Cardiovascular system,Million US$ at exchange rate,340.8
32639,Sweden,2014,5,C01A-Cardiac glycosides,% of total sales,0.0
32640,Sweden,2014,5,C-Cardiovascular system,Million of national currency units,2338.4
32641,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.9
32642,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.8
32643,Sweden,2014,5,C01A-Cardiac glycosides,Million of national currency units,15.9
32644,Sweden,2014,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.8
32645,Sweden,2014,5,C01A-Cardiac glycosides,Million US$ at exchange rate,2.3
32646,Sweden,2014,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.1
32647,Sweden,2014,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.7
32648,Sweden,2014,5,A10-Drugs used in diabetes,Million US$ at exchange rate,205.6
32649,Sweden,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,5510.9
32650,Sweden,2014,5,Total pharmaceutical sales,Million of national currency units,37808.8
32651,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
32652,Sweden,2014,5,C02-Antihypertensives,% of total sales,0.5
32653,Sweden,2014,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",161.7
32654,Sweden,2014,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.2
32655,Sweden,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",19.4
32656,Sweden,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",147.5
32657,Sweden,2014,5,M-Musculo-skeletal system,Million of national currency units,1287.3
32658,Sweden,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,187.6
32659,Sweden,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.2
32660,Sweden,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",568.4
32661,Sweden,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4332.3
32662,Sweden,2014,5,M-Musculo-skeletal system,% of total sales,3.4
32663,Sweden,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",446.8
32664,Sweden,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",35.2
32665,Sweden,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",267.9
32666,Sweden,2014,5,A10-Drugs used in diabetes,% of total sales,3.7
32667,Sweden,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.6
32668,Sweden,2014,5,J01-Antibacterials for systemic use,% of total sales,1.9
32669,Sweden,2014,5,A-Alimentary tract and metabolism,Million of national currency units,3841.9
32670,Sweden,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,560.0
32671,Sweden,2014,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",10.7
32672,Sweden,2014,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.4
32673,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",82.4
32674,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.8
32675,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,104.8
32676,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.5
32677,Sweden,2014,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
32678,Sweden,2014,5,C-Cardiovascular system,% of total sales,6.2
32679,Sweden,2014,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.7
32680,Sweden,2014,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,718.9
32681,Sweden,2014,5,A10-Drugs used in diabetes,Million of national currency units,1410.9
32682,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.1
32683,Sweden,2014,5,A02A-Antacids,Million of national currency units,81.7
32684,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.9
32685,Sweden,2014,5,A02A-Antacids,"Million US$, purchasing power parity",9.4
32686,Sweden,2014,5,A02A-Antacids,Million US$ at exchange rate,11.9
32687,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,413.6
32688,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,474.1
32689,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,69.1
32690,Sweden,2014,5,A02A-Antacids,"/capita, US$ exchange rate",1.2
32691,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",6.2
32692,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",47.4
32693,Sweden,2014,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,60.3
32694,Sweden,2014,5,R-Respiratory system,Million US$ at exchange rate,515.1
32695,Sweden,2014,5,R-Respiratory system,Million of national currency units,3534.1
32696,Sweden,2014,5,R-Respiratory system,"Million US$, purchasing power parity",405.0
32697,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.4
32698,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.6
32699,Sweden,2014,5,A02A-Antacids,% of total sales,0.2
32700,Sweden,2014,5,A02A-Antacids,"/capita, US$ purchasing power parity",1.0
32701,Sweden,2014,5,R-Respiratory system,"/capita, US$ exchange rate",53.1
32702,Sweden,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",41.8
32703,Sweden,2014,5,R-Respiratory system,% of total sales,9.3
32704,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",14.5
32705,Sweden,2014,5,N02-Analgesics,Million US$ at exchange rate,289.5
32706,Sweden,2014,5,N02-Analgesics,Million of national currency units,1985.9
32707,Sweden,2014,5,N02-Analgesics,"/capita, US$ purchasing power parity",23.5
32708,Sweden,2014,5,N02-Analgesics,"/capita, US$ exchange rate",29.9
32709,Sweden,2014,5,N02-Analgesics,"Million US$, purchasing power parity",227.6
32710,Sweden,2014,5,C08-Calcium channel blockers,% of total sales,0.5
32711,Sweden,2014,5,C08-Calcium channel blockers,Million US$ at exchange rate,29.4
32712,Sweden,2014,5,C08-Calcium channel blockers,Million of national currency units,202.0
32713,Sweden,2014,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",23.1
32714,Sweden,2014,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4
32715,Sweden,2014,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.0
32716,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.3
32717,Sweden,2014,5,R03-Drugs for obstructive airway diseases,Million of national currency units,1982.6
32718,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",54.3
32719,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",7.1
32720,Sweden,2014,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.6
32721,Sweden,2014,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,289.0
32722,Sweden,2014,5,R03-Drugs for obstructive airway diseases,% of total sales,5.2
32723,Sweden,2014,5,N02-Analgesics,% of total sales,5.3
32724,Sweden,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",23.4
32725,Sweden,2014,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",227.2
32726,Sweden,2014,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",29.8
32727,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",105.8
32728,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.9
32729,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.9
32730,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,923.3
32731,Sweden,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,1684.8
32732,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,134.6
32733,Sweden,2014,5,N06A-Antidepressants,"Million US$, purchasing power parity",82.7
32734,Sweden,2014,5,N06A-Antidepressants,"/capita, US$ exchange rate",10.8
32735,Sweden,2014,5,G03-Sex hormones and modulators of the genital system,% of total sales,2.4
32736,Sweden,2014,5,N06A-Antidepressants,Million US$ at exchange rate,105.1
32737,Sweden,2014,5,N06A-Antidepressants,Million of national currency units,721.3
32738,Sweden,2014,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",8.5
32739,Sweden,2014,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",39.3
32740,Sweden,2014,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,49.9
32741,Sweden,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.1
32742,Sweden,2014,5,N05C-Hypnotics and sedatives,% of total sales,0.9
32743,Sweden,2014,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.0
32744,Sweden,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.3
32745,Sweden,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",193.0
32746,Sweden,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,245.6
32747,Sweden,2014,5,G-Genito urinary system and sex hormones,% of total sales,4.5
32748,Sweden,2014,5,N05C-Hypnotics and sedatives,Million of national currency units,342.5
32749,Sweden,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.9
32750,Sweden,2014,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
32751,Sweden,2014,5,N05B-Anxiolytics,"/capita, US$ exchange rate",3.0
32752,Sweden,2014,5,N05B-Anxiolytics,% of total sales,0.5
32753,Sweden,2014,5,C10-Lipid modifying agents,Million US$ at exchange rate,70.1
32754,Sweden,2014,5,C10-Lipid modifying agents,Million of national currency units,480.8
32755,Sweden,2014,5,N05B-Anxiolytics,"Million US$, purchasing power parity",23.1
32756,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,141.0
32757,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",110.9
32758,Sweden,2014,5,N05B-Anxiolytics,Million US$ at exchange rate,29.4
32759,Sweden,2014,5,N05B-Anxiolytics,Million of national currency units,201.4
32760,Sweden,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,967.4
32761,Sweden,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",369.3
32762,Sweden,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",48.4
32763,Sweden,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,469.8
32764,Sweden,2014,5,N06A-Antidepressants,% of total sales,1.9
32765,Sweden,2014,5,B-Blood and blood forming organs,Million of national currency units,3223.0
32766,Sweden,2014,5,J-Antiinfectives for systemic use,Million of national currency units,3029.8
32767,Sweden,2014,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.7
32768,Sweden,2014,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",55.1
32769,Sweden,2014,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.2
32770,Sweden,2014,5,B-Blood and blood forming organs,% of total sales,8.5
32771,Sweden,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.1
32772,Sweden,2014,5,C10-Lipid modifying agents,% of total sales,1.3
32773,Sweden,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.8
32774,Sweden,2014,5,J-Antiinfectives for systemic use,% of total sales,8.0
32775,Sweden,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",45.5
32776,Sweden,2014,5,N-Nervous system,"/capita, US$ exchange rate",110.4
32777,Sweden,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",86.8
32778,Sweden,2014,5,C07-Beta blocking agents,Million US$ at exchange rate,61.1
32779,Sweden,2014,5,C07-Beta blocking agents,Million of national currency units,419.1
32780,Sweden,2014,5,N-Nervous system,% of total sales,19.4
32781,Sweden,2014,5,C07-Beta blocking agents,"/capita, US$ exchange rate",6.3
32782,Sweden,2014,5,C07-Beta blocking agents,"Million US$, purchasing power parity",48.0
32783,Sweden,2014,5,C07-Beta blocking agents,% of total sales,1.1
32784,Sweden,2014,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.0
32785,Sweden,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,441.6
32786,Sweden,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",347.2
32787,Sweden,2014,5,N-Nervous system,Million of national currency units,7342.3
32788,Sweden,2014,5,N-Nervous system,Million US$ at exchange rate,1070.2
32789,Sweden,2014,5,N-Nervous system,"Million US$, purchasing power parity",841.3
32790,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.8
32791,Sweden,2015,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,88.9
32792,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.8
32793,Sweden,2015,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",464.8
32794,Sweden,2015,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",84.6
32795,Sweden,2015,4,C03-Diuretics,"Million US$, purchasing power parity",27.3
32796,Sweden,2015,4,C03-Diuretics,Million US$ at exchange rate,28.7
32797,Sweden,2015,4,C03-Diuretics,Million of national currency units,241.9
32798,Sweden,2015,4,C03-Diuretics,% of total sales,0.6
32799,Sweden,2015,4,C03-Diuretics,"/capita, US$ exchange rate",2.9
32800,Sweden,2015,4,C03-Diuretics,"/capita, US$ purchasing power parity",2.8
32801,Sweden,2015,4,C-Cardiovascular system,Million US$ at exchange rate,285.0
32802,Sweden,2015,4,A-Alimentary tract and metabolism,% of total sales,10.1
32803,Sweden,2015,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",47.4
32804,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,66.6
32805,Sweden,2015,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",49.8
32806,Sweden,2015,4,C02-Antihypertensives,Million of national currency units,214.2
32807,Sweden,2015,4,J01-Antibacterials for systemic use,Million of national currency units,749.5
32808,Sweden,2015,4,C02-Antihypertensives,"Million US$, purchasing power parity",24.2
32809,Sweden,2015,4,C02-Antihypertensives,Million US$ at exchange rate,25.4
32810,Sweden,2015,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
32811,Sweden,2015,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
32812,Sweden,2015,4,C-Cardiovascular system,Million of national currency units,2404.2
32813,Sweden,2015,4,C01A-Cardiac glycosides,% of total sales,0.0
32814,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",7.5
32815,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,7.9
32816,Sweden,2015,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.5
32817,Sweden,2015,4,C01A-Cardiac glycosides,Million of national currency units,13.2
32818,Sweden,2015,4,C01A-Cardiac glycosides,Million US$ at exchange rate,1.6
32819,Sweden,2015,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",2.5
32820,Sweden,2015,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.6
32821,Sweden,2015,4,A10-Drugs used in diabetes,Million US$ at exchange rate,182.1
32822,Sweden,2015,4,Total pharmaceutical sales,Million US$ at exchange rate,4808.3
32823,Sweden,2015,4,Total pharmaceutical sales,Million of national currency units,40557.2
32824,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,1.9
32825,Sweden,2015,4,C02-Antihypertensives,% of total sales,0.5
32826,Sweden,2015,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",173.4
32827,Sweden,2015,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",18.6
32828,Sweden,2015,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",155.3
32829,Sweden,2015,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",16.6
32830,Sweden,2015,4,M-Musculo-skeletal system,Million of national currency units,1375.3
32831,Sweden,2015,4,M-Musculo-skeletal system,Million US$ at exchange rate,163.0
32832,Sweden,2015,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.9
32833,Sweden,2015,4,Total pharmaceutical sales,"/capita, US$ exchange rate",490.7
32834,Sweden,2015,4,Total pharmaceutical sales,"Million US$, purchasing power parity",4580.5
32835,Sweden,2015,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",467.4
32836,Sweden,2015,4,M-Musculo-skeletal system,% of total sales,3.4
32837,Sweden,2015,4,C-Cardiovascular system,"/capita, US$ exchange rate",29.1
32838,Sweden,2015,4,C-Cardiovascular system,"Million US$, purchasing power parity",271.5
32839,Sweden,2015,4,A10-Drugs used in diabetes,% of total sales,3.8
32840,Sweden,2015,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.7
32841,Sweden,2015,4,J01-Antibacterials for systemic use,% of total sales,1.8
32842,Sweden,2015,4,A-Alimentary tract and metabolism,Million of national currency units,4115.1
32843,Sweden,2015,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,487.9
32844,Sweden,2015,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.6
32845,Sweden,2015,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",9.1
32846,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",85.0
32847,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,89.2
32848,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",9.1
32849,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.7
32850,Sweden,2015,4,C-Cardiovascular system,% of total sales,5.9
32851,Sweden,2015,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",17.7
32852,Sweden,2015,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.2
32853,Sweden,2015,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,752.3
32854,Sweden,2015,4,A10-Drugs used in diabetes,Million of national currency units,1535.6
32855,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.0
32856,Sweden,2015,4,A02A-Antacids,Million of national currency units,92.4
32857,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",4.9
32858,Sweden,2015,4,A02A-Antacids,"Million US$, purchasing power parity",10.4
32859,Sweden,2015,4,A02A-Antacids,Million US$ at exchange rate,11.0
32860,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,422.0
32861,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,493.7
32862,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,58.5
32863,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",5.1
32864,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",47.7
32865,Sweden,2015,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,50.0
32866,Sweden,2015,4,A02A-Antacids,"/capita, US$ exchange rate",1.1
32867,Sweden,2015,4,R-Respiratory system,Million of national currency units,3332.4
32868,Sweden,2015,4,R-Respiratory system,Million US$ at exchange rate,395.1
32869,Sweden,2015,4,R-Respiratory system,"Million US$, purchasing power parity",376.4
32870,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.3
32871,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.9
32872,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.4
32873,Sweden,2015,4,A02A-Antacids,% of total sales,0.2
32874,Sweden,2015,4,A02A-Antacids,"/capita, US$ purchasing power parity",1.1
32875,Sweden,2015,4,R-Respiratory system,"/capita, US$ exchange rate",40.3
32876,Sweden,2015,4,R-Respiratory system,% of total sales,8.2
32877,Sweden,2015,4,R-Respiratory system,"/capita, US$ purchasing power parity",38.4
32878,Sweden,2015,4,N02-Analgesics,Million US$ at exchange rate,242.4
32879,Sweden,2015,4,C08-Calcium channel blockers,% of total sales,0.5
32880,Sweden,2015,4,N02-Analgesics,Million of national currency units,2044.8
32881,Sweden,2015,4,N02-Analgesics,"/capita, US$ purchasing power parity",23.6
32882,Sweden,2015,4,N02-Analgesics,"/capita, US$ exchange rate",24.7
32883,Sweden,2015,4,N02-Analgesics,"Million US$, purchasing power parity",230.9
32884,Sweden,2015,4,C08-Calcium channel blockers,Million US$ at exchange rate,24.1
32885,Sweden,2015,4,C08-Calcium channel blockers,Million of national currency units,203.5
32886,Sweden,2015,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.3
32887,Sweden,2015,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",2.5
32888,Sweden,2015,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",23.0
32889,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.2
32890,Sweden,2015,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1702.5
32891,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",55.8
32892,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",5.7
32893,Sweden,2015,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",6.0
32894,Sweden,2015,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,201.8
32895,Sweden,2015,4,R03-Drugs for obstructive airway diseases,% of total sales,4.2
32896,Sweden,2015,4,N02-Analgesics,% of total sales,5.0
32897,Sweden,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",19.6
32898,Sweden,2015,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",192.3
32899,Sweden,2015,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",20.6
32900,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",104.5
32901,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.7
32902,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",11.2
32903,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,925.1
32904,Sweden,2015,4,G-Genito urinary system and sex hormones,Million of national currency units,1676.9
32905,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,109.7
32906,Sweden,2015,4,N06A-Antidepressants,"Million US$, purchasing power parity",75.5
32907,Sweden,2015,4,N06A-Antidepressants,"/capita, US$ exchange rate",8.1
32908,Sweden,2015,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.3
32909,Sweden,2015,4,N06A-Antidepressants,Million US$ at exchange rate,79.2
32910,Sweden,2015,4,N06A-Antidepressants,Million of national currency units,668.4
32911,Sweden,2015,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",41.1
32912,Sweden,2015,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,43.2
32913,Sweden,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.4
32914,Sweden,2015,4,N05C-Hypnotics and sedatives,% of total sales,0.9
32915,Sweden,2015,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",4.2
32916,Sweden,2015,4,N05C-Hypnotics and sedatives,Million of national currency units,364.1
32917,Sweden,2015,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",189.4
32918,Sweden,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",20.3
32919,Sweden,2015,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,198.8
32920,Sweden,2015,4,G-Genito urinary system and sex hormones,% of total sales,4.1
32921,Sweden,2015,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",19.3
32922,Sweden,2015,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.7
32923,Sweden,2015,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.3
32924,Sweden,2015,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.4
32925,Sweden,2015,4,C10-Lipid modifying agents,Million US$ at exchange rate,57.2
32926,Sweden,2015,4,N05B-Anxiolytics,% of total sales,0.5
32927,Sweden,2015,4,C10-Lipid modifying agents,Million of national currency units,482.1
32928,Sweden,2015,4,N05B-Anxiolytics,"Million US$, purchasing power parity",22.6
32929,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,116.6
32930,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",111.1
32931,Sweden,2015,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,983.4
32932,Sweden,2015,4,N05B-Anxiolytics,Million US$ at exchange rate,23.7
32933,Sweden,2015,4,N05B-Anxiolytics,Million of national currency units,199.8
32934,Sweden,2015,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",397.6
32935,Sweden,2015,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",42.6
32936,Sweden,2015,4,B-Blood and blood forming organs,Million US$ at exchange rate,417.4
32937,Sweden,2015,4,N06A-Antidepressants,% of total sales,1.6
32938,Sweden,2015,4,B-Blood and blood forming organs,Million of national currency units,3520.9
32939,Sweden,2015,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.6
32940,Sweden,2015,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",5.8
32941,Sweden,2015,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",54.5
32942,Sweden,2015,4,B-Blood and blood forming organs,% of total sales,8.7
32943,Sweden,2015,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",40.6
32944,Sweden,2015,4,C10-Lipid modifying agents,% of total sales,1.2
32945,Sweden,2015,4,J-Antiinfectives for systemic use,Million of national currency units,3983.5
32946,Sweden,2015,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",45.9
32947,Sweden,2015,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",48.2
32948,Sweden,2015,4,N-Nervous system,"/capita, US$ exchange rate",90.6
32949,Sweden,2015,4,J-Antiinfectives for systemic use,% of total sales,9.8
32950,Sweden,2015,4,N-Nervous system,"/capita, US$ purchasing power parity",86.3
32951,Sweden,2015,4,C07-Beta blocking agents,Million US$ at exchange rate,50.9
32952,Sweden,2015,4,C07-Beta blocking agents,Million of national currency units,429.4
32953,Sweden,2015,4,N-Nervous system,% of total sales,18.5
32954,Sweden,2015,4,C07-Beta blocking agents,"/capita, US$ exchange rate",5.2
32955,Sweden,2015,4,C07-Beta blocking agents,"Million US$, purchasing power parity",48.5
32956,Sweden,2015,4,C07-Beta blocking agents,% of total sales,1.1
32957,Sweden,2015,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",4.9
32958,Sweden,2015,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,472.3
32959,Sweden,2015,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",449.9
32960,Sweden,2015,4,N-Nervous system,Million of national currency units,7485.8
32961,Sweden,2015,4,N-Nervous system,Million US$ at exchange rate,887.5
32962,Sweden,2015,4,N-Nervous system,"Million US$, purchasing power parity",845.4
32963,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
32964,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.4
32965,Sweden,2010,4,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",111.1
32966,Sweden,2010,4,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",414.0
32967,Sweden,2010,4,C03-Diuretics,"Million US$, purchasing power parity",29.8
32968,Sweden,2010,4,C03-Diuretics,"/capita, US$ exchange rate",4.0
32969,Sweden,2010,4,C03-Diuretics,Million of national currency units,269.1
32970,Sweden,2010,4,C03-Diuretics,Million US$ at exchange rate,37.3
32971,Sweden,2010,4,C-Cardiovascular system,"Million US$, purchasing power parity",345.5
32972,Sweden,2010,4,C03-Diuretics,% of total sales,0.7
32973,Sweden,2010,4,C03-Diuretics,"/capita, US$ purchasing power parity",3.2
32974,Sweden,2010,4,A-Alimentary tract and metabolism,% of total sales,10.4
32975,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,36.1
32976,Sweden,2010,4,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",55.3
32977,Sweden,2010,4,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",44.1
32978,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,5.0
32979,Sweden,2010,4,C02-Antihypertensives,Million of national currency units,137.8
32980,Sweden,2010,4,J01-Antibacterials for systemic use,Million of national currency units,1003.0
32981,Sweden,2010,4,J01-Antibacterials for systemic use,Million US$ at exchange rate,139.2
32982,Sweden,2010,4,C02-Antihypertensives,"Million US$, purchasing power parity",15.3
32983,Sweden,2010,4,C02-Antihypertensives,"/capita, US$ exchange rate",2.0
32984,Sweden,2010,4,C02-Antihypertensives,Million US$ at exchange rate,19.1
32985,Sweden,2010,4,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
32986,Sweden,2010,4,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
32987,Sweden,2010,4,C01A-Cardiac glycosides,% of total sales,0.0
32988,Sweden,2010,4,C-Cardiovascular system,Million US$ at exchange rate,432.6
32989,Sweden,2010,4,C-Cardiovascular system,Million of national currency units,3118.3
32990,Sweden,2010,4,C01A-Cardiac glycosides,Million of national currency units,14.1
32991,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.5
32992,Sweden,2010,4,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",4.0
32993,Sweden,2010,4,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.6
32994,Sweden,2010,4,C01A-Cardiac glycosides,Million US$ at exchange rate,2.0
32995,Sweden,2010,4,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.6
32996,Sweden,2010,4,Total pharmaceutical sales,Million US$ at exchange rate,5003.0
32997,Sweden,2010,4,Total pharmaceutical sales,Million of national currency units,36059.4
32998,Sweden,2010,4,A10-Drugs used in diabetes,"Million US$, purchasing power parity",143.3
32999,Sweden,2010,4,C02-Antihypertensives,% of total sales,0.4
33000,Sweden,2010,4,M-Musculo-skeletal system,Million of national currency units,1241.2
33001,Sweden,2010,4,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",15.3
33002,Sweden,2010,4,A10-Drugs used in diabetes,"/capita, US$ exchange rate",19.1
33003,Sweden,2010,4,Total pharmaceutical sales,"Million US$, purchasing power parity",3995.5
33004,Sweden,2010,4,M-Musculo-skeletal system,"/capita, US$ exchange rate",18.4
33005,Sweden,2010,4,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",14.7
33006,Sweden,2010,4,M-Musculo-skeletal system,Million US$ at exchange rate,172.2
33007,Sweden,2010,4,M-Musculo-skeletal system,"Million US$, purchasing power parity",137.5
33008,Sweden,2010,4,Total pharmaceutical sales,"/capita, US$ purchasing power parity",426.0
33009,Sweden,2010,4,Total pharmaceutical sales,"/capita, US$ exchange rate",533.5
33010,Sweden,2010,4,M-Musculo-skeletal system,% of total sales,3.4
33011,Sweden,2010,4,A10-Drugs used in diabetes,Million US$ at exchange rate,179.4
33012,Sweden,2010,4,C-Cardiovascular system,"/capita, US$ exchange rate",46.1
33013,Sweden,2010,4,A10-Drugs used in diabetes,% of total sales,3.6
33014,Sweden,2010,4,C-Cardiovascular system,"/capita, US$ purchasing power parity",36.8
33015,Sweden,2010,4,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",14.8
33016,Sweden,2010,4,A-Alimentary tract and metabolism,Million of national currency units,3736.4
33017,Sweden,2010,4,A-Alimentary tract and metabolism,Million US$ at exchange rate,518.4
33018,Sweden,2010,4,J01-Antibacterials for systemic use,% of total sales,2.8
33019,Sweden,2010,4,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",11.9
33020,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",10.9
33021,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",82.0
33022,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.1
33023,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.7
33024,Sweden,2010,4,C-Cardiovascular system,% of total sales,8.6
33025,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,102.6
33026,Sweden,2010,4,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,739.8
33027,Sweden,2010,4,A10-Drugs used in diabetes,Million of national currency units,1293.3
33028,Sweden,2010,4,A02A-Antacids,Million of national currency units,62.4
33029,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",11.8
33030,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,% of total sales,2.8
33031,Sweden,2010,4,A02A-Antacids,"/capita, US$ exchange rate",0.9
33032,Sweden,2010,4,A02A-Antacids,"Million US$, purchasing power parity",6.9
33033,Sweden,2010,4,A02A-Antacids,Million US$ at exchange rate,8.7
33034,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,727.7
33035,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,998.7
33036,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,101.0
33037,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",14.8
33038,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",110.7
33039,Sweden,2010,4,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,138.6
33040,Sweden,2010,4,R-Respiratory system,Million US$ at exchange rate,461.2
33041,Sweden,2010,4,R-Respiratory system,"Million US$, purchasing power parity",368.3
33042,Sweden,2010,4,R-Respiratory system,Million of national currency units,3323.9
33043,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.9
33044,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
33045,Sweden,2010,4,A02A-Antacids,% of total sales,0.2
33046,Sweden,2010,4,A02A-Antacids,"/capita, US$ purchasing power parity",0.7
33047,Sweden,2010,4,N-Nervous system,Million of national currency units,7256.9
33048,Sweden,2010,4,R-Respiratory system,"/capita, US$ purchasing power parity",39.3
33049,Sweden,2010,4,R-Respiratory system,"/capita, US$ exchange rate",49.2
33050,Sweden,2010,4,R-Respiratory system,% of total sales,9.2
33051,Sweden,2010,4,N02-Analgesics,Million US$ at exchange rate,280.4
33052,Sweden,2010,4,N02-Analgesics,Million of national currency units,2021.1
33053,Sweden,2010,4,N02-Analgesics,"Million US$, purchasing power parity",223.9
33054,Sweden,2010,4,N02-Analgesics,"/capita, US$ purchasing power parity",23.9
33055,Sweden,2010,4,N02-Analgesics,"/capita, US$ exchange rate",29.9
33056,Sweden,2010,4,C08-Calcium channel blockers,"Million US$, purchasing power parity",22.9
33057,Sweden,2010,4,C08-Calcium channel blockers,Million US$ at exchange rate,28.7
33058,Sweden,2010,4,J-Antiinfectives for systemic use,Million of national currency units,2649.2
33059,Sweden,2010,4,C08-Calcium channel blockers,Million of national currency units,206.8
33060,Sweden,2010,4,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4
33061,Sweden,2010,4,C08-Calcium channel blockers,% of total sales,0.6
33062,Sweden,2010,4,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.1
33063,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,2.0
33064,Sweden,2010,4,R03-Drugs for obstructive airway diseases,Million of national currency units,1932.4
33065,Sweden,2010,4,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,268.1
33066,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",10.8
33067,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",80.6
33068,Sweden,2010,4,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",8.6
33069,Sweden,2010,4,R03-Drugs for obstructive airway diseases,% of total sales,5.4
33070,Sweden,2010,4,N02-Analgesics,% of total sales,5.6
33071,Sweden,2010,4,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",214.1
33072,Sweden,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",22.8
33073,Sweden,2010,4,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",28.6
33074,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",13.2
33075,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",10.6
33076,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",99.2
33077,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,Million of national currency units,895.5
33078,Sweden,2010,4,G-Genito urinary system and sex hormones,Million of national currency units,1715.4
33079,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,124.2
33080,Sweden,2010,4,N06A-Antidepressants,"Million US$, purchasing power parity",69.3
33081,Sweden,2010,4,N06A-Antidepressants,"/capita, US$ exchange rate",9.3
33082,Sweden,2010,4,N06A-Antidepressants,"/capita, US$ purchasing power parity",7.4
33083,Sweden,2010,4,N06A-Antidepressants,Million of national currency units,625.7
33084,Sweden,2010,4,G03-Sex hormones and modulators of the genital system,% of total sales,2.5
33085,Sweden,2010,4,N06A-Antidepressants,Million US$ at exchange rate,86.8
33086,Sweden,2010,4,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",30.1
33087,Sweden,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",4.0
33088,Sweden,2010,4,N05C-Hypnotics and sedatives,Million US$ at exchange rate,37.7
33089,Sweden,2010,4,N05C-Hypnotics and sedatives,% of total sales,0.8
33090,Sweden,2010,4,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.2
33091,Sweden,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",25.4
33092,Sweden,2010,4,G-Genito urinary system and sex hormones,Million US$ at exchange rate,238.0
33093,Sweden,2010,4,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",190.1
33094,Sweden,2010,4,N05C-Hypnotics and sedatives,Million of national currency units,271.6
33095,Sweden,2010,4,G-Genito urinary system and sex hormones,% of total sales,4.8
33096,Sweden,2010,4,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.3
33097,Sweden,2010,4,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.2
33098,Sweden,2010,4,N05B-Anxiolytics,% of total sales,0.5
33099,Sweden,2010,4,N05B-Anxiolytics,"/capita, US$ exchange rate",2.8
33100,Sweden,2010,4,C10-Lipid modifying agents,Million US$ at exchange rate,100.3
33101,Sweden,2010,4,C10-Lipid modifying agents,Million of national currency units,722.6
33102,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,127.6
33103,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.6
33104,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",101.9
33105,Sweden,2010,4,N05B-Anxiolytics,"Million US$, purchasing power parity",20.8
33106,Sweden,2010,4,N05B-Anxiolytics,Million US$ at exchange rate,26.0
33107,Sweden,2010,4,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,919.4
33108,Sweden,2010,4,N05B-Anxiolytics,Million of national currency units,187.6
33109,Sweden,2010,4,C10-Lipid modifying agents,"Million US$, purchasing power parity",80.1
33110,Sweden,2010,4,B-Blood and blood forming organs,"Million US$, purchasing power parity",341.2
33111,Sweden,2010,4,B-Blood and blood forming organs,"/capita, US$ exchange rate",45.6
33112,Sweden,2010,4,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",36.4
33113,Sweden,2010,4,N06A-Antidepressants,% of total sales,1.7
33114,Sweden,2010,4,B-Blood and blood forming organs,Million US$ at exchange rate,427.3
33115,Sweden,2010,4,B-Blood and blood forming organs,Million of national currency units,3079.7
33116,Sweden,2010,4,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",8.5
33117,Sweden,2010,4,C10-Lipid modifying agents,"/capita, US$ exchange rate",10.7
33118,Sweden,2010,4,C10-Lipid modifying agents,% of total sales,2.0
33119,Sweden,2010,4,B-Blood and blood forming organs,% of total sales,8.5
33120,Sweden,2010,4,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",31.3
33121,Sweden,2010,4,N-Nervous system,% of total sales,20.1
33122,Sweden,2010,4,J-Antiinfectives for systemic use,% of total sales,7.3
33123,Sweden,2010,4,N-Nervous system,"/capita, US$ purchasing power parity",85.7
33124,Sweden,2010,4,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.2
33125,Sweden,2010,4,N-Nervous system,"/capita, US$ exchange rate",107.4
33126,Sweden,2010,4,C07-Beta blocking agents,Million US$ at exchange rate,59.7
33127,Sweden,2010,4,C07-Beta blocking agents,Million of national currency units,430.0
33128,Sweden,2010,4,C07-Beta blocking agents,"/capita, US$ exchange rate",6.4
33129,Sweden,2010,4,C07-Beta blocking agents,"Million US$, purchasing power parity",47.6
33130,Sweden,2010,4,C07-Beta blocking agents,% of total sales,1.2
33131,Sweden,2010,4,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.1
33132,Sweden,2010,4,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",293.5
33133,Sweden,2010,4,J-Antiinfectives for systemic use,Million US$ at exchange rate,367.6
33134,Sweden,2010,4,N-Nervous system,Million US$ at exchange rate,1006.9
33135,Sweden,2010,4,N-Nervous system,"Million US$, purchasing power parity",804.1
33136,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ purchasing power parity",0.7
33137,Sweden,2013,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",436.2
33138,Sweden,2013,5,J01-Antibacterials for systemic use,"Million US$, purchasing power parity",83.8
33139,Sweden,2013,5,C03-Diuretics,"Million US$, purchasing power parity",29.9
33140,Sweden,2013,5,C03-Diuretics,Million of national currency units,257.0
33141,Sweden,2013,5,C03-Diuretics,Million US$ at exchange rate,39.5
33142,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III","/capita, US$ exchange rate",0.9
33143,Sweden,2013,5,C03-Diuretics,% of total sales,0.7
33144,Sweden,2013,5,C03-Diuretics,"/capita, US$ exchange rate",4.1
33145,Sweden,2013,5,C03-Diuretics,"/capita, US$ purchasing power parity",3.1
33146,Sweden,2013,5,A-Alimentary tract and metabolism,% of total sales,10.3
33147,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III",Million of national currency units,54.1
33148,Sweden,2013,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",45.4
33149,Sweden,2013,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",60.0
33150,Sweden,2013,5,C02-Antihypertensives,Million of national currency units,154.1
33151,Sweden,2013,5,J01-Antibacterials for systemic use,Million of national currency units,720.8
33152,Sweden,2013,5,J01-Antibacterials for systemic use,Million US$ at exchange rate,110.7
33153,Sweden,2013,5,C02-Antihypertensives,"Million US$, purchasing power parity",17.9
33154,Sweden,2013,5,C02-Antihypertensives,Million US$ at exchange rate,23.7
33155,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III",Million US$ at exchange rate,8.3
33156,Sweden,2013,5,C01A-Cardiac glycosides,"/capita, US$ purchasing power parity",0.2
33157,Sweden,2013,5,C01A-Cardiac glycosides,"/capita, US$ exchange rate",0.2
33158,Sweden,2013,5,C-Cardiovascular system,Million US$ at exchange rate,352.4
33159,Sweden,2013,5,C-Cardiovascular system,Million of national currency units,2295.4
33160,Sweden,2013,5,C01A-Cardiac glycosides,% of total sales,0.0
33161,Sweden,2013,5,C01A-Cardiac glycosides,Million of national currency units,14.5
33162,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III","Million US$, purchasing power parity",6.3
33163,Sweden,2013,5,C01A-Cardiac glycosides,"Million US$, purchasing power parity",1.7
33164,Sweden,2013,5,C01A-Cardiac glycosides,Million US$ at exchange rate,2.2
33165,Sweden,2013,5,C02-Antihypertensives,"/capita, US$ purchasing power parity",1.9
33166,Sweden,2013,5,A10-Drugs used in diabetes,Million US$ at exchange rate,209.8
33167,Sweden,2013,5,Total pharmaceutical sales,Million US$ at exchange rate,5578.4
33168,Sweden,2013,5,Total pharmaceutical sales,Million of national currency units,36337.4
33169,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,% of total sales,2.0
33170,Sweden,2013,5,C02-Antihypertensives,% of total sales,0.4
33171,Sweden,2013,5,A10-Drugs used in diabetes,"Million US$, purchasing power parity",159.0
33172,Sweden,2013,5,C02-Antihypertensives,"/capita, US$ exchange rate",2.5
33173,Sweden,2013,5,A10-Drugs used in diabetes,"/capita, US$ exchange rate",21.9
33174,Sweden,2013,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",20.0
33175,Sweden,2013,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",15.1
33176,Sweden,2013,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",145.4
33177,Sweden,2013,5,M-Musculo-skeletal system,Million of national currency units,1249.9
33178,Sweden,2013,5,M-Musculo-skeletal system,Million US$ at exchange rate,191.9
33179,Sweden,2013,5,Total pharmaceutical sales,"/capita, US$ exchange rate",581.1
33180,Sweden,2013,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4226.4
33181,Sweden,2013,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",440.2
33182,Sweden,2013,5,M-Musculo-skeletal system,% of total sales,3.4
33183,Sweden,2013,5,C-Cardiovascular system,"/capita, US$ exchange rate",36.7
33184,Sweden,2013,5,C-Cardiovascular system,"Million US$, purchasing power parity",267.0
33185,Sweden,2013,5,A10-Drugs used in diabetes,% of total sales,3.8
33186,Sweden,2013,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",27.8
33187,Sweden,2013,5,A-Alimentary tract and metabolism,Million of national currency units,3749.9
33188,Sweden,2013,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,575.7
33189,Sweden,2013,5,J01-Antibacterials for systemic use,% of total sales,2.0
33190,Sweden,2013,5,J01-Antibacterials for systemic use,"/capita, US$ purchasing power parity",8.7
33191,Sweden,2013,5,J01-Antibacterials for systemic use,"/capita, US$ exchange rate",11.5
33192,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ exchange rate",11.4
33193,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"Million US$, purchasing power parity",83.2
33194,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,"/capita, US$ purchasing power parity",8.7
33195,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million US$ at exchange rate,109.8
33196,Sweden,2013,5,"C01B-Antiarrhythmics, Class I and III",% of total sales,0.1
33197,Sweden,2013,5,C-Cardiovascular system,% of total sales,6.3
33198,Sweden,2013,5,A10-Drugs used in diabetes,"/capita, US$ purchasing power parity",16.6
33199,Sweden,2013,5,M01A-Antiinflammatory and antirheumatic products non-steroids,Million of national currency units,715.4
33200,Sweden,2013,5,A10-Drugs used in diabetes,Million of national currency units,1366.8
33201,Sweden,2013,5,A02A-Antacids,Million of national currency units,75.9
33202,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,% of total sales,1.3
33203,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ purchasing power parity",5.5
33204,Sweden,2013,5,A02A-Antacids,"Million US$, purchasing power parity",8.8
33205,Sweden,2013,5,A02A-Antacids,"/capita, US$ exchange rate",1.2
33206,Sweden,2013,5,A02A-Antacids,Million US$ at exchange rate,11.7
33207,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million of national currency units,500.4
33208,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million of national currency units,457.3
33209,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),Million US$ at exchange rate,76.8
33210,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,"/capita, US$ exchange rate",7.3
33211,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,Million US$ at exchange rate,70.2
33212,Sweden,2013,5,C09-Agents acting on the Renin-Angiotensin system,"Million US$, purchasing power parity",53.2
33213,Sweden,2013,5,R-Respiratory system,Million US$ at exchange rate,545.2
33214,Sweden,2013,5,R-Respiratory system,Million of national currency units,3551.1
33215,Sweden,2013,5,R-Respiratory system,"Million US$, purchasing power parity",413.0
33216,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8
33217,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
33218,Sweden,2013,5,A02A-Antacids,% of total sales,0.2
33219,Sweden,2013,5,A02A-Antacids,"/capita, US$ purchasing power parity",0.9
33220,Sweden,2013,5,R-Respiratory system,"/capita, US$ exchange rate",56.8
33221,Sweden,2013,5,R-Respiratory system,"/capita, US$ purchasing power parity",43.0
33222,Sweden,2013,5,R-Respiratory system,% of total sales,9.8
33223,Sweden,2013,5,N02-Analgesics,Million US$ at exchange rate,302.7
33224,Sweden,2013,5,N02-Analgesics,Million of national currency units,1972.0
33225,Sweden,2013,5,N02-Analgesics,"/capita, US$ purchasing power parity",23.9
33226,Sweden,2013,5,N02-Analgesics,"Million US$, purchasing power parity",229.4
33227,Sweden,2013,5,N02-Analgesics,"/capita, US$ exchange rate",31.5
33228,Sweden,2013,5,C08-Calcium channel blockers,% of total sales,0.5
33229,Sweden,2013,5,C08-Calcium channel blockers,Million US$ at exchange rate,30.5
33230,Sweden,2013,5,J-Antiinfectives for systemic use,Million of national currency units,2367.4
33231,Sweden,2013,5,C08-Calcium channel blockers,Million of national currency units,198.7
33232,Sweden,2013,5,C08-Calcium channel blockers,"Million US$, purchasing power parity",23.1
33233,Sweden,2013,5,C08-Calcium channel blockers,"/capita, US$ purchasing power parity",2.4
33234,Sweden,2013,5,C08-Calcium channel blockers,"/capita, US$ exchange rate",3.2
33235,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),% of total sales,1.4
33236,Sweden,2013,5,R03-Drugs for obstructive airway diseases,Million US$ at exchange rate,311.5
33237,Sweden,2013,5,R03-Drugs for obstructive airway diseases,Million of national currency units,2029.1
33238,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"Million US$, purchasing power parity",58.2
33239,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ exchange rate",8.0
33240,Sweden,2013,5,A02B-Drugs for peptic ulcer and gastro-oesophageal reflux diseases (GORD),"/capita, US$ purchasing power parity",6.1
33241,Sweden,2013,5,R03-Drugs for obstructive airway diseases,% of total sales,5.6
33242,Sweden,2013,5,N02-Analgesics,% of total sales,5.4
33243,Sweden,2013,5,R03-Drugs for obstructive airway diseases,"Million US$, purchasing power parity",236.0
33244,Sweden,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ exchange rate",32.4
33245,Sweden,2013,5,R03-Drugs for obstructive airway diseases,"/capita, US$ purchasing power parity",24.6
33246,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",15.6
33247,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ exchange rate",14.8
33248,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,"Million US$, purchasing power parity",108.0
33249,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,"/capita, US$ purchasing power parity",11.2
33250,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,Million of national currency units,928.4
33251,Sweden,2013,5,G-Genito urinary system and sex hormones,Million of national currency units,1729.0
33252,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,Million US$ at exchange rate,142.5
33253,Sweden,2013,5,N06A-Antidepressants,"Million US$, purchasing power parity",86.6
33254,Sweden,2013,5,N06A-Antidepressants,"/capita, US$ purchasing power parity",9.0
33255,Sweden,2013,5,N06A-Antidepressants,"/capita, US$ exchange rate",11.9
33256,Sweden,2013,5,G03-Sex hormones and modulators of the genital system,% of total sales,2.6
33257,Sweden,2013,5,N06A-Antidepressants,Million of national currency units,744.4
33258,Sweden,2013,5,N06A-Antidepressants,Million US$ at exchange rate,114.3
33259,Sweden,2013,5,N05C-Hypnotics and sedatives,"Million US$, purchasing power parity",36.6
33260,Sweden,2013,5,N05C-Hypnotics and sedatives,Million US$ at exchange rate,48.3
33261,Sweden,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ exchange rate",5.0
33262,Sweden,2013,5,N05C-Hypnotics and sedatives,% of total sales,0.9
33263,Sweden,2013,5,N05C-Hypnotics and sedatives,"/capita, US$ purchasing power parity",3.8
33264,Sweden,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",27.6
33265,Sweden,2013,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",201.1
33266,Sweden,2013,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,265.4
33267,Sweden,2013,5,G-Genito urinary system and sex hormones,% of total sales,4.8
33268,Sweden,2013,5,N05C-Hypnotics and sedatives,Million of national currency units,314.9
33269,Sweden,2013,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",20.9
33270,Sweden,2013,5,N05B-Anxiolytics,"/capita, US$ purchasing power parity",2.4
33271,Sweden,2013,5,N05B-Anxiolytics,"/capita, US$ exchange rate",3.2
33272,Sweden,2013,5,N05B-Anxiolytics,% of total sales,0.6
33273,Sweden,2013,5,C10-Lipid modifying agents,Million US$ at exchange rate,67.7
33274,Sweden,2013,5,C10-Lipid modifying agents,Million of national currency units,440.8
33275,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,149.4
33276,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",113.2
33277,Sweden,2013,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,973.5
33278,Sweden,2013,5,N05B-Anxiolytics,Million US$ at exchange rate,30.8
33279,Sweden,2013,5,N05B-Anxiolytics,"Million US$, purchasing power parity",23.3
33280,Sweden,2013,5,N05B-Anxiolytics,Million of national currency units,200.7
33281,Sweden,2013,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",366.2
33282,Sweden,2013,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",50.3
33283,Sweden,2013,5,N06A-Antidepressants,% of total sales,2.0
33284,Sweden,2013,5,B-Blood and blood forming organs,Million of national currency units,3148.6
33285,Sweden,2013,5,B-Blood and blood forming organs,Million US$ at exchange rate,483.4
33286,Sweden,2013,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",38.1
33287,Sweden,2013,5,C10-Lipid modifying agents,"/capita, US$ purchasing power parity",5.3
33288,Sweden,2013,5,C10-Lipid modifying agents,"Million US$, purchasing power parity",51.3
33289,Sweden,2013,5,C10-Lipid modifying agents,"/capita, US$ exchange rate",7.0
33290,Sweden,2013,5,B-Blood and blood forming organs,% of total sales,8.7
33291,Sweden,2013,5,C10-Lipid modifying agents,% of total sales,1.2
33292,Sweden,2013,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",28.7
33293,Sweden,2013,5,J-Antiinfectives for systemic use,% of total sales,6.5
33294,Sweden,2013,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",37.9
33295,Sweden,2013,5,N-Nervous system,"/capita, US$ exchange rate",116.7
33296,Sweden,2013,5,N-Nervous system,"/capita, US$ purchasing power parity",88.4
33297,Sweden,2013,5,C07-Beta blocking agents,Million US$ at exchange rate,63.1
33298,Sweden,2013,5,C07-Beta blocking agents,Million of national currency units,411.0
33299,Sweden,2013,5,C07-Beta blocking agents,"/capita, US$ exchange rate",6.6
33300,Sweden,2013,5,C07-Beta blocking agents,"Million US$, purchasing power parity",47.8
33301,Sweden,2013,5,N-Nervous system,% of total sales,20.1
33302,Sweden,2013,5,C07-Beta blocking agents,% of total sales,1.1
33303,Sweden,2013,5,C07-Beta blocking agents,"/capita, US$ purchasing power parity",5.0
33304,Sweden,2013,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,363.4
33305,Sweden,2013,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",275.3
33306,Sweden,2013,5,N-Nervous system,Million US$ at exchange rate,1119.9
33307,Sweden,2013,5,N-Nervous system,Million of national currency units,7295.0
33308,Sweden,2013,5,N-Nervous system,"Million US$, purchasing power parity",848.5
33309,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.3
33310,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
33311,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.2
33312,Switzerland,2017,5,B-Blood and blood forming organs,Million of national currency units,354.0
33313,Switzerland,2017,5,B-Blood and blood forming organs,Million US$ at exchange rate,359.5
33314,Switzerland,2017,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",298.0
33315,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",78.3
33316,Switzerland,2017,5,C-Cardiovascular system,Million of national currency units,792.0
33317,Switzerland,2017,5,N-Nervous system,"/capita, US$ exchange rate",145.9
33318,Switzerland,2017,5,N-Nervous system,"/capita, US$ purchasing power parity",120.9
33319,Switzerland,2017,5,N-Nervous system,"Million US$, purchasing power parity",1022.1
33320,Switzerland,2017,5,N-Nervous system,Million of national currency units,1214.0
33321,Switzerland,2017,5,N-Nervous system,Million US$ at exchange rate,1232.9
33322,Switzerland,2017,5,N-Nervous system,% of total sales,18.6
33323,Switzerland,2017,5,C-Cardiovascular system,"Million US$, purchasing power parity",666.8
33324,Switzerland,2017,5,C-Cardiovascular system,Million US$ at exchange rate,804.3
33325,Switzerland,2017,5,C-Cardiovascular system,"/capita, US$ exchange rate",95.2
33326,Switzerland,2017,5,C-Cardiovascular system,% of total sales,12.1
33327,Switzerland,2017,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",78.9
33328,Switzerland,2017,5,Products not elsewhere classified,Million of national currency units,1298.0
33329,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,94.4
33330,Switzerland,2017,5,M-Musculo-skeletal system,Million of national currency units,427.0
33331,Switzerland,2017,5,M-Musculo-skeletal system,Million US$ at exchange rate,433.6
33332,Switzerland,2017,5,R-Respiratory system,Million of national currency units,507.0
33333,Switzerland,2017,5,R-Respiratory system,Million US$ at exchange rate,514.9
33334,Switzerland,2017,5,Products not elsewhere classified,% of total sales,19.9
33335,Switzerland,2017,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",129.3
33336,Switzerland,2017,5,Products not elsewhere classified,"/capita, US$ exchange rate",156.0
33337,Switzerland,2017,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,93.0
33338,Switzerland,2017,5,Products not elsewhere classified,Million US$ at exchange rate,1318.2
33339,Switzerland,2017,5,Products not elsewhere classified,"Million US$, purchasing power parity",1092.8
33340,Switzerland,2017,5,Total pharmaceutical sales,Million US$ at exchange rate,6621.4
33341,Switzerland,2017,5,Total pharmaceutical sales,Million of national currency units,6520.0
33342,Switzerland,2017,5,Total pharmaceutical sales,"Million US$, purchasing power parity",5489.5
33343,Switzerland,2017,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",42.5
33344,Switzerland,2017,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",35.3
33345,Switzerland,2017,5,B-Blood and blood forming organs,% of total sales,5.4
33346,Switzerland,2017,5,R-Respiratory system,"/capita, US$ exchange rate",60.9
33347,Switzerland,2017,5,R-Respiratory system,"/capita, US$ purchasing power parity",50.5
33348,Switzerland,2017,5,R-Respiratory system,"Million US$, purchasing power parity",426.9
33349,Switzerland,2017,5,Total pharmaceutical sales,"/capita, US$ exchange rate",783.4
33350,Switzerland,2017,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",649.5
33351,Switzerland,2017,5,R-Respiratory system,% of total sales,7.8
33352,Switzerland,2017,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",93.0
33353,Switzerland,2017,5,A-Alimentary tract and metabolism,% of total sales,14.3
33354,Switzerland,2017,5,M-Musculo-skeletal system,% of total sales,6.5
33355,Switzerland,2017,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",112.2
33356,Switzerland,2017,5,J-Antiinfectives for systemic use,% of total sales,8.5
33357,Switzerland,2017,5,A-Alimentary tract and metabolism,Million of national currency units,934.0
33358,Switzerland,2017,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",55.2
33359,Switzerland,2017,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,948.5
33360,Switzerland,2017,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",51.3
33361,Switzerland,2017,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",42.5
33362,Switzerland,2017,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",786.4
33363,Switzerland,2017,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",359.5
33364,Switzerland,2017,5,J-Antiinfectives for systemic use,Million of national currency units,554.0
33365,Switzerland,2017,5,G-Genito urinary system and sex hormones,Million of national currency units,347.0
33366,Switzerland,2017,5,G-Genito urinary system and sex hormones,% of total sales,5.3
33367,Switzerland,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.6
33368,Switzerland,2017,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,562.6
33369,Switzerland,2017,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",466.4
33370,Switzerland,2017,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.6
33371,Switzerland,2017,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,352.4
33372,Switzerland,2017,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",292.2
33373,Switzerland,2017,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",41.7
33374,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",9.0
33375,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
33376,Switzerland,2016,5,B-Blood and blood forming organs,Million US$ at exchange rate,324.7
33377,Switzerland,2016,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",266.2
33378,Switzerland,2016,5,B-Blood and blood forming organs,Million of national currency units,320.0
33379,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.0
33380,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",75.7
33381,Switzerland,2016,5,C-Cardiovascular system,Million of national currency units,799.0
33382,Switzerland,2016,5,N-Nervous system,"/capita, US$ exchange rate",148.0
33383,Switzerland,2016,5,N-Nervous system,"/capita, US$ purchasing power parity",121.3
33384,Switzerland,2016,5,N-Nervous system,Million of national currency units,1221.0
33385,Switzerland,2016,5,N-Nervous system,"Million US$, purchasing power parity",1015.8
33386,Switzerland,2016,5,N-Nervous system,Million US$ at exchange rate,1239.1
33387,Switzerland,2016,5,N-Nervous system,% of total sales,19.1
33388,Switzerland,2016,5,C-Cardiovascular system,"Million US$, purchasing power parity",664.7
33389,Switzerland,2016,5,C-Cardiovascular system,Million US$ at exchange rate,810.8
33390,Switzerland,2016,5,C-Cardiovascular system,"/capita, US$ exchange rate",96.8
33391,Switzerland,2016,5,C-Cardiovascular system,% of total sales,12.5
33392,Switzerland,2016,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",79.4
33393,Switzerland,2016,5,Products not elsewhere classified,Million of national currency units,1218.0
33394,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,92.3
33395,Switzerland,2016,5,M-Musculo-skeletal system,Million of national currency units,416.0
33396,Switzerland,2016,5,M-Musculo-skeletal system,Million US$ at exchange rate,422.2
33397,Switzerland,2016,5,R-Respiratory system,Million of national currency units,497.0
33398,Switzerland,2016,5,R-Respiratory system,Million US$ at exchange rate,504.4
33399,Switzerland,2016,5,Products not elsewhere classified,% of total sales,19.1
33400,Switzerland,2016,5,Products not elsewhere classified,"/capita, US$ exchange rate",147.6
33401,Switzerland,2016,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",121.0
33402,Switzerland,2016,5,Products not elsewhere classified,Million US$ at exchange rate,1236.1
33403,Switzerland,2016,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,91.0
33404,Switzerland,2016,5,Products not elsewhere classified,"Million US$, purchasing power parity",1013.3
33405,Switzerland,2016,5,Total pharmaceutical sales,Million US$ at exchange rate,6474.6
33406,Switzerland,2016,5,Total pharmaceutical sales,Million of national currency units,6380.0
33407,Switzerland,2016,5,Total pharmaceutical sales,"Million US$, purchasing power parity",5308.0
33408,Switzerland,2016,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",31.8
33409,Switzerland,2016,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",38.8
33410,Switzerland,2016,5,B-Blood and blood forming organs,% of total sales,5.0
33411,Switzerland,2016,5,R-Respiratory system,"/capita, US$ exchange rate",60.2
33412,Switzerland,2016,5,R-Respiratory system,"/capita, US$ purchasing power parity",49.4
33413,Switzerland,2016,5,R-Respiratory system,"Million US$, purchasing power parity",413.5
33414,Switzerland,2016,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",633.9
33415,Switzerland,2016,5,Total pharmaceutical sales,"/capita, US$ exchange rate",773.2
33416,Switzerland,2016,5,R-Respiratory system,% of total sales,7.8
33417,Switzerland,2016,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",91.7
33418,Switzerland,2016,5,A-Alimentary tract and metabolism,% of total sales,14.5
33419,Switzerland,2016,5,M-Musculo-skeletal system,% of total sales,6.5
33420,Switzerland,2016,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",111.9
33421,Switzerland,2016,5,J-Antiinfectives for systemic use,% of total sales,8.6
33422,Switzerland,2016,5,A-Alimentary tract and metabolism,Million of national currency units,923.0
33423,Switzerland,2016,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",54.3
33424,Switzerland,2016,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,936.7
33425,Switzerland,2016,5,J-Antiinfectives for systemic use,Million of national currency units,546.0
33426,Switzerland,2016,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",50.4
33427,Switzerland,2016,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",41.3
33428,Switzerland,2016,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",346.1
33429,Switzerland,2016,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",767.9
33430,Switzerland,2016,5,G-Genito urinary system and sex hormones,Million of national currency units,351.0
33431,Switzerland,2016,5,G-Genito urinary system and sex hormones,% of total sales,5.5
33432,Switzerland,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.9
33433,Switzerland,2016,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,554.1
33434,Switzerland,2016,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",454.3
33435,Switzerland,2016,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",66.2
33436,Switzerland,2016,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,356.2
33437,Switzerland,2016,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",292.0
33438,Switzerland,2016,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",42.5
33439,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.1
33440,Switzerland,2014,5,C-Cardiovascular system,Million of national currency units,770.0
33441,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
33442,Switzerland,2014,5,B-Blood and blood forming organs,Million US$ at exchange rate,287.1
33443,Switzerland,2014,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",205.2
33444,Switzerland,2014,5,B-Blood and blood forming organs,Million of national currency units,263.0
33445,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.3
33446,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",66.3
33447,Switzerland,2014,5,C-Cardiovascular system,"Million US$, purchasing power parity",600.7
33448,Switzerland,2014,5,N-Nervous system,"/capita, US$ exchange rate",137.0
33449,Switzerland,2014,5,N-Nervous system,% of total sales,17.3
33450,Switzerland,2014,5,N-Nervous system,"/capita, US$ purchasing power parity",97.9
33451,Switzerland,2014,5,N-Nervous system,Million of national currency units,1028.0
33452,Switzerland,2014,5,N-Nervous system,Million US$ at exchange rate,1122.1
33453,Switzerland,2014,5,N-Nervous system,"Million US$, purchasing power parity",802.0
33454,Switzerland,2014,5,C-Cardiovascular system,Million US$ at exchange rate,840.5
33455,Switzerland,2014,5,C-Cardiovascular system,% of total sales,13.0
33456,Switzerland,2014,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",73.4
33457,Switzerland,2014,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.1
33458,Switzerland,2014,5,Products not elsewhere classified,Million of national currency units,1258.0
33459,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,92.8
33460,Switzerland,2014,5,M-Musculo-skeletal system,Million US$ at exchange rate,418.1
33461,Switzerland,2014,5,M-Musculo-skeletal system,Million of national currency units,383.0
33462,Switzerland,2014,5,R-Respiratory system,Million of national currency units,476.0
33463,Switzerland,2014,5,R-Respiratory system,Million US$ at exchange rate,519.6
33464,Switzerland,2014,5,Products not elsewhere classified,% of total sales,21.2
33465,Switzerland,2014,5,Products not elsewhere classified,"/capita, US$ exchange rate",167.7
33466,Switzerland,2014,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",119.9
33467,Switzerland,2014,5,Products not elsewhere classified,Million US$ at exchange rate,1373.1
33468,Switzerland,2014,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,85.0
33469,Switzerland,2014,5,Products not elsewhere classified,"Million US$, purchasing power parity",981.5
33470,Switzerland,2014,5,Total pharmaceutical sales,Million US$ at exchange rate,6473.8
33471,Switzerland,2014,5,Total pharmaceutical sales,"Million US$, purchasing power parity",4627.2
33472,Switzerland,2014,5,Total pharmaceutical sales,Million of national currency units,5931.0
33473,Switzerland,2014,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",25.1
33474,Switzerland,2014,5,B-Blood and blood forming organs,% of total sales,4.4
33475,Switzerland,2014,5,Total pharmaceutical sales,"/capita, US$ exchange rate",790.6
33476,Switzerland,2014,5,R-Respiratory system,"/capita, US$ purchasing power parity",45.4
33477,Switzerland,2014,5,R-Respiratory system,"/capita, US$ exchange rate",63.4
33478,Switzerland,2014,5,R-Respiratory system,"Million US$, purchasing power parity",371.4
33479,Switzerland,2014,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",565.1
33480,Switzerland,2014,5,R-Respiratory system,% of total sales,8.0
33481,Switzerland,2014,5,C-Cardiovascular system,"/capita, US$ exchange rate",102.6
33482,Switzerland,2014,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",82.2
33483,Switzerland,2014,5,A-Alimentary tract and metabolism,% of total sales,14.6
33484,Switzerland,2014,5,M-Musculo-skeletal system,% of total sales,6.5
33485,Switzerland,2014,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",115.0
33486,Switzerland,2014,5,J-Antiinfectives for systemic use,% of total sales,7.7
33487,Switzerland,2014,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",51.1
33488,Switzerland,2014,5,A-Alimentary tract and metabolism,Million of national currency units,863.0
33489,Switzerland,2014,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",43.7
33490,Switzerland,2014,5,G-Genito urinary system and sex hormones,Million of national currency units,346.0
33491,Switzerland,2014,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,942.0
33492,Switzerland,2014,5,J-Antiinfectives for systemic use,Million of national currency units,459.0
33493,Switzerland,2014,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",36.5
33494,Switzerland,2014,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",673.3
33495,Switzerland,2014,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",298.8
33496,Switzerland,2014,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,501.0
33497,Switzerland,2014,5,G-Genito urinary system and sex hormones,% of total sales,5.8
33498,Switzerland,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.0
33499,Switzerland,2014,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",358.1
33500,Switzerland,2014,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",61.2
33501,Switzerland,2014,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,377.7
33502,Switzerland,2014,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",269.9
33503,Switzerland,2014,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",46.1
33504,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.9
33505,Switzerland,2013,6,C-Cardiovascular system,Million of national currency units,791.0
33506,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
33507,Switzerland,2013,6,B-Blood and blood forming organs,Million US$ at exchange rate,264.3
33508,Switzerland,2013,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",186.7
33509,Switzerland,2013,6,B-Blood and blood forming organs,Million of national currency units,245.0
33510,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.2
33511,Switzerland,2013,6,M-Musculo-skeletal system,Million of national currency units,355.0
33512,Switzerland,2013,6,N-Nervous system,"/capita, US$ exchange rate",139.4
33513,Switzerland,2013,6,N-Nervous system,% of total sales,17.6
33514,Switzerland,2013,6,N-Nervous system,"/capita, US$ purchasing power parity",98.4
33515,Switzerland,2013,6,N-Nervous system,Million of national currency units,1045.0
33516,Switzerland,2013,6,N-Nervous system,Million US$ at exchange rate,1127.4
33517,Switzerland,2013,6,N-Nervous system,"Million US$, purchasing power parity",796.2
33518,Switzerland,2013,6,C-Cardiovascular system,"Million US$, purchasing power parity",602.7
33519,Switzerland,2013,6,C-Cardiovascular system,"/capita, US$ exchange rate",105.5
33520,Switzerland,2013,6,C-Cardiovascular system,Million US$ at exchange rate,853.4
33521,Switzerland,2013,6,C-Cardiovascular system,% of total sales,13.3
33522,Switzerland,2013,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",74.5
33523,Switzerland,2013,6,Products not elsewhere classified,Million of national currency units,1238.0
33524,Switzerland,2013,6,Products not elsewhere classified,Million US$ at exchange rate,1335.6
33525,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,90.6
33526,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",64.0
33527,Switzerland,2013,6,R-Respiratory system,Million of national currency units,513.0
33528,Switzerland,2013,6,M-Musculo-skeletal system,Million US$ at exchange rate,383.0
33529,Switzerland,2013,6,R-Respiratory system,Million US$ at exchange rate,553.5
33530,Switzerland,2013,6,Products not elsewhere classified,% of total sales,20.9
33531,Switzerland,2013,6,Products not elsewhere classified,"/capita, US$ exchange rate",165.1
33532,Switzerland,2013,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",116.6
33533,Switzerland,2013,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,84.0
33534,Switzerland,2013,6,Products not elsewhere classified,"Million US$, purchasing power parity",943.3
33535,Switzerland,2013,6,Total pharmaceutical sales,Million US$ at exchange rate,6398.7
33536,Switzerland,2013,6,Total pharmaceutical sales,"Million US$, purchasing power parity",4518.9
33537,Switzerland,2013,6,Total pharmaceutical sales,Million of national currency units,5931.0
33538,Switzerland,2013,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",23.1
33539,Switzerland,2013,6,B-Blood and blood forming organs,% of total sales,4.1
33540,Switzerland,2013,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",32.7
33541,Switzerland,2013,6,R-Respiratory system,"/capita, US$ purchasing power parity",48.3
33542,Switzerland,2013,6,R-Respiratory system,"Million US$, purchasing power parity",390.9
33543,Switzerland,2013,6,R-Respiratory system,"/capita, US$ exchange rate",68.4
33544,Switzerland,2013,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",558.6
33545,Switzerland,2013,6,R-Respiratory system,% of total sales,8.6
33546,Switzerland,2013,6,Total pharmaceutical sales,"/capita, US$ exchange rate",791.0
33547,Switzerland,2013,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",80.8
33548,Switzerland,2013,6,A-Alimentary tract and metabolism,% of total sales,14.5
33549,Switzerland,2013,6,M-Musculo-skeletal system,% of total sales,6.0
33550,Switzerland,2013,6,J-Antiinfectives for systemic use,% of total sales,7.6
33551,Switzerland,2013,6,G-Genito urinary system and sex hormones,Million of national currency units,353.0
33552,Switzerland,2013,6,A-Alimentary tract and metabolism,Million of national currency units,858.0
33553,Switzerland,2013,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",42.3
33554,Switzerland,2013,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,925.7
33555,Switzerland,2013,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",653.7
33556,Switzerland,2013,6,J-Antiinfectives for systemic use,Million of national currency units,449.0
33557,Switzerland,2013,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",33.4
33558,Switzerland,2013,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",270.5
33559,Switzerland,2013,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",114.4
33560,Switzerland,2013,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,484.4
33561,Switzerland,2013,6,G-Genito urinary system and sex hormones,% of total sales,6.0
33562,Switzerland,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",33.2
33563,Switzerland,2013,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",342.1
33564,Switzerland,2013,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",59.9
33565,Switzerland,2013,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",47.3
33566,Switzerland,2013,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,380.8
33567,Switzerland,2013,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",269.0
33568,Switzerland,2013,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",47.1
33569,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.7
33570,Switzerland,2012,6,C-Cardiovascular system,Million of national currency units,876.0
33571,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
33572,Switzerland,2012,6,B-Blood and blood forming organs,Million US$ at exchange rate,236.8
33573,Switzerland,2012,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",163.9
33574,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",11.1
33575,Switzerland,2012,6,M-Musculo-skeletal system,Million of national currency units,356.0
33576,Switzerland,2012,6,B-Blood and blood forming organs,Million of national currency units,222.0
33577,Switzerland,2012,6,N-Nervous system,"/capita, US$ exchange rate",141.4
33578,Switzerland,2012,6,N-Nervous system,"/capita, US$ purchasing power parity",97.9
33579,Switzerland,2012,6,N-Nervous system,% of total sales,17.9
33580,Switzerland,2012,6,N-Nervous system,Million of national currency units,1060.0
33581,Switzerland,2012,6,N-Nervous system,Million US$ at exchange rate,1130.4
33582,Switzerland,2012,6,N-Nervous system,"Million US$, purchasing power parity",782.8
33583,Switzerland,2012,6,C-Cardiovascular system,"Million US$, purchasing power parity",646.9
33584,Switzerland,2012,6,C-Cardiovascular system,"/capita, US$ exchange rate",116.8
33585,Switzerland,2012,6,C-Cardiovascular system,Million US$ at exchange rate,934.2
33586,Switzerland,2012,6,C-Cardiovascular system,% of total sales,14.8
33587,Switzerland,2012,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",80.9
33588,Switzerland,2012,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",29.6
33589,Switzerland,2012,6,Products not elsewhere classified,Million of national currency units,1180.0
33590,Switzerland,2012,6,R-Respiratory system,Million of national currency units,494.0
33591,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",61.3
33592,Switzerland,2012,6,Products not elsewhere classified,Million US$ at exchange rate,1258.4
33593,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,88.5
33594,Switzerland,2012,6,M-Musculo-skeletal system,Million US$ at exchange rate,379.7
33595,Switzerland,2012,6,R-Respiratory system,Million US$ at exchange rate,526.8
33596,Switzerland,2012,6,Products not elsewhere classified,% of total sales,19.9
33597,Switzerland,2012,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",109.0
33598,Switzerland,2012,6,Products not elsewhere classified,"/capita, US$ exchange rate",157.4
33599,Switzerland,2012,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,83.0
33600,Switzerland,2012,6,Products not elsewhere classified,"Million US$, purchasing power parity",871.4
33601,Switzerland,2012,6,Total pharmaceutical sales,Million US$ at exchange rate,6331.6
33602,Switzerland,2012,6,Total pharmaceutical sales,"Million US$, purchasing power parity",4384.6
33603,Switzerland,2012,6,Total pharmaceutical sales,Million of national currency units,5937.0
33604,Switzerland,2012,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.5
33605,Switzerland,2012,6,B-Blood and blood forming organs,% of total sales,3.7
33606,Switzerland,2012,6,Total pharmaceutical sales,"/capita, US$ exchange rate",791.8
33607,Switzerland,2012,6,R-Respiratory system,"/capita, US$ purchasing power parity",45.6
33608,Switzerland,2012,6,R-Respiratory system,"/capita, US$ exchange rate",65.9
33609,Switzerland,2012,6,R-Respiratory system,"Million US$, purchasing power parity",364.8
33610,Switzerland,2012,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",548.3
33611,Switzerland,2012,6,R-Respiratory system,% of total sales,8.3
33612,Switzerland,2012,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",78.6
33613,Switzerland,2012,6,A-Alimentary tract and metabolism,% of total sales,14.3
33614,Switzerland,2012,6,J-Antiinfectives for systemic use,% of total sales,7.8
33615,Switzerland,2012,6,G-Genito urinary system and sex hormones,Million of national currency units,353.0
33616,Switzerland,2012,6,A-Alimentary tract and metabolism,Million of national currency units,851.0
33617,Switzerland,2012,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",42.8
33618,Switzerland,2012,6,M-Musculo-skeletal system,% of total sales,6.0
33619,Switzerland,2012,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,907.6
33620,Switzerland,2012,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",628.5
33621,Switzerland,2012,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",32.9
33622,Switzerland,2012,6,J-Antiinfectives for systemic use,Million of national currency units,463.0
33623,Switzerland,2012,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",262.9
33624,Switzerland,2012,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",113.5
33625,Switzerland,2012,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,493.8
33626,Switzerland,2012,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",47.5
33627,Switzerland,2012,6,G-Genito urinary system and sex hormones,% of total sales,5.9
33628,Switzerland,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",32.6
33629,Switzerland,2012,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",341.9
33630,Switzerland,2012,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",61.7
33631,Switzerland,2012,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",260.7
33632,Switzerland,2012,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,376.5
33633,Switzerland,2012,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",47.1
33634,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.6
33635,Switzerland,2011,6,C-Cardiovascular system,Million of national currency units,929.0
33636,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.3
33637,Switzerland,2011,6,B-Blood and blood forming organs,Million US$ at exchange rate,234.2
33638,Switzerland,2011,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",148.8
33639,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.4
33640,Switzerland,2011,6,M-Musculo-skeletal system,Million of national currency units,345.0
33641,Switzerland,2011,6,B-Blood and blood forming organs,Million of national currency units,208.0
33642,Switzerland,2011,6,N-Nervous system,"/capita, US$ exchange rate",151.3
33643,Switzerland,2011,6,N-Nervous system,"/capita, US$ purchasing power parity",96.1
33644,Switzerland,2011,6,N-Nervous system,% of total sales,18.4
33645,Switzerland,2011,6,N-Nervous system,Million US$ at exchange rate,1197.0
33646,Switzerland,2011,6,N-Nervous system,Million of national currency units,1063.0
33647,Switzerland,2011,6,N-Nervous system,"Million US$, purchasing power parity",760.6
33648,Switzerland,2011,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",29.6
33649,Switzerland,2011,6,C-Cardiovascular system,"/capita, US$ exchange rate",132.2
33650,Switzerland,2011,6,C-Cardiovascular system,"Million US$, purchasing power parity",664.8
33651,Switzerland,2011,6,C-Cardiovascular system,Million US$ at exchange rate,1046.1
33652,Switzerland,2011,6,C-Cardiovascular system,% of total sales,16.1
33653,Switzerland,2011,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",84.0
33654,Switzerland,2011,6,Products not elsewhere classified,Million of national currency units,1030.0
33655,Switzerland,2011,6,R-Respiratory system,Million of national currency units,487.0
33656,Switzerland,2011,6,Products not elsewhere classified,Million US$ at exchange rate,1159.9
33657,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",52.2
33658,Switzerland,2011,6,M-Musculo-skeletal system,Million US$ at exchange rate,388.5
33659,Switzerland,2011,6,R-Respiratory system,Million US$ at exchange rate,548.4
33660,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,82.2
33661,Switzerland,2011,6,Products not elsewhere classified,% of total sales,17.8
33662,Switzerland,2011,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",93.1
33663,Switzerland,2011,6,Products not elsewhere classified,"/capita, US$ exchange rate",146.6
33664,Switzerland,2011,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,73.0
33665,Switzerland,2011,6,Products not elsewhere classified,"Million US$, purchasing power parity",737.0
33666,Switzerland,2011,6,Total pharmaceutical sales,Million US$ at exchange rate,6504.2
33667,Switzerland,2011,6,Total pharmaceutical sales,"Million US$, purchasing power parity",4133.1
33668,Switzerland,2011,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.8
33669,Switzerland,2011,6,Total pharmaceutical sales,Million of national currency units,5776.0
33670,Switzerland,2011,6,Total pharmaceutical sales,"/capita, US$ exchange rate",822.0
33671,Switzerland,2011,6,B-Blood and blood forming organs,% of total sales,3.6
33672,Switzerland,2011,6,R-Respiratory system,"/capita, US$ purchasing power parity",44.0
33673,Switzerland,2011,6,R-Respiratory system,"Million US$, purchasing power parity",348.5
33674,Switzerland,2011,6,R-Respiratory system,"/capita, US$ exchange rate",69.3
33675,Switzerland,2011,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",522.4
33676,Switzerland,2011,6,R-Respiratory system,% of total sales,8.4
33677,Switzerland,2011,6,A-Alimentary tract and metabolism,% of total sales,14.7
33678,Switzerland,2011,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",76.6
33679,Switzerland,2011,6,J-Antiinfectives for systemic use,% of total sales,7.7
33680,Switzerland,2011,6,G-Genito urinary system and sex hormones,Million of national currency units,349.0
33681,Switzerland,2011,6,A-Alimentary tract and metabolism,Million of national currency units,847.0
33682,Switzerland,2011,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,953.8
33683,Switzerland,2011,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",606.1
33684,Switzerland,2011,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",31.2
33685,Switzerland,2011,6,J-Antiinfectives for systemic use,Million of national currency units,445.0
33686,Switzerland,2011,6,M-Musculo-skeletal system,% of total sales,6.0
33687,Switzerland,2011,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",246.9
33688,Switzerland,2011,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",120.5
33689,Switzerland,2011,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,501.1
33690,Switzerland,2011,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",49.1
33691,Switzerland,2011,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",40.2
33692,Switzerland,2011,6,G-Genito urinary system and sex hormones,% of total sales,6.0
33693,Switzerland,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",31.6
33694,Switzerland,2011,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",318.4
33695,Switzerland,2011,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",63.3
33696,Switzerland,2011,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,393.0
33697,Switzerland,2011,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",249.7
33698,Switzerland,2011,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",49.7
33699,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",6.2
33700,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.2
33701,Switzerland,2010,6,C-Cardiovascular system,Million of national currency units,946.1
33702,Switzerland,2010,6,B-Blood and blood forming organs,Million US$ at exchange rate,206.6
33703,Switzerland,2010,6,B-Blood and blood forming organs,"Million US$, purchasing power parity",147.0
33704,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.8
33705,Switzerland,2010,6,B-Blood and blood forming organs,"/capita, US$ exchange rate",26.4
33706,Switzerland,2010,6,M-Musculo-skeletal system,Million of national currency units,346.2
33707,Switzerland,2010,6,B-Blood and blood forming organs,Million of national currency units,215.5
33708,Switzerland,2010,6,N-Nervous system,"/capita, US$ exchange rate",127.7
33709,Switzerland,2010,6,N-Nervous system,"/capita, US$ purchasing power parity",90.9
33710,Switzerland,2010,6,N-Nervous system,% of total sales,18.1
33711,Switzerland,2010,6,N-Nervous system,Million US$ at exchange rate,999.4
33712,Switzerland,2010,6,N-Nervous system,Million of national currency units,1042.3
33713,Switzerland,2010,6,N-Nervous system,"Million US$, purchasing power parity",710.9
33714,Switzerland,2010,6,C-Cardiovascular system,"/capita, US$ exchange rate",115.9
33715,Switzerland,2010,6,C-Cardiovascular system,"Million US$, purchasing power parity",645.3
33716,Switzerland,2010,6,C-Cardiovascular system,Million US$ at exchange rate,907.2
33717,Switzerland,2010,6,C-Cardiovascular system,% of total sales,16.5
33718,Switzerland,2010,6,C-Cardiovascular system,"/capita, US$ purchasing power parity",82.5
33719,Switzerland,2010,6,Products not elsewhere classified,Million of national currency units,980.6
33720,Switzerland,2010,6,R-Respiratory system,Million of national currency units,484.8
33721,Switzerland,2010,6,Products not elsewhere classified,Million US$ at exchange rate,940.2
33722,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",48.7
33723,Switzerland,2010,6,M-Musculo-skeletal system,Million US$ at exchange rate,331.9
33724,Switzerland,2010,6,R-Respiratory system,Million US$ at exchange rate,464.8
33725,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,68.5
33726,Switzerland,2010,6,Products not elsewhere classified,% of total sales,17.1
33727,Switzerland,2010,6,Products not elsewhere classified,"/capita, US$ purchasing power parity",85.5
33728,Switzerland,2010,6,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,71.4
33729,Switzerland,2010,6,Products not elsewhere classified,"/capita, US$ exchange rate",120.2
33730,Switzerland,2010,6,Products not elsewhere classified,"Million US$, purchasing power parity",668.8
33731,Switzerland,2010,6,Total pharmaceutical sales,Million US$ at exchange rate,5507.8
33732,Switzerland,2010,6,Total pharmaceutical sales,"/capita, US$ exchange rate",703.9
33733,Switzerland,2010,6,Total pharmaceutical sales,"Million US$, purchasing power parity",3917.9
33734,Switzerland,2010,6,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",18.8
33735,Switzerland,2010,6,Total pharmaceutical sales,Million of national currency units,5744.2
33736,Switzerland,2010,6,B-Blood and blood forming organs,% of total sales,3.8
33737,Switzerland,2010,6,R-Respiratory system,"/capita, US$ purchasing power parity",42.3
33738,Switzerland,2010,6,R-Respiratory system,"Million US$, purchasing power parity",330.6
33739,Switzerland,2010,6,R-Respiratory system,"/capita, US$ exchange rate",59.4
33740,Switzerland,2010,6,Total pharmaceutical sales,"/capita, US$ purchasing power parity",500.7
33741,Switzerland,2010,6,R-Respiratory system,% of total sales,8.4
33742,Switzerland,2010,6,A-Alimentary tract and metabolism,% of total sales,15.2
33743,Switzerland,2010,6,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",76.3
33744,Switzerland,2010,6,J-Antiinfectives for systemic use,% of total sales,7.6
33745,Switzerland,2010,6,G-Genito urinary system and sex hormones,Million of national currency units,344.2
33746,Switzerland,2010,6,A-Alimentary tract and metabolism,Million of national currency units,875.8
33747,Switzerland,2010,6,M-Musculo-skeletal system,% of total sales,6.0
33748,Switzerland,2010,6,A-Alimentary tract and metabolism,Million US$ at exchange rate,839.8
33749,Switzerland,2010,6,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",597.4
33750,Switzerland,2010,6,J-Antiinfectives for systemic use,Million of national currency units,437.3
33751,Switzerland,2010,6,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",30.2
33752,Switzerland,2010,6,M-Musculo-skeletal system,"Million US$, purchasing power parity",236.1
33753,Switzerland,2010,6,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",107.3
33754,Switzerland,2010,6,J-Antiinfectives for systemic use,Million US$ at exchange rate,419.3
33755,Switzerland,2010,6,M-Musculo-skeletal system,"/capita, US$ exchange rate",42.4
33756,Switzerland,2010,6,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.1
33757,Switzerland,2010,6,G-Genito urinary system and sex hormones,% of total sales,6.0
33758,Switzerland,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",30.0
33759,Switzerland,2010,6,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",298.3
33760,Switzerland,2010,6,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",53.6
33761,Switzerland,2010,6,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",42.2
33762,Switzerland,2010,6,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",234.8
33763,Switzerland,2010,6,G-Genito urinary system and sex hormones,Million US$ at exchange rate,330.0
33764,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.5
33765,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,1.4
33766,Switzerland,2015,5,C-Cardiovascular system,Million of national currency units,777.0
33767,Switzerland,2015,5,B-Blood and blood forming organs,Million US$ at exchange rate,296.1
33768,Switzerland,2015,5,B-Blood and blood forming organs,"Million US$, purchasing power parity",230.6
33769,Switzerland,2015,5,B-Blood and blood forming organs,Million of national currency units,285.0
33770,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.9
33771,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",70.4
33772,Switzerland,2015,5,N-Nervous system,"/capita, US$ exchange rate",130.0
33773,Switzerland,2015,5,N-Nervous system,"/capita, US$ purchasing power parity",101.2
33774,Switzerland,2015,5,N-Nervous system,% of total sales,16.8
33775,Switzerland,2015,5,N-Nervous system,Million of national currency units,1036.0
33776,Switzerland,2015,5,N-Nervous system,"Million US$, purchasing power parity",838.3
33777,Switzerland,2015,5,N-Nervous system,Million US$ at exchange rate,1076.5
33778,Switzerland,2015,5,C-Cardiovascular system,"Million US$, purchasing power parity",628.7
33779,Switzerland,2015,5,C-Cardiovascular system,Million US$ at exchange rate,807.4
33780,Switzerland,2015,5,C-Cardiovascular system,"/capita, US$ exchange rate",97.5
33781,Switzerland,2015,5,C-Cardiovascular system,% of total sales,12.6
33782,Switzerland,2015,5,C-Cardiovascular system,"/capita, US$ purchasing power parity",75.9
33783,Switzerland,2015,5,Products not elsewhere classified,Million of national currency units,1291.0
33784,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,90.4
33785,Switzerland,2015,5,R-Respiratory system,Million of national currency units,503.0
33786,Switzerland,2015,5,M-Musculo-skeletal system,Million US$ at exchange rate,413.6
33787,Switzerland,2015,5,M-Musculo-skeletal system,Million of national currency units,398.0
33788,Switzerland,2015,5,R-Respiratory system,Million US$ at exchange rate,522.7
33789,Switzerland,2015,5,Products not elsewhere classified,% of total sales,20.9
33790,Switzerland,2015,5,Products not elsewhere classified,"/capita, US$ exchange rate",162.0
33791,Switzerland,2015,5,Products not elsewhere classified,"/capita, US$ purchasing power parity",126.1
33792,Switzerland,2015,5,Products not elsewhere classified,Million US$ at exchange rate,1341.5
33793,Switzerland,2015,5,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,87.0
33794,Switzerland,2015,5,Products not elsewhere classified,"Million US$, purchasing power parity",1044.7
33795,Switzerland,2015,5,Total pharmaceutical sales,Million US$ at exchange rate,6425.7
33796,Switzerland,2015,5,Total pharmaceutical sales,Million of national currency units,6184.0
33797,Switzerland,2015,5,Total pharmaceutical sales,"Million US$, purchasing power parity",5004.1
33798,Switzerland,2015,5,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",27.8
33799,Switzerland,2015,5,B-Blood and blood forming organs,"/capita, US$ exchange rate",35.8
33800,Switzerland,2015,5,B-Blood and blood forming organs,% of total sales,4.6
33801,Switzerland,2015,5,R-Respiratory system,"/capita, US$ purchasing power parity",49.1
33802,Switzerland,2015,5,R-Respiratory system,"/capita, US$ exchange rate",63.1
33803,Switzerland,2015,5,R-Respiratory system,"Million US$, purchasing power parity",407.0
33804,Switzerland,2015,5,Total pharmaceutical sales,"/capita, US$ purchasing power parity",604.2
33805,Switzerland,2015,5,Total pharmaceutical sales,"/capita, US$ exchange rate",775.8
33806,Switzerland,2015,5,R-Respiratory system,% of total sales,8.1
33807,Switzerland,2015,5,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",87.0
33808,Switzerland,2015,5,A-Alimentary tract and metabolism,% of total sales,14.4
33809,Switzerland,2015,5,M-Musculo-skeletal system,% of total sales,6.4
33810,Switzerland,2015,5,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",111.7
33811,Switzerland,2015,5,J-Antiinfectives for systemic use,% of total sales,9.2
33812,Switzerland,2015,5,A-Alimentary tract and metabolism,Million of national currency units,890.0
33813,Switzerland,2015,5,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",55.6
33814,Switzerland,2015,5,A-Alimentary tract and metabolism,Million US$ at exchange rate,924.8
33815,Switzerland,2015,5,J-Antiinfectives for systemic use,Million of national currency units,569.0
33816,Switzerland,2015,5,M-Musculo-skeletal system,"/capita, US$ exchange rate",49.9
33817,Switzerland,2015,5,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",38.9
33818,Switzerland,2015,5,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",720.2
33819,Switzerland,2015,5,M-Musculo-skeletal system,"Million US$, purchasing power parity",322.1
33820,Switzerland,2015,5,G-Genito urinary system and sex hormones,Million of national currency units,348.0
33821,Switzerland,2015,5,G-Genito urinary system and sex hormones,% of total sales,5.6
33822,Switzerland,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",34.0
33823,Switzerland,2015,5,J-Antiinfectives for systemic use,Million US$ at exchange rate,591.2
33824,Switzerland,2015,5,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",460.4
33825,Switzerland,2015,5,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",71.4
33826,Switzerland,2015,5,G-Genito urinary system and sex hormones,Million US$ at exchange rate,361.6
33827,Switzerland,2015,5,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",281.6
33828,Switzerland,2015,5,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",43.7
33829,United Kingdom,2012,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",39.8
33830,United Kingdom,2012,8,M-Musculo-skeletal system,Million US$ at exchange rate,568.4
33831,United Kingdom,2012,8,M-Musculo-skeletal system,Million of national currency units,359.8
33832,United Kingdom,2012,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",14.4
33833,United Kingdom,2012,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",13.0
33834,United Kingdom,2012,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",35.9
33835,United Kingdom,2012,8,N-Nervous system,% of total sales,18.7
33836,United Kingdom,2012,8,N-Nervous system,"/capita, US$ purchasing power parity",57.8
33837,United Kingdom,2012,8,B-Blood and blood forming organs,% of total sales,4.2
33838,United Kingdom,2012,8,J-Antiinfectives for systemic use,% of total sales,11.7
33839,United Kingdom,2012,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",512.8
33840,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.5
33841,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,338.3
33842,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",7.6
33843,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,534.4
33844,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",482.2
33845,United Kingdom,2012,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",8.4
33846,United Kingdom,2012,8,N-Nervous system,"/capita, US$ exchange rate",64.0
33847,United Kingdom,2012,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.0
33848,United Kingdom,2012,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",8.9
33849,United Kingdom,2012,8,M-Musculo-skeletal system,% of total sales,2.6
33850,United Kingdom,2012,8,N-Nervous system,Million US$ at exchange rate,4078.4
33851,United Kingdom,2012,8,N-Nervous system,Million of national currency units,2581.8
33852,United Kingdom,2012,8,N-Nervous system,"Million US$, purchasing power parity",3679.7
33853,United Kingdom,2012,8,A-Alimentary tract and metabolism,Million of national currency units,1384.3
33854,United Kingdom,2012,8,C-Cardiovascular system,Million of national currency units,1332.3
33855,United Kingdom,2012,8,C-Cardiovascular system,Million US$ at exchange rate,2104.6
33856,United Kingdom,2012,8,C-Cardiovascular system,"Million US$, purchasing power parity",1898.9
33857,United Kingdom,2012,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,2186.7
33858,United Kingdom,2012,8,A-Alimentary tract and metabolism,% of total sales,10.1
33859,United Kingdom,2012,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",31.0
33860,United Kingdom,2012,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",34.3
33861,United Kingdom,2012,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",1973.0
33862,United Kingdom,2012,8,R-Respiratory system,% of total sales,10.5
33863,United Kingdom,2012,8,R-Respiratory system,"Million US$, purchasing power parity",2052.8
33864,United Kingdom,2012,8,R-Respiratory system,"/capita, US$ purchasing power parity",32.2
33865,United Kingdom,2012,8,R-Respiratory system,"/capita, US$ exchange rate",35.7
33866,United Kingdom,2012,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",29.8
33867,United Kingdom,2012,8,R-Respiratory system,Million of national currency units,1440.3
33868,United Kingdom,2012,8,R-Respiratory system,Million US$ at exchange rate,2275.2
33869,United Kingdom,2012,8,C-Cardiovascular system,"/capita, US$ exchange rate",33.0
33870,United Kingdom,2012,8,C-Cardiovascular system,% of total sales,9.7
33871,United Kingdom,2012,8,J-Antiinfectives for systemic use,Million of national currency units,1606.0
33872,United Kingdom,2012,8,Total pharmaceutical sales,"/capita, US$ exchange rate",341.5
33873,United Kingdom,2012,8,Total pharmaceutical sales,"Million US$, purchasing power parity",19629.2
33874,United Kingdom,2012,8,Total pharmaceutical sales,Million US$ at exchange rate,21755.9
33875,United Kingdom,2012,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",826.6
33876,United Kingdom,2012,8,B-Blood and blood forming organs,Million US$ at exchange rate,916.2
33877,United Kingdom,2012,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",308.1
33878,United Kingdom,2012,8,B-Blood and blood forming organs,Million of national currency units,580.0
33879,United Kingdom,2012,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1081.0
33880,United Kingdom,2012,8,G-Genito urinary system and sex hormones,Million of national currency units,684.3
33881,United Kingdom,2012,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2288.9
33882,United Kingdom,2012,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,2536.9
33883,United Kingdom,2012,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",975.3
33884,United Kingdom,2012,8,G-Genito urinary system and sex hormones,% of total sales,5.0
33885,United Kingdom,2012,8,Total pharmaceutical sales,Million of national currency units,13772.5
33886,United Kingdom,2012,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.3
33887,United Kingdom,2012,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.0
33888,United Kingdom,2011,9,Total pharmaceutical sales,Million US$ at exchange rate,20802.4
33889,United Kingdom,2011,9,Total pharmaceutical sales,"/capita, US$ exchange rate",328.7
33890,United Kingdom,2011,9,Total pharmaceutical sales,"Million US$, purchasing power parity",18389.0
33891,United Kingdom,2011,9,Total pharmaceutical sales,"/capita, US$ purchasing power parity",290.6
33892,United Kingdom,2011,9,Total pharmaceutical sales,Million of national currency units,12983.6
33893,United Kingdom,2017,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",51.0
33894,United Kingdom,2017,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",26.2
33895,United Kingdom,2017,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3820.8
33896,United Kingdom,2017,7,M-Musculo-skeletal system,Million US$ at exchange rate,634.1
33897,United Kingdom,2017,7,M-Musculo-skeletal system,Million of national currency units,492.7
33898,United Kingdom,2017,7,N-Nervous system,"/capita, US$ exchange rate",62.2
33899,United Kingdom,2017,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",23.1
33900,United Kingdom,2017,7,N-Nervous system,"/capita, US$ purchasing power parity",70.6
33901,United Kingdom,2017,7,N-Nervous system,% of total sales,16.3
33902,United Kingdom,2017,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",57.9
33903,United Kingdom,2017,7,B-Blood and blood forming organs,% of total sales,6.1
33904,United Kingdom,2017,7,J-Antiinfectives for systemic use,% of total sales,13.4
33905,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",11.8
33906,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
33907,United Kingdom,2017,7,N-Nervous system,Million US$ at exchange rate,4107.6
33908,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",10.4
33909,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,685.7
33910,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",778.3
33911,United Kingdom,2017,7,N-Nervous system,"Million US$, purchasing power parity",4661.8
33912,United Kingdom,2017,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.6
33913,United Kingdom,2017,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",719.7
33914,United Kingdom,2017,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.9
33915,United Kingdom,2017,7,N-Nervous system,Million of national currency units,3191.5
33916,United Kingdom,2017,7,M-Musculo-skeletal system,% of total sales,2.5
33917,United Kingdom,2017,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",1727.9
33918,United Kingdom,2017,7,A-Alimentary tract and metabolism,Million of national currency units,1854.8
33919,United Kingdom,2017,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,532.8
33920,United Kingdom,2017,7,C-Cardiovascular system,Million of national currency units,1301.0
33921,United Kingdom,2017,7,C-Cardiovascular system,Million US$ at exchange rate,1674.4
33922,United Kingdom,2017,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",41.0
33923,United Kingdom,2017,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",36.1
33924,United Kingdom,2017,7,C-Cardiovascular system,"Million US$, purchasing power parity",1900.4
33925,United Kingdom,2017,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2709.3
33926,United Kingdom,2017,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,2387.2
33927,United Kingdom,2017,7,R-Respiratory system,% of total sales,8.5
33928,United Kingdom,2017,7,R-Respiratory system,"/capita, US$ purchasing power parity",36.9
33929,United Kingdom,2017,7,R-Respiratory system,"/capita, US$ exchange rate",32.5
33930,United Kingdom,2017,7,R-Respiratory system,"Million US$, purchasing power parity",2433.7
33931,United Kingdom,2017,7,R-Respiratory system,Million US$ at exchange rate,2144.3
33932,United Kingdom,2017,7,C-Cardiovascular system,"/capita, US$ exchange rate",25.4
33933,United Kingdom,2017,7,R-Respiratory system,Million of national currency units,1666.1
33934,United Kingdom,2017,7,C-Cardiovascular system,% of total sales,6.7
33935,United Kingdom,2017,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",28.8
33936,United Kingdom,2017,7,A-Alimentary tract and metabolism,% of total sales,9.5
33937,United Kingdom,2017,7,Total pharmaceutical sales,"Million US$, purchasing power parity",28520.4
33938,United Kingdom,2017,7,Total pharmaceutical sales,Million US$ at exchange rate,25129.6
33939,United Kingdom,2017,7,Total pharmaceutical sales,Million of national currency units,19525.1
33940,United Kingdom,2017,7,Total pharmaceutical sales,"/capita, US$ exchange rate",380.5
33941,United Kingdom,2017,7,B-Blood and blood forming organs,Million US$ at exchange rate,1522.4
33942,United Kingdom,2017,7,B-Blood and blood forming organs,Million of national currency units,1182.9
33943,United Kingdom,2017,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",431.9
33944,United Kingdom,2017,7,G-Genito urinary system and sex hormones,Million of national currency units,757.8
33945,United Kingdom,2017,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,3366.5
33946,United Kingdom,2017,7,J-Antiinfectives for systemic use,Million of national currency units,2615.7
33947,United Kingdom,2017,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,975.3
33948,United Kingdom,2017,7,G-Genito urinary system and sex hormones,% of total sales,3.9
33949,United Kingdom,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",16.8
33950,United Kingdom,2017,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.8
33951,United Kingdom,2017,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1106.9
33952,United Kingdom,2010,10,Total pharmaceutical sales,"/capita, US$ exchange rate",323.9
33953,United Kingdom,2010,10,Total pharmaceutical sales,"Million US$, purchasing power parity",18733.4
33954,United Kingdom,2010,10,Total pharmaceutical sales,Million US$ at exchange rate,20328.4
33955,United Kingdom,2010,10,Total pharmaceutical sales,"/capita, US$ purchasing power parity",298.5
33956,United Kingdom,2010,10,Total pharmaceutical sales,Million of national currency units,13156.1
33957,United Kingdom,2014,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",47.0
33958,United Kingdom,2014,8,M-Musculo-skeletal system,Million US$ at exchange rate,661.6
33959,United Kingdom,2014,8,M-Musculo-skeletal system,Million of national currency units,402.1
33960,United Kingdom,2014,8,N-Nervous system,"/capita, US$ exchange rate",75.3
33961,United Kingdom,2014,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",19.4
33962,United Kingdom,2014,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",40.9
33963,United Kingdom,2014,8,N-Nervous system,% of total sales,18.5
33964,United Kingdom,2014,8,N-Nervous system,"/capita, US$ purchasing power parity",65.5
33965,United Kingdom,2014,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",16.9
33966,United Kingdom,2014,8,B-Blood and blood forming organs,% of total sales,4.8
33967,United Kingdom,2014,8,J-Antiinfectives for systemic use,% of total sales,11.5
33968,United Kingdom,2014,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",575.7
33969,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",10.6
33970,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.0
33971,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,478.3
33972,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,787.0
33973,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",684.8
33974,United Kingdom,2014,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.2
33975,United Kingdom,2014,8,N-Nervous system,Million US$ at exchange rate,4863.8
33976,United Kingdom,2014,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.9
33977,United Kingdom,2014,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.2
33978,United Kingdom,2014,8,N-Nervous system,Million of national currency units,2955.9
33979,United Kingdom,2014,8,N-Nervous system,"Million US$, purchasing power parity",4232.1
33980,United Kingdom,2014,8,M-Musculo-skeletal system,% of total sales,2.5
33981,United Kingdom,2014,8,A-Alimentary tract and metabolism,Million of national currency units,1537.2
33982,United Kingdom,2014,8,C-Cardiovascular system,Million of national currency units,1186.8
33983,United Kingdom,2014,8,C-Cardiovascular system,Million US$ at exchange rate,1952.8
33984,United Kingdom,2014,8,C-Cardiovascular system,"Million US$, purchasing power parity",1699.2
33985,United Kingdom,2014,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,2529.4
33986,United Kingdom,2014,8,A-Alimentary tract and metabolism,% of total sales,9.6
33987,United Kingdom,2014,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",34.1
33988,United Kingdom,2014,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",39.2
33989,United Kingdom,2014,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2200.9
33990,United Kingdom,2014,8,R-Respiratory system,% of total sales,9.9
33991,United Kingdom,2014,8,R-Respiratory system,"/capita, US$ purchasing power parity",35.0
33992,United Kingdom,2014,8,R-Respiratory system,"/capita, US$ exchange rate",40.3
33993,United Kingdom,2014,8,R-Respiratory system,"Million US$, purchasing power parity",2263.7
33994,United Kingdom,2014,8,C-Cardiovascular system,"/capita, US$ exchange rate",30.2
33995,United Kingdom,2014,8,R-Respiratory system,Million of national currency units,1581.1
33996,United Kingdom,2014,8,C-Cardiovascular system,% of total sales,7.4
33997,United Kingdom,2014,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",26.3
33998,United Kingdom,2014,8,R-Respiratory system,Million US$ at exchange rate,2601.6
33999,United Kingdom,2014,8,Total pharmaceutical sales,"/capita, US$ exchange rate",407.4
34000,United Kingdom,2014,8,Total pharmaceutical sales,"Million US$, purchasing power parity",22901.2
34001,United Kingdom,2014,8,Total pharmaceutical sales,Million US$ at exchange rate,26319.6
34002,United Kingdom,2014,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",1090.1
34003,United Kingdom,2014,8,B-Blood and blood forming organs,Million US$ at exchange rate,1252.9
34004,United Kingdom,2014,8,Total pharmaceutical sales,Million of national currency units,15995.2
34005,United Kingdom,2014,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",354.5
34006,United Kingdom,2014,8,B-Blood and blood forming organs,Million of national currency units,761.4
34007,United Kingdom,2014,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1120.1
34008,United Kingdom,2014,8,G-Genito urinary system and sex hormones,Million of national currency units,680.7
34009,United Kingdom,2014,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,3034.6
34010,United Kingdom,2014,8,J-Antiinfectives for systemic use,Million of national currency units,1844.2
34011,United Kingdom,2014,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2640.4
34012,United Kingdom,2014,8,G-Genito urinary system and sex hormones,% of total sales,4.3
34013,United Kingdom,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.1
34014,United Kingdom,2014,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",17.3
34015,United Kingdom,2014,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",974.6
34016,United Kingdom,2015,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",48.8
34017,United Kingdom,2015,8,M-Musculo-skeletal system,Million US$ at exchange rate,672.8
34018,United Kingdom,2015,8,M-Musculo-skeletal system,Million of national currency units,440.4
34019,United Kingdom,2015,8,N-Nervous system,"/capita, US$ exchange rate",75.6
34020,United Kingdom,2015,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.1
34021,United Kingdom,2015,8,N-Nervous system,"/capita, US$ purchasing power parity",71.5
34022,United Kingdom,2015,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",20.0
34023,United Kingdom,2015,8,N-Nervous system,% of total sales,18.2
34024,United Kingdom,2015,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",46.1
34025,United Kingdom,2015,8,J-Antiinfectives for systemic use,% of total sales,11.8
34026,United Kingdom,2015,8,B-Blood and blood forming organs,% of total sales,5.1
34027,United Kingdom,2015,8,R-Respiratory system,"Million US$, purchasing power parity",2337.6
34028,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.1
34029,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3
34030,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,589.6
34031,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,900.8
34032,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",851.3
34033,United Kingdom,2015,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",13.8
34034,United Kingdom,2015,8,N-Nervous system,Million US$ at exchange rate,4923.1
34035,United Kingdom,2015,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",9.8
34036,United Kingdom,2015,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",10.3
34037,United Kingdom,2015,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",635.9
34038,United Kingdom,2015,8,N-Nervous system,Million of national currency units,3222.4
34039,United Kingdom,2015,8,N-Nervous system,"Million US$, purchasing power parity",4652.9
34040,United Kingdom,2015,8,M-Musculo-skeletal system,% of total sales,2.5
34041,United Kingdom,2015,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",1300.7
34042,United Kingdom,2015,8,A-Alimentary tract and metabolism,Million of national currency units,1710.8
34043,United Kingdom,2015,8,C-Cardiovascular system,Million of national currency units,1267.8
34044,United Kingdom,2015,8,C-Cardiovascular system,Million US$ at exchange rate,1936.9
34045,United Kingdom,2015,8,C-Cardiovascular system,"Million US$, purchasing power parity",1830.6
34046,United Kingdom,2015,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,2613.7
34047,United Kingdom,2015,8,A-Alimentary tract and metabolism,% of total sales,9.7
34048,United Kingdom,2015,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",37.9
34049,United Kingdom,2015,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2470.3
34050,United Kingdom,2015,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",40.1
34051,United Kingdom,2015,8,R-Respiratory system,% of total sales,9.2
34052,United Kingdom,2015,8,R-Respiratory system,"/capita, US$ purchasing power parity",35.9
34053,United Kingdom,2015,8,R-Respiratory system,"/capita, US$ exchange rate",38.0
34054,United Kingdom,2015,8,C-Cardiovascular system,"/capita, US$ exchange rate",29.7
34055,United Kingdom,2015,8,R-Respiratory system,Million of national currency units,1618.9
34056,United Kingdom,2015,8,R-Respiratory system,Million US$ at exchange rate,2473.3
34057,United Kingdom,2015,8,C-Cardiovascular system,% of total sales,7.2
34058,United Kingdom,2015,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",28.1
34059,United Kingdom,2015,8,Total pharmaceutical sales,"Million US$, purchasing power parity",25538.8
34060,United Kingdom,2015,8,Total pharmaceutical sales,Million US$ at exchange rate,27021.7
34061,United Kingdom,2015,8,Total pharmaceutical sales,Million of national currency units,17686.9
34062,United Kingdom,2015,8,Total pharmaceutical sales,"/capita, US$ exchange rate",415.0
34063,United Kingdom,2015,8,B-Blood and blood forming organs,Million US$ at exchange rate,1376.2
34064,United Kingdom,2015,8,B-Blood and blood forming organs,Million of national currency units,900.8
34065,United Kingdom,2015,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",392.2
34066,United Kingdom,2015,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3002.7
34067,United Kingdom,2015,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1081.5
34068,United Kingdom,2015,8,G-Genito urinary system and sex hormones,Million of national currency units,707.9
34069,United Kingdom,2015,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,3177.0
34070,United Kingdom,2015,8,J-Antiinfectives for systemic use,Million of national currency units,2079.5
34071,United Kingdom,2015,8,G-Genito urinary system and sex hormones,% of total sales,4.0
34072,United Kingdom,2015,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.7
34073,United Kingdom,2015,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.6
34074,United Kingdom,2015,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1022.2
34075,United Kingdom,2016,7,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",48.3
34076,United Kingdom,2016,7,N-Nervous system,"/capita, US$ exchange rate",66.9
34077,United Kingdom,2016,7,M-Musculo-skeletal system,Million US$ at exchange rate,618.1
34078,United Kingdom,2016,7,M-Musculo-skeletal system,Million of national currency units,457.8
34079,United Kingdom,2016,7,B-Blood and blood forming organs,"/capita, US$ exchange rate",21.2
34080,United Kingdom,2016,7,N-Nervous system,"/capita, US$ purchasing power parity",72.0
34081,United Kingdom,2016,7,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",51.9
34082,United Kingdom,2016,7,N-Nervous system,% of total sales,17.5
34083,United Kingdom,2016,7,B-Blood and blood forming organs,% of total sales,5.5
34084,United Kingdom,2016,7,J-Antiinfectives for systemic use,% of total sales,12.6
34085,United Kingdom,2016,7,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",22.8
34086,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",13.4
34087,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,3.3
34088,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,607.3
34089,United Kingdom,2016,7,N-Nervous system,Million US$ at exchange rate,4392.2
34090,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,820.0
34091,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",881.9
34092,United Kingdom,2016,7,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",12.5
34093,United Kingdom,2016,7,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.4
34094,United Kingdom,2016,7,M-Musculo-skeletal system,"Million US$, purchasing power parity",664.8
34095,United Kingdom,2016,7,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",10.1
34096,United Kingdom,2016,7,N-Nervous system,Million of national currency units,3253.0
34097,United Kingdom,2016,7,N-Nervous system,"Million US$, purchasing power parity",4724.1
34098,United Kingdom,2016,7,M-Musculo-skeletal system,% of total sales,2.5
34099,United Kingdom,2016,7,A-Alimentary tract and metabolism,Million of national currency units,1773.2
34100,United Kingdom,2016,7,C-Cardiovascular system,Million of national currency units,1280.2
34101,United Kingdom,2016,7,C-Cardiovascular system,Million US$ at exchange rate,1728.5
34102,United Kingdom,2016,7,C-Cardiovascular system,"Million US$, purchasing power parity",1859.1
34103,United Kingdom,2016,7,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",39.2
34104,United Kingdom,2016,7,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",36.5
34105,United Kingdom,2016,7,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2575.1
34106,United Kingdom,2016,7,A-Alimentary tract and metabolism,Million US$ at exchange rate,2394.2
34107,United Kingdom,2016,7,A-Alimentary tract and metabolism,% of total sales,9.6
34108,United Kingdom,2016,7,R-Respiratory system,% of total sales,8.9
34109,United Kingdom,2016,7,R-Respiratory system,"/capita, US$ purchasing power parity",36.6
34110,United Kingdom,2016,7,R-Respiratory system,"/capita, US$ exchange rate",34.0
34111,United Kingdom,2016,7,R-Respiratory system,Million US$ at exchange rate,2231.9
34112,United Kingdom,2016,7,C-Cardiovascular system,"/capita, US$ exchange rate",26.3
34113,United Kingdom,2016,7,R-Respiratory system,Million of national currency units,1653.0
34114,United Kingdom,2016,7,C-Cardiovascular system,% of total sales,6.9
34115,United Kingdom,2016,7,C-Cardiovascular system,"/capita, US$ purchasing power parity",28.3
34116,United Kingdom,2016,7,B-Blood and blood forming organs,"Million US$, purchasing power parity",1495.3
34117,United Kingdom,2016,7,Total pharmaceutical sales,"Million US$, purchasing power parity",26944.6
34118,United Kingdom,2016,7,Total pharmaceutical sales,Million US$ at exchange rate,25051.6
34119,United Kingdom,2016,7,R-Respiratory system,"Million US$, purchasing power parity",2400.5
34120,United Kingdom,2016,7,Total pharmaceutical sales,Million of national currency units,18554.1
34121,United Kingdom,2016,7,Total pharmaceutical sales,"/capita, US$ exchange rate",381.6
34122,United Kingdom,2016,7,B-Blood and blood forming organs,Million US$ at exchange rate,1390.3
34123,United Kingdom,2016,7,B-Blood and blood forming organs,Million of national currency units,1029.7
34124,United Kingdom,2016,7,Total pharmaceutical sales,"/capita, US$ purchasing power parity",410.4
34125,United Kingdom,2016,7,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",3408.2
34126,United Kingdom,2016,7,G-Genito urinary system and sex hormones,Million US$ at exchange rate,960.1
34127,United Kingdom,2016,7,G-Genito urinary system and sex hormones,Million of national currency units,711.1
34128,United Kingdom,2016,7,J-Antiinfectives for systemic use,Million US$ at exchange rate,3168.8
34129,United Kingdom,2016,7,J-Antiinfectives for systemic use,Million of national currency units,2346.9
34130,United Kingdom,2016,7,G-Genito urinary system and sex hormones,% of total sales,3.8
34131,United Kingdom,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.7
34132,United Kingdom,2016,7,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",14.6
34133,United Kingdom,2016,7,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",1032.7
34134,United Kingdom,2013,8,J-Antiinfectives for systemic use,"/capita, US$ exchange rate",42.2
34135,United Kingdom,2013,8,M-Musculo-skeletal system,Million US$ at exchange rate,585.3
34136,United Kingdom,2013,8,M-Musculo-skeletal system,Million of national currency units,374.4
34137,United Kingdom,2013,8,B-Blood and blood forming organs,"/capita, US$ exchange rate",15.8
34138,United Kingdom,2013,8,B-Blood and blood forming organs,"/capita, US$ purchasing power parity",14.6
34139,United Kingdom,2013,8,N-Nervous system,% of total sales,18.9
34140,United Kingdom,2013,8,B-Blood and blood forming organs,% of total sales,4.4
34141,United Kingdom,2013,8,N-Nervous system,"/capita, US$ purchasing power parity",61.9
34142,United Kingdom,2013,8,J-Antiinfectives for systemic use,"/capita, US$ purchasing power parity",38.8
34143,United Kingdom,2013,8,J-Antiinfectives for systemic use,% of total sales,11.8
34144,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",% of total sales,2.7
34145,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million of national currency units,391.9
34146,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ purchasing power parity",8.8
34147,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins",Million US$ at exchange rate,612.7
34148,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","Million US$, purchasing power parity",563.7
34149,United Kingdom,2013,8,"H-Systemic hormonal preparations, excluding sex hormones and insulins","/capita, US$ exchange rate",9.6
34150,United Kingdom,2013,8,N-Nervous system,Million US$ at exchange rate,4315.1
34151,United Kingdom,2013,8,N-Nervous system,"/capita, US$ exchange rate",67.3
34152,United Kingdom,2013,8,M-Musculo-skeletal system,"/capita, US$ purchasing power parity",8.4
34153,United Kingdom,2013,8,M-Musculo-skeletal system,"/capita, US$ exchange rate",9.1
34154,United Kingdom,2013,8,N-Nervous system,Million of national currency units,2760.2
34155,United Kingdom,2013,8,M-Musculo-skeletal system,"Million US$, purchasing power parity",538.5
34156,United Kingdom,2013,8,M-Musculo-skeletal system,% of total sales,2.6
34157,United Kingdom,2013,8,N-Nervous system,"Million US$, purchasing power parity",3970.1
34158,United Kingdom,2013,8,A-Alimentary tract and metabolism,Million of national currency units,1410.4
34159,United Kingdom,2013,8,C-Cardiovascular system,Million of national currency units,1156.4
34160,United Kingdom,2013,8,C-Cardiovascular system,Million US$ at exchange rate,1807.8
34161,United Kingdom,2013,8,C-Cardiovascular system,"Million US$, purchasing power parity",1663.3
34162,United Kingdom,2013,8,A-Alimentary tract and metabolism,Million US$ at exchange rate,2204.9
34163,United Kingdom,2013,8,A-Alimentary tract and metabolism,% of total sales,9.7
34164,United Kingdom,2013,8,A-Alimentary tract and metabolism,"/capita, US$ purchasing power parity",31.6
34165,United Kingdom,2013,8,A-Alimentary tract and metabolism,"/capita, US$ exchange rate",34.4
34166,United Kingdom,2013,8,A-Alimentary tract and metabolism,"Million US$, purchasing power parity",2028.6
34167,United Kingdom,2013,8,C-Cardiovascular system,"/capita, US$ exchange rate",28.2
34168,United Kingdom,2013,8,R-Respiratory system,% of total sales,10.5
34169,United Kingdom,2013,8,R-Respiratory system,"Million US$, purchasing power parity",2195.6
34170,United Kingdom,2013,8,R-Respiratory system,"/capita, US$ purchasing power parity",34.3
34171,United Kingdom,2013,8,R-Respiratory system,"/capita, US$ exchange rate",37.2
34172,United Kingdom,2013,8,C-Cardiovascular system,"/capita, US$ purchasing power parity",25.9
34173,United Kingdom,2013,8,R-Respiratory system,Million of national currency units,1526.5
34174,United Kingdom,2013,8,R-Respiratory system,Million US$ at exchange rate,2386.4
34175,United Kingdom,2013,8,C-Cardiovascular system,% of total sales,7.9
34176,United Kingdom,2013,8,Total pharmaceutical sales,"/capita, US$ exchange rate",356.1
34177,United Kingdom,2013,8,Total pharmaceutical sales,"Million US$, purchasing power parity",21002.7
34178,United Kingdom,2013,8,Total pharmaceutical sales,Million US$ at exchange rate,22827.9
34179,United Kingdom,2013,8,B-Blood and blood forming organs,"Million US$, purchasing power parity",934.2
34180,United Kingdom,2013,8,B-Blood and blood forming organs,Million US$ at exchange rate,1015.4
34181,United Kingdom,2013,8,B-Blood and blood forming organs,Million of national currency units,649.5
34182,United Kingdom,2013,8,Total pharmaceutical sales,"/capita, US$ purchasing power parity",327.6
34183,United Kingdom,2013,8,Total pharmaceutical sales,Million of national currency units,14602.1
34184,United Kingdom,2013,8,G-Genito urinary system and sex hormones,Million US$ at exchange rate,1063.2
34185,United Kingdom,2013,8,G-Genito urinary system and sex hormones,Million of national currency units,680.1
34186,United Kingdom,2013,8,J-Antiinfectives for systemic use,"Million US$, purchasing power parity",2487.5
34187,United Kingdom,2013,8,J-Antiinfectives for systemic use,Million US$ at exchange rate,2703.6
34188,United Kingdom,2013,8,J-Antiinfectives for systemic use,Million of national currency units,1729.4
34189,United Kingdom,2013,8,G-Genito urinary system and sex hormones,"Million US$, purchasing power parity",978.2
34190,United Kingdom,2013,8,G-Genito urinary system and sex hormones,% of total sales,4.7
34191,United Kingdom,2013,8,G-Genito urinary system and sex hormones,"/capita, US$ exchange rate",16.6
34192,United Kingdom,2013,8,G-Genito urinary system and sex hormones,"/capita, US$ purchasing power parity",15.3
